<SEC-DOCUMENT>0001193125-22-000260.txt : 20220103
<SEC-HEADER>0001193125-22-000260.hdr.sgml : 20220103
<ACCEPTANCE-DATETIME>20220103065741
ACCESSION NUMBER:		0001193125-22-000260
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		40
FILED AS OF DATE:		20220103
DATE AS OF CHANGE:		20220103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Amylyx Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001658551
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				464600503
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-261703
		FILM NUMBER:		22500357

	BUSINESS ADDRESS:	
		STREET 1:		43 THORNDIKE STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02141
		BUSINESS PHONE:		617-683-0917

	MAIL ADDRESS:	
		STREET 1:		43 THORNDIKE STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02141
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>d155225ds1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<HTML><HEAD>
<TITLE>S-1/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>As filed with the Securities and Exchange Commission on January 3, 2022. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right"><B>Registration No.&nbsp;333-261703 </B></P>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>SECURITIES AND EXCHANGE
COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Amendment No. 1
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>to </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B><I>THE SECURITIES ACT
OF&nbsp;1933 </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:22pt; font-family:ARIAL" ALIGN="center"><B>Amylyx Pharmaceuticals, Inc. </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Exact name of
registrant as specified in its charter) </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">46-4600503</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>43 Thorndike St. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Cambridge, Massachusetts 02141 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(617) <FONT
STYLE="white-space:nowrap">682-0917</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s
principal executive offices) </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Joshua B. Cohen, <FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Justin B. Klee, <FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Amylyx Pharmaceuticals, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>43 Thorndike St.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Cambridge, Massachusetts 02141 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(617) <FONT
STYLE="white-space:nowrap">682-0917</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service)
</B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><I>Copies to: </I></B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Mitchell S. Bloom, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Benjamin K. Marsh, Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Goodwin Procter
LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>100 Northern Avenue</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Boston,
Massachusetts 02210</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">570-1000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Lisa Firenze, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Stuart M. Falber, Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Jeffries <FONT
STYLE="white-space:nowrap">Oliver-Li,</FONT> Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Wilmer Cutler Pickering Hale and Dorr LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>7 World Trade Center</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>250 Greenwich
Street</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>New York, New York 10007</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(212) <FONT
STYLE="white-space:nowrap">230-8800</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL"><B>Approximate date of commencement of proposed sale to the public:</B> As soon as
practicable after this Registration Statement is declared effective. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">If any of the securities being registered on this form are to be offered on a
delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of 1933 check the following box.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">If this form is filed to register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">If this form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">If this form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, smaller reporting company, or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting
company,&#148; and &#147;emerging growth company&#148; in <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Class&nbsp;of Securities To Be Registered</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>Amount</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>to&nbsp;be</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>Registered&nbsp;(1)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>Maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>Offering Price</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>Per Share (2)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>Maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>Aggregate Offering<BR>Price
(2)(3)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount&nbsp;of<BR>Registration&nbsp;Fee&nbsp;(4)</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Common Stock, $0.0001 par value per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">10,062,500</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$20.00</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$201,250,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$18,656</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Includes 1,312,500 shares that the underwriters have the option to purchase. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(a) under the Securities Act of
1933, as amended. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Includes the aggregate offering price of shares that the underwriters have the option to purchase to cover over
allotments, if any. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Calculated pursuant to Rule 457(a) under the Securities Act of 1933, as amended. $9,270 of this registration fee was
previously paid by the Registrant in connection with the filing of its Registration Statement on Form S-1 on December 16, 2021. </P></TD></TR></TABLE>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant
shall file&nbsp;a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the Registration Statement shall become
effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#de1a1e">The information in this prospectus is not complete and may be changed. We may not sell
these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where
the offer or sale is not permitted. </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#de1a1e">Subject
To Completion. Dated January 3, 2022. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">8,750,000 Shares </P>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g155225g92x08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This is an initial public
offering of common stock by Amylyx Pharmaceuticals, Inc. </P>  <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are offering 8,750,000 shares of our common stock. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to this offering, there has been no public market for the common stock. It is currently estimated that the initial public offering price per share
will be between $18.00 and $20.00. We have applied to list our common stock on the Nasdaq Global Market under the symbol &#147;AMLX.&#148; </P>  <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We
are an &#147;emerging growth company&#148; as defined under U.S. federal securities laws and, as such, will be subject to reduced public company reporting requirements for this prospectus and future filings. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Investing in our common stock involves risks. See &#147;<A HREF="#toc155225_3">Risk Factors</A>&#148; beginning on page&nbsp;13 to read about factors
you should consider before buying shares of our common stock. </I></P>  <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities nor passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Per&nbsp;Share</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Underwriting discounts(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds, before expenses, to Amylyx Pharmaceuticals, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">See the section titled &#147;Underwriting&#148; for a description of the compensation payable to the underwriters.
</P></TD></TR></TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">At our request, the underwriters have reserved up to five percent of the shares of common stock offered by this prospectus for
sale, at the initial public offering price, to certain persons associated with us. See &#147;Underwriting&#151;Directed Share Program.&#148; </P>  <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To
the extent that the underwriters sell more than 8,750,000 shares of common stock, the underwriters have the option to purchase up to an additional 1,312,500 shares from us at the initial price to the public less the underwriting discount. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters expect to deliver the shares against payment in New York, New York on or about
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022. </P>  <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top" ALIGN="center"><B>Goldman&nbsp;Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>SVB&nbsp;Leerink</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Evercore&nbsp;ISI</B></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>H.C. Wainwright&nbsp;&amp; Co. </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Prospectus
dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc155225_1">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc155225_2">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc155225_100">SUMMARY CONSOLIDATED FINANCIAL DATA </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc155225_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc155225_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc155225_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc155225_6">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc155225_7">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc155225_8">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc155225_9">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc155225_10">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc155225_11">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc155225_12">EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc155225_13">DIRECTOR COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc155225_14">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc155225_15">PRINCIPAL STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc155225_16">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc155225_17">SHARES ELIGIBLE FOR FUTURE SALE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc155225_18">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR NON-U.S. HOLDERS OF COMMON STOCK
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc155225_19">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc155225_20">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc155225_21">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc155225_22">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc155225_23">INDEX TO FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:9.5pt; font-family:ARIAL">Neither we nor the underwriters have authorized anyone to provide you with any information or to make any
representations other than those contained in this prospectus, any amendment or supplement to this prospectus or in any free writing prospectus we may authorize to be delivered or made available to you. Neither we nor the underwriters take
responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales
are permitted. The information contained in this prospectus is accurate only as of the date on the front cover of this prospectus, regardless of the time of delivery of this prospectus or any sale of shares of our common stock. Our business,
financial condition, results of operations and prospects may have changed since that date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:9.5pt; font-family:ARIAL">For investors outside the United States: We have not,
and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United
States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:9.5pt; font-family:ARIAL">In this prospectus, unless otherwise stated or the context otherwise requires, references to &#147;Amylyx,&#148; &#147;the Company,&#148;
&#147;we,&#148; &#147;us,&#148; &#147;our&#148; and similar references refer to Amylyx Pharmaceuticals, Inc. Amylyx and other trademarks or service marks of Amylyx appearing in this prospectus are the property of Amylyx. The other trademarks, trade
names and service marks appearing in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus are referred to without the
<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the
fullest extent under applicable law, their rights thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc155225_1"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>This summary highlights, and is qualified in its entirety by, the more detailed information and financial statements included elsewhere in this
prospectus. This summary does not contain all of the information that may be important to you. You should carefully consider, among other things, the matters discussed in &#147;Risk Factors,&#148; &#147;Special Note Regarding Forward-Looking
Statements and Industry Data,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148;, and our consolidated financial statements and the accompanying notes, in each case included elsewhere in this
prospectus</I>. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Overview </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our
mission is to develop therapies that change the treatment paradigm for amyotrophic lateral sclerosis, or ALS, and a broad range of neurodegenerative diseases by keeping neurons alive. Unlike most other cells in the body that regularly die and are
replaced as part of healthy function, mature neurons are normally resistant to cell death and generally cannot regenerate. We are pursuing commercialization of our product candidate, AMX0035, which we believe is the first drug candidate to show both
a functional and survival benefit in a large-scale clinical trial of patients with ALS. We submitted a New Drug Submission, or NDS, in Canada in the second quarter of 2021 for AMX0035 for the treatment of ALS, which was accepted for review in the
third quarter of 2021, and a New Drug Application, or NDA, to the U.S. Food and Drug Administration, or FDA, in the fourth quarter of 2021, which was accepted for priority review in the same quarter. We also intend to submit a Marketing
Authorization Application, or MAA, in Europe early in the first quarter of 2022. The results of our Phase 2 clinical trial of AMX0035, known as the CENTAUR trial, were published in September 2020 in the <I>New England Journal of Medicine</I> and in
October 2020 in the <I>Journal of Muscle and Nerve</I> and demonstrated functional and survival benefits for ALS patients. We believe AMX0035 has the potential to be a foundational therapy, meaning that it could be used alone or in conjunction with
other therapies to change the treatment paradigm across a broad range of neurodegenerative diseases. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">AMX0035 is a dual UPR-Bax apoptosis
inhibitor composed of sodium phenylbutyrate, or PB, and TURSO (also known as tauroursodeoxycholic acid, or TUDCA). Through the resolution of the unfolded protein response, or UPR, and by inhibiting translocation of the Bcl-2 Associated X-protein, or
Bax, to the outer mitochondrial membrane, we have shown in multiple models that AMX0035 can keep neurons alive under a variety of different conditions and stresses, including in <I>in vitro </I>models of neurodegeneration, endoplasmic reticulum
stress, mitochondrial dysfunction, oxidative stress and disease-specific models of a variety of other conditions, as well as <I>in vivo </I>models of ALS, Alzheimer&#146;s Disease, or AD, and multiple sclerosis. We are pursuing ALS as our first
indication as it is a disease of rapid and profound neurodegeneration. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are actively pursuing regulatory approvals of AMX0035 for the
treatment of ALS in Canada, the United States and, in the near-term, Europe. We have recently initiated a Phase 3 clinical trial of AMX0035 for the treatment of ALS, known as the PHOENIX trial, at clinical trial sites in the United States and
Europe. Based on dialogue with the FDA prior to our NDA submission, including at a pre-NDA meeting recommended by the FDA and subsequent discussions, we believe that data from the PHOENIX trial will not be required for the FDA to make a
determination on the approval of AMX0035 for the treatment of ALS, although there can be no assurance that the FDA will not require further data before making a determination. The PHOENIX trial is designed to provide further data supporting the
safety and efficacy of AMX0035 for the treatment of ALS to further support our global regulatory efforts. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, we are developing
AMX0035 for other neurodegenerative diseases by leveraging our deep knowledge of and relationships in the neurodegenerative space. We believe the approach of a </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
dual UPR-Bax apoptosis inhibitor designed to help keep neurons alive could be clinically meaningful for the treatment of other neurodegenerative disease indications in addition to ALS. Many
common and rare neurodegenerative diseases are characterized by substantial neuronal cellular loss, including AD, and Wolfram syndrome, as well as Parkinson&#146;s Disease, Huntington&#146;s Disease, Progressive Supranuclear Palsy, Multi-System
Atrophy, and others. We conducted a Phase 2 clinical trial in AD, known as the PEGASUS trial, to obtain safety data along with initial efficacy and biomarker data which could help us prioritize additional indications to pursue with AMX0035. We
believe the topline results from the PEGASUS trial, reported in November 2021, provide further biological knowledge about AMX0035 which will help inform future clinical development of AMX0035 for the treatment of AD and in other potential
indications. Based on these topline results, AMX0035 met the PEGASUS trial&#146;s primary endpoint of safety and tolerability. The 6-month trial was not powered to evaluate differences between groups in efficacy outcomes and no differences were seen
in a newly developed composite outcome of cognitive, functional, and imaging measures, or in secondary efficacy endpoints of cognition, function, and imaging. In this trial, AMX0035 showed significant effects on biomarkers including the tau protein,
tau phosphorylated at threonine 181, 8-hydroxy-2&#146;-deoxyguanosine, or 8-OHdG, and the amyloid beta 42 to 40 (amyloid-&szlig;1-42, amyloid-&szlig;1-40) ratio in cerebrospinal fluid. We will continue to evaluate these data and discuss the results
of the PEGASUS trial with scientific advisors as we consider potential next steps for the development of AMX0035 for the treatment of AD within our clinical development strategy. Based on preclinical evidence, we are planning to pursue a clinical
trial in Wolfram syndrome. We intend to prioritize our development efforts around neurodegenerative diseases that result in substantial disability, and ultimately death, and where unmet medical needs are greatest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Neurodegeneration represents one of today&#146;s most significant unmet medical needs. The development of therapies that preserve neuron health has
historically presented unique challenges, including an imperfect understanding of underlying biology and a lack of translation of activity observed in preclinical studies to results in clinical trials. Currently approved therapies for many
neurodegenerative diseases are generally only symptom modifying and have demonstrated limited efficacy. There remains an urgent need for novel approaches to address most neurodegenerative diseases, especially for progressive and severe conditions
such as ALS. Since our founding in 2013, our goal has been to improve the quality of, and extend, life for patients suffering from neurodegenerative diseases. One of our key strategies towards achieving this goal has been to form direct
relationships with patients, their families, advocacy groups, and healthcare professionals to bring much needed innovation to patients. These relationships are a cornerstone of our culture and corporate strategy. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Pipeline Overview </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">AMX0035 is a
proprietary oral fixed-dose combination of two small molecules: PB, which is a small molecular chaperone that reduces the UPR, preventing cell death resulting from the UPR, and TURSO, which is a Bax inhibitor that reduces cell death through
apoptosis. While the PB and TURSO molecules individually are not proprietary to us, we own patents and patent applications covering AMX0035, including the fixed-dose combination of AMX0035 itself. We believe that our proprietary combination of these
two mechanisms of action will allow us to target abnormal cell death to better prevent neurodegeneration than treatment with either mechanism of action alone. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our current pipeline, including the stage of development of AMX0035 in our target indications, is
represented in the table below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g155225g11i55.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Clinical Development of AMX0035 for ALS and Other Indications </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We published detailed results from the CENTAUR trial in September 2020 in the <I>New England Journal of Medicine</I> and in October 2020 in the
<I>Journal of Muscle and Nerve</I>. The CENTAUR trial was a randomized, double-blind, placebo-controlled trial conducted at 25 centers of the Northeast ALS Consortium, or NEALS, and evaluated 137 adult patients with ALS. Participants that completed
the randomized period were given the option to enroll in the open-label extension, or OLE, trial in which all participants received AMX0035 for up to 35 months. We designed our Phase 2 CENTAUR trial with input from leading ALS experts from NEALS to
detect a significant difference between AMX0035 and placebo while providing the option for participants to continue with available approved therapies for the duration of the trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The primary efficacy outcome measure for the CENTAUR trial was the rate of decline in the Revised ALS Functional Rating Scale, or <FONT
STYLE="white-space:nowrap">ALSFRS-R</FONT> total score. The <FONT STYLE="white-space:nowrap">ALSFRS-R</FONT> scale is the most widely used ALS rating scale in ALS clinical practice and in ALS clinical trials. The CENTAUR trial met its primary
endpoint with a statistically significant reduction in clinical decline among participants randomized to AMX0035 (n=87) compared to placebo (n=48) (p-value of 0.03). These results showed that patients receiving AMX0035 scored an average of 2.32
points higher on the <FONT STYLE="white-space:nowrap">ALSFRS-R</FONT> as compared to patients receiving placebo after 24 weeks, a difference of 25%. In a survey of ALS clinicians and researchers conducted and sponsored by NEALS, with the objective
of determining what percentage reduction in ALSFRS-R would be considered clinically meaningful, a difference of greater than or equal to 20% in <FONT STYLE="white-space:nowrap">ALSFRS-R</FONT> total score was considered clinically meaningful by a
majority of clinicians and researchers surveyed. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Overall survival, or OS, was analyzed for all subjects randomized in the CENTAUR trial
(intention to treat, or ITT, analysis) and compared patients originally randomized to AMX0035 (n=89) with those randomized to placebo (n=48). The risk of death was 44% lower among those originally randomized to AMX0035 compared with those originally
randomized to placebo (hazard ratio, or HR, of 0.56; a 95% confidence interval, or CI, ranging from 0.34 to 0.92; and a <FONT STYLE="white-space:nowrap">p-value</FONT> of 0.023). Median survival duration was 25.0 months (95% CI of 19.0 to 33.6
months) in the group previously randomized to AMX0035 and </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
18.5 months (95% CI of 13.5 to 23.2 months) in the group previously randomized to placebo. Participants originally randomized to AMX0035 received a median 6.5&nbsp;months greater AMX0035 exposure
than those originally randomized to placebo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">AMX0035 was generally well-tolerated with an adverse event rate similar to placebo. Adverse events, or
AEs, were reported in 97% (86 out of 89) of participants receiving AMX0035 and 96% (46 out of 48) of participants receiving placebo, with the nature of the AEs being substantially similar in both groups. We believe AMX0035 is the first drug
candidate in ALS to demonstrate a statistically significant benefit both in function as measured by a prespecified mean rate change in <FONT STYLE="white-space:nowrap">ALSFRS-R</FONT> and in a longer-term analysis of OS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We submitted an NDS for AMX0035 for the treatment of ALS to Health Canada in the second quarter of 2021, which was accepted for review in the third
quarter of 2021, and an NDA for AMX0035 for the treatment of ALS to the FDA in the fourth quarter of 2021, which was accepted for priority review in the same quarter. We also intend to submit an MAA for the approval of AMX0035 for the treatment of
ALS to the European Medicines Agency&#146;s Committee for Medicinal Products for Human Use, or CHMP, early in the first quarter of 2022. We recently initiated our global <FONT STYLE="white-space:nowrap">48-week</FONT> randomized, double-blind,
placebo-controlled Phase 3 PHOENIX trial in the fourth quarter of 2021. We expect to recruit approximately 600 patients from approximately 55 European and U.S. sites. The primary endpoint of our PHOENIX trial is a composite measure of survival and
ALSFRS-R total score progression over 48 weeks. Based on dialogue with the FDA prior to our NDA submission, including at a pre-NDA meeting recommended by the FDA and subsequent discussions, we believe that data from the PHOENIX trial will not be
required for the FDA to make a determination on the approval of AMX0035 for the treatment of ALS, although there can be no assurance that the FDA will not require further data before making a determination. This trial is designed to provide further
data supporting the safety and efficacy of AMX0035 for the treatment of ALS to further support our global regulatory efforts. Any regulatory approvals we may receive may be limited or subject to restrictions or post-approval commitments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are also developing AMX0035 for the treatment of AD. We designed our multicenter, randomized, double-blind, placebo-controlled Phase 2 PEGASUS trial
with AD experts to evaluate the safety, tolerability and activity of AMX0035 in patients with late mild cognitive impairment or early-to-moderate dementia. We announced the completion of our PEGASUS trial in November 2020 and announced topline
results in the fourth quarter of 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe AMX0035 also has the potential to provide benefit in a number of additional neurodegenerative
indications. We are prioritizing these conditions on an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">indication-by-indication</FONT></FONT> basis, based on the following criteria: the strength of the data supporting
AMX0035&#146;s potential benefit; the urgency of the unmet need; the practicality of conducting clinical studies in these conditions; the efficiency of clinical development activities; and the commercial potential. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Our Strategy </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our mission is to change the
treatment paradigm for neurodegenerative diseases. Key elements of our strategy to achieve this mission include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Obtaining regulatory approval of AMX0035 for ALS in Canada, the United States and Europe. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Effectively and efficiently commercializing AMX0035 for ALS in key territories, if approved. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Maximizing the therapeutic potential of AMX0035 by expanding into additional neurodegenerative diseases.
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Continuing to cultivate a network of patient advocacy groups, key opinion leaders, research institutions, and healthcare
professionals to inform our patient-centric approach. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Deploying a strategic approach to design, acquire and develop new therapies. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Recent Development </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>FDA NDA Acceptance &amp; Priority
Review </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In December&nbsp;2021, the FDA accepted for priority review our NDA submission for AMX0035 for the treatment of ALS. The Prescription
Drug User Fee Act date, the target date by which the FDA intends to complete its review and take action on the NDA, for AMX0035 for the treatment of ALS is June 29, 2022. The FDA noted that it is currently planning to hold an advisory committee
meeting. Additionally, we are preparing to submit an expanded access program for launch in the United States in the coming months. </P>  <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Our
Company and Team </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Amylyx was founded with the ambitious goal of improving the quality and length of life for patients suffering from
neurodegenerative diseases. From a dorm room at Brown University in 2013, our <FONT STYLE="white-space:nowrap">Co-CEOs</FONT> and <FONT STYLE="white-space:nowrap">Co-Founders,</FONT> Josh Cohen and Justin Klee, set out to determine why neurons die,
and have ever since been working to develop AMX0035, which we believe is the first drug candidate to show a clear effect on function and survival in ALS, and other novel therapies. To help realize our goal, we have assembled a team with deep
scientific, clinical, business and leadership experience, bolstered by expertise in biotechnology. Our Chief Financial Officer, James Frates, brings over 20 years of experience as the Chief Financial Officer of Alkermes. Our Chief Commercial
Officer, Margaret Olinger, brings three decades of expertise in commercial launches and operations, most recently at Alexion. Our Global Head of Supply, Tom Holmes, brings more than 25 years of leadership experience at Biogen in supply chain,
biopharmaceutical manufacturing and program management. Our Global Head of Clinical Research&nbsp;&amp; Development and Chief Medical Officer, Patrick D. Yeramian, brings over 30 years of medical and pharmaceutical industry experience. Our Head of
Regulatory Affairs, Tammy Sarnelli, brings more than 30 years of experience from Biogen and other companies in early and late-stage neurology and rare disease development. Our Global Head of Human Resources, Debra Canner, brings over 20 years of
experience, having served as the Chief Human Resources Officer at Akamai and as part of Genzyme. This team brings a diverse set of skills uniquely suited to drive successful commercialization of AMX0035 in ALS while continuing to advance AMX0035 in
other indications. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Risks Associated with Our Business </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks are discussed more fully in
the &#147;Risk Factors&#148; section of this prospectus immediately following this prospectus summary. These risks include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Risks Related to Our Financial Position and Need for Capital </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>We are a clinical-stage biopharmaceutical company and we have incurred significant losses since our inception. We
anticipate that we will continue to incur significant losses for the foreseeable future.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>We have never generated revenue from product sales and may never be profitable.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>We have a limited operating history and only one product candidate, AMX0035, which is in preclinical studies and
clinical trials and has no commercial sales, which may make it difficult to evaluate the prospects for our future viability. </I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Risks Related to the Discovery and Development of Our Current or Future Product Candidates </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>We currently depend on the success of AMX0035, which is our only product candidate. If we are unable to obtain
regulatory approval for, and successfully commercialize, AMX0035, or experience significant delays in doing so, our business may be materially harmed. </I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>The denial of regulatory approval for AMX0035 in any jurisdiction could mean that we need to delay or even cease
operations, and a delay in obtaining such approval could delay commercialization of AMX0035 and adversely impact our ability to generate revenue, our business and our results of operations.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>We have never commercialized a product candidate and may experience delays or unexpected difficulties in obtaining
regulatory approval for AMX0035 for our initial or potential additional indications. </I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>AMX0035 is a fixed-dose combination drug product and certain regulatory authorities, including the FDA, require a
demonstration that each component makes a contribution to the claimed effects in addition to demonstrating that the combination is safe and effective for the intended population.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>We have concentrated our research and development efforts on the treatment of neurodegenerative and central nervous
system, or CNS, disorders, a field that has seen very limited success in product development.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>The regulatory approval processes of the FDA, Health Canada, the EMA and other comparable foreign authorities are
lengthy, time-consuming and inherently unpredictable, and if we are ultimately</I> <I>unable to obtain regulatory approval for AMX0035 or any future product candidates, our business will be substantially harmed. </I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Competitive products may reduce or eliminate the commercial opportunity for AMX0035 for our current or future
indications. If our competitors develop technologies or product candidates more rapidly than we do, or their technologies or product candidates are more effective or safer than ours, our ability to develop and successfully commercialize AMX0035 may
be adversely affected.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Risks Related to Our Dependence on Third Parties </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>We may in the future enter into collaborations with third parties for the development and commercialization of AMX0035
or any future product candidates, and our prospects with respect to those product candidates will depend in significant part on the success of those collaborations. For example, Humanitas Mirasole SpA, an entity we have no relationship with, is
conducting a Phase 3 clinical trial in</I> the EU to assess the safety and efficacy of TURSO in </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
<I>patients with ALS which may lead to additional findings as to the safety profile of TURSO. If their Phase 3 clinical trial is successful and TURSO is approved by the FDA or any other
regulatory agency, TURSO may become a commercialized product competitive with AMX0035, unless our intellectual property protections and any regulatory exclusivities we possess or may possess in the future prevent such commercialization.
</I></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>We rely on third parties to assist in conducting our clinical trials. If they do not perform satisfactorily, we may not
be able to obtain regulatory approval or commercialize AMX0035</I> <I>or any future product candidates, or such approval or commercialization may be delayed, and our business could be substantially harmed. </I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Our use of third parties to manufacture AMX0035 may increase the risk that we will not have sufficient quantities of
AMX0035, products, or necessary quantities of such materials on time or at an acceptable cost.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Risks Related to Commercialization of AMX0035 or Future Product Candidates </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>We currently have limited sales and marketing capabilities. If we are unable to establish effective sales and marketing
capabilities or enter into agreements with third parties to</I> <I>market and sell AMX0035 and any future product candidates that may be approved, we may</I> <I>not be successful in commercializing AMX0035 and any future product candidates if and
when approved, and we may be unable to generate any product revenue.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Even if AMX0035 or any future product candidate of ours receives regulatory approval, it may fail to achieve the degree
of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, in which case we may not generate significant revenues or become profitable. </I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Healthcare insurance coverage and reimbursement may be limited or unavailable for AMX0035 and any future product
candidates, if approved, which could make it difficult for us to sell any product candidates or therapies profitably.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Risks Related to Our Intellectual Property </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Our commercial success depends on our ability to protect our intellectual property and proprietary technology. </I>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Risks Related to Our Business Operations, Employee Matters and Managing Growth </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>A pandemic, epidemic, or outbreak of an infectious disease, such as the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic, may materially and adversely affect our business, including our preclinical studies, clinical trials, third parties on whom we rely, our supply chain, our ability to raise capital, our ability to conduct regular business and our financial
results.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>We depend heavily on our executive officers, principal consultants and others, and the loss of their services would
materially harm our business. </I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>We expect to expand our organization, and as a result, we may encounter difficulties in managing our growth, which could
disrupt our operations. </I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Risks Related to Our Common Stock and this Offering </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>If you purchase shares of our common stock in this offering, you will incur immediate and substantial
dilution.</I><I></I><I>&nbsp;</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>We do not know whether an active, liquid and orderly trading market will develop for our common stock or what the market
price of our common stock will be and as a result it may be difficult for you to sell your shares of our common stock.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>If we fail to remediate our material weaknesses over financial reporting controls and to implement and maintain an
effective system of internal controls, we may be unable to accurately report our results of operations, meet our reporting obligations or prevent fraud, and investor confidence in our company and the market price of our common stock may be
materially and adversely affected.</I> </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Our Corporate Information </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We were incorporated under the laws of the State of Delaware on January&nbsp;10, 2014 under the name Amylyx Pharmaceuticals, Inc. We have two wholly
owned subsidiaries, Amylyx Pharmaceuticals Canada Inc., which was formed in 2020, and Amylyx Pharmaceuticals EMEA B.V., which was formed in 2021. Our executive offices are located at 43 Thorndike Street, Cambridge, Massachusetts 02141, and our
telephone number is (617) <FONT STYLE="white-space:nowrap">682-0917.</FONT> Our website address is www.amylyx.com. The information contained on, or that can be accessed through, our website is not a part of this prospectus. We have included our
website address in this prospectus solely as an inactive textual reference. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Implications of Being an Emerging Growth Company and a Smaller
Reporting Company </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As a company with less than $1.07&nbsp;billion of revenue during our last fiscal year, we qualify as an &#147;emerging growth
company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We would cease to be an emerging growth company on the date that is the earliest of (i)&nbsp;the last day of the fiscal year in which we have total annual
gross revenues of $1.07&nbsp;billion or more; (ii)&nbsp;the last day of our fiscal year following the fifth anniversary of the date of the completion of this offering; (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in
nonconvertible debt during the previous three years; or (iv)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission. For so long as we remain an emerging growth company, we are
permitted and intend to rely on exemptions from certain disclosure and other requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">only two years of audited financial statements in addition to any required unaudited interim financial statements with
correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reduced disclosure about our executive compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">no <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on executive compensation or golden parachute
arrangements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In particular, in this prospectus, we have not included all of the executive compensation-related information that would be
required if we were not an emerging growth company. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold stock. We have elected not to &#147;opt out&#148; of
the exemption for the delayed adoption of certain accounting standards and, therefore, we will adopt new or revised accounting standards only at the time private companies adopt the new or revised accounting standard and will do so until such time
that we either (i) irrevocably elect to &#147;opt out&#148; of such extended transition period or (ii) no longer qualify as an emerging growth company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are also a &#147;smaller reporting company,&#148; meaning that the market value of our stock held by non-affiliates plus the proposed aggregate
amount of gross proceeds to us as a result of this offering is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this
offering if either (i)&nbsp;the market value of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our stock held by
non-affiliates is less than $700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting
companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our future annual reports on Form 10-K and, similar to emerging growth companies, smaller
reporting companies have reduced disclosure obligations regarding executive compensation. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc155225_2"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Common stock offered by us </P></TD>
<TD>8,750,000 shares </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Option to purchase additional shares </P></TD>
<TD>We have granted the underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to 1,312,500 shares of our common stock at the initial public offering price, less the underwriting discounts and commissions.
</TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Common stock to be outstanding immediately following this offering </P></TD>
<TD>55,216,013 shares (56,528,513 shares if the underwriters exercise their option to purchase additional shares of common stock in full). </TD></TR></TABLE> <P STYLE="font-family:ARIAL; font-size:10pt">We estimate that the net proceeds to us from
this offering, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, will be approximately $151.3 million, or approximately $174.5&nbsp;million if the underwriters exercise their option to
purchase additional shares from us in full, assuming an initial public offering price of $19.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="52%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and investments, to fund: (i)&nbsp;the regulatory approval process and pre-commercial launch, production of and, if
approved, commercial launch activities for AMX0035 for the treatment of ALS; (ii)&nbsp;the completion of our ongoing Phase 3 PHOENIX clinical trial for the treatment of amyotrophic lateral sclerosis, or ALS; (iii) the development and expansion of
our pipeline to address other neurodegenerative indications, and for formulations and derivatives of AMX0035; and (iv)&nbsp;working capital and other general corporate activities, including the continued build out of our organization. See the
&#147;Use of Proceeds&#148; section in this prospectus for a more complete description of the intended use of proceeds from this offering. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Directed share program </P></TD>
<TD> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">At our request, the underwriters have reserved for sale at the initial public offering price up to five percent of the shares of common stock offered by this
prospectus to certain of our directors, executive officers, employees, business associates and related persons in a </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="52%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:ARIAL">
directed share program. The number of shares of common stock available for sale to the general public will be reduced by the number of reserved shares sold to these individuals or entities. Any
reserved shares not purchased by these individuals or entities will be offered by the underwriters to the general public on the same terms as the other shares of common stock offered under this prospectus. See &#147;Certain Relationships and Related
Party Transactions&#148; and &#147;Underwriting&#151;Directed Share Program.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Risk factors </P></TD>
<TD>You should read the &#147;Risk Factors&#148; section of this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Exchange symbol </P></TD>
<TD>&#147;AMLX&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The number of shares of our common stock to be outstanding after this offering is based on 6,991,683 shares of
our common stock outstanding as of November 30, 2021 and 39,474,330 additional shares of our common stock issuable upon the automatic conversion of all outstanding shares of our preferred stock upon the closing of this offering, and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">5,415,815 shares of our common stock issuable upon the exercise of stock options outstanding as of November 30, 2021, at a
weighted average exercise price of $5.54 per share; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1,396,492 shares of our common stock available for future issuance as of November 30, 2021 under our 2015 Stock Option and
Grant Plan, or the 2015 Plan, which will cease to be available for issuance at the time that our 2022 Stock Option and Incentive Plan, or the 2022 Plan, becomes effective; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">7,650,000&nbsp;shares of our common stock that will become available for future issuance under our 2022 Plan, which will
become effective in connection with the completion of this offering, as well as any future increases, including annual automatic evergreen increases, in the number of shares of common stock reserved for issuance thereunder in accordance with the
terms of such plan (which includes 2,033,500 shares of our common stock issuable upon the exercise of stock options to be issued under the 2022 Plan upon the effectiveness of this offering, with an exercise price that is equal to the initial public
offering price, and 278,333 restricted stock units to be issued under the 2022 Plan upon the effectiveness of this offering); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">605,000&nbsp;shares of our common stock that will become available for future issuance under our 2022 Employee Stock
Purchase Plan, which will become effective in connection with the completion of this offering, including annual automatic evergreen increases. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unless otherwise indicated, all information in this prospectus assumes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">no exercise of the outstanding options described above; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">no exercise by the underwriters of their option to purchase up to 1,312,500 additional shares of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 39,474,330&nbsp;shares of
our common stock upon the closing of this offering; and </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the filing and effectiveness of our amended and restated certificate of incorporation and the amendment and restatement of
our bylaws prior to the closing of this offering. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc155225_100"></A>SUMMARY CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">You should read the following summary consolidated financial data together with &#147;Management&#146;s Discussion and Analysis of Financial Condition
and Results of Operations&#148; and our consolidated financial statements, related notes and other financial information included elsewhere in this prospectus. The summary consolidated financial data in this section are not intended to replace the
consolidated financial statements and are qualified in their entirety by the consolidated financial statements and related notes included elsewhere in this prospectus. We have derived the consolidated statement of operations data for the years ended
December&nbsp;31, 2019 and 2020 from our audited consolidated financial statements appearing elsewhere in this prospectus. The consolidated statements of operations data for the nine months ended September 30, 2020 and 2021 and the consolidated
balance sheet data as of September 30, 2021 have been derived from our unaudited condensed consolidated financial statements appearing elsewhere in this prospectus and have been prepared on the same basis as the audited consolidated financial
statements. In the opinion of management, the unaudited data reflects all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the financial information in those statements. Our historical results are not
necessarily indicative of results that may be expected in the future. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;ended<BR>September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except per share and per share amount)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Consolidated Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,413)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(54,373)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,554</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,005</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income (expense), net:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,287)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,276</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,270)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,228)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other (expense) income, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,275)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,214)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(162</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss </P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(33,688)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(59,587)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,716</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(42,280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share attributable to common stockholders&#151;basic and diluted(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5.55)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9.20)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6.96</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average common shares used to compute net loss per share attributable to common
stockholders&#151;basic and diluted&nbsp;(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,069,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,477,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,889,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,077,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net loss per share, basic and diluted&nbsp;(2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma weighted average shares of common stock, basic and diluted (2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,951,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,552,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">See Notes 2 and 13 to our audited consolidated financial statements and Note 11 to our unaudited condensed consolidated
financial statements, included elsewhere in this prospectus, for an explanation of the method used to calculate historical basic and diluted net loss per share attributable to common stockholders and the weighted-average common shares outstanding
used in the computation of the per share amount. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Pro forma basic and diluted net loss per share attributable to common stockholders has been prepared to give effect to
adjustments to our capital structure arising upon the completion of a qualified initial public offering and is calculated by dividing pro forma net loss attributable to common stockholders by the pro forma weighted-average common shares outstanding
for the period. Pro forma weighted-average common shares outstanding is computed by adjusting weighted-average common shares outstanding to give pro forma effect to the automatic conversion upon the completion of this offering of all shares of our
preferred stock outstanding as of September 30, 2021 into 39,474,330 shares of common stock as if the offering had occurred on January 1, 2020. </P></TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of September 30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma&nbsp;(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>as&nbsp;Adjusted&nbsp;(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Consolidated balance sheet data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash, cash equivalents, and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">278,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Working capital (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">281,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">239,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">242,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">394,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(127,501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(127,501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(127,501)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(124,070</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">We define working capital as current assets less current liabilities. See our consolidated financial statements appearing
elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Pro forma consolidated balance sheet data give effect to the automatic conversion of all outstanding shares of redeemable
convertible preferred stock into 39,474,330&nbsp;shares of common stock upon the closing of this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The pro forma as adjusted consolidated balance sheet data give further effect to the issuance and sale of shares of
common stock in this offering at an assumed initial public offering price of $19.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions
and estimated offering expenses payable by us as of September 30, 2021. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The pro forma as adjusted information discussed above is
illustrative only and will change based on the actual initial public offering price and other terms of this offering determined at pricing. A $1.00 increase (decrease) in the assumed initial public offering price of $19.00 per share, which is the
midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash, cash equivalents, and short-term investments, working capital, total assets and total
stockholders&#146; equity by $8.1&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated
offering expenses </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
payable by us. Similarly, an increase (decrease) of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the pro
forma as adjusted amount of each of cash, cash equivalents, and short-term investments, working capital, total assets and total stockholders&#146; equity by $17.7&nbsp;million, assuming no change in the assumed initial public offering price of
$19.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc155225_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Investing in our common stock involves a high degree of risk. Before you decide to invest in our common stock, you should consider carefully the
risks described below, together with the other information contained in this prospectus, including our financial statements and the related notes appearing at the end of this prospectus. We believe the risks described below are the risks that are
material to us as of the date of this prospectus. If any of the following risks actually occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected. In these circumstances,
the market price of our common stock could decline, and you may lose all or part of your investment</I>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Risks Related to Our Financial Position
and Need for Capital </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are a clinical-stage biopharmaceutical company and we have incurred significant losses since our inception. We anticipate that we
will continue to incur significant losses for the foreseeable future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Investment in biopharmaceutical product development is highly
speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become
commercially viable. We have no products approved for commercial sale and have not generated any revenue from product sales to date, and we will continue to incur significant research and development and other expenses related to our clinical
development and ongoing operations. As a result, we are not profitable and have incurred losses in each period since our inception. Since our inception, we have devoted the majority of our financial resources and efforts to research and development,
including preclinical studies and our clinical trials, and preparation for commercialization. Our financial condition and operating results, including net losses, may fluctuate significantly from quarter to quarter and year to year. Accordingly, you
should not rely upon the results of any quarterly or annual periods as indications of future operating performance. Additionally, net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#146;
equity and working capital. Our net losses were $13.7&nbsp;million and $42.3&nbsp;million for the years ended December&nbsp;31, 2019 and 2020, respectively, and $33.7 million and $59.6 million for the nine months ended September 30, 2020 and 2021,
respectively. As of September 30, 2021, we had an accumulated deficit of $127.5&nbsp;million. We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we continue our research and
development of, and seek regulatory approvals for our product candidate, AMX0035, for the treatment of amyotrophic lateral sclerosis, or ALS, Alzheimer&#146;s disease, or AD, and potential additional indications, as well as for future product
candidates we may develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We anticipate that our expenses will increase substantially if and as we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">continue to develop and conduct clinical trials for AMX0035 for the treatment of ALS, AD and potential additional
indications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">initiate and continue research, preclinical and clinical development efforts for any future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">seek to identify additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">seek regulatory approvals in Canada, the United States, the European Union, or EU, and other geographies for AMX0035 for
the treatment of ALS, AD and other indications that successfully complete clinical development; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">experience any delays or encounter any issues with any of the above, including but not limited to failed studies, negative
or mixed clinical trial results, safety issues or other regulatory challenges, the risk of which in each case may be exacerbated by the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">add operational, financial and management information systems and personnel, including personnel to support our product
candidate development and help us comply with our obligations as a public company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">hire and retain additional personnel, such as clinical, quality control, scientific, commercial and administrative
personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">maintain, expand and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establish sales, marketing, distribution, manufacturing, supply chain and other commercial infrastructure in the future to
commercialize various products for which we may obtain regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">add equipment and physical infrastructure to support our research and development; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and technologies.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our expenses could increase beyond our expectations if we are required by Health Canada, the U.S. Food and Drug Administration,
or FDA, the European Medicines Agency, or the EMA, or other regulatory authorities to perform clinical trials or conduct other studies in addition to those that we currently expect, or if there are any delays in establishing appropriate
manufacturing arrangements for or in completing our clinical trials or the development of AMX0035 or any future product candidates we may develop. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have
never generated revenue from product sales and may never be profitable. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our ability to become and remain profitable depends on our ability
to generate revenue. We do not expect to generate significant revenue, if any, unless and until we, either alone or with a collaborator, are able to obtain regulatory approval for, and successfully commercialize, AMX0035 for our initial and
potential additional indications, or any future product candidates we may develop. Successful commercialization will require achievement of many key milestones, which vary by jurisdiction and may include demonstrating safety and efficacy in clinical
trials, obtaining regulatory, including marketing, approval for these product candidates, manufacturing, marketing and selling those products for which we, or any of our future collaborators, may obtain regulatory approval, satisfying any
post-marketing requirements and obtaining reimbursement for our products from private insurance or government payors. Because of the uncertainties and risks associated with these activities, we are unable to accurately and precisely predict the
timing and amount of revenues, the extent of any further losses or if or when we might achieve profitability. We and any future collaborators may never succeed in these activities and, even if we do, or any future collaborators do, we may never
generate revenues that are large enough for us to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our failure to become and remain profitable may depress the market price of our common stock and could impair our ability to raise capital, expand our
business, diversify our product offerings or continue our operations. If we continue to suffer losses as we have in the past, investors may not receive any return on their investment and may lose their entire investment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have a limited operating history and only one product candidate, AMX0035, which is in preclinical and clinical trials and has no commercial sales, which may
make it difficult to evaluate the prospects for our future viability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a biopharmaceutical company founded in 2014, and our operations
to date have been limited to organizing, staffing and financing our company, raising capital, and conducting research and development activities, including preclinical studies and clinical trials, for AMX0035. We have not yet demonstrated an ability
to generate revenues, obtain regulatory approvals, manufacture a commercial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Accordingly, you should consider our
prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by companies in clinical development, especially clinical-stage biopharmaceutical companies such as ours. Any predictions you make about our future
success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing pharmaceutical products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives. We
are preparing to transition from a company with a development focus to a company capable of supporting commercial activities. We may not be successful in such a transition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Even if we consummate this offering, we will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay,
reduce or eliminate our product discovery and development activities or commercialization efforts. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our operations have consumed
substantial amounts of cash since inception. We expect to continue to spend substantial amounts to continue the preclinical and clinical development of AMX0035 and any future product candidates. If we are able to gain marketing approval for AMX0035
or any future product candidates that we develop, including any indication for which we are developing or may develop AMX0035, we will require significant additional amounts of cash in order to launch and commercialize such product candidates to the
extent that such launch and commercialization are not the responsibility of a collaborator that we may contract with in the future. In addition, other unanticipated costs may arise in the course of our development efforts. Because the design and
outcome of our ongoing and anticipated clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of any product candidate we develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our future capital requirements depend on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope, progress, results and costs of researching and developing AMX0035 for the treatment of ALS, AD and potential
additional indications, as well as any future product candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing of, and the costs involved in, obtaining marketing approvals for AMX0035 for the treatment of ALS, AD and
potential additional indications, and any future product candidates we may develop and pursue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of future product candidates that we may pursue and their development requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">if approved, the costs of commercialization activities for AMX0035 for any approved indications, or any other product
candidate that receives regulatory approval to the extent such costs are not the responsibility of any future collaborators, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">subject to receipt of regulatory approval, revenue, if any, received from commercial sales of AMX0035 for any approved
indications or any future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the extent to which we <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire rights to other products, product
candidates or technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our headcount growth and associated costs as we expand our research and development, increase our office space, and
establish a commercial infrastructure; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property
rights, including enforcing and defending intellectual property related claims; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ongoing costs of operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We cannot be certain that additional funding will be available on acceptable terms, or at all. As a result of the ongoing
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and actions taken to slow its spread, the global credit and financial markets have experienced extreme volatility and disruptions, including diminished liquidity and credit availability,
declines in consumer confidence, declines in economic growth, increases in unemployment rates, and uncertainty about economic stability. If the equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult,
more costly or more dilutive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have no committed source of additional capital and if we are unable to raise additional capital in sufficient
amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of AMX0035 or any future product candidates or other research and development initiatives. We may need to seek
collaborators for AMX0035 and any future product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable terms our rights to
AMX0035 and any future product candidates in markets where we otherwise would seek to pursue development or commercialization ourselves. Any of the above events could significantly harm our business, prospects, financial condition, and results of
operations and cause the price of our common stock to decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe that the net proceeds from this offering, together with our existing
cash, cash equivalents, and short-term investments, will be sufficient to meet our anticipated operating and capital expenditure requirements for at least twelve months after the registration statement of which this prospectus forms a part becomes
effective. Our estimate may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Further, changing circumstances, some of which may be beyond our control, could cause us to consume capital
significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I></I></B><B>Our history of recurring losses
and anticipated expenditures raises substantial doubts about our ability to continue as a going concern. Our ability to continue as a going concern requires that we obtain sufficient funding to finance our operations.</B><B><I> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have incurred operating losses to date and it is possible we may never generate a profit. Our financial statements included elsewhere in this
prospectus have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. If we are unable to raise sufficient capital in this offering or otherwise as
and when needed, our business, financial condition and results of operations will be materially and adversely affected, and we will need to significantly modify our operational plans to continue as a going concern. If we are unable to continue as a
going concern, we may have to liquidate our assets, and the values we receive for our assets in liquidation or dissolution could be significantly lower than the values reflected in our consolidated financial statements. Our lack of cash resources
and our potential inability to continue as a going concern may materially adversely affect our share price and our ability to raise new capital, enter into critical contractual relations with third parties and otherwise execute our development
strategy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Raising additional capital may cause dilution to our stockholders, including purchasers of common stock in this offering, restrict our operations
or require us to relinquish rights to our technologies or product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect our expenses to increase in connection with our
planned operations. Unless and until we can generate a substantial amount of revenue from AMX0035 or any future product candidates, we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
expect to finance our future cash needs through public or private equity offerings, royalty-based or debt financings, collaborations, licensing arrangements or other sources, or any combination
of the foregoing. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To the extent that we raise additional capital through the sale of common stock, convertible securities or other equity securities, your ownership
interest may be diluted, and the terms of these securities could include liquidation or other preferences and anti-dilution protections that could adversely affect your rights as a common stockholder. In addition, debt financing, if available, may
result in fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures, creating liens, redeeming stock or
declaring dividends, that could adversely impact our ability to conduct our business. In addition, securing financing could require a substantial amount of time and attention from our management and may divert a disproportionate amount of their
attention away from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our management&#146;s ability to oversee the development of AMX0035 or any future product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we raise additional funds through collaborations or marketing, distribution or licensing arrangements with third parties, we may
have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Changes in tax law could adversely affect our business and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by
the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and
changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. We urge investors to consult with their legal and tax
advisers regarding the implications of potential changes in tax laws on an investment in our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Risks Related to the Discovery and
Development of Our Current or Future Product Candidates </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We currently depend on the success of AMX0035, which is our only product candidate. If we are
unable to obtain regulatory approval for, and successfully commercialize, AMX0035, or experience significant delays in doing so, our business may be materially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We currently only have one product candidate, AMX0035, and our business and future success depends entirely on our ability to develop, obtain regulatory
approval for, and then successfully commercialize, AMX0035, which is currently in clinical development for patients with ALS and AD. To date, we have obtained limited clinical trial data supporting AMX0035, having only completed a clinical trial of
137 patients with ALS and a clinical trial in 95 patients with AD. We intend to conduct additional clinical trials of AMX0035 in ALS and other indications in the future. This may make an investment in our company riskier than similar companies that
have multiple product candidates in active development that may be able to better sustain failure of a lead product candidate. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We currently
have no products approved for sale and are investing the majority of our efforts and financial resources in the development of our product candidate, AMX0035, for the treatment of ALS, AD and other diseases. Successful continued development and
ultimate regulatory approval of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
AMX0035 for our initial and potential additional indications is critical to the future success of our business. We will need to raise sufficient funds for, and successfully enroll and complete,
our clinical development of AMX0035 for the treatment of ALS, AD and other indications. The future regulatory and commercial success of AMX0035 is subject to a number of risks, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">successful completion of preclinical studies and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">successful patient enrollment in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">successful data from our preclinical studies and clinical trials that supports an acceptable risk-benefit profile of
AMX0035 or any future product candidates in the intended populations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">satisfaction of applicable regulatory requirements, including to satisfy applicable rules governing fixed dose combination
products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">potential unforeseen safety issues or adverse side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">receipt and maintenance of marketing approvals from applicable regulatory authorities, including with any expected new
chemical entity and new clinical investigation data exclusivity and orphan drug market exclusivity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for AMX0035 or any future product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">making arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical and
commercial supplies of AMX0035 or any future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">entry into collaborations to further the development of AMX0035 or any future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when
approved, whether alone or in collaboration with others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">successfully launching commercial sales of AMX0035 or any future product candidates, if and when approved;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">acceptance of AMX0035 or any other products, if and when approved, by patients, the medical community and third-party
payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtaining and maintaining third-party coverage and adequate reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">maintaining a continued acceptable safety profile of the products following approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">effectively competing with other therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">ensuring that we promote and distribute our products consistent with all applicable healthcare laws; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">enforcing and defending intellectual property rights and claims. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Many of these risks are beyond our control, including the risks related to clinical development, the regulatory submission process, potential threats to
our intellectual property rights and the manufacturing, marketing and sales efforts of any future collaborator. If we are unable to develop, receive regulatory approval for, or successfully commercialize AMX0035 for the indications we are developing
it for, or if we experience delays as a result of any of these risks or otherwise, our business could be materially harmed. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, of the
large number of drugs in development in the pharmaceutical industry, only a small percentage result in the submission of a new drug submission, or NDS, to Health Canada, a new drug application, or NDA, to the FDA or a marketing authorization
application, or MAA, to the EMA, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
even fewer are approved for commercialization. Furthermore, even if we do receive regulatory approval for AMX0035 for any indication, any such approval may be subject to limitations on the
indications or uses or the patient populations for which we may market the product. Accordingly, even if we are able to obtain the requisite financing to continue to fund our development activities, we cannot assure you that we will successfully
develop or commercialize AMX0035 for any indication. If we or any of our future collaborators are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize AMX0035 for our initial or potential additional
indications, we may not be able to generate sufficient revenue to continue our business. In addition, our failure to demonstrate positive results in our clinical trials in any indication for which we are developing AMX0035, or to satisfy other
regulatory requirements could adversely affect our development efforts for AMX0035 in other indications. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The denial of regulatory approval for AMX0035
in any jurisdiction could mean that we need to delay or even cease operations, and a delay in obtaining such approval would delay commercialization of AMX0035 and adversely impact our ability to generate revenue, our business and our results of
operations. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are not successful in commercializing AMX0035, or are significantly delayed in doing so, our business will be
materially harmed, and we may need to curtail or cease operations. We currently have no drug products approved for sale, and we may never obtain regulatory approval to commercialize AMX0035 in any indication. The research, testing, manufacturing,
labeling, approval, sale, marketing and distribution of drug products are subject to extensive regulation by Health Canada, the FDA, the EMA, and other regulatory agencies in the United States and other countries, and such regulations differ from
country to country. We are not permitted to market AMX0035 until we receive approval or marketing authorization from the relevant regulatory authority. Health Canada, the FDA, the EMA or any other foreign regulatory agency can delay, limit or deny
approval to market AMX0035 for many reasons, including: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our inability to demonstrate to the satisfaction of Health Canada, the FDA, the EMA or any other applicable foreign
regulatory agency that AMX0035 is safe and effective for the requested indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our inability to gain agreement from applicable foreign regulatory authorities that AMX0035 is appropriate for approval
under applicable regulatory pathways; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Health Canada&#146;s, the FDA&#146;s, the EMA&#146;s or any other applicable foreign regulatory agency&#146;s disagreement
with the interpretation of data from nonclinical and clinical studies and trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our inability to demonstrate that the clinical and other benefits of AMX0035 outweigh any safety or other perceived risks;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to enroll an adequate number of patients in and successfully complete our ongoing global Phase 3 PHOENIX trial;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Health Canada&#146;s, the FDA&#146;s, the EMA&#146;s or any other applicable foreign regulatory agency&#146;s requirement
for additional nonclinical or clinical studies or trials, including studies to satisfy applicable rules governing fixed dose combination products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Health Canada&#146;s, the FDA&#146;s, the EMA&#146;s or any other applicable foreign regulatory agency&#146;s having
differing requirements for the trial protocols used in our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Health Canada&#146;s, the FDA&#146;s, the EMA&#146;s or any other applicable foreign regulatory agency&#146;s <FONT
STYLE="white-space:nowrap">non-approval</FONT> of the formulation, labeling and/or the specifications of AMX0035; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Health Canada&#146;s, the FDA&#146;s, the EMA&#146;s or any other applicable foreign regulatory agency&#146;s failure to
accept the manufacturing processes or third-party manufacturers with which we contract; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the potential for approval policies or regulations of Health Canada, the FDA, the EMA or any other applicable foreign
regulatory agencies to significantly change in a manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Of the large
number of drugs in development, only a small percentage successfully complete Health Canada, the FDA, the EMA or other regulatory approval processes and are commercialized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if we eventually complete clinical testing and receive approval of an NDS, NDA, MAA or other foreign marketing authorization for AMX0035, the FDA
or the applicable foreign regulatory agency may grant approval contingent on the performance of costly additional clinical trials, which may be required after approval. The FDA or the applicable foreign regulatory agency may also approve AMX0035 for
a more limited indication and/or a narrower patient population than we originally request, and Health Canada, the FDA, the EMA or any other applicable foreign regulatory agency may not approve the labeling that we believe is necessary or desirable
for the successful commercialization of AMX0035. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of AMX0035 and would materially adversely impact our business and prospects.
</P>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have never commercialized a product and may experience delays or unexpected difficulties in obtaining regulatory approval for AMX0035 for our
initial or potential additional indications. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our company has never obtained regulatory approval for, or commercialized, a drug. It is
possible that Health Canada, the FDA and the EMA may refuse to accept any or all of our submitted or planned NDSs, NDAs and MAAs for substantive review or may conclude after review of our data that our application is insufficient to obtain
regulatory approval for AMX0035 or any future product candidates. For example, the FDA or other regulatory authorities may require completion of our ongoing Phase 3 PHOENIX global clinical trial prior to issuing an approval decision for our
marketing applications for AMX0035. If Health Canada, the FDA, and the EMA do not approve any of our submitted or planned NDSs, NDAs or MAAs, such regulatory authorities may require that we conduct additional costly clinical, nonclinical or
manufacturing validation studies before they will reconsider our applications. Depending on the extent of these or any other required studies, approval of any NDA or other application that we submit may be significantly delayed, possibly for several
years, or may require us to expend more resources than we have available. Any failure or delay in obtaining regulatory approvals would prevent us from commercializing AMX0035 for any indication or any other product candidate, generating revenues and
achieving and sustaining profitability. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the EMA or FDA to approve any MAA, NDA or other application that we submit. For example, Health
Canada has indicated that the CENTAUR trial and the CENTAUR OLE trial are sufficient to support submission of our NDS; however, Health Canada has not reviewed our complete clinical data, to date, and therefore there is no guarantee that Health
Canada will determine that the NDS we have submitted for ALS or any future NDS we submit to be sufficient for issuing a marketing approval of AMX0035. If any of these outcomes occur, we may be forced to abandon the development of AMX0035 or any
future product candidates, which would materially adversely affect our business and could potentially cause us to cease operations. We face similar risks for our applications in other foreign jurisdictions. In addition, difficulties in obtaining
approval of AMX0035 for the treatment of ALS, AD and the other indications for which we are developing AMX0035, could adversely affect our efforts to seek approval from regulatory authorities for AMX0035 in other potential indications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>AMX0035 is a fixed-dose combination drug product and certain regulatory authorities, including the FDA, require
a demonstration that each component makes a contribution to the claimed effects in addition to demonstrating that the combination is safe and effective for the intended population. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the combination rule, the FDA may not file or approve an NDA for a fixed-dose combination product unless each component of a proposed drug product
is shown to make a contribution to the claimed effects and the dosage of each component (amount, frequency, duration) is safe and effective for the intended population. To satisfy these requirements, the FDA typically requires a clinical factorial
study, designed to assess the effects attributable to each drug in the combination product. This is particularly true when the ingredients are directed at the same sign or symptom of the disease or condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA has accepted a variety of approaches to satisfy the combination rule. In December 2015, the FDA proposed regulations that would allow the agency
to waive the requirements of the combination rule for certain drug products under particular circumstances. The FDA has not, to date, finalized these regulations, but the FDA has stated that factorial studies may be unethical (e.g., omitting a drug
known to improve survival) or impractical (there may be too many components to conduct a factorial study, meaning the trial cannot be conducted). The FDA has also stated that it may be possible to use other types of clinical and nonclinical data and
mechanistic information available to demonstrate the contributions of the individual active ingredients to the effect of the combination. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We
submitted existing preclinical and clinical data for sodium phenylbutyrate, or PB, and TURSO (also known as tauroursodeoxycholic acid, or TUDCA), in our NDA submission and the FDA has indicated it will assess the sufficiency of this information
during our NDA review period. If the FDA disagrees with our data and rationale, it may not approve our NDA for the treatment of ALS, or may require the successful completion of and data from our ongoing Phase 3 PHOENIX trial before issuing an
approval decision. Even if the FDA agrees with our data and rationale, there can be no guarantee that the FDA will issue an approval decision with respect to our NDA submission. Additionally, we will be required to separately satisfy the fixed-dose
combination rule for AMX0035 for the treatment of any other indications we pursue in advance of approval. We have only submitted preclinical data to demonstrate the clinical effects of each component in AMX0035 in our NDS and NDA and intend only to
submit preclinical data supporting this demonstration in our MAA. There can be no assurance that the FDA, Health Canada or the EMA will conclude that our preclinical data are sufficient for these purposes or, even if they are, that the results from
our preclinical studies demonstrate the clinical effects of each component in AMX0035. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Similar requirements may be imposed on us by the EMA in
the EU and comparable regulatory authorities in other jurisdictions where we intend to seek regulatory approval. While no similar combination rule formally exists in Canada, Health Canada has informed us that the contributions of the individual
drugs will be a focus of review and that it will consider the contributions of each component in connection with its review of our NDS. Health Canada has also requested additional information regarding the contributions of the individual drugs to
the overall effect of AMX0035 in connection with the review of our NDS for AMX0035 for the treatment of ALS. While we have provided responses to these information requests, there can be no assurance that Health Canada will find these responses
sufficient and, if such responses are not found to be sufficient, whether Health Canada may require additional, potentially lengthy, non-clinical studies or clinical trials to support a marketing approval. If the FDA, the EMA, Health Canada or other
comparable foreign regulatory authorities require us to conduct one or more clinical trials, such as a factorial study, the design, duration, and scope of such clinical trials will be decided upon after further discussions with those agencies and
other comparable foreign regulatory authorities. As a result, we are unable to predict with certainty the estimated timing or scope of any future clinical trials of AMX0035 we may be required to conduct to satisfy these requirements governing fixed
dose combination products in various jurisdictions. Ongoing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
third-party data in neurology, specifically within ALS, on our products or other products may influence regulatory decision making, including for fixed-dose combinations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have concentrated our research and development efforts on the treatment of neurodegenerative and central nervous system, or CNS, disorders, a field that has
seen very limited success in product development. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have focused our research and development efforts on addressing neurodegenerative and
CNS disorders. Collectively, efforts by pharmaceutical companies in the field of neurodegenerative and CNS disorders have seen very limited successes in product development. The development of neurodegenerative and CNS therapies presents unique
challenges, including an imperfect understanding of the biology, the presence of the blood brain barrier, or BBB, that can restrict the flow of drugs to the brain, a frequent lack of translatability of preclinical study results in subsequent
clinical trials and dose selection, and the product candidate having an effect that may be too small to be detected using the outcome measures selected in clinical trials or if the outcomes measured do not reach statistical significance. There are
few approved therapeutic options available for patients with ALS, AD and other neurodegenerative or CNS disorders. Our future success is highly dependent on the successful development of AMX0035 and any future product candidates for treating
neurodegenerative and CNS disorders. Developing and, if approved, commercializing AMX0035 and any future product candidates for treatment of neurodegenerative and CNS disorders subjects us to a number of challenges, including ensuring that we have
selected the optimal doses, executing an appropriate clinical trial to test for efficacy and obtaining regulatory approval from Health Canada, the FDA, the EMA and other comparable foreign regulatory authorities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The regulatory approval processes of the FDA, Health Canada, the EMA and other comparable foreign authorities are lengthy, time-consuming and inherently
unpredictable, and if we are ultimately unable to obtain regulatory approval for AMX0035 or any future product candidates, our business will be substantially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We, and any future collaborators, are not permitted to commercialize, market, promote or sell any product candidate in the United States, Canada, or the
EU without obtaining regulatory approval from the FDA, Health Canada, or the EMA, respectively. Regulatory authorities in other jurisdictions may have similar requirements. The time required to obtain approval by the FDA, Health Canada, the EMA and
other comparable foreign regulatory authorities is unpredictable, but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including substantial discretion of such regulatory authorities. In
addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#146;s clinical development and may vary among jurisdictions. While we have submitted an
NDS to Health Canada, and an NDA to the FDA, to date, we have not submitted any other similar drug approval submissions to comparable foreign regulatory authorities for AMX0035 or any other product candidate. We have not obtained approval of our NDS
from Health Canada, or our NDA from the FDA, and there can be no assurance that we will receive such approvals. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Clinical testing is expensive,
difficult to design and implement, can take many years to complete and is inherently uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. The clinical development of
AMX0035 for our initial and potential additional indications or any future product candidates is susceptible to the risk of failure inherent at any stage of development, including failure to demonstrate efficacy in a clinical trial or across a broad
population of patients, the occurrence of adverse events that are severe or medically or commercially unacceptable, failure to comply with protocols or applicable regulatory requirements, and determination by the FDA, Health Canada, the EMA or any
other comparable foreign regulatory authority that a product candidate may not continue development or is not approvable. Additionally, our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
expenses could increase if we are required by the FDA, Health Canada, the EMA or any other comparable foreign regulatory authority to perform clinical trials in addition to those currently
expected, or if there are any delays in completing our clinical trials or the development of AMX0035 in additional indications. It is possible that even if AMX0035 or any future product candidate has a beneficial effect, that effect will not be
detected during clinical evaluation as a result of one or more of a variety of factors, including the size, duration, design, measurements, conduct or analysis of our clinical trials. Conversely, as a result of the same factors, our clinical trials
may indicate an apparent positive effect of AMX0035 or any future product candidate that is greater than the actual positive effect, if any. Similarly, in our clinical trials we may fail to detect toxicity of or intolerability caused by AMX0035 or
any future product candidate, or mistakenly believe that AMX0035 or any future product candidates are toxic or not well-tolerated when that is not in fact the case. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">AMX0035 and any of our future product candidates could fail to receive regulatory approval for many reasons, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the FDA, Health Canada, the EMA or other comparable foreign regulatory authorities may disagree as to the design or
implementation of our clinical trials; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may be unable to demonstrate to the satisfaction of the FDA, Health Canada, the EMA or other comparable foreign
regulatory authorities that a product candidate is safe and effective for its proposed indication and, if necessary, that a product candidate and any active components thereof are safe and effective for the proposed indication;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the results of clinical trials may not meet the level of statistical significance required by the FDA, Health Canada, the
EMA or other comparable foreign regulatory authorities for approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may be unable to demonstrate that a product candidate&#146;s clinical and other benefits outweigh its safety risks;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the FDA, Health Canada, the EMA and comparable authorities in other countries may disagree with our interpretation of data
from clinical trials or preclinical studies and may require additional trials or studies to support marketing approval; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the data collected from clinical trials of AMX0035 or any future product candidates may not be sufficient to support the
submission of an NDA or other submission to the FDA or to obtain regulatory approval in Canada, the United States, the EU or elsewhere; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the FDA, Health Canada, the EMA or other comparable foreign regulatory authorities may find deficiencies with clinical
trial sites or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the approval policies or regulations of the FDA, Health Canada, the EMA or other comparable foreign regulatory authorities
may significantly change in a manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This lengthy approval process as
well as the unpredictability of clinical trial results may result in our failing to obtain regulatory approval to market AMX0035 or any future product candidate we develop, which would significantly harm our business, results of operations and
prospects. There is no assurance that the endpoints and trial designs used for the approval of currently approved drugs for the treatment of neurodegenerative diseases will be acceptable for future approvals, including for AMX0035. The FDA, Health
Canada, the EMA and other comparable foreign authorities have substantial discretion in the approval process and determining when or whether regulatory approval will be obtained for any product candidate that we develop. Even if we believe the data
collected from future clinical trials of AMX0035 or any future product candidates are promising, such data may not be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
sufficient to support approval by the FDA or any other regulatory authority. For example, although we believe that the results of our CENTAUR trial demonstrate that the administration of AMX0035
resulted in a statistically significant improvement of both long-term function, as measured by the <FONT STYLE="white-space:nowrap">ALSFRS-R</FONT> score, and survival (based on a longer-term analysis of CENTAUR patients), regulatory authorities may
request additional clinical data. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA reviews an NDA to determine whether the product is safe and effective for its intended use(s), with
the latter determination being made on the basis of substantial evidence. The FDA has interpreted this evidentiary standard to require typically at least two adequate and <FONT STYLE="white-space:nowrap">well-controlled</FONT> clinical
investigations to establish effectiveness of a drug product, although under certain circumstances the FDA has indicated that a single multi-center trial with certain characteristics, or one adequate and
<FONT STYLE="white-space:nowrap">well-controlled</FONT> trial with confirmatory evidence, may also satisfy this standard. Nonetheless, the FDA generally requires two adequate and well controlled Phase 3 clinical trials demonstrating safety and
efficacy before granting marketing approval of a drug product. Accordingly, there is no guarantee that the FDA will grant marketing approval to AMX0035 on the basis of the CENTAUR trial. Even though the FDA has accepted our NDA submission for
review, the FDA may still issue a Complete Response Letter if they otherwise deem our NDA submission to be deficient for approval purposes, which would delay our plans for commercialization even if we are not required to conduct additional trials.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There can be no assurance that the FDA and other regulatory agencies, including Health Canada and the EMA, will not require additional
clinical trials to support an application for the use of AMX0035 in the treatment of ALS or any other indication. This may be the case particularly as these regulatory authorities may consult with one another or as we may be required to apprise the
respective agencies of studies we are conducting of AMX0035 for ALS in conjunction with our requests for marketing approval or in response to requests and updates from the respective agency. Thus, Health Canada and the EMA may also find that our
CENTAUR trial, together with any data from our global Phase 3 PHOENIX trial that may be provided during the review period for these applications, is not sufficient to support our request for marketing authorization in those jurisdictions. It is
typically the case not just in the United States, but also in Canada and Europe, that marketing approvals are based on two Phase 3 clinical studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, disruptions caused by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may increase the likelihood that we encounter
difficulties or delays in initiating, screening, enrolling, conducting, or completing our ongoing and planned preclinical studies and clinical trials. Clinical site initiation and patient screening and enrollment may be delayed due to prioritization
of hospital resources toward the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. Investigators and patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services.
Similarly, our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to <FONT STYLE="white-space:nowrap">COVID-19,</FONT> could be limited, which in turn could
adversely impact our clinical trial operations. Additionally, we may experience interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel, quarantines or social distancing protocols imposed
or recommended by federal or state governments, employers and others in connection with the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. As a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, we may face
delays in meeting our anticipated timelines for our ongoing and planned clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, as of May 26, 2021, the FDA noted it is
continuing to ensure timely reviews of applications for medical products during the ongoing COVID-19 pandemic in line with its user fee performance goals and conducting mission critical domestic and foreign inspections to ensure compliance of
manufacturing facilities with FDA quality standards. However, the FDA may not be able to continue its current pace and approval timelines could be extended, including where a pre-approval inspection or an inspection of clinical sites is required and
due to the ongoing COVID-19 pandemic and travel restrictions the FDA is unable to complete such required inspections during the review period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Since March 2020, when foreign and domestic inspections were largely placed on hold due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the FDA has been working to resume
routine surveillance, bioresearch monitoring and <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections on a prioritized basis. The FDA has developed a rating system to assist in determining when and where it is safest to conduct
prioritized domestic inspections. As of May 2021, certain inspections, such as foreign preapproval, surveillance, and for-cause inspections that are not deemed mission-critical, remain temporarily postponed. In April 2021, the FDA issued industry
guidance formally announcing plans to employ remote interactive evaluations, using risk management methods, to meet user fee commitments and goal dates, and in July 2021, the FDA gradually transitioned into standard operational levels for domestic
surveillance inspections. As of September 2021, ongoing travel restrictions and other uncertainties continue to impact oversight operations. In November 2021, the FDA announced it is currently developing a plan for resuming prioritized foreign
inspections, including surveillance and application-related inspections, starting in February 2022. The FDA is continuing to complete mission-critical work, prioritize other higher-tiered inspectional needs (e.g., for-cause inspections), and carry
out surveillance inspections using risk-based approaches for evaluating public health. Should the FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel,
and the FDA does not determine a remote interactive evaluation to be adequate, the agency has stated that it generally intends to issue a complete response letter or defer action on the application until an inspection can be completed. Further, if
there is inadequate information to make a determination on the acceptability of a facility, the FDA may defer action on the application until an inspection can be completed. In 2020 and 2021, a number of companies announced receipt of complete
response letters due to the FDA&#146;s inability to complete required inspections for their applications. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic and may experience delays in their regulatory activities. For example, with respect to new sites or facilities in the European Economic Area, or EEA, which have never had a current Good
Manufacturing Practices, or cGMP, inspection or authorization, the EMA has stated that a distant assessment may be conducted in order to evaluate if the site could be authorized without an <FONT STYLE="white-space:nowrap">on-site</FONT> <FONT
STYLE="white-space:nowrap">pre-approval</FONT> inspection. If an approval is granted, it should be indicated that the certificate has been granted on the basis of a distant assessment and an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection
should be conducted when circumstances permit. If a cGMP certificate cannot be granted as a result of the distant assessment, a clock-stop in the regulatory approval process will be imposed until an <FONT STYLE="white-space:nowrap">on-site</FONT>
inspection is possible. In addition, even if we were to obtain approval, regulatory authorities may approve AMX0035 or any future product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge
for our products, may grant&nbsp;approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful
commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for AMX0035 or any future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In Canada, <FONT STYLE="white-space:nowrap">pre-approval</FONT> GMP inspections are not performed in association with the NDS. Instead, Health Canada
relies on a Drug Establishment License, or DEL, to determine the site&#146;s compliance with GMP. DELs can only be held by companies in Canada, and that company becomes the importer of record for the drug. To import, the sites of manufacture,
testing and packaging of the Drug Substance and Drug Product are required to be listed on the DEL. Listing is dependent on having an inspection report from a recognized sister regulatory agency such as the EMA or the FDA. As a result of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, inspection reports can now be up to three years old. The site of manufacture of the drug product for AMX0035 is in Canada and is subject to routine inspections from Health Canada. These Canadian
inspections are currently being performed remotely as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the
development and commercialization of AMX0035 or any future product candidates. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To obtain the requisite regulatory approvals to
commercialize any of AMX0035 and any future product candidates, we must demonstrate through extensive preclinical studies and clinical trials that such product candidates are safe and effective in humans. Preclinical and clinical testing are
expensive and can take many years to complete, and their outcome is inherently uncertain. Failure can occur at any time during the clinical trial process and our future clinical trial results may not be successful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may experience delays in completing our clinical trials or preclinical studies and initiating or completing additional clinical trials. We may also
experience numerous unforeseen events during our clinical trials that could delay or prevent our ability to receive marketing approval or commercialize AMX0035 or any future product candidates we develop, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulators, or institutional review boards, or IRBs, or other reviewing bodies may not authorize us or our investigators to
commence a clinical trial, or to conduct or continue a clinical trial at a prospective or specific trial site; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may not reach agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical
trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of subjects or patients required for clinical trials of AMX0035 in an indication or any future product candidate
may be larger than we anticipate, enrollment in these clinical trials may be insufficient or slower than we anticipate, and the number of clinical trials being conducted at any given time may be high and result in fewer available patients for any
given clinical trial, or patients may drop out of these clinical trials at a higher rate than we anticipate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our third-party contractors, including those manufacturing AMX0035 or any future product candidates or conducting clinical
trials on our behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may have to amend clinical trial protocol submitted to regulatory authorities or conduct additional studies to reflect
changes in regulatory requirements or guidance, which we may be required to resubmit to an IRB and regulatory authorities for <FONT STYLE="white-space:nowrap">re-examination;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">unforeseen safety events may occur during the course of a clinical trial and these events may result in the temporary
suspension or termination of a clinical trial, or require urgent safety measures or restrictions to protect human subjects during the conduct of a clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulators, IRBs or other reviewing bodies may fail to approve or subsequently find fault with the manufacturing processes
or facilities of third-party manufacturers with which we enter into agreement for clinical and commercial supplies, or the supply or quality of AMX0035 or any future product candidate or other materials necessary to conduct clinical trials of
AMX0035 or any future product candidates may be insufficient, inadequate or not available at an acceptable cost, or we may experience interruptions in supply; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the potential for approval policies or regulations of Health Canada, the FDA, the EMA or any other applicable foreign
regulatory agencies to significantly change in a manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Regulators, IRBs
of the institutions in which clinical trials are being conducted or data monitoring committees may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory
requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to
demonstrate a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Negative or inconclusive impressions of the results from our earlier clinical trials of AMX0035 for the treatment of ALS or AD, or any other clinical
trial or preclinical studies in animals that we have conducted, could mandate repeated or additional preclinical studies or clinical trials and could delay marketing approvals or result in changes to or delays in preclinical studies or clinical
trials of AMX0035 in other indications. We do not know whether any clinical trials that we may conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market AMX0035 for our initial or potential additional
indications, or any future product candidate. If later stage clinical trials, including our ongoing global Phase 3 PHOENIX trial in ALS, do not produce favorable results with very strong statistical significance, our ability to obtain regulatory
approval for AMX0035 for ALS or potential additional indications, or any future product candidate, may be adversely impacted. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our failure to
successfully initiate and complete clinical trials of AMX0035 for ALS, AD or potential additional indications and to demonstrate the efficacy and safety of AMX0035, including each component thereof; necessary to obtain regulatory approval to market
AMX0035 would significantly harm our business. Our product candidate development costs will also increase if we experience delays in testing or regulatory approvals and we may be required to obtain additional funds to complete clinical trials. We
cannot assure you that our clinical trials will begin as planned or be completed on schedule, if at all, or that we will not need to restructure our trials after they have begun. Significant clinical trial delays also could shorten any periods
during which we may have the exclusive right to commercialize AMX0035 or any future product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize such product candidates,
which may harm our business and results of operations. In addition, many of the factors that cause, or lead to, delays of clinical trials may ultimately lead to the denial of regulatory approval of AMX0035 or any future product candidate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may
prevent us or any future collaboration partners from obtaining approvals for the commercialization of AMX0035 or maintaining any conditional authorization for our initial or potential additional indications as well as for any future product
candidate we develop. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any product candidate we may develop and the activities associated with its development and commercialization,
including its design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, and distribution, are subject to comprehensive regulation by Health Canada, the FDA, the EMA and other regulatory
authorities in the United States and in other countries. Failure to obtain marketing approval for a product candidate will prevent us from commercializing that product candidate in a given jurisdiction. We have not received approval to market any
product candidates from regulatory authorities in any jurisdiction and it is possible that none of the product candidates we may seek to develop in the future will ever obtain regulatory approval. We have no experience in filing and supporting the
applications necessary to gain marketing approvals and expect to rely on third-party CROs or regulatory consultants to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and
supporting information to the various regulatory authorities for each therapeutic indication to establish the biologic product candidate&#146;s safety, purity, efficacy and potency. Securing regulatory approval also requires the submission of
information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Any product candidates we develop may not be effective, may be only moderately effective, or may prove to have
undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The process of obtaining marketing approvals, in the United States, Canada, EU and other foreign
jurisdictions, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity, and novelty of the product
candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in
the approval or rejection of an application. The FDA, Health Canada, the EMA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide during the review
process that our data are insufficient for approval and require additional preclinical, clinical or other studies. For example, Health Canada and the FDA have requested clarifying information regarding our preclinical and clinical data. In addition,
varying interpretations of the data obtained from preclinical and clinical testing could delay, limit, or prevent marketing approval of a product candidate. For example, based on dialogue with the FDA, we made our NDA submission to the FDA without
including data from our ongoing Phase&nbsp;3 PHOENIX trial; however, the FDA or other regulatory authorities may disagree with our data or rationale, or both, and thus may not approve our NDA for the treatment of ALS, or may require completion of
our ongoing Phase 3 PHOENIX global clinical trial prior to issuing an approval decision for our marketing applications for AMX0035. Additionally, the FDA has discretion to refer an application for a novel drug or a drug that presents difficult
questions of safety or efficacy to an advisory committee. The FDA has notified us that it plans to hold an advisory committee meeting to discuss our application. While no such meeting has been scheduled, it is unknown whether scheduling such meeting
in the future could lead to delays in the FDA&#146;s review or the planned timing for taking action on our application. It is also unknown whether any such advisory committee meeting, if held, would yield an unfavorable recommendation on the
FDA&#146;s approval of our application which could materially harm the outcome of the FDA&#146;s review of our application and lead to a complete response letter. As such, we may be unable to obtain the marketing approvals we pursue and any
marketing approvals we ultimately obtain, including any conditional approvals, may be limited or subject to restrictions or post-approval commitments that could render the approved product not commercially viable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we experience delays in obtaining approval or if we fail to obtain approval of any product candidates we may develop, the commercial prospects for
those product candidates, including for AMX0035 in other indications, may be harmed, and our ability to generate revenues will be materially impaired. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The
results of early-stage clinical trials and preclinical studies may not be predictive of future results. Initial data in our clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The results of preclinical studies may not be predictive of the results of clinical trials, and the results of any early-stage clinical
trials we commence may not be predictive of the results of the later-stage clinical trials. In addition, initial data in clinical trials may not be indicative of results obtained when such trials are completed. There can be no assurance that any of
our clinical trials will ultimately be successful or support further clinical development of AMX0035 or any future product candidates. There is a high failure rate for drugs and biologics proceeding through clinical trials. A number of companies in
the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies, and any such setbacks in our clinical development could have a material adverse
effect on our business and operating results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, we may utilize an &#147;open-label&#148; clinical trial design. An
&#147;open-label&#148; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most open-label clinical trials test
only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware
when they are receiving treatment. Open-label clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
trials may be subject to a &#147;patient bias&#148; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition,
open-label clinical trials may be subject to an &#147;investigator bias&#148; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information
of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with AMX0035 or any future product candidates when studied in a controlled environment with a
placebo or active control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Interim topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more
patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From time to time, we may publish interim topline or preliminary data from our clinical trials. Interim data from clinical trials that we may complete
are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or topline results also remain subject to audit and verification procedures
that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between
preliminary or interim data and final data could significantly harm our reputation and business prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Enrollment and retention of patients in clinical
trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Patient enrollment is a significant factor in the timing of clinical trials, and the timing of our clinical trials depends, in part, on the speed at
which we can recruit patients to participate in our trials, as well as completion of required <FONT STYLE="white-space:nowrap">follow-up</FONT> periods. We may not be able to initiate or continue clinical trials for AMX0035 or any future product
candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials to such trial&#146;s conclusion as required by Health Canada, the FDA, the EMA or other comparable foreign regulatory
authorities. Additionally, certain clinical trials for AMX0035 and any future product candidates may be focused on indications with relatively small patient populations, which may further limit enrollment of eligible patients or may result in slower
enrollment than we anticipate. The eligibility criteria of our clinical trials, once established, may further limit the pool of available trial participants. For example the number of patients suffering from ALS, is small and, in some cases, has not
been established with precision. If the actual number of patients with these diseases is smaller than we anticipate, we may encounter difficulties in enrolling patients in our clinical trials, thereby delaying or preventing development and approval
of AMX0035 or any future product candidates. Even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials. For example, ALS patients have significant mobility issues, morbidities and other
complications that have historically made retention in ALS trials, more challenging. These challenges are also present with many other neurodegenerative indications, including indications for which we may run clinical trials in the future. In the
past, we have had discontinuations in our clinical trials, including in our CENTAUR trial and <FONT STYLE="white-space:nowrap">CENTAUR-OLE</FONT> trial. Discontinuations may occur in the future and could result in delays of our clinical trials and
affect our ability to enroll additional patients in our clinical trials and impact the integrity of data from our clinical trials. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Patient
enrollment and retention in clinical trials depends on many factors, including the size of the patient population, the severity of the disease under investigation, the nature of the trial protocol, the existing body of safety and efficacy data for
the product candidate, the number and nature of competing treatments and ongoing clinical trials of competing therapies for the same indication, the proximity of patients to clinical sites, the eligibility criteria for the trial, the ability to
adequately monitor patients during a trial, clinicians&#146; and patients&#146; perceptions as to the potential advantages of the product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
candidate being studied, and the risk that patients will drop out of a trial before completing all site visits. There are limited patient pools from which to draw in order to complete our
clinical trials in a timely and cost-effective manner, including due to the fact that the neurological diseases we target are rare. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Furthermore,
our efforts to build relationships with patient communities may not succeed, which could result in delays in patient enrollment in our clinical trials.<STRIKE></STRIKE> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any negative results we may report in clinical trials of AMX0035 or any future product candidate may also make it difficult or impossible to recruit and
retain patients in other clinical trials of that same product candidate. Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop
AMX0035 in ALS, AD and additional indications and any future product candidates, or could render further development impossible. For example, the impact of public health epidemics, such as the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic, may delay or prevent patients from enrolling or from receiving treatment in accordance with the protocol and the required timelines, which could delay our clinical trials, or prevent us or our partners from completing our clinical trials
at all, and harm our ability to obtain approval for such product candidate. Further, if patients drop out of our clinical trials, miss scheduled doses or <FONT STYLE="white-space:nowrap">follow-up</FONT> visits, or otherwise fail to follow clinical
trial protocols, whether as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and related illness or actions taken to slow the spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> or otherwise, the integrity of data
from our clinical trials may be compromised or not accepted by Health Canada, the FDA, the EMA or other regulatory authorities, which would represent a significant setback for the applicable program. In addition, we may rely on CROs and clinical
trial sites to ensure proper and timely conduct of our future clinical trials and, while we intend to enter into agreements governing their services, we will be limited in our ability to compel their actual performance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As product candidates proceed through preclinical studies to late-stage clinical trials towards potential approval and commercialization, it is common
that various aspects of the development activities, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results. Any of these changes could cause AMX0035 or any future product candidates to
perform differently and affect the results of ongoing clinical trials or other future clinical trials conducted with the materials manufactured using altered processes. For example, if approved, we intend to commercialize a different formulation of
AMX0035 from the formulation evaluated in the CENTAUR trial. This change may lead the FDA and other regulatory authorities to delay the approval of our marketing applications until we can demonstrate through additional clinical data that there is
comparability in the bioavailability of the two different formulations or may require us to revert to the prior formulation of AMX0035 evaluated in the CENTAUR trial. Should we have to conduct comparability testing to bridge earlier clinical data
obtained from AMX0035 produced under earlier manufacturing methods or formulations with the planned commercial formulation, regulatory authorities may disagree on the interpretation of results from this testing. This could delay completion of
clinical trials, require the repetition of one or more clinical trials, increase clinical trial costs, delay approval of AMX0035 or any future product candidates and jeopardize our ability to commence sales and generate revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>AMX0035 or any future product candidate may cause undesirable side effects or have other properties that could delay or prevent its regulatory approval, limit the
commercial profile of an approved label, or result in significant negative consequences following regulatory approval, if obtained. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Undesirable side effects caused by AMX0035, or any future product candidate, could cause us or regulatory authorities to interrupt, delay or halt
clinical trials and could result in a more restrictive label </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
or the delay or denial of regulatory approval by the FDA, Health Canada, the EMA or comparable foreign regulatory authorities. Results of our clinical trials could reveal a high and unacceptable
severity and prevalence of side effects or unexpected characteristics. In clinical trials of AMX0035 to date, AMX0035 has been generally well-tolerated, with most common treatment-emergent adverse events including diarrhea, nausea, constipation,
headache, fatigue, proteinuria, and decreased appetite. Health Canada has additionally identified hypersalivation as an additional treatment-emergent adverse event in need of being addressed. However, there can be no guarantee that we would observe
a similar tolerability profile of AMX0035 in our ongoing global Phase 3 PHOENIX clinical trial or in other future clinical trials. Many compounds that initially showed promise in clinical or earlier stage testing are later found to cause undesirable
or unexpected side effects that prevented further development of the compound. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If unacceptable side effects arise in the development of AMX0035 or
any future product candidates, we, the FDA, Health Canada, the EMA or comparable foreign regulatory authorities, the IRBs, or independent ethics committees at the institutions in which our trials are conducted, or the independent safety monitoring
committee could suspend or terminate our clinical trials or regulatory authorities could order us to cease clinical trials or deny approval of AMX0035 or any future product candidates for any or all targeted indications. Treatment-emergent side
effects that are deemed to be drug-related could also affect subject recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. Undesirable side effects in one of our clinical trials for
AMX0035 in one indication could adversely affect enrollment in clinical trials, regulatory approval and commercialization of AMX0035 in other indications. Additionally, there may be negative findings regarding components of AMX0035 or future product
candidates by other parties. For example, Humanitas Mirasole SpA, or Humanitas, is conducting a Phase 3 clinical trial in the EU to assess the safety and efficacy of TURSO in patients with ALS which may lead to additional findings as to the safety
profile of TURSO. Any negative findings by third parties may impact the future approvability or labeling of AMX0035 or other product candidates we may develop. In addition, side effects may not be appropriately recognized or managed by the treating
medical staff. We have no relationship with Humanitas. If their Phase&nbsp;3 clinical trial is successful and TURSO is approved by the FDA or any other regulatory agency, TURSO may become a commercialized product competitive with AMX0035, unless our
intellectual property protections and any regulatory exclusivities we possess or may possess in the future prevent such commercialization. Inadequate training in recognizing or managing the potential side effects of AMX0035 or any future product
candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Bitter taste was frequently observed in our clinical trials of AMX0035. While bitter taste, by itself, does not present a safety risk for patients, it
may lead to higher levels of patient <FONT STYLE="white-space:nowrap">non-compliance,</FONT> which could have the effect of reducing the observed efficacy of AMX0035 in our clinical trials, including our ongoing global Phase 3 PHOENIX trial, or
limit its commercial adoption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, clinical trials of AMX0035 are conducted in carefully defined sets of patients who have agreed to enter
into clinical trials. Consequently, it is possible that our clinical trials, or those of any future collaborator, may indicate an apparent positive effect of AMX0035 or a future product candidate that is greater than the actual positive effect, if
any, or alternatively fail to identify undesirable side effects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Finally, AMX0035 is a combination of TURSO and PB. PB has been approved by the FDA
and other regulatory authorities for the treatment of patients with certain urea cycle disorders and TURSO has been approved in Italy for diseases of cirrhotic liver disorders such as primary biliary cirrhosis. It is possible that one or more of the
active moieties in AMX0035 has also been approved by FDA or other regulatory authorities. Even if AMX0035 were to receive marketing approval or be commercialized, we would continue to be subject to the risks that the FDA, EMA or similar regulatory
authorities could revoke approval of PB or TURSO or any active moiety in AMX0035, if applicable, or that efficacy, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
manufacturing or supply issues could arise with PB or TURSO or any active moiety in AMX0035, if applicable. This could result in our own products being removed from the market or being less
commercially successful. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Increasing demand for expanded access to AMX0035 could negatively affect our reputation and harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are developing AMX0035 for the treatment of ALS, AD and other potential future indications for which there are currently limited or no available
therapeutic options. It is possible for individuals or groups to target companies with disruptive social media campaigns related to a request for access to unapproved drugs for patients with significant unmet medical need. If we experience a similar
social media campaign regarding our decision to provide or not provide access to AMX0035 or any of our future product candidates under an expanded access policy, our reputation may be negatively affected and our business may be harmed. We are
preparing to submit an expanded access program to the FDA for launch in the United States in the coming months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Recent media attention to
individual patients&#146; expanded access requests has resulted in the introduction and enactment of legislation at the local and national level, including the recently enacted Accelerating Access to Critical Therapies for ALS Act and prior
&#147;Right to Try&#148; laws, such as the federal Right to Try Act of 2017, which are intended to allow patients access to unapproved therapies earlier than traditional expanded access programs and the former of which is intended to support
research and development related to ALS, specifically. A possible consequence of both activism and legislation in this area may be the need for us to initiate an expanded access program beyond that which we are preparing to submit to the FDA or to
make AMX0035 or any future product candidates more widely available sooner than anticipated. We are a small company with limited resources and unanticipated trials or access programs could result in diversion of resources from our primary goals.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, some patients who receive access to drugs prior to their commercial approval through compassionate use, expanded access programs
or right to try access have life-threatening illnesses and have exhausted all other available therapies. The risk for serious adverse events in this patient population is high, which could have a negative impact on the safety profile of AMX0035 or
future product candidates if we were to provide them to these patients, which could cause significant delays or an inability to successfully commercialize AMX0035 or future product candidates, which could materially harm our business. If we were to
provide patients with AMX0035 under an expanded access program, we may in the future need to restructure or pause any compassionate use and/or expanded access programs in order to perform the controlled clinical trials required for regulatory
approval and successful commercialization of AMX0035 or future product candidates, which could prompt adverse publicity or other disruptions related to current or potential participants in such programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The increasing use of social media platforms presents new risks and challenges. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Social media is increasingly being used to communicate about our clinical development activities and the diseases AMX0035 is being developed to treat,
and we intend to utilize appropriate social media in connection with our commercialization efforts following approval of AMX0035, if any. Social media practices in the biotechnology and biopharmaceutical industries continue to evolve and regulations
and regulatory guidance relating to such use are evolving and not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us, along
with the potential for litigation related to <FONT STYLE="white-space:nowrap">off-label</FONT> marketing or other prohibited activities and heightened scrutiny by the FDA, the SEC and other regulators. For example, patients may use social media
channels to comment on their experience in an ongoing blinded clinical trial or to report an alleged adverse event. If such disclosures occur, there is a risk that trial enrollment may be adversely impacted, that we may fail to monitor and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
comply with applicable adverse event reporting obligations or that we may not be able to defend our business or the public&#146;s legitimate interests in the face of the political and market
pressures generated by social media due to restrictions on what we may say about our product candidates. There is also a risk of inappropriate disclosure of sensitive or confidential information or negative or inaccurate posts or comments about us
on any social networking website. In addition, we may encounter attacks on social media regarding our company, management, AMX0035 or future product candidates. If any of these events were to occur or we otherwise fail to comply with applicable
regulations, we could incur liability, face regulatory actions or incur other harm to our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we fail to develop and commercialize AMX0035 for
additional indications or fail to discover, develop and commercialize other product candidates, we may be unable to grow our business and our ability to achieve our strategic objectives would be impaired. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Although the development and commercialization of AMX0035 for the treatment of ALS is our current primary focus, as part of our longer-term growth
strategy, we plan to evaluate AMX0035 in other indications and develop other product candidates. We intend to evaluate internal opportunities from AMX0035 or other potential product candidates, and also may choose to
<FONT STYLE="white-space:nowrap">in-license</FONT> or acquire other product candidates as well as commercial products to treat patients suffering from neurodegenerative diseases and CNS or other disorders with significant unmet medical needs and
limited treatment options. These other potential product candidates will require additional, time-consuming development efforts prior to commercial sale, including preclinical studies, clinical trials and approval by the FDA, Health Canada, the EMA
and/or other applicable foreign regulatory authorities. All product candidates are prone to the risks of failure that are inherent in pharmaceutical product development, including the possibility that the product candidate will not be shown to be
sufficiently safe and effective for approval by regulatory authorities. In addition, we cannot assure you that any such products that are approved will be manufactured or produced economically, successfully commercialized or widely accepted in the
marketplace or be more effective than other commercially available alternatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Research activities to identify product candidates require
substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Our research activities may initially show promise in identifying potential product candidates, yet fail to yield product
candidates for clinical development for many reasons, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the research methodology used may not be successful in identifying potential product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">competitors may develop alternatives that render our potential product candidates obsolete; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">product candidates that we develop may nevertheless be covered by third parties&#146; patents or other exclusive rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a product candidate may, on further study, be shown to have harmful side effects or other characteristics that indicate it
is unlikely to be effective or otherwise does not meet applicable regulatory criteria; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are unsuccessful in identifying and developing additional product candidates, our potential for growth and achieving our
strategic objectives may be impaired. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may not be successful in our efforts to expand our pipeline by identifying additional indications and
modifications for which to investigate AMX0035 in the future. We may expend our limited resources to pursue a particular indication or formulation for AMX0035 and fail to capitalize on product candidates, indications or formulations that may be more
profitable or for which there is a greater likelihood of success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Because we have limited financial and managerial resources, we are focused
on specific indications and modifications for AMX0035. As a result, we may fail to generate additional clinical development opportunities for AMX0035 for a number of reasons, including, that AMX0035 may in certain indications, on further study, be
shown to have harmful side effects, limited to no efficacy, or other characteristics that suggest it is unlikely to receive marketing approval and achieve market acceptance in such additional indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We plan to conduct several clinical trials for AMX0035 in parallel over the next several years, including multiple clinical trials in patients with ALS
and other indications, which may make our decision as to which indication to focus on more difficult. As a result, we may forgo or delay pursuit of opportunities with other indications that could have had greater commercial potential or likelihood
of success. In addition, we plan to explore the use of AMX0035 in patients with Wolfram syndrome and other indications. However, we may focus on or pursue one or more of our target indications over other potential indications and such development
efforts may not be successful, which would cause us to delay the clinical development and approval of AMX0035. Furthermore, research activities to identify additional indications for AMX0035 require substantial technical, financial, and human
resources. We may not successfully develop these additional modifications for chemistry-related, stability-related, or other reasons. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable
market opportunities. Our spending on current and future research and development activities for specific indications may not yield any commercially viable products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, we may pursue <FONT STYLE="white-space:nowrap">in-licenses</FONT> or acquisitions of development-stage assets or programs, which entails
additional risk to us. Identifying, selecting and acquiring promising product candidates requires substantial technical, financial, and human resources expertise. Efforts to do so may not result in the actual acquisition or license of a particular
product candidate, potentially resulting in a diversion of our management&#146;s time and the expenditure of our resources with no resulting benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For example, if we are unable to identify programs that ultimately result in approved products, we may spend material amounts of our capital and other
resources evaluating, acquiring and developing products that ultimately do not provide a return on our investment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Competitive products may reduce or
eliminate the commercial opportunity for AMX0035 for our current or future indications. If our competitors develop technologies or product candidates more rapidly than we do, or their technologies or product candidates are more effective or safer
than ours, our ability to develop and successfully commercialize AMX0035 may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The clinical and commercial landscape
for the treatment of ALS and other neurodegenerative diseases, including AD is highly competitive and subject to rapid and significant technological change. We face competition with respect to our current indications for AMX0035 and will face
competition with respect to any future indications of AMX0035 or other drug candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies
worldwide. For example, Humanitas Mirasole SpA is currently conducting a Phase 3 clinical trial in the EU to assess the safety and efficacy of TURSO in patients with ALS, which, if approved, may be commercialized as a competitor to AMX0035. If this
study meets its clinical endpoints, this monotherapy treatment could be approved by the FDA, the EMA and other regulatory authorities, and TURSO may become a commercialized product competitive with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
AMX0035, unless our intellectual property protections and any regulatory exclusivities we possess or may possess in the future prevent such commercialization. There are also a number of large
pharmaceutical and biotechnology companies that currently market and sell drugs or are pursuing the development of drug candidates for the treatment of the indications that we are pursuing. Potential competitors also include academic institutions,
government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Several large pharmaceutical companies market <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drugs for the treatment of ALS. These drugs include:
Riluzole, marketed by Sanofi-Aventis U.S. LLC, and Radicava, marketed by Mitsubishi Tanabe Pharma America, Inc. Additionally, Mitsubishi Tanabe Pharma America, Inc. is developing an oral alternative to Radicava with the potential for a near-term NDA
submission. Our potential competitors include pharmaceutical and biotechnology companies, such as Biogen, Inc., Orphazyme A/S, Biohaven Pharmaceutical Holding Co Ltd., UCB S.A., Alexion Pharmaceuticals, Inc. and Apellis Pharmaceuticals, Inc.,
specialty pharmaceutical and generic drug companies, academic institutions, government agencies and research institutions. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Many of our
competitors have significantly greater financial resources, established presence in the market, expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing
approved products than we do. Accordingly, our competitors may be more successful than we may be in obtaining regulatory approval for therapies and achieving widespread market acceptance. Our competitors&#146; products may be more effective, or more
effectively marketed and sold, than any product candidate we may commercialize and may render AMX0035 or any future product candidates obsolete or <FONT STYLE="white-space:nowrap">non-competitive</FONT> before we can recover development and
commercialization expenses. If AMX0035 is approved for the indications we are currently pursuing, it could compete with a range of therapeutic treatments that are in development. In addition, our competitors may succeed in developing, acquiring or
licensing technologies and drug products that are more effective or less costly than AMX0035 or any future product candidates that we may develop, which could render such product candidates obsolete and noncompetitive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we obtain approval for AMX0035 or any other future product candidate, we may face competition based on many different factors, including the
efficacy, safety and tolerability of our products, the ease with which our products can be administered, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities,
price, reimbursement coverage and patent position. Existing and future competing products could present superior treatment alternatives, including being more effective, safer, less expensive or marketed and sold more effectively than any products we
may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. Such competitors could also recruit our employees, which could
negatively impact our level of expertise and our ability to execute our business plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, our competitors may obtain patent protection,
regulatory exclusivities or regulatory approval and commercialize products more rapidly than we do, which may impact future approvals or sales of any of our product candidates that receive regulatory approval. If Health Canada, the FDA or the EMA
approves the commercial sale of AMX0035 or any future product candidate, we will also be competing with respect to marketing capabilities and manufacturing efficiency. We expect competition among products will be based on product efficacy and
safety, the timing and scope of regulatory approvals, availability of supply, marketing and sales capabilities, product price, reimbursement coverage by government and private third-party payors, regulatory exclusivities and patent position. Our
profitability and financial position will suffer if our product candidates receive regulatory approval, but cannot compete effectively in the marketplace. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more
resources being concentrated among a smaller number of our competitors. Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These
third parties compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites, as well as in acquiring technologies complementary to, or necessary for, our activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Off-label use for the treatment of ALS of sodium phenybutyrate, or PB, which is available as a generic drug, along with the potential sale in some jurisdictions
of TURSO, which preparations are of unknown identity and may not be legally sold for the treatment of ALS, expose us to additional risks that could reduce or eliminate the commercial opportunity for AMX0035. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are developing AMX0035 as a combination of TURSO and PB. PB has been approved by the FDA and other regulatory authorities for the treatment of
patients with certain urea cycle disorders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">TURSO is being marketed in preparations of unknown identity and without approval for the treatment of
ALS in some jurisdictions, including the United States. We face the risk that healthcare professionals may prescribe PB for the treatment of ALS and recommend that patients obtain a commercial preparation of TURSO not labeled or marketed for the
treatment of ALS on the belief that this combination could replicate the benefits of AMX0035. Patient-directed treatment with TURSO for ALS may also arise in certain jurisdictions if the Phase 3 clinical trial to assess the safety and efficacy of
TURSO in patients with ALS conducted by Humanitas Mirasole SpA in the EU reports positive results. While these practices are not recommended by the medical community and have not been approved by any regulatory authority, they may nonetheless impact
our sales of AMX0035, if approved, and/or public perception of AMX0035 in the United States or abroad. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If the FDA, Health Canada, the EMA or other
comparable foreign regulatory authorities approve generic versions of AMX0035 or any future product candidate of ours that receives regulatory approval, or such authorities do not grant our products appropriate periods of <FONT
STYLE="white-space:nowrap">non-patent</FONT> exclusivity before approving generic versions of such products, the sales of such products could be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United States, once an NDA is approved, the product covered thereby becomes a &#147;reference listed drug&#148; in the FDA&#146;s publication,
&#147;<I>Approved Drug Products with Therapeutic Equivalence Evaluations</I>,&#148; or the Orange Book. Manufacturers may seek approval of generic versions of reference listed drugs through submission of abbreviated new drug applications, or ANDAs,
in the United States. In support of an ANDA, a generic manufacturer generally must show that its product has the same active ingredient(s), dosage form, strength, route of administration, and adequate labeling as the reference listed drug and that
the generic version is bioequivalent to the reference listed drug, meaning, in part, that it is absorbed in the body at the same rate and to the same extent. Generic products may be significantly less costly to bring to market than the reference
listed drug and companies that produce generic products are generally able to offer them at lower prices. Moreover, many states allow or require substitution of therapeutically equivalent generic drugs at the pharmacy level even if the branded drug
is prescribed. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference listed drug may be lost to the generic product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA may not finally approve an ANDA for a generic product until any applicable period of <FONT STYLE="white-space:nowrap">non-patent</FONT>
exclusivity for the reference listed drug has expired. The FDCA provides a period of five years of <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity for a new drug containing a new chemical entity, or NCE. For the purposes of this
provision, an NCE is a drug that contains no active moiety that has previously been approved by the FDA in any other NDA. An active moiety is the molecule or ion responsible for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
physiological or pharmacological action of the drug substance. Specifically, in cases where such exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five
years unless the submission is accompanied by a Paragraph IV certification that a patent covering the listed drug is invalid, unenforceable or will not be infringed by the generic product. In that case, the applicant may submit its application four
years following approval of the listed drug and seek to launch its generic product even if we still have patent protection for our product unless an infringement suit is timely filed by the NDA or patent holder in which case the FDA cannot approve
the ANDA for 30 months unless a court decision in favor of the generic manufacturer is issued earlier. For fixed dose combination products, the FDA has taken the position that a combination product will be eligible for NCE exclusivity (also known as
data exclusivity) if it contains a new active moiety, even if the fixed-combination also contains a drug substance with a previously approved active moiety. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA may determine, however, that AMX0035 is not eligible for NCE exclusivity, if and when FDA approves an NDA for the product. For example, even
under its fixed dose combination product policies, the FDA may find that the active moieties in AMX0035 have been previously approved and, therefore, NCE exclusivity is not available for AMX0035. The regulatory authorities in Canada and Europe may
reach the same conclusions as the FDA since the determination of data exclusivity for new drug products in those jurisdictions is very similar to that of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If any product we develop does not receive five years of NCE exclusivity, the FDA may approve generic versions of such product three years after its
date of approval, subject to the requirement that the ANDA applicant certifies to the invalidity or <FONT STYLE="white-space:nowrap">non-infringement</FONT> of any patents listed for our products in the Orange Book. If an infringement suit is timely
filed by the NDA or patent holder, the FDA cannot finally approve the ANDA for 30 months unless a court decision in favor of the generic manufacturer is issued earlier. Three-year exclusivity is given to a drug if it contains an active moiety that
has previously been approved, and the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the NDA.
This form of data exclusivity is known as New Clinical Investigation, or NCI, exclusivity. If AMX0035 is approved with only NCI exclusivity, generic manufacturers may file their ANDAs anytime following approval of AMX0035 and seek to launch their
generic products following the expiration of the three year market exclusivity period, even if we still have patent protection for our product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In
addition, in the United States the FDCA provides a period of seven years of orphan drug exclusivity for drugs that treat small patient populations less than 200,000 patients or for which there are more than 200,000 patients but there is no
reasonable expectation that the cost of developing and making the drug for such disease or condition will be recovered from sales in the United States of such drug. If AMX0035 is granted orphan drug exclusivity, the FDA cannot finally approve a
generic or a brand product that contains the same active moiety for the same orphan indication as AMX0035, for a period of seven years, subject to certain exceptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In Canada, we were notified that Health Canada preliminarily regards AMX0035 as a New Active Substance. However, a final determination is not made until
the date of a potential Notice of Compliance (approval), or NOC. Once defined as a New Active Substance, the drug product is given eight years of data exclusivity. For the first six years, a generic product cannot be filed. After six years, a
generic product can be filed, but the NOC cannot be granted for eight years. There is no regulatory provision in Canada that provides orphan drug exclusivity to approved products for rare diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the EU, innovative medicinal products (including both small molecules and biological medicinal products), sometimes referred to as new active
substances, qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity. The data exclusivity, if granted, prevents generic or biosimilar applicants from referencing the innovator&#146;s
preclinical and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization, for a period of eight years from the date on which the
reference product was first authorized in the EU. During the additional <FONT STYLE="white-space:nowrap">two-year</FONT> period of market exclusivity, a generic or biosimilar marketing authorization can be submitted, and the innovator&#146;s data
may be referenced, but no generic or biosimilar product can be marketed until the expiration of the market exclusivity period. This <FONT STYLE="white-space:nowrap">10-year</FONT> marketing exclusivity period may be extended to 11 years if, during
the first eight of those 10 years, the marketing authorization holder obtains an approval for one or more new therapeutic indications that bring significant clinical benefits compared with existing therapies. However, even if an innovative medicinal
product gains the prescribed period of data exclusivity, another company may market another version of the product if such company obtained a marketing authorization based on an application with a complete and independent data package of
pharmaceutical tests, preclinical tests and clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Competition that AMX0035 or any future products, if approved, may face from generic
versions of such products could negatively impact our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on our investments in those product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We currently have limited marketing, sales or distribution infrastructure. If we are unable to fully develop our sales, marketing and distribution capability on
our own or through collaborations with marketing partners, we may not be successful in commercializing our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are
currently building our marketing, sales or distribution capabilities. We have not commercialized or marketed any products to date. If AMX0035 is approved for the treatment of ALS, AD, or other future indications, we will need to expand our sales and
marketing organization, either on our own or in collaboration with third parties, and add further technical expertise and supporting distribution capabilities to commercialize the approved product in key territories, which will require substantial
additional resources. Some or all of these costs may be incurred in advance of any approval of AMX0035. Any failure or delay in the development of our or third parties&#146; internal sales, marketing and distribution capabilities would adversely
impact the commercialization of AMX0035 and other future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Factors that may inhibit our efforts to commercialize our products on
our own include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our inability to recruit and retain adequate numbers of effective sales and marketing personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the inability of sales personnel to obtain access to or persuade adequate numbers of physicians to prescribe any future
products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage
relative to companies with more extensive product lines; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">unforeseen costs and expenses associated with building out an independent sales and marketing organization.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">With respect to our existing and future product candidates, we may choose to collaborate with third parties that have direct
sales forces and established distribution systems to serve as an alternative to our own sales force and distribution systems. Our product revenue may be lower than if we directly marketed or sold our products, if approved. In addition, any revenue
we receive will depend in whole or in part upon the efforts of these third parties, which may not be successful and are generally not within our control. If we are not successful in commercializing any approved products, our future product revenue
will suffer and we may incur significant additional losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we do not expand our sales and marketing capabilities successfully, either on our
own or in collaboration with third parties, we will not be successful in commercializing AMX0035 or any future product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Any of our current and future product candidates for which we, or any future collaborators, obtain regulatory
approval in the future will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. If approved, AMX0035 and any future product candidates could be subject to post-marketing restrictions
or withdrawal from the market and we, or any future collaborators, may be subject to substantial penalties if we, or they, fail to comply with regulatory requirements or if we, or they, experience unanticipated problems with our products following
approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">AMX0035 or any future product candidates for which we, or any future collaborators, obtain regulatory approval, as well as the
manufacturing processes, post-approval studies, labeling, advertising and promotional activities for such product, among other things, will be subject to ongoing requirements of and review by the FDA, Health Canada, the EMA and other applicable
regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance and
corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. For certain commercial prescription drug products, manufacturers and other parties involved in the supply chain
must also meet chain of distribution requirements and build electronic, interoperable systems for product tracking and tracing and for notifying the FDA of counterfeit, diverted, stolen and intentionally adulterated products or other products that
are otherwise unfit for distribution in the United States. We and our contract manufacturers will also be subject to user fees and periodic inspection by regulatory authorities to monitor compliance with these requirements and the terms of any
product approval we may obtain. Even if regulatory approval of a product candidate is granted, the approval may be subject to limitations on the indications or uses for which the product may be marketed or to the conditions of approval, including
the requirement in the United States to implement a Risk Evaluation and Mitigation Strategy, or REMS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA, Health Canada, the EMA and other
regulatory authorities may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. For example, the FDA and other agencies, including the Department of Justice,
closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling.
Regulatory authorities impose stringent restrictions on manufacturers&#146; communications regarding <FONT STYLE="white-space:nowrap">off-label</FONT> use. However, companies generally may share truthful and not misleading information that is
otherwise consistent with a product&#146;s approved labeling. If we, or any future collaborators, do not market AMX0035 or any of our future product candidates for which we, or they, receive regulatory approval for only their approved indications,
we, or they, may be subject to warnings or enforcement action for <FONT STYLE="white-space:nowrap">off-label</FONT> marketing if it is alleged that we are doing so. Violation of laws and regulations relating to the promotion and advertising of
prescription drugs may lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws, including the False Claims Act and any comparable foreign laws. In the EU, the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising of prescription-only medicinal products is prohibited. Violations of the rules governing the promotion of medicinal products in the EU could be
penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising and promotion of our products to the general public, and may also impose limitations on our promotional activities with health
care professionals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Post-marketing</FONT> requirements in Canada are similar to those in the United States. If an
NDS is approved, Health Canada will require that we submit a Risk Management Plan, or RMP. Health Canada may, as part of the RMP, require that we use a registry or limited distribution channels or conduct additional clinical studies. Standard
pharmacovigilance activities will also be required for any approved NDS. Any labelling changes or changes in the product supply chain would need to be submitted and approved by Health Canada. Advertising will be monitored, and will routinely be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
reviewed by the Pharmaceutical Advertising Advisory Board. Reimbursement in Canada is complex and will require submissions to both public and private payors to gain access to prescription drug
formulary lists. In addition, if there are any patents associated with AMX0035, the product will be subject to the Patented Medicine Prices Review Board, or PMPRB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, later discovery of previously unknown adverse events or other problems with our products or their manufacturers or manufacturing processes,
or failure to comply with regulatory requirements, may yield various results, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on the manufacturing of such products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on the labeling or marketing of such products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on product distribution or use; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">requirements to conduct post-marketing studies or clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">warning letters or untitled letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">withdrawal of the products from the market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">refusal to approve pending applications or supplements to approved applications that we submit; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">recall of products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on coverage by third-party payors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">fines, restitution or disgorgement of profits or revenues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">exclusion from federal health care programs such as Medicare and Medicaid; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">suspension or withdrawal of regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">refusal to permit the import or export of products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">product seizure; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Obtaining and maintaining regulatory approval of AMX0035 or any future product candidates in one jurisdiction does not mean that we will be successful in
obtaining regulatory approval of those product candidates in other jurisdictions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Obtaining and maintaining regulatory approval of AMX0035
and any future product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have
a negative effect on the regulatory approval process in others. For example, even if a regulatory authority, such as Health Canada, grants marketing approval of AMX0035, comparable regulatory authorities in the United States, EU and other foreign
jurisdictions must also approve the manufacturing, marketing and promotion of AMX0035 in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than,
those in Canada, the United States or the EU including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions
outside the United States including Canada and certain jurisdictions in the EU, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our
products is also subject to approval. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have submitted marketing applications in the United States, Canada, and plan to do so in the near-term
in the EU. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
candidates with which we must comply prior to marketing in those jurisdictions and such regulatory requirements can vary widely from country to country. Obtaining other regulatory approvals and
compliance with other regulatory requirements could result in significant delays, difficulties and costs for us and could require additional preclinical studies or clinical trials, which could be costly and time-consuming and could delay or prevent
the introduction of our products in certain countries. The foreign regulatory approval process involves all of the risks associated with FDA approval. We do not have any product candidates approved for sale in any jurisdiction, including
international markets, and we do not have experience in obtaining regulatory approval in either domestic or international markets. If we fail to comply with the regulatory requirements in international markets and/or obtain and maintain applicable
marketing approvals, our target market will be reduced and our ability to realize the full market potential of AMX0035 or any future product candidates will be harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Even though we have obtained orphan drug designation for AMX0035 for the treatment of ALS in the United States and the EU and for the treatment of Wolfram
syndrome in the United States, we may not be able to obtain or maintain the benefits associated with orphan drug status, including market exclusivity. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Regulatory authorities in some jurisdictions, including the United States and the EU, may designate drugs for relatively small patient populations as
orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 people in the United States, or
a patient population of greater than 200,000 people in the United States, but for which there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the EU, the EMA Committee for
Orphan Medicinal Products grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in
10,000 people in the EU. Additionally, designation is granted for products intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition when, without incentives, it is unlikely that sales of the
drug in the EU would be sufficient to justify the necessary investment in developing the drug or biologic product. In either case, the applicant for orphan designation must also demonstrate that no satisfactory method of diagnosis, prevention, or
treatment for the condition has been authorized (or, if such a method exists, the new product would be a significant benefit to those affected compared to the product available). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In September 2017, the FDA granted orphan drug status to AMX0035 for the treatment of patients with ALS in the United States, and in June 2020, the EMA
granted orphan drug status to AMX0035 for the treatment of patients with ALS in the EU. We also received orphan drug status for AMX0035 for the treatment of patients with Wolfram syndrome in the United States in November 2020. Generally, if a drug
with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug may be entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving
another marketing application for the same drug for that time period. Another drug may receive marketing approval prior to AMX0035. The applicable period is seven years in the United States and ten years in the EU, which may be extended by six
months and two years, respectively, in the case of product candidates that have complied with the respective regulatory agency&#146;s agreed upon pediatric investigation plan. The exclusivity period in the EU can be reduced to six years if a drug no
longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. In the EU, during the <FONT STYLE="white-space:nowrap">ten-year</FONT> period of orphan marketing
exclusivity, neither the competent authorities of the EU Member States, the EMA, or the European Commission are permitted to accept applications or grant marketing authorization for other similar medicinal products. A &#147;similar medicinal
product&#148; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. Orphan drug
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
exclusivity may be lost if the FDA or the EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to
meet the needs of patients with the rare disease or condition. In addition, even after a drug is granted orphan exclusivity and approved, the FDA and the EMA can subsequently approve another drug for the same condition before the expiration of the
seven-year (or <FONT STYLE="white-space:nowrap">ten-year</FONT> in the EU) exclusivity period if the FDA or the EMA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to
patient care. In addition, if an orphan designated product receives marketing approval for an indication broader than or different from what is designated, such product may not be entitled to orphan exclusivity. Even though the FDA has granted
orphan drug designation to AMX0035 for the treatment of ALS and Wolfram syndrome, if we receive approval for AMX0035 for a modified or different indication, our current orphan designations may not provide us with exclusivity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process. Also, regulatory
approval for any product candidate may be withdrawn, and other product candidates may obtain approval before us and receive orphan drug exclusivity, which could block us from entering the market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if we obtain orphan drug exclusivity for AMX0035, that exclusivity may not effectively protect us from competition because different drugs can be
approved for the same condition before the expiration of the orphan drug exclusivity period. For example, even if orphan drug exclusivity is granted to AMX0035 if and when it is approved, that exclusivity may not prevent the approval of TURSO by the
FDA, the EMA or other regulatory authorities as a monotherapy treatment for ALS if those regulatory agencies determine that TURSO is a different drug product from AMX0035. In addition, the regulatory authorities may find that this monotherapy
treatment is clinically superior to our fixed dose product and approve it even if we are granted orphan drug exclusivity. U.S. lawmakers have also recently raised the possibility that regulatory or legislative changes might need to be made to the
Orphan Drug Act to foster competition. This includes the introduction of legislation that, if adopted into law, would require us to demonstrate to the FDA that AMX0035 would be economically unviable when facing competition to maintain our
exclusivity. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may pursue orphan drug designation for AMX0035 for the treatment of additional indications. The incidence and prevalence of the target
patient populations for these indications will be based on our estimates and third-party data. If the market opportunity for these target populations is larger than we estimate, we may be unable to receive orphan drug designation. Additionally, if
orphan drug designation is granted, we may be unable to maintain any benefits associated with orphan drug designation, including market exclusivity. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Periodically, we make estimates regarding the incidence and prevalence of target patient populations based on various third-party sources and internally
generated analysis. Our estimates may be inaccurate or based on imprecise data. As described above, under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is intended to treat a rare disease or condition, which is generally
defined as a patient population of fewer than 200,000 people in the United States, or a patient population of greater than 200,000 people in the United States, but for which there is no reasonable expectation that the cost of developing the drug
will be recovered from sales in the United States. If our incidence or prevalence estimates for future indications for which we may seek orphan drug designation are incorrect, we may be unable to receive orphan drug designation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if the FDA grants orphan drug designation for AMX0035 for other indications, exclusive marketing rights in the United States may be limited if we
seek FDA marketing approval for an indication broader than the orphan designated indication. Additionally, any product candidate that initially receives orphan drug status designation, may lose such designation if the FDA later determines that the
request for designation was materially defective or if the manufacturer is unable to assure </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
sufficient quantities of the product to meet the needs of patients with the rare disease or condition. In addition, others may obtain orphan drug status for products addressing the same diseases
or conditions as products we are developing, thus limiting our ability to compete in the markets addressing such diseases or conditions for a significant period of time. As a result, our business and prospects could suffer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We received priority review designation for AMX0035 in the United States and may in the future pursue priority review designation for other product candidates
that we may develop, but we might not receive such future designations, and priority review designations may not lead to a faster development or regulatory review or approval process. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If the FDA determines that a product candidate offers a treatment for a serious condition and, if approved, the product would provide a significant
improvement in safety or effectiveness, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of
ten months. We have received priority review for AMX0035 and may in the future request priority review designation for any future product candidates, however, we cannot assume that any application for future indications of AMX0035 or any other
product candidate we may develop will meet the criteria for that designation. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is
eligible for such designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does not necessarily mean a faster development or regulatory review or approval process or necessarily confer any advantage with
respect to approval compared to standard FDA review and approval. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle or at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may seek Fast Track Designation by the FDA for a product candidate that we develop, and we may be unsuccessful. If we are successful, the designation may not
actually lead to a faster development or regulatory review or approval process. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may seek Fast Track Designation for future product
candidates we develop. If a product is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition, the product sponsor may
apply for Fast Track Designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant
it. Even if we do receive Fast Track Designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may rescind the Fast Track Designation if it believes that the designation is
no longer supported by data from our clinical development activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may seek Breakthrough Therapy Designation by the FDA for a product candidate that we
develop, and we may be unsuccessful. If we are successful, the designation may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing
approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may seek Breakthrough Therapy Designation for any product candidate that we develop. A breakthrough therapy is defined as a
drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over
currently approved therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication
between the FDA and the sponsor of the trial can help to identify the most efficient path </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also eligible for accelerated
approval and priority review. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe a product
candidate we develop meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of Breakthrough Therapy Designation for a product candidate may not
result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if any product candidate we develop qualifies
as a breakthrough therapy, the FDA may later decide that the drug no longer meets the conditions for qualification and rescind the designation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Product
liability lawsuits against us or any of our future collaborators could divert our resources and attention, cause us to incur substantial liabilities and limit commercialization of AMX0035 or any future product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing
and use of pharmaceutical products. Currently, we have no products that have been approved for commercial sale; however, the use of AMX0035 by us and any collaborators in clinical trials, and the sale of AMX0035, if approved, in the future, may
expose us to liability claims. Product liability claims may be brought against us or our partners by participants enrolled in our clinical trials, patients, health care providers, pharmaceutical companies, our collaborators or others using,
administering or selling any of our future approved products. If we cannot successfully defend ourselves against any such claims, we may incur substantial liabilities or be required to limit commercialization of AMX0035 or any future product
candidates. Regardless of the merits or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">decreased demand for any of our future approved products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">injury to our reputation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">termination of clinical trial sites or entire trial programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">significant litigation costs, including with respect to potential class action lawsuits; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">substantial monetary awards to, or costly settlements with, patients or other claimants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">product recalls or a change in the indications for which they may be used; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">diversion of management and scientific resources from our business operations; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the inability to commercialize AMX0035 or any future product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Although the clinical trial process is designed to identify and assess potential side effects, clinical development does not always fully characterize
the safety and efficacy profile of a new drug, and it is always possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. If AMX0035 was to cause adverse side effects during clinical trials or after approval, we may
be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use AMX0035 or any of our future product candidates. If any of our current or
future product candidates, including AMX0035, are approved for commercial sale, we will be highly dependent upon consumer perceptions of us and the safety and quality of our products. We could be adversely affected if we are subject to negative
publicity associated with illness or other adverse effects resulting from patients&#146; use or misuse of our products or any similar products distributed by other companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Although we maintain product liability insurance coverage in the amount of up to $5.0 million in the
aggregate, including clinical trial liability, this insurance may not fully cover potential liabilities that we may incur. The cost of any product liability litigation or other proceeding, even if resolved in our favor, could be substantial. We will
need to increase our insurance coverage if we commercialize AMX0035 or any future product candidate that receives regulatory approval. In addition, insurance coverage is becoming increasingly expensive. If we are unable to maintain sufficient
insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims, it could prevent or inhibit the development and commercial production and sale of AMX0035 or any future product candidates, which could harm
our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Even if we, or any future collaborators, obtain regulatory approvals for AMX0035 or
any future product candidate, the terms of approvals and ongoing regulation of our products may limit how we manufacture and market our products, which could impair our ability to generate revenue. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Once regulatory approval has been granted, an approved product and its manufacturer and marketer are subject to ongoing review and extensive regulation.
We, and any future collaborators, must therefore comply with requirements concerning advertising and promotion for AMX0035 or any future product candidate for which we or they obtain regulatory approval. Promotional communications with respect to
prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#146;s approved labeling. Thus, we and any future collaborators will not be able to promote any products we
develop for indications or uses for which they are not approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, manufacturers of approved products and those manufacturers&#146;
facilities are required to comply with extensive FDA, Health Canada and EMA requirements, including ensuring that quality control and manufacturing procedures conform to current Good Manufacturing Practices, or cGMPs, which include requirements
relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements. We, our contract manufacturers, any future collaborators and their contract manufacturers could be
subject to periodic unannounced inspections by the FDA, Health Canada and the EMA to monitor and ensure compliance with cGMPs. Despite our efforts to inspect and verify regulatory compliance, one or more of our third-party manufacturing vendors may
be found on regulatory inspection by the FDA, the EMA or other authorities to be not in compliance with cGMP regulations, which may result in shutdown of the third-party vendor or invalidation of drug product lots or processes. In some cases, a
product recall may be warranted or required, which would materially affect our ability to supply and market our drug products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Accordingly,
assuming we, or any future collaborators, receive regulatory approval for AMX0035 or one or more future product candidates, we, and any future collaborators, and our and their contract manufacturers will continue to expend time, money and effort in
all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we, and any future
collaborators, are not able to comply with post-approval regulatory requirements, we, and any future collaborators, could have the regulatory approvals for AMX0035 or any future products withdrawn by regulatory authorities and our, or any future
collaborators&#146;, ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on
our operating results and financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Laws and regulations governing any international operations we expect to have in the future may preclude us from
developing, manufacturing and selling certain products outside of the United States and will require us to develop and implement costly compliance programs. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect to engage in operations outside of the United States, including in Canada and in the EU initially, as well as other potential jurisdictions,
and we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering,
authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or
business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring us to maintain books and records that accurately and fairly
reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA
presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in
connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Various laws, regulations and executive orders, including export control and trade sanctions laws, also restrict the use and dissemination outside of
the United States, or the sharing with certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we
expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates
outside of the United States, which could limit our growth potential and increase our development costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The failure to comply with laws governing
international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The Securities and Exchange Commission, or SEC, also may suspend or bar issuers from trading securities
on U.S. exchanges for violations of the FCPA&#146;s accounting provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we fail to comply with environmental, health and safety laws and regulations,
we could become subject to fines or penalties or incur costs that could harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are subject to numerous environmental, health
and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of
hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely
eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability
could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees, but this insurance
may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, we may incur substantial costs in order to comply with current or future environmental,
health and safety laws and regulations. Environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other
sanctions. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Risks Related to Our Dependence on Third Parties </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may seek to establish collaborations and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and
commercialization plans. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The advancement of AMX0035, and any future product candidates and development programs or activities, as well as
the potential commercialization of AMX0035 and any future product candidates will require substantial additional cash to fund expenses. For some indications of AMX0035 or future product candidates, we may decide to collaborate with additional
pharmaceutical and biotechnology companies with respect to development and potential commercialization. Likely collaborators may include large and <FONT STYLE="white-space:nowrap">mid-size</FONT> pharmaceutical companies, regional and national
pharmaceutical companies and biotechnology companies. In addition, if we are able to obtain regulatory approval for product candidates from foreign regulatory authorities, we may enter into collaborations with international biotechnology or
pharmaceutical companies for the commercialization of such product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We face significant competition in seeking appropriate
collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the
proposed collaborator&#146;s evaluation of a number of factors. Those factors may include the potential differentiation of our product candidate from competing product candidates, design or results of clinical trials, the likelihood of approval by
Health Canada, the FDA, the EMA or other comparable foreign regulatory authorities and the regulatory pathway for any such approval, the potential market for the product candidate, the costs and complexities of manufacturing and delivering the
product to patients and the potential of competing products. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available for collaboration and whether such a collaboration could be
more attractive than the one with us for our product candidate. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on
acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop AMX0035 or any future product candidates or bring them to market and generate product revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Collaborations are complex and time-consuming to negotiate and document. Further, there have been a significant number of recent business combinations
among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Any collaboration agreements that we enter into in the future may contain restrictions on our ability to enter into potential
collaborations or to otherwise develop specified product candidates. We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product
candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs or activities, delay its potential commercialization or reduce the scope of any sales or marketing
activities, or increase our expenditures and undertake development or commercialization activities at our own expense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may in the future enter into collaborations with third parties for the development and commercialization of
AMX0035 or any future product candidates, and our prospects with respect to those product candidates will depend in significant part on the success of those collaborations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may rely on collaborations for the development and commercialization of AMX0035 and any future product candidates. For example, we may utilize a
variety of distribution, collaboration and other marketing arrangements with one or more third parties to facilitate commercialization of AMX0035. Our likely collaborators for any distribution, development, sales, marketing, licensing or broader
collaboration arrangements include large and <FONT STYLE="white-space:nowrap">mid-size</FONT> pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. If we enter into such collaborations, we may have
limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of AMX0035 or any future product candidates. Our ability to generate revenues from these arrangements will depend on any
future collaborators&#146; abilities to successfully perform the functions assigned to them in these arrangements. In addition, any future collaborators may have the right to abandon research or development projects and terminate applicable
agreements, including funding obligations, prior to or upon the expiration of the agreed upon terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Collaborations involving AMX0035 and any
future product candidates pose a number of risks, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these
collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may not perform their obligations as expected; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may not pursue development and commercialization of AMX0035 or any future product candidates or may elect not
to continue or renew development or commercialization programs, based on clinical trial results, changes in the collaborators&#146; strategic focus or available funding or external factors, such as an acquisition, that divert resources or create
competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial
or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with
AMX0035 or any of our future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to the
marketing and distribution of such product or products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">disagreements with collaborators, including disagreements over proprietary rights, including trade secrets and intellectual
property rights, contract interpretation, or the preferred course of development might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect
to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information
in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and
potential liability; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further
development or commercialization of the applicable product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Collaboration agreements may not lead to development or
commercialization of product candidates in the most efficient manner or at all. If any future collaborator of ours is involved in a business combination, it could decide to delay, diminish or terminate the development or commercialization of any
product candidate licensed to it by us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We rely on third parties to assist in conducting our clinical trials. If they do not perform satisfactorily, we may
not be able to obtain regulatory approval or commercialize AMX0035 or any future product candidates, or such approval or commercialization may be delayed, and our business could be substantially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have relied upon and plan to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions and
clinical investigators, to conduct our clinical trials and expect to rely on these third parties to conduct clinical trials of any future product candidate that we develop. Any of these third parties may terminate their engagements with us under
certain circumstances. We may not be able to enter into alternative arrangements or do so on commercially reasonable terms. In addition, there is a natural transition period when a new CRO begins work. As a result, delays may occur, which could
negatively impact our ability to meet our expected clinical development timelines and harm our business, financial condition and prospects. Clinical trials involve multiple clinical sites, vendors and other third parties and we are dependent on
these vendors to ensure appropriate study conduct, statistical analysis and randomization. Errors or deviations they make in any of these activities could impact the usefulness and interpretability of clinical trial results. Clinical trials from
time to time have deviations where a protocol or standard operating procedure is not perfectly carried out and where corrective actions are taken. While we may perceive these events as low risk, our perception of risk and appropriate corrective
actions may differ from that of the regulators&#146; view. Deviations from protocols or standard operating procedures during studies could result in negative regulatory opinions and outcomes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further, although our reliance on these third parties for clinical development activities limits our control over these activities, we remain
responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards. Moreover, the FDA, the EMA and competent authorities of the EU Member States
require us to comply with Good Clinical Practices, or GCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality
of trial participants are protected. The FDA enforces these GCPs through periodic inspections of trial sponsors, principal investigators, clinical trial sites and IRBs. If we or our third-party contractors fail to comply with applicable GCPs, the
clinical data generated in our clinical trials may be deemed unreliable and the FDA or the EMA may require us to perform additional clinical trials before approving AMX0035 or any future product candidates, which would delay the regulatory approval
process. We cannot be certain that, upon inspection, the FDA or the EMA will determine that any of our clinical trials comply with GCPs. For example, our clinical trial sites and investigators have in the past and may in the future engage in
protocol deviations which could impact the overall interpretability of the outcomes of our clinical trials. We are also required to register certain clinical trials and post the results of completed clinical trials on a government-sponsored
database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Furthermore, the third parties conducting clinical trials on our behalf are not our employees, and except for remedies available to us under our
agreements with such contractors, we cannot control whether or not they devote sufficient time, skill and resources to our ongoing development activities. These contractors may also have relationships with other commercial entities, including our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
competitors, for whom they may also be conducting clinical trials or other drug development activities, which could impede their ability to devote appropriate time to our clinical activities. If
these third parties, including clinical investigators, do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we may not be
able to obtain, or may be delayed in obtaining, clinical data necessary for regulatory approvals for AMX0035 or any future product candidates. If that occurs, we will not be able to, or may be delayed in our efforts to, successfully commercialize
AMX0035 or any future product candidates. In such an event, our financial results and the commercial prospects for AMX0035 or any future product candidates that we seek to develop could be harmed, our costs could increase and our ability to generate
revenues could be delayed, impaired or foreclosed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, quarantines,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place,</FONT></FONT> and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur,
related to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or other infectious diseases could impact personnel at our CROs, which could disrupt our clinical timelines, which could have a material adverse impact on our business,
prospects, financial condition, and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We also rely on other third parties to store and distribute drug supplies for our
clinical trials. Any performance failure on the part of our distributors could delay clinical development or regulatory approval of AMX0035 or any future product candidates or commercialization of any resulting products, producing additional losses
and depriving us of potential product revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our use of third parties to manufacture AMX0035 may increase the risk that we will not have sufficient
quantities of AMX0035, products, or necessary quantities of such materials on time or at an acceptable cost. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We do not own or operate
manufacturing facilities for the production of clinical or commercial quantities of AMX0035, and we currently lack the resources and the capabilities to do so. As a result, we currently rely on third parties for the manufacture and supply of the
active pharmaceutical ingredients, or APIs, in AMX0035, and for the blending and packaging of AMX0035. Our current strategy is to outsource all manufacturing of AMX0035 and any future product candidates to third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We currently engage third-party manufacturers to provide the APIs of AMX0035 and for the final drug product formulation of AMX0035 that is being used in
our clinical trials and we engage separate third-parties for the blending and packaging of finished clinical materials. We must be able to demonstrate comparability of drug substance across suppliers along with stability data across suppliers. We
currently rely on a single manufacturer to supply one of our APIs and a separate manufacturer to supply the other. Although we believe that there are several potential alternative manufacturers who could manufacture each of the APIs in AMX0035, we
may incur added costs and delays in identifying and qualifying any such replacement. In addition, we typically order raw materials and services on a purchase order basis and do not enter into long-term dedicated capacity or minimum supply
arrangements with any commercial manufacturer. Moreover, the extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic impacts our ability to procure sufficient supplies for the development of AMX0035, and any future products and
product candidates will depend on the severity and duration of the spread of the virus, and the actions undertaken to contain <FONT STYLE="white-space:nowrap">COVID-19</FONT> or treat its effects. There is no assurance that we will be able to timely
secure needed supply arrangements on satisfactory terms, or at all. Our failure to secure these arrangements as needed could have a material adverse effect on our ability to complete the development of AMX0035 or any future product candidates or, to
commercialize them, if approved. We may be unable to conclude agreements for commercial supply with third-party manufacturers, or may be unable to do so on acceptable terms. There may be difficulties in scaling up to commercial quantities and
formulation of AMX0035, and the costs of manufacturing could be prohibitive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if we are able to establish and maintain arrangements with third-party manufacturers, reliance on
third-party manufacturers entails additional risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the failure of the third-party manufacturer to comply with applicable regulatory requirements and reliance on third-parties
for manufacturing process development, regulatory compliance and quality assurance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">manufacturing delays if our third-party manufacturers give greater priority to the supply of other products over AMX0035 or
any future product candidates or otherwise do not satisfactorily perform according to the terms of the agreement between us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">limitations on supply availability resulting from capacity and scheduling constraints of third-parties;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the possible breach of manufacturing agreements by third-parties because of factors beyond our control;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the possible termination or <FONT STYLE="white-space:nowrap">non-renewal</FONT> of the manufacturing agreements by a
third-party, at a time that is costly or inconvenient to us; and </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the possible misappropriation of our proprietary information, including our trade secrets and <FONT
STYLE="white-space:nowrap">know-how.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we do not maintain our key manufacturing relationships, or if any of our contract
manufacturers fail to perform their obligations, we may fail to find replacement manufacturers or develop our own manufacturing capabilities, which could delay or impair our ability to obtain regulatory approval for our products. If we do find
replacement manufacturers, we may not be able to enter into agreements with them on terms and conditions favorable to us and there could be a substantial delay before new facilities could be qualified and registered with the FDA, Health Canada, the
EMA and other foreign regulatory authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any change in manufacturer may also involve changes in manufacturing procedures and processes, which
could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. In addition, we will need to verify that any new manufacturing process will produce our product candidate
according to the specifications previously submitted to the FDA, Health Canada, the EMA or another regulatory authority. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional
clinical trials. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In some cases, the technical skills required to manufacture AMX0035, or any future products or product candidates may be
unique or proprietary to the original contract manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a <FONT STYLE="white-space:nowrap">back-up</FONT> or alternate
supplier, or we may be unable to transfer such skills at all. Furthermore, a contract manufacturer may possess or acquire technology related to the manufacture of AMX0035 or any future product candidate that such contract manufacturer owns
independently. This would increase our reliance on such contract manufacturer or require us to obtain a license from such contract manufacturer in order to have another contract manufacturer manufacture AMX0035 or any future product candidates. If
AMX0035 for any of our initial or potential additional indications or any future product candidate is approved by any regulatory agency, we intend to utilize arrangements with third-party contract manufacturers for the commercial production of those
products. This process is difficult and time consuming and we may face competition for access to manufacturing facilities as there are a limited number of contract manufacturers operating under cGMPs that are capable of manufacturing AMX0035 or any
future product candidates. Consequently, we may not be able to reach agreement with third-party manufacturers on satisfactory terms, which could delay our commercialization. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our failure, or the failure of our third-party manufacturers, to comply with applicable
regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or voluntary recalls of AMX0035 or any future product candidates,
operating restrictions and criminal prosecutions, any of which could significantly affect supplies of AMX0035 or any future product candidates. The facilities used by our contract manufacturers to manufacture AMX0035 or any future product candidates
must be evaluated by the FDA, Health Canada, the EMA and certain other foreign regulatory authorities. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with cGMPs. If
our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, Health Canada, the EMA or others, we may not be able to secure and/or maintain regulatory
approval for our product manufactured at these facilities. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA, Health Canada, the
EMA or other comparable foreign regulatory authority finds deficiencies or does not approve these facilities for the manufacture of AMX0035 or any future product candidates, or if it withdraws any such approval in the future, we may need to find
alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market AMX0035 or any future product candidates, if approved. Furthermore, if we are required to change contract
manufacturers, we will be required to verify that the new contract manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations, which could result in further costs and delays. Contract
manufacturers may face manufacturing or quality control problems causing drug substance production and shipment delays or a situation where the contractor may not be able to maintain compliance with the applicable cGMP requirements. Any failure to
comply with cGMP requirements or other FDA, Health Canada, EMA and comparable foreign regulatory requirements could adversely affect our clinical research activities and our ability to develop AMX0035 or any future product candidates and market our
products, if approved. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA, Health Canada, the EMA and other foreign regulatory authorities require manufacturers to register
manufacturing facilities. The FDA, Health Canada, the EMA and corresponding foreign regulators also inspect these facilities to confirm compliance with cGMPs. Contract manufacturers may face manufacturing or quality control problems causing drug
substance production and shipment delays or a situation where the contractor may not be able to maintain compliance with the applicable cGMP requirements. Any failure to comply with cGMP requirements or other FDA, Health Canada, EMA and comparable
foreign regulatory requirements could adversely affect our clinical research activities and our ability to develop AMX0035 or any future product candidates and market our products following approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If any third-party manufacturer of AMX0035 or any future product candidates is unable to increase the scale of its production of such product candidates, and/or
increase the product yield of its manufacturing, then our costs to manufacture the product may increase and commercialization may be delayed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In order to produce sufficient quantities to meet the demand for clinical trials and, if approved, subsequent commercialization of AMX0035, or any future
product candidates that we may develop, our third-party manufacturers will be required to increase their production and optimize their manufacturing processes while maintaining the quality of the product. The transition to larger scale production
could prove difficult. In addition, if our third party manufacturers are not able to optimize their manufacturing processes to increase the product yield for AMX0035 or any future product candidates, or if they are unable to produce increased
amounts of such product candidates while maintaining the quality of the product, then we may not be able to meet the demands of clinical trials or market demands, which could decrease our ability to generate profits and have a material adverse
impact on our business and results of operation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Three vaccines for <FONT STYLE="white-space:nowrap">COVID-19</FONT> were granted Emergency Use
Authorization by the FDA in late 2020 and early 2021, and one of those later received marketing approval from the FDA. Additional vaccines may be authorized or approved in the future.&nbsp;The resultant demand for vaccines and potential for
manufacturing facilities and materials to be commandeered under the Defense Production Act of 1950, or equivalent foreign legislation, is having rippling effects across the contract manufacturing industry, which may make it more difficult to obtain
materials or manufacturing slots for the production needed for our clinical trials and, if approved, our future commercial supply, which could lead to delays in our trials and commercial distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may need to maintain licenses for active ingredients from third parties to develop and commercialize AMX0035 or a future product candidate, which could
increase our development costs and delay our ability to commercialize such product candidate. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Should we decide to use API in any of AMX0035
or any future product candidates that are proprietary to one or more third parties, we would need to maintain licenses to those active ingredients from those third parties. If we are unable to gain or continue to access rights to these active
ingredients prior to conducting preclinical toxicology studies intended to support clinical trials, we may need to develop alternate product candidates from these programs by either accessing or developing alternate active ingredients, resulting in
increased development costs and delays in commercialization of these product candidates. If we are unable to gain or maintain continued access rights to the desired active ingredients on commercially reasonable terms or develop suitable alternate
active ingredients, we may not be able to commercialize product candidates from these programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Risks Related to Commercialization of AMX0035 or
Future Product Candidates </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We currently have limited sales and marketing capabilities. If we are unable to establish effective sales and marketing
capabilities or enter into agreements with third parties to market and sell AMX0035 and any future product candidates that may be approved, we may not be successful in commercializing AMX0035 and any future product candidates if and when approved,
and we may be unable to generate any product revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If approved, we currently intend to seek to commercialize AMX0035 in Canada, the
United States and the EU directly with specialized teams, given the relative rarity of certain of the indications we are targeting. We currently have a limited marketing and sales team for the marketing, sales and distribution of AMX0035 and any
future product candidates, if approved. In order to commercialize AMX0035 for the treatment of ALS, AD and other indications, if approved, or any of our future product candidates that may be approved, we must build, on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">territory-by-territory</FONT></FONT> basis, marketing, sales, distribution, managerial and other capabilities or make arrangements with third parties to perform these services, and we may
not be successful in doing so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There are risks involved with both establishing our own sales and marketing capabilities and entering into
arrangements with third parties to perform these services. For example, recruiting and training a commercial organization is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which
we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly and our investment would be lost if
we cannot retain or reposition our sales and marketing personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Factors that may inhibit our efforts to commercialize AMX0035 or any future
product candidates on our own include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the inability of sales personnel to obtain access to physicians to prescribe AMX0035 or any future product that we may
develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any views or opinions expressed by ALS or AD community organizations about the efficacy of AMX0035; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the lack of complementary treatments to be offered by sales personnel, which may put us at a competitive disadvantage
relative to companies with more extensive product lines; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the availability of adequate coverage by and reimbursement from third-party payors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.
</P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue
or profitability from these revenue streams is likely to be lower than if we were to market and sell any product candidates that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and
market AMX0035 or any of our future product candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention
to sell and market AMX0035 or any future product candidates effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we may not be successful in commercializing
AMX0035 or any future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our efforts to educate the ALS, AD and other neurodegenerative disease medical communities and payors on
the benefits of AMX0035 or any future product candidates may require significant resources given the relative rarity of certain of the indications we are targeting, and may never be successful. Such efforts may require more resources than are
typically required due to the complexity and uniqueness of AMX0035 or any future product candidates, and the indications we are targeting. Even if AMX0035 or any future product candidates are approved, if we are unable to successfully market our
products successfully, we will not be able to generate significant revenues from such products, if approved. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are unable to expand our marketing
and distribution capabilities or enter into agreements with third parties to market and sell any of AMX0035 or future product candidates for which we obtain marketing approval, we will be unable to generate any product revenue. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To successfully commercialize any products that may result from our development activities, we need to continue to expand our marketing and distribution
capabilities, either on our own or with others. The development of our own marketing and distribution effort is, and will continue to be, expensive and time-consuming and could delay any product launch. Moreover, we cannot be certain that we will be
able to develop this capability successfully. We may enter into collaborations regarding any approved product candidates with other entities to utilize their established marketing and distribution capabilities, however, we may be unable to enter
into such agreements on favorable terms, if at all. If any future collaborators do not commit sufficient resources to commercialize AMX0035 or any future product candidates, or we are unable to develop the necessary capabilities on our own, we will
be unable to generate sufficient product revenue to sustain our business. We compete with many companies that currently have extensive, experienced and well-funded sales, distribution and marketing operations to recruit, hire, train and retain
marketing and sales personnel. We also face competition in our search for third parties to assist us with the sales and marketing efforts of AMX0035 and any future product candidates, if approved. Without an internal team or the support of a
third-party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The market for AMX0035 for ALS, AD and other neurodegenerative diseases and for any future product candidates we
may develop may be smaller than we expect. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We focus our research and product development on treatments of neurodegenerative diseases. We
base our market opportunity estimates on a variety of factors, including our estimates of the number of people who have these diseases, the potential scope of our approved product labels, the subset of people with these diseases who have the
potential to benefit from treatment with AMX0035 or any future product candidates, various pricing scenarios, and our understanding of reimbursement policies for rare diseases in particular countries. These estimates are based on many assumptions
and may prove incorrect, and new studies may reduce the estimated incidence or prevalence of these diseases. Estimating market opportunities can be particularly challenging for ultra-rare indications, such as the ones we currently address, as
epidemiological data is often more limited than for more prevalent indications and can require additional assumptions to assess potential patient populations. For example, as we advance AMX0035 towards commercialization, learn more about market
dynamics and engage with regulators on potential marketing approvals, our view of our products&#146; initial potential market opportunity will become more refined. We expect the approved label to initially be directed to a narrower patient
population with the opportunity to expand the label upon submission of additional clinical data. For example, we are now initially focused primarily on the annual incidence of ALS. This means the initial market opportunity for AMX0035 and any future
product candidates may be smaller than the total addressable market opportunity that could be achieved over time. If we are unable to advance AMX0035 or any future product candidates with attractive market opportunities, our future product revenues
may be smaller than anticipated, and our business may suffer. Patient identification efforts also influence the ability to address a patient population. If efforts in patient identification are unsuccessful or less impactful than anticipated, for
instance, because of a lack of diagnostic initiatives, inadequate disease awareness among healthcare professionals, or otherwise, we may not address the entirety of the opportunity we are seeking. As a result, patients may be difficult to identify
and access, the addressable patient population in Canada, the United States, the EU and elsewhere may turn out to be lower than expected, or patients may not be otherwise amenable to treatment with our products, all of which would adversely affect
our business, financial condition, results of operations and prospects. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Even if AMX0035 or any future product candidate of ours receives regulatory
approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, in which case we may not generate significant revenues or become
profitable. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have never commercialized a product, and even if AMX0035 for the treatment of any indication, or any future product
candidate of ours, is approved by the appropriate regulatory authorities for marketing and sale, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. Physicians
may be reluctant to take their patients off their current medications and switch their treatment regimen to AMX0035. Further, patients often acclimate to the treatment regime they are currently taking and do not want to switch unless their
physicians recommend switching products or are required to switch due to lack of coverage and adequate reimbursement. In addition, even if we are able to demonstrate our product candidates&#146; safety and efficacy to Health Canada, the FDA, the EMA
and other regulators, safety or efficacy concerns in the medical community may hinder market acceptance. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Efforts to educate the medical
community and third-party payors on the benefits of our current and any future product candidates may require significant resources, including management time and financial resources, and may not be successful. If AMX0035 or any future product
candidate is approved but does not achieve an adequate level of market acceptance, we may not generate significant revenues and we may not become profitable. The degree of market acceptance of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
AMX0035 and any future product candidates, if approved for commercial sale, will depend on a number of factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the efficacy and safety of the product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the potential advantages of the product compared to competitive therapies and our ability to successfully publicize these
advantages or highlight them in any marketing materials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the prevalence and severity of any side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">whether the product is designated under physician treatment guidelines as a first-, second- or third-line therapy;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability, or the ability of any future collaborators, to offer the product for sale at competitive prices;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the product&#146;s convenience and ease of administration compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the willingness of the target patient population to try, and of physicians to prescribe, the product;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">limitations or warnings, including distribution or use restrictions contained in the product&#146;s approved labeling;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the strength of sales, marketing and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in the standard of care for the targeted indications for the product; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">availability and adequacy of coverage and reimbursement from government payors, managed care plans and other third-party
payors. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any failure by AMX0035 or any other potential product candidate of ours that obtains regulatory approval to achieve
market acceptance or commercial success would adversely affect our business prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Healthcare insurance coverage and reimbursement may be limited or
unavailable for AMX0035 and any future product candidates, if approved, which could make it difficult for us to sell any product candidates or therapies profitably. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The success of AMX0035 and any future product candidates, if approved, depends on the availability of adequate coverage and reimbursement from
third-party payors. Because AMX0035 and any future product candidates represent new approaches to the treatment of the diseases they target, we cannot be sure that coverage and reimbursement will be available for, or accurately estimate the
potential revenue from, AMX0035 and any future product candidates or for any product that we may develop. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell any such product candidates will be
adversely affected. The manner and level at which reimbursement is provided for services related to any current or future product candidates we may develop (e.g., for the administration of our product candidate to patients) is also important.
Inadequate reimbursement for such services may lead to physician and payor resistance and adversely affect our ability to market or sell AMX0035 or any future product candidates we may develop. In addition, we may need to develop new reimbursement
models, in order to realize adequate value. Payors may not be able or willing to adopt such new models and patients may be unable to afford that portion of the cost that such models may require them to bear. If we determine such new models are
necessary, but we are unsuccessful in developing them, or if payors do not adopt such models, our business, financial condition, results of operations and prospects could be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated
with their treatment. Adequate coverage and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors, such as private health insurers and health maintenance organizations, are critical to
new product acceptance. Government authorities and other third-party payors decide which drugs and treatments they will cover and the reimbursement amount. Coverage and reimbursement by a third-party payor may depend upon a number of factors,
including the third-party payor&#146;s determination that the use of a product is: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. As a result, obtaining coverage and
reimbursement approval of a product from a government or other third-party payor is a time consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our
products on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">payor-by-payor</FONT></FONT> basis, with no assurance that coverage and adequate reimbursement from third-party payors will be obtained. There is significant uncertainty
related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS,
an agency within the U.S. Department of Health and Human Services, as CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payors tend to follow CMS to a substantial degree. Even if we obtain
coverage for a given product, the resulting reimbursement payment rates might not be adequate for us to achieve or sustain profitability or may require <FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. Future
coverage and reimbursement&nbsp;may be subject to increased restrictions, such as prior authorization requirements, both in the United States and in international markets. Orphan drugs are typically placed on the highest cost-sharing tier and a
substantial percentage are subject to prior authorization requirements. Reimbursement agencies in the EU may be more conservative than CMS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Outside
the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Canada, the EU and other countries has
and will continue to put pressure on the pricing and usage of drug products such as AMX0035 and any future product candidates we may develop, if approved. In many countries, particularly the countries of the EU, the prices of medical products are
subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. For example, in
Canada, price negotiations with provincial authorities can take more than 18 months before agreed-upon pricing and reimbursement rates. Prior to these negotiations, a review by a body known as the Canadian Agency for Drugs and Technologies in
Health, or CADTH, and l&#146;Institut national d&#146;excellence en sant&eacute; et en services sociaux, or INESS, are conducted, and for patented medicines, the PMPRB also has jurisdiction. Such discussions may also result in additional studies and
rationale required for combination products before reimbursement will be granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay or might even prevent our
commercial launch of the product, possibly for lengthy periods of time. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to
other available therapies. In general, the prices of products under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for products but monitor and control company
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for product candidates. Accordingly, in markets outside the
United States, the reimbursement for AMX0035 and any future product candidates we may develop may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, third-party payors may not cover, or provide adequate reimbursement for, long-term <FONT STYLE="white-space:nowrap">follow-up</FONT>
evaluations required following the use of product candidates. Patients are unlikely to use AMX0035 or any future product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of AMX0035 or
any future product candidates. Because AMX0035 and any future product candidates may have a higher cost of goods than conventional therapies and may require long-term <FONT STYLE="white-space:nowrap">follow-up</FONT> evaluations, the risk that
coverage and reimbursement rates may be inadequate for us to achieve profitability may be greater. There is significant uncertainty related to insurance coverage and reimbursement of newly approved products. It is difficult to predict at this time
what third-party payors will decide with respect to the coverage and reimbursement for AMX0035 and any future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover,
increasing efforts by governmental and other third-party payors in Canada, the EU, the United States and other foreign jurisdictions to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement
for newly approved products and, as a result, they may not cover or provide adequate payment for AMX0035 or any future product candidates. There has been increasing legislative and enforcement interest in the United States with respect to specialty
drug pricing practices. We expect to experience pricing pressures in connection with the sale of AMX0035 or any future product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, cost
containment initiatives and additional legislative changes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect
on our business and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Changes in regulations, statutes or the interpretation of existing regulations could impact our
business in the future by requiring, for example: (i)&nbsp;changes to our manufacturing arrangements; (ii)&nbsp;additions or modifications to product labeling; (iii)&nbsp;the recall or discontinuation of our products; or (iv)&nbsp;additional
record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United
States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Patient Protection and Affordable Care Act, or the ACA, was passed, which substantially changes the way
healthcare is financed by both governmental and private insurers and significantly impacts the U.S. pharmaceutical industry. The ACA, among other things, subjects biological products to potential competition by lower-cost biosimilars, addressed a
new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under
the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs and created a new Medicare Part
D coverage gap discount program, in which manufacturers must agree to offer 70% (increased from 50%, effective January&nbsp;1, 2019, pursuant to the Bipartisan Budget Act of 2018)
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the
manufacturer&#146;s outpatient drugs to be covered under Medicare Part&nbsp;D. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since its enactment, there have been numerous judicial,
administrative, executive, and legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
amendments to the ACA in the future. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the
constitutionality of the ACA. Prior to the Supreme Court&#146;s decision, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance
coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid
demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other reform measures of the
Biden administration or other efforts, if any, to challenge, repeal or replace the ACA will impact our business. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, other
legislative changes have been proposed and adopted in the United States since the ACA was enacted. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select
Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach the required goals, thereby triggering the legislation&#146;s automatic reduction to
several government programs. These reductions will remain in effect through 2030 unless additional action is taken by Congress. However, pursuant to the CARES Act and subsequent legislation, these Medicare sequester reductions will be suspended from
May&nbsp;1, 2020 through December 31, 2021 due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. The proposed legislation, if passed, would extend this suspension until the end of the pandemic. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">On May 23, 2019, CMS issued a final rule to allow Medicare Advantage plans the option to use step therapy for Part B drugs
beginning January 1, 2020. This final rule codified CMS&#146;s policy change that was effective January 1, 2019. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">On May 30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for
certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling
in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These laws and future state and federal healthcare reform measures that may be adopted in the future may result in additional
reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for AMX0035 or any future product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is
prescribed or used. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed
to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement
methodologies for drugs. CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed
products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare and
review the relationship between pricing and manufacturer patient programs. At a federal level, President Biden signed an Executive Order on July 9, 2021 affirming the administration&#146;s policy to (i) support legislative reforms that would
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
lower the prices of prescription drug and biologics, including by allowing Medicare to negotiate drug prices, by imposing inflation caps, and, by supporting the development and market entry of
lower-cost generic drugs and biosimilars; and (ii) support the enactment of a public health insurance option. Among other things, the Executive Order also directs the Department of Health and Human Services, or HHS, to provide a report on actions to
combat excessive pricing of prescription drugs, enhance the domestic drug supply chain, reduce the price that the Federal government pays for drugs, and address price gouging in the industry; and directs the FDA to work with states and Indian Tribes
that propose to develop section 804 Importation Programs in accordance with the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, and the FDA&#146;s implementing regulations. The FDA released such regulations on September 24,
2020, which went into effect on November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. On September 25, 2020, CMS that stated drugs imported by states under this rule will not be eligible for
federal rebates under Section 1927 of the Social Security Act and manufacturers would not report these drugs for &#147;best price&#148; or Average Manufacturer Price purposes. Since these drugs are not considered covered outpatient drugs, CMS
further stated it will not publish a National Average Drug Acquisition Cost for these drugs. If implemented, importation of drugs from Canada may materially and adversely affect the price we receive for any of our product candidates. Further, on
November 20, 2020, CMS issued an Interim Final Rule implementing the Most Favored Nation, or MFN, Model under which Medicare Part B reimbursement rates would have been calculated for certain drugs and biologicals based on the lowest price drug
manufacturers receive in Organization for Economic Cooperation and Development countries with a similar gross domestic product per capita. However, on August 6, 2021 CMS announced a proposed rule to rescind the Most Favored Nations rule.
Additionally, on November&nbsp;30, 2020, HHS published a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless
the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers.
Pursuant to the court order, the removal and addition of the aforementioned safe harbors have been delayed until January 1, 2023. Further, implementation of these changes and new safe harbors for point-of-sale reductions in price for prescription
pharmaceutical products and pharmacy benefit manager service fees are currently under review by the Biden administration and may be amended or repealed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additional state and federal healthcare reform measures are expected to be adopted in the future, any of which could limit the amounts that federal and
state governments will pay for healthcare products and services, which could result in reduced demand for certain pharmaceutical products or additional pricing pressures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, there have been several changes to the 340B drug pricing program, which imposes ceilings on prices that drug manufacturers can charge for
medications sold to certain health care facilities. On December&nbsp;27, 2018, the District Court for the District of Columbia invalidated a reimbursement formula change under the 340B drug pricing program, and CMS subsequently altered the FYs 2019
and 2018 reimbursement formula on specified covered outpatient drugs. The court ruled this change was not an &#147;adjustment&#148; within the Secretary&#146;s discretion but a fundamental change in the reimbursement calculation. However, most
recently, on July&nbsp;31, 2020, the U.S. Court of Appeals for the District of Columbia Circuit overturned the district court&#146;s decision and found that the changes were within the Secretary&#146;s authority. On September&nbsp;14, 2020, the
plaintiffs-appellees filed a Petition for Rehearing En Banc (i.e., before the full court), but was denied on October&nbsp;16, 2020. On Friday July 2, 2021, the Supreme Court granted the petition. It is unclear how these developments could affect
covered hospitals who might purchase our future products and affect the rates we may charge such facilities for our approved products in the future, if any. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">While some of these and other proposed measures may require additional authorization to become
effective, Congress and the Biden administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures are increasingly passing legislation and
implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency
measures and, in some cases, designed to encourage importation from other countries and bulk purchasing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Governments outside the United States may impose
strict price controls, which may adversely affect our revenues, if any. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In some countries, including Canada and certain Member States of the
EU, the pricing of prescription drugs is, in part, subject to governmental control. Additional countries may adopt similar approaches to the pricing of prescription drugs. In such countries, pricing negotiations with governmental authorities can
take considerable time after receipt of regulatory approval for a product. The EU provides options for the EU Member States to restrict the range of drug products for which their national health insurance systems provide reimbursement and to control
the prices of medicinal products for human use. EU Member States may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other
EU Member States allow companies to fix their own prices for drug products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. In addition, there can be considerable pressure by governments and
other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after coverage
and reimbursement have been obtained. Reference pricing used by various countries and parallel distribution, or arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced countries, can further reduce prices. In some
countries, we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of AMX0035 or any future product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval,
which is time-consuming and costly. We cannot be sure that such prices and reimbursement will be acceptable to us. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels
within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales by us or our strategic partners and the
potential profitability of AMX0035 or any future product candidates in those countries would be negatively affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our relationships with healthcare
providers and physicians and third-party payors may be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational
harm and diminished profits and future earnings. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Healthcare providers, physicians and third-party payors in the United States and elsewhere
play a primary role in the recommendation and prescription of pharmaceutical products. Arrangements with third-party payors and customers can expose pharmaceutical manufacturers to broadly applicable fraud and abuse and other healthcare laws and
regulations, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, or FCA, which may constrain the business or financial arrangements and relationships through which such companies conduct research, sell,
market and distribute pharmaceutical products. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent
fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of
information obtained in the course of patient recruitment for clinical trials. The applicable federal, state and foreign healthcare laws and regulations laws that may affect our ability to operate include, but are not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving,
offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, inducing, or in return for, either the referral of an individual or the purchase, lease, order or
recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. &#147;Remuneration&#148; has been interpreted broadly to
include anything of value. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, a person or entity can be found guilty of violating the statute without actual knowledge
of the statute or specific intent to violate it. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. The Anti-Kickback
Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">federal civil and criminal false claims laws and civil monetary penalty laws, including the FCA, which prohibit, among
other things, individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment to, or approval by Medicare, Medicaid or other federal healthcare programs, knowingly making, using or causing to be
made or used a false record or statement material to a false or fraudulent claim or an obligation to pay or transmit money to the federal government, or knowingly concealing or knowingly and improperly avoiding or decreasing or concealing an
obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#147;cause&#148; the submission of false or fraudulent claims.
The FCA also permits a private individual acting as a &#147;whistleblower&#148; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal
criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or
property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or
making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of
violating HIPAA without actual knowledge of the statute or specific intent to violate it; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their
respective implementing regulations, which impose, among other things, requirements on certain covered healthcare providers, health plans and healthcare clearinghouses as well as their respective business associates that perform services for them
that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information. HITECH also created new tiers of civil monetary penalties,
amended HIPAA to make civil and criminal penalties directly applicable to business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal civil actions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal Physician Payments Sunshine Act, created under the ACA, and its implementing regulations, which require
manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually to CMS, information related to
payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate
family members. Effective 2022, these reporting obligations extend to include transfers of value made, as well as ownership and investment interests held, during the previous year to certain <FONT STYLE="white-space:nowrap">non-physician</FONT>
providers such as physician assistants and nurse practitioners; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that
potentially harm consumers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to
sales or marketing arrangements and claims involving healthcare items or services reimbursed by nongovernmental third-party payors, including private insurers, and may be broader in scope than their federal equivalents; state and foreign laws that
require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to
healthcare providers; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws
governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">U.S. lawmakers and federal and state regulatory agencies have also focused on the relationships between pharmaceutical
companies and patient advocacy groups and medical organizations, with companies developing orphan drugs receiving additional scrutiny. In light of our close relationships with patient advocacy groups and healthcare professionals treating ALS and AD,
we face the risk of U.S. Congressional and federal and state inquiries and investigations related to our interactions with these groups. Addressing such investigations may require substantial resources and could potentially harm our reputation; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">European and other foreign law equivalents of each of the laws, including reporting requirements detailing interactions
with and payments to healthcare providers. Much like the Anti-Kickback Statute prohibition in the United States, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase,
supply, order or use of medicinal products is also prohibited in the EU. The provision of benefits or advantages to induce or reward improper performance is usually governed by the national anti-bribery laws of the EU Member States, and the Bribery
Act 2010 in the UK. Infringement of these laws could result in substantial fines and imprisonment. EU Directive 2001/83/EC, which is the EU Directive governing medicinal products for human use, further provides that, where medicinal products are
being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to such persons unless they are inexpensive and relevant to the practice of medicine or
pharmacy. Payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#146;s employer, his or her competent
professional organization and/or the regulatory authorities of the individual EU Member States. These requirements are </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
provided in the national laws, industry codes or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk,
public reprimands, administrative penalties, fines or imprisonment. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The distribution of pharmaceutical products is subject to
additional requirements and regulations, including extensive recordkeeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. Ensuring that our internal operations and future business
arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future
statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and
regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government-funded healthcare programs, such as Medicare and Medicaid, or
similar programs in other countries or jurisdictions, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or
similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws and the delay, reduction, termination or restructuring of our operations. Further, defending against any such actions can be costly
and time-consuming, and may require significant financial and personnel resources. Therefore, even if we successfully defend against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other
providers or entities with whom we expect to do business is found to not comply with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs and
imprisonment. If any of the above occur, it could adversely affect our ability to operate our business and our results of operations. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Compliance with
global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines
and penalties, which may have a material adverse effect on our business, financial condition or results of operations. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The regulatory
framework for the collection, use, safeguarding, sharing, transfer and other information processing worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, virtually every jurisdiction in which we
operate has established its own data security and privacy frameworks with which we must comply. For example, the collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the EU, including personal health
data, is subject to the EU General Data Protection Regulation, or the GDPR, which took effect across all member states of the EEA in May 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal
data, including requirements relating to processing health and other sensitive data, obtaining the consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing
safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR increases our obligations with respect to clinical trials
conducted in the EEA by expanding the definition of personal data to include coded data and requiring changes to informed consent practices and more detailed notices for clinical trial subjects and investigators. In addition, the GDPR also imposes
strict rules on the transfer of personal data to countries outside the EU, including the United States, and, as a result, increases the scrutiny that clinical trial sites located in the EEA should apply to transfers of personal data from such sites
to countries that are considered to lack an adequate level of data protection, such as the United States. The GDPR also permits data protection authorities to require the destruction of improperly gathered or used personal information and or impose
substantial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
fines for violations of the GDPR, which can be up to four percent of global revenues or 20&nbsp;million Euros, whichever is greater and it also confers a private right of action on data subjects
and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR provides that EU member states may make their own
further laws and regulations limiting the processing of personal data, including genetic, biometric or health data. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Similar actions are either
in place or underway in the United States. There are a broad variety of data protection laws that are applicable to our activities, and a wide range of enforcement agencies at both the state and federal levels that can review companies for privacy
and data security concerns based on general consumer protection laws. The Federal Trade Commission and state Attorneys General are all aggressive in reviewing consumers&#146; privacy and data security protections. New laws also are being considered
at both the state and federal levels. For example, the California Consumer Privacy Act&#151;which went into effect on January&nbsp;1, 2020&#151;is creating similar risks and obligations as those created by GDPR, though the Act does exempt certain
information collected as part of a clinical trial subject to the Federal Policy for the Protection of Human Subjects (the Common Rule). Many other states are considering similar legislation. A broad range of legislative measures also has been
introduced at the federal level. Accordingly, failure to comply with federal and state laws (both those currently in effect and future legislation) regarding the privacy and security of personal information could expose us to fines and penalties
under such laws. There also is the threat of consumer class actions related to these laws and the overall protection of personal data. Even if we are not determined to have violated these laws, government investigations into these issues typically
require the expenditure of significant resources and generate negative publicity, which could harm our reputation and our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Given the
breadth and depth of changes in data protection obligations, preparing for and complying with these requirements is rigorous and time-intensive and requires significant resources and a review of our technologies, systems and practices, as well as
those of any third-party collaborators, service providers, contractors or consultants that process or transfer personal data collected in the EU. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain
types of sensitive data, such as healthcare data or other personal information from our clinical trials, could require us to change our business practices and put in place additional compliance mechanisms, may interrupt or delay our development,
regulatory and commercialization activities and increase our cost of doing business, and could lead to government enforcement actions, private litigation and significant fines and penalties against us and could have a material adverse effect on our
business, financial condition or results of operations. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our commercial success depends on our ability to protect our intellectual property and proprietary technology. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our commercial success depends in large part on our ability to obtain and maintain intellectual property rights protection through patents, trademarks
and trade secrets in the United States and other countries with respect to our proprietary product candidate, AMX0035, and any future proprietary product candidates. If we do not adequately protect our intellectual property rights, competitors may
be able to erode, negate or preempt any competitive advantage we may have, which could harm our business and ability to achieve profitability. To protect our proprietary position, we have filed patent applications and may file other patent
applications in the United States or abroad related to AMX0035 or any future product candidates that are important to our business; we may also license or purchase patents or patent applications filed by others. The patent application process is
expensive and time-consuming. We may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If the scope of the patent protection we obtain is not sufficiently broad, we may not be able to
prevent others from developing and commercializing technology and products similar or identical to ours. The degree of patent protection we require to successfully compete in the marketplace may be unavailable or severely limited in some cases and
may not adequately protect our rights or permit us to gain or keep any competitive advantage. We cannot provide any assurances that any of our patents have, or that any of our pending owned patent applications that mature into issued patents will
include claims with a scope sufficient to protect our proprietary therapeutics or otherwise provide any competitive advantage. Other parties have developed or may develop technologies that may be related or competitive with our approach, and may
have filed or may file patent applications and may have been issued or may be issued patents with claims that overlap or conflict with our patent applications, either by claiming the same compounds, formulations or methods or by claiming subject
matter that could dominate our patent position. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Furthermore, patents have a limited lifespan. In the United States, the
natural expiration of a patent is generally twenty years after it is filed. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing
and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with adequate and continuing patent
protection sufficient to exclude others from commercializing products similar to AMX0035 or any future product candidates. In the event that an alternative combination, or TURSO as a single drug product, is developed and approved for use in
indications for which we may seek approval and falls outside the scope of our patent claims, the marketability and commercial success of AMX0035, if approved, could be materially harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if they are unchallenged, our owned patents and pending patent applications, if issued, may not provide us with any meaningful protection or
prevent competitors from designing around our patent claims to circumvent our patents by developing similar or alternative therapeutics in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. For example, a third party may develop a
competitive therapy that provides benefits similar to our product candidate but falls outside the scope of our patent protection or license rights. If the patent protection provided by the patent and patent applications we hold or pursue with
respect to AMX0035 or any future product candidates is not sufficiently broad to impede such competition, our ability to successfully commercialize our product candidate could be negatively affected, which would harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We, or any future partners, collaborators, or licensees, may fail to identify patentable aspects of inventions made in the course of development and
commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">It is possible that defects of form in the preparation or filing of our patent or patent applications may exist, or may arise in the future, for example
with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we or our partners, collaborators, or licensees whether current or future, fail to establish, maintain or protect such patents and other
intellectual property rights, such rights may be reduced or eliminated. If our partners, collaborators, or licensees are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent
rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in
valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The patent position of biotechnology and pharmaceutical companies carries uncertainty. In addition, the determination of patent rights with respect to
pharmaceutical compounds commonly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
involves complex legal and factual questions, which are dependent upon the current legal and intellectual property context, extant legal precedent and interpretations of the law by individuals.
As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are characterized by uncertainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pending
patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Assuming the other requirements for patentability are met, currently, the
first to file a patent application is generally entitled to the patent. However, prior to March&nbsp;16, 2013, in the United States, the first to invent was entitled to the patent. Publications of discoveries in the scientific literature often lag
behind the actual discoveries, and patent applications in the United States and other jurisdictions are not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the
inventions claimed in our patent or pending patent applications, or that we were the first to file for patent protection of such inventions. If third parties have filed prior patent applications on inventions claimed in our patents or applications
that were filed on or before March&nbsp;15, 2013, an interference proceeding in the United States can be initiated by such third parties to determine who was the first to invent any of the subject matter covered by the patent claims of our
applications. If third parties have filed such prior applications after March&nbsp;15, 2013, a derivation proceeding in the United States can be initiated by such third parties to determine whether our invention was derived from theirs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, because the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, our patents may be challenged in
the courts or patent offices in the United States and abroad. Also, while we believe that we have disclosed all potentially relevant prior art relating to our patents and patent applications, there is no assurance that we have found all such prior
art or disclosed it in every relevant jurisdiction. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published
until 18 months after filing or, in some cases, not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent
protection of such inventions. If such prior art exists, it may be used to invalidate a patent, or may prevent a patent from issuing from a pending patent application. For example, such patent filings may be subject to a third-party submission of
prior art to the U.S. Patent and Trademark Office, or USPTO, or to other patent offices around the world. Alternately or additionally, we may become involved in post-grant review procedures, oppositions, derivation proceedings, <I>ex parte</I>
reexaminations, <I>inter partes</I> review, supplemental examinations, or interference proceedings or challenges in district court, in the United States or in various foreign patent offices, including both national and regional, challenging patents
or patent applications in which we have rights, including patents on which we rely to protect our business. An adverse determination in any such challenges may result in loss of the patent or in patent or patent application claims being narrowed,
invalidated or held unenforceable, in whole or in part, or in denial of the patent application or loss or reduction in the scope of one or more claims of the patent or patent application, any of which could limit our ability to stop others from
using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pending and future patent applications may not result in patents being issued that protect our business, in whole or in part, or which effectively
prevent others from commercializing competitive products. Competitors may also be able to design around our patents. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the
value of our patents or narrow the scope of our patent protection. In addition, the laws of foreign countries may not protect our rights to the same extent or in the same manner as the laws of the United States. For example, patent laws in various
jurisdictions, including jurisdictions covering </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
significant commercial markets, such as the European Patent Office, or EPO, China and Japan, restrict the patentability of methods of treatment of the human body more than United States law does.
If these developments were to occur, they could have a material adverse effect on our ability to generate revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The patent application process
is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our future development partners will be successful in protecting AMX0035 or any future product candidates by obtaining and defending patents. These risks
and uncertainties include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee
payment and other provisions during the patent process. There are situations in which noncompliance, whether intentional or not, can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent
rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">patent applications may not result in any patents being issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">patents that may be issued or <FONT STYLE="white-space:nowrap">in-licensed</FONT> may be challenged, invalidated, modified,
revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our competitors, many of whom have substantially greater resources and many of whom have made significant investments in
competing technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use, and sell AMX0035; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent
protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts,
allowing foreign competitors a better opportunity to create, develop and market competing product candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">countries other than the United States may, under certain circumstances, force us to grant a license under our patents to a
competitor, thus allowing the competitor to compete with us in that jurisdiction or forcing us to lower the price of our drug in that jurisdiction. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Issued patents that we have or may obtain or license may not provide us with any meaningful protection, prevent competitors from competing with us or
otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. Our
competitors may also seek approval to market their own products similar to or otherwise competitive with our products. Alternatively, our competitors may seek to market generic versions of any approved products by submitting ANDAs to the FDA in
which they claim that patents owned or licensed by us are invalid, unenforceable or not infringed. In these circumstances, we may need to defend or assert our patents, or both, including by filing lawsuits alleging patent infringement. In any of
these types of proceedings, a court or other agency with jurisdiction may find our patents invalid or unenforceable, or that our competitors do not infringe our patents. Thus, even if we have valid and enforceable patents, these patents still may
not provide protection against competing products or processes sufficient to achieve our business objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, we rely on the
protection of our trade secrets and proprietary, unpatented <FONT STYLE="white-space:nowrap">know-how.</FONT> Although we have taken steps to protect our trade secrets and unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> including
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
entering into confidentiality agreements with third parties, and confidential information and invention assignment agreements with employees, consultants, collaborators, vendors, and advisors, we
cannot provide any assurances that all such agreements have been duly executed, and third parties may still obtain this information or may come upon this or similar information independently. It is possible that technology relevant to our business
will be independently developed by a person who is not a party to such a confidentiality or invention assignment agreement. We may not be able to prevent the unauthorized disclosure or use of our technical knowledge or trade secrets by consultants,
collaborators, vendors, advisors, former employees and current employees. Furthermore, if the parties to our confidentiality agreements breach or violate the terms of these agreements, we may not have adequate remedies for any such breach or
violation, and we could lose our trade secrets as a consequence of such breaches or violations. Our trade secrets could otherwise become known or be independently discovered by our competitors. Additionally, if the steps taken to maintain our trade
secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating our trade secrets. If any of these events occurs or if we otherwise lose protection for our trade secrets or proprietary <FONT
STYLE="white-space:nowrap">know-how,</FONT> our business may be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>It is difficult and costly to protect our intellectual property and our proprietary
technologies, and we may not be able to ensure their protection. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our commercial success will depend in part on obtaining and maintaining
patent protection and trade secret protection for our proprietary product candidate, AMX0035, as well as on successfully defending these patents against potential third-party challenges. Our ability to protect our product candidate from unauthorized
making, using, selling, offering to sell or importing by third parties is dependent on the extent to which we have rights under valid and enforceable patents that cover these activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The patent positions of pharmaceutical, biotechnology and other life sciences companies can be highly uncertain and involve complex legal and factual
questions for which important legal principles remain unresolved and have in recent years been the subject of much litigation. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may
diminish the value of our intellectual property. Over the past decade, U.S. federal courts have increasingly invalidated pharmaceutical and biotechnology patents during litigation often based on changing interpretations of patent law. Further, the
determination that a patent application or patent claim meets all of the requirements for patentability is a subjective determination based on the application of law and jurisprudence. The ultimate determination by the U.S. Patent and Trademark
Office, or USPTO, or by a court or other trier of fact in the United States, or corresponding foreign national patent offices or courts, on whether a claim meets all requirements of patentability cannot be assured. Accordingly, we cannot predict the
breadth of claims that may be allowed or enforced in our owned patents or patent applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We cannot provide assurances that any of our patent
applications will be found to be patentable, including over our own prior art publications or patent literature, or will issue as patents. Neither can we make assurances as to the scope of any claims that may issue from our pending and future patent
applications nor to the outcome of any proceedings by any potential third parties that could challenge the patentability, validity or enforceability of our patents and patent applications in the United States or foreign jurisdictions. Any such
challenge, if successful, could limit patent protection for our products and current or future product candidates and/or materially harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to challenges during litigation, third parties can challenge the validity of our patents in the United States using post-grant review and
<I>inter partes</I> review proceedings, which some third parties have been using to cause the cancellation of selected or all claims of issued patents of competitors. For a patent filed March&nbsp;16, 2013 or later, a petition for post-grant review
can be filed by a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
third party in a nine-month window from issuance of the patent. A petition for <I>inter partes</I> review can be filed immediately following the issuance of a patent if the patent has an
effective filing date prior to March&nbsp;16, 2013. A petition for <I>inter partes</I> review can be filed after the nine-month period for filing a post-grant review petition has expired for a patent with an effective filing date of March&nbsp;16,
2013 or later. Post-grant review proceedings can be brought on any ground of invalidity, whereas <I>inter partes</I> review proceedings can only raise an invalidity challenge based on published prior art and patents. These adversarial actions at the
USPTO review patent claims without the presumption of validity afforded to U.S. patents in lawsuits in U.S. federal courts, and use a lower burden of proof than used in litigation in U.S. federal courts. Therefore, it is generally considered easier
for a competitor or third party to have a U.S. patent invalidated in a USPTO post-grant review or <I>inter partes</I> review proceeding than invalidated in a litigation in a U.S. federal court. If any of our patents are challenged by a third party
in such a USPTO proceeding, there is no guarantee that we will be successful in defending the patent, which may result in a loss of the challenged patent right to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the EU, third parties can challenge the validity of our patents by filing an Opposition before the EPO. An adverse determination by the Opposition
Board can result in the narrowing or invalidation of a European patent. If any of our European patents are challenged by a third party in such an opposition proceeding, there is no guarantee that we will be successful in defending the patent, which
may result in a loss of the challenged patent right to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The degree of future protection for our proprietary rights is uncertain because legal
means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may not be able to generate sufficient data to support full patent applications that protect the entire breadth of
developments in one or more of our programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">it is possible that one or more of our pending patent applications will not become an issued patent or, if issued, that the
patent(s) claims will have sufficient scope to protect our technology, provide us with commercially viable patent protection or provide us with any competitive advantages; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">if our pending applications issue as patents, they may be challenged by third parties as invalid or unenforceable under
United States or foreign laws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may not successfully commercialize AMX0035, if approved, before our relevant patents expire; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may not be the first to make the inventions covered by each of our patents and pending patent applications; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may not develop additional proprietary technologies or product candidates that are separately patentable.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, to the extent that we are unable to obtain and maintain patent protection for AMX0035 or any future product
candidates or in the event that such patent protection expires, it may no longer be cost-effective to extend our portfolio by pursuing additional development of a product or product candidate for <FONT STYLE="white-space:nowrap">follow-on</FONT>
indications. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our
business would be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to patents, we also may rely on trade secrets to protect our proprietary product candidate, especially
where we do not believe patent protection is appropriate or obtainable. Trade secrets are difficult to protect. We seek to protect our confidential proprietary information, in part, by confidentiality agreements and invention assignment agreements
with our employees, consultants, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
scientific advisors, contractors and collaborators. These agreements are designed to protect our proprietary information. However, we cannot be certain that such agreements have been entered into
with all relevant parties, and we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop
substantially equivalent information and techniques. For example, our employees, consultants, contractors, outside scientific collaborators and other advisers may unintentionally or willfully disclose our information to competitors. Enforcing a
claim that a third-party entity illegally obtained and is using any of our trade secrets is expensive and time-consuming, and the outcome is unpredictable, and we may not be able to obtain adequate remedies for such breaches. We also seek to
preserve the integrity and confidentiality of our confidential proprietary information by maintaining physical security of our premises and physical and electronic security of our information technology systems, but it is possible that these
security measures could be breached. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and <FONT
STYLE="white-space:nowrap">know-how.</FONT> Notably, proprietary technology protected by a trade secret does not preempt the patenting of independently developed equivalent technology, even if such equivalent technology is invented subsequent to the
technology protected by a trade secret. If any of our confidential proprietary information were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or
information to compete with us, which could harm our competitive position. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Patent terms may be inadequate to protect our competitive position on our products
for an adequate amount of time. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural
expiration of a patent is generally 20 years from its earliest U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. The patent term of a U.S. patent may be lengthened by patent term adjustment, which compensates a patentee for
administrative delays by the United States Patent and Trademark Office in granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier-filed patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Given the amount of time required for the
development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a Patent Term Extension, or PTE, of up to five years
beyond the normal expiration of the patent to compensate patent owners for loss of enforceable patent term due to the lengthy regulatory approval process. PTE is limited to the approved indication (or any additional indications approved during the
period of extension). We anticipate applying for PTE in the United States. Similar extensions may be available in other countries where we are prosecuting patents and we likewise anticipate applying for such extensions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The granting of such patent term extensions is not guaranteed and is subject to numerous requirements. We might not be granted an extension because of,
for example, failure to apply within applicable periods, failure to apply prior to the expiration of relevant patents or failure to otherwise satisfy any of the numerous applicable requirements. Moreover, the applicable authorities, including the
FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more
limited extensions than we request. If this occurs, our competitors may be able to obtain approval of competing products following our patent expiration by referencing our clinical and preclinical data and launch their product earlier than might
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
otherwise be the case. If this were to occur, it could have a material adverse effect on our ability to generate revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Changes in the interpretation of patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our
ability to protect our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The United States Congress is responsible for passing laws establishing patentability standards. As with
any laws, implementation is left to federal agencies and the federal courts based on their interpretations of the laws. Interpretation of patent standards can vary significantly within the U.S. Patent and Trademark Office, and across the various
federal courts, including the Supreme Court. Recently, the Supreme Court has ruled on several patent cases, generally limiting the types of inventions that can be patented. Further, there are open questions regarding interpretation of patentability
standards that the Supreme Court has yet to decisively address. Absent clear guidance from the Supreme Court, the USPTO has become increasingly conservative in its interpretation of patent laws and standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to increasing uncertainty with regard to our ability to obtain patents in the future, the legal landscape in the United States has created
uncertainty with respect to the value of patents. Depending on any actions by Congress, and future decisions by the lower federal courts and the Supreme Court, along with interpretations by the USPTO, the laws and regulations governing patents could
change in unpredictable ways and could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may not be able to enforce our intellectual property rights throughout the world. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Filing, prosecuting, enforcing and defending patents on our product candidate in all countries throughout the world would be prohibitively expensive, and
our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. The requirements for patentability may differ in certain countries, particularly in developing countries; thus, even
in countries where we do pursue patent protection, there can be no assurance that any patents will issue with claims that cover our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual
property laws. Additionally, laws of some countries outside of the United States and the EU do not afford intellectual property protection to the same extent as the laws of the United States and the EU. Many companies have encountered significant
problems in protecting and defending intellectual property rights in certain foreign jurisdictions. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights. For
example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. Consequently, we may not be able to prevent third parties from practicing our inventions in certain countries outside the
United States and the EU or from selling or importing products made from our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to
develop and market their own products and, further, may export otherwise infringing products to territories where we have patent protection if our ability to enforce our patents to stop infringing activities is inadequate. These products may compete
with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Proceedings to enforce our patent rights, whether or not successful, could result in substantial costs and divert our efforts and resources from other
aspects of our business. Moreover, such proceedings could put our patents at risk of being invalidated or held unenforceable, or interpreted narrowly, and our pending patent applications at risk of not issuing, and could provoke third parties to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Furthermore, while we intend
to protect our intellectual property rights in major markets for our products, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our products, if approved. Accordingly,
our efforts to protect our intellectual property rights in such countries may be inadequate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Others may challenge inventorship or claim an ownership interest
in our intellectual property which could expose it to litigation and have a significant adverse effect on its prospects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A third party or
former employee or collaborator may claim an inventorship or ownership interest in one or more of our or our licensors&#146; patents or other proprietary or intellectual property rights. A third party could bring legal actions against us and seek
monetary damages and/or enjoin clinical testing, manufacturing and marketing of the affected product or products. While we are presently unaware of any claims or assertions by third-parties with respect to inventorship or ownership of our patents or
other intellectual property, we cannot guarantee that a third party will not assert a claim or an interest in any of such patents or intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose
valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to AMX0035 or any future product candidates. Further, regardless of the outcome, if we become involved in any litigation,
it could consume a substantial portion of our resources, and cause a significant diversion of effort by our technical and management personnel.<B> </B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we
are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing AMX0035 or any future product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our commercial success depends, in part, on our ability to develop, manufacture, market and sell our product candidate without infringing the
intellectual property and other proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights
owned or controlled by third parties. Third parties may have U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> issued patents and pending patent applications relating to compounds, methods of manufacturing compounds and/or methods of use for
the treatment of the disease indications for which we are developing AMX0035 or any future<B><I> </I></B>product candidates. If any third-party patents or patent applications are found to cover AMX0035 or any future<B><I> </I></B>product candidates
or their methods of use or manufacture, we may not be free to manufacture or market such product candidates as planned without obtaining a license, which may not be available on commercially reasonable terms, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or
threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our products candidates, including patent infringement lawsuits in the United States or abroad. There may be third-party patents or
patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the composition, use or manufacture of AMX0035 or any future<B><I> </I></B>product candidates. While we perform periodic searches
for relevant patents and patent applications with respect to our proprietary drug candidate, AMX0035, we cannot guarantee that any of our patent searches or analyses including, but not limited to, the identification of relevant patents, the scope of
patent claims or the expiration of relevant patents are complete or thorough, nor can we be certain that we have identified each and every patent and pending application in the United States and abroad that is relevant to or necessary for the
commercialization of AMX0035 or any future<B><I> </I></B>product candidates in any jurisdiction. Because patent applications can take many years to issue, there may be currently </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
pending patent applications which may later result in issued patents that AMX0035 or any future<B><I> </I></B>product candidates may be accused of infringing. In addition, third parties may
obtain patents in the future and claim that use of our technologies infringes upon these patents. Accordingly, third parties may assert infringement claims against us based on intellectual property rights that exist now or arise in the future. The
outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance. The pharmaceutical and biotechnology industries have produced a significant number of patents, and it may not always be clear to
industry participants, including us, which patents cover various types of products or methods of use or manufacture. The scope of protection afforded by a patent is subject to interpretation by the courts, and the interpretation is not always
uniform. If we were sued for patent infringement, we would need to demonstrate that our product candidate, product or method either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and
we may not be able to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we
are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could significantly harm our business and operating
results. In addition, parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources, and we may not have sufficient resources to bring
these actions to a successful conclusion. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are found to infringe a third party&#146;s intellectual property rights, we could be forced,
including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and
continue developing, manufacturing or marketing the infringing product candidate or product. If we were required to obtain a license to continue to manufacture or market the affected product, we may be required to pay substantial royalties or grant
cross-licenses to our patents. We cannot, however, assure you that any such license will be available on acceptable terms, if at all. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business
operations as a result of claims of patent infringement or violation of other intellectual property rights. Further, the outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance,
including the demeanor and credibility of witnesses and the identity of any adverse party. This is especially true in intellectual property cases that may turn on the testimony of experts as to technical facts upon which experts may reasonably
disagree. Furthermore, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our
competitors access to the same technologies licensed to us; alternatively or additionally it could include terms that impede or destroy our ability to compete successfully in the commercial marketplace. In addition, we could be found liable for
significant monetary damages, including treble damages and attorneys&#146; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing AMX0035 or any future<B><I> </I></B>product
candidates or force us to cease some of our business operations, which could harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.
Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In
addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of
operations, financial condition and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may be subject to claims by third parties asserting that our employees or we have misappropriated their
intellectual property, or claiming ownership of what we regard as our own intellectual property. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Many of our current and former
employees and our licensors&#146; current and former employees, including our senior management, were previously employed at universities or at other biotechnology or pharmaceutical companies, including some which may be competitors or potential
competitors. Some of these employees, including members of our senior management, may have executed proprietary rights, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and <FONT STYLE="white-space:nowrap">non-competition</FONT> agreements, or
similar agreements, in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be
subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such third party. Litigation may be necessary to defend against such claims. If we fail in
defending any such claims, in addition to paying monetary damages, we may sustain damages or lose key personnel, valuable intellectual property rights or the personnel&#146;s work product, which could hamper or prevent commercialization of our
technology, which in turn could materially affect our commercial development efforts. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our
technology or products. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, while we typically require our employees, consultants and contractors who may be involved in the development of intellectual property
to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own, which may result in claims by or against us
related to the ownership of such intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Even if we are successful in prosecuting or
defending against such claims, litigation could result in substantial costs and be a distraction to our senior management and scientific personnel. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If
our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our trademarks and our business may be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We rely on
both registration and common law protection for our trademarks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or
customers in our markets of interest. During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the
USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against
our trademarks, and our trademarks may not survive such proceedings. Moreover, any name we propose to use for our products in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a
trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA objects to any of our proposed product names, we may be required to expend significant
additional resources in an effort to identify a usable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. If we are unable to establish name recognition
based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Intellectual property rights do not necessarily address all potential threats to our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may
not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">others may be able to make products that are competitive to AMX0035, for example a TURSO monotherapy, or any of our future
product candidates but that are not covered by the claims of the patents that we own; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">others may independently develop similar or alternative technologies or otherwise circumvent any of our technologies
without infringing our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we or any of our collaborators might not have been the first to invent the inventions covered by the patents or patent
applications that we own; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we or any of our collaborators might not have been the first to file patent applications covering certain of the patents or
patent applications that we or they own or have obtained a license, or will own or will have obtained a license; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">it is possible that our pending patent applications will not lead to issued patents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">issued patents that we own may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a
result of legal challenges by our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our competitors might conduct research and development activities in countries where we do not have patent rights, or in
countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">ownership of our patents or patent applications may be challenged by third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on
our business; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">patent enforcement is expensive and time-consuming and difficult to predict; thus we may not be able to enforce any of our
patents against a competitor. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our reliance on third parties for research and development and manufacturing requires us to share our trade
secrets, which increases the possibility that our trade secrets will be misappropriated or disclosed, and confidentiality agreements with employees and third parties may not adequately prevent disclosure of trade secrets and protect other
proprietary information. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We consider proprietary trade secrets or confidential <FONT STYLE="white-space:nowrap">know-how</FONT> and
unpatented <FONT STYLE="white-space:nowrap">know-how</FONT> to be important to our business. We may rely on trade secrets or confidential <FONT STYLE="white-space:nowrap">know-how</FONT> to protect our technology, especially where patent protection
is believed by us to be of limited value. We rely on third parties for research and development work, and expect to rely on third parties for future manufacturing of our proprietary product candidate, AMX0035, and any future product candidates. We
also expect to collaborate with third parties on the development of AMX0035 and any future product candidates. As a result of the aforementioned collaborations, we must, at times, share trade secrets with our collaborators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Trade secrets or confidential <FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to maintain as confidential. To protect this type of
information against disclosure or appropriation by competitors, our policy is to require our employees, consultants, contractors and advisors to enter into confidentiality agreements and, if applicable, material transfer agreements, consulting
agreements or other similar agreements with us prior to beginning research or disclosing proprietary information. These agreements typically limit the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
rights of the third parties to use or disclose our confidential information, including our trade secrets. However, current or former employees, consultants, contractors and advisers may
unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. The need to share trade secrets
and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our
proprietary position is based, in part, on our <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets, a competitor&#146;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and
may have an adverse effect on our business and results of operations. Enforcing a claim that a third party obtained illegally and is using trade secrets or confidential <FONT STYLE="white-space:nowrap">know-how</FONT> is expensive, time consuming
and unpredictable. Moreover, the enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, these
agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite
our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A
competitor&#146;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may need to acquire or
license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A third party may hold intellectual property, including patent rights that are important or necessary to the development of additional future product
candidates. It may be necessary for us to use the patented or proprietary technology of one or more third parties to commercialize our current and future product candidates. If we are unable to acquire such intellectual property outright, or obtain
licenses to such intellectual property from such third parties when needed or on commercially reasonable terms, our ability to commercialize additional future product candidates, if approved, would likely be delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The risks described elsewhere pertaining to our intellectual property rights also apply to the intellectual property rights that we may <FONT
STYLE="white-space:nowrap">in-license,</FONT> and any failure by us or our licensors to obtain, maintain, defend and enforce these rights could have an adverse effect on our business. In some cases we may not have control over the prosecution,
maintenance or enforcement of the patents that we license, and may not have sufficient ability to provide input into the patent prosecution, maintenance and defense process with respect to such patents, and potential future licensors may fail to
take the steps that we believe are necessary or desirable in order to obtain, maintain, defend and enforce the licensed patents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Risks Related to
Our Business Operations, Employee Matters and Managing Growth </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>A pandemic, epidemic, or outbreak of an infectious disease, such as the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, may materially and adversely affect our business, including our preclinical studies, clinical trials, third parties on whom we rely, our supply chain, our ability to raise capital, our ability to
conduct regular business and our financial results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are subject to risks related to public health crises such as the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic and the ongoing efforts to halt its outbreak. The pandemic and policies and regulations implemented by governments in response to the pandemic, often directing businesses and governmental agencies
to cease <FONT STYLE="white-space:nowrap">non-essential</FONT> operations at physical locations, prohibiting certain nonessential gatherings and ceasing <FONT STYLE="white-space:nowrap">non-essential</FONT> travel have also had a significant impact,
both direct and indirect, on businesses </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
and commerce, as worker shortages have occurred, supply chains have been disrupted, facilities and production have been suspended, and demand for certain goods and services, such as medical
service and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. We have experienced certain impacts of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic to date, including having to make certain
alterations to our preclinical and clinical trial activities, such as scheduling certain work off-site and performing off-site assessments. For example, we had to amend our CENTAUR trial protocol to allow for remote visits by patients, instead of
patients making site visits. In addition, in some cases we were forced to delay enrollment at certain sites in our recently completed Phase 2 clinical trial for AMX0035 in AD. There can be no guarantee we will not experience other impacts, such as
being forced to further delay or pause enrollment, experiencing potential interruptions to our supply chain, facing difficulties or additional costs in enrolling patients in future clinical trials or being able to achieve full enrollment of our
studies within the timeframes we anticipate, or at all. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The impact of the COVID-19 pandemic has been and may continue to be extensive in many
aspects of society and could continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world. The full extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic,
including efforts to halt the pandemic, could ultimately impact our business, preclinical studies, clinical trials and financial results will depend on future developments, which are highly uncertain and cannot be accurately predicted, including the
rate and success of vaccination efforts, new strains of the virus for which current vaccinations may not be effective and new information which may emerge, among others. Other global health concerns could also result in social, economic, and labor
instability in the countries in which we or the third parties with whom we engage operate. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In response to the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, we have continued to take precautionary measures intended to help minimize the risk of the virus to our employees, including closing or reducing access to our executive offices and
temporarily requiring employees to work remotely, suspending all <FONT STYLE="white-space:nowrap">non-essential</FONT> travel for our employees and discouraging employee attendance at industry events and
<FONT STYLE="white-space:nowrap">in-person</FONT> work-related meetings, all of which could negatively affect our business. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">While we have been
working closely with our third-party manufacturers, distributors and other partners to manage our supply chain activities and mitigate potential disruptions to the production of AMX0035 as a result of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, if, despite vaccination efforts, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic persists for an extended period of time, there could be significant and material disruptions to
our supply chain and operations, and associated delays in the manufacturing and supply of AMX0035 and any future product candidates. Any such supply disruptions, including disruptions in procuring items that are essential for our research and
development activities and securing manufacturing slots for the products needed for such activities, could adversely impact our ability to initiate and complete preclinical studies or clinical trials and generate sales of and revenue from our
product candidates, if approved, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has affected and may in the future affect employees of third-party CROs located in
affected geographies that we rely upon to carry out our clinical trials. If current efforts to control the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic are not successful, if the spread of the virus or any variant of the virus is not
contained or increases, or if a new virus or pandemic emerges, we may experience additional disruptions that could severely impact our business and clinical trials, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays or difficulties in our commercialization efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays or difficulties in enrolling patients in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and
clinical site staff; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of sites or facilities
serving as our clinical trial sites and staff supporting the conduct of our clinical trials, including our trained therapists, or absenteeism that reduces site resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed
or recommended by federal, state or national governments, employers and others or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the integrity of clinical trial data; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">risk that participants enrolled in our clinical trials will acquire <FONT STYLE="white-space:nowrap">COVID-19</FONT> or
another virus or illness while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events or patient withdrawals from our trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">limitations in employee resources that would otherwise be focused on conducting our clinical trials, including because of
sickness of employees or their families or the desire of employees to avoid contact with large groups of people; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays in receiving authorizations from regulatory authorities to initiate our future clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">interruption in global shipping that may affect the transport of clinical trial materials, such as the AMX0035 used in our
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in local regulations as part of a response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or
other pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or the discontinuation of the clinical trials altogether; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">interruptions or delays in preclinical studies due to restricted or limited operations at research and development
laboratory facilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due
to limitations in employee resources or forced furlough of government employees; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">refusal of the FDA, Health Canada, the EMA or the other regulatory bodies to accept data from clinical trials in affected
geographies outside the United States, Canada or the EU or other relevant local geographies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any negative impact the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic or any future pandemic or similar disruption has on patient enrollment or treatment, or the development of AMX0035 and any future product candidates, could cause costly delays to clinical trial
activities, which could adversely affect our ability to obtain regulatory approval for and to commercialize AMX0035 and any future product candidates, if approved, increase our operating expenses, which could have a material adverse effect on our
financial results. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has also in the past caused significant volatility in public equity markets and disruptions to the United States and global economies and any future pandemic or similar
disruption could lead to further market dislocation. Any such increased volatility and economic dislocation may make it more difficult for us to raise capital on favorable terms, or at all. If we or any of the third parties with whom we engage were
to experience renewed shutdowns or other business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on our
business and our results of operations and financial conditions. To the extent the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or any future pandemic or similar disruption adversely affects our business and financial results, it may
also heighten many of the other risks described in this &#145;&#145;Risk Factors&#146;&#146; section, such as those relating to the timing and completion of our clinical trials and our ability to obtain future financing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We depend heavily on our executive officers, principal consultants and others, and the loss of their services
would materially harm our business. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our success depends, and will likely continue to depend, upon our ability to hire and retain the
services of our current executive officers, principal consultants and others, including Josh Cohen and Justin Klee, our <FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officers, James Frates, our Chief Financial Officer, Margaret Olinger,
our Global Head of Commercial and Chief Commercial Officer, and Patrick Yeramian, our Global Head of Clinical Research&nbsp;&amp; Development and Chief Medical Officer. We have entered into employment agreements with Mr.&nbsp;Cohen, Mr.&nbsp;Klee,
Mr.&nbsp;Frates, Ms.&nbsp;Olinger and Dr.&nbsp;Yeramian, but they may terminate their employment with us at any time. The loss of their services might impede the achievement of our research, development and commercialization objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our ability to compete in the biotechnology and pharmaceuticals industries depends upon our ability to attract and retain highly qualified managerial,
scientific and medical personnel. Our industry has experienced a high rate of turnover of management personnel in recent years. Replacing executive officers or other key employees may be difficult and may take an extended period of time because of
the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize products successfully. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key employees on
acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and
commercialization strategy. Our consultants and advisors may be employed by other entities and may have commitments under consulting or advisory contracts with those entities that may limit their availability to us. If we are unable to continue to
attract and retain highly qualified personnel, our ability to develop and commercialize AMX0035 or any future product candidates will be limited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We only
have a limited number of employees to manage and operate our business. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December 13, 2021, we had 110 full-time employees. Our
focus on the development of AMX0035 requires us to optimize cash utilization and to manage and operate our business in a highly efficient manner. We cannot assure you that we will be able to hire and/or retain adequate staffing levels to develop
AMX0035 or to run our operations and/or to accomplish all of the objectives that we otherwise would seek to accomplish. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our employees, independent
contractors, consultants, collaborators and CROs may engage in misconduct or other improper activities, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements, which could cause significant
liability for us and harm our reputation. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are exposed to the risk that our employees, independent contractors, consultants, collaborators
and CROs may engage in fraudulent conduct or other illegal activity. Misconduct by those parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">FDA regulations or similar regulations of comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory
authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">manufacturing standards; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced
by comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">laws that require the reporting of financial information or data accurately. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creating
fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of product materials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter
misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a
failure to be in compliance with such laws, standards or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against
us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of civil, criminal and administrative penalties, damages,
monetary fines, disgorgement, integrity oversight and reporting obligations, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future
earnings, and curtailment of our operations, any of which could have a material adverse effect on our ability to operate our business and our results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We expect to expand our organization, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of regulatory
affairs and sales, marketing and distribution, as well as to support our public company operations. To manage these growth activities, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities
and continue to recruit and train additional qualified personnel. Our management may need to devote a significant amount of its attention to managing these growth activities. Moreover, our expected growth could require us to relocate to a different
geographic area of the country. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion or relocation of our
operations, retain key employees, or identify, recruit and train additional qualified personnel. Our inability to manage the expansion or relocation of our operations effectively may result in weaknesses in our infrastructure, give rise to
operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. See &#147;&#151;If we fail to remediate our material weaknesses over financial reporting controls and to implement and
maintain an effective system of internal controls, we may be unable to accurately report our results of operations, meet our reporting obligations or prevent fraud, and investor confidence in our company and the market price of our common stock may
be materially and adversely affected.&#148; Our expected growth could also require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If we are unable to
effectively manage our expected growth, our expenses may increase more than expected, our ability to generate revenues could be reduced and we may not be able to implement our business strategy, including the successful commercialization of AMX0035
or any future product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Risks Related to Our Common Stock and this Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If you purchase shares of our common stock in this offering, you will incur immediate and substantial dilution. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The offering price of our common stock is substantially higher than the net tangible book value per share of our common stock, which on a pro forma basis
was $2.45 per share as of September&nbsp;30, 2021. Based on the assumed initial public offering price of $19.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, you will experience immediate
dilution of $14.15 per share, representing the difference between our pro forma net tangible book value per share after giving effect to this offering and the assumed initial public offering price. This means that you will pay a higher price per
share than the amount of our total tangible assets, less our total liabilities, divided by the number of shares of common stock outstanding. Furthermore, if the underwriters exercise their over-allotment option or our previously issued options and
other rights to acquire common stock at prices below the assumed initial public offering price are exercised, you will experience further dilution. In addition, you may also experience additional dilution if options or other rights to purchase our
common stock that we may issue in the future are exercised or converted or we issue additional shares of our common stock at prices lower than our net tangible book value at such time. For more information, see &#147;Dilution.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We do not know whether an active, liquid and orderly trading market will develop for our common stock or what the market price of our common stock will be and as
a result it may be difficult for you to sell your shares of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to this offering there has been no public market for
shares of our common stock. Although we have applied to list our common stock on the Nasdaq Global Market, an active trading market for our shares may never develop or be sustained following this offering. You may not be able to sell your shares
quickly or at the market price if trading in shares of our common stock is not active. The initial public offering price for our common stock will be determined through negotiations with the underwriters, and the negotiated price may not be
indicative of the market price of our common stock after the offering. As a result of these and other factors, you may be unable to resell your shares of our common stock at or above the initial public offering price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into
strategic partnerships or acquire companies or products by using our shares of common stock as consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The price of our stock may be
volatile, and you could lose all or part of your investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The trading price of our common stock following this offering is likely to be highly
volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#147;Risk Factors&#148; section and elsewhere in
this prospectus, these factors include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the commencement, enrollment or results of our ongoing and future preclinical studies and clinical trials, or any future
preclinical studies or clinical trials, we may conduct of AMX0035 and any future product candidates, or changes in the development status of our current and any future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any additional regulatory submissions for AMX0035 or any future product candidates and any adverse development or perceived
adverse development with respect to the applicable regulatory authority&#146;s review of such submissions, including without limitation the FDA&#146;s issuance of a &#147;refusal to file&#148; letter or a request for additional information;
</P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">adverse results or delays in our preclinical studies and clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our decision to initiate a clinical trial, not to initiate a clinical trial, or to terminate an existing clinical trial;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">adverse regulatory decisions, including failure to receive regulatory approval for AMX0035 and any future product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in laws or regulations applicable to AMX0035 and any future product candidates, including but not limited to
clinical trial requirements for approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the failure to obtain coverage and adequate reimbursement of AMX0035 and any future product candidates, if approved;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes on the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any changes to our relationship with any manufacturers, suppliers, licensors, future collaborators or other strategic
partners; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our inability to obtain adequate product supply for any approved drug product or inability to do so at acceptable prices;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our inability to establish collaborations, if needed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our failure to commercialize AMX0035 and any future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">additions or departures of key scientific or management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">unanticipated serious safety concerns related to the use of AMX0035 and any future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">introduction of new products or services offered by us or our competitors, or the release or publication of clinical trial
results from competing product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">announcements of significant acquisitions, strategic partnerships, joint ventures, or capital commitments by us or our
competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to effectively manage our growth; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">actual or anticipated variations in quarterly operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our cash position and rate of expenditures; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the
public; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">publication of research reports about us or our industry or positive or negative recommendations or withdrawal of research
coverage by securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in the market valuations of similar companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">overall performance of the equity markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">issuances of debt or equity securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">sales of our common stock by us or our stockholders in the future or the perception that such sales may occur;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">trading volume of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in accounting practices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">ineffectiveness of our internal controls; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to
obtain patent protection for our technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">significant lawsuits, including patent or stockholder litigation; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">general political and economic conditions, including the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic; and </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">other events or factors, many of which are beyond our control. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the stock market in general, and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that
have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. If the
market price of our common stock after this offering does not exceed the initial public offering price, you may not realize any return on your investment in us and may lose some or all of your investment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have broad discretion in the use of the net proceeds from this offering and may invest or spend the proceeds in ways with which you do not agree and in ways
that may not yield a return on your investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Although we currently intend to use the net proceeds from this offering in the manner
described in the section titled &#147;Use of Proceeds&#148; in this prospectus, our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that do not improve our results
of operations or enhance the value of our common stock. You will not have the opportunity to influence our decisions on how to use the net proceeds from this offering. The failure by our management to apply these funds effectively could result in
financial losses that could harm our business, cause the price of our common stock to decline and delay the development of AMX0035 or any future product candidates. Pending their use, we may invest the net proceeds from this offering in a manner
that does not produce income or that loses value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are an emerging growth company and a smaller reporting company, and the reduced reporting requirements
applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are
an emerging growth company, as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not
emerging growth companies, including not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and
proxy statements and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. We could be an emerging growth company until
December&nbsp;31, 2027, although circumstances could cause us to lose that status earlier, including if we become a &#147;large accelerated filer&#148; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Securities Exchange
Act of 1934, as amended, or the Exchange Act, or if we have total annual gross revenue of $1.07&nbsp;billion or more during any fiscal year before that time, in which cases we would no longer be an emerging growth company as of the following
December&nbsp;31 or, if we issue more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during any three year period before that time, in which case we would cease to be an emerging growth company immediately.
Even after we no longer qualify as an emerging growth company, we may still qualify as a &#147;smaller reporting company&#148;, which would allow us to take advantage of many of the same exemptions from disclosure requirements, including not being
required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. Investors may find our
common stock less attractive because we may rely on these exemptions. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as
our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our
annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million measured on the last
business day of our second fiscal quarter. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised
accounting standards. This provision allows an emerging growth company to delay the adoption of accounting standards that have different effective dates for public and private companies until those standards would otherwise apply to private
companies. We have elected to avail ourselves of this exemption from new or revised accounting standards, and therefore we will not be subject to the same requirements to adopt new or revised accounting standards as other public companies that are
not emerging growth companies. </P>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>A significant portion of our total outstanding shares is restricted from immediate resale but may be sold into the
market in the near future, which could cause the market price of our common stock to decline significantly, even if our business is doing well. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market
that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. After this offering, and assuming no exercise of the underwriters&#146; option to purchase additional shares, we will have
outstanding 55,216,013 shares of common stock based on the number of shares outstanding as of November&nbsp;30, 2021. This includes the shares that we are selling in this offering, which may be resold in the public market immediately without
restriction, unless purchased by our affiliates or existing stockholders. All of the remaining shares are currently restricted as a result of securities laws or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, but will become eligible to
be sold after the offering as described in the &#147;Shares Eligible for Future Sale&#148; section of this prospectus. Moreover, holders of an aggregate of 45,196,305 shares of our common stock will have rights, subject to specified conditions, to
require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We do not anticipate paying any cash dividends on our capital stock in the foreseeable future. Accordingly, stockholders must rely on capital appreciation, if
any, for any return on their investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have never declared nor paid cash dividends on our capital stock. We currently plan to retain
all of our future earnings, if any, to finance the operation, development and growth of our business. In addition, the terms of any future debt or credit agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of
our common stock will be your sole source of gain for the foreseeable future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Concentration of ownership of our common stock among our existing executive
officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based upon
46,488,975 shares outstanding as of December 13, 2021, upon the closing of this offering, disregarding any shares of common stock that they purchase in this offering, and assuming no exercise of the underwriters&#146; option to purchase additional
shares, our executive officers and directors, combined with our stockholders who owned more than 5% of our outstanding common stock before this offering and their affiliates, will, in the aggregate, beneficially own shares representing approximately
51.3% of our common stock (assuming no purchases of shares in this offering by any members of this group (including through our directed share program)). In particular, ALS Invest 1 B.V., or ALS Invest, will
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
own approximately 10.8% of our common stock following this offering, Morningside Venture Investments Limited, or Morningside, together with its wholly-owned subsidiary, MVIL, LLC, will own
approximately 18.9% of our common stock following this offering and Viking Global Opportunities Illiquid Investments Sub-Master LP, or Viking, will own approximately 8.8% of our common stock following this offering (assuming in each case no
purchases of shares in this offering by any members of this group (including through our directed share program)). As a result, if ALS Invest, Morningside and Viking, along with stockholders who own more than 5% of our outstanding common stock after
this offering, were to choose to act together, they would be able to significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to
act&nbsp;together, would significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of ownership control may: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delay, defer or prevent a change in control; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">entrench our management or the board of directors; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">impede a merger, consolidation, takeover or other business combination involving us that other stockholders may desire.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Some of these persons or entities may have interests different than yours. For example, because many of these stockholders
purchased their shares at prices substantially below the price at which shares are being sold in this offering and have held their shares for a longer period, they may be more interested in selling our company to an acquirer than other investors or
they may want us to pursue strategies that deviate from the interests of other stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Delaware law and provisions in our amended and restated
certificate of incorporation and amended and restated bylaws that will be in effect at the closing of this offering could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Provisions of our amended and restated certificate of incorporation and amended and restated bylaws, which will become effective immediately prior to and
upon the closing of this offering, respectively, may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium
for their shares or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our amended and restated certificate of
incorporation and amended and restated bylaws will:&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and
privileges as they may designate (including the right to approve an acquisition or other change in our control); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that the authorized number of directors may be changed only by resolution of the board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that our board of directors or any individual director may only be removed with cause and the affirmative vote of
the holders of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the voting power of all of our then-outstanding common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by
the affirmative vote of a majority of directors then in office, even if less than a quorum; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">divide our board of directors into three classes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of
stockholders and not be taken by written consent; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for
election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder&#146;s notice; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock
entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that special meetings of our stockholders may be called only by the board of directors pursuant to a resolution
adopted by a majority of the total number of authorized directors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for the following types of
actions or proceedings under state, statutory and common law: (i)&nbsp;any derivative action or proceeding brought on our behalf; (ii)&nbsp;any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former
directors, officers or other employees to us or our stockholders; (iii)&nbsp;any action or proceeding asserting a claim against us or any of our current or former directors, officers or other employees, arising out of or pursuant to any provision of
the Delaware General Corporation Law, our certificate of incorporation or our bylaws; (iv)&nbsp;any action or proceeding to interpret, apply, enforce or determine the validity of our certificate of incorporation or our bylaws; (v)&nbsp;any action or
proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of the State of Delaware; and (vi)&nbsp;any action asserting a claim against us or any of our directors, officers or other employees governed
by the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court&#146;s having personal jurisdiction over the indispensable parties named as defendants; provided these provisions of our amended and
restated certificate of incorporation and amended and restated bylaws will not apply to suits brought to enforce a duty or liability created by the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction; and
provided that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any
complaint asserting a cause of action arising under the Securities Act of 1933, as amended, or the Securities Act. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The
amendment of any of these provisions, with the exception of the ability of our board of directors to issue shares of preferred stock and designate any rights, preferences and privileges thereto, would require approval by the holders of at least <FONT
STYLE="white-space:nowrap">66-2/3%</FONT> of our then-outstanding common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, as a Delaware corporation, we are subject to
Section&nbsp;203 of the Delaware General Corporation Law. These provisions may prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time. A
Delaware corporation may opt out of this provision by express provision in its original certificate of incorporation or by amendment to its certificate of incorporation or bylaws approved by its stockholders. However, we have not opted out of this
provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could
make it more difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by our then-current board of directors, including delay or impede a merger, tender offer or proxy contest
involving our company. The existence of these provisions could negatively affect the price of our common stock and limit opportunities for you to realize value in a corporate transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For information regarding these and other provisions, see &#147;Description of Capital Stock.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>As a result of becoming a public company, we will be obligated to develop and maintain proper and effective
internal controls over financial reporting and any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a result, the value of our common shares. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We will be required, pursuant to Section 404 of the Sarbanes Oxley Act, or Section 404, to furnish a report by management on, among other things, the
effectiveness of our internal controls over financial reporting for the fiscal year ending December 31, 2023. This assessment will need to include disclosure of any material weaknesses identified by our management in our internal controls over
financial reporting. Our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting until our first annual report required to be filed with the SEC following
the date we are no longer an emerging growth company, as defined in the JOBS Act, and are not a smaller reporting company with less than $100 million in annual revenue. At such time as we are required to obtain auditor attestation, if we then have a
material weakness, we would receive an adverse opinion regarding our internal control over financial reporting from our independent registered public accounting firm. We will be required to disclose significant changes made in our internal controls
procedures on a quarterly basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are beginning the costly and challenging process of enhancing our financial reporting systems and processes as
necessary to allow for the operation of effective internal controls over financial reporting to comply with the requirements of Section 404. We may not be able to complete our assessment, testing and any required remediation of internal controls
over financial reporting in a timely fashion. Our compliance with Section 404 will require that we incur substantial legal, accounting and other compliance expense and expend significant management efforts. We currently do not have an internal audit
group. We will need to hire additional accounting and finance personnel and consultants with appropriate public company experience and technical accounting knowledge to develop and maintain the internal controls over financial reporting necessary to
comply with Section&nbsp;404. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have identified existing material weaknesses in our internal controls over financial reporting. If during the
evaluation and testing of our internal controls over financial reporting, we identify one or more additional material weaknesses in future periods, we will be unable to assert that our internal controls over financial reporting are effective. We
cannot assure you that there will not be additional material weaknesses in our internal controls over financial reporting in the future. Any failure to maintain effective internal controls over financial reporting could severely inhibit our ability
to accurately report our financial condition or results of operations. If we are unable to conclude that our internal controls over financial reporting are effective, we could lose investor confidence in the accuracy and completeness of our
financial reports, the market price of our common shares could decline, and we could be subject to sanctions or investigations by the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal controls over
financial reporting, or to implement or maintain other effective control systems required of public companies, could also negatively impact our ability to access to the capital markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, effective disclosure controls and procedures enable us to make timely and accurate disclosure of financial and non-financial information
that we are required to disclose. As a public company, if our disclosure controls and procedures are ineffective, we may be unable to report our financial results or make other disclosures accurately and on a timely basis, which could cause our
reported financial results or other disclosures to be materially misstated and result in the loss of investor confidence and cause the market price of our common shares to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we fail to remediate our material weaknesses in internal controls over financial reporting and to implement
and maintain an effective system of internal controls, we may be unable to accurately report our results of operations, meet our reporting obligations or prevent fraud, and investor confidence in our company and the market price of our common stock
may be materially and adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to the completion of this offering, we had limited accounting personnel, IT personnel and
other resources with which to address internal controls over financial reporting. In connection with the audits of our consolidated financial statements as of and for the years ended December&nbsp;31, 2019 and 2020, we identified two material
weaknesses in our internal controls over financial reporting. As defined in the standards established by the U.S. Public Company Accounting Oversight Board, or PCAOB, a &#147;material weakness&#148; is a deficiency, or combination of deficiencies in
internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Deficiencies in our internal controls over financial reporting that were considered to be a material weakness as of December 31, 2019 were related to
the lack of a sufficiently precise review over both valuations prepared by our third-party valuation experts as well as the completeness of operating expenses. We remediated the material weakness related to the review of valuation reports by adding
a precise review control that was performed by our accounting personnel with the appropriate technical expertise to review valuation reports. In addition, we have hired an accounting executive with the requisite knowledge in the application of U.S.
GAAP and SEC reporting who will be collaborating and reviewing valuation reports prepared by our third-party valuation experts. For the deficiency related to the completeness of operating expenses, we continue to take measures to remediate the
deficiency by updating our internal controls to include additional staffing as well as augmenting our controls addressing the completeness of operating expenses, as outlined below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further deficiencies in our internal controls over financial reporting that have been considered to be a material weakness as of December 31, 2020
relate to deficiencies in the design of controls over the expenditures process. Specifically, our information technology controls related to the expenditures cycle were not designed to post invoices approved in the correct period, and our controls
over the review of the completeness of operating expenses as it related to our close cycle were not appropriately designed, as we lacked sufficient personnel in our Finance and IT organizations to review and provide reasonable assurance that
transactions were being recorded timely and completely. We are in the process of implementing changes to our internal controls over financial reporting to remediate this material weakness that has been identified and these changes include hiring a
sufficient number of accounting and IT personnel to focus on our information technology systems and to adequately manage the monthly close process. However, we cannot assure you that these measures will fully address the material weaknesses and
deficiencies in our internal control over financial reporting such that we may conclude that they have been fully remediated. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon completion
of this offering, we will become subject to the Sarbanes-Oxley Act. Section&nbsp;404 will require that we include a report from management on the effectiveness of our internal control over financial reporting in our annual report on Form&nbsp;10-K
beginning with our second annual report on Form&nbsp;10-K after becoming a public company. In addition, after we become a public company, our reporting obligations may place a significant strain on our management, operational and financial resources
and systems for the foreseeable future. We may be unable to timely complete our evaluation testing and any required remediation. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the
course of documenting and testing our internal control procedures, in order to satisfy the requirements of Section 404, we may identify other weaknesses and deficiencies in our internal control over financial reporting. If we fail to maintain the
adequacy of our internal control over financial reporting, as these standards are modified, supplemented or amended from time to time, we may not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
be able to conclude on an ongoing basis that we have effective internal control over financial reporting in accordance with Section 404. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Generally speaking, if we fail to achieve and maintain an effective internal control environment, it could result in material misstatements in our
financial statements and could also impair our ability to comply with applicable financial reporting requirements and related regulatory filings on a timely basis. As a result, our businesses, financial condition, results of operations and
prospects, as well as the trading price of our common stock, may be materially and adversely affected. Additionally, ineffective internal control over financial reporting could expose us to increased risk of fraud or misuse of corporate assets and
subject us to potential delisting from the stock exchange on which we list, regulatory investigations and civil or criminal sanctions. We may also be required to restate our financial statements from prior periods. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our amended and restated bylaws will provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America
will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our amended and restated bylaws will provide that, to the fullest extent permitted by law and subject to the court&#146;s having personal
jurisdiction over the indispensable parties named as defendants, the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any derivative action or proceeding brought on our behalf; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any action or proceeding asserting a breach of fiduciary duty owed by any of our current or former directors, officers or
other employees to us or our stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any action or proceeding asserting a claim against us or any of our current or former directors, officers or other
employees arising out of or pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or bylaws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any action or proceeding to interpret, apply, enforce or determine the validity of our amended and restated certificate of
incorporation or our amended and restated bylaws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any action or proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of
the State of Delaware; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any action asserting a claim against us or any of our directors, officers or other employees that is governed by the
internal affairs doctrine. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This provision would not apply to suits brought to enforce a duty or liability created by the Exchange
Act. Furthermore, Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To
prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation further provides that the federal
district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are
facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive
forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced
by a court in those other jurisdictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These exclusive forum provisions may limit a stockholder&#146;s ability to bring a claim in a judicial
forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive forum provision in
our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm
our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could
result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect that we
will need significant additional capital in the future to continue our planned operations, including conducting clinical trials, commercialization efforts if we are able to obtain marketing approval of any of AMX0035 or any future product
candidates, research and development activities, and costs associated with operating a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a
manner we determine from time to time. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders,
and new investors could gain rights, preferences and privileges senior to the holders of our common stock, including shares of common stock sold in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to our 2022 Stock Option and Incentive Plan, or the 2022 Plan, our management is authorized to grant stock options to our employees, directors
and consultants. Additionally, the number of shares of our common stock reserved for issuance under our 2022 Plan will automatically increase on January&nbsp;1 of each year, beginning on January&nbsp;1, 2023 and continuing through and including
January&nbsp;1, 2032, by 5.0% of the total number of shares of our capital stock outstanding on December&nbsp;31 of the preceding calendar year, or a lesser number of shares determined by our board of directors. In addition, pursuant to our ESPP,
the number of shares of our common stock reserved for issuance will automatically increase on January&nbsp;1 of each calendar year, beginning on January&nbsp;1, 2023 (through January&nbsp;1, 2032), by the lesser of (i) 1.0% of the total number of
shares of our common stock outstanding on the last day of the calendar month before the date of the automatic increase, and (ii)&nbsp;1,210,000 shares; provided that before the date of any such increase, our board of directors may determine that
such increase will be less than the amount set forth in clauses (i)&nbsp;and (ii). Unless our board of directors elects not to increase the number of shares available for future grant each year, our stockholders may experience additional dilution,
which could cause our stock price to fall. </P>  <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>General Risk Factors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new
compliance initiatives. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As a public company, we will incur significant legal, accounting, and other expenses that we did not incur as a
private company. We will be subject to the reporting requirements of the Exchange Act, which will require, among other things, that we file with the SEC annual, quarterly, and current reports with respect to our business and financial condition. In
addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and the Nasdaq Global Market to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment
and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act (Dodd-Frank Act) was enacted. There are significant
corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
additional rules and regulations in these areas such as &#147;say on pay&#148; and proxy access. Emerging growth companies and smaller reporting companies are exempted from certain of these
requirements, but we may be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment and the current high level of government intervention
and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some
activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition, and results of
operations. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules and
regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount
or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees
or as executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Cyber-attacks or other failures in our telecommunications or information technology systems, or those of our collaborators, CROs,
third-party logistics providers, distributors or other contractors or consultants, could result in information theft, data corruption and significant disruption of our business operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We, our collaborators, our CROs, third-party logistics providers, distributors and other contractors and consultants utilize information technology, or
IT, systems and networks to process, transmit and store electronic information in connection with our business activities. As use of digital technologies has increased, cyber incidents, including third parties gaining access to employee accounts
using stolen or inferred credentials, computer malware, viruses, spamming or other means, and deliberate attacks and attempts to gain unauthorized access to computer systems and networks, have increased in frequency and sophistication. Cyber-attacks
also could include phishing attempts or <FONT STYLE="white-space:nowrap">e-mail</FONT> fraud to cause payments or information to be transmitted to an unintended recipient. These threats pose a risk to the security of our, our collaborators&#146;,
our CROs&#146;, third-party logistics providers&#146;, distributors&#146; and other contractors&#146; and consultants&#146; systems and networks, and the confidentiality, availability and integrity of our data. There can be no assurance that we will
be successful in preventing cyber-attacks or successfully mitigating their effects. Similarly, there can be no assurance that our collaborators, CROs, third-party logistics providers, distributors and other contractors and consultants will be
successful in protecting our clinical and other data that is stored on their systems. Any cyber-attack, data breach or destruction or loss of data could result in a violation of applicable U.S. and international privacy, data protection and other
laws, and subject us to litigation and governmental investigations and proceedings by federal, state and local regulatory entities in the United States and by international regulatory entities, resulting in exposure to material civil and/or criminal
liability. Further, our general liability insurance and corporate risk program may not cover all potential claims to which we are exposed and may not be adequate to indemnify us for all liability that maybe imposed; and could have a material adverse
effect on our business and prospects. For example, the loss of clinical trial data from completed, ongoing or future clinical trials for AMX0035 or any of our future product candidates could result in delays in our development and regulatory
approval efforts and significantly increase our costs to recover or reproduce the data. In addition, we may suffer reputational harm or face litigation or adverse regulatory action as a result of cyber-attacks or other data security breaches and may
incur significant additional expense to implement further data protection measures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our ability to use net operating losses and research and development credits to offset future taxable income may
be subject to certain limitations. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December 31, 2020, we had U.S. federal and state net operating loss carryforwards of
$46.8&nbsp;million and $44.9&nbsp;million, respectively, some of which begin to expire in 2034. As of December&nbsp;31, 2020, we also had U.S. federal and state research and development tax credit carryforwards of $1.6&nbsp;million and
$0.7&nbsp;million, respectively, which begin to expire in 2029. These net operating loss and tax credit carryforwards could expire unused and be unavailable to offset future taxable income or tax liabilities, respectively. U.S. federal and certain
state net operating losses generated in taxable years beginning after December&nbsp;31, 2017 are not subject to expiration. Federal net operating losses generally may not be carried back to prior taxable years except that, under the Coronavirus Aid,
Relief and Economic Security Act, federal net operating losses generated in 2018, 2019 and 2020 may be carried back to each of the five taxable years preceding the taxable year in which the loss arises. Additionally, for taxable years beginning
after December&nbsp;31, 2020, the deductibility of federal net operating losses generated in taxable years beginning after December 31, 2017 is limited to 80% of our taxable income in such taxable year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, and corresponding provisions of state law, a
corporation that undergoes an &#147;ownership change&#148; is subject to limitations on its ability to utilize its <FONT STYLE="white-space:nowrap">pre-change</FONT> net operating loss carryforwards or tax credits, or NOLs or credits, to offset
future taxable income. For these purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders or groups of stockholders who owns at least five percent of a corporation&#146;s stock increases its
ownership by more than 50 percentage points over its lowest ownership percentage within a specified testing period. Our existing federal and state NOLs and our existing research and development credits may be subject to limitations arising from
previous ownership changes and, if we undergo an ownership change, our ability to utilize NOLs or credits could be further limited by Sections 382 and 383 of the Code. We have not yet completed a Section&nbsp;382 analysis.<B> </B>In addition, this
offering or future changes in our stock ownership, many of which are outside of our control, could result in an ownership change under Sections 382 and 383 of the Code. Our NOLs or credits may also be impaired under state law. Accordingly, we may
not be able to utilize a material portion of our NOLs or credits. Furthermore, our ability to utilize our NOLs or credits is conditioned upon our attaining profitability and generating U.S. federal and state taxable income. As described above, we
have incurred significant net losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future; and therefore, we do not know whether or when we will generate the U.S. federal or state taxable
income necessary to utilize our NOLs or credits that are subject to limitation by Sections 382 and 383 of the Code. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may not be entitled to forgiveness
of our loan under the Paycheck Protection Program of the Coronavirus Aid, Relief, and Economic Security Act, and our application for the loan could in the future be determined to have been impermissible or could result in damage to our reputation.
</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In April 2020, we received proceeds of $0.3&nbsp;million from a loan, or the PPP Loan, under the Paycheck Protection Program, or the
PPP, of the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, a portion of which may be forgiven, which we have used to retain employees, maintain payroll and make lease and utility payments. The PPP Loan had a maturity date of
April&nbsp;19, 2022 and an annual interest rate of 1.0%. Payments of principal and interest on the PPP Loan were originally deferred for the first six months of the term. Thereafter, we were required to pay the lender equal monthly payments of
principal and interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the PPP, we applied for and were granted forgiveness for the entirety of the PPP Loan. The amount of loan proceeds
eligible for forgiveness was originally based on a formula that takes into account a number of factors, including the amount of loan proceeds used by us during the eight-week </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
period after the loan origination for certain purposes, including payroll costs, interest on certain mortgage obligations, rent payments on certain leases, and certain qualified utility payments,
provided that at least 75% of the loan amount was used for eligible payroll costs. Subject to the other requirements and limitations on loan forgiveness, only loan proceeds spent on payroll and other eligible costs during the covered eight-week
period qualified for forgiveness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In order to apply for the PPP Loan, we were required to certify, among other things, that the current economic
uncertainty made the PPP Loan request necessary to support our ongoing operations. We made this certification in good faith after analyzing, among other things, our financial situation and access to alternative forms of capital, and believe that we
satisfied all eligibility criteria for the PPP Loan, and that our receipt of the PPP Loan is consistent with the broad objectives of the PPP. The certification described above does not contain any objective criteria and is subject to interpretation.
If, despite our good-faith belief that given our Company&#146;s circumstances we satisfied all eligible requirements for the PPP Loan, we are later determined to have violated any of the laws or governmental regulations that apply to us in
connection with the PPP Loan, such as the FCA, or it is otherwise determined that we were ineligible to receive the PPP Loan, we may be subject to penalties, including significant civil, criminal and administrative penalties and could be required to
repay the PPP Loan in its entirety. In addition, receipt of a PPP Loan may result in adverse publicity and damage to reputation, and a review or audit by the U.S. Small Business Administration or other government entity or claims under the FCA could
consume significant financial and management resources. Notwithstanding the forgiveness of the PPP Loan, on October 7, 2021, we repaid the PPP Loan in full. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We could be subject to securities class action litigation. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This
risk is especially relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#146;s
attention and resources, which could harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our failure to meet Nasdaq&#146;s continued listing requirements could result in a delisting of our
common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If, after listing, we fail to satisfy the continued listing requirements of the Nasdaq Global Market, such as the corporate
governance requirements or the minimum closing bid price requirement, may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase
our common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market
price or improve the liquidity of our common stock, prevent our common stock from dropping below the minimum bid price requirement or prevent future <FONT STYLE="white-space:nowrap">non-compliance</FONT> with the listing requirements of the Nasdaq
Global Market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If securities analysts publish negative evaluations of our stock, the price of our stock could decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The trading market for our common stock depends in part on the research and reports that industry or securities analysts may publish about us or our
business. If one or more of the analysts who may cover us issues an adverse opinion about our company, our stock price would likely decline. If one or more of these analysts ceases research coverage of us or fails to regularly publish reports on us,
we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc155225_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This prospectus contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of
historical facts, contained in this prospectus, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management and expected market growth are
forward-looking statements. The words &#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148;
&#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;target,&#148; &#147;would&#148; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying
words. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These forward-looking statements include, among other things, statements about: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our use of the net proceeds from this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to obtain and maintain regulatory approval of AMX0035 and any future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to successfully commercialize and market AMX0035 and any future product candidates, if approved;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to contract with third-party suppliers, manufacturers and other service providers and their ability to perform
adequately; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the potential market size, opportunity and growth potential for AMX0035 and any future product candidates, if approved;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to build our own sales and marketing capabilities, or seek collaborative partners, to commercialize AMX0035 and
any future product candidates, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to obtain funding for our operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and
development activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified
professionals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to advance AMX0035 and any future product candidates into, and successfully complete, clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to recruit and enroll suitable patients in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing or likelihood of the accomplishment of various scientific, clinical, regulatory filings and approvals and other
product development objectives; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the pricing and reimbursement of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the degree of market acceptance AMX0035 and any future product candidates by physicians, patients, third-party payors and
others in the medical community; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the rate and degree of market acceptance of AMX0035 and any future product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the implementation of our business model, strategic plans for our business, product candidates and technology;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our product
candidates and technology; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">developments relating to our competitors and our industry; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the accuracy of our estimates regarding expenses, capital requirements and needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our financial performance; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">other risks and uncertainties, including those listed under the section titled &#147;Risk Factors.&#148;
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not
place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the
cautionary statements included in this prospectus, particularly in the &#147;Risk Factors&#148; section, that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements
do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures or investments that we may make or enter into. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">You should read this prospectus and the documents that we have filed as exhibits to the registration statement of which this prospectus is a part
completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or
otherwise, except as required by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc155225_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We estimate that the net proceeds to us from our issuance and sale of 8,750,000 shares of our common stock in this offering will be approximately
$151.3&nbsp;million, assuming an initial public offering price of $19.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and
estimated offering expenses payable by us. If the underwriters exercise in full their option to purchase additional shares, we estimate that the net proceeds from this offering will be approximately $174.5&nbsp;million, after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A $1.00 increase or decrease in the assumed initial public
offering price of $19.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease our net proceeds from this offering by approximately $8.1&nbsp;million, assuming that the number
of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions. An increase or decrease of 1,000,000 shares in the number of shares offered by us, as
set forth on the cover page of this prospectus, would increase or decrease our net proceeds from this offering by approximately $17.7&nbsp;million, assuming no change in the assumed initial public offering price per share and after deducting
estimated underwriting discounts and commissions. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We currently estimate that we will use the net proceeds from this offering, together with
our existing cash, cash equivalents, and short-term investments, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approximately $100.0 million to fund the regulatory approval process and pre-commercial launch, production of and, if
approved, commercial launch activities for AMX0035 for the treatment of ALS; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approximately $15.0 million to fund the completion of our ongoing Phase 3 PHOENIX clinical trial for the treatment of ALS;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approximately $10.0 million to fund the development and expansion of our pipeline to address other neurodegenerative
indications, and for formulations and derivatives of AMX0035; and </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the remainder for working capital and other general corporate activities, which may include funding for the costs of
operating as a public company. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This expected use of the net proceeds from this offering along with our existing cash, cash
equivalents, and short-term investments represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. For example, we may use a portion of the net
proceeds for the acquisition of businesses, products or technologies to continue to build our pipeline, our research and development capabilities and our intellectual property position, although we currently have no agreements, commitments or
understandings with respect to any such transaction. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our development and our sales and marketing and commercialization
efforts, demand for AMX0035 or any future products, if approved, our operating costs, the status of and results from clinical trials, any collaborations that we may enter into with third parties for AMX0035 or any future product candidates and any
unforeseen cash needs. Moreover, our estimates of the costs to fund our current and future trials are based on the designs of the trials. If we were to modify the design of any of these trials, for instance, to increase the number of patients in the
trials, our costs to fund the trials could increase. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on our current plans, we believe that our existing cash, cash equivalents and short-term
investments, together with the net proceeds from this offering, will be sufficient to meet our anticipated operating and capital expenditure requirements for at least twelve months after the registration statement of which this prospectus forms a
part becomes effective. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. We do not have any committed external source of funds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pending our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments, including
short-term, investment-grade, interest-bearing instruments and U.S. government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc155225_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have never declared nor paid cash dividends on our common stock. We currently intend to retain all of our future earnings, if any, to finance the
growth and development of our business. We do not intend to pay cash dividends in respect of our common stock in the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc155225_7"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth our cash, cash equivalents, and short-term investments and our capitalization as of September 30, 2021: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on a pro forma basis to give effect to (i) the automatic conversion of all outstanding shares of our preferred stock into
an aggregate of 39,474,330&nbsp;shares of common stock, based on the applicable conversion rates, upon the closing of this offering, and (ii) the filing and effectiveness of our restated certificate of incorporation upon the closing of this
offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on a pro forma as adjusted basis to give further effect to our issuance and sale of 8,750,000 shares of our common stock in
this offering at an assumed initial public offering price of $19.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us as of September 30, 2021. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our capitalization following the closing of this offering will
depend on the actual initial public offering price and other terms of this offering determined at pricing. Cash, cash equivalents, and short-term investments are not components of our total capitalization. You should read this table together with
our financial statements and the related notes appearing at the end of this prospectus and the section of this prospectus titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of September 30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>As&nbsp;Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands, except share and per<BR>share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash, cash equivalents, and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">278,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series A redeemable convertible preferred stock, $0.0001 par value; 6,289,609 shares authorized, issued and
outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series B redeemable convertible preferred stock, $0.0001 par value; 15,100,000 shares authorized, 14,496,835
issued and outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series C-1 redeemable convertible preferred stock, $0.0001 par value; 13,150,430 shares authorized, issued
and outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series C-2 redeemable convertible preferred stock, $0.0001 par value; 3,170,585 shares authorized, issued
and outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stockholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock, $0.0001 par value; 56,500,000 shares authorized, 6,799,157 shares issued and outstanding,
actual; 300,000,000 shares authorized, 46,273,487 shares issued and outstanding, pro forma; 300,000,000 shares authorized, 55,023,487 shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">242,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">394,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(127,501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(127,501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(127,501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(124,070</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">115,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">115,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">266,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A $1.00 increase (decrease) in the assumed initial public offering price of $19.00 per share,
which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash, cash equivalents, and short-term investments, additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; equity (deficit) and total capitalization by $8.1&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains
the same and after deducting estimated underwriting discounts and commissions. An increase (decrease) of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the pro
forma as adjusted amount of each of cash, cash equivalents, and short-term investments, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; equity (deficit) and total capitalization by $17.7&nbsp;million,
assuming no change in the assumed initial public offering price per share and after deducting estimated underwriting discounts and commissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The table above excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">4,195,341 shares of our common stock issuable upon the exercise of stock options outstanding as of September 30, 2021, at a
weighted average exercise price of $4.31 per share; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1,430,000 shares of our common stock issuable upon the exercise of stock options granted after September 30, 2021, at a
weighted average exercise price of $8.47 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">2,809,492 shares of our common stock available for future issuance as of September 30, 2021 under our 2015 Plan, which will
cease to be available for issuance at the time that our 2022 Plan becomes effective; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">7,650,000&nbsp;shares of our common stock that will become available for future issuance under our 2022 Plan, which will
become effective in connection with the completion of this offering, as well as any future increases, including annual automatic evergreen increases, in the number of shares of common stock reserved for issuance thereunder in accordance with the
terms of such plan (which includes 2,033,500 shares of our common stock issuable upon the exercise of stock options to be issued under our 2022 Plan upon the effectiveness of this offering, with an exercise price that is equal to the initial public
offering price, and 278,333 restricted stock units to be issued under our 2022 Plan upon the effectiveness of this offering); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">605,000&nbsp;shares of our common stock that will become available for future issuance under our 2022 Employee Stock
Purchase Plan, which will become effective in connection with the completion of this offering, including annual automatic evergreen increases. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc155225_8"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the
public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our historical net tangible book value (deficit) as of September 30, 2021 was $(125.8) million, or $(18.50) per share of our common stock. Our
historical net tangible book value (deficit) is the amount of our total tangible assets less our total liabilities and redeemable convertible preferred stock, which is not included within stockholders&#146; equity (deficit). Historical net tangible
book value (deficit) per share represents our historical net tangible book value (deficit) divided by the 6,799,157 shares of our common stock outstanding as of September 30, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our pro forma net tangible book value as of September 30, 2021 was $113.6&nbsp;million, or $2.45 per share of our common stock. Pro forma net tangible
book value represents the amount of our total tangible assets less our total liabilities, after giving effect to the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into an aggregate of
39,474,330&nbsp;shares of our common stock upon the closing of this offering. Pro forma net tangible book value per share represents pro forma net tangible book value divided by the total number of shares outstanding as of September 30, 2021, after
giving effect to the foregoing adjustments and the automatic conversion of all outstanding shares of our preferred stock into common stock upon the closing of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">After giving further effect to our issuance and sale of 8,750,000 shares of our common stock in this offering at an assumed initial public offering
price of $19.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as
adjusted net tangible book value as of September 30, 2021 would have been $266.6 million, or $4.85 per share. This represents an immediate increase in pro forma as adjusted net tangible book value per share of $2.40 to existing stockholders and
immediate dilution of $14.15 in pro forma as adjusted net tangible book value per share to new investors purchasing common stock in this offering. Dilution per share to new investors is determined by subtracting pro forma as adjusted net tangible
book value per share after this offering from the assumed initial public offering price per share paid by new investors. The following table illustrates this dilution on a per share basis: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Historical net tangible book value (deficit) per share as of September 30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18.50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increase per share attributable to the pro forma adjustments described<BR>above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net tangible book value (deficit) per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increase in pro forma as adjusted net tangible book value per share attributable to new investors purchasing
shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dilution per share to new investors purchasing shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A $1.00 increase or decrease in the assumed initial public offering price of $19.00 per share, which is the
midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease our pro forma as adjusted net tangible book value by $8.1 million, our pro forma as adjusted net tangible book value per share after this offering
by $0.15 and dilution per share to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
new investors purchasing shares in this offering by $0.85, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after
deducting estimated underwriting discounts and commissions. An increase of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase the pro forma as adjusted net tangible book value
per share after this offering by $0.22 and decrease the dilution per share to new investors participating in this offering by $0.22, assuming no change in the assumed initial public offering price and after deducting estimated underwriting discounts
and commissions. A decrease of 1,000,000&nbsp;shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would decrease the pro forma as adjusted net tangible book value per share after this offering by $0.24
and increase the dilution per share to new investors participating in this offering by $0.24, assuming no change in the assumed initial public offering price and after deducting estimated underwriting discounts and commissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If the underwriters exercise their option to purchase additional shares in full, our pro forma as adjusted net tangible book value per share after this
offering would be $5.14 per share, representing an immediate increase in pro forma as adjusted net tangible book value per share of $2.69 to existing stockholders and immediate dilution in pro forma as adjusted net tangible book value per share of
$13.86 to new investors purchasing common stock in this offering, assuming an initial public offering price of $19.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us. If any shares are issued upon exercise of outstanding options, you will experience further dilution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table summarizes, on the pro forma as adjusted basis described above, the differences between the number of shares of common stock
purchased from us, the total consideration paid to us and the average price per share paid by existing stockholders and by new investors purchasing shares of common stock in this offering. The calculation below is based on an assumed initial public
offering price of $19.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average&nbsp;Price<BR>Per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,273,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">239,905,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">166,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,023,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">406,155,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A $1.00 increase or decrease in the assumed initial public offering price of $19.00 per share, which is the
midpoint of the price range set forth on the cover page of this prospectus, would increase or&nbsp;decrease the total consideration paid by new investors by $8.8&nbsp;million and, in the case of an&nbsp;increase, would increase the percentage of
total consideration paid by new investors by one percentage point and, in the case of a decrease, would decrease the percentage of total consideration paid by new investors by one&nbsp;percentage point, assuming that the number of shares offered by
us, as set forth on the cover page of this prospectus, remains the same. An increase or decrease of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase or decrease the total
consideration paid by new investors by $19.0&nbsp;million and, in the case of an increase, would increase the percentage of total consideration paid by new investors by three&nbsp;percentage points and, in the case of a decrease, would decrease the
percentage of total consideration paid by new investors by three&nbsp;percentage points, assuming no change in the assumed initial public offering price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The table above assumes no exercise of the underwriters&#146; option to purchase additional shares
in this offering. If the underwriters&#146; option to purchase additional shares is exercised in full, the number of shares of our common stock held by existing stockholders would be reduced to 82% of the total number of shares of our common stock
outstanding after this offering, and the number of shares of common stock held by new investors participating in the offering would be increased to 18% of the total number of shares of our common stock outstanding after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The number of shares purchased from us by existing stockholders is based on 46,273,487 shares of our common stock outstanding as of September 30, 2021
after giving effect to the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 39,474,330 shares of common stock upon the closing of this offering, and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">4,195,341 shares of our common stock issuable upon the exercise of stock options outstanding as of September 30, 2021, at a
weighted average exercise price of $4.31 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1,430,000 shares of our common stock issuable upon the exercise of stock options granted after September 30, 2021, at a
weighted average exercise price of $8.47 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">2,809,492 shares of our common stock available for future issuance as of September&nbsp;30, 2021 under our 2015 Plan which
will cease to be available for issuance at the time that our 2022 Plan becomes effective; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">7,650,000&nbsp;shares of our common stock that will become available for future issuance under our 2022 Plan, which will
become effective in connection with the completion of this offering, as well as any future increases, including annual automatic evergreen increases, in the number of shares of common stock reserved for issuance thereunder in accordance with the
terms of such plan (which includes 2,033,500 shares of our common stock issuable upon the exercise of stock options to be issued under the 2022 Plan upon the effectiveness of this offering, with an exercise price that is equal to the initial public
offering price, and 278,333 restricted stock units to be issued under the 2022 Plan upon the effectiveness of this offering); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">605,000&nbsp;shares of our common stock that will become available for future issuance under our 2022 Employee Stock
Purchase Plan, which will become effective in connection with the completion of this offering, including annual automatic evergreen increases. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc155225_9"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial
statements and the related notes included at the end of this prospectus. This discussion and other parts of this prospectus contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives,
expectations and intentions. As a result of many factors, including those factors set forth in the &#147;Risk Factors&#148; section of this prospectus, our actual results could differ materially from the results described in or implied by the
forward-looking statements contained in the following discussion and analysis</I>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our mission is to develop therapies that change the treatment paradigm for amyotrophic lateral sclerosis, or ALS, and a broad range of neurodegenerative
diseases by keeping neurons alive. Unlike most other cells in the body that regularly die and are replaced as part of healthy function, mature neurons are normally resistant to cell death and generally cannot regenerate. We are pursuing
commercialization of our product candidate, AMX0035, which we believe is the first drug candidate to show both a functional and survival benefit in a large-scale clinical trial of patients with ALS. We submitted a New Drug Submission, or NDS, in
Canada in the second quarter of 2021 for AMX0035 for the treatment of ALS, which was accepted for review in the third quarter of 2021, and a New Drug Application, or NDA, to the U.S. Food and Drug Administration, or FDA, in the fourth quarter of
2021, which was accepted for priority review in the same quarter. We also intend to submit a Marketing Authorization Application, or MAA, in Europe early in the first quarter of 2022. In November 2021, we announced that we had dosed the first
participants in our global Phase 3 clinical trial evaluating the safety and efficacy of AMX0035 for the treatment of ALS, known as the PHOENIX trial. The results of our Phase 2 clinical trial of AMX0035, known as the CENTAUR trial, were published in
September 2020 in the <I>New England Journal of Medicine</I> and in October 2020 in the <I>Journal of Muscle and Nerve</I> and demonstrated functional and survival benefits for ALS patients. We believe AMX0035 has the potential to be a foundational
therapy, meaning that it could be used alone or in conjunction with other therapies to change the treatment paradigm across a broad range of neurodegenerative diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">AMX0035 is a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate, or PB, and TURSO (also known as tauroursodeoxycholic acid, or TUDCA).
Through the resolution of the unfolded protein response, or UPR, and by inhibiting translocation of the Bcl-2 Associated X-protein, or Bax, to the outer mitochondrial membrane, we have shown in multiple models that AMX0035 can keep neurons alive
under a variety of different conditions and stresses, including in in vitro models of neurodegeneration, endoplasmic reticulum stress, mitochondrial dysfunction, oxidative stress and disease-specific models of a variety of other conditions, as well
as in vivo models of Alzheimer&#146;s Disease, or AD, and multiple sclerosis. We are pursuing ALS as our first indication as it is a disease of rapid and profound neurodegeneration, and we are focused on the development and potential
commercialization of AMX0035 for ALS globally. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We were incorporated under the laws of the State of Delaware on January&nbsp;10, 2014. In October
2020 and August 2021, we created wholly owned subsidiaries, Amylyx Pharmaceuticals Canada, Inc., or Amylyx Canada, in Calgary, Canada and Amylyx Pharmaceuticals EMEA B.V, or Amylyx EMEA, in Amsterdam, Netherlands. Amylyx EMEA did not have operations
as of September 30, 2021. Since inception, we have devoted substantially all of our efforts to research and development activities, including recruiting management and technical staff, raising capital, producing materials for <FONT
STYLE="white-space:nowrap">non-clinical</FONT> and clinical studies, and building infrastructure to support such activities. Our expenses have primarily been for research and development and related general and administrative costs. We have
generated revenues through five grants from ALS Association, ALS Finding a Cure Foundation, Cure Alzheimer&#146;s Fund, Alzheimer&#146;s Drug Discovery Foundation and Alzheimer&#146;s Association, or the Grantors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since inception, we have also financed our operations through the issuance of redeemable
convertible preferred stock, convertible notes and, to a lesser extent, a government loan. From August 2016 to November 2017, we issued and sold Series A preferred stock for an aggregate purchase price of approximately $7.7&nbsp;million. In July
2017, we received $2.3&nbsp;million from the issuance of convertible promissory notes, or the 2017 Notes. In November 2018, we received $13.0&nbsp;million from the issuance of convertible promissory notes, or the 2018 Notes. In December 2019, we
received $0.6&nbsp;million from the issuance of convertible promissory notes, or the 2019 Notes. In January, February, and April 2020, we received $15.4&nbsp;million in aggregate from the issuance of convertible promissory notes, or the 2020 Notes.
The 2017 Notes, 2018 Notes, 2019 Notes and 2020 Notes, or the Old Notes, were to mature on December&nbsp;31, 2021. We also received $0.3&nbsp;million of net proceeds in April 2020 pursuant to the PPP Loan, which we repaid in full in October 2021. In
June 2020, we issued and sold shares of Series&nbsp;B preferred stock for an aggregate purchase price of approximately $30.0&nbsp;million. The Old Notes automatically converted into shares of Series&nbsp;B preferred stock pursuant to their original
terms in June 2020 in connection with our Series&nbsp;B financing. From December 2020 to February 2021, we received $27.3&nbsp;million from the issuance of convertible promissory notes, or the 2021 Notes, of which $1.2&nbsp;million was received in
December 2020 and $26.1&nbsp;million was received in January and February 2021. In July 2021, we issued and sold shares of Series C-1 preferred stock, or the Series&nbsp;C-1 preferred stock, for an aggregate purchase price of approximately
$135.0&nbsp;million. The 2021 Notes automatically converted into shares of Series&nbsp;C-2 preferred stock pursuant to their original terms in July 2021 in connection with our sale of Series&nbsp;C-1 preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have incurred&nbsp;operating losses since inception, including a net loss of $13.7&nbsp;million and $42.3&nbsp;million for the years ended
December&nbsp;31, 2019 and 2020, respectively. Our net losses were $33.7&nbsp;million and $59.6&nbsp;million for the nine months ended September&nbsp;30, 2020 and 2021, respectively. As of September&nbsp;30, 2021, we had an accumulated deficit of
$127.5&nbsp;million. These losses have resulted primarily from costs incurred in connection with research and development activities and general and administrative costs associated with our operations. We expect to continue to incur significant
expenses and increasing operating losses for the foreseeable future as we advance AMX0035 and any future product candidates through preclinical and clinical development, hire additional clinical, scientific, management and administrative personnel,
seek regulatory approval and pursue commercialization of any approved product candidates. To date, we have primarily developed AMX0035 internally, with assistance from our network of contract research organizations, or CROs, and other advisors. This
has resulted in increased research and development spending but has enabled us to manage AMX0035 efficiently through the development and manufacturing process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Following the closing of this offering, we expect to incur additional costs associated with operating as a public company, including significant legal,
accounting, investor relations and other expenses that we did not incur as a private company. As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can
generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, including potential collaborations with other companies, royalty financings, or other
strategic transactions. Our inability to raise capital as and when needed could have a negative impact on our financial condition and ability to pursue our business strategies. There can be no assurances, however, that the current operating plan
will be achieved or that additional funding will be available on terms acceptable to us, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of September&nbsp;30, 2021, we had cash,
cash equivalents and short-term investments of $125.7&nbsp;million. We believe that our existing cash, cash equivalents and short-term investments, together with the net proceeds from this offering, will be sufficient to meet our anticipated
operating and capital expenditure requirements for at least twelve months after the registration statement of which this prospectus forms a part becomes effective. We have based this estimate on assumptions that may
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See&nbsp;&#147;&#151;Liquidity and Capital Resources&#151;Funding Requirements&#148; below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The development of AMX0035 and any future product candidates could be disrupted and materially adversely affected in the future by a pandemic, epidemic
or outbreak of an infectious disease, such as the <FONT STYLE="white-space:nowrap">ongoing&nbsp;COVID-19&nbsp;pandemic.</FONT> The spread <FONT STYLE="white-space:nowrap">of&nbsp;COVID-19&nbsp;and</FONT> identification of new variants of the virus
has impacted the global economy and our operations, including requiring us to make certain alterations to our preclinical and clinical trial activities, such as scheduling certain work off-site and performing off-site assessments. In addition, we
had to amend our CENTAUR trial protocol to allow for remote visits by patients, instead of patients making site visits and in certain cases we were forced to delay enrollment at certain sites in our Phase 2 clinical trial for AMX0035 in AD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In spite of current vaccination efforts, if the disruption due to the&nbsp;ongoing <FONT STYLE="white-space:nowrap">COVID-19&nbsp;pandemic</FONT>
continues, our ongoing global Phase 3 PHOENIX clinical trial for AMX0035 for the treatment of ALS could be delayed due to government orders and site policies on account of the pandemic. Additionally, some patients may be unwilling or unable to
travel to study sites, enroll in our trials or be unable to comply with clinical trial protocols, which would delay our ability to conduct preclinical studies and clinical trials or release clinical trial results, as well as delay our ability to
obtain regulatory approval for and commercialize AMX0035. Furthermore, <FONT STYLE="white-space:nowrap">COVID-19</FONT> could continue to affect our employees or the employees of research sites and service providers on whom we rely as well as those
of companies with which we do business, including our suppliers, thereby disrupting our business operations. Existing or renewed quarantines and travel restrictions imposed by governments in the jurisdictions in which we and the companies with which
we do business operate could materially impact the ability of employees to access preclinical and clinical sites, laboratories, manufacturing sites and offices. We have implemented and continue to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">follow&nbsp;work-at-home&nbsp;policies</FONT></FONT> and may experience limitations in employee resources. Our continued reliance on personnel working from home may negatively impact productivity, or disrupt, delay or
otherwise adversely impact our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In April 2020, we borrowed $0.3&nbsp;million through the PPP Loan. PPP loans were intended to assist
companies impacted by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic to fund certain types of expenditures, including payroll costs, rent and utility payments. The PPP Loan was forgiven in March 2021 and notwithstanding the
forgiveness of the PPP Loan, we repaid it in full in October 2021. We are still assessing our business plans and the impact <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic</FONT> may have on our ability to advance the testing,
development and manufacturing of AMX0035, including as a result of adverse impacts on the research sites, service providers, vendors, or suppliers on whom we rely, or to raise financing to support the development of AMX0035. No assurances can be
given that this analysis will enable us to avoid part or all of any impact from the spread <FONT STYLE="white-space:nowrap">of&nbsp;COVID-19&nbsp;or</FONT> its consequences, including downturns in business sentiment generally or in our sector in
particular. We cannot presently predict the scope and severity of any potential further disruptions, but if we or any of the third parties on whom we rely or with whom we conduct business, were to experience renewed shutdowns or other business
disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and adversely impacted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Components of
Our Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our revenue
to date has been comprised of grant revenue, which are amounts earned from performing contracted research and development services. These grants generally require us to meet certain research milestones in order for funds to be provided. To date, we
have not generated any revenue from product sales. If our development efforts for AMX0035 or any future product candidates are successful </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
and result in regulatory approval, or if we enter into collaboration or license agreements with third parties, we may generate revenue in the future from product sales or payments from such
collaboration or license agreements, or a combination of product sales and payments from such agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Operating Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Research and Development Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Research and development
expenses consist primarily of costs incurred in connection with the research and development of AMX0035. We expense research and development costs as incurred. These expenses include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">expenses incurred under agreements with CROs, contract manufacturing organizations, or CMOs, as well as investigative sites
and consultants that conduct our clinical trials, preclinical studies and other scientific development services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap">manufacturing&nbsp;scale-up&nbsp;expenses</FONT> and the cost of acquiring and
manufacturing preclinical studies, including manufacturing registration and validation batches, as well as clinical trial materials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">expenses to acquire technologies to be used in research and development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">employee-related expenses, including salaries, payroll taxes, related benefits and stock-based compensation expense for
employees engaged in research and development functions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">costs related to compliance with quality and regulatory requirements. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid
expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Certain of our indirect research and development expenses are not tracked on an indication-by-indication&nbsp;basis for AMX0035. We do not allocate
employee costs and facilities, including depreciation or other indirect costs, to specific indications because these costs are deployed across multiple indications and, as such, are not separately classified. We use internal resources to oversee the
research and discovery as well as to manage our preclinical development, process development, manufacturing and clinical development activities. These employees work across multiple indications and, therefore, we do not track their costs by
indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Research and development activities are central to our business model. Product candidates such as AMX0035 in later stages of clinical
development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials and related product manufacturing expenses. We expect that our
research and development expenses will increase substantially in connection with our planned clinical development activities in the near term and in the future.&nbsp;At this time, we cannot accurately estimate or know the nature, timing and costs of
the efforts that will be necessary to complete the clinical development of AMX0035 and any future product candidates. Our clinical development costs may vary significantly based on factors such as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">per patient trial costs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of trials required for approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of sites included in the trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the countries in which the trials are conducted; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the length of time required to enroll eligible patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of patients that participate in the trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of doses that patients receive; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the <FONT STYLE="white-space:nowrap">drop-out</FONT> or discontinuation rates of patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">potential additional safety monitoring requested by regulatory agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the duration of patient participation in the trials and <FONT STYLE="white-space:nowrap">follow-up</FONT> periods;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the cost and timing of manufacturing our current or future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the phase of development of our current or future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the efficacy and safety profile of our current or future product candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of product candidates we are developing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The successful development and commercialization of AMX0035 and any future product candidates is highly uncertain, due to the numerous risks and
uncertainties associated with product development and commercialization, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing and progress of nonclinical and clinical development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number and scope of nonclinical and clinical trials for separate indications we decide to pursue;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">raising necessary additional funds; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the progress of the development efforts of parties with whom we may enter into collaboration arrangements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to maintain our current development activities and to establish new ones; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to establish new licensing or collaboration arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the successful initiation and completion of clinical trials with safety, tolerability and efficacy profiles that are
satisfactory to Health Canada, the U.S. Food and Drug Administration, or the FDA, the European Medicines Association, or the EMA, or any other comparable foreign regulatory authority; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the receipt and related terms of regulatory approvals from applicable regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the availability of drug substance and drug product for use in production of AMX0035; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establishing and maintaining agreements with third-party manufacturers for clinical supply for our clinical trials and
commercial manufacturing, if AMX0035 is approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to obtain and maintain patents, trade secret protection and regulatory exclusivity, both in the United States
and internationally; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to protect our rights in our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the commercialization of AMX0035, if and when approved; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL">&#149; obtaining and maintaining third-party insurance coverage and adequate reimbursement; </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the acceptance of AMX0035, if approved, by patients, the medical community and third-party payors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">competition with other product; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a continued acceptable safety profile of our therapies following approval. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A change in the outcome of any of these variables with respect to the development of AMX0035 or any
future product candidates. We may never succeed in obtaining regulatory approval for AMX0035 or any future product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>General and Administrative
Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, sales,
marketing, as well as administrative functions. General and administrative expenses also include legal fees relating to patent and corporate matters; professional fees for accounting, auditing, tax and administrative consulting services; insurance
costs; administrative travel expenses; marketing expenses; rent expense and other operating costs. We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research
activities and development of AMX0035. We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance, and director and officer insurance costs as well as investor and public relations expenses associated with being
a public company. Additionally, we are pursuing regulatory approval of AMX0035 for the treatment of ALS, initially in Canada, the United States and Europe. As we prepare for a potential approval in each territory, we anticipate an increase in
payroll and expense as a result of our preparation for commercial operations, especially as it relates to the sales and marketing of AMX0035. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Other Income
(Expense), Net </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Interest Expense </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Interest expense
consists of coupon interests and amortization of derivative discounts associated with our Old Notes. Also, included in interest expense is a contingent beneficial conversion feature recorded upon conversion of our 2017 Notes into shares of Series B
redeemable convertible preferred stock and the immediate charge to interest expense for the remaining unamortized debt discount associated with our 2017 Notes upon conversion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Interest Income </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Interest income consists of interest income
earned on our cash and cash equivalents, and money market funds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Other (Expense) Income, Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Other (expense) income, net consists primarily of (i)&nbsp;extinguishment gain from the conversion of our 2019 Notes and 2020 Notes into Series B
redeemable convertible preferred stock in June 2020, (ii)&nbsp;the amortization of premiums and accretion of discounts on our short-term investments, (iii)&nbsp;income from our short-term investments and (iv) unrealized gain on foreign exchange
transactions. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Change in Fair Value of Derivative Liability </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Change in fair value of derivative liability is comprised of adjustments to the fair value of embedded derivatives associated with certain redemption
features of our Old Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Old Notes contain redemption features which we determined were embedded derivatives. For the respective Old Notes,
we bundled these features together and accounted for the feature as a single, compound embedded derivative at each issuance. The embedded derivative was recorded as a liability and measured at fair value at inception of the Old Notes. The fair value
was remeasured at the end of each reporting period and immediately prior to the conversion of the Old Notes. Changes in the estimated fair value during the period were recorded as a component of other income (expense). Subsequent to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
June 2020, when the Old Notes converted into shares of our Series B redeemable convertible preferred stock, we no longer have an outstanding embedded derivative liability. Prior to such
conversion, the embedded derivative liability was recorded at fair value utilizing an income approach that identified the cash flows using
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;&#147;with-and-without&#148;&nbsp;valuation</FONT></FONT> methodology. The inputs used to determine the estimated fair value of the derivative instrument were based primarily
on the probability of an underlying event triggering the embedded derivative occurring and the timing of such event. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Change in Fair Value of Convertible
Notes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Change in fair value of convertible notes is comprised of adjustments to the fair value of our 2021 Notes. As permitted under ASC
Topic 825, <I>Financial Instruments </I>(ASC 825), we elected the fair value option to account for our 2021 Notes, and as a result, we measured our 2021 Notes at fair value at each financial reporting period and immediately before conversion in July
2021. All changes to the fair value of our 2021 Notes for the nine months ended September 2021 resulted in a loss. Our 2021 Notes converted into shares of Series&nbsp;C-2 redeemable convertible preferred stock concurrently with the issuance of our
Series&nbsp;C-1 redeemable convertible preferred stock. Immediately prior to the conversion, we determined the fair value of our 2021 Notes based on the fair value of the Series&nbsp;C-1 redeemable convertible preferred stock and the conversion
price at which these notes converted, which was at 85% of the fair value of the Series&nbsp;C-1 redeemable convertible preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Income Taxes
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The provision for income taxes primarily consists of state minimum taxes in the United States, which do not fluctuate when there is a
pre-tax loss. Since our inception, we have incurred significant net losses and anticipate that we will continue to incur significant losses for the foreseeable future.Therefore, we do not know whether or when we will generate the U.S. federal or
state taxable income necessary to utilize our Net Operating Losses, or NOLs, or research and development tax credits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December 31, 2019, and
2020, we had federal net operating loss carryforwards of approximately $10.1 million and $46.8 million, respectively, and state net operating loss carryforwards of approximately $9.2 million and $44.9 million, respectively, which are available to
reduce future taxable income. Of the $46.8 million federal net operating loss carryforwards, $1.3 million begin to expire in 2034 and the remaining $45.5 million net operating losses carryforward indefinitely. The $44.9 million of Massachusetts net
operating loss carryforwards begin to expire in 2034. As of December 31, 2019, and 2020, we also had federal tax credits of $0.7 million and $1.6 million, respectively, and state tax credits of $0.4 million and $0.7 million, respectively. The tax
credit carryforwards will expire at various dates beginning in 2029. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There were no provisions for income taxes for the nine months ended
September&nbsp;30, 2020 and 2021 because we have historically incurred operating losses and we maintain a full valuation allowance against our net deferred tax assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I></I></B><B><I>Comparison of the Nine Months Ended September 30, 2020 and 2021</I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table summarizes our results of operations for the nine months ended September&nbsp;30, 2020 and September 30, 2021: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(54,373</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,960</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income (expense), net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57.1</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,287</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*NM</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(260</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(97.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,214</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,939</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(354.2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(33,688</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(59,587</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,899</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">NM - not meaningful </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Grant Revenue </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Grant revenue for the nine months ended
September&nbsp;30, 2020 was consistent with the grant revenue for the nine months ended September&nbsp;30, 2021 at $0.3&nbsp;million. The immaterial decrease in grant revenue was primarily a result of final milestones being achieved during the nine
months ended September&nbsp;30, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table summarizes our research and development expenses for the nine months ended September&nbsp;30, 2020 and September&nbsp;30, 2021: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">AMX0035 - ALS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other indications</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Payroll and personnel-related</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Indirect costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I></I></B>Research and development expenses were $19.6&nbsp;million for the nine months ended
September&nbsp;30, 2020, as compared to $30.6&nbsp;million for the nine months ended September&nbsp;30, 2021. The increase of $11.1&nbsp;million was primarily due to a $5.6&nbsp;million increase in spend on indications, a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
$3.3&nbsp;million increase in payroll and personnel-related costs, a $1.6&nbsp;million increase in all other indirect costs, and a $0.5&nbsp;million increase in AMX0035 for the ALS indication.
The increase in spending on other potential indications was primarily due to increased costs for CROs and consultants to support the advancement of our clinical trial activities. The increase in payroll and personnel-related costs was primarily due
to increased payroll expense, including stock-based compensation, as a result of an increase in headcount to support our growth. The increase in indirect costs was primarily due to an increase in consulting costs as a result of our growth in 2021 as
compared to 2020. The increase in spending on AMX0035 for the ALS indication was a result of increased program activity for the nine months ended September&nbsp;30, 2021 as compared to the nine months ended September&nbsp;30, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>General and Administrative Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">General and
administrative expenses were $11.1&nbsp;million for the nine months ended September&nbsp;30, 2020 compared to $24.0&nbsp;million for the nine months ended September&nbsp;30, 2021. The increase of $12.9&nbsp;million was primarily due a
$4.4&nbsp;million increase in payroll and personnel-related costs, a $1.4&nbsp;million increase in stock-based compensation expense, and a $7.2&nbsp;million increase in advertising costs and other professional fees, offset by a $0.1&nbsp;million
decrease in public relations fees. The increase in payroll and personnel-related costs was driven by an increase in headcount, which resulted in an increase in bonus expense, 401(k) match, payroll expense and other personnel-related costs. The
increase in stock-based compensation expense was primarily due to an increase in fair value of our common stock and an increase in the number of stock options granted to employees resulting from increased headcount. The increase in advertising and
other professional fees was due to increased expenditure on advertising, promotion and marketing to support our growth and expansion, and increased expenditures on legal fees, and outside professional services, including accounting, tax and audit
fees. The decrease in public relations fees was primarily driven by fewer public relations activities for the nine months ended September&nbsp;30, 2021 as compared to 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Other Income (Expense), Net </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:ARIAL"><I>Interest Income
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Interest income for the nine months ended September 30, 2020 and 2021 was less than $0.1&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:ARIAL"><I>Interest Expense </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Interest expense was
$2.3&nbsp;million for the nine months ended September&nbsp;30, 2020 as compared to no interest expense for the nine months ended September&nbsp;30, 2021. The interest expense was primarily related to the amortization of the derivative discount
associated with our 2020 Notes, the recognition of a contingent beneficial conversion feature associated with our 2017 Notes upon the conversion of these notes into Series B redeemable convertible preferred stock in June 2020, and an immediate
charge to interest expense for the unamortized derivative discount associated with our 2017 Notes upon conversion of these notes. We recorded no interest expense for the nine months ended September&nbsp;30, 2021 as we elected to account for our 2021
Notes under the fair value option. Accordingly, all changes to the fair value of our 2021 Notes, inclusive of interest expense are included in change in fair value of convertible notes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:ARIAL"><I>Change in Fair Value of Derivative Liability </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The change in fair value of derivative liability was a $1.3&nbsp;million loss for the nine months ended September&nbsp;30, 2020 as compared to no change
in fair value of derivative liability for the nine months ended September&nbsp;30, 2021. The change in fair value of derivative liability was related to the issuance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
of our 2020 Notes, which included embedded derivatives, and a change in the fair value of our 2019 and 2020 notes resulting from a change in the probability of the settlement scenarios for these
notes, including the timing of the conversion of these notes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:ARIAL"><I>Change in Fair Value of Convertible Notes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There was no change in fair value of convertible notes for the nine months ended September&nbsp;30, 2020 as compared to a $5.2&nbsp;million recorded for
the nine months ended September&nbsp;30, 2021. There was no change in fair value of convertible notes for the nine months ended September 30, 2021 as we did not elect to account for our Old Notes under the fair value option. The $5.2&nbsp;million
recorded for the nine months ended September&nbsp;30, 2021 represented a loss and was related to our 2021 Notes, which were measured quarterly at fair value. The change in fair value was primarily due to interest expense for our 2021 Notes at the
stated interest rate and the conversion of our 2021 Notes into shares of Series&nbsp;C-2 redeemable convertible preferred stock at 15% discount to the fair value of the Series&nbsp;C-1 redeemable convertible preferred stock issued in July 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:ARIAL"><I>Other Income, Net </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Other income, net was a
gain of $0.3&nbsp;million for the nine months ended September&nbsp;30, 2020, compared to a gain of less than $0.1&nbsp;million for the nine months ended September&nbsp;31, 2021. The $0.3&nbsp;million gain in 2020 was related to the extinguishment
gain from the conversion of our 2019 Notes and 2020 Notes into 1,058,033 shares of our Series&nbsp;B redeemable convertible preferred stock. The less than $0.1&nbsp;million of other income for the nine months ended September&nbsp;30, 2021 was
primarily due to unrealized gain on foreign exchange transactions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Comparison of the Years Ended December&nbsp;31, 2019 and 2020 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table summarizes our results of operations for the years ended December&nbsp;31, 2019 and 2020: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(776</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(54.4</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,554</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,005</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,451</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income (expense), net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(162</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(92.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,276</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,012</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,209</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(235.3</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other (expense) income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*NM</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(162</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*NM</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,716</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(42,280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,564</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">NM - not meaningful </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Grant Revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Grant revenue was $1.4&nbsp;million for the year ended December&nbsp;31, 2019, compared to $0.7&nbsp;million for the year ended December&nbsp;31, 2020.
The decrease of $0.8&nbsp;million was primarily due to less contracted research and development services being performed during the year ended December&nbsp;31, 2020 than during the year ended December&nbsp;31, 2019. We performed less contracted
research and development services in 2020 as compared to 2019 as we completed more contracted research and development services in 2019 than in 2020 based on the terms of the grant agreements with our Grantors. Our grant agreements provide estimated
timelines over which contracted research and development services would be provided to the Grantors. As less research and development services were scheduled to be provided in 2020, this resulted in the recognition of less revenue during the year
ended December&nbsp;31, 2020 as compared to 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table summarizes our research and development expenses for the years ended December 31, 2019 and 2020: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">AMX0035 - ALS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other indications</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Payroll and personnel-related</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Indirect costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*NM</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">NM - not meaningful </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Research and development expenses were $11.9&nbsp;million for the year ended December&nbsp;31, 2019, compared to $24.6&nbsp;million for the year ended
December&nbsp;31, 2020. During these years, all our research and development expenses were related to the development of and clinical trials of AMX0035. The increase of $12.7&nbsp;million was primarily due to a $5.5&nbsp;million increase in spending
on AMX0035 for the ALS indication, a $0.7&nbsp;million increase in spending on the other indications, a $2.1&nbsp;million increase in payroll and personnel-related costs, and a $4.4&nbsp;million increase in all other indirect costs. The increases in
spending on AMX0035 were primarily as a result of increased program activity in the year ended December&nbsp;31, 2020 as compared to the year ended December&nbsp;31, 2019, as we purchased more manufacturing supplies and ran more validation batches
in anticipation of commercialization. The increase in payroll-related costs and health insurance was primarily due to increase in the number of employees in our research and development department. Increase in the indirect costs is primarily due to
the increase in consulting costs due to increase used of consultants in our research and development department in 2020 as compared to 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>General and
Administrative Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">General and administrative expenses were $3.1&nbsp;million for the year ended December&nbsp;31, 2019 compared to
$15.1&nbsp;million for the year ended December&nbsp;31, 2020. The increase of $12.0&nbsp;million was primarily due to a $3.0&nbsp;million increase in commercial expenses, a $5.6&nbsp;million increase in professional fees, a $3.3&nbsp;million
increase in payroll-related costs and a $0.1&nbsp;million increase in rent expense. The increase in commercial expenses was primarily due to an increase in spending for brand development, public relations and market research for AMX0035 as we pursue
commercialization. The increase in professional fees was primarily due to increased expenditure on legal fees and outside professional </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
services, including accounting, tax and audit fees. The increase in payroll related costs was primarily due to increase in headcount, related to hiring additional personnel in general and
administrative functions to support our growth initiatives. The increase in rent expense was primarily due to the lease of an additional office space in 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Other Income (Expense), Net </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:ARIAL"><I>Interest Income
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Interest income for the years ended December&nbsp;31, 2019 and 2020 was $0.2&nbsp;million and less than $0.1&nbsp;million, respectively. The
decrease in interest income was primarily due to a decrease in interest rates during the year ended December&nbsp;31, 2020, as compared to the year-ended December&nbsp;31, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:ARIAL"><I>Interest Expense </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Interest expense was
$1.3&nbsp;million for the year ended December&nbsp;31, 2019 compared to $2.3&nbsp;million for the year ended December&nbsp;31, 2020. The increase of $1.0&nbsp;million was primarily due to $1.6&nbsp;million of interest expense recorded as a result of
the amortization of derivative discount associated with our 2020 Notes, the recognition of a contingent beneficial conversion feature associated with our 2017 Notes upon the conversion of these notes into Series B redeemable convertible preferred
stock in June 2020, and immediate charge to interest expense for the unamortized derivative discount associated with our 2017 Notes upon conversion of these notes, offset by a $0.6&nbsp;million decrease in interest expense recorded on our 2017
Notes, 2018 Notes and 2019 Notes as these notes converted into Series B redeemable convertible preferred stock in June 2020. This conversion resulted in our recognition of less interest expense on these notes during the year ended December&nbsp;31,
2020 as compared to year ended December&nbsp;31, 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:ARIAL"><I>Change in Fair Value of Derivative Liability </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The change in fair value of derivative liability resulted in a gain of $0.9 million for the year ended December 31, 2019, compared to a loss of $1.3
million for the year ended December 31, 2020. The change of $2.2 million was primarily due to the issuance of the 2020 Notes, which included embedded derivatives, and a change in the probability related to the settlement scenarios associated with
our 2019 Notes and 2020 Notes including the timing of the conversion of these notes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:ARIAL"><I>Other Expense (Income), Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Other expense, net was a loss of less than $0.1&nbsp;million for the year ended December&nbsp;31, 2019, compared to a gain of $0.3&nbsp;million for the
year ended December&nbsp;31, 2020. The less than $0.1&nbsp;million of loss in 2019 was related to a loss on foreign currency transaction. The $0.3&nbsp;million gain in 2020 was related to the extinguishment gain from the conversion of our 2019 Notes
and 2020 Notes into 1,058,033 shares of our Series B redeemable convertible preferred stock and represented the difference between the fair value of the Series B redeemable convertible preferred stock of $18.0&nbsp;million and the carrying value of
the 2019 and 2020 Notes including derivative liability of $18.3&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:ARIAL"><I>Sources of Liquidity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since our inception, we
have incurred significant operating losses and generated revenues through five grants from the Grantors. We have not yet commercialized any products. To date, we have financed our operations primarily through the sale and issuance of convertible
preferred stock, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
convertible notes, grant agreements with the Grantors and, to a lesser extent, a government loan. As of September 30, 2021, we had cash, cash equivalents and short-term investments of $125.7
million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From inception through September 30, 2021, we have raised $234.3&nbsp;million in aggregate proceeds, net of issuance costs, primarily from
the issuance of convertible preferred stock, convertible notes and grant agreements. In July 2021, we issued and sold shares of Series C-1 preferred stock for an aggregate purchase price of approximately $135.0 million. The 2021 Notes automatically
converted into shares of Series C-2 preferred stock pursuant to their original terms in July 2021 in connection with our sale of Series C-1 preferred stock. Based on our current operational plans and assumptions, we believe that our existing cash,
cash equivalents and short-term investments, together with the net proceeds from this offering, will be sufficient to meet our anticipated operating and capital expenditure requirements for at least twelve months after the registration statement of
which this prospectus forms a part becomes effective. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Funding Requirements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities,
manufacturing and clinical trials of AMX0035 and any future product candidates, and prepare for the commercial launch of AMX0035, if approved. In addition, upon the closing of this offering, we expect to incur additional costs associated with
operating as a public company, including significant legal, accounting, investor relations and other expenses that we did not incur as a private company. Our expenses will also increase as we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">continue our research and development efforts, including our ongoing global Phase 3 PHOENIX trial of AMX0035 for the
treatment of ALS; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">pursue commercialization of AMX0035 for the treatment of ALS, initially in Canada, the United States and Europe;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">submit investigational new drug applications, or INDs, of AMX0035 for the treatment of Wolfram syndrome and potentially for
other indications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">conduct preclinical studies and clinical trials for potential future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">seek to identify and develop, acquire <FONT STYLE="white-space:nowrap">or&nbsp;in-license&nbsp;additional</FONT> product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">experience any delays or encounter any issues with any of the above, including but not limited to failed studies, complex
results, safety issues, or other regulatory challenges; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">develop the necessary processes, controls and manufacturing data to obtain marketing approval for AMX0035 or any future
product candidates and to support manufacturing on a commercial scale; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">seek regulatory approvals for AMX0035 or any future product candidates that successfully complete clinical trials, if any;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">hire and retain additional personnel, such <FONT STYLE="white-space:nowrap">as&nbsp;non-clinical,&nbsp;clinical,</FONT>
quality assurance, regulatory affairs, manufacturing, distribution, legal, compliance, finance, general and administrative, commercial and scientific personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">develop, maintain, expand and protect our intellectual property portfolio; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">transition our organization to being a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Following this offering, we will be a publicly traded company and will incur significant legal, accounting and other expenses that we were not required
to incur as a private company. In addition, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the Sarbanes-Oxley Act of 2002, as well as rules adopted by the SEC and the Nasdaq Global Market, require public companies to implement specified corporate governance practices that are currently
not applicable to us as a private company. Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or Section&nbsp;404, we will first be required to furnish a report by our management on our internal control over financial reporting for the
year ending December&nbsp;31, 2023. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting
firm. To achieve compliance with Section&nbsp;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will
need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as
appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. We expect these rules and regulations will increase our
legal and financial compliance costs and will make some activities more time-consuming and costly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on our current operational plans and
assumptions, we expect that the net proceeds from this offering, combined with our current cash, cash equivalents and short-term investments, will be sufficient to fund operations for at least twelve months after the registration statement of which
this prospectus forms a part becomes effective. We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. As we progress with our development activities and
the regulatory review process, we expect to incur significant commercialization expenses related to product <FONT STYLE="white-space:nowrap">manufacturing,&nbsp;pre-commercial&nbsp;activities</FONT> and commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on our recurring losses, expectation of continuing operating losses and negative cash flows from operations in the foreseeable future, and the
need to raise additional capital to finance future operations, we have concluded that there is substantial doubt about our ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that
might result from the outcome of this uncertainty. Accordingly, the consolidated financial statements have been prepared on a basis that assumes we will continue as a going concern, and which contemplates the realization of assets and satisfaction
of liabilities and commitments in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Because of the numerous risks and uncertainties associated with research,
development and commercialization of product candidates and programs, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many
factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope, progress, results and costs of drug discovery, laboratory testing, preclinical and clinical development for
AMX0035 and any future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs, timing and outcome of potential future commercialization activities, including manufacturing, marketing, sales
and distribution for AMX0035 or any future product candidates for which we receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs, timing and outcome of regulatory review of AMX0035 and any future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to establish and maintain collaborations and license agreements on favorable terms, if at all;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to enroll clinical trials in a timely manner and to quickly resolve any delays or clinical holds that may be
imposed on our development activities; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">timing delays with respect to preclinical and clinical development of AMX0035 and any future product candidates, including
as result of the&nbsp;ongoing <FONT STYLE="white-space:nowrap">COVID-19&nbsp;pandemic</FONT> or other pandemics or disruptions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs of expanding our facilities to accommodate our expected growth in personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property
rights and defending intellectual property-related claims; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the extent to which we acquire technologies or other assets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the sales price and availability of adequate third-party coverage and reimbursement for AMX0035 and any future product
candidates, if and when approved; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs of operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Until such time, if ever, that we can generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through equity
offerings, debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of
common stock, convertible securities or other equity securities, current ownership interests will be diluted. If we raise additional funds through collaborations or marketing, distribution or licensing arrangements with third parties, we may have to
relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. In addition, debt financing, if available, may result in fixed payment obligations and may
involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures, creating liens, redeeming stock or declaring dividends, that could adversely
impact our ability to conduct our business. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and
market product candidates that we would otherwise prefer to develop and market ourselves. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Cash Flows </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Comparison of the Nine Months Ended September 30, 2020 and 2021 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table summarizes our sources and uses of cash for the nine months ended September 30, 2020 and September 30, 2021: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,809</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,746</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,220</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,220</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">249.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Effect of exchange rate changes on cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">63,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">257.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Operating Activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During
the nine months ended September 30, 2020, operating activities used $27.8 million of cash, primarily resulting from our net loss of $33.7 million, $1.7 million of non-cash interest expense, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
$1.3 million of change in fair value of derivative liability, $0.3 million of extinguishment gain from the conversion of our 2019 Notes and 2020 Notes into Series B redeemable convertible
preferred stock, $0.1 million of stock-based compensation expense, offset by $3.1 million increase in net cash provided by changes in our operating assets and liabilities. Net cash provided by changes in our operating assets and liabilities was
primarily due to favorable changes in working capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the nine months ended September 30, 2021, operating activities used $46.6 million of
cash, primarily resulting from our net loss of $59.6 million, $5.2 million of change in fair value of convertible notes, $2.0 million of stock-based compensation expense, $0.1 million of depreciation expense and net amortization of premiums and
discounts on investments, offset by $5.7 million increase in net cash provided by changes in our operating assets and liabilities. Net cash provided by changes in our operating assets and liabilities primarily consisted of a $8.1 million increase in
accrued expenses and deferred rent due to increased spending for external research and development to support our growth, and a $0.1 million decrease in other assets, offset by a $1.8 million increase in prepaid expenses and other current assets due
to increase in sign-on bonuses as a result of an increase in headcount and increase in other receivables related to milestones achieved under the grant agreements for which we were owed by the Grantors, and a $0.7 million net decrease in other
working capital accounts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Investing Activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There
were no cash flows from investing activities during the nine months ended September 30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the nine months ended September 30, 2021, net
cash used in investing activities was $49.2 million, resulting from $49.1 million of purchases of short-term investments and $0.2 million of purchases of property and equipment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Financing Activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the nine months ended September
30, 2020, net cash provided by financing activities was $45.6 million. This amount consisted of $30.0 million of net proceeds from the sale of our Series B redeemable convertible preferred stock, $10.6 million of net proceeds from the issuance of
the 2020 Notes, $4.8 million of net proceeds from the issuance of the 2020 Notes to related parties, and $0.3 million of proceeds from the PPP loan obtained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the nine months ended September 30, 2021, net cash provided by financing activities was $159.7&nbsp;million. This amount consisted of $134.8
million of net proceeds from the issuance of our Series <FONT STYLE="white-space:nowrap">C-1</FONT> redeemable convertible preferred stock, $14.3 million of net proceeds from the issuance of convertible notes to related parties, $11.9 million of net
proceeds from the issuance of the convertible notes and $0.2 million of proceeds from exercises of stock options, offset by a $1.5 million payment of deferred offering costs and less than $0.1 million of issuance costs related to the conversion of
the convertible notes, which was related to the 2021 Notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Comparison of the Years Ended December&nbsp;31, 2019 and 2020 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table summarizes our sources and uses of cash for the years ended December 31, 2019 and 2020: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,687</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(36,697</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,010</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*NM</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net (decrease) increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,019</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(199.6</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">NM - not meaningful </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Operating Activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the year ended December 31,
2019, operating activities used $10.7 million of cash, primarily resulting from our net loss of $13.7 million and $0.9 million change in fair value of derivative liability, partially offset by a non-cash interest expense of $0.4 million and net cash
provided by changes in our operating assets and liabilities of $3.5 million. Net cash provided by changes in our operating assets and liabilities primarily consisted of a $1.3 million increase in accounts payable due to outstanding invoices to CROs,
and other vendors in connection with our increased level of operating activities in 2019, and a $1.3 million increase in accrued expenses and other current liabilities, which was primarily due to increased costs associated with AMX0035. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the year ended December 31, 2020, operating activities used $36.7 million of cash, primarily resulting from our net loss of $42.3 million and
$0.3 million of extinguishment gain from the conversion of our 2019 Notes and 2020 Notes into Series B redeemable convertible preferred stock, partially offset by $1.7 million of non-cash interest expense, $2.7 million of net cash provided by
changes in our operating assets and liabilities, $1.3 million of change in fair value of derivative liability, and $0.2 million of non-cash stock compensation expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The increase in non-cash interest expense was primarily due to the amortization of the derivative discount associated with the 2020 Notes and the
recognition of a contingent beneficial conversion feature associated with our 2017 Notes upon the conversion of these Notes into Series B redeemable convertible preferred stock. Net cash provided by changes in our operating assets and liabilities
primarily consisted of a $1.4 million increase in accounts payable, a $1.4 million increase in accrued expenses and other current liabilities and a $0.6 million increase in accrued interest on our Notes, partially offset by a $0.7 million increase
in prepaid expenses and other current assets. The increases in accounts payable, accrued expenses and other current liabilities were primarily due to timing of invoicing and cash disbursement to our vendors in connection with our increased level of
operating activities in 2020. The increase in prepaid expenses and other current assets was primarily due to subscription to a health data analytics software program used in the research and development of AMX0035 and future product candidates in
2020 and increase in sign-on bonus payments to our employees in our research and development department as a result of an increase in headcount. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Investing
Activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There were no cash flows from investing activities during the year ended December 31, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the year ended December 31, 2020, net cash used in investing activities was $0.2 million,
driven by purchases of property and equipment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Financing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the year ended December 31, 2019, net cash provided by financing activities was $0.7&nbsp;million, consisting primarily of $0.6 million of net
proceeds from the issuance of the 2019 Notes and proceeds from the exercise of stock options of less than $0.1 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the year ended
December 31, 2020, net cash provided by financing was $46.8 million, consisting of $30.0 million of net proceeds from the sale of Series B redeemable convertible preferred stock, $15.4 million of net proceeds from the issuance of the 2020 Notes, net
of issuance costs, $1.2&nbsp;million of proceeds received in advance of the issuance of the 2021 Notes and $0.3 million of net proceeds received from the PPP Loan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In April 2020, we received the PPP Loan from First Republic Bank. Under the terms of the CARES Act and the PPP Loan, all or portion of the principal
amount of the PPP Loan is subject to forgiveness so long as, over the 24-week period following our receipt of the proceeds of the PPP Loan, we use those proceeds for payroll costs, rent, utility costs or the maintenance of employee and compensation
levels. The PPP Loan was forgiven in March 2021 and notwithstanding the forgiveness of the PPP Loan, we repaid it in full on October 7, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Contractual
Obligations and Commitments </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In October 2018, we entered into an operating lease for our office space in Cambridge, Massachusetts, which was to
expire on December&nbsp;31, 2018. In January 2020, we entered into an amendment to extend the lease term of our office space and to lease additional office space, or Expansion Space. Pursuant to the amendment, our lease of both the office space and
the Expansion Space will expire in October 2026. The terms of the amendment include an option for a <FONT STYLE="white-space:nowrap">one-time,</FONT> five-year extension of the lease of the Expansion Space. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have certain payment obligations under our grant agreements. Under the terms of the respective grant agreements with each Grantor, we will be
required to make royalty payments upon future events such as our achievement of commercialization, in connection with the sale of products developed under these agreements and the receipt of cash proceeds resulting from revenue generated from the
project for which the grants were used. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For our grant agreements with ALS Association and ALS Finding a Cure, we will be required to pay royalties
over time in the amount equal to 150% of the grants received up to a maximum of $2.3&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the terms of our grant agreements
with Alzheimer&#146;s Drug Discovery Foundation, the Alzheimer&#146;s Association, and Cure Alzheimer&#146;s Fund, we will be required to make royalty payments over time up to the maximum amount of $15.0&nbsp;million to each Grantor. As the
achievement and timing of these future royalty payments are not probable or estimable, such amounts have not been included in our balance sheets as of December&nbsp;31, 2019, December 31, 2020 and, September 30, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We enter into contracts in the normal course of business with CROs and other third-party vendors for clinical trials, clinical and commercial supply
manufacturing, support <FONT STYLE="white-space:nowrap">for&nbsp;pre-commercial&nbsp;activities,</FONT> research and development activities and other services and products for our operations. These contracts are generally cancelable upon written
notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For additional information on our contractual obligation and commitments please see Note 15 &#151;
Commitments and Contingencies to our consolidated financial statements and Note 13 to our condensed consolidated financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Critical Accounting Policies and Significant Judgments and Estimates </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our consolidated financial statements are prepared in accordance with&nbsp;U.S. GAAP. The preparation of our consolidated financial statements and
related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base
our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and
liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">While our significant accounting policies are described in more detail in Note&nbsp;2 to our consolidated financial statements appearing at the end of
this prospectus, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Accrued Research and Development Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As part of
the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to
identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs.&nbsp;The majority of
our service providers invoice us in arrears for services performed, on a <FONT STYLE="white-space:nowrap">pre-determined</FONT> schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued
expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of these estimates with the service providers and make adjustments if
necessary.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The estimate of&nbsp;accrued&nbsp;research&nbsp;and&nbsp;development&nbsp;expense is dependent, in part, upon the receipt of timely and
accurate reporting from CROs, CMOs and other third-party service providers. Examples of estimated accrued research and development expenses include fees paid to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">vendors in connection with preclinical development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">CROs and investigative sites in connection with preclinical studies and clinical trials; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">CMOs in connection with drug substance and drug product formulation of preclinical study and clinical trial materials.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We base our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts
expended pursuant to quotes and contracts with multiple CMOs and CROs that conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract
and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing service fees, we estimate the time period over
which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
we adjust the accrual or the amount of prepaid expenses accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the
status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material
adjustments to our prior estimates of accrued research and development expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Valuation of Derivative Liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with our issuance of the 2017 Notes, 2018 Notes, 2019 Notes, and 2020 Notes, we recognized derivative liabilities associated with the
redemption features as they met the requirements for separate accounting as derivatives. The derivative instruments were recorded at fair value at inception and were subject to remeasurement to fair value the end of each reporting period and
immediately prior to conversion, with any changes in fair value recognized in the statements of operations and comprehensive loss. The primary inputs for the&nbsp;valuation&nbsp;approach included the probability of achieving various settlement
scenarios that provide the lenders the rights or the obligations to receive cash at maturity or a variable number of shares upon the completion of qualified financing, and stock or asset sale. The fair value of the derivative instruments associated
with each note was estimated using a <FONT STYLE="white-space:nowrap">two-step</FONT> approach to&nbsp;valuation, employing a probability-weighted scenario&nbsp;valuation&nbsp;method and then comparing the instrument&#146;s value <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">with-and-without</FONT></FONT> the derivative&nbsp;features&nbsp;in order to estimate their combined fair value, using unobservable inputs. In order to estimate the fair value of the 2017,
2018, 2019,&nbsp;and 2020&nbsp;Notes, we estimated the future payoff in each scenario, discounted them to a present value and then probability weighted them based upon our best estimate of likelihood of each event occurring. In June 2020, in
connection with our issuance of the Series B redeemable convertible preferred stock, our 2017, 2018, 2019 and 2020 Notes converted into shares of Series B redeemable convertible preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Fair Value Option </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As permitted under ASC Topic 825,
Financial Instruments (ASC 825), we elected the fair value option to account for our 2021 Notes, which converted into Series C-2 redeemable convertible preferred stock in July 2021. In accordance with ASC 825, we recorded the 2021 Notes at fair
value with changes in fair value recorded in the condensed consolidated statement of operations as of September 30, 2021. As a result of applying the fair value option, direct costs and fees related to the 2021 Notes were expensed as incurred and
were not deferred. We concluded it was appropriate to apply the fair value option to the 2021 Notes because they are liabilities that are not, in whole or in part, classified as a component of the stockholders&#146; deficit. In addition, the 2021
Notes met other applicable criteria for electing fair value option under ASC 825. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In determining the fair value of the 2021 Notes under the fair
value option, we used a scenario-based analysis to incorporate estimates and assumptions concerning our prospects and market indications into a model to estimate the value of the 2021 Notes. The most significant estimates and assumptions used as
inputs are those concerning timing, probability of possible scenarios for conversion or settlement of the 2021 Notes and discount rates. The fair value of the 2021 Notes upon settlement in July 2021 was determined based on the fair value of the
Series C-1 redeemable convertible preferred stock issued. This method was selected as we concluded that the contemporaneous financing transaction was an arm&#146;s length transaction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Stock-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We account for stock-based
compensation under the provisions of ASC 718-10, Compensation&#151;Stock Compensation, which requires all share-based payments to employees, non-employees and directors, including grants of stock options and restricted stock, to be recognized in the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
consolidated statements of operations based on their fair values on the date of grant over the requisite service period, which is generally the vesting period of the respective award. Forfeitures
are accounted for as they occur. Generally, we issue stock option awards with only service-based vesting conditions and record the expense for these awards using the straight-line method. We classify stock-based compensation expense in the same
manner in which the awards recipient&#146;s payroll or service provider&#146;s costs are classified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The fair value of each option grant is
estimated on the date of grant using the Black-Scholes option pricing model, which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the award, the risk-free interest rate,
and expected dividends. We estimate the expected stock price volatility based on the historical volatility of publicly traded peer companies. The expected term of our stock options has been determined utilizing the &#147;simplified&#148; method for
awards that qualify as &#147;plain vanilla&#148; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term
of the award. There is no expected dividend yield since we have never paid cash dividends on common stock and do not expect to pay any cash dividends in the foreseeable future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Common Stock Valuations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As there has been no public
market for our common stock, the estimated fair value of common stock has determined by our Board of Directors as of the date of each option grant, with input from management, considering third-party valuations of our common stock as well as our
Board of Directors&#146; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent third-party valuation through the date of the grant. Historically, these
independent third-party valuations of our equity instruments were performed contemporaneously with identified value inflection points. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of
Certified Public Accountants&#146; Accounting and Valuation Guide, <I>Valuation of Privately Held Company Equity Securities Issued as Compensation or the Practice Aid</I>. The Practice Aid identifies various available methods for allocating the
enterprise value across classes of series of capital stock in determining the fair value of our common stock at each valuation date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The
assumptions used to determine the estimated fair value of our common stock are based on numerous objective and subjective factors, combined with management judgment, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">external market conditions affecting the pharmaceutical and biotechnology industry and trends within the industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our stage of development and business strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the rights, preferences, and privileges of our redeemable convertible preferred stock relative to those of our common
stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the prices at which we sold shares of our redeemable convertible preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our financial condition and operating results, including our levels of available capital resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the progress of our research and development efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">equity market conditions affecting comparable public companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">economic outlook including economic growth, inflation and unemployment, interest rate environment, and global economic
trends; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the lack of marketability of our common stock </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In accordance with the Practice Aid, we determined the hybrid method of the option pricing method, or
OPM, and the Probability-Weighted Expected Return Method, or PWERM, was the most appropriate method for determining the fair value of our common stock based on our stage of development and other relevant factors. The OPM uses option theory to value
the various classes of a company&#146;s securities in light of their respective claims to the enterprise value. Total shareholders&#146; equity value is allocated to the various share classes based upon their respective claims on a series of call
options with strike prices at various value levels depending upon the rights and preferences of each class. A Black-Scholes closed form option pricing model is employed in this analysis, with an option term assumption that is consistent with the
expected time to a liquidity event and a volatility assumption based on the estimated stock price volatility of a peer group of comparable public companies over a similar term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The PWERM values each class of equity based on an analysis of the range of potential future enterprise values of the company and the manner in which
those values would accrue to the owners of the different classes of equity. This method involves estimating the overall value of the subject company under various liquidity event scenarios and allocating the value to the various share classes based
on their respective claim on the proceeds as of the date of each event. These different scenarios typically include an initial public offering, an acquisition, or a liquidation of the business, each resulting in a different value. For each scenario,
the future value of each share class is calculated and discounted to a present value. The results of each scenario are then probability weighted in order to arrive at an estimate of fair value for each share class as of a current date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The hybrid method is a hybrid between the PWERM and OPM, estimating the probability-weighted value across multiple scenarios, but using the OPM to
estimate the allocation of value within one or more of the scenarios. In our hybrid method, two types of future event scenarios were considered: an initial public offering, or IPO, and a non-IPO scenario accounting for all other potential future
exits. Under both scenarios, the enterprise value was determined at each valuation date using a combination of the cost approach; the income approach, specifically a discounted cash flow analysis; and the market approach, specifically a backsolve to
the last round of financing. The relative probabilities between the future exit scenarios were determined by our board of directors based on an analysis of performance and market conditions at the time, including then current IPO valuations of
similarly situated companies and expectations as to the timing and likely prospects of future event scenarios. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The assumptions underlying these
valuations represented management&#146;s best estimates, which involved inherent uncertainties and the application of management&#146;s judgment. As a result, if we had used significantly different assumptions or estimates, the fair value of our
common stock and our stock-based compensation expense could have been materially different. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Following the closing of this offering, our board of
directors will determine the fair market value of our common stock based on its closing price as reported on the date of grant on the primary stock exchange on which our common stock is traded. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Internal Control over Financial Reporting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the course of
reviewing our consolidated financial statements in preparation for this offering, our management identified deficiencies that we concluded represented material weaknesses in our internal control over financial reporting attributable to our lack of
sufficient financial reporting and accounting personnel. SEC guidance regarding management&#146;s report on internal control over financial reporting defines a material weakness as a deficiency or combination of deficiencies in internal control over
financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated financial statements will not be prevented or detected and corrected on a timely basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Deficiencies in our internal controls over financial reporting that were considered to be a material
weakness as of December 31, 2019 were related to the lack of a sufficiently precise review over both valuations prepared by our third-party valuation experts as well as the completeness of operating expenses. We remediated the material weakness
related to the review of valuation reports by adding a precise review control that was performed by our accounting personnel with the appropriate technical expertise to review valuation reports. In addition, we have hired an accounting executive
with the requisite knowledge in the application of U.S. GAAP and SEC reporting who will be collaborating and reviewing valuation reports prepared by our third-party valuation experts. For the deficiency related to the completeness of operating
expenses, we continue to take measures to remediate the deficiency by updating our internal controls to include additional staffing as well as augmenting our controls addressing the completeness of operating expenses, as outlined below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further deficiencies in our internal controls over financial reporting that have been considered to be a material weakness as of December 31, 2020
relate to deficiencies in the design of controls over the expenditures process. Specifically, our information technology controls related to the expenditures cycle were not designed to post invoices approved in the correct period, and our controls
over the review of the completeness of operating expenses as it related to our close cycle were not appropriately designed, as we lacked sufficient personnel in our Finance and IT organizations to review and provide reasonable assurance that
transactions were being recorded timely and completely. We are in the process of implementing changes to our internal controls over financial reporting to remediate this material weakness that has been identified and these changes include hiring a
sufficient number of accounting and IT personnel to focus on our information technology systems and to adequately manage the monthly close process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">However, there can be no assurance that we will be successful in pursuing these measures or that these measures will significantly improve or remediate
the material weaknesses described above. There is also no assurance that we have identified all of our material weaknesses or that we will not in the future have additional material weaknesses. See &#147;Risk Factors&#151;Risks Related to Our Common
Stock and this Offering&#151;If we fail to remediate our material weaknesses in internal controls over financial reporting and to implement and maintain an effective system of internal controls, we may be unable to accurately report our results of
operations, meet our reporting obligations or prevent fraud, and investor confidence in our company and the market price of our common stock may be materially and adversely affected.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Emerging Growth Company and Smaller Reporting Company Status </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, permits an &#147;emerging growth company&#148; such as us to take advantage of an
extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected to use this extended transition period for complying with
new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i)&nbsp;are no longer an emerging growth company or (ii)&nbsp;affirmatively and irrevocably opt out of the
extended transition period provided in the JOBS Act. As a result, we will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies, and our consolidated financial statements may
not be comparable to other public companies that comply with new or revised accounting pronouncements as of public company effective dates. We may choose to early adopt any new or revised accounting standards whenever such early adoption is
permitted for private companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We will cease to be an emerging growth company on the date that is the earliest of (i)&nbsp;the last day of the
fiscal year in which we have total annual gross revenues of $1.07&nbsp;billion or more, (ii)&nbsp;the last day of our fiscal year following the fifth anniversary of the date of the closing of this offering, (iii)&nbsp;the date on
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
which we have issued more than $1.0 billion in nonconvertible debt during the previous three years or (iv)&nbsp;the date on which we are deemed to be a large, accelerated filer under the rules of
the Securities and Exchange Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are also a &#147;smaller reporting company&#148;, meaning that the market value of our stock held by
non-affiliates plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be
a smaller reporting company after this offering if either (i)&nbsp;the market value of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year
and the market value of our stock held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure
requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and,
similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Recently Issued
Accounting Pronouncements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A description of recently issued accounting pronouncements that may potentially impact our financial position and
results of operations is disclosed in Note&nbsp;2 to our consolidated financial statements appearing at the end of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc155225_10"></A>BUSINESS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Introduction </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our mission is to develop therapies that
change the treatment paradigm for amyotrophic lateral sclerosis, or ALS, and a broad range of neurodegenerative diseases by keeping neurons alive. Unlike most other cells in the body that regularly die and are replaced as part of healthy function,
mature neurons are normally resistant to cell death and generally cannot regenerate. We are pursuing commercialization of our product candidate, AMX0035, which we believe is the first drug candidate to show both a functional and survival benefit in
a large-scale clinical trial of patients with ALS. We submitted a New Drug Submission, or NDS, in Canada in the second quarter of 2021 for AMX0035 for the treatment of ALS, which was accepted for review in the third quarter of 2021, and a New Drug
Application, or NDA, to the U.S. Food and Drug Administration, or FDA, in the fourth quarter of 2021, which was accepted for priority review in the same quarter. We also intend to submit a Marketing Authorization Application, or MAA, in Europe early
in the first quarter of 2022. The results of our Phase 2 clinical trial of AMX0035, known as the CENTAUR trial, were published in September 2020 in the <I>New England Journal of Medicine</I> and in October 2020 in the <I>Journal of Muscle and
Nerve</I> and demonstrated functional and survival benefits for ALS patients. We believe AMX0035 has the potential to be a foundational therapy, meaning that it could be used alone or in conjunction with other therapies to change the treatment
paradigm across a broad range of neurodegenerative diseases. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">AMX0035 is a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate,
or PB, and TURSO (also known as tauroursodeoxycholic acid, or TUDCA). Through the resolution of the unfolded protein response, or UPR, and by inhibiting translocation of the Bcl-2 Associated X-protein, or Bax, to the outer mitochondrial membrane, we
have shown in multiple models that AMX0035 can keep neurons alive under a variety of different conditions and stresses, including in in vitro models of neurodegeneration, endoplasmic reticulum stress, mitochondrial dysfunction, oxidative stress and
disease-specific models of a variety of other conditions, as well as in vivo models of ALS, Alzheimer&#146;s Disease, or AD, and multiple sclerosis. We are pursuing ALS as our first indication as it is a disease of rapid and profound
neurodegeneration, and we are focused on the development and potential commercialization of AMX0035 for ALS globally. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are actively pursuing
regulatory approvals of AMX0035 for the treatment of ALS in Canada, the United States and, in the near-term, Europe. We recently have initiated a Phase 3 clinical trial of AMX0035 for the treatment of ALS, known as PHOENIX trial, at clinical trial
sites in the United States and Europe. This trial, is designed to provide further data supporting AMX0035. Based on dialogue with the FDA prior to our NDA submission, including at a pre-NDA meeting recommended by the FDA and subsequent discussions,
we believe that data from the PHOENIX trial will not be required for the FDA to make a determination on the approval of AMX0035 for the treatment of ALS, although there can be no assurance that the FDA will not require further data before making a
determination. The PHOENIX trial is designed to provide further data supporting the safety and efficacy of AMX0035 for the treatment of ALS to further support our global regulatory efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, we are developing AMX0035 for other neurodegenerative diseases by leveraging our deep knowledge of and relationships in the
neurodegenerative space. We believe the approach of a dual UPR-Bax apoptosis inhibitor designed to help keep neurons alive could be clinically meaningful for the treatment of other neurodegenerative disease indications in addition to ALS. Many
common and rare neurodegenerative diseases are characterized by substantial neuronal cellular loss, including AD and Wolfram syndrome, as well as Parkinson&#146;s Disease, Huntington&#146;s Disease, Progressive Supranuclear Palsy, Multi-System
Atrophy, and others. We conducted a Phase&nbsp;2 clinical trial in AD, known as the PEGASUS trial, to obtain safety data along with initial efficacy and biomarker data which could help us prioritize additional indications to pursue with AMX0035. We
believe the topline results </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
from the PEGASUS trial, reported in November 2021, provide further biological knowledge about AMX0035 which will help inform future clinical development of AMX0035 for the treatment of AD and in
other potential indications. Based on these topline results, AMX0035 met the PEGASUS trial&#146;s primary endpoint of safety and tolerability. The 6-month trial was not powered to evaluate differences between groups in efficacy outcomes and no
differences were seen in a newly developed composite outcome of cognitive, functional, and imaging measures, or secondary efficacy endpoints of cognition, function, and imaging. In this trial, AMX0035 showed significant effects on biomarkers
including the tau protein, tau phosphorylated at threonine 181, <FONT STYLE="white-space:nowrap">8-hydroxy-2&#146;</FONT> - deoxyguanosine, or 8-OHdG, and the amyloid beta 42 to 40 (amyloid-&szlig;1-42, amyloid-&szlig;1-40) ratio in cerebrospinal
fluid. We will continue to evaluate these data and discuss the results of the PEGASUS trial with scientific advisors as we consider potential next steps for the development of AMX0035 for the treatment of AD within our clinical development strategy.
Based on preclinical evidence, we are planning to pursue a clinical trial in Wolfram syndrome. We intend to prioritize our development efforts around neurodegenerative diseases that result in substantial disability, and ultimately death, and where
unmet medical needs are greatest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since our founding in 2013, our goal has been to improve the quality of, and extend, life for patients suffering
from neurodegenerative diseases. One of our key strategies towards achieving this goal has been to form direct relationships with patients, their families, advocacy groups, and healthcare professionals to bring much needed innovation to patients.
Throughout the development of AMX0035, we have partnered with members of the disease communities we serve, including the ALS Association, the Northeast ALS Consortium, or NEALS, ALS Finding a Cure, the Healey Center at Massachusetts General
Hospital, the Cure Alzheimer&#146;s Fund, the Alzheimer&#146;s Association and the Alzheimer&#146;s Drug Discovery Foundation, to ensure our goals are aligned with patient needs. In addition, many of the key opinion leaders in the ALS community were
and are investigators in our recent and ongoing trials. These relationships are a cornerstone of our culture and corporate strategy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our current
pipeline, including the stage of development of AMX0035 in our target indications, is represented in the table below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g155225g11i55.jpg" ALT="LOGO">
 </P>  <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">AMX0035 is a proprietary oral fixed-dose
combination of two small molecules: PB, which is a small molecular chaperone that reduces the UPR, preventing cell death resulting from the UPR, and TURSO, (also known as tauroursodeoxycholic acid, or TUDCA), which is a Bax inhibitor that reduces
cell death through apoptosis. While the PB and TURSO molecules individually are not proprietary to us, we own patents and patent applications covering AMX0035, including the fixed-dose combination of AMX0035 itself. We believe that our proprietary
combination of these two mechanisms of action will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
allow us to target abnormal cell death to better prevent neurodegeneration than treatment with either mechanism of action alone. In <I>in vitro </I>studies, PB and TURSO were observed in
combination to prevent nearly 100% of neuron death. However, PB and TURSO alone only prevented a moderate percentage of neuron death in <I>in vitro</I> studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The results of our CENTAUR trial were published in September 2020 in the <I>New England Journal of Medicine</I> and in October 2020 in the <I>Journal of
Muscle and Nerve.</I> Trial results showed that patients receiving AMX0035 experienced statistically significant benefit in function, as measured by the Revised ALS Functional Rating Scale, or <FONT STYLE="white-space:nowrap">ALSFRS-R,</FONT> as
well as statistically significant improvement in overall survival, or OS, when analyzing the full randomized population through the open-label extension, or OLE, trial (July&nbsp;20, 2020 data cutoff). AMX0035 was shown to be generally
well-tolerated with the prevalence of adverse events comparable across placebo and treatment groups. We believe AMX0035 is the first drug candidate in ALS to demonstrate a statistically significant benefit both in function as measured by a
prespecified mean rate change in <FONT STYLE="white-space:nowrap">ALSFRS-R</FONT> and in a longer-term analysis of OS, which are both important outcomes for people with ALS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Company and Team </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Amylyx was founded with the ambitious
goal of improving the quality and length of life for patients suffering from neurodegenerative diseases. From a dorm room at Brown University in 2013, our <FONT STYLE="white-space:nowrap">Co-CEOs</FONT> and
<FONT STYLE="white-space:nowrap">Co-Founders,</FONT> Josh Cohen and Justin Klee set out to determine why neurons die, and have ever since been working to develop AMX0035, which we believe is the first drug candidate to show a clear effect on
function and survival in ALS, and other novel therapies. To help realize our goal, we have assembled a team with deep scientific, clinical, business and leadership experience, bolstered by expertise in biotechnology. Our Chief Financial Officer,
James Frates, brings over 20 years of experience as the Chief Financial Officer of Alkermes. Our Chief Commercial Officer, Margaret Olinger, brings three decades of expertise in commercial launches and operations, most recently at Alexion. Our
Global Head of Supply, Tom Holmes, brings more than 25 years of leadership experience at Biogen in supply chain, biopharmaceutical manufacturing and program management. Our Global Head of Clinical Research&nbsp;&amp; Development and Chief Medical
Officer, Patrick D. Yeramian, brings over 30 years of medical and pharmaceutical industry experience. Our Head of Regulatory Affairs, Tammy Sarnelli, brings more than 30 years of experience from Biogen and other companies in early and late-stage
neurology and rare disease development. Our Global Head of Human Resources, Debra Canner, brings over 20 years of experience, having served as the Chief of Human Resources Officers at Akamai and as part of Genzyme. This team brings a diverse set of
skills uniquely suited to drive successful commercialization of AMX0035 in ALS while continuing to advance AMX0035 in other indications. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our mission is to change the treatment paradigm for neurodegenerative diseases. Key elements of our strategy to achieve this mission include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Obtaining regulatory approval of AMX0035 for ALS in Canada, the United States and Europe.</I></B> Based on the
results from our CENTAUR trial, we have been exploring pathways towards regulatory approval in several territories, including Canada, the United States and Europe. We believe that the CENTAUR trial may be able to support regulatory approval in
Canada and the United States and marketing authorization in Europe. We submitted an NDS in Canada in the second quarter of 2021, and an NDA in the United States in the fourth quarter of 2021. We also intend to submit an MAA in Europe early in the
first quarter of 2022. We initiated our global Phase 3 PHOENIX trial of AMX0035 for the treatment of ALS in the fourth quarter of 2021 to further support our global regulatory efforts. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Effectively and efficiently commercializing AMX0035 for ALS in key territories, if approved.</I></B> We submitted an
NDS in Canada in the second quarter of 2021 and an NDA in the United States in the fourth quarter of 2021. We also intend to submit an MAA in Europe early in the first quarter of 2022 and, subject to receiving marketing approval, we would expect to
launch AMX0035 for ALS in Canada and the United States in the third quarter of 2022. We are currently building our sales team, internal capabilities and outside vendor network to support commercialization. We believe these capabilities, coupled with
our understanding of the ALS patient and medical community, will enable us to launch AMX0035 for ALS successfully, if approved. We anticipate that our commercial infrastructure will be scalable for subsequent launches in the United States and other
key markets if we receive marketing approval in these territories as well. Our commercial operations are led by Margaret Olinger, who was an early commercial employee at Alexion and helped lead the launches of Soliris for the treatment of
generalized myasthenia gravis and Strensiq for the treatment of perinatal/infantile- and juvenile-onset hypophosphatasia. </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Maximizing the therapeutic potential of AMX0035 by expanding into additional neurodegenerative diseases.</I></B> We
believe the data from the CENTAUR trial showing a functional and survival benefit for ALS patients treated with AMX0035 validates its mechanism of targeting endoplasmic reticulum, or ER, stress and mitochondrial dysfunction. Based on our extensive
understanding of disease pathways, we believe AMX0035 may provide benefit across multiple diseases characterized by neurodegeneration. As we select the next indications for AMX0035 we will prioritize those indications which we believe, if
successful, will most rapidly lead to marketed products and to patient benefit. We conducted our Phase&nbsp;2&nbsp;PEGASUS clinical trial in AD to obtain safety data along with initial efficacy and biomarker data which will help us evaluate the
development of AMX0035 for the treatment of AD within our clinical development strategy. We expect to submit an IND for AMX0035 in Wolfram syndrome in the first half of 2022. We expect to submit an IND for two additional indications in 2022.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Continuing to cultivate a network of patient advocacy groups, key opinion leaders, research institutions, and
healthcare professionals to inform our patient-centric approach.</I></B> We have cultivated a network of key constituents, which we believe will continue to help us to develop therapies in an efficient and impactful manner. Integrating the
experiences and insights from these parties, which include patients, their families, and organizations such as the ALS Association, NEALS, ALS Finding a Cure, the Healey Center at Massachusetts General Hospital, the Cure Alzheimer&#146;s Fund, the
Alzheimer&#146;s Association and the Alzheimer&#146;s Drug Discovery Foundation, continues to inform our approach to developing therapies that can potentially transform the lives of patients and their families. We intend to will continue to engage
with each of these constituents through conferences, clinical trials and informal communications as we further develop and pursue commercialization of AMX0035. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Deploying a strategic approach to design, acquire and develop new therapies. </I></B>We follow a scientifically
rigorous approach to evaluating new opportunities to broaden our portfolio. We plan to target assets that allow us to leverage our experience with neurodegenerative pathways and AMX0035&#146;s mechanism of action, focusing primarily on preventing
neuron death. When evaluating assets, we consider not only our ability to apply our experience with AMX0035 but also a variety of factors, including unmet medical need, biological rationale, feasibility of clinical development, potential for
regulatory approval, costs of development, competitive landscape and commercial potential. </P></TD></TR></TABLE>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Neurodegenerative Disease </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The prevention of neurodegeneration represents one of today&#146;s most significant unmet medical needs. The development of therapies that preserve
neuron health has historically presented unique </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
challenges, including an imperfect understanding of underlying biology and a lack of translation of activity observed in preclinical studies to results in clinical trials. Currently approved
therapies for many neurodegenerative diseases are generally only symptom modifying and have demonstrated limited efficacy. There remains an urgent need for novel approaches to address most neurodegenerative diseases, especially for progressive and
severe conditions such as ALS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The Role of the Endoplasmic Reticulum and Mitochondria in Neurodegenerative Disease </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unlike most other cells in the body that regularly die and are replaced as part of healthy function, mature neurons are normally resistant to cell death
and generally cannot regenerate. Neuron death is only triggered when multiple stress factors are activated beyond the neuron&#146;s recovery capacity, a circumstance commonly seen in neurodegenerative disorders. Most neurodegenerative disorders have
complex pathophysiology, with multiple pathways contributing and converging to eventually cause neuron death. A large fraction of these pathological changes in neurons can be linked to dysfunction in the ER and mitochondria that affect metabolism
and secretion of lipids and proteins, calcium homeostasis, and energy production. Dysfunction in these two essential cellular structures is implicated across many neurodegenerative disorders, highlighting the central role they play in maintaining
neuron health and survival and providing the rationale for our focus, which is to rescue ER and mitochondrial function, and to protect and preserve neurons. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>ER Stress </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The ER is responsible for protein and lipid
synthesis, folding and quality control of proteins, and storing calcium for cellular energy production by the mitochondria. The ER is also a primary sensor of stressful intracellular conditions, activating a wide number of molecular pathways that
belong to a specific process, referred to as the ER stress response, that controls protein homeostasis. ER stress, or dysfunction associated with protein misfolding and aggregation, has been implicated in the pathogenesis of neurodegenerative
disease. In neurodegenerative disorders, misfolded proteins and accumulations of protein aggregates can cause oxidative stress and a feedback loop resulting in ER stress. When the ER stress response is activated due to misfolded and aggregated
proteins, the UPR, is engaged as a regulatory mechanism to reduce the load of misfolded proteins and restore a healthy cellular state. Molecular chaperones are the critical regulators of protein homeostasis under ER stress. Pathological conditions
such as neurodegenerative diseases that disturb protein folding and maturation can trigger ER stress and engage the UPR. When the natural protein homeostasis in the cell cannot be achieved, the UPR triggers cellular death, or apoptosis, as
illustrated in the graphic below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>The Role of the ER in Neurodegenerative Disease </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g155225g22z92.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Mitochondrial Dysfunction </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The mitochondria are a central regulatory point for the control of cell death. When mitochondria detect sufficient cell damage, they signal for the cell
to initiate a cell death cascade. Among other steps, this cascade includes the recruitment of a series of apoptotic proteins including <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Bcl-2-associated</FONT></FONT> X protein, or
BAX, the release of cytochrome c from a pore in the mitochondrial membrane called the mitochondrial permeability transition pore, and finally the activation of caspase 3, an executioner protein for apoptosis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In neurodegenerative diseases, triggers such as altered calcium homeostasis, glutamate excitation of the cell, damage to the mitochondria or
mitochondrial DNA and detection of aberrant double-stranded DNA and accumulation of unfolded proteins at the mitochondria all lead to mitochondrially mediated cell death. Inhibition of proteins such as BAX could result in a greater threshold for
cell death and longer survival of key neurons implicated in the progression of neurodegenerative disease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Linkage Between Mitochondria and ER </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The mitochondria and the ER are often physically linked by a membrane called the mitochondrial associated ER membrane, or MAM. Through this linkage,
calcium and molecules are shuttled between the two organelles. It is our belief that this connection, or crosstalk, allows the cell to integrate responses between the two organelles and that activation of mitochondrial damage pathways will activate
the UPR and <I>vice versa</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Both the mitochondria and the UPR in the ER can trigger cell death. As such, we believe both pathways
are crucial to the pathogenesis of neurodegenerative diseases and both need to be addressed simultaneously to effect a substantial change in survival of neurons undergoing neurodegenerative processes. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>The Role of the ER and Mitochondria in Neuron Death </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g155225g36n42.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL" ALIGN="center">The figure above depicts events of ER stress and mitochondrial dysfunction associated with eventual
cell injury and death. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Background and Rationale for AMX0035 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have designed AMX0035 to reduce neuron death through simultaneous mitigation of ER stress and mitochondrial dysfunction. AMX0035 is a coformulation of
two small molecules, PB and TURSO. PB has been shown to reduce ER stress through upregulation of a protein known as DJ-1 that is a master chaperone regulator, recruitment of other chaperone proteins, and as a small molecular chaperone. TURSO is a
bile acid that has been shown to recover mitochondrial bioenergetic deficits through incorporation into the mitochondrial membrane, reducing BAX translocation to the mitochondrial membrane, reducing mitochondrial permeability, and increasing the
apoptotic threshold of the cell. Through our research, we identified the specific ratios at which the combination of PB and TURSO target these critical, connected pathways and show synergistic activity in improving neuronal cell viability <I>in</I>
<I>vitro</I>. We then developed AMX0035 as an optimized oral formulation to be tested <I>in vivo</I> and clinically. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our preclinical studies have
shown that PB and TURSO, in combination, can inhibit a number of pathological pathways associated with neurodegenerative diseases in cell culture and animal models. For example, in an <I>in vitro </I>model of neurodegeneration, we tested the
potential abilities of PB and TURSO individually and in combination to prevent oxidative-induced neuronal death, or cell viability, which was measured using a PrestoBlue reagent. In this experiment, hydrogen peroxide was applied to rat primary
cortical neurons in a concentration sufficient to kill approximately 40% of the neurons. Particular doses of PB and TURSO individually protected against some of the neuron death, and cell </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
viability reached approximately 80%. However, when these rat primary cortical neurons were dosed with particular ratios of PB and TURSO in combination, nearly 100% of oxidative-induced neuron
death was prevented. The results of this <I>in vitro</I> model are shown in the graphic below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g155225g80r72.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, we have observed benefit from the administration of particular ratios of PB and TURSO across <I>in
vitro </I>models of ER stress, mitochondrial dysfunction, oxidative stress, and disease specific models of ALS, AD, Parkinson&#146;s disease, multiple sclerosis, or MS, Friedreich&#146;s Ataxia, primary mitochondrial myopathies and a variety of
other conditions. We have also conducted <I>in vivo </I>models of PB and TURSO, in combination, including models of ALS, AD and MS. Additionally, academic groups have conducted studies with monotherapy treatment with TURSO and/or PB in models of
ALS, AD, MS, Parkinson&#146;s Disease, Huntington&#146;s Disease, Progressive Supranuclear Palsy, Multi-System Atrophy, <FONT STYLE="white-space:nowrap">X-linked</FONT> adrenoleukodystrophy, and a variety of other models. We believe this body of
evidence collectively supports the use of this combination to treat neurodegenerative indications and led us to pursue the development of our proprietary drug candidate, AMX0035. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>AMX0035 for the Treatment of ALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Overview of ALS </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are initially developing AMX0035 for the treatment of ALS, an adult-onset, progressive, and fatal neurodegenerative disorder of the neuromuscular
system resulting in muscle weakness and paralysis leading to death. ALS involves the progressive degeneration of motor neurons in the spinal cord and brain that are responsible for controlling voluntary muscle movement. This progressive loss of
motor neurons leads to muscle weakness, loss of muscle mass, and inability to control movement. ALS remains universally fatal with a median survival of less than three years from symptom onset and less than two years from diagnosis. Despite being
classified as a rare disease by the FDA and the EMA, ALS is considered one of the more common adult-onset neuromuscular diseases worldwide. Public sources estimate approximately 25,000 prevalence ALS patients in the United States. We believe the
prevalence is closer to 30,000 in the United States based on research that we have conducted in collaboration with expert consulting groups. Approximately 40,000 ALS patients are estimated to be located in Europe and about 3,000 ALS patients are
located in Canada. Over 90% of patients have no family history of ALS, known as &#147;sporadic&#148; ALS. While other development approaches seek to address genetic instances of ALS, AMX0035 is designed to target all instances of ALS, regardless of
whether it is sporadic or genetic. Due to the <FONT STYLE="white-space:nowrap">two-year</FONT> median survival of patients diagnosed with ALS, a high proportion of the patient population has been recently diagnosed and a therapy that is able to
improve </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the survival of patients with ALS has the potential to increase the number of patients who are able to continue living with their disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Medical costs for patients newly diagnosed with ALS in the United States are substantial and increase rapidly with each disability milestone. Care of
patients with ALS is intensive and requires a team of medical professionals, special equipment, and assistance with daily activities. Caregivers are often forced to miss work or give up employment opportunities to provide care, leading to increased
financial strain. The disease also impacts the patient&#146;s family, who generally provide the bulk of caregiving, which often entails the provision of <FONT STYLE="white-space:nowrap">24-hour</FONT> care. The constant adaptation of caregivers to
the demands of the ALS disease progression requires significant physical effort and mental exhaustion particularly during the advanced stages of the disease. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Significant Unmet Need in ALS </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">ALS is a heterogeneous
disease that arises from multiple mechanistic underpinnings, leading patients to experience variable onset and delayed diagnosis, persistent progression and loss of muscle function, and shortened survival. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There is a significant unmet need for ALS therapies that target multiple pathogenic pathways, are disease-modifying, and can provide both functional and
survival benefit to patients. Only two <FONT STYLE="white-space:nowrap">FDA-approved</FONT> therapeutic agents for ALS, riluzole, an anti-glutamatergic agent, and edaravone, a free-radical scavenger, have been shown to modulate the course of ALS. In
pivotal clinical trials, riluzole demonstrated longer time to tracheostomy or death compared to placebo and edaravone demonstrated longer retention of function compared to placebo. However, a need remains for ALS therapies that demonstrate both
retention of function and longer survival, allowing patients to maintain greater independence for longer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Due to the multi-pathway pathophysiology
of ALS, experts agree that successful treatment will likely require concurrent targeting of multiple key neuronal death pathways. There is a strong rationale for treatments that target identified convergence points of these critical pathways,
including in the ER and mitochondria, and we believe that a therapy that targets multiple pathways at once, like AMX0035, aligns with the emerging ALS treatment paradigm. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Clinical Development of AMX0035 for ALS </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We
designed our Phase 2 CENTAUR trial with input from leading ALS experts from NEALS to detect a significant difference between AMX0035 and placebo. The study also provided the option for participants to continue with available approved therapies,
riluzole and edaravone, for the duration of the trial. The FDA granted Orphan Drug Designation for AMX0035 for the treatment of patients with ALS in September 2017. The EMA granted orphan designation to AMX0035 for the treatment of patients with ALS
in April 2020. In December 2019, we announced positive topline results from our CENTAUR trial. The trial met its primary endpoint, and we published detailed trial data in the <I>New England Journal of</I> <I>Medicine </I>in September 2020 and in the
<I>Journal of Muscle and Nerve</I> in October 2020. We submitted an NDS in Canada in the second quarter of 2021 and an NDA in the United States in the fourth quarter of 2021. We also intend to submit and an MAA in Europe early in the first quarter
of 2022. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>CENTAUR, Our Phase 2 Trial of AMX0035 in ALS </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In September 2020, we published detailed results from the Phase 2, randomized, double-blind, placebo-controlled CENTAUR trial. The CENTAUR trial was
conducted at 25 centers of the NEALS, and evaluated adult patients with ALS. Key inclusion criteria were definite ALS defined by the revised El Escorial criteria, which entails having various clinical signs and symptoms, defined as upper and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
lower motor neuron signs, in at least three defined body regions, less than 18 months from symptom onset and slow vital capacity, or SVC, greater than 60%. These criteria were chosen to select a
homogenous, rapidly progressing patient population to potentially increase the likelihood of observing a treatment effect. Participants were allowed to continue on their selected standard of care, including treatment with riluzole and/or edaravone.
Eligible participants (n=137) were randomized <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">two-to-one</FONT></FONT> to treatment with AMX0035, one sachet (each containing one gram of TURSO and three grams of PB) given once daily
for the first three weeks, and if tolerated, the dose was then increased to twice-daily for the remainder of a 24 week treatment period, or matching placebo. Two participants did not have <FONT STYLE="white-space:nowrap">follow-up</FONT> efficacy
assessments and were not included in the efficacy population (modified intention to treat, or mITT, n=135). These two participants were included in the safety population (intention to treat, or ITT, n=137). Upon completion of the <FONT
STYLE="white-space:nowrap">24-week,</FONT> parallel group phase of the trial, participants were eligible to enroll in the OLE trial in which all participants were followed up to 35 months while participants and physicians remained blinded to the
original treatment group. Of participants completing the CENTAUR trial randomization phase, 92% elected to enroll in the OLE. The first protocol of the OLE was completed in March 2021. Actual duration of patient treatments across the randomization
phase and the OLE, both with the PB-TURSO combination and via placebo, are shown in the graphic below: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g155225g23s23.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The primary efficacy outcome measure for the CENTAUR trial was the rate of decline in the <FONT
STYLE="white-space:nowrap">ALSFRS-R</FONT> total score. The <FONT STYLE="white-space:nowrap">ALSFRS-R</FONT> scale is the most widely used ALS rating scale in ALS clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
practice and in ALS clinical trials. It measures patient&#146;s functional ability and is broken down into four domains: bulbar (which includes speech, salivation and swallowing), fine motor
(which includes handwriting, cutting food/handling utensils, dressing and hygiene), gross motor (which includes turning in bed, walking, and climbing stairs) and breathing (which includes dyspnea, orthopnea and respiratory insufficiency). A decrease
of one point on the <FONT STYLE="white-space:nowrap">ALSFRS-R</FONT> scale can reflect severe limitations in a patient&#146;s independence, and a <FONT STYLE="white-space:nowrap">two-point</FONT> increase on the
<FONT STYLE="white-space:nowrap">ALSFRS-R</FONT> scale would be associated with: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">eating successfully with some difficulty instead of needing a feeding tube; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">being short of breath only while walking instead of having difficulty breathing while sitting or lying down; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">being able to dress independently instead of needing assistance. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The CENTAUR trial met its primary endpoint with a statistically significant reduction in clinical decline among participants randomized to AMX0035
(n=87) compared to placebo (n=48) (p-value of 0.03) over 24 weeks. These results showed that patients receiving AMX0035 scored an average of 2.32 points higher on the <FONT STYLE="white-space:nowrap">ALSFRS-R</FONT> as compared to patients receiving
placebo after 24 weeks, a difference of 25%, as shown in the graph below. In a survey of ALS clinicians and researchers conducted and sponsored by NEALS, with the objective of determining what percentage reduction in ALSFRS-R would be considered
clinically meaningful, a difference of greater than or equal to 20% in <FONT STYLE="white-space:nowrap">ALSFRS-R</FONT> total score was considered clinically meaningful by a majority of clinicians and researchers surveyed. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g155225g13a00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Secondary efficacy outcomes measuring disease free progression were the decline in muscle strength as measured by
Accurate Test of Limb Isometric Strength, or ATLIS, testing and lung function measured by SVC, both expressed as percent of predicted values and key study events including death, permanent ventilation and hospitalization. Neurofilament was also
measured as a biologic measure. The analysis also indicated statistically significant preservation of upper limb strength with AMX0035 treatment measured on ATLIS (p=0.042), while the lower limb measure did not reach statistical significance
(p=0.34). An average of these two, referred to as the total ATLIS score, trended in favor of AMX0035 (p=0.11). There was also a trend in favor of AMX0035 therapy preserving lung function as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
measured by SVC, with a numerical difference of 5.11% although this was not statistically significant (p=0.076). These efficacy data are summarized in the table below. In addition, a
time-to-event analysis was conducted on key study events including death, permanent ventilation and hospitalization events over the 24-week randomized phase of the trial. Because enrollment of patients in the CENTAUR trial was limited to patients
who, in the investigator&#146;s opinion, would be able to complete 6-month follow up, few events of this nature were expected during the initial, 24-week randomized phase of the trial. As a result, we observed a positive, but not statistically
significant, difference between the trial&#146;s treatment and control groups during the 24-week randomized phase of the study. There was no statistically significant difference between the rate of decline in plasma levels of the neurofilament
observed in the trial&#146;s treatment and control groups during the 24-week randomized phase of the study. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g155225g96o04.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Phosphorylated neurofilament heavy chain was measured in plasma in the CENTAUR trial. There were no statistically
significant differences between groups in this outcome. A limitation of this outcome is that it was measured in plasma rather than cerebrospinal fluid and the ultimate relevance of this outcome in ALS is still under investigation by the field.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">It is important to note that most (77%) participants were receiving riluzole or edaravone at or before study entry, with a greater proportion receiving
edaravone in the placebo group (50%) compared with the AMX0035 group (25%). <FONT STYLE="white-space:nowrap">Pre-specified</FONT> analyses were conducted to determine if the use of concomitant medications impacted results. These analyses found that
AMX0035&#146;s effect on the primary outcome was consistent regardless of baseline use of concomitant medications (riluzole and/or edaravone). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">OS
was analyzed for all subjects randomized in the CENTAUR trial (ITT analysis) and compared patients originally randomized to AMX0035 (n=89) with those randomized to placebo (n=48). In this analysis, the vital status of each participant was measured
by a participant locating service which used sources such as the U.S. social security death index up to July&nbsp;20, 2020 even if he or she did not continue into the OLE, stopped study drug, dropped out of the study or was lost to <FONT
STYLE="white-space:nowrap">follow-up.</FONT> Over the duration of follow up, the risk of death was 44% lower among those originally randomized to AMX0035 compared with those originally randomized to placebo (hazard ratio, or HR, of 0.56; a 95%
confidence interval, or CI, ranging from 0.34 to 0.92; and a <FONT STYLE="white-space:nowrap">p-value</FONT> of 0.023). Median survival duration was 25.0 months (95% CI of 19.0 to 33.6 months) in the group previously randomized to AMX0035 and 18.5
months (95% CI of 13.5 to 23.2 months) in the group previously randomized to placebo as seen in the graph below. Participants originally randomized to AMX0035 received a median 6.5&nbsp;months more of AMX0035 treatments than those originally
randomized to placebo. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g155225g11d11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We also performed sensitivity analyses on the CENTAUR trial data, including a joint rank test, which showed no bias
in the estimate of the primary functional outcome by loss of data due to participant death. Sensitivity analyses were also performed to account for missing data and death or death-equivalent events. These sensitivity analyses yielded results similar
to the primary analysis. In sensitivity analyses designed to account for concomitant medication use, the treatment effect size was consistent between primary analysis and analyses corrected for concomitant medication use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">AMX0035 was generally well-tolerated with an adverse event rate substantially similar to placebo. Adverse events, or AEs, were reported in 97% (86 out
of 89) of participants receiving AMX0035 and 96% (46 out of 48) of participants receiving placebo, with the nature of the AEs being substantially similar in both groups. The most commonly occurring (greater than or equal to 5%) AEs in either
treatment group are shown in the table below. Because of the progressive neurodegenerative nature of ALS, many of these AEs (<I>e.g.</I>, muscle weakness, falls, dyspnea, fatigue) were likely attributable to the underlying ALS disease. Events
occurring in greater than or equal to 5% of patients in either treatment group and more frequently (greater than or equal to 2% of patients) in patients who received AMX0035 compared with those who received placebo were predominantly
gastrointestinal events, which were <FONT STYLE="white-space:nowrap">non-serious</FONT> and mostly mild in intensity and declined considerably in occurrence after three weeks on treatment. A total of 19% of the patients in the AMX0035 treatment
group and 8% of the patients in the placebo group discontinued their participation in the trial due to AEs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The most commonly occurring AEs were diarrhea, constipation, nausea, muscular weakness, fall,
headache, dizziness and viral upper respiratory tract infection. Health Canada also noted the occurrence of hypersalivation. Consistent with the known safety profile of TURSO, diarrhea and nausea occurred more frequently in patients who received
AMX0035 compared with those who received placebo. In contrast, muscular weakness, fall, constipation and headache occurred more frequently in patients who received placebo. The observed AEs from the CENTAUR trial are summarized in the chart below.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="12" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Adverse Events (AEs)<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP> Occurring in </B><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT><B></B><B>5% of Patients in either Treatment Group<BR>(Safety Population, n=137)<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>MedDRA System Organ Class</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Preferred Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Placebo&nbsp;+&nbsp;SOC</B><br><B>(n=48)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AMX0035&nbsp;+&nbsp;SOC</B><br><B>(n=89)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Overall</B><br><B>(n=137)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Gastrointestinal disorders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29&nbsp;(60.4%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60&nbsp;(67.4%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89&nbsp;(65.0%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Musculoskeletal and connective tissue disorders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21&nbsp;(43.8%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38&nbsp;(42.7%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59&nbsp;(43.1%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Injury, poisoning and procedural complications</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23&nbsp;(47.9%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35&nbsp;(39.3%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58&nbsp;(42.3%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Nervous system disorders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19 (39.6%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33 (37.1%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52 (38.0%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Infections and infestations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21 (43.8%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28 (31.5%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49 (35.8%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Respiratory, thoracic and mediastinal disorders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10 (20.8%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29 (32.6%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39 (28.5%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Investigations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10 (20.8%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26 (29.2%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36 (26.3%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General disorders and administration site conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13 (27.1%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20 (22.5%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33 (24.1%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Skin and subcutaneous tissue disorders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8 (16.7%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16 (18.0%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24 (17.5%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Psychiatric disorders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9 (18.8%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14 (15.7%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23 (16.8%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Renal and urinary disorders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8 (16.7%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10 (11.2%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18 (13.1%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Metabolism and nutrition disorders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4 (8.3%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10 (11.2%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14 (10.2%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cardiac disorders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0 (0.0%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7&nbsp;(7.9%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7 (5.1%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Eye disorders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 (2.1%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5 (5.6%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6 (4.4%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Includes serious adverse events. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Serious adverse events, or SAEs, occurred less frequently in the AMX0035 treatment group (12.4% of patients) compared with the placebo treatment group
(18.8% of patients). This difference was largely driven by a higher incidence of respiratory events, including respiratory failure in the placebo treatment group (8.3% of patients), compared with the AMX0035 treatment group (3.4% of patients). ALS
disease progression often leads to respiratory failure, and it is the most common cause of death in patients with ALS. The observed SAEs from the CENTAUR trial are summarized in the chart below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Serious Adverse Events (SAEs) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g155225g31v63.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Overall, a total of seven patients (two (4% of patients) who received placebo and five (6% of total
patients) who received AMX0035) died during the conduct of the <FONT STYLE="white-space:nowrap">24-week,</FONT> double-blind study. None of the deaths was considered by the investigator to be related to AMX0035. Consistent with the most common cause
of death in patients with ALS, the majority (four of seven patients) of deaths during the study were from respiratory failure (two patients in each group). Other causes of death (in the AMX0035 group) included post-extubational supraglottic and
infraglottic aspiration (attributed to aspiration pneumonia), diverticulitis, and subdural hematoma secondary to a fall. Death equivalent was defined as either tracheostomy or permanent assisted ventilation, or PAV. PAV was defined as more than
22&nbsp;hours daily of <FONT STYLE="white-space:nowrap">non-invasive</FONT> mechanical ventilation for more than one week (seven days). One patient in the placebo group (2% of patients) and none in the AMX0035 group experienced a death equivalent
event (i.e.,&nbsp;tracheostomy) during the <FONT STYLE="white-space:nowrap">24-week</FONT> study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe AMX0035 is the first drug candidate in
ALS to demonstrate a statistically significant benefit both in function as measured by a prespecified mean rate change in <FONT STYLE="white-space:nowrap">ALSFRS-R</FONT> and in a longer-term analysis of OS, both important outcomes for people with
ALS. In summary, patients in our CENTAUR trial showed a statistically significant improvement in function and a statistically significant improvement in overall survival and AMX0035 was shown to be generally well-tolerated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Clinical Development Plan of AMX0035 in ALS </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We submitted
an NDS for AMX0035 for the treatment of ALS to Health Canada in the second quarter of 2021, which was accepted for review in the third quarter of 2021, an NDA to the FDA in the fourth quarter of 2021, which was accepted for priority review in the
same quarter. The Prescription Drug User Fee Act date, the target date by which the FDA intends to complete its review and take action on the NDA, for AMX0035 for the treatment of ALS is June&nbsp;29, 2022. We also intend to submit an MAA for
approval of AMX0035 for the treatment of ALS to the EMA Committee for Medicinal Products for Human Use early in the first quarter of 2022. We recently initiated our global <FONT STYLE="white-space:nowrap">48-week</FONT> PHOENIX, randomized,
double-blind, placebo-controlled trial in the fourth quarter of 2021. We expect to recruit approximately 600 patients from approximately 55 European and U.S. sites. The primary endpoints our PHOENIX trial will be a composite measure of survival and
ALSFRS-R total score progression over 48&nbsp;weeks and safety and tolerability over 48&nbsp;weeks. The secondary endpoints of our PHOENIX trial will be SVC, ALSAQ-40 (a questionnaire which provides a subjective health measure to specifically assess
quality of life for patients with ALS), EQ5D-5L (a standard qualify of life measure), decline in King&#146;s (a staging measurement in ALS based on the number of central nervous system (CNS) regions involved and requirement for gastrostomy or
noninvasive ventilation) and MiToS stages (a functional staging measure that can be derived prospectively from the ALSFRS-R subscore using standard methods), ventilation free survival, and long-term survival. Key inclusion criteria for the PHOENIX
trial include ALS patients with clinically definite or clinically probable ALS by El Escorial criteria <FONT STYLE="white-space:nowrap">(2-4</FONT> body areas with clinical signs consistent with ALS), &lt;24 months from symptom onset, SVC &gt;55%,
and riluzole/edaravone use permitted. Based on dialogue with the FDA prior to our NDA submission, including at a pre-NDA meeting recommended by the FDA and subsequent discussions, we believe that data from the PHOENIX trial will not be required for
the FDA to make a determination on the approval of AMX0035 for the treatment of ALS, although there can be no assurance that the FDA will not require further data before making a determination. The PHOENIX trial is designed to provide further data
supporting the safety and efficacy of AMX0035 for the treatment of ALS to further support our global regulatory efforts. Because any marketing approval we may ultimately obtain in Europe and Canada may be limited, subject to restrictions or
conditional on post-approval commitments, we may need to provide post-marketing support in those jurisdictions. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any regulatory approvals we
may receive may be limited or subject to restrictions or postapproval commitments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>AMX0035 for the Treatment of Other Potential Indications </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on our extensive understanding of disease pathways, we believe AMX0035 may provide benefit across multiple diseases, including AD, Wolfram
syndrome, Parkinson&#146;s Disease, Huntington&#146;s Disease, Progressive Supranuclear Palsy, Multi-System Atrophy, primary lateral sclerosis, ischemic stroke, MS, Friedreich&#146;s ataxia, Leigh&#146;s syndrome and Leber&#146;s hereditary optic
neuropathy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are prioritizing these conditions on an indication-by-indication basis, based on the strength of the data supporting AMX0035&#146;s
potential, including the data from our recently completed PEGASUS trial; the urgency of the unmet need; the practicality of conducting clinical trials in these conditions; the efficiency of clinical development activities; and the commercial
potential. For some of these indications, given the data already produced by the company on AMX0035, we believe it may be possible to move directly into Phase&nbsp;3 evaluations of safety and efficacy which could allow for a rapid development
pathway. We will prioritize those indications which we believe have the greatest chance of providing patients with benefit and the most rapid pathway to market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We plan to submit an IND for AMX0035 in Wolfram syndrome in the first half of 2022. Subject to acceptance of this IND, we plan to initiate a proof of
concept Phase&nbsp;2 clinical trial in Wolfram syndrome. Additionally, we plan to submit potential additional INDs for AMX0035 in other indications in the first half of 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Clinical Development of AMX0035 for AD </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We designed
our multicenter, randomized, double-blind, placebo-controlled Phase&nbsp;2 PEGASUS trial with AD experts to evaluate the safety, tolerability and activity of AMX0035 in patients with late mild cognitive impairment, or MCI, or early-to-moderate
dementia. The PEGASUS trial was designed to have broad entry criteria to include participants at different stages of AD to allow us to assess the biological effect of AMX0035 across the spectrum of disease and determine if there are any patients who
might see a greater benefit from therapy. Eligible participants (n=95), adults ages 55 to 89 years old, were randomized three-to-two to treatment with AMX0035, one sachet (each containing one gram of TURSO and three grams of PB) given twice-daily
over 24 weeks, or matching placebo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The primary investigator for the PEGASUS trial, Dr. Steven Arnold, presented topline results from the PEGASUS
trial at the Clinical Trials on Alzheimer&#146;s Disease conference, or CTAD, which was held during the fourth quarter of 2021. Based on these topline results, AMX0035 was generally well-tolerated with approximately 80% of patients completing dosing
in the trial in the AMX0035 arm. Safety results are depicted in the figure below. As in the CENTAUR trial, a higher percentage of patients in the AMX0035 arm had gastrointestinal adverse events. However, no serious adverse events were attributed to
AMX0035 in the PEGASUS trial. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g155225g22b30.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The 6-month trial was not powered to evaluate differences between the AMX0035 and placebo arms in
cognition, function or imaging. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The primary endpoint of the trial was to compare the safety and tolerability of a fixed-dose combination of AMX0035
versus placebo in subjects with MCI (high or intermediate likelihood due to AD) or dementia due to AD over a 24-week treatment period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The
secondary endpoints of the trial were to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">determine the effects of AMX0035 treatment on whole brain and regional brain atrophy, as assessed by volumetric MRI;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">assess the impact of AMX0035 treatment on clinical symptoms as measured by the Alzheimer&#146;s Disease Assessment
Scale-Cognitive Subscale, or ADAS-Cog, the Dementia Severity Rating Scale, or DSRS, and the FAQ; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">assess the effect of AMX0035 treatment on measures of neuropsychiatric symptoms, as assessed by the Neuropsychiatric
Inventory Questionnaire; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">measure the effects of AMX0035 treatment on functional MRI measures including connectivity with resting state Blood
Oxygenation Level Dependent imaging. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, the trial evaluated differences between the AMX0035 and placebo arms as
measured by GST, a newly developed composite outcome of cognitive, functional, and imaging measures named the Global Statistical Test, or GST, over the 24-week treatment period. The GST is a combination of three change-from-baseline to end-of-study
endpoints: Cognition (Modified Alzheimer&#146;s Disease Composite Score, or MADCOMS), Function (Functional Activities Questionnaire, or FAQ) and Total Hippocampal Brain Volume (Magnetic Resonance Imaging, or MRI). The GST is calculated for each
subject as a mean score across the above three component endpoints for each subject in the trial. This mean score was then analyzed as an efficacy variable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Finally, the exploratory objectives of the trial were to measure the effect of AMX0035 treatment on biochemical markers of amyloid-&szlig;1-42,
amyloid-&szlig;1-40, total tau (t-tau), tau phosphorylated at threonine 181 (ptau&nbsp;181), neuronal injury markers, mitochondrial redox and function markers, and neuroinflammation, as assessed in cerebrospinal fluid (CSF) from all volunteers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">While functional MRI analyses remain ongoing, no significant differences between dosing groups were observed for any efficacy endpoints in this trial
(p&gt;0.05). Key efficacy results are included in the figure below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g155225g23a23.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">a</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Hippocampal volume component is based on standard ADNI MRI algorithm but was also assessed via additional MRI algorithms
included in the Statistical Analysis Plan and yielded similar findings. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g155225g24x25.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Significant impacts on multiple biomarkers of interest in AD were observed in the trial. In CSF, the AMX0035-group
showed significant reductions of tau protein&nbsp;181 (p&lt;0.001) and phosphorylated tau protein (p&lt;0.001) compared with the placebo group, modulation of the amyloid beta 42/40 ratio (p&lt;0.05) and increase of 8-hydroxy-2&#146; -deoxyguanosine,
(p&lt;0.01). These topline results from the PEGASUS trial are still subject to further audit and verification procedures and additional biomarker results are not yet available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe the biomarker and imaging outcomes from the trial have substantially improved and will continue to inform our knowledge of the impact of
AMX0035 on the neurodegenerative pathways relevant to the progression of AD, which have been and will be informative as we continue clinical development of AMX0035 in AD and other potential indications. We believe these insights will help us to
examine any effects of AMX0035 on AD&#146;s progression, which could inform future work in AD as well as clinical trial design for other indications. We will continue to evaluate these data and discuss the results of the PEGASUS trial with
scientific advisors as we consider potential next steps for the development of AMX0035 for the treatment of AD within our clinical development strategy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Clinical Development of AMX0035 for Wolfram Syndrome </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Wolfram syndrome is a rare, pediatric, life-threatening disease thought to be caused by variants in the Wolfram syndrome WFS1 gene, or WFS1, and, in a
small fraction of patients, pathogenic variants in the CDGSH iron sulfur domain protein&nbsp;2 CISD2 gene, or CISD2. Wolfram syndrome results in deafness, blindness, ataxia, neurodegeneration and ultimately death. There are currently no drugs
approved for Wolfram syndrome. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Wolfram syndrome appears to be a disease of ER stress. WFS1 encodes and produces the vital wolframin protein, which
appears to be involved in ER regulatory processes. WFS1 deficiency leads to chronic ER stress and the UPR. WFS1 also negatively regulates activating transcription factor&nbsp;6 (ATF6), a UPR molecule, resulting in cell death. Furthermore, a recent
study suggested that WFS1 impacts mitochondrial function by transporting Ca2+ from the ER to the mitochondria through the MAM. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">AMX0035 targets
pathways central to Wolfram syndrome, including the UPR, and has shown beneficial effects in a variety of models of Wolfram syndrome, including cellular models and patient-derived cell line models. For example, to test the potential effects of
AMX0035 in the modulation of ER stress in the context of Wolfram syndrome, the effects of PB, TURSO and AMX0035 were tested in an <I>in&nbsp;vitro</I> model of wild-type and WFS1-deficient pancreatic beta cell lines. In these cells, when compared
with the control group, only AMX0035, but not PB or TURSO alone, was able to significantly prevent tunicamycin-induced cell death in WFS1-deficient pancreatic beta cell lines as measured by caspase&nbsp;3&nbsp;/&nbsp;7 activity (p&nbsp;equal to
0.017). Additionally, a combination of PB and TURSO was studied <I>in&nbsp;vitro</I> in human patient-derived neural progenitor cells harboring mutations in WFS1, which cause Wolfram Syndrome. Both PB and TURSO, when applied alone, were observed to
inhibit cell death in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
each of three different human cell lines as compared to control conditions, and the application of PB and TURSO in combination was observed to result in significantly lower levels of cell death
in three separate patient-derived Wolfram syndrome cell lines differentiated to produce patient-derived neural progenitor cells, as compared to either the control or treatment with PB or TURSO alone. In each of these models of Wolfram syndrome, use
of AMX0035 was observed to have significant synergistic effects lowering cell death as compared to either the control group or treatment with PB or TURSO alone. For these reasons, we believe AMX0035 is a promising clinical candidate for Wolfram
syndrome and we are planning to pursue a clinical trial in this disease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Patient Advocacy </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The patient advocacy landscapes for ALS, AD and other neurodegenerative diseases are large, and encompass groups at the international, multiregional and
country-specific level. We have built strong medical and commercial relationships at the international level, with our current emphasis being on ALS advocacy groups in Canada, the United States and Europe. We plan to engage country-specific groups
in Europe based on clinical trial results, as well as our medical and commercial priorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Working with key advocacy groups is critical to our
mission, as patients are at the center of everything we do. This starts with transparent communication and awareness about our science, data and development plans. We seek ensure that these advocacy groups are informed and able to answer questions
from their members about PB, TURSO and AMX0035. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We engaged with patient advocacy groups in the United States and Europe for feedback on the design
of our ongoing global Phase 3 PHOENIX trial of AMX0035 for the treatment of ALS, which is emblematic of the partnerships we are building with the community. In addition, we treat patient advocacy groups as important stakeholders as we address access
to AMX0035 outside ongoing clinical trials, such as expanded access and compassionate use programs. We have sought and will continue to seek guidance and insights from as many patient advocacy groups as possible and have plans in place to engage
groups on an ongoing basis. These groups have also reviewed messaging and press releases from the company to ensure they take into account the patient voice. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Commercialization </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe the global commercial
opportunity for AMX0035 in ALS is driven by its being the first and only treatment for ALS of which we are aware that potentially provides a combination of longer retention of function, improved survival, a generally well-tolerated side effect
profile and convenient oral administration. AMX0035 has been shown to have a significant impact on clinically meaningful endpoints, including reducing time to first hospitalization and permanent ventilation in ALS patients. AMX0035 is also being
considered for other neurodegenerative disorders. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">ALS is a rare disease, but public sources estimate that ALS affects at least 200,000 people
worldwide, with a prevalence in the United States of approximately 25,000 ALS patients. We believe the prevalence is closer to 30,000 in the United States based on research that we have conducted in collaboration with expert consulting groups.
Approximately 40,000 ALS patients are estimated to be living with ALS in Europe and about 3,000 ALS patients are estimated to be living with ALS in Canada. In the United States, ALS is treated by neurologists at certified ALS Centers or by other
neurologists. In Canada and in Europe, most ALS patients are treated at ALS Centers. The vast majority of people with ALS (over 90%) have sporadic disease, showing no clear family history. Most people who develop ALS are between the ages of 40 and
70, with a median age of 55 at the time of diagnosis. However, cases of the disease do occur in people in their twenties and thirties. People with ALS spend approximately <FONT STYLE="white-space:nowrap">one-third</FONT> of their disease course
searching for a diagnosis and, once diagnosed, there are few approved therapies available. ALS is a relentlessly progressive and highly heterogenous </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
disease that arises from multiple mechanistic underpinnings, leading patients to experience variable onset, persistent progression, and shortened survival. The disease remains universally fatal
with median survival of less than three years from symptom onset and less than two years from diagnosis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have conducted market research with
physicians, patients, caregivers, nurses, and payors in the United States, Western Europe and Canada to understand the unmet need and potential of AMX0035 in ALS. Clinicians universally report dissatisfaction with currently approved therapies and
state the need for additional options for their ALS patients. When shown a target product profile for AMX0035, the majority of ALS specialists and neurologists with whom we spoke are open to utilizing it in <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">early-to-mid-stage</FONT></FONT></FONT> patients, with some also stating the potential for use in late-stage patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We submitted an NDS for AMX0035 in ALS with Health Canada in the second quarter of 2021 which was accepted for review in the third quarter of 2021,
based on the clinical data from the CENTAUR trial and feedback from Health Canada and submitted an NDA to the FDA in the fourth quarter of 2021, which was accepted for priority review in the same quarter. We also intend to submit an MAA in Europe
early in the first quarter of 2022. We also plan to discuss AMX0035 with other health authorities around the world to determine the most appropriate path forward in their respective territories. We also initiated our ongoing Phase 3 PHOENIX trial in
the fourth quarter of 2021 to further support the safety and efficacy of AMX0035 for the treatment of ALS and our global regulatory efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our <FONT STYLE="white-space:nowrap">pre-launch</FONT> activities include building awareness of and education regarding the disease severity and
pathophysiology of ALS, increasing understanding of the clinical impact of a change in a patient&#146;s <FONT STYLE="white-space:nowrap">ALSFRS-R</FONT> score, and building general awareness of our company through active participation in key
neurology conferences, patient meetings, partnerships with patient advocacy groups, targeted omnichannel initiatives and payor education in each of the key territories. In addition, we intend to continue to pursue an active public relations
strategy. For example, the double-blind results of our CENTAUR trial have already been published in the <I>New England Journal of Medicine</I>, while the long-term survival study results appeared in the <I>Journal of Muscle</I><I></I><I>&nbsp;&amp;
Nerve</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If AMX0035 is approved, our initial plans are to build out our commercial operations in Canada, the United States and Europe. There are
175 ALS Association certified, recognized, or affiliated centers in the United States, 17 Canadian ALS Research Network Clinics in Canada, and less than 11 ALS Centers of Excellence per country in the major EU countries, which we plan to target with
a specialty key account management team. We will continue to evaluate market entry opportunities beyond these geographies either on our own or with a partner. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Overview </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The biotechnology and pharmaceutical industries are characterized by rapid technological advancement, significant competition and an emphasis on
proprietary products. We face potential competition from many different sources, including major and specialty pharmaceutical and biotechnology companies, academic research institutions, governmental agencies and public and private research
institutions. Any product candidates that we successfully develop and commercialize, including AMX0035, may compete with current therapies and new therapies that may become available in the future. We believe that the key competitive factors
affecting the success of any of our product candidates will include efficacy, safety profile, dosing, cost, effectiveness of promotional support and intellectual property protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Many of our competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and
development,&nbsp;preclinical&nbsp;testing, clinical trials, manufacturing, and marketing than we do. Future collaborations and mergers and acquisitions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
may result in further resource concentration among a smaller number of competitors. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may
obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market or make our development more complicated. These competitors may also vie for a similar pool of qualified
scientific and management talent, sites and patient populations for clinical trials, as well as for technologies complementary to, or necessary for, our programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>AMX0035 for the Treatment of ALS </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the past 30
years, only two product candidates have been approved for the treatment of ALS in the United States and Canada, and only one product candidate has been approved for the treatment of ALS in Europe. These two approved drugs, riluzole (marketed under
the name Rilutek) and edaravone (marketed under name Radicava in the United States and Radicut in Japan), are often used in combination. We expect that further therapies and drugs which may be approved in the future will also be used in combination
with existing drugs, absent incompatibility or other barriers to combination. For example, Mitsubishi Tanabe Pharma America, Inc. is developing an oral alternative to Radicava with the potential for a near-term NDA submission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There are currently no approved treatments for ALS which show both a functional and survival benefit for ALS patients. Patients with ALS are commonly
treated with riluzole and edaravone, which are palliative in nature. We believe that these two drugs will not directly compete with AMX0035, if approved, as we believe that successful treatment will likely require concurrent targeting of multiple
key neuron death pathways. However, we are aware of several product candidates in clinical development that may compete with AMX0035 for the treatment of ALS, if approved, including product candidates being developed by Biogen, Biohaven and UCB. To
date, we believe none of the above product candidates has shown statistically significant clinical results on prespecified outcomes in any prior trials. We anticipate that ALS will continue to be an area of research in the healthcare sector and that
drug candidates will continue to be developed and studied for treatment of the disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">While we anticipate the general practice in ALS will
continue to be the combination of approved agents, our commercial potential could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more
convenient or are less expensive than products that we may develop. In addition, we are aware of one ongoing clinical study in Europe which is evaluating the effects on ALS of TURSO, one of the two components in AMX0035. The outcome of this study
could have an impact on the commercial potential of AMX0035. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A large number of trials and studies are ongoing in the many additional
neurodegenerative diseases which we are evaluating for future clinical work for AMX0035 including AD, Wolfram syndrome, Parkinson&#146;s Disease, Huntington&#146;s Disease, Progressive Supranuclear Palsy, Multi-System Atrophy, primary lateral
sclerosis, ischemic stroke, MS, Friedreich&#146;s ataxia, Leigh&#146;s syndrome and Leber&#146;s hereditary optic neuropathy. Some of these diseases also have therapies approved which impact disease progression. The competitive landscape in these
diseases will affect the potential opportunity for AMX0035. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Supply and Manufacturing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Currently, we do not have the infrastructure nor internal capability to manufacture AMX0035 for use in clinical development, and if approved,
commercialization. We rely, and expect to continue to rely for the foreseeable future, on third-party contract manufacturing organizations, or CMOs, for the production of AMX0035 in compliance with current Good Manufacturing Process, or cGMP,
requirements, for use in clinical trials under the guidance of members of our organization. For </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
AMX0035, we utilize two active pharmaceutical ingredients, or APIs, PB and TURSO, which are manufactured and released to us from third-party manufacturers. We have long term, single-source supply
agreements in place for these APIs, including authorization to reference the relevant drug master files with these vendors. We have single-source arrangements for the manufacturing and packaging of bulk drug at established CMOs for our clinical
trials, and we expect that these CMOs will supply commercial product if AMX0035 is approved. We manufacture AMX0035 bulk drug at Patheon Inc., or Patheon, a subsidiary of Thermo Fisher Scientific Inc., located in Whitby, Canada. We have <FONT
STYLE="white-space:nowrap">scaled-up</FONT> our third-party manufacturing capabilities in a manner that we believe will support commercial demand and have entered into agreements covering the manufacture of AMX0035 through 2025. Following
manufacturing, bulk drug is then sent to PCI Pharma Services in Rockford, IL, for primary and secondary packaging. As we look to markets outside of the United States, we plan to add additional manufacturing and distribution sites to support local
market demand. In addition, we utilize a risk-based approach to bring on additional manufacturing sites as needed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have built a team of
pharmaceutical industry technical operations leaders. This team has significant technical, manufacturing, analytical, quality, regulatory, including cGMP, and project management experience to oversee our third-party manufacturers and maintain
quality and regulatory compliance. In addition, members of this team have been involved in commercializing and launching rare disease products across the globe. We plan to continue to build our technical operations team as we move towards
commercialization. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Manufacturing Agreement with Patheon </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November 2019, we entered into a master manufacturing services agreement, or the Manufacturing Agreement, with Patheon, pursuant to which Patheon
provides cGMP manufacturing, quality control, quality assurance, stability testing, packaging and related services to us. We have executed an initial product agreement under the Manufacturing Agreement, which covers AMX0035. The Manufacturing
Agreement has an initial term ending in December 2025, and will automatically renew if there is a product agreement in effect, with the renewal period ending upon the termination of the last product agreement in effect. The product agreement
covering AMX0035 has an initial term ending in December 2025 and automatically renews for successive terms of two years, unless either party gives prior notice of its intent not to review. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may terminate the Manufacturing Agreement or any product agreement: upon 30 days&#146; prior written notice if any government or regulatory authority
permanently prevents us from selling AMX0035 in Canada, the EU or the United States, if approved, or upon 90 days&#146; prior written notice, if we no longer intend to order manufacturing services due to AMX035&#146;s discontinuance in the market.
Patheon may terminate any product agreement under the Manufacturing Agreement upon 30 days&#146; prior written notice, if we project zero volume for twelve successive months during the term of such product agreement. Additionally, Patheon may
terminate the Manufacturing Agreement or any product agreement if payment in full of any overdue, undisputed invoice is not received within 30 days of Patheon&#146;s suspension of manufacturing services for nonpayment or, in certain circumstances,
upon nine months&#146; prior written notice if we assign any rights under the Manufacturing Agreement or a product agreement. In addition, either party may terminate the Manufacturing Agreement or any product agreement for cause, including the other
party&#146;s uncured material breach and upon written notice, in the case of the other party&#146;s insolvency or bankruptcy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Supply Agreement with CU Chemie
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In October 2019, we entered into a supply agreement with CU Chemie Uetikon, GmbH, or CU Chemie, a division of the SEQENS group, pursuant to
which CU Chemie agreed to supply to us, on a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> basis, bulk drug substance of PB, for use in the manufacture of AMX0035. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
agreement has an initial term of five years and will automatically renew for successive terms of two years, unless earlier terminated. After the expiration of the initial term, either party may
terminate the agreement for convenience upon three months&#146; prior written notice. Additionally, either party may terminate the agreement in the case of the other party&#146;s uncured material breach or upon the insolvency or bankruptcy of the
other party. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Supply Agreement with ICE </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In
December 2019, we entered into a supply agreement with Prodotti Chimici e Alimentari S.p.A. (now ICE S.p.A., or ICE), as amended in July 2021, pursuant to which ICE agreed to supply to us, on a <FONT STYLE="white-space:nowrap">non-exclusive</FONT>
basis, bulk drug substance of TURSO, which we use in the manufacture of AMX0035. The agreement has an initial term of five years and will automatically renew for successive terms of five years, unless earlier terminated. ICE may terminate the
agreement upon three months written notice. Additionally, either party may terminate the agreement in the case of the other party&#146;s insolvency or bankruptcy, or in case of the other party&#146;s uncured breach. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Intellectual Property </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Intellectual property is of vital
importance in our field and to pharmaceuticals generally. Our commercial success depends in part on our ability to obtain intellectual property that protects AMX0035 and its uses, and any future product candidates. We seek to protect and enhance
proprietary technology, inventions and improvements that are commercially important to the development of our business and AMX0035, in particular, by seeking, maintaining and defending U.S. and foreign patent rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are actively building our intellectual property portfolio in our therapeutic area, including around AMX0035. Our current patent portfolio as of the
date of this prospectus includes three patent families. In those three families, we currently own a total of 71 issued patents and pending patent applications directed to our technologies, including AMX0035. Currently, our patent portfolio includes
four issued U.S. patents, 47 issued foreign patents, six pending U.S. patent applications and 14 pending foreign patent applications. Our issued patents and pending applications cover the relative amounts of a phenylbutyrate compound and a bile acid
(such as TUDCA) and some of our issued and pending claims cover the specific ratio of those two drugs. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our earliest in time patent family
relates to compositions of a bile acid and a phenylbutyrate compound (including TURSO and <FONT STYLE="white-space:nowrap">4-PBA)</FONT> and methods of treating neurodegenerative disease, and its associated causes at a cellular level, using those
compositions. This family includes four issued U.S. patents and 47 issued foreign patents (including rights in countries in which our issued European patent was validated). The foreign jurisdictions in which we have been issued patents include
Albania, Austria, Australia, Bosnia and Herzegovina, Belgium, Bulgaria, China, Croatia, Cyprus, Czech Republic, Denmark, Estonia, European Union, Finland, France, Germany, Greece, Hong Kong, Hungary, Ireland, Iceland, Italy, Japan, Lithuania,
Latvia, Macao, Macedonia, Malta, Monaco, Montenegro, Netherlands, Norway, Poland, Portugal, Romania, San Marino, Serbia, Slovenia, Slovakia, South Korea, Spain, Sweden, Switzerland, Turkey, and United Kingdom. We also have patent applications
pending in Australia, Canada, China, European Union, Hong Kong, Japan, South Korea, and the United States. In this family, we have composition of matter claims issued in the United States (U.S. Patent No.&nbsp;11,071,742, which was issued on
July&nbsp;27, 2021) and Australia, and pending in applications filed in China and Hong Kong. These issued patents and others that issue from this family may first begin to expire as early as December 2033. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our second patent family is directed to specific compositions of a phenylbutyrate compound and a bile acid (including TURSO and <FONT
STYLE="white-space:nowrap">4-PBA)</FONT> and methods of manufacturing those compositions. We have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
patent applications pending in this family in the United States, Argentina and Taiwan, as well as a Patent Cooperation Treaty (PCT) application. In this family, we have composition of matter
claims pending in applications filed in the United States, Argentina, and Taiwan. Although no patents have yet issued from this family, we expect the term on patents issuing from this family to extend until at least July 2040. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our third patent family is directed to methods of treating particular symptoms of ALS and/or reducing the associated adverse events with combinations of
a phenylbutyrate compound and a bile acid (including TURSO and <FONT STYLE="white-space:nowrap">4-PBA).</FONT> We have patent applications pending in this family in the United&nbsp;States and Taiwan, as well as a Patent Cooperation Treaty (PCT)
application. Currently, we do not have any composition of matter claims pending in this family. Although no patents have yet issued from this family, we expect the term on patents issuing from this family to extend until at least August 2040. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We cannot be sure that patents will be granted with respect to any of our pending patent applications nor with respect to any patent applications that
may be filed by us in the future. Further, we cannot be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in protecting our commercial products. Finally, we cannot be sure that
our granted patents, and any future patents granted to us, will be found valid and/or enforceable following a litigation or administrative procedure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In January 2021, Bruschettini S.r.l. and Lederer&nbsp;&amp; Keller Patentanw&auml;lte Partnerschaft mbB each filed oppositions at the European Patent
Office to our issued European Patent, EP2978419. At a high level, this patent claims various methods of treating neurodegenerative disease (and or the causes or conditions thereof) with a bile acid and a phenylbutyrate compound. The opponents
contend that the patent should be revoked in its entirety on various grounds, including for allegedly having an insufficient disclosure and for lack of inventive step. The EPO has issued a preliminary opinion dated October&nbsp;13, 2021, and a
summon to attend oral proceedings (also dated October&nbsp;13, 2021) that sets a date of June 2, 2022 for the oral proceedings. While we believe that this opposition lacks merit, the Opposition Board could revoke our patent in its entirety or limit
the scope of our issued claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The term of individual patents depends upon the legal term of the patents in the countries in which they are
obtained. In most countries in which we file, the patent term is 20 years from the date of filing of the first <FONT STYLE="white-space:nowrap">non-provisional</FONT> application to which priority is claimed. In the United States, patent term may be
lengthened by patent term adjustment, which compensates a patentee for administrative delays by the United States Patent and Trademark Office in granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier-filed
patent. In the United States, the term of a patent that covers an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug may also be eligible for a patent term extension of up to five years under the Hatch-Waxman Act, which is designed to
compensate for the patent term lost during the FDA regulatory review process. The length of the patent term extension is calculated based on the length of time it takes for regulatory review. A patent term extension under the Hatch-Waxman Act cannot
extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Moreover, a patent can only be extended once, and thus, if a single patent is
applicable to multiple products, it can only be extended based on one product. Similar provisions are available in Europe and certain other foreign jurisdictions to extend the term of a patent that covers an approved drug. When possible, depending
upon the length of clinical trials and other factors involved in the submission of an NDA, we expect to apply for patent term extensions for patents covering our product candidates and/or their methods of use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We also rely on trademarks, trade secrets, <FONT STYLE="white-space:nowrap">know-how,</FONT> continuing technological innovation, confidentiality
agreements, and invention assignment agreements to develop and maintain our proprietary position. The confidentiality agreements are designed to protect our proprietary information and the invention assignment agreements are designed to grant us
ownership of technologies that are developed for us by our employees, consultants, or other third parties. We seek to preserve the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we
have confidence in our agreements and security measures, either may be breached, and we may not have adequate remedies. In addition, our trade secrets may otherwise become known or independently discovered by competitors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our commercial success also depends in part on our ability to operate without infringing on the proprietary rights of others and to prevent others from
infringing our proprietary rights. A comprehensive discussion on risks relating to intellectual property is provided under the section of this prospectus entitled &#147;Risk Factors&#151;Risks Related to Our Intellectual Property.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have conducted searches of the patent landscape at certain points and in certain jurisdictions with respect to AMX0035, and based on these searches
and our analyses, we have not identified any issued patents that we believe are valid and could be successfully asserted to block our ability to commercialize AMX0035. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">European Patent EP3016654, entitled &#147;Tauroursodeoxycholic acid (TUDCA) for Use in the Treatment of Neurodegenerative Disorders,&#148; is owned by
Bruschettini S.r.l. The patent relates to use of TURSO in the treatment of amyotrophic lateral sclerosis in a mammal. An opposition has been filed to the grant of EP3016654 at the European Patent Office (EPO), asking the EPO to revoke EP3016654. The
EPO issued a preliminary opinion on November&nbsp;18, 2019 finding that at least the main claim of EP3016654 lacked novelty. Oral proceedings were held before an Opposition Division of the EPO on June&nbsp;11, 2021. At the end of the oral
proceedings, the Opposition Division announced the decision revoking all claims of EP3016654. A written decision has been issued; however Bruschettini has appealed the decision of the Opposition Division to the Board of Appeal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Government Regulation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA and comparable regulatory
authorities in state and local jurisdictions and in other countries, including Canada and member states of the European Union, or EU, impose requirements upon companies involved in the clinical development, manufacture, marketing and distribution of
drugs, such as those we are developing. These agencies and other federal, state and local entities regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, storage, record
keeping, approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling and export and import of our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>U.S. Government Regulation of Drug Products </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the
United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and
foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval,
may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#146;s refusal to approve pending New Drug Applications, or NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters,
product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The process required by the FDA before a drug may be marketed in the United States generally involves
the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#146;s good
laboratory practice, or GLP, regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Submission to the FDA of an IND application, which must become effective before human clinical trials may begin;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Approval by an independent IRB at each clinical site before each trial may be initiated; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Performance of adequate and well-controlled human clinical trials in accordance with current Good Clinical Practices, or
cGCP, requirements to establish the safety and efficacy of the proposed drug product for each indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Submission to the FDA of an NDA, including payment of application user fees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">A determination by the FDA within 60 days of its receipt of an NDA to accept the marketing application for review;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Satisfactory completion of an FDA advisory committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced
to assess compliance with current good manufacturing practice, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#146;s identity, strength, quality and purity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Satisfactory completion of FDA audits of clinical trial sites to assure compliance with cGCPs and the integrity of the
clinical data; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">FDA review and approval of the NDA. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Preclinical Studies </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Preclinical studies include laboratory
evaluation of product chemistry, toxicity and formulation, as well as <I>in vitro</I> and animal studies to assess potential safety and efficacy. The conduct of preclinical studies is subject to federal regulations and requirements, including good
laboratory practice regulations for safety/toxicology studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">An IND sponsor must submit the results of the preclinical tests, together with
manufacturing information, analytical data and any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an
investigational product to humans and must become effective before human clinical trials may begin. Some preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue even after the IND is submitted. An
IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the
IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to initiate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Clinical Trials </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Clinical trials involve the administration
of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with cGCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their
participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol
for each clinical trial and any subsequent protocol amendments must be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
submitted to the FDA as part of the IND. In addition, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it is
initiated at that institution. The IRB also must review and approve the informed consent form that must be provided to each clinical trial subject or his or her legal representative, and must monitor the clinical trial until completion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public
dissemination on their www.clinicaltrials.gov website. Information related to the product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as part of the registration
of the clinical trial. Although sponsors are obligated to disclose the results of their clinical trials after completion, disclosure of the results can be delayed in some cases for up to two years after the date of completion of the trial. Failure
to timely register a covered clinical study or to submit study results as provided for in the law can give rise to civil monetary penalties and also prevent the <FONT STYLE="white-space:nowrap">non-compliant</FONT> party from receiving future grant
funds from the federal government. The NIH&#146;s Final Rule on ClinicalTrials.gov registration and reporting requirements became effective in 2017, and both the NIH and FDA recently signaled the government&#146;s willingness to begin enforcing
those requirements against <FONT STYLE="white-space:nowrap">non-compliant</FONT> clinical trial sponsors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Human clinical trials are typically
conducted in three sequential phases, which may overlap or be combined: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Phase 1: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and
tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to
preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Phase 3: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial
sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for
the labeling of the product. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after
initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a
condition of approval on an NDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and
more frequently if serious adverse events occur. Written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies or animal or in vitro testing that suggest a
significant risk for human subjects and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar
days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#146;s initial
receipt of the information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Phase 1, Phase 2 and Phase 3 trials may not be completed successfully within any specified period, or at all.
Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s
requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety
monitoring board or committee. This group provides authorization for whether a trial may move forward at designated check points based on access to certain data from the trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry
and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches
of product and, among other things, companies must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted
to demonstrate that the drug does not undergo unacceptable deterioration over its shelf life. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Expanded Access to an Investigational Drug for Treatment Use
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Expanded access, sometimes called &#147;compassionate use,&#148; is the use of investigational products outside of clinical trials to treat
patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. The rules and regulations related to expanded access are intended to improve access to
investigational products for patients who may benefit from investigational therapies. FDA regulations allow access to investigational products under an IND by the company or the treating physician for treatment purposes on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis for: individual patients (single-patient IND applications for treatment in emergency settings and <FONT STYLE="white-space:nowrap">non-emergency</FONT>
settings); <FONT STYLE="white-space:nowrap">intermediate-size</FONT> patient populations; and larger populations for use of the investigational product under a treatment protocol or treatment IND application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">When considering an IND application for expanded access to an investigational product with the purpose of treating a patient or a group of patients, the
sponsor and treating physicians or investigators will determine suitability when all of the following criteria apply: patient(s) have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory
alternative therapy to diagnose, monitor, or treat the disease or condition; the potential patient benefit justifies the potential risks of the treatment and the potential risks are not unreasonable in the context or condition to be treated; and the
expanded use of the investigational drug for the requested treatment will not interfere with initiation, conduct, or completion of clinical investigations that could support marketing approval of the product or otherwise compromise the potential
development of the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There is no obligation for a sponsor to make its drug products available for expanded access; however, as required by
the 21st Century Cures Act, or Cures Act, passed in 2016, if a sponsor has a policy regarding how it responds to expanded access requests, it must make that policy publicly available. Sponsors are required to make such policies publicly available
upon the earlier of initiation of a Phase 2 or Phase 3 trial; or 15 days after the investigational drug or biologic receives designation as a breakthrough therapy, fast track product, or regenerative medicine advanced therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, on May&nbsp;30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain
patients to access certain investigational products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical
trials and without obtaining FDA permission under FDA expanded access program. There is no obligation for a manufacturer to make its investigational products available to eligible patients as a result of the Right to Try Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Combination Rule for Fixed-Dose Combination Products </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the combination rule, the FDA may not file or approve an NDA for a fixed-dose combination product unless each component of a proposed drug product
is shown to make a contribution to the claimed effects and the dosage of each component (amount, frequency, duration) is safe and effective for the intended population. To satisfy these requirements, the FDA typically requires a clinical factorial
study, designed to assess the effects attributable to each drug in the combination product. This is particularly true when the ingredients are directed at the same sign or symptom of the disease or condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The FDA has accepted a variety of approaches to satisfy the combination rule. In December 2015, the FDA proposed regulations that would allow the agency to waive the
requirements of the combination rule for certain drug products under particular circumstances. The FDA has not, to date, finalized these regulations, but the FDA has stated that factorial studies may be unethical (e.g., omitting a drug known to
improve survival) or impractical (there may be too many components to conduct a factorial study, meaning the trial cannot be conducted). The FDA has also stated that it may be possible to use other types of clinical and nonclinical data and
mechanistic information available to demonstrate the contributions of the individual active ingredients to the effect of the combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Similar requirements may
be imposed on us by the EMA in the EU and comparable regulatory authorities in other jurisdictions. While no similar combination rule formally exists in Canada, Health Canada may consider the contributions of each component in a combination product
in connection with review of the NDS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>NDA Submission and Marketing Approval </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information
relating to the product&#146;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the
submission of an NDA is subject to a substantial application user fee. The FDA will initially review an NDA for completeness before it accepts it for &#147;filing.&#148; Under the FDA&#146;s procedures, the agency has 60 days from its receipt of the
NDA to determine whether the application will be accepted for filing based on the agency&#146;s threshold determination that the application is sufficiently complete to permit substantive review. Under the Prescription Drug User Fee Act, or PDUFA,
guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#147;filing&#148; of a standard NDA, for a new molecular entity to review and act on the submission, and six months from the filing date of a new molecular
entity NDA with priority review. Accordingly, this review process typically takes 12 months and eight months, respectively from the date the NDA is submitted to the FDA. The FDA does not always meet its PDUFA goal dates for standard or priority
NDAs, and the review process is often extended by FDA requests for additional information or clarification. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is
manufactured, processed, packaged or held meets standards designed to assure the product&#146;s continued safety, quality and purity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition,
under the Pediatric Research Equity Act of 2003, or PREA, as amended, certain NDAs or supplements to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric
subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or
all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. A sponsor who is planning to submit a marketing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
application for a drug that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration must submit an initial Pediatric Study Plan, or
PSP, within 60 days of an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-Phase</FONT></FONT> 2 meeting or, if there is no such meeting, as early as practicable before initiation of the Phase 3 or Phase 2/3 study. The
initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such
detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on
the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials and/or other clinical development
programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to
determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The
resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> substantive review. The FDA reviews an NDA to
determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#146;s continued safety, quality and purity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA may refer an application for a novel drug or a drug that presents difficult questions of safety or efficacy to an advisory committee. An
advisory committee is a panel of independent experts, including clinicians and other scientific experts, which reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is
not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA also may
require the submission of a Risk Evaluation and Mitigation Strategy, or REMS, if it determines that a REMS is necessary to ensure that the benefits of the drug outweigh its risks and to assure the safe use of the drug. A REMS may include one or more
elements, including medication guides, physician communication plans, patient package insert and/or elements to assure safe use, such as restricted distribution methods, patient registries or other risk minimization tools. The FDA determines the
requirement for a REMS, as well as the specific REMS provisions, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a
proposed REMS. The FDA will not approve the NDA without a REMS, if required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Before approving an NDA, the FDA typically will inspect the facility
or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of
the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with cGCP requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the
manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a Complete Response Letter. A Complete Response Letter generally contains a statement of specific conditions that must be met in order to
secure final approval of the NDA and may require additional clinical or preclinical testing in order for FDA to reconsider the application. If a Complete Response Letter is issued, the applicant may either resubmit the NDA, addressing all of the
deficiencies identified in the letter, or withdraw the application. Even with submission of this additional information, the FDA ultimately may decide that the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#146;s satisfaction, the FDA will typically issue an approval letter. An
approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if the FDA
approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be
conducted to further assess a drug&#146;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk
management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance
programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Orphan Drug Designation and Exclusivity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the Orphan
Drug Act, the FDA may grant orphan designation to a drug product intended to treat a rare disease or condition, which is generally a disease or condition that affects either (i)&nbsp;fewer than 200,000 individuals in the United States, or
(ii)&nbsp;more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered
from sales of the product. A company must request orphan drug designation before submitting an NDA. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan drug designation does not convey
any advantage in or shorten the duration of the regulatory review and approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If a product with orphan status receives the first FDA
approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product is entitled to orphan product exclusivity. Orphan product
exclusivity means that the FDA may not approve any other applications to market the same product for the same indication for seven years, except in certain limited circumstances. If a drug designated as an orphan drug ultimately receives marketing
approval for an indication broader than what it was designated for, it may not be entitled to exclusivity. Orphan exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product with the same
active ingredient for the same indication is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not
able to meet market demand. Further, the FDA may approve more than one product for the same orphan indication or disease as long as the products contain different active ingredients. Moreover, competitors may receive approval of different products
for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan drug has exclusivity. U.S. lawmakers have also recently raised the possibility that
regulatory or legislative changes might need to be made to the Orphan Drug Act to foster competition. This includes the introduction of legislation that, if adopted into law, would require us to demonstrate to the FDA that AMX0035 would be
economically unviable when facing competition to maintain our exclusivity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Expedited Development and Priority Review Programs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA maintains several programs intended to facilitate and expedite development and review of new drugs to address unmet medical needs in the
treatment of serious or life-threatening diseases </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
or conditions. These programs include Fast Track designation, Breakthrough Therapy designation, Priority Review and Accelerated Approval, and the purpose of these programs is to either expedite
the development or review of important new drugs to get them to patients earlier than under standard FDA development and review procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA
has a FastTrack program that is intended to expedite or facilitate the process for reviewing new drugs that meet certain criteria. Specifically, new drugs are eligible for Fast Track designation if they are intended to treat a serious or life
threatening condition and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to both the product and the specific indication for which it is being studied. The
sponsor can request the FDA to designate the product for Fast Track status any time before receiving NDA approval, but ideally no later than the <FONT STYLE="white-space:nowrap">pre-NDA</FONT> meeting. Fast Track designation provides increased
opportunities for sponsor interactions with the FDA during preclinical and clinical development, in addition to the potential for rolling review once a marketing application is filed, meaning that the agency may review portions of the marketing
application before the sponsor submits the complete application, as well as priority review, discussed below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, a drug may be eligible
for designation as a breakthrough therapy if the product is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product
may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. The benefits of Breakthrough Therapy designation include the same benefits as Fast Track designation, plus intensive guidance
from the FDA to ensure an efficient drug development program. A product may also be eligible for priority review if it treats a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and
effectiveness compared to available therapies. The FDA determines at the time that the marketing application is submitted, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis, whether the proposed
drug represents a significant improvement in treatment, prevention or diagnosis of disease when compared with other available therapies. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug
designated for priority review in an effort to facilitate the review and to shorten the FDA&#146;s goal for taking action on an NDA for a new molecular entity from ten months to six months from the date of filing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A product may also be eligible for accelerated approval if it treats a serious or life-threatening disease or condition, generally provides a meaningful
advantage over available therapies and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM,
that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of accelerated approval, the FDA requires that a sponsor perform adequate and well-controlled post-marketing clinical trials. If the FDA concludes that a
drug shown to be effective can be safely used only if distribution or use is restricted, it will require such post-marketing restrictions, as it deems necessary to assure safe use of the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for
qualification or decide that the time period for FDA review or approval will not be shortened. Fast Track designation, Breakthrough Therapy designation and Priority Review designation do not change the standards for approval, but may expedite the
development or review process. Drugs granted accelerated approval also must meet the same statutory standards for safety and effectiveness as those granted traditional approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>U.S. <FONT STYLE="white-space:nowrap">Non-Patent</FONT> Exclusivity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Data exclusivity provisions under the FDCA can delay the submission or the approval of certain <FONT STYLE="white-space:nowrap">follow-on</FONT>
applications. The FDCA provides a five-year period of data exclusivity within the United </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same
active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an Abbreviated New Drug Application, or ANDA, for a generic version of the drug or a
505(b)(2) NDA for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, such a <FONT STYLE="white-space:nowrap">follow-on</FONT> application may be submitted
after four years if it contains a certification of patent invalidity or <FONT STYLE="white-space:nowrap">non-infringement.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA has
previously taken the position that new chemical entity or NCE exclusivity is not available for fixed-dose combination products if one of the active moieties in the combination product had been previously approved in a drug product. In October 2014,
however, the FDA reversed that position when it issued final guidance stating that an application for a fixed-dose combination product will be eligible for <FONT STYLE="white-space:nowrap">5-year</FONT> NCE exclusivity if it contains a drug
substance with a single, new active moiety, even if the fixed-combination also contains a drug substance with a previously approved active moiety. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDCA also provides three years of market exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations,
other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an existing drug. This three-year
exclusivity period covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving <FONT STYLE="white-space:nowrap">follow-on</FONT> applications that do not reference the protected
clinical data. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies
and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pediatric exclusivity is another type of
regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing regulatory exclusivity periods or listed patents. This <FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity may be granted
based on the voluntary completion of a pediatric trial in accordance with an <FONT STYLE="white-space:nowrap">FDA-issued</FONT> &#147;Written Request&#148; for such a trial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Post-approval Requirements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Drugs manufactured or distributed
pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and
reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There are continuing, annual user fee
requirements for any marketed products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For
example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">FDA regulations require that products be manufactured in specific facilities and in accordance with cGMP regulations which require, among other things,
quality control and quality assurance, the maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. In addition, drug manufacturers and other entities involved in the manufacture and
distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
for compliance with cGMP requirements. Manufacturers and other parties involved in the drug supply chain for prescription drug products must also comply with product tracking and tracing
requirements and for notifying FDA of counterfeit, diverted, stolen and intentionally adulterated products or products that are otherwise unfit for distribution in the United States. Changes to the manufacturing process are strictly regulated and
often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party
manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Once an approval of a drug is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or
if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with
regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions
under a REMS program. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Other potential consequences include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or
product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Fines, warning letters or holds on post-approval clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or withdrawal of product
approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Product seizure or detention, or refusal to permit the import or export of products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted by a
manufacturer and any third parties acting on behalf of a manufacturer only for the approved indications and in a manner consistent with the approved label for the product. The FDA and other agencies actively enforce the laws and regulations
prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant liability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Other U.S. Healthcare Laws </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Healthcare providers,
physicians, and third-party payors will play a primary role in the recommendation and prescription of drug products for which we obtain marketing approval. Arrangements with third-party payors, healthcare providers and physicians, in connection with
the clinical research, sales, marketing and promotion of products, once approved, and related activities, may expose a pharmaceutical manufacturer to broadly applicable fraud and abuse and other healthcare laws and regulations. In the United States,
these laws include, without limitation, state and federal anti-kickback, false claims, physician transparency, and patient data privacy and security laws and regulations, including but not limited to those described below: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the Anti-Kickback Statute, or AKS, which makes it illegal for any person or entity, including a prescription drug
manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer or pay any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, that is intended
to induce or reward, referrals including the purchase, recommendation, order or prescription of a particular drug for which </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs. The AKS has been interpreted to apply to arrangements between therapeutic product manufacturers
on one hand and prescribers, purchasers, and formulary managers on the other. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Further, courts have
found that if &#147;one purpose&#148; of remuneration is to induce referrals, the AKS is violated. In addition, the government may assert that a claim including items or services resulting from a violation of the AKS constitutes a false or
fraudulent claim for purposes of the federal False Claims Act, or FCA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal civil and criminal false claims laws, including the FCA, which can be enforced by private citizens through
&#147;qui tam&#148; or &#147;whistleblower&#148; actions, and civil monetary penalty laws, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims
for payment or approval from Medicare, Medicaid, or other federal health care programs that are false or fraudulent; knowingly making or causing a false statement material to a false or fraudulent claim or an obligation to pay or transmit money or
property to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing such an obligation. Pharmaceutical and other healthcare companies have been, and continue to be, prosecuted under these laws, among other
things, for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product and for causing false claims to be submitted because of the companies&#146; marketing of the product for
unapproved, <FONT STYLE="white-space:nowrap">off-label,</FONT> and thus generally <FONT STYLE="white-space:nowrap">non-reimbursable,</FONT> uses. Similar to the AKS, a person or entity does not need to have actual knowledge of these statutes or
specific intent to violate them in order to have committed a violation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal
criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or
property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or
making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Like the AKS, the Patient Protection and Affordable Care Act, or the ACA, amended the
intent standard for certain healthcare fraud statutes under HIPAA such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their
respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the
creation, use, receipt, maintenance or disclosure of individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information. HITECH also created four new tiers of civil
monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and
seek attorneys&#146; fees and costs associated with pursuing federal civil actions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal Physician Payments Sunshine Act, created under the ACA, and its implementing regulations, which require
manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program to report annually to the Centers for Medicare and Medicaid Services, or CMS,
under the Open Payments Program, information related to payments or other transfers of value made </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and
their immediate family members. Effective January&nbsp;1, 2022, these reporting obligations will extend to include transfers of value made during the previous year to certain <FONT STYLE="white-space:nowrap">non-physician</FONT> providers such as
physician assistants and nurse practitioners; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer
protection and unfair competition laws which may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales and marketing arrangements as well as submitting claims involving healthcare items or services
reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated
by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing and marketing
information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities; state and local laws requiring the registration of pharmaceutical sales
representatives; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance
efforts. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors
available, it is possible that some of a pharmaceutical manufacturer&#146;s business activities could be subject to challenge under one or more of such laws. Efforts to ensure that business arrangements comply with applicable healthcare laws involve
substantial costs. It is possible that governmental and enforcement authorities will conclude that a pharmaceutical manufacturer&#146;s business practices do not comply with current or future statutes, regulations or case law interpreting applicable
fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against a pharmaceutical manufacturer, and it is not successful in defending itself or asserting its rights, those actions could have a significant impact
on its business, including the imposition of significant civil, criminal and administrative penalties, damages, disgorgement, imprisonment, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare
programs, reporting obligations and oversight if we become subject to integrity and oversight agreements to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance,</FONT> contractual damages, reputational harm, diminished profits and
future earnings, and curtailment of operations, any of which could adversely affect a pharmaceutical manufacturer&#146;s ability to operate its business and the results of operations. In addition, commercialization of any drug product outside the
United States will also likely be subject to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United
States, numerous federal and state laws and regulations, including state data breach notification laws, state and federal health information privacy laws, and federal and state consumer protection laws, govern the collection, use, disclosure, and
protection of health-related and other personal information. For example California recently enacted the California Consumer Privacy Act, or CCPA, which creates new individual privacy rights for California consumers (as defined in the law) and
places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA will require covered companies to provide certain disclosures to consumers about its data collection, use and sharing
practices, and to provide affected California residents with ways to <FONT STYLE="white-space:nowrap">opt-out</FONT> of certain sales or transfers of personal information. The CCPA went into effect on January&nbsp;1, 2020, and the California State
Attorney General has submitted various versions of final regulations. The California State Attorney General also now has the authority to commence enforcement actions against violators as of July&nbsp;1, 2020. Further, a new California privacy law,
the California Privacy Rights Act, or CPRA, was passed by California voters on November&nbsp;3, 2020. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
CPRA will create additional obligations with respect to processing and storing personal information that are scheduled to take effect on January&nbsp;1, 2023 (with certain provisions having
retroactive effect to January&nbsp;1, 2022). We will continue to monitor developments related to the CPRA and anticipate additional costs and expenses associated with CPRA compliance. Other U.S. states also are considering omnibus privacy
legislation (with one additional law already passed in Colorado and Virginia) and industry organizations regularly adopt and advocate for new standards in these areas. While the CCPA and CPRA contain an exception for certain activities involving PHI
under HIPAA, we cannot yet determine the impact the CCPA, CPRA or other such future laws, regulations and standards may have on our business, as these laws either do not yet apply to us or are not yet in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the event we decide to conduct clinical trials or continue to enroll subjects in our ongoing or future clinical trials, we may be subject to
additional privacy restrictions, under state and federal law or other obligations. We also may become subject to laws in other countries, including the General Data Protection Regulation in Europe. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Current and Future U.S. Healthcare Reform Legislation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Payors, whether domestic or foreign, or governmental or private, are developing increasingly sophisticated methods of controlling healthcare costs and
those methods are not always specifically adapted for new technologies such as gene therapy and therapies addressing rare diseases such as those we are developing. In both the United States and certain foreign jurisdictions, there have been a number
of legislative and regulatory changes to the health care system that could impact our ability to sell our products profitably. In particular, in 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education
Reconciliation Act of 2010, or collectively, the ACA, was enacted, which, among other things, subjected biologic products to potential competition by lower-cost biosimilars; addressed a new methodology by which rebates owed by manufacturers under
the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; extended the Medicaid
Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations; subjected manufacturers to new annual fees and taxes for certain branded prescription drugs; created a new Medicare Part D coverage
gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, effective as of January 1, 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to
eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; and provided incentives to programs that increase the federal government&#146;s comparative
effectiveness research. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain
aspects of the ACA. On June 17, 2021, the Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#146;s decision,
President Biden issued an Executive Order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The Executive Order also instructed
certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and
policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other healthcare reform measures of the Biden administrations or other efforts, if any, to challenge repeal or
replace the ACA, will impact our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, other legislative changes have been proposed and adopted in the United States since the ACA
was enacted. In August 2011, the Budget Control Act of 2011, among other things, created </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013
through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went
into effect in 2013, and, due to subsequent legislative amendments, will remain in effect through 2030 unless additional Congressional action is taken. Pursuant to the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, as well as
subsequent legislation, these reductions have been suspended from May 1, 2020 through December 31, 2021 due to the COVID-19 pandemic. The American Taxpayer Relief Act of 2012 further reduced Medicare payments to several providers, including
hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. The Bipartisan Budget Act of 2018, also amended the ACA, effective
January&nbsp;1, 2019, by increasing the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and closing the coverage
gap in most Medicare drug plans, commonly referred to as the &#147;donut hole.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Canadian Review and Approval Process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In Canada, our small molecule product candidates and our research and development activities are primarily regulated by the Food and Drugs Act and the
rules and regulations thereunder, which are enforced by Health Canada. Health Canada regulates, among other things, the research, development, testing, approval, manufacture, packaging, labeling, storage, recordkeeping, advertising, promotion,
distribution, marketing, post-approval monitoring and import and export of pharmaceutical products. The drug approval process under Canadian laws requires licensing of manufacturing facilities, carefully controlled research and testing of products,
government review and approval of experimental results prior to giving approval to sell drug products. Regulators also typically require that rigorous and specific standards such Continuing Good Manufacturing Practices, or cGMP, Good Laboratory
Practices, or GLP, and Continuing Good Clinical Practices, or cGCP, are followed in the manufacture, nonclinical development and clinical development, respectively, of any drug product. The processes for obtaining regulatory approvals in Canada,
along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources. For further information, see &#147;Risk Factors.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The principal steps required for drug approval in Canada are as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Nonclinical Safety Pharmacology and Toxicology Studies </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><FONT
STYLE="white-space:nowrap">Non-clinical</FONT> studies are conducted in vitro and in animals to evaluate pharmacokinetics, metabolism and possible toxic effects to provide evidence of the safety of the drug candidate prior to its administration to
humans in clinical studies and throughout development. Such studies are conducted in accordance with applicable laws and GLP. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Clinical Trials </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Similar regulations apply in Canada regarding clinical trials as in the United States. In Canada, Research Ethics Boards, or REBs, are used to review and
approve clinical trial plans. Clinical trials involve the administration of an investigational new drug to human subjects under the supervision of qualified investigators, in most cases a physician, in accordance with cGCP requirements, which
include review and approval by REBs. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the trial procedures, the parameters to be used in monitoring safety and the efficacy criteria to be
evaluated and a statistical analysis plan. Human clinical trials for new drugs are typically conducted in three sequential phases, Phase 1, Phase 2 and Phase 3, as discussed above in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the context of government regulation in the United States. Similar to the FDA, Health Canada also accepts foreign clinical trial data in support of marketing applications. Additionally, the
manufacture of investigational drugs for the conduct of human clinical trials is subject to cGMP requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>New Drug Submission </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In Canada, upon successful completion of Phase 3 clinical trials or earlier stage trials if agreeable to Health Canada, the company sponsoring a new drug
then assembles all the nonclinical and clinical data and other testing relating to the product&#146;s pharmacology, chemistry, manufacture, and controls, and submits it to Health Canada as part of a New Drug Submission, or NDS. The NDS is then
reviewed by Health Canada for approval to market the drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Health Canada will not approve the product unless compliance with cGMP&#151;a quality
system regulating manufacturing&#151;is satisfactory and the NDS contains data that provide substantial evidence that the drug is safe and effective in the indication and at the dosage studied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The testing and approval process for an NDS requires substantial time, effort and financial resources, and may take several years to complete. This is
necessary to help ensure the efficacy, safety and quality of the product. Data obtained from nonclinical and clinical testing are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory
approval. Health Canada may not grant approval of an NDS on a timely basis, or at all. In Canada, NDSs are subject to user fees and these fees are typically increased annually to reflect inflation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Health Canada also has authority to grant conditional approval of an NDS for a serious, life-threatening or severely debilitating disease or condition
for which there is promising evidence of clinical effectiveness based on the available data that the drug has the potential to provide: effective treatment, prevention or diagnosis of a disease or condition for which no drug is presently marketed in
Canada or a significant increase in efficacy and/or significant decrease in risk such that the overall benefit/risk profile is improved over existing therapies, preventatives or diagnostic agents for a disease or condition that is not adequately
managed by a drug marketed in Canada. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if Health Canada approves a product candidate, it may limit the approved indications for use of the
product candidate, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#146;s safety after
approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Health Canada may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After
approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements, notification, and regulatory authority review and approval.
Further, should new safety information arise, additional testing, product labeling or regulatory notification may be required. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>European Union Approval
Process </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The process governing approval of medicinal products in the EU generally follows the same lines as in the United States. It entails
satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication. It also requires the submission to the relevant competent authorities
of an MAA and granting of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
marketing authorization by these authorities before the product can be marketed and sold in the EU Following the UK&#146;s departure from the EU, a separate marketing authorization will be
required in order to place medicinal products on the market in Great Britain (under the Northern Irish Protocol, the EU regulatory framework will continue to apply in Northern Ireland and centralized EU authorizations will continue to be
recognized). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Clinical Trial Approval </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Clinical
Trials Directive 2001/20/EC, the Directive 2005/28/EC on GCP and the related national implementing provisions of the individual Member States of the European Union, or EU Member States, govern the system for the approval of clinical trials in the
EU. Under this system, an applicant must obtain prior approval from the national competent authority, or NCA, of the EU Member States in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial at a
specific study site after an independent ethics committee, or EC, has issued a favorable opinion. The clinical trial application must be accompanied by, among other documents, an investigational medicinal product dossier (the Common Technical
Document) with supporting information prescribed by Directive 2001/20/EC, Directive 2005/28/EC, and corresponding national laws of the EU Member States and further detailed in applicable guidance documents. Under the current regime all suspected
unexpected serious adverse reactions to the investigated drug that occur during the clinical trial have to be reported to the NCA and ECs of the EU Member State where they occurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In April 2014, the new Clinical Trials Regulation, (EU) No 536/2014, was adopted, which is set to replace the current Clinical Trials Directive. The
Clinical Trials Regulation will be directly applicable in all EU Member States without the need for any national implementing legislation. It will overhaul the current system of approvals for clinical trials in the EU. The new Clinical Trials
Regulation aims to simplify and streamline the approval of clinical trials in the EU. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the new coordinated procedure for the approval of
clinical trials, the sponsor of a clinical trial will be required to submit a single application for approval of a clinical trial to a reporting EU Member State through a centralized EU Portal. The submission procedure will be the same irrespective
of whether the clinical trial is to be conducted in a single EU Member State or in more than one EU Member State. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Clinical Trials Regulation
has not yet become effective. It is expected that the new Clinical Trials Regulation will come into effect following confirmation of the full functionality of the Clinical Trials Information System, the centralized EU portal and database for
clinical trials foreseen by the new Clinical Trials Regulation, through an independent audit. This is currently expected to occur in December 2021. When the Clinical Trials Regulation becomes applicable, the existing Clinical Trial Directive and
national legislation put in place to implement the Directive will be repealed. Following implementation of the Clinical Trials Regulation, a transitional period will be in effect for one year where new clinical trial applications can be submitted
either under the existing Clinical Trials Directive or under the new Clinical Trials Regulation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>PRIME Designation in the EU </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies
currently exist. The PRIority MEdicines, or PRIME, scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation where the marketing authorization
application will be made through the centralized procedure. Eligible products must target conditions for which where is an unmet medical need (there is no satisfactory method of diagnosis, prevention or treatment in the EEA or, if there is, the new
medicine will bring a major therapeutic </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
advantage) and they must demonstrate the potential to address the unmet medical need by introducing new methods of therapy or improving existing ones. Products from small- and <FONT
STYLE="white-space:nowrap">medium-sized</FONT> enterprises, or SMEs, may qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited
to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated MAA assessment once a dossier has been submitted. Importantly, a dedicated contact and
rapporteur from the EMA&#146;s Committee for Human Medicinal Products, or CHMP, or Committee for Advanced Therapies, are appointed early in PRIME scheme facilitating increased understanding of the product at EMA&#146;s Committee level. A <FONT
STYLE="white-space:nowrap">kick-off</FONT> meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Fixed-Dose Combination Guideline </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As with the FDA, the EMA
has also issued regulations to address review and approval of fixed-dose combination products. This EMA&#146;s Guideline on clinical development of fixed combination medicinal products came into force on October&nbsp;1, 2017. The basic scientific
requirements for any fixed combination medicinal product are justification of the pharmacological and medical rationale for the combination, and establishment of the evidence base for the relevant contribution of all active substances to the desired
therapeutic effect (efficacy and/or safety) and a positive benefit-risk for the combination in the targeted indication. For products that involve initial combination of two active ingredients, the EMA has indicated that the design of clinical
efficacy/safety studies to support a fixed combination medicinal product application for initial treatment will depend on its rationale, specifically to achieve superior efficacy or improved safety compared to use of the single active substances. In
situations when it has been established that monotherapy will not be adequate, appropriate or ethical to reach the desired therapeutic effect, initial use of combination therapy should be easily justified (<I>e.g. </I>HIV). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Marketing Authorization </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To obtain a marketing authorization
for a product European Economic Area (<I>i.e.</I>, the EU as well as Iceland, Liechtenstein and Norway), or EEA, an applicant must submit an MAA either under a centralized procedure administered by the EMA, or one of the procedures administered by
competent authorities in the EU Member States (decentralized procedure, national procedure or mutual recognition procedure). A marketing authorization may be granted only to an applicant established in the EEA. Regulation (EC) No 1901/2006 provides
that prior to obtaining a marketing authorization in the EU, applicants have to demonstrate compliance with all measures included in an <FONT STYLE="white-space:nowrap">EMA-approved</FONT> Paediatric Investigation Plan, or PIP, covering all subsets
of the pediatric population, unless the EMA has granted (1)&nbsp;a product-specific waiver, (2)&nbsp;a class waiver or (3)&nbsp;a deferral for one or more of the measures included in the PIP (for example, when this data is not needed or appropriate
because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over
existing treatments for pediatric patients). Products that are granted a marketing authorization with the results of the pediatric clinical trials conducted in accordance with the PIP (even where such results are negative) are eligible for six
months&#146; supplementary protection certificate extension (if any is in effect at the time of approval). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The centralized procedure provides for
the grant of a single marketing authorization by the European Commission that is valid across the EEA. Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by
certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products (<I>i.e.</I> gene therapy, somatic-cell therapy and tissue-engineered medicinal products)and products with a new active
substance indicated for the treatment of certain diseases, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
including HIV, AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and viral diseases. For products with a new active substance indicated for the
treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of public health, the centralized procedure may be optional. The centralized procedure may at the request of the applicant also
be used in certain other cases. We anticipate that the centralized procedure will be mandatory for the product candidates we are developing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the centralized procedure, the CHMP is responsible for conducting the initial assessment of a product and for several post-authorization and
maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops, when
additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Clock stops may extend the timeframe of evaluation of an MAA considerably beyond 210 days. Accelerated evaluation might be
granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation. If the CHMP accepts such request, the time limit of 210
days will be reduced to 150 days (excluding clock stops) but it is possible that the CHMP can revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment. At
the end of this period, the CHMP provides a scientific opinion on whether or not a marketing authorization should be granted in relation to a medicinal product. Where the CHMP gives a positive opinion, the EMA provides the opinion together with
supporting documentation to the European Commission, who make the final decision to grant a marketing authorization, which is issued within 67 days of receipt of the EMA&#146;s recommendation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The European Commission may grant a <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;marketing authorization under exceptional
circumstances&#148;. Such authorization is intended for products for which the applicant can demonstrate that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use, because either (i)&nbsp;the
indications for which the product in question is intended are encountered so rarely that the applicant cannot reasonably be expected to provide comprehensive evidence; (ii)&nbsp;in the present state of scientific knowledge, comprehensive information
cannot be provided; or (iii)&nbsp;it would be contrary to generally accepted principles of medical ethics to collect such information. Consequently, marketing authorization under exceptional circumstances may be granted subject to certain specific
obligations, which may include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the applicant must complete an identified program of studies within a time period specified by the competent authority, the
results of which form the basis of a reassessment of the benefit/risk profile; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the medicinal product in question may be supplied on medical prescription only and may in certain cases be administered
only under strict medical supervision, possibly in a hospital and in the case of a radiopharmaceutical, by an authorized person; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the package leaflet and any medical information must draw the attention of the medical practitioner to the fact that the
particulars available concerning the medicinal product in question are as yet inadequate in certain specified respects. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A
marketing authorization under exceptional circumstances is subject to annual review to reassess the risk-benefit balance in an annual reassessment procedure. Continuation of the authorization is linked to the annual reassessment and a negative
assessment could potentially result in the marketing authorization being suspended or revoked. The renewal of a marketing authorization of a medicinal product under exceptional circumstances, however, follows the same rules as a &#147;normal&#148;
marketing authorization. Thus, a marketing authorization under exceptional circumstances is granted for an initial five years, after which the authorization will become valid indefinitely, unless the EMA decides that safety grounds merit one
additional five-year renewal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The EU medicines rules expressly permit the EU Member States to adopt national legislation prohibiting
or restricting the sale, supply or use of any medicinal product containing, consisting of or derived from a specific type of human or animal cell, such as embryonic stem cells. While the products we have in development do not make use of embryonic
stem cells, it is possible that the national laws in certain EU Member States may prohibit or restrict us from commercializing our products, even if they have been granted an EU marketing authorization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unlike the centralized authorization procedure, the decentralized marketing authorization procedure requires a separate application to, and leads to
separate approval by, the competent authorities of each EU Member State in which the product is to be marketed. This application is identical to the application that would be submitted to the EMA for authorization through the centralized procedure.
The reference EU Member State prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application. The resulting assessment report is submitted to the concerned EU Member States who, within 90 days of
receipt, must decide whether to approve the assessment report and related materials. If a concerned EU Member State cannot approve the assessment report and related materials due to concerns relating to a potential serious risk to public health,
disputed elements may be referred to the European Commission, whose decision is binding on all EU Member States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The mutual recognition procedure
similarly is based on the acceptance by the competent authorities of the EU Member States of the marketing authorization of a medicinal product by the competent authorities of other EU Member States. The holder of a national marketing authorization
may submit an application to the competent authority of an EU Member State requesting that this authority recognize the marketing authorization delivered by the competent authority of another EU Member State. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Conditional Marketing Authorization </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The European Commission
may also grant a <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;conditional marketing authorization&#148; prior to obtaining the comprehensive clinical data required for an application for a full marketing authorization. Such conditional
marketing authorizations may be granted for product candidates (including medicines designated as orphan medicinal products), if (i)&nbsp;the risk-benefit balance of the product candidate is positive, (ii)&nbsp;it is likely that the applicant will
be in a position to provide the required comprehensive clinical trial data post-authorization, (iii)&nbsp;the product fulfills an unmet medical need and (iv)&nbsp;the benefit to public health of the immediate availability on the market of the
medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including
obligations with respect to the completion of ongoing or new studies, and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance
remains positive, and after an assessment of the need for additional or modified conditions and/or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications
for a conditional marketing authorization. A conditional marketing authorization can be converted into a standard centralized marketing authorization (no longer subject to specific obligations) once the marketing authorization holder fulfils the
obligations imposed and the complete data confirm that the medicine&#146;s benefits continue to outweigh its risks. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Regulatory Data Protection in the EU
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the EEA, innovative medicinal products approved on the basis of a complete independent data package qualify for eight years of data
exclusivity upon marketing authorization and an additional two years of market exclusivity. Data exclusivity, if granted, prevents applicants for authorization of generics or biosimilars of these innovative products from referencing the
innovator&#146;s preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
authorization, for a period of eight years from the date on which the reference product was first authorized in the EEA. During an additional <FONT STYLE="white-space:nowrap">two-year</FONT>
period of market exclusivity, a generic or biosimilar MAA can be submitted and authorized, and the innovator&#146;s data may be referenced, but no generic or biosimilar medicinal product can be placed on the EEA market until the expiration of the
market exclusivity. The overall <FONT STYLE="white-space:nowrap">ten-year</FONT> period will be extended to a maximum of 11 years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for
one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be an
innovative medical product so that the innovator gains the prescribed period of data exclusivity, another company nevertheless could also market another version of the product if such company obtained marketing authorization based on an MAA with a
complete independent data package of pharmaceutical tests, preclinical tests and clinical trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Periods of Authorization and Renewals </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A marketing authorization has an initial validity for five years in principle. The marketing authorization may be renewed after five years on the basis
of a <FONT STYLE="white-space:nowrap">re-evaluation</FONT> of the risk-benefit balance by the EMA (for a centrally authorized product) or by the competent authority of the relevant EU Member State(for a centrally authorized product). To this end,
the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted,
at least six months before the marketing authorization ceases to be valid. The European Commission or the competent authorities of the EU Member States may decide, on justified grounds relating to pharmacovigilance, to proceed with one further
five-year period of marketing authorization. Once subsequently definitively renewed, the marketing authorization shall be valid for an unlimited period. Any authorization which is not followed by the actual placing of the medicinal product on the
EEA market (in case of centralized procedure) or on the market of the authorizing EU Member State within three years after authorization, or if the product is removed from the market for three consecutive years, ceases to be valid (the <FONT
STYLE="white-space:nowrap">so-called</FONT> sunset clause). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Orphan Drug Designation and Exclusivity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Regulation (EC) No.&nbsp;141/2000, as implemented by Regulation (EC) No.&nbsp;847/2000 provides that a drug can be designated as an orphan drug by the
European Commission if its sponsor can establish: that the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition and either (i)&nbsp;the prevalence of the condition is affecting
not more than five in ten thousand persons in the EU when the application is made, or (ii)&nbsp;that without incentives it is unlikely that the marketing of the drug in the EU would generate sufficient return to justify the necessary investment in
its development. In each case, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the drug will be
of significant benefit to those affected by that condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Once authorized, orphan medicinal products are entitled to ten years of market
exclusivity in all EU Member States and in addition a range of other benefits during the development and regulatory review process including scientific assistance for study protocols, authorization through the centralized marketing authorization
procedure and a reduction or elimination of registration and marketing authorization fees. During the period of market exclusivity, marketing authorization may only be granted for a &#147;similar medicinal product&#148; with the same orphan
indication if: (i)&nbsp;the marketing authorization holder for the original orphan medicinal product consents to the authorization of the second orphan product; or (ii)&nbsp;the manufacturer of the original orphan medicinal product is unable to
supply sufficient quantities. Marketing authorization may also be granted to a similar medicinal product with the same orphan indication if it is established that this product is safer, more effective or otherwise
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
clinically superior to the original orphan medicinal product. A &#147;similar medicinal product&#148; is defined as a medicinal product containing a similar active substance or substances as
contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The period of market exclusivity may, in addition, be reduced to six years if at the end of the fifth year, it is established that the
product no longer meets the criteria for orphan drug designation because, for example, the original orphan medicinal product is sufficiently profitable not to justify maintenance of market exclusivity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Regulatory Requirements After a Marketing Authorization has been Obtained </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Where an authorization for a medicinal product in the EU is obtained, the holder of the marketing authorization is required to comply with a range of
requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Compliance with the EU&#146;s stringent pharmacovigilance or safety reporting rules must be ensured. These rules can impose
post-authorization studies and additional monitoring obligations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The manufacturing of authorized medicinal products, for which a separate manufacturer&#146;s license is mandatory, must
also be conducted in strict compliance with the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice.
These requirements include compliance with EU cGMP standards when manufacturing medicinal products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the EU with the intention to import
the active pharmaceutical ingredients into the EU. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The marketing and promotion of authorized drugs, including industry-sponsored continuing medical education and advertising
directed toward the prescribers of drugs and/or the general public, are strictly regulated in the EU notably under Directive 2001/83EC, as amended, and are also subject to EU Member State national laws. <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Direct-to-consumer</FONT></FONT> advertising of prescription medicines is prohibited across the EU. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>General Data
Protection Regulation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the EU, including
personal health data, is subject to the EU General Data Protection Regulation, or GDPR, which became effective on May&nbsp;25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data,
including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards
to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries
outside the EU, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to <FONT STYLE="font-family:Times New Roman">&#128;</FONT>20&nbsp;million or
4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for
damages resulting from violations of the GDPR. Compliance with the GDPR will be a rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure full compliance.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Brexit and the Regulatory Framework in the United Kingdom </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On June&nbsp;23, 2016, the electorate in the United Kingdom voted in favor of leaving the EU, commonly referred to as Brexit. Following protracted
negotiations, the United Kingdom left the EU on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
January&nbsp;31, 2020. A transition period began on February&nbsp;1, 2020, during which EU pharmaceutical law remained applicable to the United Kingdom, however this ended on December&nbsp;31,
2020. Since the regulatory framework in the United Kingdom covering quality, safety and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales and distribution of pharmaceutical products is derived from EU
Directives and Regulations, Brexit could materially impact the future regulatory regime that applies to products and the approval of product candidates in the United Kingdom, as the United Kingdom legislation now has the potential to diverge from EU
legislation. It remains to be seen how Brexit will impact regulatory requirements for product candidates and products in the United Kingdom in the long-term. The MHRA has recently published detailed guidance for industry and organizations to follow
from January&nbsp;1, 2021 now that the transition period is over, which will be updated as the United Kingdom&#146;s regulatory position on medical products evolves over time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Furthermore, while the Data Protection Act of 2018 in the United Kingdom that &#147;implements&#148; and complements the EU&#146;s GDPR, is now
effective in the United Kingdom, it is still unclear whether transfer of data from the European Economic Area, or EEA, to the United Kingdom will remain lawful under GDPR. The Trade and Cooperation Agreement provides for a transitional period during
which the United Kingdom will be treated like an EU Member State in relation to processing and transfers of personal data for four months from January&nbsp;1, 2021. This may be extended by two further months. After such period, the United Kingdom
will be a &#147;third country&#148; under the GDPR unless the European Commission adopts an adequacy decision in respect of transfers of personal data to the United Kingdom. The United Kingdom has already determined that it considers all of the EU
and EEA member states to be adequate for the purposes of data protection, ensuring that data flows from the United Kingdom to the EU and EEA remain unaffected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Pricing Decisions for Approved Products </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the EU, pricing
and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the
cost-effectiveness of a particular product candidate to currently available therapies or <FONT STYLE="white-space:nowrap">so-called</FONT> health technology assessments, in order to obtain reimbursement or pricing approval. For example, EU Member
States have the option to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU Member States may approve a specific price for a
product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other EU Member States allow companies to fix their own prices for products, but monitor and control
prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the EU have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage
health care expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the EU. The downward pressure on health care costs in general, particularly prescription products, has become intense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further
complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States, and parallel trade, i.e., arbitrage between
<FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced EU Member States, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow
favorable reimbursement and pricing arrangements for any products, if approved in those countries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Rest of the World Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For other countries outside of Canada, the EU and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements
governing the conduct of clinical trials, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
product licensing, pricing and reimbursement vary from country to country. Additionally, the clinical trials must be conducted in accordance with GCP requirements and the applicable regulatory
requirements and the ethical principles that have their origin in the Declaration of Helsinki. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we fail to comply with applicable foreign
regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Coverage and Reimbursement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Successful
commercialization of new drug products depends in part on the extent to which reimbursement for those drug products will be available from government health administration authorities, private health insurers, and other organizations. In the United
States, government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drug products they will pay for and establish reimbursement levels. The availability and extent of
reimbursement by governmental and private payors is essential for most patients to be able to afford a drug product. Sales of drug products depend substantially, both domestically and abroad, on the extent to which the costs of drugs products are
paid for by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to
control costs by limiting coverage and the amount of reimbursement for particular drug products. Third-party payors are increasingly challenging the price, examining the medical necessity, and reviewing the cost-effectiveness of medical products,
therapies and services, in addition to questioning their safety and efficacy. Obtaining reimbursement for our products may be particularly difficult because of the higher prices often associated with branded drugs and drugs administered under the
supervision of a physician. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA and foreign approvals. These
studies could result in delays or disadvantageous coverage for products we develop. Our product candidates may not be considered medically necessary or cost-effective. Obtaining coverage and reimbursement approval of a product from a government or
other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our product on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">payor-by-payor</FONT></FONT> basis, with no assurance that coverage and adequate reimbursement will be obtained. A payor&#146;s decision to provide coverage for a product does not imply that an adequate reimbursement rate
will be approved. Further, one payor&#146;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to
maintain price levels sufficient to realize an appropriate return on its investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize any product
candidate that we successfully develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In many countries, the prices of drug products are subject to varying price control mechanisms as part of
national health systems. In general, the prices of drug products under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for drug products, but monitor and control company
profits. Accordingly, in markets outside the United States, the reimbursement for drug products may be reduced compared with the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In
the United States, the principal decisions about reimbursement for new drug products are typically made by CMS, an agency within the HHS. CMS decides whether and to what extent a new drug product will be covered and reimbursed under Medicare, and
private payors tend to follow CMS to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
a substantial degree. However, no uniform policy of coverage and reimbursement for drug products exists among third-party payors and coverage and reimbursement levels for drug products can differ
significantly from payor to payor. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#146;s determination that use of a drug product is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We cannot be sure that coverage or reimbursement will be available for any product that we commercialize and, if coverage and reimbursement are
available, what the level of reimbursement will be. Coverage may also be more limited than the purposes for which the product is approved by the FDA or comparable foreign regulatory authorities. Future coverage and reimbursement may be subject to
increased restrictions, such as prior authorization requirements, and to changes in the rates of reimbursement for orphan drug products both in the United States and in international markets. Reimbursement may impact the demand for, or the price of,
any product for which we obtain regulatory approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The MMA established the Medicare Part D program to provide a voluntary prescription drug
benefit to Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. While all Medicare drug plans must give at least a
standard level of coverage set by Medicare, Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each Part D prescription drug plan can develop its own drug formulary that identifies which drugs it will
cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used
by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for drugs for which we obtain marketing approval. Any
negotiated prices for any of our products covered by a Part D prescription drug plan will likely be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payors
often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from
<FONT STYLE="white-space:nowrap">non-governmental</FONT> payors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For a drug product to receive federal reimbursement under the Medicaid or Medicare
Part B programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program. The required 340B discount on a given product is calculated based on the
average manufacturer price, or AMP, and Medicaid rebate amounts reported by the manufacturer. As of 2010, the ACA expanded the types of entities eligible to receive discounted 340B pricing, although under the current state of the law these newly
eligible entities (with the exception of children&#146;s hospitals) will not be eligible to receive discounted 340B pricing on orphan drugs. As the required 340B discount is determined based on average manufacturer price, or AMP, and Medicaid rebate
data, the revisions to the Medicaid rebate formula and AMP definition described above could cause the required 340B discount to increase. The American Recovery and Reinvestment Act of 2009 provides funding for the federal government to compare the
effectiveness of different treatments for the same illness. The plan for the research was published in 2012 by HHS, the Agency for Healthcare Research and Quality and the NIH, and periodic reports on the status of the research and related
expenditures are made to Congress. Although the results of the comparative effectiveness studies are not intended to mandate coverage policies for public or private payors, it is not clear what effect, if any, the research will have on the sales of
our product candidates, if any such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
drug or the condition that they are intended to treat are the subject of a trial. It is also possible that comparative effectiveness research demonstrating benefits in a competitor&#146;s drug
could adversely affect the sales of our product candidate. If third-party payors do not consider our drugs to be cost-effective compared to other available therapies, they may not cover our drugs after approval as a benefit under their plans or, if
they do, the level of payment may not be sufficient to allow us to sell our drugs on a profitable basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These laws and future state and federal
healthcare reform measures may be adopted in the future, any of which may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any product candidates for which we may obtain
regulatory approval or the frequency with which any such product candidate is prescribed or used. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Outside of the United States, the pricing of
pharmaceutical products and medical devices is subject to governmental control in many countries. For example, in the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed
only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost effectiveness of a particular therapy to currently available therapies or
<FONT STYLE="white-space:nowrap">so-called</FONT> health technology assessments, in order to obtain reimbursement or pricing approval. Other countries may allow companies to fix their own prices for products, but monitor and control product volumes
and issue guidance to physicians to limit prescriptions. Efforts to control prices and utilization of pharmaceutical products and medical devices will likely continue as countries attempt to manage healthcare expenditures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Legal Proceedings </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are not currently subject to any
material legal proceedings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Facilities </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our offices are
located in Cambridge, Massachusetts and consist of approximately 8,850 square feet of leased office space. The lease expires in October 2026. We believe that our facilities are adequate for our current needs and that suitable additional or
substitute space would be available if needed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employees and Human Capital </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;13, 2021, we had 110 full-time employees, including a total of 14&nbsp;employees with M.D. and/or Ph.D. degrees. Of our workforce,
45&nbsp;employees are directly engaged in research and development with the rest providing administrative, business and operations support. None of our employees are represented by labor unions or covered by collective bargaining agreements. We
consider the relationship with our employees to be good. We also use outside consultants and contractors with unique expertise and skills for limited engagements. As of December&nbsp;13, 2021, we utilized multiple outside consultants or contractors
that represented approximately 13 full-time equivalents to supplement our full-time workforce. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our human capital is integral to helping us achieve
our goal to end the suffering caused by neurodegenerative diseases. Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal
purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards and cash-based performance bonus awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc155225_11"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Officers and Directors </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table
sets forth the name, age as of January&nbsp;3, 2022, and position of each of our executive officers and directors. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="56%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Position</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Executive&nbsp;Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Joshua Cohen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer and Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Justin Klee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">James Frates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Margaret Olinger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Commercial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Patrick D. Yeramian, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">George&nbsp;Mclean&nbsp;Milne&nbsp;Jr,&nbsp;Ph.D.(1)(2)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chair</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Isaac Cheng, M.D.(2)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Paul Fonteyne(1)(2)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Daphne Quimi(1)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Member of audit committee </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Member of compensation committee </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Member of nominating and corporate governance committee </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Executive Officers </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Joshua Cohen</I></B> has
served as our Co-Chief Executive Officer and a member of our board of directors since January 2014. Mr. Cohen has a B.S. in Biomedical Engineering from Brown University. We believe that Mr. Cohen is qualified to serve on our board of directors
because of his experience, qualifications, attributes and skills, including his familiarity with our company, as its Co-Founder, as well as his knowledge and familiarity with corporate management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Justin Klee </I></B>has served as our Co-Chief Executive Officer and a member of our board of directors since January 2014. Mr. Klee has a B.S. in
Neuroscience from Brown University. We believe that Mr. Klee is qualified to serve on our board of directors because of his experience, qualifications, attributes and skills, including his familiarity with our company, as its Co-Founder, as well as
his knowledge and familiarity with corporate management. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>James Frates </I></B>has served as our Chief Financial Officer since January
2021. Previously, Mr.&nbsp;Frates served as Chief Financial Officer of Alkermes plc, a biopharmaceutical company, and its predecessor organization, from September 1998 to January 2021. Mr. Frates has an A.B. in Government from Harvard College and an
M.B.A. from the Harvard Graduate School of Business Administration. Mr. Frates serves as a member of the board of directors of Sage Therapeutics, Inc., a biopharmaceutical company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Margaret Olinger</I></B> has served as our Chief Commercial Officer since May 2019. Previously, Ms.&nbsp;Olinger served in various leadership and
commercial positions for more than a decade at Alexion Pharmaceuticals, a biopharmaceutical company. Ms. Olinger has a B.S. in Business Administration from Albertus Magnus College and an M.B.A. from New Haven University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Patrick D. Yeramian, M.D.</I></B> has served as our Chief Medical Officer since March 2019. Dr.&nbsp;Yeramian has over 25 years of experience in
the pharmaceutical industry has extensive leadership </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
experience in both early and late-stage clinical development at several innovative biopharmaceutical companies. Most recently, Dr Yeramian was the Chief Medical Officer for Tapimmune Inc., an <FONT
STYLE="white-space:nowrap">immune-oncology</FONT> company, from February 2015 to January 2017 and for Biovie Inc., a biotechnology company developing innovative drug therapies for liver disease, from October 2016 to March 2019. Earlier, from 2011 to
2015, he was the Medical Director for the Vaccine and Gene Therapy Institute of Florida. Dr.&nbsp;Yeramian received his M.D. from the University of Paris, as well as an M.Sc. in Experimental Oncology and a graduate degree in Molecular Virology. He
also earned an M.B.A. from Rutgers University. He completed his medical residency in oncology at the Saint-Louis Hospital in Paris.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Non-Employee Directors
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>George Mclean Milne Jr, Ph.D. </I></B>has served on our board of directors since 2015 and as chair of our board since December 2021.
Dr. Milne has served as a Venture Partner of Radius Ventures, LLC, a venture investment firm specializing in in entrepreneurs and companies transforming healthcare, since January 2003. Dr. Milne has served on the board of directors of Charles River
Laboratories International, Inc., a laboratory services company, since May 2002. Dr. Milne had also served on the board of directors of Mettler-Toledo, Inc., an instrument manufacturing company, from June 1999 to May 2016. Dr. Milne has a B.S. in
Chemistry from Yale University and a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology. We believe that Dr. Milne is qualified to serve on our board of directors because of his experience, qualifications, attributes and
skills, including his more than 30 years of experience in senior executive management roles with large, international businesses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Isaac
Cheng, M.D.</I></B><B><I> </I></B>has served as a member of our board of directors since March 2016. Dr.&nbsp;Cheng is an investment professional at the Morningside Technology Advisory, LLC, a group that invests in venture capital and private equity
opportunities. He has served in this role since 2006. Dr.&nbsp;Cheng served on the board of directors of Atea Pharmaceuticals, Inc., a biopharmaceutical company, from March 2019 to April 2021. Dr. Cheng also served on the board of directors of
NuCana PLC, a biopharmaceutical company, from May 2017 to March 2020 and Liquidia Technologies, Inc., a biotechnology company, from January 2010 to July 2018. Dr. Cheng received his M.D. and B.S. from the Tufts University School of Medicine. We
believe Dr. Cheng is qualified to serve on our board ofdirectors due to his financial expertise, experience as a venture capitalist, industry experience and his experience in serving on the board of directors of public and private life sciences
companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Paul Fonteyne </I></B>has served as a member of our board of directors since March 2021. Mr.&nbsp;Fonteyne is the retired chairman
and CEO of Boehringer-Ingelheim, or BI, USA. He was with BI or BI subsidiaries from 2003 to December 2018 and made substantial contributions to BI USA. Prior to 2003, Mr. Fonteyne served in leadership positions at Merck and Co. Inc. as well as Abbot
Laboratories. From December 2017 until its reverse merger with Adicet Bio in September 2020, Mr. Fonteyne served as a member of the board of directors of ResTORbio Inc., a biotechnology company and was chair of its Compensation Committee. Mr.
Fonteyne has also served on the board of PhRMA, chaired the National Pharmaceutical Council and is actively participating as a founder in biopharma spinouts from Yale University in the field of Alzheimer&#146;s disease and Pulmonary disease. Mr.
Fonteyne received his M.B.A. from Carnegie-Mellon University and his M.S. in Chemical Engineering from the Polytechnic School at the University of Brussels. We believe Mr. Fonteyne is qualified to serve on our board of directors because of his
experience, qualifications, attributes and skills, including his past experience in the life sciences industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Daphne Quimi</I></B> has
served as a member of our board of directors since June 2021. Ms. Quimi has more than 25 years of executive experience in the pharmaceutical and biotechnology industries with expertise in global finance operations, company building, and rare disease
drug commercialization. She currently serves as Chief Financial Officer of Amicus Therapeutics, Inc. (&#147;Amicus&#148;), a biotechnology </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
company. Ms. Quimi has served in this role since January 2019, after holding various roles at Amicus since 2007. Prior to that, Ms. Quimi served as Director of Consolidations and External
Reporting at Bristol-Myers Squibb Company, a global biopharmaceutical company, from 2005 to 2007. Ms. Quimi received a B.S. in Accountancy from Monmouth University and an M.B.A. from the Stern School of Business of New York University. We believe
Ms. Quimi is qualified to serve on our board of directors due to her financial expertise and industry experience. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Composition and Election of Directors
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Board Composition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors
currently consists of six members, each of whom is a member pursuant to the board composition provisions of our certificate of incorporation and agreements with our stockholders. These board composition provisions will terminate upon the completion
of this offering. Upon the termination of these provisions, there will be no further contractual obligations regarding the election of our directors, which are described in &#147;Certain Relationships and Related Party Transactions.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation and bylaws that will become effective as of the closing date of this offering provide that the
authorized number of directors may be changed only by resolution of our board of directors. Our certificate of incorporation and bylaws will also provide that our directors may be removed only for cause by the affirmative vote of the holders of at
least 66 2/3% of our shares of capital stock present in person or by proxy and entitled to vote, and that any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote
of a majority of our directors then in office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have no formal policy regarding board diversity. Our priority in selection of board members is
identification of members who will further the interests of our stockholders through his or her established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of
our business and understanding of the competitive landscape. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Staggered Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In accordance with the terms of our certificate of incorporation and bylaws that will become effective as of the closing date of this offering, our board
of directors will be divided into three classes, Class&nbsp;I, Class&nbsp;II and Class&nbsp;III, with members of each class serving staggered three-year terms. Upon the closing of this offering, the members of the classes will be divided as follows:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the Class&nbsp;I directors will be Justin Klee and Isaac Cheng, M.D., and their term will expire at the annual meeting of
stockholders to be held in 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the Class&nbsp;II directors will be Paul Fonteyne and George Mclean Milne Jr, Ph.D., and their term will expire at the
annual meeting of stockholders to be held in 2023; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the Class&nbsp;III directors will be Joshua Cohen and Daphne Quimi, and their term will expire at the annual meeting of
stockholders to be held in 2024. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon the expiration of the term of a class of directors, directors in that class will be
eligible to be elected for a new three-year term at the annual meeting of stockholders in the year in which their term expires. Our amended and restated certificate of incorporation and amended and restated bylaws, both of which will become
effective immediately prior to the completion of the offering provide that the number of our directors shall be fixed from time to time by a resolution of the majority of our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The division of our board of directors into three classes with staggered three-year terms may delay or
prevent stockholder efforts to effect a change of our management or a change in control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Director Independence </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Applicable Nasdaq Global Market rules require a majority of a listed company&#146;s board of directors to be comprised of independent directors within
one year of listing. In addition, the Nasdaq Global Market rules require that, subject to specified exceptions, each member of a listed company&#146;s audit, compensation and nominating and corporate governance committees be independent. Audit
committee members must also satisfy the independence criteria set forth in <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3</FONT> under the Exchange Act and compensation committee members must also satisfy the independence criteria set forth in <FONT
STYLE="white-space:nowrap">Rule&nbsp;10C-1</FONT> under the Exchange Act. Under applicable Nasdaq Global Market rules, a director will only qualify as an &#147;independent director&#148; if, in the opinion of the listed company&#146;s board of
directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of <FONT
STYLE="white-space:nowrap">Rule&nbsp;10A-3,</FONT> a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee, accept,
directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries. In order to be considered
independent for purposes of <FONT STYLE="white-space:nowrap">Rule&nbsp;10C-1,</FONT> the board must consider, for each member of a compensation committee of a listed company, all factors specifically relevant to determining whether a director has a
relationship to such company which is material to that director&#146;s ability to be independent from management in connection with the duties of a compensation committee member, including, but not limited to: the source of compensation of the
director, including any consulting, advisory or other compensatory fee paid by such company to the director; and whether the director is affiliated with the company or any of its subsidiaries or affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In December 2021, our board of directors undertook a review of the composition of our board of directors and its committees and the independence of each
director. Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our board of directors has determined that each of George Mclean Milne Jr,
Ph.D., Isaac Cheng, M.D., Paul Fonteyne, and Daphne Quimi is an &#147;independent director&#148; as defined under applicable Nasdaq Global Market rules, including, in the case of all the members of our audit committee, the independence criteria set
forth in <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3</FONT> under the Exchange Act, and in the case of all the members of our compensation committee, the independence criteria set forth in <FONT STYLE="white-space:nowrap">Rule&nbsp;10C-1</FONT>
under the Exchange Act. In making such determination, our board of directors considered the relationships that each such <FONT STYLE="white-space:nowrap">non-employee</FONT> director has with our company and all other facts and circumstances that
our board of directors deemed relevant in determining his or her independence, including the beneficial ownership of our capital stock by each <FONT STYLE="white-space:nowrap">non-employee</FONT> director. Mr.&nbsp;Cohen and Mr.&nbsp;Klee are not
independent directors under these rules because they are our <FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There are no
family relationships among any of our directors or executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We intend to adopt a policy, subject to and effective upon the effectiveness
of the registration statement of which this prospectus forms a part, that outlines a process for our securityholders to send communications to the board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Leadership Structure and Board&#146;s Role in Risk Oversight </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors will be chaired by George Mclean Milne Jr, Ph.D. Our corporate governance guidelines provide that, if the Chair of the board of
directors is a member of management </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
or does not otherwise qualify as independent, the independent directors of the board may or may not elect a lead independent director. Our corporate governance guidelines further provide the
flexibility for our board of directors to modify our leadership structure in the future, as it deems appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Risk is inherent with every
business, and how well a business manages risk can ultimately determine its success. We face a number of risks, including risks relating to our financial condition, development and commercialization activities, operations, strategic direction and
intellectual property as more fully discussed under &#147;Risk Factors&#148; in this prospectus. Management is responsible for the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> management of risks we
face, while our board of directors, as a whole and through its committees, has responsibility for the oversight of risk management. In its risk oversight role, our board of directors has the responsibility to satisfy itself that the risk management
processes designed and implemented by management are adequate and functioning as designed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The role of the board of directors in overseeing the
management of our risks is conducted primarily through committees of the board of directors, as disclosed in the descriptions of each of the committees below and in the charters of each of the committees. The full board of directors (or the
appropriate board committee in the case of risks that are under the purview of a particular committee) discusses with management our major risk exposures, their potential impact on us, and the steps we take to manage them. When a board committee is
responsible for evaluating and overseeing the management of a particular risk or risks, the chair of the relevant committee reports on the discussion to the full board of directors during the committee reports portion of the next board meeting. This
enables the board of directors and its committees to coordinate the risk oversight role, particularly with respect to risk interrelationships. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Committees
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee. Each
of these committees will operate under a charter that has been approved by our board of directors. The composition of each committee will be effective as of the date of this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Audit Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The members of our audit committee
are Daphne Quimi, Paul Fonteyne, and George Mclean Milne Jr, Ph.D., and Daphne Quimi is the chair of the audit committee. Effective as of the date of this prospectus, our audit committee&#146;s responsibilities will include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">appointing, approving the compensation of, and assessing the independence of our independent registered public accounting
firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap">pre-approving</FONT> auditing and permissible
<FONT STYLE="white-space:nowrap">non-audit</FONT> services, and the terms of such services, to be provided by our independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing the overall audit plan with our independent registered public accounting firm and members of management
responsible for preparing our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly
financial statements and related disclosures as well as critical accounting policies and practices used by us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">coordinating the oversight and reviewing the adequacy of our internal control over financial reporting;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establishing policies and procedures for the receipt and retention of accounting-related complaints and concerns;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">recommending based upon the audit committee&#146;s review and discussions with management and our independent registered
public accounting firm whether our audited financial statements shall be included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as they
relate to our financial statements and accounting matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">preparing the audit committee report required by SEC rules to be included in our annual proxy statement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing all related person transactions for potential conflict of interest situations and approving all such
transactions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing quarterly earnings releases. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">All audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> services, other than <I>de minimis</I> <FONT STYLE="white-space:nowrap">non-audit</FONT>
services, to be provided to us by our independent registered public accounting firm must be approved in advance by our audit committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board
of directors has determined that Daphne Quimi is an &#147;audit committee financial expert&#148; as defined in applicable SEC rules and that each of the members of our audit committee possesses the financial sophistication required for audit
committee members under Nasdaq Global Market rules. Under the applicable Nasdaq Global Market rules, a company listed in connection with its initial public offering is permitted to phase in its compliance with the independent audit committee
requirements set forth in Nasdaq Global Market rules on the same schedule as it is permitted to phase in its compliance with the independence audit committee requirement pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3(b)(1</FONT>
)(iv)(A) under the Exchange Act, that is, (1)&nbsp;one independent member at the time of listing; (2)&nbsp;a majority of independent members within 90 days of listing; and (3)&nbsp;all independent members within one year of listing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Compensation Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The members of our
compensation committee are Paul Fonteyne, Isaac Cheng, M.D., and George Mclean Milne Jr, Ph.D., and Paul Fonteyne is the chair of the compensation committee. Effective as of the date of this prospectus, our compensation committee&#146;s
responsibilities will include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">annually reviewing and approving corporate goals and objectives relevant to the compensation of our <FONT
STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">evaluating the performance of our <FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officers in light of such
corporate goals and objectives and determining the compensation of our <FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and approving the compensation of our other executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and establishing our overall management compensation, philosophy and policy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">overseeing and administering our compensation and similar plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">evaluating and assessing potential and current compensation advisors in accordance with the independence standards
identified in the applicable Nasdaq Global Market rules; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">retaining and approving the compensation of any compensation advisors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and making recommendations to our board of directors about our policies and procedures for the grant of
equity-based awards; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">evaluating and making recommendations to the board of directors about director compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">preparing the compensation committee report required by SEC rules, if and when required, to be included in our annual proxy
statement; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and approving the retention or termination of any consulting firm or outside advisor to assist in the evaluation
of compensation matters. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The members of our nominating and corporate governance committee are Isaac Cheng, M.D., Paul Fonteyne, Daphne Quimi and George Mclean Milne Jr, Ph.D.,
and Isaac Cheng, M.D. is the chair of the nominating and corporate governance committee. Effective as of the date of this prospectus, our nominating and corporate governance committee&#146;s responsibilities will include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">developing and recommending to the board of directors criteria for board and committee membership; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establishing procedures for identifying and evaluating board of director candidates, including nominees recommended by
stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing the size and composition of the board of directors to ensure that it is composed of members containing the
appropriate skills and expertise to advise us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">identifying individuals qualified to become members of the board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">recommending to the board of directors the persons to be nominated for election as directors and to each of the
board&#146;s committees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">developing and recommending to the board of directors a code of business conduct and ethics and a set of corporate
governance guidelines; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">overseeing the evaluation of our board of directors and management. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">None of our executive officers serves, or in the past year has served, as a member of the board of directors or compensation committee, or other
committee serving an equivalent function, of any other entity that has one or more of its executive officers serving as a member of our board of directors or our compensation committee. None of the members of our compensation committee is, or has
ever been, an officer or employee of our company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We plan to adopt a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive
officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, which will be effective upon the closing of this offering. Following this offering, we will post a copy of the code on the
Corporate Governance section of our website. If we make any substantive amendments to, or grant any waivers from, the code of business conduct and ethics for any officer or director, we will disclose the nature of such amendment or waiver on our
website or in a Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc155225_12"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This section describes the material elements of compensation awarded to, earned by or paid to each of our named executive officers for the years ended
December&nbsp;31, 2020 and 2021. We are an &#147;emerging growth company,&#148; within the meaning of the JOBS Act, and have elected to comply with the reduced compensation disclosure requirements available to emerging growth companies under the
JOBS Act. This section also provides qualitative information regarding the manner and context in which compensation is awarded to and earned by our named executive officers and is intended to place in perspective the data presented in the tables and
narrative that follow. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following
discussion contains forward-looking statements that are based on our current plans and expectations regarding our future compensation programs. The actual amount and form of compensation that we pay and the compensation policies and practices that
we adopt in the future may differ materially from the currently-planned programs that are summarized in this discussion. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The compensation
provided to our named executive officers for the fiscal years ended December&nbsp;31, 2020 and 2021 is detailed in the 2021 Summary Compensation Table and accompanying footnotes and narrative that follow. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our named executive officers for the fiscal year ended December&nbsp;31, 2021, which consisted of our <FONT STYLE="white-space:nowrap">Co-Chief</FONT>
Executive Officers and our two most highly-compensated executive officers other than our Co-Chief Executive Officers, were: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Joshua B. Cohen, our <FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer and Director;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Justin Klee, our <FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer and Director; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">James M. Frates, our Chief Financial Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Margaret Olinger, MBA, our Chief Commercial Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2021 Summary Compensation Table </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table
provides information regarding the total compensation awarded to, earned by, and paid to our named executive officers for services rendered to us in all capacities during the years listed below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive Plan<BR>Compensation<BR>($) (2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)(4)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Joshua B. Cohen<BR><I><FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer and
Director</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">417,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">698,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,124,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">370,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">97,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">203,500</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">670,500</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Justin Klee<BR><I><FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer and
Director</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">417,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">698,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,124,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">370,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">97,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">203,500</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">670,500</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">James&nbsp;M. Frates (3)<BR><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">375,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">615,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,052,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,050,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Margaret Olinger, MBA<BR><I>Chief Commercial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">296,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">677,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">360,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">515,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)<B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B></B>The amounts reported represent the aggregate grant date fair value of the stock options awarded to the named
executive officers during fiscal years 2020 and 2021, calculated in accordance with </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Financial Accounting Standards Board, or FASB Accounting Standards Codification 718, or ASC Topic 718, <I>Compensation&#151;Stock Compensation</I>. Such grant date fair value does not take into
account any estimated forfeitures. The assumptions used in calculating the grant date fair value of the awards reported in this column are set forth in the notes to our consolidated financial statements included elsewhere in this prospectus. The
amounts reported in this column reflect the accounting cost for the stock options and do not correspond to the actual economic value that may be received upon exercise of the stock options or any sale of any of the underlying shares of common stock.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Each of our named executive officers is eligible to earn cash incentive compensation for 2021 based on achievement of
pre-established performance goals. Such amounts have not yet been determined, but are expected to be determined and paid in the first quarter of 2022 and will be reported at such time as required by SEC rules. The amounts reported for 2020 represent
bonuses earned in 2020, and paid in February 2021, based on the achievement of <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals as determined by our board of directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Mr. Frates joined our company as our Chief Financial Officer in January 2021. The amount reported in the
&#147;Bonus&#148; column represents bonus payments to Mr.&nbsp;Frates pursuant to his employment agreement, including a $325,000 signing bonus and $290,000 one-time additional bonus. Pursuant to the terms of his employment agreement, Mr.&nbsp;Frates
is obligated to repay the signing bonus in the event that he terminates his employment with us other than for &#147;good reason&#148; or is terminated by us other than for &#147;just cause&#148; prior to January 25, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The amounts reported in the &#147;All Other Compensation&#148; column represent matching contributions under our 401(k)
Plan. </P></TD></TR></TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Narrative to Summary Compensation Table </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Base Salaries </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Each named executive officer&#146;s
base salary is a fixed component of annual compensation for performing specific duties and functions, and has been established by our board of directors taking into account each individual&#146;s role, responsibilities, skills, and expertise. Base
salaries are reviewed annually, typically in connection with our annual performance review process, approved by our board of directors, and adjusted from time to time to realign salaries with market levels after taking into account individual
responsibilities, performance, and experience. For fiscal year ended 2020 and 2021, the annual base salary for (i)&nbsp;Mr.&nbsp;Cohen was $370,000 and $417,833, (ii) Mr.&nbsp;Klee was $370,000 and $417,833, and (iii) Ms.&nbsp;Olinger was $360,200
and $372,000, respectively. For fiscal year 2021, the annual base salary for Mr.&nbsp;Frates was $375,000. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Annual Bonuses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For the fiscal year ended, 2020, each named executive officer other than Mr.&nbsp;Frates, who joined the Company in 2021, was eligible to earn an annual
cash bonus based on the achievement of corporate performance metrics and, with respect to Ms.&nbsp;Olinger, on the achievement of corporate and individual performance metrics as determined by the board of directors. The 2020 target annual bonus, as
a percentage of base salary, for Mr.&nbsp;Cohen, Mr.&nbsp;Klee, and Ms.&nbsp;Olinger was 50%, 50%, and 40%, respectively. Based on its evaluation of the performance during fiscal year 2020, the board of directors awarded bonuses to Mr.&nbsp;Cohen,
Mr.&nbsp;Klee, and Ms.&nbsp;Olinger as set forth in the Summary Compensation Table above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For the fiscal year ended December&nbsp;31, 2021, each
named executive officer was eligible to earn an annual cash bonus based on the achievement of corporate performance metrics and, with respect to Ms.&nbsp;Olinger and Mr. Frates, on the achievement of corporate and individual performance metrics as
determined by the board of directors. The 2021 target annual bonus, as a percentage of base salary, for Mr.&nbsp;Cohen, Mr.&nbsp;Klee, Ms.&nbsp;Olinger and Mr.&nbsp;Frates was 50%, 50%, 40%, and 40%, respectively. The
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
annual cash bonuses earned by each named executive director for the fiscal year ended December&nbsp;31, 2021 have not yet been determined, but are expected to be determined and paid in the first
quarter of 2022 and will be reported at such time as required by SEC rules. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Equity Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Although we do not yet have a formal policy with respect to the grant of equity incentive awards to our executive officers, we believe that equity grants
provide our executives with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executives and our stockholders. In addition, we believe that equity grants promote executive retention
because they incentivize our executive officers to remain in our employment during the vesting period. Accordingly, our board of directors periodically reviews the equity incentive compensation of our named executive officers and may grant equity
incentive awards to them from time to time. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In February 2020, Mr.&nbsp;Cohen and Mr.&nbsp;Klee each received options to purchase 100,000 shares of common
stock. In February 2021, Mr. Cohen and Mr. Klee each received options to purchase 200,000 shares of common stock and Ms. Olinger received an option to purchase 65,000 shares of common stock, vesting over four years subject to a one year cliff and
continued service. In January 2021, Mr. Frates received an option to purchase 452,000 shares of common stock. All options granted to the named executive officers in 2021 vest over four years subject to a one year cliff and continued service. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Employment Arrangements with our Named Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have entered into an employment agreement with each of the named executive officers in connection with their employment with us, which set forth the
terms and conditions of their respective employment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Employment Arrangements in Place During the Fiscal Year Ended December&nbsp;31, 2021 for Our Named
Executive Officers </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Joshua B. Cohen </I></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On
July&nbsp;1, 2015, we entered into an employment agreement with Mr.&nbsp;Cohen, who currently serves as our <FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer. In April 2021, we amended the employment agreement with Mr.&nbsp;Cohen
effective February 19, 2021. The employment agreement provides for Mr.&nbsp;Cohen&#146;s <FONT STYLE="white-space:nowrap">at-will</FONT> employment and an annual base salary, cash bonus, a stock option bonus, as well as his ability to participate in
our employee benefit plans generally. Mr.&nbsp;Cohen&#146;s employment agreement provides that if his employment is terminated by us without &#147;just cause&#148; (as defined in Mr.&nbsp;Cohen&#146;s employment agreement), or he resigns for
&#147;good reason&#148; (as defined in Mr.&nbsp;Cohen&#146;s employment agreement), Mr.&nbsp;Cohen will be entitled to receive (i)&nbsp;continuation of his then-current base salary for twelve (12)&nbsp;months, (ii) any cash bonus earned for a prior
year that has not been paid, (iii)&nbsp;a <FONT STYLE="white-space:nowrap">pro-rata</FONT> share of any bonus for which he is or becomes eligible, or &#147;pro rata bonus&#148;, (iv) continuation of health benefits or payments equal to the Company
portion of health insurance premiums for up to 12 months, and (v)&nbsp;continued vesting of stock options for twelve (12)&nbsp;months. If such termination occurs less than three (3)&nbsp;months prior to or twelve (12)&nbsp;months following a
&#147;change of control&#148; (as defined in Mr.&nbsp;Cohen&#146;s employment agreement) the aforementioned severance benefits shall apply except that no pro rata bonus shall be paid and any unvested stock options held by Mr.&nbsp;Cohen shall become
fully vested and exercisable as of immediately prior to such change in control. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Justin Klee </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On July&nbsp;1, 2015, we entered into an employment agreement with Mr.&nbsp;Klee, who currently serves as our
<FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer. In April 2021, we amended the employment agreement with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Mr.&nbsp;Klee effective February 19, 2021. The employment agreement provides for Mr.&nbsp;Klee&#146;s <FONT STYLE="white-space:nowrap">at-will</FONT> employment and an annual base salary, cash
bonus, a stock option bonus, as well as his ability to participate in our employee benefit plans generally. Mr.&nbsp;Klee&#146;s employment agreement provides that if his employment is terminated by us without &#147;just cause&#148; (as defined in
Mr.&nbsp;Klee&#146;s employment agreement), or he resigns for &#147;good reason&#148; (as defined in Mr.&nbsp;Klee&#146;s employment agreement), Mr.&nbsp;Klee will be entitled to receive (i)&nbsp;continuation of his then-current base salary for
twelve (12)&nbsp;months, (ii) any cash bonus earned for a prior year that has not been paid, (iii)&nbsp;a pro rata bonus, (iv)&nbsp;continuation of health benefits or payments equal to the Company portion of health insurance premiums for up to 12
months, and (v)&nbsp;continued vesting of stock options for twelve (12)&nbsp;months. If such termination occurs less than three (3)&nbsp;months prior to or twelve (12)&nbsp;months following a &#147;change of control&#148; (as defined in
Mr.&nbsp;Klee&#146;s employment agreement) the aforementioned severance benefits shall apply except that no pro rata bonus shall be paid and any unvested stock options held by Mr.&nbsp;Cohen shall become fully vested and exercisable as of
immediately prior to such change in control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>James M. Frates </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On January 25, 2021, we entered into an employment agreement with Mr.&nbsp;Frates, who serves as our Chief Financial Officer. The employment agreement
provides for Mr.&nbsp;Frates at-will employment and an annual base salary, a $325,000 sign-on bonus, $290,000 additional bonus payment, annual cash bonus, stock option bonus, an initial stock option grant as well as his ability to participate in our
employee benefit plans generally. Pursuant to Mr.&nbsp;Frates&#146; employment agreement, if prior to January&nbsp;25, 2022, Mr.&nbsp;Frates terminates his employment other than with &#147;good reason&#148;, or is terminated by the Company other
than for &#147;just cause&#148; (as such terms are defined in Mr.&nbsp;Frates&#146; employment agreement), Mr.&nbsp;Frates would be required to repay the sign-on bonus. Mr.&nbsp;Frates&#146; employment agreement also provides that if his employment
is terminated by us without just cause or if he resigns for good reason and such termination or resignation occurs less than three (3) months prior to or twelve (12) months following a &#147;change of control&#148; (as such terms are defined in
Mr.&nbsp;Frates&#146; employment agreement), Mr.&nbsp;Frates will be entitled to receive (i) continuation of his then-current base salary for twelve&nbsp;(12) months, (ii) reimbursement of the company portion of health insurance premiums for up to
twelve (12) months, and (iii) 100% acceleration of unvested stock options as of immediately prior to such change of control. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Margaret Olinger, MBA </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On May&nbsp;13, 2019, we entered into an employment agreement with Ms.&nbsp;Olinger, who currently serves as our Chief Commercial Officer. We amended the
employment agreement with Ms.&nbsp;Olinger in August 2019 and April 2021, the latter amendment effective as of February 19, 2021. The employment agreement provides for Ms.&nbsp;Olinger&#146;s <FONT STYLE="white-space:nowrap">at-will</FONT>
employment and an annual base salary, annual cash bonus, a stock option bonus, an initial stock option grant as well as her ability to participate in our employee benefit plans generally. Ms.&nbsp;Olinger employment agreement provides that if her
employment is terminated by us without &#147;just cause&#148; or if she resigns for &#147;good reason&#148; (as such terms are defined in Ms.&nbsp;Olinger&#146;s employment agreement), Ms.&nbsp;Olinger will be entitled to receive
(i)&nbsp;continuation of her then-current base salary for six (6)&nbsp;months, and (ii)&nbsp;reimbursement of the company portion of health insurance premiums for up to six (6)&nbsp;months. In addition, if such termination or resignation occurs less
than three (3)&nbsp;months prior to or twelve (12)&nbsp;months following a &#147;change of control&#148; (as defined in Ms.&nbsp;Olinger&#146;s employment agreement) she shall be entitled to 100% acceleration of unvested stock options as of
immediately prior to such change in control. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>New Employment Agreement with Joshua B. Cohen </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We plan to enter into a new employment agreement with Mr.&nbsp;Cohen, which will be effective upon the closing of this offering, pursuant to which we
will continue to employ Mr.&nbsp;Cohen as our Co-Chief </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Executive Officer on an &#147;at-will&#148; basis. Mr.&nbsp;Cohen&#146;s new employment agreement provides an annual base salary of $540,000, subject to periodic review by our compensation
committee. In addition, the new employment agreement provides that Mr.&nbsp;Cohen is eligible to receive cash incentive compensation, which target amount shall be 60% of Mr.&nbsp;Cohen&#146;s annual base salary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the event of a termination of Mr.&nbsp;Cohen&#146;s employment by the Company without &#147;cause&#148; or by Mr. Cohen for &#147;good reason&#148;
(as such terms are defined in his new employment agreement), subject to Mr.&nbsp;Cohen&#146;s execution and non-revocation of a release, Mr.&nbsp;Cohen will be entitled to receive (i) cash severance equal to the sum of twelve (12) months of base
salary, plus a pro-rated portion of his target bonus for the year in which his termination occurs, payable in substantially equal installments over twelve (12) months, (ii) acceleration of time-based equity awards that would have become fully vested
and exercisable or nonforfeitable had Mr.&nbsp;Cohen remained employed by the Company for the twelve (12) month period immediately following the date of termination, and (iii) subject to Mr.&nbsp;Cohen&#146;s election to receive continued health
benefits under COBRA and copayment of premium amounts at the applicable active employees&#146; rate, monthly payments equal to employer contribution amount that the Company would have made to provide health insurance to the executive if the
executive had remained employed by the Company until the earliest of (A) twelve (12) months following termination; (B) the date he becomes eligible for group medical plan benefits under any other employer&#146;s group medical plan; or (C) the
expiration of Mr.&nbsp;Cohen&#146;s COBRA health continuation period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, upon a &#147;change in control&#148; (as defined in Mr.
Cohen&#146;s new employment agreement), except as otherwise set forth in the applicable equity award agreement, any equity awards with performance-based conditions and restrictions, or &#147;performance-based equity awards&#148;, held by
Mr.&nbsp;Cohen to the extent then outstanding and unearned, shall be deemed earned based on the greater of target or actual performance as measured through such change in control, and such performance-based equity awards that are deemed earned shall
be subject to time-based vesting, based on Mr.&nbsp;Cohen&#146;s continued employment, for the remainder of the performance period and shall be subject to accelerated vesting upon a termination of his employment to the extent provided for under his
employment agreement as described below. Any performance-based equity awards that are not deemed earned upon a change in control shall be forfeited for no consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In lieu of the payments and benefits described above, in the event that Mr.&nbsp;Cohen&#146;s employment is terminated by us without &#147;cause&#148;,
or by him for &#147;good reason,&#148; in each case, within twelve (12) months following a change in control, and subject to Mr.&nbsp;Cohen&#146;s execution and non-revocation of a release, Mr.&nbsp;Cohen will be entitled to receive (i) a lump sum
in cash equal to 1.5 times the sum of Mr.&nbsp;Cohen&#146;s then current base salary (or the base salary in effect immediately prior to the change in control, if higher) plus Mr. Cohen&#146;s target bonus for the current year (or the target bonus in
effect immediately prior to the change in control, if higher); (ii) full acceleration of vesting of all time-based equity awards, and any performance-based awards that are then outstanding and eligible to vest based on Mr. Cohen&#146;s continued
employment shall accelerate and become fully vested and exercisable; and (iii) subject to Mr.&nbsp;Cohen&#146;s election to receive continued health benefits under COBRA and copayment of premium amounts at the active employees&#146; rate, monthly
payments equal to employer contribution amount that the Company would have made to provide health insurance to the executive if the executive had remained employed by the Company until the earliest of (A) eighteen (18) months following termination;
(B) the date he becomes eligible for group medical plan benefits under any other employer&#146;s group medical plan; or (C) the expiration of Mr.&nbsp;Cohen&#146;s COBRA health continuation period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The payments and benefits provided under Mr. Cohen&#146;s new employment agreement in connection with a change in control may not be eligible for
federal income tax deduction for the Company pursuant to Section 280G of the Internal Revenue Code. These payments and benefits may also be subject to an excise tax under Section 4999 of the Internal Revenue Code. If the payments or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
benefits payable to Mr. Cohen in connection with a change in control would be subject to the excise tax imposed under Section 4999 of the Internal Revenue Code, then those payments or benefits
will be reduced if such reduction would result in a higher net after-tax benefit to him. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to his new employment agreement, Mr. Cohen will
be subject to standard confidentiality and nondisclosure, assignment of intellectual property work product and post-termination non-solicitation of employees, consultants and customers covenants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>New Employment Agreement with Justin Klee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We plan to
enter into a new employment agreement with Mr.&nbsp;Klee, which will be effective upon the closing of this offering, pursuant to which we will continue to employ Mr.&nbsp;Klee as our Co-Chief Executive Officer on an &#147;at-will&#148; basis.
Mr.&nbsp;Klee&#146;s new employment agreement provides an annual base salary of $540,000, subject to periodic review by our compensation committee. In addition, the new employment agreement provides that Mr.&nbsp;Klee is eligible to receive cash
incentive compensation, which target amount shall be 60% of Mr.&nbsp;Klee&#146;s annual base salary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the event of a termination of
Mr.&nbsp;Klee&#146;s employment by the Company without &#147;cause&#148; or by Mr.&nbsp;Klee for &#147;good reason&#148; (as such terms are defined in his new employment agreement), subject to Mr.&nbsp;Klee&#146;s execution and non-revocation of a
release, Mr.&nbsp;Klee will be entitled to receive (i) cash severance equal to the sum of twelve (12) months of base salary, plus a pro-rated portion of his target bonus for the year in which his termination occurs, payable in substantially equal
installments over twelve (12) months, (ii) acceleration of time-based equity awards that would have become fully vested and exercisable or nonforfeitable had Mr.&nbsp;Klee remained employed by the Company for the twelve (12) month period immediately
following the date of termination, and (iii) subject to Mr.&nbsp;Klee&#146;s election to receive continued health benefits under COBRA and copayment of premium amounts at the applicable active employees&#146; rate, monthly payments equal to employer
contribution amount that the Company would have made to provide health insurance to the executive if the executive had remained employed by the Company until the earliest of (A) twelve (12) months following termination; (B) the date he becomes
eligible for group medical plan benefits under any other employer&#146;s group medical plan; or (C) the expiration of Mr.&nbsp;Klee&#146;s COBRA health continuation period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, upon a &#147;change in control&#148; (as defined in Mr. Klee&#146;s new employment agreement), except as otherwise set forth in the
applicable equity award agreement, any equity awards with performance-based conditions and restrictions, or &#147;performance-based equity awards&#148;, held by Mr.&nbsp;Klee to the extent then outstanding and unearned, shall be deemed earned based
on the greater of target or actual performance as measured through such change in control, and such performance-based equity awards that are deemed earned shall be subject to time-based vesting, based on Mr.&nbsp;Klee&#146;s continued employment,
for the remainder of the performance period and shall be subject to accelerated vesting upon a termination of his employment to the extent provided for under his employment agreement as described below. Any performance-based equity awards that are
not deemed earned upon a change in control shall be forfeited for no consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In lieu of the payments and benefits described above, in the
event that Mr.&nbsp;Klee&#146;s employment is terminated by us without &#147;cause&#148;, or by him for &#147;good reason,&#148; in each case, within twelve (12) months following a change in control, and subject to Mr.&nbsp;Klee&#146;s execution and
non-revocation of a release, Mr.&nbsp;Klee will be entitled to receive (i) a lump sum in cash equal to 1.5 times the sum of Mr.&nbsp;Klee&#146;s then current base salary (or the base salary in effect immediately prior to the change in control, if
higher) plus Mr. Klee&#146;s target bonus for the current year (or the target bonus in effect immediately prior to the change in control, if higher); (ii) full acceleration of vesting of all time-based equity awards, and any performance-based awards
that are then outstanding and eligible to vest based on Mr. Klee&#146;s continued employment shall accelerate and become fully vested and exercisable; and (iii) subject to Mr.&nbsp;Klee&#146;s election to receive continued health benefits under
COBRA and copayment of premium </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
amounts at the active employees&#146; rate, monthly payments equal to employer contribution amount that the Company would have made to provide health insurance to the executive if the executive
had remained employed by the Company until the earliest of (A) 18 months following termination; (B) the date he becomes eligible for group medical plan benefits under any other employer&#146;s group medical plan; or (C) the expiration of
Mr.&nbsp;Klee&#146;s COBRA health continuation period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The payments and benefits provided under Mr. Klee&#146;s new employment agreement in
connection with a change in control may not be eligible for federal income tax deduction for the Company pursuant to Section 280G of the Internal Revenue Code. These payments and benefits may also be subject to an excise tax under Section 4999 of
the Internal Revenue Code. If the payments or benefits payable to Mr. Klee in connection with a change in control would be subject to the excise tax imposed under Section 4999 of the Internal Revenue Code, then those payments or benefits will be
reduced if such reduction would result in a higher net after-tax benefit to him. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to his new employment agreement, Mr. Klee will be subject
to standard confidentiality and nondisclosure, assignment of intellectual property work product and post-termination non-solicitation of employees, consultants and customers covenants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>New Employment Agreement with James M. Frates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We plan
to enter into a new employment agreement with Mr. Frates, which will be effective upon the closing of this offering, pursuant to which we will continue to employ Mr. Frates as our Chief Financial Officer on an &#147;at-will&#148; basis. Mr.
Frates&#146; new employment agreement provides an annual base salary of $440,000, subject to periodic review by our compensation committee. In addition, the new employment agreement provides that Mr. Frates is eligible to receive cash incentive
compensation, which target amount shall be 40% of Mr. Frates&#146; annual base salary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the event of a termination of Mr. Frates&#146; employment
by the Company without &#147;cause&#148; or by him for &#147;good reason&#148; (as such terms are defined in his new employment agreement), subject to Mr.&nbsp;Frates&#146; execution and non-revocation of a release, Mr. Frates will be entitled to
receive (i) cash severance equal to the sum of nine (9) months of base salary payable in substantially equal installments over nine (9) months and, (ii) subject to Mr. Frates&#146; election to receive continued health benefits under COBRA and
copayment of premium amounts at the applicable active employees&#146; rate, monthly payments equal to employer contribution amount that the Company would have made to provide health insurance to the executive if the executive had remained employed
by the Company until the earliest of (A) nine (9) months following termination; (B) the date he becomes eligible for group medical plan benefits under any other employer&#146;s group medical plan; or (C) the expiration of Mr.&nbsp;Frates&#146; COBRA
health continuation period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, upon a &#147;change in control&#148; (as defined in Mr. Frates&#146; new employment agreement), except as
otherwise set forth in the applicable equity award agreement, any equity awards with performance-based conditions and restrictions, or &#147;performance-based equity awards&#148;, held by Mr.&nbsp;Frates to the extent then outstanding and unearned,
shall be deemed earned based on the greater of target or actual performance as measured through such change in control, and such performance-based equity awards that are deemed earned shall be subject to time-based vesting, based on
Mr.&nbsp;Frates&#146; continued employment, for the remainder of the performance period and shall be subject to accelerated vesting upon a termination of her employment to the extent provided for under her employment agreement as described below.
Any performance-based equity awards that are not deemed earned upon a change in control shall be forfeited for no consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, in
lieu of the payments and benefits described above, in the event that Mr. Frates&#146; employment is terminated by us without cause, or by him for good reason, in each case, within twelve (12) months following a change in control and subject to Mr.
Frates&#146; execution and non-revocation of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
release, Mr. Frates will be entitled to receive (i) a lump sum in cash equal to 1.0 times the sum of Mr.&nbsp;Frates&#146; then current base salary (or the base salary in effect immediately prior
to the change in control, if higher) plus Mr. Frates&#146; target bonus for the current year (or the target bonus in effect immediately prior to the change in control, if higher); (ii) full acceleration of vesting of all time-based equity awards,
and any performance-based awards that are then outstanding and eligible to vest based on Mr. Frates&#146; continued employment shall accelerate and become fully vested and exercisable; and (iii) subject to Mr. Frates&#146; election to receive
continued health benefits under COBRA and copayment of premium amounts at the active employees&#146; rate, monthly payments equal to employer contribution amount that the Company would have made to provide health insurance to the executive if the
executive had remained employed by the Company until the earliest of (A) twelve (12) months following termination; (B) the date he becomes eligible for group medical plan benefits under any other employer&#146;s group medical plan; or (C) the
expiration of Mr. Frates&#146; COBRA health continuation period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The payments and benefits provided under Mr. Frates&#146; new employment agreement
in connection with a change in control may not be eligible for federal income tax deduction for the Company pursuant to Section 280G of the Internal Revenue Code. These payments and benefits may also be subject to an excise tax under Section 4999 of
the Internal Revenue Code. If the payments or benefits payable to Mr. Frates in connection with a change in control would be subject to the excise tax imposed under Section 4999 of the Internal Revenue Code, then those payments or benefits will be
reduced if such reduction would result in a higher net after-tax benefit to him. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to his new employment agreement, Mr. Frates will be
subject to standard confidentiality and nondisclosure, assignment of intellectual property work product and post-termination non-solicitation of employees, consultants and customers covenants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>New Employment Agreement with Margaret Olinger, MBA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We plan to enter into a new employment agreement with Ms.&nbsp;Olinger, which will be effective upon the closing of this offering, pursuant to which we
will continue to employ Ms.&nbsp;Olinger as our Chief Commercial Officer on an &#147;at-will&#148; basis. Ms.&nbsp;Olinger&#146;s new employment agreement provides an annual base salary will of $425,000, subject to periodic review by our
compensation committee. In addition, the new employment agreement provides that Ms.&nbsp;Olinger is eligible to receive cash incentive compensation, which target amount shall be 40% of Ms.&nbsp;Olinger&#146;s annual base salary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the event of a termination of Ms.&nbsp;Olinger&#146;s employment by the Company without &#147;cause&#148; or by her for &#147;good reason&#148; (as
such terms are defined in her new employment agreement), subject to Ms.&nbsp;Olinger&#146;s execution and non-revocation of a release, Ms.&nbsp;Olinger will be entitled to receive (i) cash severance equal to the sum of nine (9) months of base salary
payable in substantially equal installments over nine (9) months and, (ii) subject to Ms.&nbsp;Olinger&#146;s election to receive continued health benefits under COBRA and copayment of premium amounts at the applicable active employees&#146; rate,
monthly payments equal to employer contribution amount that the Company would have made to provide health insurance to the executive if the executive had remained employed by the Company until the earliest of (A) nine (9) months following
termination; (B) the date she becomes eligible for group medical plan benefits under any other employer&#146;s group medical plan; or (C) the expiration of Ms.&nbsp;Olinger&#146;s COBRA health continuation period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, upon a &#147;change in control&#148; (as defined in Ms. Olinger&#146;s new employment agreement), except as otherwise set forth in the
applicable equity award agreement, any equity awards with performance-based conditions and restrictions, or &#147;performance-based equity awards,&#148; held by Ms.&nbsp;Olinger to the extent then outstanding and unearned, shall be deemed earned
based on the greater of target or actual performance as measured through such change in control, and such performance-based equity awards that are deemed earned shall be subject to time-based vesting,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
based on Ms. Olinger&#146;s continued employment, for the remainder of the performance period and shall be subject to accelerated vesting upon a termination of her employment to the extent
provided for under her employment agreement as described below. Any performance-based equity awards that are not deemed earned upon a change in control shall be forfeited for no consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, in lieu of the payments and benefits described above, in the event that Ms.&nbsp;Olinger&#146;s employment is terminated by us without
cause, or by her for good reason, in each case, within twelve months following a change in control and subject to Ms.&nbsp;Olinger&#146;s execution and non-revocation of a release, Ms.&nbsp;Olinger will be entitled to receive (i) a lump sum in cash
equal to 1.0 times the sum of Ms.&nbsp;Olinger&#146;s then current base salary (or the base salary in effect immediately prior to the change in control, if higher) plus Ms. Olinger&#146;s target bonus for the current year (or the target bonus in
effect immediately prior to the change in control, if higher); (ii) full acceleration of vesting of all time-based equity awards, and any performance-based awards that are then outstanding and eligible to vest based on Ms. Olinger&#146;s continued
employment shall accelerate and become fully vested and exercisable; and, (iii) subject to Ms. Olinger&#146;s election to receive continued health benefits under COBRA and copayment of premium amounts at the active employees&#146; rate, monthly
payments equal to employer contribution amount that the Company would have made to provide health insurance to the executive if the executive had remained employed by the Company until the earliest of (A) twelve (12) months following termination;
(B) the date she becomes eligible for group medical plan benefits under any other employer&#146;s group medical plan; or (C) the expiration of Ms. Olinger&#146;s COBRA health continuation period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The payments and benefits provided under Ms. Olinger&#146;s new employment agreement in connection with a change in control may not be eligible for
federal income tax deduction for the Company pursuant to Section 280G of the Internal Revenue Code. These payments and benefits may also be subject to an excise tax under Section 4999 of the Internal Revenue Code. If the payments or benefits payable
to Ms. Olinger in connection with a change in control would be subject to the excise tax imposed under Section 4999 of the Internal Revenue Code, then those payments or benefits will be reduced if such reduction would result in a higher net
after-tax benefit to her. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to her new employment agreement, Ms. Olinger will be subject to standard confidentiality and nondisclosure,
assignment of intellectual property work product and post-termination non-solicitation of employees, consultants and customers covenants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Outstanding Equity Awards at Fiscal 2021 <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth information regarding outstanding equity awards held by our named executive officers as of December&nbsp;31, 2021: </P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards (1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Options<BR>(#)Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Options<BR>(#)Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Joshua B. Cohen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/16/2018</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/16/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/26/2020</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/26/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/19/2021</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/19/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Justin Klee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/16/2018</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/16/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/26/2020</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/26/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/19/2021</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/19/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">James M. Frates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/25/2021</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">452,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/25/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Margaret Olinger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/13/2019</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/13/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/13/2019</TD>
<TD NOWRAP VALIGN="bottom">(7)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/13/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/19/2021</TD>
<TD NOWRAP VALIGN="bottom">(8)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/21/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">All stock options have been granted pursuant to the terms of our 2015 Stock Option and Restricted Stock Plan, as amended.
Pursuant to their respective employment agreements, in the event that Mr.&nbsp;Klee or Mr.&nbsp;Cohen are terminated without cause or resign for good reason, their time-based stock options will accelerate by twelve (12) months, and in the event that
Mr.&nbsp;Klee, Mr.&nbsp;Cohen, Ms.&nbsp;Olinger or Mr.&nbsp;Frates is terminated without cause or resigns for good reason within 12&nbsp;months following a change in control, any unvested shares subject to the executive&#146;s time-based stock
options will fully accelerate. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">6,977 shares subject to this stock option vested on March&nbsp;16, 2018 and the remainder is scheduled to vest thereafter
in 47 monthly installments of 6,969 shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">25,012 shares subject to this stock option vested on February&nbsp;26, 2021 and the remainder is scheduled to vest
thereafter in 36 monthly installments of 2,083 shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">50,024 shares subject to this stock option vest on February&nbsp;19, 2022 and the remainder is scheduled to vest
thereafter in 36 monthly installments of 4,166 shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">113,024 shares subject to this stock option vest on January&nbsp;25, 2022 and the remainder is scheduled to vest
thereafter in 36 monthly installments of 9,416 shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">33,898 shares subject to this stock option vested on November&nbsp;13, 2019 and the remainder is scheduled to vest
thereafter in 36 monthly installments of 2,421 shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">33,898 shares subject to this stock option vested on February&nbsp;1, 2020 and the remainder is scheduled to vest
thereafter in 36 monthly installments of 2,421 shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">16,256 shares subject to this stock option vest on February&nbsp;19, 2022 and the remainder is scheduled to vest
thereafter in 36 monthly installments of 1,354 shares. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors approved option grants and restricted stock units
to our named executive officers that will become effective upon our initial public offering, or the IPO Grants. The IPO Grants will be granted under our 2022 Plan contingent and effective upon the effectiveness of the registration statement of which
this prospectus forms a part. The options will have an exercise price per share equal to the initial public offering price in the offering. Mr.&nbsp;Cohen and Mr.&nbsp;Klee will each receive options to purchase 337,500 shares of common stock and
75,000 restricted stock units, Mr.&nbsp;Frates will receive options to purchase 142,500 shares of common stock and 31,667 restricted stock units, and Ms.&nbsp;Olinger will receive options to purchase 127,500 shares of common stock and 28,333
restricted stock units. The options granted in connection with the IPO Grants will vest as follows: 25% of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
shares subject to each award shall vest on the first anniversary of the effective date of the grant and the remaining 75% of the shares subject to each award shall vest in 36 monthly installments
thereafter, subject to the named executive officer&#146;s continued service to us through each applicable vesting date. The restricted stock units granted in connection with the IPO Grants will vest as follows: 25% of the shares subject to each
award shall vest on the first anniversary of the effective date of the grant and the remaining 75% of the shares subject to each award shall vest in three yearly installments thereafter, subject to the named executive officer&#146; continued service
to us through each applicable vesting date. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employee Benefits and Equity Compensation Plans </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>2015 Stock Option and Restricted Stock Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board
of directors adopted, and our stockholders approved our 2015 Plan in April 2015. The 2015 Plan was most recently amended by our board of directors in February 2021. Under the 2015 Plan, 8,474,374 shares of our common stock have been reserved for
issuance in the form of incentive stock options,&nbsp;non-qualified&nbsp;stock options, and restricted stock. The shares issuable pursuant to awards granted under the 2015 Plan are authorized but unissued shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The 2015 Plan is administered by our board of directors or a committee designated by our board of directors, or the &#147;administrator,&#148; whose
construction and interpretation of the terms and provisions of the 2015 Plan shall be final and conclusive. The administrator has full power to select the individuals to whom awards will be granted and to determine the specific terms and conditions
of each award, subject to the provisions of the 2015 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The option exercise price of each option granted under the 2015 Plan is determined by
the administrator and may not be less than the fair market value of a share of common stock on the date of grant. The term of each option is fixed by the administrator and may not exceed 10 years from the date of grant. The administrator determines
at what time or times each option may be exercised when granting the option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The 2015<B> </B>Plan provides that upon the occurrence of an
&#147;acquisition event&#148; (as defined in the 2015<B> </B>Plan), the administrator shall take any one or more or none of the following actions with respect to any outstanding options: provide for the assumption or substitution of such awards by
the acquiring or succeeding corporation or its affiliate; upon written notice to optionees, provide that all outstanding options will become fully exercisable as of a specified time prior to the acquisition event and will terminate immediately prior
to the consummation of such acquisition event if not exercised; in the event of a merger where the holders of the Company&#146;s common stock will receive a cash or stock payment for each share surrendered in the merger, make or provide for cash or
stock payment to holders of options equal to the difference between (i)&nbsp;the per share cash or stock consideration in the acquisition event multiplied by the number of shares subject to outstanding options that the holders elect to exercise, and
(ii)&nbsp;the aggregate exercise price of all such outstanding options that the holders actually exercise in exchange for the termination of all such outstanding options; provide that all or any outstanding options shall become fully exercisable as
of immediately prior to such acquisition event; or provide for a combination of any one or more of the foregoing options or any other plan which would be equitable, in the good faith judgment of the administrator to the holders of outstanding
options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The administrator may amend the 2015 Plan but no such action may adversely affect the rights of an award holder without such holder&#146;s
consent. Approval by our stockholders of amendments to the 2015 Plan must be obtained if required by law. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of November 30, 2021, options to
purchase 5,415,815 shares of common stock were outstanding under the 2015 Plan. Our board of directors has determined not to make any further awards under the 2015 Plan following the completion of this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>2022 Stock Option and Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with this offering, our board of directors, upon the recommendation of the compensation committee of the board of directors, or the
compensation committee, adopted the 2022 <B></B>Plan, which will be subsequently approved by our stockholders. The 2022 <B></B>Plan is expected to become effective on the date immediately prior to the date on which the registration statement of
which this prospectus is part is declared effective by the SEC. The 2022 Plan is expected to replace our 2015 Plan, as our board of directors has determined not to make additional awards under the 2015 Plan following the closing of this offering.
The 2022 Plan will provide flexibility to our compensation committee to use various equity-based incentive awards as compensation tools to motivate our workforce. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We initially reserved 7,650,000 shares of our common stock, or the Initial Limit, for the issuance of awards under the 2022 Plan. The 2022 Plan will
provide that the number of shares reserved and available for issuance under the plan will automatically increase each January&nbsp;1, beginning on January&nbsp;1, 2023, by five percent (5%) of the outstanding number of shares of our common stock on
the immediately preceding December&nbsp;31, or such lesser number of shares as determined by our compensation committee, or the Annual Increase. This number will be subject to adjustment in the event of a stock split, stock dividend or other change
in our capitalization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares we issue under the 2022 Plan will be authorized but unissued shares or shares that we reacquire. The shares of
common stock underlying any awards that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without any issuance of stock, expire
or are otherwise terminated (other than by exercise) under the 2022 Plan and the 2015 Plan will be added back to the shares of common stock available for issuance under the 2022 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The maximum aggregate number of shares that may be issued in the form of incentive stock options may not exceed the Initial Limit cumulatively increased
on January&nbsp;1, 2023, and on each January&nbsp;1 thereafter by the lesser of the Annual Increase for such year or 7,650,000&nbsp;shares of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The grant date fair value of all awards made under our 2022 Plan and all other cash compensation paid by us to any
<FONT STYLE="white-space:nowrap">non-employee</FONT> director in any calendar year for services as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director shall not exceed $750,000; provided, however, that such amount shall be $1,000,000 for
the calendar year in which the applicable <FONT STYLE="white-space:nowrap">non-employee</FONT> director is initially elected or appointed to the board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The 2022 Plan will be administered by our compensation committee. Our compensation committee will have full power to select, from among the individuals
eligible for awards, the individuals to whom awards will be granted, to make any combination of awards to participants, and to determine the specific terms and conditions of each award, subject to the provisions of the 2022 Plan. Persons eligible to
participate in the 2022 Plan will be those full or part-time employees, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and consultants of us and our affiliates, as selected from time to time by our compensation committee in its
discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The 2022 Plan will permit the granting of both options to purchase common stock intended to qualify as incentive stock options under
Section&nbsp;422 of the Internal Revenue Code and options that do not so qualify. The option exercise price of each option will be determined by our compensation committee but may not be less than 100% of the fair market value of our common stock on
the date of grant. The term of each option will be fixed by our compensation committee and may not exceed ten years from the date of grant. Our compensation committee will determine at what time or times each option may be exercised. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our compensation committee may award stock appreciation rights subject to such conditions and
restrictions as it may determine. Stock appreciation rights entitle the recipient to shares of common stock or cash, equal to the value of the appreciation in our stock price over the exercise price. The exercise price of each stock appreciation
right may not be less than 100% of the fair market value of the common stock on the date of grant. The term of each stock appreciation right will be fixed by our compensation committee and may not exceed ten years from the date of grant. Our
compensation committee will determine at what time or times each stock appreciation right may be exercised. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our compensation committee will be
permitted to award restricted shares of common stock and restricted stock units to participants subject to such conditions and restrictions as it may determine. These conditions and restrictions may include the achievement of certain performance
goals and/or continued employment or service relationship with us through a specified vesting period. Our compensation committee will also be permitted to grant shares of common stock that are free from any restrictions under the 2022 Plan.
Unrestricted stock may be granted to participants in recognition of past services or other valid consideration and may be issued in lieu of cash compensation due to such participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our compensation committee will be permitted to grant cash bonuses under the 2022 Plan to participants, subject to the achievement of certain
performance goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The 2022 Plan will provide that upon the effectiveness of a &#147;sale event,&#148; as defined in the 2022 Plan, an acquirer or
successor entity may assume, continue or substitute outstanding awards under the 2022 Plan. To the extent that awards granted under our 2022 Plan are not assumed or continued or substituted by the successor entity, except as may be otherwise
provided in the relevant award certificate, all awards with time-based vesting, conditions or restrictions will become fully vested and nonforfeitable as of the effective time of the sale event, and all awards with conditions and restrictions
relating to the attainment of performance goals may become vested and nonforfeitable in connection with a sale event in the compensation committee&#146;s discretion or to the extent specified in the relevant award certificate. Upon the effective
time of the sale event, all outstanding awards granted under the 2022 Plan will terminate to the extent not assumed, continued or substituted. In the event of such termination, individuals holding options and stock appreciation rights will be
permitted to exercise such options and stock appreciation rights (to the extent exercisable) within a specified period of time prior to the sale event. In addition, in connection with the termination of the 2022 Plan upon a sale event, we may make
or provide for a payment, in cash or in kind, to participants holding vested and exercisable options and stock appreciation rights equal to the difference between the per share cash consideration payable to stockholders in the sale event and the
exercise price of the options or stock appreciation rights and we may make or provide for a payment, in cash or in kind, to participants holding other vested awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors will be permitted to amend or discontinue the 2022 Plan and our compensation committee will be permitted to amend the exercise
price of options and amend or cancel outstanding awards for purposes of satisfying changes in law or any other lawful purpose but no such action may adversely affect rights under an award without the holder&#146;s consent. Certain amendments to the
2022 Plan will require the approval of our stockholders. The administrator of the 2022 Plan is specifically authorized to exercise its discretion to reduce the exercise price of outstanding stock options and stock appreciation rights or effect the
repricing of such awards through cancellation and <FONT STYLE="white-space:nowrap">re-grants</FONT> without stockholder consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">No awards will be
granted under the 2022 Plan after the date that is 10&nbsp;years from the date of&nbsp;stockholder approval. No awards under the 2022 Plan have been made prior to the date of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with this offering, our board of directors, upon the recommendation of the compensation committee of the board of directors, or the
compensation committee, adopted the 2022 Employee Stock Purchase Plan, or ESPP, which will be subsequently approved by our stockholders. The ESPP is intended to qualify as an &#147;employee stock purchase plan&#148; within the meaning of Section
423(b) of the Code. The ESPP initially reserves and authorizes the issuance of up to a total of 605,000 shares of common stock to participating employees. The ESPP provides that the number of shares reserved and available for issuance will
automatically increase each January 1, beginning on January 1, 2023 and each January 1 thereafter through January 1, 2032, by the least of (i)&nbsp;1% of the outstanding number of shares of our common stock on the immediately preceding December 31,
(ii)&nbsp;1,210,000 shares or (iii) such number of shares of common stock as determined by the ESPP administrator. The number of shares reserved under the ESPP is subject to adjustment in the event of a stock split, stock dividend or other change in
our capitalization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">All employees whose customary employment is for more than five months per calendar year and 20&nbsp;hours per week and have
completed such period of service as the administrator may require are eligible to participate in the ESPP. However, any participating employee who would own 5% or more of the total combined voting power or value of all classes of stock after an
option were granted under the ESPP would not be eligible to purchase shares under the ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may make one or more offerings each year to our
employees to purchase shares under the ESPP. The compensation committee shall determine, in its discretion, when the initial offering and any subsequent offering shall occur and the duration of each offering. Each eligible employee may elect to
participate in any offering by submitting an enrollment form at least 15 business days before the relevant offering date. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Each employee who is
a participant in the ESPP may purchase shares of our common stock by authorizing payroll deductions of up to fifteen percent (15%) of his or her base compensation during an offering period. Unless the participating employee has previously withdrawn
from the offering, his or her accumulated payroll deductions will be used to purchase shares of our common stock on the last business day of the purchase period at a price equal to 85% of the fair market value of the shares of our common stock on
the first business day or the last business day of the purchase period, whichever is lower. Under applicable tax rules, an employee may purchase no more than $25,000 worth of shares of common stock, valued at the start of the offering period, under
the ESPP in any calendar year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The accumulated payroll deductions of any employee who is not a participant on the last day of an offering period
will be refunded. An employee&#146;s rights under the ESPP terminate upon voluntary withdrawal from the plan or when the employee ceases employment with us for any reason. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Executive Cash Incentive Bonus Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of
directors adopted the Executive Cash Incentive Bonus Plan, or the Bonus Plan, in connection with this offering. The Bonus Plan provides for cash bonus payments based upon the attainment of performance targets established by our compensation
committee. The payment targets will be related to financial and operational measures or objectives with respect to our company, or corporate performance goals, as well as individual performance objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our compensation committee may select corporate performance goals from among the following: developmental, publication, clinical or regulatory
milestones; cash flow (including, but not limited to, operating cash flow and free cash flow); revenue; corporate revenue; earnings before interest, taxes, depreciation and amortization; net income (loss) (either before or after interest, taxes,
depreciation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
and/or amortization); changes in the market price of our common stock; economic value-added; acquisitions, licenses or strategic transactions; financing or other capital raising transactions;
operating income (loss); return on capital, assets, equity, or investment; stockholder returns; return on sales; total shareholder return; gross or net profit levels; productivity; expense efficiency; margins; operating efficiency; working capital;
earnings (loss) per share of our common stock; bookings, sales or market shares; number of prescriptions or prescribing physicians; coverage decisions; leadership development, employee retention, and recruiting and other human resources matters, any
of which may be measured in absolute terms, as compared to any incremental increase, in terms of growth, or as compared to results of a peer group. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Each executive officer who is selected to participate in the Bonus Plan will have a target bonus opportunity set for each performance period. The bonus
formulas will be adopted in each performance period by the compensation committee and communicated to each executive. The corporate performance goals will be measured at the end of each performance period after our financial reports have been
published or such other appropriate time as the compensation committee determines. If the corporate performance goals and individual performance objectives are met, payments will be made as soon as practicable following the end of each performance
period, but not later than 74 days after the end of the fiscal year in which such performance period ends. Subject to the rights contained in any agreement between the executive officer and us, an executive officer must be employed by us on the
bonus payment date to be eligible to receive a bonus payment. The Bonus Plan also permits the compensation committee to approve additional bonuses to executive officers in its sole discretion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>401(k) Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We maintain a <FONT
STYLE="white-space:nowrap">tax-qualified</FONT> retirement plan that provides eligible U.S. employees with an opportunity to save for retirement on a <FONT STYLE="white-space:nowrap">tax-advantaged</FONT> basis. Plan participants are able to defer
eligible compensation subject to applicable annual Internal Revenue Code limits. We provide a safe-harbor contribution of 3% of employee compensation to employees who satisfy the minimum service requirements. The 401(k) plan is intended to be
qualified under Section&nbsp;401(a) of the Internal Revenue Code with the 401(k) plan&#146;s related trust intended to be tax exempt under Section&nbsp;501(a) of the Internal Revenue Code. As a <FONT STYLE="white-space:nowrap">tax-qualified</FONT>
retirement plan, contributions to the 401(k) plan and earnings on those contributions are not taxable to the employees until distributed from the 401(k) plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Nonqualified Deferred Compensation </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our named
executive officers did not participate in, or earn any benefits under, a nonqualified deferred compensation plan sponsored by us during fiscal 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Other Benefits </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our named executive officers are
eligible to participate in our employee benefit plans on the same basis as our other employees, including our health and welfare plans. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><A NAME="toc155225_13"></A>DIRECTOR COMPENSATION </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT
STYLE="white-space:nowrap">Non-employee</FONT> Director Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table presents the total compensation for each person
who served as a <FONT STYLE="white-space:nowrap">non-employee</FONT> member of our board of directors during the fiscal year ended December&nbsp;31, 2021. Other than as set forth in the table and described more fully below, we did not pay any
compensation, make any equity awards or <FONT STYLE="white-space:nowrap">non-equity</FONT> awards to, or pay any other compensation to any of the <FONT STYLE="white-space:nowrap">non-employee</FONT> members of our board of directors in 2021 for
their services as members of the board of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
directors. Joshua&nbsp;B. Cohen and Justin Klee, our <FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officers, received no additional compensation for their service as directors. See
the section titled &#147;Executive Compensation&#148; for more information on the compensation paid to or earned by Messrs.&nbsp;Cohen and Klee as employees for the year ended December&nbsp;31, 2021. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned<BR>or Paid in<BR>Cash&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)&nbsp;(1)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">George Mclean Milne Jr., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Daphne Quimi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">379,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">379,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Paul Fonteyne</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">367,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">367,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Isaac Cheng, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stephen D. Chubb (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Walter Gilbert (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Felix von Coerper (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The amounts reported represent the aggregate grant date fair value of the stock options awarded to the <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors during fiscal year 2021, calculated in accordance with ASC Topic&nbsp;718. Such grant date fair value does not take into account any estimated forfeitures. The assumptions used in calculating
the grant date fair value of the awards reported in this column are set forth in the notes to our financial statements included elsewhere in this prospectus. The amounts reported in this column reflect the accounting cost for the stock options and
do not correspond to the actual economic value that may be received upon exercise of the stock options or any sale of any of the underlying shares of common stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">As of December&nbsp;31, 2021, the <FONT STYLE="white-space:nowrap">non-employee</FONT> members of our board of directors
held the following aggregate number of unexercised options: </P></TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="26%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Securities</B><br><B>Underlying&nbsp;Unexercised&nbsp;Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">George Mclean Milne Jr., Ph.D. . . . . . . . . .</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Daphne Quimi . . . . . . . . . . . . . . . .</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Paul Fonteyne . . . . . . . . . . . . . . . . .</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stephen D. Chubb . . . . . . . . . . . . . . . . .</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL">Except as set forth above, no <FONT STYLE="white-space:nowrap">non-employee</FONT> member of our board of
directors held unexercised options or unvested shares of our common stock as of December&nbsp;31, 2021. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Stephen D. Chubb resigned from our board of directors in August 2021. The board accelerated unvested options held by
Mr.&nbsp;Chubb. The amount reported in the Option Awards column includes the incremental fair value of the accelerated stock options as of the modification date, which was $13,440. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Walter Gilbert resigned from our board of directors in April 2021. In connection with his resignation, the board amended
options held by Mr.&nbsp;Chubb to accelerate all unvested options and to extend the post-termination exercise period to ten years following the date of grant. No additional incremental fair value was recognized by the Company in connection with this
modification. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Felix von Coerper resigned from our board of directors in December 2021. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with this offering, our board of directors has adopted a new <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation
policy that will become effective upon the effectiveness of the registration statement of which this prospectus is a part. The policy is designed to enable us to attract and retain, on a long-term </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
basis, highly qualified <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. Under the policy, each director who is not an employee will be paid cash compensation from and after the
completion of this offering as set forth below: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Annual<BR>Retainer</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Board of Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Retainer for chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Audit Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Retainer for chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Compensation Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Retainer for chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Nominating and Corporate Governance Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 4,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Retainer for chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 8,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy will provide
that, upon initial election to our board of directors, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will be granted an equity award of stock options to purchase 38,000 shares (the &#147;Initial Grant&#148;). The Initial Grant
will vest in <FONT STYLE="white-space:nowrap">one-third</FONT> on the first anniversary of the date of grant, and the remaining <FONT STYLE="white-space:nowrap">two-thirds</FONT> will vest in equal monthly installments over two years, provided,
however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to service as our director. Furthermore, on the date of each of our annual meeting of stockholders upon the completion of this offering,
each <FONT STYLE="white-space:nowrap">non-employee</FONT> director who continues as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director following such meeting will be granted an annual equity award of stock options, to purchase 19,000
shares (the &#147;Annual Grant&#148;). The Annual Grant will vest in full upon the earlier of (i)&nbsp;the first anniversary of the date of grant or (ii)&nbsp;the date of the next annual meeting; provided, however, that all vesting shall cease if
the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board of directors determines that the circumstances warrant continuation of vesting. In addition, all vested options remain exercisable for
twelve (12)&nbsp;months if the director resigns from the board of directors or otherwise ceases to serve as a director. Notwithstanding the foregoing, if an outside director was initially elected to the board of directors within twelve
(12)&nbsp;months preceding the annual meeting, then such outside director shall receive an Annual Grant that is <FONT STYLE="white-space:nowrap">pro-rated</FONT> on a monthly basis for time serving as an outside director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors approved the grant of options to purchase 8,400 shares of stock to each of George Mclean Milne&nbsp;Jr., Paul Fonteyne, Isaac
Cheng and Daphne Quimi, which will be effective upon our initial public offering, or the Director IPO Grants. 100% of the shares underlying the Director IPO Grants will vest on the date of our 2022 annual meeting of stockholders, subject to the
director&#146;s continued service through the vesting date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc155225_14"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Other than the compensation agreements and other arrangements described under &#147;Executive Compensation&#148; and &#147;Director Compensation&#148;
in this prospectus and the transactions described below, since January&nbsp;1, 2018, there has not been and there is not currently proposed, any transaction or series of similar transactions to which we were, or will be, a party in which the amount
involved exceeded, or will exceed, $120,000 and in which any director, executive officer, holder of five percent or more of any class of our capital stock or any member of the immediate family of, or entities affiliated with, any of the foregoing
persons, had, or will have, a direct or indirect material interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe the terms obtained or consideration that we paid or received, as
applicable, in connection with the transactions described below were comparable to terms available or the amounts that we would pay or receive, as applicable, in <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2018 Convertible Promissory Note Financing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November 2018,
we issued and sold convertible promissory notes to various investors, or the 2018 Notes in the aggregate principal amount of approximately $13.0 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The table below sets forth the principal amount of 2018 Notes purchased by related parties. In connection with the sale of our Series B preferred stock
in June 2020, all such outstanding notes converted into Series B preferred stock in accordance with their terms. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cash Purchase<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>of Series B<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">ALS Invest 1 B.V. (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,963,968.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,417,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Morningside Venture Investments Limited (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,963,968.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,417,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stephen D. Chubb (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">220,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">George Mclean Milne Jr, Ph.D. (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">220,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Walter Gilbert (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,467,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,205,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">ALS Invest 1 B.V. holds more than 5% of our voting securities. Felix von Coerper, who served as a member of our board of
directors until December 2021, is a Managing Partner at ALS Investment Fund, an investment fund that is affiliated with ALS Invest 1 B.V. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Morningside Venture Investments Limited holds more than 5% of our voting securities. Isaac Cheng, M.D., a member of our
board of directors, is an investment professional at the Morningside Technology Advisory, LLC, a company that is affiliated with Morningside Venture Investments Limited. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Stephen D. Chubb was a member of our board of directors until his resignation in August 2021. </P></TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">George Mclean Milne Jr, Ph.D. is a member of our board of directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Walter Gilbert was a member of our board of directors until his resignation in April 2021. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2020 Convertible Promissory Note Financing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From January 2020
to April 2020, we issued and sold convertible promissory notes to various investors, or the 2020 Notes, in the aggregate principal amount of approximately $15.4 million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The table below sets forth the principal amount of 2020 Notes purchased by related parties. In
connection with the sale of our Series B preferred stock in June 2020, all such outstanding notes converted into Series B preferred stock in accordance with their terms. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cash Purchase<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>of Series B<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Morningside Venture Investments Limited (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,644,025.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stephen D. Chubb (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">250,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">George Mclean Milne Jr, Ph.D. (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">650,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Walter Gilbert (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">250,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,794,025.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">316,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Morningside Venture Investments Limited holds more than 5% of our voting securities. Isaac Cheng, M.D., a member of our
board of directors, is an investment professional at the Morningside Technology Advisory, LLC, a company that is affiliated with Morningside Venture Investments Limited. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Stephen D. Chubb was a member of our board of directors until his resignation in August 2021. </P></TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">George Mclean Milne Jr, Ph.D. is a member of our board of directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Walter Gilbert was a member of our board of directors until his resignation in April 2021. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Series&nbsp;B Preferred Stock Financing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In June 2020, we
issued and sold an aggregate of 14,496,835 shares of Series B preferred stock at a price per share of $16.974077, for an aggregate purchase price of approximately $64.4&nbsp;million. Included in this amount was approximately $34.4&nbsp;million of
outstanding principal and interest on convertible promissory notes issued between July 2017 and April 2020, including the 2017 Notes, 2018 Notes, 2019 Notes and 2020 Notes, all of which converted into Series B preferred stock in this financing in
accordance with their terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth the aggregate cash purchase price of the Series&nbsp;B preferred stock purchased by our
directors, executive officers and 5% stockholders and their affiliates and the number of shares of our Series B preferred stock issued in consideration of such amounts. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cash Purchase<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>of Series B<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Morningside Venture Investments Limited (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,536,127.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,563,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">George Mclean Milne Jr, Ph.D. (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">200,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,736,127.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,575,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Morningside Venture Investments Limited holds more than 5% of our voting securities. Isaac Cheng, M.D., a member of our
board of directors, is an investment professional at the Morningside Technology Advisory, LLC, a company that is affiliated with Morningside Venture Investments Limited. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">George Mclean Milne Jr, Ph.D. is a member of our board of directors. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth the aggregate principal and interest under the 2017 Notes, 2018 Notes,
and 2020 Notes converted by ALS Invest 1 B.V., Morningside Venture Investments Limited, Stephen D. Chubb, George Mclean Milne Jr, Ph.D. and Walter Gilbert, respectively, as our 5% stockholder, director, or executive officer, and the number of shares
of our Series B preferred stock issued upon conversion of such securities. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal&nbsp;and<BR>Interest</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares&nbsp;of<BR>Series&nbsp;B&nbsp;Preferred&nbsp;Stock<BR>Received Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">ALS Invest 1 B.V. (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,203,147.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,178,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Morningside Venture Investments Limited (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,446,627.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,986,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stephen D. Chubb (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">610,181.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">285,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">George Mclean Milne Jr, Ph.D. (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,022,105.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">321,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Walter Gilbert (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">449,919.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,731,980.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,944,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">ALS Invest 1 B.V. holds more than 5% of our voting securities. Felix von Coerper, who served as a member of our board of
directors until December 2021, is a Managing Partner at ALS Investment Fund, an investment fund that is affiliated with ALS Invest 1 B.V. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Morningside Venture Investments Limited holds more than 5% of our voting securities. Isaac Cheng, M.D., a member of our
board of directors, is an investment professional at the Morningside Technology Advisory, LLC, a company that is affiliated with Morningside Venture Investments Limited. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Stephen D. Chubb was a member of our board of directors until his resignation in August 2021. </P></TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">George Mclean Milne Jr, Ph.D. is a member of our board of directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Walter Gilbert was a member of our board of directors until his resignation in April 2021. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2021 Convertible Promissory Note Financing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In January 2021,
we issued and sold convertible promissory notes to various investors, or the 2021 Notes, in the aggregate principal amount of approximately $27.3 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The
table below sets forth the principal amount of 2021 Notes purchased by related parties. In connection with the sale of our Series C preferred stock in July 2021, all such outstanding notes converted into Series C-2 preferred stock in accordance with
their terms. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cash Purchase<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>of Series C-2<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Morningside Venture Investments Limited (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,972,064.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,621,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">George Mclean Milne Jr, Ph.D. (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">200,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Walter Gilbert (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,272,064.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,656,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Morningside Venture Investments Limited holds more than 5% of our voting securities. Isaac Cheng, M.D., a member of our
board of directors, is an investment professional at the Morningside Technology Advisory, LLC, a company that is affiliated with Morningside Venture Investments Limited. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">George Mclean Milne Jr, Ph.D. is a member of our board of directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Walter Gilbert was a member of our board of directors until his resignation in April 2021. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Series C Preferred Stock Financing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In July 2021, we issued and sold an aggregate of 13,150,430 shares of Series C-1 preferred stock at a price per share of $10.265809 and 3,170,585 shares
of Series C-2 preferred stock at a price per share of $8.725938, for an aggregate purchase price of approximately $162.7 million. Included in this amount was approximately $27.7 million of outstanding principal and interest on the 2021 Notes,all of
which converted into Series C-2 preferred stock in this financing in accordance with their terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth the aggregate cash
purchase price of the Series C-1 preferred stock purchased by our directors, executive officers and 5% stockholders and their affiliates and the number of shares of our Series C-1 preferred stock issued in consideration of such amounts. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cash&nbsp;Purchase<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>of Series C-1<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Morningside Venture Investments Limited (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,999,996.41 </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">974,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Viking Global Opportunities Illiquid Investments Sub-Master LP (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,999,992.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,870,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">George Mclean Milne Jr, Ph.D. (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199,998.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Justin B. Klee (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,994.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Joshua B. Cohen (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,994.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60,299,976.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,873,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Morningside Venture Investments Limited, which includes MVIL, LLC, a <FONT STYLE="white-space:nowrap">wholly-owned</FONT>
subsidiary of Morningside Venture Investments Limited, holds more than 5% of our voting securities. Isaac Cheng, M.D., a member of our board of directors, is an investment professional at the Morningside Technology Advisory, LLC, a company that is
affiliated with Morningside Venture Investments Limited. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Viking Global Opportunities Illiquid Investments Sub-Master LP holds more than 5% of our voting securities and has the
contractual right to designate a director to our board of directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">George Mclean Milne Jr, Ph.D. is a member of our board of directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Justin B. Klee is our Co-Chief Executive Officer and a member of our board of directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Joshua B. Cohen is our Co-Chief Executive Officer and a member of our board of directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth the aggregate principal and interest under the 2021 Notes converted by Morningside Venture Investments Limited, Stephen
D. Chubb, George Mclean Milne Jr, Ph.D. and Walter Gilbert, respectively, as our 5% stockholder, director, or executive officer, and the number of shares of our Series C-2 preferred stock issued upon conversion of such securities. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal and<BR>Interest</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares&nbsp;of<BR>Series C-2 Preferred<BR>Stock&nbsp;Received&nbsp;Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Morningside Venture Investments Limited (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,149,489.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,621,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">George Mclean Milne Jr, Ph.D. (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">202,547.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Walter Gilbert (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">101,273.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,453,311.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,656,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Morningside Venture Investments Limited, which includes MVIL, LLC, a <FONT STYLE="white-space:nowrap">wholly-owned</FONT>
subsidiary of Morningside Venture Investments Limited holds more than 5% of our voting securities. Isaac Cheng, M.D., a member of our board of directors, is an investment professional at the Morningside Technology Advisory, LLC, a company that is
affiliated with Morningside Venture Investments Limited. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">George Mclean Milne Jr, Ph.D. is a member of our board of directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Walter Gilbert was a member of our board of directors until his resignation in April 2021. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investors&#146; Rights Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a party to an amended and restated investors&#146; rights agreement, dated as of July&nbsp;1, 2021, or investors&#146; rights agreement, with
holders of our preferred stock, including some of our 5% stockholders and entities affiliated with our directors. Such holders consisted of entities affiliated with ALS Invest 1 B.V. Morningside Venture Investments Limited and Viking Global
Opportunities Illiquid Investments Sub-Master LP , each a 5% stockholder. Each of ALS Invest 1 B.V. and Morningside Venture Investments Limited has appointed representatives to our board of directors. The investor rights agreement provides these
holders the right, following the completion of this offering, to demand that we file&nbsp;a registration statement or request that their shares be covered by a registration statement that we are otherwise filing. See &#147;Description of Capital
Stock&#151;Registration Rights&#148; for additional information regarding these registration rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Voting Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a party to an amended and restated voting agreement, dated as of July&nbsp;1, 2021, or voting agreement, with holders of our preferred stock,
including some of our 5% stockholders and entities affiliated with our directors. Such holders consisted of entities affiliated with ALS Invest 1 B.V. and Morningside Venture Investments Limited, each a 5% stockholder. Each of ALS Invest 1 B.V. and
Morningside Venture Investments Limited have appointed representatives to our board of directors. The voting agreement provides the holders the right to elect certain directors to the Board. Pursuant to the voting agreement, we agreed to appoint to
our board of directors one representative designated by ALS Invest 1 B.V., Felix von Coerper, one representative designated by Morningside Venture Investments Limited, Isaac S. Cheng, and one representative designated by Viking Global Opportunities
Illiquid Investments Sub-Master LP, who will be named at a subsequent date. The voting agreement will terminate upon completion of this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Right of First
Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a party to an amended and restated right of first refusal and <FONT
STYLE="white-space:nowrap">co-sale</FONT> agreement, dated as of July&nbsp;1, 2021, or right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreement, with holders of our preferred stock, including some of our 5% stockholders
and entities affiliated with our directors. Such holders consisted of entities affiliated with ALS Invest 1 B.V. Morningside Venture Investments Limited and Viking Global Opportunities Illiquid Investments Sub-Master LP, each a 5% stockholder. Each
of ALS Invest 1 B.V. and Morningside Venture Investments Limited have appointed representatives to our board of directors. The right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreement provides the key holders, as defined
in the right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreement, the right to purchase all or any portion of transfer stock, as defined in the right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT>
agreement, as well as the right of <FONT STYLE="white-space:nowrap">co-sale</FONT> and to participate in any proposed transfers. The agreement will terminate upon completion of this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employment Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">See the &#147;Executive
Compensation&#151;Agreements with Our Named Executive Officers&#148; section of this prospectus for a further discussion of these arrangements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Indemnification
Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our certificate of incorporation that will become effective as of the closing date of this offering provides that we will indemnify
our directors and officers to the fullest extent permitted by Delaware law. In addition, we plan to enter into indemnification agreements with each of our officers and directors that may be broader in scope than the specific indemnification
provisions contained in the Delaware General Corporation Law. See &#147;Executive Compensation&#151;Limitations on Liability and Indemnification&#148; for additional information regarding these agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Directed Share Program </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">At our request, the underwriters have reserved for sale at the initial public offering price up to five&nbsp;percent of the shares of common stock
offered by this prospectus to certain individuals and entities through a directed share program, including some of our directors, executive officers, employees, business associates and related persons. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Policies and Procedures for Related Person Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our
board of directors reviews and approves transactions with directors, officers and holders of 5% or more of our voting securities and their affiliates, each a related party. Prior to this offering, the material facts as to the related party&#146;s
relationship or interest in the transaction are disclosed to our board of directors prior to their consideration of such transaction, and the transaction is not considered approved by our board of directors unless a majority of the directors who are
not interested in the transaction approve the transaction. Further, when stockholders are entitled to vote on a transaction with a related party, the material facts of the related party&#146;s relationship or interest in the transaction are
disclosed to the stockholders, who must approve the transaction in good faith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with this offering, we have adopted a written related
party transactions policy that such transactions must be approved by our audit committee. This policy will become effective on the date on which the registration statement of which this prospectus is part is declared effective by the SEC. Pursuant
to this policy, the audit committee has the primary responsibility for reviewing and approving or disapproving &#147;related party transactions,&#148; which are transactions between us and related persons in which the aggregate amount involved
exceeds or may be expected to exceed $120,000 and in which a related person has or will have a direct or indirect material interest. For purposes of this policy, a related person will be defined as a director, executive officer, nominee for
director, or greater than 5% beneficial owner of our common stock, in each case since the beginning of the most recently completed year, and their immediate family members. Our audit committee charter will provide that the audit committee shall
review and approve or disapprove any related party transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc155225_15"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth information with respect to the beneficial ownership of our common stock as of December 13, 2021 by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each of our directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">all of our directors and executive officers as a group; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common stock.
</P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The column entitled &#147;Percentage of Shares Beneficially Owned&#151;Before Offering&#148; is based on a total of
46,488,975 shares of our common stock outstanding as of December 13, 2021, assuming the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 39,474,330 shares of our common stock upon the closing of this
offering. The column entitled &#147;Percentage of Shares Beneficially Owned&#151;After Offering&#148; is based on 55,238,975 shares of our common stock to be outstanding after this offering, including the 8,750,000 shares of our common stock that we
are selling in this offering, but not including any additional shares issuable upon exercise of outstanding options, any exercise by the underwriters of their option to purchase additional shares, or any purchases that may be made through our
directed share program or otherwise in this offering. See &#147;Underwriting&#151;Directed Share Program.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Beneficial ownership is
determined in accordance with the rules and regulations of the SEC and includes voting or investment power with respect to our common stock. Shares of our common stock subject to options that are currently exercisable or exercisable within
60&nbsp;days after December 13, 2021 are considered outstanding and beneficially owned by the person holding the options for the purpose of calculating the percentage ownership of that person but not for the purpose of calculating the percentage
ownership of any other person. Except as otherwise noted, the persons and entities in this table have sole voting and investment power with respect to all of the shares of our common stock beneficially owned by them, subject to community property
laws, where applicable. Except as otherwise set forth below, the address of the beneficial owner is c/o Amylyx Pharmaceuticals, Inc., 43 Thorndike St., Cambridge, MA 02141. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of&nbsp;Shares&nbsp;Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Beneficially&nbsp;Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B><I>5% Stockholders</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Morningside Venture Investments Limited<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,415,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">ALS Invest 1 B.V.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,955,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Viking Global Opportunities Illiquid Investments Sub-Master
LP<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,870,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B><I>Named Executive Officers and Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Joshua Cohen<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,864,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Justin Klee<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,864,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">James Frates<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Margaret Olinger<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Patrick D. Yeramian, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">George Mclean Milne Jr, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">885,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Isaac Cheng, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Paul Fonteyne</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Daphne Quimi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I>All Current Executive Officers and Directors as a Group (ten persons)</I><SUP
STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,109,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Represents beneficial ownership of less than 1% of our outstanding stock. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of (i) 8,794,106 shares of common stock issuable upon conversion of convertible preferred stock held by
Morningside Venture Investments Limited, or Morningside, and (ii)&nbsp;1,621,544 shares of common stock issuable upon conversion of preferred stock held by MVIL, LLC, a wholly-owned subsidiary of Morningside. Cheung Ka Ho, Frances Anne Elizabeth
Richard, Peter Stuart Allenby Edwards and Jill Marie Franklin are directors of Morningside, and may be deemed to have joint voting and dispositive power with respect to the shares held by Morningside. Each of Mr.&nbsp;Cheung, Ms.&nbsp;Richard,
Mr.&nbsp;Edwards and Ms.&nbsp;Franklin disclaim beneficial ownership of the shares held by Morningside. The address of Morningside is 2nd&nbsp;Floor, Le Prince de Galles, 3-5 Avenue Citronniers, MC 98000, Monaco. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of 5,955,889 shares of common stock issuable upon conversion of convertible preferred stock held by ALS Invest 1
B.V., or ALS. ALS is managed by SUNU Ventures BV. Felix-Andr&#233; von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the shares held by ALS. The address for ALS and SUNU Ventures BV
is Eerste Weteringdwarsstraat 54E, 1017 TP Amsterdam, The&nbsp;Netherlands. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of 4,870,536 shares of common stock issuable upon conversion of convertible preferred stock held by Viking
Global Opportunities Illiquid Investments Sub-Master LP, or Opportunities Fund. Opportunities Fund has the authority to dispose of and vote the shares directly owned by it, which power may be exercised by its general partner, Viking Global
Opportunities Portfolio&nbsp;GP LLC, or Opportunities GP, and by Viking Global Investors LP, or VGI, which provides managerial services to Opportunities Fund. O. Andreas Halvorsen, David C. Ott and Rose Shabet, as Executive Committee members of
Viking Global Partners LLC (the general partner of VGI) and Viking Global Opportunities Parent GP LLC (the sole member of Viking Global Opportunities&nbsp;GP LLC, which is the sole member of Opportunities GP), have shared authority to direct the
voting and disposition of investments beneficially owned by Opportunities Fund and Opportunities&nbsp;GP. The address of each of the entities is c/o Viking Global Investors LP, 55&nbsp;Railroad Avenue, Greenwich, CT 06830. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of (i)&nbsp;2,484,195 shares of common stock, (ii)&nbsp;4,870 shares of common stock issuable upon conversion of
convertible preferred stock and (iii)&nbsp;375,475 shares of common stock underlying stock options exercisable within 60 days of December&nbsp;13, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of (i)&nbsp;2,484,195 shares of common stock, (ii)&nbsp;4,870 shares of common stock issuable upon conversion of
convertible preferred stock and (iii)&nbsp;375,475 shares of common stock underlying stock options exercisable within 60 days of December&nbsp;13, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of 113,024 shares of common stock underlying stock options exercisable within 60 days of December 13, 2021.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of (i) 176,741 shares of common stock and (ii)&nbsp;12,105 shares of common stock underlying stock options
exercisable within 60 days of December&nbsp;13, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of (i) 178,000 shares of common stock and (ii)&nbsp;15,506 shares of common stock underlying stock options
exercisable within 60 days of December&nbsp;13, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of (i)&nbsp;194,081 shares of common stock, (ii)&nbsp;689,425 shares of common stock issuable upon conversion of
convertible preferred stock and (iii)&nbsp;2,000 shares of common stock underlying stock options exercisable within 60 days of December&nbsp;13, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Dr. Cheng, a member of our board of directors, is an investment professional at Morningside Technology Advisory, LLC, an
indirect advisor to Morningside Venture Investments Limited and MVIL, LLC. Dr.&nbsp;Cheng has no voting or dispositive power over the shares held by the Morningside shareholder entities and therefore disclaims beneficial ownership of all shares
referred to in Footnote&nbsp;1 above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">See footnotes 4 through 10 above. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc155225_16"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>The following descriptions are summaries of the material terms of our amended and restated certificate of incorporation, which will be effective
prior to the closing of this offering and amended and restated bylaws, which will be effective upon the effectiveness of the registration statement of which this prospectus is a part. The descriptions of the common stock and preferred stock give
effect to changes to our capital structure that will occur immediately prior to the completion of this offering. We refer in this section to our amended and restated certificate of incorporation as our certificate of incorporation, and we refer to
our amended and restated bylaws as our bylaws</I>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon completion of this offering, our authorized capital stock will consist of 300,000,000&nbsp;shares of common stock, par value $0.0001 per share, and
10,000,000&nbsp;shares of preferred stock, par value $0.0001 per share, all of which shares of preferred stock will be undesignated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of November
30, 2021, 6,991,683 shares of our common stock, 6,289,609 shares of our Series A preferred stock, 14,496,835 shares of our Series&nbsp;B preferred stock, 13,150,430 shares of our Series C-1 preferred stock and 3,170,585 shares of our Series C-2
preferred stock were outstanding and held by 126 stockholders of record. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our
common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend
rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in all assets remaining after
payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock. The shares to be issued by us in this offering will be, when issued and paid for, validly issued, fully paid and <FONT
STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Preferred Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon the completion of this offering, all outstanding shares of our preferred stock will be converted into shares of our common stock. Upon the
consummation of this offering, our board of directors will have the authority, without further action by our stockholders, to issue up to 10,000,000&nbsp;shares of preferred stock in one or more series and to fix the rights, preferences, privileges
and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the
designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive
dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. Immediately after consummation
of this offering, no shares of preferred stock will be outstanding, and we have no present plan to issue any shares of preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon the completion of this offering, the holders of 45,196,305 shares of our common stock, including those issuable upon the conversion of preferred
stock, will be entitled to rights with respect to the registration of these securities under the Securities Act. These rights are provided under the terms of an amended and restated investors&#146; rights agreement, or the investors&#146; rights
agreement, between us and holders of our preferred stock. The investors&#146; rights agreement includes demand registration rights, short-form registration rights and piggyback registration rights. All fees, costs and expenses of underwritten
registrations under this agreement will be borne by us and all selling expenses, including underwriting discounts and selling commissions, will be borne by the holders of the shares being registered. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Demand Registration Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Beginning 180&nbsp;days
after the effective date of this registration statement, the holders of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, including those issuable
upon the conversion of preferred stock, are entitled to demand registration rights. Under the terms of the investors&#146; rights agreement, we will be required, upon the written request of the holders of at least 25% of our outstanding registrable
securities, as defined in the investors&#146; rights agreement, or a lesser percent if the total amount of registrable shares requested to be registered has an anticipated aggregate offering price to the public, net of selling expenses, of least
$15.0&nbsp;million, to file&nbsp;a registration statement and use commercially reasonable efforts to effect the registration of all or a portion of their registrable securities for public resale. We are required to effect only two registrations
pursuant to this provision of the investors&#146; rights agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Short-Form Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the investor rights agreement, if we are eligible to file&nbsp;a registration statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-3,</FONT> upon the written request of the holders of at least 10% of our outstanding registrable securities, as defined in the investors&#146; rights agreement, may demand in writing that we register
their registrable securities under the Securities Act so long as the total amount of registrable shares requested to be registered has an anticipated aggregate offering price to the public, net of selling expenses, of least $3.0&nbsp;million. We are
required to effect only two registrations in any twelve month period pursuant to this provision of the investors&#146; rights agreement. The right to have such shares registered on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> is further
subject to other specified conditions and limitations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the investors&#146; rights agreement, if we register any of our securities either for our own account or for the account of other security
holders, the holders of these shares are entitled to include their shares in the registration. Subject to certain exceptions contained in the investors&#146; rights agreement, we and the underwriters may limit the number of shares included in the
underwritten offering to the number of shares which we and the underwriters determine in our sole discretion will not jeopardize the success of the offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Indemnification </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our investor rights agreement
contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of registrable securities in the event of material misstatements or omissions in the registration statement attributable to us, and they are
obligated to indemnify us for material misstatements or omissions attributable to them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Expiration of Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The demand registration rights and short form registration rights granted under the investor rights agreement will terminate on the fifth anniversary of
the completion of this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Anti-Takeover Effects of our Certificate of Incorporation and Bylaws and Delaware Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our certificate of incorporation and bylaws include a number of provisions that may have the effect of delaying, deferring or preventing another party
from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue <FONT STYLE="white-space:nowrap">non-negotiated</FONT>
takeover attempts. These provisions include the items described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Board Composition and Filling Vacancies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our certificate of incorporation provides for the division of our board of directors into three classes serving staggered three-year terms, with one
class being elected each year. Our certificate of incorporation also provides that directors may be removed only for cause and then only by the affirmative vote of the holders of <FONT STYLE="white-space:nowrap">66-2/3%</FONT> or more of the shares
then entitled to vote at an election of directors. Further, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled by the affirmative vote of a majority
of our directors then in office even if less than a quorum. The classification of directors, together with the limitations on removal of directors and treatment of vacancies, has the effect of making it more difficult for stockholders to change the
composition of our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>No Written Consent of Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our certificate of incorporation provides that all stockholder actions are required to be taken by a vote of the stockholders at an annual or special
meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our bylaws or removal of directors by
our stockholders without holding a meeting of stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Meetings of Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our certificate of incorporation and bylaws provide that only a majority of the members of our board of directors then in office may call special
meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our bylaws limit the business that may be conducted at an annual meeting of
stockholders to those matters properly brought before the meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Advance Notice Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or
new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken.
Generally, to be timely, notice must be received at our principal executive offices not less than 90&nbsp;days nor more than 120&nbsp;days prior to the first anniversary date of the annual meeting for the preceding year. Our bylaws specify the
requirements as to form and content of all stockholders&#146; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Amendment to Certificate of Incorporation and Bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any amendment of our certificate of incorporation must first be approved by a majority of our board of directors, and if required by law or our
certificate of incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment
of the provisions relating to stockholder action, board composition, limitation of liability and the amendment of our bylaws and certificate of incorporation must be approved by not less than <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the
outstanding shares entitled to vote on the amendment, and not less than 66-2/3% of the outstanding shares of each class entitled to vote thereon as a class. Our bylaws may be amended by the affirmative vote of a majority of the directors then in
office, subject to any limitations set forth in the bylaws; and may also be amended by the affirmative vote of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the outstanding shares entitled to vote on the amendment, or, if our board of
directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Undesignated Preferred Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our certificate of
incorporation will provide for 10,000,000 authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to discourage an attempt to obtain control of us by means of a
merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of
directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or
stockholder group. In this regard, our certificate of incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock
could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of
delaying, deterring or preventing a change in control of us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Exclusive Jurisdiction for Certain Actions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our bylaws provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and
exclusive forum for (i)&nbsp;any derivative action or proceeding brought on our behalf, (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers and employees to us or our stockholders,
(iii)&nbsp;any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our bylaws, or (iv)&nbsp;any action asserting a claim that is governed by the internal affairs
doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein. Although we believe this provision benefits us by providing increased consistency in the application of
Delaware law in the types of lawsuits to which it applies, the provision may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar exclusive forum provisions in other companies&#146; bylaws has
been challenged in legal proceedings, and it is possible that a court could rule that this provision in our bylaws is inapplicable or unenforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our bylaws also provide that the United States Federal District Courts will be the exclusive forum for resolving any complaint asserting a cause of
action arising under the Securities Act or the Exchange Act, unless we consent in writing to an alternative forum, is intended to allow for the consolidation of multi-jurisdiction litigation, avoid state court forum shopping, provide efficiencies in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
managing the procedural aspects of securities litigation and reduce the risk that the outcome of cases in multiple jurisdictions could be inconsistent. Although our bylaws contain the choice of
forum provisions described above, it is possible that a court could rule that such provisions are inapplicable for a particular claim or action or that such provisions are unenforceable. For example, under the Securities Act, federal courts have
concurrent jurisdiction over all suits brought to enforce any duty or liability created by the Securities Act, and investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Section&nbsp;203 of the Delaware General Corporation Law </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon completion of this offering, we will be subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law. In general,
Section&nbsp;203 prohibits a publicly held Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a three-year period following the time that this stockholder becomes an interested
stockholder, unless the business combination is approved in a prescribed manner. Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">before the stockholder became interested, our board of directors approved either the business combination or the
transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested
stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers,
and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">at or after the time the stockholder became interested, the business combination was approved by our board of directors and
authorized at an annual or special meeting of the stockholders by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL">Section&nbsp;203 defines a business combination to include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; any sale, transfer, lease, pledge or
other disposition involving the interested stockholder of 10% or more of the assets of the corporation; subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the
interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share
of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial
benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In general, Section&nbsp;203 defines an interested stockholder as any entity or
person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Exchange Listing </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have applied to list our common stock
on the Nasdaq Global Market under the trading symbol &#147;AMLX.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The transfer agent and registrar for our common stock will be Computershare Trust Company, N.A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc155225_17"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to this offering, there has been no public market for our shares. Future sales of our common stock in the public market, or the availability of
such shares for sale in the public market, could adversely affect market prices prevailing from time to time. As described below, only a limited number of shares will be available for sale shortly after this offering due to contractual and legal
restrictions on resale. Nevertheless, sales of our common stock in the public market after such restrictions lapse, or the perception that those sales may occur, could adversely affect the prevailing market price at such time and our ability to
raise equity capital in the future. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on the number of shares outstanding as of November 30, 2021, upon the completion of this offering
55,216,013 shares of our common stock will be outstanding, assuming the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 39,474,330 shares of our common stock upon the closing of this offering, no exercise
of the underwriters&#146; option to purchase additional shares and no exercise of outstanding options. Of the outstanding shares, all of the shares sold in this offering will be freely tradable, except that any shares held by our affiliates, as that
term is defined in Rule&nbsp;144 under the Securities Act, may only be sold in compliance with the limitations described below, and any shares purchased in the directed share program described below and in &#147;Underwriting&#148; by our executive
officers and directors and other parties subject to the lock-up agreements described below will be subject to lock-up restrictions as described below. All remaining shares of common stock held by existing stockholders immediately prior to the
completion of this offering will be &#147;restricted securities&#148; as such term is defined in Rule 144. These restricted securities were issued and sold by us, or will be issued and sold by us, in private transactions and are eligible for public
sale only if registered under the Securities Act or if they qualify for an exemption from registration under the Securities Act, including the exemptions provided by Rule 144 or Rule 701, summarized below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, at our request, the underwriters have reserved up to 5% of the shares of common stock offered for sale pursuant to this prospectus for sale
to some of our directors, executive officers, employees, business associates and related persons in a directed share program. The number of shares freely transferable upon completion of this offering will be reduced by the number of directed shares
purchased by our executive officers and directors and other parties subject to the lock-up agreements described below, and there will be a corresponding increase in the number of shares that become eligible for sale after 180 days from the date of
this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule&nbsp;144 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In general, under
Rule&nbsp;144, beginning 90&nbsp;days after the date of this prospectus, any person who is not our affiliate and has not been our affiliate at any time during the preceding three months and has held their shares for at least six months, including
the holding period of any prior owner other than one of our affiliates, may sell shares without restriction, subject to the availability of current public information about us. In addition, under Rule&nbsp;144, any person who is not our affiliate
and has not been our affiliate at any time during the preceding three months and has held their shares for at least one year, including the holding period of any prior owner other than one of our affiliates, would be entitled to sell an unlimited
number of shares immediately upon the closing of this offering without regard to whether current public information about us is available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Beginning 90&nbsp;days after the date of this prospectus, a person who is our affiliate or who was our affiliate at any time during the preceding three
months may sell any unrestricted securities, as well as restricted securities that the person has beneficially owned for at least six months, including the holding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
period of any prior owner other than one of our affiliates, under Rule&nbsp;144. Affiliates selling restricted or unrestricted securities may sell a number of shares within
any&nbsp;three-month&nbsp;period that does not exceed the greater of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1% of the number of shares then outstanding, which will equal approximately 552,160 shares immediately after this offering,
assuming no exercise of the underwriters&#146; option to purchase additional shares; or </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the average weekly trading volume of our common stock on the Nasdaq Global Market during the four calendar weeks preceding
the filing of a notice on Form&nbsp;144 with respect to the sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Sales under Rule&nbsp;144 by our affiliates are also subject to
manner of sale provisions and notice requirements and to the availability of current public information about us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule&nbsp;701 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In general, under Rule&nbsp;701 of the Securities Act, any of our employees, consultants or advisors, other than our affiliates, who purchased shares
from us in connection with a qualified compensatory stock plan or other written agreement is eligible to resell these shares 90&nbsp;days after the date of this prospectus in reliance on Rule&nbsp;144, but without compliance with the holding period
requirements of Rule&nbsp;144 and without regard to the volume of such sales or the availability of public information about us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">However,
substantially all Rule&nbsp;701 shares are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements as described below and under &#147;Underwriting&#148; included elsewhere in this prospectus and will become eligible for sale upon the
expiration of the restrictions set forth in those agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">All of our directors and executive officers and substantially all of our stockholders have signed a <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreement which prevents them from selling any of our common stock or any securities convertible into or exercisable or exchangeable for common stock for a period of not less than 180&nbsp;days from the date of this prospectus without the prior
written consent of Goldman Sachs&nbsp;&amp; Co. LLC, SVB Leerink LLC and Evercore Group L.L.C., subject to certain exceptions. See the section entitled &#147;Underwriting&#148; appearing elsewhere in this prospectus for more information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon completion of this offering,
certain holders of our securities will be entitled to various rights with respect to registration of their shares under the Securities Act.&nbsp;Registration of these shares under the Securities Act would result in these shares becoming fully
tradable without restriction under the Securities Act immediately upon the effectiveness of the registration.&nbsp;See the section entitled &#147;Description of Capital Stock&#151;Registration Rights&#148; appearing elsewhere in this prospectus for
more information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Equity Incentive Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We intend to
file one or more registration statements on <FONT STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> under the Securities Act to register our shares issued or reserved for issuance under our equity incentive plans. The first such registration statement
is expected to be filed soon after the date of this prospectus and will automatically become effective upon filing with the SEC. Accordingly, shares registered under such registration statement will be available for sale in the open market, unless
such shares are subject to vesting restrictions with us or the <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc155225_18"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>FOR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS OF COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following discussion is a summary of certain U.S. federal income tax considerations applicable to <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holders (as defined below) with respect to their ownership and disposition of shares of our common stock issued pursuant to this offering. For purposes of this discussion, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder means a beneficial
owner of our common stock that is for U.S. federal income tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a <FONT STYLE="white-space:nowrap">non-resident</FONT> alien individual; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a corporation or any other organization taxable as a corporation for U.S. federal income tax purposes that is created or
organized in or under laws other than the laws of the United States, any state thereof, or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an estate, the income of which is not subject to U.S. federal income tax on a net income basis; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a trust that (1) has not made an election to be treated as a U.S. person under applicable U.S. Treasury Regulations and (2)
either (i) is not subject to the primary supervision of a court within the United States or (ii) is not subject to the substantial control of one or more U.S. persons. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This discussion does not address the tax treatment of partnerships or other entities that are pass-through entities for U.S. federal income tax purposes
or persons that hold their common stock through partnerships or other pass-through entities. A partner in a partnership or other pass-through entity that will hold our common stock should consult his, her or its tax advisor regarding the tax
consequences of holding and disposing of our common stock through a partnership or other pass-through entity, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This discussion is
based on current provisions of the U.S. Internal Revenue Code of 1986, as amended, or the Code, existing and proposed U.S. Treasury Regulations promulgated thereunder, current administrative rulings and judicial decisions, all as in effect as of the
date of this prospectus and, all of which are subject to change or to differing interpretation, possibly with retroactive effect. Any such change or differing interpretation could alter the tax consequences to
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders described in this prospectus. There can be no assurance that the Internal Revenue Service, which we refer to as the IRS, will not challenge one or more of the tax consequences described
herein. We assume in this discussion that a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds shares of our common stock as a capital asset within the meaning of Section&nbsp;1221 of the Code, which is generally property held for
investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This discussion does not address all aspects of U.S. federal income taxation that may be relevant to a particular <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder in light of that <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s individual circumstances including the alternative minimum tax, or the Medicare tax on net investment income, the
timing of income accruals required under Section&nbsp;451(b) of the Code, the rules regarding qualified small business stock within the meaning of Section&nbsp;1202 of the Code and any election to apply
<FONT STYLE="white-space:nowrap">Section&nbsp;1400Z-2</FONT> of the Code to gains recognized with respect to shares of our common stock. This discussion also does not address any U.S. state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
taxes or any other aspect of any U.S. federal tax other than the income tax. This discussion also does not consider any specific facts or circumstances that may apply to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and does not address
the special tax rules applicable to particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> or governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">financial institutions; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">brokers or dealers in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulated investment companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">pension plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations that
accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#147;qualified foreign pension funds,&#148; or entities wholly owned by a &#147;qualified foreign pension fund&#148;;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons deemed to sell our common stock under the constructive sale provisions of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons that hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security or other
integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons who have elected to mark securities to market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons who have a functional currency other than the U.S. dollar; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as
compensation; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">certain U.S. expatriates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This discussion is for general information only and is not tax advice. Accordingly, all prospective <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holders of our common stock should consult their tax advisors with respect to the U.S. federal, state, local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of the purchase, ownership and disposition of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Distributions on Our Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Distributions, if any, on
our common stock will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current
and accumulated earnings and profits, the excess will be treated as a <FONT STYLE="white-space:nowrap">tax-free</FONT> return of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s investment, up to such holder&#146;s tax basis in the
common stock. Any remaining excess will be treated as capital gain, subject to the tax treatment described below in &#147;Gain on sale or other taxable disposition of our common stock.&#148; Any such distributions will also be subject to the
discussions below under the sections titled &#147;Backup withholding and information reporting&#148; and &#147;Withholding and information reporting requirements&#151;FATCA.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Subject to the discussion in the following two paragraphs in this section, dividends paid to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder
generally will be subject to withholding of U.S. federal income tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence. If we or another
withholding agent apply over-withholding or if a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder does not timely provide us with the required certification, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may be entitled to a
refund or credit of any excess tax withheld by timely filing an appropriate claim with the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Dividends that are treated as effectively connected
with a trade or business conducted by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United States and, if an applicable income tax treaty so provides, that are attributable to a permanent establishment or a fixed base
maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United States, are generally exempt from the 30% withholding tax if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder satisfies applicable certification
and disclosure requirements. However, such U.S. effectively connected income, net of specified deductions and credits, is taxed at the same U.S. federal income tax rates applicable to United States persons (as defined in the Code). Any U.S.
effectively connected income received by a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a corporation may also, under certain circumstances, be subject to an additional &#147;branch profits tax&#148; at a 30% rate or
such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder of our common stock who claims the benefit of an applicable income tax treaty between the United States and such holder&#146;s country of residence generally will be required to provide a properly
executed IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or successor form) to the applicable withholding agent and satisfy applicable
certification and other requirements. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders are urged to consult their tax advisors regarding their entitlement to benefits under a relevant income tax treaty. A
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may obtain a refund or credit of any excess amounts withheld by timely filing a U.S. tax return with the
IRS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Gain on Sale or Other Taxable Disposition of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Subject to the discussions below under &#147;Backup withholding and information reporting&#148; and &#147;Withholding and information reporting
requirements&#151;FATCA,&#148; a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will not be subject to any U.S. federal income tax on any gain realized upon such holder&#146;s sale or other taxable disposition of shares of our
common stock unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct of a U.S.
trade or business and, if an applicable income tax treaty so provides, is attributable to a permanent establishment or a fixed-base maintained by such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States, in which case the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be taxed on a net income basis at the U.S. federal income tax rates applicable to United States persons (as defined in the Code) and, if the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a foreign corporation, the branch profits tax described above in &#147;Distributions on our common stock&#148; also may apply; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual who is present in the United
States for a period or periods aggregating 183&nbsp;days or more in the taxable year of the disposition and certain other conditions are met, in which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be subject to a 30% tax (or
such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence) on the net gain derived from the disposition, which may be offset by certain U.S. source capital losses of
the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder, if any (even though the individual is not considered a resident of the United States), provided that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder has timely filed U.S.
federal income tax returns with respect to such losses; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we are, or have been, at any time during the five-year period preceding such sale or other taxable disposition (or the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s holding period, if shorter) a &#147;U.S. real property holding corporation,&#148; unless our common stock is regularly traded on an established securities market and the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder holds no more than 5% of our outstanding common stock, directly or indirectly, actually or constructively, during the shorter of the <FONT STYLE="white-space:nowrap">5-year</FONT> period ending on
the date of the disposition or the period that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder held our common stock. Generally, a corporation is a U.S. real property holding corporation only if the fair market value of its U.S. real
property interests equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or business. Although there can be no assurance, we do not believe that we
are, or have been, a U.S. real property holding corporation, or that we are likely to become one in the future. No assurance can be provided that our common stock will be regularly traded on an established securities market for purposes of the rules
described above </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Backup Withholding and Information Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We must report annually to the IRS and to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder the gross amount of the distributions on our
common stock paid to such holder and the tax withheld, if any, with respect to such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
distributions. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders may have to comply with specific certification procedures to establish that the holder is not a United&nbsp;States person
(as defined in the Code) in order to avoid backup withholding at the applicable rate with respect to dividends on our common stock. Dividends paid to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders subject to withholding of U.S. federal
income tax, as described above in &#147;Distributions on our common stock,&#148; generally will be exempt from U.S. backup withholding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Information
reporting and backup withholding will generally apply to the proceeds of a disposition of our common stock by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder effected by or through the U.S. office of any broker, U.S. or foreign, unless the
holder certifies its status as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a
payment of disposition proceeds to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder where the transaction is effected outside the United States through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker. However, for
information reporting purposes, dispositions effected through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected
through a U.S. office of a broker. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the application of the information reporting and backup withholding rules to them. Copies of information returns
may be made available to the tax authorities of the country in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or is incorporated under the provisions of a specific treaty or agreement. Backup withholding is not an
additional tax. Any amounts withheld under the backup withholding rules from a payment to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder can be refunded or credited against the <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder&#146;s U.S. federal income tax liability, if any, provided that an appropriate claim is filed with the IRS in a timely manner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Withholding and
Information Reporting Requirements&#151;FATCA </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Provisions of the Code commonly referred to as the Foreign Account Tax Compliance Act, or FATCA,
generally impose a U.S. federal withholding tax at a rate of 30% on payments of dividends on our common stock paid to a foreign entity unless (i)&nbsp;if the foreign entity is a &#147;foreign financial institution,&#148; such foreign entity
undertakes certain due diligence, reporting, withholding, and certification obligations, (ii)&nbsp;if the foreign entity is not a &#147;foreign financial institution,&#148; such foreign entity identifies certain of its U.S. investors, if any, or
(iii)&nbsp;the foreign entity is otherwise exempt under FATCA. Under applicable U.S. Treasury regulations, withholding under FATCA currently applies to payments of dividends on our common stock. Although the FATCA provisions of the Code would
require FATCA withholding on gross proceeds, currently proposed U.S. Treasury Regulations provide that FATCA withholding does not apply to gross proceeds from the disposition of property of a type that can produce U.S. source dividends or interest.
Taxpayers (including withholding agents) can generally rely on the proposed Treasury Regulations until final Treasury Regulations are issued. Under certain circumstances, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may be eligible for
refunds or credits of this withholding tax. An intergovernmental agreement between the United States and an applicable foreign country may modify the requirements described in this paragraph. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders
should consult their tax advisors regarding the possible implications of this legislation on their investment in our common stock and the entities through which they hold our common stock, including, without limitation, the process and deadlines for
meeting the applicable requirements to prevent the imposition of the 30% withholding tax under FATCA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc155225_19"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We and the underwriters named below have entered into an underwriting agreement with respect to the shares being offered. Subject to certain conditions,
each underwriter has severally agreed to purchase the number of shares indicated in the following table. Goldman Sachs&nbsp;&amp; Co. LLC, SVB Leerink LLC and Evercore Group L.L.C. are acting as joint book-running managers of this offering and as
representatives of the underwriters. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Underwriters</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Number&nbsp;of&nbsp;Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">SVB Leerink LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Evercore Group L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">H.C. Wainwright&nbsp;&amp; Co., LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters are committed to take and pay for all of the shares being offered, if any are taken, other than
the shares covered by the option described below unless and until this option is exercised. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters have an option to buy up to an
additional 1,312,500 shares from us to cover sales by the underwriters of a greater number of shares than the total number set forth in the table above. They may exercise that option for 30 days. If any shares are purchased pursuant to this option,
the underwriters will severally purchase shares in approximately the same proportion as set forth in the table above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table shows the
per share and total underwriting discounts and commissions to be paid to the underwriters by us. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase 1,312,500 additional shares. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full&nbsp;Exercise</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Shares sold by the underwriters to the public will initially be offered at the initial public offering price set forth
on the cover of this prospectus. Any shares sold by the underwriters to securities dealers may be sold at a discount of up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share from the initial
public offering price. After the initial offering of the shares, the representatives may change the offering price and the other selling terms. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the
underwriters&#146; right to reject any order in whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We and our officers, directors, and holders of substantially all of our common
stock have agreed with the underwriters, subject to certain exceptions, not to dispose of or hedge any of their common stock or securities convertible into or exchangeable for shares of common stock during the period from the date of this prospectus
continuing through the date 180 days after the date of this prospectus, except with the prior written consent of the representatives. See &#147;Shares Available for Future Sale&#148; for a discussion of certain transfer restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to the offering, there has been no public market for the shares. The initial public offering price has been negotiated among us and the
representatives. Among the factors to be considered in determining the initial public offering price of the shares, in addition to prevailing market conditions, will be our historical performance, estimates of the business potential and our earnings
prospects, an assessment of our management and the consideration of the above factors in relation to market valuation of companies in related businesses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">An application has been made to quote the common stock on the Nasdaq Global Market under the symbol
&#147;AMLX.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with the offering, the underwriters may purchase and sell shares of common stock in the open market. These
transactions may include short sales, stabilizing transactions and purchases to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in the
offering, and a short position represents the amount of such sales that have not been covered by subsequent purchases. A &#147;covered short position&#148; is a short position that is not greater than the amount of additional shares for which the
underwriters&#146; option described above may be exercised. The underwriters may cover any covered short position by either exercising their option to purchase additional shares or purchasing shares in the open market. In determining the source of
shares to cover the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase additional shares pursuant to the
option described above. &#147;Naked&#148; short sales are any short sales that create a short position greater than the amount of additional shares for which the option described above may be exercised. The underwriters must cover any such naked
short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market after pricing that
could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of common stock made by the underwriters in the open market prior to the completion of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting
discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Purchases to cover a short position and stabilizing transactions, as well as other purchases by the underwriters for their own accounts, may have the
effect of preventing or retarding a decline in the market price of our stock, and together with the imposition of the penalty bid, may stabilize, maintain or otherwise affect the market price of the common stock. As a result, the price of the common
stock may be higher than the price that otherwise might exist in the open market. The underwriters are not required to engage in these activities and may end any of these activities at any time. These transactions may be effected on the Nasdaq
Global Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We
estimate that our share of the total expenses of the offering, excluding underwriting discounts and commissions, will be approximately $3.3 million. We have agreed to reimburse the underwriters for certain of their expenses in an amount up to
$40,000. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have agreed to indemnify the several underwriters against certain liabilities, including liabilities under the Securities Act of
1933. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include
sales and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and <FONT STYLE="white-space:nowrap">non-financial</FONT>
activities and services. Certain of the underwriters and their respective affiliates have provided, and may in the future provide, a variety of these services to the issuer and to persons and entities with relationships with the issuer, for which
they received or will receive customary fees and expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the ordinary course of their various business activities, the underwriters and their
respective affiliates, officers, directors and employees may purchase, sell or hold a broad array of investments and actively trade securities, derivatives, loans, commodities, currencies, credit default swaps and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
other financial instruments for their own account and for the accounts of their customers, and such investment and trading activities may involve or relate to assets, securities or instruments of
the issuer (directly, as collateral securing other obligations or otherwise) or persons and entities with relationships with the issuer. The underwriters and their respective affiliates may also communicate independent investment recommendations,
market color or trading ideas or publish or express independent research views in respect of such assets, securities or instruments and may at any time hold, or recommend to clients that they should acquire, long and/or short positions in such
assets, securities and instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Other than in the United States, no action has been taken by us or the underwriters that would permit a public
offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other
offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of
that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an
offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Directed Share Program </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">At our request, the underwriters have
reserved for sale at the initial public offering price up to five percent of the shares of common stock offered by this prospectus, to certain individuals and entities through a directed share program, including some of our directors, executive
officers, employees, business associates and related persons. The number of shares of common stock available for sale to the general public will be reduced by the number of reserved shares of common stock sold to these persons. Any reserved shares
of common stock not purchased by these persons will be offered by the underwriters to the general public on the same terms as the other shares of common stock offered under this prospectus. We have agreed to indemnify the underwriters against
certain liabilities and expenses, including liabilities under the Securities Act, in connection with sales of the reserved shares of common stock. Goldman Sachs &amp; Co. LLC will administer our directed share program. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Selling Restrictions </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>European Economic Area </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In relation to each Member State of the European Economic Area, each being a Relevant State, no shares have been offered or will be offered pursuant to
the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State
and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that the shares may be offered to the public in that Relevant State at any time: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to any legal entity which is a qualified investor as defined under Article 2 of the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the Prospectus
Regulation), subject to obtaining the prior consent of representatives of any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">in any other circumstances falling within Article 1(4) of the Prospectus Regulation. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">225 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">provided that no such offer of the shares shall require us or any of the representatives to publish a
prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For
the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to the shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares
to be offered so as to enable an investor to decide to purchase or subscribe for any shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129.<B><I> </I></B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>United Kingdom </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">No shares have been offered or will be
offered pursuant to the offering to the public in the United Kingdom prior to the publication of a prospectus in relation to the shares which has been approved by the Financial Conduct Authority, except that the shares may be offered to the public
in the United Kingdom at any time: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK
Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">in any other circumstances falling within Section&nbsp;86 of the Financial Services and Markets Act 2000, or FSMA.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>provided</I> that no such offer of the shares shall require the Issuer or any Manager to publish a prospectus pursuant to
Section&nbsp;85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to the shares in the United Kingdom
means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares and the expression &#147;UK
Prospectus Regulation&#148; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.<B><I> </I></B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Canada </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares may be sold only to purchasers
purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are
permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares must be made in accordance with an exemption from,
or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Securities legislation in certain provinces or
territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the
purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or
territory for particulars of these rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to section 3A.3 of National Instrument <FONT
STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT>
regarding underwriter conflicts of interest in connection with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">226 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Hong Kong </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong), or the SFO, of Hong Kong and any rules made thereunder; or (b)&nbsp;in other circumstances which do not result in the document
being a &#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong, or the CO or which do not constitute an offer to the public within the meaning of the CO. No advertisement,
invitation or document relating to the shares has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to
be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to
&#147;professional investors&#148; as defined in the SFO and any rules made thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Singapore </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Each joint book-running manager has acknowledged that this prospectus has not been registered as a prospectus with the Monetary Authority of Singapore.
Accordingly, each joint book-running manager has represented and agreed that it has not offered or sold any shares or caused the shares to be made the subject of an invitation for subscription or purchase and will not offer or sell any shares or
cause the shares to be made the subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this prospectus or any other document or material in connection with the offer or
sale, or invitation for subscription or purchase, of the shares, whether directly or indirectly, to any person in Singapore other than: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">(a) to an
institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289) of Singapore, as modified or amended from time to time, or the SFA, pursuant to Section&nbsp;274 of the SFA; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to
Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified in Section&nbsp;275 of the SFA; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">otherwise pursuant to, and in
accordance with the conditions of, any other applicable provision of the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Where the shares are subscribed or purchased under Section&nbsp;275
of the SFA by a relevant person which is: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">(a) a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the
sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or a trust (where the trustee is not an accredited investor) whose sole purpose is to
hold investments and each beneficiary of the trust is an individual who is an accredited investor, securities or securities- based derivatives contracts (each term as defined in Section&nbsp;2(1) of the SFA) of that corporation or the
beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section&nbsp;275 of the SFA except:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">(i) to an institutional investor or to a relevant person, or to any person arising from an offer referred to in Section&nbsp;275(1A) or
Section&nbsp;276(4)(i)(B) of the SFA; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">where no consideration is or will be given for the transfer; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">227 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">where the transfer is by operation of law; as specified in Section&nbsp;276(7) of the SFA; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives Contracts) Regulations
2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Singapore SFA Product Classification&#151;In connection with Section&nbsp;309B of the SFA and the CMP Regulations 2018, unless otherwise
specified before an offer of Notes, we have determined, and hereby notify all relevant persons (as defined in Section&nbsp;309A(1) of the SFA), that the shares are &#147;prescribed capital markets products&#148; (as defined in the CMP Regulations
2018) and Excluded Investment Products (as defined in MAS Notice SFA <FONT STYLE="white-space:nowrap">04-N12:</FONT> Notice on the Sale of Investment Products and MAS Notice <FONT STYLE="white-space:nowrap">FAA-N16:</FONT> Notice on Recommendations
on Investment Products).<B><I> </I></B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Japan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The
shares have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act. Accordingly, none of the shares nor any interest therein may be offered or sold, directly or indirectly, in Japan or
to, or for the benefit of, any &#147;resident&#148; of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for
<FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with,
the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Switzerland </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares may not be publicly offered in
Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange or regulated trading facility in Switzerland. This document does not constitute a prospectus within the meaning of, and has been prepared without
regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any
other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in
Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Neither this document nor any other offering or marketing material relating to the offering, us or the shares have been or will be
filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, and the offer of shares has not
been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Dubai International Financial Centre </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This
document relates to an Exempt Offer in accordance with the Markets Rules 2012 of the Dubai Financial Services Authority, or DFSA. This document is intended for distribution only to persons of a type specified in the Markets Rules 2012 of the DFSA.
It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify
the information set forth herein and has no responsibility for this document. The securities to which this document relates may be illiquid and/or subject to restrictions on their resale. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">228 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand the contents of this document you should consult an authorized
financial advisor. In relation to its use in the Dubai International Financial Centre, or DIFC, this document is strictly private and confidential and is being distributed to a limited number of investors and must not be provided to any person other
than the original recipient, and may not be reproduced or used for any other purpose. The interests in the securities may not be offered or sold directly or indirectly to the public in the DIFC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>United Arab Emirates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares have not been, and
are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates (including the DIFC) other than in compliance with the laws of the United Arab Emirates (and the DIFC) governing the issue, offering and sale of securities.
Further, this prospectus does not constitute a public offer of securities in the United Arab Emirates (including the DIFC) and is not intended to be a public offer. This prospectus has not been approved by or filed with the Central Bank of the
United Arab Emirates, the Securities and Commodities Authority or the DFSA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Australia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">does not constitute a disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001, or the
Corporations Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">has not been, and will not be, lodged with the Australian Securities and Investments Commission, or ASIC, as a disclosure
document for the purposes of the Corporations Act and does not purport to include the information required of a disclosure document for the purposes of the Corporations Act; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">may only be provided in Australia to select investors who are able to demonstrate that they fall within one or more of the
categories of investors, available under section 708 of the Corporations Act, or Exempt Investors. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares may not be directly
or indirectly offered for subscription or purchased or sold, and no invitations to subscribe for or buy the shares may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any shares may be
distributed in Australia, except where disclosure to investors is not required under Chapter 6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the shares,
you represent and warrant to us that you are an Exempt Investor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As any offer of shares under this document will be made without disclosure in
Australia under Chapter 6D.2 of the Corporations Act, the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter 6D.2 if none of the exemptions
in section 708 applies to that resale. By applying for the shares you undertake to us that you will not, for a period of 12 months from the date of issue of the shares, offer, transfer, assign or otherwise alienate those shares to investors in
Australia except in circumstances where disclosure to investors is not required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Bermuda </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Shares may be offered or sold in Bermuda only
in compliance with the provisions of the Investment Business Act of 2003 of Bermuda which regulates the sale of securities in Bermuda. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">229 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Additionally, <FONT STYLE="white-space:nowrap">non-Bermudian</FONT> persons (including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted
to do so under applicable Bermuda legislation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Saudi Arabia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This document may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of Securities Regulations as
issued by the board of the Saudi Arabian Capital Market Authority, or CMA pursuant to resolution number <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-11-2004</FONT></FONT> dated 4 October&nbsp;2004 as amended by resolution
number <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-28-2008,</FONT></FONT> as amended. The CMA does not make any representation as to the accuracy or completeness of this document and expressly disclaims any liability
whatsoever for any loss arising from, or incurred in reliance upon, any part of this document. Prospective purchasers of the securities offered hereby should conduct their own due diligence on the accuracy of the information relating to the
securities. If you do not understand the contents of this document, you should consult an authorized financial adviser. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>British Virgin Islands </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares are not being, and may not be offered to the public or to any person in the British Virgin Islands for purchase or subscription by or on our
behalf. The shares may be offered to companies incorporated under the BVI Business Companies Act, 2004 (British Virgin Islands), or BVI Companies, but only where the offer will be made to, and received by, the relevant BVI Company entirely outside
of the British Virgin Islands. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>China </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This
prospectus will not be circulated or distributed in the People&#146;s Republic of China, or PRC, and the shares will not be offered or sold, and will not be offered or sold to any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or
resale directly or indirectly to any residents of the PRC except pursuant to any applicable laws and regulations of the PRC. Neither this prospectus nor any advertisement or other offering material may be distributed or published in the PRC, except
under circumstances that will result in compliance with applicable laws and regulations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Korea </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares have not been and will not be registered under the Financial Investments Services and Capital Markets Act of Korea and the decrees and
regulations thereunder, or the FSCMA, and the shares have been and will be offered in Korea as a private placement under the FSCMA. None of the shares may be offered, sold or delivered directly or indirectly, or offered or sold to any person for <FONT
STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to the applicable laws and regulations of Korea, including the FSCMA and the Foreign Exchange Transaction Law of
Korea and the decrees and regulations thereunder, or the FETL. The shares have not been listed on any of securities exchanges in the world including, without limitation, the Korea Exchange in Korea. Furthermore, the purchaser of the shares shall
comply with all applicable regulatory requirements (including but not limited to requirements under the FETL) in connection with the purchase of the shares. By the purchase of the shares, the relevant holder thereof will be deemed to represent and
warrant that if it is in Korea or is a resident of Korea, it purchased the shares pursuant to the applicable laws and regulations of Korea. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Malaysia
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">No prospectus or other offering material or document in connection with the offer and sale of the shares has been or will be registered with
the Securities Commission of Malaysia, or Commission, for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">230 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the Commission&#146;s approval pursuant to the Capital Markets and Services Act 2007. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or
invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in
Malaysia other than (i)&nbsp;a closed end fund approved by the Commission; (ii)&nbsp;a holder of a Capital Markets Services License; (iii)&nbsp;a person who acquires the shares, as principal, if the offer is on terms that the shares may only be
acquired at a consideration of not less than RM250,000 (or its equivalent in foreign currencies) for each transaction; (iv)&nbsp;an individual whose total net personal assets or total net joint assets with his or her spouse exceeds RM3&nbsp;million
(or its equivalent in foreign currencies), excluding the value of the primary residence of the individual; (v)&nbsp;an individual who has a gross annual income exceeding RM300,000 (or its equivalent in foreign currencies) per annum in the preceding
twelve&nbsp;months; (vi)&nbsp;an individual who, jointly with his or her spouse, has a gross annual income of RM400,000 (or its equivalent in foreign currencies), per annum in the preceding twelve&nbsp;months; (vii)&nbsp;a corporation with total net
assets exceeding RM10&nbsp;million (or its equivalent in a foreign currencies) based on the last audited accounts; (viii)&nbsp;a partnership with total net assets exceeding RM10&nbsp;million (or its equivalent in foreign currencies); (ix)&nbsp;a
bank licensee or insurance licensee as defined in the Labuan Financial Services and Securities Act 2010; (x)&nbsp;an Islamic bank licensee or takaful licensee as defined in the Labuan Financial Services and Securities Act 2010; and (xi)&nbsp;any
other person as may be specified by the Commission; provided that, in the each of the preceding categories (i)&nbsp;to (xi), the distribution of the shares is made by a holder of a Capital Markets Services License who carries on the business of
dealing in securities. The distribution in Malaysia of this prospectus is subject to Malaysian laws. This prospectus does not constitute and may not be used for the purpose of public offering or an issue, offer for subscription or purchase,
invitation to subscribe for or purchase any securities requiring the registration of a prospectus with the Commission under the Capital Markets and Services Act 2007. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Taiwan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares have not been and will not be
registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an offer within
the meaning of the Securities and Exchange Act of Taiwan that requires a registration or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorized to offer, sell, give advice regarding or otherwise
intermediate the offering and sale of the shares in Taiwan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>South Africa </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Due to restrictions under the securities laws of South Africa, no &#147;<I>offer to the public</I>&#148; (as such term is defined in the South African
Companies Act, No.&nbsp;71 of 2008 (as amended or <FONT STYLE="white-space:nowrap">re-enacted),</FONT> or the South African Companies Act) is being made in connection with the issue of the shares in South Africa. Accordingly, this document does not,
nor is it intended to, constitute a &#147;<I>registered prospectus</I>&#148; (as that term is defined in the South African Companies Act) prepared and registered under the South African Companies Act and has not been approved by, and/or filed with,
the South African Companies and Intellectual Property Commission or any other regulatory authority in South Africa. The shares are not offered, and the offer shall not be transferred, sold, renounced or delivered, in South Africa or to a person with
an address in South Africa, unless one or other of the following exemptions stipulated in section 96 (1)&nbsp;applies: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Section&nbsp;96(1)
(a)&nbsp;the offer, transfer, sale, renunciation or delivery is to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">persons whose ordinary business, or part of whose ordinary business, is to deal in securities, as principal or agent;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">231 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">the South African Public Investment Corporation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">persons or entities regulated by the Reserve Bank of South Africa; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">authorized financial service providers under South African law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">financial institutions recognized as such under South African law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">a wholly owned subsidiary of any person or entity contemplated in (c), (d) or (e), acting as agent in the capacity of an
authorized portfolio manager for a pension fund, or as manager for a collective investment scheme (in each case duly registered as such under South African law); or </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">(vii) any combination of the person in (i)&nbsp;to (vi); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Section&nbsp;96(1) (b)&nbsp;the total contemplated acquisition cost of the securities, for any single addressee acting as principal is equal to or
greater than ZAR1,000,000 or such higher amount as may be promulgated by notice in the Government Gazette of South Africa pursuant to section 96(2)(a) of the South African Companies Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">232 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc155225_20"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The validity of the shares of our common stock offered hereby is being passed upon for us by Goodwin Procter LLP, Boston, Massachusetts. Certain legal
matters relating to this offering will be passed upon for the underwriters by Wilmer Cutler Pickering Hale and Dorr LLP, New York, New York. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc155225_21">
</A>EXPERTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The financial statements as of December&nbsp;31, 2019 and 2020, and for each of the two years in the period ended December&nbsp;31,
2020 included in this Prospectus have been audited by Deloitte&nbsp;&amp; Touche LLP, an independent registered public accounting firm, as stated in their report herein (which report expresses an unqualified opinion on the financial statements and
includes an explanatory paragraph referring to the Company&#146;s ability to continue as a going concern). Such financial statements have been so included in reliance upon the report of such firm given upon their authority as experts in accounting
and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc155225_22"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act with respect to the
common stock we are offering by this prospectus. This prospectus does not contain all of the information included in the registration statement. For further information pertaining to us and our common stock, you should refer to the registration
statement and to its exhibits. Whenever we make reference in this prospectus to any of our contracts, agreements or other documents, the references are not necessarily complete, and you should refer to the exhibits attached to the registration
statement for copies of the actual contract, agreement or other document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon completion of the offering, you may access, free of charge, our
Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and amendments to those reports filed or
furnished pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon the completion of the offering, we will be subject to the informational requirements of the Exchange Act and will file annual, quarterly and
current reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration statement, at the SEC&#146;s website at www.sec.gov. We also maintain a website at www.amylyx.com. Information contained
on or accessed through our website is not a part of this prospectus and the inclusion of our website address in this prospectus is an inactive textual reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">233 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc155225_23"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Audited Consolidated Financial Statements as of December 31, 2019 and 2020, and for the Years Ended
December 31, 2019 and 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin155225_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin155225_2">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin155225_3">Consolidated Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin155225_4">Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#146;
 Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin155225_5">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin155225_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Unaudited Interim Condensed Consolidated Financial Statements as of December&nbsp;31, 2020 and September
30, 2021, and for the Nine Months Ended September 30, 2020 and 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin155225_7">Condensed Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin155225_8">Condensed Consolidated Statements of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin155225_9">Condensed Consolidated Statements of Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin155225_10">Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#146;
 Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin155225_11">Condensed Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin155225_12">Notes to Unaudited Condensed Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin155225_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">To the stockholders<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>and the Board of Directors of Amylyx Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We have audited the accompanying
consolidated balance sheets&nbsp;of Amylyx Pharmaceuticals, Inc. and subsidiary (the &#147;Company&#148;) as of December&nbsp;31, 2019 and 2020, the related consolidated statements of operations and comprehensive loss, redeemable convertible
preferred stock and stockholders&#146; deficit, and cash flows, for each of the two years in the period ended December&nbsp;31, 2020, and the related notes (collectively referred to as the &#147;financial statements&#148;). In our opinion, the
financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2019 and 2020, and the results of its operations and its cash flows for each of the two years in the period ended
December&nbsp;31, 2020, in conformity with accounting principles generally accepted in the United States of America. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Going Concern </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements,
the Company has incurred recurring losses from operations that raise substantial doubt about its ability to continue as a going concern. Management&#146;s plans in regard to these matters are also described in Note 1. The financial statements do not
include any adjustments that might result from the outcome of this uncertainty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Basis for Opinion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to
have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an
opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Our audits included
performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial
statements. We believe that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">/s/ Deloitte &amp; Touche LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Boston, Massachusetts </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">April 26, 2021 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We have served as the Company&#146;s auditor since 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin155225_2"></A>AMYLYX PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>CONSOLIDATED BALANCE SHEETS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Amounts in
thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accrued interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accrued interest&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Convertible notes, net of unamortized discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Convertible notes&#151;related parties, net of unamortized discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">PPP Loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Proceeds received in advance of issuance of 2021 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Commitments and contingencies (Note 15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Series A redeemable convertible preferred stock, $0.0001 par value; 6,401,500 and 6,289,609 shares authorized
as of December&nbsp;31, 2019 and 2020, respectively; 6,289,609 shares issued and outstanding as of December&nbsp;31, 2019 and 2020, respectively; aggregate liquidation preference of $7,730</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Series B redeemable convertible preferred stock, $0.0001 par value; 0 and 15,100,000 shares authorized as of
December&nbsp;31, 2019 and 2020, respectively; 0 and 14,496,835 shares issued and outstanding as of December&nbsp;31, 2019 and 2020, respectively; aggregate liquidation preference of $0 and $246,070 as of December&nbsp;31, 2019 and 2020,
respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Common stock, $0.0001 par value; 14,000,000 and 35,000,000 shares authorized as of December&nbsp;31, 2019 and
2020, respectively; 5,994,246 and 6,137,206 shares issued and outstanding as of December 31, 2019 and 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,634</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(67,914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,357</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(66,725</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Total liabilities, redeemable convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin155225_3"></A>AMYLYX PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Amounts in thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,554</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,005</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income (expense), net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,276</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other (expense) income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(162</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,716</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6.96</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average shares used in computing net loss per share attributable to common stockholders&#151;basic
and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,889,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,077,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin155225_4"></A>AMYLYX PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Amounts in thousands, except share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A<BR>Redeemable<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B<BR>Redeemable<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance at December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,289,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,875,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,915</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,776</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Cumulative-effect adjustment from adoption of ASU <FONT STYLE="white-space:nowrap">2018-07</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of common stock upon exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Vesting of restricted stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,716</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,716</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance at December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,289,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,994,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,634</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,357</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of Series B redeemable convertible preferred stock, net of issuance costs of $35</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,767,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,958</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Conversion of convertible notes and accrued interest into</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Series B redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,729,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,429</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Recognition of contingent beneficial conversion feature</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of common stock upon exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance at December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,289,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,496,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">64,387</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,137,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(67,914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(66,725</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin155225_5"></A>AMYLYX PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Amounts in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash flows used in operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,716</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(42,280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(939</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-cash</FONT> interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Depreciation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Gain on extinguishment of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(268</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(651</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(107</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued expenses, other current liabilities and deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued interest and accrued interest&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,687</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,697</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash flows used in investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash flows provided by financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds from PPP Loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds from issuance of convertible notes&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds from issuance of convertible notes, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds from issuance of Series B redeemable convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds received in advance of issuance of 2021 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net (decrease) increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,019</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash, cash equivalents and restricted cash, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash, cash equivalents and restricted cash, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Supplemental disclosure of cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adoption of ASU <FONT STYLE="white-space:nowrap">2018-07</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Recognition of initial derivative liability and associated debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Conversion of convertible notes and accrued interest into Series B redeemable convertible preferred
stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin155225_6"></A>AMYLYX PHARMACEUTICALS,&nbsp;INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>1. NATURE OF
BUSINESS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Amylyx Pharmaceuticals,&nbsp;Inc. (&#147;Amylyx&#148;) was incorporated under the laws of the State of Delaware on January&nbsp;10,
2014. In October 2020, Amylyx created a wholly owned subsidiary, Amylyx Pharmaceuticals Canada, Inc. (&#147;Amylyx Canada&#148;, and together with &#147;Amylyx&#148;, the &#147;Company&#148;), in Calgary, Canada. As of December&nbsp;31, 2020, Amylyx
Canada did not have operations. The Company is headquartered in Cambridge, Massachusetts. The Company is a clinical stage biotechnology company with a goal to improve the quality and length of life of patients suffering from neurodegenerative
disease. The Company is pursuing commercialization of its asset, AMX0035, which it believes is the first drug candidate to show both a functional and survival benefit in a large-scale clinical trial of patients with amyotrophic lateral sclerosis, or
ALS. The Company believes AMX0035 has the potential to be a foundational therapy, meaning a that it could be used alone or in conjunction with other therapies to change the treatment paradigm across a broad range neurodegenerative diseases. The
Company has designed AMX0035 to target two key pathways of neuron death, specifically endoplasmic reticulum, or ER, stress and mitochondrial dysfunction. The Company is focused on the development of and potential commercialization of AMX0035 for ALS
globally. In addition, the Company is developing AMX0035 for other neurodegenerative diseases by leveraging its unique knowledge and relationships in the neurodegenerative space. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Risks and Uncertainties </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company is subject to
risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, the outcome of clinical trials, development by competitors of new technological innovations, dependence on key personnel,
protection of proprietary technology, compliance with government regulations, ability to secure additional capital to fund operations, and risks associated with the <FONT STYLE="white-space:nowrap">COVID-19</FONT> global pandemic, including
potential delays associated with the Company&#146;s ongoing and anticipated trials. <FONT STYLE="white-space:nowrap">COVID-19</FONT> may have an adverse impact on the Company&#146;s operations, supply chains and distribution systems or those of its
contractors, and increase expenses, including as a result of impacts associated with preventive and precautionary measures that are being taken, such as restrictions on travel and border crossings, quarantine polices and social distancing. The
Company and its contractors may experience disruptions in supply of items that are essential for its research and development activities, including, for example, raw materials and bulk drug substances that the Company imports from Europe and Canada
used in the manufacturing of AMX0035, and any future product candidates. In addition, the spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> has disrupted global healthcare and healthcare regulatory systems which could divert healthcare
resources away from, or materially delay, U.S. Food and Drug Administration (&#147;FDA&#148;) approval and approval by other health authorities worldwide with respect to AMX0035 and any future product candidates. Furthermore, the Company&#146;s
clinical trials may be negatively affected by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak. Site initiation, patient enrollment and patient <FONT STYLE="white-space:nowrap">follow-up</FONT> visits may be delayed, for example, due to
prioritization of hospital resources toward the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak, travel restrictions, the inability to access sites for initiation and monitoring, and difficulties recruiting or retaining patients in the
Company&#146;s ongoing and planned clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There can be no assurance that the Company will be able to successfully complete the
development of, or receive regulatory approval for, any products developed, and if approved, that any products will be commercially viable. Any products resulting from the Company&#146;s current research and development efforts will require
significant additional research and development, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel,
infrastructure, and extensive compliance reporting capabilities. The Company has not generated any revenues from the sale of any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
products to date. Even if the Company&#146;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Going Concern </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In accordance with Accounting Standards
Update (&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">2014-15,</FONT> <I>Disclosure of Uncertainties About an Entity&#146;s Ability to Continue as a Going Concern (Subtopic <FONT STYLE="white-space:nowrap">205-40)</FONT></I>, the Company has
evaluated whether there are conditions and events that raise substantial doubt about the Company&#146;s ability to continue as a going concern within one year after the date the consolidated financial statements are issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since its inception, the Company has devoted substantially all of its efforts to research and development activities, including recruiting management
and technical staff, raising capital, producing materials for <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical studies, and building infrastructure to support such activities. Expenses have primarily been for research and
development and related general and administrative costs. The Company has generated revenues through five grants from ALS Association, ALS Finding a Cure Foundation, Cure Alzheimer&#146;s Fund, Alzheimer&#146;s Drug Discovery Foundation and
Alzheimer&#146;s Association (collectively, the &#147;Grantors&#148;). In addition to money received from its grants, the Company has also financed its operations through the issuance of redeemable convertible preferred stock and convertible notes
(see Notes 9 and 6, respectively). In addition, the Company has financed its operation pursuant to the loan under the Paycheck Protection Program, or the PPP, of the Coronavirus Aid, Relief, and Economic Security (&#147;CARES&#148;) Act (the
&#147;PPP Loan&#148;) as administered by the Small Business Administration (&#147;SBA&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The accompanying consolidated financial statements
have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred recurring losses and negative cash flows from operations since
inception. As of December&nbsp;31, 2020, the Company had an accumulated deficit of $67.9&nbsp;million. The Company expects its operating losses and negative operating cash flows to continue into the foreseeable future as it continues to build
capabilities and develop AMX0035, and any future product candidates. These conditions raise substantial doubt regarding the Company&#146;s ability to continue as a going concern within one year of the issuance date of the consolidated financial
statements. The Company&#146;s plans to address the capital shortfall include negotiating additional equity financing and alternative sources of financial support and considering cost containment efforts. Because of the uncertainty inherent in these
efforts, the Company has concluded that substantial doubt exists with respect to its ability to continue as a going concern for at least the next twelve months from the date these consolidated financial statements are issued. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Basis of
Presentation and Consolidation&#151;</I></B>The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#147;GAAP&#148;) and include the accounts
of the Company and its wholly owned subsidiary, Amylyx Canada, after elimination of all significant intercompany accounts and transactions. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in
the Accounting Standards Codification (&#147;ASC&#148;) and ASU of the Financial Accounting Standards Board (&#147;FASB&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Use of
Estimates&#151;</I></B>The preparation of the consolidated financial statements in conformity with GAAP requires the Company&#146;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date
of the financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Management considers many factors in selecting appropriate financial accounting policies in developing the estimates and assumptions that are used in the preparation of the financial statements.
Management must apply significant judgment in this process. Management&#146;s estimation process often may yield a range of potentially reasonable estimates and management must select an amount that falls within that range of reasonable estimates.
Estimates are used in the following areas, among others: determining the fair value of the Company&#146;s common stock; determining the fair value of derivative liabilities; accrued expenses; stock option valuations; valuation allowance for deferred
tax assets and research and development expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Grant Revenue&#151;</I></B>Grant revenue consists of amounts earned from performing
contracted research and development services. The grants between the Company and the Grantors generally provide for the Company to meet certain research milestones in order for funds to be provided. The Company accounts for grant received to perform
research and development services in accordance with ASC <FONT STYLE="white-space:nowrap">730-20,</FONT> <I>Research and Development Arrangements</I>, which requires an assessment, at the inception of the grant, of whether the grant is a liability
or a contract to perform research and development services for others. If the Company is obligated to repay the grant funds to the Grantor regardless of the outcome of the research and development activities, then the Company is required to estimate
and recognize that liability. Alternatively, if the Company is not required to repay, or if it is required to repay the grant funds only if the research and development activities are successful, then the grant agreement is accounted for as a
contract to perform research and development services for others, in which case, grant revenue is recognized as the related research and development expenses are incurred. The Company recognizes grant revenue using the output method that is based on
total funds spent relative to the total grant received and receivable. The Company obtained funding from the Grantors of $1.4&nbsp;million and $0.7&nbsp;million, which was recorded as grant revenue in the Company&#146;s consolidated statements of
operations and comprehensive loss during the years ended December&nbsp;31, 2019 and 2020, respectively. Under the terms of the grants, the Company will be required to pay royalties upon occurrence of contingent future events (see Note 15). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Comprehensive Loss&#151;</I></B>Comprehensive loss includes net loss, as well as other changes in stockholders&#146; deficit that result from
transactions and economic events other than those with stockholders. For the years ended December&nbsp;31, 2019 and 2020, there were no items, other than net loss, that were included in the Company&#146;s comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Cash and Cash Equivalents&#151;</I></B>The Company considers all highly liquid investments with an original maturity of three months or less at
the date of purchase to be cash equivalents. Cash equivalents represent funds invested in readily available checking and money market funds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Restricted Cash&#151;</I></B>As of December&nbsp;31, 2019, the Company maintained a restricted cash account with a balance of less than
$0.1&nbsp;million. The restricted cash as of December&nbsp;31, 2019 was related to the grant money that the Company received. Such funds were expected to be used within twelve months and as such have been classified as a current asset on the
consolidated balance sheet as of December&nbsp;31, 2019. As December&nbsp;31, 2020, restricted cash of $0.2&nbsp;million represents collateral provided for a letter of credit issued as a security deposit in connection with the Company&#146;s lease
of its corporate office. The lease expires in October 2026 at which time the cash will be released from restriction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Concentrations of Credit
Risk&#151;</I></B>Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash. Periodically, the Company maintains deposits in an accredited financial institution in excess of federally
insured limits. The Company deposits its cash in a financial institution that it believes has high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal
credit risk associated with commercial banking relationships. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Convertible Note&#151;Derivative&#151;</I></B>The Company reviews the terms of the convertible
note issued to determine whether there are features, including redemption and conversion features, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument
contains more than one embedded derivative instrument that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at the end of each reporting period and immediately prior to
the conversion or the extinguishment of the convertible note. Changes in the fair value are reported in the consolidated statement of operations and comprehensive loss for the year ended December&nbsp;31, 2020. When the convertible note contains
embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then
allocated to the host instruments themselves, usually resulting in those host instruments being recorded at a discount from their face value. The discount from the face value of the convertible note, together with the stated interest on the host
instrument, is amortized over the life of the host instrument through periodic charges to interest expense. The Company&#146;s convertible notes, as further discussed in Note&nbsp;6, had embedded derivatives that required bifurcation from the host
instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Convertible Note&#151;Beneficial Conversion Feature&#151;</I></B>If the conversion feature is not treated as a derivative, the
Company assesses whether it is a beneficial conversion feature (&#147;BCF&#148;). A BCF exists if the conversion price of the convertible note is less than the price of the stock into which it is convertible to on the commitment date. This typically
occurs when the conversion price is less than the fair value of the stock on the date the instrument was issued. The value of a BCF is equal to the intrinsic value of the feature, the difference between the effective conversion price and the fair
value of the stock into which it is convertible to and is recorded as additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital and as a debt discount in the consolidated balance sheets. The Company amortizes the debt discount as <FONT
STYLE="white-space:nowrap">non-cash</FONT> interest expense over the life of the underlying convertible note using the effective interest method. If the convertible note is retired early, the associated debt discount is then recognized immediately
as <FONT STYLE="white-space:nowrap">non-cash</FONT> interest expense in the consolidated statements of operations and comprehensive. If the conversion feature does not qualify for either the derivative treatment or as a BCF, the convertible note is
treated as traditional debt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Fair Value Measurements&#151;</I></B>Assets and liabilities recorded at fair value on a recurring basis on the
consolidated balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability
(an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of
observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Level</I></B><B><I></I></B><B><I>&nbsp;1</I></B>&#151;Quoted prices in active markets for identical assets or
liabilities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Level</I></B><B><I></I></B><B><I>&nbsp;2</I></B>&#151;Observable inputs (other than Level&nbsp;1 quoted prices), such
as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Level</I></B><B><I></I></B><B><I>&nbsp;3</I></B>&#151;Unobservable inputs that are supported by little or no market
activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To the extent that the valuation is based on models or inputs that are less observable or unobservable
in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&nbsp;3. A financial instrument&#146;s
level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The
Company&#146;s financial instruments consist of cash, cash equivalents, restricted cash, accounts receivable, accounts payable, accrued expenses and convertible notes. These financial instruments are stated at their respective carrying amounts,
which approximate fair value due to the short-term nature of these assets and liabilities. The Company&#146;s derivative liability is carried at fair value, determined according to Level&nbsp;3 inputs in the fair value hierarchy described above (see
Note 8). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Debt Issuance Costs&#151;</I></B>Debt issuance costs associated with the Company&#146;s convertible notes are recorded as a<B>
</B>reduction of the carrying value of the convertible notes on the Company&#146;s consolidated balance sheets and are<B> </B>amortized to interest expense over the term of the respective convertible notes using the effective interest method.<B>
</B>During June 2020, all convertible notes converted into shares of Series B redeemable convertible preferred stock. The remaining debt issuance costs were either amortized to <FONT STYLE="white-space:nowrap">non-cash</FONT> interest expense or
recorded to Series B redeemable convertible preferred stock depending on the accounting for the conversion of the convertible notes. For the convertible notes that converted under the conversion feature and for which there was no contingent
beneficial conversion feature, the remaining debt issuance costs were recorded as a component of the Series B redeemable convertible preferred stock. For the convertible notes that converted under the conversion feature and for which there was a
contingent beneficial conversion feature, the remaining debt issuance costs were recorded as a charge to <FONT STYLE="white-space:nowrap">non-cash</FONT> interest expense. For the convertible notes that converted under the redemption features, the
remaining debt issuance costs were extinguished and recorded as other (expense) income, net. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Property and Equipment,
net&#151;</I></B>Property and equipment are stated at cost, net of accumulated depreciation. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful lives of the respective assets. Maintenance
and repairs that do not improve or extend the life of the assets are expensed when incurred. Upon sale or retirement of assets, the cost and accumulated depreciation are removed from the consolidated balance sheets and any resulting gain or loss is
reflected in the consolidated statements of operations and comprehensive loss in the period realized. The range of useful lives of property and equipment is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="55%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>Estimated&nbsp;Useful&nbsp;Life</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Lesser of the estimated life or remaining lease term</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">4 years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Not depreciated</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Impairment of Long-Lived Assets&#151;</I></B>The Company evaluates assets for potential impairment when events or
changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to
generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company has not recognized any impairment losses in the years ended
December&nbsp;31, 2019 and 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Research and Development&#151;</I></B>Research and development expenses include costs directly attributable
to the conduct of research and development activities. Expenditures relating to research and development are expensed in the period incurred. Nonrefundable advance payments for goods and services that will be used in future research and development
activities are expensed when the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
activity has been performed or when the goods have been received rather than when the payment is made. In addition, research and development related salaries and benefits, facility, and overhead
costs, supplies and other related costs are included in research and development expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Patent-Related Costs&#151;</I></B>Patent-related
costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the
accompanying consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Stock-Based Compensation Expense&#151;</I></B>The Company accounts
for stock-based compensation under the provisions of <FONT STYLE="white-space:nowrap">ASC&nbsp;718-10,</FONT><I>&nbsp;Compensation&#151;Stock Compensation</I>&nbsp;, which requires all share-based payments to employees, <FONT
STYLE="white-space:nowrap">non-employees</FONT> and directors, including grants of stock options and restricted stock, to be recognized in the consolidated statements of operations and comprehensive loss based on their fair values on the date of
grant over the requisite service period, which is generally the vesting period of the respective award. Forfeitures are accounted for as they occur. Generally, the Company issues stock option awards with only service-based vesting conditions and
records the expense for these awards using the straight-line method. The Company classifies stock-based compensation expense in the same manner in which the awards recipient&#146;s payroll or service provider&#146;s costs are classified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The fair value of each restricted common stock award is estimated on the date of grant based on the fair value of the Company&#146;s common stock on
that same date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model, which requires
inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the award, the risk-free interest rate, and expected dividends. As there is no public market for the Company&#146;s common stock, the
estimated fair value of common stock was determined by the Company&#146;s Board of Directors as of the date of each option grant, with input from management, considering third-party valuations of its common stock as well as the Company&#146;s Board
of Directors&#146; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent third-party valuation through the date of the grant. These third-party valuations
were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#146; Accounting and Valuation Guide, <I>Valuation of Privately Held Company Equity Securities Issued as Compensation</I>. The Company
estimates its expected stock price volatility based on the historical volatility of publicly traded peer companies. The expected term of the Company&#146;s stock options has been determined utilizing the &#147;simplified&#148; method for awards that
qualify as &#147;plain vanilla&#148; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award.
There is no expected dividend yield since the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Contingencies&#151;</I></B>From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business
activities. The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the loss is a range and no amount within the range is a better estimate, the minimum amount of the range
is recorded as a liability on the Company&#146;s consolidated balance sheets. The Company does not accrue for contingent losses that, in its judgement, are considered to be reasonably possible, but not probable; however, it discloses the range of
reasonably possible losses. There were no loss or gain contingencies recorded in the Company&#146;s consolidated financial statements as of and during the year ended December 2019 and 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Leases&#151;</I></B>The Company leases&nbsp;its office, and may from time to time, enter into
other lease agreements in conducting its business. At the inception of each&nbsp;lease, the Company evaluates the&nbsp;lease&nbsp;agreement to determine whether the&nbsp;lease&nbsp;is an&nbsp;operating&nbsp;or&nbsp;capital&nbsp;lease in accordance
with ASC 840,<I>&nbsp;Leases</I>&nbsp;(ASC 840). When any one of the four test criteria in ASC 840 is met, the&nbsp;lease&nbsp;then qualifies as a&nbsp;capital&nbsp;lease. If the lease agreements contain renewal options, tenant improvement
allowances,&nbsp;rent&nbsp;holidays or&nbsp;rent&nbsp;escalation clauses, the Company records a deferred&nbsp;rent&nbsp;asset or liability equal to the difference between the&nbsp;rent&nbsp;expense and future minimum&nbsp;lease&nbsp;payments due.
The&nbsp;rent&nbsp;expense related to&nbsp;operating&nbsp;leases&nbsp;is recognized on a&nbsp;straight-line&nbsp;basis in the statements of&nbsp;operations&nbsp;and comprehensive loss over the term of each&nbsp;lease. The Company did not have
capital leases as of December&nbsp;31, 2019 and 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Income Taxes&#151;</I></B>The Company accounts for income taxes using the asset and
liability approach. Deferred tax assets and liabilities represent future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities and for loss carryforwards using enacted
tax rates expected to be in effect in the years in which the differences reverse. A valuation allowance is established to reduce deferred tax assets to the amounts expected to be realized. The Company also recognizes a tax benefit from uncertain tax
positions only if it is &#147;more likely than not&#148; that the position is sustainable based on its technical merits. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. To
date, the Company has not incurred interest and penalties related to uncertain tax positions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Segment Information&#151;</I></B>An operating
segment is defined as a component of a business that engages in business activities for which it may earn revenues and incur expenses and for which discrete financial information is available that is evaluated regularly by the chief operating
decision maker or makers in order to make decisions about resources to be allocated to the segment and assess its performance. The Company operates and manages the business as one reporting and one operating segment, which is the business of
developing therapeutics for neurodegenerative disorders. The Company has determined that its chief executive officers are the chief operating decision maker (&#147;CODM&#148;). The CODM reviews consolidated operating results to make decisions about
allocating resources or capital to specific compounds or projects in line with the Company&#146;s overall strategies and goals. As of December&nbsp;31, 2019, the Company operated in one geographic region in the United States. As of December&nbsp;31,
2020, the Company had offices in two geographic regions in United States and Canada, but operations were only in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Net
income (loss) per share&#151;</I></B>The Company follows the <FONT STYLE="white-space:nowrap">two-class</FONT> method when computing net income (loss) per share as the Company has issued shares that meet the definition of participating securities.
The <FONT STYLE="white-space:nowrap">two-class</FONT> method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed
earnings. The <FONT STYLE="white-space:nowrap">two-class</FONT> method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive
dividends as if all income for the period had been distributed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Basic net income (loss) per share attributable to common stockholders is computed
by dividing the net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income
(loss) attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net
income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares. For purpose of this calculation, stock options, convertible notes, and
redeemable convertible preferred stock are considered potential dilutive common shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company&#146;s redeemable convertible preferred stock contractually entitles the holders of such
shares to participate in dividends but does not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss attributable to common stockholders, such
losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share
attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Emerging Growth Company Status&#151;</I></B>The Company is an emerging growth company (&#147;EGC&#148;) as defined in the Jumpstart Our Business
Startups Act of 2012, as amended (the &#147;JOBS Act&#148;), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these
exemptions until it is no longer an EGC under Section&nbsp;107 of the JOBS Act and has elected to use the extended transition period for complying with new or revised accounting standards. As a result of this election, the Company&#146;s
consolidated financial statements may not be comparable to companies that comply with public company FASB standards&#146; effective dates. The Company intends to take advantage of the reduced reporting requirements and exemptions up until the last
day of the fiscal year following the fifth anniversary of an offering or such earlier time that it is no longer an EGC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Recent Accounting Pronouncements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>New Accounting Pronouncements Not Yet Adopted&#151;</I></B>In February 2016, the FASB issued ASU
<FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT><I>&nbsp;Leases</I> <I>(Topic</I><I></I><I>&nbsp;842)</I>&nbsp;(&#147;ASC&nbsp;842&#148;), which sets out the principles for the recognition, measurement, presentation, and disclosure of
leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether the lease is effectively a
financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, for finance and operating leases, respectively. A
lessee is also required to record a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and a lease liability for all leases with a term of greater than 12&nbsp;months regardless of their
classification. ASC&nbsp;842 provides a lessee with an option to not account for leases with a term of 12&nbsp;month or less as leases in the scope of the new standard. ASC&nbsp;842 supersedes the previous leases standard, ASC&nbsp;840
<I>Leases</I>. In July 2018, the FASB issued supplemental adoption guidance and clarification to ASC&nbsp;842 within ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-10,</FONT><I>&nbsp;Codification Improvements to Topic</I><I></I><I>&nbsp;842,
Leases</I>&nbsp;and ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-11,</FONT><I>&nbsp;Leases (Topic</I><I></I><I>&nbsp;842): Targeted Improvements</I>. ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-11</FONT> provides another transition
method in addition to the existing modified retrospective transition method by allowing entities to initially apply the new leasing standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of accumulated
deficit in the period of adoption. In July 2019, the FASB delayed the effective date for this ASU for <FONT STYLE="white-space:nowrap">non-public</FONT> entities (including emerging growth companies), and this ASU is effective for fiscal years
beginning after December&nbsp;15, 2021 and interim periods within fiscal years beginning after December&nbsp;15, 2022, with early adoption permitted. The ASU is effective for the Company on January&nbsp;1, 2022 and the Company intends to adopt the
ASU when it becomes effective. The Company is currently evaluating the impact the adoption of these ASUs will have on its consolidated financial statements and related disclosures. The Company expects to recognize a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and corresponding lease liability for its real estate operating leases upon adoption. See Note&nbsp;15 for more information related to the Company&#146;s lease obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In June&nbsp;2016, the FASB <FONT STYLE="white-space:nowrap">issued&nbsp;ASU&nbsp;No.&nbsp;2016-13,</FONT><I>&nbsp;Financial Instruments&#151;Credit
Losses (Topic 326) Measurement of Credit Losses on Financial Instruments</I><FONT STYLE="white-space:nowrap">&nbsp;(&#147;ASU&nbsp;2016-13&#148;),</FONT> which requires an entity to utilize a new impairment model known as the current expected credit
loss model to estimate its lifetime &#147;expected credit loss&#148; and record an allowance that, when deducted from the amortized cost </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
basis of the financial assets and certain other instruments, including but not limited to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt
securities. Credit losses relating to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to
the <FONT STYLE="white-space:nowrap">security.&nbsp;ASU&nbsp;2016-13</FONT> requires a cumulative effect adjustment to the consolidated balance sheet as of the beginning of the first reporting period in which the guidance is effective. In November
2019, the FASB <FONT STYLE="white-space:nowrap">issued&nbsp;ASU&nbsp;2019-10,</FONT><I>&nbsp;Financial Instruments&#151;Credit Losses (Topic 326),</I><I></I><I>&nbsp;Derivatives and Hedging (Topic 815) and Leases (Topic
842):</I><I></I><I>&nbsp;Effective Dates</I>, which defers the effective date <FONT STYLE="white-space:nowrap">of&nbsp;ASU&nbsp;2016-13</FONT> to fiscal years beginning after December&nbsp;15, 2022 for all entities except Securities and Exchange
Commission filers that are not smaller reporting <FONT STYLE="white-space:nowrap">companies.&nbsp;ASU&nbsp;2016-13</FONT> will be effective for the Company beginning January 1, 2023. The Company intends to adopt the ASU when it becomes effective.
The Company is currently evaluating the impact of this ASU and does not expect that adoption of this standard will have a material impact on its consolidated financial statements and related disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In August&nbsp;2020, the FASB issued Accounting Standards <FONT STYLE="white-space:nowrap">Update&nbsp;2020-06,</FONT> <I>Accounting for Convertible
Instruments and Contracts in an Entity&#146;s Own Equity&#148;, (&#147;ASU</I><I></I><I><FONT STYLE="white-space:nowrap">&nbsp;2020-06&#148;)</FONT></I><FONT STYLE="white-space:nowrap">.&nbsp;ASU&nbsp;2020-06&nbsp;simplifies</FONT> the accounting
for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#146;s own <FONT STYLE="white-space:nowrap">equity.&nbsp;ASU&nbsp;2020-06&nbsp;removes</FONT> from U.S.
GAAP the separation models for (i)&nbsp;convertible debt with a cash conversion feature and (ii)&nbsp;convertible instruments with a beneficial conversion feature. As a result, after adopting the&nbsp;ASU&#146;s guidance, entities will not
separately present in equity an embedded conversion feature in such debt. Instead, the entity will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of
account), unless (1)&nbsp;a convertible instrument contains features that require bifurcation as a derivative under ASC 815 or (2)&nbsp;a convertible debt instrument was issued at a substantial premium.&nbsp;In addition, the&nbsp;ASU&nbsp;also
states that entities must apply the <FONT STYLE="white-space:nowrap">if-converted</FONT> method to all convertible instruments for calculation of diluted earnings per share and the treasury stock method is no longer available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">ASU&nbsp;2020-06&nbsp;is</FONT> effective for all public entities, excluding smaller reporting entities, for fiscal
years beginning after December&nbsp;15, 2021, including interim periods within those fiscal years. For all other entities, this ASU is effective for fiscal years beginning after December&nbsp;15, 2023, including interim periods within those fiscal
years. Early adoption is permitted for fiscal years beginning after December&nbsp;31, 2020. The Company expects to early adopt this guidance beginning from January&nbsp;1, 2021. The Company is currently assessing the impact that this ASU will have
on its consolidated financial statements and related disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Recently Adopted Accounting Pronouncements&#151;</I></B>In May 2014, the
FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2014-09,</FONT> <I>Revenue from Contracts with Customers (Topic 606) </I><FONT STYLE="white-space:nowrap">(&#147;ASU&nbsp;2014-09&#148;).</FONT> Under ASC 606, an entity recognizes revenue
when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an
entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the transaction
price; (iv)&nbsp;allocate the transaction price to the performance obligations in the contract; and (v)&nbsp;recognize revenue when (or as) the entity satisfies a performance obligation.&nbsp;The ASU also states that an entity should recognize as an
asset the incremental costs of obtaining a contract that the entity expects to recover and amortize that cost over a period consistent with the period over which the transfer to the customer of the underlying good or services occurs. The Company
adopted ASC 606 on January&nbsp;1, 2019 utilizing the modified retrospective method of transition. Accordingly, the consolidated financial statements for the years ended December&nbsp;31, 2019 and 2020 are presented under ASC 606. The adoption of
the new standard did not result in a material change in the timing or amount of revenue recognized. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In August 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-13,</FONT> <I>Fair
Value Measurement (Topic</I><I></I><I>&nbsp;820):</I> <I>Disclosure Framework&#151;Changes to the Disclosure Requirements for Fair Value Measurement </I>(&#147;ASU <FONT STYLE="white-space:nowrap">2018-13&#148;).</FONT> The ASU modifies, and in
certain cases eliminates, the disclosure requirements on fair value measurements in Topic&nbsp;820. The amendments in ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-13</FONT> were effective for the Company on January&nbsp;1, 2020. Early adoption
is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-13</FONT> and delay adoption of the additional disclosures until their effective date. The
Company early adopted this standard on January&nbsp;1, 2019 and it had no impact on its consolidated financial statements and footnote disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In June 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07,</FONT> <I>Compensation-Stock Compensation
(Topic</I><I></I><I>&nbsp;718): Improvements to Nonemployee Share-Based Payment Accounting</I><I></I><FONT STYLE="white-space:nowrap">&nbsp;(&#147;ASU&nbsp;2018-07&#148;).</FONT> <FONT STYLE="white-space:nowrap">ASU&nbsp;2018-07</FONT> amends the
FASB ASC to expand the scope of FASB ASC Topic&nbsp;718,<I>&nbsp;Compensation-Stock Compensation</I>, to include accounting for share-based payment transactions for acquiring goods and services from
<FONT STYLE="white-space:nowrap">non-employees.</FONT> The amendments in <FONT STYLE="white-space:nowrap">ASU&nbsp;2018-07</FONT> are effective for all entities for annual periods, and interim periods within those annual periods, beginning after
December&nbsp;15, 2018. The Company adopted this guidance on January&nbsp;1, 2019. After the adoption of <FONT STYLE="white-space:nowrap">ASU&nbsp;2018-07,</FONT> the measurement date for nonemployee awards is the later of the adoption date of <FONT
STYLE="white-space:nowrap">ASU&nbsp;2018-07</FONT> or the date of grant, without recognition for changes in the fair value of the award. Stock-based compensation costs for nonemployees are recognized as expense over the vesting period on a
straight-line basis. The adoption of this standard did not have a material impact on the Company&#146;s financial position, results of operations or cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In August 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">2018-13,</FONT> which eliminates certain disclosure requirements for fair value
measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The Company adopted this standard on January&nbsp;1, 2020 and it did not have a material impact on its
consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>3. PROPERTY AND EQUIPMENT, NET </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Property and equipment, net consisted of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less: accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company did not have any property and equipment as of December&nbsp;31, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>4. ACCRUED EXPENSES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Accrued expenses consisted of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">External research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Payroll and employee related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued legal and other professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>5. PPP LOAN </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In April 2020,
the Company obtained a PPP&nbsp;Loan&nbsp;from First Republic Bank in the aggregate amount of $0.3&nbsp;million, which was established under the CARES Act. Under the terms of the CARES Act and the&nbsp;PPP, all or a portion of the principal amount
of the&nbsp;PPP&nbsp;Loan&nbsp;is subject to forgiveness so long as, over the <FONT STYLE="white-space:nowrap">24-week</FONT> period following the Company&#146;s receipt of the proceeds of the&nbsp;PPP&nbsp;Loan, the Company uses those proceeds for
payroll costs, rent, utility costs or the maintenance of employee and compensation levels. The&nbsp;PPP&nbsp;Loan&nbsp;is unsecured, guaranteed by the SBA, and has <FONT STYLE="white-space:nowrap">a&nbsp;two-year&nbsp;term,</FONT> maturing
in&nbsp;April 2022.&nbsp;Interest accrues on the PPP&nbsp;Loan&nbsp;beginning with the initial disbursement. The application for the forgiveness of the PPP Loan can be made during an <FONT STYLE="white-space:nowrap">8-week</FONT> period beginning
from the date of initial disbursement. Unless forgiven in whole or in part in accordance with the PPP regulation, the terms of the PPP Loan provide for the Company to make monthly payments of the principal and interest on the outstanding principal
balance of the PPP Loan equal to the balance of the PPP Loan amortized over the term of the PPP Loan beginning seven (7)&nbsp;months from the initial disbursement until maturity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The terms of the&nbsp;PPP&nbsp;loan&nbsp;provide for customary events of default including, among other things, payment defaults, breach of
representations and warranties, and insolvency events. The Company has determined to account for the PPP Loan as debt under ASC 470, <I>Debt</I>. As of December&nbsp;31, 2020, the outstanding balance of the PPP Loan was $0.3&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>6. CONVERTIBLE NOTES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Convertible Notes, Net of Unamortized Discount
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Convertible notes, net of unamortized discount consisted of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Principal value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Note discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,031</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Convertible notes, net of unamortized discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In June 2020, the convertible notes converted into Series B redeemable convertible preferred stock. There were no
convertible notes outstanding as of December&nbsp;31, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Issuance of the 2017 Notes, 2018 Notes, 2019 Notes and 2020 Notes (collectively, the &#147;Notes&#148;) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In July 2017, the Company commenced an offering to issue $2.3&nbsp;million convertible notes (&#147;2017 Notes&#148;) to certain investors with a
maturity date of December&nbsp;31, 2021. These 2017 Notes carried both a voluntary conversion feature and an automatic conversion feature. The 2017 Notes were secured and carried an interest rate of 6%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November 2018, the Company commenced an offering to issue $13.0&nbsp;million convertible notes (&#147;2018 Notes&#148;) with a maturity date of
December&nbsp;31, 2021. These 2018 Notes carried both a voluntary conversion feature and an automatic conversion feature. The 2018 Notes were secured and carried an interest rate of 6%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In December 2019, the Company issued $0.6&nbsp;million of convertible notes (&#147;2019 Notes&#148;) to certain investors with a maturity date of
December&nbsp;31, 2021. These 2019 Notes carried an automatic conversion feature only. The 2019 Notes were secured and carried an interest rate of 2%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In January, February and April 2020, the Company issued, in aggregate, $15.4&nbsp;million in convertible notes (&#147;2020 Notes&#148;) to certain
investors with a maturity date of December&nbsp;31, 2021. These 2020 Notes carried an automatic conversion feature only. The 2020 Notes were secured and carried an interest rate of 2%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Notes contained the following features: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Automatic Conversion Features &#151;</I></B>The Notes were to automatically convert into Conversion Shares upon (i)&nbsp;the sale of substantially
all of the assets of the Company (&#147;Asset Sale&#148;), (ii) the occurrence of a transaction or series of transactions in which holders of 100% of the Company&#146;s outstanding shares of stock immediately before such transaction held 50% or less
of the outstanding shares of the Company&#146;s stock or the surviving corporation immediately after such transaction (&#147;Stock Sale&#148;), and (iii)&nbsp;sale of equity securities of any kind after the issuance of the Notes for which the
Company had received consideration of at least $5.0&nbsp;million (&#147;Financing&#148;, and together with the Asset Sale and Stock Sale, collectively, &#147;Triggering Events&#148;). In the event of an Asset Sale or Stock Sale, the Conversion
Shares would be Common Stock of the Company. In the event of a Financing event, the Conversion Shares would be the class of equity shares issued in such transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Conversion Price&#151;</I></B>Upon the occurrence of a Triggering Event, the 2017 Notes would convert based on the amount equal to the lesser of
(i)&nbsp;85% of the share price paid by the investors in the Financing, Asset Sale or Stock Sale and (ii)&nbsp;$25.0&nbsp;million divided by the fully diluted capital. Upon the occurrence of a Triggering Event, the 2018 Notes, would convert based on
the amount equal to the lesser of (i)&nbsp;85% of the share price paid by the investors in the Financing, Asset Sale or Stock Sale and (ii)&nbsp;$30.0&nbsp;million divided by the fully diluted capital. Upon the occurrence of a Triggering Event, the
2019 and 2020 Notes would convert based on the amount equal to 90% of the share price paid by the investors in the Financing, Asset Sale or Stock Sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Voluntary Conversion Feature&#151;</I></B>Under the terms of the 2017 Notes, the holders of the 2017 Notes had the option to convert their notes
at any time prior to maturity into shares of the Company&#146;s common stock at a conversion price equal to the $25.0&nbsp;million divided by the fully diluted capital, provided their notes had not been previously converted pursuant to a Triggering
Event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the terms of the 2018 Notes, the holders of the 2018 Notes had the option to convert their notes at any time prior to the maturity
into shares of the Company&#146;s common stock at a conversion price equal to the $30.0&nbsp;million divided by the fully diluted capital, provided their notes had not been previously converted pursuant to a Triggering Event. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Embedded Derivatives </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company assessed all the terms of the Notes in order to identify any potential embedded features and determined that the following redemption
features required bifurcation and separate accounting as derivatives: automatic conversion feature in connection with a Financing, Asset Sale and Stock Sale. For the respective Notes, the Company bundled these features together and accounted for the
features as a single, compound embedded derivative. The Company determined the fair value of the embedded derivative as the difference between the estimated fair value of the respective Notes with and without the redemption features, which resulted
in the Company recording the respective Notes at a discount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The fair value of the bifurcated embedded derivatives as of the respective issuance
dates of the 2017 Notes, 2018 Notes, 2019 Notes and 2020 Notes was determined to be $0.3&nbsp;million, $0.9&nbsp;million, $0.2&nbsp;million, and $4.6&nbsp;million, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company amortized the debt discount over the contractual life of the Notes as a <FONT STYLE="white-space:nowrap">non-cash</FONT> interest expense
utilizing the effective interest method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">At each financial reporting period, and immediately prior to conversion, the Company remeasured the fair
value of the derivative liability bifurcated from the Notes and recognized changes in the fair value of derivative liability in the statements of operations and comprehensive loss. As of December&nbsp;31, 2019, the derivative related to the 2017
Notes and 2018 Notes had no fair value as (i)&nbsp;the conversion under Asset Sale and Stock Sale scenario was eliminated because these scenarios were not likely to occur and (ii)&nbsp;there was no difference between the fair value of the 2017 Notes
and 2018 Notes with and without the redemption features. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2019, the fair value of the derivative liability related to the
2019 Notes was $0.2&nbsp;million. As of December&nbsp;31, 2020, there was no derivative liability due to the conversion of the Notes in June 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Conversion
of the Notes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In June 2020, the Company consummated a financing transaction in which it issued shares of Series B redeemable convertible
preferred stock. The consummation of this financing transaction resulted in the automatic conversion of the Notes into shares of Series B redeemable convertible preferred stock pursuant to their original terms. The Company accounted for the
conversion of the 2017 Notes and 2018 Notes as a conversion as these notes converted pursuant to the conversion features in their original terms. The 2017 Notes and 2018 Notes converted into 2,737,494 and 8,933,907 shares of Series B redeemable
convertible preferred stock, respectively, at the effective conversion prices of $0.9988 and $1.5929, respectively. The 2019 Notes and 2020 Notes converted into 42,366 and 1,015,667 shares of Series B redeemable convertible preferred stock,
respectively, at the conversion price of $15.2767. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The 2017 Notes and 2018 Notes contained contingent beneficial conversion features, which were
not readily determinable upon the issuance of the notes because the conversion features were contingent upon the occurrence of an undetermined future financing transaction and neither the timing, including the type of security that would be issued
in such transaction, nor the value of such transaction could be estimated at the time the notes were issued. Upon the automatic conversion of the 2017 Notes in connection with the consummation of the financing transaction that resulted in the
issuance of the Series B redeemable convertible preferred stock, the Company initially recorded $0.6&nbsp;million as a debt discount that was immediately recognized through interest expense with an offset to additional
<FONT STYLE="white-space:nowrap">paid-in</FONT> capital to reflect the contingent beneficial conversion feature associated with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the conversion of the 2017 Notes into Series B redeemable convertible preferred stock. The intrinsic value of the beneficial conversion feature was calculated as the difference between
(i)&nbsp;the effective conversion price for the 2017 Notes, which was represented by the price at which the 2017 Notes converted into Series B redeemable convertible preferred stock and (ii)&nbsp;the fair value of the existing Series A redeemable
convertible preferred stock at the original commitment date (which is the only class available to benchmark to). Additionally, as the 2017 Notes included a contingent beneficial conversion feature, the Company recognized all of the unamortized
discount remaining at the date of conversion relating to the original allocation of proceeds to the bifurcated derivative to interest expense. This amounted to $0.1&nbsp;million and resulted in an increase in the carrying value of the 2017 Notes and
an immediate charge to <FONT STYLE="white-space:nowrap">non-cash</FONT> interest expense in the consolidated statements of operations and comprehensive loss. Also, there were no beneficial conversion features recorded for the Series B redeemable
convertible preferred stock, which are convertible into common stock at any time, issued upon the conversion of the 2017 Notes as there was no intrinsic value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon the automatic conversion of the 2018 Notes in connection with the consummation of the financing transaction that resulted in the issuance of the
Series B redeemable convertible preferred stock, the Company did not record beneficial conversion feature for the 2018 Notes as there was no intrinsic value attributed to the contingent beneficial conversion feature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The fair value of the Series B redeemable convertible preferred stock issued upon conversion of the 2017 Notes and the proceeds allocated to the 2017
Notes were $46.5 million and $2.6 million, respectively. The fair value of the Series B redeemable convertible preferred stock issued upon conversion of the 2018 Notes and the proceeds allocated to the 2018 Notes were $151.6&nbsp;million and
$13.7&nbsp;million, respectively. The Series B redeemable convertible preferred stock issued upon conversion of the Notes and in exchange for cash payment did not contain a recognized beneficial conversion feature at the time of issuance, but the
shares do contain a contingent beneficial conversion feature to the extent the security&#146;s conversion price decreases below the commitment date fair value of the Company&#146;s common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon conversion of the 2017 Notes and 2018 Notes, the Company derecognized the carrying values of these notes including accrued interest of
$16.4&nbsp;million and recognized Series B redeemable convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company accounted for the conversion of the 2019 Notes and
2020 Notes as an extinguishment as these notes converted pursuant to redemption features that were bifurcated as embedded derivatives at the original commitment date. The Company recorded a gain on extinguishment of convertible notes of
$0.3&nbsp;million, which is included in other expense, net in the statements of operations and other comprehensive loss. The gain on extinguishment of convertible notes is the excess of (i)&nbsp;the total carrying value of the 2019 Notes and 2020
Notes including accrued interest of $12.2&nbsp;million and the derivative liability of $6.1&nbsp;million over (ii)&nbsp;the fair value of the shares of Series B redeemable convertible preferred stock into which the 2019 Notes and 2020 Notes
converted of $18.0&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Convertible Notes&#151;Related Parties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Convertible notes&#151;related parties, net of unamortized discount consisted of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Principal value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Note discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(642</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Convertible notes&#151;related parties, net of unamortized discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There were no convertible notes issued to related parties that were outstanding as of
December&nbsp;31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with the issuance of the 2017 Notes, the Company issued, in aggregate, $1.2&nbsp;million of convertible notes
to certain related parties. These notes were issued under the same terms and conditions as the 2017 Notes. In June 2020, these convertible notes converted into Series B redeemable convertible preferred stock together with the 2017 Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with the issuance of the 2018 Notes, the Company issued, in aggregate, $10.5&nbsp;million of convertible notes to certain related parties.
These notes were issued under the same terms and conditions as the 2018 Notes. In June 2020, these convertible notes converted into Series B redeemable convertible preferred stock together with the 2018 Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with the issuance of the 2020 Notes, the Company issued, in aggregate, $4.8&nbsp;million of convertible notes to certain related parties.
These notes were issued under the same terms and conditions as the 2020 Notes. In June 2020, these convertible notes converted into Series B redeemable convertible preferred stock together with 2020 Notes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>7. PROCEEDS RECEIVED IN ADVANCE OF ISSUANCE OF 2021 NOTES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In
January 2021, the Company entered into subscription agreements with certain investors pursuant to which the Company would issue convertible notes (&#147;2021 Notes&#148;) in the aggregate amount of $27.3&nbsp;million thereafter. In advance of the
issuance of the 2021 Notes, the Company received $1.2&nbsp;million in proceeds from certain investors in December 2020. The Company recorded these proceeds as proceeds received in advance of issuance of 2021 Notes on the consolidated balance sheet
as of December&nbsp;31, 2020, as the subscription agreement and commitment to issue notes was not effective until January 2021 and the amount is not reasonably expected to be repaid by using the Company&#146;s current assets or creating current
liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>8. FAIR VALUE MEASUREMENTS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following
table presents information about the Company&#146;s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total financial liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="12"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The fair value of the derivative liabilities was measured using a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">with-and-without</FONT></FONT> valuation methodology. Inputs used to determine the estimated fair value of the derivative instruments include the probability estimates of potential settlement scenarios for the convertible
promissory notes, a present value discount rate and an estimate of the expected timing of settlement.&nbsp;Certain unobservable inputs used in the fair value measurement of the derivative instruments associated with the convertible promissory notes
are the scenario probabilities and the discount rate estimated at the valuation date.&nbsp;Generally, an increase or decrease in the discount rate would result in a directionally opposite impact to the fair value measurement of the derivative
instruments. Also, changes in the probability scenarios would have varying impacts depending on the weighting of each specific scenario. Heavier weighting toward a qualified financing would result in an increase in the fair value of the derivative
liability. Changes in these assumptions can materially affect the fair value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">An initial fair value valuation was performed at each date of
issuance of the outstanding convertible notes and subsequently remeasured as of each reporting period and immediately prior to conversion. The change in fair value between measurement dates was determined to be a gain of $0.9&nbsp;million and a loss
of $1.3&nbsp;million for the years ended December&nbsp;31, 2019 and 2020, respectively, which was recognized in the<B> </B>consolidated statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table set forth the significant inputs to the probability weighted valuation model used to value the derivative liability as of
December&nbsp;31, 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Type of Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expected Date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Probability<BR>of Event</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Discount<BR>Rate</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Qualified Financing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">March&nbsp;31,&nbsp;2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.59</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017&nbsp;Notes&nbsp;and&nbsp;2018&nbsp;Notes</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stock or Asset Sale</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">December&nbsp;31,&nbsp;2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017 Notes and 2018 Notes</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Note Reaches Maturity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">December&nbsp;31, 2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017 Notes and 2018 Notes</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Qualified Financing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">June&nbsp;30, 2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019 Notes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stock or Asset Sale</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">March&nbsp;31, 2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019 Notes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Note Reaches Maturity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">December&nbsp;31, 2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019 Notes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table set forth the significant inputs to the probability weighted valuation model used to value the
derivative liability at issuance of the 2020 Notes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Type of Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expected Date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Probability<BR>of Event</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Discount<BR>Rates</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible<BR>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Qualified Financing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">June&nbsp;30,&nbsp;2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020&nbsp;Notes</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stock or Asset Sale</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">March&nbsp;31,&nbsp;2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020 Notes</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Note Reaches Maturity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">December&nbsp;31,&nbsp;2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020 Notes</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table set forth the significant inputs to the probability weighted valuation model used to value the
derivative liability upon conversion of the Notes in June 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Type of Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Expected<BR>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Probability<BR>of Event</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Discount<BR>Rates</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Convertible Notes</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Qualified Financing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">June&nbsp;18,&nbsp;2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2017, 2018, 2019 and 2020 Notes</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stock or Asset Sale</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">n/a</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2017, 2018, 2019 and 2020 Notes</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Note Reaches Maturity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">n/a</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2017, 2018, 2019 and 2020 Notes</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There were no other assets or liabilities that were measured at fair value on a recurring basis as of December&nbsp;31,
2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table presents changes in the derivative liabilities with significant unobservable
inputs (Level&nbsp;3): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Derivative<BR>Liability</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Balance as of January&nbsp;1, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Decrease in derivative liability resulting from change in estimated fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(939</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increase in derivative liability resulting from issuance of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Balance as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increase in derivative liability resulting from issuance of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increase in derivative liability resulting from change in estimated fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Derivative liability settled upon conversion of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,128</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Balance as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>9. REDEEMABLE CONVERTIBLE PREFERRED STOCK </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In August 2016, the Company consummated a financing transaction in which it issued Series A redeemable convertible preferred stock. The issuance of the
Series A redeemable convertible preferred stock occurred pursuant to the Series A Preferred Stock Purchase Agreement the Company entered into with certain investors (the &#147;Series A Agreement&#148;). In connection with the issuance of the Series
A redeemable convertible preferred stock, certain convertible notes issued by the Company including interest accrued on such notes also converted into 2,333,276 shares of Series A redeemable convertible preferred stock. In connection with the
conversion of these notes, the Company recorded a loss on extinguishment of convertible notes of $0.6 million, which is calculated as the difference between the fair value of the Series A redeemable convertible preferred stock and the carrying value
of the notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">At the initial closing of the issuance of the Series A redeemable convertible preferred stock, the Company issued
3,000,731&nbsp;shares of Series&nbsp;A redeemable convertible preferred stock at $1.22907 per share for a total consideration of $3.7&nbsp;million. Between November 2016 and November 2017, the Company issued, in aggregate, an additional 955,602
shares of Series A redeemable convertible preferred stock at $1.22907 per share for a total consideration of $1.2&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The aggregate
purchase price of the Series&nbsp;A redeemable convertible preferred stock was $7.7&nbsp;million and incurred issuance costs of $0.1&nbsp;million, recorded as a reduction to Series&nbsp;A redeemable convertible preferred stock carrying value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In June 2020, the Company entered into a Series&nbsp;B Preferred Stock Purchase Agreement (the &#147;Series&nbsp;B Agreement&#148;) with certain
investors in which the Company issued 1,767,401 shares of Series B redeemable convertible preferred stock, $0.0001 par value, for a total consideration of $30.0&nbsp;million. In connection with the issuance of these shares, the carrying value
including accrued interest of the Notes totaling $34.7&nbsp;million automatically converted into 12,729,434 shares of Series B redeemable convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On June&nbsp;18, 2020, the Company amended its certificate of incorporation in which (i)&nbsp;the Company authorized 15,100,000 of shares of Series B
redeemable convertible preferred stock and (ii)&nbsp;the authorized number of Series A redeemable convertible preferred stock was decreased to 6,289,609 shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of each consolidated balance sheet date, the Company&#146;s redeemable convertible preferred stock
consisted of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(dollars in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred&nbsp;Shares<BR>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Stock<BR>Issuable Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series A preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,401,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,289,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,289,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,401,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,289,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,289,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(dollars in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred&nbsp;Shares<BR>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Stock<BR>Issuable Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series A preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,289,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,289,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,407,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series B preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,496,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,496,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,389,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,786,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">253,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,904,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2020, the holders of the Series A redeemable convertible preferred stock and Series B redeemable
convertible preferred stock (the &#147;Preferred Stock&#148;) have the following rights and preferences: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Conversion&#151;</I></B>On
June&nbsp;18, 2020, in connection with the conversion of the 2017 Notes, the Company adjusted the conversion price for the Series A redeemable convertible preferred stock of $1.229073 per share to $1.2065. The adjustment was made in accordance with
the anti-dilution provisions in the certificate of incorporation then in effect immediately prior to the conversion of the 2017 Notes. The adjustment to the conversion price resulted in neither modification nor extinguishment of the Series A
redeemable convertible preferred stock as the terms of the Series A redeemable convertible preferred stock were not amended. The adjustment to the conversion price resulted in additional 117,650 shares of common stock to be issued to holders of the
Series A redeemable convertible preferred stock upon conversion of such shares into common stock. As of December&nbsp;31, 2020, these additional shares of common stock were not issued and outstanding. Each Series B redeemable convertible preferred
stock is convertible into an equivalent number of common stock, at any time, at the option of the holder. The initial conversion price is the original issue price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The conversion price for the Preferred Stock is subject to adjustments for stock splits, stock dividends, or similar recapitalization, and subject to
adjustments in accordance with the antidilution provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares of Preferred Stock will automatically convert into common shares of the
Company immediately upon either (a)&nbsp;the closing of the sale of shares of common stock to the public at a price of at least $50.922231 per share (subject to adjustments for stock dividends, stock split, combination, or other similar
recapitalization with respect to the common stock), in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $50.0&nbsp;million of proceeds,
net of the underwriting discount and commissions, to the Company or (b)&nbsp;the date and time, or the occurrence of an event, specified by vote or written consent of the holders of a majority of the then outstanding shares of Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Dividends</I></B>&#151;Dividends may be paid to the holders of the Series&nbsp;A redeemable convertible preferred stock. The holders the Series A
redeemable convertible preferred stock are entitled to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
receive <FONT STYLE="white-space:nowrap">non-cumulative</FONT> dividends at a rate per annum of $0.073744 per share when and if declared by the Board of Directors. The holders of the Series B
redeemable convertible preferred stock are entitled to receive a <FONT STYLE="white-space:nowrap">non-cumulative</FONT> dividend at the rate of 6% per annum of the Series B original issue price per share when and if declared by the Board of
Directors. As of December&nbsp;31, 2019, and 2020, no cash dividends have been declared or paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Voting Rights</I></B>&#151; The holders of
the Preferred Stock are entitled to vote on any matter presented to stockholders of the Company for consideration. Each holder of the Preferred Stock will be entitled to cast the number of votes equal to the number of shares of common stock into
which the shares of the Preferred Stock held by such holder are convertible on such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Redemption&#151;</I></B>The Preferred Stock does
not contain any mandatory redemption features. In accordance with FASB ASC Topic&nbsp;480, <I>Distinguishing Liabilities from Equity (ASC</I><I></I><I>&nbsp;480)</I>, preferred stock issued with redemption provisions that are outside of the control
of the Company or that contain certain redemption rights in a deemed liquidation event is required to be presented outside of stockholders&#146; deficit on the face of the consolidated balance sheet. The Company classified the Preferred Stock
outside of the stockholders&#146; deficit as mezzanine equity because in the event of certain deemed liquidation events, which included events such as a sale or merger, that were not solely within the control of the Company, the shares of the
Preferred Stock would become redeemable at the option of the holders. As of December&nbsp;31, 2019 and 2020, the Company did not adjust the carrying values of the Preferred Stock to the redemption values of such shares since a deemed liquidation
event did not occur and the shares were not probable of becoming redeemable in the future as of the consolidated balance sheet dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Liquidation&#151;</I></B>In the event of a liquidation, deemed liquidation, dissolution or winding up of the Company, holders of the Preferred
Stock will be entitled to be paid out of the assets of the Company that are available for distribution before any payment is made to the holders of common stock. The amount to paid will be the greater of (i)&nbsp;respective original issue prices
plus any dividends declared but unpaid or (ii)&nbsp;the amount that would have been payable had all shares of Preferred Stock been converted into common stock immediately before such event. If upon any such liquidation, deemed liquidation,
dissolution or winding up of the Company, the assets of the Company available for distribution to its stockholders shall be insufficient to pay the holders of Preferred Stock the full amount to which they shall be entitled, the holders of Preferred
Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or
with respect to such shares were paid in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">After the payment of all preferential amounts required to be paid to the holders of Preferred Stock,
the remaining assets of the Company available for distribution to its stockholders shall be distributed among the holders of the shares of common stock on a pro rata basis based on the number of shares held by each such holder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>10. STOCKHOLDERS&#146; DEFICIT </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Common
Stock&#151;</I></B>Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#146;s stockholders provided, however, that, except as otherwise required by law, holders of common stock shall not be
entitled to vote on any amendment to the Corporation&#146;s Certificate of Incorporation that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or
together with the holders of one or more other such series, to vote thereon pursuant to the Certificate of Incorporation or pursuant to the Delaware General Corporation Law. Common stockholders are entitled to receive dividends, as may be declared
by the Company&#146;s Board of Directors, if any, subject </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
to the preferential dividend rights of the Preferred Stock. No dividends have been declared or paid during the years ended December&nbsp;31, 2019 and 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">At December&nbsp;31, 2019, the Company did not have sufficient authorized and unissued shares available to satisfy the potential number of shares that
would be required to satisfy Series A redeemable convertible preferred stock and stock options into common stock. However, management had the ability and intent to increase authorized shares, which they did on June&nbsp;16, 2020. At
December&nbsp;31, 2019, the Company adopted the sequencing approach based on the earliest issuance date. Therefore, stock option grants, being the first in priority as the Company established the Company&#146;s 2015 Stock Option and Grant Plan (the
&#147;2015 Plan&#148;) prior to the issuance of the Series A redeemable preferred stock, were allocated sufficient common shares. The Company allocated the remainder of the authorized and unissued shares to the Series A redeemable convertible. This
sequencing approach did not change the classification of the Series A redeemable preferred stock nor the stock options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company&#146;s common
stock available for future issuance is summarized below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock authorized</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,994,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,137,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock authorized and reserved for future issuances:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock reserved for the conversion of</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series A redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,117,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,289,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock reserved for issuance upon conversion of</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series A redeemable convertible preferred stock based on adjustments to the conversion price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock reserved for the conversion of Series B redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,496,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock reserved for the exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,224,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,012,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock reserved for future issuance of share-based awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">663,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,170,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total common stock authorized and reserved for future issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,005,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,086,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Unreserved common stock available for future issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,775,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>11. STOCK OPTION AND GRANT PLAN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>2015 Plan&#151;</I></B>The Company sponsors the 2015 Plan to encourage and enable the officers, employees, directors, consultants, and other key
persons to acquire a proprietary interest in the Company. The 2015 Plan provides for the granting of incentive stock options, <FONT STYLE="white-space:nowrap">non-statutory</FONT> stock options, and restricted stock awards to eligible employees,
officers, directors, consultants, and advisors as determined by the Board of Directors. Terms of restricted stock awards and stock option agreements, including vesting requirements, are determined by the Board of Directors or compensation committee
of the Board of Directors, subject to the provisions of the 2015 Plan. The options issued the 2015 Plan expire ten years from the grant date. The options generally vest over four or five years, with 25% vesting on the first anniversary and the
balance vesting ratably over the remaining three to four years. Through amendments on December&nbsp;9, 2015, July&nbsp;30, 2016, February&nbsp;15, 2019, and February&nbsp;26, 2020 the total number of share-based awards authorized for issuance was
increased to a total of 4,990,374. As of December&nbsp;31, 2020, there were 1,170,692&nbsp;common shares available for future grant under the 2015 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company estimates the fair value of stock option awards on the grant date using the Black-Scholes
option pricing model with the following weighted-average assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fair value of underlying common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.40</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.85</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83.01</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81.35</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The per share weighted average grant date fair value of stock options granted during the year
ended&nbsp;December&nbsp;31, 2019 and 2020 was&nbsp;$0.26 and $2.95, respectively. As of&nbsp;December&nbsp;31, 2020, total unrecognized compensation expense related to stock options totaled $3.2&nbsp;million which is expected to be recognized over
a weighted average period of&nbsp;1.6 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table summarizes the activity under the Company&#146;s stock option activity under the
2015 Plan during the year ended December&nbsp;31, 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Term<BR>(in&nbsp;years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding at January&nbsp;1, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,224,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,125,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(142,960</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cancelled or forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(195,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,012,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Exercisable at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,421,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Unvested at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,590,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the options
and the fair value of the Company&#146;s common stock for those options that had exercise prices lower than the fair value of the Company&#146;s common stock. The aggregate intrinsic value of options exercised during the years ended
December&nbsp;31, 2019 and 2020, was $0.1&nbsp;million and $0.4&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There were no restricted shares granted, vested, or
forfeited during the year ended December&nbsp;31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The grant date fair value and the stock-based compensation expense related to the vesting
of restricted stock under the 2015 Plan was $0 during the years ended December&nbsp;31, 2019 and 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Stock-Based Compensation Expense&#151;</I></B>The Company recorded stock-based compensation
expense in the following expense categories of its statements of operations and compressive loss: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>12. INCOME TAXES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There was
no provision for (benefit from) income taxes for the years ended December&nbsp;31, 2019 and 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A reconciliation of the Company&#146;s effective
income tax rate to the U.S. statutory federal income tax rate of 21% for the years ended December&nbsp;31, 2019 and 2020 is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Tax at statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">State income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Permanent items</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.1</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.8</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">ASC <FONT STYLE="white-space:nowrap">740-10</FONT> liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.1</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.4</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Prior year adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50.5</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28.2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Effective income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Deferred tax assets and liabilities reflect the net tax effects of net operating loss and tax credit carryforwards and
temporary differences between the carrying amount of assets and liabilities for financial reporting and the amounts used for tax purposes. Significant components of the Company&#146;s deferred tax assets and liabilities were as follows for the years
ended December&nbsp;31, 2019 and 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Federal net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">State net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Capitalized research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accruals and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,919</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,900</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Prepaid Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(194</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(194</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company has evaluated the positive and negative evidence bearing upon its ability to realize the
deferred tax assets. The Company has considered its history of cumulative net losses incurred since inception and has concluded that it is more likely than not that it will not realize the benefits of the deferred tax assets. Accordingly, a full
valuation allowance has been established against the net deferred tax assets as of December&nbsp;31, 2020 and 2019. The Company reevaluates the positive and negative evidence at each reporting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2019, and 2020, the Company had federal net operating loss carryforwards of approximately $10.1&nbsp;million and
$46.8&nbsp;million, respectively, and state net operating loss carryforwards of approximately $9.2&nbsp;million and $44.9&nbsp;million, respectively, which are available to reduce future taxable income. Of the $46.8&nbsp;million federal net
operating loss carryforwards, $1.3&nbsp;million begin to expire in 2034 and the remaining $45.5&nbsp;million net operating losses carryforward indefinitely. The $44.9&nbsp;million of Massachusetts net operating loss carryforwards begin to expire in
2034. As of December&nbsp;31, 2019, and 2020, the Company also had federal tax credits of $0.7&nbsp;million and $1.6&nbsp;million, respectively, and state tax credits of $0.4&nbsp;million and $0.7&nbsp;million, respectively. The tax credit
carryforwards will expire at various dates beginning in 2029. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The 2017 Tax Cuts and Jobs Act (&#147;TCJA&#148;) will generally allow losses
incurred after 2017 to be carried over indefinitely but will generally limit the net operating loss deduction to the lesser of the net operating loss carryover or 80% of a corporation&#146;s taxable income (subject to Section 382 of the Internal
Revenue Code of 1986, as amended). Also, there will be no carryback for losses incurred after 2017. Losses incurred prior to 2018 will generally be deductible to the extent of the lesser of a corporation&#146;s net operating loss carryover or 100%
of a corporation&#146;s taxable income and be available for twenty years from the period the loss was generated. On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the &#147;CARES Act&#148;) was passed by the U.S. Congress and
signed into United States law. The CARES Act temporarily allows the Company to carryback federal net operating losses arising in 2018, 2019, and 2020 to each of the five taxable years preceding the taxable year in which the loss arises. The net
operating losses generated in these years could fully offset prior year taxable income without the 80% taxable income limitation under the TCJA. Additionally, the CARES Act temporarily suspends the 80% taxable income limitation, allowing the net
operating losses carryforward to fully offset taxable income in tax years beginning before January&nbsp;1,&nbsp;2021 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The utilization of the net
operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section&nbsp;382 of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;) due to ownership
changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. The Company has not conducted a formal study to
assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as
defined by Section&nbsp;382 and 383 of the Code, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards may be subject to an annual limitation under Section&nbsp;382 and
383 of the Code, which is determined by first multiplying the value of the Company&#146;s stock at the time of the ownership change by the applicable long-term <FONT STYLE="white-space:nowrap">tax-exempt</FONT> rate, and then could be subject to
additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company has not yet conducted a study of research and development credit carryforward. Such a study, once undertaken by the Company, may result in
an adjustment to the Company&#146;s research &amp; development credit carryforward. A full valuation allowance has been provided against the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Company&#146;s research and development credit and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to
the balance sheet or statement of operations if an adjustment is required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">ASC 740 requires a valuation allowance to reduce the deferred tax assets
reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a
valuation allowance against its deferred tax assets as of December&nbsp;31, 2019 and 2020, because the Company&#146;s management has determined that it is more likely than not that these assets will not be fully realized. The increase in the
valuation allowance recoded during the year primarily relates to the net operating loss incurred by the Company as well as the increase in research and development credits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table reflects the roll-forward of the Company&#146;s valuation allowance: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Valuation allowance at beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increases recorded to income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Valuation allowance at end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company accounts for Uncertainty in Income Taxes under the provisions of ASC 740 which defines the thresholds for
recognizing the benefits of tax return positions in the consolidated financial statements as &#147;more likely than not&#148; to be sustained by the taxing authority. The tax benefit is measured based on the largest benefit that has a greater than
50% likelihood of being realized upon ultimate settlement. As of December&nbsp;31, 2019, and 2020, the Company has recorded an unrecognized tax benefit of $0.2&nbsp;million and $0.3&nbsp;million, respectively. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Balance at beginning of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Settlement/decreases related to tax positions taken during prior years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increases related to tax positions taken during prior years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increases related to tax positions taken during the current year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Balance at end of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company has reviewed the tax positions taken, or to be taken, in its tax returns for all tax years currently open to
examination by a taxing authority. Unrecognized tax benefits represent the aggregate tax effect of differences between tax return positions and the benefits recognized in the consolidated financial statements. As of December&nbsp;31, 2019, and 2020,
the Company had $0.2&nbsp;million and $0.3&nbsp;million respectively, of net unrecognized tax benefits, related to tax credit carryforwards. The Company does not expect the amount of unrecognized tax benefits to change over next 12 months. The
Company accrues interest and penalties related to unrecognized tax benefits as a component of its &#147;Provision for (benefit from) income taxes.&#148; The Company did not recognize any interest or penalties related to uncertain tax positions
during the two years ended December&nbsp;31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company files U.S. federal and state income tax returns in various jurisdictions. The tax
filings related to the Company&#146;s federal and state taxes are currently open to examination for tax years </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
2017 through 2020. There are currently no federal or state audits in process. In addition, the Company generated federal and state research and development tax credits in tax year 2016 which
would subject this year to examination when the credits are utilized in a future year. There are currently no federal or state examinations in progress. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In March 2020, the CARES Act was signed into law. The Company considered these provisions under the CARES Act and concluded that it did not have a
material impact to the Company&#146;s results of operations, cash flows and consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>13. NET LOSS PER SHARE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Net Loss per Share Attributable To Common Stockholders&#151;</I></B>Because the Company reports a net loss attributable to common stockholders,
basic and diluted net loss per share attributable to common stockholders are the same for both years presented. All preferred stock and stock options have been excluded from the computation of diluted weighted-average shares outstanding because such
securities would have an antidilutive impact. The following common stock equivalents outstanding as of December&nbsp;31, 2019 and 2020 have been excluded from the calculation of diluted net loss per share because their inclusion would have been
antidilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,224,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,012,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,289,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,904,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,870,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>14. RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Convertible Notes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with the issuance of
the 2017 Notes, the 2018 Notes and 2020 Notes, the Company issued, in aggregate, $16.5&nbsp;million of convertible promissory Notes to ALS Invest 1 B.V, Morningside Ventures Investments Limited, and certain members of the board of directors of the
Company. ALS Invest 1. B.V and Morningside Ventures Investments Limited are each a 5% significant stockholder and have appointed representatives to the board of directors of the Company. ALS Invest 1 B.V and Morningside Ventures Investments Limited
have each designated a member to the board of directors of the Company. These notes were issued under the same terms and conditions as the 2018 Notes and 2020 Notes (See Note 6). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Employment Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In July 2015, the Company
entered into employment agreements, as subsequently amended in April 2021, with Joshua Cohen and Justin Klee. Joshua Cohen and Justin Klee are <FONT STYLE="white-space:nowrap">co-founders</FONT> of the Company and both are currently <FONT
STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer <FONT STYLE="white-space:nowrap">(Co-CEO)</FONT> of the Company. The employment agreements with Mr.&nbsp;Cohen and Mr., Klee provide an annual base salary, cash bonus, a stock option
bonus, and the ability to participate in the employee benefit plans. The employment agreements with Mr.&nbsp;Cohen and Mr.&nbsp;Klee are <FONT STYLE="white-space:nowrap">at-will</FONT> employment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>15. COMMITMENTS AND CONTINGENCIES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Operating
Leases&#151;</I></B>In October 2018, the Company entered into a lease agreement (&#147;Original Lease&#148;) for its office space in Cambridge, Massachusetts. The lease commenced in December 2018 and was set to expire in December 2023. The Original
Lease did not include an option to renew at the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
end of the term. The Original Lease called for a security deposit of less than $0.1&nbsp;million. The annual rent was subject to fixed annual increases. The security deposit is included in other
assets on the consolidated balance sheet as of December&nbsp;31, 2019. The Company analyzed the terms of the Original Lease and determined that it was an operating lease (see Note 2). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In January 2020, the Company entered into an amendment (&#147;Lease Amendment&#148;) to extend the lease term of the Original Lease and to lease an
additional office space (&#147;Expansion Space&#148;). The extension of the term of the Original Lease and the lease term for the Expansion Space is six years from the date the Expansion Space was delivered to the Company, which occurred in October
2020. As a result of the Lease Amendment, the lease term of the Original Lease and the Expansion Space will expire in October 2026. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Rent expense,
including common area maintenance, parking and other rental fees for the years ended December&nbsp;31, 2019 and 2020, was $0.1&nbsp;million and $0.2&nbsp;million, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Future minimum payments under the noncancelable operating lease as of December&nbsp;31, 2020, are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Minimum&nbsp;Lease<BR>Payments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B><U>Years Ending December&nbsp;31,</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Letter of Credit&#151;</I></B>As of December&nbsp;31, 2019, the Company had paid a security deposit of less than
$0.1&nbsp;million to the landlord in connection with the Original Lease, which was set to expire in 2023. In connection with the Lease Amendment, the Company received back the initial security deposit and issued a security deposit in the form of a
letter of credit to the landlord in the amount of $0.2&nbsp;million. The security deposit will mature in 2026. The letter of credit is collateralized by restricted cash and has been classified as such on the consolidated balance sheet as of
December&nbsp;31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Legal Proceedings&#151;</I></B>The Company is not currently a party to any material legal proceedings. At each
reporting date, the Company evaluates whether or not a potential loss amount or potential range of loss is probable and reasonably estimated under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company
recognizes expenses for its costs related to its legal proceedings, as incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Royalty Payments&#151;</I></B>Between August 2016 and
February 2019, the Company entered into grant agreements with the Grantors. Under the terms of the grant agreements, the Company was granted, in aggregate, $4.3&nbsp;million in grants. These grants were provided to the Company for the purpose of
furthering the research and development of AMX0035 as a therapeutic benefit for ALS disease and Alzheimer&#146;s diseases. Under the terms of the arrangements, the Company would receive tranche of funds as it completes certain milestones. Pursuant
to the terms of the grant agreements, the Company has certain payment obligations that are contingent upon future events such as the achievement of commercialization or the receipt of proceeds from a revenue generating transaction resulting from the
projects for which the grants are used for. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the terms of the respective grant agreements among the Company, ALS Association and ALS
Finding a Cure, the Company will be required to make royalty payments to each Grantor in the total amount equal to 150% of the grant received. The royalty payments will be achieved through a combination of the following payment methods: (i)&nbsp;an
annual installment payment of 3% of net sales of any products developed under the project for which the grant was used for and (ii) 3% of cash proceeds resulting from revenue generating transaction under the project for which the grants are used
for. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the terms of the respective grant agreements among the Company, Alzheimer&#146;s Drug Discovery Foundation, the Alzheimer&#146;s
Association, and Cure Alzheimer&#146;s Fund, the Company will make royalty payments up to the maximum amount of $15.0&nbsp;million to each Grantor (or $45.0&nbsp;million in aggregate). The royalty payment will be made through a combination of the
following payment methods: (i) 4% of annual net sales of any product commercialized from the project for which the grant was used for and directly related to the treatment of the Alzheimer&#146;s disease and (ii) 15% of all royalties and cash
proceeds resulting from revenue generated transactions associated with the projects for which the grants were used for under the grant agreements. As the achievement and timing of these future royalty payments are not probable or estimable, such
amounts have not been included in the consolidated balance sheets as of December&nbsp;31, 2019 and 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>16. SUBSEQUENT EVENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2020, and for the year then ended, the Company evaluated subsequent events through April 26, 2021, the date on which these
consolidated financial statements were available for issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>2021 Notes&#151;</I></B>In January and February 2021, the Company received
$27.3&nbsp;million from the issuance of convertible notes due on June&nbsp;30, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>PPP Loan&#151;</I></B>The Company applied for
forgiveness of the&nbsp;PPP&nbsp;Loan. In March 2021, the PPP Loan was forgiven. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin155225_7"></A>AMYLYX PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>CONDENSED CONSOLIDATED BALANCE SHEETS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Amounts
in thousands, except share and per share amounts) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 12,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 76,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 14,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 130,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 3,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 3,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accrued interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">PPP Loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Proceeds received in advance of issuance of 2021 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Commitments and contingencies (Note 13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Series A redeemable convertible preferred stock, $0.0001 par value; 6,289,609 shares authorized as of
December&nbsp;31, 2020 and September&nbsp;31, 2021; 6,289,609 shares issued and outstanding as of December&nbsp;31, 2020 and September&nbsp;30, 2021, respectively; aggregate liquidation preference of $7,730</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Series B redeemable convertible preferred stock, $0.0001 par value; 15,100,000 shares authorized as of
December&nbsp;31, 2020 and September&nbsp;30, 2021; 14,496,835 shares issued and outstanding as of December&nbsp;31, 2020 and September&nbsp;30, 2021; aggregate liquidation preference of $246,070</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">C-1</FONT> redeemable convertible preferred stock, $0.0001 par value;
0 and 13,150,430 shares authorized as of December&nbsp;31, 2020 and September&nbsp;30, 2021, respectively; 0 and 13,150,430 shares issued and outstanding as of December&nbsp;31, 2020 and September&nbsp;30, 2021, respectively; aggregate liquidation
preference of $0 and $135,000 as of December&nbsp;31, 2020 and September&nbsp;30, 2021, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">C-2</FONT> redeemable convertible preferred stock, $0.0001 par value;
0 and 3,170,585 shares authorized as of December&nbsp;31, 2020 and September&nbsp;30, 2021, respectively; 0 and 3,170,585 shares issued and outstanding as of December&nbsp;31, 2020 and September&nbsp;30, 2021, respectively; aggregate liquidation
preference of $0 and $27,666 as of December&nbsp;31, 2020 and September&nbsp;30, 2021, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Common stock, $0.0001 par value; 35,000,000 and 56,500,000 shares authorized as of December&nbsp;31, 2020 and
September&nbsp;30, 2021, respectively; 6,137,206 and 6,799,157 shares issued and outstanding as of December&nbsp;31, 2020 and September&nbsp;30, 2021, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(67,914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(127,501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(66,725</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(124,070</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Total liabilities, redeemable convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 14,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 130,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated
financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin155225_8"></A>AMYLYX PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Amounts in thousands, except share and per share amounts) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(54,373</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income (expense), net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,287</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,214</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,688</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59,587</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share attributable to common stockholders &#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5.55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9.20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average shares used in computing net loss per share attributable to common stockholders&#151;basic
and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,069,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,477,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated
financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin155225_9"></A>AMYLYX PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Amounts in thousands) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(33,688</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(59,587</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other comprehensive income (loss):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Foreign currency translation adjustment, net of tax of $0 for the nine months ended September&nbsp;30, 2020
and 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Unrealized loss on short-term investments, net of tax of $0 for the nine&nbsp;months ended
September&nbsp;30, 2020 and 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(33,688</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(59,588</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin155225_10"></A>AMYLYX PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Amounts in thousands, except share amounts) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A<BR>Redeemable<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B<BR>Redeemable<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C-1<BR>Redeemable<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C-2<BR>Redeemable<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR>Paid-In</B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive</B><br><B>Loss </B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit </B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance as of December 31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,289,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,994,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,634</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,357</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of Series&nbsp;B redeemable convertible preferred stock, net of issuance costs of $35</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,767,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Conversion of convertible notes and accrued interest into Series B redeemable convertible preferred
stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,729,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Recognition of contingent beneficial conversion feature</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of common stock upon exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,688</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,688</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance as of September 30, 2020</B> <B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,289,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,496,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">64,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,093,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(59,322</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(58,270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A<BR>Redeemable<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B<BR>Redeemable<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C-1<BR>Redeemable<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C-2<BR>Redeemable<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR>Paid-In</B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive</B><br><B>Loss </B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit </B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance as of December 31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,289,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,496,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">64,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,137,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(67,914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(66,725</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of Series&nbsp;C-1 redeemable convertible preferred stock, net of issuance costs of $209</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,150,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Conversion of convertible notes and accrued interest into Series C-2 redeemable convertible preferred stock,
net of issuance costs of $50</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,170,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of common stock upon exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">661,951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59,587</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59,587</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance as of September 30, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,289,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,496,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">64,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,150,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">134,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,170,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,799,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(127,501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(124,070</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin155225_11"></A>AMYLYX PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Amounts in thousands) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash flows used in operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(33,688</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(59,587</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-cash</FONT> interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Depreciation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net amortization of premiums and discounts on investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Gain on extinguishment of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(268</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(476</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,764</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(716</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued expenses and deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued interest and accrued interest&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,809</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash flows used in investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(167</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Purchases of investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,053</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,220</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds from PPP Loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds from issuance of convertible notes&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds from issuance of convertible notes, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Issuance costs related to conversion of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds from issuance of Series B redeemable convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds from issuance of Series <FONT STYLE="white-space:nowrap">C-1</FONT> redeemable convertible
preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Payment of deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,527</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Effect of exchange rate changes on cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash, cash equivalents and restricted cash, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash, cash equivalents and restricted cash, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 20,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 76,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Supplemental disclosure of cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Recognition of initial derivative liability and associated debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 4,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Conversion of convertible notes into Series B redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 34,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Conversion of convertible notes and accrued interest into Series <FONT STYLE="white-space:nowrap">C-2</FONT>
redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 32,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Unrealized loss on short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Purchases of property and equipment included in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deferred offering costs included in accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin155225_12"></A>AMYLYX PHARMACEUTICALS,&nbsp;INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>1. NATURE OF BUSINESS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Amylyx Pharmaceuticals,&nbsp;Inc. (&#147;Amylyx&#148;) was incorporated under the laws of the State of Delaware on January&nbsp;10, 2014. In October 2020
and August 2021, Amylyx created wholly owned subsidiaries, Amylyx Pharmaceuticals Canada, Inc. (&#147;Amylyx Canada&#148;) in Calgary, Canada, and Amylyx Pharmaceuticals EMEA B.V. in Amsterdam, the Netherlands (&#147;Amylyx EMEA&#148;, and
collectively with &#147;Amylyx Canada&#148; and &#147;Amylyx&#148;, the &#147;Company&#148;). As of September 30, 2021, Amylyx EMEA did not have operations. The Company is headquartered in Cambridge, Massachusetts. The Company is a clinical stage
biotechnology company with a goal to improve the quality and length of life of patients suffering from neurodegenerative disease. The Company is pursuing commercialization of its asset, AMX0035, which it believes is the first therapeutic to show
both a functional and survival benefit in a large-scale clinical trial of patients with amyotrophic lateral sclerosis, or ALS. The Company believes AMX0035 has the potential to be a foundational therapy across a broad range of neurodegenerative
diseases. The Company has designed AMX0035 to target two key pathways of neuron death, specifically endoplasmic reticulum, or ER, stress and mitochondrial dysfunction. The Company is focused on the development of and potential commercialization of
AMX0035 for ALS globally. In addition, the Company is developing AMX0035 for other neurodegenerative diseases by leveraging its unique knowledge and relationships in the neurodegenerative space. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Risks and Uncertainties </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company is subject to
risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, the outcome of clinical trials, development by competitors of new technological innovations, dependence on key personnel,
protection of proprietary technology, compliance with government regulations, ability to secure additional capital to fund operations, and risks associated with the <FONT STYLE="white-space:nowrap">COVID-19</FONT> global pandemic, including
potential delays associated with the Company&#146;s ongoing and anticipated trials. <FONT STYLE="white-space:nowrap">COVID-19</FONT> may have an adverse impact on the Company&#146;s operations, supply chains and distribution systems or those of its
contractors, and increase expenses, including as a result of impacts associated with preventive and precautionary measures that are being taken, such as restrictions on travel and border crossings, quarantine polices and social distancing. The
Company and its contractors may experience disruptions in supply of items that are essential for its research and development activities, including, for example, raw materials and bulk drug substances that the Company imports from Europe and Canada
used in the manufacturing of AMX0035, and any future product candidates. In addition, the spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> has disrupted global healthcare and healthcare regulatory systems which could divert healthcare
resources away from, or materially delay, U.S. Food and Drug Administration (&#147;FDA&#148;) approval and approval by other health authorities worldwide with respect to AMX0035 and any future product candidates. Furthermore, the Company&#146;s
clinical trials may be negatively affected by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak. Site initiation, patient enrollment and patient <FONT STYLE="white-space:nowrap">follow-up</FONT> visits may be delayed, for example, due to
prioritization of hospital resources toward the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak, travel restrictions, the inability to access sites for initiation and monitoring, and difficulties recruiting or retaining patients in the
Company&#146;s ongoing and future clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There can be no assurance that the Company will be able to successfully complete the development
of, or receive regulatory approval for, any products developed, and if approved, that any products will be commercially viable. Any products resulting from the Company&#146;s current research and development efforts will require significant
additional research and development, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel, infrastructure,
and extensive compliance reporting capabilities. The Company has not generated any revenues from the sale of any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
products to date. Even if the Company&#146;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Going Concern </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In accordance with Accounting Standards
Update (&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">2014-15,</FONT> <I>Disclosure of Uncertainties about an Entity&#146;s Ability to Continue as a Going Concern (Subtopic <FONT STYLE="white-space:nowrap">205-40)</FONT></I>, the Company has
evaluated whether there are conditions and events that raise substantial doubt about the Company&#146;s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since its inception, the Company has devoted substantially all of its efforts to research and development activities, including recruiting management
and technical staff, raising capital, producing materials for <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical studies, and building infrastructure to support such activities. Expenses have primarily been for research and
development and related general and administrative costs. The Company has generated revenues through five grants from ALS Association, ALS Finding a Cure Foundation, Cure Alzheimer&#146;s Fund, Alzheimer&#146;s Drug Discovery Foundation and
Alzheimer&#146;s Association (collectively, the &#147;Grantors&#148;). In addition to money received from its grants, the Company has also financed its operations through the issuance of redeemable convertible preferred stock and convertible notes
(see Notes 8 and 6, respectively). In addition, the Company has financed its operations pursuant to the loan under the Paycheck Protection Program, or the PPP, of the Coronavirus Aid, Relief, and Economic Security (&#147;CARES&#148;) Act (the
&#147;PPP Loan&#148;) as administered by the Small Business Administration (&#147;SBA&#148;). In October 2021, the Company repaid the outstanding balance of its PPP Loan in full (see Note 14). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The accompanying condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets
and satisfaction of liabilities in the normal course of business. The Company has incurred recurring losses and negative cash flows from operations since inception. As of September 30, 2021, the Company had an accumulated deficit of
$127.5&nbsp;million. The Company expects its operating losses and negative operating cash flows to continue into the foreseeable future as it continues to build capabilities and develop AMX0035, and any future product candidates. These conditions
raise substantial doubt regarding the Company&#146;s ability to continue as a going concern within one year of the issuance date of the condensed consolidated financial statements. The Company&#146;s plans to address the capital shortfall include
negotiating additional equity financing and alternative sources of financial support and considering cost containment efforts. Due to the uncertainty inherent in these efforts, the Company has concluded that substantial doubt exists with respect to
its ability to continue as a going concern for at least the next twelve months from the date these condensed consolidated financial statements are issued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Basis of Presentation and Consolidation&#151;</I></B>The accompanying unaudited condensed
consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#147;GAAP&#148;) and include the accounts of the Company and its wholly owned subsidiaries, Amylyx
Canada and Amylyx EMEA, after elimination of all intercompany accounts and transactions. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification
(&#147;ASC&#148;) and ASU of the Financial Accounting Standards Board (&#147;FASB&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Unaudited interim condensed financial
information</I></B>&#151;The accompanying condensed consolidated balance sheet as of September 30, 2021, condensed consolidated statements of operations, condensed consolidated statements of comprehensive loss, condensed consolidated
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
statements of redeemable convertible preferred stock and stockholders&#146; deficit, and condensed consolidated statements of cash flows for the nine months ended September 30, 2020 and 2021, are
unaudited. The condensed consolidated balance sheet as of December 31, 2020 was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The accompanying condensed consolidated financial statements have been prepared on the basis consistent with the audited annual financial statements as
of and for the year ended December&nbsp;31, 2020, and reflect all adjustments which are, in the opinion of management, necessary for the fair presentation of the Company&#146;s financial position as of September 30, 2021, and the condensed results
of its operations and its cash flows for the nine months ended September 30, 2020 and 2021. All such adjustments made to the condensed consolidated financial statements are normal and recurring in nature. The financial data and other information
disclosed in these notes related to the nine months ended September 30, 2020 and 2021 are also unaudited. The condensed consolidated results of operations for the nine months ended September 30, 2021 are not necessarily indicative of the results to
be expected for the full year ending December 31, 2021 or any other period. These condensed consolidated financial statements should be read in conjunction with the Company&#146;s audited financial statements included elsewhere in this prospectus.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the nine months ended September 30, 2021, there were no other significant changes to the Company&#146;s significant accounting policies as
described in the Company&#146;s audited condensed consolidated financial statements as of and for the year ended December 31, 2020 except as described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Use of Estimates&#151;</I></B>The preparation of the condensed consolidated financial statements in conformity with GAAP requires the
Company&#146;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amount of expenses during the reporting periods. Actual results could
differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies in developing the estimates and assumptions that are used in the preparation of the condensed consolidated financial statements.
Management must apply significant judgment in this process. Management&#146;s estimation process often may yield a range of potentially reasonable estimates and management must select an amount that falls within that range of reasonable estimates.
Estimates are used in the following areas, among others: determining the fair value of the Company&#146;s common stock; determining the fair value of derivative liabilities; determining the fair value of convertible notes, accrued expenses; stock
option valuations; valuation of short-term investments; valuation allowance for deferred tax assets and research and development expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Restricted Cash&#151;</I></B>As of December&nbsp;31, 2020 and September 30, 2021, the Company maintained a restricted cash account with a balance
of $0.2&nbsp;million. The restricted cash represents collateral provided for a letter of credit issued as a security deposit in connection with the Company&#146;s lease of its corporate office. The lease expires in October 2026 at which time the
cash will be released from restriction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Short-Term Investments&#151;</I></B>Short-term investments are composed of corporate debt securities
and commercial paper with maturities of less than one year from the balance sheet date. The Company classifies all of its short-term investments as available-for-sale. Accordingly, these investments are recorded at fair value, which is determined
based on quoted market prices. Unrealized gains and losses on available-for-sale securities are included as a separate component of other accumulated comprehensive loss. The cost of short-term investments is adjusted for amortization of premiums and
accretion of discounts until maturity. Such amortization and accretion are included in other income, net. Realized gains and losses are included in other income, net. The Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
evaluates short-term investments for other-than-temporary impairment at the balance sheet date. Declines in fair value, if any, determined to be other than temporary-than-temporary are also
included in other income, net. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">When assessing short-term investments for other-than-temporary declines in value, the Company considers such factors
as, among other things, how significant the decline in value is as a percentage of the original cost, how long the market value of the investment has been less than its original cost, and the Company&#146;s ability and intent to retain the
investment for a period of time sufficient to allow for any anticipated recovery in fair value and market conditions in general. As of September 30, 2021, there were no impairment charges on short-term investments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Fair Value Option&#151;</I></B>As permitted under ASC 825, <I>Financial Instruments</I>, (&#147;ASC 825&#148;) the Company elected the fair value
option to account for the 2021 Notes (as defined in Note 6). In accordance with ASC 825, the Company recorded the 2021 Notes at fair value with changes in fair value recorded in the condensed consolidated statement of operations for the nine months
ended September 30, 2021. As a result of applying the fair value option, direct costs and fees related to the 2021 Notes were expensed as incurred. The Company concluded it was appropriate to apply the fair value option to the 2021 Notes because
they are liabilities that are not, in whole or in part, classified as a component of stockholders&#146; deficit. In addition, the 2021 Notes met other applicable criteria for electing fair value option under ASC 825. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Deferred Offering Costs&#151;</I></B>The Company capitalizes certain legal, professional accounting and other third-party fees that are directly
associated with in-process equity financings, including the initial public offering (IPO), as deferred costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&#146; deficit as
a reduction of proceeds generated as a result of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the condensed consolidated statements of
operations and condensed consolidated statements of comprehensive loss. The Company recorded deferred offering costs of $1.7 million, which are included in the condensed consolidated balance sheet as of September 30, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Property and Equipment, net&#151;</I></B>Property and equipment are stated at cost, net of accumulated depreciation. Depreciation of property and
equipment is calculated using the straight-line method over the estimated useful lives of the respective assets. Maintenance and repairs that do not improve or extend the life of the assets are expensed when incurred. Upon sale or retirement of
assets, the cost and accumulated depreciation are removed from the condensed consolidated balance sheets and any resulting gain or loss is reflected in the condensed consolidated statements of operations and condensed consolidated statements of
comprehensive loss in the period realized. The range of useful lives of property and equipment is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="55%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>Estimated Useful Life</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Lesser of the estimated life or remaining lease term</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">4 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Computer hardware and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">3 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Not depreciated</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Foreign Currency Translation&#151;</I></B>The functional currency of the Company is the U.S. dollar. The
functional currency of the Company&#146;s foreign subsidiaries is the applicable local currency. Assets and liabilities denominated in foreign currencies are translated into U.S. dollars, the reporting currency, at the exchange rate prevailing at
the balance sheet date. Income and expenses denominated in foreign currencies are translated into U.S. dollars at the average exchange rate for the period. Adjustments </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
from foreign currency translation, net of tax are included as a separate component of other comprehensive loss in the condensed consolidated statements of comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Fair Value Measurements&#151;</I></B>Assets and liabilities recorded at fair value on a recurring basis in the condensed consolidated balance
sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in
the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and
minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Level</I></B><B><I></I></B><B><I>&nbsp;1</I></B>&#151;Quoted prices in active markets for identical assets or
liabilities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Level</I></B><B><I></I></B><B><I>&nbsp;2</I></B>&#151;Observable inputs (other than Level&nbsp;1 quoted prices), such
as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Level</I></B><B><I></I></B><B><I>&nbsp;3</I></B>&#151;Unobservable inputs that are supported by little or no market
activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value
requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&nbsp;3. A financial instrument&#146;s level within the fair value hierarchy is based on
the lowest level of any input that is significant to the fair value measurement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company&#146;s financial instruments consist of cash, cash
equivalents, restricted cash, accounts receivable, short-term investments, accounts payable, accrued expenses and convertible notes. The Company&#146;s short-term investments are carried at fair value, determined according to Level 2 inputs to the
fair value hierarchy described above. The Company&#146;s 2021 Notes (as defined in Note 6) and derivative liability is carried at fair value, determined according to Level 3 inputs in the fair value hierarchy described above (see Note 7). The
remaining financial instruments are stated at their respective carrying amounts, which approximate fair value due to the short-term nature of these assets and liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Recent Accounting Pronouncements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>New Accounting
Pronouncements Not Yet Adopted&#151;</I></B>In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT><I>&nbsp;Leases</I> <I>(Topic</I><I></I><I>&nbsp;842)</I>&nbsp;(&#147;ASC&nbsp;842&#148;), which sets out the
principles for the recognition, measurement, presentation, and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or
operating leases based on the principle of whether the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis
over the term of the lease, for finance and operating leases, respectively. A lessee is also required to record a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and a lease liability for all leases
with a term of greater than 12&nbsp;months regardless of their classification. ASC&nbsp;842 provides a lessee with an option to not account for leases with a term of 12&nbsp;month or less as leases in the scope of the new standard. ASC&nbsp;842
supersedes the previous leases standard, ASC&nbsp;840 <I>Leases</I>. In July 2018, the FASB issued supplemental adoption guidance and clarification to ASC&nbsp;842 within </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-10,</FONT><I>&nbsp;Codification Improvements to Topic</I><I></I><I>&nbsp;842, Leases</I>&nbsp;and ASU
<FONT STYLE="white-space:nowrap">No.&nbsp;2018-11,</FONT><I>&nbsp;Leases (Topic</I><I></I><I>&nbsp;842): Targeted Improvements</I>. ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-11</FONT> provides another transition method in addition to the
existing modified retrospective transition method by allowing entities to initially apply the new leasing standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of accumulated deficit in the period of
adoption. In July 2019, the FASB delayed the effective date for this ASU for <FONT STYLE="white-space:nowrap">non-public</FONT> entities (including emerging growth companies), and this ASU is effective for fiscal years beginning after
December&nbsp;15, 2021 and interim periods within fiscal years beginning after December&nbsp;15, 2022, with early adoption permitted. The ASU is effective for the Company on January&nbsp;1, 2022 and the Company intends to adopt the ASU when it
becomes effective. The Company is currently evaluating the impact the adoption of these ASUs will have on its consolidated financial statements and related disclosures. The standard is expected to have a material impact on the consolidated balance
sheet related to the recognition of right-of-use assets and lease liabilities for operating leases. The standard is not expected to have a material impact on the consolidated statement of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In June&nbsp;2016, the FASB <FONT STYLE="white-space:nowrap">issued&nbsp;ASU&nbsp;No.&nbsp;2016-13,</FONT><I>&nbsp;Financial Instruments&#151;Credit
Losses (Topic 326) Measurement of Credit Losses on Financial Instruments</I><FONT STYLE="white-space:nowrap">&nbsp;(&#147;ASU&nbsp;2016-13&#148;),</FONT> which requires an entity to utilize a new impairment model known as the current expected credit
loss model to estimate its lifetime &#147;expected credit loss&#148; and record an allowance that, when deducted from the amortized cost basis of the financial assets and certain other instruments, including but not limited to <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities. Credit losses relating to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt
securities will be recorded through an allowance for credit losses rather than as a direct write-down to the <FONT STYLE="white-space:nowrap">security.&nbsp;ASU&nbsp;2016-13</FONT> requires a&nbsp;cumulative effect adjustment to the consolidated
balance sheet as of the beginning of the first reporting period in which the guidance is effective. In November 2019, the FASB <FONT STYLE="white-space:nowrap">issued&nbsp;ASU&nbsp;2019-10,</FONT><I> Financial Instruments&#151;Credit Losses (Topic
326),</I><I></I><I>&nbsp;Derivatives and Hedging (Topic 815) and Leases (Topic 842):</I><I></I><I>&nbsp;Effective Dates</I>, which defers the effective date <FONT STYLE="white-space:nowrap">of&nbsp;ASU&nbsp;2016-13</FONT> to fiscal years beginning
after December&nbsp;15, 2022 for all entities except Securities and Exchange Commission filers that are not smaller reporting companies. <FONT STYLE="white-space:nowrap">ASU&nbsp;2016-13</FONT> will be effective for the Company beginning January 1,
2023. The Company intends to adopt the ASU when it becomes effective. The Company is currently evaluating the impact of this ASU on its consolidated financial statements and related disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Recently Adopted Accounting Pronouncements</I></B>&#151;In August&nbsp;2020, the FASB issued ASU&nbsp;2020-06, <I>Debt with Conversion and Other
Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity&#146;s Own Equity</I> (<I>Subtopic 815-40</I>). ASU <FONT STYLE="white-space:nowrap">2020-06</FONT> simplifies the accounting for certain financial instruments with
characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#146;s own equity. ASU 2020-06 removes from U.S. GAAP the separation models for (i)&nbsp;convertible debt with a cash conversion feature and
(ii)&nbsp;convertible instruments with a beneficial conversion. In addition, the new guidance amends the accounting for certain contracts in an entity&#146;s own equity that are currently accounted for as derivatives because of specific settlement
provisions. Also, the new guidance requires entities to apply the <FONT STYLE="white-space:nowrap">if-converted</FONT> method to all convertible instruments for calculation of diluted earnings per share and the treasury stock method is no longer
available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company early adopted ASU 2020-06 on January 1, 2021 using the modified retrospective transition approach. The adoption of this
guidance did not have a material impact on the Company&#146;s condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>3. SHORT-TERM INVESTMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Short-term investments, which are classified as available-for-sale, consisted of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized<BR>Cost&nbsp;Basis</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized<BR>Loss</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair<BR>Values</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Corporate debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>4. PROPERTY AND EQUIPMENT, NET </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Property and equipment, net consisted of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Computer hardware and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less: accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>5. ACCRUED EXPENSES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Accrued
expenses consisted of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">External research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Payroll and employee related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued legal and other professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">PPP Loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In April 2020, the Company obtained a PPP&nbsp;Loan&nbsp;from First Republic Bank in the aggregate amount of
$0.3&nbsp;million, which was established under the CARES Act. Interest accrues on the PPP&nbsp;Loan&nbsp;beginning with the initial disbursement. The Company has determined to account for the PPP Loan as debt under ASC 470, <I>Debt</I>. The PPP Loan
had an outstanding balance of $0.3 million as of December&nbsp;31, 2020 and September 30, 2021. The outstanding balance of the PPP Loan is included in accrued expenses in the condensed consolidated balance sheet as of September 30, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In March 2021, the PPP Loan was forgiven in full. Notwithstanding the forgiveness, the Company intends to repay it, and has recorded the principal and
accrued interest in its condensed consolidated balance sheets. See Note 14, <I>Subsequent Events</I>, to these notes to condensed consolidated financial statements for additional information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>6. CONVERTIBLE NOTES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Convertible notes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There were no convertible notes
outstanding as of December&nbsp;31, 2020 and September 30, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Issuance of the 2017 Notes, 2018 Notes, 2019 Notes and 2020 Notes (collectively, the
&#147;Notes&#148;) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In July 2017, the Company issued $2.3&nbsp;million convertible notes (&#147;2017 Notes&#148;) to certain investors with a
maturity date of December&nbsp;31, 2021. The 2017 Notes were secured and carried an interest rate of 6%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November 2018, the Company issued
$13.0&nbsp;million convertible notes (&#147;2018 Notes&#148;) with a maturity date of December&nbsp;31, 2021. The 2018 Notes were secured and carried an interest rate of 6%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In December 2019, the Company issued $0.6&nbsp;million of convertible notes (&#147;2019 Notes&#148;) to certain investors with a maturity date of
December&nbsp;31, 2021. The 2019 Notes were secured and carried an interest rate of 2%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In January, February and April 2020, the Company issued, in
aggregate, $15.4&nbsp;million in convertible notes (&#147;2020 Notes&#148;) to certain investors with a maturity date of December&nbsp;31, 2021. The 2020 Notes were secured and carried an interest rate of 2%. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Embedded Derivatives </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company assessed all the
terms of the Notes in order to identify any potential embedded features and determined that the redemption features (which are discussed in Note 6 to the Company&#146;s audited consolidated financial statements included elsewhere in this prospectus)
included in the Notes required bifurcation and separate accounting as derivatives. The Company bundled these features together and accounted for the features as a single, compound embedded derivative. The Company determined the fair value of the
embedded derivative as the difference between the estimated fair value of the respective Notes with and without the redemption features, which resulted in the Company recording the respective Notes at a discount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The fair value of the bifurcated embedded derivatives as of the respective issuance dates of the 2017 Notes, 2018 Notes, 2019 Notes and 2020 Notes was
determined to be $0.3&nbsp;million, $0.9&nbsp;million, $0.2&nbsp;million, and $4.6&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company amortized the debt
discount over the contractual life of the Notes as a <FONT STYLE="white-space:nowrap">non-cash</FONT> interest expense utilizing the effective interest method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2020, there was no derivative liability due to the conversion of the Notes in June 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Conversion of the Notes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In June 2020, the Company
consummated a financing transaction in which it issued shares of Series B redeemable convertible preferred stock. The consummation of this financing transaction resulted in the automatic conversion of the Notes into shares of Series B redeemable
convertible preferred stock pursuant to their original terms. Immediately prior to conversion of the Notes, the Company remeasured the fair value of the derivative liability bifurcated from the Notes and recognized changes in the fair value of
derivative liability. The Company recognized $1.3 million of net loss related to change in fair value of derivative liability in its condensed consolidated statement of operations for the nine months ended September&nbsp;30, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company accounted for the conversion of the 2017 Notes and 2018 Notes as a conversion as these
Notes converted pursuant to the conversion features in their original terms. Upon the automatic conversion of the 2017 Notes, the Company recorded a contingent beneficial conversion feature of $0.6&nbsp;million as debt discount that was recognized
through interest expense and included in the condensed consolidated statement of operations for the nine months ended September&nbsp;30, 2020. Additionally, the Company recognized all of the unamortized discount remaining at the date of conversion
relating to the original allocation of proceeds to the bifurcated derivative to interest expense. This amounted to $0.1&nbsp;million and resulted in an increase in the carrying value of the 2017 Notes and an immediate charge to non-cash interest
expense, which is included in interest expense in the condensed consolidated statement of operations for the nine months ended September&nbsp;30, 2020. The Company recorded a total interest expense of $2.3 million in the condensed consolidated
statement of operations for the nine months ended September&nbsp;30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon conversion of the 2017 Notes and 2018 Notes, the Company
derecognized the carrying values of these notes including accrued interest of $16.4&nbsp;million and recognized Series B redeemable convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company accounted for the conversion of the 2019 Notes and 2020 Notes as an extinguishment as these notes converted pursuant to redemption features
that were bifurcated as embedded derivatives at the original commitment date. The Company recorded a gain on extinguishment of convertible notes of $0.3&nbsp;million, which is included in other income, net in the condensed consolidated statement of
operations for the nine months ended September 30, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Issuance of the 2021 Notes (the &#147;2021 Notes&#148;) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In January 2021, the Company issued, in aggregate, $27.3 million in convertible notes (&#147;2021 Notes&#148;) to certain investors, including related
parties, of which proceeds of $1.2 million were received in advance of issuance of the 2021 Notes in December 2020 and the remaining proceeds of $26.1&nbsp;million were received in January and February 2021. The 2021 Notes were to mature on June 30,
2022 and carried both automatic and optional conversion features. The 2021 Notes were secured and carried an interest rate of 3%. The Company recorded the $1.2&nbsp;million of proceeds received in December 2020 as proceeds received in advance of
issuance of 2021 Notes in the condensed consolidated balance sheet as of December 31, 2020, as the subscription agreement and commitment to issue the 2021 Notes was not effective until January 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The 2021 Notes contained the following features: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Automatic Conversion Features</I></B>&#151;The 2021 Notes were to automatically convert into Conversion Shares upon (i) an IPO, (ii) any
transaction in which the Company merges with, consolidates with or enters into other similar transaction with a Special Purpose acquisition Corp (&#147;SPAC&#148;), resulting in some or all of its shares being registered for sale under applicable
securities laws and listed for trading on a national or foreign exchange (&#147;De-SPAC transaction&#148;), (iii) the acquisition of the Company by another person or entity by means of any transaction in which holders of the outstanding voting
securities of the Company immediately before such transaction held less than 50% of the voting securities of the Company or the surviving corporation after such transaction or a sale of all or substantially all of the assets of the Company but
excluding De-SPAC transaction, IPO, and the occurrence of equity financing in which the Company sold shares of its preferred stock for new money and which was neither an IPO or a Qualified Financing (&#147;Change of Control&#148;) and (iv) the
closing of a sale of an equity transaction in which the Company sold shares with an aggregate gross proceeds of at least $10.0 million (&#147;Qualified Financing&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the event of a Change of Control, De-SPAC transaction, or an IPO, the Conversion Shares would be
common stock of the Company. In the event of a Qualified Financing, the Conversion Shares would be shares of preferred stock issued in such transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Optional Conversion Feature</I></B>&#151;The holders of the 2021 Notes had the option to elect to convert their notes into Conversion Shares at
the Conversion Price upon the occurrence of an equity financing in which the Company sold shares of its preferred stock for new money and which was neither an IPO or a Qualified Financing (&#147;Non-Qualified Financing&#148; and together with the
IPO, De-SPAC transaction, Change of Control, and the Qualified Financing, collectively, the &#147;Conversion Events&#148;). In the event of a Non-Qualified Financing, the Conversion Shares would be the class of equity shares issued in such
transaction. The 2021 Notes would be deemed to have converted into the Conversion Shares if no election was made by the holders of the 2021 Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Conversion Price</I></B>&#151;Upon the occurrence of an IPO, the 2021 Notes would convert into shares of common stock at the conversion price
equal to the lesser of (i) 85% of the price at which the Company offered each share of common stock in the IPO without deducting any amount for discounts, commissions, fees, or other costs and (ii) $600.0 million divided by the fully diluted
capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon the occurrence of a De-SPAC transaction, the 2021 Notes would convert into shares of common stock at the conversion price equal to
the lesser of (i) 85% of the common stock price in the De-SPAC transaction, which would be determined by dividing (x) the total consideration to be paid to common stockholders upon a De-SPAC transaction less the principal amount of the 2021 Notes
including accrued and unpaid interest by (y) the common stock issued and outstanding immediately prior to the De-SPAC transaction and that would be exchanged as a result of the De-SPAC transaction including common stock that would be issued upon the
exercise of stock options immediately before the Change of Control transaction but excluding the common stock issuable upon conversion of the 2021 Notes and (ii) $600.0 million divided by the fully diluted capital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon the occurrence of a Change of Control, the 2021 Notes would convert into shares of common stock at the conversion price equal to the lesser of (i)
85% of the common stock price in the Change of Control, which would be determined by dividing (x) the total consideration to be paid to common stockholders upon a Change of Control less the principal amount of the 2021 Notes including accrued and
unpaid interest by (y) the common stock issued and outstanding immediately prior to the Change of Control and that would be exchanged upon a Change of Control including common stock that would be issued upon the exercise of stock options before the
Change of Control but excluding the common stock issuable upon conversion of the 2021 Notes and (ii) $600.0 million divided by the fully diluted capital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon a Qualified Financing, the 2021 Notes would convert into shares of preferred stock issued in the Non-Qualified Financing at the conversion price
equal to the lesser of (i) 85% of the lowest price at which the Company sold shares of its stock in the Qualified Financing and (ii) $600.0 million divided by the fully diluted capital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Repayment</I></B>&#151;Each holder of the 2021 Notes had the option to elect to receive a payment in the amount equal to the principal amount plus
accrued and unpaid interests upon a Change of Control. If a Change of Control occurred and no election was made by the holder, the principal amount and accrued and unpaid interest would be deemed to have automatically be converted into shares of the
Company&#146;s common stock of the Company immediately prior to the close of the Change of Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company qualified for and elected to
account for the 2021 Notes under the fair value option and, in doing so, bypassed the analysis of potential embedded derivative features. The Company believes that the fair value option better reflects the underlying economics of the 2021 Notes. As
a result, the 2021 Notes were recorded at fair value upon issuance, which was determined to be equal to principal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
amounts of these notes of $27.3 million. At each financial reporting period, and immediately prior to conversion, the Company remeasured the fair value of the 2021 Notes. The total interest
expense and change in fair value of the 2021 Notes from issuance date to the conversion date totaled $5.2 million, which is recorded as change in fair value of convertible notes in the condensed consolidated statement of operations for the nine
months ended September 30, 2021. The accrued interest on the 2021 Notes based on the stated interest rate was $0.4 million as of September 30, 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Conversion of the 2021 Notes </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In July 2021, the Company consummated a financing transaction in which it issued shares of Series C-1 redeemable convertible preferred stock. The
consummation of this financing transaction resulted in the automatic conversion of the 2021 Notes into shares of Series C-2 redeemable convertible preferred stock (together with the Series C-1 redeemable convertible preferred stock, the &#147;Series
C Preferred Stock&#148;) pursuant to their original terms. The Series C Preferred Stock was determined to have a fair value of $10.265809. Under the fair value option, the 2021 Notes were remeasured to fair value immediately prior to conversion at a
price per share equal to the fair value of the Series C-1 redeemable convertible preferred stock. The Company recorded $5.2 million loss related to change in fair value of the 2021 Notes in its condensed consolidated statement of operations for the
nine months ended September 30, 2021. The 2021 Notes converted into 3,170,585 shares of Series C-2 redeemable convertible preferred stock at the effective conversion price of $8.725938. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Convertible Notes&#151;Related Parties </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There were no
convertible notes issued to related parties that were outstanding as of December&nbsp;31, 2020 and September 30, 2021. In connection with the issuance of the 2021 Notes, the Company issued, in aggregate, $14.3&nbsp;million of convertible notes to
certain related parties. These notes were issued under the same terms and conditions as the 2021 Notes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>7. FAIR VALUE MEASUREMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table presents information about the Company&#146;s financial assets and liabilities measured at fair value on a recurring basis and
indicates the level of the fair value hierarchy utilized to determine such fair values: </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="12"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Short-term investments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Corporate debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Valuation of Short-Term Investments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company estimates the fair values of the short-term investments by taking into consideration valuations obtained from third-party pricing sources.
These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market
pricing based on real-time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs. The Company validates the prices provided by our third-party pricing sources by understanding the models
used, obtaining market values from other pricing sources and analyzing pricing data in certain instances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Valuation of Derivative Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The fair value of the derivative liabilities was measured using a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">with-and-without</FONT></FONT> valuation methodology. Inputs used to determine the estimated fair value of the derivative instruments include the probability estimates of potential
settlement scenarios for the convertible promissory notes, a present value discount rate and an estimate of the expected timing of settlement.&nbsp;Certain unobservable inputs used in the fair value measurement of the derivative instruments
associated with the convertible promissory notes are the scenario probabilities and the discount rate estimated at the valuation date.&nbsp;Generally, an increase or decrease in the discount rate would result in a directionally opposite impact to
the fair value measurement of the derivative instruments. Also, a change in the probability scenarios would have varying impacts depending on the weighting of each specific scenario. Heavier weighting toward a qualified financing would result in an
increase in the fair value of the derivative liability. Changes in these assumptions can materially affect the fair value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets
forth the significant inputs to the probability weighted valuation model used to value the derivative liability at issuance of the 2020 Notes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Type of Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expected Date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Probability<BR>of Event</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Discount<BR>Rates</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible&nbsp;Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Qualified Financing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">June&nbsp;30,&nbsp;2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020&nbsp;Notes</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stock or Asset Sale</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">March&nbsp;31,&nbsp;2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020 Notes</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Note Reaches Maturity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">December&nbsp;31,&nbsp;2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020 Notes</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth the significant inputs to the probability weighted valuation model used to value the
derivative liability upon conversion of the Notes in June 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Type of Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Expected&nbsp;Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Probability<BR>of Event</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Discount<BR>Rates</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Convertible Notes</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Qualified Financing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">June&nbsp;18,&nbsp;2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2017, 2018, 2019 and 2020 Notes</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stock or Asset Sale</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">n/a</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2017, 2018, 2019 and 2020 Notes</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Note Reaches Maturity</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">n/a</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2017, 2018, 2019 and 2020 Notes</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Valuation of the 2021 Notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">At the issuance date of the 2021 Notes, the Company determined that the fair value of the 2021 Notes approximated the principal amounts of the 2021 Notes
as the transaction was deemed to be at arm&#146;s length. Subsequent measurement of fair value of the 2021 Notes at each reporting period was estimated based on significant inputs not observable in the market, which represents a Level 3 measurement
within the fair value hierarchy. The Company used a scenario-based analysis to incorporate estimates and assumptions concerning the Company&#146;s prospects and market indications into a model to estimate the value of the 2021 Notes. The most
significant estimates and assumptions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
used as inputs are those concerning timing, probability of possible scenarios for conversion or settlement of the 2021 Notes and discount rates. The fair value of the 2021 Notes upon settlement
in July 2021 was determined based on the fair value of the Series C-1 redeemable convertible preferred stock issued. This method was selected as the Company concluded that the contemporaneous financing transaction was an arm&#146;s length
transaction. The issuance of the Series C-1 redeemable convertible preferred stock was considered to be a Qualified Financing (see Note 6) pursuant to the original terms of the 2021 Notes. Accordingly, the fair value calculation for the 2021 Notes
immediately before conversion considered both the fair value of the Series C-1 redeemable convertible preferred stock and the conversion price, which was 85% of the fair value of the Series C-1 redeemable convertible preferred stock. The fair value
of the 2021 Notes as of June 30, 2021 was determined to be the same as that on the settlement date in July 2021 based on management&#146;s determination of no material changes to the assumptions underlying the determination of the fair value of the
2021 Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth the significant inputs to the probability weighted valuation model used to value the 2021 Notes as of
March 31, 2021: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Type of Event </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expected&nbsp;Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Probability&nbsp;of&nbsp;Event</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Discount&nbsp;Rates</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">SPAC / IPO Transaction</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">August&nbsp;31,&nbsp;2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.72</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Qualified Financing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">June 30, 2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.72</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Non-Qualified Financing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">June 30, 2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.72</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Notes reaches maturity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">June 30, 2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.72</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table represents changes in the derivative liabilities and 2021 Notes with significant unobservable inputs
(Level 3): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Derivative<BR>Liability </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021&nbsp;Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands) </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Balance as of January 1, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increase in derivative liability resulting from issuance of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increase in derivative liability resulting from change in estimated fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Derivative liability settled upon conversion of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,128</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Balance as of December 31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Initial fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Conversion of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,548</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Balance as of September 30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There were no other assets or liabilities that were measured at fair value on a recurring basis as of December&nbsp;31,
2020 and September 30, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>8. REDEEMABLE CONVERTIBLE PREFERRED STOCK </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In July 2021, the Company consummated a financing transaction in which it issued 13,150,430 shares of Series C-1 redeemable convertible preferred stock.
In connection with the issuance of these shares, the principal including accrued interest of the 2021 Notes totaling $27.7 million automatically converted into 3,170,585 shares of Series C-2 redeemable convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On July 1, 2021, the Company amended its certificate of incorporation in which it authorized 13,150,430 shares of Series C-1 redeemable convertible
preferred stock and 3,170,585 shares of Series C-2 redeemable convertible preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company&#146;s redeemable convertible preferred stock consisted of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(dollars in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred&nbsp;Shares<BR>Issued&nbsp;and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Stock<BR>Issuable&nbsp;Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series A preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,289,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,289,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,407,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series B preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,496,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,496,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,389,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,786,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">253,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,904,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September 30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(dollars in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred&nbsp;Shares<BR>Issued&nbsp;and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Stock<BR>Issuable&nbsp;Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series A preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,289,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,289,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,407,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series B preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,496,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,746,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series C-1 preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,150,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,150,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,150,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series C-2 preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,170,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,170,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,170,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,710,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,107,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">239,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">416,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,474,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of September 30, 2021, the holders of the Series C Preferred Stock (together with the &#147;Series A redeemable
convertible preferred stock&#148; and &#147;Series B redeemable convertible preferred stock&#148;, collectively, the &#147;Preferred Stock&#148;) have the following rights and preferences: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Conversion</I></B> &#150; In July 2021, in connection with the conversion of the 2021 Notes, the Company adjusted the conversion price for the
Series B redeemable convertible preferred stock of $16.974077 per share to $14.6942. The adjustment was made in accordance with the anti-dilution provisions in the certificate of incorporation then in effect immediately prior to the conversion of
the 2021 Notes. The adjustment to the conversion price resulted in additional 2,249,224 shares of common stock into which Series B redeemable convertible preferred stock would be convertible. As of September 30, 2021, these additional shares were
not issued and outstanding. Each share of Preferred Stock is convertible into an equivalent number of common stock, at any time, at the option of the holder. The initial conversion price for the Series C-1 redeemable convertible preferred stock and
Series C-2 redeemable convertible preferred stock is the respective original issue prices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The conversion price for the Preferred Stock is subject
to adjustments for stock splits, stock dividends, or similar recapitalization, and subject to adjustments in accordance with the anti-dilution provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares of Preferred Stock will automatically convert into common stock of the Company immediately upon either (a)&nbsp;the closing of the sale of
shares of common stock to the public in a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act, resulting in at least $75.0&nbsp;million of proceeds, net of the underwriting discount
and commissions, to the Company (a &#147;Qualified IPO&#148;) or (b)&nbsp;the date and time, or the occurrence of an event, specified by vote or written consent of the holders of a majority of the then outstanding shares of Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Dividends</I></B>&#151;Dividends may be paid to the holders of the Series&nbsp;A redeemable convertible preferred stock. The holders the Series A
redeemable convertible preferred stock are entitled to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
receive <FONT STYLE="white-space:nowrap">non-cumulative</FONT> dividends at a rate per annum of $0.073744 per share when and if declared by the Board of Directors. The holders of the Series B
redeemable convertible preferred stock are entitled to receive a <FONT STYLE="white-space:nowrap">non-cumulative</FONT> dividend at the rate of 6% per annum of the Series B original issue price per share when and if declared by the Board of
Directors. As of December&nbsp;31, 2020, and September&nbsp;30, 2021, no cash dividends were declared or paid. From and after the date of issuance of the Series C Preferred Stock, the Company will not set, declare, pay or set aside unless holders of
the Series C Preferred Stock then outstanding shall first receive, or simultaneously receive, dividends on each outstanding share of Series C Preferred Stock in an amount equal to (i) in the case of dividends being distributed to common stock or any
class or series of capital stock that is convertible into common stock, the equivalent dividend on an as-converted basis or (ii) in the case of dividends being distributed on a series or class not convertible into common stock, an additional
dividend equal to a dividend rate calculated based on the respective original issue price of the Series C Preferred Stock. The original issue price per share for the Series C-1 redeemable convertible preferred stock and Series C-2 redeemable
convertible preferred stock was $10.265809 and $8.725938, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Voting Rights</I></B>&#151; The holders of the Preferred Stock are
entitled to vote on any matter presented to stockholders of the Company for consideration. Each holder of the Preferred Stock will be entitled to cast the number of votes equal to the number of shares of common stock into which the shares of the
Preferred Stock held by such holder are convertible on such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Redemption&#151;</I></B>The Preferred Stock does not contain any mandatory
redemption features. In accordance with FASB ASC Topic&nbsp;480, <I>Distinguishing Liabilities from Equity (ASC</I><I></I><I>&nbsp;480)</I>, preferred stock issued with redemption provisions that are outside of the control of the Company or that
contain certain redemption rights in a deemed liquidation event is required to be presented outside of stockholders&#146; deficit on the face of the condensed consolidated balance sheets. The Company classified the Preferred Stock outside of the
stockholders&#146; deficit as mezzanine equity because in the event of certain deemed liquidation events, which included events such as a sale or merger, that were not solely within the control of the Company, the shares of the Preferred Stock would
become redeemable at the option of the holders. As of December&nbsp;31, 2020 and September 30, 2021, the Company did not adjust the carrying values of the Preferred Stock to the redemption values of such shares since a deemed liquidation event did
not occur and the shares were not probable of becoming redeemable in the future as of the condensed consolidated balance sheet dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Liquidation&#151;</I></B>In the event of a liquidation, deemed liquidation, dissolution or winding up of the Company, holders of the Preferred
Stock will be entitled to be paid out of the assets of the Company that are available for distribution before any payment is made to the holders of common stock. The amount to paid will be the greater of (i)&nbsp;the respective original issue prices
plus any dividends declared but unpaid or (ii)&nbsp;the amount that would have been payable had all shares of Preferred Stock been converted into common stock immediately before such event. If upon any such liquidation, deemed liquidation,
dissolution or winding up of the Company, the assets of the Company available for distribution to its stockholders shall be insufficient to pay the holders of Preferred Stock the full amount to which they shall be entitled, the holders of Preferred
Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or
with respect to such shares were paid in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">After the payment of all preferential amounts required to be paid to the holders of Preferred Stock,
the remaining assets of the Company available for distribution to its stockholders shall be distributed among the holders of the shares of common stock on a pro rata basis based on the number of shares held by each such holder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>9. STOCKHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Common Stock&#151;</B>The Company had reserved shares of common stock for issuance in connection with the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock authorized</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000,000<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>56,500,000</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,137,206<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>6,799,157</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock authorized and reserved for future issuances:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series A redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,407,259<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>6,407,256</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series B redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,496,835<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>16,746,059</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series C-1 redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>13,150,430</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series C-2 redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>3,170,585</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock reserved for exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,012,092<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>4,195,341</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock reserved for future issuance of share-based awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,170,692<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>2,809,492</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total common stock authorized and reserved for future issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,086,878<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>46,479,163</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Unreserved common stock available for future issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,775,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,221,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>10. STOCK OPTION AND GRANT PLAN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>2015 Stock Plan&#151;</I></B>The Company sponsors the 2015 Plan to encourage and enable the officers, employees, directors, consultants, and other
key persons to acquire a proprietary interest in the Company. The 2015 Stock Plan provides for the granting of incentive stock options, <FONT STYLE="white-space:nowrap">non-statutory</FONT> stock options, and restricted stock awards to eligible
employees, officers, directors, consultants, and advisors as determined by the Board of Directors. Terms of restricted stock awards and stock option agreements, including vesting requirements, are determined by the Board of Directors or compensation
committee of the Board of Directors, subject to the provisions of the 2015 Plan. The options issued the 2015 Stock Plan expire ten years from the grant date. The options generally vest over four or five years, with 25% vesting on the first
anniversary and the balance vesting ratably over the remaining three to four years. Through amendments on December&nbsp;9, 2015, July&nbsp;30, 2016, February&nbsp;15, 2019, February&nbsp;26, 2020 and July 1, 2021, the total number of share-based
awards authorized for issuance was increased to a total of 8,474,374. As of September 30, 2021, there were 2,809,492 common shares available for future grant under the 2015 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company estimates the fair value of stock option awards on the grant date using the <FONT STYLE="white-space:nowrap">Black-Scholes</FONT> option
pricing model with the following weighted-average assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fair value of underlying common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.08</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.73</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81.64</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76.28</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The per share weighted average grant date fair value of stock options granted during the nine months ended September 30,
2020 and 2021 was&nbsp;$1.91 and $4.53, respectively. As of&nbsp;September&nbsp;30, 2021, total unrecognized compensation expense related to stock options totaled $9.4&nbsp;million which is expected to be recognized over a weighted average period
of&nbsp;2.4 years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table summarizes the activity under the Company&#146;s stock option activity under the
2015 Plan during the nine months ended September 30, 2021: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Term<BR>(in&nbsp;years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding as of December 31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,012,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,947,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(661,951</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cancelled or forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding as of September 30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,195,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Exercisable as of September 30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,320,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Unvested as of September 30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,874,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the
options and the fair value of the Company&#146;s common stock for those options that had exercise prices lower than the fair value of the Company&#146;s common stock. The aggregate intrinsic value of options exercised during the nine months ended
September 30, 2020 and 2021, was $0.1&nbsp;million and $4.5&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The total fair value of stock options vested during the
nine months ended September 30, 2020 and 2021 was $0.1 million and $0.7 million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Stock-Based Compensation
Expense&#151;</I></B>The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended<BR>September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>11. NET LOSS PER SHARE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Net Loss per Share Attributable to Common Stockholders&#151;</I></B>Because the Company reports a net loss attributable to common stockholders,
basic and diluted net loss per share attributable to common stockholders are the same for both periods presented. All preferred stock and stock options have been excluded from the computation of diluted weighted-average shares outstanding because
such securities would have an antidilutive impact. The following common stock equivalents outstanding at each period end have been excluded from the calculation of diluted net loss per share because their inclusion would have been antidilutive: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,633,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,195,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,904,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,474,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>12. RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Convertible Notes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with the issuance of
the 2021 Notes, the Company issued, in aggregate, $14.3&nbsp;million of convertible promissory notes to Morningside Ventures Investments Limited, and certain members of the board of directors of the Company. Morningside Ventures Investments Limited
is a 5% significant stockholder and has appointed representatives to the board of directors of the Company. Morningside Ventures Investments Limited has designated a member to the board of directors of the Company. These notes were issued under the
same terms and conditions as the 2021 Notes (see Note 6). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>13. COMMITMENTS AND CONTINGENCIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Operating Leases&#151;</I></B>The Company&#146;s lease commitments did not materially change during the nine months ended September 30, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Letter of Credit&#151;</I></B>Restricted cash consists of cash serving as collateral for a letter of credit issued for the Company&#146;s office
space. As of December 31, 2020 and September 31, 2021, the Company&#146;s restricted cash balance was $0.2 million on its condensed consolidated balance sheets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Legal Proceedings&#151;</I></B>The Company does not believe that it is party to any pending legal proceedings that are likely to have a material
effect on its business, financial condition, or results of operations for the nine months ended September 30, 2021. At each reporting date, the Company evaluates whether or not a potential loss amount or potential range of loss is probable and
reasonably estimated under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company recognizes expenses for its costs related to its legal proceedings, as incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Royalty Payments&#151;</I></B>The Company&#146;s commitments under the royalty agreements with the Grantors did not materially change during the
nine months ended September 30, 2021. The Company did not record a liability for future royalty payments in the condensed consolidated balance sheets as of December&nbsp;31, 2020 and September 30, 2021 as the achievement and timing of the future
royalty payments were not probable or estimable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>14. SUBSEQUENT EVENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For its condensed consolidated financial statements, the Company has performed an evaluation of subsequent events through November 24, 2021, which is the
date the condensed consolidated financial statements were issued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>PPP Loan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In October 2021, the Company repaid the $0.3 million outstanding balance of its PPP Loan. See Note 5, <I>Accrued Expenses</I>, to these notes to
condensed consolidated financial statements for additional information regarding the loan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>  <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>8,750,000 Shares </B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g155225g92x08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">Common Stock </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">Prospectus </P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top"><B>Goldman&nbsp;Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>SVB&nbsp;Leerink</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Evercore&nbsp;ISI</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>H.C. Wainwright&nbsp;&amp; Co. </B></P> <P STYLE="font-size:80pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022 </P>
<P STYLE="margin-top:80pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Through and including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022, (the 25th day after the date of this
prospectus), all dealers effecting transactions in the common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to a dealer&#146;s obligation to deliver a
prospectus when acting as an underwriter and with respect to an unsold allotment or subscription. </P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;13.
Other Expenses of Issuance and Distribution. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth the expenses to be incurred in connection with the offering
described in this Registration Statement, other than underwriting discounts and commissions, all of which will be paid by us. All amounts are estimates except the Securities and Exchange Commission&#146;s registration fee, the Financial Industry
Regulatory Authority,&nbsp;Inc. filing fee and the exchange listing fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Securities and Exchange Commission registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Financial Industry Regulatory Authority,&nbsp;Inc. filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Exchange listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accountants&#146; fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">858,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Transfer Agent&#146;s fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">295,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Miscellaneous fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>    <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;14. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Section&nbsp;145 of the Delaware General Corporation Law, or the DGCL, authorizes a corporation to indemnify its directors and officers against
liabilities arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover
expenses (including attorneys&#146; fees) judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding if the director or officer acted in good
faith and in a manner the director or officer reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the director or
officer&#146;s conduct was unlawful. Section&nbsp;145 permits corporations to pay expenses (including attorneys&#146; fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding upon receipt of an
undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined that such director or officer is not entitled to be indemnified by the corporation as authorized in Section&nbsp;145. In addition,
Section&nbsp;145 provides that a corporation has the power to purchase and maintain insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or
arising out of their status as such, whether or not the corporation would have the power to indemnify the director or officer against such liability under Section&nbsp;145. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have adopted provisions in both our certificate of incorporation and bylaws to be in effect upon the completion of this offering that limit or
eliminate the personal liability of our directors to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. Consequently, a director will not be personally liable to us or our stockholders for monetary damages or
breach of fiduciary duty as a director, except for liability for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any unlawful payments related to dividends or unlawful stock purchases, redemptions or other distributions; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These limitations of liability do not alter director liability under the federal securities laws and do not affect the availability of equitable
remedies such as an injunction or rescission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, our bylaws provide that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we will indemnify our directors, officers and, in the discretion of our board of directors, certain employees to the
fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we will advance reasonable expenses, including attorneys&#146; fees, to our directors and, in the discretion of our board
of directors, to our officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of us, subject to limited exceptions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have entered into indemnification agreements with each of our directors and intend to enter into such agreements with certain of our executive
officers. These agreements provide that we will indemnify each of our directors, certain of our executive officers and, at times, their affiliates to the fullest extent permitted by Delaware law. We will advance expenses, including attorneys&#146;
fees (but excluding judgments, fines and settlement amounts), to each indemnified director, executive officer or affiliate in connection with any proceeding in which indemnification is available and we will indemnify our directors and officers for
any action or proceeding arising out of that person&#146;s services as a director or officer brought on behalf of us or in furtherance of our rights. Additionally, certain of our directors or officers may have certain rights to indemnification,
advancement of expenses or insurance provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director&#146;s or officer&#146;s services as a director
referenced herein. Nonetheless, we have agreed in the indemnification agreements that our obligations to those same directors or officers are primary and any obligation of such affiliates or other third parties to advance expenses or to provide
indemnification for the expenses or liabilities incurred by those directors are secondary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We also maintain general liability insurance which
covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriting agreement filed as Exhibit 1.1 to this registration statement provides for indemnification of us and our directors and officers by the
underwriters against certain liabilities under the Securities Act and the Exchange Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;15. Recent Sales of Unregistered Securities. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Set forth below is information regarding shares of our common stock and shares of our preferred stock issued, and stock options granted, by us within the
past three years that were not registered under the Securities Act. Included is the consideration, if any, we received for such shares and options and information relating to the section of the Securities Act, or rule of the Securities and Exchange
Commission, under which exemption from registration was claimed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>(a) Issuances of Convertible Notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On November&nbsp;9, 2018, we issued convertible promissory notes to various investors in the principal amount of $12,978,100.00. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From December&nbsp;17, 2019 to April&nbsp;22, 2020, we issued convertible promissory notes to various
investors in the principal amount of $16,042,503.77. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From January&nbsp;27, 2021 to February&nbsp;9, 2021, we issued convertible promissory notes to
various investors in the principal amount of $27,320,508.40. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">No underwriters were involved in the foregoing issuances of securities. The securities
described in this section&nbsp;(a) of Item&nbsp;15 were issued to investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section&nbsp;4(a)(2) under the Securities Act and Regulation&nbsp;D
promulgated thereunder relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. The recipients of securities in the transactions described above represented that they
were accredited investors and were acquiring the securities for their own account for investment purposes only and not with a view to, or for sale in connection with, any distribution thereof and that they could bear the risks of the investment and
could hold the securities for an indefinite period of time and appropriate legends were affixed to the instruments representing such securities issued in such transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>(b) Issuances of Capital Stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In June 2020, we
issued and sold an aggregate of 14,496,835 shares of Series B preferred stock at a price per share of $16.974077, for an aggregate purchase price of approximately $64.4&nbsp;million. Included in this amount was approximately $34.4&nbsp;million of
outstanding principal and interest on the convertible promissory notes issued between July 2017 and April 2020, all of which converted into Series B preferred stock in this financing in accordance with their terms. In July 2021, we issued and sold
an aggregate of 13,150,430 shares of Series C-1 preferred stock at a price per share of $10.265809 and 3,170,585 shares of Series C-2 preferred stock at a price per share of $8.725938, for an aggregate purchase price of approximately $162.7 million.
Included in this amount was approximately $27.7 million of outstanding principal and interest on the convertible promissory notes issued between January 2021 and February 2021, all of which converted into Series C-2 preferred stock in this financing
in accordance with their terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">No underwriters were involved in the foregoing issuance of securities. The securities described in this
section&nbsp;(b) of Item&nbsp;15 were issued to investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section&nbsp;4(a)(2) under the Securities Act and Regulation&nbsp;D promulgated
thereunder relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. The recipients of securities in the transactions described above represented that they were
accredited investors and were acquiring the securities for their own account for investment purposes only and not with a view to, or for sale in connection with, any distribution thereof and that they could bear the risks of the investment and could
hold the securities for an indefinite period of time and appropriate legends were affixed to the instruments representing such securities issued in such transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>(c) Stock Option Grants and Option Exercises. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As
of the date of this registration statement, we have granted options to purchase an aggregate of 7,196,882 shares of common stock, with exercise prices ranging from $0.001 to $8.47 per share, to employees, directors, and consultants pursuant to our
2015 Plan. Of these, options for 119,000 shares have been terminated, options for 1,690,871 shares have been exercised, and options for 5,387,011 shares remain outstanding. 1,396,492 shares remain available for grant under our 2015 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">No underwriters were involved in the foregoing issuances of securities. The issuances of stock options described in this paragraph&nbsp;(c) of
Item&nbsp;15 were issued pursuant to written compensatory plans or arrangements with our employees, directors, consultants and advisors, in reliance on the exemption </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
provided by Rule&nbsp;701 promulgated under the Securities Act, or pursuant to Section&nbsp;4(a)(2) under the Securities Act, relative to transactions by an issuer not involving any public
offering, to the extent an exemption from such registration was required. All recipients either received adequate information about us or had access, through employment or other relationships, to such information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;16. Exhibits and Financial Statement Schedules. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>(a)
Exhibits. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The exhibits to the registration statement are listed in the Exhibit Index attached hereto and incorporated by reference herein.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>(b) Financial Statement Schedules. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">No financial
statement schedules are provided because the information called for is not required or is shown either in the financial statements or the related notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit<BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d155225dex11.htm">Form of Underwriting Agreement.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000119312521359405/d155225dex31.htm">Third Amended and Restated Certificate of Incorporation of the Registrant (as currently in effect). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000119312521359405/d155225dex32.htm">Amended and Restated Bylaws of the Registrant (as currently in effect).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d155225dex33.htm">Form of Restated Certificate of Incorporation of the Registrant (to be effective prior to the closing of this offering).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d155225dex34.htm">Form of Amended and Restated Bylaws of the Registrant (to be effective prior to the closing of this offering).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d155225dex41.htm">Specimen stock certificate evidencing the shares of common stock. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000119312521359405/d155225dex42.htm">Second Amended and Restated Investors&#146; Rights Agreement, dated as of July 1, 2021, among the Registrant and the other parties
thereto.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d155225dex51.htm">Opinion of Goodwin Procter&nbsp;LLP.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d155225dex101.htm">2015 Stock Option and Incentive Plan and forms of award agreements thereunder. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d155225dex102.htm">2022 Stock Option and Incentive Plan and form of award agreements thereunder.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d155225dex103.htm">2022 Employee Stock Purchase Plan.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d155225dex104.htm">Executive Cash Incentive Bonus Plan.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d155225dex105.htm">Non-Employee Director Compensation Plan.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000119312521359405/d155225dex106.htm">Lease Agreement, dated as of October&nbsp;23, 2018, as amended, by and between the Registrant and Bullfinch Square Limited
Partnership.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d155225dex107.htm">Employment Agreement, dated as of July 1, 2015, between the Registrant and Josh Cohen (as currently in effect). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d155225dex108.htm">Employment Agreement, dated as of August 1, 2015, between the Registrant and Justin Klee (as currently in effect). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d155225dex109.htm">Employment Agreement, dated as of January 25, 2021, between the Registrant and James Frates (as currently in effect). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d155225dex1010.htm">Employment Agreement, dated as of May 13, 2019, between the Registrant and Margaret Olinger, as amended (as currently in effect). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d155225dex1011.htm">Employment Agreement, dated as of March 18, 2019, between the Registrant and Patrick&nbsp;D. Yeramian, M.D., as amended (as currently in effect). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d155225dex1012.htm">Form of Employment Agreement, between the Registrant and Josh Cohen (to be entered into in connection with this offering). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d155225dex1013.htm">Form of Employment Agreement, between the Registrant and Justin Klee (to be entered into in connection with this offering). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d155225dex1014.htm">Form of Employment Agreement, between the Registrant and James Frates (to be entered into in connection with this offering).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d155225dex1015.htm">Form of Employment Agreement, between the Registrant and Margaret Olinger (to be entered into in connection with this offering).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d155225dex1016.htm">Form of Employment Agreement, between the Registrant and Patrick D. Yeramian, M.D. (to be entered into in connection with this offering).</A></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit<BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.17#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001658551/000119312521359405/d155225dex1012.htm">Form of Director Indemnification Agreement.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.18#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001658551/000119312521359405/d155225dex1013.htm">Form of Officer Indemnification Agreement. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.19+**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001658551/000119312521359405/d155225dex1014.htm">Master Manufacturing Services Agreement, dated as of November&nbsp;12, 2019, by and between the Registrant and Patheon Inc.
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.20+**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001658551/000119312521359405/d155225dex1015.htm">Supply Agreement, dated as of October&nbsp;29, 2019, by and between the Registrant and CU Chemie Uetikon GmbH.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.21+**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001658551/000119312521359405/d155225dex1016.htm">Research, Development and Supply Agreement, dated as of December&nbsp;
9, 2019, and Deed of Amendment, dated as of July 26, 2021, by and between the Registrant and ICE S.p.A. (formerly Prodotti Chimici e Alimentari S.p.A.), as amended.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000119312521359405/d155225dex211.htm">Subsidiaries of the Registrant.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d155225dex231.htm">Consent of Deloitte&nbsp;&amp; Touche LLP, independent registered public accounting firm. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d155225dex51.htm">Consent of Goodwin Procter&nbsp;LLP (included in Exhibit&nbsp;5.1).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000119312521359405/d155225ds1.htm#poa">Power of Attorney (included on signature page).</A></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Filed herewith. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Previously filed. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">+</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Portions of this exhibit (indicated by asterisks) have been omitted in accordance with Item&nbsp;601(b)(10) of Regulation
S-K. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Indicates a management contract or any compensatory plan, contract or arrangement. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;17. Undertakings. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">(a) The undersigned registrant
hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">(b) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is,
therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful
defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">(c) The undersigned registrant hereby undertakes that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus
filed as part of this registration statement in reliance upon Rule&nbsp;430A and contained in a form of prospectus filed by the registrant pursuant to Rule&nbsp;424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of
this registration statement as of the time it was declared effective. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form
of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="poa"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Registration Statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 3<SUP STYLE="font-size:85%; vertical-align:top">rd</SUP> day of January, 2022. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AMYLYX PHARMACEUTICALS,&nbsp;INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Joshua Cohen</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Joshua Cohen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I><FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer</I></TD></TR>
</TABLE></DIV>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed
by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="20%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Joshua Cohen</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Joshua
Cohen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer and Director (Principal Executive Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>January&nbsp;3,&nbsp;2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Justin Klee</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Justin
Klee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer and Director (Principal Executive Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>January&nbsp;3,&nbsp;2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ James M. Frates</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">James M.
Frates, MBA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>January&nbsp;3,&nbsp;2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">George Mclean Milne Jr,
Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>January&nbsp;3,&nbsp;2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Paul Fonteyne, MS, MBS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>January&nbsp;3,&nbsp;2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Isaac Cheng, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>January&nbsp;3,&nbsp;2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Daphne Quimi, MBA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>January&nbsp;3,&nbsp;2022</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">*By: /s/ Joshua Cohen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:10pt"><U>Name:</U> Joshua Cohen</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL"><U>Title: Attorney-in-fact</U></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d155225dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amylyx Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&#151;
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I><U>Underwriting Agreement </U></I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">[&#149;], 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SVB Leerink LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Evercore Group L.L.C. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As representatives (the &#147;Representatives&#148;) of the several Underwriters named in Schedule I hereto, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Goldman Sachs&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 West Street, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10282-2198 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o SVB Leerink LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">53 State Street, 40<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02109 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Evercore Group L.L.C. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">55 E. 52nd St. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10055 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amylyx Pharmaceuticals,
Inc., a Delaware corporation (the &#147;Company&#148;), proposes, subject to the terms and conditions stated in this agreement (this &#147;Agreement&#148;), to issue and sell to the Underwriters named in Schedule I hereto (the
&#147;Underwriters&#148;) an aggregate of [&#149;] shares<B> </B>(the &#147;Firm Shares&#148;)<B> </B>and, at the election of the Underwriters, up to [&#149;] additional shares (the &#147;Optional Shares&#148;) of common stock, par value $0.0001 per
share (&#147;Stock&#148;) of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section&nbsp;2 hereof being collectively called the &#147;Shares&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC (the &#147;Directed Share Underwriter&#148;) has agreed to reserve up to [&#149;] of the Shares to be
purchased by it under this Agreement for sale at the direction of the Company to certain parties related to the Company (such parties, collectively, &#147;Participants&#148; and such program, the &#147;Directed Share Program&#148;). The Shares to be
sold by the Directed Share Underwriter pursuant to the Directed Share Program are hereinafter called the &#147;Directed Shares.&#148; Any Directed Shares not confirmed for purchase by the deadline established therefor by the Directed Share
Underwriter in consultation with the Company will be offered to the public by the Underwriters as set forth in the Prospectus. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The Company represents and warrants to, and agrees with, each of the Underwriters that:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) A registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-261703)</FONT> (the &#147;Initial Registration Statement&#148;) in respect of the Shares has been filed with the Securities and Exchange Commission (the &#147;Commission&#148;); the Initial Registration
Statement and any <FONT STYLE="white-space:nowrap">post-effective</FONT> amendment thereto, each in the form heretofore delivered to you, have been declared effective by the Commission in such form; other than a registration statement, if any,
increasing the size of the offering (a &#147;Rule 462(b) Registration Statement&#148;), filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the &#147;Act&#148;), which became effective upon filing, no other document with
respect to the Initial Registration Statement has been filed with the Commission; and no stop order suspending the effectiveness of the Initial Registration Statement, any post-effective amendment thereto or the Rule 462(b) Registration Statement,
if any, has been issued and no proceeding for that purpose or pursuant to Section&nbsp;8A of the Act has been initiated or threatened by the Commission (any preliminary prospectus included in the Initial Registration Statement or filed with the
Commission pursuant to Rule 424(a) of the rules and regulations of the Commission under the Act is hereinafter called a &#147;Preliminary Prospectus&#148;; the various parts of the Initial Registration Statement and the Rule 462(b) Registration
Statement, if any, including all exhibits thereto and including the information contained in the form of final prospectus filed with the Commission pursuant to Rule 424(b) under the Act in accordance with Section&nbsp;5(a) hereof and deemed by
virtue of Rule 430A under the Act to be part of the Initial Registration Statement at the time it was declared effective, each as amended at the time such part of the Initial Registration Statement became effective or such part of the Rule 462(b)
Registration Statement, if any, became or hereafter becomes effective, are hereinafter collectively called the &#147;Registration Statement&#148;; the Preliminary Prospectus relating to the Shares that was included in the Registration Statement
immediately prior to the Applicable Time (as defined in Section&nbsp;1(c) hereof) is hereinafter called the &#147;Pricing Prospectus&#148;;<B> </B>such final prospectus, in the form first filed pursuant to Rule 424(b) under the Act, is hereinafter
called the &#147;Prospectus&#148;; any oral or written communication with potential investors undertaken in reliance on Section&nbsp;5(d)<B> </B>of the Act or Rule 163B under the Act is hereinafter called a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">&#147;Testing-the-Waters</FONT></FONT> Communication&#148;; and any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is a written communication within
the meaning of Rule 405 under the Act is hereinafter called a &#147;Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication&#148;;<B> </B>and any &#147;issuer free writing
prospectus&#148; as defined in Rule 433 under the Act relating to the Shares is hereinafter called an &#147;Issuer Free Writing Prospectus&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) (A) No order preventing or suspending the use of any Preliminary Prospectus or any Issuer Free Writing Prospectus has been issued by the
Commission, and (B)&nbsp;each Preliminary Prospectus, at the time of filing thereof, conformed in all material respects to the requirements of the Act and the rules and regulations of the Commission thereunder, and did not contain an untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; <I>provided</I>, <I>however</I>,
that this representation and warranty shall not apply to any statements or omissions made in reliance upon and in conformity with the Underwriter Information (as defined in Section&nbsp;9(b) of this Agreement); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) For the purposes of this Agreement, the &#147;Applicable Time&#148; is [&#149;] (Eastern
time) on the date of this Agreement. The Pricing Prospectus, as supplemented by the information listed on Schedule II(c) hereto, taken together (collectively, the &#147;Pricing Disclosure Package&#148;), as of the Applicable Time, did not, and as of
each Time of Delivery (as defined in Section&nbsp;4(a) of this Agreement) (as supplemented by any post-effective amendment thereto) will not, include any untrue statement of a material fact or omit to state any material fact necessary in order to
make the statements therein, in the light of the circumstances under which they were made, not misleading; and each Issuer Free Writing Prospectus and each Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication does not conflict with the information contained in the Registration Statement, the Pricing Prospectus or the Prospectus and each Issuer
Free Writing Prospectus and each Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, as supplemented by and taken together with the Pricing Disclosure Package, as of the
Applicable Time, did not , and as of each<B> </B>Time of Delivery (as supplemented by any post-effective amendment thereto) will not, include any untrue statement of a material fact or omit to state any material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not misleading; provided, however, that this representation and warranty shall not apply to statements or omissions made in reliance upon and in conformity with the
Underwriter Information; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) No documents were filed with the Commission since the Commission&#146;s close of business on the business
day immediately prior to the date of this Agreement and prior to the execution of this Agreement, except as set forth on Schedule II(b) hereto; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Registration Statement conforms, and the Prospectus and any further amendments or supplements to the Registration Statement and the
Prospectus will conform, in all material respects to the requirements of the Act and the rules and regulations of the Commission thereunder and do not and will not, as of the applicable effective date as to each part of the Registration Statement,
as of the applicable filing date as to the Prospectus and any amendment or supplement thereto, and as of each<B> </B>Time of Delivery, contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or
necessary to make the statements therein not misleading; provided, however, that this representation and warranty shall not apply to any statements or omissions made in reliance upon and in conformity with the Underwriter Information; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Neither the Company nor any of its subsidiaries has, since the date of the latest audited financial statements included in the Pricing
Prospectus, (i)&nbsp;sustained any material loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree or
(ii)&nbsp;entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company and its subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that is
material to the Company and its subsidiaries taken as a whole, in each case otherwise than as set forth or contemplated in the Pricing Prospectus; and, since the respective dates as of which information is given in the Registration Statement and the
Pricing Prospectus, there has not been (x)&nbsp;any change in the capital stock (other than as a result of (i)&nbsp;the exercise, if any, of stock options or the award, if any, of stock options or restricted stock in the ordinary course of business
pursuant to the Company&#146;s equity plans that are described in the Pricing Prospectus and the Prospectus or (ii)&nbsp;the issuance, if any, of stock upon conversion of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company securities as described in the Pricing Prospectus and the Prospectus) or <FONT STYLE="white-space:nowrap">long-term</FONT> debt of the Company or any of its subsidiaries or (y)&nbsp;any
Material Adverse Effect (as defined below); as used in this Agreement, &#147;Material Adverse Effect&#148; shall mean any material adverse change or effect, or any development involving a prospective material adverse change or effect, in or
affecting (i)&nbsp;the business, properties, general affairs, management, financial position, stockholders&#146; equity, results of operations or prospects of the Company and its subsidiaries, taken as a whole, except as set forth or contemplated in
the Pricing Prospectus, or (ii)&nbsp;the ability of the Company to perform its obligations under this Agreement, including the issuance and sale of the Shares, or to consummate the transactions contemplated in the Pricing Prospectus and the
Prospectus; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The Company and its subsidiaries do not own any real property and have good and marketable title to all personal property
owned by them, in each case free and clear of all liens, encumbrances and defects except such as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the
Company and its subsidiaries; and any real property and buildings held under lease by the Company and its subsidiaries are held by them under valid, subsisting and enforceable leases with such exceptions as are not material and do not materially
interfere with the use made and proposed to be made of such property and buildings by the Company and its subsidiaries; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Each of the
Company and its subsidiaries has been (i)&nbsp;duly organized and is validly existing and in good standing under the laws of its jurisdiction of organization, with power and authority (corporate and other) to own and/or lease its properties and
conduct its business as described in the Pricing Prospectus, and (ii)&nbsp;duly qualified as a foreign corporation or other form of entity for the transaction of business and is in good standing under the laws of each other jurisdiction in which it
owns or leases properties or conducts any business so as to require such qualification, except, in the case of this clause (ii), where the failure to be so qualified or in good standing would not, individually or in the aggregate, have a Material
Adverse Effect, and each subsidiary of the Company has been listed in the Registration Statement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Company has an authorized
capitalization as set forth in the Pricing Prospectus and all of the issued shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and
conform, in all material respects, to the description of the Stock contained in the Pricing Disclosure Package and Prospectus; and all of the issued shares of capital stock of the Company&#146;s subsidiaries have been duly and validly authorized and
issued, are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and (except, in the case of any foreign subsidiary, for directors&#146; qualifying shares) are owned directly or indirectly by the Company, free and clear of all
liens, encumbrances, equities or claims; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) The unissued Shares to be issued and sold by the Company to the Underwriters hereunder have
been duly and validly authorized and, when issued and delivered against payment therefor as provided herein, will be duly and validly issued and fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and will conform in all material
respects to the description of the Stock contained in the Pricing Disclosure Package and the Prospectus; and the issuance of the Shares is not subject to any preemptive or similar rights; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) The issue and sale of the Shares and the compliance by the Company with this Agreement
and the consummation of the transactions contemplated in this Agreement and the Pricing Prospectus will not conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, (A)&nbsp;any indenture,
mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company
or any of its subsidiaries is subject, (B)&nbsp;the certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> (or other applicable organizational document) of the Company or any of its subsidiaries, or (C)&nbsp;any statute or
any judgment, order, rule or regulation of any court or governmental agency or body having jurisdiction over the Company or any of its subsidiaries or any of their properties (except in the case of clauses (A)&nbsp;and (C), for such defaults,
breaches, or violations as would not, individually or in the aggregate, have a Material Adverse Effect); and no consent, approval, authorization, order, registration or qualification of or with any such court or governmental agency or body is
required for the issue and sale of the Shares or the consummation by the Company of the transactions contemplated by this Agreement or the offering of the Directed Shares in any jurisdiction where the Directed Shares are being offered, except such
as have been obtained under the Act<B>, </B>the approval by the Financial Industry Regulatory Authority (&#147;FINRA&#148;) of the underwriting terms and arrangements and such consents, approvals, authorizations, registrations or qualifications as
may be required under state securities or Blue Sky laws in connection with the purchase and distribution of the Shares by the Underwriters; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) Neither the Company nor any of its subsidiaries is (i)&nbsp;in violation of its certificate of incorporation or <FONT
STYLE="white-space:nowrap">by-laws</FONT> (or other applicable organizational document), (ii) in violation of any statute or any judgment, order, rule or regulation of any court or governmental agency or body having jurisdiction over the Company or
any of its subsidiaries or any of their properties, or (iii)&nbsp;in default in the performance or observance of any obligation, agreement, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement, lease or other
agreement or instrument to which it is a party or by which it or any of its properties may be bound, except, in the case of the foregoing clauses (ii)&nbsp;and (iii), for such violations or defaults as would not, individually or in the aggregate,
have a Material Adverse Effect; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) The statements set forth in the Pricing Prospectus and Prospectus under the caption &#147;Description
of Capital Stock&#148;, insofar as they purport to constitute a summary of the terms of the Stock, under the caption &#147;Material U.S. Federal Income Tax Consequences for <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders&#148;, and under
the caption &#147;Underwriting&#148;, insofar as they purport to describe the provisions of the laws and documents referred to therein, are accurate, complete and fair in all material respects; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) Other than as set forth in the Pricing Prospectus, there are no legal, governmental or regulatory investigations, actions, demands,
claims, suits, arbitrations, inquiries or proceedings (&#147;Actions&#148;) pending to which the Company or any of its subsidiaries or, to the Company&#146;s knowledge, any officer or director of the Company, is a party or of which any property of
the Company or any of its subsidiaries is the subject which, if determined adversely to the Company or any of its subsidiaries (or such officer or director), would individually or in the aggregate have a Material Adverse Effect; and, to the
Company&#146;s knowledge, no such proceedings are threatened or contemplated by governmental authorities or others; there are no current or pending Actions that are required under the Act to be described in the Registration Statement or the Pricing
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Prospectus that are not so described therein; and there are no statutes, regulations or contracts or other documents that are required under the Act to be filed as exhibits to the Registration
Statement or described in the Registration Statement, the Pricing Prospectus that are not so filed as exhibits to the Registration Statement or described in the Registration Statement and the Pricing Prospectus; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) The Company is not and, after giving effect to the offering and sale of the Shares and the application of the proceeds thereof, will not
be an &#147;investment company&#148;, as such term is defined in the Investment Company Act of 1940, as amended (the &#147;Investment Company Act&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) At the time of filing the Initial Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that
the Company or any offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) under the Act) of the Shares, and at the date hereof, the Company was not and is not an &#147;ineligible issuer,&#148; as defined under Rule 405
under the Act; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) There are (and prior to the Time of Delivery, will be) no debt securities or preferred stock issued or guaranteed by
the Company that are rated by a &#147;nationally recognized statistical rating organization&#148;, as such term is defined in Section&nbsp;3(a)(62) under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) Deloitte&nbsp;&amp; Touche LLP, which has certified certain financial statements of the Company and its subsidiaries, is an independent
public accounting firm as required by the Act and the rules and regulations of the Commission thereunder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) The Company maintains a
system of internal control over financial reporting (as such term is defined in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> under the Exchange Act) that (i)&nbsp;complies with the requirements of the Exchange Act, (ii)&nbsp;has been
designed by the Company&#146;s principal executive officer and principal financial officer, or under their supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles and (iii)&nbsp;is sufficient to provide reasonable assurance that (A)&nbsp;transactions are executed in accordance with management&#146;s general or specific
authorization, (B)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain accountability for assets, (C)&nbsp;access to assets is
permitted only in accordance with management&#146;s general or specific authorization and (D)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to
any differences; and the Company&#146;s internal control over financial reporting is effective and the Company is not aware of any material weaknesses in its internal control over financial reporting (it being understood that this subsection shall
not require the Company to comply with Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended (the &#147;Sarbanes-Oxley Act&#148;) as of an earlier date than it would otherwise be required to so comply under applicable law); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) Since the date of the latest audited financial statements included in the Pricing Prospectus and the Prospectus, there has been no change
in the Company&#146;s internal control over financial reporting that has materially and adversely affected, or is reasonably likely to materially and adversely affect, the Company&#146;s internal control over financial reporting; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) The Company maintains disclosure controls and procedures (as such term is defined in
Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> under the Exchange Act) that comply with the requirements of the Exchange Act; such disclosure controls and procedures have been designed to ensure that material information relating to the
Company and its subsidiaries is made known to the Company&#146;s principal executive officer and principal financial officer by others within those entities; and such disclosure controls and procedures are effective; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) This Agreement has been duly authorized, executed and delivered by the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) Neither the Company nor any of its subsidiaries, nor any director or officer of the Company nor, to the Company&#146;s knowledge, any
other employee of the Company or any of its subsidiaries, any agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries has (i)&nbsp;made, offered, promised or authorized any unlawful
contribution, gift, entertainment or other unlawful expense (or taken any act in furtherance thereof); (ii) made, offered, promised or authorized any direct or indirect unlawful payment; or (iii)&nbsp;violated or is in violation of any provision of
the Foreign Corrupt Practices Act of 1977, as amended, or the rules and regulations thereunder, the Bribery Act 2010 of the United Kingdom or any other applicable anti-corruption, anti-bribery or related law, statute or regulation (collectively,
&#147;Anti-Corruption Laws&#148;); the Company and its subsidiaries have conducted their businesses in compliance with Anti-Corruption Laws and have instituted and maintained and will continue to maintain policies and procedures reasonably designed
to promote and achieve compliance with such laws and with the representations and warranties contained herein; neither the Company nor any of its subsidiaries will use, directly or indirectly, the proceeds of the offering in furtherance of an offer,
payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any person in violation of Anti-Corruption Laws; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with the requirements of
applicable anti-money laundering laws, including, but not limited to, the Bank Secrecy Act of 1970, as amended by the USA PATRIOT ACT of 2001, and the rules and regulations promulgated thereunder, and the anti-money laundering laws of the various
jurisdictions in which the Company and its subsidiaries conduct business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by any governmental agency (collectively, the
&#147;Money Laundering Laws&#148;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is
pending or, to the knowledge of the Company, threatened; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) Neither the Company nor any of its subsidiaries, nor any director or officer
of the Company nor, to the Company&#146;s knowledge, any other employee of the Company or its subsidiary or any agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries is (i)&nbsp;currently the
subject or the target of any sanctions administered or enforced by the U.S. Government, including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (&#147;OFAC&#148;), or the U.S. Department of State
and including, without limitation, the designation as a &#147;specially designated national&#148; or &#147;blocked person,&#148; the European Union, Her Majesty&#146;s Treasury, the United Nations Security Council, or other relevant sanctions
authority </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(collectively, &#147;Sanctions&#148;), (ii) located, organized, or resident in a country or territory that is the subject or target of Sanctions (a &#147;Sanctioned Jurisdiction&#148;), and the
Company will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i)&nbsp;to fund or
facilitate any activities of or business with any person, or in any country or territory, that, at the time of such funding, is the subject or the target of Sanctions or (ii)&nbsp;in any other manner that will result in a violation by any person
(including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions; neither the Company nor any of its subsidiaries is engaged in, or has, at any time in the past five years, engaged in, any
dealings or transactions with or involving any individual or entity that was or is, as applicable, at the time of such dealing or transaction, the subject or target of Sanctions or with any Sanctioned Jurisdiction; the Company and its subsidiaries
have instituted, and maintain, policies and procedures designed to promote and achieve continued compliance with Sanctions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) The
financial statements included in the Registration Statement, the Pricing Prospectus and the Prospectus, together with the related schedules and notes, present fairly in all material respects the financial position of the Company and its subsidiaries
at the dates indicated and the statement of operations, stockholders&#146; equity and cash flows of the Company and its subsidiaries for the periods specified; said financial statements have been prepared in conformity with U.S. generally accepted
accounting principles (&#147;GAAP&#148;) applied on a consistent basis throughout the periods involved. The supporting schedules, if any, present fairly in accordance with GAAP, in all material respects, the information required to be stated
therein. The selected financial data and the summary financial information included in the Registration Statement, the Pricing Prospectus and the Prospectus present fairly, in all material respects, the information shown therein and, other than <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> measures, have been compiled on a basis consistent with that of the audited financial statements included therein. Except as included therein, no historical or pro forma financial statements or supporting
schedules are required to be included in the Registration Statement, the Pricing Prospectus or the Prospectus under the Act or the rules and regulations promulgated thereunder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) From the time of initial confidential submission of a registration statement relating to the Shares with the Commission (or, if earlier,
the first date on which a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication was made) through the date hereof, the Company has been and is an &#147;emerging growth company&#148; as
defined in Section&nbsp;2(a)(19) of the Act (an &#147;Emerging Growth Company&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) There are no persons with registration rights
or other similar rights to have any securities registered pursuant to the Registration Statement or otherwise registered by the Company under the Act except as have been validly waived or complied with in connection with the offering of the Shares;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) No labor disturbance by or dispute with current or former employees or officers of the Company or any if its subsidiaries exists or,
to the Company&#146;s knowledge, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of the Company&#146;s or any of its subsidiaries&#146; principal
suppliers, manufacturers or contractors. Neither the Company nor any of its subsidiaries is a party to any collective bargaining agreement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) The Company and its subsidiaries have insurance covering their respective properties,
operations, personnel and business, including business interruption insurance, which insurance is in amounts and insures against such losses and risks as are reasonable and is ordinary and customary for comparable companies in the same or similar
businesses; and neither the Company nor any of its subsidiaries has (i)&nbsp;not received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such
insurance nor (ii)&nbsp;any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be reasonably necessary
to continue its business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) The Company&#146;s board of directors meets the independence requirements of, and has established an audit
committee, a compensation committee and a nominating and corporate governance committee, in each case, that meets the independence requirements of, the rules and regulations of the Commission and the Exchange; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) The Company and its subsidiaries, and to the Company&#146;s knowledge, their respective directors, officers and employees, are, and at
all times have been, in compliance with applicable Health Care Laws (defined herein) including, but not limited to, the rules and regulations of the Food and Drug Administration (&#147;FDA&#148;), the U.S. Department of Health and Human Services
Office of Inspector General, the Centers for Medicare&nbsp;&amp; Medicaid Services, the Office for Civil Rights, and any other governmental agency or body having jurisdiction over the Company or any of its properties, and has not engaged in any
activities which are, as applicable, cause for false claims liability, civil penalties, or mandatory or permissive exclusion from Medicare, Medicaid, or any other local, state or federal healthcare program, except for such noncompliance that would
not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. For purposes of this Agreement, &#147;Health Care Laws&#148; shall mean, as applicable, the federal Anti-kickback Statute (42 U.S.C. &#167; <FONT
STYLE="white-space:nowrap">1320a-7b(b)),</FONT> the Physician Payments Sunshine Act (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7h),</FONT> the civil False Claims Act (31 U.S.C. &#167;&#167; 3729 et seq.), the criminal False Claims Act
(42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(a)),</FONT> applicable criminal laws relating to health care fraud and abuse, the exclusion laws (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7),</FONT> the civil monetary
penalties law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7a),</FONT> the health care fraud criminal provisions under the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. &#167;&#167; 1320d et seq.)
(&#147;HIPAA&#148;), the exclusion laws (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7),</FONT> the civil monetary penalties law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7a),</FONT> HIPAA, as amended by the Health
Information Technology for Economic and Clinical Health Act (42 U.S.C. &#167;&#167; 17921 et seq.), the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167;&#167; 301 et seq.), the Patient Protection and Affordable Care Act of 2010 (Pub. Law <FONT
STYLE="white-space:nowrap">111-148),</FONT> as amended by the Health Care and Education Reconciliation Act of 2010 (Pub. Law <FONT STYLE="white-space:nowrap">111-152),</FONT> and the regulations promulgated pursuant to the aforementioned statutes.
Neither the Company nor any of its subsidiaries is a party to or has any ongoing reporting obligations pursuant to any corporate integrity agreement, deferred prosecution agreement, monitoring agreement, consent decree, settlement order, plan of
correction or similar agreement imposed by any governmental authority. Neither the Company nor any of its subsidiaries has received any written notification, correspondence or any other written communication, including, without limitation, any Form
FDA 483, notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the FDA or any similar regulatory authority, or any notification of any pending or, to the Company&#146;s knowledge, threatened claim, suit,
proceeding, hearing, enforcement, investigation, arbitration or other action, from any governmental authority of alleging material <FONT STYLE="white-space:nowrap">non-compliance</FONT> by, or material liability of, the Company or its subsidiaries
under any Health Care Laws; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) Each of the Company and its subsidiaries possesses, and is in material compliance with
the terms of, all applications, certificates, approvals, clearances, registrations, exemptions, franchises, licenses, permits, consents and other authorizations issued by the appropriate Governmental Authorities and necessary to conduct their
respective businesses (collectively, &#147;Licenses&#148;), including, without limitation, all Licenses required by the FDA, or any component thereof, and/or by any other U.S., state, local or foreign government or drug regulatory agency
(collectively, the &#147;Regulatory Agencies&#148;), except where a failure to so possess or noncompliance would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. All such Licenses are in full force and
effect and neither the Company nor any of its subsidiaries is in violation of any term or conditions of any such License, except where a failure to be in full force or effect or such violation would not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect. Each of the Company and its subsidiaries has fulfilled and performed all of its respective obligations with respect to such Licenses and, no event has occurred which allows, or after notice or lapse of
time would allow, revocation or termination thereof or results in any other impairment of the rights of the holder of any such License, except for such failure or occurrence that would not, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect. Neither the Company nor any of its subsidiaries has received any notice of proceedings from the applicable Regulatory Agency proposing to revoke or materially adversely modify any such Licenses and, to the
Company&#146;s knowledge, no Regulatory Agency has taken any action to limit, suspend or revoke any such License possessed by the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) To the Company&#146;s knowledge, the manufacturing facilities and operations of its suppliers are operated in compliance in all material
respects with all applicable statutes, rules, regulations and policies of the Regulatory Agencies; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) None of the Company&#146;s
product candidates have received marketing approval from any Regulatory Agencies. The <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials that are described in the Registration Statement, the Pricing Prospectus and the
Prospectus were and, if still pending, are being, conducted in all material respects in accordance with the protocols submitted to the FDA or any foreign governmental body exercising comparable authority, and all applicable laws and regulations; the
descriptions of the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials conducted by or, to the Company&#146;s knowledge, on behalf of the Company or by a licensor, and the results thereof, contained in the Registration
Statement, the Pricing Prospectus and the Prospectus are accurate and complete in all material respects; the Company is not aware of any other <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials, the results of which call
into question the results described in the Registration Statement, the Pricing Prospectus and the Prospectus; and the Company has not received any notices or correspondence from the FDA, any foreign, state or local governmental body exercising
comparable authority or any Institutional Review Board or ethics committee or similar body requiring the termination, suspension, material modification or clinical hold of any <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical
trials conducted by or, to the Company&#146;s knowledge, on behalf of the Company or by a licensor; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) Neither the Company nor its subsidiaries, nor any of their respective officers,
employees or directors, nor, to the Company&#146;s knowledge, any of its or their respective agents or clinical investigators, or licensors, has, for the past three (3)&nbsp;years, been excluded, suspended or debarred from participation in any U.S.
federal or foreign health care program or human clinical research or, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion, or
convicted of any crime or engaged in any conduct that would reasonably be expected to result in debarment under 21 U.S.C. &#167; 335a or comparable foreign law; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) The Company and each subsidiary owns or has valid and enforceable licenses or other rights to all patents and patent applications,
copyrights, trademarks, trademark registrations, service marks, service mark registrations, trade names, service names and <FONT STYLE="white-space:nowrap">know-how</FONT> (including trade secrets and other unpatented and/or unpatentable proprietary
or confidential information, systems or procedures) and all other technology and intellectual property rights necessary for the conduct, or the proposed conduct, of the business of the Company in the manner described in the Pricing Prospectus and
the Prospectus (collectively, the &#147;Company Intellectual Property&#148;); to the Company&#146;s knowledge, there are no rights of third parties to any of the patents, trademarks and copyrights within the Company Intellectual Property disclosed
in the Registration Statement and the Prospectus as being owned by the Company and its subsidiaries and such patents, trademark and copyrights are owned by the Company and its subsidiaries free and clear of all material liens, security interests, or
encumbrances; to the Company&#146;s knowledge, the patents, trademarks and copyrights held or licensed by the Company and its subsidiaries included within the Company Intellectual Property are valid, enforceable and subsisting; and other than as
disclosed in the Pricing Prospectus and the Prospectus, (i)&nbsp;neither the Company nor its subsidiaries is obligated to pay a material royalty, grant a license, or provide other material consideration to any third party in connection with the
Company Intellectual Property, (ii)&nbsp;no action, suit, claim or other proceeding is pending or, to the knowledge of the Company, is threatened, alleging that the conduct of the business of the Company in the manner described in the Pricing
Prospectus and the Prospectus is infringing, misappropriating, diluting or otherwise violating any intellectual property rights of others, (iii)&nbsp;no action, suit, claim or other proceeding is pending or, to the knowledge of the Company, is
threatened, challenging the validity, enforceability, scope, registration, ownership or use of any of the Company Intellectual Property, (iv)&nbsp;no action, suit, claim or other proceeding is pending or, to the knowledge of the Company, is
threatened, challenging the Company&#146;s and its subsidiaries&#146; rights in or to any Company Intellectual Property, and the Company is unaware of any facts which could form a reasonable basis for any such action, suit, proceeding or claim,
(v)&nbsp;the Company has not received written notice of any claim of infringement, misappropriation or conflict with any asserted rights of others with respect to any of the Company&#146;s or its subsidiaries&#146; products, proposed products,
processes or Company Intellectual Property, (vi)&nbsp;to the knowledge of the Company, the development, manufacture, sale, and any currently proposed use of any of the products, proposed products or processes of the Company and its subsidiaries
referred to in the Pricing Prospectus and the Prospectus, in the current or proposed conduct of the business of the Company, do not currently, and will not upon commercialization, to the knowledge of the Company, infringe any right or valid patent
claim of any third party, (vii)&nbsp;to the Company&#146;s knowledge, no third party has any ownership right in or to any Company Intellectual Property in any field of use that is exclusively licensed to the Company or its subsidiaries, other than
any licensor to the Company or its subsidiaries of such Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Intellectual Property, (viii)&nbsp;no employee, consultant or independent contractor of the Company or any of its subsidiaries is, to the Company&#146;s knowledge, in violation in any material
respect of any term of any employment contract, patent disclosure agreement, invention assignment agreement, <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement,
nondisclosure agreement, or any restrictive covenant to or with a former employer or independent contractor where the basis of such violation relates to such employee&#146;s employment or independent contractor&#146;s engagement with the Company or
actions undertaken while employed or engaged with the Company, (ix)&nbsp;the Company has taken reasonable measures to protect its material confidential information and material trade secrets and to maintain and safeguard the material Company
Intellectual Property, including the execution of appropriate nondisclosure and confidentiality agreements and (x)&nbsp;the Company has complied with the material terms of each agreement pursuant to which the Company Intellectual Property has been
licensed to the Company, and any such agreements are in full force and effect; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) All patents and patent applications owned by or
licensed to the Company and its subsidiaries or under which the Company and its subsidiaries have rights have, to the knowledge of the Company, been duly and properly filed and maintained; to the knowledge of the Company, there are no material
defects in any of the patents or patent applications disclosed in the Registration Statement and the Prospectus as being owned by the Company or its subsidiaries; to the knowledge of the Company, the parties prosecuting such applications have
complied with their duty of candor and disclosure to the United States Patent and Trademark Office (the &#147;USPTO&#148;) in connection with such applications; and the Company is not aware of any facts required to be disclosed to the USPTO that
were not disclosed to the USPTO and which would preclude the grant of a patent in connection with any such application or could form the basis of a finding of invalidity with respect to any patents that have issued with respect to such applications;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) Any statistical, industry-related and market-related data included in each of the Registration Statement, the Pricing Prospectus and
the Prospectus are based on or derived from sources that the Company reasonably believes to be reliable and accurate in all material respects; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) The Company and its subsidiaries possess all licenses, certificates, permits and other authorizations issued by, and have made all
declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities having jurisdiction over the Company and its subsidiaries that are necessary for the ownership or lease of their respective
properties or the conduct of their respective businesses as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, except where the failure to possess or make the same would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect; and except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor any of its subsidiaries has received notice of any revocation
or modification of any such license, certificate, permit or authorization, except where such revocation or modification would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) All United States federal income tax returns of the Company and its subsidiaries
required by law to be filed have been filed and all taxes shown as due on such returns or that otherwise have been assessed, which are due and payable, have been paid, except assessments against which appeals have been or will be promptly taken and
as to which adequate reserves have been provided. The Company and its subsidiaries have filed all other tax returns that are required to have been filed by them pursuant to applicable foreign, state, local or other law except insofar as the failure
to file such returns would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, and has paid all taxes due pursuant to such returns or pursuant to any assessment received by the Company and its
subsidiaries, except for such taxes, if any, as are being contested in good faith and as to which adequate reserves have been provided and except insofar as the failure to pay such taxes would not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) The Company has not taken and will not take, directly or indirectly, any action that is
designed to or that has constituted or might reasonably be expected to cause or result in stabilization or manipulation of the price of the Shares; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) Neither the Company nor any of its subsidiaries is a party to any contract, agreement or understanding with any person (other than this
Agreement) that would give rise to a valid claim against the Company or any of its subsidiaries or any Underwriter for a brokerage commission, finder&#146;s fee or like payment in connection with the offering and sale of the Shares; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr) No relationship, direct or indirect, exists between or among the Company or any of its subsidiaries, on the one hand, and the directors,
officers, stockholders, customers or suppliers of the Company or any of its subsidiaries, on the other, that is required by the Act to be described in the Registration Statement and the Prospectus and that is not so described in such documents and
in the Registration Statement, the Pricing Disclosure Package and the Prospectus; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) There are no contracts, arrangements or documents
which are required to be described in the Registration Statement or to be filed as exhibits thereto which have not been so described and filed as required; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt) Except as would not reasonably be expected to have a Material Adverse Effect, (i)&nbsp;The Company&#146;s and its subsidiaries&#146;
information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#147;IT Systems&#148;) are adequate for, and operate and perform in all material respects as
required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, and are, to the knowledge of the Company, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware
and other corruptants; (ii)&nbsp;the Company and its subsidiaries have implemented and maintained reasonable controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous
operation, redundancy and security of all IT Systems and data (including all personal or personally identifiable data (&#147;Personal Data&#148;)) used in connection with their businesses; to the knowledge of the Company, there have been no
breaches, violations, outages or unauthorized uses of or accesses to any Personal Data, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal review or
investigations relating to the same; the Company and its subsidiaries are presently in compliance in all material respects with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or
governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access,
misappropriation or modification; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu) The Company and each director and officer of the Company, in their capacities as such,
are in compliance, to the extent required, with all provisions of the Sarbanes-Oxley Act, and all rules and regulations promulgated thereunder applicable to, and the Company at such time, and is taking steps designed to ensure that it will be in
compliance, at all times, with the other provisions of the Sarbanes-Oxley Act when they become applicable to the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv) None of
the subsidiaries of the Company is a &#147;significant subsidiary&#148; of the Company as such term is defined in Rule <FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Exchange Act;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ww) The Registration Statement, the Pricing Disclosure Package and the Prospectus, any Preliminary Prospectus and any Issuer Free
Writing Prospectuses comply in all material respects, and any further amendments or supplements thereto will comply in all material respects, with any applicable laws or regulations of foreign jurisdictions in which the Pricing Disclosure Package,
the Prospectus, any Preliminary Prospectus and any Issuer Free Writing Prospectus, as amended or supplemented, if applicable, are distributed in connection with the Directed Share Program; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx) The Company has specifically directed in writing the allocation of Shares to each Participant in the Directed Share Program, and neither
the Directed Share Underwriter nor any other Underwriter has had any involvement or influence, directly or indirectly, in such allocation decision; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(yy) The Company has not offered, nor caused the Directed Share Underwriter or its affiliates to offer, Shares to any person pursuant to the
Directed Share Program (i)&nbsp;for any consideration other than the cash payment of the initial public offering price per share set forth in Schedule II hereof or (ii)&nbsp;with the specific intent to unlawfully influence (x)&nbsp;a customer or
supplier of the Company to alter the customer or supplier&#146;s terms, level or type of business with the Company or (y)&nbsp;a trade journalist or publication to write or publish favorable information about the Company or its products; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(zz) No forward-looking statement (within the meaning of Section&nbsp;27A of the Act and Section&nbsp;21E of the Exchange Act) included in any
of the Registration Statement, the Pricing Prospectus or the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Subject to the terms and conditions herein set forth, the Company agrees to issue and sell to each of the Underwriters, and each of the
Underwriters agrees, severally and not jointly, to purchase from the Company, at a purchase price per share of $[&#149;], the number of Firm Shares set forth opposite the name of such Underwriter in Schedule I hereto and (b)&nbsp;in the event and to
the extent that the Underwriters shall exercise the election to purchase Optional Shares as provided below, the Company agrees to issue and sell to each of the Underwriters, and each of the Underwriters agrees, severally and not jointly, to purchase
from the Company, at the purchase price per share set forth in clause (a)&nbsp;of this Section&nbsp;2 (provided that the purchase price per Optional Share shall be reduced by an amount per share equal to any dividends or distributions declared by
the Company and payable on the Firm Shares but not payable on the Optional Shares), that portion of the number of Optional Shares as to which such election shall have been exercised (to be adjusted by you so as to eliminate fractional shares)
determined by multiplying such number of Optional Shares by a fraction, the numerator of which is the maximum number of Optional Shares which such Underwriter is entitled to purchase as set forth opposite the name of such Underwriter in Schedule I
hereto and the denominator of which is the maximum number of Optional Shares that all of the Underwriters are entitled to purchase hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby grants to the Underwriters the right to purchase at their election up to
[&#149;] Optional Shares, at the purchase price per share set forth in the paragraph above, provided that the purchase price per Optional Share shall be reduced by an amount per share equal to any dividends or distributions declared by the Company
and payable on the Firm Shares but not payable on the Optional Shares. Any such election to purchase Optional Shares may be exercised only by written notice from you to the Company, given within a period of 30 calendar days after the date of this
Agreement, setting forth the aggregate number of Optional Shares to be purchased and the date on which such Optional Shares are to be delivered, as determined by you but in no event earlier than the First Time of Delivery (as defined in
Section&nbsp;4 hereof) or, unless you and the Company otherwise agree in writing, earlier than two or later than ten business days after the date of such notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Upon the authorization by you of the release of the Shares, the several Underwriters propose to offer the Shares for sale upon the terms
and conditions set forth in the Pricing Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. (a) The Shares to be purchased by each Underwriter
hereunder, in definitive or book-entry form, and in such authorized denominations and registered in such names as the Representatives may request upon at least forty-eight hours&#146; prior notice to the Company shall be delivered by or on behalf of
the Company to the Representatives, through the facilities of the Depository Trust Company (&#147;DTC&#148;), for the account of such Underwriter, against payment by or on behalf of such Underwriter of the purchase price therefor by wire transfer of
Federal <FONT STYLE="white-space:nowrap">(same-day)</FONT> funds to the account specified by the Company to the Representatives at least forty-eight hours in advance. The Company will cause the certificates, if any, representing the Shares to be
made available for checking and packaging at least twenty-four hours prior to the Time of Delivery (as defined below) with respect thereto at the office of DTC or its designated custodian<B> </B>(the &#147;Designated Office&#148;). The time and date
of such delivery and payment shall be, with respect to the Firm Shares, 9:30 a.m., New York City time, on [&#149;], 2022 or such other time and date as the Representatives and the Company may agree upon in writing, and, with respect to the Optional
Shares, 9:30 a.m., New York time, on the date specified by the Representatives in the written notice given by the Representatives of the Underwriters&#146; election to purchase such Optional Shares, or such other time and date as the Representatives
and the Company may agree upon in writing. Such time and date for delivery of the Firm Shares is herein called the &#147;First Time of Delivery&#148;, such time and date for delivery of the Optional Shares, if not the First Time of Delivery, is
herein called the &#147;Second Time of Delivery&#148;, and each such time and date for delivery is herein called a &#147;Time of Delivery&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The documents to be delivered at each<B> </B>Time of Delivery by or on behalf of the parties hereto pursuant to Section&nbsp;8 hereof,
including the cross receipt for the Shares and any additional documents requested by the Underwriters pursuant to Section&nbsp;8(j) hereof, will be delivered at the offices of Wilmer Cutler Hale Pickering and Dorr LLP, 7 World Trade Center 250
Greenwich Street New York, NY 10007 (the &#147;Closing Location&#148;), and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Shares will be delivered at the Designated Office, all at such Time of Delivery. A meeting will be held at the Closing Location at [&#149;] p.m., New York City time, on the New York Business Day
next preceding such Time of Delivery, at which meeting the final drafts of the documents to be delivered pursuant to the preceding sentence will be available for review by the parties hereto. For the purposes of this Section&nbsp;4, &#147;New York
Business Day&#148; shall mean each Monday, Tuesday, Wednesday, Thursday and Friday which is not a day on which banking institutions in New York City are generally authorized or obligated by law or executive order to close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. The Company agrees with each of the Underwriters: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) To prepare the Prospectus in a form approved by you and to file such Prospectus pursuant to Rule 424(b) under the Act not later than the
Commission&#146;s close of business on the second business day following the execution and delivery of this Agreement, or, if applicable, such earlier time as may be required by Rule 430A(a)(3) under the Act; to make no further amendment or any
supplement to the Registration Statement or the Prospectus prior to the last Time of Delivery which shall be disapproved by you promptly after reasonable notice thereof; to advise you, promptly after it receives notice thereof, of the time when any
amendment to the Registration Statement has been filed or becomes effective or any amendment or supplement to the Prospectus has been filed and to furnish you with copies thereof; to file promptly all material required to be filed by the Company
with the Commission pursuant to Rule 433(d) under the Act; to advise you, promptly after it receives notice thereof, of the issuance by the Commission of any stop order or of any order preventing or suspending the use of any Preliminary Prospectus
or other prospectus in respect of the Shares, of the suspension of the qualification of the Shares for offering or sale in any jurisdiction, of the initiation or threatening of any proceeding for any such purpose, or of any request by the Commission
for the amending or supplementing of the Registration Statement or the Prospectus or for additional information; and, in the event of the issuance of any stop order or of any order preventing or suspending the use of any Preliminary Prospectus or
other prospectus or suspending any such qualification, to promptly use its best efforts to obtain the withdrawal of such order; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
Promptly from time to time to take such action as you may reasonably request to qualify the Shares for offering and sale under the securities laws of such jurisdictions as you may reasonably request and to comply with such laws so as to permit the
continuance of sales and dealings therein in such jurisdictions for as long as may be necessary to complete the distribution of the Shares, provided that in connection therewith the Company shall not be required to qualify as a foreign corporation
(where not otherwise required) or to file a general consent to service of process in any jurisdiction (where not otherwise required); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)
Prior to 10:00 a.m., New York City time, on the New York Business Day next succeeding the date of this Agreement (or such other time as may be agreed to by you and the Company) and from time to time, to furnish the Underwriters with written and
electronic copies of the Prospectus in New York City in such quantities as you may reasonably request, and, if the delivery of a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act) is required at any time prior to
the expiration of nine months after the time of issue of the Prospectus in connection with the offering or sale of the Shares and if at such time any event shall have occurred as a result of which the Prospectus as then amended or supplemented would
include an untrue statement of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made when such Prospectus (or in lieu
thereof, the notice referred to in Rule 173(a) under the Act)<B> </B>is delivered, not misleading, or, if for any other reason it shall be necessary during such same period to amend or supplement the Prospectus in order to comply with the Act, to
notify you and upon your request to prepare and furnish without charge to each Underwriter and to any dealer (whose name and address the Underwriters shall furnish to the Company in connection with such request) in securities as many written and
electronic copies as you may from time to time reasonably request of an amended Prospectus or a supplement to the Prospectus which will correct such statement or omission or effect such compliance; and in case any Underwriter is required to deliver
a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act)<B> </B>in connection with sales of any of the Shares at any time nine months or more after the time of issue of the Prospectus, upon your request but at the
expense of such Underwriter, to prepare and deliver to such Underwriter as many written and electronic copies as you may request of an amended or supplemented Prospectus complying with Section&nbsp;10(a)(3) of the Act; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) To make generally available to its securityholders as soon as practicable (which may be satisfied by filing with the Commission&#146;s
Electronic Data Gathering, Analysis and Retrieval System (&#147;EDGAR&#148;) or any successor thereto), but in any event not later than sixteen months after the effective date of the Registration Statement (as defined in Rule 158(c) under the Act),
an earnings statement of the Company and its subsidiaries (which need not be audited) complying with Section&nbsp;11(a) of the Act and the rules and regulations of the Commission thereunder (including, at the option of the Company, Rule 158); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)(1) During the period beginning from the date hereof and continuing to and including the date 180<B> </B>days after the date of the
Prospectus (the <FONT STYLE="white-space:nowrap">&#147;Lock-Up</FONT> Period&#148;), not to (i)&nbsp;offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise transfer or dispose of, directly or
indirectly, or file with or confidentially submit to the Commission a registration statement under the Act relating to, any securities of the Company that are substantially similar to the Shares, including but not limited to any options or warrants
to purchase shares of Stock or any securities that are convertible into or exchangeable for, or that represent the right to receive, Stock or any such substantially similar securities, or publicly disclose the intention to make any offer, sale,
pledge, disposition or filing or (ii)&nbsp;enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Stock or any such other securities, whether any such transaction described in
clause (i)&nbsp;or (ii) above is to be settled by delivery of Stock or such other securities, in cash or otherwise (other than the Shares to be sold hereunder or pursuant to employee stock option plans existing on, or upon the conversion or exchange
of convertible or exchangeable securities outstanding as of, the date of this Agreement), without the prior written consent of the Representatives; <I>provided</I>, that the restrictions contained in this paragraph shall not apply to (a)&nbsp;the
Shares to be sold by the Company hereunder, (b)&nbsp;the issuance by the Company of shares of Stock or any other security pursuant to the exercise of an option or warrant or the conversion and/or exchange of a security in each case outstanding on
the date hereof and described in the Registration Statement and the Prospectus, (c)&nbsp;grants of options, restricted shares or restricted share units to officers, directors, employees and consultants of the Company in accordance with the terms of
an incentive compensation plan described in the Registration Statement and the Prospectus, or the issuance by the Company of shares of Common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock upon the exercise thereof, (d)&nbsp;the filing by the Company of a registration statement with the Commission on Form <FONT STYLE="white-space:nowrap">S-8</FONT> in connection with such
aforesaid plan, or (e)&nbsp;the issuance of shares of Stock, or any securities convertible into or exercisable or exchangeable for shares of Stock, or the entry into an agreement to issue shares of Stock, in each case in connection with any bona
fide merger, joint venture, strategic alliance, commercial or other collaborative transaction, or the acquisition or license by the Company of the business, property, technology or other assets of another individual or entity that is an unaffiliated
third party of the Company, or the assumption of an employee benefit plan in connection with such a merger or acquisition, provided, that the aggregate number of shares of Stock or securities convertible into or exercisable for Stock (on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> or as exercised basis, as the case may be) that the Company may sell or issue or agree to sell or issue pursuant to clause (e)&nbsp;above shall not exceed 5% of the total number of shares of the
Company&#146;s Stock issued and outstanding immediately following the completion of the transactions contemplated by this Agreement and with respect to any transaction described in clauses (b)-(e) of this subsection (e)(1) occurring during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period, any transferee or other recipient of Stock or other Company securities agrees to be bound in writing, until the end of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, by the restrictions
set forth in a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter in the form described in Section&nbsp;8(h) hereof; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)(2) If
the Representatives, in their sole discretion, agree to release or waive the restrictions set forth in a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter described in Section&nbsp;8(h) hereof for an officer or director of the Company and
provide the Company with notice of the impending release or waiver at least three business days before the effective date of the release or waiver, the Company agrees to announce the impending release or waiver by a press release substantially in
the form of Annex II hereto through a major news service at least two business days before the effective date of the release or waiver. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) During a period of three (3)&nbsp;years from the effective date of the Registration Statement, to furnish to its stockholders as soon as
practicable after the end of each fiscal year an annual report (including a balance sheet and statements of income, stockholders&#146; equity and cash flows of the Company and its consolidated subsidiaries certified by independent public
accountants) and, as soon as practicable after the end of each of the first three quarters of each fiscal year (beginning with the fiscal quarter ending after the effective date of the Registration Statement), to make available to its stockholders
consolidated summary financial information of the Company and its subsidiaries for such quarter in reasonable detail, provided, that no reports, documents or other information needs to be furnished pursuant to this Section&nbsp;5(f) to the extent
they are available on EDGAR; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) During a period of three (3)&nbsp;years from the effective date of the Registration Statement, to
furnish to you copies of all reports or other communications (financial or other) furnished to stockholders, and to deliver to you (i)&nbsp;as soon as they are available, copies of any reports and financial statements furnished to or filed with the
Commission or any national securities exchange on which any class of securities of the Company is listed; and (ii)&nbsp;such additional information concerning the business and financial condition of the Company as you may from time to time
reasonably request (such financial statements to be on a consolidated basis to the extent the accounts of the Company and its subsidiaries are consolidated in reports furnished to its stockholders generally or to the Commission), provided, that no
reports, documents or other information needs to be furnished pursuant to this Section&nbsp;5(g) to the extent they are available on EDGAR; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) To use the net proceeds received by it from the sale of the Shares pursuant to this
Agreement in the manner specified in the Pricing Prospectus under the caption &#147;Use of Proceeds&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) To use its best efforts
to<B> </B>list, subject to notice of issuance, the Shares on the Exchange; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) To file with the Commission such information on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> or Form <FONT STYLE="white-space:nowrap">10-K</FONT> as may be required by Rule 463 under the Act; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) If the Company elects to rely upon Rule 462(b), the Company shall file a Rule 462(b) Registration Statement with the Commission in
compliance with Rule 462(b) by 10:00 P.M., Washington, D.C. time, on the date of this Agreement, and the Company shall at the time of filing either pay to the Commission the filing fee for the Rule 462(b) Registration Statement or give irrevocable
instructions for the payment of such fee pursuant to Rule 111(b) under the Act; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) Upon request of any Underwriter, to furnish, or cause
to be furnished, to such Underwriter an electronic version of the Company&#146;s trademarks, servicemarks and corporate logo for use on the website, if any, operated by such Underwriter for the purpose of facilitating the <FONT
STYLE="white-space:nowrap">on-line</FONT> offering of the Shares (the &#147;License&#148;); provided, however, that the License shall be used solely for the purpose described above, is granted without any fee and may not be assigned or transferred;
and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) To promptly notify you if the Company ceases to be an Emerging Growth Company at any time prior to the later of
(i)&nbsp;completion of the distribution of the Shares within the meaning of the Act and (ii)&nbsp;the last Time of Delivery; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) To
comply with all applicable securities and other laws, rules and regulations in each jurisdiction in which the Directed Shares are offered in connection with the Directed Share Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. (a) The Company represents and agrees that, without the prior consent of the Representatives, it has not made and will not make any offer
relating to the Shares that would constitute a &#147;free writing prospectus&#148; as defined in Rule 405 under the Act; each Underwriter represents and agrees that, without the prior consent of the Company and the Representatives, it has not made
and will not make any offer relating to the Shares that would constitute a free writing prospectus required to be filed with the Commission; any such free writing prospectus the use of which has been consented to by the Company and the
Representatives is listed on Schedule II(a) [or Schedule II(c)] hereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company has complied and will comply with the
requirements of Rule 433 under the Act applicable to any Issuer Free Writing Prospectus, including timely filing with the Commission or retention where required and legending;<B> </B>and the Company represents that it has satisfied and agrees that
it will satisfy the conditions under Rule 433 under the Act to avoid a requirement to file with the Commission any electronic road show; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Company agrees that if at any time following issuance of an Issuer Free Writing
Prospectus or Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication any event occurred or occurs as a result of which such Issuer Free Writing Prospectus or Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication would conflict with the information in the Registration Statement, the Pricing Prospectus or the Prospectus or would include an untrue
statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances then prevailing, not misleading, the Company will give prompt notice thereof to the Representatives
and, if requested by the Representatives, will prepare and furnish without charge to each Underwriter an Issuer Free Writing Prospectus, Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communication or other document which will correct such conflict, statement or omission<B>;</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Company represents and agrees
that (i)&nbsp;it has not engaged in, or authorized any other person to engage in, any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications, other than <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications with the prior consent of the Representatives with entities that the Company reasonably believes are qualified institutional buyers as defined in Rule 144A under the Act or
institutions that are accredited investors as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Act; and (ii)&nbsp;it has not distributed, or authorized any other person to distribute, any Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications, other than those distributed with the prior consent of the Representatives that are listed on Schedule II(c) hereto; and the Company
reconfirms that the Underwriters have been authorized to act on its behalf in engaging in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Each Underwriter represents and agrees that any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications undertaken by it were with entities that such Underwriter reasonably believes are qualified institutional buyers as defined in Rule
144A under the Act or institutions that are accredited investors as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. The Company covenants and agrees with the several Underwriters that the Company will pay or cause to be paid the following: (i)&nbsp;the
fees, disbursements and expenses of the Company&#146;s counsel and accountants in connection with the registration of the Shares under the Act and all other expenses in connection with the preparation, printing, reproduction and filing of the
Registration Statement, any Preliminary Prospectus, any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, any Issuer Free Writing Prospectus and the Prospectus and amendments
and supplements thereto and the mailing and delivering of copies thereof to the Underwriters and dealers; (ii)&nbsp;the cost of printing or producing any Agreement among Underwriters, this Agreement, the Blue Sky Memorandum, closing documents
(including any compilations thereof) and any other documents in connection with the offering, purchase, sale and delivery of the Shares; (iii)&nbsp;all expenses in connection with the qualification of the Shares for offering and sale under state
securities laws as provided in Section&nbsp;5(b) hereof, including the reasonable fees and disbursements of counsel for the Underwriters in connection with such qualification and in connection with the Blue Sky survey (iv)&nbsp;the costs and
expenses of the Company relating to investor presentations on any &#147;road show&#148; undertaken in connection with the marketing of the offering of the Shares, including, without limitation, expenses associated with the preparation or
dissemination of any electronic road show, expenses associated with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations (with the prior approval of the Company), travel and
lodging expenses of the representatives and officers of the Company and any such consultants, and 50% of the cost of any aircraft chartered in connection with the road show; (v)&nbsp;all fees and expenses in connection with listing the Shares on the
Exchange; (vi)&nbsp;the filing fees incident to, and the reasonable fees and disbursements of counsel for the Underwriters in connection with, any required review by FINRA of the terms of the sale of the Shares; (vii)&nbsp;the cost of preparing
stock certificates; (viii)&nbsp;the cost and charges of any transfer agent or registrar; (ix)&nbsp;all fees and disbursements of counsel for the Underwriters in connection with the Directed Share Program and stamp duties, similar taxes or duties or
other taxes, if any, incurred by the Underwriters in connection with the Directed Share Program, and (x)&nbsp;all other costs and expenses incident to the performance of its obligations hereunder which are not otherwise specifically provided for in
this Section; provided that the aggregate amount of fees of counsel payable by the Company pursuant to subsections (iii)&nbsp;and, solely with respect to fees and disbursements for underwriters&#146; counsel, subsection (vi), shall not exceed
$40,000 in the aggregate. It is understood, however, that, except as provided in this Section, and Sections 9, 10 and 13 hereof, the Underwriters will pay all of their own costs and expenses, including the fees of their counsel, stock transfer taxes
on resale of any of the Shares by them, and any advertising expenses connected with any offers they may make and the travel and lodging expenses incurred by representatives of the Underwriters in connection with any road show. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. The obligations of the Underwriters hereunder<B>, </B>as to the Shares to be delivered at each Time of Delivery,<B> </B>shall be subject,
in their discretion, to the condition that all representations and warranties and other statements of the Company herein are, at and as of the Applicable Time and such Time of Delivery, true and correct, the condition that the Company shall have
performed all of its obligations hereunder theretofore to be performed, and the following additional conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The
Prospectus shall have been filed with the Commission pursuant to Rule 424(b) under the Act within the applicable time period prescribed for such filing by the rules and regulations under the Act and in accordance with Section&nbsp;5(a) hereof; all
material required to be filed by the Company pursuant to Rule 433(d) under the Act shall have been filed with the Commission within the applicable time period prescribed for such filing by Rule 433; if the Company has elected to rely upon Rule
462(b) under the Act, the Rule 462(b) Registration Statement shall have become effective by 10:00 P.M., Washington, D.C. time, on the date of this Agreement; no stop order suspending the effectiveness of the Registration Statement or any part
thereof shall have been issued and no proceeding for that purpose or pursuant to Section&nbsp;8A of the Act shall have been initiated or threatened by the Commission; no stop order suspending or preventing the use of the Pricing Prospectus,
Prospectus or any Issuer Free Writing Prospectus shall have been initiated or threatened by the Commission; and all requests for additional information on the part of the Commission shall have been complied with to your reasonable satisfaction; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Wilmer Cutler Pickering Hale and Dorr LLP, counsel for the Underwriters, shall have furnished to you their written opinion
and negative assurance letter, each dated such Time of Delivery, in form and substance satisfactory to the Representatives, and such counsel shall have received such papers and information as they may reasonably request to enable them to pass upon
such matters; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)<B></B>&nbsp;(i) Goodwin Procter LLP, counsel for the Company, shall have
furnished to you their written opinion and negative assurance letter, each dated such Time of Delivery, in form and substance satisfactory to the Representatives, and (ii)&nbsp;Fish&nbsp;&amp; Richardson, intellectual property counsel for the
Company, shall have furnished to you their written opinion and negative assurance letter, each dated such Time of Delivery, in form and substance satisfactory to the Representatives; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) On the date of the Prospectus at a time prior to the execution of this Agreement, at 9:30 a.m., New York City time, on the
effective date of any <FONT STYLE="white-space:nowrap">post-effective</FONT> amendment to the Registration Statement filed subsequent to the date of this Agreement and also at each Time of Delivery, Deloitte&nbsp;&amp; Touche LLP shall have
furnished to you a letter or letters, dated the respective dates of delivery thereof, in form and substance satisfactory to the Representatives; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) (i) Neither the Company nor any of its subsidiaries shall have sustained since the date of the latest audited financial
statements included in the Pricing Prospectus any loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree,
otherwise than as set forth or contemplated in the Pricing Prospectus, and (ii)&nbsp;since the respective dates as of which information is given in the Pricing Prospectus there shall not have been any change in the capital stock or <FONT
STYLE="white-space:nowrap">long-term</FONT> debt of the Company or any of its subsidiaries or any change or effect, or any development involving a prospective change or effect, in or affecting (x)&nbsp;the business, properties, general affairs,
management, financial position, stockholders&#146; equity or results of operations of the Company and its subsidiaries, taken as a whole, except as set forth or contemplated in the Pricing Prospectus, or (y)&nbsp;the ability of the Company to
perform its obligations under this Agreement, including the issuance and sale of the Shares, or to consummate the transactions contemplated in the Pricing Prospectus and the Prospectus, the effect of which, in any such case described in clause
(i)&nbsp;or (ii), is in your judgment so material and adverse as to make it impracticable or inadvisable to proceed with the public offering or the delivery of the Shares being delivered at such Time of Delivery on the terms and in the manner
contemplated in the Pricing Prospectus and the Prospectus; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) On or after the Applicable Time there shall not have
occurred any of the following: (i)&nbsp;a suspension or material limitation in trading in securities generally on the Exchange; (ii)&nbsp;a suspension or material limitation in trading in the Company&#146;s securities on the<B> </B>Exchange;
(iii)&nbsp;a general moratorium on commercial banking activities declared by either Federal or New York State authorities or a material disruption in commercial banking or securities settlement or clearance services in the United States;
(iv)&nbsp;the outbreak or escalation of hostilities involving the United States or the declaration by the United States of a national emergency or war or (v)&nbsp;the occurrence of any other calamity or crisis or any change in financial, political
or economic conditions in the United States or elsewhere, if the effect of any such event specified in clause (iv)&nbsp;or (v) in your judgment makes it impracticable or inadvisable to proceed with the public offering or the delivery of the Shares
being delivered at such Time of Delivery on the terms and in the manner contemplated in the Pricing Prospectus and the Prospectus; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The Shares to be sold at such Time of Delivery shall have been duly
listed, subject to notice of issuance, for quotation on the Exchange; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) The Company shall have obtained and delivered to
the Underwriters executed copies of an agreement from officers, directors, and certain stockholders and optionholders of the Company, substantially in the form attached as Annex I hereto; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Company shall have complied with the provisions of Section&nbsp;5(c) hereof with respect to the furnishing of
prospectuses on the New York Business Day next succeeding the date of this Agreement (or such other time as may be agreed to by you and the Company); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) The Company shall have furnished or caused to be furnished to you at such Time of Delivery certificates of officers of the
Company satisfactory to you as to the accuracy of the representations and warranties of the Company herein at and as of such Time of Delivery, as to the performance by the Company of all of its obligations hereunder to be performed at or prior to
such Time of Delivery, as to the matters set forth in subsections (a)&nbsp;and (e) of this Section and as to such other matters as you may reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. (a) The Company will indemnify and hold harmless each Underwriter against any losses, claims, damages or liabilities, joint or several, to
which such Underwriter may become subject, under the Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a
material fact contained in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, any Issuer Free Writing Prospectus, any &#147;roadshow&#148; as defined in Rule
433(h) under the Act (a &#147;roadshow&#148;), any &#147;issuer information&#148; filed or required to be filed pursuant to Rule 433(d) under the Act or any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, and will reimburse each Underwriter for any documented legal or other expenses reasonably incurred by such Underwriter in connection with investigating or defending any such action or claim as
such expenses are incurred; <I>provided</I>, <I>however</I>, that the Company shall not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue
statement or omission or alleged omission made in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus or any <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, in reliance upon and in conformity with the Underwriter Information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each Underwriter, severally and not jointly, will indemnify and hold harmless the Company against any losses, claims, damages or
liabilities to which the Company may become subject, under the Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of
a material fact contained in the Registration Statement, any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus, or any roadshow or any <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, any
Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus, or any roadshow or any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, in reliance upon and in conformity with the Underwriter Information; and will reimburse the Company for any legal or other expenses
reasonably incurred by the Company in connection with investigating or defending any such action or claim as such expenses are incurred. As used in this Agreement with respect to an Underwriter and an applicable document, &#147;Underwriter
Information&#148; shall mean the written information furnished to the Company by such Underwriter through the Representatives expressly for use therein; it being understood and agreed upon that the only such information furnished by any Underwriter
consists of the following information in the Prospectus furnished on behalf of each Underwriter: the concession and reallowance figures appearing in the [&#149;] paragraph under the caption &#147;Underwriting&#148;, and the information contained in
the [&#149;] paragraph under the caption &#147;Underwriting&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Promptly after receipt by an indemnified party under subsection
(a)&nbsp;or (b) above of notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party under such subsection, notify the indemnifying party in writing of the
commencement thereof; provided that the failure to notify the indemnifying party shall not relieve it from any liability that it may have under the preceding paragraphs of this Section&nbsp;9 except to the extent that it has been materially
prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and provided further that the failure to notify the indemnifying party shall not relieve it from any liability that it may have to an indemnified party otherwise
than under the preceding paragraphs of this Section&nbsp;9. In case any such action shall be brought against any indemnified party and it shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be entitled to
participate therein and, to the extent that it shall wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel reasonably satisfactory to such indemnified party (who shall not, except with the
consent of the indemnified party, be counsel to the indemnifying party), and, after notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof, the indemnifying party shall not be liable to such
indemnified party under such subsection for any legal expenses of other counsel or any other expenses, in each case subsequently incurred by such indemnified party, in connection with the defense thereof other than reasonable costs of investigation.
No indemnifying party shall, without the written consent of the indemnified party, effect the settlement or compromise of, or consent to the entry of any judgment with respect to, any pending or threatened action or claim in respect of which
indemnification or contribution may be sought hereunder (whether or not the indemnified party is an actual or potential party to such action or claim) unless such settlement, compromise or judgment (i)&nbsp;includes an unconditional release of the
indemnified party from all liability arising out of such action or claim and (ii)&nbsp;does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of any indemnified party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) If the indemnification provided for in this Section&nbsp;9 is unavailable to or
insufficient to hold harmless an indemnified party under subsection (a)&nbsp;or (b) above in respect of any losses, claims, damages or liabilities (or actions in respect thereof) referred to therein, then each indemnifying party shall contribute to
the amount paid or payable by such indemnified party as a result of such losses, claims, damages or liabilities (or actions in respect thereof) in such proportion as is appropriate to reflect the relative benefits received by the Company on the one
hand and the Underwriters on the other from the offering of the Shares. If, however, the allocation provided by the immediately preceding sentence is not permitted by applicable law, then each indemnifying party shall contribute to such amount paid
or payable by such indemnified party in such proportion as is appropriate to reflect not only such relative benefits but also the relative fault of the Company on the one hand and the Underwriters on the other in connection with the statements or
omissions which resulted in such losses, claims, damages or liabilities (or actions in respect thereof), as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Underwriters on
the other shall be deemed to be in the same proportion as the total net proceeds from the offering (before deducting expenses) received by the Company bear to the total underwriting discounts and commissions received by the Underwriters, in each
case as set forth in the table on the cover page of the Prospectus. The relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to
state a material fact relates to information supplied by the Company on the one hand or the Underwriters on the other and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or
omission. The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this subsection (d)&nbsp;were determined by <I>pro rata</I> allocation (even if the Underwriters were treated as one entity for such
purpose) or by any other method of allocation which does not take account of the equitable considerations referred to above in this subsection (d). The amount paid or payable by an indemnified party as a result of the losses, claims, damages or
liabilities (or actions in respect thereof) referred to above in this subsection (d)&nbsp;shall be deemed to include any documented legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending
any such action or claim. Notwithstanding the provisions of this subsection (d), no Underwriter shall be required to contribute any amount in excess of the amount by which the total price at which the Shares underwritten by it and distributed to the
public were offered to the public exceeds the amount of any damages which such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent
misrepresentation (within the meaning of Section&nbsp;11(f) of the Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#146; obligations in this subsection (d)&nbsp;to
contribute are several in proportion to their respective underwriting obligations and not joint. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The obligations of the Company under this Section&nbsp;9 shall be in addition to any
liability which the Company may otherwise have and shall extend, upon the same terms and conditions, to each employee, officer and director of each Underwriter and each person, if any, who controls any Underwriter within the meaning of the Act and
each broker-dealer or other affiliate of any Underwriter; and the obligations of the Underwriters under this Section&nbsp;9 shall be in addition to any liability which the respective Underwriters may otherwise have and shall extend, upon the same
terms and conditions, to each officer and director of the Company (including any person who, with his or her consent, is named in the Registration Statement as about to become a director of the Company) and to each person, if any, who controls the
Company within the meaning of the Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. (a) The Company will indemnify and hold harmless the Directed Share Underwriter against any
losses, claims, damages and liabilities to which the Directed Share Underwriter may become subject, under the Act or otherwise, insofar as such losses, claims damages or liabilities (or actions in respect thereof)&nbsp;(i) arise out of or are based
upon an untrue statement or alleged untrue statement of a material fact contained in any material prepared by or with the consent of the Company for distribution to Participants in connection with the Directed Share Program or arise out of or are
based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii)&nbsp;arise out of or are based upon the failure of any Participant to pay for
and accept delivery of Directed Shares that the Participant agreed to purchase, or (iii)&nbsp;are related to, arise out of or are in connection with the Directed Share Program, and will reimburse the Directed Share Underwriter for any legal or other
expenses reasonably incurred by the Directed Share Underwriter in connection with investigating or defending any such action or claim as such expenses are incurred; provided, however, that with respect to clauses (ii)&nbsp;and (iii) above, the
Company shall not be liable in any such case to the extent that any such loss, claim, damage or liability is finally judicially determined to have resulted from the bad faith or gross negligence of the Directed Share Underwriter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Promptly after receipt by the Directed Share Underwriter of notice of the commencement of any action, the Directed Share Underwriter
shall, if a claim in respect thereof is to be made against the Company, notify the Company in writing of the commencement thereof; provided that the failure to notify the Company shall not relieve the Company from any liability that it may have
under the preceding paragraph of this Section&nbsp;10 except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and provided further that the failure to notify the Company
shall not relieve it from any liability that it may have to the Directed Share Underwriter otherwise than under the preceding paragraph of this Section&nbsp;10. In case any such action shall be brought against the Directed Share Underwriter and it
shall notify the Company of the commencement thereof, the Company shall be entitled to participate therein and, to the extent that it shall wish, to assume the defense thereof, with counsel satisfactory to the Directed Share Underwriter (who shall
not, except with the consent of the Directed Share Underwriter, be counsel to the Company), and, after notice from the Company to the Directed Share Underwriter of its election so to assume the defense thereof, the Company shall not be liable to the
Directed Share Underwriter under this subsection for any legal expenses of other counsel or any other expenses, in each case subsequently incurred by the Directed Share Underwriter, in connection with the defense thereof other than reasonable costs
of investigation. The Company shall not, without the written consent of the Directed Share Underwriter, effect the settlement or compromise of, or consent to the entry of any judgment with respect to, any pending or threatened action or claim in
respect of which indemnification or contribution may be sought hereunder (whether or not the Directed Share Underwriter is an actual or potential party to such action or claim) unless such settlement, compromise or judgment (i)&nbsp;includes an
unconditional release of the Directed Share Underwriter from all liability arising out of such action or claim and (ii)&nbsp;does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of the
Directed Share Underwriter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If the indemnification provided for in this Section&nbsp;10 is unavailable to or
insufficient to hold harmless the Directed Share Underwriter under subsection (a)&nbsp;above in respect of any losses, claims, damages or liabilities (or actions in respect thereof) referred to therein, then the Company shall contribute to the
amount paid or payable by the Directed Share Underwriter as a result of such losses, claims, damages or liabilities (or actions in respect thereof) in such proportion as is appropriate to reflect the relative benefits received by the Company on the
one hand and the Directed Share Underwriter on the other from the offering of the Directed Shares. If, however, the allocation provided by the immediately preceding sentence is not permitted by applicable law, then the Company shall contribute to
such amount paid or payable by the Directed Share Underwriter in such proportion as is appropriate to reflect not only such relative benefits but also the relative fault of the Company on the one hand and the Directed Share Underwriter on the other
in connection with any statements or omissions which resulted in such losses, claims, damages or liabilities (or actions in respect thereof), as well as any other relevant equitable considerations. The relative benefits received by the Company on
the one hand and the Directed Share Underwriter on the other shall be deemed to be in the same proportion as the total net proceeds from the offering of the Directed Shares (before deducting expenses) received by the Company bear to the total
underwriting discounts and commissions received by the Directed Share Underwriter for the Directed Shares. If the loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement of a material fact or
arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, the relative fault shall be determined by reference to, among
other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company on the one hand or the Directed Share Underwriter on the
other and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and the Directed Share Underwriter agree that it would not be just and equitable if
contribution pursuant to this subsection (c)&nbsp;were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to above in this subsection (c). The amount paid or
payable by the Directed Share Underwriter as a result of the losses, claims, damages or liabilities (or actions in respect thereof) referred to above in this subsection (c)&nbsp;shall be deemed to include any legal or other expenses reasonably
incurred by the Directed Share Underwriter in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this subsection (c), the Directed Share Underwriter shall not be required to contribute any amount
in excess of the amount by which the total price at which the Directed Shares sold by it and distributed to the Participants exceeds the amount of any damages which the Directed Share Underwriter has otherwise been required to pay by reason of such
untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Act) shall be entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The obligations of the Company under this Section&nbsp;10 shall be in addition to any
liability which the Company may otherwise have and shall extend, upon the same terms and conditions, to each employee, officer and director of the Directed Share Underwriter and each person, if any, who controls the Directed Share Underwriter within
the meaning of the Act and each broker-dealer or other affiliate of the Directed Share Underwriter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. (a) If any Underwriter shall
default in its obligation to purchase the Shares which it has agreed to purchase hereunder at a Time of Delivery, you may in your discretion arrange for you or another party or other parties to purchase such Shares on the terms contained herein. If
within <FONT STYLE="white-space:nowrap">thirty-six</FONT> hours after such default by any Underwriter you do not arrange for the purchase of such Shares, then the Company shall be entitled to a further period of
<FONT STYLE="white-space:nowrap">thirty-six</FONT> hours within which to procure another party or other parties satisfactory to you to purchase such Shares on such terms. In the event that, within the respective prescribed periods, you notify the
Company that you have so arranged for the purchase of such Shares, or the Company notifies you that it has so arranged for the purchase of such Shares, you or the Company shall have the right to postpone such Time of Delivery for a period of not
more than seven days, in order to effect whatever changes may thereby be made necessary in the Registration Statement or the Prospectus, or in any other documents or arrangements, and the Company agrees to file promptly any amendments or supplements
to the Registration Statement or the Prospectus which in your opinion may thereby be made necessary. The term &#147;Underwriter&#148; as used in this Agreement shall include any person substituted under this Section with like effect as if such
person had originally been a party to this Agreement with respect to such Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If, after giving effect to any arrangements for the
purchase of the Shares of a defaulting Underwriter or Underwriters by you and the Company as provided in subsection (a)&nbsp;above, the aggregate number of such Shares which remains unpurchased does not exceed
<FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate number of all the Shares to be purchased at such Time of Delivery, then the Company shall have the right to require each <FONT STYLE="white-space:nowrap">non-defaulting</FONT>
Underwriter to purchase the number of shares which such Underwriter agreed to purchase hereunder at such Time of Delivery and, in addition, to require each <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter to purchase its pro rata
share (based on the number of Shares which such Underwriter agreed to purchase hereunder) of the Shares of such defaulting Underwriter or Underwriters for which such arrangements have not been made; but nothing herein shall relieve a defaulting
Underwriter from liability for its default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If, after giving effect to any arrangements for the purchase of the Shares of a
defaulting Underwriter or Underwriters by you and the Company as provided in subsection (a)&nbsp;above, the aggregate number of such Shares which remains unpurchased exceeds <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate
number of all the Shares to be purchased at such Time of Delivery, or if the Company shall not exercise the right described in subsection (b)&nbsp;above to require <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters to purchase
Shares of a defaulting Underwriter or Underwriters, then this Agreement (or, with respect to the Second Time of Delivery, the obligations of the Underwriters to purchase and of the Company to sell the Optional Shares) shall thereupon terminate,
without liability on the part of any <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter or the Company, except for the expenses to be borne by the Company and the Underwriters as provided in Section&nbsp;7 hereof and the indemnity
and contribution agreements in Sections 9 and 10 hereof; but nothing herein shall relieve a defaulting Underwriter from liability for its default. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. The respective indemnities, rights of contribution, agreements, representations,
warranties and other statements of the Company and the several Underwriters, as set forth in this Agreement or made by or on behalf of them, respectively, pursuant to this Agreement, shall remain in full force and effect, regardless of any
investigation (or any statement as to the results thereof) made by or on behalf of any Underwriter or any director, officer, employee, affiliate or controlling person of any Underwriter, or the Company, or any officer or director or controlling
person of the Company, and shall survive delivery of and payment for the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. If this Agreement shall be terminated pursuant to
Section&nbsp;11 hereof, the Company shall not then be under any liability to any Underwriter except as provided in Sections&nbsp;7 and 9 hereof; but, if for any other reason, any Shares are not delivered by or on behalf of the Company as provided
herein or the Underwriters decline to purchase the Shares for any reason permitted under this Agreement, the Company will reimburse the Underwriters through you for all
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses approved in writing by you, including fees and disbursements of counsel, reasonably incurred and documented by the Underwriters in making
preparations for the purchase, sale and delivery of the Shares not so delivered, but the Company shall then be under no further liability to any Underwriter except as provided in Sections 7 and 9 hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. In all dealings hereunder, the Representatives shall act on behalf of each of the Underwriters, and the parties hereto shall be entitled
to act and rely upon any statement, request, notice or agreement on behalf of any Underwriter made or given by you jointly or by Goldman Sachs&nbsp;&amp; Co. LLC on behalf of you as the Representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All statements, requests, notices and agreements hereunder shall be in writing, and if to the Underwriters shall be delivered or sent by mail, telex or
facsimile transmission to you as the Representatives in care of Goldman Sachs&nbsp;&amp; Co. LLC, 200 West Street, New York, New York <FONT STYLE="white-space:nowrap">10282-2198,</FONT> Attention: Registration Department; in care of SVB Leerink LLC,
1301 Avenue of the Americas, 12th Floor New York, New York 10019, Attention: Stuart R. Nyman; and in care of Evercore Group L.L.C., 55 E. 52nd St. New York, NY 10055; and if to the Company shall be delivered or sent by mail, telex or facsimile
transmission to the address of the Company set forth in the Registration Statement, Attention: <FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officers, with a copy (which shall not constitute notice) to Goodwin Procter LLP, 100 Northern
Avenue, Boston, MA 02210, Attention: Mitchell S. Bloom&nbsp;&amp; Benjamin K. Marsh; provided, however, that any notice to an Underwriter pursuant to Section&nbsp;9(c) hereof shall be delivered or sent by mail, telex or facsimile transmission to
such Underwriter at its address set forth in its Underwriters&#146; Questionnaire, or telex constituting such Questionnaire, which address will be supplied to the Company by you upon request; provided, however, that notices under subsection 5(e)
shall be in writing, and if to the Underwriters shall be delivered or sent by mail, telex or facsimile transmission to you as the Representatives at Goldman Sachs&nbsp;&amp; Co. LLC, 200 West Street, New York, New York 10282-2198, Attention: Control
Room; in care of SVB Leerink LLC, 1301 Avenue of the Americas, 12th Floor New York, New York 10019, Attention: Stuart R. Nyman; and in care of Evercore Group L.L.C., 55 E. 52nd St. New York, NY 10055. Any such statements, requests, notices or
agreements shall take effect upon receipt thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. <FONT
STYLE="white-space:nowrap">107-56</FONT> (signed into law October&nbsp;26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the Company, which information may include
the name and address of their respective clients, as well as other information that will allow the Underwriters to properly identify their respective clients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. This Agreement shall be binding upon, and inure solely to the benefit of, the Underwriters, the Company and, to the extent provided in
Sections 9, 10 and 12 hereof, the officers and directors of the Company and each person who controls the Company or any Underwriter, or any director, officer, employee, or affiliate of any Underwriter, and their respective heirs, executors,
administrators, successors and assigns, and no other person shall acquire or have any right under or by virtue of this Agreement. No purchaser of any of the Shares from any Underwriter shall be deemed a successor or assign by reason merely of such
purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. Time shall be of the essence of this Agreement. As used herein, the term &#147;business day&#148; shall mean any day when
the Commission&#146;s office in Washington, D.C. is open for business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. The Company acknowledges and agrees that (i)&nbsp;the purchase
and sale of the Shares pursuant to this Agreement is an <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> commercial transaction between the Company, on the one hand, and the several Underwriters, on the other, (ii)&nbsp;in connection
therewith and with the process leading to such transaction each Underwriter is acting solely as a principal and not the agent or fiduciary of the Company, (iii)&nbsp;no Underwriter has assumed an advisory or fiduciary responsibility in favor of the
Company with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company on other matters) or any other obligation to the Company except the
obligations expressly set forth in this Agreement, (iv)&nbsp;the Company has consulted its own legal and financial advisors to the extent it deemed appropriate, and (v)&nbsp;none of the activities of the Underwriters in connection with the
transactions contemplated herein constitutes a recommendation, investment advice, or solicitation of any action by the Underwriters with respect to any entity or natural person. The Company agrees that it will not claim that the Underwriters, or any
of them, has rendered advisory services of any nature or respect, or owes a fiduciary or similar duty to the Company, in connection with such transaction or the process leading thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. This Agreement supersedes all prior agreements and understandings (whether written or oral) between the Company and the Underwriters, or
any of them, with respect to the subject matter hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. This Agreement and any transaction contemplated by this Agreement and any
claim, controversy or dispute arising under or related thereto shall be governed by and construed in accordance with the laws of the State of New York without regard to principles of conflict of laws that would results in the application of any
other law than the laws of the State of New York. The Company agrees that any suit or proceeding arising in respect of this Agreement or any transaction contemplated by this Agreement will be tried exclusively in the U.S. District Court for the
Southern District of New York or, if that court does not have subject matter jurisdiction, in any state court located in The City and County of New York and the Company agrees to submit to the jurisdiction of, and to venue in, such courts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. The Company and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right
to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. This Agreement may be executed by any one or more of the parties hereto in any number of
counterparts, each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered
by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to
have been duly and validly delivered and be valid and effective for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. Notwithstanding anything herein to the contrary,
the Company is authorized to disclose to any persons the U.S. federal and state income tax treatment and tax structure of the potential transaction and all materials of any kind (including tax opinions and other tax analyses) provided to the Company
relating to that treatment and structure, without the Underwriters imposing any limitation of any kind. However, any information relating to the tax treatment and tax structure shall remain confidential (and the foregoing sentence shall not apply)
to the extent necessary to enable any person to comply with securities laws. For this purpose, &#147;tax structure&#148; is limited to any facts that may be relevant to that treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23. Recognition of the U.S. Special Resolution Regimes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the
transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any
such interest and obligation, were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In the event that any
Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted
to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) As used in this section: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;BHC Act Affiliate&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be interpreted in accordance with, 12
U.S.C. &#167; 1841(k). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Covered Entity&#148; means any of the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance
with, 12 C.F.R. &#167; 382.2(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Default Right&#148; has the meaning assigned to that term in, and shall be interpreted in
accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;U.S. Special Resolution Regime&#148; means each of
(i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding, please sign and return to us counterparts hereof, and upon the acceptance hereof by
you, on behalf of each of the Underwriters, this letter and such acceptance hereof shall constitute a binding agreement between each of the Underwriters and the Company. It is understood that your acceptance of this letter on behalf of each of the
Underwriters is pursuant to the authority set forth in a form of Agreement among Underwriters, the form of which shall be submitted to the Company for examination upon request, but without warranty on your part as to the authority of the signers
thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page Follows] </I></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Amylyx Pharmaceuticals, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Accepted as of the date hereof:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Goldman Sachs&nbsp;&amp; Co. LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>By:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>Name:</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>Title:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SVB Leerink LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>By:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>Name:</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>Title:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Evercore Group L.L.C.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>By:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>Name:</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>Title:</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On behalf of each of the Underwriters </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Underwriting Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE I </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Number&nbsp;of<BR>Firm<BR>Shares&nbsp;to<BR>be<BR>Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Optional<BR>Shares&nbsp;to&nbsp;be<BR>Purchased&nbsp;if<BR>Maximum<BR>Option<BR>Exercised</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVB Leerink LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Evercore Group L.L.C.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">H.C. Wainwright&nbsp;&amp; Co., LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Issuer Free Writing Prospectuses not included in the Pricing Disclosure Package: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) Information other than the Pricing Prospectus that comprise the Pricing Disclosure Package: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial public offering price per share for the Shares is $ [&#149;] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of Shares purchased by the Underwriters is [&#149;]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[Add any other pricing disclosure.] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEX I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amylyx Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[&#149;], 2021 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp;
Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SVB Leerink LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Evercore Group L.L.C. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Goldman Sachs&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 West Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10282-2198 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o SVB Leerink LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Federal Street, 37th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts 02110 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Evercore Group L.L.C. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">55 East 52nd Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10055 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Re: <U>Amylyx
Pharmaceuticals, Inc. - <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that Goldman Sachs&nbsp;&amp; Co. LLC, SVB Leerink LLC and Evercore Group L.L.C., as representatives (the
&#147;Representatives&#148;), propose to enter into an underwriting agreement (the &#147;Underwriting Agreement&#148;) on behalf of the several Underwriters named in Schedule I to such agreement (collectively, the &#147;Underwriters&#148;), with
Amylyx Pharmaceuticals, Inc., a Delaware corporation (the &#147;Company&#148;), providing for a public offering (the &#147;Public Offering&#148;) of the Common Stock of the Company (the &#147;Shares&#148;) pursuant to a Registration Statement on
Form <FONT STYLE="white-space:nowrap">S-1</FONT> to be filed with the Securities and Exchange Commission (the &#147;SEC&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
consideration of the agreement by the Underwriters to offer and sell the Shares, and of other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the undersigned agrees that, during the period beginning from
the date of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement and continuing to and including the date 180 days after the date set forth on the final prospectus (the &#147;Prospectus&#148;) used to sell the Shares (the <FONT
STYLE="white-space:nowrap">&#147;Lock-Up</FONT> Period&#148;), the undersigned shall not, and shall not cause or direct any of its affiliates to, (i) </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
offer, sell, contract to sell, pledge, grant any option to purchase, lend or otherwise dispose of any shares of Common Stock of the Company, or any options or warrants to purchase any shares of
Common Stock of the Company, or any securities convertible into, exchangeable for or that represent the right to receive shares of Common Stock of the Company (such options, warrants or other securities, collectively, &#147;Derivative
Instruments&#148;), including without limitation any such shares or Derivative Instruments now owned or hereafter acquired by the undersigned (such Common Stock and Derivative Instruments, collectively, the &#147;Undersigned&#146;s Shares&#148;),
(ii) engage in any hedging or other transaction or arrangement (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative
transaction or instrument, however described or defined) which is designed to or which reasonably could be expected to lead to or result in a sale, loan, pledge or other disposition (whether by the undersigned or someone other than the undersigned),
or transfer of any of the economic consequences of ownership, in whole or in part, directly or indirectly, of any of the Undersigned&#146;s Shares, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled
by delivery of Common Stock or other securities, in cash or otherwise (any such sale, loan, pledge or other disposition, or transfer of economic consequences, a &#147;Transfer&#148;) or (iii)&nbsp;otherwise publicly announce any intention to engage
in or cause any action or activity described in clause (i)&nbsp;above or transaction or arrangement described in clause (ii)&nbsp;above. The undersigned represents and warrants that the undersigned is not, and has not caused or directed any of its
affiliates to be or become, currently a party to any agreement or arrangement that provides for, is designed to or which reasonably could be expected to lead to or result in any Transfer during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Period. For the avoidance of doubt, the undersigned agrees that the foregoing provisions shall be equally applicable to any issuer-directed or other Shares the undersigned may purchase in the Public Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the undersigned is not a natural person, the undersigned represents and warrants that no single natural person, entity or &#147;group&#148;
(within the meaning of Section&nbsp;13(d)(3) of the Securities Exchange Act of 1934, as amended), other than a natural person, entity or &#147;group&#148; (as described above) that has executed a <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreement in substantially the same form as this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, beneficially owns, directly or indirectly, 50% or more of the common equity interests, or 50% or more of the voting power, in the
undersigned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the undersigned is an officer or director of the Company, (i)&nbsp;the Representatives agree that, at least three
business days before the effective date of any release or waiver of the foregoing restrictions in connection with a transfer of the Undersigned&#146;s Shares, the Representatives will notify the Company of the impending release or waiver, and
(ii)&nbsp;the Company has agreed in the Underwriting Agreement to announce the impending release or waiver by press release through a major news service at least two business days before the effective date of the release or waiver. Any release or
waiver granted by the Representatives hereunder to any such officer or director shall only be effective two business days after the publication date of such press release. The provisions of this paragraph will not apply if (a)&nbsp;the release or
waiver is effected solely to permit a transfer not for consideration and (b)&nbsp;the transferee has agreed in writing to be bound by the same terms described in this letter to the extent and for the duration that such terms remain in effect at the
time of the transfer. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the undersigned may transfer or otherwise dispose of the
Undersigned&#146;s Shares: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as a bona fide gift or gifts or to a charitable organization or educational institution for no value, provided
that the donee or donees thereof agree to be bound in writing by the restrictions set forth herein; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any member of the undersigned&#146;s immediate family or any trust for the direct or indirect benefit of the
undersigned or the immediate family of the undersigned, provided that the member of the undersigned&#146;s immediate family or trustee of the trust agrees to be bound in writing by the restrictions set forth herein, and provided further that any
such transfer shall not involve a disposition for value; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by will or other testamentary document or by intestacy, provided that any filing made under Section&nbsp;16 of
the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), shall include a footnote noting the circumstances described in this clause; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">pursuant to a court order or settlement or other domestic order related to the distribution of assets in
connection with the dissolution of a marriage or civil union, provided that any filing made under Section&nbsp;16 of the Exchange Act shall include a footnote noting the circumstances described in this clause; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to general or limited partners, members, stockholders, other equity holders or trust beneficiaries of the
undersigned or to any investment fund or other entity that controls or manages, or is under common control with, the undersigned, provided that any such transferee agrees to be bound in writing by the restrictions set forth herein;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">acquired in the Public Offering (other than any issuer-directed shares of Common Stock purchased in the Public
Offering by an officer or director of the Company) or acquired in open market transactions after the completion of the Public Offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">prior to the first public filing of a prospectus for the Public Offering, provided that the transferee agrees
to be bound in writing by the restrictions set forth herein; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by surrender or forfeiture of shares of Common Stock or other securities of the Company to the Company to
satisfy tax withholding obligations upon exercise or vesting or the exercise price upon a cashless net exercise, in each case, of share options, equity awards, warrants or other rights to acquire shares of Common Stock, provided that any filing made
under Section&nbsp;16 of the Exchange Act shall include a footnote noting the circumstances described in this clause; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">pursuant to a bona fide third-party tender offer, merger, consolidation, business combination, stock purchase
or other similar transaction or series of related transactions approved by the Board of Directors of the Company and made to all holders of the Company&#146;s capital stock involving a Change in Control, provided that in the event that such tender
offer, merger, consolidation, business combination, stock purchase or transaction or series of related transactions is not completed, the Undersigned&#146;s Shares shall remain subject to the restrictions set forth herein; </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(x)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the conversion of outstanding preferred shares of the Company described in the Prospectus and outstanding as of
the date of the Prospectus into shares of Common Stock as described in the Prospectus, provided that the shares of Common Stock received upon conversion shall be subject to the restrictions set forth herein; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">with the prior written consent of the Representatives on behalf of the Underwriters </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In addition, with respect to clauses (i), (ii), (iii), (iv), (v), (vi) and (viii)&nbsp;above, it shall be a condition to such transfer that no
filing under the Exchange Act or other disclosure of such transfer shall be required or voluntarily made during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, except (a)&nbsp;as contemplated by clauses (iii), (iv) and (viii)&nbsp;above
and (b)&nbsp;any required filings on Form 5 the filing deadline for which falls during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">For purposes of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, &#147;immediate family&#148; shall mean any relationship by
blood, marriage or adoption, not more remote than first cousin and &#147;Change in Control&#148; shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related
transactions, in each case occurring subsequent to the Public Offering, to a person or group of affiliated persons (other than an Underwriter pursuant to the Public Offering), of the Company&#146;s voting securities if, after such transfer, such
person or group of affiliated persons would hold more than 50% of the outstanding voting securities of the Company (or the surviving entity). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In addition, notwithstanding the foregoing, (1)&nbsp;if the undersigned is a corporation, the corporation may transfer the capital stock of
the Company to any wholly-owned subsidiary of such corporation; <U>provided</U>, <U>however</U>, that in any such case, it shall be a condition to the transfer that the transferee execute an agreement stating that the transferee is receiving and
holding such capital stock subject to the provisions of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement and there shall be no further transfer of such capital stock except in accordance with this
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, and provided further that any such transfer shall not involve a disposition for value; provided, further that no filing under the Exchange Act or other public disclosure reporting a
reduction in beneficial ownership of Common Stock shall be required or shall be voluntarily made during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period and (2)&nbsp;the restrictions on transfer and disposition of the Undersigned&#146;s
Shares during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period shall not apply to the repurchase of the Undersigned&#146;s Shares by the Company pursuant to any contractual arrangement in effect on the date of this agreement and disclosed
in the Prospectus that provides for the repurchase of the undersigned&#146;s Common Stock or in connection with the termination of the undersigned&#146;s employment or other service with the Company; <U>provided</U> that no filing under the Exchange
Act or other public disclosure of such repurchase shall be voluntarily made during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period and any filing under the Exchange Act or other public disclosure required to be made during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period shall include a statement to the effect that such repurchase related to the circumstances described in this clause (2). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The undersigned now has, and, except as contemplated by the terms hereof, for the duration of this
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement will have, good and marketable title to the Undersigned&#146;s Shares, free and clear of all liens, encumbrances, and claims whatsoever. The undersigned also agrees and consents to the entry
of stop transfer instructions with the Company&#146;s transfer agent and registrar against the transfer of the Undersigned&#146;s Shares except in compliance with the foregoing restrictions. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In addition, the undersigned may enter into any plan designed to satisfy the requirements of
Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> (a <FONT STYLE="white-space:nowrap">&#147;10b5-1</FONT> Plan&#148;) under the Exchange Act (other than the entry into such a plan in such a manner as to allow the sale of shares of Common Stock, in
each case, within the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period); provided, however that, no sale of shares of Common Stock may be made under such <FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period; provided further that no filing under the Exchange Act or public disclosure regarding the establishment of such plan shall be voluntarily made during the
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period and any such filing or public disclosure that is required to be made during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period shall include a statement to the effect that no disposition
of the Undersigned&#146;s Shares may be made under such plan during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary contained herein, this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement will automatically
terminate and the undersigned will be released from all of his, her or its obligations hereunder upon the earliest to occur, if any, of (i)&nbsp;prior to the execution of the Underwriting Agreement, the Company advises the Representatives in writing
that it has determined not to proceed with the Public Offering of the Shares, (ii)&nbsp;prior to the execution of the Underwriting Agreement, the date on which the Company files an application to withdraw the registration statement related to the
Public Offering of the Shares or (iii)&nbsp;the Underwriting Agreement is executed but is terminated (other than the provisions thereof which survive termination) prior to payment for and delivery of the Shares to be sold thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that none of the Underwriters has made any recommendation or provided any investment or other advice
to the undersigned with respect to this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement or the subject matter hereof, and the undersigned has consulted its own legal, accounting, financial, regulatory, tax and other advisors with respect
to this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement and the subject matter hereof to the extent the undersigned has deemed appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The undersigned understands that the Company and the Underwriters are relying upon this <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreement in proceeding toward consummation of the Public Offering and that the Company shall be deemed a third-party beneficiary hereto. The undersigned further understands that this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement is
irrevocable and shall be binding upon the undersigned&#146;s heirs, legal representatives, successors, and assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Remainder of page
intentionally blank] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exact Name of Shareholder</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Authorized Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Lockup Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>ANNEX II </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Press Release </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amylyx
Pharmaceuticals, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>[Date] </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amylyx
Pharmaceuticals, Inc. (the &#147;Company&#148;) announced today that Goldman Sachs&nbsp;&amp; Co. LLC, SVB Leerink LLC and Evercore Group L.L.C., the lead book-running managers in the Company&#146;s recent public sale
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, is [waiving] [releasing] a <FONT STYLE="white-space:nowrap">lock-up</FONT> restriction with respect
to&nbsp;&nbsp;&nbsp;&nbsp;shares of the Company&#146;s common stock held by [certain officers or directors] [an officer or director] of the Company.&nbsp;&nbsp;&nbsp;&nbsp;The [waiver] [release] will take effect
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20&nbsp;&nbsp;&nbsp;&nbsp;, and the shares may be sold
on or after such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This press release is not an offer for sale of the securities in the United States or in any other jurisdiction where such
offer is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended. </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.3
<SEQUENCE>3
<FILENAME>d155225dex33.htm
<DESCRIPTION>EX-3.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOURTH<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMYLYX
PHARMACEUTICALS, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amylyx Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the
&#147;Corporation&#148;), hereby certifies as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;The name of the Corporation is Amylyx Pharmaceuticals,
Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was January&nbsp;10, 2014 (the &#147;Original Certificate&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;This Fourth Amended and Restated Certificate of Incorporation (the &#147;Certificate&#148;) amends, restates and
integrates the provisions of the Third Amended and Restated Certificate of Incorporation that was filed with the Secretary of State of the State of Delaware on July&nbsp;1, 2021, as amended (the &#147;Amended and Restated Certificate&#148;), and was
duly adopted in accordance with the provisions of Sections 228, 242 and 245 of the General Corporation Law of the State of Delaware (the &#147;DGCL&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;The text of the Amended and Restated Certificate is hereby amended and restated in its entirety to provide as herein
set forth in full. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE I </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The name of the Corporation is Amylyx Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE II </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The address of the
Corporation&#146;s registered office in the State of Delaware is 251 Little Falls Drive, in the City of Wilmington, County of New Castle 19808. The name of its registered agent at such address is Corporation Service Company. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE III </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the
Corporation is to engage in any lawful act or activity for which corporations may be organized under the DGCL. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE IV </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>CAPITAL STOCK </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total
number of shares of capital stock which the Corporation shall have authority to issue is three hundred ten million (310,000,000), of which (i)&nbsp;three hundred million (300,000,000) shares shall be a class designated as common stock, par value
$0.0001 per share (the &#147;Common Stock&#148;), and (ii)&nbsp;ten million (10,000,000) shares shall be a class designated as undesignated preferred stock, par value $0.0001 per share (the &#147;Undesignated Preferred Stock&#148;). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in any certificate of designations of any series of
Undesignated Preferred Stock, the number of authorized shares of the class of Common Stock or Undesignated Preferred Stock may from time to time be increased or decreased (but not below the number of shares of such class outstanding) by the
affirmative vote of the holders of a majority in voting power of the outstanding shares of capital stock of the Corporation irrespective of the provisions of Section&nbsp;242(b)(2) of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The powers, preferences and rights of, and the qualifications, limitations and restrictions upon, each class or series of stock shall be
determined in accordance with, or as set forth below in, this Article&nbsp;IV. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A. <U>COMMON STOCK</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Subject to all the rights, powers and preferences of the Undesignated Preferred Stock and except as provided by law or in this Certificate (or
in any certificate of designations of any series of Undesignated Preferred Stock): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;the holders of the Common
Stock shall have the exclusive right to vote for the election of directors of the Corporation (the &#147;Directors&#148;) and on all other matters requiring stockholder action, each outstanding share entitling the holder thereof to one vote on each
matter properly submitted to the stockholders of the Corporation for their vote; <U>provided</U>, <U>however</U>, that, except as otherwise required by law, holders of Common Stock, as such, shall not be entitled to vote on any amendment to this
Certificate (or on any amendment to a certificate of designations of any series of Undesignated Preferred Stock) that alters or changes the powers, preferences, rights or other terms of one or more outstanding series of Undesignated Preferred Stock
if the holders of such affected series of Undesignated Preferred Stock are entitled to vote, either separately or together with the holders of one or more other such series, on such amendment pursuant to this Certificate (or pursuant to a
certificate of designations of any series of Undesignated Preferred Stock) or pursuant to the DGCL; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;dividends
may be declared and paid or set apart for payment upon the Common Stock out of any assets or funds of the Corporation legally available for the payment of dividends, but only when and as declared by the Board of Directors or any authorized committee
thereof; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;upon the voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the
net assets of the Corporation shall be distributed pro rata to the holders of the Common Stock. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B. <U>UNDESIGNATED PREFERRED STOCK</U>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Board of Directors or any authorized committee thereof is expressly authorized, to the fullest extent permitted by law, to provide by
resolution or resolutions for, out </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the unissued shares of Undesignated Preferred Stock, the issuance of the shares of Undesignated Preferred Stock in one or more series of such stock, and by filing a certificate of designations
pursuant to applicable law of the State of Delaware, to establish or change from time to time the number of shares of each such series, and to fix the designations, powers, including voting powers, full or limited, or no voting powers, preferences
and the relative, participating, optional or other special rights of the shares of each series and any qualifications, limitations and restrictions thereof. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE V </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>STOCKHOLDER ACTION
</U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Action without Meeting</U>. Any action required or permitted to be taken by the stockholders of the
Corporation at any annual or special meeting of stockholders of the Corporation must be effected at a duly called annual or special meeting of stockholders and may not be taken or effected by a written consent of stockholders in lieu thereof.
Notwithstanding anything herein to the contrary, the affirmative vote of not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) of the outstanding shares of capital stock entitled to vote thereon, and the affirmative vote of not less
than <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) of the outstanding shares of each class entitled to vote thereon as a class, shall be required to amend or repeal any provision of this Article V, Section&nbsp;1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Special Meetings</U>. Except as otherwise required by statute and subject to the rights, if any, of the holders
of any series of Undesignated Preferred Stock, special meetings of the stockholders of the Corporation may be called only by the Board of Directors acting pursuant to a resolution approved by the affirmative vote of a majority of the Directors then
in office, and special meetings of stockholders may not be called by any other person or persons. Only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders of the
Corporation. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE VI </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>DIRECTORS </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>General</U>. The business and affairs of the Corporation shall be managed by or under the direction of the Board
of Directors except as otherwise provided herein or required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Election of Directors</U>. Election of
Directors need not be by written ballot unless the <FONT STYLE="white-space:nowrap">By-laws</FONT> of the Corporation (the <FONT STYLE="white-space:nowrap">&#147;By-laws&#148;)</FONT> shall so provide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Number of Directors; Term of Office</U>. The number of Directors of the Corporation shall be fixed solely and
exclusively by resolution duly adopted from time to time by the Board of Directors. The Directors, other than those who may be elected by the holders of any series of Undesignated Preferred Stock, shall be classified, with respect to the term for
which they severally hold office, into three classes. The initial Class&nbsp;I Directors of the Corporation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall be Justin Klee and Isaac Cheng; the initial Class&nbsp;II Directors of the Corporation shall be Paul Fonteyne and George Milne; and the initial Class&nbsp;III Directors of the Corporation
shall be Joshua Cohen and Daphne Quimi. The initial Class&nbsp;I Directors shall serve for a term expiring at the annual meeting of stockholders to be held in 2022, the initial Class&nbsp;II Directors shall serve for a term expiring at the annual
meeting of stockholders to be held in 2023, and the initial Class&nbsp;III Directors shall serve for a term expiring at the annual meeting of stockholders to be held in 2024. The mailing address of each person who is to serve initially as a director
is c/o Amylyx Pharmaceuticals, Inc., 43 Thorndike St., Cambridge, MA 02141. At each annual meeting of stockholders, Directors elected to succeed those Directors whose terms expire shall be elected for a term of office to expire at the third
succeeding annual meeting of stockholders after their election. Notwithstanding the foregoing, the Directors elected to each class shall hold office until their successors are duly elected and qualified or until their earlier resignation, death or
removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, whenever, pursuant to the provisions of Article&nbsp;IV of this Certificate, the holders of any
one or more series of Undesignated Preferred Stock shall have the right, voting separately as a series or together with holders of other such series, to elect Directors at an annual or special meeting of stockholders, the election, term of office,
filling of vacancies and other features of such directorships shall be governed by the terms of this Certificate and any certificate of designations applicable to such series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything herein to the contrary, the affirmative vote of not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT>
(2/3) of the outstanding shares of capital stock entitled to vote thereon, and the affirmative vote of not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) of the outstanding shares of each class entitled to vote thereon as a
class, shall be required to amend or repeal any provision of this Article VI, Section&nbsp;3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Vacancies</U>.
Subject to the rights, if any, of the holders of any series of Undesignated Preferred Stock to elect Directors and to fill vacancies in the Board of Directors relating thereto, any and all vacancies in the Board of Directors, however occurring,
including, without limitation, by reason of an increase in the size of the Board of Directors, or the death, resignation, disqualification or removal of a Director, shall be filled solely and exclusively by the affirmative vote of a majority of the
remaining Directors then in office, even if less than a quorum of the Board of Directors, and not by the stockholders. Any Director appointed in accordance with the preceding sentence shall hold office for the remainder of the full term of the class
of Directors in which the new directorship was created or the vacancy occurred and until such Director&#146;s successor shall have been duly elected and qualified or until his or her earlier resignation, death or removal. Subject to the rights, if
any, of the holders of any series of Undesignated Preferred Stock to elect Directors, when the number of Directors is increased or decreased, the Board of Directors shall, subject to Article VI.3 hereof, determine the class or classes to which the
increased or decreased number of Directors shall be apportioned; <U>provided</U>, <U>however</U>, that no decrease in the number of Directors shall shorten the term of any incumbent Director. In the event of a vacancy in the Board of Directors, the
remaining Directors, except as otherwise provided by law, shall exercise the powers of the full Board of Directors until the vacancy is filled. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Removal</U>. Subject to the rights, if any, of any series of
Undesignated Preferred Stock to elect Directors and to remove any Director whom the holders of any such series have the right to elect, any Director (including persons elected by Directors to fill vacancies in the Board of Directors) may be removed
from office (i)&nbsp;only with cause and (ii)&nbsp;only by the affirmative vote of the holders of not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) of the outstanding shares of capital stock then entitled to vote at an election
of Directors. At least forty-five (45)&nbsp;days prior to any annual or special meeting of stockholders at which it is proposed that any Director be removed from office, written notice of such proposed removal and the alleged grounds thereof shall
be sent to the Director whose removal will be considered at the meeting. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE VII </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>LIMITATION OF LIABILITY </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of his or
her fiduciary duty as a Director, except for liability (a)&nbsp;for any breach of the Director&#146;s duty of loyalty to the Corporation or its stockholders, (b)&nbsp;for acts or omissions not in good faith or which involve intentional misconduct or
a knowing violation of law, (c)&nbsp;under Section&nbsp;174 of the DGCL or (d)&nbsp;for any transaction from which the Director derived an improper personal benefit. If the DGCL is amended after the effective date of this Certificate to authorize
corporate action further eliminating or limiting the personal liability of Directors, then the liability of a Director of the Corporation shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any amendment, repeal or modification of this Article&nbsp;VII by either of (i)&nbsp;the stockholders of the Corporation or (ii)&nbsp;an
amendment to the DGCL, shall not adversely affect any right or protection existing at the time of such amendment, repeal or modification with respect to any acts or omissions occurring before such amendment, repeal or modification of a person
serving as a Director at the time of such amendment, repeal or modification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything herein to the contrary, the
affirmative vote of not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) of the outstanding shares of capital stock entitled to vote thereon, and the affirmative vote of not less than
<FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) of the outstanding shares of each class entitled to vote thereon as a class, shall be required to amend or repeal any provision of this Article VII. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE VIII </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>AMENDMENT OF <FONT
STYLE="white-space:nowrap">BY-LAWS</FONT> </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment by Directors</U>. Except as otherwise provided by
law, the <FONT STYLE="white-space:nowrap">By-laws</FONT> of the Corporation may be amended or repealed by the Board of Directors by the affirmative vote of a majority of the Directors then in office. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment by Stockholders</U>. Except as otherwise provided
therein, the <FONT STYLE="white-space:nowrap">By-laws</FONT> of the Corporation may be amended or repealed at any annual meeting of stockholders, or special meeting of stockholders called for such purpose, by the affirmative vote of at least not
less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) of the outstanding shares of capital stock entitled to vote on such amendment or repeal, voting together as a single class. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE IX </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>AMENDMENT OF
CERTIFICATE OF INCORPORATION </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation reserves the right to amend or repeal this Certificate in the manner now or hereafter
prescribed by statute and this Certificate, and all rights conferred upon stockholders herein are granted subject to this reservation. Except as otherwise required by this Certificate or by law, whenever any vote of the holders of capital stock of
the Corporation is required to amend or repeal any provision of this Certificate, such amendment or repeal shall require the affirmative vote of the majority of the outstanding shares of capital stock entitled to vote on such amendment or repeal,
and the affirmative vote of the majority of the outstanding shares of each class entitled to vote thereon as a class, at a duly constituted meeting of stockholders called expressly for such purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[End of Text] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION is executed as of this
&nbsp;&nbsp;&nbsp;&nbsp; day of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AMYLYX PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Joshua B. Cohen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Justin B. Klee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.4
<SEQUENCE>4
<FILENAME>d155225dex34.htm
<DESCRIPTION>EX-3.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECOND AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BY-LAWS</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMYLYX
PHARMACEUTICALS, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(the &#147;Corporation&#148;) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE I </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Stockholders
</U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Annual Meeting</U>. The annual meeting of stockholders (any such meeting being referred to in
these <FONT STYLE="white-space:nowrap">By-laws</FONT> as an &#147;Annual Meeting&#148;) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors of the Corporation (the &#147;Board of
Directors&#148;), which time, date and place may subsequently be changed at any time by vote of the Board of Directors. The Board of Directors may, in its sole discretion, determine that a meeting of stockholders shall not be held at any place, but
may instead be held solely by means of remote communication as authorized by Section&nbsp;211(a)(2) of the General Corporation Law of the State of Delaware (the &#147;DGCL&#148;). In the absence of any such designation or determination,
stockholders&#146; meetings shall be held at the Corporation&#146;s principal executive office. If no Annual Meeting has been held for a period of thirteen (13)&nbsp;months after the Corporation&#146;s last Annual Meeting, a special meeting in lieu
thereof may be held, and such special meeting shall have, for the purposes of these <FONT STYLE="white-space:nowrap">By-laws</FONT> or otherwise, all the force and effect of an Annual Meeting. Any and all references hereafter in these <FONT
STYLE="white-space:nowrap">By-laws</FONT> to an Annual Meeting or Annual Meetings also shall be deemed to refer to any special meeting(s) in lieu thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2.&nbsp;&nbsp;&nbsp;&nbsp;Notice of Stockholder Business and Nominations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Annual Meetings of Stockholders</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1)&nbsp;&nbsp;&nbsp;&nbsp;Nominations of persons for election to the Board of Directors of the Corporation and the proposal of
other business to be considered by the stockholders may be brought before an Annual Meeting (i)&nbsp;by or at the direction of the Board of Directors or (ii)&nbsp;by any stockholder of the Corporation who was a stockholder of record at the time of
giving of notice provided for in this <FONT STYLE="white-space:nowrap">By-law,</FONT> who is entitled to vote at the meeting, who is present (in person or by proxy) at the meeting and who complies with the notice procedures set forth in this <FONT
STYLE="white-space:nowrap">By-law</FONT> as to such nomination or business. For the avoidance of doubt, the foregoing clause (ii)&nbsp;shall be the exclusive means for a stockholder to bring nominations or business properly before an Annual Meeting
(other than matters properly brought under Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> (or any successor rule) under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;)), and such stockholder must comply with the
notice and other procedures set forth in Article I, Section&nbsp;2(a)(2) and (3)&nbsp;of this <FONT STYLE="white-space:nowrap">By-law</FONT> to </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
bring such nominations or business properly before an Annual Meeting. In addition to the other requirements set forth in this <FONT STYLE="white-space:nowrap">By-law,</FONT> for any proposal of
business to be considered at an Annual Meeting, it must be a proper subject for action by stockholders of the Corporation under Delaware law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2)&nbsp;&nbsp;&nbsp;&nbsp;For nominations or other business to be properly brought before an Annual Meeting by a stockholder
pursuant to clause (ii)&nbsp;of Article I, Section&nbsp;2(a)(1) of this <FONT STYLE="white-space:nowrap">By-law,</FONT> the stockholder must (i)&nbsp;have given Timely Notice (as defined below) thereof in writing to the Secretary of the Corporation,
(ii)&nbsp;have provided any updates or supplements to such notice at the times and in the forms required by this <FONT STYLE="white-space:nowrap">By-law</FONT> and (iii)&nbsp;together with the beneficial owner(s), if any, on whose behalf the
nomination or business proposal is made, have acted in accordance with the representations set forth in the Solicitation Statement (as defined below) required by this <FONT STYLE="white-space:nowrap">By-law.</FONT> To be timely, a stockholder&#146;s
written notice shall be received by the Secretary at the principal executive offices of the Corporation not later than the close of business on the ninetieth (90th) day nor earlier than the close of business on the one hundred twentieth (120th) day
prior to the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the preceding year&#146;s Annual Meeting; <U>provided</U>, <U>however</U>, that in the event the Annual Meeting is first convened more than thirty (30)&nbsp;days before or
more than sixty (60)&nbsp;days after such anniversary date, or if no Annual Meeting were held in the preceding year, notice by the stockholder to be timely must be received by the Secretary of the Corporation not later than the close of business on
the later of the ninetieth (90th) day prior to the scheduled date of such Annual Meeting or the tenth (10th) day following the day on which public announcement of the date of such meeting is first made (such notice within such time periods shall be
referred to as &#147;Timely Notice&#148;). Notwithstanding anything to the contrary provided herein, for the first Annual Meeting following the initial public offering of common stock of the Corporation, a stockholder&#146;s notice shall be timely
if received by the Secretary at the principal executive offices of the Corporation not later than the close of business on the later of the ninetieth (90th) day prior to the scheduled date of such Annual Meeting or the tenth (10th) day following the
day on which public announcement of the date of such Annual Meeting is first made or sent by the Corporation. Such stockholder&#146;s Timely Notice shall set forth: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;as to each person whom the stockholder proposes to nominate for election or reelection as a
director, all information relating to such person that is required to be disclosed in solicitations of proxies for election of directors in an election contest, or is otherwise required, in each case pursuant to Regulation 14A under the Exchange Act
(including such person&#146;s written consent to being named in the proxy statement as a nominee and to serving as a director if elected); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;as to any other business that the stockholder proposes to bring before the meeting, a brief
description of the business desired to be brought before the meeting, the reasons for conducting such business at the meeting, and any material interest in such business of each Proposing Person (as defined below); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C)&nbsp;&nbsp;&nbsp;&nbsp;(i) the name and address of the stockholder giving the notice, as they appear on the
Corporation&#146;s books, and the names and addresses of the other Proposing Persons (if any) and (ii)&nbsp;as to each Proposing Person, the following </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
information: (a)&nbsp;the class or series and number of all shares of capital stock of the Corporation which are, directly or indirectly, owned beneficially or of record by such Proposing Person
or any of its affiliates or associates (as such terms are defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> promulgated under the Exchange Act), including any shares of any class or series of capital stock of the Corporation as to which
such Proposing Person or any of its affiliates or associates has a right to acquire beneficial ownership at any time in the future, (b)&nbsp;all Synthetic Equity Interests (as defined below) in which such Proposing Person or any of its affiliates or
associates, directly or indirectly, holds an interest including a description of the material terms of each such Synthetic Equity Interest, including without limitation, identification of the counterparty to each such Synthetic Equity Interest and
disclosure, for each such Synthetic Equity Interest, as to (x)&nbsp;whether or not such Synthetic Equity Interest conveys any voting rights, directly or indirectly, in such shares to such Proposing Person, (y)&nbsp;whether or not such Synthetic
Equity Interest is required to be, or is capable of being, settled through delivery of such shares and (z)&nbsp;whether or not such Proposing Person and/or, to the extent known, the counterparty to such Synthetic Equity Interest has entered into
other transactions that hedge or mitigate the economic effect of such Synthetic Equity Interest, (c)&nbsp;any proxy (other than a revocable proxy given in response to a public proxy solicitation made pursuant to, and in accordance with, the Exchange
Act), agreement, arrangement, understanding or relationship pursuant to which such Proposing Person has or shares a right to, directly or indirectly, vote any shares of any class or series of capital stock of the Corporation, (d)&nbsp;any rights to
dividends or other distributions on the shares of any class or series of capital stock of the Corporation, directly or indirectly, owned beneficially by such Proposing Person that are separated or separable from the underlying shares of the
Corporation, and (e)&nbsp;any performance-related fees (other than an asset based fee) that such Proposing Person, directly or indirectly, is entitled to based on any increase or decrease in the value of shares of any class or series of capital
stock of the Corporation or any Synthetic Equity Interests (the disclosures to be made pursuant to the foregoing clauses (a)&nbsp;through (e) are referred to, collectively, as &#147;Material Ownership Interests&#148;) and (iii)&nbsp;a description of
the material terms of all agreements, arrangements or understandings (whether or not in writing) entered into by any Proposing Person or any of its affiliates or associates with any other person for the purpose of acquiring, holding, disposing or
voting of any shares of any class or series of capital stock of the Corporation; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D)&nbsp;&nbsp;&nbsp;&nbsp;(i) a
description of all agreements, arrangements or understandings by and among any of the Proposing Persons, or by and among any Proposing Persons and any other person (including with any proposed nominee(s)), pertaining to the nomination(s) or other
business proposed to be brought before the meeting of stockholders (which description shall identify the name of each other person who is party to such an agreement, arrangement or understanding), and (ii)&nbsp;identification of the names and
addresses of other stockholders (including beneficial owners) known by any of the Proposing Persons to support such nominations or other business proposal(s), and to the extent known the class and number of all shares of the Corporation&#146;s
capital stock owned beneficially or of record by such other stockholder(s) or other beneficial owner(s); and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(E)&nbsp;&nbsp;&nbsp;&nbsp;a statement whether or not the stockholder giving
the notice and/or the other Proposing Person(s), if any, will deliver a proxy statement and form of proxy to holders of, in the case of a business proposal, at least the percentage of voting power of all of the shares of capital stock of the
Corporation required under applicable law to approve the proposal or, in the case of a nomination or nominations, at least the percentage of voting power of all of the shares of capital stock of the Corporation reasonably believed by such Proposing
Person to be sufficient to elect the nominee or nominees proposed to be nominated by such stockholder (such statement, the &#147;Solicitation Statement&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Article I of these <FONT STYLE="white-space:nowrap">By-laws,</FONT> the term &#147;Proposing Person&#148;
shall mean the following persons: (i)&nbsp;the stockholder of record providing the notice of nominations or business proposed to be brought before a stockholders&#146; meeting, and (ii)&nbsp;the beneficial owner(s), if different, on whose behalf the
nominations or business proposed to be brought before a stockholders&#146; meeting is made. For purposes of this Section&nbsp;2 of Article&nbsp;I of these <FONT STYLE="white-space:nowrap">By-laws,</FONT> the term &#147;Synthetic Equity
Interest&#148; shall mean any transaction, agreement or arrangement (or series of transactions, agreements or arrangements), including, without limitation, any derivative, swap, hedge, repurchase or <FONT STYLE="white-space:nowrap">so-called</FONT>
&#147;stock borrowing&#148; agreement or arrangement, the purpose or effect of which is to, directly or indirectly: (a)&nbsp;give a person or entity economic benefit and/or risk similar to ownership of shares of any class or series of capital stock
of the Corporation, in whole or in part, including due to the fact that such transaction, agreement or arrangement provides, directly or indirectly, the opportunity to profit or avoid a loss from any increase or decrease in the value of any shares
of any class or series of capital stock of the Corporation, (b)&nbsp;mitigate loss to, reduce the economic risk of or manage the risk of share price changes for, any person or entity with respect to any shares of any class or series of capital stock
of the Corporation, (c)&nbsp;otherwise provide in any manner the opportunity to profit or avoid a loss from any decrease in the value of any shares of any class or series of capital stock of the Corporation, or (d)&nbsp;increase or decrease the
voting power of any person or entity with respect to any shares of any class or series of capital stock of the Corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3)&nbsp;&nbsp;&nbsp;&nbsp;A stockholder providing Timely Notice of nominations or business proposed to be brought before an
Annual Meeting shall further update and supplement such notice, if necessary, so that the information (including, without limitation, the Material Ownership Interests information) provided or required to be provided in such notice pursuant to this <FONT
STYLE="white-space:nowrap">By-law</FONT> shall be true and correct as of the record date for the meeting and as of the date that is ten (10)&nbsp;business days prior to such Annual Meeting, and such update and supplement shall be received by the
Secretary at the principal executive offices of the Corporation not later than the close of business on the fifth (5th) business day after the record date for the Annual Meeting (in the case of the update and supplement required to be made as of the
record date), and not later than the close of business on the eighth (8th) business day prior to the date of the Annual Meeting (in the case of the update and supplement required to be made as of ten (10)&nbsp;business days prior to the meeting).
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything in the second sentence
of Article I, Section&nbsp;2(a)(2) of this <FONT STYLE="white-space:nowrap">By-law</FONT> to the contrary, in the event that the number of directors to be elected to the Board of Directors of the Corporation is increased and there is no public
announcement naming all of the nominees for director or specifying the size of the increased Board of Directors made by the Corporation at least ten (10)&nbsp;days before the last day a stockholder may deliver a notice of nomination in accordance
with the second sentence of Article I, Section&nbsp;2(a)(2), a stockholder&#146;s notice required by this <FONT STYLE="white-space:nowrap">By-law</FONT> shall also be considered timely, but only with respect to nominees for any new positions created
by such increase, if it shall be received by the Secretary of the Corporation not later than the close of business on the tenth (10th) day following the day on which such public announcement is first made by the Corporation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>General</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1)&nbsp;&nbsp;&nbsp;&nbsp;Only such persons who are nominated in accordance with the provisions of this <FONT
STYLE="white-space:nowrap">By-law</FONT> shall be eligible for election and to serve as directors and only such business shall be conducted at an Annual Meeting as shall have been brought before the meeting in accordance with the provisions of this <FONT
STYLE="white-space:nowrap">By-law</FONT> or in accordance with Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the Exchange Act. The Board of Directors or a designated committee thereof shall have the power to determine whether a nomination
or any business proposed to be brought before the meeting was made in accordance with the provisions of this <FONT STYLE="white-space:nowrap">By-law.</FONT> If neither the Board of Directors nor such designated committee makes a determination as to
whether any stockholder proposal or nomination was made in accordance with the provisions of this <FONT STYLE="white-space:nowrap">By-law,</FONT> the presiding officer of the Annual Meeting shall have the power and duty to determine whether the
stockholder proposal or nomination was made in accordance with the provisions of this <FONT STYLE="white-space:nowrap">By-law.</FONT> If the Board of Directors or a designated committee thereof or the presiding officer, as applicable, determines
that any stockholder proposal or nomination was not made in accordance with the provisions of this <FONT STYLE="white-space:nowrap">By-law,</FONT> such proposal or nomination shall be disregarded and shall not be presented for action at the Annual
Meeting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2)&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise required by law, nothing in this Article I, Section&nbsp;2 shall
obligate the Corporation or the Board of Directors to include in any proxy statement or other stockholder communication distributed on behalf of the Corporation or the Board of Directors information with respect to any nominee for director or any
other matter of business submitted by a stockholder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing provisions
of this Article I, Section&nbsp;2, if the nominating or proposing stockholder (or a qualified representative of the stockholder) does not appear at the Annual Meeting to present a nomination or any business, such nomination or business shall be
disregarded, notwithstanding that proxies in respect of such vote may have been received by the Corporation. For purposes of this Article I, Section&nbsp;2, to be considered a qualified representative of the proposing stockholder, a person must be
authorized by a written instrument executed by such stockholder or an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders and such person must produce such written instrument or electronic
transmission, or a reliable reproduction of the written instrument or electronic transmission, to the presiding officer at the meeting of stockholders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4)&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this <FONT STYLE="white-space:nowrap">By-law,</FONT> &#147;public announcement&#148;
shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to
Section&nbsp;13, 14 or 15(d) of the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(5)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing provisions of
this <FONT STYLE="white-space:nowrap">By-law,</FONT> a stockholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to the matters set forth in this <FONT
STYLE="white-space:nowrap">By-law.</FONT> Nothing in this <FONT STYLE="white-space:nowrap">By-law</FONT> shall be deemed to affect any rights of (i)&nbsp;stockholders to have proposals included in the Corporation&#146;s proxy statement pursuant to
Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> (or any successor rule), as applicable, under the Exchange Act and, to the extent required by such rule, have such proposals considered and voted on at an Annual Meeting or (ii)&nbsp;the holders of
any series of Undesignated Preferred Stock (as defined in the Certificate (as defined below)) to elect directors under specified circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Special Meetings</U>. Except as otherwise required by statute and subject to the rights, if any, of the
holders of any series of Undesignated Preferred Stock, special meetings of the stockholders of the Corporation may be called only by the Board of Directors acting pursuant to a resolution approved by the affirmative vote of a majority of the
Directors then in office. The Board of Directors may postpone or reschedule any previously scheduled special meeting of stockholders. Only those matters set forth in the notice of the special meeting may be considered or acted upon at a special
meeting of stockholders of the Corporation. Nominations of persons for election to the Board of Directors of the Corporation and stockholder proposals of other business shall not be brought before a special meeting of stockholders to be considered
by the stockholders unless such special meeting is held in lieu of an annual meeting of stockholders in accordance with Article I, Section&nbsp;1 of these <FONT STYLE="white-space:nowrap">By-laws,</FONT> in which case such special meeting in lieu
thereof shall be deemed an Annual Meeting for purposes of these <FONT STYLE="white-space:nowrap">By-laws</FONT> and the provisions of Article I, Section&nbsp;2 of these <FONT STYLE="white-space:nowrap">By-laws</FONT> shall govern such special
meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4.&nbsp;&nbsp;&nbsp;&nbsp;Notice of Meetings; Adjournments. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;A notice of each Annual Meeting stating the hour, date and place, if any, of such Annual Meeting and the means of
remote communication, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, shall be given not less than ten (10)&nbsp;days nor more than sixty (60)&nbsp;days before the Annual Meeting, to
each stockholder entitled to vote thereat by delivering such notice to such stockholder or by mailing it, postage prepaid, addressed to such stockholder at the address of such stockholder as it appears on the Corporation&#146;s stock transfer books.
Without limiting the manner by which notice may otherwise be given to stockholders, any notice to stockholders may be given by electronic transmission in the manner provided in Section&nbsp;232 of the DGCL. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Notice of all special meetings of stockholders shall be given in
the same manner as provided for Annual Meetings, except that the notice of all special meetings shall state the purpose or purposes for which the meeting has been called. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Notice of an Annual Meeting or special meeting of stockholders need not be given to a stockholder if a waiver of
notice is executed, or waiver of notice by electronic transmission is provided, before or after such meeting by such stockholder or if such stockholder attends such meeting, unless such attendance is for the express purpose of objecting at the
beginning of the meeting to the transaction of any business because the meeting was not lawfully called or convened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors may postpone and reschedule any previously scheduled Annual Meeting or special meeting of
stockholders and any record date with respect thereto, regardless of whether any notice or public disclosure with respect to any such meeting has been sent or made pursuant to Section&nbsp;2 of this Article&nbsp;I of these <FONT
STYLE="white-space:nowrap">By-laws</FONT> or otherwise. In no event shall the public announcement of an adjournment, postponement or rescheduling of any previously scheduled meeting of stockholders commence a new time period for the giving of a
stockholder&#146;s notice under this Article I of these <FONT STYLE="white-space:nowrap">By-laws.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;When
any meeting is convened, the presiding officer may adjourn the meeting if (i)&nbsp;no quorum is present for the transaction of business, (ii)&nbsp;the Board of Directors determines that adjournment is necessary or appropriate to enable the
stockholders to consider fully information which the Board of Directors determines has not been made sufficiently or timely available to stockholders, or (iii)&nbsp;the Board of Directors determines that adjournment is otherwise in the best
interests of the Corporation. When any Annual Meeting or special meeting of stockholders is adjourned to another hour, date or place, notice need not be given of the adjourned meeting other than an announcement at the meeting at which the
adjournment is taken of the hour, date and place, if any, to which the meeting is adjourned and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned
meeting; provided, however, that if the adjournment is for more than thirty (30)&nbsp;days from the meeting date, or if after the adjournment a new record date is fixed for the adjourned meeting, notice of the adjourned meeting and the means of
remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting shall be given to each stockholder of record entitled to vote thereat and each stockholder who, by law or
under the Fourth Amended and Restated Certificate of Incorporation of the Corporation (as the same may hereafter be amended and/or restated, the &#147;Certificate&#148;) or these <FONT STYLE="white-space:nowrap">By-laws,</FONT> is entitled to such
notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Quorum</U>. A majority of the outstanding shares entitled to vote, present in person or by
remote communication, if applicable, or represented by proxy, shall constitute a quorum at any meeting of stockholders. If less than a quorum is present at a meeting, the holders of voting stock representing a majority of the voting power present at
the meeting or the presiding officer may adjourn the meeting from time to time, and the meeting may be held as adjourned without further notice, except as provided in Section&nbsp;4 of this Article&nbsp;I. At such adjourned meeting at which a quorum
is present, any business may be transacted which might have been transacted at the meeting as originally noticed. The stockholders present at a duly constituted meeting may continue to transact business until adjournment, notwithstanding the
withdrawal of enough stockholders to leave less than a quorum. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Voting and Proxies</U>. Stockholders shall have one
vote for each share of stock entitled to vote owned by them of record according to the stock ledger of the Corporation as of the record date, unless otherwise provided by law or by the Certificate. Stockholders may vote either (i)&nbsp;in person,
(ii)&nbsp;by written proxy or (iii)&nbsp;by a transmission permitted by Section&nbsp;212(c) of the DGCL. Any copy, facsimile telecommunication or other reliable reproduction of the writing or transmission permitted by Section&nbsp;212(c) of the DGCL
may be substituted for or used in lieu of the original writing or transmission for any and all purposes for which the original writing or transmission could be used, provided that such copy, facsimile telecommunication or other reproduction shall be
a complete reproduction of the entire original writing or transmission. Proxies shall be filed in accordance with the procedures established for the meeting of stockholders. Except as otherwise limited therein or as otherwise provided by law,
proxies authorizing a person to vote at a specific meeting shall entitle the persons authorized thereby to vote at any adjournment of such meeting, but they shall not be valid after final adjournment of such meeting. A proxy with respect to stock
held in the name of two or more persons shall be valid if executed by or on behalf of any one of them unless at or prior to the exercise of the proxy the Corporation receives a specific written notice to the contrary from any one of them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Action at Meeting</U>. When a quorum is present at any meeting of stockholders, any matter before any
such meeting (other than an election of a director or directors) shall be decided by a majority of the votes properly cast for and against such matter, except where a larger vote is required by law, by the Certificate or by these <FONT
STYLE="white-space:nowrap">By-laws.</FONT> Any election of directors by stockholders shall be determined by a plurality of the votes properly cast on the election of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Stockholder Lists</U>. The Secretary or an Assistant Secretary (or the Corporation&#146;s transfer agent
or other person authorized by these <FONT STYLE="white-space:nowrap">By-laws</FONT> or by law) shall prepare and make, at least ten (10)&nbsp;days before every Annual Meeting or special meeting of stockholders, a complete list of the stockholders
entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for a
period of at least ten (10)&nbsp;days prior to the meeting in the manner provided by law. The list shall also be open to the examination of any stockholder during the whole time of the meeting as provided by law. In the event that the Corporation
determines to make the list available on an electronic network, the Corporation may take reasonable steps to ensure that such information is available only to stockholders of the Corporation. If the meeting is to be held at a place, then a list of
stockholders entitled to vote at the meeting shall be produced and kept at the time and place of the meeting during the whole time thereof, and may be examined by any stockholder who is present. If the meeting is to be held solely by means of remote
communication, then such list shall also be open to the examination of any stockholder during the whole time of the meeting on a reasonably accessible electronic network, and the information required to access such list shall be provided with the
notice of the meeting. Such list shall presumptively determine the identity of the stockholders entitled to vote at the meeting and the number of shares held by each of them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Presiding Officer</U>. The Board of Directors shall
designate a representative to preside over all Annual Meetings or special meetings of stockholders, provided that if the Board of Directors does not so designate such a presiding officer, then the Chairman of the Board, if one is elected, shall
preside over such meetings. If the Board of Directors does not so designate such a presiding officer and there is no Chairman of the Board or the Chairman of the Board is unable to so preside or is absent, then the Chief Executive Officer, if one is
elected, shall preside over such meetings, provided further that if there is no Chief Executive Officer or the Chief Executive Officer is unable to so preside or is absent, then the President shall preside over such meetings. The presiding officer
at any Annual Meeting or special meeting of stockholders shall have the power, among other things, to adjourn such meeting at any time and from time to time, subject to Sections&nbsp;4 and&nbsp;5 of this Article&nbsp;I. The order of business and all
other matters of procedure at any meeting of the stockholders shall be determined by the presiding officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION
10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Inspectors of Elections</U>. The Corporation shall, in advance of any meeting of stockholders, appoint one or more inspectors to act at the meeting and make a written report thereof. The Corporation may designate one or
more persons as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders, the presiding officer shall appoint one or more inspectors to act at the meeting. Any inspector
may, but need not, be an officer, employee or agent of the Corporation. Each inspector, before entering upon the discharge of his or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and
according to the best of his or her ability. The inspectors shall perform such duties as are required by the DGCL, including the counting of all votes and ballots. The inspectors may appoint or retain other persons or entities to assist the
inspectors in the performance of the duties of the inspectors. The presiding officer may review all determinations made by the inspectors, and in so doing the presiding officer shall be entitled to exercise his or her sole judgment and discretion
and he or she shall not be bound by any determinations made by the inspectors. All determinations by the inspectors and, if applicable, the presiding officer, shall be subject to further review by any court of competent jurisdiction. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE II </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Directors
</U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Powers</U>. The business and affairs of the Corporation shall be managed by or under the
direction of the Board of Directors except as otherwise provided by the Certificate or required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION
2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Number and Terms</U>. The number of directors of the Corporation shall be fixed solely and exclusively by resolution duly adopted from time to time by the Board of Directors. The directors shall hold office in the manner
provided in the Certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Qualification</U>. No director need be a stockholder of the
Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Vacancies</U>. Vacancies in the Board of Directors
shall be filled in the manner provided in the Certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Removal</U>. Directors may be removed
from office only in the manner provided in the Certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Resignation</U>. A director may resign
at any time by electronic transmission or by giving written notice to the Chairman of the Board, if one is elected, the President or the Secretary. A resignation shall be effective upon receipt, unless the resignation otherwise provides. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Regular Meetings</U>. The regular meetings of the Board of Directors may be held at such hour, date and
place as the Board of Directors may by resolution from time to time determine and publicize by means of reasonable notice given to any director who is not present at the meeting at which such resolution is adopted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Special Meetings</U>. Special meetings of the Board of Directors may be called, orally or in writing, by
or at the request of a majority of the directors, the Chairman of the Board, if one is elected, or the President. The person calling any such special meeting of the Board of Directors may fix the hour, date and place thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice of Meetings</U>. Notice of the hour, date and place of all special meetings of the Board of
Directors shall be given to each director by the Secretary or an Assistant Secretary, or in case of the death, absence, incapacity or refusal of such persons, by the Chairman of the Board, if one is elected, or the President or such other officer
designated by the Chairman of the Board, if one is elected, or the President. Notice of any special meeting of the Board of Directors shall be given to each director in person, by telephone, or by facsimile, electronic mail or other form of
electronic communication, sent to his or her business or home address, at least twenty-four (24)&nbsp;hours in advance of the meeting, or by written notice mailed to his or her business or home address, at least forty-eight (48)&nbsp;hours in
advance of the meeting. Such notice shall be deemed to be delivered when hand-delivered to such address, read to such director by telephone, deposited in the mail so addressed, with postage thereon prepaid if mailed, dispatched or transmitted if
sent by facsimile transmission or by electronic mail or other form of electronic communications. A written waiver of notice signed or electronically transmitted before or after a meeting by a director and filed with the records of the meeting shall
be deemed to be equivalent to notice of the meeting. The attendance of a director at a meeting shall constitute a waiver of notice of such meeting, except where a director attends a meeting for the express purpose of objecting at the beginning of
the meeting to the transaction of any business because such meeting is not lawfully called or convened. Except as otherwise required by law, by the Certificate or by these <FONT STYLE="white-space:nowrap">By-laws,</FONT> neither the business to be
transacted at, nor the purpose of, any meeting of the Board of Directors need be specified in the notice or waiver of notice of such meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Quorum</U>. At any meeting of the Board of Directors, a majority of the total number of directors shall
constitute a quorum for the transaction of business, but if less than a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
quorum is present at a meeting, a majority of the directors present may adjourn the meeting from time to time, and the meeting may be held as adjourned without further notice. Any business which
might have been transacted at the meeting as originally noticed may be transacted at such adjourned meeting at which a quorum is present. For purposes of this section, the total number of directors includes any unfilled vacancies on the Board of
Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Action at Meeting</U>. At any meeting of the Board of Directors at which a quorum is
present, the vote of a majority of the directors present shall constitute action by the Board of Directors, unless otherwise required by law, by the Certificate or by these <FONT STYLE="white-space:nowrap">By-laws.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 12.&nbsp;&nbsp;&nbsp;&nbsp;<U>Action by Consent</U>. Any action required or permitted to be taken at any meeting of the Board of
Directors may be taken without a meeting if all members of the Board of Directors consent thereto in writing or by electronic transmission and the writing or writings or electronic transmission or transmissions are filed with the records of the
meetings of the Board of Directors. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form. Such consent shall be treated as a resolution of the
Board of Directors for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 13.&nbsp;&nbsp;&nbsp;&nbsp;<U>Manner of Participation</U>. Directors may participate in
meetings of the Board of Directors by means of conference telephone or other communications equipment by means of which all directors participating in the meeting can hear each other, and participation in a meeting in accordance herewith shall
constitute presence in person at such meeting for purposes of these <FONT STYLE="white-space:nowrap">By-laws.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION
14.&nbsp;&nbsp;&nbsp;&nbsp;<U>Presiding Director</U>. The Board of Directors shall designate a representative to preside over all meetings of the Board of Directors, provided that if the Board of Directors does not so designate such a presiding
director or such designated presiding director is unable to so preside or is absent, then the Chairman of the Board, if one is elected, shall preside over all meetings of the Board of Directors. If both the designated presiding director, if one is
so designated, and the Chairman of the Board, if one is elected, are unable to preside or are absent, the Board of Directors shall designate an alternate representative to preside over a meeting of the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 15.&nbsp;&nbsp;&nbsp;&nbsp;<U>Committees</U>. The Board of Directors, by vote of a majority of the directors then in office, may elect
one or more committees, including, without limitation, a Compensation Committee, a Nominating and Corporate Governance Committee and an Audit Committee, and may delegate thereto some or all of its powers except those which by law, by the Certificate
or by these <FONT STYLE="white-space:nowrap">By-laws</FONT> may not be delegated. Except as the Board of Directors may otherwise determine, any such committee may make rules for the conduct of its business, but unless otherwise provided by the Board
of Directors or in such rules, its business shall be conducted so far as possible in the same manner as is provided by these <FONT STYLE="white-space:nowrap">By-laws</FONT> for the Board of Directors. All members of such committees shall hold such
offices at the pleasure of the Board of Directors. The Board of Directors may abolish any such committee at any time. Any committee to which the Board of Directors delegates any of its powers or duties shall keep records of its meetings and shall
report its action to the Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 16.&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation of Directors</U>. Directors shall receive
such compensation for their services as shall be determined by a majority of the Board of Directors, or a designated committee thereof, provided that directors who are serving the Corporation as employees and who receive compensation for their
services as such, shall not receive any salary or other compensation for their services as directors of the Corporation. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE III
</U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Officers </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Enumeration</U>. The officers of the Corporation shall consist of a President, a Treasurer, a Secretary
and such other officers, including, without limitation, a Chairman of the Board of Directors, a Chief Executive Officer and one or more Vice Presidents (including Executive Vice Presidents or Senior Vice Presidents), Assistant Vice Presidents,
Assistant Treasurers and Assistant Secretaries, as the Board of Directors may determine. The Board may elect or appoint <FONT STYLE="white-space:nowrap">Co-Chairmen</FONT> of the Board, <FONT STYLE="white-space:nowrap">Co-Presidents</FONT> or <FONT
STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officers and, in such case, references in these <FONT STYLE="white-space:nowrap">By-laws</FONT> to the Chairman of the Board, the President or the Chief Executive Officer shall refer to either
such <FONT STYLE="white-space:nowrap">Co-Chairman</FONT> of the Board, <FONT STYLE="white-space:nowrap">Co-President</FONT> or <FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Election</U>. At the regular annual meeting of the Board of Directors following the Annual Meeting, the
Board of Directors shall elect the President, the Treasurer and the Secretary. Other officers may be elected by the Board of Directors at such regular annual meeting of the Board of Directors or at any other regular or special meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Qualification</U>. No officer need be a stockholder or a director. Any person may occupy more than one
office of the Corporation at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Tenure</U>. Except as otherwise provided by the Certificate
or by these <FONT STYLE="white-space:nowrap">By-laws,</FONT> each of the officers of the Corporation shall hold office until the regular annual meeting of the Board of Directors following the next Annual Meeting and until his or her successor is
elected and qualified or until his or her earlier resignation or removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Resignation</U>. Any
officer may resign by delivering his or her written or electronically transmitted resignation to the Corporation addressed to the President or the Secretary, and such resignation shall be effective upon receipt, unless the resignation otherwise
provides. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Removal</U>. Except as otherwise provided by law or by resolution of the Board of
Directors, the Board of Directors may remove any officer with or without cause by the affirmative vote of a majority of the directors then in office. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Absence or Disability</U>. In the event of the absence
or disability of any officer, the Board of Directors may designate another officer to act temporarily in place of such absent or disabled officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Vacancies</U>. Any vacancy in any office may be filled for the unexpired portion of the term by the Board
of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9.&nbsp;&nbsp;&nbsp;&nbsp;<U>President</U>. The President shall, subject to the direction of the Board of
Directors, have such powers and shall perform such duties as the Board of Directors may from time to time designate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION
10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Chairman of the Board</U>. The Chairman of the Board, if one is elected, shall have such powers and shall perform such duties as the Board of Directors may from time to time designate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Chief Executive Officer</U>. The Chief Executive Officer, if one is elected, shall have such powers and
shall perform such duties as the Board of Directors may from time to time designate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 12.&nbsp;&nbsp;&nbsp;&nbsp;<U>Vice
Presidents and Assistant Vice Presidents</U>. Any Vice President (including any Executive Vice President or Senior Vice President) and any Assistant Vice President shall have such powers and shall perform such duties as the Board of Directors or the
Chief Executive Officer may from time to time designate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 13.&nbsp;&nbsp;&nbsp;&nbsp;<U>Treasurer and Assistant Treasurers</U>.
The Treasurer shall, subject to the direction of the Board of Directors and except as the Board of Directors or the Chief Executive Officer may otherwise provide, have general charge of the financial affairs of the Corporation and shall cause to be
kept accurate books of account. The Treasurer shall have custody of all funds, securities, and valuable documents of the Corporation. He or she shall have such other duties and powers as may be designated from time to time by the Board of Directors
or the Chief Executive Officer. Any Assistant Treasurer shall have such powers and perform such duties as the Board of Directors or the Chief Executive Officer may from time to time designate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 14.&nbsp;&nbsp;&nbsp;&nbsp;<U>Secretary and Assistant Secretaries</U>. The Secretary shall record all the proceedings of the meetings
of the stockholders and the Board of Directors (including committees of the Board of Directors) in books kept for that purpose. In his or her absence from any such meeting, a temporary secretary chosen at the meeting shall record the proceedings
thereof. The Secretary shall have charge of the stock ledger (which may, however, be kept by any transfer or other agent of the Corporation). The Secretary shall have custody of the seal of the Corporation, and the Secretary, or an Assistant
Secretary shall have authority to affix it to any instrument requiring it, and, when so affixed, the seal may be attested by his or her signature or that of an Assistant Secretary. The Secretary shall have such other duties and powers as may be
designated from time to time by the Board of Directors or the Chief Executive Officer. In the absence of the Secretary, any Assistant Secretary may perform his or her duties and responsibilities. Any Assistant Secretary shall have such powers and
perform such duties as the Board of Directors or the Chief Executive Officer may from time to time designate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 15.&nbsp;&nbsp;&nbsp;&nbsp;<U>Other Powers and Duties</U>. Subject to these <FONT
STYLE="white-space:nowrap">By-laws</FONT> and to such limitations as the Board of Directors may from time to time prescribe, the officers of the Corporation shall each have such powers and duties as generally pertain to their respective offices, as
well as such powers and duties as from time to time may be conferred by the Board of Directors or the Chief Executive Officer. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE
IV </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Capital Stock </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Certificates of Stock</U>. Each stockholder shall be entitled to a certificate of the capital stock of
the Corporation in such form as may from time to time be prescribed by the Board of Directors. Such certificate shall be signed by the Chairman of the Board, the President or a Vice President and by the Treasurer or an Assistant Treasurer, or the
Secretary or an Assistant Secretary. The Corporation seal and the signatures by the Corporation&#146;s officers, the transfer agent or the registrar may be facsimiles. In case any officer, transfer agent or registrar who has signed or whose
facsimile signature has been placed on such certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if he or she were such officer,
transfer agent or registrar at the time of its issue. Every certificate for shares of stock which are subject to any restriction on transfer and every certificate issued when the Corporation is authorized to issue more than one class or series of
stock shall contain such legend with respect thereto as is required by law. Notwithstanding anything to the contrary provided in these <FONT STYLE="white-space:nowrap">By-laws,</FONT> the Board of Directors of the Corporation may provide by
resolution or resolutions that some or all of any or all classes or series of its stock shall be uncertificated shares (except that the foregoing shall not apply to shares represented by a certificate until such certificate is surrendered to the
Corporation), and by the approval and adoption of these <FONT STYLE="white-space:nowrap">By-laws</FONT> the Board of Directors has determined that all classes or series of the Corporation&#146;s stock may be uncertificated, whether upon original
issuance, <FONT STYLE="white-space:nowrap">re-issuance,</FONT> or subsequent transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION
2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Transfers</U>. Subject to any restrictions on transfer and unless otherwise provided by the Board of Directors, shares of stock that are represented by a certificate may be transferred on the books of the Corporation by
the surrender to the Corporation or its transfer agent of the certificate theretofore properly endorsed or accompanied by a written assignment or power of attorney properly executed, with transfer stamps (if necessary) affixed, and with such proof
of the authenticity of signature as the Corporation or its transfer agent may reasonably require. Shares of stock that are not represented by a certificate may be transferred on the books of the Corporation by submitting to the Corporation or its
transfer agent such evidence of transfer and following such other procedures as the Corporation or its transfer agent may require. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Record Holders</U>. Except as may otherwise be required by law, by the Certificate or by these <FONT
STYLE="white-space:nowrap">By-laws,</FONT> the Corporation shall be entitled to treat the record holder of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock as shown on its books as the owner of such stock for all purposes, including the payment of dividends and the right to vote with respect thereto, regardless of any transfer, pledge or other
disposition of such stock, until the shares have been transferred on the books of the Corporation in accordance with the requirements of these <FONT STYLE="white-space:nowrap">By-laws.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Record Date</U>. In order that the Corporation may determine the stockholders entitled to notice of or to
vote at any meeting of stockholders or any adjournment thereof or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of
stock or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record
date: (a)&nbsp;in the case of determination of stockholders entitled to vote at any meeting of stockholders, shall, unless otherwise required by law, not be more than sixty (60)&nbsp;nor less than ten (10)&nbsp;days before the date of such meeting
and (b)&nbsp;in the case of any other action, shall not be more than sixty (60)&nbsp;days prior to such other action. If no record date is fixed: (i)&nbsp;the record date for determining stockholders entitled to notice of or to vote at a meeting of
stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held; and (ii)&nbsp;the record
date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Replacement of Certificates</U>. In case of the alleged loss, destruction or mutilation of a certificate
of stock of the Corporation, a duplicate certificate may be issued in place thereof, upon such terms as the Board of Directors may prescribe. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE V </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Indemnification </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION
1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>. For purposes of this Article: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;&#147;Corporate Status&#148;
describes the status of a person who is serving or has served (i)&nbsp;as a Director of the Corporation, (ii)&nbsp;as an Officer of the Corporation, (iii)&nbsp;as a <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee of the Corporation, or
(iv)&nbsp;as a director, partner, trustee, officer, employee or agent of any other corporation, partnership, limited liability company, joint venture, trust, employee benefit plan, foundation, association, organization or other legal entity which
such person is or was serving at the request of the Corporation. For purposes of this Section&nbsp;1(a), a Director, Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee of the Corporation who is serving or has served as a
director, partner, trustee, officer, employee or agent of a Subsidiary shall be deemed to be serving at the request of the Corporation. Notwithstanding the foregoing, &#147;Corporate Status&#148; shall not include the status of a person who is
serving or has served as a director, officer, employee or agent of a constituent corporation absorbed in a merger or consolidation transaction with the Corporation with respect to such person&#146;s activities prior to said transaction, unless
specifically authorized by the Board of Directors or the stockholders of the Corporation; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;&#147;Director&#148; means any person who serves or has served
the Corporation as a director on the Board of Directors of the Corporation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp; &#147;Disinterested
Director&#148; means, with respect to each Proceeding in respect of which indemnification is sought hereunder, a Director of the Corporation who is not and was not a party to such Proceeding; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;&#147;Expenses&#148; means all attorneys&#146; fees, retainers, court costs, transcript costs, fees of expert
witnesses, private investigators and professional advisors (including, without limitation, accountants and investment bankers), travel expenses, duplicating costs, printing and binding costs, costs of preparation of demonstrative evidence and other
courtroom presentation aids and devices, costs incurred in connection with document review, organization, imaging and computerization, telephone charges, postage, delivery service fees, and all other disbursements, costs or expenses of the type
customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, settling or otherwise participating in, a Proceeding; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;&#147;Liabilities&#148; means judgments, damages, liabilities, losses, penalties, excise taxes, fines and amounts
paid in settlement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">(f)&nbsp;&nbsp;&nbsp;&nbsp;&#147;Non-Officer</FONT> Employee&#148; means any person
who serves or has served as an employee or agent of the Corporation, but who is not or was not a Director or Officer; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;&#147;Officer&#148; means any person who serves or has served the Corporation as an officer of the Corporation
appointed by the Board of Directors of the Corporation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;&#147;Proceeding&#148; means any threatened, pending
or completed action, suit, arbitration, alternate dispute resolution mechanism, inquiry, investigation, administrative hearing or other proceeding, whether civil, criminal, administrative, arbitrative or investigative; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;&#147;Subsidiary&#148; shall mean any corporation, partnership, limited liability company, joint venture, trust or
other entity of which the Corporation owns (either directly or through or together with another Subsidiary of the Corporation) either (i)&nbsp;a general partner, managing member or other similar interest or (ii)&nbsp;(A) fifty percent (50%) or more
of the voting power of the voting capital equity interests of such corporation, partnership, limited liability company, joint venture or other entity, or (B)&nbsp;fifty percent (50%) or more of the outstanding voting capital stock or other voting
equity interests of such corporation, partnership, limited liability company, joint venture or other entity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2.&nbsp;&nbsp;&nbsp;&nbsp;Indemnification of Directors and Officers. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Subject to the operation of Section&nbsp;4 of this Article V of these
<FONT STYLE="white-space:nowrap">By-laws,</FONT> each Director and Officer shall be indemnified and held harmless by the Corporation to the fullest extent authorized by the DGCL, as the same exists or may hereafter be amended (but, in the case of
any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than such law permitted the Corporation to provide prior to such amendment), and to the extent authorized in this
Section&nbsp;2. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1)&nbsp;&nbsp;&nbsp;&nbsp;<U>Actions, Suits and Proceedings Other than By or In the Right of the
Corporation</U>. Each Director and Officer shall be indemnified and held harmless by the Corporation against any and all Expenses and Liabilities that are incurred or paid by such Director or Officer or on such Director&#146;s or Officer&#146;s
behalf in connection with any Proceeding or any claim, issue or matter therein (other than an action by or in the right of the Corporation), which such Director or Officer is, or is threatened to be made, a party to or participant in by reason of
such Director&#146;s or Officer&#146;s Corporate Status, if such Director or Officer acted in good faith and in a manner such Director or Officer reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect
to any criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2)&nbsp;&nbsp;&nbsp;&nbsp;<U>Actions, Suits and Proceedings By or In the Right of the Corporation</U>. Each Director and
Officer shall be indemnified and held harmless by the Corporation against any and all Expenses that are incurred by such Director or Officer or on such Director&#146;s or Officer&#146;s behalf in connection with any Proceeding or any claim, issue or
matter therein by or in the right of the Corporation, which such Director or Officer is, or is threatened to be made, a party to or participant in by reason of such Director&#146;s or Officer&#146;s Corporate Status, if such Director or Officer
acted in good faith and in a manner such Director or Officer reasonably believed to be in or not opposed to the best interests of the Corporation; provided, however, that no indemnification shall be made under this Section&nbsp;2(a)(2) in respect of
any claim, issue or matter as to which such Director or Officer shall have been finally adjudged by a court of competent jurisdiction to be liable to the Corporation, unless, and only to the extent that, the Court of Chancery of the State of
Delaware (the &#147;Court of Chancery&#148;) or another court in which such Proceeding was brought shall determine upon application that, despite adjudication of liability, but in view of all the circumstances of the case, such Director or Officer
is fairly and reasonably entitled to indemnification for such Expenses that such court deems proper. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3)&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival of Rights</U>. The rights of indemnification provided by this Section&nbsp;2 shall
continue as to a Director or Officer after he or she has ceased to be a Director or Officer and shall inure to the benefit of his or her heirs, executors, administrators and personal representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4)&nbsp;&nbsp;&nbsp;&nbsp;<U>Actions by Directors or Officers</U>. Notwithstanding the foregoing, the Corporation shall
indemnify any Director or Officer seeking indemnification in connection with a Proceeding initiated by such Director or Officer only if such Proceeding (including any parts of such Proceeding not initiated by such Director or Officer) was authorized
in advance by the Board of Directors of the Corporation, unless such Proceeding was brought to enforce such Officer&#146;s or Director&#146;s rights to indemnification or, in the case of Directors, advancement of Expenses under these <FONT
STYLE="white-space:nowrap">By-laws</FONT> in accordance with the provisions set forth herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification of
<FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employees</U>. Subject to the operation of Section&nbsp;4 of this Article V of these <FONT STYLE="white-space:nowrap">By-laws,</FONT> each <FONT STYLE="white-space:nowrap">Non-Officer</FONT>
Employee may, in the discretion of the Board of Directors of the Corporation, be indemnified by the Corporation to the fullest extent authorized by the DGCL, as the same exists or may hereafter be amended, against any or all Expenses and Liabilities
that are incurred by such <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee or on such <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee&#146;s behalf in connection with any threatened, pending or completed Proceeding, or any
claim, issue or matter therein, which such <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee is, or is threatened to be made, a party to or participant in by reason of such <FONT STYLE="white-space:nowrap">Non-Officer</FONT>
Employee&#146;s Corporate Status, if such <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee acted in good faith and in a manner such <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee reasonably believed to be in or not opposed
to the best interests of the Corporation and, with respect to any criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful. The rights of indemnification provided by this Section&nbsp;3 shall exist as to a <FONT
STYLE="white-space:nowrap">Non-Officer</FONT> Employee after he or she has ceased to be a <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee and shall inure to the benefit of his or her heirs, personal representatives, executors and
administrators. Notwithstanding the foregoing, the Corporation may indemnify any <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee seeking indemnification in connection with a Proceeding initiated by such
<FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee only if such Proceeding was authorized in advance by the Board of Directors of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Determination</U>. Unless ordered by a court, no indemnification shall be provided pursuant to this
Article V to a Director, to an Officer or to a <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee unless a determination shall have been made that such person acted in good faith and in a manner such person reasonably believed to be in or
not opposed to the best interests of the Corporation and, with respect to any criminal Proceeding, such person had no reasonable cause to believe his or her conduct was unlawful. Such determination shall be made by (a)&nbsp;a majority vote of the
Disinterested Directors, even though less than a quorum of the Board of Directors, (b)&nbsp;a committee comprised of Disinterested Directors, such committee having been designated by a majority vote of the Disinterested Directors (even though less
than a quorum), (c) if there are no such Disinterested Directors, or if a majority of Disinterested Directors so directs, by independent legal counsel in a written opinion, or (d)&nbsp;by the stockholders of the Corporation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5.&nbsp;&nbsp;&nbsp;&nbsp;Advancement of Expenses to Directors Prior to Final Disposition. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Corporation shall advance all Expenses incurred by or on behalf of any Director in connection with any
Proceeding in which such Director is involved by reason of such Director&#146;s Corporate Status within thirty (30)&nbsp;days after the receipt by the Corporation of a written statement from such Director requesting such advance or advances from
time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by such Director and shall be preceded or accompanied by an undertaking by or on behalf of
such Director to repay any Expenses so advanced if it shall ultimately be determined that such Director is not entitled to be indemnified against such Expenses. Notwithstanding the foregoing, the Corporation shall advance all Expenses incurred by or
on behalf of any Director seeking advancement of expenses hereunder </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in connection with a Proceeding initiated by such Director only if such Proceeding (including any parts of such Proceeding not initiated by such Director) was (i)&nbsp;authorized by the Board of
Directors of the Corporation, or (ii)&nbsp;brought to enforce such Director&#146;s rights to indemnification or advancement of Expenses under these <FONT STYLE="white-space:nowrap">By-laws.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;If a claim for advancement of Expenses hereunder by a Director is not paid in full by the Corporation within thirty
(30)&nbsp;days after receipt by the Corporation of documentation of Expenses and the required undertaking, such Director may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim and if successful in
whole or in part, such Director shall also be entitled to be paid the expenses of prosecuting such claim. The failure of the Corporation (including its Board of Directors or any committee thereof, independent legal counsel, or stockholders) to make
a determination concerning the permissibility of such advancement of Expenses under this Article V shall not be a defense to an action brought by a Director for recovery of the unpaid amount of an advancement claim and shall not create a presumption
that such advancement is not permissible. The burden of proving that a Director is not entitled to an advancement of expenses shall be on the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;In any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an
undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that the Director has not met any applicable standard for indemnification set forth in the DGCL. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6.&nbsp;&nbsp;&nbsp;&nbsp;Advancement of Expenses to Officers and <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employees Prior
to Final Disposition. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Corporation may, at the discretion of the Board of Directors of the Corporation,
advance any or all Expenses incurred by or on behalf of any Officer or any <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee in connection with any Proceeding in which such person is involved by reason of his or her Corporate Status as an
Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee upon the receipt by the Corporation of a statement or statements from such Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee requesting such advance or
advances from time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by such Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee
and shall be preceded or accompanied by an undertaking by or on behalf of such person to repay any Expenses so advanced if it shall ultimately be determined that such Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee is not
entitled to be indemnified against such Expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;In any suit brought by the Corporation to recover an
advancement of expenses pursuant to the terms of an undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that the Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee has not met any
applicable standard for indemnification set forth in the DGCL. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7.&nbsp;&nbsp;&nbsp;&nbsp;Contractual Nature of Rights. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The provisions of this Article&nbsp;V shall be deemed to be a contract between the Corporation and each Director and
Officer entitled to the benefits hereof at any time while this Article&nbsp;V is in effect, in consideration of such person&#146;s past or current and any future </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
performance of services for the Corporation. Neither amendment, repeal or modification of any provision of this Article&nbsp;V nor the adoption of any provision of the Certificate inconsistent
with this Article&nbsp;V shall eliminate or reduce any right conferred by this Article&nbsp;V in respect of any act or omission occurring, or any cause of action or claim that accrues or arises or any state of facts existing, at the time of or
before such amendment, repeal, modification or adoption of an inconsistent provision (even in the case of a proceeding based on such a state of facts that is commenced after such time), and all rights to indemnification and advancement of Expenses
granted herein or arising out of any act or omission shall vest at the time of the act or omission in question, regardless of when or if any proceeding with respect to such act or omission is commenced. The rights to indemnification and to
advancement of expenses provided by, or granted pursuant to, this Article&nbsp;V shall continue notwithstanding that the person has ceased to be a director or officer of the Corporation and shall inure to the benefit of the estate, heirs, executors,
administrators, legatees and distributes of such person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;If a claim for indemnification hereunder by a
Director or Officer is not paid in full by the Corporation within sixty (60)&nbsp;days after receipt by the Corporation of a written claim for indemnification, such Director or Officer may at any time thereafter bring suit against the Corporation to
recover the unpaid amount of the claim, and if successful in whole or in part, such Director or Officer shall also be entitled to be paid the expenses of prosecuting such claim. The failure of the Corporation (including its Board of Directors or any
committee thereof, independent legal counsel, or stockholders) to make a determination concerning the permissibility of such indemnification under this Article V shall not be a defense to an action brought by a Director or Officer for recovery of
the unpaid amount of an indemnification claim and shall not create a presumption that such indemnification is not permissible. The burden of proving that a Director or Officer is not entitled to indemnification shall be on the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;In any suit brought by a Director or Officer to enforce a right to indemnification hereunder, it shall be a defense
that such Director or Officer has not met any applicable standard for indemnification set forth in the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION
8.&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT STYLE="white-space:nowrap">Non-Exclusivity</FONT> of Rights</U>. The rights to indemnification and to advancement of Expenses set forth in this Article V shall not be exclusive of any other right which any
Director, Officer, or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee may have or hereafter acquire under any statute, provision of the Certificate or these <FONT STYLE="white-space:nowrap">By-laws,</FONT> agreement, vote of
stockholders or Disinterested Directors or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>. The Corporation may maintain
insurance, at its expense, to protect itself and any Director, Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee against any liability of any character asserted against or incurred by the Corporation or any such Director,
Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee, or arising out of any such person&#146;s Corporate Status, whether or not the Corporation would have the power to indemnify such person against such liability under the DGCL or
the provisions of this Article&nbsp;V. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Other Indemnification</U>. The Corporation&#146;s
obligation, if any, to indemnify or provide advancement of Expenses to any person under this Article V as a result of such person serving, at the request of the Corporation, as a director, partner, trustee, officer, employee or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall be reduced by any amount such person may collect as indemnification or advancement
of Expenses from such other corporation, partnership, joint venture, trust, employee benefit plan or enterprise (the &#147;Primary Indemnitor&#148;). Any indemnification or advancement of Expenses under this Article V owed by the Corporation as a
result of a person serving, at the request of the Corporation, as a director, partner, trustee, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall only be in excess
of, and shall be secondary to, the indemnification or advancement of Expenses available from the applicable Primary Indemnitor(s) and any applicable insurance policies. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE VI </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Miscellaneous Provisions </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Fiscal Year</U>. The fiscal year of the Corporation shall be determined by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Seal</U>. The Board of Directors shall have power to adopt and alter the seal of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Execution of Instruments</U>. All deeds, leases, transfers, contracts, bonds, notes and other obligations
to be entered into by the Corporation in the ordinary course of its business without director action may be executed on behalf of the Corporation by the Chairman of the Board, if one is elected, the President or the Treasurer or any other officer,
employee or agent of the Corporation as the Board of Directors or the executive committee of the Board of Directors may authorize. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Voting of Securities</U>. Unless the Board of Directors otherwise provides, the Chairman of the Board, if
one is elected, the President or the Treasurer may waive notice of and act on behalf of the Corporation, or appoint another person or persons to act as proxy or attorney in fact for the Corporation with or without discretionary power and/or power of
substitution, at any meeting of stockholders or shareholders of any other corporation or organization, any of whose securities are held by the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Resident Agent</U>. The Board of Directors may appoint a resident agent upon whom legal process may be
served in any action or proceeding against the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Corporate Records</U>. The original or
attested copies of the Certificate, <FONT STYLE="white-space:nowrap">By-laws</FONT> and records of all meetings of the incorporators, stockholders and the Board of Directors and the stock transfer books, which shall contain the names of all
stockholders, their record addresses and the amount of stock held by each, may be kept outside the State of Delaware and shall be kept at the principal office of the Corporation, at an office of its counsel, at an office of its transfer agent or at
such other place or places as may be designated from time to time by the Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Certificate</U>. All references in these <FONT
STYLE="white-space:nowrap">By-laws</FONT> to the Certificate shall be deemed to refer to the Fourth Amended and Restated Certificate of Incorporation of the Corporation, as amended and/or restated and in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Exclusive Jurisdiction of Delaware Courts or the United States Federal District Courts</U>. Unless the
Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for any state law claims for (i)&nbsp;any derivative action or proceeding brought on
behalf of the Corporation, (ii)&nbsp;any action asserting a claim of, or a claim based on, a breach of a fiduciary duty owed by any current or former director, officer or other employee of the Corporation to the Corporation or the Corporation&#146;s
stockholders, (iii)&nbsp;any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law or the Certificate or <FONT STYLE="white-space:nowrap">By-laws</FONT> (including the interpretation, validity or
enforceability thereof), or (iv)&nbsp;any action asserting a claim governed by the internal affairs doctrine. Unless the Corporation consents in writing to the selection of an alternative forum, the federal district courts of the United States of
America shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. Any person or entity purchasing or otherwise acquiring any interest in shares of capital
stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Section&nbsp;8. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION
9.&nbsp;&nbsp;&nbsp;&nbsp;Amendment of <FONT STYLE="white-space:nowrap">By-laws.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment by
Directors</U>. Except as provided otherwise by law, these <FONT STYLE="white-space:nowrap">By-laws</FONT> may be amended or repealed by the Board of Directors by the affirmative vote of a majority of the directors then in office. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment by Stockholders</U>. These <FONT STYLE="white-space:nowrap">By-laws</FONT> may be amended or repealed
at any Annual Meeting, or special meeting of stockholders called for such purpose in accordance with these <FONT STYLE="white-space:nowrap">By-Laws,</FONT> by the affirmative vote of at least 66 2/3% of the outstanding shares entitled to vote on
such amendment or repeal, voting together as a single class; provided, however, that if the Board of Directors recommends that stockholders approve such amendment or repeal at such meeting of stockholders, such amendment or repeal shall only require
the affirmative vote of the majority of the outstanding shares entitled to vote on such amendment or repeal, voting together as a single class. Notwithstanding the foregoing, stockholder approval shall not be required unless mandated by the
Certificate, these <FONT STYLE="white-space:nowrap">By-laws,</FONT> or other applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION
10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>. If mailed, notice to stockholders shall be deemed given when deposited in the mail, postage prepaid, directed to the stockholder at such stockholder&#146;s address as it appears on the records of the
Corporation. Without limiting the manner by which notice otherwise may be given to stockholders, any notice to stockholders may be given by electronic transmission in the manner provided in Section&nbsp;232 of the DGCL. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Waivers</U>. A written waiver of any notice, signed by
a stockholder or director, or waiver by electronic transmission by such person, whether given before or after the time of the event for which notice is to be given, shall be deemed equivalent to the notice required to be given to such person.
Neither the business to be transacted at, nor the purpose of, any meeting need be specified in such a waiver. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adopted [&#9679;], subject to and effective
upon the closing of the Corporation&#146;s initial public offering on its Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>5
<FILENAME>d155225dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g73339dsp031.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK COMMON STOCK PAR VALUE $0.0001 AMYLYX Certificate Number ZQ00000000
Shares * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * AMYLYX
PHARMACEUTICALS, INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE THIS CERTIFIES THAT ** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David
Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander
David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr.
Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample
**** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David
Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander
David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr.
Alexander David Sample **** Mr. Sample **** Mr. Sample SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP XXXXXX XX X MR. SAMPLE &amp; MRS. SAMPLE &amp; MR. SAMPLE &amp; MRS. SAMPLE is the owner of
**000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares**** </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">000000**Shares****000000**Shares****000000**Shares***
*000000**Shares****000000**Shares****000000**Shares**** </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****
000000**Shares**** </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">000000** Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares**** </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares**** </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares**** </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000 000**Shares**** </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares**** </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">000000**Shares****0000 00**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares**** </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">000000**Shares****000000**Shares****000000**Shares****00000 0**Shares****000000**Shares****000000**Shares**** </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000 **Shares**** </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000** Shares**** </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares**** </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">000000**Shares****000000**Shares****000000**Shares****000000** Shares****000000**Shares****000000**Shares**** </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**S THIS CERTIFICATE IS TRANSFERABLE IN CITIES DESIGNATED BY THE TRANSFER AGENT,
AVAILABLE ONLINE AT www.computershare.com ***ZERO HUNDRED THOUSAND ZERO HUNDRED AND ZERO*** FULLY-PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF Amylyx Pharmaceuticals, Inc. (hereinafter called the &#147;Company&#148;), transferable on the books
of the Company in person or by duly authorized attorney, upon surrender of this Certificate properly endorsed. This Certificate and the shares represented hereby, are issued and shall be held subject to all of the provisions of the Certificate of
Incorporation, as amended, and the By-Laws, as amended, of the Company (copies of which are on file with the Company and with the Transfer Agent), to all of which each holder, by acceptance hereof, assents. This Certificate is not valid unless
countersigned and registered by the Transfer Agent and Registrar. Witness the facsimile seal of the Company and the facsimile signatures of its duly authorized officers. FACSIMILE SIGNATURE TO COME President FACSIMILE SIGNATURE TO COME Secretary
AMYLYX PHARMACEUTICALS, INC. DELAWARE CORPORATE Seal 1/10/2014 DATED DD-MMM-YYYY COUNTERSIGNED AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N.A. TRANSFER AGENT AND REGISTRAR, By AUTHORIZED SIGNATURE SECURITY INSTRUCTIONS ON REVERSE AMYLYX PO BOX
505006, Louisville, KY 40233-5006 MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 CUSIP/IDENTIFIER XXXXXX XX X Holder ID XXXXXXXXXX Insurance Value 1,000,000.00 Number of Shares 123456 DTC 12345678 123456789012345 Certificate Numbers
Num/No. Denom. Total 1234567890/1234567890 1 1 1 1234567890/1234567890 2 2 2 1234567890/1234567890 3 3 3 1234567890/1234567890 4 4 4 1234567890/1234567890 5 5 5 1234567890/1234567890 6 6 6 Total Transaction 7 1 2 3 4 5 6 7 </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMYLYX PHARMACEUTICALS, INC. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE COMPANY WILL FURNISH WITHOUT CHARGE TO EACH SHAREHOLDER WHO SO REQUESTS, A SUMMARY OF THE POWERS, DESIGNATIONS, PREFERENCES AND RELATIVE, PARTICIPATING,
OPTIONAL OR OTHER SPECIAL RIGHTS OF EACH CLASS OF STOCK OF THE COMPANY AND THE QUALIFICATIONS, LIMITATIONS OR RESTRICTIONS OF SUCH PREFERENCES AND RIGHTS, AND THE VARIATIONS IN RIGHTS, PREFERENCES AND LIMITATIONS DETERMINED FOR EACH SERIES, WHICH
ARE FIXED BY THE CERTIFICATE OF INCORPORATION OF THE COMPANY, AS AMENDED, AND THE RESOLUTIONS OF THE BOARD OF DIRECTORS OF THE COMPANY, AND THE AUTHORITY OF THE BOARD OF DIRECTORS TO DETERMINE VARIATIONS FOR FUTURE SERIES. SUCH REQUEST MAY BE MADE
TO THE OFFICE OF THE SECRETARY OF THE COMPANY OR TO THE TRANSFER AGENT. THE BOARD OF DIRECTORS MAY REQUIRE THE OWNER OF A LOST OR DESTROYED STOCK CERTIFICATE, OR HIS LEGAL REPRESENTATIVES, TO GIVE THE COMPANY A BOND TO INDEMNIFY IT AND ITS TRANSFER
AGENTS AND REGISTRARS AGAINST ANY CLAIM THAT MAY BE MADE AGAINST THEM ON ACCOUNT OF THE ALLEGED LOSS OR DESTRUCTION OF ANY SUCH CERTIFICATE. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="68%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or regulations:</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">TEN&nbsp;COM - as tenants in common</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"><FONT STYLE="white-space:nowrap">UNIF&nbsp;GIFT&nbsp;MIN&nbsp;ACT&nbsp;-..........................................&nbsp;
Custodian.................................................</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Cust)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Minor)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">TEN&nbsp;ENT &nbsp;&nbsp;- as tenants by the entireties</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;under&nbsp;Uniform&nbsp;Gifts&nbsp;to&nbsp;Minors&nbsp;Act.................................................</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(State)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">JT TEN &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- as joint tenants with right of survivorship</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"><FONT STYLE="white-space:nowrap">UNIF&nbsp;TRF&nbsp;MIN&nbsp;ACT&nbsp;&nbsp;&nbsp;-..................................&nbsp;Custodian&nbsp;(until&nbsp;age&nbsp;
......................................&nbsp;)</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:4.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and not as tenants in
common</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Cust)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;..............................under&nbsp;Uniform&nbsp;Transfers&nbsp;to&nbsp;Minors&nbsp;Act................</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Minor)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(State)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="padding-bottom:6pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt; padding-right:2pt">Additional abbreviations may also be used though not in the
above list.</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="50%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">PLEASE&nbsp;INSERT&nbsp;SOCIAL&nbsp;SECURITY&nbsp;OR&nbsp;OTHER&nbsp;IDENTIFYING NUMBER OF ASSIGNEE</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">For value received,
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;&nbsp;hereby sell, assign and transfer unto&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING POSTAL ZIP CODE, OF ASSIGNEE) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;Shares </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">of the common stock represented by the within Certificate, and do hereby irrevocably constitute and appoint </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Attorney </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">to transfer the said stock on the books of the within-named Company with full power of substitution in the premises. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;
20<U>&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Signature:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Signature:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature(s) Guaranteed: Medallion Guarantee Stamp</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (Banks, Stockbrokers, Savings and Loan Associations and Credit Unions) WITH
MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE <FONT STYLE="white-space:nowrap">17Ad-15.</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Notice: The signature to this assignment must</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:8.00em; margin-right:1.00em; font-size:10pt; font-family:Times New Roman">correspond with the name as written upon the face of the certificate, in every particular, without alteration or
enlargement, or any change whatever.</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><B>SECURITY INSTRUCTIONS</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">THIS IS WATERMARKED PAPER. DO NOT ACCEPT WITHOUT NOTING WATERMARK. HOLD TO LIGHT TO VERIFY WATERMARK.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">


<IMG SRC="g73339sp23.jpg" ALT="LOGO">
&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">The IRS requires that the named transfer agent (&#147;we&#148;) report the cost basis of certain shares or units acquired after
January 1, 2011. If your shares or units are covered by the legislation, and you requested to sell or transfer the shares or units using a specific cost basis calculation method, then we have processed as you requested. If you did not specify a cost
basis calculation method, then we have defaulted to the first in, first out (FIFO) method. Please consult your tax advisor if you need additional information about cost basis.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman"><B>If you do not keep in contact with the issuer or do not have any activity in your
account for the time period specified by state law, your property may become subject to state unclaimed property laws and transferred to the appropriate state.</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="right">


<IMG SRC="g73339sp32.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt"></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>6
<FILENAME>d155225dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g73339g0101013030822.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwin Procter <SMALL>LLP</SMALL></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The New York
Times Building</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">620 Eighth Avenue</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10018</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">goodwinlaw.com</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+1 212 813 8800</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">January&nbsp;3,
2022&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amylyx Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">43 Thorndike St. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, Massachusetts 02141 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Re: <U>Securities Registered under Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT></U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as counsel to you in connection with your filing of a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT>
(File <FONT STYLE="white-space:nowrap">No.&nbsp;333-261703)</FONT> (as amended or supplemented, the &#147;Registration Statement&#148;) pursuant to the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), relating to the registration
of the offering by Amylyx Pharmaceuticals, Inc., a Delaware corporation (the &#147;Company&#148;) of up to 10,062,500 shares (the &#147;Shares&#148;) of the Company&#146;s Common Stock, $0.0001 par value per share, including Shares purchasable by
the underwriters upon their exercise of an <FONT STYLE="white-space:nowrap">over-allotment</FONT> option granted to the underwriters by the Company. The Shares are being sold to the several underwriters named in, and pursuant to, an underwriting
agreement among the Company and such underwriters (the &#147;Underwriting Agreement&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have reviewed such documents and made such
examination of law as we have deemed appropriate to give the opinions set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinions set forth below, on
certificates of officers of the Company.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The opinion set forth below is limited to
the Delaware General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, upon
issuance and delivery against payment therefor in accordance with the terms of the Underwriting Agreement, the Shares will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration Statement and to the references to our firm under the
caption &#147;Legal Matters&#148; in the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations
thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Goodwin Procter LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GOODWIN PROCTER LLP</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>7
<FILENAME>d155225dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMYLYX PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2015 STOCK OPTION AND RESTRICTED STOCK PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Purpose</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose
of this plan (the &#147;Plan&#148;) is to secure for Amylyx Pharmaceuticals, Inc. (the &#147;Corporation&#148;) and its shareholders the benefits arising from capital stock ownership by employees, officers and directors of, and consultants or
advisors to, the Corporation who are expected to contribute to the Corporation&#146;s future growth and success. Except where the context otherwise requires, the term &#147;Corporation&#148; shall include all future subsidiaries of the Corporation
as defined in Section&nbsp;424(f) of the Internal Revenue Code of 1986, as amended or replaced from time to time (the &#147;Code&#148;). Those provisions of the Plan which make express reference to Section&nbsp;422 shall apply only to Incentive
Stock Options (as that term is defined in the Plan). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Plan is intended to be a written compensatory benefit plan within the meaning
of Rule 701 of the federal Securities Act of 1933, as amended, and is intended to qualify under similar provisions of applicable State Blue Sky laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Type of Options, Restricted Stock Grants, and Administration</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Types of Options</U>. Options granted pursuant to the Plan shall be authorized by action of the Administrator (as defined below) and may
be either incentive stock options (&#147;Incentive Stock Options&#148;) meeting the requirements of Section&nbsp;422 of the Code or <FONT STYLE="white-space:nowrap">non-statutory</FONT> options which are not intended to meet the requirements of
Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Restricted Stock</U>. Shares of the Corporation&#146;s $0.0001 par value common stock (&#147;Common
Stock&#148;) issued pursuant to the Plan and subject to restrictions as the Administrator shall determine (&#147;Restricted Stock&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Administration</U>. The Plan will be administered by the Administrator, whose construction and interpretation of the terms and
provisions of the Plan shall be final and conclusive. The Administrator may, in its sole discretion, (i)&nbsp;grant options to purchase shares Common Stock and issue shares upon exercise of such options as provided in the Plan and (ii)&nbsp;issue
Restricted Stock. The Administrator shall have authority, subject to the express provisions of the Plan, to determine the optionees; to set exercise prices, the number of shares subject to each option grant, and the vesting or other schedule by
which any option may be exercisable; to construe, amend, and terminate the respective option agreements; to determine the terms and provisions of the respective option agreements, which need not be identical; to determine, subject to Section&nbsp;3
hereof, the persons who will be issued Restricted Stock pursuant to the Plan, the price to be paid for any such shares, the method of payment for such shares, and the restrictions to which such shares will be subject; to construe and interpret the
Plan; to prescribe, amend and rescind rules and regulations relating to the Plan; and to make all other determinations in the judgment of the Administrator necessary or desirable for the administration of the Plan and the agreements entered into
pursuant to the Plan. The Administrator may correct any defect or supply any omission or reconcile any inconsistency in the Plan or in any option agreement in the manner and to the extent it shall deem expedient to carry the Plan into effect and it
shall be the sole and final judge of such expediency. No director or person acting pursuant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to authority delegated by the Administrator shall be liable for any action or determination under the Plan made in good faith. To the extent permitted by applicable law, the Administrator may
delegate any or all of its powers under the Plan to the Compensation Committee (the &#147;Committee&#148;). If and when the Common Stock is registered under the Securities Exchange Act of 1934 (the &#147;Exchange Act&#148;) the Administrator shall
appoint one such Committee of two members, each member of which shall be an &#147;outside director&#148; within the meaning of Section&nbsp;162(m) of the Code and a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; as defined
in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act). All references in the Plan to the term &#147;Administrator&#148; shall mean either the Corporation&#146;s Board of Directors or the Compensation Committee
thereof, to the extent the Compensation Committee is at the time responsible for the administration of the Plan). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Eligibility</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of Restricted Stock may be issued, and Options may be granted, to persons who are, at the time of issuance or grant, employees,
officers or directors of, or consultants or advisors to, the Corporation, or any subsidiary; <U>provided</U>, that the class of employees to whom Incentive Stock Options may be granted shall be limited to all employees of the Corporation, or any
subsidiary. A person who has been granted an option may, if he or she is otherwise eligible, be granted additional options if the Administrator shall so determine. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Stock Subject to Plan</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to adjustment as provided in Section&nbsp;15 below, the maximum number of shares of Common Stock of the Corporation which may be
issued and sold under the Plan is Seven Hundred Two Thousand Five Hundred Eighty Four (702,584) shares. If an option granted under the Plan shall expire or terminate for any reason without having been exercised in full, the unpurchased shares
subject to such option shall again be available for subsequent option grants under the Plan. If shares issued upon exercise of an option under the Plan are tendered to the Corporation in payment of the exercise price of an option granted under the
Plan, such tendered shares shall again be available for subsequent option grants under the Plan; provided, that in no event shall such shares be made available pursuant to exercise of Incentive Stock Options. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Forms of Option Agreements; Restricted Stock</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a condition to any grant under the Plan, each recipient shall execute: (a)&nbsp;an option or Restricted Stock agreement (as the case may
be) in such form not inconsistent with the Plan as may be approved by the Administrator and (b)&nbsp;a joinder agreement and limited power of attorney, each in forms attached to a stockholders agreement if applicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Purchase Price</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
<U>General</U>. The purchase price per share of Common Stock deliverable upon the exercise of an option shall be determined by the Administrator, <U>provided, however</U>, that the exercise price shall not be less than 100% of the fair value of such
stock, as determined by the Administrator, at the time of grant of such option, or less than 110% of such fair market value in the case of options described in Section&nbsp;11(b). The purchase price per share of Restricted Stock to be issued to a
recipient hereunder shall be determined by the Administrator. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Payment of Purchase Price</U>. Options granted under the Plan may provide for the
payment of the exercise price by (i)&nbsp;delivery of cash or a check to the order of the Corporation in an amount equal to the exercise price of such options, or, to the extent provided in the applicable option agreement, (ii)&nbsp;by delivery to
the Corporation of shares of Common Stock of the Corporation already owned by the optionee having a fair market value equal in amount to the exercise price of the options being exercised, (iii)&nbsp;by any other means which the Administrator
determines are consistent with the purpose of the Plan and with applicable laws and regulations (including, without limitation, the provisions of Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> and Regulation T promulgated by the Federal Reserve
Board) or (iv)&nbsp;by any combination of such methods of payment. The fair market value of any shares of the Corporation&#146;s Common Stock or other <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration which may be delivered upon
exercise of an option or which may be delivered pursuant to a Restricted Stock agreement shall be determined by the Administrator. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.
<U>Option Period</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each option and all rights thereunder shall expire on such date as shall be set forth in the applicable option
agreement, except that, in the case of an Incentive Stock Option, such date shall not be later than ten years after the date on which the option is granted and, in all cases, options shall be subject to earlier termination as provided in the Plan.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Exercise of Options</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each option granted under the Plan shall be exercisable either in full or in installments at such time or times and during such period as
shall be set forth in the agreement evidencing such option, subject to the provisions of the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Nontransferability of
Options</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as the Administrator may otherwise determine or provide in the applicable option agreement, options shall not be
assignable or transferable by the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the life of the optionee, shall be exercisable only by the optionee;
provided, however, that <FONT STYLE="white-space:nowrap">non-statutory</FONT> options may be transferred pursuant to a qualified domestic relations order (as defined in Code Section&nbsp;414(p)). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Effect of Termination of Employment or Other Relationship.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the provisions of the Plan, the Administrator shall determine the period of time during which an optionee may exercise an option
following (i)&nbsp;the termination of the optionee&#146;s employment or other relationship with the Corporation, or any subsidiary, or (ii)&nbsp;the death or disability of the optionee. Such periods shall be set forth in the agreement evidencing
such option. For the purposes of the Plan, employment shall not be deemed to be terminated solely because an optionee is transferred from the Corporation to any subsidiary thereof or to an acquiring or succeeding corporation (or an affiliate
thereof). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Incentive Stock Options</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options granted under the Plan which are intended to be Incentive Stock Options shall be subject to the following additional terms and
conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Express Designation</U>. All Incentive Stock Options granted under the Plan shall, at the time of grant, be
specifically designated as such in the option agreement covering such Incentive Stock Options. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>10% Shareholder</U>. If any employee
to whom an Incentive Stock Option is to be granted under the Plan is, at the time of the grant of such option, the owner of stock possessing more than 10% of the total combined voting power of all classes of stock of the Corporation (after taking
into account the attribution of stock ownership rules of Section&nbsp;424(d) of the Code), then the following special provisions shall be applicable to the Incentive Stock Option granted to such individual: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the purchase price per share of the Common Stock subject to such Incentive Stock Option shall not be less than 110% of the
fair market value of one share of Common Stock at the time of grant; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the option exercise period shall not exceed
five years from the date of grant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Dollar Limitation</U>. For so long as the Code shall so provide, options granted to any employee
under the Plan (and any other incentive stock option plans of the Corporation) which are intended to constitute Incentive Stock Options shall not constitute Incentive Stock Options to the extent that such options, in the aggregate, become
exercisable for the first time in any one calendar year for shares of Common Stock with an aggregate fair market value (determined as of the respective date or dates of grant) of more than $100,000. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Termination of Employment, Death or Disability</U>. No Incentive Stock Option may be exercised unless, at the time of such exercise, the
optionee is, and has been continuously since the date of grant of his or her option, employed by the Corporation, or any subsidiary, except that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) an Incentive Stock Option may be exercised within the period of three months after the date the optionee ceases to be an
employee of the Corporation, or any subsidiary (or within such lesser period as may be specified in the applicable option agreement); <U>provided</U>, that the agreement with respect to such option may designate a longer exercise period and that any
exercise after such three-month period shall be treated as the exercise of a <FONT STYLE="white-space:nowrap">non-statutory</FONT> option under the Plan; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) if the optionee dies while in the employ of the Corporation, or any subsidiary, or within three months after the optionee
ceases to be such an employee, the Incentive Stock Option may be exercised by the person to whom it is transferred by will or the laws of descent and distribution within the period of one year after the date of death (or within such lesser period as
may be specified in the applicable option agreement); and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) if the optionee becomes disabled (within the meaning of
Section&nbsp;22(e)(3) of the Code or any successor provision thereto) while in the employ of the Corporation, or any subsidiary, the Incentive Stock Option may be exercised within the period of one year after the date the optionee ceases to be such
an employee because of such disability (or within such lesser period as may be specified in the applicable option agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For all
purposes of the Plan and any option granted hereunder, &#147;employment&#148; shall be defined in accordance with the provisions of <FONT STYLE="white-space:nowrap">Section&nbsp;1.421-7(h)</FONT> of the Income Tax Regulations (or any successor
regulations) and shall include employment by the Corporation, or any subsidiary. Employment shall not be deemed to be terminated because an optionee is transferred from one of the Corporation, or any subsidiary to another one of the Corporation, or
any subsidiary. Notwithstanding the foregoing provisions, no Incentive Stock Option may be exercised after its expiration date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.
<U>Additional Provisions</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Additional Option Provisions</U>. The Administrator may, in its sole discretion, include additional
provisions in option agreements covering options granted under the Plan, including, without limitation, restrictions on transfer, repurchase rights, commitments to pay cash bonuses, to make, arrange for or guaranty loans or to transfer other
property to optionees upon exercise of options, or such other provisions as shall be determined by the Administrator; <U>provided</U> that such additional provisions shall not be inconsistent with any other term or condition of the Plan and such
additional provisions shall not cause any Incentive Stock Option granted under the Plan to fail to qualify as an Incentive Stock Option within the meaning of Section&nbsp;422 of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Acceleration, Extension, Etc</U>. The Administrator may, in its sole discretion, (i)&nbsp;accelerate the date or dates on which all or
any particular option or options granted under the Plan may be exercised or (ii)&nbsp;extend the dates during which all, or any particular, option or options granted under the Plan may be exercised; <U>provided, however</U>, that no such extension
shall be permitted if it would cause the Plan to fail to comply with Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>General Restrictions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Investment Representations</U>. The Corporation may require any person to whom an option is granted, or any shares of Restricted Stock
are being issued, as a condition of exercising such option or acquiring such shares, to give written assurances in substance and form satisfactory to the Corporation to the effect that such person is acquiring the Common Stock for his or her own
account for investment and not with any present intention of selling or otherwise distributing the same, and to such other effects as the Corporation deems necessary or appropriate in order to comply with federal and applicable state securities
laws, or with covenants or representations made by the Corporation in connection with any public offering of its Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Compliance With Securities Laws</U>. Each option shall be subject to the requirement
that if, at any time, counsel to the Corporation shall determine that the listing, registration or qualification of the shares subject to such option upon any securities exchange or under any state or federal law, or the consent or approval of any
governmental or regulatory body, or that the disclosure of <FONT STYLE="white-space:nowrap">non-public</FONT> information or the satisfaction of any other condition is necessary as a condition of, or in connection with, the issuance or purchase of
shares thereunder, such option may not be exercised, in whole or in part, unless such listing, registration, qualification, consent or approval, or satisfaction of such condition shall have been effected or obtained on conditions acceptable to the
Administrator. Nothing herein shall be deemed to require the Corporation to apply for or to obtain such listing, registration or qualification, or to satisfy such condition. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Rights as a Shareholder</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holder of an option shall have no rights as a shareholder with respect to any shares covered by the option (including, without limitation,
any rights to receive dividends or <FONT STYLE="white-space:nowrap">non-cash</FONT> distributions with respect to such shares) until the date of issue of a stock certificate to him or her for such shares. No adjustment shall be made for dividends or
other rights for which the record date is prior to the date such stock certificate is issued. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Adjustment Provisions for
Recapitalizations and Related Transactions.</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. If, through or as a result of any merger, consolidation, sale of all
or substantially all of the assets of the Corporation, reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar transaction, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the outstanding shares of Common Stock are increased, decreased or exchanged for a different number or kind of shares or
other securities of the Corporation, or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) additional shares or new or different shares or other securities of the
Corporation or other <FONT STYLE="white-space:nowrap">non-cash</FONT> assets are distributed with respect to such shares of Common Stock or other securities, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">an appropriate and proportionate adjustment shall be made in (x)&nbsp;the maximum number and kind of shares reserved for issuance under the Plan, (y)&nbsp;the
number and kind of shares or other securities subject to any then outstanding options under the Plan, and (z)&nbsp;the price for each share subject to any then outstanding options under the Plan, without changing the aggregate purchase price as to
which such options remain exercisable. Notwithstanding the foregoing, no adjustment shall be made pursuant to this Section&nbsp;15 if such adjustment would cause the Plan to fail to comply with Section&nbsp;422 of the Code. If this Section&nbsp;15
applies and Section&nbsp;16 also applies to any event, then Section&nbsp;16 shall be applicable to such event and this Section&nbsp;15 shall not be applicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Administrator Authority to Make Adjustments</U>. Any adjustments under this Section&nbsp;15 will be made by the Administrator, whose
determination as to what adjustments, if any, will be made and the extent thereof will be final, binding and conclusive. No fractional shares will be issued under the Plan on account of any such adjustments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Merger, Consolidation, Asset Sale, Liquidation, etc.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. Subject to Section&nbsp;16(b), if an Acquisition Event (as defined below) is expected to occur, the Administrator shall
take any one or more or none of the following actions with respect to then Outstanding Options (which term shall include all vested and unvested, but unexercised Options specified in all issued, outstanding and then currently binding Stock Option
Agreements): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) provide that such Outstanding Options shall be assumed, or equivalent options shall be substituted, by
the acquiring or succeeding corporation (or an affiliate thereof), <U>provided</U> that any such options substituted for Outstanding Incentive Stock Options shall meet the requirements of Section&nbsp;424(a) of the Code; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) upon written notice to the optionees, provide that all then unexercised Outstanding Options will become exercisable in
full as of a specified time (the &#147;Acceleration Time&#148;) prior to the Acquisition Event and will terminate immediately prior to the consummation of such Acquisition Event, except to the extent exercised by the optionees between the
Acceleration Time and the consummation of such Acquisition Event; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) in the event of a merger under the terms of which
holders of the Common Stock of the Corporation will receive upon consummation thereof a cash or stock payment for each share surrendered in the merger (the &#147;Merger Price&#148;), make or provide for a cash or stock payment to each optionee equal
to (A)&nbsp;the Merger Price times the number of shares of Common Stock issuable to that Optionee upon the exercise by that Optionee of such of that Optionee&#146;s Outstanding Options (whether or not then exercisable at prices not in excess of the
Merger Price) which that Optionee actually elects to exercise, less (B)&nbsp;the aggregate exercise price of all such Outstanding Options which the Optionee actually exercises in exchange for the termination of all of that Optionee&#146;s
Outstanding Options; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) provide that all or any Outstanding Options shall become exercisable in full immediately prior
to such event; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) provide for a combination of any one or more of the foregoing options or any other plan which would
be equitable, in the good faith judgment of the Administrator, to the holders of Outstanding Options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An &#147;Acquisition Event&#148; shall mean:
(A)&nbsp;any merger or consolidation which results in the voting securities of the Corporation outstanding immediately prior thereto representing immediately thereafter (either by remaining outstanding or by being converted into voting securities of
the surviving or acquiring entity) less than 50% of the combined voting power of the voting securities of the Corporation or such surviving or acquiring entity outstanding immediately after such merger or consolidation, (B)&nbsp;any sale of all or
substantially all of the assets of the Corporation, or (C)&nbsp;the complete liquidation of the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Substitute Options</U>. The Corporation may grant options under the Plan in
substitution for options held by employees of another corporation who become employees of the Corporation, or a subsidiary of the Corporation, as the result of a merger or consolidation of the employing corporation with the Corporation or a
subsidiary of the Corporation, or as a result of the acquisition by the Corporation, or one of its subsidiaries, of property or stock of the employing corporation. The Corporation may direct that substitute options be granted on such terms and
conditions as the Administrator considers appropriate in the circumstances. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>No Special Employment Rights</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nothing contained in the Plan or in any option shall confer upon any optionee any right with respect to the continuation of his or her
employment by the Corporation or interfere in any way with the right of the Corporation at any time to terminate such employment or to increase or decrease the compensation of the optionee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>Other Employee Benefits</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as to plans which by their terms include such amounts as compensation, the amount of any compensation deemed to be received by an
employee as a result of the exercise of an option or the sale of shares received upon such exercise will not constitute compensation with respect to which any other employee benefits of such employee are determined, including, without limitation,
benefits under any bonus, pension, profit-sharing, life insurance or salary continuation plan, except as otherwise specifically determined by the Administrator. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <U>Amendment of the Plan</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Administrator may at any time, and from time to time, modify or amend the Plan in any respect, except that if at any time the approval
of the shareholders of the Corporation is required under Section&nbsp;422 of the Code or any successor provision with respect to Incentive Stock Options, the approval of the shareholders shall be required to ratify such modification or amendment.
Amendments shall become effective as described in Section&nbsp;22(a). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The termination or any modification or amendment of the Plan
shall not, without the consent of an optionee, affect his or her rights under an option previously granted to him or her. With the consent of the optionee affected, the Administrator may amend outstanding option agreements in a manner not
inconsistent with the Plan. The Administrator shall have the right to amend or modify the terms and provisions of the Plan and of any outstanding Incentive Stock Options granted under the Plan to the extent necessary to qualify any or all such
options for such favorable federal income tax treatment (including deferral of taxation upon exercise) as may be afforded incentive stock options under Section&nbsp;422 of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <U>Withholding</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Corporation shall have the right to deduct from payments of any kind otherwise due to the optionee any federal, state or local taxes of any kind required by law to be withheld with respect to any shares issued upon exercise of options under the
Plan, or any Restricted Stock issued under the Plan. Subject to the prior approval of the Corporation, which may be withheld by the Corporation in its sole discretion, the optionee may elect to satisfy such obligations, in whole or in part, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) by causing the Corporation to withhold shares of Common Stock otherwise
issuable pursuant to the exercise of an option, or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) by delivering to the Corporation shares of Common Stock already
owned by the optionee. The shares so delivered or withheld shall have a fair market value equal to such withholding obligation. The fair market value of the shares used to satisfy such withholding obligation shall be determined by the Corporation as
of the date that the amount of tax to be withheld is to be determined. An optionee who has made an election pursuant to this Section&nbsp;20(a) may only satisfy his or her withholding obligation with shares of Common Stock which are not subject to
any repurchase, forfeiture, unfulfilled vesting or other similar requirements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <U>Cancellation and New Grant of Options, Etc</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator shall have the authority to effect, at any time and from time to time, with the consent of the affected optionees, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the cancellation of any or all outstanding options under the Plan and the grant in substitution therefor of new options
under the Plan covering the same or different numbers of shares of Common Stock and having an option exercise price per share which may be lower or higher than the exercise price per share of the cancelled options, or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the amendment of the terms of any and all outstanding options under the Plan to provide an option exercise price per share
which is higher or lower than the then current exercise price per share of such outstanding options. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. <U>Effective Date and Duration of
the Plan</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Effective Date</U>. The Plan shall become effective as of the date marked below, but no Incentive Stock Option
granted under the Plan shall become exercisable unless and until the Plan shall have been approved by the Corporation&#146;s shareholders. If such shareholder approval is not obtained within twelve months after the effective date of the Plan, no
options previously granted under the Plan shall be deemed to be Incentive Stock Options and no Incentive Stock Options shall be granted thereafter. Amendments to the Plan not requiring shareholder approval shall become effective when adopted by the
Administrator; amendments requiring shareholder approval (as provided in Section&nbsp;19) shall become effective when adopted by the Administrator, but no Incentive Stock Option granted after the date of such amendment shall become exercisable (to
the extent that such amendment to the Plan was required to enable the Corporation to grant such Incentive Stock Option to a particular optionee) unless and until such amendment shall have been approved by the Corporation&#146;s shareholders. If such
shareholder approval is not obtained within twelve months of the Administrator&#146;s adoption of such amendment, any Incentive Stock Options granted on or after the date of such amendment shall terminate to the extent that such amendment to the
Plan was required to enable the Corporation to grant such option to a particular optionee. Subject to this limitation, options may be granted under the Plan at any time after the effective date and before the date fixed for termination of the Plan.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination</U>. Unless sooner terminated in accordance with Section&nbsp;16, the
Plan shall terminate, with respect to Incentive Stock Options, upon the earlier of the following events: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the close of
business on the day next preceding the tenth anniversary of the date of its adoption by the Administrator, or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the
date on which all shares available for issuance under the Plan shall have been issued pursuant to the exercise or cancellation of options granted under the Plan. Unless sooner terminated in accordance with Section&nbsp;16, the Plan shall terminate
with respect to options which are not Incentive Stock Options on the date specified in (ii)&nbsp;above. If the date of termination is determined under (i)&nbsp;above, then options outstanding on such date shall continue to have force and effect in
accordance with the provisions of the instruments evidencing such options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23. <U>Provision for Foreign Participants</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator may, without amending the Plan, modify awards or options granted to participants who are foreign nationals or employed
outside the United States to recognize differences in laws, rules, regulations or customs of such foreign jurisdictions with respect to tax, securities, currency, employee benefit or other matters. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">AMYLYX PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Effective Date: April&nbsp;1, 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:&nbsp;<U>/s/Joshua
Cohen&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Joshua Cohen, President</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hereunto Duly Authorized</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMYLYX PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INCENTIVE STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Grant of Option</U>. Effective as of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>(&#147;Date of
Grant&#148;), <B>AMYLYX PHARMACEUTICALS, INC.</B>, a Delaware corporation (the &#147;Corporation&#148;), hereby grants to <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>(the &#147;Optionee&#148;), an option, pursuant
to the Corporation&#146;s 2015 Stock Option and Restricted Stock Plan, as amended (the &#147;Plan&#148;), to purchase an aggregate of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>shares of the Corporation&#146;s
$0.0001 par value common stock (&#147;Common Stock&#148;) at a price of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>per share, purchasable as set forth in and subject to the terms and conditions of this option and
the Plan. Except where the context otherwise requires, the term &#147;Corporation&#148; shall include all present and future subsidiaries of the Corporation as defined in Sections 424(e) and 424(f) of the Internal Revenue Code of 1986, as amended or
replaced from time to time (the &#147;Code&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Incentive Stock Option</U>. This option is intended to qualify as an incentive
stock option (&#147;Incentive Stock Option&#148;) within the meaning of Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Exercise of Option and
Provisions for Termination</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Vesting Schedule</U>. Except as otherwise provided in this Agreement, this option may be exercised
prior to the tenth (10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>)&nbsp;anniversary of the Date of Grant (hereinafter the &#147;Expiration Date&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The options shall vest as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>of the shares subject to this option shall vest and become
exercisable on <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) on the
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of each of the thirty-six (36)&nbsp;months commencing on
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>and continuing through to and including <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, an additional
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>shares subject to this option shall vest and become exercisable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The right of exercise shall be cumulative so that if the Option is not exercised to the maximum extent permissible during any exercise period,
it shall be exercisable, in whole or in part, with respect to all shares not so purchased at any time prior to the Expiration Date or the earlier termination of this option. This Option may not be exercised at any time on or after the Expiration
Date, except as otherwise provided in Section&nbsp;3(e) below. This Option may not be exercised more frequently than twice in any calendar year. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Exercise Procedure</U>. Subject to the conditions set forth in this Agreement, this option shall be exercised by the Optionee&#146;s
delivery of a written notice of exercise in the form of attached hereto and marked as <U>Exhibit 1</U> to the Treasurer of the Corporation, specifying the number of shares to be purchased and the purchase price to be paid therefor and accompanied by
payment in full in accordance with Section&nbsp;4, if applicable, and a joinder agreement and limited power of attorney, each in form attached to that certain Stockholders Agreement defined in the Plan. Such exercise shall be effective upon receipt
by the Treasurer of the Corporation of such written notice together with the required payment and the said joinder agreement and limited power of attorney executed by the Optionee. The Optionee may purchase less than the number of shares covered
hereby, provided that no partial exercise of this option may be for any fractional share or for fewer than ten whole shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Continuous Employment Required</U>. Except as otherwise provided in this
Section&nbsp;3, this option may not be exercised unless the Optionee, at the time he exercises this option, is, and has been at all times since the Date of Grant of this option, an employee of the Corporation or any subsidiary. For all purposes of
this option, (i)&nbsp;&#147;employment&#148; shall be defined in accordance with the provisions of Section&nbsp;1.421-7(h) of the Income Tax Regulations or any successor regulations and shall include employment by the Corporation or any subsidiary,
and (ii)&nbsp;if this option shall be assumed or a new option substituted therefor in a transaction to which Section&nbsp;424(a) of the Code applies, employment by such assuming or substituting corporation (hereinafter called the &#147;Successor
Corporation&#148;) shall be considered for all purposes of this option to be employment by the Corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Exercise Period Upon
Termination of Employment</U>. If the Optionee ceases to be employed by the Corporation or any subsidiary for any reason, then, except as provided in paragraphs (e), and (f)&nbsp;below, the right to exercise this option shall terminate three
(3)&nbsp;months after such cessation (but in no event after the Expiration Date), <U>provided that</U> this option shall be exercisable only to the extent that the Optionee was entitled to exercise this option on the date of such cessation. The
Corporation&#146;s obligation to deliver shares upon the exercise of this option shall be subject to the satisfaction of all applicable federal, state and local income and employment tax withholding requirements, arising by reason of this option
being treated as a non-statutory option or otherwise. Notwithstanding the foregoing, if the Optionee, prior to the Expiration Date, materially violates the non-competition or confidentiality provisions of any employment contract, confidentiality and
nondisclosure agreement or other agreement between the Optionee and the Corporation or any subsidiary, the right to exercise this option shall terminate immediately upon written notice to the Optionee from the Corporation or any subsidiary
describing such violation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Exercise Period Upon Death or Disability</U>. If the Optionee dies or becomes disabled (within the
meaning of Section&nbsp;22(e)(3) of the Code) prior to the Expiration Date while he is an employee of the Corporation or any subsidiary, or if the Optionee dies within three (3)&nbsp;months after the Optionee ceases to be an employee of the
Corporation or any subsidiary (other than as the result of a discharge for &#147;cause&#148; as specified in paragraph (f)&nbsp;below), this option shall be exercisable within the period of one (1)&nbsp;year following the date of death or disability
of the Optionee (but in no event after the Expiration Date), by the Optionee or by the person to whom this option is transferred by will or the laws of descent and distribution, provided that this option shall be exercisable only to the extent this
option was exercisable by the Optionee on the date of his death or disability. Except as otherwise indicated by the context, the term &#147;Optionee,&#148; as used in this option, shall be deemed to include the estate of the Optionee or any person
who acquires the right to exercise this option by bequest or inheritance or otherwise by reason of the death of the Optionee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Discharge for Cause</U>. If the Optionee, prior to the Expiration Date, is discharged
by the Corporation or any subsidiary for &#147;cause&#148; (as defined below), the right to exercise this option shall terminate immediately upon the Optionee being given notice of such cessation of employment whether the actual cessation of
employment is immediate or occurs at a later date. &#147;Cause&#148; shall mean willful misconduct in connection with the Optionee&#146;s employment or willful failure to perform his employment responsibilities in the best interests of the
Corporation or any subsidiary (including, without limitation, breach by the Optionee of any provision of any employment, nondisclosure, non-competition or other similar agreement between the Optionee and the Corporation or any subsidiary), as
determined by the Corporation or any subsidiary, which determination shall be conclusive. The Optionee shall be considered to have been discharged &#147;for cause&#148; if the Corporation or any subsidiary determines, within thirty (30)&nbsp;days
after the Optionee&#146;s resignation, that discharge for cause was warranted. In the event Optionee&#146;s employment relationship with the Corporation is suspended pending investigation of whether such relationship shall be terminated for
&#147;cause&#148;, all Optionee&#146;s rights under this option, including the right to exercise this option, shall be suspended during the investigation period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Payment of Purchase Price</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Method of Payment</U>. Payment of the purchase price for shares purchased upon exercise of this option shall be made: (i)&nbsp;by
delivery to the Corporation of cash or a check to the order of the Corporation in an amount equal to the purchase price of such shares, (ii)&nbsp;subject to the consent of the Corporation, by delivery to the Corporation of shares of Common Stock of
the Corporation then owned by the Optionee having a fair market value equal in amount to the purchase price of such shares, (iii)&nbsp;by any other means which the Administrator (as that term is defined in the Plan) determines are consistent with
the purpose of the Plan and with applicable laws and regulations (including, without limitation, the provisions of Rule 16b-3 under the Securities Exchange Act of 1934 and Regulation T promulgated by the Federal Reserve Board), or (iv)&nbsp;by any
combination of such methods of payment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Valuation of Shares or Other Non-Cash Consideration Tendered in Payment of Purchase
Price</U>. For the purposes hereof, the fair market value of any share of the Corporation&#146;s Common Stock or other non-cash consideration which may be delivered to the Corporation in exercise of this option shall be determined in good faith by
the Administrator. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Delivery of Shares Tendered in Payment of Purchase Price</U>. If the Optionee exercises options by delivery of
shares of Common Stock of the Corporation, the certificate or certificates representing the shares of Common Stock of the Corporation to be delivered shall be duly executed in blank by the Optionee or shall be accompanied by a stock power duly
executed in blank suitable for purposes of transferring such shares to the Corporation. Fractional shares of Common Stock of the Corporation will not be accepted in payment of the purchase price of shares acquired upon exercise of this option. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Restrictions on Use of Option Stock</U>. Notwithstanding the foregoing, no shares of Common Stock of the Corporation may be tendered in
payment of the purchase price of shares purchased upon exercise of this option if the shares to be so tendered were acquired within twelve (12)&nbsp;months before the date of such tender through the exercise of an option granted under the Plan or
any other stock option or restricted stock plan of the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Delivery of Shares; Compliance With Securities Laws, Etc.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. The Corporation shall, upon payment of the option price for the number of shares purchased and paid for, make prompt
delivery of such shares to the Optionee, <U>provided</U> that if any law or regulation requires the Corporation to take any action with respect to such shares before the issuance thereof, then the date of delivery of such shares shall be extended
for the period necessary to complete such action. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Listing, Qualification, Etc</U>. This option shall be subject to the requirement
that if, at any time, counsel to the Corporation shall determine that the listing, registration or qualification of the shares subject hereto upon any securities exchange or under any state or federal law, or the consent or approval of any
governmental or regulatory body, or that the disclosure of non-public information or the satisfaction of any other condition is necessary as a condition of, or in connection with, the issuance or purchase of shares hereunder, this option may not be
exercised, in whole or in part, unless such listing, registration, qualification, consent or approval, disclosure or satisfaction of such other condition shall have been effected or obtained on terms acceptable to the Administrator. Nothing herein
shall be deemed to require the Corporation to apply for, effect or obtain such listing, registration, qualification, or disclosure, or to satisfy such other condition. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Nontransferability of Option</U>. Except as provided in paragraph (e)&nbsp;of Section&nbsp;3, this option is personal and no rights
granted hereunder may be transferred, assigned, pledged or hypothecated in any way (whether by operation of law or otherwise), nor shall any such rights be subject to execution, attachment or similar process. Upon any attempt to transfer, assign,
pledge, hypothecate or otherwise dispose of this option or of such rights contrary to the provisions hereof, or upon the levy of any attachment or similar process upon this option or such rights, this option and such rights shall, at the election of
the Corporation, become null and void. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>No Special Employment Rights</U>. Nothing contained in the Plan or this option shall be
construed or deemed by any person under any circumstances to bind the Corporation or any subsidiary to continue the employment of the Optionee for the period within which this option may be exercised. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Rights as a Shareholder</U>. The Optionee shall have no rights as a shareholder with respect to any shares which may be purchased by
exercise of this option (including, without limitation, any rights to receive dividends or non-cash distributions with respect to such shares) unless and until a certificate representing such shares is duly issued and delivered to the Optionee. No
adjustment shall be made for dividends or other rights for which the record date is prior to the date such stock certificate is issued. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.
<U>Adjustment Provisions</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. In the event of a transaction described in Section&nbsp;15(a) of the Plan, the Optionee
shall, with respect to this option or any unexercised portion hereof, be entitled to the rights and benefits, and be subject to the limitations, set forth in Section&nbsp;15(a) of the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Administrator Authority to Make Adjustments</U>. Any adjustments under this Section&nbsp;9 will be made by the Administrator, whose
determination as to what adjustments, if any, will be made and the extent thereof will be final, binding and conclusive. No fractional shares will be issued pursuant to this option on account of any such adjustments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Limits on Adjustments</U>. No adjustment shall be made under this Section&nbsp;9
which would, within the meaning of any applicable provision of the Code, constitute a modification, extension or renewal of this option or a grant of additional benefits to the Optionee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Mergers, Consolidation, Distributions, Liquidations Etc.</U> In the event of a merger, consolidation, distribution, liquidation or other
similar event described in Article 9 of the Plan, the Optionee shall, with respect to this option or any unexercised portion hereof, be entitled to the rights and benefits, and be subject to the limitations, set forth in Article 9 of the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Withholding Taxes</U>. The Corporation&#146;s obligation to deliver shares upon the exercise of this option shall be subject to the
Optionee&#146;s satisfaction of all applicable federal, state and local income and employment tax withholding requirements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.
<U>Limitations on Disposition of Incentive Stock Option Shares</U>. It is understood and intended that this option shall qualify as an &#147;incentive stock option&#148; as defined in Section&nbsp;422 of the Code. Accordingly, the Optionee
understands that in order to obtain the benefits of an incentive stock option under Section&nbsp;422 of the Code, no sale or other disposition may be made of any shares acquired upon exercise of the option within one (1)&nbsp;year after the day of
the transfer of such shares to the Optionee, nor within two (2)&nbsp;years after the grant of the option. If the Optionee intends to dispose, or does dispose (whether by sale, exchange, gift, transfer or otherwise), of any such shares within said
periods, he will notify the Corporation in writing within ten days after such disposition. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Investment Representations; Legends</U>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Representations</U>. The Optionee represents, warrants and covenants that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Any shares purchased upon exercise of this option shall be acquired for the Optionee&#146;s account for investment only and
not with a view to, or for sale in connection with, any distribution of the shares in violation of the Securities Act of 1933 (the &#147;Securities Act&#148;) or any rule or regulation under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Optionee has had such opportunity as he has deemed adequate to obtain from representatives of the Corporation such
information as is necessary to permit the Optionee to evaluate the merits and risks of his investment in the Corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) The Optionee is able to bear the economic risk of holding shares acquired pursuant to the exercise of this option for an
indefinite period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) The Optionee understands that (A)&nbsp;the shares acquired pursuant to the exercise of this option
will not be registered under the Securities Act and are &#147;restricted securities&#148; within the meaning of Rule 144 under the Securities Act; (B)&nbsp;such shares cannot be sold, transferred or otherwise disposed of unless they are subsequently
registered under the Securities Act or an exemption from registration is then available; (C)&nbsp;in any event, an exemption from registration under Rule 144 or otherwise under the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Securities Act may not be available for at least two years and even then will not be available unless a public market then exists for the Common Stock, adequate information concerning the
Corporation is then available to the public and other terms and conditions of Rule 144 are complied with; and (D)&nbsp;there is now no registration statement on file with the Securities and Exchange Commission with respect to any stock of the
Corporation and the Corporation has no obligation or current intention to register any shares acquired pursuant to the exercise of this option under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) The Optionee agrees that, if the Corporation offers any of its Common Stock for sale pursuant to a registration statement
under the Securities Act, the Optionee will not, without the prior written consent of the Corporation, directly or indirectly offer, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any
option, right or warrant for the sale of or otherwise dispose of or transfer any shares purchased upon exercise of this option, for such period not to exceed (a)&nbsp;one hundred eighty (180)&nbsp;days following the effective date of the relevant
registration statement filed under the Securities Act in connection with the Company&#146;s initial public offering of Registrable Securities, or (b)&nbsp;ninety (90)&nbsp;days following the effective date of the relevant registration statement in
connection with any other public offering of Registrable Securities; <U>provided</U>, <U>however</U>, that all officers and directors of the Company and all 1% or greater stockholders of the Company enter into similar agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By making payment upon exercise of this option, the Optionee shall be deemed to have reaffirmed, as of the date of such payment, the
representations made in this Section&nbsp;13. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Legends on Stock Certificates</U>. All stock certificates representing shares of
Common Stock issued to the Optionee upon exercise of this option shall have affixed thereto legends substantially in the following forms, in addition to any other legends required by applicable state law: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;The shares of stock represented by this certificate have not been registered under the Securities Act of 1933 and may not be transferred,
sold or otherwise disposed of in the absence of an effective registration statement with respect to the shares evidenced by this certificate, filed and made effective under the Securities Act of 1933, or an opinion of counsel satisfactory to the
Corporation to the effect that registration under such Act is not required.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;The shares of stock represented by this
certificate are subject to certain restrictions on transfer contained in an Option Agreement, a copy of which will be furnished upon request by the, issuer.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Except as provided herein, this option may not be amended or otherwise modified unless evidenced in writing and signed by the Corporation
and the Optionee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) All notices under this option shall be mailed or delivered by hand or overnight courier to the parties at their
respective addresses set forth beneath their names below or at such other address as may be designated in writing by either of the parties to one another. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) This option shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Signature Page Follows </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DATED effective as of the Date of Grant. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">AMYLYX PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: &nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Justin Klee, President</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Hereunto Duly Authorized</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OPTIONEE&#146;S ACCEPTANCE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby accepts the foregoing option and agrees to the terms and conditions thereof. The undersigned hereby acknowledges
receipt of a copy of the Corporation&#146;s 2015 Stock Option and Restricted Stock Plan, as amended. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">OPTIONEE:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:
&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Notice of Option Exercise </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TO: The Treasurer of AMYLYX PHARMACEUTICALS, INC.: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned, in accordance with the provisions of a Stock Option Agreement (&#147;Agreement&#148;) between AMYLYX PHARMACEUTICALS, INC.
(&#147;Corporation&#148;) and the undersigned, hereby gives notice pursuant to Section&nbsp;3(b) of the Agreement of the undersigned&#146;s exercise of the option pursuant to the Agreement to purchase
(#)<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> common shares of the Corporation for the aggregate payment for said shares of $<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(&#147;Price&#148;) payable as follows (please check one): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">by the tender of a check for immediately available funds for the entire Price (enclose check made payable to &#147;AMYLYX PHARMACEUTICALS, INC.&#148;);</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">subject to the consent of the Corporation, by tendering (#)____________ shares of the Corporation&#146;s (type)_____________ stock;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">subject to the consent of the Corporation, by tendering $____________ in cash (enclose check made payable to &#147;AMYLYX PHARMACEUTICALS, INC.&#148;) and (#)____________ shares of the Corporation&#146;s (type)_____________ stock;
or</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">by alternative means approved by the Corporation&#146;s Administrator as follows:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned represents and warrants to the Corporation that all of the representations and warranties set
forth in Section&nbsp;13(a) of the Agreement are true and correct as of the date of this Notice. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMYLYX PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>NON-STATUTORY STOCK OPTION AGREEMENT (CANADIAN) </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Grant of Option</U>. Effective <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(&#147;Date of Grant&#148;), AMYLYX PHARMACEUTICALS, INC., a Delaware corporation (the &#147;Corporation&#148;), hereby grants to <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> (the
&#147;Optionee&#148;) an option, pursuant to the Corporation&#146;s 2015 Stock Option and Restricted Stock Plan (the &#147;Plan&#148;), to purchase an aggregate of
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> shares of the Corporation&#146;s $0.0001 par value common stock (&#147;Common Stock&#148;) at a price of
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> per share, purchasable as set forth in and subject to the terms and conditions of this option and the Plan. Except where the context otherwise
requires, the term &#147;Corporation&#148; shall include all present and future subsidiaries of the Corporation as defined in Sections 424(e) and 424(f) of the Internal Revenue Code of 1986, as amended or replaced from time to time (the
&#147;Code&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Non-Statutory Stock Option</U>. This option is not intended to qualify as an incentive stock option within the
meaning of Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Exercise of option and Provisions for Termination</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Vesting Schedule</U>. Except as otherwise provided in this Agreement, this option may be exercised prior to the tenth
(10th)&nbsp;anniversary of the Date of Grant (hereinafter the &#147;Expiration Date&#148;). The right to exercise this option shall vest as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> of the shares subject to this
option shall vest and become exercisable on <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) on the <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> day of each of the thirty-six (36)&nbsp;months commencing on <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> and continuing through to and including
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, an additional <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> shares subject to this
option shall vest and become exercisable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The right of exercise shall be cumulative so that if the option is not exercised to the maximum
extent permissible during any exercise period, it shall be exercisable, in whole or in part, with respect to all shares not so purchased at any time prior to the Expiration Date or the earlier termination of this option. This option may not be
exercised at any time on or after the Expiration Date, except as otherwise provided in Section&nbsp;3(e) below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Exercise
Procedure</U>. Subject to the conditions set forth in this Agreement, this option shall be exercised by the Optionee&#146;s delivery of a written notice of exercise in the form attached hereto and marked as <U>Exhibit 1</U> to the Treasurer of the
Corporation, specifying the number of shares to be purchased and the purchase price to be paid therefor and accompanied by payment in full in accordance with Section&nbsp;4. Such exercise shall be effective upon receipt by the Treasurer of the
Corporation of such written notice together with the required payment. The Optionee may purchase less than the number of shares covered hereby, provided that no partial exercise of this option may be for any fractional share or for fewer than ten
(10)&nbsp;whole shares. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Continuous Relationship with the Corporation</U>. Except as otherwise provided in
this Section&nbsp;3, this option may not be exercised unless the Optionee, at the time it exercises this option, is, and has been at all times since the date of grant of this option, an employee, officer or director of, or consultant or advisor to,
the Corporation or any subsidiary (an &#147;Eligible Optionee&#148;). Notwithstanding anything to the contrary in the Plan, and unless otherwise determined by the Administrator, an employee or officer of the Corporation or any subsidiary shall be
deemed to cease to be an Eligible Optionee and to have ceased &#147;employment&#148; on the date the Optionee ceases to be employed and actively performing employment duties for the Corporation or any subsidiary for any reason, but in any case
(i)&nbsp;without regard to whether the Optionee&#146;s employment with the Corporation or any subsidiary is terminated with or without cause, with or without notice, lawfully or unlawfully or with or without any adequate compensation in lieu of
notice, and (ii)&nbsp;does not include any severance period or notice period to which the Optionee might then be entitled or any period of salary continuance or deemed employment or other damages paid or payable to the Optionee in respect of the
termination of employment, and, in the case of both subsections (i)&nbsp;and (ii), whether pursuant to any applicable statute, contract, civil law, the common law or otherwise. Any such severance period or notice period shall not be considered a
period of employment for the purposes of the Optionee&#146;s rights under the Plan or this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Exercise Period Upon
Termination of Relationship with the Corporation</U>. If the Optionee ceases to be an Eligible Optionee for any reason, then, except as provided in paragraphs (e)&nbsp;and (f)&nbsp;below, the right to exercise this option shall terminate sixty
(60)&nbsp;days after such cessation (but in no event after the Expiration Date), and no amount shall be payable to the Optionee in respect thereof as compensation, damages or otherwise, including on account of severance, payment in lieu of notice or
damages for wrongful dismissal, <U>provided</U> that this option shall be exercisable only to the extent that the Optionee was entitled to exercise this option on the date of such cessation. The Corporation&#146;s obligation to deliver shares upon
the exercise of this option shall be subject to the satisfaction of all applicable federal, state, provincial and local income and employment tax withholding and source deduction requirements. Notwithstanding the foregoing, if the Optionee, prior to
the Expiration Date, materially violates the noncompetition or confidentiality provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Optionee and the Corporation or any subsidiary, the
right to exercise this option shall terminate immediately upon written notice to the Optionee from the Corporation or any subsidiary describing such violation, and no amount shall be payable to the Optionee in respect thereof as compensation,
damages or otherwise, including on account of severance, payment in lieu of notice or damages for wrongful dismissal. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Exercise
Period Upon Death or Disability</U>. If the Optionee dies or becomes disabled (within the meaning of Section&nbsp;22(e)(3) of the Code) prior to the Expiration Date while it is an Eligible Optionee, or if the Optionee dies within three
(3)&nbsp;months after the Optionee ceases to be an Eligible Optionee (other than as the result of a termination of such relationship by the Corporation or any subsidiary for &#147;cause&#148; as specified in paragraph (f)&nbsp;below), the right to
exercise this option shall terminate one (1)&nbsp;year following the date of death or disability of the Optionee (whether or not such exercise occurs before the Expiration Date), by the Optionee or by the person to whom this option is transferred by
will or the laws of descent and distribution, and no amount shall be payable to the Optionee in respect thereof as compensation, damages or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
otherwise, including on account of severance, payment in lieu of notice or damages for wrongful dismissal, provided that this option shall be exercisable only to the extent that this option was
exercisable by the Optionee on the date of his death or disability. Except as otherwise indicated by the context, the term &#147;Optionee,&#148; as used in this option, shall be deemed to include the estate of the Optionee or any person who acquires
the right to exercise this option by bequest or inheritance or otherwise by reason of the death of the Optionee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Discharge for
Cause</U>. If the Optionee, prior to the Expiration Date, is discharged by the Corporation or any subsidiary for &#147;cause&#148; (as defined below), the right to exercise this option shall terminate immediately upon such cessation of employment,
and no amount shall be payable to the Optionee in respect thereof as compensation, damages or otherwise, including on account of severance, payment in lieu of notice or damages for wrongful dismissal. &#147;Cause&#148; shall mean willful misconduct
by the Optionee or willful failure to perform his responsibilities in the best interests of the Corporation or any subsidiary (including, without limitation, breach by the Optionee of any provision of any employment, consulting, advisory,
nondisclosure, non-competition or other similar agreement between the Optionee and the Corporation or any subsidiary), as determined by the Corporation or any subsidiary, which determination shall be conclusive. The Optionee shall be considered to
have been discharged for &#147;cause&#148; if the Corporation or any subsidiary determines, within thirty (30)&nbsp;days after the Optionee&#146;s resignation, that discharge for cause was warranted. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Payment of Purchase Price</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Method of Payment</U>. Payment of the purchase price for shares purchased upon exercise of this option shall be made: (i)&nbsp;by
delivery to the Corporation of cash or a check to the order of the Corporation in an amount equal to the purchase price of such shares, (ii)&nbsp;by any other means which the Administrator (as that term is defined in the Plan) determines are
consistent with the purpose of the Plan and with applicable laws and regulations (including, without limitation, the provisions of Rule 16b-3 under the Securities Exchange Act of 1934 and Regulation T promulgated by the Federal Reserve Board), or
(iii)&nbsp;by any combination of such methods of payment. For purposes of this Agreement, Section&nbsp;6(b)(ii) of the Plan shall be of no force or effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Valuation of Non-Cash Consideration Tendered in Payment of Purchase Price</U>. For the purposes hereof, the fair market value of any
non-cash consideration which may be delivered to the Corporation in exercise of this option shall be determined in good faith by the Administrator. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Delivery of Shares; Compliance With Securities Laws, Etc.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. The Corporation shall, upon payment of the option price for the number of shares purchased and paid for, make prompt
delivery of such shares to the Optionee, provided that if any law or regulation requires the Corporation to take any action with respect to such shares before the issuance thereof, then the date of delivery of such shares shall be extended for the
period necessary to complete such action. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Listing, Qualification, Etc</U>. This option shall be subject to the requirement that
if, at any time, counsel to the Corporation shall determine that the listing, registration or qualification of the shares subject hereto upon any securities exchange or under any state, foreign or federal law, or the consent or approval of any
governmental or regulatory body, or that the disclosure of non-public information or the satisfaction of any other condition is necessary as a condition of, or in connection with, the issuance or purchase of shares hereunder, this option may not be
exercised, in whole or in part, unless such listing, registration, qualification, consent or approval, disclosure or satisfaction of such other condition shall have been effected or obtained on terms acceptable to the Administrator. Nothing herein
shall be deemed to require the Corporation to apply for, effect or obtain such listing, registration, qualification or disclosure, or to satisfy such other condition. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Nontransferability of Option</U>. Except as provided in paragraph (e)&nbsp;of Section&nbsp;3, this option is personal and no rights
granted hereunder may be transferred, assigned, pledged or hypothecated in any way (whether by operation of law or otherwise) nor shall any such rights be subject to execution, attachment or similar process, except that this option may be
transferred: (i)&nbsp;by will or the laws of descent and distribution or (ii)&nbsp;pursuant to a qualified domestic relations order as defined in Section&nbsp;414(p) of the Code. Upon any attempt to transfer, assign, pledge, hypothecate or otherwise
dispose of this option or of such rights contrary to the provisions hereof, or upon the levy of any attachment or similar process upon this option or such rights, this option and such rights shall, at the election of the Corporation, become null and
void. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>No Special Employment or Similar Rights</U>. Nothing contained in the Plan or this option shall be construed or deemed by any
person under any circumstances to create or to bind the Corporation or any subsidiary to enter into or continue any relationship (whether employment, independent contractor, agency, or other) of the Optionee with the Corporation or any subsidiary
for the period within which this option may be exercised. Nothing in this Agreement or the Plan may be construed to provide the Optionee with any rights whatsoever to compensation or damages in lieu of notice or continued participation in, or
entitlements under, this Agreement or the Plan as a consequence of the termination of Optionee&#146;s employment with the Corporation or any subsidiary (regardless of the reason for the termination and the party causing the termination, including a
termination without cause). The amount of any compensation received or deemed to be received by an Optionee as a result of his or her participation in the Plan will not constitute compensation, earnings or wages with respect to which any other
employee benefits of that Optionee are determined, including, without limitation, benefits under any bonus, pension, profit-sharing, insurance, termination, severance or salary continuation plan or any other employee benefit plans, nor under any
applicable employment standards or other legislation, except as otherwise specifically determined by the Administrator. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Rights as a
Shareholder</U>. The Optionee shall have no rights as a shareholder with respect to any shares which may be purchased by exercise of this option (including, without limitation, any rights to receive dividends or non-cash distributions with respect
to such shares) unless and until a certificate representing such shares is duly issued and delivered to the Optionee. No adjustment shall be made for dividends or other rights for which the record date is prior to the date such stock certificate is
issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Adjustment Provisions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. In the event of a merger, consolidation, sale of all or substantially all of the securities or assets, or reorganization,
recapitalization, etc. the Optionee shall, with respect to this option or any unexercised portion hereof, be entitled to an appropriate adjustment of the shares to be issued pursuant to this option. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Administrator Authority to Make Adjustments</U>. Any adjustments under this Section&nbsp;9 will be made by the Administrator, whose
determination as to what adjustments, if any, will be made and the extent thereof will be final, binding and conclusive. No fractional shares will be issued pursuant to this option on account of any such adjustments. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Mergers, Consolidation, Distributions, Liquidations Etc</U>. In the event of a merger, consolidation, distribution, liquidation or other
similar event, the Optionee shall, with respect to this option or any unexercised portion hereof, be entitled to the rights and benefits, and be subject to the limitations, set forth in Article 9 of the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Withholding Taxes</U>. The Corporation&#146;s obligation to deliver shares upon the exercise of this option shall be subject to the
Optionee&#146;s satisfaction of all applicable federal, state, provincial and local income and employment tax withholding and source deduction requirements. For purposes of this Agreement, Sections 20(i) and 20(ii) of the Plan shall be of no force
or effect and shall be deleted in their entirety and replaced with the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;by disposing of a portion of the option to the
Corporation in respect of a number of shares of Common Stock otherwise issuable pursuant to the exercise of the option having an aggregate fair market value equal to such withholding obligation. The fair market value of such shares shall be
determined by the Corporation as of the date that the amount of tax to be withheld is to be determined.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Investment
Representations; Legends</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Representations</U>. The Optionee represents, warrants and covenants that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Any shares purchased upon exercise of this option shall be acquired for the Optionee&#146;s account for investment only,
and not with a view to, or for sale in connection with, any distribution of the shares in violation of the Securities Act of 1933 (the &#147;Securities Act&#148;), or any rule or regulation under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Optionee has had such opportunity as it has deemed adequate to obtain from representatives of the Corporation such
information as is necessary to permit the Optionee to evaluate the merits and risks of his investment in the Corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) The Optionee is able to bear the economic risk of holding such shares acquired pursuant to the exercise of this option
for an indefinite period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) The Optionee understands that: (A)&nbsp;the shares acquired pursuant to
the exercise of this option will not be registered under the Securities Act and are &#147;restricted securities&#148; within the meaning of Rule 144 under the Securities Act; (B)&nbsp;such shares cannot be sold, transferred or otherwise disposed of
unless they are subsequently registered under the Securities Act or an exemption from registration is then available; (C)&nbsp;in any event, an exemption from registration under Rule 144 or otherwise under the Securities Act may not be available for
at least two years and even then will not be available unless a public market then exists for the Common Stock, adequate information concerning the Corporation is then available to the public, and other terms and conditions of Rule 144 are complied
with; and (D)&nbsp;there is now no registration statement on file with the Securities and Exchange Commission with respect to any stock of the Corporation and the Corporation has no obligation or current intention to register any shares acquired
pursuant to the exercise of this option under the Securities Act. The Optionee further understands that the grant of this option and the issuance of the shares acquired pursuant to the exercise of this option have not been qualified by a prospectus
in any province or territory of Canada, this option and the shares are being issued in reliance on an exemption from the prospectus requirements in Canada and the shares may not be sold or otherwise transferred in the absence of a prospectus or an
exemption from the prospectus requirements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) The Optionee agrees that, if the Corporation offers any of his Common
Stock for sale pursuant to a registration statement under the Securities Act, the Optionee will not, without the prior written consent of the Corporation, directly or indirectly offer, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant for the sale of or otherwise dispose of or transfer any shares purchased upon exercise of this option, for such period not to exceed (a)&nbsp;one hundred eighty
(180)&nbsp;days following the effective date of the relevant registration statement filed under the Securities Act in connection with the Company&#146;s initial public offering of Registrable Securities, or (b)&nbsp;ninety (90)&nbsp;days following
the effective date of the relevant registration statement in connection with any other public offering of Registrable Securities; <U>provided</U>, <U>however</U>, that all officers and directors of the Company and all One (1%)&nbsp;percent or
greater stockholders of the Company enter into similar agreements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By making payment upon exercise of this option, the Optionee shall be
deemed to have reaffirmed, as of the date of such payment, the representations made in this Section&nbsp;12. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Legends on Stock
Certificate</U>. All stock certificates representing shares of Common Stock issued to the Optionee upon exercise of this option shall have affixed thereto legends substantially in the following forms, in addition to any other legends required by
applicable state Law: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;The shares of stock represented by this certificate have not been registered under the Securities Act of 1933
and may not be transferred, sold or otherwise disposed of in the absence of an effective registration statement with respect to the shares evidenced by this certificate, filed and made effective under the Securities Act of 1933, or an opinion of
counsel satisfactory to the Corporation to the effect that registration under such Act is not required.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;The shares of stock represented by this certificate are subject to certain
restrictions on transfer contained in an Option Agreement, a copy of which will be furnished upon request by the, issuer.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.
<U>Miscellaneous</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Except as provided herein, this option may not be amended or otherwise modified unless evidenced in writing and
signed by the Corporation and the Optionee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Optionee agrees to provide the Corporation with all information (including personal
information) required by the Corporation to administer the Plan. The Optionee consents to the Corporation and any of its affiliates sharing and exchanging the Optionee&#146;s information held in order to administer and operate the Plan (including
personal details, data relating to the Optionee&#146;s participation, salary, taxation and employment and sensitive personal data, including data relating to physical or mental health, criminal conviction or the alleged commission of offences) (the
&#147;Information&#148;) and providing the Administrator, the Corporation&#146;s and/or any of its affiliates&#146; agents, officers, employees and/or third parties with the Information for the administration and operation of the Plan and the
Optionee accepts that this may involve the Information being sent to a country outside of Canada which may not have the same level of data protection laws as Canada, and law enforcement agencies in that country may access the Information in
accordance with local laws. The Optionee acknowledges that the collection, processing and transfer of the Information is important to the Plan administration and that failure to consent to same may prohibit participation in the Plan or the
Optionee&#146;s receipt of this option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) All notices under this option shall be mailed or delivered by hand or overnight courier to the
parties at their respective addresses set forth beneath their names below or at such other address as may be designated in writing by either of the parties to one another. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) This option shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The parties to this Agreement acknowledge that it is their express wish that this Agreement, as well as all documents, notices, and legal
proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English only. Les parties reconnaissent avoir exig&eacute; que cette convention (&laquo;Agreement&raquo;) ainsi que tous les
documents, avis et proc&eacute;dures judiciaires, &eacute;x&eacute;cut&eacute;s, donn&eacute;s ou intent&eacute;s en vertu de, ou li&eacute;s directement ou indirectement &agrave; la pr&eacute;sente soient r&eacute;dig&eacute;s en anglais
uniquement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Page 6 Ends Here. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DATED: Effective as of the Date of Grant. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">AMYLYX PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Justin Klee, President</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Hereunto Duly Authorized</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OPTIONEE&#146;S ACCEPTANCE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby accepts the foregoing option and agrees to the terms and conditions thereof. The undersigned hereby acknowledges
receipt of a copy of the Corporation&#146;s 2015 Stock Option and Restricted Stock Plan. The undersigned specifically acknowledges and agrees that the provisions of this Agreement and the Plan may take away or limit the undersigned&#146;s common law
rights to this option and any common law rights to damages as compensation for the loss, or continued vesting, of such options during any reasonable notice period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Participation in the Plan by the undersigned is voluntary, and the undersigned acknowledges and agrees that he or she has not been induced to enter into this
Agreement or acquire any option by expectation of employment or appointment or continued employment or appointment. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">OPTIONEE</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>Address</U>:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT 1 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Notice of Option Exercise </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">TO:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Treasurer of AMYLYX PHARMACEUTICALS, INC.: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned, in accordance with the provisions of a Stock Option Agreement (&#147;Agreement&#148;) between AMYLYX PHARMACEUTICALS, INC.
(&#147;Corporation&#148;) and the undersigned, hereby gives notice pursuant to Section&nbsp;3(b) of the Agreement of the undersigned&#146;s exercise of the option pursuant to the Agreement to purchase
(#)<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> common shares of the Corporation for the aggregate payment for said shares of $<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(&#147;Price&#148;) payable as follows (please check one): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">by the tender of a check for immediately available funds for the entire Price (enclose check made payable to &#147;AMYLYX PHARMACEUTICALS, INC.&#148;);</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">by alternative means approved by the Corporation&#146;s Administrator as follows:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned represents and warrants to the Corporation that all of the representations and
warranties set forth in Section&nbsp;12(a) of the Agreement are true and correct as of the date of this Notice. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMYLYX PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>NON-STATUTORY STOCK OPTION AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Grant of Option</U>. Effective <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(&#147;Date of Grant&#148;), AMYLYX PHARMACEUTICALS, INC., a Delaware corporation (the &#147;Corporation&#148;), hereby grants to <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> (the
&#147;Optionee&#148;) an option, pursuant to the Corporation&#146;s 2015 Stock Option and Restricted Stock Plan (the &#147;Plan&#148;), to purchase an aggregate of
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> shares of the Corporation&#146;s $0.0001 par value common stock (&#147;Common Stock&#148;) at a price of
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> per share, purchasable as set forth in and subject to the terms and conditions of this option and the Plan. Except where the context otherwise
requires, the term &#147;Corporation&#148; shall include all present and future subsidiaries of the Corporation as defined in Sections 424(e) and 424(f) of the Internal Revenue Code of 1986, as amended or replaced from time to time (the
&#147;Code&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Non-Statutory Stock Option</U>. This option is not intended to qualify as an incentive stock option within the
meaning of Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Exercise of option and Provisions for Termination</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Vesting Schedule</U>. Except as otherwise provided in this Agreement, this option may be exercised prior to the tenth
(10th)&nbsp;anniversary of the Date of Grant (hereinafter the &#147;Expiration Date&#148;). The right to exercise this option shall vest as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> of the shares subject to this
option shall vest and become exercisable on <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) on the <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> day of each of the thirty-six (36)&nbsp;months commencing on <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> and continuing through to and
including <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, an additional <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> shares subject
to this option shall vest and become exercisable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The right of exercise shall be cumulative so that if the option is not exercised to the
maximum extent permissible during any exercise period, it shall be exercisable, in whole or in part, with respect to all shares not so purchased at any time prior to the Expiration Date or the earlier termination of this option. This option may not
be exercised at any time on or after the Expiration Date, except as otherwise provided in Section&nbsp;3(e) below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Exercise
Procedure</U>. Subject to the conditions set forth in this Agreement, this option shall be exercised by the Optionee&#146;s delivery of a written notice of exercise in the form attached hereto and marked as <U>Exhibit 1</U> to the Treasurer of the
Corporation, specifying the number of shares to be purchased and the purchase price to be paid therefor and accompanied by payment in full in accordance with Section&nbsp;4. Such exercise shall be effective upon receipt by the Treasurer of the
Corporation of such written notice together with the required payment. The Optionee may purchase less than the number of shares covered hereby, provided that no partial exercise of this option may be for any fractional share or for fewer than ten
(10)&nbsp;whole shares. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Continuous Relationship with the Corporation</U>. Except as otherwise provided in
this Section&nbsp;3, this option may not be exercised unless the Optionee, at the time it exercises this option, is, and has been at all times since the date of grant of this option, an employee, officer or director of, or consultant or advisor to,
the Corporation or any subsidiary (an &#147;Eligible Optionee&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Exercise Period Upon Termination of Relationship with the
Corporation</U>. If the Optionee ceases to be an Eligible Optionee for any reason, then, except as provided in paragraphs (e)&nbsp;and (f)&nbsp;below, the right to exercise this option shall terminate sixty (60)&nbsp;days after such cessation (but
in no event after the Expiration Date), <U>provided</U> that this option shall be exercisable only to the extent that the Optionee was entitled to exercise this option on the date of such cessation. The Corporation&#146;s obligation to deliver
shares upon the exercise of this option shall be subject to the satisfaction of all applicable federal, state and local income and employment tax withholding requirements. Notwithstanding the foregoing, if the Optionee, prior to the Expiration Date,
materially violates the noncompetition or confidentiality provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Optionee and the Corporation or any subsidiary, the right to exercise this
option shall terminate immediately upon written notice to the Optionee from the Corporation or any subsidiary describing such violation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Exercise Period Upon Death or Disability</U>. If the Optionee dies or becomes disabled (within the meaning of Section&nbsp;22(e)(3) of
the Code) prior to the Expiration Date while it is an Eligible Optionee, or if the Optionee dies within three (3)&nbsp;months after the Optionee ceases to be an Eligible Optionee (other than as the result of a termination of such relationship by the
Corporation or any subsidiary for &#147;cause&#148; as specified in paragraph (f)&nbsp;below), this option shall be exercisable, within the period of one (1)&nbsp;year following the date of death or disability of the Optionee (whether or not such
exercise occurs before the Expiration Date), by the Optionee or by the person to whom this option is transferred by will or the laws of descent and distribution, provided that this option shall be exercisable only to the extent that this option was
exercisable by the Optionee on the date of his death or disability. Except as otherwise indicated by the context, the term &#147;Optionee,&#148; as used in this option, shall be deemed to include the estate of the Optionee or any person who acquires
the right to exercise this option by bequest or inheritance or otherwise by reason of the death of the Optionee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Discharge for
Cause</U>. If the Optionee, prior to the Expiration Date, is discharged by the Corporation or any subsidiary for &#147;cause&#148; (as defined below), the right to exercise this option shall terminate immediately upon such cessation of employment.
&#147;Cause&#148; shall mean willful misconduct by the Optionee or willful failure to perform his responsibilities in the best interests of the Corporation or any subsidiary (including, without limitation, breach by the Optionee of any provision of
any employment, consulting, advisory, nondisclosure, non-competition or other similar agreement between the Optionee and the Corporation or any subsidiary), as determined by the Corporation or any subsidiary, which determination shall be conclusive.
The Optionee shall be considered to have been discharged for &#147;cause&#148; if the Corporation or any subsidiary determines, within thirty (30)&nbsp;days after the Optionee&#146;s resignation, that discharge for cause was warranted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Payment of Purchase Price</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Method of Payment</U>. Payment of the purchase price for shares purchased upon exercise of this option shall be made: (i)&nbsp;by
delivery to the Corporation of cash or a check to the order of the Corporation in an amount equal to the purchase price of such shares, (ii)&nbsp;subject to the consent of the Corporation, by delivery to the Corporation of shares of Common Stock of
the Corporation then owned by the Optionee having a fair market value equal in amount to the purchase price of such shares, (iii)&nbsp;by any other means which the Administrator (as that term is defined in the Plan) determines are consistent with
the purpose of the Plan and with applicable laws and regulations (including, without limitation, the provisions of Rule 16b-3 under the Securities Exchange Act of 1934 and Regulation T promulgated by the Federal Reserve Board), or (iv)&nbsp;by any
combination of such methods of payment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Valuation of Shares or Other Non-Cash Consideration Tendered in Payment of Purchase
Price</U>. For the purposes hereof, the fair market value of any share of the Corporation&#146;s Common Stock or other non-cash consideration which may be delivered to the Corporation in exercise of this option shall be determined in good faith by
the Administrator. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Delivery of Shares Tendered in Payment of Purchase Price</U>. If the Optionee exercises this option by delivery
of shares of Common Stock of the Corporation, the certificate or certificates representing the shares of Common Stock of the Corporation to be delivered shall be duly executed in blank by the Optionee or shall be accompanied by a stock power duly
executed in blank suitable for purposes of transferring such shares to the Corporation. Fractional shares of Common Stock of the Corporation will not be accepted in payment of the purchase price of shares acquired upon exercise of this option. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Restrictions on Use of Option Stock</U>. Notwithstanding the foregoing, no shares of Common Stock of the Corporation may be tendered in
payment of the purchase price of shares purchased upon exercise of this option if the shares to be so tendered were acquired within twelve (12)&nbsp;months before the date of such tender through the exercise of an option granted under the Plan or
any other stock option or restricted stock plan of the Corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Delivery of Shares; Compliance With Securities Laws, Etc.</U>
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. The Corporation shall, upon payment of the option price for the number of shares purchased and paid for, make prompt
delivery of such shares to the Optionee, provided that if any law or regulation requires the Corporation to take any action with respect to such shares before the issuance thereof, then the date of delivery of such shares shall be extended for the
period necessary to complete such action. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Listing, Qualification, Etc</U>. This option shall be subject to the requirement that if,
at any time, counsel to the Corporation shall determine that the listing, registration or qualification of the shares subject hereto upon any securities exchange or under any state or federal law, or the consent or approval of any governmental or
regulatory body, or that the disclosure of non-public information or the satisfaction of any other condition is necessary as a condition of, or in connection with, the issuance or purchase of shares hereunder, this option may not be exercised, in
whole or in part, unless such listing, registration, qualification, consent or approval, disclosure or satisfaction of such other condition shall have been effected or obtained on terms acceptable to the Administrator. Nothing herein shall be deemed
to require the Corporation to apply for, effect or obtain such listing, registration, qualification or disclosure, or to satisfy such other condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Nontransferability of Option</U>. Except as provided in paragraph (e)&nbsp;of
Section&nbsp;3, this option is personal and no rights granted hereunder may be transferred, assigned, pledged or hypothecated in any way (whether by operation of law or otherwise) nor shall any such rights be subject to execution, attachment or
similar process, except that this option may be transferred: (i)&nbsp;by will or the laws of descent and distribution or (ii)&nbsp;pursuant to a qualified domestic relations order as defined in Section&nbsp;414(p) of the Code. Upon any attempt to
transfer, assign, pledge, hypothecate or otherwise dispose of this option or of such rights contrary to the provisions hereof, or upon the levy of any attachment or similar process upon this option or such rights, this option and such rights shall,
at the election of the Corporation, become null and void. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>No Special Employment or Similar Rights</U>. Nothing contained in the Plan
or this option shall be construed or deemed by any person under any circumstances to create or to bind the Corporation or any subsidiary to enter into or continue any relationship (whether employment, independent contractor, agency, or other) of the
Optionee with the Corporation or any subsidiary for the period within which this option may be exercised. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Rights as a
Shareholder</U>. The Optionee shall have no rights as a shareholder with respect to any shares which may be purchased by exercise of this option (including, without limitation, any rights to receive dividends or non-cash distributions with respect
to such shares) unless and until a certificate representing such shares is duly issued and delivered to the Optionee. No adjustment shall be made for dividends or other rights for which the record date is prior to the date such stock certificate is
issued. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Adjustment Provisions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. In the event of a merger, consolidation, sale of all or substantially all of the securities or assets, or reorganization,
recapitalization, etc. the Optionee shall, with respect to this option or any unexercised portion hereof, be entitled to an appropriate adjustment of the shares to be issued pursuant to this option. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Administrator Authority to Make Adjustments</U>. Any adjustments under this Section&nbsp;9 will be made by the Administrator, whose
determination as to what adjustments, if any, will be made and the extent thereof will be final, binding and conclusive. No fractional shares will be issued pursuant to this option on account of any such adjustments. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Mergers, Consolidation, Distributions, Liquidations Etc</U>. In the event of a merger, consolidation, distribution, liquidation or other
similar event, the Optionee shall, with respect to this option or any unexercised portion hereof, be entitled to the rights and benefits, and be subject to the limitations, set forth in Article 9 of the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Withholding Taxes</U>. The Corporation&#146;s obligation to deliver shares upon the
exercise of this option shall be subject to the Optionee&#146;s satisfaction of all applicable federal, state and local income and employment tax withholding requirements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Investment Representations; Legends</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Representations</U>. The Optionee represents, warrants and covenants that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Any shares purchased upon exercise of this option shall be acquired for the Optionee&#146;s account for investment only,
and not with a view to, or for sale in connection with, any distribution of the shares in violation of the Securities Act of 1933 (the &#147;Securities Act&#148;), or any rule or regulation under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Optionee has had such opportunity as it has deemed adequate to obtain from representatives of the Corporation such
information as is necessary to permit the Optionee to evaluate the merits and risks of his investment in the Corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) The Optionee is able to bear the economic risk of holding such shares acquired pursuant to the exercise of this option
for an indefinite period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) The Optionee understands that: (A)&nbsp;the shares acquired pursuant to the exercise of
this option will not be registered under the Securities Act and are &#147;restricted securities&#148; within the meaning of Rule 144 under the Securities Act; (B)&nbsp;such shares cannot be sold, transferred or otherwise disposed of unless they are
subsequently registered under the Securities Act or an exemption from registration is then available; (C)&nbsp;in any event, an exemption from registration under Rule 144 or otherwise under the Securities Act may not be available for at least two
years and even then will not be available unless a public market then exists for the Common Stock, adequate information concerning the Corporation is then available to the public, and other terms and conditions of Rule 144 are complied with; and
(D)&nbsp;there is now no registration statement on file with the Securities and Exchange Commission with respect to any stock of the Corporation and the Corporation has no obligation or current intention to register any shares acquired pursuant to
the exercise of this option under the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) The Optionee agrees that, if the Corporation offers any of his
Common Stock for sale pursuant to a registration statement under the Securities Act, the Optionee will not, without the prior written consent of the Corporation, directly or indirectly offer, sell, contract to sell, sell any option or contract to
purchase, purchase any option or contract to sell, grant any option, right or warrant for the sale of or otherwise dispose of or transfer any shares purchased upon exercise of this option, for such period not to exceed (a)&nbsp;one hundred eighty
(180)&nbsp;days following the effective date of the relevant registration statement filed under the Securities Act in connection with the Company&#146;s initial public offering of Registrable Securities, or (b)&nbsp;ninety (90)&nbsp;days following
the effective date of the relevant registration statement in connection with any other public offering of Registrable Securities; <U>provided</U>, <U>however</U>, that all officers and directors of the Company and all One (1%)&nbsp;percent or
greater stockholders of the Company enter into similar agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By making payment upon exercise of this option, the Optionee shall be deemed to have
reaffirmed, as of the date of such payment, the representations made in this Section&nbsp;12. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Legends on Stock Certificate</U>. All
stock certificates representing shares of Common Stock issued to the Optionee upon exercise of this option shall have affixed thereto legends substantially in the following forms, in addition to any other legends required by applicable state Law:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;The shares of stock represented by this certificate have not been registered under the Securities Act of 1933 and may not be
transferred, sold or otherwise disposed of in the absence of an effective registration statement with respect to the shares evidenced by this certificate, filed and made effective under the Securities Act of 1933, or an opinion of counsel
satisfactory to the Corporation to the effect that registration under such Act is not required.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;The shares of stock
represented by this certificate are subject to certain restrictions on transfer contained in an Option Agreement, a copy of which will be furnished upon request by the, issuer.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Miscellaneous</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
Except as provided herein, this option may not be amended or otherwise modified unless evidenced in writing and signed by the Corporation and the Optionee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) All notices under this option shall be mailed or delivered by hand or overnight courier to the parties at their respective addresses set
forth beneath their names below or at such other address as may be designated in writing by either of the parties to one another. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) This
option shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Page 6 Ends Here. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DATED: Effective as of the Date of Grant. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">AMYLYX PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Justin Klee, President</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Hereunto Duly Authorized</P></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OPTIONEE&#146;S ACCEPTANCE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby accepts the foregoing option and agrees to the terms and conditions thereof. The undersigned hereby acknowledges
receipt of a copy of the Corporation&#146;s 2015 Stock Option and Restricted Stock Plan. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">OPTIONEE</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>Address</U>:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT 1 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Notice of Option Exercise </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">TO:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Treasurer of AMYLYX PHARMACEUTICALS, INC.: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned, in accordance with the provisions of a Stock Option Agreement (&#147;Agreement&#148;) between AMYLYX PHARMACEUTICALS, INC.
(&#147;Corporation&#148;) and the undersigned, hereby gives notice pursuant to Section&nbsp;3(b) of the Agreement of the undersigned&#146;s exercise of the option pursuant to the Agreement to purchase
(#)<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> common shares of the Corporation for the aggregate payment for said shares of $<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(&#147;Price&#148;) payable as follows (please check one): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">by the tender of a check for immediately available funds for the entire Price (enclose check made payable to &#147;AMYLYX PHARMACEUTICALS, INC.&#148;);</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">subject to the consent of the Corporation, by tendering (#)____________ shares of the Corporation&#146;s (type)_____________ stock;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">subject to the consent of the Corporation, by tendering $____________ in cash (enclose check made payable to &#147;AMYLYX PHARMACEUTICALS, INC.&#148;) and (#)____________ shares of the Corporation&#146;s (type)_____________ stock;
or</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">by alternative means approved by the Corporation&#146;s Administrator as follows:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned represents and warrants to the Corporation that all of the representations and
warranties set forth in Section&nbsp;12(a) of the Agreement are true and correct as of the date of this Notice. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>8
<FILENAME>d155225dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMYLYX PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2022 STOCK OPTION AND INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 1. <U>GENERAL PURPOSE OF THE PLAN; DEFINITIONS</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The name of the plan is the Amylyx Pharmaceuticals, Inc. 2022 Stock Option and Incentive Plan (as amended from time to time, the
&#147;Plan&#148;). The purpose of the Plan is to encourage and enable the officers, employees, <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors and Consultants of Amylyx Pharmaceuticals, Inc. (the &#147;Company&#148;) and its
Affiliates upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its business to acquire a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the
Company&#146;s welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company&#146;s behalf and strengthening their desire to remain with the Company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following terms shall be defined as set forth below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Act&#148;</I> means the Securities Act of 1933, as amended, and the rules and regulations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Administrator&#148;</I> means either the Board or the compensation committee of the Board or a similar committee performing the
functions of the compensation committee and which is comprised of not less than two <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors who are independent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Affiliate</I>&#148; means, at the time of determination, any &#147;parent&#148; or &#147;subsidiary&#148; of the Company as such
terms are defined in Rule 405 of the Act. The Board will have the authority to determine the time or times at which &#147;parent&#148; or &#147;subsidiary&#148; status is determined within the foregoing definition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Award&#148;</I> or <I>&#147;Awards,&#148;</I> except where referring to a particular category of grant under the Plan, shall include
Incentive Stock Options, <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Options, Stock Appreciation Rights, Restricted Stock Units, Restricted Stock Awards, Unrestricted Stock Awards, Cash-Based Awards, and Dividend Equivalent Rights.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Award Certificate&#148;</I> means a written or electronic document setting forth the terms and provisions applicable to an Award
granted under the Plan. Each Award Certificate is subject to the terms and conditions of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Board&#148;</I> means the
Board of Directors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Cash-Based Award&#148;</I> means an Award entitling the recipient to receive a
cash-denominated payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Code&#148;</I> means the Internal Revenue Code of 1986, as amended, and any successor Code, and
related rules, regulations and interpretations. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Consultant&#148;</I> means a consultant or adviser who provides <I>bona fide</I>
services to the Company or an Affiliate as an independent contractor and who qualifies as a consultant or advisor under Instruction A.1.(a)(1) of Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Dividend Equivalent Right&#148;</I> means an Award entitling the grantee to receive credits based on ordinary cash dividends that
would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other award to which it relates) if such shares had been issued to and held by the grantee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Effective Date&#148;</I> means the date on which the Plan becomes effective as set forth in Section&nbsp;19. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Exchange Act&#148;</I> means the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Fair Market Value&#148;</I> of the Stock on any given date means the fair market value of the Stock determined in good faith by the
Administrator; provided, however, that if the Stock is listed on the National Association of Securities Dealers Automated Quotation System (&#147;NASDAQ&#148;), NASDAQ Global Market, The New York Stock Exchange or another national securities
exchange or traded on any established market, the determination shall be made by reference to market quotations. If there are no market quotations for such date, the determination shall be made by reference to the last date preceding such date for
which there are market quotations; provided further, however, that if the date for which Fair Market Value is determined is the Registration Date, the Fair Market Value shall be the &#147;Price to the Public&#148; (or equivalent) set forth on the
cover page for the final prospectus relating to the Company&#146;s initial public offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Incentive Stock Option&#148;</I>
means any Stock Option designated and qualified as an &#147;incentive stock option&#148; as defined in Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT
STYLE="white-space:nowrap">&#147;Non-Employee</FONT> Director&#148;</I> means a member of the Board who is not also an employee of the Company or any Subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">&#147;Non-Qualified</FONT> Stock Option&#148;</I> means any Stock Option that is not an Incentive Stock
Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Option&#148;</I> or <I>&#147;Stock Option&#148;</I> means any option to purchase shares of Stock granted pursuant to
Section&nbsp;5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Registration Date&#148; </I>means the date upon which the registration statement on Form <FONT
STYLE="white-space:nowrap">S-1</FONT> that is filed by the Company with respect to its initial public offering is declared effective by the Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Restricted Shares&#148;</I> means the shares of Stock underlying a Restricted Stock Award that remain subject to a risk of forfeiture
or the Company&#146;s right of repurchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Restricted Stock Award&#148;</I> means an Award of Restricted Shares subject to such
restrictions and conditions as the Administrator may determine at the time of grant. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Restricted Stock Units&#148;</I> means an Award of stock units subject to such
restrictions and conditions as the Administrator may determine at the time of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Sale Event&#148;</I> means (i)&nbsp;the
sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, (ii)&nbsp;a merger, reorganization or consolidation pursuant to which the holders of the Company&#146;s outstanding voting power
and outstanding stock immediately prior to such transaction do not own a majority of the outstanding voting power and outstanding stock or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable)
immediately upon completion of such transaction, (iii)&nbsp;the sale of all of the Stock of the Company to an unrelated person, entity or group thereof acting in concert, or (iv)&nbsp;any other transaction in which the owners of the Company&#146;s
outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon completion of the transaction other than as a result of the
acquisition of securities directly from the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Sale Price</I>&#148; means the value as determined by the Administrator of
the consideration payable, or otherwise to be received by stockholders, per share of Stock pursuant to a Sale Event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Section</I><I></I><I>&nbsp;409A&#148;</I> means Section&nbsp;409A of the Code and the regulations and other guidance promulgated
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Service Relationship&#148; </I>means any relationship as an employee, director or Consultant of the Company or any
Affiliate (e.g., a Service Relationship shall be deemed to continue without interruption in the event an individual&#146;s status changes from full-time employee to part-time employee or Consultant). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Stock&#148;</I> means the Common Stock, par value $0.0001 per share, of the Company, subject to adjustments pursuant to
Section&nbsp;3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Stock Appreciation Right&#148;</I> means an Award entitling the recipient to receive shares of Stock (or cash,
to the extent explicitly provided for in the applicable Award Certificate) having a value equal to the excess of the Fair Market Value of the Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by the
number of shares of Stock with respect to which the Stock Appreciation Right shall have been exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Subsidiary&#148;</I>
means any corporation or other entity (other than the Company) in which the Company has at least a 50&nbsp;percent interest, either directly or indirectly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Ten Percent Owner&#148;</I> means an employee who owns or is deemed to own (by reason of the attribution rules of Section&nbsp;424(d)
of the Code) more than 10&nbsp;percent of the combined voting power of all classes of stock of the Company or any parent or subsidiary corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Unrestricted Stock Award&#148;</I> means an Award of shares of Stock free of any restrictions. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">SECTION</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">2. <U>ADMINISTRATION OF PLAN; ADMINISTRATOR AUTHORITY TO SELECT GRANTEES AND DETERMINE AWARDS</U>
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Administration of Plan</U>. The Plan shall be administered by the Administrator. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Powers of Administrator</U>. The Administrator shall have the power and authority to
grant Awards consistent with the terms of the Plan, including the power and authority: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) to select the individuals to whom Awards may
from time to time be granted; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) to determine the time or times of grant, and the extent, if any, of Incentive Stock Options, <FONT
STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Restricted Stock Units, Unrestricted Stock Awards, Cash-Based Awards, and Dividend Equivalent Rights, or any combination of the
foregoing, granted to any one or more grantees; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) to determine the number of shares of Stock to be covered by any Award; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) to determine and modify from time to time the terms and conditions, including restrictions, not inconsistent with the terms of the Plan,
of any Award, which terms and conditions may differ among individual Awards and grantees, and to approve the forms of Award Certificates; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) to accelerate at any time the exercisability or vesting of all or any portion of any Award; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) subject to the provisions of Section&nbsp;5(c), to extend at any time the period in which Stock Options may be exercised; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) at any time to adopt, alter and repeal such rules, guidelines and practices for administration of the Plan and for its own acts and
proceedings as it shall deem advisable; to interpret the terms and provisions of the Plan and any Award (including related written instruments); to make all determinations it deems advisable for the administration of the Plan; to decide all disputes
arising in connection with the Plan; and to otherwise supervise the administration of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All decisions and interpretations of the
Administrator shall be binding on all persons, including the Company and Plan grantees. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Delegation of Authority to Grant
Awards</U>. Subject to applicable law, the Administrator, in its discretion, may delegate to a committee consisting of one or more officers of the Company, including the Chief Executive Officer of the Company, all or part of the Administrator&#146;s
authority and duties with respect to the granting of Awards to individuals who are (i)&nbsp;not subject to the reporting and other provisions of Section&nbsp;16 of the Exchange Act and (ii)&nbsp;not members of the delegated committee. Any such
delegation by the Administrator shall include a limitation as to the amount of Stock underlying Awards that may be granted during the period of the delegation and shall contain guidelines as to the determination of the exercise price and the vesting
criteria. The Administrator may revoke or amend the terms of a delegation at any time but such action shall not invalidate any prior actions of the Administrator&#146;s delegate or delegates that were consistent with the terms of the Plan. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Award Certificate</U>. Awards under the Plan shall be evidenced by Award Certificates
that set forth the terms, conditions and limitations for each Award which may include, without limitation, the term of an Award and the provisions applicable in the event employment or service terminates. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Indemnification</U>. Neither the Board nor the Administrator, nor any member of either or any delegate thereof, shall be liable for any
act, omission, interpretation, construction or determination made in good faith in connection with the Plan, and the members of the Board and the Administrator (and any delegate thereof) shall be entitled in all cases to indemnification and
reimbursement by the Company in respect of any claim, loss, damage or expense (including, without limitation, reasonable attorneys&#146; fees) arising or resulting therefrom to the fullest extent permitted by law and/or under the Company&#146;s
articles or bylaws or any directors&#146; and officers&#146; liability insurance coverage which may be in effect from time to time and/or any indemnification agreement between such individual and the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Foreign Award Recipients</U>. Notwithstanding any provision of the Plan to the contrary, in order to comply with the laws in other
countries in which the Company and its Subsidiaries operate or have employees or other individuals eligible for Awards, the Administrator, in its sole discretion, shall have the power and authority to: (i)&nbsp;determine which Subsidiaries shall be
covered by the Plan; (ii)&nbsp;determine which individuals outside the United States are eligible to participate in the Plan; (iii)&nbsp;modify the terms and conditions of any Award granted to individuals outside the United States to comply with
applicable foreign laws; (iv)&nbsp;establish subplans and modify exercise procedures and other terms and procedures, to the extent the Administrator determines such actions to be necessary or advisable (and such subplans and/or modifications shall
be attached to this Plan as appendices); provided, however, that no such subplans and/or modifications shall increase the share limitations contained in Section&nbsp;3(a) hereof; and (v)&nbsp;take any action, before or after<B> </B>an Award is made,
that the Administrator determines to be necessary or advisable to obtain approval or comply with any local governmental regulatory exemptions or approvals. Notwithstanding the foregoing, the Administrator may not take any actions hereunder, and no
Awards shall be granted, that would violate the Exchange Act or any other applicable United States securities law, the Code, or any other applicable United States governing statute or law. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">SECTION</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">3. <U>STOCK ISSUABLE UNDER THE PLAN; MERGERS; SUBSTITUTION</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Stock Issuable</U>. The maximum number of shares of Stock reserved and available for issuance under the Plan shall be 7,650,000 shares
(the &#147;Initial Limit&#148;), subject to adjustment as provided in this Section&nbsp;3, plus on January&nbsp;1, 2023 and each January&nbsp;1 thereafter, the number of shares of Stock reserved and available for issuance under the Plan shall be
cumulatively increased by (i)&nbsp;five percent (5%) of the number of shares of Stock issued and outstanding on the immediately preceding December&nbsp;31 or (ii)&nbsp;such lesser number of shares as determined by the Administrator (the &#147;Annual
Increase&#148;). Subject to such overall limitation, the maximum aggregate number of shares of Stock that may be issued in the form of Incentive Stock Options shall not exceed the Initial Limit, as cumulatively increased on January&nbsp;1, 2023 and
each January&nbsp;1 thereafter by the lesser of the Annual Increase for such year or 7,650,000 shares of Stock, subject in all cases to adjustment as provided in Section&nbsp;3(b). For purposes of this limitation, the shares of Stock underlying any
awards under the Plan and under the Company&#146;s 2015 Stock Option and Restricted Stock Plan, as amended, that are forfeited, canceled, held back upon exercise of an option or settlement of an award to cover the exercise price or tax withholding,
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reacquired by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise) shall be added back to the shares of Stock available for
issuance under the Plan and, to the extent permitted under Section&nbsp;422 of the Code and the regulations promulgated thereunder, the shares of Stock that may be issued as Incentive Stock Options. In the event the Company repurchases shares of
Stock on the open market, such shares shall not be added to the shares of Stock available for issuance under the Plan. Subject to such overall limitations, shares of Stock may be issued up to such maximum number pursuant to any type or types of
Award. The shares available for issuance under the Plan may be authorized but unissued shares of Stock or shares of Stock reacquired by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Changes in Stock</U>. Subject to Section&nbsp;3(c) hereof, if, as a result of any reorganization, recapitalization, reclassification,
stock dividend, extraordinary cash dividend, stock split, reverse stock split or other similar change in the Company&#146;s capital stock, the outstanding shares of Stock are increased or decreased or are exchanged for a different number or kind of
shares or other securities of the Company, or additional shares or new or different shares or other securities of the Company or other <FONT STYLE="white-space:nowrap">non-cash</FONT> assets are distributed with respect to such shares of Stock or
other securities, or, if, as a result of any merger or consolidation, sale of all or substantially all of the assets of the Company, the outstanding shares of Stock are converted into or exchanged for securities of the Company or any successor
entity (or a parent or subsidiary thereof), the Administrator shall make an appropriate or proportionate adjustment in (i)&nbsp;the maximum number of shares reserved for issuance under the Plan, including the maximum number of shares that may be
issued in the form of Incentive Stock Options, (ii)&nbsp;the number and kind of shares or other securities subject to any then outstanding Awards under the Plan, (iii)&nbsp;the repurchase price, if any, per share subject to each outstanding
Restricted Stock Award, and (iv)&nbsp;the exercise price for each share subject to any then outstanding Stock Options and Stock Appreciation Rights under the Plan, without changing the aggregate exercise price (i.e., the exercise price multiplied by
the number of shares subject to Stock Options and Stock Appreciation Rights) as to which such Stock Options and Stock Appreciation Rights remain exercisable. The Administrator shall also make equitable or proportionate adjustments in the number of
shares subject to outstanding Awards and the exercise price and the terms of outstanding Awards to take into consideration cash dividends paid other than in the ordinary course or any other extraordinary corporate event. The adjustment by the
Administrator shall be final, binding and conclusive. No fractional shares of Stock shall be issued under the Plan resulting from any such adjustment, but the Administrator in its discretion may make a cash payment in lieu of fractional shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Mergers and Other Transactions</U>. In the case of and subject to the consummation of a Sale Event, the parties thereto may cause the
assumption or continuation of Awards theretofore granted by the successor entity, or the substitution of such Awards with new Awards of the successor entity or parent thereof, with appropriate adjustment as to the number and kind of shares and, if
appropriate, the per share exercise prices, as such parties shall agree. To the extent the parties to such Sale Event do not provide for the assumption, continuation or substitution of Awards, upon the effective time of the Sale Event, the Plan and
all outstanding Awards granted hereunder shall terminate. In such case, except as may be otherwise provided in the relevant Award Certificate, all Awards with time-based vesting, conditions or restrictions shall become fully vested and exercisable
or nonforfeitable as of the effective time of the Sale Event, and all Awards with conditions and restrictions relating to the attainment of performance </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
goals may become vested and exercisable or nonforfeitable in connection with a Sale Event in the Administrator&#146;s discretion or to the extent specified in the relevant Award Certificate. In
the event of such termination, (i)&nbsp;the Company shall have the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding Options and Stock Appreciation Rights, in exchange for the cancellation
thereof, in an amount equal to the difference between (A)&nbsp;the Sale Price multiplied by the number of shares of Stock subject to outstanding Options and Stock Appreciation Rights (to the extent then exercisable at prices not in excess of the
Sale Price) and (B)&nbsp;the aggregate exercise price of all such outstanding Options and Stock Appreciation Rights (provided that, in the case of an Option or Stock Appreciation Right with an exercise price equal to or greater than the Sale Price,
such Option or Stock Appreciation Right shall be cancelled for no consideration); or (ii)&nbsp;each grantee shall be permitted, within a specified period of time prior to the consummation of the Sale Event as determined by the Administrator, to
exercise all outstanding Options and Stock Appreciation Rights (to the extent then exercisable) held by such grantee. The Company shall also have the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the
grantees holding other Awards in an amount equal to the Sale Price multiplied by the number of vested shares of Stock under such Awards. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Maximum Awards to <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</U>. Notwithstanding anything to the contrary in this
Plan, the value of all Awards awarded under this Plan and all other cash compensation paid by the Company to any <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director in any calendar year for service as a
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director shall not exceed $750,000; provided, however, that such amount shall be $1,000,000 for the calendar year in which the applicable <FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Director is initially elected or appointed to the Board. For the purpose of these limitations, the value of any Award shall be its grant date fair value, as determined in accordance with ASC 718 or successor provision but excluding the impact of
estimated forfeitures related to service-based vesting provisions. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">SECTION</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">4. <U>ELIGIBILITY</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Grantees under the Plan will be such employees, <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors and Consultants of the Company
and its Affiliates as are selected from time to time by the Administrator in its sole discretion; provided that Awards may not be granted to employees, Directors or Consultants who are providing services only to any &#147;parent&#148; of the
Company, as such term is defined in Rule 405 of the Act, unless (i)&nbsp;the stock underlying the Awards is treated as &#147;service recipient stock&#148; under Section&nbsp;409A or (ii)&nbsp;the Company, in consultation with its legal counsel, has
determined that such Awards are exempt from or otherwise comply with Section&nbsp;409A. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">SECTION</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">5. <U>STOCK OPTIONS</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Award of Stock Options</U>. The Administrator may grant Stock Options under the Plan. Any Stock Option granted under the Plan shall be
in such form as the Administrator may from time to time approve. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock Options granted under the Plan may be either Incentive Stock
Options or <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Options. Incentive Stock Options may be granted only to employees of the Company or any Subsidiary that is a &#147;subsidiary corporation&#148; within the meaning of
Section&nbsp;424(f) of the Code. To the extent that any Option does not qualify as an Incentive Stock Option, it shall be deemed a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock Options granted pursuant to this Section&nbsp;5 shall be subject to the following
terms and conditions and shall contain such additional terms and conditions, not inconsistent with the terms of the Plan, as the Administrator shall deem desirable. If the Administrator so determines, Stock Options may be granted in lieu of cash
compensation at the optionee&#146;s election, subject to such terms and conditions as the Administrator may establish. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Exercise
Price</U>. The exercise price per share for the Stock covered by a Stock Option granted pursuant to this Section&nbsp;5 shall be determined by the Administrator at the time of grant but shall not be less than 100&nbsp;percent of the Fair Market
Value on the date of grant. In the case of an Incentive Stock Option that is granted to a Ten Percent Owner, the exercise price of such Incentive Stock Option shall be not less than 110&nbsp;percent of the Fair Market Value on the grant date.
Notwithstanding the foregoing, Stock Options may be granted with an exercise price per share that is less than 100&nbsp;percent of the Fair Market Value on the date of grant (i)&nbsp;pursuant to a transaction described in, and in a manner consistent
with, Section&nbsp;424(a) of the Code, (ii)&nbsp;to individuals who are not subject to U.S. income tax on the date of grant or (iii)&nbsp;if the Stock Option is otherwise compliant with Section&nbsp;409A. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Option Term</U>. The term of each Stock Option shall be fixed by the Administrator, but no Stock Option shall be exercisable more than
ten years after the date the Stock Option is granted. In the case of an Incentive Stock Option that is granted to a Ten Percent Owner, the term of such Stock Option shall be no more than five years from the date of grant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Exercisability; Rights of a Stockholder</U>. Stock Options shall become exercisable at such time or times, whether or not in
installments, as shall be determined by the Administrator at or after the grant date. The Administrator may at any time accelerate the exercisability of all or any portion of any Stock Option. An optionee shall have the rights of a stockholder only
as to shares acquired upon the exercise of a Stock Option and not as to unexercised Stock Options. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Method of Exercise</U>. Stock
Options may be exercised in whole or in part, by giving written or electronic notice of exercise to the Company, specifying the number of shares to be purchased. Payment of the purchase price may be made by one or more of the following methods
except to the extent otherwise provided in the Award Certificate: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) In cash, by certified or bank check or other instrument acceptable
to the Administrator; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Through the delivery (or attestation to the ownership following such procedures as the Company may prescribe)
of shares of Stock that are not then subject to restrictions under any Company plan. Such surrendered shares shall be valued at Fair Market Value on the exercise date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) By the optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to
promptly deliver to the Company cash or a check payable and acceptable to the Company for the purchase price; provided that in the event the optionee chooses to pay the purchase price as so provided, the optionee and the broker shall comply with
such procedures and enter into such agreements of indemnity and other agreements as the Company shall prescribe as a condition of such payment procedure; or </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) With respect to Stock Options that are not Incentive Stock Options, by a &#147;net
exercise&#148; arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment instruments will be received subject to collection. The transfer to the optionee on the records of the Company or of the transfer agent of the shares
of Stock to be purchased pursuant to the exercise of a Stock Option will be contingent upon receipt from the optionee (or a purchaser acting in his stead in accordance with the provisions of the Stock Option) by the Company of the full purchase
price for such shares and the fulfillment of any other requirements contained in the Award Certificate or applicable provisions of laws (including the satisfaction of any withholding taxes that the Company is obligated to withhold with respect to
the optionee). In the event an optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the optionee upon the exercise of the Stock Option shall be
net of the number of attested shares. In the event that the Company establishes, for itself or using the services of a third party, an automated system for the exercise of Stock Options, such as a system using an internet website or interactive
voice response, then the paperless exercise of Stock Options may be permitted through the use of such an automated system. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Annual
Limit on Incentive Stock Options</U>. To the extent required for &#147;incentive stock option&#148; treatment under Section&nbsp;422 of the Code, the aggregate Fair Market Value (determined as of the time of grant) of the shares of Stock with
respect to which Incentive Stock Options granted under this Plan and any other plan of the Company or its parent and subsidiary corporations become exercisable for the first time by an optionee during any calendar year shall not exceed $100,000. To
the extent that any Stock Option exceeds this limit, it shall constitute a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">SECTION</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">6. <U>STOCK APPRECIATION RIGHTS</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Award of Stock Appreciation Rights</U>. The Administrator may grant Stock Appreciation Rights under the Plan. A Stock Appreciation Right
is an Award entitling the recipient to receive shares of Stock (or cash, to the extent explicitly provided for in the applicable Award Certificate) having a value equal to the excess of the Fair Market Value of a share of Stock on the date of
exercise over the exercise price of the Stock Appreciation Right multiplied by the number of shares of Stock with respect to which the Stock Appreciation Right shall have been exercised. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Exercise Price of Stock Appreciation Rights</U>. The exercise price of a Stock Appreciation Right shall not be less than
100&nbsp;percent of the Fair Market Value of the Stock on the date of grant. Notwithstanding the foregoing, Stock Appreciation Rights may be granted with an exercise price per share that is less than 100&nbsp;percent of the Fair Market Value on the
date of grant (i)&nbsp;pursuant to a transaction described in, and in a manner consistent with, Section 424(a) of the Code, (ii)&nbsp;to individuals who are not subject to U.S. income tax on the date of grant, or (iii)&nbsp;if the Stock Appreciation
Right is otherwise compliant with Section&nbsp;409A. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Grant and Exercise of Stock Appreciation Rights</U>. Stock Appreciation Rights may be
granted by the Administrator independently of any Stock Option granted pursuant to Section&nbsp;5 of the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Terms and Conditions
of Stock Appreciation Rights</U>. Stock Appreciation Rights shall be subject to such terms and conditions as shall be determined on the date of grant by the Administrator. The term of a Stock Appreciation Right may not exceed ten years. The terms
and conditions of each such Award shall be determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">SECTION</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">7. <U>RESTRICTED STOCK AWARDS</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Nature of Restricted Stock Awards</U>. The Administrator may grant Restricted Stock Awards under the Plan. A Restricted Stock Award is
any Award of Restricted Shares subject to such restrictions and conditions as the Administrator may determine at the time of grant. Conditions may be based on continuing employment (or other Service Relationship) and/or achievement of <FONT
STYLE="white-space:nowrap">pre-established</FONT> performance goals and objectives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Rights as a Stockholder</U>. Upon the grant of
the Restricted Stock Award and payment of any applicable purchase price, a grantee shall have the rights of a stockholder with respect to the voting of the Restricted Shares and receipt of dividends; provided that if the lapse of restrictions with
respect to the Restricted Stock Award is tied to the attainment of performance goals, any dividends paid by the Company during the performance period shall accrue and shall not be paid to the grantee until and to the extent the performance goals are
met with respect to the Restricted Stock Award. Unless the Administrator shall otherwise determine, (i)&nbsp;uncertificated Restricted Shares shall be accompanied by a notation on the records of the Company or the transfer agent to the effect that
they are subject to forfeiture until such Restricted Shares are vested as provided in Section&nbsp;7(d) below, and (ii)&nbsp;certificated Restricted Shares shall remain in the possession of the Company until such Restricted Shares are vested as
provided in Section&nbsp;7(d) below, and the grantee shall be required, as a condition of the grant, to deliver to the Company such instruments of transfer as the Administrator may prescribe. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Restrictions</U>. Restricted Shares may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of except as
specifically provided herein or in the Restricted Stock Award Certificate. Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section&nbsp;16 below, in writing after the Award is issued, if a
grantee&#146;s employment (or other Service Relationship) with the Company and its Subsidiaries terminates for any reason, any Restricted Shares that have not vested at the time of termination shall automatically and without any requirement of
notice to such grantee from or other action by or on behalf of, the Company be deemed to have been reacquired by the Company at their original purchase price (if any) from such grantee or such grantee&#146;s legal representative simultaneously with
such termination of employment (or other Service Relationship), and thereafter shall cease to represent any ownership of the Company by the grantee or rights of the grantee as a stockholder. Following such deemed reacquisition of Restricted Shares
that are represented by physical certificates, a grantee shall surrender such certificates to the Company upon request without consideration. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Vesting of Restricted Shares</U>. The Administrator at the time of grant shall
specify the date or dates and/or the attainment of <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals, objectives and other conditions on which the <FONT STYLE="white-space:nowrap">non-transferability</FONT> of the Restricted
Shares and the Company&#146;s right of repurchase or forfeiture shall lapse. Subsequent to such date or dates and/or the attainment of such <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals, objectives and other conditions,
the shares on which all restrictions have lapsed shall no longer be Restricted Shares and shall be deemed &#147;vested.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">SECTION</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">8. <U>RESTRICTED STOCK UNITS</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Nature of Restricted Stock Units</U>. The Administrator may grant Restricted Stock Units under the Plan. A Restricted Stock Unit is an
Award of stock units that may be settled in shares of Stock (or cash, to the extent explicitly provided for in the Award Certificate) upon the satisfaction of such restrictions and conditions at the time of grant. Conditions may be based on
continuing employment (or other Service Relationship) and/or achievement of <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals and objectives. The terms and conditions of each such Award shall be determined by the
Administrator, and such terms and conditions may differ among individual Awards and grantees. Except in the case of Restricted Stock Units with a deferred settlement date that complies with Section&nbsp;409A, at the end of the vesting period, the
Restricted Stock Units, to the extent vested, shall be settled in the form of shares of Stock (or cash, to the extent explicitly provided for in the Award Certificate). Restricted Stock Units with deferred settlement dates are subject to
Section&nbsp;409A and shall contain such additional terms and conditions as the Administrator shall determine in its sole discretion in order to comply with the requirements of Section&nbsp;409A. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Election to Receive Restricted Stock Units in Lieu of Compensation</U>. The Administrator may, in its sole discretion, permit a grantee
to elect to receive a portion of future cash compensation otherwise due to such grantee in the form of an award of Restricted Stock Units. Any such election shall be made in writing and shall be delivered to the Company no later than the date
specified by the Administrator and in accordance with Section&nbsp;409A and such other rules and procedures established by the Administrator. Any such future cash compensation that the grantee elects to defer shall be converted to a fixed number of
Restricted Stock Units based on the Fair Market Value of Stock on the date the compensation would otherwise have been paid to the grantee if such payment had not been deferred as provided herein. The Administrator shall have the sole right to
determine whether and under what circumstances to permit such elections and to impose such limitations and other terms and conditions thereon as the Administrator deems appropriate. Any Restricted Stock Units that are elected to be received in lieu
of cash compensation shall be fully vested, unless otherwise provided in the Award Certificate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Rights as a Stockholder</U>. A
grantee shall have the rights as a stockholder only as to shares of Stock acquired by the grantee upon settlement of Restricted Stock Units; provided, however, that the grantee may be credited with Dividend Equivalent Rights with respect to the
stock units underlying his or her Restricted Stock Units, subject to the provisions of Section&nbsp;11 and such terms and conditions as the Administrator may determine. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Termination</U>. Except as may otherwise be provided by the Administrator either in
the Award Certificate or, subject to Section&nbsp;16 below, in writing after the Award is issued, a grantee&#146;s right in all Restricted Stock Units that have not vested shall automatically terminate upon the grantee&#146;s termination of
employment (or cessation of Service Relationship) with the Company and its Subsidiaries for any reason. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">SECTION</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">9. <U>UNRESTRICTED STOCK AWARDS</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Grant or Sale of Unrestricted Stock</U>. The Administrator may grant (or sell at par value or such higher purchase price determined by the
Administrator) an Unrestricted Stock Award under the Plan. An Unrestricted Stock Award is an Award pursuant to which the grantee may receive shares of Stock free of any restrictions under the Plan. Unrestricted Stock Awards may be granted in respect
of past services or other valid consideration, or in lieu of cash compensation due to such grantee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">SECTION</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">10. <U>CASH-BASED AWARDS</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Grant of Cash-Based Awards</U>. The Administrator may grant Cash-Based Awards under the Plan. A Cash-Based Award is an Award that entitles
the grantee to a payment in cash upon the attainment of specified performance goals. The Administrator shall determine the maximum duration of the Cash-Based Award, the amount of cash to which the Cash-Based Award pertains, the conditions upon which
the Cash-Based Award shall become vested or payable, and such other provisions as the Administrator shall determine. Each Cash-Based Award shall specify a cash-denominated payment amount, formula or payment ranges as determined by the Administrator.
Payment, if any, with respect to a Cash-Based Award shall be made in accordance with the terms of the Award and may be made in cash. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">SECTION</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">11. <U>DIVIDEND EQUIVALENT RIGHTS</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Dividend Equivalent Rights</U>. The Administrator may grant Dividend Equivalent Rights under the Plan. A Dividend Equivalent Right is an
Award entitling the grantee to receive credits based on cash dividends that would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other Award to which it relates) if such shares had been issued to the grantee. A
Dividend Equivalent Right may be granted hereunder to any grantee as a component of an award of Restricted Stock Units or as a freestanding award. The terms and conditions of Dividend Equivalent Rights shall be specified in the Award Certificate.
Dividend equivalents credited to the holder of a Dividend Equivalent Right may be paid currently or may be deemed to be reinvested in additional shares of Stock, which may thereafter accrue additional equivalents. Any such reinvestment shall be at
Fair Market Value on the date of reinvestment or such other price as may then apply under a dividend reinvestment plan sponsored by the Company, if any. Dividend Equivalent Rights may be settled in cash or shares of Stock or a combination thereof,
in a single installment or installments. A Dividend Equivalent Right granted as a component of an Award of Restricted Stock Units shall provide that such Dividend Equivalent Right shall be settled only upon settlement or payment of, or lapse of
restrictions on, such other Award, and that such Dividend Equivalent Right shall expire or be forfeited or annulled under the same conditions as such other Award. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination</U>. Except as may otherwise be provided by the Administrator either in
the Award Certificate or, subject to Section&nbsp;16 below, in writing after the Award is issued, a grantee&#146;s rights in all Dividend Equivalent Rights shall automatically terminate upon the grantee&#146;s termination of employment (or cessation
of Service Relationship) with the Company and its Subsidiaries for any reason. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">SECTION</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">12. <U>TRANSFERABILITY OF AWARDS</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Transferability</U>. Except as provided in Section&nbsp;12(b) below, during a grantee&#146;s lifetime, his or her Awards shall be
exercisable only by the grantee, or by the grantee&#146;s legal representative or guardian in the event of the grantee&#146;s incapacity. No Awards shall be sold, assigned, transferred or otherwise encumbered or disposed of by a grantee other than
by will or by the laws of descent and distribution or pursuant to a domestic relations order. No Awards shall be subject, in whole or in part, to attachment, execution, or levy of any kind, and any purported transfer in violation hereof shall be
null and void. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Administrator Action</U>. Notwithstanding Section&nbsp;12(a), the Administrator, in its discretion, may provide
either in the Award Certificate regarding a given Award or by subsequent written approval that the grantee (who is an employee or director) may transfer his or her <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Options to his or her
immediate family members, to trusts for the benefit of such family members, or to partnerships in which such family members are the only partners, provided that the transferee agrees in writing with the Company to be bound by all of the terms and
conditions of this Plan and the applicable Award. In no event may an Award be transferred by a grantee for value. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Family
Member</U>. For purposes of Section&nbsp;12(b), &#147;family member&#148; shall mean a grantee&#146;s child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">mother-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">father-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">son-in-law,</FONT></FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">daughter-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">brother-in-law,</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">sister-in-law,</FONT></FONT> including adoptive relationships, any person sharing the grantee&#146;s household (other than a tenant of the grantee), a trust in which these persons (or the grantee) have more than
50&nbsp;percent of the beneficial interest, a foundation in which these persons (or the grantee) control the management of assets, and any other entity in which these persons (or the grantee) own more than 50&nbsp;percent of the voting interests.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Designation of Beneficiary</U>. To the extent permitted by the Company, each grantee to whom an Award has been made under the Plan
may designate a beneficiary or beneficiaries to exercise any Award or receive any payment under any Award payable on or after the grantee&#146;s death. Any such designation shall be on a form provided for that purpose by the Administrator and shall
not be effective until received by the Administrator. If no beneficiary has been designated by a deceased grantee, or if the designated beneficiaries have predeceased the grantee, the beneficiary shall be the grantee&#146;s estate. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">SECTION</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">13. <U>TAX WITHHOLDING</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Payment by Grantee</U>. Each grantee shall, no later than the date as of which the value of an Award or of any Stock or other amount
received thereunder first becomes includable in the gross income of the grantee for income tax purposes, pay to the Company, or make arrangements satisfactory to the Administrator regarding payment of, any Federal, state, or local taxes of any kind
required by law to be withheld by the Company with respect to such income. The Company and its Subsidiaries shall, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to the grantee. The
Company&#146;s obligation to deliver evidence of book entry (or stock certificates) to any grantee is subject to and conditioned on tax withholding obligations being satisfied by the grantee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Payment in Stock</U>. The Administrator may require the Company&#146;s tax withholding obligation to be satisfied, in whole or in part,
by the Company withholding from shares of Stock to be issued pursuant to any Award a number of shares with an aggregate Fair Market Value (as of the date the withholding is effected) that would satisfy the withholding amount due; provided, however,
that the amount withheld does not exceed the maximum statutory tax rate or such lesser amount as is necessary to avoid liability accounting treatment.&nbsp;&nbsp;&nbsp;&nbsp;For purposes of share withholding, the Fair Market Value of withheld shares
shall be determined in the same manner as the value of Stock includible in income of the grantees. The Administrator may also require the Company&#146;s tax withholding obligation to be satisfied, in whole or in part, by an arrangement whereby a
certain number of shares of Stock issued pursuant to any Award are immediately sold and proceeds from such sale are remitted to the Company in an amount that would satisfy the withholding amount due. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">SECTION</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">14. <U>SECTION</U><U></U><U>&nbsp;409A AWARDS</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Awards are intended to be exempt from Section&nbsp;409A to the greatest extent possible and to otherwise comply with Section&nbsp;409A. The
Plan and all Awards shall be interpreted in accordance with such intent. To the extent that any Award is determined to constitute &#147;nonqualified deferred compensation&#148; within the meaning of Section&nbsp;409A (a &#147;409A Award&#148;), the
Award shall be subject to such additional rules and requirements as specified by the Administrator from time to time in order to comply with Section&nbsp;409A. In this regard, if any amount under a 409A Award is payable upon a &#147;separation from
service&#148; (within the meaning of Section&nbsp;409A) to a grantee who is then considered a &#147;specified employee&#148; (within the meaning of Section&nbsp;409A), then no such payment shall be made prior to the date that is the earlier of
(i)&nbsp;six months and one day after the grantee&#146;s separation from service, or (ii)&nbsp;the grantee&#146;s death, but only to the extent such delay is necessary to prevent such payment from being subject to interest, penalties and/or
additional tax imposed pursuant to Section&nbsp;409A. Further, the settlement of any 409A Award may not be accelerated except to the extent permitted by Section&nbsp;409A. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">SECTION</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">15. <U>TERMINATION OF SERVICE RELATIONSHIP, TRANSFER, LEAVE OF ABSENCE, ETC.</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Termination of Service Relationship</U>. If the grantee&#146;s Service Relationship is with an Affiliate and such Affiliate ceases to be
an Affiliate, the grantee shall be deemed to have terminated his or her Service Relationship for purposes of the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) For purposes of
the Plan, the following events shall not be deemed a termination of a Service Relationship: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) a transfer to the employment of the Company from an Affiliate or from the Company to an
Affiliate, or from one Affiliate to another; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) an approved leave of absence for military service or sickness, or for any other
purpose approved by the Company, if the employee&#146;s right to <FONT STYLE="white-space:nowrap">re-employment</FONT> is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the
Administrator otherwise so provides in writing. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">SECTION</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">16. <U>AMENDMENTS AND TERMINATION</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board may, at any time, amend or discontinue the Plan and the Administrator may, at any time, amend or cancel any outstanding Award for the
purpose of satisfying changes in law or for any other lawful purpose, but no such action shall materially and adversely affect rights under any outstanding Award without the holder&#146;s consent. The Administrator is specifically authorized to
exercise its discretion to reduce the exercise price of outstanding Stock Options or Stock Appreciation Rights or effect the repricing of such Awards through cancellation and <FONT STYLE="white-space:nowrap">re-grants.</FONT> To the extent required
under the rules of any securities exchange or market system on which the Stock is listed, to the extent determined by the Administrator to be required by the Code to ensure that Incentive Stock Options granted under the Plan are qualified under
Section&nbsp;422 of the Code, Plan amendments shall be subject to approval by Company stockholders. Nothing in this Section&nbsp;16 shall limit the Administrator&#146;s authority to take any action permitted pursuant to Section&nbsp;3(b) or 3(c).
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">SECTION</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">17. <U>STATUS OF PLAN</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the portion of any Award that has not been exercised and any payments in cash, Stock or other consideration not received by a
grantee, a grantee shall have no rights greater than those of a general creditor of the Company unless the Administrator shall otherwise expressly determine in connection with any Award or Awards. In its sole discretion, the Administrator may
authorize the creation of trusts or other arrangements to meet the Company&#146;s obligations to deliver Stock or make payments with respect to Awards hereunder, provided that the existence of such trusts or other arrangements is consistent with the
foregoing sentence. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">SECTION</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">18. <U>GENERAL PROVISIONS</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>No Distribution</U>. The Administrator may require each person acquiring Stock pursuant to an Award to represent to and agree with the
Company in writing that such person is acquiring the shares without a view to distribution thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Issuance of Stock</U>. To the
extent certificated, stock certificates to grantees under this Plan shall be deemed delivered for all purposes when the Company or a stock transfer agent of the Company shall have mailed such certificates in the United States mail, addressed to the
grantee, at the grantee&#146;s last known address on file with the Company. Uncertificated Stock shall be deemed delivered for all purposes when the Company or a Stock transfer agent of the Company shall have given to the grantee by electronic mail
(with proof of receipt) or by United States mail, addressed to the grantee, at the grantee&#146;s last known address on file with the Company, notice of issuance and recorded the issuance in its records (which may include electronic &#147;book
entry&#148; records). Notwithstanding anything herein to the contrary, the Company </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall not be required to issue or deliver any evidence of book entry or certificates evidencing shares of Stock pursuant to the exercise or settlement of any Award, unless and until the
Administrator has determined, with advice of counsel (to the extent the Administrator deems such advice necessary or advisable), that the issuance and delivery is in compliance with all applicable laws, regulations of governmental authorities and,
if applicable, the requirements of any exchange on which the shares of Stock are listed, quoted or traded. Any Stock issued pursuant to the Plan shall be subject to any stop-transfer orders and other restrictions as the Administrator deems necessary
or advisable to comply with federal, state or foreign jurisdiction, securities or other laws, rules and quotation system on which the Stock is listed, quoted or traded. The Administrator may place legends on any Stock certificate or notations on any
book entry to reference restrictions applicable to the Stock. In addition to the terms and conditions provided herein, the Administrator may require that an individual make such reasonable covenants, agreements, and representations as the
Administrator, in its discretion, deems necessary or advisable in order to comply with any such laws, regulations, or requirements. The Administrator shall have the right to require any individual to comply with any timing or other restrictions with
respect to the settlement or exercise of any Award, including a window-period limitation, as may be imposed in the discretion of the Administrator. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Stockholder Rights</U>. Until Stock is deemed delivered in accordance with Section&nbsp;18(b), no right to vote or receive dividends or
any other rights of a stockholder will exist with respect to shares of Stock to be issued in connection with an Award, notwithstanding the exercise of a Stock Option or any other action by the grantee with respect to an Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Other Compensation Arrangements; No Employment Rights</U>. Nothing contained in this Plan shall prevent the Board from adopting other or
additional compensation arrangements, including trusts, and such arrangements may be either generally applicable or applicable only in specific cases. The adoption of this Plan and the grant of Awards do not confer upon any employee any right to
continued employment with the Company or any Subsidiary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Trading Policy Restrictions</U>. Option exercises and other Awards under
the Plan shall be subject to the Company&#146;s insider trading policies and procedures, as in effect from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Clawback
Policy</U>. Awards under the Plan shall be subject to the Company&#146;s clawback policy, as in effect from time to time. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">SECTION</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">19. <U>EFFECTIVE DATE OF PLAN</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Plan shall become effective upon the date immediately preceding the Registration Date, subject to prior stockholder approval in accordance
with applicable state law, the Company&#146;s bylaws and articles of incorporation, and applicable stock exchange rules. No grants of Stock Options and other Awards may be made hereunder after the tenth anniversary of the Effective Date and no
grants of Incentive Stock Options may be made hereunder after the tenth anniversary of the date the Plan is approved by the Board. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">SECTION</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">20. <U>GOVERNING LAW</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Plan and all Awards and actions taken thereunder shall be governed by, and construed in accordance with, the General Corporation Law of
the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts, applied without regard to conflict of law
principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DATE APPROVED BY BOARD OF DIRECTORS: December 26, 2021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DATE APPROVED BY STOCKHOLDERS: December 29, 2021 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INCENTIVE STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE AMYLYX PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2022 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Optionee:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No. of Option Shares:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Option Exercise Price per Share:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>[FMV on Grant Date (110% of FMV if a 10% owner)]</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Grant Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Expiration Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>[No more than 10 years (5 years if a 10% owner)]</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Amylyx Pharmaceuticals, Inc. 2022 Stock Option and Incentive Plan, as amended through the date
hereof (the &#147;Plan&#148;), Amylyx Pharmaceuticals, Inc. (the &#147;Company&#148;) hereby grants to the Optionee named above an option (the &#147;Stock Option&#148;) to purchase on or prior to the Expiration Date specified above all or part of
the number of shares of Common Stock, par value $0.0001 per share (the &#147;Stock&#148;), of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Exercisability Schedule</U>. No portion of this Stock Option may be exercised until such portion shall have become exercisable.
Except as set forth below, and subject to the discretion of the Administrator (as defined in Section&nbsp;1 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable with respect to the following number
of Option Shares on the dates indicated so long as the Optionee continues to have a Service Relationship with the Company or a Subsidiary on such dates: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Incremental Number of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Option Shares Exercisable*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Exercisability&nbsp;Date</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Max. of $100,000 per yr. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the close of business on the Expiration
Date, subject to the provisions hereof and of the Plan. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Manner of Exercise</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this
Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be
purchased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i)&nbsp;in cash, by
certified or bank check or other instrument acceptable to the Administrator; (ii)&nbsp;through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially
owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii)&nbsp;by the Optionee delivering to the Company a properly
executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to
pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment
procedure; or (iv)&nbsp;a combination of (i), (ii)&nbsp;and (iii)&nbsp;above. Payment instruments will be received subject to collection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i)&nbsp;the
Company&#146;s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii)&nbsp;the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and
(iii)&nbsp;the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent
resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock
transferred to the Optionee upon the exercise of the Stock Option shall be net of the shares of Stock attested to. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The shares of Stock
purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or
regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder
of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have
transferred the shares to the Optionee, and the Optionee&#146;s name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect
to such shares of Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The minimum number of shares with respect to which this Stock Option may be exercised at
any one time shall be 100 shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date
hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination of Service Relationship</U>. If the Optionee&#146;s Service Relationship with the Company or a Subsidiary (as
defined in the Plan) terminates, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Termination Due to Death</U>. If the Optionee&#146;s Service Relationship with the Company or a Subsidiary terminates by reason of the
Optionee&#146;s death, any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of death, may thereafter be exercised by the Optionee&#146;s legal representative or legatee for a period of 12 months from the
date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of death shall terminate immediately and be of no further force or effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination Due to Disability</U>. If the Optionee&#146;s Service Relationship with the Company or a Subsidiary terminates by reason of
the Optionee&#146;s disability (as determined by the Administrator), any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of such termination, may thereafter be exercised by the Optionee for a period of 12
months from the date of disability or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of disability shall terminate immediately and be of no further force or effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Termination for Cause</U>. If the Optionee&#146;s Service Relationship with the Company or a Subsidiary terminates for Cause, any
portion of this Stock Option outstanding on such date shall terminate immediately and be of no further force and effect. For purposes hereof, &#147;Cause&#148; shall mean, unless otherwise provided in an employment or other service agreement between
the Company and the Optionee, a determination by the Administrator that the Optionee shall be dismissed as a result of (i)&nbsp;any material breach by the Optionee of any agreement between the Optionee and the Company; (ii)&nbsp;the conviction of,
indictment for or plea of nolo contendere by the Optionee to a felony or a crime involving moral turpitude; or (iii)&nbsp;any material misconduct or willful and deliberate non-performance (other than by reason of disability) by the Optionee of the
Optionee&#146;s duties to the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Other Termination</U>. If the Optionee&#146;s Service Relationship with the Company or a
Subsidiary terminates for any reason other than the Optionee&#146;s death, the Optionee&#146;s disability, or Cause, and unless otherwise determined by the Administrator, any portion of this Stock Option outstanding on such date may be exercised, to
the extent exercisable on the date of termination, for a period of three months from the date of termination or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of termination shall
terminate immediately and be of no further force or effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator&#146;s determination of the reason for termination of the Optionee&#146;s
Service Relationship with the Company or a Subsidiary shall be conclusive and binding on the Optionee and his or her representatives or legatees. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Incorporation of Plan</U>. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the
terms and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Transferability</U>. This Agreement is personal to the Optionee, is non-assignable and is not transferable in any manner, by
operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee&#146;s lifetime, only by the Optionee, and thereafter, only by the Optionee&#146;s legal representative
or legatee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Status of the Stock Option</U>. This Stock Option is intended to qualify as an &#147;incentive stock option&#148; under
Section&nbsp;422 of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), but the Company does not represent or warrant that this Stock Option qualifies as such. The Optionee should consult with his or her own tax advisors regarding
the tax effects of this Stock Option and the requirements necessary to obtain favorable income tax treatment under Section&nbsp;422 of the Code, including, but not limited to, holding period requirements and that <B><I>t</I></B><B><I>his Stock
Option must be exercised within three months after termination of employment as an employee (or 12 months in the case of death or disability) to qualify as an &#147;incentive stock option</I></B>.&#148; To the extent any portion of this Stock Option
does not so qualify as an &#147;incentive stock option,&#148; such portion shall be deemed to be a non-qualified stock option. If the Optionee intends to dispose or does dispose (whether by sale, gift, transfer or otherwise) of any Option Shares
within the one-year period beginning on the date after the transfer of such shares to him or her, or within the two-year period beginning on the day after the grant of this Stock Option, he or she will so notify the Company within 30 days after such
disposition. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Tax Withholding</U>. The Optionee shall, not later than the date as of which the exercise of this Stock Option becomes
a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event. The
Company shall have the authority to cause the required tax withholding obligation to be satisfied, in whole or in part, by (i)&nbsp;withholding from shares of Stock to be issued to the Optionee a number of shares of Stock with an aggregate Fair
Market Value that would satisfy the withholding amount due; or (ii)&nbsp;causing its transfer agent to sell from the number of shares of Stock to be issued to the Optionee, the number of shares of Stock necessary to satisfy the Federal, state and
local taxes required by law to be withheld from the Optionee on account of such transfer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>No Obligation to Continue Service
Relationship</U>. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Optionee&#146;s Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall
interfere in any way with the right of the Company or any Subsidiary to terminate the Optionee&#146;s Service Relationship with the Company or a Subsidiary at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Integration</U>. This Agreement constitutes the entire agreement between the parties
with respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Data Privacy Consent</U>. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the
Company, its subsidiaries and affiliates and certain agents thereof (together, the &#147;Relevant Companies&#148;) may process any and all personal or professional data, including but not limited to Social Security or other identification number,
home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#147;Relevant Information&#148;). By entering into this Agreement, the Optionee
(i)&nbsp;authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii)&nbsp;waives any privacy rights the Optionee may have with respect to the Relevant Information; (iii)&nbsp;authorizes
the Relevant Companies to store and transmit such information in electronic form; and (iv)&nbsp;authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have
access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Notices</U>. Notices hereunder shall be mailed or delivered to the Company at its
principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AMYLYX PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#146;s instructions to the Optionee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Optionee&#146;s Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Optionee&#146;s name and address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NON-QUALIFIED STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR NON-EMPLOYEE DIRECTORS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE AMYLYX PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2022 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Optionee:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No. of Option Shares:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Option Exercise Price per Share:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>[FMV on Grant Date]</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Grant Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Expiration Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>[No more than 10 years]</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Amylyx Pharmaceuticals, Inc. 2022 Stock Option and Incentive Plan, as amended through the date
hereof (the &#147;Plan&#148;), Amylyx Pharmaceuticals, Inc. (the &#147;Company&#148;) hereby grants to the Optionee named above, who is a Non-Employee Director of the Company but is not an employee of the Company, an option (the &#147;Stock
Option&#148;) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value $0.0001 per share (the &#147;Stock&#148;), of the Company specified above at the Option Exercise Price per
Share specified above subject to the terms and conditions set forth herein and in the Plan. This Stock Option is not intended to be an &#147;incentive stock option&#148; under Section&nbsp;422 of the Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Exercisability Schedule</U>. No portion of this Stock Option may be exercised until such portion shall have become exercisable. Except as
set forth below, and subject to the discretion of the Administrator (as defined in Section&nbsp;2 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable with respect to the following number of Option
Shares on the dates indicated so long as the Optionee remains in service as a member of the Board on such dates: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Incremental Number of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Option Shares Exercisable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Exercisability&nbsp;Date</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary herein or in the Plan, all outstanding Option Shares shall become
fully exercisable upon a Sale Event. Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Manner of Exercise</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this
Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be
purchased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i)&nbsp;in cash, by
certified or bank check or other instrument acceptable to the Administrator; (ii)&nbsp;through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially
owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii)&nbsp;by the Optionee delivering to the Company a properly
executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to
pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment
procedure; (iv)&nbsp;by a &#147;net exercise&#148; arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the
aggregate exercise price; or (v)&nbsp;a combination of (i), (ii), (iii)&nbsp;and (iv)&nbsp;above. Payment instruments will be received subject to collection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i)&nbsp;the
Company&#146;s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii)&nbsp;the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and
(iii)&nbsp;the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent
resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock
transferred to the Optionee upon the exercise of the Stock Option shall be net of the shares of Stock attested to. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The shares of Stock
purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or
regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder
of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have transferred the shares to the Optionee, and the Optionee&#146;s name shall have been
entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect to such shares of Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The minimum number of shares with respect to which this Stock Option may be exercised at any one time shall be 100 shares, unless the
number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date
hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination as Non-Employee Director</U>. If the Optionee ceases to be a Non-Employee Director of the Company, the period
within which to exercise the Stock Option may be subject to earlier termination as set forth below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Termination Due to Death</U>.
If the Optionee&#146;s service as a Non-Employee Director terminates by reason of the Optionee&#146;s death, any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of death, may thereafter be exercised by
the Optionee&#146;s legal representative or legatee for a period of 12 months from the date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of death shall terminate immediately
and be of no further force or effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Other Termination</U>. If the Optionee ceases to be a Non-Employee Director for any reason
other than the Optionee&#146;s death, any portion of this Stock Option outstanding on such date may be exercised, to the extent exercisable on the date the Optionee ceased to be a Non-Employee Director, for a period of 12 months from the date the
Optionee ceased to be a Non-Employee Director or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date the Optionee ceases to be a Non-Employee Director shall terminate immediately and be of no
further force or effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Incorporation of Plan</U>. Notwithstanding anything herein to the contrary, this Stock Option shall be
subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a
different meaning is specified herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Transferability</U>. This Agreement is personal to the Optionee, is non-assignable and is not
transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee&#146;s lifetime, only by the Optionee, and thereafter, only by the
Optionee&#146;s legal representative or legatee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>No Obligation to Continue as a Non-Employee Director</U>. Neither the Plan nor this
Stock Option confers upon the Optionee any rights with respect to continuance as a Non-Employee Director. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Integration</U>. This Agreement constitutes the entire agreement between the parties
with respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Data Privacy Consent</U>. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the
Company, its subsidiaries and affiliates and certain agents thereof (together, the &#147;Relevant Companies&#148;) may process any and all personal or professional data, including but not limited to Social Security or other identification number,
home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#147;Relevant Information&#148;). By entering into this Agreement, the Optionee
(i)&nbsp;authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii)&nbsp;waives any privacy rights the Optionee may have with respect to the Relevant Information; (iii)&nbsp;authorizes
the Relevant Companies to store and transmit such information in electronic form; and (iv)&nbsp;authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have
access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.
<U>Notices</U>. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as
one party may subsequently furnish to the other party in writing. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AMYLYX PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#146;s instructions to the Optionee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Optionee&#146;s Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Optionee&#146;s name and address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NON-QUALIFIED STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR COMPANY EMPLOYEES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE AMYLYX PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2022 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Optionee:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No. of Option Shares:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Option Exercise Price per Share:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>[FMV on Grant Date]</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Grant Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Expiration Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>[No more than 10 years]</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Amylyx Pharmaceuticals, Inc. 2022 Stock Option and Incentive Plan, as amended through the date
hereof (the &#147;Plan&#148;), Amylyx Pharmaceuticals, Inc. (the &#147;Company&#148;) hereby grants to the Optionee named above an option (the &#147;Stock Option&#148;) to purchase on or prior to the Expiration Date specified above all or part of
the number of shares of Common Stock, par value $0.0001 per share (the &#147;Stock&#148;), of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan.
This Stock Option is not intended to be an &#147;incentive stock option&#148; under Section&nbsp;422 of the Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Exercisability Schedule</U>. No portion of this Stock Option may be exercised until such portion shall have become exercisable. Except as
set forth below, and subject to the discretion of the Administrator (as defined in Section&nbsp;1 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable with respect to the following number of Option
Shares on the dates indicated so long as the Optionee continues to have a Service Relationship with the Company or a Subsidiary on such dates: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Incremental Number of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Option Shares Exercisable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Exercisability&nbsp;Date</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the close
of business on the Expiration Date, subject to the provisions hereof and of the Plan. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Manner of Exercise</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this
Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be
purchased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i)&nbsp;in cash, by
certified or bank check or other instrument acceptable to the Administrator; (ii)&nbsp;through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially
owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii)&nbsp;by the Optionee delivering to the Company a properly
executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to
pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment
procedure; (iv)&nbsp;by a &#147;net exercise&#148; arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the
aggregate exercise price; or (v)&nbsp;a combination of (i), (ii), (iii)&nbsp;and (iv)&nbsp;above. Payment instruments will be received subject to collection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i)&nbsp;the
Company&#146;s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii)&nbsp;the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and
(iii)&nbsp;the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent
resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock
transferred to the Optionee upon the exercise of the Stock Option shall be net of the shares of Stock attested to. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The shares of Stock
purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or
regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder
of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have
transferred the shares to the Optionee, and the Optionee&#146;s name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect
to such shares of Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The minimum number of shares with respect to which this Stock Option may be exercised at
any one time shall be 100 shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date
hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination of Service Relationship</U>. If the Optionee&#146;s Service Relationship with the Company or a Subsidiary (as
defined in the Plan) terminates, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Termination Due to Death</U>. If the Optionee&#146;s Service Relationship with the Company or a Subsidiary terminates by reason of the
Optionee&#146;s death, any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of death, may thereafter be exercised by the Optionee&#146;s legal representative or legatee for a period of 12 months from the
date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of death shall terminate immediately and be of no further force or effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination Due to Disability</U>. If the Optionee&#146;s Service Relationship with the Company or a Subsidiary terminates by reason of
the Optionee&#146;s disability (as determined by the Administrator), any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of such termination, may thereafter be exercised by the Optionee for a period of 12
months from the date of disability or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of disability shall terminate immediately and be of no further force or effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Termination for Cause</U>. If the Optionee&#146;s Service Relationship with the Company or a Subsidiary terminates for Cause, any
portion of this Stock Option outstanding on such date shall terminate immediately and be of no further force and effect. For purposes hereof, &#147;Cause&#148; shall mean, unless otherwise provided in an employment or other service agreement between
the Company and the Optionee, a determination by the Administrator that the Optionee shall be dismissed as a result of (i)&nbsp;any material breach by the Optionee of any agreement between the Optionee and the Company; (ii)&nbsp;the conviction of,
indictment for or plea of nolo contendere by the Optionee to a felony or a crime involving moral turpitude; or (iii)&nbsp;any material misconduct or willful and deliberate non-performance (other than by reason of disability) by the Optionee of the
Optionee&#146;s duties to the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Other Termination</U>. If the Optionee&#146;s Service Relationship with the Company or a
Subsidiary terminates for any reason other than the Optionee&#146;s death, the Optionee&#146;s disability or Cause, and unless otherwise determined by the Administrator, any portion of this Stock Option outstanding on such date may be exercised, to
the extent exercisable on the date of termination, for a period of three months from the date of termination or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of termination shall
terminate immediately and be of no further force or effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator&#146;s determination of the reason for termination of the Optionee&#146;s
Service Relationship with the Company or a Subsidiary shall be conclusive and binding on the Optionee and his or her representatives or legatees. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Incorporation of Plan</U>. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the
terms and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Transferability</U>. This Agreement is personal to the Optionee, is non-assignable and is not transferable in any manner, by
operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee&#146;s lifetime, only by the Optionee, and thereafter, only by the Optionee&#146;s legal representative
or legatee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Tax Withholding</U>. The Optionee shall, not later than the date as of which the exercise of this Stock Option becomes a
taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event. The Company
shall have the authority to cause the required tax withholding obligation to be satisfied, in whole or in part, by (i)&nbsp;withholding from shares of Stock to be issued to the Optionee a number of shares of Stock with an aggregate Fair Market Value
that would satisfy the withholding amount due; or (ii)&nbsp;causing its transfer agent to sell from the number of shares of Stock to be issued to the Optionee, the number of shares of Stock necessary to satisfy the Federal, state and local taxes
required by law to be withheld from the Optionee on account of such transfer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>No Obligation to Continue Service Relationship</U>.
Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Optionee&#146;s Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any
way with the right of the Company or any Subsidiary to terminate the Optionee&#146;s Service Relationship with the Company or a Subsidiary at any time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Integration</U>. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes all
prior agreements and discussions between the parties concerning such subject matter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Data Privacy Consent</U>. In order to
administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#147;Relevant Companies&#148;) may process any and all personal or
professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this
Agreement (the &#147;Relevant Information&#148;). By entering into this Agreement, the Optionee (i)&nbsp;authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii)&nbsp;waives any
privacy rights the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Optionee may have with respect to the Relevant Information; (iii)&nbsp;authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv)&nbsp;authorizes the
transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance
with applicable law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Notices</U>. Notices hereunder shall be mailed or delivered to the Company at its principal place of business
and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AMYLYX PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#146;s instructions to the Optionee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;<U></U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Optionee&#146;s Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Optionee&#146;s name and address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTRICTED STOCK UNIT AWARD AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR COMPANY EMPLOYEES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE AMYLYX PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2022 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Grantee:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No. of Restricted Stock Units:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Grant Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Amylyx Pharmaceuticals, Inc. 2022 Stock Option and Incentive Plan, as amended through the date
hereof (the &#147;Plan&#148;), Amylyx Pharmaceuticals, Inc. (the &#147;Company&#148;) hereby grants an award of the number of Restricted Stock Units listed above (an &#147;Award&#148;) to the Grantee named above. Each Restricted Stock Unit shall
relate to one share of Common Stock, par value $0.0001 per share (the &#147;Stock&#148;), of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Restrictions on Transfer
of Award</U>. This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise
encumbered or disposed of until (i)&nbsp;the Restricted Stock Units have vested as provided in Paragraph 2 of this Agreement and (ii)&nbsp;shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this Agreement.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Vesting of Restricted Stock Units</U>. The restrictions and conditions of Paragraph&nbsp;1 of this Agreement shall lapse on the
Vesting Date or Dates specified in the following schedule so long as the Grantee continues to have a Service Relationship with the Company or a Subsidiary on such Vesting Dates. If a series of Vesting Dates is specified, then the restrictions and
conditions in Paragraph&nbsp;1 shall lapse only with respect to the number of Restricted Stock Units specified as vested on such date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Incremental Number of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Restricted Stock Units Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Vesting Date</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>(__%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>(__%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>(__%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>(__%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 2. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination of Service Relationship</U>. If the Grantee&#146;s Service Relationship with the Company or a Subsidiary terminates for any
reason (including death or disability) prior to the satisfaction of the vesting conditions set forth in Paragraph 2 above, any Restricted Stock Units that have not vested as of such date shall automatically and without notice terminate and be
forfeited, and neither the Grantee nor any of his or her successors, heirs, assigns, or personal representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Issuance of Shares of Stock</U>. As soon as practicable following each Vesting Date
(but in no event later than two and one-half months after the end of the year in which the Vesting Date occurs), the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate number of Restricted Stock Units that have
vested pursuant to Paragraph 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Incorporation of Plan</U>. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the
terms and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Tax Withholding</U>. The Grantee shall, not later than the date as of which the receipt of this Award becomes a taxable event for
Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event. The Company shall have the
authority to cause the required tax withholding obligation to be satisfied, in whole or in part, by (i)&nbsp;withholding from shares of Stock to be issued to the Grantee a number of shares of Stock with an aggregate Fair Market Value that would
satisfy the withholding amount due; or (ii)&nbsp;causing its transfer agent to sell from the number of shares of Stock to be issued to the Grantee, the number of shares of Stock necessary to satisfy the Federal, state and local taxes required by law
to be withheld from the Grantee on account of such transfer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Section&nbsp;409A of the Code.</U> This Agreement shall be interpreted
in such a manner that all provisions relating to the settlement of the Award are exempt from the requirements of Section&nbsp;409A of the Code as &#147;short-term deferrals&#148; as described in Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>No Obligation to Continue Service Relationship</U>. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or
this Agreement to continue the Grantee&#146;s Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Grantee&#146;s
Service Relationship with the Company or a Subsidiary at any time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Integration</U>. This Agreement constitutes the entire agreement
between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Data Privacy Consent</U>. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the
Company, its subsidiaries and affiliates and certain agents thereof (together, the &#147;Relevant Companies&#148;) may process any and all personal or professional data, including but not limited to Social Security or other identification number,
home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#147;Relevant Information&#148;). By entering into this Agreement, the Grantee
(i)&nbsp;authorizes the Company to collect, process, register and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transfer to the Relevant Companies all Relevant Information; (ii)&nbsp;waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii)&nbsp;authorizes the Relevant
Companies to store and transmit such information in electronic form; and (iv)&nbsp;authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have access to, and
the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.
<U>Notices</U>. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one
party may subsequently furnish to the other party in writing. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AMYLYX PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#146;s instructions to the Grantee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Grantee&#146;s Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Grantee&#146;s name and address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTRICTED STOCK UNIT AWARD AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR NON-EMPLOYEE DIRECTORS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE AMYLYX PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2022 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="69%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Grantee:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No. of Restricted Stock Units:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Grant Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Amylyx Pharmaceuticals, Inc. 2022 Stock Option and Incentive Plan, as amended through the date
hereof (the &#147;Plan&#148;), Amylyx Pharmaceuticals, Inc. (the &#147;Company&#148;) hereby grants an award of the number of Restricted Stock Units listed above (an &#147;Award&#148;) to the Grantee named above. Each Restricted Stock Unit shall
relate to one share of Common Stock, par value $0.0001 per share (the &#147;Stock&#148;), of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Restrictions on Transfer
of Award</U>. This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise
encumbered or disposed of until (i)&nbsp;the Restricted Stock Units have vested as provided in Paragraph 2 of this Agreement and (ii)&nbsp;shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this Agreement.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Vesting of Restricted Stock Units</U>. The restrictions and conditions of Paragraph&nbsp;1 of this Agreement shall lapse on the
Vesting Date or Dates specified in the following schedule so long as the Grantee remains in service as a member of the Board on such Vesting Dates. If a series of Vesting Dates is specified, then the restrictions and conditions in Paragraph&nbsp;1
shall lapse only with respect to the number of Restricted Stock Units specified as vested on such date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Incremental Number of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Restricted Stock Units Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Vesting Date</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U></I>(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary herein or in the Plan, all outstanding Restricted Stock Units shall
become fully vested upon a Sale Event. The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 2. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.
<U>Termination of Service as a Non-Employee Director</U>. If the Grantee&#146;s service with the Company as a member of the Board terminates for any reason (including death or disability) prior to the satisfaction of the vesting conditions set forth
in Paragraph 2 above, any Restricted Stock Units that have not vested as of such date shall automatically and without notice terminate and be forfeited, and neither the Grantee nor any of his or her successors, heirs, assigns, or personal
representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units. </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Issuance of Shares of Stock</U>. As soon as practicable following each Vesting Date
(but in no event later than two and one-half months after the end of the year in which the Vesting Date occurs), the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate number of Restricted Stock Units that have
vested pursuant to Paragraph 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Incorporation of Plan</U>. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the
terms and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Section&nbsp;409A of the Code.</U> This Agreement shall be interpreted in such a manner that all provisions relating to the
settlement of the Award are exempt from the requirements of Section&nbsp;409A of the Code as &#147;short-term deferrals&#148; as described in Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>No Obligation to Continue as a Non-Employee Director</U>. Neither the Plan nor this Award confers upon the Grantee any rights with
respect to continuance as a Non-Employee Director. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Integration</U>. This Agreement constitutes the entire agreement between the
parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Data Privacy Consent</U>. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the
Company, its subsidiaries and affiliates and certain agents thereof (together, the &#147;Relevant Companies&#148;) may process any and all personal or professional data, including but not limited to Social Security or other identification number,
home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#147;Relevant Information&#148;). By entering into this Agreement, the Grantee
(i)&nbsp;authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii)&nbsp;waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii)&nbsp;authorizes
the Relevant Companies to store and transmit such information in electronic form; and (iv)&nbsp;authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have
access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Notices</U>. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or
delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AMYLYX PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#146;s instructions to the Grantee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Grantee&#146;s Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Grantee&#146;s name and address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTRICTED STOCK AWARD AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE AMYLYX PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2022 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="69%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Grantee:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No. of Shares:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Grant Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Amylyx Pharmaceuticals, Inc. 2022 Stock Option and Incentive Plan, as amended through the date
hereof (the &#147;Plan&#148;), Amylyx Pharmaceuticals, Inc. (the &#147;Company&#148;) hereby grants a Restricted Stock Award (an &#147;Award&#148;) to the Grantee named above. Upon acceptance of this Award, the Grantee shall receive the number of
shares of Common Stock, par value $0.0001 per share (the &#147;Stock&#148;), of the Company specified above, subject to the restrictions and conditions set forth herein and in the Plan. The Company acknowledges the receipt from the Grantee of
consideration with respect to the par value of the Stock in the form of cash, past or future services rendered to the Company by the Grantee or such other form of consideration as is acceptable to the Administrator. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Award</U>. The shares of Restricted Stock awarded hereunder shall be issued and held by the Company&#146;s transfer agent in book entry
form, and the Grantee&#146;s name shall be entered as the stockholder of record on the books of the Company. Thereupon, the Grantee shall have all the rights of a stockholder with respect to such shares, including voting and dividend rights,
subject, however, to the restrictions and conditions specified in Paragraph&nbsp;2 below. The Grantee shall (i)&nbsp;sign and deliver to the Company a copy of this Award Agreement and (ii)&nbsp;deliver to the Company a stock power endorsed in blank.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Restrictions and Conditions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Any book entries for the shares of Restricted Stock granted herein shall bear an appropriate legend, as determined by the Administrator in
its sole discretion, to the effect that such shares are subject to restrictions as set forth herein and in the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Shares of
Restricted Stock granted herein may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of by the Grantee prior to vesting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If the Grantee&#146;s Service Relationship with the Company and its Subsidiaries is voluntarily or involuntarily terminated for any reason
(including death) prior to vesting of shares of Restricted Stock granted herein, all shares of Restricted Stock shall immediately and automatically be forfeited and returned to the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Vesting of Restricted Stock</U>. The restrictions and conditions in Paragraph&nbsp;2 of this Agreement shall lapse on the Vesting Date or
Dates specified in the following schedule so long as the Grantee continues to have a Service Relationship with the Company or a Subsidiary on such Dates. If a series of Vesting Dates is specified, then the restrictions and conditions in
Paragraph&nbsp;2 shall lapse only with respect to the number of shares of Restricted Stock specified as vested on such date. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Incremental Number</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">of Shares Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Vesting&nbsp;Date</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to such Vesting Date or Dates, the shares of Stock on which all restrictions and conditions have lapsed shall no
longer be deemed Restricted Stock. The Administrator may at any time accelerate the vesting schedule specified in this Paragraph&nbsp;3. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Dividends</U>. Dividends on shares of Restricted Stock shall be paid currently to the Grantee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Incorporation of Plan</U>. Notwithstanding anything herein to the contrary, this Award shall be subject to and governed by all the terms
and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Transferability</U>. This Agreement is personal to the Grantee, is non-assignable and is not transferable in any manner, by operation of
law or otherwise, other than by will or the laws of descent and distribution. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Tax Withholding</U>. The Grantee shall, not later than
the date as of which the receipt of this Award becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to
be withheld on account of such taxable event. The Company shall have the authority to cause the required tax withholding obligation to be satisfied, in whole or in part, by (i)&nbsp;withholding from shares of Stock to be issued or released by the
transfer agent a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due; or (ii)&nbsp;causing its transfer agent to sell from the number of shares of Stock to be issued or released by the transfer
agent, the number of shares of Stock necessary to satisfy the Federal, state and local taxes required by law to be withheld from the Grantee on account of such transfer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Election Under Section&nbsp;83(b)</U>. The Grantee and the Company hereby agree that the Grantee may, within 30 days following the Grant
Date of this Award, file with the Internal Revenue Service and the Company an election under Section&nbsp;83(b) of the Code. In the event the Grantee makes such an election, he or she agrees to provide a copy of the election to the Company. The
Grantee acknowledges that he or she is responsible for obtaining the advice of his or her tax advisors with regard to the Section&nbsp;83(b) election and that he or she is relying solely on such advisors and not on any statements or representations
of the Company or any of its agents with regard to such election. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>No Obligation to Continue Service Relationship</U>. Neither the Company nor any
Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Grantee in a Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the
Company or any Subsidiary to terminate Grantee&#146;s Service Relationship with the Company or a Subsidiary at any time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.
<U>Integration</U>. This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Data Privacy Consent</U>. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the
Company, its subsidiaries and affiliates and certain agents thereof (together, the &#147;Relevant Companies&#148;) may process any and all personal or professional data, including but not limited to Social Security or other identification number,
home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#147;Relevant Information&#148;). By entering into this Agreement, the Grantee
(i)&nbsp;authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii)&nbsp;waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii)&nbsp;authorizes
the Relevant Companies to store and transmit such information in electronic form; and (iv)&nbsp;authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have
access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Notices</U>. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or
delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AMYLYX PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#146;s instructions to the Grantee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Grantee&#146;s Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Grantee&#146;s name and address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>9
<FILENAME>d155225dex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMYLYX PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2022 EMPLOYEE STOCK PURCHASE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the Amylyx Pharmaceuticals, Inc. 2022 Employee Stock Purchase Plan (the &#147;Plan&#148;) is to provide eligible employees of
Amylyx Pharmaceuticals, Inc. (the &#147;Company&#148;) and each Designated Subsidiary (as defined in Section&nbsp;11) with opportunities to purchase shares of the Company&#146;s common stock, par value $0.0001 per share (the &#147;Common
Stock&#148;). An aggregate of 605,000 shares of Common Stock have been approved and reserved for this purpose, plus on January&nbsp;1, 2023, and each January&nbsp;1 thereafter through January&nbsp;1, 2032 the number of shares of Common Stock
reserved and available for issuance under the Plan shall be cumulatively increased by the least of (i) 1,210,000 shares of Common Stock, (ii)&nbsp;one percent (1%) of the number of shares of Common Stock issued and outstanding on the immediately
preceding December 31st, or (iii)&nbsp;such number of shares of Common Stock as determined by the Administrator (as defined in Section&nbsp;1). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan includes two components: a Code Section&nbsp;423 Component (the &#147;423 Component&#148;) and a
<FONT STYLE="white-space:nowrap">non-Code</FONT> Section&nbsp;423 Component (the <FONT STYLE="white-space:nowrap">&#147;Non-423</FONT> Component&#148;). It is intended for the 423 Component to constitute an &#147;employee stock purchase plan&#148;
within the meaning of Section&nbsp;423(b) of the U.S. Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), and the 423 Component shall be interpreted in accordance with that intent. Under the
<FONT STYLE="white-space:nowrap">Non-423</FONT> Component, which does not qualify as an &#147;employee stock purchase plan&#148; within the meaning of Section&nbsp;423(b) of the Code, options will be granted pursuant to rules, procedures or <FONT
STYLE="white-space:nowrap">sub-plans</FONT> adopted by the Administrator designed to achieve tax, securities laws or other objectives for eligible employees. Except as otherwise provided herein, the <FONT STYLE="white-space:nowrap">Non-423</FONT>
Component will operate and be administered in the same manner as the 423 Component. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise defined herein, capitalized terms in this Plan shall have the meaning
ascribed to them in Section&nbsp;11. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Administration</U>. The Plan will be administered by the person or persons (the
&#147;Administrator&#148;) appointed by the Company&#146;s Board of Directors (the &#147;Board&#148;) for such purpose. The Administrator has authority at any time to: (i)&nbsp;adopt, alter and repeal such rules, guidelines and practices for the
administration of the Plan and for its own acts and proceedings as it shall deem advisable; (ii)&nbsp;interpret the terms and provisions of the Plan; (iii)&nbsp;make all determinations it deems advisable for the administration of the Plan;
(iv)&nbsp;decide all disputes arising in connection with the Plan; and (v)&nbsp;otherwise supervise the administration of the Plan. All interpretations and decisions of the Administrator shall be binding on all persons, including the Company and the
Participants. No member of the Board or individual exercising administrative authority with respect to the Plan shall be liable for any action or determination made in good faith with respect to the Plan or any option granted hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Offerings</U>. The Company may make one or more offerings to eligible employees to purchase Common Stock under the Plan
(&#147;Offerings&#148;). The Administrator shall determine, in its discretion, when the initial Offering and any subsequent Offering shall occur and the duration of each such Offering, provided that no Offering shall exceed 27 months in duration.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Eligibility</U>. All individuals classified as employees on the payroll records of the Company and each Designated Subsidiary are
eligible to participate in any one or more of the Offerings under the Plan, provided that as of the first day of the applicable Offering (the &#147;Offering Date&#148;) they are customarily employed for more than five months per calendar year (or
such lesser period of time as the Administrator shall determine in advance of the Offering) by the Company or a Designated Subsidiary for more than 20 hours a week (or such lesser number of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
hours per week as the Administrator shall determine in advance of an Offering) and have completed such period of service prior to the Offering Date as the Administrator may require (but in no
event will the required period of continuous employment be equal to or greater than two (2)&nbsp;years). Notwithstanding any other provision herein, individuals who are not contemporaneously classified as employees of the Company or a Designated
Subsidiary for purposes of the Company&#146;s or applicable Designated Subsidiary&#146;s payroll system are not considered to be eligible employees of the Company or any Designated Subsidiary and shall not be eligible to participate in the Plan. In
the event any such individuals are reclassified as employees of the Company or a Designated Subsidiary for any purpose, including, without limitation, common law or statutory employees, by any action of any third party, including, without
limitation, any government agency, or as a result of any private lawsuit, action or administrative proceeding, such individuals shall, notwithstanding such reclassification, remain ineligible for participation. Notwithstanding the foregoing, the
exclusive means for individuals who are not contemporaneously classified as employees of the Company or a Designated Subsidiary on the Company&#146;s or Designated Subsidiary&#146;s payroll system to become eligible to participate in this Plan is
through an amendment to this Plan, duly executed by the Company, which specifically renders such individuals eligible to participate herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Participation</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>Participants</U>. An eligible employee who is not a Participant in any prior Offering may participate in a subsequent Offering by submitting an enrollment form to his or her appropriate payroll location at least 15 business days before the
Offering Date (or by such other deadline as shall be established by the Administrator for the Offering). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Enrollment</U>. The enrollment form will (a)&nbsp;state a whole percentage to be
deducted from an eligible employee&#146;s Compensation (as defined in Section&nbsp;11) per pay period, (b)&nbsp;authorize the purchase of Common Stock in each Offering in accordance with the terms of the Plan and (c)&nbsp;specify the exact name or
names in which shares of Common Stock purchased for such individual are to be issued pursuant to Section&nbsp;10. An employee who does not enroll in accordance with these procedures will be deemed to have waived the right to participate. Unless a
Participant files a new enrollment form or withdraws from the Plan, such Participant&#146;s deductions and purchases will continue at the same percentage of Compensation for future Offerings, provided he or she remains eligible. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding the foregoing, participation in the Plan will neither be permitted nor be denied contrary to the requirements of the Code.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Employee Contributions</U>. Each eligible employee may authorize payroll deductions at a minimum of one percent (1%) up to a
maximum of fifteen percent (15%) of such employee&#146;s Compensation for each pay period. The Company will maintain book accounts showing the amount of payroll deductions made by each Participant for each Offering. No interest will accrue or be
paid on payroll deductions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Deduction Changes</U>. Except in the event of a Participant increasing his or her payroll deduction
from 0&nbsp;percent during the first Offering as specified in Section&nbsp;4(a) or as may be determined by the Administrator in advance of an Offering, a Participant may not increase or decrease his or her payroll deduction during any Offering, but
may increase or decrease his or her payroll deduction with respect to the next Offering (subject to the limitations of Section&nbsp;5) by filing a new enrollment form at least fifteen (15)&nbsp;business days before the next Offering Date (or by such
other deadline as shall be established by the Administrator for the Offering). The Administrator may, in advance of any Offering, establish rules permitting a Participant to increase, decrease or terminate his or her payroll deduction during an
Offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Withdrawal</U>. A Participant may withdraw from participation in the Plan by
delivering a written notice of withdrawal to his or her appropriate payroll location. The Participant&#146;s withdrawal will be effective as of the next business day. Following a Participant&#146;s withdrawal, the Company will promptly refund such
individual&#146;s entire account balance under the Plan to him or her (after payment for any Common Stock purchased before the effective date of withdrawal). Partial withdrawals are not permitted. Such an employee may not begin participation again
during the remainder of the Offering, but may enroll in a subsequent Offering in accordance with Section&nbsp;4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Grant of
Options</U>. On each Offering Date, the Company will grant to each eligible employee who is then a Participant in the Plan an option (&#147;Option&#148;) to purchase on the last day of such Offering (the &#147;Exercise Date&#148;), at the Option
Price hereinafter provided for, the lowest of (a)&nbsp;a number of shares of Common Stock determined by dividing such Participant&#146;s accumulated payroll deductions on such Exercise Date by the Option Price (as defined herein), (b)&nbsp;the
number of shares determined by dividing $25,000 by the Fair Market Value of the Common Stock on the Offering Date for such Offering; or (c)&nbsp;such other lesser maximum number of shares as shall have been established by the Administrator in
advance of the Offering; provided, however, that such Option shall be subject to the limitations set forth below. Each Participant&#146;s Option shall be exercisable only to the extent of such Participant&#146;s accumulated payroll deductions on the
Exercise Date. The purchase price for each share purchased under each Option (the &#147;Option Price&#148;) will be eighty-five percent (85%) of the Fair Market Value of the Common Stock on the Offering Date or the Exercise Date, whichever is less.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, no Participant may be granted an option hereunder if such
Participant, immediately after the option was granted, would be treated as owning stock possessing five&nbsp;percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or any Parent or Subsidiary (as
defined in Section&nbsp;11). For purposes of the preceding sentence, the attribution rules of Section&nbsp;424(d) of the Code shall apply in determining the stock ownership of a Participant, and all stock which the Participant has a contractual
right to purchase shall be treated as stock owned by the Participant. In addition, no Participant may be granted an Option which permits such Participant rights to purchase stock under the Plan, and any other employee stock purchase plan of the
Company and its Parents and Subsidiaries, to accrue at a rate which exceeds $25,000 of the fair market value of such stock (determined on the option grant date or dates) for each calendar year in which the Option is outstanding at any time. The
purpose of the limitation in the preceding sentence is to comply with Section&nbsp;423(b)(8) of the Code and shall be applied taking Options into account in the order in which they were granted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Exercise of Option and Purchase of Shares</U>. Each employee who continues to be a Participant in the Plan on the Exercise Date shall be
deemed to have exercised his or her Option on such date and shall acquire from the Company such number of whole shares of Common Stock reserved for the purpose of the Plan as his or her accumulated payroll deductions on such date will purchase at
the Option Price, subject to any other limitations contained in the Plan. Any amount remaining in a Participant&#146;s account at the end of an Offering solely by reason of the inability to purchase a fractional share will be carried forward to the
next Offering; any other balance remaining in a Participant&#146;s account at the end of an Offering will be refunded to the Participant promptly. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Issuance of Certificates</U>. Certificates or book-entries at the Company&#146;s
transfer agent representing shares of Common Stock purchased under the Plan may be issued only in the name of the employee, in the name of the employee and another person of legal age as joint tenants with rights of survivorship, or in the name of a
broker authorized by the employee to be his, her or their nominee for such purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Definitions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Compensation&#148; means the regular or basic rate of compensation. The Administrator, in its discretion, may establish a
different definition of Compensation for an Offering, which for the Section&nbsp;423 Component shall apply on a uniform and nondiscriminatory basis. Further, the Administrator will have discretion to determine the application of this definition to
eligible employees outside the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Designated Subsidiary&#148; means any present or future Subsidiary (as
defined below) that has been designated by the Board to participate in the Plan. The Board may so designate any Subsidiary, or revoke any such designation, at any time and from time to time, either before or after the Plan is approved by the
stockholders, and may further designate such companies or Participants as participating in the 423 Component or the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. The Board may also determine which Subsidiaries or eligible employees may
be excluded from participation in the Plan, to the extent consistent with Section&nbsp;423 of the Code or as implemented under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component, and determine which Designated Subsidiary or Subsidiaries
will participate in separate Offerings (to the extent that the Company makes separate Offerings). For purposes of the 423 Component, only the Company and its Subsidiaries may be Designated Subsidiaries; provided, however, that at any given time, a
Subsidiary that is a Designated Subsidiary under the 423 Component will not be a Designated Subsidiary under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. The current list of Designated Subsidiaries is attached hereto as Appendix A.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Fair Market Value of the Common Stock&#148; on any given date means the fair
market value of the Common Stock determined in good faith by the Administrator; provided, however, that if the Common Stock is admitted to quotation on the National Association of Securities Dealers Automated Quotation System (&#147;NASDAQ&#148;),
the NASDAQ Global Market, The New York Stock Exchange or another national securities exchange, the determination shall be made by reference to the closing price on such date. If there is no closing price for such date, the determination shall be
made by reference to the last date preceding such date for which there is a closing price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Parent&#148; means a
&#147;parent corporation&#148; with respect to the Company, as defined in Section&nbsp;424(e) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term
&#147;Participant&#148; means an individual who is eligible as determined in Section&nbsp;3 and who has complied with the provisions of Section&nbsp;4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Subsidiary&#148; means a &#147;subsidiary corporation&#148; with respect to the Company, as defined in Section&nbsp;424(f) of
the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Rights on Termination of Employment</U>. If a Participant&#146;s employment terminates for any reason before the
Exercise Date for any Offering, no payroll deduction will be taken from any pay due and owing to the Participant and the balance in the Participant&#146;s account will be paid to such Participant or, in the case of such Participant&#146;s death, to
his or her designated beneficiary as if such Participant had withdrawn from the Plan under Section&nbsp;7. An employee will be deemed to have terminated employment, for this purpose, if the corporation that employs him or her, having been a
Designated Subsidiary, ceases to be a Subsidiary, or if the employee is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transferred to any corporation other than the Company or a Designated Subsidiary; provided, however, that if a Participant transfers from an Offering under the 423 Component to an Offering under
the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component, the exercise of the Participant&#146;s Option will be qualified under the 423 Component only to the extent that such exercise complies with Section&nbsp;423 of the Code. If a Participant
transfers from an Offering under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component to an Offering under the 423 Component, the exercise of the Participant&#146;s Option will remain <FONT STYLE="white-space:nowrap">non-qualified</FONT>
under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. An employee will not be deemed to have terminated employment for this purpose if the employee is on an approved leave of absence for military service or sickness or for any other
purpose approved by the Company, if the employee&#146;s right to reemployment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise provides in
writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Special Rules and <FONT STYLE="white-space:nowrap">Sub-Plans</FONT></U>. Notwithstanding anything herein to the contrary,
the Administrator may adopt special rules applicable to the employees of a particular Designated Subsidiary, whenever the Administrator determines that such rules are necessary or appropriate for the implementation of the Plan in a jurisdiction
where such Designated Subsidiary has employees; provided that if such special rules or <FONT STYLE="white-space:nowrap">sub-plans</FONT> are inconsistent with the requirements of Section&nbsp;423(b) of the Code, the employees subject to such special
rules or <FONT STYLE="white-space:nowrap">sub-plans</FONT> will participate in the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. Any special rules or <FONT STYLE="white-space:nowrap">sub-plans</FONT> established pursuant to this
Section&nbsp;13 shall, to the extent possible, result in the employees subject to such rules having substantially the same rights as other Participants in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Optionees Not Stockholders</U>. Neither the granting of an Option to a Participant nor the deductions from his or her pay shall
constitute such Participant a holder of the shares of Common Stock covered by an Option under the Plan until such shares have been purchased by and issued to him or her. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Rights Not Transferable</U>. Rights under the Plan are not transferable by a
Participant other than by will or the laws of descent and distribution, and are exercisable during the Participant&#146;s lifetime only by the Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Application of Funds</U>. All funds received or held by the Company under the Plan may be combined with other corporate funds and may
be used for any corporate purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>Adjustment in Case of Changes Affecting Common Stock</U>. In the event of a subdivision of
outstanding shares of Common Stock, the payment of a dividend in Common Stock or any other change affecting the Common Stock, the number of shares approved for the Plan shall be equitably or proportionately adjusted to give proper effect to such
event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>Amendment of the Plan</U>. The Board may at any time and from time to time amend the Plan in any respect, except that
without the approval within 12 months of such Board action by the stockholders, no amendment shall be made increasing the number of shares approved for the Plan or making any other change that would require stockholder approval in order for the 423
Component of the Plan, as amended, to qualify as an &#147;employee stock purchase plan&#148; under Section&nbsp;423(b) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.
<U>Insufficient Shares</U>. If the total number of shares of Common Stock that would otherwise be purchased on any Exercise Date plus the number of shares purchased under previous Offerings under the Plan exceeds the maximum number of shares
issuable under the Plan, the shares then available shall be apportioned among Participants in proportion to the amount of payroll deductions accumulated on behalf of each Participant that would otherwise be used to purchase Common Stock on such
Exercise Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <U>Termination of the Plan</U>. The Plan may be terminated at any time by the Board.
Upon termination of the Plan, all amounts in the accounts of Participants shall be promptly refunded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <U>Governmental
Regulations</U>. The Company&#146;s obligation to sell and deliver Common Stock under the Plan is subject to obtaining all governmental approvals required in connection with the authorization, issuance, or sale of such stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. <U>Governing Law</U>. This Plan and all Options and actions taken thereunder shall be governed by, and construed in accordance with the
General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts, applied without regard
to conflict of law principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23. <U>Issuance of Shares</U>. Shares may be issued upon exercise of an Option from authorized but
unissued Common Stock, from shares held in the treasury of the Company, or from any other proper source. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24. <U>Tax Withholding</U>.
Participation in the Plan is subject to any minimum required tax withholding on income of the Participant in connection with the Plan. Each Participant agrees, by entering the Plan, that the Company and its Subsidiaries shall have the right to
deduct any such taxes from any payment of any kind otherwise due to the Participant, including shares issuable under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25.
<U>Notification Upon Sale of Shares Under the 423 Component</U>. Each Participant agrees, by entering the 423 Component of the Plan, to give the Company prompt notice of any disposition of shares purchased under the Plan where such disposition
occurs within two years after the date of grant of the Option pursuant to which such shares were purchased or within one year after the date such shares were purchased. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">26. <U>Effective Date and Approval of Shareholders</U>. This Plan shall take effect on the
date immediately preceding the date upon which the registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> that is filed by the Company with respect to its initial public offering is declared effective by the Securities and
Exchange Commission following stockholder approval in accordance with applicable state law, the Company&#146;s bylaws and articles of incorporation, each as amended, and applicable stock exchange rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">APPENDIX A </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Designated Subsidiaries</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>10
<FILENAME>d155225dex104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMYLYX PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXECUTIVE CASH INCENTIVE BONUS PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Purpose</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Executive Cash Incentive Bonus Plan (the &#147;<B><I>Incentive</I></B> <B><I>Plan</I></B>&#148;) is intended to promote the achievement of
excellent performance and business results, aligning eligible executives of Amylyx Pharmaceuticals, Inc. (the &#147;<B><I>Company</I></B>&#148;) and its subsidiaries goals and interests to those of the Company and its stockholders. The plan enables
the Company to attract, retain, motivate and reward highly qualified executives who are responsible for providing leadership to the Company as it attains its significant business objectives. The Incentive Plan is for the benefit of Covered
Executives (as defined below). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Covered Executives</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, the Compensation Committee of the Board of Directors of the Company (the &#147;<B><I>Compensation</I></B>
<B><I>Committee</I></B>&#148;) may select certain key executives (the &#147;<B><I>Covered</I></B> <B><I>Executives</I></B>&#148;) to be eligible to receive bonuses hereunder. Participation in this Plan does not change the &#147;at will&#148; nature
of a Covered Executive&#146;s employment with the Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Administration</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee shall have the sole discretion and authority to administer and interpret the Incentive Plan. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Bonus Determinations</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Corporate Performance Goals</U>. A Covered Executive may receive a bonus payment under the Incentive Plan based upon the attainment of
one or more performance objectives that are established by the Compensation Committee and relate to financial and operational metrics with respect to the Company or any of its subsidiaries (the &#147;<B><I>Corporate Performance Goals</I></B>&#148;),
including, without limitation, the following: developmental, publication, clinical, supply chain or regulatory milestones; cash flow (including, but not limited to, operating cash flow and free cash flow); revenue; corporate revenue; earnings before
interest, taxes, depreciation and amortization; net income (loss) (either before or after interest, taxes, depreciation and/or amortization); changes in the market price of the Company&#146;s common stock; economic value-added; acquisitions or
strategic transactions, including licenses, collaborations, joint ventures or promotion arrangements; operating income (loss); return on capital, assets, equity, or investment; stockholder returns; return on sales; gross or net profit levels;
productivity; expense efficiency; margins; operating efficiency; working capital; earnings (loss) per share of the Company&#146;s common stock; sales or market shares; any of which may be (A)&nbsp;measured in absolute terms or compared to any
incremental increase, (B)&nbsp;measured in terms of growth, (C)&nbsp;compared to another company or companies or to results of a peer group, (D)&nbsp;measured against the market as a whole and/or as compared to applicable market indices and/or
(E)&nbsp;measured on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> or <FONT STYLE="white-space:nowrap">post-tax</FONT> basis (if applicable). Further, any Corporate Performance Goals may be used to measure the performance of the Company as a
whole or a business unit or other segment of the Company, or one or more product lines or specific markets.&nbsp;The Corporate Performance Goals may differ from Covered Executive to Covered Executive.<B> </B> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Calculation of Corporate Performance Goals</U>. At the beginning of each applicable
performance period, the Compensation Committee will determine whether any significant element(s) will be included in or excluded from the calculation of any Corporate Performance Goal with respect to any Covered Executive.&nbsp;In all other
respects, Corporate Performance Goals will be calculated in accordance with the Company&#146;s financial statements, generally accepted accounting principles, or under a methodology established by the Compensation Committee at the beginning of the
performance period and that is consistently applied with respect to a Corporate Performance Goal in the relevant performance period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)
<U>Target; Minimum; Maximum</U>. Each Corporate Performance Goal shall have a &#147;target&#148; (100&nbsp;percent attainment of the Corporate Performance Goal) and may also have a &#147;minimum&#148; hurdle and/or a &#147;maximum&#148; amount. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Bonus Requirements; Individual Goals</U>. Except as otherwise set forth in this Section&nbsp;4(d): (i) any bonuses paid to Covered
Executives under the Incentive Plan shall be based upon objectively determinable bonus formulas that tie such bonuses to one or more performance targets relating to the Corporate Performance Goals, (ii)&nbsp;bonus formulas for Covered Executives
shall be adopted in each performance period by the Compensation Committee and communicated to each Covered Executive at the beginning of each performance period and (iii)&nbsp;no bonuses shall be paid to Covered Executives unless and until the
Compensation Committee makes a determination with respect to the attainment of the performance targets relating to the Corporate Performance Goals. Notwithstanding the foregoing, the Compensation Committee may adjust bonuses payable under the
Incentive Plan based on achievement of one or more individual performance objectives or pay bonuses (including, without limitation, discretionary bonuses) to Covered Executives under the Incentive Plan based on individual performance goals and/or
upon such other terms and conditions as the Compensation Committee may in its discretion determine. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Individual Target Bonuses</U>.
The Compensation Committee shall establish a target bonus opportunity for each Covered Executive for each performance period. For each Covered Executive, the Compensation Committee shall have the authority to apportion the target award so that a
portion of the target award shall be tied to attainment of Corporate Performance Goals and a portion of the target award shall be tied to attainment of individual performance objectives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Employment Requirement</U>. Subject to any additional terms contained in a written agreement between the Covered Executive and the
Company, the payment of a bonus to a Covered Executive with respect to a performance period shall be conditioned upon the Covered Executive&#146;s employment by the Company on the bonus payment date. If a Covered Executive was not employed for an
entire performance period, the Compensation Committee may pro rate the bonus based on the number of days employed during such period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Timing of Payment</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) With respect to Corporate Performance Goals established and measured on a basis more frequently than annually (e.g., quarterly or
semi-annually), the Corporate Performance Goals will be measured at the end of each performance period after the Company&#146;s financial reports with respect to such period(s) have been published. If the Corporate Performance Goals and/or
individual goals for such period are met, payments will be made as soon as practicable following the end of such period, but not later 74 days after the end of the fiscal year in which such performance period ends. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) With respect to Corporate Performance Goals established and measured on an annual or multi-year basis, Corporate Performance Goals will be
measured as of the end of each such performance period (e.g., the end of each fiscal year) after the Company&#146;s financial reports with respect to such period(s) have been published. If the Corporate Performance Goals and/or individual goals for
any such period are met, bonus payments will be made as soon as practicable, but not later than 74 days after the end of the relevant fiscal year. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) For the avoidance of doubt, bonuses earned at any time in a fiscal year must be paid no later than 74 days after the last day of such
fiscal year. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Amendment and Termination</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company reserves the right to amend or terminate the Incentive Plan at any time in its sole discretion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>11
<FILENAME>d155225dex105.htm
<DESCRIPTION>EX-10.5
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMYLYX PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NON-EMPLOYEE DIRECTOR COMPENSATION POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of this <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy (the &#147;Policy&#148;) of Amylyx Pharmaceuticals, Inc.
(the &#147;Company&#148;) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries (&#147;Outside
Directors&#148;). This Policy will become effective as of the effective time of the registration statement for the Company&#146;s initial public offering of equity securities (the &#147;Effective Date&#148;). In furtherance of the purpose stated
above, all Outside Directors shall be paid compensation for services provided to the Company as set forth below: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Cash Retainers </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Annual Retainer for Board Membership</U>: $40,000 for general availability and participation in meetings and conference calls of our Board
of Directors, to be paid quarterly in arrears, <FONT STYLE="white-space:nowrap">pro-rated</FONT> based on the number of actual days served by the director during such calendar quarter. No additional compensation will be paid for attending individual
meetings of the Board of Directors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>Annual Retainer for Board Chair:</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>Additional Annual Retainers for Committee Membership:</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee Chair:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee member:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation Committee Chair:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation Committee member:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Corporate Governance Committee Chair:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 8,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Corporate Governance Committee member:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 4,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Chair and committee member retainers are in addition to retainers for members of the Board of Directors.
No additional compensation will be paid for attending individual committee meetings of the Board of Directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Equity Retainers </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Initial Award</U>: An initial, <FONT STYLE="white-space:nowrap">one-time</FONT> stock option award (the &#147;Initial Award&#148;) to
purchase/covering 38,000 shares under the Company&#146;s 2022 Stock Option and Incentive Plan will be granted to each new Outside Director upon his or her election to the Board of Directors, which shall vest
<FONT STYLE="white-space:nowrap">one-third</FONT> on the first anniversary of the date of grant, and the remaining <FONT STYLE="white-space:nowrap">two-thirds</FONT> will vest in equal monthly installments over two years, provided, however, that all
vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director of the Company. In addition, all vested options remain exercisable for twelve (12)&nbsp;months if the director resigns from the Board
of Directors or otherwise ceases to serve as a director. The Initial Award shall expire ten years from the date of grant, and shall have a per share exercise price equal to the Fair Market Value (as defined in the Company&#146;s 2022 Stock Option
and Incentive Plan) of the Company&#146;s common stock on the date of grant. This Initial Award applies only to Outside Directors who are first elected to the Board of Directors subsequent to the Effective Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Annual Award</U>: On each date of each Annual Meeting of Stockholders of the Company
following the Effective Date (the &#147;Annual Meeting&#148;), each continuing Outside Director, other than a director receiving an Initial Award, will receive an annual stock option award (the &#147;Annual Award&#148;) to purchase/covering 19,000
shares under the Company&#146;s 2022 Stock Option and Incentive Plan, which shall vest in full upon the earlier of (i)&nbsp;the first anniversary of the date of grant or (ii)&nbsp;the date of the next Annual Meeting; provided, however, that all
vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. In addition, all vested options
remain exercisable for twelve (12)&nbsp;months if the director resigns from the Board of Directors or otherwise ceases to serve as a director. Notwithstanding the foregoing, if an Outside Director was initially elected to the Board of Directors
within twelve (12)&nbsp;months preceding the Annual Meeting, then such Outside Director shall receive Annual Award that is <FONT STYLE="white-space:nowrap">pro-rated</FONT> on a monthly basis for time serving as an Outside Director. Such Annual
Award shall expire ten years from the date of grant, and shall have a per share exercise price equal to the Fair Market Value (as defined in the Company&#146;s 2022 Stock Option and Incentive Plan) of the Company&#146;s common stock on the date of
grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Value</U>: For purposes of this Policy, &#147;Value&#148; means with respect to any stock option award, the grant date fair
value of the option (i.e., Black-Scholes Value) determined in accordance with the reasonable assumptions and methodologies employed by the Company for calculating the fair value of options under Financial Accounting Standard Board (&#147;FASB&#148;)
Accounting Standards Codification (&#147;ASC&#148;) Topic 718. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Sale Event Acceleration</U>: All outstanding Initial Awards and Annual
Awards held by an Outside Director shall become fully vested and exercisable upon a Sale Event (as defined in the Company&#146;s 2022 Stock Option and Incentive Plan). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Expenses </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company will
reimburse all reasonable out-of-pocket expenses incurred by non-employee directors in attending meetings of the Board of Directors or any committee thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Maximum Annual Compensation </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The aggregate amount of compensation, including both equity compensation and cash compensation, paid by the Company to any Outside Director in
a calendar year for services as an Outside Director shall not exceed $750,000; provided, however, that such amount shall be $1,000,000 for the calendar year in which the applicable Outside Director is initially elected or appointed to the Board of
Directors; (or such other limits as may be set forth in Section&nbsp;3(b) of the Company&#146;s 2022 Stock Option and Incentive Plan or any similar provision of a successor plan). For this purpose, the &#147;amount&#148; of equity compensation paid
in a calendar year shall be determined based on the grant date fair value thereof, as determined in accordance with FASB ASC Topic 718 or its successor provision, but excluding the impact of estimated forfeitures related to service-based vesting
conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adopted December 29, 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>12
<FILENAME>d155225dex107.htm
<DESCRIPTION>EX-10.7
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.7</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.7 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS EMPLOYMENT AGREEMENT </B>(the &#147;<U>Agreement</U>&#148;) is made and entered into as of the 1st day of July, 2015 (the
&#147;Effective Date&#148;), by and between <B>JOSHUA B. COHEN </B>of 373 Columbia Street, Apt. 1, Cambridge, MA 02141 (the &#147;Employee&#148;) and <B>AMYLYX PHARMACEUTICALS, INC., </B>a Delaware corporation duly organized under law and having a
usual place of business 210 Broadway #201, Cambridge, MA 02139 (the &#147;<U>Company</U>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is engaged in the business of researching, discovering, developing and commercializing therapeutics for the treatment of
neurodegenerative diseases (the &#147;<U>Business</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company desires to employ the Employee as the Chief Executive Officer
and the Employee desires to be so employed by the Company, on the terms and conditions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company desires to bind the
Employee to certain restrictive covenants, and Employee agrees to be so bound on the terms and conditions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW,
THEREFORE, for good and valuable consideration, including the mutual covenants and agreements herein contained, the receipt and legal sufficiency of which are hereby acknowledged, accepted and agreed to, the parties hereto agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Term of Employment.</U> Subject to the terms hereof, the Employee&#146;s employment hereunder shall commence on
the Effective Date and shall be <FONT STYLE="white-space:nowrap">at-will;</FONT> meaning that either party may terminate this Agreement at any time upon twenty (20)&nbsp;days prior written notice to the other, and upon the expiration of the
aforesaid twenty (20)&nbsp;day period, this Agreement shall terminate and thereafter be null and void and without further force or effect except for those provisions which survive in accordance with this Agreement. The term of the Employee&#146;s
employment under this Agreement is hereafter referred to as the &#147;Employment Term&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Employment
Duties.</U> During the Employment Term, the Employee shall serve as the Chief Executive Officer, subject to the terms and conditions of this Agreement, and shall report to and take direction from the Company&#146;s Board of Directors (the
&#147;Board&#148;). The Employee agrees that he will faithfully and diligently perform the services and assume such duties and responsibilities as are assigned to him by the Board and that he will carry out and perform the duties and
responsibilities customarily associated with said position and office. The Employee shall devote his best efforts and full business time and attention to the business and affairs of the Company and the performance of his duties hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Employee shall initially be located in Cambridge, Massachusetts and shall travel on behalf of the Company as needed and requested. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Employee represents and warrants to the Company as follows: (i)&nbsp;that he is under no
contractual or other restriction or obligation which is inconsistent with the execution of this Agreement, or which will interfere with the performance of his duties hereunder, nor does the Employee have any obligation of confidentiality to any
third party which interferes with his obligations hereunder; (ii)&nbsp;that the execution and performance of this Agreement will not violate any policies or procedures of any academic institution or corporation (public or private) with which he is
involved or associated with and that he has received all of the necessary written permission(s) to enter into this Agreement and (iii)&nbsp;that in providing the services to the Company, he will not use any resources belonging to any corporation,
company, institution (public, private, profit or <FONT STYLE="white-space:nowrap">non-profit),</FONT> or other third party, including, but not limited to utilities, facilities, computers, laboratories or supplies or otherwise engage the services,
consult with or employ any individual not previously approved in writing by the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation.</U>
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Base Salary.</U> Subject to the provisions of this Agreement, the Company shall pay the Employee a base
salary at the initial rate of Sixty Thousand ($60,000.00) Dollars calculated on an annual basis (the &#147;Base Salary&#146;&#146;), which shall be paid in accordance with the Company&#146;s normal payroll procedures and policies. Any adjustments to
the Base Salary shall be approved by the Board after discussion with the Employee, provided, however, that the Base Salary may not be reduced. All payments made to the Employee pursuant to this Agreement shall be treated as wages for withholding and
employment tax purposes as provided by law, except that reimbursement of expenses will not be so treated to the extent permitted by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Cash Bonus.</U> In addition to the Base Salary, the Employee may be entitled to a bonus based upon the
successful completion of certain goals and objectives approved by the Board. These goals may relate to the achievement of corporate goals; the achievement of individual goals or a combination of the same. When the goals are agreed to, they shall be
identified on <U>Exhibit &#147;A&#148;</U> and added to this Agreement. The decision of the Board as to whether or not the goals have been achieved and the amount of the bonus to be awarded, if any, shall be final and binding on the parties. A
bonus, if awarded, shall not be added to the Base Salary and, if awarded, will be paid within forty five (45)&nbsp;days after the end of the year with respect to which the bonus is being awarded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock Option Bonus.</U> The Company agrees that, from time to time during the Employment Term, the Employee may
be eligible for additional stock option grants as determined, on an annual basis, by the Board and based upon the successful completion of annual goals and objectives as determined by the Board. All such grants shall vest in accordance with the
Company&#146;s standard form option grant agreement. The decision of the Board as to whether or not to award any stock options shall be final and binding on the parties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Benefits.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Employee may be entitled, during the Employment Term, to receive paid medical, dental, and disability insurance
if, and to the extent available and to participate in any and all employee benefit plans and programs, including, without limitation, life insurance, and 401(k) plans, as are maintained from time to time, for employees of the Company subject to plan
terms and applicable Company policies. (the &#147;Benefits&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;During the Employment Term, the Employee shall be entitled to
four (4)&nbsp;weeks paid vacation per calendar year, to be taken at times mutually acceptable to Employee and the Company, and national and state holidays as are observed by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Reimbursement of Expenses.</U> The Employee shall be entitled to reimbursement for ordinary, necessary and
reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> business expenses, which Employee incurs in connection with performing his duties under this Agreement. The reimbursement of all such expenses
shall be made in accordance with the Company&#146;s customary practices and policies (including presentation of evidence reasonably satisfactory to the Company of the amounts and nature of such expenses) for reimbursement of expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Restrictive Covenants.</U> As partial consideration of the Company entering into this Agreement, the Employee
agrees that at all times during which the Employee is employed by the Company and continuing for a period of one (1)&nbsp;year following the expiration or termination of the Employee&#146;s employment under this Agreement for any reason (the
&#147;Restricted Period&#148;), the Employee shall not, directly or indirectly, without the prior written consent of the Company, any place in the world: (A)&nbsp;engage or participate, as an owner, partner, shareholder (except as the holder of not
more than one percent (1%) of the outstanding stock of a publicly-traded company), member, employee, adviser, consultant, sales representative, officer, director, agent or otherwise, in any Competitive Business (as defined below); (B) without
limiting the generality of the foregoing, solicit any customer of the Company to purchase from any source other than the Company any product or service which is distributed, sold or provided by the Company during the term of Employee&#146;s
employment or as of the date of termination or expiration of the Employee&#146;s employment or otherwise interfere with any relationship between the Company and any customer or former customer of the Company; (C)&nbsp;solicit any employee,
consultant or advisor to the Company to leave the employ of or cease consulting or advising for the Company or solicit or request any employee of or consultant or advisor to the Company to join the employ of, or begin consulting or advising for any
individual or entity which directly or indirectly competes with the Company or (D)&nbsp;without limiting the generality of clause (A)&nbsp;above, solicit any supplier, distributor, manufacturer, licensor, or licensee of the Company to cease doing
any business with, or to limit or alter its business relationship with the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used herein, a <U>&#147;Competitive
Business&#148;</U> shall mean a business which is directly or indirectly competitive with the business of the Company as conducted at the time of the expiration or termination of Employee&#146;s employment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Proprietary Rights.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.1&nbsp;&nbsp;&nbsp;&nbsp; <U>Definitions.</U> For the purposes of this Article 7, the terms set forth below shall have the following
meanings: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.1.1 <U>Concept and Ideas.</U> Those concepts and ideas disclosed by the Company to
Employee or which are first developed or conceived by Employee during the Employment Term and which relate to the Company&#146;s present, past or prospective activities, services and products, all of which shall remain the sole and exclusive
property of the Company (hereinafter, collectively referred as &#147;Concepts and Ideas&#148;). Further, the Employee shall have no publication rights hereunder and all of the same shall belong exclusively to the Company. Employee acknowledges and
agrees that all works and tasks performed by Employee for or on behalf of the Company, or in connection therewith during the Employment Terms (the &#147;Works&#148;) are owned by the Company. Employee acknowledges and agrees that, to the fullest
extent allowed by law, all of the Works are &#147;works made for hire,&#148; as that phrase is defined in the Copyright Revision Act of 1976 (17 U.S.C. &#167; IOI) (the &#147;Act&#148;) in that either: (i)&nbsp;such Works are and will be prepared
within the scope of this Agreement or (ii)&nbsp;such Works have been and will be specifically ordered or commissioned for use as set forth in the Act. The Company shall therefore be deemed to be the sole author and owner of any and all right, title,
and interest therein, including, without limitation, all intellectual property rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.1.2. <U>Confidential Information.</U>
Confidential Information means that secret or proprietary information of whatever kind or nature disclosed to Employee by or on behalf of the Company during the Employment Term (whether or not invented, discovered or developed by Employee) or first
developed by Employee hereunder or otherwise during the Employment Term, or any other information derived from the Confidential Information. Such secret or proprietary information shall include (unless such information is generally available to the
public or known in the industry through no action of Employee) information relating to the design, manufacture, application, trade secrets, know how, research and development relating to the Company&#146;s products, materials, operating and other
cost data, price lists and data relating to the Company&#146;s products. Such secret or proprietary information shall specifically include, without limitation, all such secret or proprietary information contained in the Company&#146;s manuals,
memoranda, plans, drawings and designs, specifications, supply sources, customer lists and records legended or otherwise identified by the Company or the Board as Confidential Information. The Employee&#146;s obligations with respect to Confidential
Information will cease when the Confidential Information: (i)&nbsp;becomes part of the public domain through no wrongful act of the Employee, or (ii)&nbsp;is approved for release by prior written authorization of the Company. However, Confidential
Information shall be considered Confidential Information even if a portion or specific sections of the Confidential Information are known or generally available to the general public; and the Confidential Information shall not lose its character and
status as Confidential Information unless and until all of the Confidential Information is in the public domain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2.&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT STYLE="white-space:nowrap">Non-Disclosure</FONT> to Third Parties.</U> Except as required by
Employee&#146;s duties, Employee shall not, at any time, now or in the future, directly or indirectly, use, publish, disseminate, reproduce or otherwise disclose any Confidential Information, Concepts and Ideas relating to the present, past or
prospective business of the Company to any third party. Further, and recognizing the highly competitive nature of the Company&#146;s business and the need to protect its intellectual property, all publication rights shall belong solely to the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Documents, etc.</U> All documents, procedural manuals, guides, specifications, plans, drawings,
designs and similar materials, lists of present, past or prospective customers, customer proposals, invitations to submit proposals, price lists and data relating to the pricing of the Company&#146;s products and services, records, notebooks and
similar repositories of or containing Confidential Information (including all copies thereof) that come into Employee&#146;s possession or control by reason of Employee&#146;s relationship with the Company, whether prepared by Employee or others:
(a) are and shall remain the property of the Company, (b)&nbsp;will not be used by Employee in any way adverse to the Company, (c)&nbsp;will not be removed from the Company&#146;s premises (except as Employee&#146;s duties require) and (d)&nbsp;at
the termination (for whatever reason) of Employee&#146;s relationship with the Company, will be left with, or forthwith returned by Employee to, the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Patents, etc</U>. Any interest in patents, patent
applications, inventions, technological innovations, improvements, enhancements, copyrights, copyrightable works, developments, discoveries, designs, processes, formulas, <FONT STYLE="white-space:nowrap">know-how,</FONT> data and analysis, whether
patentable or not (collectively, the &#147;Inventions&#148;), which Employee as a result of rendering the Services to the Company under this Agreement may conceive or develop shall belong exclusively to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment.</U> The Employee hereby irrevocably assigns and, to the extent any such assignment cannot be made
at present, hereby agrees to irrevocably and automatically assign to the Company, without further compensation or consideration of his rights, title and interest in and to all Concepts, Ideas, Works, and Inventions and any and all related patents,
patent applications, copyrights, copyright applications, licenses, trademarks, trade names and other proprietary or intellectual property rights in the United States and throughout the world. The Employee agrees that he will promptly, without any
additional costs, expense or consideration, execute when presented, whether during the Employment Term or at any time thereafter, all documents, agreements, applications and instruments and perform all lawful acts which the Company considers
necessary or advisable to secure its rights hereunder and to carry out the intent of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Specific Performance.</U> Employee agrees that any violation by him of Sections 6 or 7 of this Agreement would be
highly injurious to the Company and would cause irreparable harm to the Company. By reason of the foregoing, Employee consents and agrees that if he violates or threatens to violate any provision(s) of Sections 6 or 7 of this Agreement, the Company
shall be entitled, in addition to any other rights and remedies that it may have, to apply to any court of competent jurisdiction for specific performance and/or injunctive or other equitable relief (without the requirement of posting of a bond or
other security) in order to enforce, or prevent any continuing or potential violation of, the provisions of such Section(s). The Employee also recognizes that the territorial, time and scope limitations set forth in Sections 6 and 7, as applicable,
are reasonable and are properly required and necessary for the protection of the Company and in the event that any such territorial, time or scope limitation is deemed to be unreasonable by a court of competent jurisdiction, the Company and the
Employee agree, and Employee submits, to the reduction of any or all of said territorial, time or scope limitations to such an area, period or scope as said court shall deem reasonable under the circumstances. If such partial enforcement is not
possible, the provision shall be deemed severed, and the remaining provisions of this Agreement shall remain in full force and effect. Employee acknowledges that Sections 6 and 7 of this Agreement shall survive termination or expiration of the
Employee&#146;s employment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination.</U> Notwithstanding the notice provision of
Article 1 hereof, Employee&#146;s employment with the Company: (i)&nbsp;shall terminate upon the Employee&#146;s resignation, death or disability, (ii)&nbsp;may be terminated without prior notice by the Board for Just Cause (as defined herein) and
(iii)&nbsp;may be terminated without cause by either party upon twenty (20)&nbsp;days prior notice to the other party as set forth in Article 1 hereof. As used in this Agreement, &#147;<U>Just Cause</U>&#148; means any of the following, as
determined by the Board, in its reasonable judgment: (1)&nbsp;Employee&#146;s continuous failure or continuous refusal to perform the duties and responsibilities as are requested of him by the Company; (2)&nbsp;Employee&#146;s gross negligence or
willful misconduct in the performance of Employee&#146;s duties or (3)&nbsp;the commission by Employee of any act of embezzlement against Company or the commission of any felony or act involving moral turpitude. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as hereinafter provided, effective as of the termination or expiration date of the Employee&#146;s employment hereunder for any reason,
or for no reason, or in the event the Employee resigns, or his death or disability then, in any of such events, the Employee shall be paid his Base Salary and benefits through the date of expiration or termination and all the rights and options
granted to the Employee pursuant to Articles 3 and 4 hereof shall cease and terminate as of the date of the Employee&#146;s termination, expiration or resignation and thereafter shall be null and void and without further force or effect.
Notwithstanding anything to the contrary herein contained, it is expressly agreed and understood that: (i)&nbsp;if the Employee is terminated by the Company without cause, or the Employee terminates his employment for Good Reason, as hereinafter
defined, prior to a &#147;Change of Control&#148; then the Employee shall be entitled to severance payments equal to twelve (12)&nbsp;months continuation of his Base Salary, a <FONT STYLE="white-space:nowrap">pro-rata</FONT> share of any bonus for
which the Employee was eligible, continuation of benefits for the twelve (12)&nbsp;months severance period (or additional compensation in an amount reflecting the cost to the Company of such benefits if the benefit plans do not provide for
continuation) and continued vesting of stock options for twelve (12)&nbsp;months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All severance payments of Base Salary and benefits
pursuant to subsection (i)&nbsp;will be paid in accordance with the provisions of this Agreement. Alternatively, if the Employee is terminated by the Company without cause, or the Employee terminates his employment for Good Reason, as hereinafter
defined, within nine (9)&nbsp;months following a &#147;Change of Control,&#148; the Employee shall be entitled to a <FONT STYLE="white-space:nowrap">one-time</FONT> severance payment equal to twelve (12)&nbsp;months of his Base Salary as of the date
of termination, and such severance payment shall be paid as of the date of termination. If the Employee remains employed by the Company following the nine (9)&nbsp;months after a &#147;Change of Control,&#148; the severance benefits described in
subsection (i)&nbsp;shall again apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, &#147;Good Reason&#148; is defined to exist upon: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The relocation of the Company&#146;s offices such that the Employee&#146;s daily commute is increased by at
least fifteen (15)&nbsp;miles each way without the written consent of the Employee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Material reduction of the Employee&#146;s Base Salary without the prior consent of the employee (other than in
connection with, and substantially proportionate to reductions by the Company of the Base Salary of more than 50% of its employees); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Material diminution in Employee&#146;s duties, authority or responsibilities without the prior consent of the
Employee, other than changes in duties, authority or responsibilities resulting from the Employee&#146;s misconduct; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provided, however, that any reduction in duties, authority or responsibilities or reduction in the level of management to which the Employee
reports resulting solely from a Change in Control which results in the Company being acquired by and made a part of a larger entity shall not constitute Good Reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice.</U> Any notice provided for in this Agreement must be in writing and must be either personally
delivered, mailed by first class mail (postage prepaid and return receipt requested), sent by reputable overnight courier service (charges prepaid), or sent by confirmed facsimile at the address indicated below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="68%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>To the Company:</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>To Employee:</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">AMYLYX&nbsp;PHARMACEUTICALS,&nbsp;INC.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Joshua B. Cohen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">210 Broadway #201</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">373 Columbia Street, Apt. 1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cambridge, MA 02139 </TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02141 </P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn: Justin Klee, President</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or such other address and/or to the attention of such other person as the recipient party shall have designated by notice
given in accordance with this Section&nbsp;10. All notices under this Agreement shall be deemed to have been given:&nbsp;&nbsp;&nbsp;&nbsp;(a) if delivered in person or sent by confirmed facsimile then on the date delivered, (b)&nbsp;if by overnight
courier, one (1)&nbsp;day following delivery to recipient, facsimile transmission or delivery to the courier (as the case may be) or (c)&nbsp;if mailed, three (3)&nbsp;business days following deposit in the U.S. mail. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp; <U>Code Section&nbsp;409A Compliance.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The intent of the parties is that payments and benefits under this Agreement comply with, or be exempt from Code
Section&nbsp;409A, and, accordingly, this Agreement shall be interpreted and applied so as to be in compliance therewith. The Company and the Executive agree to work together in good faith to consider amendments to this Agreement and to take such
reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to the Executive under Section&nbsp;409A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;A termination of employment shall not be deemed to have occurred
for purposes of any provision of this Agreement providing for the payment of any amounts or benefits upon or following a termination of employment that are considered <FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred
compensation&#148; under Code Section&nbsp;409A unless such termination is also a &#147;separation from service&#148; within the meaning of Code Section&nbsp;409A and, for purposes of any such provision of this Agreement, references to a
&#147;termination&#148;, &#147;termination of employment&#148;, or like terms shall mean &#147;separation from service&#148;. If the Executive is deemed on the date of termination to be a &#147;specified employee&#148; within the meaning of that
term under Code Section&nbsp;409A(a)(2)(B), then with regard to any payment that is considered <FONT STYLE="white-space:nowrap">non-qualified</FONT> deferred compensation under Code Section&nbsp;409A payable on account of a &#147;separation from
service,&#148; such payment or benefit shall be made or provided at the date which is the earlier of (A)&nbsp;the expiration of the six (6)&nbsp;-month period measured from the date of such &#147;separation from service&#148; of the Executive, and
(B) the date of the Executive&#146;s death (the &#147;Delay Period&#148;). Upon the expiration of the Delay Period, all payments and benefits delayed pursuant to this Section&nbsp;26(b) (whether they would have otherwise been payable in a single sum
or in installments in the absence of such delay) shall be paid or reimbursed to the Executive in a lump sum and any remaining payments and benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates
specified for them herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;With regard to any provision herein that provides for reimbursement of costs and
expenses or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits, except as permitted by Code Section&nbsp;409A, (i)&nbsp;the right to reimbursement or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits shall not be subject to liquidation
or exchange for another benefit, (ii)&nbsp;the amount of expenses eligible for reimbursement, or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits, provided during any taxable year shall not affect the expenses eligible for reimbursement, or <FONT
STYLE="white-space:nowrap">in-kind</FONT> benefits to be provided, in any other taxable year, provided that the foregoing clause (ii)&nbsp;shall not be violated with regard to expenses reimbursed under any arrangement covered by Internal Revenue
Code Section&nbsp;105(b) solely because such expenses are subject to a limit related to the period the arrangement is in effect and (iii)&nbsp;such payments shall be made on or before the last day of Executive&#146;s taxable year following the
taxable year in which the expense occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of Code Section&nbsp;409A, the Executive&#146;s right to receive any installment payments
pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments. In no event may the Executive, directly or indirectly, designate the calendar year of any payment to be made under this Agreement that is
considered nonqualified deferred compensation. In no event shall the timing of Executive&#146;s execution of the General Release, directly or indirectly, result in the Executive designating the calendar year of payment, and if a payment that is
subject to execution of the General Release could be made in more than one taxable year, payment shall be made in the later taxable year. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&nbsp;&nbsp;&nbsp;&nbsp; <U>Indemnification.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;To the fullest extent permitted under applicable law, Employee shall not be liable to the Company or any of its
equity holders for any loss, claim, damage or liability arising from any act or omission performed or omitted by the Employee in connection with the Company&#146;s business or affairs (including any error in judgment in providing any advice or
counsel), except for any loss, claim, damage or liability primarily attributable to the Employee&#146;s willful misconduct, recklessness, or gross negligence, as finally determined by a court of competent jurisdiction, or as otherwise required by
law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall, to the fullest extent permitted by applicable
law, indemnify and hold the Employee harmless against any and all losses, claims, damages, liabilities, costs or Expenses (as defined below) (including judgments and amounts paid in settlement) to which the Employee may become subject in connection
with any matter arising out of or in connection with the Company&#146;s business or affairs, or by reason of the fact that the Employee is or was serving at the Company&#146;s request as a director, officer, employee or agent of another corporation
or other enterprise, unless (i)&nbsp;a court of competent jurisdiction, in a judgment that has become final and that is no longer subject to appeal or review, determines that any such loss, claim, damage, liability, cost or Expense is primarily
attributable to the Employee&#146;s willful misconduct, recklessness, or gross negligence, or (ii)&nbsp;it is determined in accordance with applicable law that the Employee did not act in good faith and did not reasonably believe that the
Employee&#146;s conduct was in or not opposed to the Company&#146;s best interests and, with respect to any criminal Proceeding (as defined below), had no reasonable cause to believe that the Employee&#146;s conduct was unlawful. The termination of
a Proceeding by judgment, order, settlement, or conviction, or upon a plea of nolo contendere or its equivalent, is not, of itself, automatically determinative that Employee did not meet the relevant standard of conduct described in this subsection.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;If any Employee becomes involved in any capacity in any Proceeding in connection with any matter arising out
of or in connection with the Company&#146;s business or affairs, or by reason of the fact that the Employee is or was serving at the Company&#146;s request as an Executive Chairman, director, officer, employee or agent of another corporation or
other enterprise, the Company shall pay (as they are incurred) the Employee&#146;s Expenses (as defined below) incurred in connection therewith after the Company receives (i)&nbsp;a written affinnation by the Employee of the Employee&#146;s good
faith belief that it has met the standard of conduct necessary for indemnification, and (ii)&nbsp;a written undertaking by or on behalf of the Employee to repay to the Company the amount of any such Expense paid to the extent that it is ultimately
detennined that the Employee is not entitled to be indemnified by the Company in connection with such Proceeding as provided in the exceptions contained herein or under applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;If for any reason (other than anything described in Section&nbsp;12(b)(i) or (ii)) the foregoing indemnification is
unavailable to the Employee, or insufficient to hold it harmless, then the Company shall, to the fullest extent permitted by applicable law, contribute to the amount paid or payable by the Employee as a result of such loss, claim, damage or
liability in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Employee on the other hand or, if such allocation is not pennitted by applicable law, to reflect not only the relative
benefits referred to above but also any other relevant equitable considerations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;In any suit brought to
enforce a right to indemnification or to recover an advancement of Expenses, the burden of proving that the Employee is not entitled to be indemnified, or to an advancement of Expenses, hereunder is on the Company (or any equity holder of the
Company acting derivatively or otherwise on behalf of the Company or its equity holders). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp; As used in this
Agreement, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;the term <U>&#147;Proceeding&#148;</U> means: (i)&nbsp;any threatened, pending or completed
action, suit, arbitration or other alternate dispute resolution mechanism, investigation, inquiry, judicial, administrative or legislative hearing, whether brought by or in the right of the Company or otherwise, including any and all appeals
thereof, whether of a civil, criminal, administrative, legislative, arbitrative, investigative or other nature or (ii)&nbsp;any inquiry, hearing or investigation that the Employee reasonably believes might lead to the institution of any such action,
suit, alternative dispute resolution mechanism or hearing, whether judicial, administrative or legislative; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the term <U>&#147;Expenses&#148;</U> means any and all
expenses, including attorneys&#146; and experts&#146; fees, court costs and all other expenses, paid or payable in connection with investigating, defending, being a witness in or participating in (including on appeal), or preparing to investigate,
defend, be a witness in or participate in (including on appeal), any Proceeding.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&nbsp;&nbsp;&nbsp;&nbsp;<U>General
Provisions.</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability.</U>&nbsp;&nbsp;&nbsp;&nbsp;Whenever possible, each provision of this Agreement
shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such
invalidity, illegality or unenforceability shall not affect any other provision or any other jurisdiction, and this Agreement shall be reformed, construed and enforced in such jurisdiction so as to best give effect to the intent of the parties under
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Complete Agreement.</U> This Agreement embodies the complete agreement and understanding
among the parties and supersedes and preempts any prior understandings, agreements or representations by or between the parties, written or oral, which may have related to the subject matter hereof in any way. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts.</U> This Agreement may be executed in separate counterparts, each of which is deemed to be an
original and all of which taken together constitute one and the same agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Success and Assigns.</U>
Except as otherwise provided herein, this Agreement shall bind and inure to the benefit of and be enforceable by the Employee and the Company, and their respective heirs, legal representatives, successors and assigns, including any successor to the
Company by means of merger or consolidation; provided that the rights and obligations of Employee under this Agreement shall not be assignable. The Company is defined to mean an affiliate or subsidiary of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Choice of Law.</U> This Agreement shall be governed and construed in accordance with the internal laws of the
Commonwealth of Massachusetts without giving effect to any choice of law or conflict of law provision or rule (whether of the Commonwealth of Massachusetts or any other jurisdiction) that would cause the application of the laws of any jurisdiction
other than the Commonwealth of Massachusetts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Consent to Jurisdiction.</U> The parties irrevocably consent
and submit to the jurisdiction of any local, state or federal court within the County of Middlesex and in The Commonwealth of Massachusetts for the enforcement of this Agreement. The parties irrevocably waive any objection he may have to venue in
the defense of an inconvenient forum to the maintenance of such actions or proceedings to enforce this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver.</U> The failure of any party to enforce any of the
provisions of this Agreement shall in no way be construed as a waiver of such provisions and shall not affect the right of such party thereafter to enforce each and every provision of this Agreement in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings.</U> The headings contained in this Agreement are for convenience of reference only and shall not
affect the meaning or interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments.</U> This Agreement shall not be amended
or modified unless pursuant to an agreement in writing signed by the Company and the Employee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)
&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival,</U> Notwithstanding anything to the contrary herein contained, Sections 6, 7, 8, 9, 11, 12 and 13 hereof shall remain in effect following the expiration or termination of this Agreement and Employee&#146;s
employment hereunder and the rights and obligations of the parties shall survive the termination or expiration of Employee&#146;s employment to the extent that any performance is required following termination or expiration of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page Follows </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have, executed this Agreement as a document, under
seal, on the date first written above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="19%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="7">AMYLYX PHARMACEUTICALS, INC</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter B. Finn</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Peter B. Finn, Esq., Secretary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Hereunto Duly Authorized</TD></TR></TABLE>
</DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">EMPLOYEE:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joshua B. Cohen</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Joshua B. Cohen</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> </div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>EXHIBIT &#147;A&#148;</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>SECTION 3(b): GOALS AND OBJECTIVES</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>13
<FILENAME>d155225dex108.htm
<DESCRIPTION>EX-10.8
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.8</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.8 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS EMPLOYMENT AGREEMENT </B>(the &#147;<U>Agreement</U>&#148;) is made and entered into as of the 1<SUP
STYLE="font-size:85%; vertical-align:top">st</SUP> day of August, 2015 (the &#147;Effective Date&#148;), by and between <B>JUSTIN KLEE </B>of 169 Monsignor O&#146;Brien Highway, Apt. 403, Cambridge, MA 02141 (the &#147;Employee&#148;) and <B>AMYLYX
PHARMACEUTICALS, INC., </B>a Delaware corporation duly organized under law and having a usual place of business 210 Broadway #201, Cambridge, MA 02139 (the &#147;<U>Company</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is
engaged in the business of researching, discovering, developing and commercializing therapeutics for the treatment of neurodegenerative diseases (the &#147;<U>Business</U>&#148;) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company desires to employ the Employee as the President and the Employee desires to be so employed by the Company, on the terms and
conditions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company desires to bind the Employee to certain restrictive covenants, and Employee agrees to be so
bound on the terms and conditions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, for good and valuable consideration, including the mutual covenants
and agreements herein contained, the receipt and legal sufficiency of which are hereby acknowledged, accepted and agreed to, the parties hereto agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Term of Employment.</U> Subject to the terms hereof, the Employee&#146;s employment hereunder shall commence on
the Effective Date and shall be <FONT STYLE="white-space:nowrap">at-will;</FONT> meaning that either party may terminate this Agreement at any time upon twenty (20)&nbsp;days prior written notice to the other, and upon the expiration of the
aforesaid twenty (20)&nbsp;day period, this Agreement shall terminate and thereafter be null and void and without further force or effect except for those provisions which survive in accordance with this Agreement. The term of the Employee&#146;s
employment under this Agreement is hereafter referred to as the &#147;Employment Term&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2,&nbsp;&nbsp;&nbsp;&nbsp;<U>Employment
Duties.</U> During the Employment Term, the Employee shall serve as the President, subject to the terms and conditions of this Agreement, and shall report to and take direction from the Company&#146;s Board of Directors (the &#147;Board&#148;). The
Employee agrees that he will faithfully and diligently perform the services and assume such duties and responsibilities as are assigned to him by the Board and that he will carry out and perform the duties and responsibilities customarily associated
with said position and office. The Employee shall devote his best efforts and full business time and attention to the business and affairs of the Company and the performance of his duties hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Employee shall initially be located in Cambridge, Massachusetts and shall travel on behalf of the Company as needed and requested. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Employee represents and warrants to the Company as follows: (i)&nbsp;that he is under no
contractual or other restriction or obligation which is inconsistent with the execution of this Agreement, or which will interfere with the performance of his duties hereunder, nor does the Employee have any obligation of confidentiality to any
third party which interferes with his obligations hereunder; (ii)&nbsp;that the execution and performance of this Agreement will not violate any policies or procedures of any academic institution or corporation (public or private) with which he is
involved or associated with and that he has received all of the necessary written permission(s) to enter into this Agreement and (iii)&nbsp;that in providing the services to the Company, he will not use any resources belonging to any corporation,
company, institution (public, private, profit or <FONT STYLE="white-space:nowrap">non-profit),</FONT> or other third party, including, but not limited to utilities, facilities, computers, laboratories or supplies or otherwise engage the services,
consult with or employ any individual not previously approved in writing by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation.</U>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Base Salary</U>. Subject to the provisions of this Agreement, the Company shall pay the Employee a base
salary at the initial rate of Sixty Thousand ($60,000.00) Dollars calculated on an annual basis (the &#147;Base Salary&#148;), which shall be paid in accordance with the Company&#146;s normal payroll procedures and policies. Any adjustments to the
Base Salary shall be approved by the Board after discussion with the Employee, provided, however, that the Base Salary may not be reduced. All payments made to the Employee pursuant to this Agreement shall be treated as wages for withholding and
employment tax purposes as provided by law, except that reimbursement of expenses will not be so treated to the extent permitted by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Cash Bonus.</U> In addition to the Base Salary, the Employee may be entitled to a bonus based upon the
successful completion of certain goals and objectives approved by the Board. These goals may relate to the achievement of corporate goals; the achievement of individual goals or a combination of the same. When the goals are agreed to, they shall be
identified on <U>Exhibit &#147;A&#148;</U> and added to this Agreement. The decision of the Board as to whether or not the goals have been achieved and the amount of the bonus to be awarded, if any, shall be final and binding on the parties. A
bonus, if awarded, shall not be added to the Base Salary and, if awarded, will be paid within forty five (45)&nbsp;days after the end of the year with respect to which the bonus is being awarded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock Option Bonus.</U> The Company agrees that, from time to time during the Employment Term, the Employee may
be eligible for additional stock option grants as determined, on an annual basis, by the Board and based upon the successful completion of annual goals and objectives as determined by the Board. All such grants shall vest in accordance with the
Company&#146;s standard form option grant agreement. The decision of the Board as to whether or not to award any stock options shall be final and binding on the parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Benefits.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Employee may be entitled, during the Employment Term, to receive paid medical, dental, and disability insurance
if, and to the extent available and to participate in any and all employee benefit plans and programs, including, without limitation, life insurance, and 401(k) plans, as are maintained from time to time, for employees of the Company subject to plan
terms and applicable Company policies. (the &#147;Benefits&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;During the Employment Term, the Employee shall be entitled to
four (4)&nbsp;weeks paid vacation per calendar year, to be taken at times mutually acceptable to Employee and the Company, and national and state holidays as are observed by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Reimbursement of Expenses.</U> The Employee shall be entitled to reimbursement for ordinary, necessary and
reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> business expenses, which Employee incurs in connection with performing his duties under this Agreement. The reimbursement of all such expenses
shall be made in accordance with the Company&#146;s customary practices and policies (including presentation of evidence reasonably satisfactory to the Company of the amounts and nature of such expenses) for reimbursement of expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Restrictive Covenants.</U> As partial consideration of the Company entering into this Agreement, the Employee
agrees that at all times during which the Employee is employed by the Company and continuing for a period of one (1)&nbsp;year following the expiration or termination of the Employee&#146;s employment under this Agreement for any reason (the
&#147;Restricted Period&#148;), the Employee shall not, directly or indirectly, without the prior written consent of the Company, any place in the world: (A)&nbsp;engage or participate, as an owner, partner, shareholder (except as the holder of not
more than one percent (1%) of the outstanding stock of a publicly-traded company), member, employee, adviser, consultant, sales representative, officer, director, agent or otherwise, in any Competitive Business (as defined below); (B) without
limiting the generality of the foregoing, solicit any customer of the Company to purchase from any source other than the Company any product or service which is distributed, sold or provided by the Company during the term of Employee&#146;s
employment or as of the date of termination or expiration of the Employee&#146;s employment or otherwise interfere with any relationship between the Company and any customer or former customer of the Company; (C)&nbsp;solicit any employee,
consultant or advisor to the Company to leave the employ of or cease consulting or advising for the Company or solicit or request any employee of or consultant or advisor to the Company to join the employ of, or begin consulting or advising for any
individual or entity which directly or indirectly competes with the Company or (D)&nbsp;without limiting the generality of clause (A)&nbsp;above, solicit any supplier, distributor, manufacturer, licensor, or licensee of the Company to cease doing
any business with, or to limit or alter its business relationship with the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used herein, a <U>&#147;Competitive
Business&#148;</U> shall mean a business which is directly or indirectly competitive with the business of the Company as conducted at the time of the expiration or termination of Employee&#146;s employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Proprietary Rights.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions.</U> For the purposes of this Article 7, the terms set forth below shall have the following
meanings: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.11&nbsp;&nbsp;&nbsp;&nbsp;<U>Concept and Ideas.</U> Those concepts and ideas disclosed by the Company to Employee or which
are first developed or conceived by Employee during the Employment Term and which relate to the Company&#146;s present, past or prospective activities, services and products, all of which shall remain the sole and exclusive property of the Company
(hereinafter, collectively referred as &#147;Concepts and Ideas&#148;). Further, the Employee shall have no publication rights hereunder and all of the same shall belong exclusively to the Company. Employee acknowledges and agrees that all works and
tasks performed by Employee for or on behalf of the Company, or in connection therewith during the Employment Terms (the &#147;Works&#148;) are owned by the Company. Employee acknowledges and agrees that, to the fullest extent allowed by law, all of
the Works are &#147;works made for hire,&#148; as that phrase is defined in the Copyright Revision Act of 1976 (17 U.S.C. &#167; 101) (the &#147;Act&#148;) in that either: (i)&nbsp;such Works are and will be prepared within the scope of this
Agreement or (ii)&nbsp;such Works have been and will be specifically ordered or commissioned for use as set forth in the Act. The Company shall therefore be deemed to be the sole author and owner of any and all right, title, and interest therein,
including, without limitation, all intellectual property rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.1.2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Confidential Information.</U> Confidential Information
means that secret or proprietary information of whatever kind or nature disclosed to Employee by or on behalf of the Company during the Employment Term (whether or not invented, discovered or developed by Employee) or first developed by Employee
hereunder or otherwise during the Employment Term, or any other information derived from the Confidential Information. Such secret or proprietary information shall include (unless such information is generally available to the public or known in the
industry through no action of Employee) information relating to the design, manufacture, application, trade secrets, know how, research and development relating to the Company&#146;s products, materials, operating and other cost data, price lists
and data relating to the Company&#146;s products. Such secret or proprietary information shall specifically include, without limitation, all such secret or proprietary information contained in the Company&#146;s manuals, memoranda, plans, drawings
and designs, specifications, supply sources, customer lists and records legended or otherwise identified by the Company or the Board as Confidential Information. The Employee&#146;s obligations with respect to Confidential Information will cease
when the Confidential Information: (i)&nbsp;becomes part of the public domain through no wrongful act of the Employee, or (ii)&nbsp;is approved for release by prior written authorization of the Company. However, Confidential Information shall be
considered Confidential Information even if a portion or specific sections of the Confidential Information are known or generally available to the general public; and the Confidential Information shall not lose its character and status as
Confidential Information unless and until all of the Confidential Information is in the public domain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Disclosure to Third Parties.</U> Except as required by Employee&#146;s duties, Employee shall not, at any
time, now or in the future, directly or indirectly, use, publish, disseminate, reproduce or otherwise disclose any Confidential Information, Concepts and Ideas relating to the present, past or prospective business of the Company to any third party.
Further, and recognizing the highly competitive nature of the Company&#146;s business and the need to protect its intellectual property, all publication rights shall belong solely to the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Documents, etc</U>. All documents, procedural manuals,
guides, specifications, plans, drawings, designs and similar materials, lists of present, past or prospective customers, customer proposals, invitations to submit proposals, price lists and data relating to the pricing of the Company&#146;s products
and services, records, notebooks and similar repositories of or containing Confidential Information (including all copies thereof) that come into Employee&#146;s possession or control by reason of Employee&#146;s relationship with the Company,
whether prepared by Employee or others: (a) are and shall remain the property of the Company, (b)&nbsp;will not be used by Employee in any way adverse to the Company, (c)&nbsp;will not be removed from the Company&#146;s premises (except as
Employee&#146;s duties require) and (d)&nbsp;at the termination (for whatever reason) of Employee&#146;s relationship with the Company, will be left with, or forthwith returned by Employee to, the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Patents, etc</U>. Any interest in patents, patent applications, inventions, technological innovations,
improvements, enhancements, copyrights, copyrightable works, developments, discoveries, designs, processes, formulas, <FONT STYLE="white-space:nowrap">know-how,</FONT> data and analysis, whether patentable or not (collectively, the
&#147;Inventions&#148;), which Employee as a result of rendering the Services to the Company under this Agreement may conceive or develop shall belong exclusively to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment.</U> The Employee hereby irrevocably assigns and, to the extent any such assignment cannot be made
at present, hereby agrees to irrevocably and automatically assign to the Company, without further compensation or consideration of his rights, title and interest in and to all Concepts, Ideas, Works, and Inventions and any and all related patents,
patent applications, copyrights, copyright applications, licenses, trademarks, trade names and other proprietary or intellectual property rights in the United States and throughout the world. The Employee agrees that he will promptly, without any
additional costs, expense or consideration, execute when presented, whether during the Employment Term or at any time thereafter, all documents, agreements, applications and instruments and perform all lawful acts which the Company considers
necessary or advisable to secure its rights hereunder and to carry out the intent of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Specific Performance.</U> Employee agrees that any violation by him of Sections 6 or 7 of this Agreement would be
highly injurious to the Company and would cause irreparable harm to the Company. By reason of the foregoing, Employee consents and agrees that if he violates or threatens to violate any provision(s) of Sections 6 or 7 of this Agreement, the Company
shall be entitled, in addition to any other rights and remedies that it may have, to apply to any court of competent jurisdiction for specific performance and/or injunctive or other equitable relief (without the requirement of posting of a bond or
other security) in order to enforce, or prevent any continuing or potential violation of, the provisions of such Section(s). The Employee also recognizes that the territorial, time and scope limitations set forth in Sections 6 and 7, as applicable,
are reasonable and are properly required and necessary for the protection of the Company and in the event that any such territorial, time or scope limitation is deemed to be unreasonable by a court of competent jurisdiction, the Company and the
Employee agree, and Employee submits, to the reduction of any or all of said territorial, time or scope limitations to such an area, period or scope as said court shall deem reasonable under the circumstances. If such partial enforcement is not
possible, the provision shall be deemed severed, and the remaining provisions of this Agreement shall remain in full force and effect. Employee acknowledges that Sections 6 and 7 of this Agreement shall survive termination or expiration of the
Employee&#146;s employment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination.</U> Notwithstanding the notice provision of
Article 1 hereof, Employee&#146;s employment with the Company: (i)&nbsp;shall terminate upon the Employee&#146;s resignation, death or disability, (ii)&nbsp;may be terminated without prior notice by the Board for Just Cause (as defined herein) and
(iii)&nbsp;may be terminated without cause by either party upon twenty (20)&nbsp;days prior notice to the other party as set forth in Article 1 hereof. As used in this Agreement, &#147;<U>Just Cause</U>&#148; means any of the following, as
determined by the Board, in its reasonable judgment: (1)&nbsp;Employee&#146;s continuous failure or continuous refusal to perform the duties and responsibilities as are requested of him by the Company; (2)&nbsp;Employee&#146;s gross negligence or
willful misconduct in the performance of Employee&#146;s duties or (3)&nbsp;the commission by Employee of any act of embezzlement against Company or the commission of any felony or act involving moral turpitude. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as hereinafter provided, effective as of the termination or expiration date of the Employee&#146;s employment hereunder for any reason,
or for no reason, or in the event the Employee resigns, or his death or disability then, in any of such events, the Employee shall be paid his Base Salary and benefits through the date of expiration or termination and all the rights and options
granted to the Employee pursuant to Articles 3 and 4 hereof shall cease and terminate as of the date of the Employee&#146;s termination, expiration or resignation and thereafter shall be null and void and without further force or effect.
Notwithstanding anything to the contrary herein contained, it is expressly agreed and understood that: (i)&nbsp;if the Employee is terminated by the Company without cause, or the Employee terminates his employment for Good Reason, as hereinafter
defined, prior to a &#147;Change of Control&#148; then the Employee shall be entitled to severance payments equal to twelve (12)&nbsp;months continuation of his Base Salary, a <FONT STYLE="white-space:nowrap">pro-rata</FONT> share of any bonus for
which the Employee was eligible, continuation of benefits for the twelve (12)&nbsp;months severance period (or additional compensation in an amount reflecting the cost to the Company of such benefits if the benefit plans do not provide for
continuation) and continued vesting of stock options for twelve (12)&nbsp;months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All severance payments of Base Salary and benefits
pursuant to subsection (i)&nbsp;will be paid in accordance with the provisions of this Agreement. Alternatively, if the Employee is terminated by the Company without cause, or the Employee terminates his employment for Good Reason, as hereinafter
defined, within nine (9)&nbsp;months following a &#147;Change of Control,&#148; the Employee shall be entitled to a <FONT STYLE="white-space:nowrap">one-time</FONT> severance payment equal to twelve (12)&nbsp;months of his Base Salary as of the date
of termination, and such severance payment shall be paid as of the date of termination. If the Employee remains employed by the Company following the nine (9)&nbsp;months after a &#147;Change of Control,&#148; the severance benefits described in
subsection (i)&nbsp;shall again apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, &#147;Good Reason&#148; is defined to exist upon: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The relocation of the Company&#146;s offices such that the Employee&#146;s daily commute is increased by at
least fifteen (15)&nbsp;miles each way without the written consent of the Employee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Material reduction of the Employee&#146;s Base Salary without the prior consent of the employee (other than in
connection with, and substantially proportionate to reductions by the Company of the Base Salary of more than 50% of its employees); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Material diminution in Employee&#146;s duties, authority or responsibilities without the prior consent of the
Employee, other than changes in duties, authority or responsibilities resulting from the Employee&#146;s misconduct; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provided, however, that any reduction in duties, authority or responsibilities or reduction in the level of management to which the Employee
reports resulting solely from a Change in Control which results in the Company being acquired by and made a part of a larger entity shall not constitute Good Reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice.</U> Any notice provided for in this Agreement must be in writing and must be either personally
delivered, mailed by first class mail (postage prepaid and return receipt requested), sent by reputable overnight courier service (charges prepaid), or sent by confirmed facsimile at the address indicated below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>To the Company:</U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>To Employee:</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AMYLYX PHARMACEUTICALS, INC. </P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Justin Klee</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">210 Broadway #20 I</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">169 Monsignor O&#146;Brien Highway, Apt. 403</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02139</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02141</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attn: Joshua B. Cohen, CEO</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or such other address and/or to the attention of such other person as the recipient party shall have designated by notice
given in accordance with this Section&nbsp;10. All notices under this Agreement shall be deemed to have been given: (a)&nbsp;if delivered in person or sent by confirmed facsimile then on the date delivered, (b)&nbsp;if by overnight courier, one
(1)&nbsp;day following delivery to recipient, facsimile transmission or delivery to the courier (as the case may be) or (c)&nbsp;if mailed, three (3)&nbsp;business days following deposit in the U.S. mail. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Code Section 409A Compliance.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The intent of the parties is that payments and benefits under this Agreement comply with, or be exempt from Code
Section&nbsp;409A, and, accordingly, this Agreement shall be interpreted and applied so as to be in compliance therewith. The Company and the Executive agree to work together in good faith to consider amendments to this Agreement and to take such
reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to the Executive under Section&nbsp;409A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;A termination of employment shall not be deemed to have occurred
for purposes of any provision of this Agreement providing for the payment of any amounts or benefits upon or following a termination of employment that are considered <FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred
compensation&#148; under Code Section&nbsp;409A unless such termination is also a &#147;separation from service&#148; within the meaning of Code Section&nbsp;409A and, for purposes of any such provision of this Agreement, references to a
&#147;termination&#148;, &#147;termination of employment&#148;, or like terms shall mean &#147;separation from service&#148;. If the Executive is deemed on the date of termination to be a &#147;specified employee&#148; within the meaning of that
term under Code Section&nbsp;409A(a)(2)(B), then with regard to any payment that is considered <FONT STYLE="white-space:nowrap">non-qualified</FONT> deferred compensation under Code Section&nbsp;409A payable on account of a &#147;separation from
service,&#148; such payment or benefit shall be made or provided at the date which is the earlier of (A)&nbsp;the expiration of the six (6)- month period measured from the date of such &#147;separation from service&#148; of the Executive, and (B)
the date of the Executive&#146;s death (the &#147;Delay Period&#148;). Upon the expiration of the Delay Period, all payments and benefits delayed pursuant to this Section&nbsp;26(b) (whether they would have otherwise been payable in a single sum or
in installments in the absence of such delay) shall be paid or reimbursed to the Executive in a lump sum and any remaining payments and benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates specified
for them herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;With regard to any provision herein that provides for reimbursement of costs and expenses or <FONT
STYLE="white-space:nowrap">in-kind</FONT> benefits, except as permitted by Code Section&nbsp;409A, (i)&nbsp;the right to reimbursement or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits shall not be subject to liquidation or exchange for
another benefit, (ii)&nbsp;the amount of expenses eligible for reimbursement, or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits, provided during any taxable year shall not affect the expenses eligible for reimbursement, or <FONT
STYLE="white-space:nowrap">in-kind</FONT> benefits to be provided, in any other taxable year, provided that the foregoing clause (ii)&nbsp;shall not be violated with regard to expenses reimbursed under any arrangement covered by Internal Revenue
Code Section&nbsp;105(b) solely because such expenses are subject to a limit related to the period the arrangement is in effect and (iii)&nbsp;such payments shall be made on or before the last day of Executive&#146;s taxable year following the
taxable year in which the expense occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of Code Section&nbsp;409A, the Executive&#146;s right to receive any installment payments
pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments. In no event may the Executive, directly or indirectly, designate the calendar year of any payment to be made under this Agreement that is
considered nonqualified deferred compensation. In no event shall the timing of Executive&#146;s execution of the General Release, directly or indirectly, result in the Executive designating the calendar year of payment, and if a payment that is
subject to execution of the General Release could be made in more than one taxable year, payment shall be made in the later taxable year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;To the fullest extent permitted under applicable law, Employee shall not be liable to the Company or any of its
equity holders for any loss, claim, damage or liability arising from any act or omission performed or omitted by the Employee in connection with the Company&#146;s business or affairs (including any error in judgment in providing any advice or
counsel), except for any loss, claim, damage or liability primarily attributable to the Employee&#146;s willful misconduct, recklessness, or gross negligence, as finally determined by a court of competent jurisdiction, or as otherwise required by
law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall, to the fullest extent permitted by applicable
law, indemnify and hold the Employee harmless against any and all losses, claims, damages, liabilities, costs or Expenses (as defined below) (including judgments and amounts paid in settlement) to which the Employee may become subject in connection
with any matter arising out of or in connection with the Company&#146;s business or affairs, or by reason of the fact that the Employee is or was serving at the Company&#146;s request as a director, officer, employee or agent of another corporation
or other enterprise, unless (i)&nbsp;a court of competent jurisdiction, in a judgment that has become final and that is no longer subject to appeal or review, determines that any such loss, claim, damage, liability, cost or Expense is primarily
attributable to the Employee&#146;s willful misconduct, recklessness, or gross negligence, or (ii)&nbsp;it is determined in accordance with applicable law that the Employee did not act in good faith and did not reasonably believe that the
Employee&#146;s conduct was in or not opposed to the Company&#146;s best interests and, with respect to any criminal Proceeding (as defined below), had no reasonable cause to believe that the Employee&#146;s conduct was unlawful. The termination of
a Proceeding by judgment, order, settlement, or conviction, or upon a plea of nolo contendere or its equivalent, is not, of itself, automatically determinative that Employee did not meet the relevant standard of conduct described in this subsection.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;If any Employee becomes involved in any capacity in any Proceeding in connection with any matter arising out
of or in connection with the Company&#146;s business or affairs, or by reason of the fact that the Employee is or was serving at the Company&#146;s request as an Executive Chairman, director, officer, employee or agent of another corporation or
other enterprise, the Company shall pay (as they are incurred) the Employee&#146;s Expenses (as defined below) incurred in connection therewith after the Company receives (i)&nbsp;a written affirmation by the Employee of the Employee&#146;s good
faith belief that it has met the standard of conduct necessary for indemnification, and (ii)&nbsp;a written undertaking by or on behalf of the Employee to repay to the Company the amount of any such Expense paid to the extent that it is ultimately
determined that the Employee is not entitled to be indemnified by the Company in connection with such Proceeding as provided in the exceptions contained herein or under applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;If for any reason (other than anything described in Section&nbsp;12(b)(i) or (ii)) the foregoing indemnification is
unavailable to the Employee, or insufficient to hold it harmless, then the Company shall, to the fullest extent permitted by applicable law, contribute to the amount paid or payable by the Employee as a result of such loss, claim, damage or
liability in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Employee on the other hand or, if such allocation is not permitted by applicable law, to reflect not only the relative
benefits referred to above but also any other relevant equitable considerations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;In any suit brought to
enforce a right to indemnification or to recover an advancement of Expenses, the burden of proving that the Employee is not entitled to be indemnified, or to an advancement of Expenses, hereunder is on the Company (or any equity holder of the
Company acting derivatively or otherwise on behalf of the Company or its equity holders). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;As used in this
Agreement, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;the term &#147;<U>Proceeding</U>&#148; means: (i)&nbsp;any threatened, pending or completed
action, suit, arbitration or other alternate dispute resolution mechanism, investigation, inquiry, judicial, administrative or legislative hearing, whether brought by or in the right of the Company or otherwise, including any and all appeals
thereof, whether of a civil, criminal, administrative, legislative, arbitrative, investigative or other nature or (ii)&nbsp;any inquiry, hearing or investigation that the Employee reasonably believes might lead to the institution of any such action,
suit, alternative dispute resolution mechanism or hearing, whether judicial, administrative or legislative; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the term &#147;<U>Expenses</U>&#148; means any and all
expenses, including attorneys&#146; and experts&#146; fees, court costs and all other expenses, paid or payable in connection with investigating, defending, being a witness in or participating in (including on appeal), or preparing to investigate,
defend, be a witness in or participate in (including on appeal), any Proceeding.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&nbsp;&nbsp;&nbsp;&nbsp;<U>General
Provisions.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability.</U> Whenever possible, each provision of this Agreement shall be interpreted
in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality
or unenforceability shall not affect any other provision or any other jurisdiction, and this Agreement shall be reformed, construed and enforced in such jurisdiction so as to best give effect to the intent of the parties under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Complete Agreement.</U> This Agreement embodies the complete agreement and understanding among the parties and
supersedes and preempts any prior understandings, agreements or representations by or between the parties, written or oral, which may have related to the subject matter hereof in any way. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts.</U> This Agreement may be executed in separate counterparts, each of which is deemed to be an
original and all of which taken together constitute one and the same agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Success and Assigns.</U>
Except as otherwise provided herein, this Agreement shall bind and inure to the benefit of and be <U></U><U></U>enforceable by the Employee and the Company, and their respective heirs, legal representatives, successors and assigns, including any
successor to the Company by means of merger or consolidation; provided that the rights and obligations of Employee under this Agreement shall not be assignable. The Company is defined to mean an affiliate or subsidiary of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Choice of Law.</U> This Agreement shall be governed and construed in accordance with the internal laws of the
Commonwealth of Massachusetts without giving effect to any choice of law or conflict of law provision or rule (whether of the Commonwealth of Massachusetts or any other jurisdiction) that would cause the application of the laws of any jurisdiction
other than the Commonwealth of Massachusetts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Consent to Jurisdiction.</U> The parties irrevocably consent
and submit to the jurisdiction of any local, state or federal <U></U>court within the County of Middlesex and in The Commonwealth of Massachusetts for the enforcement of this Agreement. The parties irrevocably waive any objection he may have to
venue in the defense of an inconvenient forum to the maintenance of such actions or proceedings to enforce this Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver.</U> The failure of any party to enforce any of the
provisions of this Agreement shall in no way be construed as a waiver of such provisions and shall not affect the right of such party thereafter to enforce each and every provision of this Agreement in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings.</U> The headings contained in this Agreement are for convenience of reference only and shall not
affect the meaning or interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments.</U> This Agreement shall not be amended
or modified unless pursuant to an agreement in writing signed by the Company and the Employee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">G)&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival.</U>
Notwithstanding anything to the contrary herein contained, Sections 6, 7, 8, 9, 11, 12 and 13 hereof shall remain in effect following the expiration or termination of this Agreement and Employee&#146;s employment hereunder and the rights and
obligations of the parties shall survive the termination or expiration of Employee&#146;s employment to the extent that any performance is required following termination or expiration of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page Follows </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have, executed this Agreement as a document, under
seal, on the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AMYLYX PHARMACEUTICALS, INC.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>EMPLOYEE:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-bottom:1pt; margin-top:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter B. Finn</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Justin Klee</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Peter B. Finn, Esq., Secretary</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Justin Klee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Hereunto Duly Authorized</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>EXHIBIT &#147;A&#148; </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>SECTION 3(b): GOALS AND OBJECTIVES </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>14
<FILENAME>d155225dex109.htm
<DESCRIPTION>EX-10.9
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.9</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.9 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS EMPLOYMENT AGREEMENT </B>(the &#147;Agreement&#148;) is made and entered into as of the 25th day of January, 2021 (the &#147;Effective
Date&#148;), by and between <B>JAMES FRATES </B>of 471 Grove&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Street,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Needham,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
MA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;02492 (the &#147;Employee&#148;) and <B>AMYLYX</B> <B>PHARMACEUTICALS, INC., </B>a Delaware corporation duly organized under law and having a usual place of business at 43
Thorndike Street, Cambridge, MA 02141 (the &#147;Company&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is engaged in the business of researching, discovering, developing and commercializing therapeutics for the treatment of
neurodegenerative diseases (the &#147;Business&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company desires to employ the Employee as the Chief Financial Officer, and the
Employee desires to be so employed by the Company, on the terms and conditions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company desires to bind the Employee
to certain restrictive covenants, and Employee agrees to be so bound on the terms and conditions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, for
good and valuable consideration, including the mutual covenants and agreements herein contained, the receipt and legal sufficiency of which are hereby acknowledged, accepted and agreed to, the parties hereto agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Term of Employment.</U> Subject to the terms hereof, the Employee&#146;s employment hereunder shall commence on
the Effective Date and shall be <FONT STYLE="white-space:nowrap">at-will;</FONT> meaning that, subject to Section&nbsp;9, either party may terminate this Agreement at any time upon ten (10)&nbsp;calendar days prior written notice to the other, and
upon the expiration of the aforesaid ten (10)&nbsp;calendar day period, this Agreement shall terminate and thereafter be null and void and without further force or effect except for those provisions which survive in accordance with this Agreement.
The term of the Employee&#146;s employment under this Agreement is hereafter referred to as the &#147;Employment Term&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Employment Duties.</U> During the Employment Term, the Employee shall serve as the Chief Financial Officer,
subject to the terms and conditions of this Agreement, and shall report to and take direction from the President or his designee. The Employee agrees that he will faithfully and diligently perform the services and assume such duties and
responsibilities as are assigned to him by the President or his designee and that he will carry out and perform the duties and responsibilities customarily associated with said position and office. The Employee shall devote his best efforts and all
of his business time and attention to the business and affairs of the Company and the performance of his duties hereunder. Notwithstanding the foregoing, as long as it does not interfere with the Employee&#146;s full-time employment hereunder, the
Employee may continue to serve on up to two <FONT STYLE="white-space:nowrap">(2)&nbsp;for-profit</FONT> boards of directors ( provided they do not compete with the Company) and otherwise participate in educational, welfare, social, religious and
civic organizations (including serving on the board of same). The Employee shall be located in the Company&#146;s offices in Cambridge, Massachusetts and travel on behalf of the Company as needed and requested. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Employee represents and warrants to the Company as follows: (i)&nbsp;that he is under no
contractual or other restriction or obligation which is inconsistent with the execution of this Agreement, or which will interfere with the performance of his duties hereunder, nor does the Employee have any obligation of confidentiality to any
third party which interferes with his obligations hereunder; (ii)&nbsp;that the execution and performance of this Agreement will not violate any policies or procedures of any academic institution or corporation (public or private) with which he is
involved or associated with and that he has received all of the necessary written permission(s) to enter into this Agreement and (iii)&nbsp;that in providing the services to the Company, he will not use any resources belonging to any corporation,
company, institution (public, private, profit or <FONT STYLE="white-space:nowrap">non-profit),</FONT> or other third party, including, but not limited to utilities, facilities, computers, laboratories or supplies or otherwise engage the services,
consult with or employ any individual not previously approved in writing by the Company and will not disclose or discuss the confidential information of any third party to the Company. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Compensation. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Base Salary</U>. Subject to the provisions of this Agreement, the Company shall pay the Employee a base salary at
the rate of Four Hundred Thousand ($400,000.00) per annum (the &#147;Base Salary&#148;), which shall be paid in accordance with the Company&#146;s normal payroll procedures and policies. Any adjustments to the Base Salary shall be approved by the
Board of Directors (the &#147;Board&#148;) (and the Board shall review Employee&#146;s Base Salary annually). All payments made to the Employee pursuant to this Agreement shall be treated as wages for withholding and employment tax purposes as
provided by law, except that reimbursement of expenses will not be so treated to the extent permitted by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT STYLE="white-space:nowrap">Sign-on</FONT> Bonus.</U> As partial consideration for the Employee entering
into this Agreement, the Company agrees, subject to the terms hereof, to pay the Employee, during the Employment Term, a <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus in the total amount of Three Hundred Twenty-five Thousand ($325,000.00)
Dollars (the <FONT STYLE="white-space:nowrap">&#147;Sign-on</FONT> Bonus&#148;). The <FONT STYLE="white-space:nowrap">Sign-on</FONT> Bonus shall be paid as follows: One Hundred <FONT STYLE="white-space:nowrap">Sixty-two</FONT> Thousand Five Hundred
($162,500.00) Dollars shall be paid within the first thirty (30)&nbsp;calendar days after the Effective Date (the &#147;First Payment&#148;) and One Hundred <FONT STYLE="white-space:nowrap">Sixty-two</FONT> Thousand Five Hundred ($162,500.00)
Dollars shall be payable on, or within ten (10)&nbsp;calendar days after, the date that is six (6)&nbsp;months after the Effective Date (the &#147;Second Payment&#148;). All <FONT STYLE="white-space:nowrap">Sign-on</FONT> Bonus payments made to the
Employee pursuant to this Section&nbsp;3(b) shall be treated as wages for withholding and employment tax purposes. Notwithstanding anything to the contrary herein contained if, prior to the first
(1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> anniversary of the Effective Date, the Employee terminates his employment for any reason (other than for Good Reason as defined in Article 9), or the Employee is terminated for Just Cause as
defined in Article 9 then, in either case, the Employee agrees to repay One Hundred (100%) percent of the <FONT STYLE="white-space:nowrap">Sign-on</FONT> Bonus net of all withholdings within thirty (30)&nbsp;calendar days following the termination
date and the Company may, to the extent legally permitted, offset such amount against amounts payable by the Company to the Employee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional Bonus Payment.</U> In addition to the <FONT
STYLE="white-space:nowrap">Sign-on</FONT> Bonus described in Section&nbsp;3(b), the Company acknowledges that the Employee is entitled to an annual bonus for work in 2020 in the amount of Two Hundred Ninety Thousand ($290,000) Dollars which is due
from Alkermes, Inc. (the &#147;2020 Alkermes Annual Bonus&#148;). The Company acknowledges that the Employee may not receive the 2020 Alkermes Annual Bonus because of his employment by the Company. The Employee agrees that he will use his best
efforts to have Alkermes pay the 2020 Alkermes Annual Bonus. If Alkermes fails or refuses to pay the 2020 Alkermes Annual Bonus, then the Employee shall notify the Company and the Company shall pay the same up to a maximum of Two Hundred Ninety
Thousand ($290,000) Dollars. If Alkermes pays a portion of the 2020 Alkermes Annual Bonus, the Company shall only be responsible for the unpaid portion. The 2020 Alkermes Annual Bonus, if due, shall be paid by the Company as follows: fifty (50%)
percent shall be paid within thirty (30)&nbsp;calendar days of the date that the Company receives written notice from the Employee that Alkermes has finally determined not to make the payment (the &#147;Payment Notice&#148;) and fifty (50%) percent
shall be paid on, or within ten (10)&nbsp;calendar days after, the date that is six (6)&nbsp;months after the Payment Notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Annual Cash Bonus.</U> In addition to the Base Salary, the Employee may be entitled to a bonus of up to forty
(40%) percent of his then Base Salary (the &#147;Annual Cash Bonus&#148;), based upon the successful completion of certain goals and objectives approved by the Board. These goals may relate to the achievement of corporate goals, the achievement of
individual goals or a combination of the same. When the goals are agreed to (which the parties agree shall be by February 15), they shall be identified on <U>Exhibit &#147;A</U>&#148; and added to this Agreement. The decision of the Board as to
whether or not the goals have been achieved and the amount of the bonus to be awarded, if any, shall be final and binding on the parties. A bonus, if awarded, shall not be added to the Base Salary and, if awarded, will be paid within sixty
(60)&nbsp;calendar days after the end of the calendar year with respect to which the goals relate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock
Option Bonus.</U> The Company agrees that, from time to time during the Employment Term, the Employee may be eligible for stock option grants, in addition to the stock option grant provided in Section&nbsp;4(a) hereof, as determined, on an annual
basis, by the Board and based upon the successful completion of annual goals and objectives as determined by the Board; and when determined, annexed hereto and made a part hereof. All such grants shall vest in accordance with the Company&#146;s
standard form option grant agreement. The decision of the Board as to whether or not to award any stock options shall be final and binding on the parties. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Stock Options</U>, Benefits and Indemnification. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock Options:</U> So long as this Agreement remains in full force and effect, and subject to approval by the
Board, the Employee will be granted the right and option to purchase up to Four Hundred Fifty Two Thousand (452,000) shares (the &#147;Shares&#148;) of the Common Capital Stock of the Company (the &#147;Stock&#148;) at an exercise price based upon
the fair market value of the Common Stock on the date the grant is approved by the Board. The options granted above shall vest in accordance with the following schedule: One Hundred Thirteen Thousand Twenty-four (113,024) options shall vest on the
first anniversary of the Effective Date, and thereafter, an additional Nine Thousand Four Hundred Sixteen (9,416) options shall vest monthly over the following three (3)&nbsp;years during the Employment Term, with the first monthly vesting occurring
on the first monthly anniversary following the initial vesting and on the like monthly anniversary dates thereafter. As a condition precedent to this grant, the Employee shall execute and deliver the Company&#146;s standard form Incentive Stock
Option Agreement and the grant shall be subject to the terms and conditions of the Incentive Stock Option Agreement and the Company&#146;s Stock Option and Restricted Stock Plan (collectively, the &#147;Equity Documents&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Benefits:</U> The Employee may be entitled, during the
Employment Term, to receive paid medical, dental, and disability insurance if, and to the extent available and to participate in any and all employee benefit plans and programs, including, without limitation, life insurance, and 401(k) plans, as are
maintained from time to time, for employees of the Company subject to plan terms and applicable Company policies (the &#147;Benefits&#148;). Further, during the Employment Term, the Employee shall be entitled, with prior written approval of either
the President or the CEO if the request is of greater than five (5)&nbsp;days, to an unlimited number of vacation and sick days, and national and state holidays as are observed by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification:</U> The Company agrees to indemnify the Employee to the maximum extent allowable under the
terms and conditions of its <FONT STYLE="white-space:nowrap">By-Laws</FONT> and under applicable law. Further, the Employee will be covered by the Company&#146;s directors&#146; and officers&#146; liability insurance coverage as in effect from time
to time (which shall include reasonable, market terms, including tail coverage) and the Indemnification Agreement that the Company is providing to Employee in connection herewith as annexed hereto as <U>Exhibit &#147;B</U>&#148; and made a part
hereof (the <U>&#147;Indemnification Agreement</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Reimbursement of Expenses.</U> The Employee shall
be entitled to reimbursement for ordinary, necessary and reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> business expenses, which Employee incurs in connection with performing his duties under
this Agreement. The reimbursement of all such expenses shall be made in accordance with the Company&#146;s customary practices and policies (including presentation of evidence reasonably satisfactory to the Company of the amounts and nature of such
expenses) for reimbursement of expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Restrictive Covenants.</U> As partial consideration of the Company
entering into this Agreement, the Employee agrees that at all times during which the Employee is employed by the Company and continuing for a period of one (1)&nbsp;year following the expiration or termination of the Employee&#146;s employment under
this Agreement for any reason (the &#147;Restricted Period&#148;), the Employee shall not, directly or indirectly, without the prior written consent of the Company, any place in the world: (A)&nbsp;solicit any customer of the Company to purchase
from any source other than the Company any product or service which is distributed, sold or provided by the Company during the term of Employee&#146;s employment or as of the date of termination or expiration of the Employee&#146;s employment or
otherwise interfere with any relationship between the Company and any customer or former customer of the Company such that the customer limits or adversely alters its business with the Company; (B)&nbsp;solicit any employee, consultant or advisor to
the Company to leave the employ of or cease consulting or advising for the Company or solicit or request any employee of or consultant or advisor to the Company to join the employ of, or begin consulting or advising for any individual or entity
which directly or indirectly competes with the Company; or (C)&nbsp;without limiting the generality of clause (A)&nbsp;above, solicit any supplier, distributor, manufacturer, licensor, or licensee of the Company to cease doing any business, or to
limit or adversely alter its business relationship, with the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Proprietary Rights.</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions.</U> For the purposes of this Article 7, the terms set forth below shall have the following meanings:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.11 <U>Concept and Ideas.</U> Those concepts and ideas disclosed by the Company to Employee or which are first developed or conceived by
Employee during the Employment Term and which relate to the Company&#146;s present, past or prospective activities, services and products, all of which shall remain the sole and exclusive property of the Company (hereinafter, collectively referred
as &#147;Concepts and Ideas&#148;). Further, the Employee shall have no publication rights hereunder and all of the same shall belong exclusively to the Company. Employee acknowledges and agrees that all works and tasks performed by Employee for or
on behalf of the Company, or in connection therewith during the Employment Terms (the &#147;Works&#148;) are owned by the Company. Employee acknowledges and agrees that, to the fullest extent allowed by law, all of the Works are &#147;works made for
hire,&#148; as that phrase is defined in the Copyright Revision Act of 1976 (17 U.S.C. &#167; 101) (the &#147;Act&#148;) in that either: (i)&nbsp;such Works are and will be prepared within the scope of this Agreement or (ii)&nbsp;such Works have
been and will be specifically ordered or commissioned for use as set forth in the Act. The Company shall therefore be deemed to be the sole author and owner of any and all right, title, and interest therein, including, without limitation, all
intellectual property rights. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.1.2. <U>Confidential Information.</U> Confidential Information means that secret or proprietary
information of whatever kind or nature disclosed to Employee by or on behalf of the Company during the Employment Term (whether or not invented, discovered or developed by Employee) or first developed by Employee hereunder or otherwise during the
Employment Term, or any other information derived from the Confidential Information. Such secret or proprietary information shall include (unless such information is generally available to the public or known in the industry through no action of
Employee) information relating to the design, manufacture, application, trade secrets, know how, research and development relating to the Company&#146;s products, materials, operating and other cost data, price lists and data relating to the
Company&#146;s products. Such secret or proprietary information shall specifically include, without limitation, all such secret or proprietary information contained in the Company&#146;s manuals, memoranda, plans, drawings and designs,
specifications, supply sources, customer lists and records legended or otherwise identified by the Company or the Board as Confidential Information. The Employee&#146;s obligations with respect to Confidential Information will cease when the
Confidential Information: (i)&nbsp;becomes part of the public domain through no wrongful act of the Employee, or (ii)&nbsp;is approved for release by prior written authorization of the Company. However, Confidential Information shall be considered
Confidential Information even if a portion or specific sections of the Confidential Information are known or generally available to the general public; and the Confidential Information shall not lose its character and status as Confidential
Information unless and until all of the Confidential Information is in the public domain. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.2.&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT STYLE="white-space:nowrap">Non-Disclosure</FONT> to
Third Parties.</U> Except as required by Employee&#146;s duties, Employee shall not, at any time, now or in the future, directly or indirectly, use, publish, disseminate, reproduce or otherwise disclose any Confidential Information, Concepts and
Ideas relating to the present, past or prospective business of the Company to any third party. Further, and recognizing the highly competitive nature of the Company&#146;s business and the need to protect its intellectual property, all publication
rights shall belong solely to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Documents,</U> <U>etc</U>. All documents, procedural manuals,
guides, specifications, plans, drawings, designs and similar materials, lists of present, past or prospective customers, customer proposals, invitations to submit proposals, price lists and data relating to the pricing of the Company&#146;s products
and services, records, notebooks and similar repositories of or containing Confidential Information (including all copies thereof) that come into Employee&#146;s possession or control by reason of Employee&#146;s relationship with the Company,
whether prepared by Employee or others: (a)&nbsp;are and shall remain the property of the Company, (b)&nbsp;will not be used by Employee in any way adverse to the Company, (c)&nbsp;will not be removed from the Company&#146;s premises (except as
Employee&#146;s duties require) and (d)&nbsp;at the termination (for whatever reason) of Employee&#146;s relationship with the Company, will be left with, or forthwith returned by Employee to, the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Patents, etc</U>. Any interest in patents, patent applications, inventions, technological innovations,
improvements, enhancements, copyrights, copyrightable works, developments, discoveries, designs, processes, formulas, <FONT STYLE="white-space:nowrap">know-how,</FONT> data and analysis, whether patentable or not (collectively, the
&#147;Inventions&#148;), which Employee as a result of rendering the Services to the Company under this Agreement may conceive or develop shall belong exclusively to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment.</U> The Employee hereby irrevocably and voluntarily assigns and, to the extent any such assignment
cannot be made at present, hereby agrees to irrevocably and voluntarily automatically assign to the Company, without further compensation or consideration of his rights, title and interest in and to all Concepts, Ideas, Works, and Inventions and any
and all related patents, patent applications, copyrights, copyright applications, licenses, trademarks, trade names and other proprietary or intellectual property rights in the United States and throughout the world. The Employee agrees that he will
promptly, without any additional costs, expense or consideration, execute when presented, whether during the Employment Term or at any time thereafter, all documents, agreements, applications and instruments and perform all lawful acts which the
Company considers necessary or advisable to secure its rights hereunder and to carry out the intent of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.6 <U>Notice of Immunity Provision.</U> Pursuant to the provisions of the Federal Defend
Trade Secrets Act of 2016 (&#147;DTSA&#148;), notice is hereby given by the Company to the Employee that, under the DTSA, an individual shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of
a trade secret that: (A)&nbsp;is made: (i)&nbsp;in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney and (ii)&nbsp;solely for the purpose of reporting or investigating a suspected
violation of law or (B)&nbsp;is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Specific Performance.</U> Employee agrees that any violation by him of Sections 6 or 7 of this Agreement would be
highly injurious to the Company and would cause irreparable harm to the Company. By reason of the foregoing, Employee consents and agrees that if he violates or threatens to violate any provision(s) of Sections 6 or 7 of this Agreement, the Company
shall be entitled, in addition to any other rights and remedies that it may have, to apply to any court of competent jurisdiction for specific performance and/or injunctive or other equitable relief (without the requirement of posting of a bond or
other security) in order to enforce, or prevent any continuing or potential violation of, the provisions of such Section(s). The Employee also recognizes that the territorial, time and scope limitations set forth in Sections 6 and 7, as applicable,
are reasonable and are properly required and necessary for the protection of the Company and in the event that any such territorial, time or scope limitation is deemed to be unreasonable by a court of competent jurisdiction, the Company and the
Employee agree, and Employee submits, to the reduction of any or all of said territorial, time or scope limitations to such an area, period or scope as said court shall deem reasonable under the circumstances. If such partial enforcement is not
possible, the provision shall be deemed severed, and the remaining provisions of this Agreement shall remain in full force and effect. Employee acknowledges that Sections 6 and 7 of this Agreement shall survive termination or expiration of the
Employee&#146;s employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination.</U> Notwithstanding the provisions of Article 1 hereof,
Employee&#146;s employment with the Company: (i)&nbsp;shall terminate upon the Employee&#146;s resignation, death or Disability (as hereinafter defined), (ii) may be terminated without prior written notice by the Board for Just Cause (as defined
herein) and (iii)&nbsp;may be terminated without Just Cause by the Company, or for any reason by Employee, upon ten (10)&nbsp;calendar days prior notice to the other party as set forth in Article 1 hereof. As used in this Agreement, &#147;Just
Cause&#148; means any of the following, as determined by the Board, in its reasonable judgment: (1)&nbsp;Employee&#146;s willful failure or willful refusal to perform the duties and responsibilities of his position as are reasonably requested of him
by the Company; (2)&nbsp;Employee&#146;s gross negligence or willful misconduct in the performance of Employee&#146;s duties; (3)&nbsp;the Employee&#146;s conviction for embezzlement against the Company or a felony; (4)&nbsp;the Employee&#146;s
material violation of a policy of the Company (e.g., the Company&#146;s anti-harassment and/or anti-discrimination policies); or (5)&nbsp;a material breach of this Agreement by the Employee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the Board shall not reach a determination that &#147;Just Cause&#148; has
occurred (and thus shall not terminate Employee&#146;s employment) until it (x)&nbsp;has delivered to Employee written notice of the alleged bases for invoking &#147;Just Cause&#148;, (y) provided Employee with thirty (30)&nbsp;days therefrom to
effect a cure (to the extent a cure is possible), and (z)&nbsp;determined, by a majority vote of the Board, that Employee has not cured the alleged basis for &#147;Just Cause.&#148; For purposes of this Article 9 and Agreement,
&#147;Disability&#148; shall mean, at any time the Company or any of its affiliates sponsors a long-term disability plan for the Company&#146;s employees, &#147;disability&#148; as defined in such long-term disability plan for the purpose of
determining a participant&#146;s eligibility for benefits, <I>provided, however, </I>if the long-term disability plan contains multiple definitions of disability, &#147;Disability&#148; shall refer to that definition of disability which, if Employee
qualified for such disability benefits, would provide coverage for the longest period of time. The determination of whether Employee has a Disability shall be made by the person or persons required to make disability determinations under the
long-term disability plan. At any time the Company does not sponsor a long-term disability plan for its employees, &#147;Disability&#148; shall mean Employee&#146;s inability to perform, with or without reasonable accommodation, the essential
functions of Employee&#146;s positions hereunder for a total of three months during any <FONT STYLE="white-space:nowrap">six-month</FONT> period as a result of incapacity due to mental or physical illness as determined by a physician selected by the
Company or its insurers and acceptable to Employee or Employee&#146;s legal representative, with such agreement as to acceptability not to be unreasonably withheld or delayed. Any refusal by Employee to submit to a medical examination for the
purpose of determining Disability shall be deemed to constitute conclusive evidence of Employee&#146;s Disability. Notwithstanding the foregoing, nothing herein shall abrogate Employee&#146;s rights under state or federal law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as hereinafter provided, effective as of the termination or expiration date of the Employee&#146;s employment hereunder for any reason,
or for no reason, or in the event the Employee resigns, or in the event of his death or Disability then, in any of such events, the Employee shall be paid his Base Salary and benefits through the date of expiration or termination, and all the rights
and options granted to the Employee pursuant to Articles 3 and 4 hereof shall cease and terminate as of the date of the Employee&#146;s termination, expiration or resignation and thereafter shall be null and void and without further force or effect.
Notwithstanding anything to the contrary herein contained, it is expressly agreed and understood that: if the Employee is terminated by the Company without Just Cause or the Employee terminates his employment for Good Reason, as hereinafter defined,
prior to a &#147;Change of Control&#148; then the Employee shall be entitled to severance payments equal to nine (9)&nbsp;months continuation of his Base Salary and COBRA payments for nine (9)&nbsp;months; further, if Employee&#146;s earned but
unpaid Annual Cash Bonus from the previously completed calendar year has not yet been paid out, then Company shall pay it along with the first severance payment unless the Employee has voluntarily resigned without Good Reason, in which event no
payment shall be made. All severance payments of Base Salary will be paid over such nine (9)&nbsp;month period beginning on the first regularly scheduled payroll date after termination and in accordance with the provisions of Article 3(a), but shall
terminate and be forfeited in the event that a court of competent jurisdiction determines that Employee is in material breach of any of Employee&#146;s obligations under Articles 6 or 7. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Alternatively, if the Employee is terminated by the Company without Just Cause or the
Employee terminates his employment for Good Reason, as hereinafter defined, three (3)&nbsp;months prior to or within twelve (12)&nbsp;months following a &#147;Change of Control,&#148; then the Employee shall be entitled to severance payments equal
to twelve (12)&nbsp;months of his Base Salary as of the date of termination, COBRA payments for twelve (12)&nbsp;months after termination, and acceleration of all unvested stock options; further, if Employee&#146;s earned but unpaid Annual Cash
Bonus from the previously completed calendar year has not yet been paid out, then Company shall pay it along with the first severance payment unless the Employee has voluntarily resigned without Good Reason, in which event no payment shall be made.
All severance payments of Base Salary will be paid over such twelve (12)&nbsp;month period after termination in accordance with the provisions of Article 3(a), but shall terminate and be forfeited in the event that a court of competent jurisdiction
determines that Employee is in material breach of any of Employee&#146;s obligations under Articles 6 or 7. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this
Agreement, &#147;Good Reason&#148; is defined to exist upon: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The relocation of the Company&#146;s offices such that the Employee&#146;s daily commute is increased by at
least thirty (30)&nbsp;miles each way without the written consent of the Employee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Material reduction of the Employee&#146;s Base Salary without the prior consent of the Employee (other than in
connection with, and substantially proportionate to reductions by the Company of the Base Salary of more than 50% of its employees); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Material diminution in Employee&#146;s duties, authority or responsibilities without the prior consent of the
Employee; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any action or inaction that constitutes a material breach by the Company of this Agreement or any other
agreement between Employee and the Company. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provided, however, that in each case of (A)-(D): above, (x)&nbsp;written
notice of Employee&#146;s resignation for Good Reason must be delivered to the Company within ninety (90)&nbsp;days after the initial occurrence of any such event, (b)&nbsp;the Company must have thirty (30)&nbsp;days to adequately cure such event,
and (c)&nbsp;Employee must tender his resignation within thirty (30)&nbsp;days after the Company&#146;s failure to cure such event, in order for Employee&#146;s resignation with Good Reason to be effective hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice.</U>&nbsp;&nbsp;&nbsp;&nbsp;Any notice provided for in this Agreement must be in writing and must be
either personally delivered, mailed by first class mail (postage prepaid and return receipt requested), sent by reputable overnight courier service (charges prepaid), or sent by confirmed facsimile at the address indicated below: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Company:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMYLYX PHARMACEUTICALS, INC.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">43 Thorndike Street</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02141</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attn: Justin Klee, President</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To Employee:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">James Frates</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">471 Grove Street</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Needham, MA 02492</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or such other address and/or to the attention of such other person as the recipient party shall have designated by notice
given in accordance with this Section&nbsp;10. All notices under this Agreement shall be deemed to have been given: (a)&nbsp;if delivered in person or sent by confirmed facsimile then on the date delivered, (b)&nbsp;if by overnight courier, one
(1)&nbsp;calendar day following delivery to recipient, facsimile transmission or delivery to the courier (as the case may be) or (c)&nbsp;if mailed, three (3)&nbsp;calendar days following deposit in the U.S. mail. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Code Section&nbsp;409A Compliance. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The intent of the parties is that payments and benefits under this Agreement comply with, or be exempt from Code
Section&nbsp;409A, and, accordingly, this Agreement shall be interpreted and applied so as to be in compliance therewith. The Company and the Employee agree to work together in good faith to consider amendments to this Agreement and to take such
reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to the Employee under Section&nbsp;409A. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement
providing for the payment of any amounts or benefits upon or following a termination of employment that are considered <FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; under Code Section&nbsp;409A unless such
termination is also a &#147;separation from service&#148; within the meaning of Code Section&nbsp;409A and, for purposes of any such provision of this Agreement, references to a &#147;termination&#148;, &#147;termination of employment&#148;, or like
terms shall mean &#147;separation from service&#148;. If the Employee is deemed on the date of termination to be a &#147;specified employee&#148; within the meaning of that term under Code Section&nbsp;409A(a)(2)(B), then with regard to any payment
that is considered <FONT STYLE="white-space:nowrap">non-qualified</FONT> deferred compensation under Code Section&nbsp;409A payable on account of a &#147;separation from service,&#148; such payment or benefit shall be made or provided at the date
which is the earlier of (A)&nbsp;the expiration of the six (6)&nbsp;month period measured from the date of such &#147;separation from service&#148; of the Employee, and (B) the date of the Employee&#146;s death (the &#147;Delay Period&#148;). Upon
the expiration of the Delay Period, all payments and benefits delayed pursuant to this Section&nbsp;26(b) (whether they would have otherwise been payable in a single sum or in installments in the absence of such delay) shall be paid or reimbursed to
the Employee in a lump sum and any remaining payments and benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;With regard to any provision herein that provides for
reimbursement of costs and expenses or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits, except as permitted by Code Section&nbsp;409A: (i)&nbsp;the right to reimbursement or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits shall not
be subject to liquidation or exchange for another benefit, (ii)&nbsp;the amount of expenses eligible for reimbursement, or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits, provided during any taxable year shall not affect the expenses
eligible for reimbursement, or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits to be provided, in any other taxable year, provided that the foregoing clause (ii)&nbsp;shall not be violated with regard to expenses reimbursed under any
arrangement covered by Internal Revenue Code Section&nbsp;105(b) solely because such expenses are subject to a limit related to the period the arrangement is in effect and (iii)&nbsp;such payments shall be made on or before the last day of
Employee&#146;s taxable year following the taxable year in which the expense occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of Code Section&nbsp;409A, the
Employee&#146;s right to receive any installment payments pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments. In no event may the Employee, directly or indirectly, designate the calendar year
of any payment to be made under this Agreement that is considered nonqualified deferred compensation. In no event shall the timing of Employee&#146;s execution of the General Release, directly or indirectly, result in the Employee designating the
calendar year of payment, and if a payment that is subject to execution of the General Release could be made in more than one taxable year, payment shall be made in the later taxable year. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;280G Provision. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Anything in this Agreement to the contrary notwithstanding; in the event that the amount of any compensation,
payment or distribution by the Company to or for the benefit of the Employee, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section&nbsp;280G of
the Internal Revenue Code of 1986, as amended (the <U>&#147;</U><U>Code</U><U>&#148;</U>) and the applicable regulations thereunder (the &#147;<U>Aggregate Payments</U>&#148;), would be subject to the excise tax imposed by Section&nbsp;4999 of the
Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which the Employee becomes subject to the excise tax imposed by Section&nbsp;4999 of the
Code; <U>provided</U> that such reduction shall only occur if it would result in the Employee receiving a higher After Tax Amount (as defined below) than the Employee would receive if the Aggregate Payments were not subject to such reduction. In
such event, the Aggregate Payments shall be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is
subject to Section&nbsp;280G of the Code: (1)&nbsp;cash payments not subject to Section&nbsp;409A of the Code; (2) cash payments subject to Section&nbsp;409A of the Code; (3)&nbsp;equity-based payments and acceleration; and <FONT
STYLE="white-space:nowrap">(4)&nbsp;non-cash</FONT> forms of benefits; <U>provided</U> that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. <FONT
STYLE="white-space:nowrap">&#167;l.280G-l,</FONT> <FONT STYLE="white-space:nowrap">Q&amp;A-24(b)</FONT> or (c)&nbsp;shall be reduced before any amounts that are subject to calculation under Treas. Reg.
<FONT STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q&amp;A-24(b)</FONT> or (c). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) For purposes of this Section, the &#147;After Tax Amount&#148; means the amount of the
Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on the Employee as a result of the Employee&#146;s receipt of the Aggregate Payments. For purposes of determining the After Tax Amount, the Employee
shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal
rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to this Section shall
be made by a nationally recognized accounting firm selected by the Company (the &#147;<U>Accounting Firm</U>&#148;), which shall provide detailed supporting calculations both to the Company and the Employee within 15 business days of the date of
termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Employee. Any determination by the Accounting Firm shall be binding upon the Company and the Employee. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">General Provisions. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability.</U> Whenever possible, each provision of this Agreement shall be interpreted in such manner as to
be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability
shall not affect any other provision or any other jurisdiction, and this Agreement shall be reformed, construed and enforced in such jurisdiction so as to best give effect to the intent of the parties under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Complete Agreement.</U> This Agreement, the Indemnification Agreement and the Equity Documents embody the
complete agreement and understanding among the parties and supersedes and preempts any prior understandings, agreements or representations by or between the parties, written or oral, which may have related to the subject matter hereof in any way.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts.</U> This Agreement may be executed in separate counterparts, each of which is deemed to be an
original and all of which taken together constitute one and the same agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Success and Assigns.</U>
Except as otherwise provided herein, this Agreement shall bind and inure to the benefit of and be enforceable by the Employee and the Company, and their respective heirs, legal representatives, successors and assigns, including any successor to the
Company by means of merger or consolidation; provided that the rights and obligations of Employee under this Agreement shall not be assignable. The Company is defined to include any affiliate or subsidiary of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp; <U>Choice of Law.</U> This Agreement shall be governed and
construed m accordance with the internal laws of the Commonwealth of Massachusetts without giving effect to any choice of law or conflict of law provision or rule (whether of the Commonwealth of Massachusetts or any other jurisdiction) that would
cause the application of the laws of any jurisdiction other than the Commonwealth of Massachusetts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Consent
to Jurisdiction.</U> The parties irrevocably consent and submit to the jurisdiction of any local, state or federal court within the County of Middlesex and in The Commonwealth of Massachusetts for the enforcement of this Agreement. The parties
irrevocably waive any objection they may have to venue in the defense of an inconvenient forum to the maintenance of such actions or proceedings to enforce this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver.</U> The failure of any party to enforce any of the provisions of this Agreement shall in no way be
construed as a waiver of such provisions and shall not affect the right of such party thereafter to enforce each and every provision of this Agreement in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings.</U> The headings contained in this Agreement are for convenience of reference only and shall not
affect the meaning or interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments.</U> This Agreement shall not be amended
or modified unless pursuant to an agreement in writing signed by the Company and the Employee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival.</U> Notwithstanding anything to the contrary herein contained, Sections 6, 7, 8, 9, 10, 11 and 12
hereof shall remain in effect following the expiration or termination of this Agreement and Employee&#146;s employment hereunder and the rights and obligations of the parties shall survive the termination or expiration of Employee&#146;s employment
to the extent that any performance is required following termination or expiration of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Signature Page Follows
</I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF, </B>the parties hereto have, executed this Agreement as a document,
under seal, on the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">AMYLYX PHARMACEUTICALS, INC.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">EMPLOYEE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Justin Klee</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ James Frates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">(name) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(title)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">James Frates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">Hereunto Duly Authorized</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>EXHIBIT &#147;A&#148;</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SECTION 3(d): GOALS AND OBJECTIVES </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>EXHIBIT &#147;B&#148;</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">INDEMNIFICATION AGREEMENT </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>15
<FILENAME>d155225dex1010.htm
<DESCRIPTION>EX-10.10
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.10</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.10 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS EMPLOYMENT AGREEMENT </B>(the &#147;<U>Agreement</U>&#148;) is made and entered into as of the 13<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> day of May 2019 (the &#147;Effective Date&#148;), by and between <B>MARGARET OLINGER,</B> <B>MBA </B>of 5134 Cote du Rhone Way, Sarasota, FL 34238 (the &#147;Employee&#148;) and <B>AMYLYX</B>
<B>PHARMACEUTICALS, INC., </B>a Delaware corporation duly organized under law and having a usual place of business at 43 Thorndike Street, Cambridge, MA 02141 (the &#147;Company&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is
engaged in the business of researching, discovering, developing and commercializing therapeutics for the treatment of neurodegenerative diseases (the &#147;Business&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company desires to employ the Employee as Chief Commercial Officer, and the Employee desires to be so employed by the Company, on the
terms and conditions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company desires to bind the Employee to certain restrictive covenants, and Employee agrees to
be so bound on the terms and conditions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, for good and valuable consideration, including the mutual
covenants and agreements herein contained, the receipt and legal sufficiency of which are hereby acknowledged, accepted and agreed to, the parties hereto agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Term of Employment</U>. Subject to the terms hereof, the Employee&#146;s employment hereunder shall commence on the Effective Date and
shall be <FONT STYLE="white-space:nowrap">at-will;</FONT> meaning that either party may terminate this Agreement at any time upon ten (10) days prior written notice to the other, and upon the expiration of the aforesaid ten (10) day period, this
Agreement shall terminate and thereafter be null and void and without further force or effect except for those provisions which survive in accordance with this Agreement. The term of the Employee&#146;s employment under this Agreement is hereafter
referred to as the &#147;Employment Term&#148;. As of the Effective Date, the Employee will be employed for twenty (20)&nbsp;hours per week (1,040 hours on an annualized basis) which includes approximately one (1)&nbsp;week per month in the
Company&#146;s offices in Cambridge, Massachusetts. It is the intention (but not the obligation), of both parties to increase the Employee&#146;s time to forty (40)&nbsp;hours per week on a basis and timing that is mutually agreed to. If the
increase in hours is mutually agreed to, the increase will not occur prior to October&nbsp;1, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Employment Duties</U>. During
the Employment Term, the Employee shall serve as Chief Commercial Officer, subject to the terms and conditions of this Agreement, and shall report to and take direction from the President of the Company or his designee. The Employee agrees that she
will faithfully and diligently perform the services and assume such duties and responsibilities as are assigned to her by the President and that she will carry out and perform the duties and responsibilities customarily associated with said position
and office. The Employee shall devote her best efforts and applicable business time and attention to the business and affairs of the Company and the performance of her duties hereunder. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Employee shall initially be located in West Haven, Connecticut and shall travel on
behalf of the Company as needed and requested. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Employee represents and warrants to the Company as follows: (i)&nbsp;that she is under
no contractual or other restriction or obligation which is inconsistent with the execution of this Agreement, or which will interfere with the performance of her duties hereunder, nor does the Employee have any obligation of confidentiality to any
third party which interferes with her obligations hereunder; (ii)&nbsp;that the execution and performance of this Agreement will not violate any policies or procedures of any academic institution or corporation (public or private) with which she is
involved or associated with and that she has received all of the necessary written permission(s) to enter into this Agreement and (iii)&nbsp;that in providing the services to the Company, she will not use any resources belonging to any corporation,
company, institution (public, private, profit or <FONT STYLE="white-space:nowrap">non-profit),</FONT> or other third party, including, but not limited to utilities, facilities, computers, laboratories or supplies or otherwise engage the services,
consult with or employ any individual not previously approved in writing by the Company; and agrees that she will not disclose any confidential information belonging to a third party without that third parties express, prior written consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Compensation</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>Base Salary</U>. Subject to the provisions of this Agreement, the Company shall pay the Employee a base salary as set forth on <U>Schedule 1</U> annexed hereto and made a part hereof, as if set out verbatim (the &#147;Base Salary&#148;), which
shall be paid in accordance with the Company&#146;s normal payroll procedures and policies. Any adjustments to the Base Salary shall be approved by the Board of Directors (the &#147;Board&#148;). All payments made to the Employee pursuant to this
Agreement shall be treated as wages for withholding and employment tax purposes as provided by law, except that reimbursement of expenses will not be so treated to the extent permitted by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Annual Cash Bonus</U>. In addition to the Base Salary, the Employee may be entitled to a target bonus of thirty five (35%) percent of
her then Base Salary (the &#147;Annual Cash Bonus&#148;), based upon the successful completion of certain goals and objectives approved by the Board. These goals may relate to the achievement of corporate goals; the achievement of individual goals
or a combination of the same. When the goals are agreed to, they shall be identified on <U>Exhibit</U> &#147;<U>A</U>&#148; and added to this Agreement. The decision of the Board as to whether or not the goals have been achieved and the amount of
the bonus to be awarded, if any, shall be final and binding on the parties. A bonus, if awarded, shall not be added to the Base Salary and, if awarded, will be paid within sixty (60)&nbsp;days after the end of the calendar year with respect to which
the bonus is being awarded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Stock Option Bonus</U>. The Company agrees that, from time to time during the Employment Term, the
Employee may be eligible for stock option grants as determined, on an annual basis, by the Board and based upon the successful completion of annual goals and objectives as determined by the Board. All such grants shall vest in accordance with the
Company&#146;s standard form option grant agreement. The decision of the Board as to whether or not to award any stock options shall be final and binding on the parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Stock Options and Benefits</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Stock Options:</U> So long as this Agreement remains in full force and effect, and subject to approval by the Board, the Employee will
be granted the right and option to purchase up to One Hundred Thirty Five Thousand Five Hundred Eighty (135,580) shares (the &#147;Shares&#148;) of the Common Capital Stock of the Company (the &#147;Stock&#148;) at an exercise price based upon the
fair market value of the Common Stock on the date the grant is approved by the Board. The options granted herein shall vest in accordance with the following schedule: Thirty Three Thousand Eight Hundred Ninety Eight (33,898) options shall vest on
November&nbsp;13, 2019, and thereafter, an additional Two Thousand Four Hundred Twenty One (2,421) options shall vest monthly with the first monthly vesting occurring on December&nbsp;13, 2019 and on the 13<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> day of each month thereafter occurring during the Employment Term. As a condition precedent to this grant, the Employee shall execute and deliver the Company&#146;s standard form Incentive Stock
Option Agreement and the grant shall be subject to the terms and conditions of the Incentive Stock Option Agreement and the Company&#146;s Stock Option and Restricted Stock Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">At such time as the parties agree to increase the Employee&#146;s time commitment to forty (40)&nbsp;hours, the Employee will be granted the
right and option to purchase up to an additional One Hundred Thirty Five Thousand Five Hundred Eighty (135,580) Shares of the Common Capital Stock of the Company at an exercise price based upon the fair market value of the Common Stock on the date
the grant is approved by the Board. The additional options granted herein shall vest in accordance with the following schedule: Thirty Three Thousand Eight Hundred Ninety Eight (33,898) options shall vest six (6)&nbsp;months from the date that the
Employee commenced working as a full time employee, and thereafter, an additional Two Thousand Four Hundred Twenty One (2,421) options shall vest monthly with the first monthly vesting occurring on the applicable monthly date of the seventh (7<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>) month following the Employee becoming a full time employee and on the like monthly anniversary date thereafter occurring during the Employment Term. As a condition precedent to this grant, the
Employee shall execute and deliver the Company&#146;s standard form Incentive Stock Option Agreement and the grant shall be subject to the terms and conditions of the Incentive Stock Option Agreement and the Company&#146;s Stock Option and
Restricted Stock Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Benefits:</U> The Employee may be entitled, during the Employment Term, to receive paid medical, dental,
and disability insurance if, and to the extent available and to participate in any and all employee benefit plans and programs, including, without limitation, life insurance, and 401 (k) plans, as are maintained from time to time, for employees of
the Company subject to plan terms and applicable Company policies (the &#147;Benefits&#148;). Further, during the Employment Term, the Employee shall be entitled, with prior written approval of either the President or the CEO if the request is of
greater than five (5)&nbsp;days, to an unlimited number of vacation and sick days, and national and state holidays as are observed by the Company. Notwithstanding anything to the contrary herein contained, it is agreed and understood that until such
time as the Employee is a full time Employee, as defined in Article 1 hereof, the Company&#146;s obligation to provide medical coverage shall be capped at a cost to the Company of Five Hundred ($500) Dollars per month; which shall be continued for a
period of six (6)&nbsp;months once and if the Employee becomes a full time Employee. At the conclusion of the six (6)&nbsp;months period, the Company and the Employee will mutually agree on the medical cost coverage to be provided to the Employee
thereafter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Reimbursement of Expenses</U>. The Employee shall be entitled to reimbursement for
ordinary, necessary and reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> business expenses, which Employee incurs in connection with performing her duties under this Agreement. The
reimbursement of all such expenses shall be made in accordance with the Company&#146;s customary practices and policies (including presentation of evidence reasonably satisfactory to the Company of the amounts and nature of such expenses) for
reimbursement of expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Restrictive Covenants</U>. As partial consideration of the Company entering into this Agreement, the
Employee agrees that at all times during which the Employee is employed by the Company and continuing for a period of one (1)&nbsp;year following the expiration or termination of the Employee&#146;s employment under this Agreement for any reason
(the &#147;Restricted Period&#148;), the Employee shall not, directly or indirectly, without the prior written consent of the Company, any place in the world: (A)&nbsp;solicit any customer of the Company to purchase from any source other than the
Company any product or service which is distributed, sold or provided by the Company during the term of Employee&#146;s employment or as of the date of termination or expiration of the Employee&#146;s employment or otherwise interfere with any
relationship between the Company and any customer or former customer of the Company; (B)&nbsp;solicit any employee, consultant or advisor to the Company to leave the employ of or cease consulting or advising for the Company or solicit or request any
employee of or consultant or advisor to the Company to join the employ of, or begin consulting or advising for any individual or entity which directly or indirectly competes with the Company or (C)&nbsp;without limiting the generality of clause
(A)&nbsp;above, solicit any supplier, distributor, manufacturer, licensor, or licensee of the Company to cease doing any business with, or to limit or alter its business relationship with the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Proprietary Rights</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.1 <U>Definitions.</U> For the purposes of this Article 7, the terms set forth below shall have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.11 <U>Concept and Ideas.</U> Those concepts and ideas disclosed by the Company to Employee or which are first developed or conceived by
Employee during the Employment Term and which relate to the Company&#146;s present, past or prospective activities, services and products, all of which shall remain the sole and exclusive property of the Company (hereinafter, collectively referred
as &#147;Concepts and Ideas&#148;). Further, the Employee shall have no publication rights hereunder and all of the same shall belong exclusively to the Company. Employee acknowledges and agrees that all works and tasks performed by Employee for or
on behalf of the Company, or in connection therewith during the Employment Terms (the &#147;Works&#148;) are owned by the Company. Employee acknowledges and agrees that, to the fullest extent allowed by law, all of the Works are &#147;works made for
hire,&#148; as that phrase is defined in the Copyright Revision Act of 1976 (17 U.S.C. &#167; 101) (the &#147;Act&#148;) in that either: (i)&nbsp;such Works are and will be prepared within the scope of this Agreement or (ii)&nbsp;such Works have
been and will be specifically ordered or commissioned for use as set forth in the Act. The Company shall therefore be deemed to be the sole author and owner of any and all right, title, and interest therein, including, without limitation, all
intellectual property rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.1.2. <U>Confidential Information.</U> Confidential Information means that secret or
proprietary information of whatever kind or nature disclosed to Employee by or on behalf of the Company during the Employment Term (whether or not invented, discovered or developed by Employee) or first developed by Employee hereunder or otherwise
during the Employment Term, or any other information derived from the Confidential Information. Such secret or proprietary information shall include (unless such information is generally available to the public or known in the industry through no
action of Employee) information relating to the design, manufacture, application, trade secrets, know how, research and development relating to the Company&#146;s products, materials, operating and other cost data, price lists and data relating to
the Company&#146;s products. Such secret or proprietary information shall specifically include, without limitation, all such secret or proprietary information contained in the Company&#146;s manuals, memoranda, plans, drawings and designs,
specifications, supply sources, customer lists and records legended or otherwise identified by the Company or the Board as Confidential Information. The Employee&#146;s obligations with respect to Confidential Information will cease when the
Confidential Information: (i)&nbsp;becomes part of the public domain through no wrongful act of the Employee, or (ii)&nbsp;is approved for release by prior written authorization of the Company. However, Confidential Information shall be considered
Confidential Information even if a portion or specific sections of the Confidential Information are known or generally available to the general public; and the Confidential Information shall not lose its character and status as Confidential
Information unless and until all of the Confidential Information is in the public domain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.2.
<U><FONT STYLE="white-space:nowrap">Non-Disclosure</FONT> to Third Parties.</U> Except as required by Employee&#146;s duties, Employee shall not, at any time, now or in the future, directly or indirectly, use, publish, disseminate, reproduce or
otherwise disclose any Confidential Information, Concepts and Ideas relating to the present, past or prospective business of the Company to any third party. Further, and recognizing the highly competitive nature of the Company&#146;s business and
the need to protect its intellectual property, all publication rights shall belong solely to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.3. <U>Documents, etc.</U> All
documents, procedural manuals, guides, specifications, plans, drawings, designs and similar materials, lists of present, past or prospective customers, customer proposals, invitations to submit proposals, price lists and data relating to the pricing
of the Company&#146;s products and services, records, notebooks and similar repositories of or containing Confidential Information (including all copies thereof) that come into Employee&#146;s possession or control by reason of Employee&#146;s
relationship with the Company, whether prepared by Employee or others: (a)&nbsp;are and shall remain the property of the Company, (b)&nbsp;will not be used by Employee in any way adverse to the Company, (c)&nbsp;will not be removed from the
Company&#146;s premises (except as Employee&#146;s duties require) and (d)&nbsp;at the termination (for whatever reason) of Employee&#146;s relationship with the Company, will be left with, or forthwith returned by Employee to, the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.4. <U>Patents, etc.</U> Any interest in patents, patent applications, inventions, technological innovations, improvements, enhancements,
copyrights, copyrightable works, developments, discoveries, designs, processes, formulas, <FONT STYLE="white-space:nowrap">know-how,</FONT> data and analysis, whether patentable or not (collectively, the &#147;Inventions&#148;), which Employee as a
result of rendering the Services to the Company under this Agreement may conceive or develop shall belong exclusively to the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.5. <U>Assignment</U><U>.</U> The Employee hereby irrevocably and voluntarily assigns and,
to the extent any such assignment cannot be made at present, hereby agrees to irrevocably and voluntarily automatically assign to the Company, without further compensation or consideration of her rights, title and interest in and to all Concepts,
Ideas, Works, and Inventions and any and all related patents, patent applications, copyrights, copyright applications, licenses, trademarks, trade names and other proprietary or intellectual property rights in the United States and throughout the
world. The Employee agrees that she will promptly, without any additional costs, expense or consideration, execute when presented, whether during the Employment Term or at any time thereafter, all documents, agreements, applications and instruments
and perform all lawful acts which the Company considers necessary or advisable to secure its rights hereunder and to carry out the intent of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.6 <U>Notice of Immunity Provision</U>. Pursuant to the provisions of the Federal Defend Trade Secrets Act of 2016 (&#147;DTSA&#148;), notice
is hereby given by the Company to the Employee that, under the DTSA, an individual shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (A)&nbsp;is made: (i)&nbsp;in
confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney and (ii)&nbsp;solely for the purpose of reporting or investigating a suspected violation of law or (B)&nbsp;is made in a complaint or
other document filed in a lawsuit or other proceeding, if such filing is made under seal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Specific Performance</U>. Employee agrees
that any violation by her of Sections 6 or 7 of this Agreement would be highly injurious to the Company and would cause irreparable harm to the Company. By reason of the foregoing, Employee consents and agrees that if she violates or threatens to
violate any provision(s) of Sections 6 or 7 of this Agreement, the Company shall be entitled, in addition to any other rights and remedies that it may have, to apply to any court of competent jurisdiction for specific performance and/or injunctive
or other equitable relief (without the requirement of posting of a bond or other security) in order to enforce, or prevent any continuing or potential violation of, the provisions of such Section(s). The Employee also recognizes that the
territorial, time and scope limitations set forth in Sections 6 and 7, as applicable, are reasonable and are properly required and necessary for the protection of the Company and in the event that any such territorial, time or scope limitation is
deemed to be unreasonable by a court of competent jurisdiction, the Company and the Employee agree, and Employee submits, to the reduction of any or all of said territorial, time or scope limitations to such an area, period or scope as said court
shall deem reasonable under the circumstances. If such partial enforcement is not possible, the provision shall be deemed severed, and the remaining provisions of this Agreement shall remain in full force and effect. Employee acknowledges that
Sections 6 and 7 of this Agreement shall survive termination or expiration of the Employee&#146;s employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Termination</U>.
Notwithstanding the notice provision of Article 1 hereof, Employee&#146;s employment with the Company: (i)&nbsp;shall terminate upon the Employee&#146;s resignation, death or disability, (ii)&nbsp;may be terminated without prior written notice by
the Board for Just Cause (as defined herein) and (iii)&nbsp;may be terminated without cause by either party upon ten (10) days prior notice to the other party as set forth in Article 1 hereof. As used in this Agreement, &#147;Just Cause&#148; means
any of the following, as determined by the Board, in its reasonable judgment: (1)&nbsp;Employee&#146;s failure or refusal to perform the duties and responsibilities as are requested of her by the Company; (2)&nbsp;Employee&#146;s negligence or
misconduct in the performance of Employee&#146;s duties or (3)&nbsp;the Employee is charged with an act of embezzlement against the Company or a felony. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as hereinafter provided, effective as of the termination or expiration date of the
Employee&#146;s employment hereunder for any reason, or for no reason, or in the event the Employee resigns, termination or her death or disability then, in any of such events, the Employee shall be paid her Base Salary and benefits through the date
of expiration or termination and all the rights and options granted to the Employee pursuant to Articles 3 and 4 hereof shall cease and terminate as of the date of the Employee&#146;s termination, expiration or resignation and thereafter shall be
null and void and without further force or effect. Notwithstanding anything to the contrary herein contained, it is expressly agreed and understood that: (i)&nbsp;if the Employee is terminated by the Company without cause, or the Employee terminates
her employment for Good Reason, as hereinafter defined, prior to a &#147;Change of Control&#148; then the Employee shall be entitled to severance payments equal to six (6)&nbsp;months continuation of her Base Salary, continuation of benefits for the
six (6)&nbsp;months severance period (or additional compensation in an amount reflecting the cost to the Company of such benefits if the benefit plans do not provide for continuation) All severance payments of Base Salary and benefits pursuant to
subsection (i)&nbsp;will be paid in accordance with the provisions of Articles 3 and 4. Alternatively, if the Employee is terminated by the Company without cause, or the Employee terminates her employment for Good Reason, as hereinafter defined,
within nine (9)&nbsp;months following a &#147;Change of Control,&#148; the Employee shall be entitled to a <FONT STYLE="white-space:nowrap">one-time</FONT> severance payment equal to six (6) months of her Base Salary as of the date of termination,
and such severance payment shall be paid as of the date of termination and 100% vesting acceleration of unvested options. If the Employee remains employed by the Company following the nine (9)&nbsp;months after a &#147;Change of Control,&#148; the
severance benefits described in subsection (i)&nbsp;shall again apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, &#147;Good Reason&#148; is defined
to exist upon: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The relocation of the Company&#146;s offices such that the Employee&#146;s daily commute is increased by at
least thirty (30)&nbsp;miles each way without the written consent of the Employee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Material reduction of the Employee&#146;s Base Salary without the prior consent of the employee (other than in
connection with, and substantially proportionate to reductions by the Company of the Base Salary of more than 50% of its employees); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Material diminution in Employee&#146;s duties, authority or responsibilities without the prior consent of the
Employee, other than changes in duties, authority or responsibilities resulting from the Employee&#146;s misconduct; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provided, however, that any reduction in duties, authority or responsibilities or reduction in the level of management to which the Employee
reports following or in connection with a Change in Control shall not constitute Good Reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement,
&#147;Change of Control&#148; means: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The occurrence of any of the following events: (a)&nbsp;a merger or consolidation in which
the Company is not the surviving entity (or survives only as a subsidiary of another entity whose stockholders did not own all or substantially all of the Company&#146;s capital stock in substantially the same proportions as immediately prior to
such transaction); (b) the sale of all or substantially all of the Company&#146;s assets to any other person or entity (other than to a wholly-owned subsidiary of the Company); or (c)&nbsp;the dissolution or liquidation of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Notice</U>. Any notice provided for in this Agreement must be in writing and must be either personally delivered, mailed by first class
mail (postage prepaid and return receipt requested), sent by reputable overnight courier service (charges prepaid), or sent by confirmed facsimile at the address indicated below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><U>To the Company:</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>To Employee:</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">AMYLYX PHARMACEUTICALS, INC.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Margaret Olinger, MBA</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">43 Thorndike Street</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">240 Country Hill Drive</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Cambridge, MA 02141</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">West Haven, CT 06516</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn: Justin Klee, President</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or such other address and/or to the attention of such other person as the recipient party shall have designated by notice
given in accordance with this Section&nbsp;10. All notices under this Agreement shall be deemed to have been given: (a)&nbsp;if delivered in person or sent by confirmed facsimile then on the date delivered, (b)&nbsp;if by overnight courier, one
(1)&nbsp;day following delivery to recipient, facsimile transmission or delivery to the courier (as the case may be) or (c)&nbsp;if mailed, three (3)&nbsp;business days following deposit in the U.S. mail. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Code Section&nbsp;409A Compliance</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The intent of the parties is that payments and benefits under this Agreement comply with, or be exempt from Code Section&nbsp;409A, and,
accordingly, this Agreement shall be interpreted and applied so as to be in compliance therewith. The Company and the Executive agree to work together in good faith to consider amendments to this Agreement and to take such reasonable actions which
are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to the Executive under Section&nbsp;409A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment
of any amounts or benefits upon or following a termination of employment that are considered <FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; under Code Section&nbsp;409A unless such termination is also a
&#147;separation from service&#148; within the meaning of Code Section&nbsp;409A and, for purposes of any such provision of this Agreement, references to a &#147;termination&#148;, &#147;termination of employment&#148;, or like terms shall mean
&#147;separation from service&#148;. If the Executive is deemed on the date of termination to be a &#147;specified employee&#148; within the meaning of that term under Code Section&nbsp;409A(a)(2)(B), then with regard to any payment that is
considered <FONT STYLE="white-space:nowrap">non-qualified</FONT> deferred compensation under Code Section&nbsp;409A payable on account of a &#147;separation from service,&#148; such payment or benefit shall be made or provided at the date which is
the earlier of (A)&nbsp;the expiration of the six (6)&nbsp;month period measured from the date of such &#147;separation from service&#148; of the Executive, and (B)&nbsp;the date of the Executive&#146;s death (the &#147;Delay Period&#148;). Upon the
expiration of the Delay Period, all payments and benefits delayed pursuant to this Section&nbsp;26(b) (whether they would have otherwise been payable in a single sum or in installments in the absence of such delay) shall be paid or reimbursed to the
Executive in a lump sum and any remaining payments and benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) With regard to any provision herein that provides for reimbursement of costs and
expenses or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits, except as permitted by Code Section&nbsp;409A: (i)&nbsp;the right to reimbursement or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits shall not be subject to liquidation
or exchange for another benefit, (ii)&nbsp;the amount of expenses eligible for reimbursement, or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits, provided during any taxable year shall not affect the expenses eligible for reimbursement, or <FONT
STYLE="white-space:nowrap">in-kind</FONT> benefits to be provided, in any other taxable year, provided that the foregoing clause (ii)&nbsp;shall not be violated with regard to expenses reimbursed under any arrangement covered by Internal Revenue
Code Section&nbsp;105(b) solely because such expenses are subject to a limit related to the period the arrangement is in effect and (iii)&nbsp;such payments shall be made on or before the last day of Executive&#146;s taxable year following the
taxable year in which the expense occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of Code Section&nbsp;409A, the Executive&#146;s right to receive any installment
payments pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments. In no event may the Executive, directly or indirectly, designate the calendar year of any payment to be made under this Agreement
that is considered nonqualified deferred compensation. In no event shall the timing of Executive&#146;s execution of the General Release, directly or indirectly, result in the Executive designating the calendar year of payment, and if a payment that
is subject to execution of the General Release could be made in more than one taxable year, payment shall be made in the later taxable year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>General Provisions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Severability</U>. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any
other provision or any other jurisdiction, and this Agreement shall be reformed, construed and enforced in such jurisdiction so as to best give effect to the intent of the parties under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Complete Agreement</U>. This Agreement embodies the complete agreement and understanding among the parties and supersedes and preempts
any prior understandings, agreements or representations by or between the parties, written or oral, which may have related to the subject matter hereof in any way. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Counterparts</U>. This Agreement may be executed in separate counterparts, each of which is deemed to be an original and all of which
taken together constitute one and the same agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Success and Assigns</U>. Except as otherwise provided herein, this Agreement shall
bind and inure to the benefit of and be enforceable by the Employee and the Company, and their respective heirs, legal representatives, successors and assigns, including any successor to the Company by means of merger or consolidation; provided that
the rights and obligations of Employee under this Agreement shall not be assignable. The Company is defined to mean an affiliate or subsidiary of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Choice of Law</U>. This Agreement shall be governed and construed in accordance with the internal laws of the Commonwealth of
Massachusetts without giving effect to any choice of law or conflict of law provision or rule (whether of the Commonwealth of Massachusetts or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the
Commonwealth of Massachusetts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Consent to Jurisdiction</U>. The parties irrevocably consent and submit to the jurisdiction of any
local, state or federal court within the County of Middlesex and in The Commonwealth of Massachusetts for the enforcement of this Agreement. The parties irrevocably waive any objection she may have to venue in the defense of an inconvenient forum to
the maintenance of such actions or proceedings to enforce this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Waiver</U>. The failure of any party to enforce any of
the provisions of this Agreement shall in no way be construed as a waiver of such provisions and shall not affect the right of such party thereafter to enforce each and every provision of this Agreement in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Headings</U>. The headings contained in this Agreement are for convenience of reference only and shall not affect the meaning or
interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Amendments</U>. This Agreement shall not be amended or modified unless pursuant to an agreement
in writing signed by the Company and the Employee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) <U>Survival</U>. Notwithstanding anything to the contrary herein contained,
Sections 6, 7, 8, 9, 11 and 12 hereof shall remain in effect following the expiration or termination of this Agreement and Employee&#146;s employment hereunder and the rights and obligations of the parties shall survive the termination or expiration
of Employee&#146;s employment to the extent that any performance is required following termination or expiration of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k)
<U>Termination of Consulting Agreement</U>. Effective as of the Effective Date of this Agreement, the Consulting Agreement dated as of March&nbsp;19, 2018 by and between the Company and Margaret Olinger, MBA (the &#147;Consulting Agreement&#148;)
shall be declared null and void and without further force or effect except for those terms which shall survive and remain in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page Follows </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF, </B>the parties hereto have, executed this Agreement as a document,
under seal, on the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AMYLYX PHARMACEUTICALS, INC.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">EMPLOYEE:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joshua Cohen</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Margaret Olinger</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Joshua Cohen, CEO</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Margaret Olinger, MBA</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Hereunto Duly Authorized</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>EXHIBIT &#147;A&#148; </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>SECTION 3(b): GOALS AND OBJECTIVES </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE 1 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Employee&#146;s Base Salary and Target Bonus are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Engaged for<BR>Twenty&nbsp;(20)&nbsp;Hours<BR>Per Week</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Engaged for<BR>Forty&nbsp;(40)&nbsp;Hours<BR>Per Week</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Base Salary</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">350,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Target Bonus %</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Target Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">236,250.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">472,500.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FIRST AMENDMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT
AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT </B>(the &#147;First Amendment&#148;) is made and entered into as of the 1<SUP
STYLE="font-size:85%; vertical-align:top">st</SUP> day of August, 2019 (the &#147;First Amendment Effective Date&#148;) by and between: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><B><U>AMYLYX PHARMACEUTICALS, INC.</U></B><B>, </B>a Delaware corporation duly organized under law and having a usual place of business at 43
Thorndike St, Cambridge, MA 02141 (hereinafter referred to as the &#147;COMPANY&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>AND </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><B><U>MARGARET OLINGER, MBA.</U></B><B>, </B>of 5134 Cote du Rhone Way, Sarasota, FL 34238 (hereinafter referred to as the
&#147;EMPLOYEE&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and the Employee entered into a certain Employment Agreement (the &#147;Agreement&#148;) dated as of
May&nbsp;13, 2019 (the &#147;Effective Date&#148;), and now wish to amend the Agreement in accordance with the terms and conditions of this First Amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW THEREFORE, </B>for good and valuable consideration including the herein representations, warranties, covenants and agreements, the
receipt and legal sufficiency of which are hereby acknowledged, accepted and agreed to, the Company and the Employee hereby agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;The last two (2)&nbsp;sentences of Article 1 of the Agreement are hereby deleted in their entirety and in lieu
thereof there is hereby substituted, the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;Notwithstanding anything to the contrary herein contained, it is agreed and
understood that the Employee&#146;s work with the Company will be increased to full-time, i.e. forty (40)&nbsp;hours per week effective as of August&nbsp;1, 2019.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;Except as herein specifically amended, the Agreement is hereby ratified, confirmed and approved in all respects.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURE PAGE FOLLOWS </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EXECUTED as an instrument, under seal, as of the Effective Date. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AMYLYX PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Justin Klee</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Justin Klee, President</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Hereunto Duly
Authorized</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Margaret Olinger</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Margaret Olinger, MBA</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>16
<FILENAME>d155225dex1011.htm
<DESCRIPTION>EX-10.11
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.11</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.11 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS EMPLOYMENT AGREEMENT </B>(the &#147;<U>Agreement</U>&#148;) is made and entered into as of the 18<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> day of March 2019 (the &#147;Effective Date&#148;), by and between <B>PATRICK D. YERAMIAN,</B> <B>M.D. </B>of 1815 SW 22<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> Avenue Circle, Boca
Raton, FL. 33486 (the &#147;Employee&#148;) and <B>AMYLYX PHARMACEUTICALS, INC., </B>a Delaware corporation duly organized under law and having a usual place of business at 43 Thorndike Street, Cambridge, MA 02141 (the &#147;Company&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is
engaged in the business of researching, discovering, developing and commercializing therapeutics for the treatment of neurodegenerative diseases (the &#147;Business&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company desires to employ the Employee as Chief Medical Officer, and the Employee desires to be so employed by the Company, on the terms
and conditions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company desires to bind the Employee to certain restrictive covenants, and Employee agrees to be so
bound on the terms and conditions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, for good and valuable consideration, including the mutual covenants
and agreements herein contained, the receipt and legal sufficiency of which are hereby acknowledged, accepted and agreed to, the parties hereto agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">l. <U>Term of Employment.</U> Subject to the terms hereof, the Employee&#146;s employment hereunder shall commence on the Effective Date and
shall be <FONT STYLE="white-space:nowrap">at-will;</FONT> meaning that either party may terminate this Agreement at any time upon ten (10)&nbsp;days prior written notice to the other, and upon the expiration of the aforesaid ten ( l 0) day period,
this Agreement shall terminate and thereafter be null and void and without further force or effect except for those provisions which survive in accordance with this Agreement. The term of the Employee&#146;s employment under this Agreement is
hereafter referred to as the &#147;Employment Term&#148;. As of the Effective Date, the Employee will be employed for twenty (20)&nbsp;hours per week (1,040 hours on an annualized basis) which includes approximately one (1)&nbsp;week per month in
the Company&#146;s offices in Cambridge, Massachusetts. It is the intention (but not the obligation), of both parties to increase the Employee&#146;s time to forty (40)&nbsp;hours per week on a basis and timing that is mutually agreed to. If the
increase in hours is mutually agreed to, the increase will not occur prior to December 31, 2019. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Employment Duties.</U> During the Employment Term, the Employee shall serve as Chief Medical
Officer, subject to the terms and conditions of this Agreement, and shall report to and take direction from the President of the Company or his designee. The Employee agrees that he will faithfully and diligently perform the services and assume such
duties and responsibilities as are assigned to him by the President and that he will carry out and perform the duties and responsibilities customarily associated with said position and office. The Employee shall devote his best efforts and
applicable business time and attention to the business and affairs of the Company and the performance of his duties hereunder. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Employee shall initially be located in Boca Raton, Florida and shall travel on behalf of
the Company as needed and requested. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Employee represents and warrants to the Company as follows: (i)&nbsp;that he is under no
contractual or other restriction or obligation which is inconsistent with the execution of this Agreement, or which will interfere with the performance of his duties hereunder, nor does the Employee have any obligation of confidentiality to any
third party which interferes with his obligations hereunder; (ii)&nbsp;that the execution and performance of this Agreement will not violate any policies or procedures of any academic institution or corporation (public or private) with which he is
involved or associated with and that he has received all of the necessary written permission(s) to enter into this Agreement and (iii)&nbsp;that in providing the services to the Company, he will not use any resources belonging to any corporation,
company, institution (public, private, profit or non- profit), or other third party, including, but not limited to utilities, facilities, computers, laboratories or supplies or otherwise engage the services, consult with or employ any individual not
previously approved in writing by the Company. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Compensation.</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Base Salmy</U>. Subject to the provisions of this Agreement, the Company shall pay the Employee a base salary as
set forth on <U>Schedule&nbsp;1</U> annexed hereto and made a part hereof, as if set out verbatim (the &#147;Base Salary&#148;), which shall be paid in accordance with the Company&#146;s normal payroll procedures and policies. Any adjustments to the
Base Salary shall be approved by the Board of Directors (the &#147;Board&#148;). All payments made to the Employee pursuant to this Agreement shall be treated as wages for withholding and employment tax purposes as provided by law, except that
reimbursement of expenses will not be so treated to the extent permitted by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Annual Cash Bonus.</U> In
addition to the Base Salary, the Employee may be entitled to a target bonus of thirty (30%) percent of his then Base Salary (the &#147;Annual Cash Bonus&#148;), based upon the successful completion of certain goals and objectives approved by the
Board. These goals may relate to the achievement of corporate goals; the achievement of individual goals or a combination of the same. When the goals are agreed to, they shall be identified on <U>Exhibit &#147;A&#148;</U> and added to this
Agreement. The decision of the Board as to whether or not the goals have been achieved and the amount of the bonus to be awarded, if any, shall be final and binding on the parties. A bonus, if awarded, shall not be added to the Base Salary and, if
awarded, will be paid within sixty (60) days after the end of the calendar year with respect to which the bonus is being awarded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock Option Bonus.</U> The Company agrees that, from time to time during the Employment Term, the Employee may
be eligible for additional stock option grants as determined, on an annual basis, by the Board and based upon the successful completion of annual goals and objectives as determined by the Board. All such grants shall vest in accordance with the
Company&#146;s standard form option grant agreement. The decision of the Board as to whether or not to award any stock options shall be final and binding on the parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Stock Options and Benefits.</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock Options:</U> So long as this Agreement remains in full force and effect, and subject to approval by the
Board, the Employee will be granted the right and option to purchase up to One Hundred Twenty Three Two Hundred Fifty Four (123,254) shares (the &#147;Shares&#148;) of the Common Capital Stock of the Company (the &#147;Stock&#148;) at an exercise
price based upon the fair market value of the Common Stock on the date the grant is approved by the Board. The options granted above shall vest in accordance with the following schedule: Thirty Thousand Eight Hundred Fourteen (30,814) options shall
vest on September&nbsp;18, 2019, and thereafter, an additional Two Thousand Two Hundred One (2,201) options shall vest monthly with the first monthly vesting occurring on October 18, 2019 and on the 18th day of each month thereafter occurring during
the Employment Term. As a condition precedent to this grant, the Employee shall execute and deliver the Company&#146;s standard form Incentive Stock Option Agreement and the grant shall be subject to the terms and conditions of the Incentive Stock
Option Agreement and the Company&#146;s Stock Option and Restricted Stock Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">At such time as the parties agree to increase the
Employee&#146;s time commitment to forty (40)&nbsp;hours, the Employee will be granted the right and option to purchase up to an additional One Hundred Twenty Two Hundred Fifty Three (123,253) Shares of the Common Capital Stock of the Company at an
exercise price based upon the fair market value of the Common Stock on the date the grant is approved by the Board. The additional options granted herein shall vest in accordance with the following schedule: Thirty Thousand Eight Hundred Fourteen
(30,814) options shall vest six (6)&nbsp;months from the date that the Employee commenced working as a full time employee, and thereafter, an additional Two Thousand Two Hundred One (2,201) options shall vest monthly with the first monthly vesting
occurring on the 18th of seventh (7<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) month following the Employee becoming a full time employee and on the like monthly anniversary date thereafter occurring during the Employment Term. As a
condition precedent to this grant, the Employee shall execute and deliver the Company&#146;s standard form Incentive Stock Option Agreement and the grant shall be subject to the terms and conditions of the Incentive Stock Option Agreement and the
Company&#146;s Stock Option and Restricted Stock Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Benefits:</U> The Employee may be entitled, during the Employment
Term, to receive paid medical, dental, and disability insurance if, and to the extent available and to participate in any and all employee benefit plans and programs, including, without limitation, life insurance, and 401 (k) plans, as are
maintained from time to time, for employees of the Company subject to plan terms and applicable Company policies (the &#147;Benefits&#148;). Further, during the Employment Term, the Employee shall be entitled, with prior written approval of either
the President or the CEO if the request is of greater than five (5)&nbsp;days, to an unlimited number of vacation and sick days, and national and state holidays as are observed by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Reimbursement of Expenses.</U> The Employee shall be entitled to reimbursement for ordinary, necessary and
reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> business expenses, which Employee incurs in connection with performing his duties under this Agreement. The reimbursement of all such expenses
shall be made in accordance with the Company&#146;s customary practices and policies (including presentation of evidence reasonably satisfactory to the Company of the amounts and nature of such expenses) for reimbursement of expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Restrictive Covenants.</U> As partial consideration of the
Company entering into this Agreement, the Employee agrees that at all times during which the Employee is employed by the Company and continuing for a period of one (1)&nbsp;year following the expiration or termination of the Employee&#146;s
employment under this Agreement for any reason (the &#147;Restricted Period&#148;), the Employee shall not, directly or indirectly, without the prior written consent of the Company, any place in the world: (A)&nbsp;solicit any customer of the
Company to purchase from any source other than the Company any product or service which is distributed, sold or provided by the Company during the term of Employee&#146;s employment or as of the date of termination or expiration of the
Employee&#146;s employment or otherwise interfere with any relationship between the Company and any customer or former customer of the Company; (B)&nbsp;solicit any employee, consultant or advisor to the Company to leave the employ of or cease
consulting or advising for the Company or solicit or request any employee of or consultant or advisor to the Company to join the employ of, or begin consulting or advising for any individual or entity which directly or indirectly competes with the
Company or (C)&nbsp;without limiting the generality of clause (A)&nbsp;above, solicit any supplier, distributor, manufacturer, licensor, or licensee of the Company to cease doing any business with, or to limit or alter its business relationship with
the Company. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Proprietary Rights.</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions.</U> For the purposes of this Article 7, the terms set forth below shall have the following meanings:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.1.1 <U>Concept and Ideas.</U> Those concepts and ideas disclosed by the Company to Employee or which are first developed or conceived
by Employee during the Employment Term and which relate to the Company&#146;s present, past or prospective activities, services and products, all of which shall remain the sole and exclusive property of the Company (hereinafter, collectively
referred as &#147;Concepts and Ideas&#148;). Further, the Employee shall have no publication rights hereunder and all of the same shall belong exclusively to the Company. Employee acknowledges and agrees that all works and tasks performed by
Employee for or on behalf of the Company, or in connection therewith during the Employment Terms (the &#147;Works&#148;) are owned by the Company. Employee acknowledges and agrees that, to the fullest extent allowed by law, all of the Works are
&#147;works made for hire,&#148; as that phrase is defined in the Copyright Revision Act of 1976 (17 U.S.C. &#167; 101) (the &#147;Act&#148;) in that either: (i)&nbsp;such Works are and will be prepared within the scope of this Agreement or
(ii)&nbsp;such Works have been and will be specifically ordered or commissioned for use as set forth in the Act. The Company shall therefore be deemed to be the sole author and owner of any and all right, title, and interest therein, including,
without limitation, all intellectual property rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.1.2. <U>Confidential Information.</U> Confidential Information means that secret
or proprietary information of whatever kind or nature disclosed to Employee by or on behalf of the Company during the Employment Term (whether or not invented, discovered or developed by Employee) or first developed by Employee hereunder or
otherwise during the Employment Term, or any other information derived from the Confidential Information. Such secret or proprietary information shall include (unless such information is generally available to the public or known in the industry
through no action of Employee) information relating to the design, manufacture, application, trade secrets, know how, research and development relating to the Company&#146;s products, materials, operating and other cost data, price lists and data
relating to the Company&#146;s products. Such secret or proprietary information shall specifically include, without limitation, all such secret or proprietary information contained in the Company&#146;s manuals, memoranda, plans, drawings and
designs, specifications, supply sources, customer lists and records legended or otherwise identified by the Company or the Board as Confidential Information. The Employee&#146;s obligations with respect to Confidential Information will cease when
the Confidential Information: (i)&nbsp;becomes part of the public domain through no wrongful act of the Employee, or (ii)&nbsp;is approved for release by prior written authorization of the Company. However, Confidential Information shall be
considered Confidential Information even if a portion or specific sections of the Confidential Information are known or generally available to the general public; and the Confidential Information shall not lose its character and status as
Confidential Information unless and until all of the Confidential Information is in the public domain. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.2.&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT STYLE="white-space:nowrap">Non-Disclosure</FONT> to
Third Parties.</U> Except as required by Employee&#146;s duties, Employee shall not, at any time, now or in the future, directly or indirectly, use, publish, disseminate, reproduce or otherwise disclose any Confidential Information, Concepts and
Ideas relating to the present, past or prospective business of the Company to any third party. Further, and recognizing the highly competitive nature of the Company&#146;s business and the need to protect its intellectual property, all publication
rights shall belong solely to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Documents, etc</U>. All documents, procedural manuals, guides,
specifications, plans, drawings, designs and similar materials, lists of present, past or prospective customers, customer proposals, invitations to submit proposals, price lists and data relating to the pricing of the Company&#146;s products and
services, records, notebooks and similar repositories of or containing Confidential Information (including all copies thereof) that come into Employee&#146;s possession or control by reason of Employee&#146;s relationship with the Company, whether
prepared by Employee or others: (a)&nbsp;are and shall remain the property of the Company, (b)&nbsp;will not be used by Employee in any way adverse to the Company, (c)&nbsp;will not be removed from the Company&#146;s premises (except as
Employee&#146;s duties require) and (d)&nbsp;at the termination (for whatever reason) of Employee&#146;s relationship with the Company, will be left with, or forthwith returned by Employee to, the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Patents, etc</U>. Any interest in patents, patent applications, inventions, technological innovations,
improvements, enhancements, copyrights, copyrightable works, developments, discoveries, designs, processes, formulas, <FONT STYLE="white-space:nowrap">know-how,</FONT> data and analysis, whether patentable or not (collectively, the
&#147;Inventions&#148;), which Employee as a result of rendering the Services to the Company under this Agreement may conceive or develop shall belong exclusively to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment.</U> The Employee hereby irrevocably and voluntarily assigns and, to the extent any such assignment
cannot be made at present, hereby agrees to irrevocably and voluntarily automatically assign to the Company, without further compensation or consideration of his rights, title and interest in and to all Concepts, Ideas, Works, and Inventions and any
and all related patents, patent applications, copyrights, copyright applications, licenses, trademarks, trade names and other proprietary or intellectual property rights in the United States and throughout the world. The Employee agrees that he will
promptly, without any additional costs, expense or consideration, execute when presented, whether during the Employment Term or at any time thereafter, all documents, agreements, applications and instruments and perform all lawful acts which the
Company considers necessary or advisable to secure its rights hereunder and to carry out the intent of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.6 <U>Notice of Immunity Provision.</U> Pursuant to the provisions of the Federal Defend
Trade Secrets Act of 20 I 6 (&#147;<U>DTSA</U>&#148;), notice is hereby given by the Company to the Employee that, under the DTSA, an individual shall not be held criminally or civilly liable under any federal or state trade secret law for the
disclosure of a trade secret that: (A)&nbsp;is made: (i)&nbsp;in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney and (ii)&nbsp;solely for the purpose of reporting or investigating a
suspected violation of law or (B)&nbsp;is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Specific Performance.</U> Employee agrees that any violation by him of Sections 6 or 7 of this Agreement would be
highly injurious to the Company and would cause irreparable harm to the Company. By reason of the foregoing, Employee consents and agrees that if he violates or threatens to violate any provision(s) of Sections 6 or 7 of this Agreement, the Company
shall be entitled, in addition to any other rights and remedies that it may have, to apply to any court of competent jurisdiction for specific performance and/or injunctive or other equitable relief (without the requirement of posting of a bond or
other security) in order to enforce, or prevent any continuing or potential violation of, the provisions of such Section(s). The Employee also recognizes that the territorial, time and scope limitations set forth in Sections 6 and 7, as applicable,
are reasonable and are properly required and necessary for the protection of the Company and in the event that any such territorial, time or scope limitation is deemed to be unreasonable by a court of competent jurisdiction, the Company and the
Employee agree, and Employee submits, to the reduction of any or all of said territorial, time or scope limitations to such an area, period or scope as said court shall deem reasonable under the circumstances. If such partial enforcement is not
possible, the provision shall be deemed severed, and the remaining provisions of this Agreement shall remain in full force and effect. Employee acknowledges that Sections 6 and 7 of this Agreement shall survive termination or expiration of the
Employee&#146;s employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination.</U> Notwithstanding the notice provision of Article 1 hereof,
Employee&#146;s employment with the Company: (i)&nbsp;shall terminate upon the Employee&#146;s resignation, death or disability, (ii)&nbsp;may be terminated without prior notice by the Board for Just Cause (as defined herein) and (iii)&nbsp;may be
terminated without cause by either party upon ten (I 0) days prior notice to the other party as set forth in Article 1 hereof. As used in this Agreement, &#147;Just Cause&#148; means any of the following, as determined by the Board, in its
reasonable judgment: (1)&nbsp;Employee&#146;s continuous failure or continuous refusal to perform the duties and responsibilities as are requested of him by the Company; (2)&nbsp;Employee&#146;s gross negligence or willful misconduct in the
performance of Employee&#146;s duties or (3)&nbsp;the Employee is charged with an act of embezzlement against the Company or a felony. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective as of the termination or expiration date of the Employee&#146;s employment hereunder for any reason, or for no reason, or in the
event the Employee resigns, or his death or disability then, in any of such events, the Employee shall be paid his Base Salary and benefits through the date of expiration or termination and all the rights and unvested options granted to the Employee
pursuant to Articles 3 and 4 hereof shall cease and terminate as of the date of the Employee&#146;s termination, expiration or resignation and thereafter shall be null and void and without further force or effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice.</U> Any notice provided for in this Agreement must be
in writing and must be either personally delivered, mailed by first class mail (postage prepaid and return receipt requested), sent by reputable overnight courier service (charges prepaid), or sent by confirmed facsimile at the address indicated
below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="65%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><U>To the Company:</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>To Employee:</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">AMYLYX&nbsp;PHARMACEUTICALS,&nbsp;INC.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Patrick D. Yeramian, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">43 Thorndike Street</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">1815 Parkside Cir. S.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Cambridge, MA 02141</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Boca Raton, FL 33486</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Attn: Justin Klee, President</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or such other address and/or to the attention of such other person as the recipient party shall have designated by notice
given in accordance with this Section&nbsp;10. All notices under this Agreement shall be deemed to have been given: (a)&nbsp;if delivered in person or sent by confirmed facsimile then on the date delivered, (b)&nbsp;if by overnight courier, one
(1)&nbsp;day following delivery to recipient, facsimile transmission or delivery to the courier (as the case may be) or (c)&nbsp;if mailed, three (3)&nbsp;business days following deposit in the U.S. mail. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Code Section&nbsp;409A Compliance.</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The intent of the parties is that payments and benefits under this Agreement comply with, or be exempt from Code
Section&nbsp;409A, and, accordingly, this Agreement shall be interpreted and applied so as to be in compliance therewith. The Company and the Executive agree to work together in good faith to consider amendments to this Agreement and to take such
reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to the Executive under Section&nbsp;409A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement
providing for the payment of any amounts or benefits upon or following a termination of employment that are considered <FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; under Code Section&nbsp;409A unless such
termination is also a &#147;separation from service&#148; within the meaning of Code Section&nbsp;409A and, for purposes of any such provision of this Agreement, references to a &#147;termination&#148;, &#147;termination of employment&#148;, or like
terms shall mean &#147;separation from service&#148;. If the Executive is deemed on the date of termination to be a &#147;specified employee&#148; within the meaning of that term under Code Section&nbsp;409A(a)(2)(B), then with regard to any payment
that is considered <FONT STYLE="white-space:nowrap">non-qualified</FONT> deferred compensation under Code Section&nbsp;409A payable on account of a &#147;separation from service,&#148; such payment or benefit shall be made or provided at the date
which is the earlier of (A)&nbsp;the expiration of the six (6)&nbsp;month period measured from the date of such &#147;separation from service&#148; of the Executive, and (B)&nbsp;the date of the Executive&#146;s death (the &#147;Delay Period&#148;).
Upon the expiration of the Delay Period, all payments and benefits delayed pursuant to this Section&nbsp;26(b) (whether they would have otherwise been payable in a single sum or in installments in the absence of such delay) shall be paid or
reimbursed to the Executive in a lump sum and any remaining payments and benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;With regard to any provision herein that provides for
reimbursement of costs and expenses or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits, except as permitted by Code Section&nbsp;409A: (i)&nbsp;the right to reimbursement or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits shall not
be subject to liquidation or exchange for another benefit, (ii)&nbsp;the amount of expenses eligible for reimbursement, or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits, provided during any taxable year shall not affect the expenses
eligible for reimbursement, or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits to be provided, in any other taxable year, provided that the foregoing clause (ii)&nbsp;shall not be violated with regard to expenses reimbursed under any
arrangement covered by Internal Revenue Code Section&nbsp;105(b) solely because such expenses are subject to a limit related to the period arrangement is in effect and (iii)&nbsp;such payments shall be made on or before the last day of
Executive&#146;s taxable year following the taxable year in which the expense occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of Code Section&nbsp;409A, the
Executive&#146;s right to receive any installment payments pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments. In no event may the Executive, directly or indirectly, designate the calendar
year of any payment to be made under this Agreement that is considered nonqualified deferred compensation. In no event shall the timing of Executive&#146;s execution of the General Release, directly or indirectly, result in the Executive designating
the calendar year of payment, and if a payment that is subject to execution of the General Release could be made in more than one taxable year, payment shall be made in the later taxable year. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&nbsp;&nbsp;&nbsp;&nbsp;<U>General Provisions.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability.</U> Whenever possible, each provision of this Agreement shall be interpreted in such manner as to
be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability
shall not affect any other provision or any other jurisdiction, and this Agreement shall be reformed, construed and enforced in such jurisdiction so as to best give effect to the intent of the parties under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Complete Agreement.</U>&nbsp;&nbsp;&nbsp;&nbsp;This Agreement embodies the complete agreement and understanding
among the parties and supersedes and preempts any prior understandings, agreements or representations by or between the parties, written or oral, which may have related to the subject matter hereof in any way. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts.</U> This Agreement may be executed in separate counterparts, each of which is deemed to be an
original and all of which taken together constitute one and the same agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Success and Assigns.</U>
Except as otherwise provided herein, this Agreement shall bind and inure to the benefit of and be enforceable by the Employee and the Company, and their respective heirs, legal representatives, successors and assigns, including any successor to the
Company by means of merger or consolidation; provided that the rights and obligations of Employee under this Agreement shall not be assignable. The Company is defined to mean an affiliate or subsidiary of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Choice of Law.</U> This Agreement shall be governed and
construed in accordance with the internal laws of the Commonwealth of Massachusetts without giving effect to any choice of law or conflict of law provision or rule (whether of the Commonwealth of Massachusetts or any other jurisdiction) that would
cause the application of the laws of any jurisdiction other than the Commonwealth of Massachusetts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Consent
to Jurisdiction.</U> The parties irrevocably consent and submit to the jurisdiction of any local, state or federal court within the County of Middlesex and in The Commonwealth of Massachusetts for the enforcement of this Agreement. The parties
irrevocably waive any objection he may have to venue in the defense of an inconvenient forum to the maintenance of such actions or proceedings to enforce this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver.</U> The failure of any party to enforce any of the provisions of this Agreement shall in no way be
construed as a waiver of such provisions and shall not affect the right of such party thereafter to enforce each and every provision of this Agreement in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings.</U> The headings contained in this Agreement are for convenience of reference only and shall not
affect the meaning or interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments.</U> This Agreement shall not be amended
or modified unless pursuant to an agreement in writing signed by the Company and the Employee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>. Notwithstanding anything to the contrary herein contained, Sections 6, 7, 8, 9, 11 and 12 hereof
shall remain in effect following the expiration or termination of this Agreement and Employee&#146;s employment hereunder and the rights and obligations of the parties shall survive the termination or expiration of Employee&#146;s employment to the
extent that any performance is required following termination or expiration of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
of Consulting Agreement.</U>&nbsp;&nbsp;&nbsp;&nbsp;Effective as of the Effective Date of this Agreement, the Consulting Agreement dated as of January&nbsp;25, 2018 by and between the Company and DLx Therapeutics LLC (the &#147;Consulting
Agreement&#148;) shall be declared null and void and without further force or effect except for those terms which shall survive and remain in full force and effect; provided; however that the <FONT STYLE="white-space:nowrap">Non-Qualified</FONT>
Stock Option Agreement dated February 16, 2018 by and between the Company and Patrick D. Yeramian, M.D. shall remain in full force and effect in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page Follows </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF, </B>the patties hereto have, executed this Agreement as a document,
under seal, on the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AMYLYX PHARMACEUTICALS, INC.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>EMPLOYEE:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Justin Klee</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Patrick Yeramian</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Justin Klee, President</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Patrick Yeramian, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Hereunto Duly Authorized</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE 1 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Employee&#146;s Base Salary and Target Bonus are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Engaged for<BR>Twenty&nbsp;(20)&nbsp;Hours<BR>Per Week</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Engaged for<BR>Forty&nbsp;(40)&nbsp;Hours<BR>Per Week</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Base Salary</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">360,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Target Bonus %</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Target Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">234,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">468,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>EXHIBIT &#147;A&#148; </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>SECTION 3(b): GOALS AND OBJECTIVES </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73339g0103014621857.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 Thorndike Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cambridge, MA 02141 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone: <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-561-571-6262</FONT></FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:53%; font-size:10pt; font-family:Times New Roman">November 26, 2019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patrick D. Yeramian, M.D.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1815 SW 22<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> Avenue Circle </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boca Raton, FL. 33486 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Dr.&nbsp;Yeramian: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is hereby made to a certain Employment Agreement dated as of March&nbsp;18, 2019 (the &#147;Agreement&#148;), by and between Amylyx
Pharmaceuticals, Inc. (the &#147;Company&#148;) and Patrick D. Yeramian, M.D. (the &#147;Employee&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with Article 1 of
the Agreement, you were initially employed for a period of twenty (20)&nbsp;hours per week with the understanding that your time would be increased to forty (40)&nbsp;hours by mutual agreement. Article 1 also provides that the increase in hours
would not occur prior to December 31, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recognizing your increasing workload and expanding duties as Chief Medical Officer, you and
the Company have agreed that your time commitment will increase to forty (40)&nbsp;hours per week as of November&nbsp;26, 2019 and, in addition, the last sentence of the Agreement prohibiting any increase in hours prior to December&nbsp;31, 2019 is
hereby stricken and deleted from the Agreement by mutual consent. Accordingly, as of November&nbsp;26, 2019 you are employed by the Company on a full time basis which automatically, and in accordance with the terms of the Agreement, adjusts your
Base Salary and initiates the vesting of stock options as provided for in second paragraph of Section&nbsp;4(a) of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
your records, please countersign a copy of this Letter Agreement and return the same to me at your earliest convenience. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Kind regards.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">AMYLYX PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joshua B. Cohen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Joshua B. Cohen, Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Hereunto Duly Authorized</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">The within Letter Agreement, and terms and conditions herein are hereby acknowledged, accepted and agreed to:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Patrick D. Yeramian</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Patrick D. Yeramian, M.D.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>17
<FILENAME>d155225dex1012.htm
<DESCRIPTION>EX-10.12
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.12</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.12 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Employment Agreement (&#147;<U>Agreement</U>&#148;) is made between Amylyx Pharmaceuticals, Inc., a Delaware corporation (the
&#147;<U>Company</U>&#148;), and Joshua B. Cohen (the &#147;<U>Executive</U>&#148;) and is effective as of the closing of the Company&#146;s first underwritten public offering of its equity securities pursuant to an effective registration statement
under the Securities Act of 1933, as amended (the &#147;<U>Effective Date</U>&#148;). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below) and subject to Section&nbsp;12, this Agreement
supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i)&nbsp;the employment agreement between the Executive and the Company dated July&nbsp;1, 2015
and later amended February&nbsp;19, 2021<B> </B>(the &#147;<U>Prior Agreement</U>&#148;), and (ii) any other offer letter, employment agreement or severance agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company desires to continue to employ the Executive and the Executive desires to continue to be employed by the Company on the
new terms and conditions contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE,<I> </I>in consideration of the mutual covenants and agreements herein
contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Employment</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>Term</U>. The Company shall employ the Executive and the Executive shall be employed by the Company pursuant to this Agreement commencing as of the Effective Date and continuing until such employment is terminated in accordance with the
provisions hereof (the &#147;<U>Term</U>&#148;). The Executive&#146;s employment with the Company shall continue to be &#147;at will,&#148; meaning that the Executive&#146;s employment may be terminated by the Company or the Executive at any time
and for any reason subject to the terms of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Position and Duties</U>. The Executive shall serve as the <FONT
STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer (&#147;<U>CEO</U>&#148;) of the Company and shall have such powers and duties as may from time to time be prescribed by the Board of Directors (the &#147;<U>Board</U>&#148;). In addition,
the Executive currently serves on the Company&#146;s Board and shall continue to so serve for as long as the Executive remains the CEO, subject to the terms of any applicable governing documents or bylaws applicable to the Board; <I>provided</I>
that the Executive shall be deemed to have resigned from the Board and from any related positions upon ceasing to serve as CEO for any reason. The Executive shall devote the Executive&#146;s full working time and efforts to the business and affairs
of the Company. Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the approval of the Board, or engage in religious, charitable or other community activities as long as such services and activities do not
interfere with the Executive&#146;s performance of the Executive&#146;s<B> </B>duties to the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Location</U>. The
Executive&#146;s primary work location will be in the Company&#146;s office, currently located in Cambridge, Massachusetts; <I>provided</I> that the Executive may be required to travel regularly for business, consistent with the Company&#146;s
business needs. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Compensation and Related Matters</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Base Salary</U>. The Executive&#146;s initial base salary shall be paid at the rate of $540,000 per year. The Executive&#146;s base
salary shall be subject to periodic review by<B> </B>the Board or the Compensation Committee of the Board (the &#147;<U>Compensation Committee</U>&#148;). The base salary in effect at any given time is referred to herein as &#147;<U>Base
Salary</U>.&#148; The Base Salary shall be payable in a manner that is consistent with the Company&#146;s usual payroll practices for its executive officers. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Incentive Compensation</U>. The Executive shall be eligible to receive cash incentive compensation as determined by the Board or the
Compensation Committee from time to time. The Executive&#146;s initial target annual incentive compensation shall be 60% of the Executive&#146;s Base Salary. The target annual incentive compensation in effect at any given time is referred to herein
as &#147;<U>Target Bonus</U>.&#148; The actual amount of the Executive&#146;s annual incentive compensation, if any, shall be determined in the sole discretion of the Board or the Compensation Committee. Any annual incentive compensation will be
paid no later than March 15<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the calendar year following the calendar year to which such bonus relates. Except as otherwise provided herein or as may be provided by the Board or the
Compensation Committee, the Executive must be employed by the Company on the date such incentive compensation is paid in order to earn or receive any annual incentive compensation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Expenses</U>. The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by the Executive
during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its executive officers. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Other Benefits</U>. The Executive shall be eligible to participate in or receive benefits under the Company&#146;s employee benefit
plans in effect from time to time, subject to the terms of such plans. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Paid Time Off</U>. The Executive shall be entitled to take
paid time off in accordance with the Company&#146;s applicable paid time off policy for executives, as may be in effect from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Equity</U>. The equity awards held by the Executive shall continue to be governed by the terms and conditions of the Company&#146;s
applicable equity incentive plan(s) and the applicable award agreement(s) governing the terms of such equity awards (collectively, the &#147;<U>Equity Documents</U>&#148;); <I>provided, however</I>, and notwithstanding anything to the contrary in
the Equity Documents, Section&nbsp;5(b) of this Agreement shall apply in the event of a termination by the Company without Cause or by the Executive for Good Reason outside the Change in Control Period, Section&nbsp;6 of this Agreement shall apply
in the event of a Change in Control and Section&nbsp;7(a)(ii) of this Agreement shall apply in the event of a termination by the Company without Cause or by the Executive for Good Reason in either event within the Change in Control Period (as such
terms are defined below). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination</U>. The Executive&#146;s employment hereunder may be terminated without any breach of this
Agreement under the following circumstances: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Death</U>. The Executive&#146;s employment hereunder shall terminate upon death. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Disability</U>. The Company may terminate the Executive&#146;s employment if the Executive is disabled and unable to perform or expected
to be unable to perform the essential functions of the Executive&#146;s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any <FONT
STYLE="white-space:nowrap">12-month</FONT> period. If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive&#146;s then existing position or
positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or the
Executive&#146;s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the issue. The
Executive shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and the Executive shall fail to submit such certification, the Company&#146;s determination of such issue
shall be binding on the Executive. Nothing in this Section&nbsp;3(b) shall be construed to waive the Executive&#146;s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. &#167;2601
<I>et seq</I>. and the Americans with Disabilities Act, 42 U.S.C. &#167;12101 <I>et seq.</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Termination by the Company for
Cause</U>. The Company may terminate the Executive&#146;s employment hereunder for Cause. For purposes of this Agreement, &#147;<U>Cause</U>&#148; shall mean any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) conduct by the Executive constituting a material act of misconduct in connection with the performance of the Executive&#146;s duties,
including, without limitation, (A)&nbsp;willful failure or refusal to perform material responsibilities that have been requested by the Board; (B)&nbsp;dishonesty to the Board with respect to any material matter; or (C)&nbsp;misappropriation of
funds or property of the Company or any of its subsidiaries or affiliates other than the occasional, customary and <I>de minimis</I> use of Company property for personal purposes; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) the commission by the Executive of acts satisfying the elements of (A)&nbsp;any felony or (B)&nbsp;a misdemeanor involving moral
turpitude, deceit, dishonesty or fraud; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) any misconduct by the Executive, regardless of whether or not in the course of the
Executive&#146;s employment, that would reasonably be expected to result in material injury or reputational harm to the Company or any of its subsidiaries or affiliates if the Executive were to continue to be employed in the same position; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) continued unsatisfactory performance or <FONT STYLE="white-space:nowrap">non-performance</FONT> by the Executive of the Executive&#146;s
duties hereunder (other than by reason of the Executive&#146;s physical or mental illness, incapacity or disability) which has continued for more than 30 days following written notice of such unsatisfactory performance or <FONT
STYLE="white-space:nowrap">non-performance</FONT> from the Board; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) a breach by the Executive of any of the provisions contained in Section&nbsp;9 of this
Agreement or the Restrictive Covenants Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) a material violation by the Executive of any of the Company&#146;s written
employment policies; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) the Executive&#146;s failure to cooperate with a bona fide internal investigation or an investigation by
regulatory or law enforcement authorities, after being instructed by the Company to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the inducement of others to
fail to cooperate or to produce documents or other materials in connection with such investigation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Termination by the Company
without Cause</U>. The Company may terminate the Executive&#146;s employment hereunder at any time without Cause. Any termination by the Company of the Executive&#146;s employment under this Agreement which does not constitute a termination for
Cause under Section&nbsp;3(c) and does not result from the death or disability of the Executive under Section&nbsp;3(a) or (b)&nbsp;shall be deemed a termination without Cause. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Termination by the Executive</U>. The Executive may terminate employment hereunder at any time for any reason, including but not limited
to, Good Reason. For purposes of this Agreement, &#147;<U>Good Reason</U>&#148; shall mean that the Executive has completed all steps of the Good Reason Process (hereinafter defined) following the occurrence of any of the following events without
the Executive&#146;s consent (each, a &#147;<U>Good Reason Condition</U>&#148;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) a material diminution in the
Executive&#146;s responsibilities, authority or duties; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) a material diminution in the Executive&#146;s Base Salary
except for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">across-the-board</FONT></FONT> salary reductions based on the Company&#146;s financial performance similarly affecting all or substantially all senior management employees
of the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) a material change in the geographic location of the principal office of the Company to which the
Executive is assigned, such that there is an increase of at least thirty (30)&nbsp;miles of driving distance to such location from the Executive&#146;s principal residence as of such change; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) a material breach of this Agreement by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#147;<U>Good Reason Process</U>&#148; consists of the following steps: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) the Executive reasonably determines in good faith that a Good Reason Condition has occurred; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) the Executive notifies the Company in writing of the first occurrence of the Good Reason Condition within 60 days of the
first occurrence of such condition; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) the Executive cooperates in good faith with the Company&#146;s
efforts, for a period of not less than 30 days following such notice (the &#147;<U>Cure Period</U>&#148;), to remedy the Good Reason Condition; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) notwithstanding such efforts, the Good Reason Condition continues to exist at the end of the Cure Period; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) the Executive terminates employment within 60 days after the end of the Cure Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company cures the Good Reason Condition during the Cure Period, Good Reason shall be deemed not to have occurred. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Matters Related to Termination</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Notice of Termination</U>. Except for termination as specified in Section&nbsp;3(a), any termination of the Executive&#146;s employment
by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a &#147;<U>Notice of Termination</U>&#148; shall mean a notice which shall
indicate the specific termination provision in this Agreement relied upon. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Date of Termination</U>. &#147;<U>Date of
Termination</U>&#148; shall mean: (i)&nbsp;if the Executive&#146;s employment is terminated by death, the date of death; (ii)&nbsp;if the Executive&#146;s employment is terminated on account of disability under Section&nbsp;3(b) or by the Company
for Cause under Section&nbsp;3(c), the date on which Notice of Termination is given; (iii)&nbsp;if the Executive&#146;s employment is terminated by the Company without Cause under Section&nbsp;3(d), the date on which a Notice of Termination is given
or the date otherwise specified by the Company in the Notice of Termination; (iv)&nbsp;if the Executive&#146;s employment is terminated by the Executive under Section&nbsp;3(e) other than for Good Reason, 30 days after the date on which a Notice of
Termination is given, and (v)&nbsp;if the Executive&#146;s employment is terminated by the Executive under Section&nbsp;3(e) for Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding the
foregoing, in the event that the Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Accrued Obligations</U>. If the Executive&#146;s employment with the Company is terminated for any reason, the Company
shall pay or provide to the Executive (or to the Executive&#146;s<B> </B>authorized representative or estate)&nbsp;(i) any Base Salary earned through the Date of Termination; (ii)&nbsp;unpaid expense reimbursements (subject to, and in accordance
with, Section&nbsp;2(c) of this Agreement); and (iii)&nbsp;any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance
with the terms of such employee benefit plans (collectively, the &#147;<U>Accrued Obligations</U>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Resignation of All Other Positions</U>. To the extent applicable, the Executive shall
be deemed to have resigned from all officer and board member positions that the Executive holds with the Company or any of its respective subsidiaries and affiliates upon the termination of the Executive&#146;s employment for any reason. The
Executive shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.
<U>Severance Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason Outside the Change in Control Period</U>. If the Executive&#146;s employment is terminated by the Company without Cause as provided in
Section&nbsp;3(d), or the Executive terminates employment for Good Reason as provided in Section&nbsp;3(e), in each case outside of the Change in Control Period, then, in addition to the<B> </B>Accrued Obligations, and subject to (i)&nbsp;the
Executive signing a separation agreement and release in a form and manner satisfactory to the Company, which shall include, without limitation, a general release of claims against the Company and all related persons and entities that shall not
release the Executive&#146;s rights under this Agreement, a reaffirmation of all of the Executive&#146;s Continuing Obligations (as defined below), and, in the Company&#146;s sole discretion, a <FONT STYLE="white-space:nowrap">one-year</FONT>
post-employment noncompetition agreement, and shall provide that if the Executive breaches any of the Continuing Obligations, all payments of the Severance Amount shall immediately cease (the &#147;<U>Separation Agreement</U>&#148;), and
(ii)&nbsp;the Separation Agreement becoming irrevocable, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement), which shall include a seven (7)&nbsp;business day revocation period: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) the Company shall pay the Executive an amount equal to the sum of (i) 12 months of the Executive&#146;s Base Salary plus (ii)&nbsp;a <FONT
STYLE="white-space:nowrap">pro-rata</FONT> portion of the Target Bonus (pursuant to Section&nbsp;2(b)) for the calendar year in which the Date of Termination occurs based on the number of days the Executive was employed by the Company in such
calendar year (the &#147;<U>Severance Amount</U>&#148;); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) notwithstanding anything to the contrary in any applicable option
agreement or other stock-based award agreement, the stock options and other stock-based awards held by the Executive that are solely subject to time-based vesting (&#147;<U>Time-Based Equity Awards</U>&#148;) and that would have become fully vested
and exercisable or nonforfeitable had the Executive remained employed by the Company for the <FONT STYLE="white-space:nowrap">12-month</FONT> period immediately following the Date of Termination, shall immediately accelerate and become fully vested
and exercisable or nonforfeitable as of the later of (i)&nbsp;the Date of Termination or (ii)&nbsp;the effective date of the Release (the &#147;<U>Accelerated Vesting Date</U>&#148;), <I>provided</I> that in order to effectuate the accelerated
vesting contemplated by this subsection, the unvested portion of the Executive&#146;s Time-Based Equity Awards that would otherwise be forfeited on the Date of Termination will be delayed until the earlier of (A)&nbsp;the effective date of the
Release (at which time acceleration will occur), or (B)&nbsp;the date that the Release can no longer become fully effective (at which time the unvested portion of the Executive&#146;s Time-Based Equity Awards will be forfeited). Notwithstanding the
foregoing, no additional time-based vesting of the Time-Based Equity Awards shall occur during the period between the Date of Termination and the Accelerated Vesting Date; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) subject to the Executive&#146;s copayment of premium amounts at the applicable active
employees&#146; rate and the Executive&#146;s proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#147;<U>COBRA</U>&#148;), the Company shall pay to the group health plan provider or the
COBRA provider a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company until the earliest of (i)&nbsp;the <FONT
STYLE="white-space:nowrap">12-month</FONT> anniversary of the Date of Termination; (ii)&nbsp;the date that the Executive becomes eligible for group medical plan benefits under any other employer&#146;s group medical plan; or (iii)&nbsp;the cessation
of the Executive&#146;s health continuation rights under COBRA; <I>provided, however</I>, that if the Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially
violating applicable law (including, without limitation, Section&nbsp;2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to the Executive for the time period specified above. Such
payments to the Executive shall be subject to <FONT STYLE="white-space:nowrap">tax-related</FONT> deductions and withholdings and paid on the Company&#146;s regular payroll dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts payable under Section&nbsp;5, to the extent taxable, shall be paid out in substantially equal installments in accordance with the Company&#146;s
payroll practice over 12 months commencing within 60<B> </B>days after the Date of Termination; <I>provided, however</I>, that if the <FONT STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year and ends in a second calendar
year, such payments, to the extent they qualify as <FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; within the meaning of Section&nbsp;409A of the Internal Revenue Code of 1986, as amended (the
&#147;<U>Code</U>&#148;), shall begin to be paid in the second calendar year by the last day of such <FONT STYLE="white-space:nowrap">60-day</FONT> period; <I>provided, further</I>, that the initial payment shall include a <FONT
STYLE="white-space:nowrap">catch-up</FONT> payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury
Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Change in Control</U>. Upon a Change in Control,
except as otherwise explicitly set forth in the applicable equity award agreement, any stock options and other stock-based awards held by the Executive with conditions and restrictions relating to the attainment of performance goals
(&#147;<U>Performance-Based Equity Awards</U>&#148;), to the extent then outstanding and unearned, shall be deemed earned based on the greater of target or actual performance as measured through such Change in Control, and such Performance-Based
Equity Awards that are deemed earned shall be subject to time-based vesting, based on Executive&#146;s continued employment, for the remainder of the performance period and shall be subject to accelerated vesting upon a termination of
Executive&#146;s employment to the extent provided for in Section&nbsp;7(a)(ii) below. Any Performance-Based Equity Awards that are not deemed earned upon a Change in Control shall be forfeited for no consideration upon such Change in Control. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Severance Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason within the Change in Control
Period</U>. The provisions of this Section&nbsp;7 shall apply in lieu of, and expressly supersede, the provisions of Section&nbsp;5 if (i)&nbsp;the Executive&#146;s employment is terminated either (a)&nbsp;by the Company without Cause as provided in
Section&nbsp;3(d), or (b)&nbsp;by the Executive for Good Reason as provided in Section&nbsp;3(e), and (ii)&nbsp;the Date of Termination is on or within three (3)&nbsp;months prior to or 12 months after the occurrence of the first event constituting
a Change in Control (such period, the &#147;<U>Change in Control Period</U>&#148;). These provisions shall terminate and be of no further force or effect after the Change in Control Period. </P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If the Executive&#146;s employment is terminated by the Company without Cause as
provided in Section&nbsp;3(d) or the Executive terminates employment for Good Reason as provided in Section&nbsp;3(e) and in each case the Date of Termination occurs during the Change in Control Period, then, in addition to the Accrued Obligations,
and subject to the signing of a general release of claims against the Company and all related persons and entities that shall not release the Executive&#146;s rights under this Agreement (the &#147;<U>Release</U>&#148;) by the Executive and the
Release becoming fully effective, all within the time frame set forth in the Release but in no event more than 60 days after the Date of Termination: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) the Company shall pay the Executive a lump sum in cash in an amount equal to 1.5 times the sum of (A)&nbsp;the
Executive&#146;s then-current Base Salary (or the Executive&#146;s Base Salary in effect immediately prior to the Change in Control, if higher) plus (B)&nbsp;the Executive&#146;s Target Bonus for the then-current year (or the Executive&#146;s Target
Bonus in effect immediately prior to the Change in Control, if higher) (the &#147;<U>Change in Control Payment</U>&#148;); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) notwithstanding anything to the contrary in any applicable option agreement or other stock-based award agreement, all
Time-Based Equity Awards and any Performance-Based Equity Awards that are then outstanding and eligible to vest based on Executive&#146;s continued employment as provided for under Section&nbsp;6&nbsp;above shall immediately accelerate and become
fully vested and exercisable or nonforfeitable as of the Accelerated Vesting Date, <I>provided</I> that in order to effectuate the accelerated vesting contemplated by this subsection, the unvested portion of the Executive&#146;s Time-Based Equity
Awards and Performance-Based Equity Awards that would otherwise be forfeited on the Date of Termination will be delayed until the earlier of (A)&nbsp;the effective date of the Release (at which time acceleration will occur), or (B)&nbsp;the date
that the Release can no longer become fully effective (at which time the unvested portion of the Executive&#146;s Time-Based Equity Awards and Performance-Based Equity Awards will be forfeited). Notwithstanding the foregoing, no additional
time-based vesting of the Time-Based Equity Awards or Performance-Based Equity Awards shall occur during the period between the Date of Termination and the Accelerated Vesting Date; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) subject to the Executive&#146;s copayment of premium amounts at the applicable active employees&#146; rate and the
Executive&#146;s proper election to receive benefits under COBRA, the Company shall pay to the group health plan provider or the COBRA provider a monthly payment equal to the monthly employer contribution that the Company would have made to provide
health insurance to the Executive if the Executive had remained employed by the Company until the earliest of (A)&nbsp;the <FONT STYLE="white-space:nowrap">18-month</FONT> anniversary of the Date of Termination; (B)&nbsp;the date that the Executive
becomes eligible for group medical plan benefits under any other employer&#146;s group medical plan; or (C)&nbsp;the cessation of the Executive&#146;s health continuation rights under COBRA; <I>provided, however</I>, that if the Company determines
that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section&nbsp;2716 of the Public Health Service Act), then the
Company shall convert such payments to payroll payments directly to the Executive for the time period specified above. Such payments to the Executive shall be subject to <FONT STYLE="white-space:nowrap">tax-related</FONT> deductions and withholdings
and paid on the Company&#146;s regular payroll dates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts payable under this Section&nbsp;7(a), to the extent taxable, shall be paid or commence to be
paid within 60 days after the Date of Termination; <I>provided, however</I>, that if the <FONT STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year and ends in a second calendar year, such payments to the extent they qualify
as <FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; within the meaning of Section&nbsp;409A of the Code, shall be paid or commence to be paid in the second calendar year by the last day of such <FONT
STYLE="white-space:nowrap">60-day</FONT> period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Additional Limitation</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any compensation, payment or
distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section&nbsp;280G of the Code,
and the applicable regulations thereunder (the &#147;<U>Aggregate Payments</U>&#148;), would be subject to the excise tax imposed by Section&nbsp;4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of
all of the Aggregate Payments shall be $1.00 less than the amount at which the Executive becomes subject to the excise tax imposed by Section&nbsp;4999 of the Code; <I>provided</I> that such reduction shall only occur if it would result in the
Executive receiving a higher After Tax Amount (as defined below) than the Executive would receive if the Aggregate Payments were not subject to such reduction. In such event, the Aggregate Payments shall be reduced in the following order, in each
case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section&nbsp;280G of the Code: (A)&nbsp;cash payments not subject to
Section&nbsp;409A of the Code; (B)&nbsp;cash payments subject to Section&nbsp;409A of the Code; (C)&nbsp;equity-based payments and acceleration; and <FONT STYLE="white-space:nowrap">(D)&nbsp;non-cash</FONT> forms of benefits; <I>provided</I> that in
the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q&amp;A-24(b)</FONT> or
(c)&nbsp;shall be reduced before any amounts that are subject to calculation under Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q&amp;A-24(b)</FONT> or (c). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) For purposes of this Section&nbsp;7(b), the &#147;<U>After Tax Amount</U>&#148; means the amount of the Aggregate Payments
less all federal, state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive&#146;s receipt of the Aggregate Payments. For purposes of determining the After Tax Amount, the Executive shall be deemed to
pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual
taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to Section&nbsp;7(b)(i)
shall be made by a nationally recognized accounting firm selected by the Company (the &#147;<U>Accounting Firm</U>&#148;), which shall provide detailed supporting calculations both to the Company and the Executive within 15 business days of the Date
of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive. Any determination by the Accounting Firm shall be binding upon the Company and the Executive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Definitions</U>. For purposes of this Agreement, &#147;<U>Change in Control</U>&#148;
shall have the meaning ascribed to the term &#147;Sale Event&#148; as used in the Company&#146;s 2022 Stock Option and Incentive Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.
<U>Section 409A</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive&#146;s separation
from service within the meaning of Section&nbsp;409A of the Code, the Company determines that the Executive is a &#147;specified employee&#148; within the meaning of Section&nbsp;409A(a)(2)(B)(i) of the Code, then to the extent any payment or
benefit that the Executive becomes entitled to under this Agreement or otherwise on account of the Executive&#146;s separation from service would be considered deferred compensation otherwise subject to the 20&nbsp;percent additional tax imposed
pursuant to Section&nbsp;409A(a) of the Code as a result of the application of Section&nbsp;409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (i)&nbsp;six
months and one day after the Executive&#146;s separation from service, or (ii)&nbsp;the Executive&#146;s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a <FONT
STYLE="white-space:nowrap">catch-up</FONT> payment covering amounts that would otherwise have been paid during the <FONT STYLE="white-space:nowrap">six-month</FONT> period but for the application of this provision, and the balance of the
installments shall be payable in accordance with their original schedule. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) All <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits
provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively
practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided or
reimbursable expenses incurred in one taxable year shall not affect the <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other
aggregate limitation applicable to medical expenses). Such right to reimbursement or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits is not subject to liquidation or exchange for another benefit. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To the extent that any payment or benefit described in this Agreement constitutes
<FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; under Section&nbsp;409A of the Code, and to the extent that such payment or benefit is payable upon the Executive&#146;s termination of employment, then such
payments or benefits shall be payable only upon the Executive&#146;s &#147;separation from service.&#148; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in
Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h).</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The parties intend that this Agreement will be
administered in accordance with Section&nbsp;409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section&nbsp;409A of the Code, the provision shall be read in such a manner so that all payments
hereunder comply with Section&nbsp;409A of the Code. Each payment pursuant to this Agreement or the Restrictive Covenants Agreement is intended to constitute a separate payment for purposes of Treasury Regulation
<FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section&nbsp;409A of the Code and all
related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Company makes no representation or warranty and shall have no liability to the
Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section&nbsp;409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Continuing Obligations</U>.<U> </U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Restrictive Covenants Agreement</U>. In consideration for the increase of the Executive&#146;s Base Salary and Target Bonus provided for
in this Agreement, such increases the Executive acknowledges the Executive would not otherwise be entitled to receive and are consideration that is fair and reasonable and independent of the Executive&#146;s continued employment with the Company,
the Executive is required to enter into the Employee Confidentiality, Assignment and Nonsolicitation Agreement, attached hereto as <U>Exhibit A</U> (the &#147;<U>Restrictive Covenants Agreement</U>&#148;). For purposes of this Agreement, the
obligations in this Section&nbsp;9, the obligations that arise in the Restrictive Covenants Agreement and the obligations that arise in Sections <FONT STYLE="white-space:nowrap">6-8</FONT> of the Prior Agreement, and any other agreement relating to
confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the &#147;<U>Continuing Obligations</U>.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Third-Party Agreements and Rights</U>. The Executive hereby confirms that the Executive is not bound by the terms of any agreement with
any previous employer or other party which restricts in any way the Executive&#146;s use or disclosure of information, other than confidentiality restrictions (if any), or the Executive&#146;s engagement in any business. The Executive represents to
the Company that the Executive&#146;s execution of this Agreement, the Executive&#146;s employment with the Company and the performance of the Executive&#146;s proposed duties for the Company will not violate any obligations the Executive may have
to any such previous employer or other party. In the Executive&#146;s work for the Company, the Executive will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other party,
and the Executive will not bring to the premises of the Company any copies or other tangible embodiments of <FONT STYLE="white-space:nowrap">non-public</FONT> information belonging to or obtained from any such previous employment or other party.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Litigation and Regulatory Cooperation</U>. During and after the Executive&#146;s employment, the Executive shall cooperate fully
with the Company in (i)&nbsp;the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while the Executive was
employed by the Company, and (ii)&nbsp;the investigation, whether internal or external, of any matters about which the Company believes the Executive may have knowledge or information. The Executive&#146;s full cooperation in connection with such
claims, actions or investigations shall include, but not be limited to, being available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times.
During and after the Executive&#146;s employment, the Executive also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review
relates to events or occurrences that transpired while the Executive was employed by the Company. The Company shall reimburse the Executive for any reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with the Executive&#146;s performance of obligations pursuant to this Section&nbsp;9(c). </P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Relief</U>. The Executive agrees that it would be difficult to measure any damages
caused to the Company which might result from any breach by the Executive of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly<B>,</B> the Executive agrees that if the
Executive breaches, or proposes to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such
breach without showing or proving any actual damage to the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Consent to Jurisdiction</U>. The parties hereby consent to the
jurisdiction of the state and federal courts of the<B> </B>Commonwealth of Massachusetts. Accordingly, with respect to any such court action, the Executive (a)&nbsp;submits to the exclusive personal jurisdiction of such courts; (b)&nbsp;consents to
service of process; and (c)&nbsp;waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Waiver of Jury Trial</U>. Each of the Executive and the Company irrevocably and unconditionally WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY
PROCEEDING (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE EXECUTIVE&#146;S EMPLOYMENT BY THE COMPANY OR ANY AFFILIATE OF THE COMPANY, INCLUDING WITHOUT LIMITATION THE EXECUTIVE&#146;S OR THE
COMPANY&#146;S PERFORMANCE UNDER, OR THE ENFORCEMENT OF, THIS AGREEMENT. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Integration</U>. This Agreement<B>, </B>together with the
Restrictive Covenants Agreement and the certain Director and Officer Indemnification Agreement to which the Executive and the Company are parties, constitutes the entire agreement between the parties with respect to the subject matter hereof and
supersedes all prior agreements between the parties concerning such subject matter, including the Prior Agreement, <I>provided</I> that Sections <FONT STYLE="white-space:nowrap">6-8</FONT> of the Prior Agreement, the Equity Documents and any other
agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall remain in full force and effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.
<U>Withholding; Tax Effect</U>. All payments made by the Company to the Executive under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law. Nothing in this Agreement shall be construed
to require the Company to make any payments to compensate the Executive for any adverse tax effect associated with any payments or benefits or for any deduction or withholding from any payment or benefit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Assignment; Successors and Assigns</U>. Neither the Executive nor the Company may
make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; <I>provided, however</I>, that the Company may assign its rights and obligations under this Agreement
(including the Restrictive Covenants Agreement) without the Executive&#146;s consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization or consolidation, into which the Company merges or to whom
it transfers all or substantially all of its properties or assets; <I>provided, further</I> that if the Executive remains employed or becomes employed by the Company, the purchaser or any of their affiliates in connection with any such transaction,
then the Executive shall not be entitled to any payments, benefits or vesting pursuant to Section&nbsp;5 or Section&nbsp;7 of this Agreement solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding upon the
Executive and the Company, and each of the Executive&#146;s and the Company&#146;s respective successors, executors, administrators, heirs and permitted assigns. In the event of the Executive&#146;s death after the Executive&#146;s termination of
employment but prior to the completion by the Company of all payments due to the Executive under this Agreement, the Company shall continue such payments to the Executive&#146;s beneficiary designated in writing to the Company prior to the
Executive&#146;s death (or to the Executive&#146;s estate, if the Executive fails to make such designation). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Enforceability</U>. If
any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder
of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be
valid and enforceable to the fullest extent permitted by law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Survival</U>. For the avoidance of doubt, the provisions of this
Agreement shall survive the termination of the Executive&#146;s employment to the extent necessary to effectuate the terms contained herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>Waiver</U>. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of
any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any
subsequent breach. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>Notices</U>. Any notices, requests, demands and other communications provided for by this Agreement shall be
sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed
in writing with the Company or, in the case of the Company, at its main offices, attention of the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <U>Amendment</U>. This
Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <U>Effect on Other Plans and Agreements</U>. An election by the Executive to resign for
Good Reason under the provisions of this Agreement shall not be deemed a voluntary termination of employment by the Executive for the purpose of interpreting the provisions of any of the Company&#146;s benefit plans, programs or policies. Nothing in
this Agreement shall be construed to limit the rights of the Executive under the Company&#146;s benefit plans, programs or policies except as otherwise provided in Section&nbsp;9 hereof, and except that the Executive shall have no rights to any
severance benefits under any Company severance pay plan, offer letter or otherwise. In the event that the Executive is party to an agreement with the Company providing for payments or benefits under such plan or agreement and under this Agreement,
the terms of this Agreement shall govern and the Executive may receive payment under this Agreement only and not both. Further, Section&nbsp;5 and Section&nbsp;7 of this Agreement are mutually exclusive and in no event shall the Executive be
entitled to payments or benefits pursuant to both Section&nbsp;5 and Section&nbsp;7 of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <U>Governing Law</U>. This is a
Massachusetts contract and shall be construed under and be governed in all respects by the laws of the Commonwealth of Massachusetts, without giving effect to the conflict of laws principles thereof. With respect to any disputes concerning federal
law, such disputes shall be determined in accordance with the law as it would be interpreted and applied by the United States Court of Appeals for the First Circuit. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. <U>Counterparts</U>. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be
taken to be an original; but such counterparts shall together constitute one and the same document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement effective on the Effective
Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AMYLYX PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EXECUTIVE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Joshua B. Cohen</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>18
<FILENAME>d155225dex1013.htm
<DESCRIPTION>EX-10.13
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.13</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.13 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Employment Agreement (&#147;<U>Agreement</U>&#148;) is made between Amylyx Pharmaceuticals, Inc., a Delaware corporation (the
&#147;<U>Company</U>&#148;), and Justin Klee (the &#147;<U>Executive</U>&#148;) and is effective as of the closing of the Company&#146;s first underwritten public offering of its equity securities pursuant to an effective registration statement
under the Securities Act of 1933, as amended (the &#147;<U>Effective Date</U>&#148;). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below) and subject to Section&nbsp;12, this Agreement
supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i)&nbsp;the employment agreement between the Executive and the Company dated August&nbsp;1, 2015
and later amended February&nbsp;19, 2021<B> </B>(the &#147;<U>Prior Agreement</U>&#148;), and (ii) any other offer letter, employment agreement or severance agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company desires to continue to employ the Executive and the Executive desires to continue to be employed by the Company on the
new terms and conditions contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE,<I> </I>in consideration of the mutual covenants and agreements herein
contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Employment</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>Term</U>. The Company shall employ the Executive and the Executive shall be employed by the Company pursuant to this Agreement commencing as of the Effective Date and continuing until such employment is terminated in accordance with the
provisions hereof (the &#147;<U>Term</U>&#148;). The Executive&#146;s employment with the Company shall continue to be &#147;at will,&#148; meaning that the Executive&#146;s employment may be terminated by the Company or the Executive at any time
and for any reason subject to the terms of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Position and Duties</U>. The Executive shall serve as the <FONT
STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer (the &#147;<U>CEO</U>&#148;) of the Company and shall have such powers and duties as may from time to time be prescribed by the Board of Directors (the &#147;<U>Board</U>&#148;). In
addition, the Executive currently serves on the Company&#146;s Board and shall continue to so serve for as long as the Executive remains the CEO, subject to the terms of any applicable governing documents or bylaws applicable to the Board;
<I>provided</I> that the Executive shall be deemed to have resigned from the Board and from any related positions upon ceasing to serve as CEO for any reason. The Executive shall devote the Executive&#146;s full working time and efforts to the
business and affairs of the Company. Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the approval of the Board, or engage in religious, charitable or other community activities as long as such services and
activities do not interfere with the Executive&#146;s performance of the Executive&#146;s<B> </B>duties to the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
<U>Location</U>. The Executive&#146;s primary work location will be in the Company&#146;s office, currently located in Cambridge, Massachusetts; <I>provided</I> that the Executive may be required to travel regularly for business, consistent with the
Company&#146;s business needs. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Compensation and Related Matters</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Base Salary</U>. The Executive&#146;s initial base salary shall be paid at the rate of $540,000 per year. The Executive&#146;s base
salary shall be subject to periodic review by<B> </B>the Board or the Compensation Committee of the Board (the &#147;<U>Compensation Committee</U>&#148;). The base salary in effect at any given time is referred to herein as &#147;<U>Base
Salary</U>.&#148; The Base Salary shall be payable in a manner that is consistent with the Company&#146;s usual payroll practices for its executive officers. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Incentive Compensation</U>. The Executive shall be eligible to receive cash incentive compensation as determined by the Board or the
Compensation Committee from time to time. The Executive&#146;s initial target annual incentive compensation shall be 60% of the Executive&#146;s Base Salary. The target annual incentive compensation in effect at any given time is referred to herein
as &#147;<U>Target Bonus</U>.&#148; The actual amount of the Executive&#146;s annual incentive compensation, if any, shall be determined in the sole discretion of the Board or the Compensation Committee. Any annual incentive compensation will be
paid no later than March 15<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the calendar year following the calendar year to which such bonus relates. Except as otherwise provided herein or as may be provided by the Board or the
Compensation Committee, the Executive must be employed by the Company on the date such incentive compensation is paid in order to earn or receive any annual incentive compensation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Expenses</U>. The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by the Executive
during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its executive officers. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Other Benefits</U>. The Executive shall be eligible to participate in or receive benefits under the Company&#146;s employee benefit
plans in effect from time to time, subject to the terms of such plans. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Paid Time Off</U>. The Executive shall be entitled to take
paid time off in accordance with the Company&#146;s applicable paid time off policy for executives, as may be in effect from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Equity</U>. The equity awards held by the Executive shall continue to be governed by the terms and conditions of the Company&#146;s
applicable equity incentive plan(s) and the applicable award agreement(s) governing the terms of such equity awards (collectively, the &#147;<U>Equity Documents</U>&#148;); <I>provided, however</I>, and notwithstanding anything to the contrary in
the Equity Documents, Section&nbsp;5(b) of this Agreement shall apply in the event of a termination by the Company without Cause or by the Executive for Good Reason outside the Change in Control Period, Section&nbsp;6 of this Agreement shall apply
in the event of a Change in Control and Section&nbsp;7(a)(ii) of this Agreement shall apply in the event of a termination by the Company without Cause or by the Executive for Good Reason in either event within the Change in Control Period (as such
terms are defined below). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination</U>. The Executive&#146;s employment hereunder may be terminated without any breach of this
Agreement under the following circumstances: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Death</U>. The Executive&#146;s employment hereunder shall terminate upon death. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Disability</U>. The Company may terminate the Executive&#146;s employment if the Executive is disabled and unable to perform or expected
to be unable to perform the essential functions of the Executive&#146;s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any <FONT
STYLE="white-space:nowrap">12-month</FONT> period. If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive&#146;s then existing position or
positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or the
Executive&#146;s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the issue. The
Executive shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and the Executive shall fail to submit such certification, the Company&#146;s determination of such issue
shall be binding on the Executive. Nothing in this Section&nbsp;3(b) shall be construed to waive the Executive&#146;s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. &#167;2601
<I>et seq</I>. and the Americans with Disabilities Act, 42 U.S.C. &#167;12101 <I>et seq.</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Termination by the Company for
Cause</U>. The Company may terminate the Executive&#146;s employment hereunder for Cause. For purposes of this Agreement, &#147;<U>Cause</U>&#148; shall mean any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) conduct by the Executive constituting a material act of misconduct in connection with the performance of the Executive&#146;s duties,
including, without limitation, (A)&nbsp;willful failure or refusal to perform material responsibilities that have been requested by the Board; (B)&nbsp;dishonesty to the Board with respect to any material matter; or (C)&nbsp;misappropriation of
funds or property of the Company or any of its subsidiaries or affiliates other than the occasional, customary and <I>de minimis</I> use of Company property for personal purposes; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) the commission by the Executive of acts satisfying the elements of (A)&nbsp;any felony or (B)&nbsp;a misdemeanor involving moral
turpitude, deceit, dishonesty or fraud; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) any misconduct by the Executive, regardless of whether or not in the course of the
Executive&#146;s employment, that would reasonably be expected to result in material injury or reputational harm to the Company or any of its subsidiaries or affiliates if the Executive were to continue to be employed in the same position; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) continued unsatisfactory performance or <FONT STYLE="white-space:nowrap">non-performance</FONT> by the Executive of the Executive&#146;s
duties hereunder (other than by reason of the Executive&#146;s physical or mental illness, incapacity or disability) which has continued for more than 30 days following written notice of such unsatisfactory performance or <FONT
STYLE="white-space:nowrap">non-performance</FONT> from the Board; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) a breach by the Executive of any of the provisions contained in Section&nbsp;9 of this
Agreement or the Restrictive Covenants Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) a material violation by the Executive of any of the Company&#146;s written
employment policies; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) the Executive&#146;s failure to cooperate with a bona fide internal investigation or an investigation by
regulatory or law enforcement authorities, after being instructed by the Company to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the inducement of others to
fail to cooperate or to produce documents or other materials in connection with such investigation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Termination by the Company
without Cause</U>. The Company may terminate the Executive&#146;s employment hereunder at any time without Cause. Any termination by the Company of the Executive&#146;s employment under this Agreement which does not constitute a termination for
Cause under Section&nbsp;3(c) and does not result from the death or disability of the Executive under Section&nbsp;3(a) or (b)&nbsp;shall be deemed a termination without Cause. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Termination by the Executive</U>. The Executive may terminate employment hereunder at any time for any reason, including but not limited
to, Good Reason. For purposes of this Agreement, &#147;<U>Good Reason</U>&#148; shall mean that the Executive has completed all steps of the Good Reason Process (hereinafter defined) following the occurrence of any of the following events without
the Executive&#146;s consent (each, a &#147;<U>Good Reason Condition</U>&#148;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) a material diminution in the Executive&#146;s
responsibilities, authority or duties; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) a material diminution in the Executive&#146;s Base Salary except for <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">across-the-board</FONT></FONT> salary reductions based on the Company&#146;s financial performance similarly affecting all or substantially all senior management employees of the Company;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) a material change in the geographic location of the principal office of the Company to which the Executive is assigned, such that
there is an increase of at least thirty (30)&nbsp;miles of driving distance to such location from the Executive&#146;s principal residence as of such change; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) a material breach of this Agreement by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#147;<U>Good Reason Process</U>&#148; consists of the following steps: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) the Executive reasonably determines in good faith that a Good Reason Condition has occurred; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) the Executive notifies the Company in writing of the first occurrence of the Good Reason Condition within 60 days of the first occurrence
of such condition; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) the Executive cooperates in good faith with the Company&#146;s efforts, for a period
of not less than 30 days following such notice (the &#147;<U>Cure Period</U>&#148;), to remedy the Good Reason Condition; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)
notwithstanding such efforts, the Good Reason Condition continues to exist at the end of the Cure Period; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) the Executive
terminates employment within 60 days after the end of the Cure Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company cures the Good Reason Condition during the Cure Period, Good Reason
shall be deemed not to have occurred. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Matters Related to Termination</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Notice of Termination</U>. Except for termination as specified in Section&nbsp;3(a), any termination of the Executive&#146;s employment
by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a &#147;<U>Notice of Termination</U>&#148; shall mean a notice which shall
indicate the specific termination provision in this Agreement relied upon. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Date of Termination</U>. &#147;<U>Date of
Termination</U>&#148; shall mean: (i)&nbsp;if the Executive&#146;s employment is terminated by death, the date of death; (ii)&nbsp;if the Executive&#146;s employment is terminated on account of disability under Section&nbsp;3(b) or by the Company
for Cause under Section&nbsp;3(c), the date on which Notice of Termination is given; (iii)&nbsp;if the Executive&#146;s employment is terminated by the Company without Cause under Section&nbsp;3(d), the date on which a Notice of Termination is given
or the date otherwise specified by the Company in the Notice of Termination; (iv)&nbsp;if the Executive&#146;s employment is terminated by the Executive under Section&nbsp;3(e) other than for Good Reason, 30 days after the date on which a Notice of
Termination is given, and (v)&nbsp;if the Executive&#146;s employment is terminated by the Executive under Section&nbsp;3(e) for Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding the
foregoing, in the event that the Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Accrued Obligations</U>. If the Executive&#146;s employment with the Company is terminated for any reason, the Company
shall pay or provide to the Executive (or to the Executive&#146;s<B> </B>authorized representative or estate)&nbsp;(i) any Base Salary earned through the Date of Termination; (ii)&nbsp;unpaid expense reimbursements (subject to, and in accordance
with, Section&nbsp;2(c) of this Agreement); and (iii)&nbsp;any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance
with the terms of such employee benefit plans (collectively, the &#147;<U>Accrued Obligations</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Resignation of All Other
Positions</U>. To the extent applicable, the Executive shall be deemed to have resigned from all officer and board member positions that the Executive holds with the Company or any of its respective subsidiaries and affiliates upon the termination
of the Executive&#146;s employment for any reason. The Executive shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Severance Pay and Benefits Upon Termination by the Company without Cause or by the
Executive for Good Reason Outside the Change in Control Period</U>. If the Executive&#146;s employment is terminated by the Company without Cause as provided in Section&nbsp;3(d), or the Executive terminates employment for Good Reason as provided in
Section&nbsp;3(e), in each case outside of the Change in Control Period, then, in addition to the<B> </B>Accrued Obligations, and subject to (i)&nbsp;the Executive signing a separation agreement and release in a form and manner satisfactory to the
Company, which shall include, without limitation, a general release of claims against the Company and all related persons and entities that shall not release the Executive&#146;s rights under this Agreement, a reaffirmation of all of the
Executive&#146;s Continuing Obligations (as defined below), and, in the Company&#146;s sole discretion, a <FONT STYLE="white-space:nowrap">one-year</FONT> post-employment noncompetition agreement, and shall provide that if the Executive breaches any
of the Continuing Obligations, all payments of the Severance Amount shall immediately cease (the &#147;<U>Separation Agreement</U>&#148;), and (ii)&nbsp;the Separation Agreement becoming irrevocable, all within 60 days after the Date of Termination
(or such shorter period as set forth in the Separation Agreement), which shall include a seven (7)&nbsp;business day revocation period: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) the Company shall pay the Executive an amount equal to the sum of (i) 12 months of the Executive&#146;s Base Salary plus (ii)&nbsp;a <FONT
STYLE="white-space:nowrap">pro-rata</FONT> portion of the Target Bonus (pursuant to Section&nbsp;2(b)) for the calendar year in which the Date of Termination occurs based on the number of days the Executive was employed by the Company in such
calendar year (the &#147;<U>Severance Amount</U>&#148;); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) notwithstanding anything to the contrary in any applicable option
agreement or other stock-based award agreement, the stock options and other stock-based awards held by the Executive that are solely subject to time-based vesting (&#147;<U>Time-Based Equity Awards</U>&#148;) and that would have become fully vested
and exercisable or nonforfeitable had the Executive remained employed by the Company for the <FONT STYLE="white-space:nowrap">12-month</FONT> period immediately following the Date of Termination, shall immediately accelerate and become fully vested
and exercisable or nonforfeitable as of the later of (i)&nbsp;the Date of Termination or (ii)&nbsp;the effective date of the Release (the &#147;<U>Accelerated Vesting Date</U>&#148;), <I>provided</I> that in order to effectuate the accelerated
vesting contemplated by this subsection, the unvested portion of the Executive&#146;s Time-Based Equity Awards that would otherwise be forfeited on the Date of Termination will be delayed until the earlier of (A)&nbsp;the effective date of the
Release (at which time acceleration will occur), or (B)&nbsp;the date that the Release can no longer become fully effective (at which time the unvested portion of the Executive&#146;s Time-Based Equity Awards will be forfeited). Notwithstanding the
foregoing, no additional time-based vesting of the Time-Based Equity Awards shall occur during the period between the Date of Termination and the Accelerated Vesting Date; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) subject to the Executive&#146;s copayment of premium amounts at the applicable active
employees&#146; rate and the Executive&#146;s proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#147;<U>COBRA</U>&#148;), the Company shall pay to the group health plan provider or the
COBRA provider a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company until the earliest of (i)&nbsp;the <FONT
STYLE="white-space:nowrap">12-month</FONT> anniversary of the Date of Termination; (ii)&nbsp;the date that the Executive becomes eligible for group medical plan benefits under any other employer&#146;s group medical plan; or (iii)&nbsp;the cessation
of the Executive&#146;s health continuation rights under COBRA; <I>provided, however</I>, that if the Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially
violating applicable law (including, without limitation, Section&nbsp;2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to the Executive for the time period specified above. Such
payments to the Executive shall be subject to <FONT STYLE="white-space:nowrap">tax-related</FONT> deductions and withholdings and paid on the Company&#146;s regular payroll dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts payable under Section&nbsp;5, to the extent taxable, shall be paid out in substantially equal installments in accordance with the Company&#146;s
payroll practice over 12 months commencing within 60<B> </B>days after the Date of Termination; <I>provided, however</I>, that if the <FONT STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year and ends in a second calendar
year, such payments, to the extent they qualify as <FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; within the meaning of Section&nbsp;409A of the Internal Revenue Code of 1986, as amended (the
&#147;<U>Code</U>&#148;), shall begin to be paid in the second calendar year by the last day of such <FONT STYLE="white-space:nowrap">60-day</FONT> period; <I>provided, further</I>, that the initial payment shall include a <FONT
STYLE="white-space:nowrap">catch-up</FONT> payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury
Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Change in Control</U>. Upon a Change in Control,
except as otherwise explicitly set forth in the applicable equity award agreement, any stock options and other stock-based awards held by the Executive with conditions and restrictions relating to the attainment of performance goals
(&#147;<U>Performance-Based Equity Awards</U>&#148;), to the extent then outstanding and unearned, shall be deemed earned based on the greater of target or actual performance as measured through such Change in Control, and such Performance-Based
Equity Awards that are deemed earned shall be subject to time-based vesting, based on Executive&#146;s continued employment, for the remainder of the performance period and shall be subject to accelerated vesting upon a termination of
Executive&#146;s employment to the extent provided for in Section&nbsp;7(a)(ii) below. Any Performance-Based Equity Awards that are not deemed earned upon a Change in Control shall be forfeited for no consideration upon such Change in Control. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Severance Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason within the Change in Control
Period</U>. The provisions of this Section&nbsp;7 shall apply in lieu of, and expressly supersede, the provisions of Section&nbsp;5 if (i)&nbsp;the Executive&#146;s employment is terminated either (a)&nbsp;by the Company without Cause as provided in
Section&nbsp;3(d), or (b)&nbsp;by the Executive for Good Reason as provided in Section&nbsp;3(e), and (ii)&nbsp;the Date of Termination is on or within three (3)&nbsp;months prior to or 12 months after the occurrence of the first event constituting
a Change in Control (such period, the &#147;<U>Change in Control Period</U>&#148;). These provisions shall terminate and be of no further force or effect after the Change in Control Period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If the Executive&#146;s employment is terminated by the Company without Cause as
provided in Section&nbsp;3(d) or the Executive terminates employment for Good Reason as provided in Section&nbsp;3(e) and in each case the Date of Termination occurs during the Change in Control Period, then, in addition to the Accrued Obligations,
and subject to the signing of a general release of claims against the Company and all related persons and entities that shall not release the Executive&#146;s rights under this Agreement (the &#147;<U>Release</U>&#148;) by the Executive and the
Release becoming fully effective, all within the time frame set forth in the Release but in no event more than 60 days after the Date of Termination: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) the Company shall pay the Executive a lump sum in cash in an amount equal to 1.5 times the sum of (A)&nbsp;the Executive&#146;s
then-current Base Salary (or the Executive&#146;s Base Salary in effect immediately prior to the Change in Control, if higher) plus (B)&nbsp;the Executive&#146;s Target Bonus for the then-current year (or the Executive&#146;s Target Bonus in effect
immediately prior to the Change in Control, if higher) (the &#147;<U>Change in Control Payment</U>&#148;); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) notwithstanding
anything to the contrary in any applicable option agreement or other stock-based award agreement, all Time-Based Equity Awards and any Performance-Based Equity Awards that are then outstanding and eligible to vest based on Executive&#146;s continued
employment as provided for under Section&nbsp;6&nbsp;above shall immediately accelerate and become fully vested and exercisable or nonforfeitable as of the Accelerated Vesting Date, <I>provided</I> that in order to effectuate the accelerated vesting
contemplated by this subsection, the unvested portion of the Executive&#146;s Time-Based Equity Awards and Performance-Based Equity Awards that would otherwise be forfeited on the Date of Termination will be delayed until the earlier of (A)&nbsp;the
effective date of the Release (at which time acceleration will occur), or (B)&nbsp;the date that the Release can no longer become fully effective (at which time the unvested portion of the Executive&#146;s Time-Based Equity Awards and
Performance-Based Equity Awards will be forfeited). Notwithstanding the foregoing, no additional time-based vesting of the Time-Based Equity Awards or Performance-Based Equity Awards shall occur during the period between the Date of Termination and
the Accelerated Vesting Date; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) subject to the Executive&#146;s copayment of premium amounts at the applicable active
employees&#146; rate and the Executive&#146;s proper election to receive benefits under COBRA, the Company shall pay to the group health plan provider or the COBRA provider a monthly payment equal to the monthly employer contribution that the
Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company until the earliest of (A)&nbsp;the <FONT STYLE="white-space:nowrap">18-month</FONT> anniversary of the Date of Termination;
(B)&nbsp;the date that the Executive becomes eligible for group medical plan benefits under any other employer&#146;s group medical plan; or (C)&nbsp;the cessation of the Executive&#146;s health continuation rights under COBRA; <I>provided,
however</I>, that if the Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section&nbsp;2716 of the
Public Health Service Act), then the Company shall convert such payments to payroll payments directly to the Executive for the time period specified above. Such payments to the Executive shall be subject to
<FONT STYLE="white-space:nowrap">tax-related</FONT> deductions and withholdings and paid on the Company&#146;s regular payroll dates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts payable under this Section&nbsp;7(a), to the extent taxable, shall be paid or commence to be
paid within 60 days after the Date of Termination; <I>provided, however</I>, that if the <FONT STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year and ends in a second calendar year, such payments to the extent they qualify
as <FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; within the meaning of Section&nbsp;409A of the Code, shall be paid or commence to be paid in the second calendar year by the last day of such <FONT
STYLE="white-space:nowrap">60-day</FONT> period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Additional Limitation</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any compensation, payment or distribution by
the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section&nbsp;280G of the Code, and the
applicable regulations thereunder (the &#147;<U>Aggregate Payments</U>&#148;), would be subject to the excise tax imposed by Section&nbsp;4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of
the Aggregate Payments shall be $1.00 less than the amount at which the Executive becomes subject to the excise tax imposed by Section&nbsp;4999 of the Code; <I>provided</I> that such reduction shall only occur if it would result in the Executive
receiving a higher After Tax Amount (as defined below) than the Executive would receive if the Aggregate Payments were not subject to such reduction. In such event, the Aggregate Payments shall be reduced in the following order, in each case, in
reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section&nbsp;280G of the Code: (A)&nbsp;cash payments not subject to Section&nbsp;409A
of the Code; (B)&nbsp;cash payments subject to Section&nbsp;409A of the Code; (C)&nbsp;equity-based payments and acceleration; and <FONT STYLE="white-space:nowrap">(D)&nbsp;non-cash</FONT> forms of benefits; <I>provided</I> that in the case of all
the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q&amp;A-24(b)</FONT> or (c)&nbsp;shall be reduced
before any amounts that are subject to calculation under Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q&amp;A-24(b)</FONT> or (c). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) For purposes of this Section&nbsp;7(b), the &#147;<U>After Tax Amount</U>&#148; means the amount of the Aggregate Payments less all
federal, state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive&#146;s receipt of the Aggregate Payments. For purposes of determining the After Tax Amount, the Executive shall be deemed to pay
federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual
taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) The determination as to whether a reduction in the Aggregate Payments shall be made
pursuant to Section&nbsp;7(b)(i) shall be made by a nationally recognized accounting firm selected by the Company (the &#147;<U>Accounting Firm</U>&#148;), which shall provide detailed supporting calculations both to the Company and the Executive
within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive. Any determination by the Accounting Firm shall be binding upon the Company and the Executive. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Definitions</U>. For purposes of this Agreement, &#147;<U>Change in Control</U>&#148; shall have the meaning ascribed to the term
&#147;Sale Event&#148; as used in the Company&#146;s 2022 Stock Option and Incentive Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Section 409A</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive&#146;s separation from service within the
meaning of Section&nbsp;409A of the Code, the Company determines that the Executive is a &#147;specified employee&#148; within the meaning of Section&nbsp;409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive
becomes entitled to under this Agreement or otherwise on account of the Executive&#146;s separation from service would be considered deferred compensation otherwise subject to the 20&nbsp;percent additional tax imposed pursuant to
Section&nbsp;409A(a) of the Code as a result of the application of Section&nbsp;409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (i)&nbsp;six months and one
day after the Executive&#146;s separation from service, or (ii)&nbsp;the Executive&#146;s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a
<FONT STYLE="white-space:nowrap">catch-up</FONT> payment covering amounts that would otherwise have been paid during the <FONT STYLE="white-space:nowrap">six-month</FONT> period but for the application of this provision, and the balance of the
installments shall be payable in accordance with their original schedule. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) All <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits
provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively
practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided or
reimbursable expenses incurred in one taxable year shall not affect the <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other
aggregate limitation applicable to medical expenses). Such right to reimbursement or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits is not subject to liquidation or exchange for another benefit. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To the extent that any payment or benefit described in this Agreement constitutes
<FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; under Section&nbsp;409A of the Code, and to the extent that such payment or benefit is payable upon the Executive&#146;s termination of employment, then such
payments or benefits shall be payable only upon the Executive&#146;s &#147;separation from service.&#148; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in
Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h).</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The parties intend that this Agreement will be administered in accordance with
Section&nbsp;409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section&nbsp;409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with
Section&nbsp;409A of the Code. Each payment pursuant to this Agreement or the Restrictive Covenants Agreement is intended to constitute a separate payment for purposes of Treasury Regulation
<FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section&nbsp;409A of the Code and all
related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions of this
Agreement are determined to constitute deferred compensation subject to Section&nbsp;409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Continuing Obligations</U>.<U> </U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Restrictive Covenants Agreement</U>. In consideration for the increase of the Executive&#146;s Base Salary and Target Bonus provided for
in this Agreement, such increases the Executive acknowledges the Executive would not otherwise be entitled to receive and are consideration that is fair and reasonable and independent of the Executive&#146;s continued employment with the Company,
the Executive is required to enter into the Employee Confidentiality, Assignment and Nonsolicitation Agreement, attached hereto as <U>Exhibit A</U> (the &#147;<U>Restrictive Covenants Agreement</U>&#148;). For purposes of this Agreement, the
obligations in this Section&nbsp;9, the obligations that arise in the Restrictive Covenants Agreement and the obligations that arise in Sections <FONT STYLE="white-space:nowrap">6-8</FONT> of the Prior Agreement, and any other agreement relating to
confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the &#147;<U>Continuing Obligations</U>.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Third-Party Agreements and Rights</U>. The Executive hereby confirms that the Executive is not bound by the terms of any agreement with
any previous employer or other party which restricts in any way the Executive&#146;s use or disclosure of information, other than confidentiality restrictions (if any), or the Executive&#146;s engagement in any business. The Executive represents to
the Company that the Executive&#146;s execution of this Agreement, the Executive&#146;s employment with the Company and the performance of the Executive&#146;s proposed duties for the Company will not violate any obligations the Executive may have
to any such previous employer or other party. In the Executive&#146;s work for the Company, the Executive will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other party,
and the Executive will not bring to the premises of the Company any copies or other tangible embodiments of <FONT STYLE="white-space:nowrap">non-public</FONT> information belonging to or obtained from any such previous employment or other party.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Litigation and Regulatory Cooperation</U>. During and after the Executive&#146;s
employment, the Executive shall cooperate fully with the Company in (i)&nbsp;the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or
occurrences that transpired while the Executive was employed by the Company, and (ii)&nbsp;the investigation, whether internal or external, of any matters about which the Company believes the Executive may have knowledge or information. The
Executive&#146;s full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness
on behalf of the Company at mutually convenient times. During and after the Executive&#146;s employment, the Executive also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local
regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company. The Company shall reimburse the Executive for any reasonable <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with the Executive&#146;s performance of obligations pursuant to this Section&nbsp;9(c). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Relief</U>. The Executive agrees that it would be difficult to measure any damages caused to the Company which might result from any
breach by the Executive of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly<B>,</B> the Executive agrees that if the Executive breaches, or proposes to breach, any portion
of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the
Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Consent to Jurisdiction</U>. The parties hereby consent to the jurisdiction of the state and federal courts of the<B>
</B>Commonwealth of Massachusetts. Accordingly, with respect to any such court action, the Executive (a)&nbsp;submits to the exclusive personal jurisdiction of such courts; (b)&nbsp;consents to service of process; and (c)&nbsp;waives any other
requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.
<U>Waiver of Jury Trial</U>. Each of the Executive and the Company irrevocably and unconditionally WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY PROCEEDING (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE
EXECUTIVE&#146;S EMPLOYMENT BY THE COMPANY OR ANY AFFILIATE OF THE COMPANY, INCLUDING WITHOUT LIMITATION THE EXECUTIVE&#146;S OR THE COMPANY&#146;S PERFORMANCE UNDER, OR THE ENFORCEMENT OF, THIS AGREEMENT. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Integration</U>. This Agreement<B>, </B>together with the Restrictive Covenants Agreement and the certain Director and Officer
Indemnification Agreement to which the Executive and the Company are parties, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements between the parties concerning such
subject matter, including the Prior Agreement, <I>provided</I> that Sections <FONT STYLE="white-space:nowrap">6-8</FONT> of the Prior Agreement, the Equity Documents and any other agreement relating to confidentiality, assignment of inventions, or
other restrictive covenants shall remain in full force and effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Withholding; Tax Effect</U>. All payments made by the Company to
the Executive under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law. Nothing in this Agreement shall be construed to require the Company to make any payments to compensate the
Executive for any adverse tax effect associated with any payments or benefits or for any deduction or withholding from any payment or benefit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Assignment; Successors and Assigns</U>. Neither the Executive nor the Company may
make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; <I>provided, however</I>, that the Company may assign its rights and obligations under this Agreement
(including the Restrictive Covenants Agreement) without the Executive&#146;s consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization or consolidation, into which the Company merges or to whom
it transfers all or substantially all of its properties or assets; <I>provided, further</I> that if the Executive remains employed or becomes employed by the Company, the purchaser or any of their affiliates in connection with any such transaction,
then the Executive shall not be entitled to any payments, benefits or vesting pursuant to Section&nbsp;5 or Section&nbsp;7 of this Agreement solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding upon the
Executive and the Company, and each of the Executive&#146;s and the Company&#146;s respective successors, executors, administrators, heirs and permitted assigns. In the event of the Executive&#146;s death after the Executive&#146;s termination of
employment but prior to the completion by the Company of all payments due to the Executive under this Agreement, the Company shall continue such payments to the Executive&#146;s beneficiary designated in writing to the Company prior to the
Executive&#146;s death (or to the Executive&#146;s estate, if the Executive fails to make such designation). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Enforceability</U>. If
any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder
of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be
valid and enforceable to the fullest extent permitted by law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Survival</U>. For the avoidance of doubt, the provisions of this
Agreement shall survive the termination of the Executive&#146;s employment to the extent necessary to effectuate the terms contained herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>Waiver</U>. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of
any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any
subsequent breach. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>Notices</U>. Any notices, requests, demands and other communications provided for by this Agreement shall be
sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed
in writing with the Company or, in the case of the Company, at its main offices, attention of the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <U>Amendment</U>. This
Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <U>Effect on Other Plans and Agreements</U>. An election by the Executive to resign for
Good Reason under the provisions of this Agreement shall not be deemed a voluntary termination of employment by the Executive for the purpose of interpreting the provisions of any of the Company&#146;s benefit plans, programs or policies. Nothing in
this Agreement shall be construed to limit the rights of the Executive under the Company&#146;s benefit plans, programs or policies except as otherwise provided in Section&nbsp;9 hereof, and except that the Executive shall have no rights to any
severance benefits under any Company severance pay plan, offer letter or otherwise. In the event that the Executive is party to an agreement with the Company providing for payments or benefits under such plan or agreement and under this Agreement,
the terms of this Agreement shall govern and the Executive may receive payment under this Agreement only and not both. Further, Section&nbsp;5 and Section&nbsp;7 of this Agreement are mutually exclusive and in no event shall the Executive be
entitled to payments or benefits pursuant to both Section&nbsp;5 and Section&nbsp;7 of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <U>Governing Law</U>. This is a
Massachusetts contract and shall be construed under and be governed in all respects by the laws of the Commonwealth of Massachusetts, without giving effect to the conflict of laws principles thereof. With respect to any disputes concerning federal
law, such disputes shall be determined in accordance with the law as it would be interpreted and applied by the United States Court of Appeals for the First Circuit. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. <U>Counterparts</U>. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be
taken to be an original; but such counterparts shall together constitute one and the same document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement effective on the Effective
Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AMYLYX PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EXECUTIVE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Justin Klee</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>19
<FILENAME>d155225dex1014.htm
<DESCRIPTION>EX-10.14
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.14</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.14 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Employment Agreement (&#147;<U>Agreement</U>&#148;) is made between Amylyx Pharmaceuticals, Inc., a Delaware corporation (the
&#147;<U>Company</U>&#148;), and James Frates (the &#147;<U>Executive</U>&#148;) and is effective as of the closing of the Company&#146;s first underwritten public offering of its equity securities pursuant to an effective registration statement
under the Securities Act of 1933, as amended (the &#147;<U>Effective Date</U>&#148;). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below) and subject to Section&nbsp;12, this Agreement
supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i)&nbsp;the employment agreement between the Executive and the Company dated January&nbsp;25,
2021<B> </B>(the &#147;<U>Prior Agreement</U>&#148;), and (ii) any other offer letter, employment agreement or severance agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company desires to continue to employ the Executive and the Executive desires to continue to be employed by the Company on the
new terms and conditions contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE,<I> </I>in consideration of the mutual covenants and agreements herein
contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Employment</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>Term</U>. The Company shall employ the Executive and the Executive shall be employed by the Company pursuant to this Agreement commencing as of the Effective Date and continuing until such employment is terminated in accordance with the
provisions hereof (the &#147;<U>Term</U>&#148;). The Executive&#146;s employment with the Company shall continue to be &#147;at will,&#148; meaning that the Executive&#146;s employment may be terminated by the Company or the Executive at any time
and for any reason subject to the terms of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Position and Duties</U>. The Executive shall serve as the Chief
Financial Officer of the Company and shall have such powers and duties as may from time to time be prescribed by the <FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officers (individually and collectively, the &#147;<U>CEO</U>&#148;) or
other duly authorized executive. The Executive shall devote the Executive&#146;s full working time and efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the
approval of the Board of Directors of the Company (the &#147;<U>Board</U>&#148;), or engage in religious, charitable or other community activities as long as such services and activities do not interfere with the Executive&#146;s performance of the
Executive&#146;s<B> </B>duties to the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Location</U>. The Executive&#146;s primary work location will be in the
Company&#146;s office, currently located in Cambridge, Massachusetts; <I>provided</I> that the Executive may be required to travel regularly for business, consistent with the Company&#146;s business needs. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Compensation and Related Matters</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Base Salary</U>. The Executive&#146;s initial base salary shall be paid at the rate of $440,000 per year. The Executive&#146;s base
salary shall be subject to periodic review by<B> </B>the Board or the Compensation Committee of the Board (the &#147;<U>Compensation Committee</U>&#148;). The base salary in effect at any given time is referred to herein as &#147;<U>Base
Salary</U>.&#148; The Base Salary shall be payable in a manner that is consistent with the Company&#146;s usual payroll practices for its executive officers. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Incentive Compensation</U>. The Executive shall be eligible to receive cash incentive compensation as determined by the Board or the
Compensation Committee from time to time. The Executive&#146;s initial target annual incentive compensation shall be 40% of the Executive&#146;s Base Salary. The target annual incentive compensation in effect at any given time is referred to herein
as &#147;<U>Target Bonus</U>.&#148; The actual amount of the Executive&#146;s annual incentive compensation, if any, shall be determined in the sole discretion of the Board or the Compensation Committee. Any annual incentive compensation will be
paid no later than March 15<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the calendar year following the calendar year to which such bonus relates. Except as otherwise provided herein or as may be provided by the Board or the
Compensation Committee, the Executive must be employed by the Company on the date such incentive compensation is paid in order to earn or receive any annual incentive compensation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Expenses</U>. The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by the Executive
during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its executive officers. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Other Benefits</U>. The Executive shall be eligible to participate in or receive benefits under the Company&#146;s employee benefit
plans in effect from time to time, subject to the terms of such plans. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Paid Time Off</U>. The Executive shall be entitled to take
paid time off in accordance with the Company&#146;s applicable paid time off policy for executives, as may be in effect from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Equity</U>. The equity awards held by the Executive shall continue to be governed by the terms and conditions of the Company&#146;s
applicable equity incentive plan(s) and the applicable award agreement(s) governing the terms of such equity awards (collectively, the &#147;<U>Equity Documents</U>&#148;); <I>provided, however</I>, and notwithstanding anything to the contrary in
the Equity Documents, Section&nbsp;6 of this Agreement shall apply in the event of a Change in Control and Section&nbsp;7(a)(ii) of this Agreement shall apply in the event of a termination by the Company without Cause or by the Executive for Good
Reason in either event within the Change in Control Period (as such terms are defined below). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination</U>. The Executive&#146;s
employment hereunder may be terminated without any breach of this Agreement under the following circumstances: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Death</U>. The
Executive&#146;s employment hereunder shall terminate upon death. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Disability</U>. The Company may terminate the Executive&#146;s employment if the
Executive is disabled and unable to perform or expected to be unable to perform the essential functions of the Executive&#146;s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180
days (which need not be consecutive) in any <FONT STYLE="white-space:nowrap">12-month</FONT> period. If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the
Executive&#146;s then existing position or positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the
Company to whom the Executive or the Executive&#146;s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this
Agreement be conclusive of the issue. The Executive shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and the Executive shall fail to submit such certification, the
Company&#146;s determination of such issue shall be binding on the Executive. Nothing in this Section&nbsp;3(b) shall be construed to waive the Executive&#146;s rights, if any, under existing law including, without limitation, the Family and Medical
Leave Act of 1993, 29 U.S.C. &#167;2601 <I>et seq</I>. and the Americans with Disabilities Act, 42 U.S.C. &#167;12101 <I>et seq.</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
<U>Termination by the Company for Cause</U>. The Company may terminate the Executive&#146;s employment hereunder for Cause. For purposes of this Agreement, &#147;<U>Cause</U>&#148; shall mean any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) conduct by the Executive constituting a material act of misconduct in connection with the performance of the Executive&#146;s duties,
including, without limitation, (A)&nbsp;willful failure or refusal to perform material responsibilities that have been requested by the CEO; (B)&nbsp;dishonesty to the CEO with respect to any material matter; or (C)&nbsp;misappropriation of funds or
property of the Company or any of its subsidiaries or affiliates other than the occasional, customary and <I>de minimis</I> use of Company property for personal purposes; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) the commission by the Executive of acts satisfying the elements of (A)&nbsp;any felony or (B)&nbsp;a misdemeanor involving moral
turpitude, deceit, dishonesty or fraud; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) any misconduct by the Executive, regardless of whether or not in the course of the
Executive&#146;s employment, that would reasonably be expected to result in material injury or reputational harm to the Company or any of its subsidiaries or affiliates if the Executive were to continue to be employed in the same position; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) continued unsatisfactory performance or <FONT STYLE="white-space:nowrap">non-performance</FONT> by the Executive of the Executive&#146;s
duties hereunder (other than by reason of the Executive&#146;s physical or mental illness, incapacity or disability) which has continued for more than 30 days following written notice of such unsatisfactory performance or <FONT
STYLE="white-space:nowrap">non-performance</FONT> from the CEO; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) a breach by the Executive of any of the provisions contained in
Section&nbsp;9 of this Agreement or the Restrictive Covenants Agreement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) a material violation by the Executive of any of the Company&#146;s written employment
policies; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) the Executive&#146;s failure to cooperate with a bona fide internal investigation or an investigation by regulatory or
law enforcement authorities, after being instructed by the Company to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the inducement of others to fail to
cooperate or to produce documents or other materials in connection with such investigation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Termination by the Company without
Cause</U>. The Company may terminate the Executive&#146;s employment hereunder at any time without Cause. Any termination by the Company of the Executive&#146;s employment under this Agreement which does not constitute a termination for Cause under
Section&nbsp;3(c) and does not result from the death or disability of the Executive under Section&nbsp;3(a) or (b)&nbsp;shall be deemed a termination without Cause. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Termination by the Executive</U>. The Executive may terminate employment hereunder at any time for any reason, including but not limited
to, Good Reason. For purposes of this Agreement, &#147;<U>Good Reason</U>&#148; shall mean that the Executive has completed all steps of the Good Reason Process (hereinafter defined) following the occurrence of any of the following events without
the Executive&#146;s consent (each, a &#147;<U>Good Reason Condition</U>&#148;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) a material diminution in the Executive&#146;s
responsibilities, authority or duties; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) a material diminution in the Executive&#146;s Base Salary except for <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">across-the-board</FONT></FONT> salary reductions based on the Company&#146;s financial performance similarly affecting all or substantially all senior management employees of the Company;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) a material change in the geographic location of the principal office of the Company to which the Executive is assigned, such that
there is an increase of at least thirty (30)&nbsp;miles of driving distance to such location from the Executive&#146;s principal residence as of such change; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) a material breach of this Agreement by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#147;<U>Good Reason Process</U>&#148; consists of the following steps: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) the Executive reasonably determines in good faith that a Good Reason Condition has occurred; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) the Executive notifies the Company in writing of the first occurrence of the Good Reason Condition within 60 days of the first occurrence
of such condition; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) the Executive cooperates in good faith with the Company&#146;s efforts, for a period of not less than 30 days
following such notice (the &#147;<U>Cure Period</U>&#148;), to remedy the Good Reason Condition; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) notwithstanding such efforts, the Good Reason Condition continues to exist at the end
of the Cure Period; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) the Executive terminates employment within 60 days after the end of the Cure Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company cures the Good Reason Condition during the Cure Period, Good Reason shall be deemed not to have occurred. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Matters Related to Termination</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Notice of Termination</U>. Except for termination as specified in Section&nbsp;3(a), any termination of the Executive&#146;s employment
by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a &#147;<U>Notice of Termination</U>&#148; shall mean a notice which shall
indicate the specific termination provision in this Agreement relied upon. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Date of Termination</U>. &#147;<U>Date of
Termination</U>&#148; shall mean: (i)&nbsp;if the Executive&#146;s employment is terminated by death, the date of death; (ii)&nbsp;if the Executive&#146;s employment is terminated on account of disability under Section&nbsp;3(b) or by the Company
for Cause under Section&nbsp;3(c), the date on which Notice of Termination is given; (iii)&nbsp;if the Executive&#146;s employment is terminated by the Company without Cause under Section&nbsp;3(d), the date on which a Notice of Termination is given
or the date otherwise specified by the Company in the Notice of Termination; (iv)&nbsp;if the Executive&#146;s employment is terminated by the Executive under Section&nbsp;3(e) other than for Good Reason, 30 days after the date on which a Notice of
Termination is given, and (v)&nbsp;if the Executive&#146;s employment is terminated by the Executive under Section&nbsp;3(e) for Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding the
foregoing, in the event that the Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Accrued Obligations</U>. If the Executive&#146;s employment with the Company is terminated for any reason, the Company
shall pay or provide to the Executive (or to the Executive&#146;s<B> </B>authorized representative or estate)&nbsp;(i) any Base Salary earned through the Date of Termination; (ii)&nbsp;unpaid expense reimbursements (subject to, and in accordance
with, Section&nbsp;2(c) of this Agreement); and (iii)&nbsp;any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance
with the terms of such employee benefit plans (collectively, the &#147;<U>Accrued Obligations</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Resignation of All Other
Positions</U>. To the extent applicable, the Executive shall be deemed to have resigned from all officer and board member positions that the Executive holds with the Company or any of its respective subsidiaries and affiliates upon the termination
of the Executive&#146;s employment for any reason. The Executive shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Severance Pay and Benefits Upon Termination by the Company without Cause or by the
Executive for Good Reason Outside the Change in Control Period</U>. If the Executive&#146;s employment is terminated by the Company without Cause as provided in Section&nbsp;3(d), or the Executive terminates employment for Good Reason as provided in
Section&nbsp;3(e), in each case outside of the Change in Control Period, then, in addition to the<B> </B>Accrued Obligations, and subject to (i)&nbsp;the Executive signing a separation agreement and release in a form and manner satisfactory to the
Company, which shall include, without limitation, a general release of claims against the Company and all related persons and entities that shall not release the Executive&#146;s rights under this Agreement, a reaffirmation of all of the
Executive&#146;s Continuing Obligations (as defined below), and, in the Company&#146;s sole discretion, a <FONT STYLE="white-space:nowrap">one-year</FONT> post-employment noncompetition agreement, and shall provide that if the Executive breaches any
of the Continuing Obligations, all payments of the Severance Amount shall immediately cease (the &#147;<U>Separation Agreement</U>&#148;), and (ii)&nbsp;the Separation Agreement becoming irrevocable, all within 60 days after the Date of Termination
(or such shorter period as set forth in the Separation Agreement), which shall include a seven (7)&nbsp;business day revocation period: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) the Company shall pay the Executive an amount equal to nine (9)&nbsp;months of the Executive&#146;s Base Salary (the &#147;<U>Severance
Amount</U>&#148;); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) subject to the Executive&#146;s copayment of premium amounts at the applicable active employees&#146; rate and
the Executive&#146;s proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#147;<U>COBRA</U>&#148;), the Company shall pay to the group health plan provider or the COBRA provider a monthly
payment equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company until the earliest of (i)&nbsp;the nine (9)&nbsp;month anniversary
of the Date of Termination; (ii)&nbsp;the date that the Executive becomes eligible for group medical plan benefits under any other employer&#146;s group medical plan; or (iii)&nbsp;the cessation of the Executive&#146;s health continuation rights
under COBRA; <I>provided, however</I>, that if the Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without
limitation, Section&nbsp;2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to the Executive for the time period specified above. Such payments to the Executive shall be subject to <FONT
STYLE="white-space:nowrap">tax-related</FONT> deductions and withholdings and paid on the Company&#146;s regular payroll dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts payable under
Section&nbsp;5, to the extent taxable, shall be paid out in substantially equal installments in accordance with the Company&#146;s payroll practice over nine (9)&nbsp;months commencing within 60<B> </B>days after the Date of Termination;
<I>provided, however</I>, that if the <FONT STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year and ends in a second calendar year, such payments, to the extent they qualify as
<FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; within the meaning of Section&nbsp;409A of the Internal Revenue Code of 1986, as amended (the &#147;<U>Code</U>&#148;), shall begin to be paid in the second
calendar year by the last day of such <FONT STYLE="white-space:nowrap">60-day</FONT> period; <I>provided, further</I>, that the initial payment shall include a <FONT STYLE="white-space:nowrap">catch-up</FONT> payment to cover amounts retroactive to
the day immediately following the Date of Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Change in Control</U>. Upon a Change in Control, except as otherwise explicitly set
forth in the applicable equity award agreement, any stock options and other stock-based awards held by the Executive with conditions and restrictions relating to the attainment of performance goals (&#147;<U>Performance-Based Equity
Awards</U>&#148;), to the extent then outstanding and unearned, shall be deemed earned based on the greater of target or actual performance as measured through such Change in Control, and such Performance-Based Equity Awards that are deemed earned
shall be subject to time-based vesting, based on Executive&#146;s continued employment, for the remainder of the performance period and shall be subject to accelerated vesting upon a termination of Executive&#146;s employment to the extent provided
for in Section&nbsp;7(a)(ii) below. Any Performance-Based Equity Awards that are not deemed earned upon a Change in Control shall be forfeited for no consideration upon such Change in Control. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Severance Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason within the Change in Control
Period</U>. The provisions of this Section&nbsp;7 shall apply in lieu of, and expressly supersede, the provisions of Section&nbsp;5 if (i)&nbsp;the Executive&#146;s employment is terminated either (a)&nbsp;by the Company without Cause as provided in
Section&nbsp;3(d), or (b)&nbsp;by the Executive for Good Reason as provided in Section&nbsp;3(e), and (ii)&nbsp;the Date of Termination is on or within three (3)&nbsp;months prior to or 12 months after the occurrence of the first event constituting
a Change in Control (such period, the &#147;<U>Change in Control Period</U>&#148;). These provisions shall terminate and be of no further force or effect after the Change in Control Period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If the Executive&#146;s employment is terminated by the Company without Cause as provided in Section&nbsp;3(d) or the Executive terminates
employment for Good Reason as provided in Section&nbsp;3(e) and in each case the Date of Termination occurs during the Change in Control Period, then, in addition to the Accrued Obligations, and subject to the signing of a general release of claims
against the Company and all related persons and entities that shall not release the Executive&#146;s rights under this Agreement (the &#147;<U>Release</U>&#148;) by the Executive and the Release becoming fully effective, all within the time frame
set forth in the Release but in no event more than 60 days after the Date of Termination: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) the Company shall pay the Executive a lump
sum in cash in an amount equal to 1.0 times the sum of (A)&nbsp;the Executive&#146;s then-current Base Salary (or the Executive&#146;s Base Salary in effect immediately prior to the Change in Control, if higher) plus (B)&nbsp;the Executive&#146;s
Target Bonus for the then-current year (or the Executive&#146;s Target Bonus in effect immediately prior to the Change in Control, if higher) (the &#147;<U>Change in Control Payment</U>&#148;); and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) notwithstanding anything to the contrary in any applicable option agreement or other
stock-based award agreement, all stock options and other stock-based awards held by the Executive that are subject solely to time-based vesting ( &#147;<U>Time-Based Equity Awards</U>&#148;) and any Performance-Based Equity Awards that are then
outstanding and eligible to vest based on Executive&#146;s continued employment as provided for under Section&nbsp;6&nbsp;above shall immediately accelerate and become fully vested and exercisable or nonforfeitable as of the later of (i)&nbsp;the
Date of Termination or (ii)&nbsp;the effective date of the Release (the &#147;<U>Accelerated Vesting Date</U>&#148;), <I>provided</I> that in order to effectuate the accelerated vesting contemplated by this subsection, the unvested portion of the
Executive&#146;s Time-Based Equity Awards and Performance-Based Equity Awards that would otherwise be forfeited on the Date of Termination will be delayed until the earlier of (A)&nbsp;the effective date of the Release (at which time acceleration
will occur), or (B)&nbsp;the date that the Release can no longer become fully effective (at which time the unvested portion of the Executive&#146;s Time-Based Equity Awards and Performance-Based Equity Awards will be forfeited). Notwithstanding the
foregoing, no additional time-based vesting of the Time-Based Equity Awards or Performance-Based Equity Awards shall occur during the period between the Date of Termination and the Accelerated Vesting Date; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) subject to the Executive&#146;s copayment of premium amounts at the applicable active employees&#146; rate and the Executive&#146;s
proper election to receive benefits under COBRA, the Company shall pay to the group health plan provider or the COBRA provider a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance
to the Executive if the Executive had remained employed by the Company until the earliest of (A)&nbsp;the <FONT STYLE="white-space:nowrap">12-month</FONT> anniversary of the Date of Termination; (B)&nbsp;the date that the Executive becomes eligible
for group medical plan benefits under any other employer&#146;s group medical plan; or (C)&nbsp;the cessation of the Executive&#146;s health continuation rights under COBRA; <I>provided, however</I>, that if the Company determines that it cannot pay
such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section&nbsp;2716 of the Public Health Service Act), then the Company shall convert
such payments to payroll payments directly to the Executive for the time period specified above. Such payments to the Executive shall be subject to <FONT STYLE="white-space:nowrap">tax-related</FONT> deductions and withholdings and paid on the
Company&#146;s regular payroll dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts payable under this Section&nbsp;7(a), to the extent taxable, shall be paid or commence to be paid
within 60 days after the Date of Termination; <I>provided, however</I>, that if the <FONT STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year and ends in a second calendar year, such payments to the extent they qualify as <FONT
STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; within the meaning of Section&nbsp;409A of the Code, shall be paid or commence to be paid in the second calendar year by the last day of such <FONT
STYLE="white-space:nowrap">60-day</FONT> period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Additional Limitation</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any compensation, payment or distribution by
the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section&nbsp;280G of the Code, and the
applicable regulations thereunder (the &#147;<U>Aggregate Payments</U>&#148;), would be subject to the excise tax imposed by Section&nbsp;4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of
the Aggregate Payments shall be $1.00 less than the amount at which the Executive becomes subject to the excise tax imposed by Section&nbsp;4999 of the Code; <I>provided</I> that such reduction shall only occur if it would result in the Executive
receiving a higher After Tax Amount (as defined below) than the Executive would receive if the Aggregate Payments were not subject to such reduction. In such event, the Aggregate Payments shall be reduced in the following order, in each case, in
reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section&nbsp;280G of the Code: (A)&nbsp;cash payments not subject to Section&nbsp;409A
of the Code; (B)&nbsp;cash payments subject to Section&nbsp;409A of the Code; (C)&nbsp;equity-based payments and acceleration; and <FONT STYLE="white-space:nowrap">(D)&nbsp;non-cash</FONT> forms of benefits; <I>provided</I> that in the case of all
the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q&amp;A-24(b)</FONT> or (c)&nbsp;shall be reduced
before any amounts that are subject to calculation under Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q&amp;A-24(b)</FONT> or (c). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) For purposes of this Section&nbsp;7(b), the &#147;<U>After Tax Amount</U>&#148; means
the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive&#146;s receipt of the Aggregate Payments. For purposes of determining the After Tax
Amount, the Executive shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at
the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to Section&nbsp;7(b)(i) shall be made by a
nationally recognized accounting firm selected by the Company (the &#147;<U>Accounting Firm</U>&#148;), which shall provide detailed supporting calculations both to the Company and the Executive within 15 business days of the Date of Termination, if
applicable, or at such earlier time as is reasonably requested by the Company or the Executive. Any determination by the Accounting Firm shall be binding upon the Company and the Executive. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Definitions</U>. For purposes of this Agreement, &#147;<U>Change in Control</U>&#148; shall have the meaning ascribed to the term
&#147;Sale Event&#148; as used in the Company&#146;s 2022 Stock Option and Incentive Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Section 409A</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive&#146;s separation from service within the
meaning of Section&nbsp;409A of the Code, the Company determines that the Executive is a &#147;specified employee&#148; within the meaning of Section&nbsp;409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive
becomes entitled to under this Agreement or otherwise on account of the Executive&#146;s separation from service would be considered deferred compensation otherwise subject to the 20&nbsp;percent additional tax imposed pursuant to
Section&nbsp;409A(a) of the Code as a result of the application of Section&nbsp;409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (i)&nbsp;six months and one
day after the Executive&#146;s separation from service, or (ii)&nbsp;the Executive&#146;s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a
<FONT STYLE="white-space:nowrap">catch-up</FONT> payment covering amounts that would otherwise have been paid during the <FONT STYLE="white-space:nowrap">six-month</FONT> period but for the application of this provision, and the balance of the
installments shall be payable in accordance with their original schedule. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) All <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided and expenses
eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no
event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided or reimbursable expenses
incurred in one taxable year shall not affect the <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation
applicable to medical expenses). Such right to reimbursement or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits is not subject to liquidation or exchange for another benefit. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To the extent that any payment or benefit described in this Agreement constitutes
<FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; under Section&nbsp;409A of the Code, and to the extent that such payment or benefit is payable upon the Executive&#146;s termination of employment, then such
payments or benefits shall be payable only upon the Executive&#146;s &#147;separation from service.&#148; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in
Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h).</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The parties intend that this Agreement will be
administered in accordance with Section&nbsp;409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section&nbsp;409A of the Code, the provision shall be read in such a manner so that all payments
hereunder comply with Section&nbsp;409A of the Code. Each payment pursuant to this Agreement or the Restrictive Covenants Agreement is intended to constitute a separate payment for purposes of Treasury Regulation
<FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section&nbsp;409A of the Code and all
related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions of this
Agreement are determined to constitute deferred compensation subject to Section&nbsp;409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Continuing Obligations</U>.<U> </U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Restrictive Covenants Agreement</U>. In consideration for the increase of the Executive&#146;s Base Salary and Target Bonus provided for
in this Agreement, such increases the Executive acknowledges the Executive would not otherwise be entitled to receive and are consideration that is fair and reasonable and independent of the Executive&#146;s continued employment with the Company,
the Executive is required to enter into the Employee Confidentiality, Assignment and Nonsolicitation Agreement, attached hereto as <U>Exhibit A</U> (the &#147;<U>Restrictive Covenants Agreement</U>&#148;). For purposes of this Agreement, the
obligations in this Section&nbsp;9, the obligations that arise in the Restrictive Covenants Agreement and the obligations that arise in Sections <FONT STYLE="white-space:nowrap">6-8</FONT> of the Prior Agreement, and any other agreement relating to
confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the &#147;<U>Continuing Obligations</U>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Third-Party Agreements and Rights</U>. The Executive hereby confirms that the
Executive is not bound by the terms of any agreement with any previous employer or other party which restricts in any way the Executive&#146;s use or disclosure of information, other than confidentiality restrictions (if any), or the
Executive&#146;s engagement in any business. The Executive represents to the Company that the Executive&#146;s execution of this Agreement, the Executive&#146;s employment with the Company and the performance of the Executive&#146;s proposed duties
for the Company will not violate any obligations the Executive may have to any such previous employer or other party. In the Executive&#146;s work for the Company, the Executive will not disclose or make use of any information in violation of any
agreements with or rights of any such previous employer or other party, and the Executive will not bring to the premises of the Company any copies or other tangible embodiments of <FONT STYLE="white-space:nowrap">non-public</FONT> information
belonging to or obtained from any such previous employment or other party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Litigation and Regulatory Cooperation</U>. During and
after the Executive&#146;s employment, the Executive shall cooperate fully with the Company in (i)&nbsp;the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company
which relate to events or occurrences that transpired while the Executive was employed by the Company, and (ii)&nbsp;the investigation, whether internal or external, of any matters about which the Company believes the Executive may have knowledge or
information. The Executive&#146;s full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being available to meet with counsel to answer questions or to prepare for discovery or trial and to
act as a witness on behalf of the Company at mutually convenient times. During and after the Executive&#146;s employment, the Executive also shall cooperate fully with the Company in connection with any investigation or review of any federal, state
or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company. The Company shall reimburse the Executive for any reasonable <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with the Executive&#146;s performance of obligations pursuant to this Section&nbsp;9(c). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Relief</U>. The Executive agrees that it would be difficult to measure any damages caused to the Company which might result from any
breach by the Executive of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly<B>,</B> the Executive agrees that if the Executive breaches, or proposes to breach, any portion
of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the
Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Consent to Jurisdiction</U>. The parties hereby consent to the jurisdiction of the state and federal courts of the<B>
</B>Commonwealth of Massachusetts. Accordingly, with respect to any such court action, the Executive (a)&nbsp;submits to the exclusive personal jurisdiction of such courts; (b)&nbsp;consents to service of process; and (c)&nbsp;waives any other
requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Waiver of Jury Trial</U>. Each of the Executive and the Company irrevocably and
unconditionally WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY PROCEEDING (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE EXECUTIVE&#146;S EMPLOYMENT BY THE COMPANY OR ANY AFFILIATE OF THE COMPANY,
INCLUDING WITHOUT LIMITATION THE EXECUTIVE&#146;S OR THE COMPANY&#146;S PERFORMANCE UNDER, OR THE ENFORCEMENT OF, THIS AGREEMENT. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.
<U>Integration</U>. This Agreement<B>, </B>together with the Restrictive Covenants Agreement and the certain Officer Indemnification Agreement to which the Executive and the Company are parties, constitutes the entire agreement between the parties
with respect to the subject matter hereof and supersedes all prior agreements between the parties concerning such subject matter, including the Prior Agreement, <I>provided</I> that Sections 2(b) and <FONT STYLE="white-space:nowrap">6-8</FONT> of
the Prior Agreement, the Equity Documents and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall remain in full force and effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Withholding; Tax Effect</U>. All payments made by the Company to the Executive under this Agreement shall be net of any tax or other
amounts required to be withheld by the Company under applicable law. Nothing in this Agreement shall be construed to require the Company to make any payments to compensate the Executive for any adverse tax effect associated with any payments or
benefits or for any deduction or withholding from any payment or benefit. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Assignment; Successors and Assigns</U>. Neither the
Executive nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; <I>provided, however</I>, that the Company may assign its rights and
obligations under this Agreement (including the Restrictive Covenants Agreement) without the Executive&#146;s consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization or consolidation, into
which the Company merges or to whom it transfers all or substantially all of its properties or assets; <I>provided, further</I> that if the Executive remains employed or becomes employed by the Company, the purchaser or any of their affiliates in
connection with any such transaction, then the Executive shall not be entitled to any payments, benefits or vesting pursuant to Section&nbsp;5 or Section&nbsp;7 of this Agreement solely as a result of such transaction. This Agreement shall inure to
the benefit of and be binding upon the Executive and the Company, and each of the Executive&#146;s and the Company&#146;s respective successors, executors, administrators, heirs and permitted assigns. In the event of the Executive&#146;s death after
the Executive&#146;s termination of employment but prior to the completion by the Company of all payments due to the Executive under this Agreement, the Company shall continue such payments to the Executive&#146;s beneficiary designated in writing
to the Company prior to the Executive&#146;s death (or to the Executive&#146;s estate, if the Executive fails to make such designation). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Enforceability</U>. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any
section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to
which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Survival</U>. For the avoidance of doubt, the provisions of this Agreement shall
survive the termination of the Executive&#146;s employment to the extent necessary to effectuate the terms contained herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.
<U>Waiver</U>. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party
of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>Notices</U>. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing
and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the
Company or, in the case of the Company, at its main offices, attention of the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <U>Amendment</U>. This Agreement may be amended
or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <U>Effect on
Other Plans and Agreements</U>. An election by the Executive to resign for Good Reason under the provisions of this Agreement shall not be deemed a voluntary termination of employment by the Executive for the purpose of interpreting the provisions
of any of the Company&#146;s benefit plans, programs or policies. Nothing in this Agreement shall be construed to limit the rights of the Executive under the Company&#146;s benefit plans, programs or policies except as otherwise provided in
Section&nbsp;9 hereof, and except that the Executive shall have no rights to any severance benefits under any Company severance pay plan, offer letter or otherwise. In the event that the Executive is party to an agreement with the Company providing
for payments or benefits under such plan or agreement and under this Agreement, the terms of this Agreement shall govern and the Executive may receive payment under this Agreement only and not both. Further, Section&nbsp;5 and Section&nbsp;7 of this
Agreement are mutually exclusive and in no event shall the Executive be entitled to payments or benefits pursuant to both Section&nbsp;5 and Section&nbsp;7 of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <U>Governing Law</U>. This is a Massachusetts contract and shall be construed under and be governed in all respects by the laws of the
Commonwealth of Massachusetts, without giving effect to the conflict of laws principles thereof. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be interpreted and applied
by the United States Court of Appeals for the First Circuit. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. <U>Counterparts</U>. This Agreement may be executed in any number of
counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement effective on the Effective
Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AMYLYX PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EXECUTIVE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">James Frates</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>20
<FILENAME>d155225dex1015.htm
<DESCRIPTION>EX-10.15
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.15</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.15 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Employment Agreement (&#147;<U>Agreement</U>&#148;) is made between Amylyx Pharmaceuticals, Inc., a Delaware corporation (the
&#147;<U>Company</U>&#148;), and Margaret Olinger, M.B.A. (the &#147;<U>Executive</U>&#148;) and is effective as of the closing of the Company&#146;s first underwritten public offering of its equity securities pursuant to an effective registration
statement under the Securities Act of 1933, as amended (the &#147;<U>Effective Date</U>&#148;). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below) and subject to Section&nbsp;12, this
Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i)&nbsp;the employment agreement between the Executive and the Company dated
May&nbsp;13, 2019 and later amended August&nbsp;1, 2019 and twice amended February&nbsp;19, 2021 (the &#147;<U>Prior Agreement</U>&#148;), and (ii) any other offer letter, employment agreement or severance agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company desires to continue to employ the Executive and the Executive desires to continue to be employed by the Company on the
new terms and conditions contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE,<I> </I>in consideration of the mutual covenants and agreements herein
contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Employment</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>Term</U>. The Company shall employ the Executive and the Executive shall be employed by the Company pursuant to this Agreement commencing as of the Effective Date and continuing until such employment is terminated in accordance with the
provisions hereof (the &#147;<U>Term</U>&#148;). The Executive&#146;s employment with the Company shall continue to be &#147;at will,&#148; meaning that the Executive&#146;s employment may be terminated by the Company or the Executive at any time
and for any reason subject to the terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Position and Duties</U>. The Executive shall serve as the Chief
Commercial Officer of the Company and shall have such powers and duties as may from time to time be prescribed by the <FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officers (individually and collectively, the &#147;<U>CEO</U>&#148;) or
other duly authorized executive. The Executive shall devote the Executive&#146;s full working time and efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the
approval of the Board of Directors of the Company (the &#147;<U>Board</U>&#148;), or engage in religious, charitable or other community activities as long as such services and activities do not interfere with the Executive&#146;s performance of the
Executive&#146;s<B> </B>duties to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Location</U>. The Executive&#146;s primary work location will be West Haven,
Connecticut; <I>provided</I> that the Executive will be expected to travel to the Company&#146;s headquarters, currently located in Cambridge, Massachusetts, from time to time, as well as to engage in other reasonable business travel, to perform the
Executive&#146;s duties and responsibilities under this Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Compensation and Related Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Base Salary</U>. The Executive&#146;s initial base salary shall be paid at the rate of $425,000 per year. The Executive&#146;s base
salary shall be subject to periodic review by<B> </B>the Board or the Compensation Committee of the Board (the &#147;<U>Compensation Committee</U>&#148;). The base salary in effect at any given time is referred to herein as &#147;<U>Base
Salary</U>.&#148; The Base Salary shall be payable in a manner that is consistent with the Company&#146;s usual payroll practices for its executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Incentive Compensation</U>. The Executive shall be eligible to receive cash incentive compensation as determined by the Board or the
Compensation Committee from time to time. The Executive&#146;s initial target annual incentive compensation shall be 40% percent of the Executive&#146;s Base Salary. The target annual incentive compensation in effect at any given time is referred to
herein as &#147;<U>Target Bonus</U>.&#148; The actual amount of the Executive&#146;s annual incentive compensation, if any, shall be determined in the sole discretion of the Board or the Compensation Committee. Any annual incentive compensation will
be paid no later than March 15<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the calendar year following the calendar year to which such bonus relates. Except as otherwise provided herein or as may be provided by the Board or the
Compensation Committee, the Executive must be employed by the Company on the date such incentive compensation is paid in order to earn or receive any annual incentive compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Expenses</U>. The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by the Executive
during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Other Benefits</U>. The Executive shall be eligible to participate in or receive benefits under the Company&#146;s employee benefit
plans in effect from time to time, subject to the terms of such plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Paid Time Off</U>. The Executive shall be entitled to take
paid time off in accordance with the Company&#146;s applicable paid time off policy for executives, as may be in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Equity</U>. The equity awards held by the Executive shall continue to be governed by the terms and conditions of the Company&#146;s
applicable equity incentive plan(s) and the applicable award agreement(s) governing the terms of such equity awards (collectively, the &#147;<U>Equity Documents</U>&#148;); <I>provided, however</I>, and notwithstanding anything to the contrary in
the Equity Documents, Section&nbsp;6 of this Agreement shall apply in the event of a Change in Control and Section&nbsp;7(a)(ii) of this Agreement shall apply in the event of a termination by the Company without Cause or by the Executive for Good
Reason in either event within the Change in Control Period (as such terms are defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination</U>. The Executive&#146;s
employment hereunder may be terminated without any breach of this Agreement under the following circumstances: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Death</U>. The
Executive&#146;s employment hereunder shall terminate upon death. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Disability</U>. The Company may terminate the Executive&#146;s employment if the
Executive is disabled and unable to perform or expected to be unable to perform the essential functions of the Executive&#146;s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180
days (which need not be consecutive) in any <FONT STYLE="white-space:nowrap">12-month</FONT> period. If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the
Executive&#146;s then existing position or positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the
Company to whom the Executive or the Executive&#146;s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this
Agreement be conclusive of the issue. The Executive shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and the Executive shall fail to submit such certification, the
Company&#146;s determination of such issue shall be binding on the Executive. Nothing in this Section&nbsp;3(b) shall be construed to waive the Executive&#146;s rights, if any, under existing law including, without limitation, the Family and Medical
Leave Act of 1993, 29 U.S.C. &#167;2601 <I>et seq</I>. and the Americans with Disabilities Act, 42 U.S.C. &#167;12101 <I>et seq.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
<U>Termination by the Company for Cause</U>. The Company may terminate the Executive&#146;s employment hereunder for Cause. For purposes of this Agreement, &#147;<U>Cause</U>&#148; shall mean any of the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) conduct by the Executive constituting a material act of misconduct in connection with the performance of the Executive&#146;s duties,
including, without limitation, (A)&nbsp;willful failure or refusal to perform material responsibilities that have been requested by the CEO; (B)&nbsp;dishonesty to the CEO with respect to any material matter; or (C)&nbsp;misappropriation of funds or
property of the Company or any of its subsidiaries or affiliates other than the occasional, customary and <I>de minimis</I> use of Company property for personal purposes; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) the commission by the Executive of acts satisfying the elements of (A)&nbsp;any felony or (B)&nbsp;a misdemeanor involving moral
turpitude, deceit, dishonesty or fraud; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) any misconduct by the Executive, regardless of whether or not in the course of the
Executive&#146;s employment, that would reasonably be expected to result in material injury or reputational harm to the Company or any of its subsidiaries or affiliates if the Executive were to continue to be employed in the same position; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) continued unsatisfactory performance or <FONT STYLE="white-space:nowrap">non-performance</FONT> by the Executive of the Executive&#146;s
duties hereunder (other than by reason of the Executive&#146;s physical or mental illness, incapacity or disability) which has continued for more than 30 days following written notice of such unsatisfactory performance or <FONT
STYLE="white-space:nowrap">non-performance</FONT> from the CEO; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) a breach by the Executive of any of the provisions contained in
Section&nbsp;9 of this Agreement or the Restrictive Covenants Agreement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) a material violation by the Executive of any of the Company&#146;s written employment
policies; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) the Executive&#146;s failure to cooperate with a bona fide internal investigation or an investigation by regulatory
or law enforcement authorities, after being instructed by the Company to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the inducement of others to fail to
cooperate or to produce documents or other materials in connection with such investigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Termination by the Company without
Cause</U>. The Company may terminate the Executive&#146;s employment hereunder at any time without Cause. Any termination by the Company of the Executive&#146;s employment under this Agreement which does not constitute a termination for Cause under
Section&nbsp;3(c) and does not result from the death or disability of the Executive under Section&nbsp;3(a) or (b)&nbsp;shall be deemed a termination without Cause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Termination by the Executive</U>. The Executive may terminate employment hereunder at any time for any reason, including but not
limited to, Good Reason. For purposes of this Agreement, &#147;<U>Good Reason</U>&#148; shall mean that the Executive has completed all steps of the Good Reason Process (hereinafter defined) following the occurrence of any of the following events
without the Executive&#146;s consent (each, a &#147;<U>Good Reason Condition</U>&#148;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) a material diminution in the
Executive&#146;s responsibilities, authority or duties; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) a material diminution in the Executive&#146;s Base Salary
except for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">across-the-board</FONT></FONT> salary reductions based on the Company&#146;s financial performance similarly affecting all or substantially all senior management employees
of the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) a material change in the geographic location of the principal office of the Company to which the
Executive is assigned, such that there is an increase of at least thirty (30)&nbsp;miles of driving distance to such location from the Executive&#146;s principal residence as of such change; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) a material breach of this Agreement by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#147;<U>Good Reason Process</U>&#148; consists of the following steps: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) the Executive reasonably determines in good faith that a Good Reason Condition has occurred; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) the Executive notifies the Company in writing of the first occurrence of the Good Reason Condition within 60 days of the
first occurrence of such condition; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) the Executive cooperates in good faith with the Company&#146;s efforts, for a
period of not less than 30 days following such notice (the &#147;<U>Cure Period</U>&#148;), to remedy the Good Reason Condition; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) notwithstanding such efforts, the Good Reason Condition continues to
exist at the end of the Cure Period; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) the Executive terminates employment within 60 days after the end of the Cure
Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company cures the Good Reason Condition during the Cure Period, Good Reason shall be deemed not to have occurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Matters Related to Termination</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Notice of Termination</U>. Except for termination as specified in Section&nbsp;3(a), any termination of the Executive&#146;s employment
by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a &#147;<U>Notice of Termination</U>&#148; shall mean a notice which shall
indicate the specific termination provision in this Agreement relied upon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Date of Termination</U>. &#147;<U>Date of
Termination</U>&#148; shall mean: (i)&nbsp;if the Executive&#146;s employment is terminated by death, the date of death; (ii)&nbsp;if the Executive&#146;s employment is terminated on account of disability under Section&nbsp;3(b) or by the Company
for Cause under Section&nbsp;3(c), the date on which Notice of Termination is given; (iii)&nbsp;if the Executive&#146;s employment is terminated by the Company without Cause under Section&nbsp;3(d), the date on which a Notice of Termination is given
or the date otherwise specified by the Company in the Notice of Termination; (iv)&nbsp;if the Executive&#146;s employment is terminated by the Executive under Section&nbsp;3(e) other than for Good Reason, 30 days after the date on which a Notice of
Termination is given, and (v)&nbsp;if the Executive&#146;s employment is terminated by the Executive under Section&nbsp;3(e) for Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding the
foregoing, in the event that the Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Accrued Obligations</U>. If the Executive&#146;s employment with the Company is terminated for any reason, the Company
shall pay or provide to the Executive (or to the Executive&#146;s<B> </B>authorized representative or estate)&nbsp;(i) any Base Salary earned through the Date of Termination; (ii)&nbsp;unpaid expense reimbursements (subject to, and in accordance
with, Section&nbsp;2(c) of this Agreement); and (iii)&nbsp;any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance
with the terms of such employee benefit plans (collectively, the &#147;<U>Accrued Obligations</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Resignation of All Other
Positions</U>. To the extent applicable, the Executive shall be deemed to have resigned from all officer and board member positions that the Executive holds with the Company or any of its respective subsidiaries and affiliates upon the termination
of the Executive&#146;s employment for any reason. The Executive shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Severance Pay and Benefits Upon Termination by the Company without Cause or by the
Executive for Good Reason Outside the Change in Control Period</U>. If the Executive&#146;s employment is terminated by the Company without Cause as provided in Section&nbsp;3(d), or the Executive terminates employment for Good Reason as provided in
Section&nbsp;3(e), in each case outside of the Change in Control Period, then, in addition to the<B> </B>Accrued Obligations, and subject to (i)&nbsp;the Executive signing a separation agreement and release in a form and manner satisfactory to the
Company, which shall include, without limitation, a general release of claims against the Company and all related persons and entities that shall not release the Executive&#146;s rights under this Agreement, a reaffirmation of all of the
Executive&#146;s Continuing Obligations (as defined below), and, in the Company&#146;s sole discretion, a <FONT STYLE="white-space:nowrap">one-year</FONT> post-employment noncompetition agreement, and shall provide that if the Executive breaches any
of the Continuing Obligations, all payments of the Severance Amount shall immediately cease (the &#147;<U>Separation Agreement</U>&#148;), and (ii)&nbsp;the Separation Agreement becoming irrevocable, all within 60 days after the Date of Termination
(or such shorter period as set forth in the Separation Agreement), which shall include a seven (7)&nbsp;business day revocation period: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) the Company shall pay the Executive an amount equal to nine (9)&nbsp;months of the Executive&#146;s Base Salary (the &#147;<U>Severance
Amount</U>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) subject to the Executive&#146;s copayment of premium amounts at the applicable active employees&#146; rate and
the Executive&#146;s proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#147;<U>COBRA</U>&#148;), the Company shall pay to the group health plan provider or the COBRA provider a monthly
payment equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company until the earliest of (i)&nbsp;the nine (9)&nbsp;month anniversary
of the Date of Termination; (ii)&nbsp;the date that the Executive becomes eligible for group medical plan benefits under any other employer&#146;s group medical plan; or (iii)&nbsp;the cessation of the Executive&#146;s health continuation rights
under COBRA; <I>provided, however</I>, that if the Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without
limitation, Section&nbsp;2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to the Executive for the time period specified above. Such payments to the Executive shall be subject to <FONT
STYLE="white-space:nowrap">tax-related</FONT> deductions and withholdings and paid on the Company&#146;s regular payroll dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts payable under
Section&nbsp;5, to the extent taxable, shall be paid out in substantially equal installments in accordance with the Company&#146;s payroll practice over nine (9)&nbsp;months commencing within 60<B> </B>days after the Date of Termination;
<I>provided, however</I>, that if the <FONT STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year and ends in a second calendar year, such payments, to the extent they qualify as
<FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; within the meaning of Section&nbsp;409A of the Internal Revenue Code of 1986, as amended (the &#147;<U>Code</U>&#148;), shall begin to be paid in the second
calendar year by the last day of such <FONT STYLE="white-space:nowrap">60-day</FONT> period; <I>provided, further</I>, that the initial payment shall include a <FONT STYLE="white-space:nowrap">catch-up</FONT> payment to cover amounts retroactive to
the day immediately following the Date of Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Change in Control</U>. Upon a Change in Control, except as otherwise explicitly set
forth in the applicable equity award agreement, any stock options and other stock-based awards held by the Executive with conditions and restrictions relating to the attainment of performance goals (&#147;<U>Performance-Based Equity
Awards</U>&#148;), to the extent then outstanding and unearned, shall be deemed earned based on the greater of target or actual performance as measured through such Change in Control, and such Performance-Based Equity Awards that are deemed earned
shall be subject to time-based vesting, based on Executive&#146;s continued employment, for the remainder of the performance period and shall be subject to accelerated vesting upon a termination of Executive&#146;s employment to the extent provided
for in Section&nbsp;7(a)(ii) below. Any Performance-Based Equity Awards that are not deemed earned upon a Change in Control shall be forfeited for no consideration upon such Change in Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Severance Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason within the Change in
Control Period</U>. The provisions of this Section&nbsp;7 shall apply in lieu of, and expressly supersede, the provisions of Section&nbsp;5 if (i)&nbsp;the Executive&#146;s employment is terminated either (a)&nbsp;by the Company without Cause as
provided in Section&nbsp;3(d), or (b)&nbsp;by the Executive for Good Reason as provided in Section&nbsp;3(e), and (ii)&nbsp;the Date of Termination is on or within three (3)&nbsp;months prior to or 12 months after the occurrence of the first event
constituting a Change in Control (such period, the &#147;<U>Change in Control Period</U>&#148;). These provisions shall terminate and be of no further force or effect after the Change in Control Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If the Executive&#146;s employment is terminated by the Company without Cause as provided in Section&nbsp;3(d) or the Executive terminates
employment for Good Reason as provided in Section&nbsp;3(e) and in each case the Date of Termination occurs during the Change in Control Period, then, in addition to the Accrued Obligations, and subject to the signing of a general release of claims
against the Company and all related persons and entities that shall not release the Executive&#146;s rights under this Agreement (the &#147;<U>Release</U>&#148;) by the Executive and the Release becoming fully effective, all within the time frame
set forth in the Release but in no event more than 60 days after the Date of Termination: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) the Company shall pay the
Executive a lump sum in cash in an amount equal to 1.0 times the sum of (A)&nbsp;the Executive&#146;s then-current Base Salary (or the Executive&#146;s Base Salary in effect immediately prior to the Change in Control, if higher) plus (B)&nbsp;the
Executive&#146;s Target Bonus for the then-current year (or the Executive&#146;s Target Bonus in effect immediately prior to the Change in Control, if higher) (the &#147;<U>Change in Control Payment</U>&#148;); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) notwithstanding anything to the contrary in any applicable option agreement or other stock-based award agreement, all
stock options and other stock-based awards held by the Executive that are subject solely to time-based vesting ( &#147;<U>Time-Based Equity Awards</U>&#148;) and any Performance-Based Equity Awards that are then outstanding and eligible to vest
based on Executive&#146;s continued employment as provided for under Section&nbsp;6&nbsp;above shall immediately accelerate and become fully vested and exercisable or nonforfeitable as of the later of (i)&nbsp;the Date of Termination or
(ii)&nbsp;the effective date of the Release (the &#147;<U>Accelerated Vesting Date</U>&#148;), <I>provided</I> that in order to effectuate the accelerated vesting contemplated by this subsection, the unvested portion of the Executive&#146;s
Time-Based Equity Awards and Performance-Based Equity Awards that would otherwise be forfeited on the Date of Termination will be delayed until the earlier of (A)&nbsp;the effective date of the Release (at which time acceleration will occur), or
(B)&nbsp;the date that the Release can no longer become fully effective (at which time the unvested portion of the Executive&#146;s Time-Based Equity Awards and Performance-Based Equity Awards will be forfeited). Notwithstanding the foregoing, no
additional time-based vesting of the Time-Based Equity Awards or Performance-Based Equity Awards shall occur during the period between the Date of Termination and the Accelerated Vesting Date; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) subject to the Executive&#146;s copayment of premium amounts at the
applicable active employees&#146; rate and the Executive&#146;s proper election to receive benefits under COBRA, the Company shall pay to the group health plan provider or the COBRA provider a monthly payment equal to the monthly employer
contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company until the earliest of (A)&nbsp;the <FONT STYLE="white-space:nowrap">12-month</FONT> anniversary of the
Date of Termination; (B)&nbsp;the date that the Executive becomes eligible for group medical plan benefits under any other employer&#146;s group medical plan; or (C)&nbsp;the cessation of the Executive&#146;s health continuation rights under COBRA;
<I>provided, however</I>, that if the Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation,
Section&nbsp;2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to the Executive for the time period specified above. Such payments to the Executive shall be subject to <FONT
STYLE="white-space:nowrap">tax-related</FONT> deductions and withholdings and paid on the Company&#146;s regular payroll dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts payable under
this Section&nbsp;7(a), to the extent taxable, shall be paid or commence to be paid within 60 days after the Date of Termination; <I>provided, however</I>, that if the <FONT STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year
and ends in a second calendar year, such payments to the extent they qualify as <FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; within the meaning of Section&nbsp;409A of the Code, shall be paid or commence to
be paid in the second calendar year by the last day of such <FONT STYLE="white-space:nowrap">60-day</FONT> period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Additional
Limitation</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any
compensation, payment or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with
Section&nbsp;280G of the Code, and the applicable regulations thereunder (the &#147;<U>Aggregate Payments</U>&#148;), would be subject to the excise tax imposed by Section&nbsp;4999 of the Code, then the Aggregate Payments shall be reduced (but not
below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which the Executive becomes subject to the excise tax imposed by Section&nbsp;4999 of the Code; <I>provided</I> that such reduction shall only occur
if it would result in the Executive receiving a higher After Tax Amount (as defined below) than the Executive would receive if the Aggregate Payments were not subject to such reduction. In such event, the Aggregate Payments shall be reduced in the
following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section&nbsp;280G of the Code: (A)&nbsp;cash
payments not subject to Section&nbsp;409A of the Code; (B)&nbsp;cash payments subject to Section&nbsp;409A of the Code; (C)&nbsp;equity-based payments and acceleration; and <FONT STYLE="white-space:nowrap">(D)&nbsp;non-cash</FONT> forms of benefits;
<I>provided</I> that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.280G-1,</FONT>
<FONT STYLE="white-space:nowrap">Q&amp;A-24(b)</FONT> or (c)&nbsp;shall be reduced before any amounts that are subject to calculation under Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.280G-1,</FONT>
<FONT STYLE="white-space:nowrap">Q&amp;A-24(b)</FONT> or (c). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) For purposes of this Section&nbsp;7(b), the &#147;<U>After Tax
Amount</U>&#148; means the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive&#146;s receipt of the Aggregate Payments. For purposes of
determining the After Tax Amount, the Executive shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state
and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to Section&nbsp;7(b)(i)
shall be made by a nationally recognized accounting firm selected by the Company (the &#147;<U>Accounting Firm</U>&#148;), which shall provide detailed supporting calculations both to the Company and the Executive within 15 business days of the Date
of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive. Any determination by the Accounting Firm shall be binding upon the Company and the Executive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Definitions</U>. For purposes of this Agreement, &#147;<U>Change in Control</U>&#148; shall have the meaning ascribed to the term
&#147;Sale Event&#148; as used in the Company&#146;s 2022 Stock Option and Incentive Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Section 409A</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive&#146;s separation from service within the
meaning of Section&nbsp;409A of the Code, the Company determines that the Executive is a &#147;specified employee&#148; within the meaning of Section&nbsp;409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive
becomes entitled to under this Agreement or other wise on account of the Executive&#146;s separation from service would be considered deferred compensation otherwise subject to the 20&nbsp;percent additional tax imposed pursuant to
Section&nbsp;409A(a) of the Code as a result of the application of Section&nbsp;409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (i)&nbsp;six months and one
day after the Executive&#146;s separation from service, or (ii)&nbsp;the Executive&#146;s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a
<FONT STYLE="white-space:nowrap">catch-up</FONT> payment covering amounts that would otherwise have been paid during the <FONT STYLE="white-space:nowrap">six-month</FONT> period but for the application of this provision, and the balance of the
installments shall be payable in accordance with their original schedule. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) All <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided and expenses
eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no
event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided or reimbursable expenses
incurred in one taxable year shall not affect the <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation
applicable to medical expenses). Such right to reimbursement or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits is not subject to liquidation or exchange for another benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To the extent that any payment or benefit described in this Agreement constitutes
<FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; under Section&nbsp;409A of the Code, and to the extent that such payment or benefit is payable upon the Executive&#146;s termination of employment, then such
payments or benefits shall be payable only upon the Executive&#146;s &#147;separation from service.&#148; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in
Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The parties intend that this Agreement will be
administered in accordance with Section&nbsp;409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section&nbsp;409A of the Code, the provision shall be read in such a manner so that all payments
hereunder comply with Section&nbsp;409A of the Code. Each payment pursuant to this Agreement or the Restrictive Covenants Agreement is intended to constitute a separate payment for purposes of Treasury Regulation
<FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section&nbsp;409A of the Code and all
related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions of this
Agreement are determined to constitute deferred compensation subject to Section&nbsp;409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Continuing Obligations</U>.<U> </U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Restrictive Covenants Agreement</U>. In consideration for the increase of the Executive&#146;s Base Salary and Target Bonus provided
for in this Agreement, such increases the Executive acknowledges the Executive would not otherwise be entitled to receive and are consideration that is fair and reasonable and independent of the Executive&#146;s continued employment with the
Company, the Executive is required to enter into the Employee Confidentiality, Assignment and Nonsolicitation Agreement, attached hereto as <U>Exhibit A</U> (the &#147;<U>Restrictive Covenants Agreement</U>&#148;). For purposes of this Agreement,
the obligations in this Section&nbsp;9, the obligations that arise in the Restrictive Covenants Agreement and the obligations that arise in Sections <FONT STYLE="white-space:nowrap">6-8</FONT> of the Prior Agreement, and any other agreement relating
to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the &#147;<U>Continuing Obligations</U>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Third-Party Agreements and Rights</U>. The Executive hereby confirms that the
Executive is not bound by the terms of any agreement with any previous employer or other party which restricts in any way the Executive&#146;s use or disclosure of information, other than confidentiality restrictions (if any), or the
Executive&#146;s engagement in any business. The Executive represents to the Company that the Executive&#146;s execution of this Agreement, the Executive&#146;s employment with the Company and the performance of the Executive&#146;s proposed duties
for the Company will not violate any obligations the Executive may have to any such previous employer or other party. In the Executive&#146;s work for the Company, the Executive will not disclose or make use of any information in violation of any
agreements with or rights of any such previous employer or other party, and the Executive will not bring to the premises of the Company any copies or other tangible embodiments of <FONT STYLE="white-space:nowrap">non-public</FONT> information
belonging to or obtained from any such previous employment or other party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Litigation and Regulatory Cooperation</U>. During and
after the Executive&#146;s employment, the Executive shall cooperate fully with the Company in (i)&nbsp;the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company
which relate to events or occurrences that transpired while the Executive was employed by the Company, and (ii)&nbsp;the investigation, whether internal or external, of any matters about which the Company believes the Executive may have knowledge or
information. The Executive&#146;s full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being available to meet with counsel to answer questions or to prepare for discovery or trial and to
act as a witness on behalf of the Company at mutually convenient times. During and after the Executive&#146;s employment, the Executive also shall cooperate fully with the Company in connection with any investigation or review of any federal, state
or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company. The Company shall reimburse the Executive for any reasonable <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with the Executive&#146;s performance of obligations pursuant to this Section&nbsp;9(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Relief</U>. The Executive agrees that it would be difficult to measure any damages caused to the Company which might result from any
breach by the Executive of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly<B>,</B> the Executive agrees that if the Executive breaches, or proposes to breach, any portion
of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Consent to Jurisdiction</U>. The parties hereby consent to the jurisdiction of the state and federal courts of the<B>
</B>Commonwealth of Massachusetts. Accordingly, with respect to any such court action, the Executive (a)&nbsp;submits to the exclusive personal jurisdiction of such courts; (b)&nbsp;consents to service of process; and (c)&nbsp;waives any other
requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Waiver of Jury Trial</U>. Each of the Executive and the Company irrevocably and
unconditionally WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY PROCEEDING (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE EXECUTIVE&#146;S EMPLOYMENT BY THE COMPANY OR ANY AFFILIATE OF THE COMPANY,
INCLUDING WITHOUT LIMITATION THE EXECUTIVE&#146;S OR THE COMPANY&#146;S PERFORMANCE UNDER, OR THE ENFORCEMENT OF, THIS AGREEMENT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.
<U>Integration</U>. This Agreement<B>, </B>together with the Restrictive Covenants Agreement and the certain Officer Indemnification Agreement to which the Executive and the Company are parties, constitutes the entire agreement between the parties
with respect to the subject matter hereof and supersedes all prior agreements between the parties concerning such subject matter, including the Prior Agreement, <I>provided</I> that Sections <FONT STYLE="white-space:nowrap">6-8</FONT> of the Prior
Agreement, the Equity Documents and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall remain in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Withholding; Tax Effect</U>. All payments made by the Company to the Executive under this Agreement shall be net of any tax or other
amounts required to be withheld by the Company under applicable law. Nothing in this Agreement shall be construed to require the Company to make any payments to compensate the Executive for any adverse tax effect associated with any payments or
benefits or for any deduction or withholding from any payment or benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Assignment; Successors and Assigns</U>. Neither the
Executive nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; <I>provided, however</I>, that the Company may assign its rights and
obligations under this Agreement (including the Restrictive Covenants Agreement) without the Executive&#146;s consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization or consolidation, into
which the Company merges or to whom it transfers all or substantially all of its properties or assets; <I>provided, further</I> that if the Executive remains employed or becomes employed by the Company, the purchaser or any of their affiliates in
connection with any such transaction, then the Executive shall not be entitled to any payments, benefits or vesting pursuant to Section&nbsp;5 or Section&nbsp;7 of this Agreement solely as a result of such transaction. This Agreement shall inure to
the benefit of and be binding upon the Executive and the Company, and each of the Executive&#146;s and the Company&#146;s respective successors, executors, administrators, heirs and permitted assigns. In the event of the Executive&#146;s death after
the Executive&#146;s termination of employment but prior to the completion by the Company of all payments due to the Executive under this Agreement, the Company shall continue such payments to the Executive&#146;s beneficiary designated in writing
to the Company prior to the Executive&#146;s death (or to the Executive&#146;s estate, if the Executive fails to make such designation). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Enforceability</U>. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any
section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to
which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Survival</U>. For the avoidance of doubt, the provisions of this Agreement shall
survive the termination of the Executive&#146;s employment to the extent necessary to effectuate the terms contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.
<U>Waiver</U>. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party
of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>Notices</U>. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing
and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the
Company or, in the case of the Company, at its main offices, attention of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <U>Amendment</U>. This Agreement may be amended
or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <U>Effect on
Other Plans and Agreements</U>. An election by the Executive to resign for Good Reason under the provisions of this Agreement shall not be deemed a voluntary termination of employment by the Executive for the purpose of interpreting the provisions
of any of the Company&#146;s benefit plans, programs or policies. Nothing in this Agreement shall be construed to limit the rights of the Executive under the Company&#146;s benefit plans, programs or policies except as otherwise provided in
Section&nbsp;9 hereof, and except that the Executive shall have no rights to any severance benefits under any Company severance pay plan, offer letter or otherwise. In the event that the Executive is party to an agreement with the Company providing
for payments or benefits under such plan or agreement and under this Agreement, the terms of this Agreement shall govern and the Executive may receive payment under this Agreement only and not both. Further, Section&nbsp;5 and Section&nbsp;7 of this
Agreement are mutually exclusive and in no event shall the Executive be entitled to payments or benefits pursuant to both Section&nbsp;5 and Section&nbsp;7 of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <U>Governing Law</U>. This is a Massachusetts contract and shall be construed under and be governed in all respects by the laws of the
Commonwealth of Massachusetts, without giving effect to the conflict of laws principles thereof. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be interpreted and applied
by the United States Court of Appeals for the First Circuit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. <U>Counterparts</U>. This Agreement may be executed in any number of
counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement effective on the Effective
Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AMYLYX PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EXECUTIVE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Margaret Olinger,
M.B.A.</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>21
<FILENAME>d155225dex1016.htm
<DESCRIPTION>EX-10.16
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.16</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.16 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Employment Agreement (&#147;<U>Agreement</U>&#148;) is made between Amylyx Pharmaceuticals, Inc., a Delaware corporation (the
&#147;<U>Company</U>&#148;), and Patrick D. Yeramian, M.D. (the &#147;<U>Executive</U>&#148;) and is effective as of the closing of the Company&#146;s first underwritten public offering of its equity securities pursuant to an effective registration
statement under the Securities Act of 1933, as amended (the &#147;<U>Effective Date</U>&#148;). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below) and subject to Section&nbsp;12, this
Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i)&nbsp;the employment agreement between the Executive and the Company dated
March&nbsp;18, 2019 and later modified November&nbsp;26, 2019 and later twice amended February&nbsp;19, 2021<B> </B>(the &#147;<U>Prior Agreement</U>&#148;), and (ii) any other offer letter, employment agreement or severance agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company desires to continue to employ the Executive and the Executive desires to continue to be employed by the Company on the
new terms and conditions contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE,<I> </I>in consideration of the mutual covenants and agreements herein
contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Employment</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>Term</U>. The Company shall employ the Executive and the Executive shall be employed by the Company pursuant to this Agreement commencing as of the Effective Date and continuing until such employment is terminated in accordance with the
provisions hereof (the &#147;<U>Term</U>&#148;). The Executive&#146;s employment with the Company shall continue to be &#147;at will,&#148; meaning that the Executive&#146;s employment may be terminated by the Company or the Executive at any time
and for any reason subject to the terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Position and Duties</U>. The Executive shall serve as the Chief Medical
Officer of the Company and shall have such powers and duties as may from time to time be prescribed by the <FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officers (individually and collectively, the &#147;<U>CEO</U>&#148;) or other duly
authorized executive. The Executive shall devote the Executive&#146;s full working time and efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the approval of
the Board of Directors of the Company (the &#147;<U>Board</U>&#148;), or engage in religious, charitable or other community activities as long as such services and activities do not interfere with the Executive&#146;s performance of the
Executive&#146;s<B> </B>duties to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Location</U>. The Executive&#146;s primary work location will be Boca Raton,
Florida; <I>provided</I> that the Executive will be expected to travel to the Company&#146;s headquarters, currently located in Cambridge, Massachusetts, from time to time, as well as to engage in other reasonable business travel, to perform the
Executive&#146;s duties and responsibilities under this Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Compensation and Related Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Base Salary</U>. The Executive&#146;s initial base salary shall be paid at the rate of $428,000 per year. The Executive&#146;s base
salary shall be subject to periodic review by<B> </B>the Board or the Compensation Committee of the Board (the &#147;<U>Compensation Committee</U>&#148;). The base salary in effect at any given time is referred to herein as &#147;<U>Base
Salary</U>.&#148; The Base Salary shall be payable in a manner that is consistent with the Company&#146;s usual payroll practices for its executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Incentive Compensation</U>. The Executive shall be eligible to receive cash incentive compensation as determined by the Board or the
Compensation Committee from time to time. The Executive&#146;s initial target annual incentive compensation shall be 40% of the Executive&#146;s Base Salary. The target annual incentive compensation in effect at any given time is referred to herein
as &#147;<U>Target Bonus</U>.&#148; The actual amount of the Executive&#146;s annual incentive compensation, if any, shall be determined in the sole discretion of the Board or the Compensation Committee. Any annual incentive compensation will be
paid no later than March 15<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the calendar year following the calendar year to which such bonus relates. Except as otherwise provided herein or as may be provided by the Board or the
Compensation Committee, the Executive must be employed by the Company on the date such incentive compensation is paid in order to earn or receive any annual incentive compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Expenses</U>. The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by the Executive
during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Other Benefits</U>. The Executive shall be eligible to participate in or receive benefits under the Company&#146;s employee benefit
plans in effect from time to time, subject to the terms of such plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Paid Time Off</U>. The Executive shall be entitled to take
paid time off in accordance with the Company&#146;s applicable paid time off policy for executives, as may be in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Equity</U>. The equity awards held by the Executive shall continue to be governed by the terms and conditions of the Company&#146;s
applicable equity incentive plan(s) and the applicable award agreement(s) governing the terms of such equity awards (collectively, the &#147;<U>Equity Documents</U>&#148;); <I>provided, however</I>, and notwithstanding anything to the contrary in
the Equity Documents, Section&nbsp;6 of this Agreement shall apply in the event of a Change in Control and Section&nbsp;7(a)(ii) of this Agreement shall apply in the event of a termination by the Company without Cause or by the Executive for Good
Reason in either event within the Change in Control Period (as such terms are defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination</U>. The Executive&#146;s
employment hereunder may be terminated without any breach of this Agreement under the following circumstances: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Death</U>. The
Executive&#146;s employment hereunder shall terminate upon death. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Disability</U>. The Company may terminate the Executive&#146;s employment if the
Executive is disabled and unable to perform or expected to be unable to perform the essential functions of the Executive&#146;s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180
days (which need not be consecutive) in any <FONT STYLE="white-space:nowrap">12-month</FONT> period. If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the
Executive&#146;s then existing position or positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the
Company to whom the Executive or the Executive&#146;s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this
Agreement be conclusive of the issue. The Executive shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and the Executive shall fail to submit such certification, the
Company&#146;s determination of such issue shall be binding on the Executive. Nothing in this Section&nbsp;3(b) shall be construed to waive the Executive&#146;s rights, if any, under existing law including, without limitation, the Family and Medical
Leave Act of 1993, 29 U.S.C. &#167;2601 <I>et seq</I>. and the Americans with Disabilities Act, 42 U.S.C. &#167;12101 <I>et seq.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
<U>Termination by the Company for Cause</U>. The Company may terminate the Executive&#146;s employment hereunder for Cause. For purposes of this Agreement, &#147;<U>Cause</U>&#148; shall mean any of the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) conduct by the Executive constituting a material act of misconduct in connection with the performance of the Executive&#146;s duties,
including, without limitation, (A)&nbsp;willful failure or refusal to perform material responsibilities that have been requested by the CEO; (B)&nbsp;dishonesty to the CEO with respect to any material matter; or (C)&nbsp;misappropriation of funds or
property of the Company or any of its subsidiaries or affiliates other than the occasional, customary and <I>de minimis</I> use of Company property for personal purposes; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) the commission by the Executive of acts satisfying the elements of (A)&nbsp;any felony or (B)&nbsp;a misdemeanor involving moral
turpitude, deceit, dishonesty or fraud; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) any misconduct by the Executive, regardless of whether or not in the course of the
Executive&#146;s employment, that would reasonably be expected to result in material injury or reputational harm to the Company or any of its subsidiaries or affiliates if the Executive were to continue to be employed in the same position; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) continued unsatisfactory performance or <FONT STYLE="white-space:nowrap">non-performance</FONT> by the Executive of the Executive&#146;s
duties hereunder (other than by reason of the Executive&#146;s physical or mental illness, incapacity or disability) which has continued for more than 30 days following written notice of such unsatisfactory performance or <FONT
STYLE="white-space:nowrap">non-performance</FONT> from the CEO; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) a breach by the Executive of any of the provisions contained in
Section&nbsp;9 of this Agreement or the Restrictive Covenants Agreement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) a material violation by the Executive of any of the Company&#146;s written employment
policies; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) the Executive&#146;s failure to cooperate with a bona fide internal investigation or an investigation by regulatory
or law enforcement authorities, after being instructed by the Company to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the inducement of others to fail to
cooperate or to produce documents or other materials in connection with such investigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Termination by the Company without
Cause</U>. The Company may terminate the Executive&#146;s employment hereunder at any time without Cause. Any termination by the Company of the Executive&#146;s employment under this Agreement which does not constitute a termination for Cause under
Section&nbsp;3(c) and does not result from the death or disability of the Executive under Section&nbsp;3(a) or (b)&nbsp;shall be deemed a termination without Cause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Termination by the Executive</U>. The Executive may terminate employment hereunder at any time for any reason, including but not
limited to, Good Reason. For purposes of this Agreement, &#147;<U>Good Reason</U>&#148; shall mean that the Executive has completed all steps of the Good Reason Process (hereinafter defined) following the occurrence of any of the following events
without the Executive&#146;s consent (each, a &#147;<U>Good Reason Condition</U>&#148;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) a material diminution in the
Executive&#146;s responsibilities, authority or duties; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) a material diminution in the Executive&#146;s Base Salary
except for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">across-the-board</FONT></FONT> salary reductions based on the Company&#146;s financial performance similarly affecting all or substantially all senior management employees
of the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) a material change in the geographic location of the principal office of the Company to which the
Executive is assigned, such that there is an increase of at least thirty (30)&nbsp;miles of driving distance to such location from the Executive&#146;s principal residence as of such change; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) a material breach of this Agreement by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The &#147;<U>Good Reason Process</U>&#148; consists of the following steps: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) the Executive reasonably determines in good faith that a Good Reason Condition has occurred; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) the Executive notifies the Company in writing of the first occurrence of the Good Reason Condition within 60 days of the
first occurrence of such condition; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) the Executive cooperates in good faith with the Company&#146;s efforts, for a
period of not less than 30 days following such notice (the &#147;<U>Cure Period</U>&#148;), to remedy the Good Reason Condition; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) notwithstanding such efforts, the Good Reason Condition continues to
exist at the end of the Cure Period; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) the Executive terminates employment within 60 days after the end of the Cure
Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company cures the Good Reason Condition during the Cure Period, Good Reason shall be deemed not to have occurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Matters Related to Termination</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Notice of Termination</U>. Except for termination as specified in Section&nbsp;3(a), any termination of the Executive&#146;s employment
by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a &#147;<U>Notice of Termination</U>&#148; shall mean a notice which shall
indicate the specific termination provision in this Agreement relied upon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Date of Termination</U>. &#147;<U>Date of
Termination</U>&#148; shall mean: (i)&nbsp;if the Executive&#146;s employment is terminated by death, the date of death; (ii)&nbsp;if the Executive&#146;s employment is terminated on account of disability under Section&nbsp;3(b) or by the Company
for Cause under Section&nbsp;3(c), the date on which Notice of Termination is given; (iii)&nbsp;if the Executive&#146;s employment is terminated by the Company without Cause under Section&nbsp;3(d), the date on which a Notice of Termination is given
or the date otherwise specified by the Company in the Notice of Termination; (iv)&nbsp;if the Executive&#146;s employment is terminated by the Executive under Section&nbsp;3(e) other than for Good Reason, 30 days after the date on which a Notice of
Termination is given, and (v)&nbsp;if the Executive&#146;s employment is terminated by the Executive under Section&nbsp;3(e) for Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding the
foregoing, in the event that the Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Accrued Obligations</U>. If the Executive&#146;s employment with the Company is terminated for any reason, the Company
shall pay or provide to the Executive (or to the Executive&#146;s<B> </B>authorized representative or estate)&nbsp;(i) any Base Salary earned through the Date of Termination; (ii)&nbsp;unpaid expense reimbursements (subject to, and in accordance
with, Section&nbsp;2(c) of this Agreement); and (iii)&nbsp;any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance
with the terms of such employee benefit plans (collectively, the &#147;<U>Accrued Obligations</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Resignation of All Other
Positions</U>. To the extent applicable, the Executive shall be deemed to have resigned from all officer and board member positions that the Executive holds with the Company or any of its respective subsidiaries and affiliates upon the termination
of the Executive&#146;s employment for any reason. The Executive shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Severance Pay and Benefits Upon Termination by the Company without Cause or by the
Executive for Good Reason Outside the Change in Control Period</U>. If the Executive&#146;s employment is terminated by the Company without Cause as provided in Section&nbsp;3(d), or the Executive terminates employment for Good Reason as provided in
Section&nbsp;3(e), in each case outside of the Change in Control Period, then, in addition to the<B> </B>Accrued Obligations, and subject to (i)&nbsp;the Executive signing a separation agreement and release in a form and manner satisfactory to the
Company, which shall include, without limitation, a general release of claims against the Company and all related persons and entities that shall not release the Executive&#146;s rights under this Agreement, a reaffirmation of all of the
Executive&#146;s Continuing Obligations (as defined below), and, in the Company&#146;s sole discretion, a <FONT STYLE="white-space:nowrap">one-year</FONT> post-employment noncompetition agreement, and shall provide that if the Executive breaches any
of the Continuing Obligations, all payments of the Severance Amount shall immediately cease (the &#147;<U>Separation Agreement</U>&#148;), and (ii)&nbsp;the Separation Agreement becoming irrevocable, all within 60 days after the Date of Termination
(or such shorter period as set forth in the Separation Agreement), which shall include a seven (7)&nbsp;business day revocation period: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) the Company shall pay the Executive an amount equal to nine (9)&nbsp;months of the Executive&#146;s Base Salary (the &#147;<U>Severance
Amount</U>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) subject to the Executive&#146;s copayment of premium amounts at the applicable active employees&#146; rate and
the Executive&#146;s proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#147;<U>COBRA</U>&#148;), the Company shall pay to the group health plan provider or the COBRA provider a monthly
payment equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company until the earliest of (i)&nbsp;the nine (9)&nbsp;month anniversary
of the Date of Termination; (ii)&nbsp;the date that the Executive becomes eligible for group medical plan benefits under any other employer&#146;s group medical plan; or (iii)&nbsp;the cessation of the Executive&#146;s health continuation rights
under COBRA; <I>provided, however</I>, that if the Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without
limitation, Section&nbsp;2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to the Executive for the time period specified above. Such payments to the Executive shall be subject to <FONT
STYLE="white-space:nowrap">tax-related</FONT> deductions and withholdings and paid on the Company&#146;s regular payroll dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts payable under
Section&nbsp;5, to the extent taxable, shall be paid out in substantially equal installments in accordance with the Company&#146;s payroll practice over nine (9)&nbsp;months commencing within 60<B> </B>days after the Date of Termination;
<I>provided, however</I>, that if the <FONT STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year and ends in a second calendar year, such payments, to the extent they qualify as
<FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; within the meaning of Section&nbsp;409A of the Internal Revenue Code of 1986, as amended (the &#147;<U>Code</U>&#148;), shall begin to be paid in the second
calendar year by the last day of such <FONT STYLE="white-space:nowrap">60-day</FONT> period; <I>provided, further</I>, that the initial payment shall include a <FONT STYLE="white-space:nowrap">catch-up</FONT> payment to cover amounts retroactive to
the day immediately following the Date of Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Change in Control</U>. Upon a Change in Control, except as otherwise explicitly set
forth in the applicable equity award agreement, any stock options and other stock-based awards held by the Executive with conditions and restrictions relating to the attainment of performance goals (&#147;<U>Performance-Based Equity
Awards</U>&#148;), to the extent then outstanding and unearned, shall be deemed earned based on the greater of target or actual performance as measured through such Change in Control, and such Performance-Based Equity Awards that are deemed earned
shall be subject to time-based vesting, based on Executive&#146;s continued employment, for the remainder of the performance period and shall be subject to accelerated vesting upon a termination of Executive&#146;s employment to the extent provided
for in Section&nbsp;7(a)(ii) below. Any Performance-Based Equity Awards that are not deemed earned upon a Change in Control shall be forfeited for no consideration upon such Change in Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Severance Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason within the Change in
Control Period</U>. The provisions of this Section&nbsp;7 shall apply in lieu of, and expressly supersede, the provisions of Section&nbsp;5 if (i)&nbsp;the Executive&#146;s employment is terminated either (a)&nbsp;by the Company without Cause as
provided in Section&nbsp;3(d), or (b)&nbsp;by the Executive for Good Reason as provided in Section&nbsp;3(e), and (ii)&nbsp;the Date of Termination is on or within three (3)&nbsp;months prior to or 12 months after the occurrence of the first event
constituting a Change in Control (such period, the &#147;<U>Change in Control Period</U>&#148;). These provisions shall terminate and be of no further force or effect after the Change in Control Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If the Executive&#146;s employment is terminated by the Company without Cause as provided in Section&nbsp;3(d) or the Executive terminates
employment for Good Reason as provided in Section&nbsp;3(e) and in each case the Date of Termination occurs during the Change in Control Period, then, in addition to the Accrued Obligations, and subject to the signing of a general release of claims
against the Company and all related persons and entities that shall not release the Executive&#146;s rights under this Agreement (the &#147;<U>Release</U>&#148;) by the Executive and the Release becoming fully effective, all within the time frame
set forth in the Release but in no event more than 60 days after the Date of Termination: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) the Company shall pay the
Executive a lump sum in cash in an amount equal to 1.0 times the sum of (A)&nbsp;the Executive&#146;s then-current Base Salary (or the Executive&#146;s Base Salary in effect immediately prior to the Change in Control, if higher) plus (B)&nbsp;the
Executive&#146;s Target Bonus for the then-current year (or the Executive&#146;s Target Bonus in effect immediately prior to the Change in Control, if higher) (the &#147;<U>Change in Control Payment</U>&#148;); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) notwithstanding anything to the contrary in any applicable option agreement or other stock-based award agreement, all
stock options and other stock-based awards held by the Executive that are subject solely to time-based vesting ( &#147;<U>Time-Based Equity Awards</U>&#148;) and any Performance-Based Equity Awards that are then outstanding and eligible to vest
based on Executive&#146;s continued employment as provided for under Section&nbsp;6&nbsp;above shall immediately accelerate and become fully vested and exercisable or nonforfeitable as of the later of (i)&nbsp;the Date of Termination or
(ii)&nbsp;the effective date of the Release (the &#147;<U>Accelerated Vesting Date</U>&#148;), <I>provided</I> that in order to effectuate the accelerated vesting contemplated by this subsection, the unvested portion of the Executive&#146;s
Time-Based Equity Awards and Performance-Based Equity Awards that would otherwise be forfeited on the Date of Termination will be delayed until the earlier of (A)&nbsp;the effective date of the Release (at which time acceleration will occur), or
(B)&nbsp;the date that the Release can no longer become fully effective (at which time the unvested portion of the Executive&#146;s Time-Based Equity Awards and Performance-Based Equity Awards will be forfeited). Notwithstanding the foregoing, no
additional time-based vesting of the Time-Based Equity Awards or Performance-Based Equity Awards shall occur during the period between the Date of Termination and the Accelerated Vesting Date; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) subject to the Executive&#146;s copayment of premium amounts at the
applicable active employees&#146; rate and the Executive&#146;s proper election to receive benefits under COBRA, the Company shall pay to the group health plan provider or the COBRA provider a monthly payment equal to the monthly employer
contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company until the earliest of (A)&nbsp;the <FONT STYLE="white-space:nowrap">12-month</FONT> anniversary of the
Date of Termination; (B)&nbsp;the date that the Executive becomes eligible for group medical plan benefits under any other employer&#146;s group medical plan; or (C)&nbsp;the cessation of the Executive&#146;s health continuation rights under COBRA;
<I>provided, however</I>, that if the Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation,
Section&nbsp;2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to the Executive for the time period specified above. Such payments to the Executive shall be subject to <FONT
STYLE="white-space:nowrap">tax-related</FONT> deductions and withholdings and paid on the Company&#146;s regular payroll dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts payable under
this Section&nbsp;7(a), to the extent taxable, shall be paid or commence to be paid within 60 days after the Date of Termination; <I>provided, however</I>, that if the <FONT STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year
and ends in a second calendar year, such payments to the extent they qualify as <FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; within the meaning of Section&nbsp;409A of the Code, shall be paid or commence to
be paid in the second calendar year by the last day of such <FONT STYLE="white-space:nowrap">60-day</FONT> period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Additional
Limitation</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any
compensation, payment or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with
Section&nbsp;280G of the Code, and the applicable regulations thereunder (the &#147;<U>Aggregate Payments</U>&#148;), would be subject to the excise tax imposed by Section&nbsp;4999 of the Code, then the Aggregate Payments shall be reduced (but not
below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which the Executive becomes subject to the excise tax imposed by Section&nbsp;4999 of the Code; <I>provided</I> that such reduction shall only occur
if it would result in the Executive receiving a higher After Tax Amount (as defined below) than the Executive would receive if the Aggregate Payments were not subject to such reduction. In such event, the Aggregate Payments shall be reduced in the
following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section&nbsp;280G of the Code: (A)&nbsp;cash
payments not subject to Section&nbsp;409A of the Code; (B)&nbsp;cash payments subject to Section&nbsp;409A of the Code; (C)&nbsp;equity-based payments and acceleration; and <FONT STYLE="white-space:nowrap">(D)&nbsp;non-cash</FONT> forms of benefits;
<I>provided</I> that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.280G-1,</FONT>
<FONT STYLE="white-space:nowrap">Q&amp;A-24(b)</FONT> or (c)&nbsp;shall be reduced before any amounts that are subject to calculation under Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.280G-1,</FONT>
<FONT STYLE="white-space:nowrap">Q&amp;A-24(b)</FONT> or (c). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) For purposes of this Section&nbsp;7(b), the &#147;<U>After Tax
Amount</U>&#148; means the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive&#146;s receipt of the Aggregate Payments. For purposes of
determining the After Tax Amount, the Executive shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state
and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to Section&nbsp;7(b)(i)
shall be made by a nationally recognized accounting firm selected by the Company (the &#147;<U>Accounting Firm</U>&#148;), which shall provide detailed supporting calculations both to the Company and the Executive within 15 business days of the Date
of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive. Any determination by the Accounting Firm shall be binding upon the Company and the Executive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Definitions</U>. For purposes of this Agreement, &#147;<U>Change in Control</U>&#148; shall have the meaning ascribed to the term
&#147;Sale Event&#148; as used in the Company&#146;s 2022 Stock Option and Incentive Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Section 409A</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive&#146;s separation from service within the
meaning of Section&nbsp;409A of the Code, the Company determines that the Executive is a &#147;specified employee&#148; within the meaning of Section&nbsp;409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive
becomes entitled to under this Agreement or otherwise on account of the Executive&#146;s separation from service would be considered deferred compensation otherwise subject to the 20&nbsp;percent additional tax imposed pursuant to
Section&nbsp;409A(a) of the Code as a result of the application of Section&nbsp;409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (i)&nbsp;six months and one
day after the Executive&#146;s separation from service, or (ii)&nbsp;the Executive&#146;s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a
<FONT STYLE="white-space:nowrap">catch-up</FONT> payment covering amounts that would otherwise have been paid during the <FONT STYLE="white-space:nowrap">six-month</FONT> period but for the application of this provision, and the balance of the
installments shall be payable in accordance with their original schedule. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) All <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided and expenses
eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no
event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided or reimbursable expenses
incurred in one taxable year shall not affect the <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation
applicable to medical expenses). Such right to reimbursement or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits is not subject to liquidation or exchange for another benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To the extent that any payment or benefit described in this Agreement constitutes
<FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; under Section&nbsp;409A of the Code, and to the extent that such payment or benefit is payable upon the Executive&#146;s termination of employment, then such
payments or benefits shall be payable only upon the Executive&#146;s &#147;separation from service.&#148; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in
Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The parties intend that this Agreement will be
administered in accordance with Section&nbsp;409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section&nbsp;409A of the Code, the provision shall be read in such a manner so that all payments
hereunder comply with Section&nbsp;409A of the Code. Each payment pursuant to this Agreement or the Restrictive Covenants Agreement is intended to constitute a separate payment for purposes of Treasury Regulation
<FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section&nbsp;409A of the Code and all
related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions of this
Agreement are determined to constitute deferred compensation subject to Section&nbsp;409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Continuing Obligations</U>.<U> </U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Restrictive Covenants Agreement</U>. In consideration for the increase of the Executive&#146;s Base Salary and Target Bonus provided
for in this Agreement, such increases the Executive acknowledges the Executive would not otherwise be entitled to receive and are consideration that is fair and reasonable and independent of the Executive&#146;s continued employment with the
Company, the Executive is required to enter into the Employee Confidentiality, Assignment and Nonsolicitation Agreement, attached hereto as <U>Exhibit A</U> (the &#147;<U>Restrictive Covenants Agreement</U>&#148;). For purposes of this Agreement,
the obligations in this Section&nbsp;9, the obligations that arise in the Restrictive Covenants Agreement and the obligations that arise in Sections <FONT STYLE="white-space:nowrap">6-8</FONT> of the Prior Agreement, and any other agreement relating
to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the &#147;<U>Continuing Obligations</U>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Third-Party Agreements and Rights</U>. The Executive hereby confirms that the
Executive is not bound by the terms of any agreement with any previous employer or other party which restricts in any way the Executive&#146;s use or disclosure of information, other than confidentiality restrictions (if any), or the
Executive&#146;s engagement in any business. The Executive represents to the Company that the Executive&#146;s execution of this Agreement, the Executive&#146;s employment with the Company and the performance of the Executive&#146;s proposed duties
for the Company will not violate any obligations the Executive may have to any such previous employer or other party. In the Executive&#146;s work for the Company, the Executive will not disclose or make use of any information in violation of any
agreements with or rights of any such previous employer or other party, and the Executive will not bring to the premises of the Company any copies or other tangible embodiments of <FONT STYLE="white-space:nowrap">non-public</FONT> information
belonging to or obtained from any such previous employment or other party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Litigation and Regulatory Cooperation</U>. During and
after the Executive&#146;s employment, the Executive shall cooperate fully with the Company in (i)&nbsp;the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company
which relate to events or occurrences that transpired while the Executive was employed by the Company, and (ii)&nbsp;the investigation, whether internal or external, of any matters about which the Company believes the Executive may have knowledge or
information. The Executive&#146;s full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being available to meet with counsel to answer questions or to prepare for discovery or trial and to
act as a witness on behalf of the Company at mutually convenient times. During and after the Executive&#146;s employment, the Executive also shall cooperate fully with the Company in connection with any investigation or review of any federal, state
or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company. The Company shall reimburse the Executive for any reasonable <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with the Executive&#146;s performance of obligations pursuant to this Section&nbsp;9(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Relief</U>. The Executive agrees that it would be difficult to measure any damages caused to the Company which might result from any
breach by the Executive of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly<B>,</B> the Executive agrees that if the Executive breaches, or proposes to breach, any portion
of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Consent to Jurisdiction</U>. The parties hereby consent to the jurisdiction of the state and federal courts of the<B>
</B>Commonwealth of Massachusetts. Accordingly, with respect to any such court action, the Executive (a)&nbsp;submits to the exclusive personal jurisdiction of such courts; (b)&nbsp;consents to service of process; and (c)&nbsp;waives any other
requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Waiver of Jury Trial</U>. Each of the Executive and the Company irrevocably and
unconditionally WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY PROCEEDING (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE EXECUTIVE&#146;S EMPLOYMENT BY THE COMPANY OR ANY AFFILIATE OF THE COMPANY,
INCLUDING WITHOUT LIMITATION THE EXECUTIVE&#146;S OR THE COMPANY&#146;S PERFORMANCE UNDER, OR THE ENFORCEMENT OF, THIS AGREEMENT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.
<U>Integration</U>. This Agreement<B>, </B>together with the Restrictive Covenants Agreement and the certain Officer Indemnification Agreement to which the Executive and the Company are parties, constitutes the entire agreement between the parties
with respect to the subject matter hereof and supersedes all prior agreements between the parties concerning such subject matter, including the Prior Agreement, <I>provided</I> that Sections <FONT STYLE="white-space:nowrap">6-8</FONT> of the Prior
Agreement, the Equity Documents and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall remain in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Withholding; Tax Effect</U>. All payments made by the Company to the Executive under this Agreement shall be net of any tax or other
amounts required to be withheld by the Company under applicable law. Nothing in this Agreement shall be construed to require the Company to make any payments to compensate the Executive for any adverse tax effect associated with any payments or
benefits or for any deduction or withholding from any payment or benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Assignment; Successors and Assigns</U>. Neither the
Executive nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; <I>provided, however</I>, that the Company may assign its rights and
obligations under this Agreement (including the Restrictive Covenants Agreement) without the Executive&#146;s consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization or consolidation, into
which the Company merges or to whom it transfers all or substantially all of its properties or assets; <I>provided, further</I> that if the Executive remains employed or becomes employed by the Company, the purchaser or any of their affiliates in
connection with any such transaction, then the Executive shall not be entitled to any payments, benefits or vesting pursuant to Section&nbsp;5 or Section&nbsp;7 of this Agreement solely as a result of such transaction. This Agreement shall inure to
the benefit of and be binding upon the Executive and the Company, and each of the Executive&#146;s and the Company&#146;s respective successors, executors, administrators, heirs and permitted assigns. In the event of the Executive&#146;s death after
the Executive&#146;s termination of employment but prior to the completion by the Company of all payments due to the Executive under this Agreement, the Company shall continue such payments to the Executive&#146;s beneficiary designated in writing
to the Company prior to the Executive&#146;s death (or to the Executive&#146;s estate, if the Executive fails to make such designation). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Enforceability</U>. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any
section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to
which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Survival</U>. For the avoidance of doubt, the provisions of this Agreement shall
survive the termination of the Executive&#146;s employment to the extent necessary to effectuate the terms contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.
<U>Waiver</U>. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party
of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>Notices</U>. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing
and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the
Company or, in the case of the Company, at its main offices, attention of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <U>Amendment</U>. This Agreement may be amended
or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <U>Effect on
Other Plans and Agreements</U>. An election by the Executive to resign for Good Reason under the provisions of this Agreement shall not be deemed a voluntary termination of employment by the Executive for the purpose of interpreting the provisions
of any of the Company&#146;s benefit plans, programs or policies. Nothing in this Agreement shall be construed to limit the rights of the Executive under the Company&#146;s benefit plans, programs or policies except as otherwise provided in
Section&nbsp;9 hereof, and except that the Executive shall have no rights to any severance benefits under any Company severance pay plan, offer letter or otherwise. In the event that the Executive is party to an agreement with the Company providing
for payments or benefits under such plan or agreement and under this Agreement, the terms of this Agreement shall govern and the Executive may receive payment under this Agreement only and not both. Further, Section&nbsp;5 and Section&nbsp;7 of this
Agreement are mutually exclusive and in no event shall the Executive be entitled to payments or benefits pursuant to both Section&nbsp;5 and Section&nbsp;7 of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <U>Governing Law</U>. This is a Massachusetts contract and shall be construed under and be governed in all respects by the laws of the
Commonwealth of Massachusetts, without giving effect to the conflict of laws principles thereof. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be interpreted and applied
by the United States Court of Appeals for the First Circuit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. <U>Counterparts</U>. This Agreement may be executed in any number of
counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement effective on the Effective
Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AMYLYX PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EXECUTIVE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Patrick D. Yeramian,
M.D.</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>22
<FILENAME>d155225dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use in this Registration Statement No. 333-261703 on Form S-1 of our report dated April 26, 2021, relating to the financial statements of
Amylyx Pharmaceuticals, Inc. We also consent to the reference to us under the heading &#147;Experts&#148; in such Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/
Deloitte&nbsp;&amp; Touche LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">January 3, 2022 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g155225g11d11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g155225g11d11.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1EL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &5"^9( X0DE-! 0      $<< @   @  ' )0  AR<C,R.#8T,1P"!0 N
M36EC<F]S;V9T(%=O<F0@+2!0<F]J96-T($%M8F5R("T@1F]R;2!3+3$N9&]C
M>  X0DE-!"4      !#2ZC6%B-%@ORP[+HQOJ%R@.$))300Z      #E
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M<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
M    0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T
M=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,
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M;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT
M;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #
MO_XU  (  0.__C4  @ !.$))300F       .             #^    X0DE-
M! T       0   !:.$))3009       $    'CA"24T#\P      "0
M     0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ !
M &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M   ! #4    ! "T    &       !.$))30/X      !P  #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z     #_____________________
M________ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M      0     .$))300:      -M    !@             $?0  !Q@    <
M %  <@!O &H 90!C '0 ( !! &T 8@!E '( (  M "  1@!O '( ;0 @ %,
M+0 Q "T ,0 Q #@    !                          $
M!Q@   1]                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   1]     %)G:'1L;VYG   '&     9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   $?0    !29VAT
M;&]N9P  !Q@    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     (X0DE-! P     #J\    !    H    &4   '@  "]8   #I,
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MS*G$8^,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0'_P  1" %P D4# 1$  A$! Q$!_\0 '@ !  (" P$! 0
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MA1O:'@0,FU<QDF0HQDY'@@!.U +,BAB6W6&NB@Y< P$2RMI_>'+PH(X:!9O
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M2VF"1@@J\020*^R_:[JB0AO(98B2=^GDFH9+NP61>4T89]$,&)0E/ YE25!
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M[#1E?5>+!=CRIJE<8^UN&$CQJ) 02Z@ MKX.-$,"/!V"=>A%2%K\'SX+;_\
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MM[*2]CR&5L99;:U:5K>*48^^M8Y1$9I.!D1F ;7+04#2/J(>+?W<F_T_Z/\
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M4IBE,4KA>(8']W[YUMKWJ]--^\6E'MN*_@H1[6]>TO?\24^JM_Q:WZ;Q3?\
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MX_ 93)Q">T@B:-I6MX3/=V=HUS<*JLUO:)=3PO=S@.FXK=9&!=%(#.H-7/\
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MDF:S'D20HBY2=HDY01&[9!&-L$564M;>&#2Q\MQ:V%(!(\;&DC$V40=M.RP
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MI2XNY5*R>UPSQ9"U-K%(+N&UB1#810R,;6*W_$2-4@ $D$A/HOHSR>2-S?\
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MXS1./N,OC.GTQQA$F'6\L\G')<V]NUE,V1FNUOIN]+'JWDAF1#<#D!);-&S
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M<AGC4!$$L8+*VO)90BL[$ZWJG=<_<"-('DD"*%D$:@A'8DDHYT0#L!220OH
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M%8LS$!0#OTJ1I$5.X6'#0.QYWOTUKR2=Z 'DFNIS'KU8ZJU-ZA(ZY0,G6RQ
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M:O7B=RAFT^-DMWAR#IQ\9-N,-]I?W2J>-NX1KKL*UR]4?MRP14ND\QEUD1U
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M&15A$J"4R,Y9F4Z T#LCQN:VO;OV4RW-G-R0J/<XEY >1:0HW#@JZ T23_\
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M:S)))%,CI$-R,-Z0:)V=@>- G_*H^^N;XO??13__ .^;_P#<\L_467_,9O\
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MDUS''INZ2_;8&.9=NI+_ (O,D[!#'?%$5OCKAU?+2Q2*%]P1.VQP'$.I#QL
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MW]!Z^DOPJL,SC6( N 22!_X<OQ]/]RI!ZEY+<;XO+Q\%T:U/0,I*1VI8$9N
ML,MIX!1+XFGMO0\6>PWOWXSR/=N.(=U[.E;1I*D[W6M,7?7R-):PB1$;@Q[D
M:Z;0;6G8'T(/IKS5BXO[:U=4FD*LR\@.#'QO6]@$#S\/6L'1/)OQ_P"W3R:-
M4;(BT2[PA,FF*/JEA$'6-'Z0M][;LY"B@^TS[:5)2IW3F][_ 'O6]Y)<8O)8
MZ/VF6-H%#!.XDR<@7/@?@W+:)'GX?.H1<X[(GV9ECN0??[4T'-#P\\BLB%-J
M?3?G?I\:\S/+#R=C^7=]A;YP)-?D9:LU<CE-QCMQ,C!O@$KZG6I:<:2T352
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M9#(YD4?(.3R \GQOXFK7:BX&/MQ\#Y*<%X$_,KK1_96#_<@Y1]V= _H=7?\
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M'TT0L_WB]EJ<]_M:MKVK?PBX[HN;CO1=B;OR]Z$1=@0R%R9(A" HB"/M>V
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M=RVN$PUC>W&2LL3C;3(7<:0W5];6-M!>7,,8C$<4]S%$LTL:"*((CNRJ(XP
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MRLXOIN^B>]BM;:*]N\/](4=U=1PQ)<W,=OC,.+=+B95$LR0"200K(S"(2,$
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M-&2Q(\L!&[(H)]0H4;]%%7.RC5NGIK\V*4Q2F*5\K_@*_P"%7]F\4JI'@?\
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M(A4^A#J1Z ZV#K8!&Q4:L^3/%'IB[PF[[7&":&/'D2KY,W#,@R"9&->DVFX
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M7+=D)63(:$990](29S[QAYCNE$&%/./D...K4O>&9F(+,6( 4%B20H&@!OT
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M*E[9>]-?O+GLV!8WA9%]EN.4@9D7M."X7\8J"OGC\?D2!ZD5%[5; ,>_%I"
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M3%*8I3%*8I3%*8I3%*^5_P !7_"K^S>*54CP/_W2N,?\BE_[U3V7,A_C)_\
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MLA0PZGD:2YMEK:O83SSK9XDE02 6'$D;\$KMN)(\D;.O39JXI) )\'Y>H_2
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M&C9HWWQYQMLHVU((Y,#H,&*D&I()^^KG@4:.1HG7DK .NB>++X8:(.] C>B
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MD:ROR;BQ1(V"B,%22W&LP0M'-)+';&"/ML#"'CY32<AQ8*LAC72A@"77?,;
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M2ZGT*N671(UHT,,; J5)4JJ\>3<0$_%XC?N$? KH^ =[ KO\QY#1N11TN!3
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M\EOW3_I38^8_:*?,XW](@_SL?_$QP?\ );]T_P"E-CYC]HI\SC?TB#_.Q_\
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ME>,_$GRBR'RRGW.=5A3I!)3RWR'W5;CM[6Z^\XMUU:M[4MQ:E*WO>]Y;%_?
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M(DAHA3VI2R2S\E-RC[[Z4/@Q6@H@*^Q1\>A2)$9+L1EQLR2$PDDLQ/XO+\5
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M'1\7$"'RDE(2,B6.&$#'A$ED/NH;:95O>_2K'&\K!$')B&.MA0 H)8DL0H
M))) U\:L,RHI9CH#0]"3LG0  !)))   ))J A?+_ )5+]4YARNL(L]F/Z:KJ
M C4S&U6S-QM4F^4%Q,?9*];F3848Z"F6#95#)@<B.(Y"LH8-FM @RD20;8]B
MF$$T[<4$/9VI=2S+,&*,NB05TOJ">1.EV0=0BYB,D<:\F[AD 8*VE:(@,K;
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MPV%8B.>V\\NN2=$@X6]0949MH:V]%@32MM=5:==ESG(28DX0S=>F8<?XN.*
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M#'U=>?9#[V'^I3VNW_+/W<G\E/KP^+WWF.?T&Z/^R&/JZ\^R'WL/]2GM=O\
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MUX?%[[S'/Z#='_9#'U=>?9#[V'^I3VNW_+/W<G\E-^</B]O6]?NFN?;KT_\
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M)757XVK7]$7%WV2Y?+W6L[GZ:?!.MUDIGG=D^E;-O2Y(@04L,IF#W$F.MI!
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M%X3J@=6,;21\HVDC*R=MY$#!78'@]0].XSJ:SM[+*BY:WM,A996%;>\N+/\
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M[J''$.NC(;<<2XXE:MI6K6\EG;?)F;EZ[8G8\^#Y\CS\=_/UK 51K2@!?0
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ML>(#LC:5.+3M[8K+6W=Z6\ZO6U^UO2W7%?PEJWL68^K$_K)/_OH !Z #?KH
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MR\<_U;N@_P"I;'<Q_P";7?\ &1?V5.-W]K;_ '$G]Q3Z)^:/WY>.?ZMW0?\
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MO-Z?4,ZX2VT(3T<8L+7+">\6R7L3%6E6Y:WN' !%G<M:.D\4%T-QO*FPIUS
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MVESU1>7EDZ7-T;*"P1\7.8K8I(93:E1*()9)+:/TT@SER,6&6Y'R$4MUG6E
MRK+8Y[&V]J:VDAEIY]M&U>Q[:=)>7K;:D*]=;WZ:^7S((Y7021RA3XDB):-M
M@':EE4D>=':CR#7Z@LYS<6T,S07%L73S!=(L<\9!*ZD1'D4$ZY#3L.)!WO8&
M6R*K-,4IBE,4JHWEEQ&\]MJ94+!2=?+A(^JW)T>BS816F+)>9"!+C*I)'2;<
MB,(D>N.E$'10)XJPFK Y'SI+NW(8)"?8=(9VQP-XEQ<17"3R7EB&R$#(6M,=
M%<I->Q1PF-I"]VJ)%+)'(KFU$UNJD7#Z^0_2[T+F^N\--C[&YQTUC!B<XR8&
M_@E[>4S]SCYK3#7,]V+F.%8L6\LMQ:03PM"F2>UR$L@:PA6M(N'.^IVROU/D
M\[SMY//WJM3F.LV6DG4QN?O9%>:$VQ1P]6"UPYL- ,+%:;FY]UR0D3!]%Q<$
M-',%;E$V[#)8JRN;S,P9'>3%U?-A[6^BO3;XX7)).1?V>TFCGN3R;V:V BBB
M<)/<22,@A/'SG3G569Q^(Z0R'3K#IQ\3A$ZPRF"N,(N0ZADQPBX]/P#(9:SG
ML<:AB49#(.US<SPM-9XZ.V68W8O:UKT;;U[/L>B$:]C?IZH]$ZU[._3>]?B_
MD^S>]?9]F]Z^W/"?/X^3Y^?Z?\_7SY^?FONH&@ !H   ?+]'CQXK[Q6:8I3%
M*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I7"2SHEAX=2MI2^TXTI2=:V
MK27$[1O:?7[/:UK?KKUUO7K^76\#P0?E6"-@CYUYW._@S>#EHX#\PD[:61PG
MD]DXLHE!,<(OI-$L=$LM!^!O38H#;)!D'&V^Q%5\^-0"1&D3$BTA2Q"W&,Z8
MRMR/:-!-7$ZW&B">U(KK)N,DDZ8HH=3X( /@C=4O8(=PG;;AC:+QH=Q"C)I]
M#R5#-Q(UHD_#Q4P\K\5_W,+$%===-G[5=(?E="X=!3TY!032([EM#EBI9F*<
MC8ML$4RP6$@KV[!8U[:TZZ*$Y'1<<AEUDB":\,RF/LI'&9Y;EE5G.YI5"EN3
M%F"J![B;/R+5+';]M@W<9G$20AF"^(T.P"% !8D^\P 'R45C>L>&E2ZO:>ER
MYEPL<%6^W1O,(KL=.C18AT2Y"\GFURU>4)+%BN2=>?DPE(K=D6(LA,A L,M@
MHBI)&Y-6T-\\*1*(T9[<S-;R,7!C,Z\7!56"N%/OIO6F)WL>*Q+:K*TC%V42
MK&LJC6G$3%ET2#QWLJQ \KZ:/FNQ.^'=1FN(7[AZ+?9P8B^]BE^TD3S;,2]*
MQ=CENT"]NW'!LN!Z!>B!K$(U&-MDLK+7$;6EPK9>]$ZPM](+B*X,:;BMUMP@
M+<2BP>S[)WOEQ)/Q'+1UKQ63:J8GB#, \K2EM+L,TG=(UK6M^/@=?'?FN'OO
MA_#>3U&@:1V2]3,FQ6>@P-[AY6JQ0%3D$-1P<C$3]6-6P](:,KUTKLQ+UVQC
M>K*RHF0?8TK6_16EM>M:2M+!&HYQ/$RNQ=?>(*N/33HP5E(\!E!UXI/;+<(J
M2.VED5P5 !\;VAWR'%@2K>/0ZJ);+^#1Y%8(CH58&G7X"L7^3ZU..C15"Y@Y
M:(F5[$S(?2!(M_DJB=;5P\0?-3DG6XUN0%?#=DM1Q\C)P00<4U/'E9T:)R@9
MXA H)EF"LL!7B#$'" L$57.B#Q#*JM[U0M81%70'BKF4Z$<?(=T,&TY7EXY,
M5V21R()*Z DJT^%%7GKC*=!B^A72L7$OK-3Z_%2T<Q7RD0-AJW%3>%MC"!R$
M40P2$95)(V05\9[U\:>V,4R[\(QL)R)+]U01M%&\8A>$JW/;*]P+C9(8'88!
M=@C:;!\^:D-HI<R!W5C*LH("GBRP]GP"/0J2?.]-Y\^E;KQ?Q>K_ ![H5RZ@
MS:).?M][K%:K%E>;A*Q4(><56B9$MNWSU?IT5#P\OT*8<DEM3=L>%:>("&#
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MN;\TNW22A%#-MN+<E!:7"3+\6PYIW21WSD,-$N)=;84M33FD2Q0M,6"O$G$
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)FBD_I(W^FO_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g155225g11i55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g155225g11i55.jpg
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ME)FEL[8G-$5E@H72*$=GA(FA4V)D9H;#T?_$ !X! 0 !!0$! 0$
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M.O1H4M]Y4=#PKSG6]8KG'B2ILB/S+,1<-#H6M.NH3TNKCN-!)4'&B&B%+2K
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MOQH4-G+KC;6')#[:,N.(1A7>4G&;C33K[B6F6W'G5G"&VD*<<6<$X2A *E'
M)P 3@$U:??8BM+?DO-1V&AK.//N(::;3D#66XXI*$#) RI0&2!O-8^HW>EW\
M5D[0[?5[L$3*=A*,U$^)L@I,UA#3C\3)$-+FQ,2F4/,K=CY>\:VAUI2T8PXG
M.:GXTB*OFI+#T=S5"N;?:6RO5.0%:CB4JU200#C!P<'95N+,ASFN>A2HTQG6
M*.>BOM2&M=."I'.,K6C6 ()3G(R,C:*E'+-9-8Z08$1"0T-+*C8I@PU/?$"I
M$Z*R2*LBDQUDWAL%QU,J<T-1+BKGN16G40TR8ZI&6\/-Y56&W%(6XE"U-ME(
M<6$J*$%>0@+4!JI*RE02%$:VJ<9P:MJ=:2XVTIQM+KH66FE+2''0V$EPMH)"
MEAL*25E((0%)UL9&>VJ1'3(;B*?93*>9>D,QE.HQ(=CQEQVY#[;.5>,6RPY*
MBMO.I3E#2Y,="U)4\WA5.#@JP=4$ G!P"02 3N!(2H@;R <;C5>LD*"2H:Q"
ME!.1K%*2D*4!O(25)"B!@%20=XSS<BIIQ2G%*<4IQ2M%3W1ST]L[,(7Z9:R-
M:VJ:VI;.H1\\P;J(FTRJO-HM1UAL[7[RGPJ9Q+1IBN0 K%K'S<2I 8V7AFX%
ME"&4@Y43I&[]=##3&2PAZ$W"8M8;+3[C*7DR7YD.4,.:J+BAU3A96G5#C:%-
MJ9<;YQ*N+?T3L0N+DY<IR/<WKE*OJG@]%:DJC+A1+;<8)RR%N69UA#(DMKUE
M-/.I>1(9=YE2:VUSX-O4%,J]1(:FW'LFOFP#H,EK?;E0A:.S8Q]+CZVLFMA(
M%LC$U*]7;P(F4B[&GX]FM@RR6/SS,CV06?BO9>3+RY>ELZ0\^F; B.MNAQ$N
M"^JX\RN09;4Q;I0J<'8ZTR8[8++*VFN:265MD8(P(')]:HD:*NV76X,/,%ER
M!=(B+-TA$--OD6]I@.(M98F-*ARW5)D2FY$CG5)D-OI)5K9LMX,[29JP[(/3
MK;L)_.S(Q9PHU*8UJ0*C;!8VJ:S9[0-NI'7<N^J(G\4N.],@3[/- IDG[,XT
M)2W,&,![:-+K@VU$:2Q%'0R@((,M*%M-&0665QT2DQ@AKI! 4AE+I#3.7,I6
M7+SO)Y9WG[@\N5.5W12Z70I-O6ZV_($029+<QR N:7'^AH4M#DA;&L]((: 4
MV&KJK?2/3:CND9O !<;S$L42T[VLA0,ZY5I5>L#'4 SK5=KK\]I^KJ*Q!0<Q
MJ:EG:W($%1QEB9$G1"I0L*(OP,:]Z^R'[>NW.L1E-*8MK*' 'TNM&UF7S#J2
M'M13CC<Z0V\'$+;*5)4A#:T!5;>/HO$BW=N\,2YJ'TR;U(=9)C*8?3?!;S)8
M6%1BZAIIVV0WHZFG6WDJ0M#CKK3BD527]3\TO<-C;'V0]MW9-M.V"T2V#S.3
M.N2JZU+B;_U9U*-4Q\TQ1W;8[$K5KUM7JX" 6D^4S5M<$G:X(C#G,#RK&P]T
M]PCQ8D408C#33*2U\[EH#R56R;:#(#9DA@%YB6ZZXZRTCGI:.=<4L:[9T_N&
MM$N?<+@;K<)3TB2I+XYVWN&.I%[MND AJ>$,RBF/)@,1V&)+[G1H#ACM)0=1
MT=^R^#BU<?)6LA#V9MZLM[ -6\KL* $F4!V+<(EGW^<ZDH *8X;U^8F"AE3V
M/9#> CU=E""\NOD'1%B)F^QN2BEG2N:TAE"HD%[HK;"(JG$R0IA3-K;M"W$A
MN4VE:WXC3?.!T+;2ZD.-(;V@UR- +:\[)<1<+I'$YZ4[.;95!*)29%\>TA;8
M67H+JVFXMPD/<R6%-.J8<+3[CVQ0]#.<M7=TXI3BE.*4XI437?:,B8R.7=*F
M@A(LKU,CP%V,.F8_<(X])=^J,Q<S,/NV5D4M!-X$A"BC8]29JXJ8RL.YOB-)
M*2L1WR@,B05!IS5#!64!\JU<!DK!0'"=0K!2%9V5BF=""TMF9%#BI!B)09#0
M6J6E =5&2G7UC(#9#A9 YP((64ZNVLT'-!["-C& !88<$3<.*AE0\^*3&RTL
MO.1WE1IT)U^*_AJ0RZPYEIU>$/-.-*[%H4G%MQMQI9;=0MM:<:R'$J0M.0",
MI4 1D$$9&T$'<:O-/-/MI=8=;>:7G4=:6EQM6"4G56@E*L*!2<$X((.T&C9D
M0\7E@&BHUT[ 'P"TX(W.BK+PA1600B#"<L:EW,R,/(RQ)6- FO,HC3) P@S'
M<<<A24M"VX&TNE"PTI:FTN%*@VI: A2T)7C5*T)6A2D@DI"T$@!0R#S1=6P'
M6R^VVAU;(6DNH:=4XEMQ;8.NEMQ33J4+("5J;<"22A0']$&!!\=%, 2HTV)F
MI6N&4$3HI(=+0VZMEQ<6;#=>C2$H>:<96IIU>$NMK;5G"T*Q@MM;2U-NH6VM
M.Q2%I*%I) ("DJ (R"#M&X@T:>:?;2ZPZV\TL$H=:6EQM8!*24K02E0!!!P3
M@@C>*Z#EMJK,"R%7K-7VA=-7/;MY)PR.1 JK@H<R8*-V28J3B.#6-$R8Y2>@
MFY%5#'2&9TC#<9UMU508>*F4!ETKD:I80&UE3P6LMH+*<9<UW 4)U K66"D9
M4"*H,J,E$AU4A@-1"L2G"\V$1BTV'7!(65:K);:4EQ?.%.HVH+5A)!K.MN-O
M-MO,N(=:=0AQIUM:5MN-K3A2'&UISE*T+3G"D+3G*5)SC.,YQG&>6R""0000
M<$'801O!'415X$$ @@@@$$'((.T$$;""-QK]\BIIQ2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*U@ZS-46O>/31L_55(PSZ46^)6XHM3\D=$;:\@N=
M<,37\/EHTT7AV./'2WV&R$.7$??;;8?BR&W%-+W%@G,VV[PYLC/,L*=4L +4
M3K1W4)&$*2O!6M()2I*@"2% C-<YI;;)5YT>N5MAXZ3*1'2WE3: -27'=6H*
M=2MK*6VU*2'$*0I0"5)4#@^:%LZ+^LVF(V*,U;;RA5RR[KL%R+;"JUX&Z<MV
MSZT0T] J&H9QD+JDAIJKU<OI0\+\VVN",B-U6^X6&ODVBW>5$FTI'7LZ06"1
MT1<QAM',V]J.W%?C+N#$-U$]3\Y+;DU-P>?1<&EZ["EJY^+AR,F3'"D2#\\E
M:(Z6Q!/:MLIQPR+P]+<GQIC=IE7&,NTHB6I;S-L<M$:.[9WV@W)0VD19N69J
MH4Q25Q*@MS!]9=QWKM?4%-OVZ5['E">I:-C8L38.\:5K&)%+].HX7HUB#5)-
M?K^MJ=BL;&*(7"OE+6YD[9I63\&<<(0"2:ED,.6!BVP9\B-;NB!RT*,146VR
M)BBBZK7<BI]+KLM_GHB.^C2,<VR.:4EI*D<_B2V=+)5ZN5JB3KN;@IK2%/3T
MS[Q#MR4NV!#5F#<53#$"((T]T%$V'DOR%<^A;SB'1%OJYZ,ZV[G8[9M%L$J!
M9%&.HF1KFJFMTS%3Z35=EZ5Z8ZA6JZ$L]2/A9E:DYMM!VD75!J%EKD0=89V9
M\>T#$G56A.MCW+1Z.RS#+FLT6[4);S=O3J2'X=QO$AYUQE]MQ+PYB3";UGVG
ME+:3JJ97S?,UNI5FTPE2)5R#.I(+M^5;XKUW67(<:X6C1Z+'89D17V51U&5"
MN3Q1$DL(;?7KB2WSQD56H[I"ZWXSS-L\^7)6Q&M3;YUK7[/-ZB;;@O6JR?Z@
M*]LNDUF81FW.WS'29W5&;1KP5:Y,^[FJ+:<5<M,L,UFDU*QP<M=]T=4"QS<<
M13.MDQUE-J8YMYYJV.Q)#J4)CL)"&IO,REL!$9N2R7FTM),A]I6O;T5TP2H2
M>>EF>FUWNW1Y*[]*YV/&?OD>X0XRW%RY2RX_;.DP&I2ES'H4@1G5ON"'%?1;
M8#ILZB9+U@*[DVMO'66E@NL>IF?4A->ZD=J6;8&JI=B)T+X+EVVQU2T.V7;U
MAH]:A;4L(EPL7O,<5DR$KC<TW,$BY#6"[=K4D-MP(5NF7!R99TON.VB$U%FI
M:1)Z;S#+[(9@M27E0FEA"(Q7S;CI2VA:P=FQH]?E*>=NUSO-NM#-NTA7%:8T
M@N4F=:UR'8/<WI4B-),BZ2(4=%RD-*<=F!KGF8X<>6TVH;6]!R]UGM"#MG=0
MDLZC:.X"SM[)U<L\=:@4<(V(#5&J@J_7SS,&358):O5:!>BH3(@1):M5PL#Y
M2%@H]+<7I=)1;VKFN':TMF'!0(R'D!HJD.%;C[[CKK14'E-NO*C(<YQP<RPT
M$*U D#I]"C>'[(W<;ZI\7*ZNJFN1G2^$0V0VU%C,L,/I0J*AUB,W-=9YII0D
MRGU.HYU2R=T.<_76TXI3BE:!]66K-TF=F4_:.H:&*V7W.GGJ/T"=K<NZBJ//
M$2]RS=3F*U<&9IN*^/(A!4S7,V#883+K9AA@G#F"H153<B,CI[)-M[<-^%/D
MKA_FK:KHVZF.N2EQ,!,UMY@I;4%(<6F4E32B.;)0I*U(R#7$:3VV[NW&)<K5
M":N.+%?[(]'7,;AN-+NR[8['E!;R5-N,M+@*1(0"'DI<2MI#I!0-+:!HGK0&
M[*-ZZU_;;W6&M*(TQ0 ^RB^U+DUI&+6P?0;2ZK9 5=TB24Y6[;'-[LF![/#L
M\2M2W@QD38I$B>#+0Y8VS;^5<M'UQ$2I3$9[N@;A*<B-PXYN*GG-)9#S+CMQ
M1AUA3=N2ME3*G4AQMQI(2XVI*V>1A672YNX.P($J9&%H%H@M7!VY2Q9TQV-"
MHL:0PQ9W,QY27KPMF2B0B.HM/-2%*6RZA3<B5D^G[K7E:WJ@D7"W"*R-BW>,
M>K3O7->9MX,;2*ZNHP6D[?7L?,I!(?K.K[)%W8].U%Z8'A)=JP0;(NAMKB^@
M3%E%ST>3+>6I4!>N8Y;>&CD9,9N&B;)<D0.B8U%S'HBXS29_1VEHYI;723K=
M).2Y8]+UV^*TVBZM<VF8E^.=,IJYKMR=MT)F'=>Z&L'&[='GM3'W+6)3S3H?
M3(,(%/0ASW#I+ZV["B]$IFY]H2;:2&;YC"9]5ZBMBT2L2"KW3_K.!HR>(J(&
MU" =8AQNH,-<[/(CQ!4-YN 07 LN2-4GN!%PQ?-'6C&0FWPPPA=L4XEZU1)+
MP0+G+5<D./NLK<>4JUN,,@J6H%2==K4?2':JEZ+Z82.FN+N]Q5*<;O26EQ;]
M/A1E.FQVY%F6W%8DM,QT)OK,N04H;00VX42.<C++)Y;STM];%B1M*4)V%=P!
M"=7>J:SZ_P 5+>EEI,9W;UG']-ZM S3<6LG!42<)$%:=M=;HHTS,KHU@D_&(
M#GH-@>C/Q&O.CS1A!<6,ZA+UE9E=(MK,A0@,KNPNB6U/-K*5N-R(("VREU90
M%(4%M!0F9HWI>^+FIN?,8<<8TDD0>BWF1#2;K(;T?[AK>3&>:0MIIR)<\MO)
M4PV'%)6V4/J2KN:0*[WD]?9>O'2FXB]="V[JE*WDJ0M.YF]52JB0FT?&@P4+
M75L!!];5K--"D)M?%&*>Y*9OQ",:ML.;8FTRR@ZFXMVT:,MNMH@-O+8LR(R$
M,V\S0^E,GNFXJ6PXY,>Y]Q"75MR #%2IMA26CJH559G;TK3=YAYRZNL,RM)'
M)KBY-W%M5%6N%W#91;Y3+-OCF(RXMAMZ(5":M+LE"Y"0IQOV+YP=?5Z<4IQ2
MG%*<4KQ7ZE^A;J$NO4)N+<&IYE;BCQ,6F]0?3[ FF$0$_1=!Y.E*R:D'8JUI
M:BA"&K]&)K,J:\EN--;V;8<NNK?;6Y'^@VC22UQ[7 @3DO*4XI^UW1005_F$
ML7!YL-'&2XB9<B\E()4DQ&L8! /R+2'0N^3+[=;K;%1TH:$2^V)M;H0/=2TJ
MSQWE/I)PEERW6;HZEJ 2L7%_*M893SUOI&ZP=9S*G2-?7"RQ*W2:=1:W5KA
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M[GIWD/\ H;*_;7?PA7B#YJ3Z+6W[&1^"NM5^?>Z\C4XI3BE.*5**5=;5KJU
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ME&<2X--L+89;0!JQF5K<&2'EN)UU.)))!1MU4D #O363#<6ZEYQ:LYD/)0C
M!:0VLMI0H 9UCJE2LD_"&,"O2;FOK,KYJ_"T_P!M&+_O3U/^'+;SV#R$_J*?
M_P!^SOXK K\X/FK_ .Z=%_X4M7\>N]>8?/L]>9J<4IQ2G%*<4IQ2G%*<4IQ2
MG%*SM7_--7?V=$?PA'YBSOTE,^Q9'\"NLZU_1*W?9T3^,-U]-=V_-$?_ &8+
M_OZ3SQS;OTI"^Q6/X%-?IC>?HE<?LV5_&7*JDK]2O_3Z_-VSO3XAZ17,N;U>
M+Y*KXE[%_K_X\<VK6X>3\,5JG?AGR^DU 2/LS]S^+FQ9W#Q'TUJ7]RO;Z4U
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M5_C\3_*^,'@>PTR.([13TXI?VWU?X_$_ROC!X'L-,CB.T4].*7]M]7^/Q/\
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MJ[K:$IRI2E*SGZ92LJ[<Y\20[';'HT9QV.I2W&&G%GGWP"M;25*. X !DG8
M-_#97ZGW+2>]1YLQEF4A+;,E]I">C1E80AY:$C*F23A(&TY)Z\FJPGF%,85E
ML/5D]GL_V(UG/U__ .85GFS:T9LJB J(HY /Z8DC?C@[X:T;FFFD0SB:@8&?
MTG"/5GKCGVX5#YMM(,]_Q8VJI[%9QC_895,_8Q^>#Y^[S/;T2L)&V$H__BI0
M^F ZGJP'-.])TD@3VQO_ ,!@YWD=<?P5$INPCS.,Y;AU-/J[<=M(I^>S_"$S
MS-;T,T=5M,!76<"7,'7C]?\ 8^#96N>Y0M+$YU;DV,?ZA;SU9ZXIJ)3=K6MG
M"\ML5-/=]G^P2EY]N?K]X#GV<S$Z#Z,E0!MZB/LR:.H_ZQ[<*U;W*7IDCX-T
M;&TCZ'6T[O'$/MV5!']NW"'-FD([=53*G-16I*E4:F.-J1!Q(\G\6PX!4PRI
M/E#O?4TVA3W:GQV7,MHRG9(T T44 3;5X!P!TZ?UG&_I/MX*TLCE8TY;)U+L
MR/';+8=QQUP_+ZZCD[J"V.SWO%N5!/9V]G_H[H6?\/>KF>W/^#'ZGV<]KDWT
M/5\*V.':1^G[@/#U2?)U5J'^6/E 1\&\,C(^M5I.-N.N$?.*B4_J6VJPG.6Y
M503]C_T;:]SV?7_/5G/;S-9Y,M"UG"K2X>KZ(W(<.$OPUJ'>6SE'3\&^,C;]
M9[,=^WKMYJ)2NJO<;7U!"G8]:L?[F6N,^SN^OUU;/K^F^Y^I]?FR;Y*-!E#)
MM+NX'Z)7/K__ !?MYJU#_+MRGH5A.D# &_Z"6,^3;;C[=E89WJVW4GV$J=C.
M?_PPUMZO;]FJY^QRY[TV@N?H0YC@;E<_QP5C^_SRI9/YXF-AQ] [%P!^MWA\
M-8UWJ_W@GZDI3<>O'_W7:TS[<=OVJ?Z>O]3L>]/H+]:'/)<[IV[9A]-!R\\J
M.W\\+.PX^@EBX _6WPUB)?6#O-UEYE9>G>+=;6TYA.KM:)5E#B%)7C"TU3"D
M9RG.<84G.%)SV93G&<=O)')/H*#GN0[]T[GL_P#]RI]_CE1^,+/W$L7Y-K$M
M]8V]H,9B)&,T]+$5AJ.SA>KM9O+2TPTEMM*W7JFMUU6$I3WG'%J<7G&5+4I6
M<YX]Z?03KL[A\/=.Z?),%4GEZY41L]T+.T'?9+%LP,_6[;ZO#MKJ.=;'4"GU
MX-TS'MSV?!3J[/L__P 0_P!/U>#R3Z" D=QW>'T3N?4=_P"FSU51[_G*E\86
M/N)8OR=6,>ZX.H9/;W3U,QV?_A/JS/U^SZ]/^_R?>FT$QGN.YU_XSNG5C_7/
M#3W^^5(Y_/"QL'UCL7$#ZW>&L<_UT=1C?U-@I?V/]R75?V.WZ].SR4\DV@BL
M_F.YLQ_C.Z?CE/?\Y4OC"Q]Q+%^3JQKO7AU(IQVXL=+QGU__ '1ZI^Y]>FY^
MSV\N#DCT#) [CN[2/\9W/\;JVKE^Y4P<#2&/L_\  [%MV?[NK%N]?'4NGZFR
MTO';[/\ T0ZFSV>O/_\ 9?K]G9RH\D6@0('<=WJ'T3NF\YV_ISP;O8T^_P#\
MJGQAC^6QV/\ )XV>?PULUTE[)O'5O?#]4W*9@D ]9J4LX+9K=0HM27Y?(*"1
MKN9J@57B)(,YBR'$MM3$/887G*V,M9<=\9\;Y5]$K#HNJQ)LD-403D7$R0J3
M*D\X8ZH8:QTIY[4U.=<^!JZQ5WV<)QZ,Y =/]*M.6M*E:37%N>JUNV=$(MP8
M,+FA+3=#(R(4>.'.<Z,SCG-<HU.\*=96=_/H1=0_\E*?XM>_F]SY!@<!V"O1
M&3Q/::?0BZA_Y*4_Q:]_-[C X#L%,GB>TT^A%U#_ ,E*?XM>_F]Q@<!V"F3Q
M/::?0BZA_P"2E/\ %KW\WN,#@.P4R>)[33Z$74/_ "4I_BU[^;W&!P'8*9/$
M]II]"+J'_DI3_%KW\WN,#@.P4R>)[37AEMSJQW/TZ[ZW+JK5)6IAJK5KA*AP
M$D]8ZSL))QM6$=U<HH:J,V:\K&$I[$^-2TG.,X;:;3G&,??^3+0;172:S=(N
MUL6_*0X\E3R)TZ.%I#S@0"VQ);;&JD)3L0"<9)).:\C<N?*AI[H1I&B+H]?$
M0X+K#*DQG+7:9>HM4=I2U!Z7"?>(6LJ407"!G52 D"HC_5)>K?[<Z1_D6TY_
M,;GTSWGM /K.]]U+I^-U\-_LB>5OXR1_N#8/R93^J2]6_P!N=(_R+:<_F-Q[
MSV@'UG>^ZET_&Z?V1/*W\9(_W!L'Y,I_5)>K?[<Z1_D6TY_,;CWGM /K.]]U
M+I^-T_LB>5OXR1_N#8/R97(UX2CJV;=;<5;J(\EMQ"U,NZ7U!AIU*58SEIS+
M-*:>PAS&,I7EIUIW"<YRVXA?8K \CV@&"!:'TD@@*%TN>1D8R,RR,C>,@CB"
M-E2GYHOE:2I).D498!!*%6&Q!*@#DI446Y*@%;CJJ2K!V*!P1],G@_.MG4'5
M[1T#55ZK4[;E:AL8N%$:A0T,N)^D9](:QA]"GYM=F/YQC"5*=EAI+B!Q%;F5
M0IQ'S9I[H'<-"Y^%%R79Y2U=S[AJ[]A/1I6J EN6VD;=@0^@%UH !QMKVMR3
M\J]HY2[3K(#4#2. TCNQ:-?:G)">G0-8E;UO>6=A[YR*XH1Y!)++TC=[: 0*
MS13CK(@6TXGS9W7&H$1M:>TP/3GNK2UA6.U.<ISV9QVXSG&?5G/."1\(>7T&
MOK*_@GR>D58& (/&.S 83C'V,#H>,?\ @\C)&XD>6IP. [*>8@GZ#"OBZ)^)
MXR>)[33 X#L%/,03]!A7Q=$_$\9/$]II@<!V"GF()^@PKXNB?B>,GB>TTP.
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MQF^6Z?#F0E,7";:M-;H8UED+@MO7&TL0;TDQI<L(D3'5,,)DL\VCNF)FS09
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M&(SF2Y56$2'FV5Y2J=)RE6$N*2K.%8SC.,XQV9QG'9[>>-;>\R(D,%UL$1F
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MBR%9^PEES.?9G[">;)BX0 =LZ&-O7)9'6/\ /K1/6>[Y/YEW'>#^D9.[&_\
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MNR7=:UJ"4(3;9BE*4HX2E*0R25$D   DG8*]]O!M^#6FSI8_:NV!N6IC?BY
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M9EIPB0S$BQHN9DQ3TGR:,PQXSQ3+:4P5*. 22$C"023@9)P,[ADDX&S))J0
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M*D(E+QA<E+T1:7U8PIW"L^O@K65:Y6HK&Y142H8W=]G.SQU 2D)U0E(3M[T
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M)XGM-,#@.P4^"W7'VCUCXGA?BN,GB>TTP. [!3X+=<?:/6/B>%^*XR>)[33
MX#L%/@MUQ]H]8^)X7XKC)XGM-,#@.P4^"W7'VCUCXGA?BN,GB>TTP. [!3X+
M=<?:/6/B>%^*XR>)[33 X#L%/@MUQ]H]8^)X7XKC)XGM-,#@.P4^"W7'VCUC
MXGA?BN,GB>TTP. [!3X+=<?:/6/B>%^*XR>)[33 X#L%/@MUQ]H]8^)X7XKC
M)XGM-,#@.P4^"W7'VCUCXGA?BN,GB>TTP. [!3X+=<?:/6/B>%^*XR>)[33
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M2JM7I$F3(=6](D2'A,1QY]]YQ2G'7G7%*<==<4I;BU*6M659SG.J6 '7
M\X  ,  %6  -@ ZA7BC2YEJ/I/I&PPTVPPQ?KLRRRRA+;3+3<Z0AMIIM 2AM
MMM"0A"$)"4) 2D  "LOQ7-TXI3BE.*5LWTT=2]HZ>[1AYG,@O1R\AK%GK&7?
MI7$_2M^=A/C%8;C&8K>,=F>U#)!E"8DM2>[%E0^'TUT*A:6PLC4C7>,A709V
MKL.\]%E:H*G(KBB<'"EL+)<:!!=:=^K\EG*G=.3FZ8/.SM')SJ#=;5KC(. C
MI\#7(0U/:0 ""4M3&DB/(*2EA^-[[U>^U?946@V^H%8Y<(7\ZOQI+"OID*\U
M/I>C265=CD:9%=PIF5%>2AYAY"VW$)6G*<>3;E;IEIFOV^X1UQI<990ZRL;0
M=Z5(4,I<:<20MIQ!4AQ!"DJ4D@G]%+)>[7I%:X=YLTQJ=;IS0=CR&B<$9(6V
MX@@+:>:6%-OL.)2ZRZE3;B4K20+6Y@UM:<4IQ2G%*<4IQ2HW7?J[#^V2?^]X
M7%*DG%*<4IQ2G%*P$8 -%7T#M04($8V!5X$\8&L$B(PDDD.2>BRB5?R63&?(
M10Y62/@KGLQLJ2I<6/(\0X]':[#@YYI3"UJ#3BDJ6D$ZNNG(2YJY"2M(4K!/
M$C.%$52E"$/HE)::,AMM;;;JDIYQ+;A2I;0<U2M+:U(05@;"4@D$@5?73]US
M#NI6B;'U=L6I*U'U,:IP 8V9K%V:\5#3A\X[':!;$UM9'HL/%KUW;&XCSHZ8
MIA@J#(-3 !^(Q-BL22&ON-K,%33S+O28,C6YA_ 2L*2 5LOM@GFWF\C(R4K2
M0M!P2$U6B]&XB1%EL="NL+4Z7$UBMM2'%$-2HCQ">?BOA*M5> MM:5M.I"D@
MJW$ZEMOF-(ZW8N006(*39-RIM7S@\4#AQ,"-9C<<7)*3)]ALM.!LH@M/*=0D
MK:@45QW*&\S?&J:COZ>NA R<>OY,U7NM>J9-VNX>ARQ]8256)MA"QJ&VL0XX
M&3!L>E1&OYKD=LB1@I'[-$;3)6.IJCFR3-AAUY+52GV9N2N6VICY/1D]G74.
MW?UFE-*[1,4@KKAR;681#3[T>Z,2B\IB/5+!9(X_=-E-P!H.<N SK<.?H[E?
M9;>>S;#=KP/4H>T)E/.J 9!/L3U#?G;MZNKKK'Z\ZW#-KM&L:?9M.VJFFRAR
M76MX1R 2]-LZ3-6F2J-H^.5F3Z7 B2F]ION#(;#I!X,@=+-#\-+FM>-<0J=7
M?M!X8Z]F3V#?X=E=.[^$2H-6$;=1$I5GE6_6LS;@04 G2@42+;C^JFQBI48:
M4P55%?C2VS, I/R/<GOUX/Y2X<;@$([P]I48._=ZCU^+PURF/" !H(&T'X.F
M]CD1-8],(4H^/?IY8+,)T\[K&JR9(#,.SMRK/7"IO<-(G5LZ/0Q$L-4](#S"
MXBA4>"04P=@X^O'I%=1[PC>O,DA@>-KW8CQ$A<T4WR:"-'6"7D@P8"LDH\.&
M"*25$'( 4KEZ60BR' 3AM4<15REQ6V17"4U3MQ@XVGLS[>'?BK.UYUC =C61
MBO#->7")%D"5RF[:@A43]0D%UC-A'(@D29KEA(LG6,"M:6!),R,RZ,&'GA]8
M=?<+8+MB%",>KKZNH^/T]58>'UO5Q&K+=L\[K;8 6!444=Q<61#&NN%8=YVO
M;-,PC24C"15P0*'VVDGC!GR[#LL927 YO+,D@0<"Q%,$G'7C/FS4'%^$.KUT
MM#],UUJ38!L["DT)\JHUD,"@!@UNV8,UG-03?61D?[(QA>8ZM(H5DL.7$?&D
M9)N/'R9;#*8\(W$^;./!P[?+<LKJ<FE]3T#<6O=96&RUVZ6DD'4!+.N@[QYJ
M'1;2TS+ UV,/,M%"YH_7&10H63* 8ZH!)!A1%;B(PJ>IC;C(ZMO5M]'AK*].
M74"C=SMW'^7T(](I2:@]-L&LCLX[56IMO%3"C],EOE(L,@Q;*=F%ALQWV&XY
M,06K1]$0)*,3JR"5%;/<4IQ2G%*<4IQ2G%*<4IQ2G%*<4KYJ_"T_VT8O^]/4
M_P"'+;SV#R$_J*?_ -^SOXK K\X/FK_[IT7_ (4M7\>N]>8?/L]>9J<4IQ2G
M%*<4IQ2G%*<4IQ2G%*SM7_--7?V=$?PA'YBSOTE,^Q9'\"NLZU_1*W?9T3^,
M-U]+.POS16']FB?[^D<\>VO]*0_L6/\ P*:_2J_?1*X_9TS^&<K7@_[7/NJ_
M!SJXV]'C'H%<9*WJ\9]*:I8Y_OOZWG01MZ/&/0*Y2X?!/E])JD+#_OGW%?N,
M<Z6'])Y/EK@[AO5Y/PA5+6#\_P#KL_Q<Z*)U_P"RKY:XRX[CXODJK)GM5]U7
MX.;JN:.\_N/PC42E^W_#^ZXJ1N\JO2:BLW_ZOX^*H<ZO+\E>,W7#_NUH_:<"
M_?9;G2VG]*G]M7Z$UZ;Y(?U)J_WK,_@HM:W2&6)-'%R(L81%D0#Q.&24V?DR
M#YM<J&S.B37:PY(6Q!$AHD9^(DO$BL(E2):V)3SSC*$LZ",_)C:<7:-+E7F7
M&GV&V3;:ES1Z-'T>L:8DQ^#+A,Z4M1FWI]WO<J4Q,59ILM]<6-"0_$98;?6I
M_P"RK0VY:(SC;<5MQF9(:D%,Y:YLLN-)>:=5;E.%+,6(VVMKI332$N+=*'%K
M4@!&!"07B1<9!8E0X+DJ?"C)GDIF!PV"J1*9CMRR)%64H'06776U29SBT(C-
M]KJEIPGMQOKW/:MEHN<]^+.GMP[?.E*M]LAFXW2>F+$>DN0[9;4)6Y<9[[32
MT18#2'')3I2RAM:EZIPXC*I$F.RAQIE3KS+8>D.AB.R7'4-I=D/DA+#*%*27
M'E$);3E1(QFNU:9,&78SDD:,BA8#Q2:N**A%)1R)!9\>O"8\8Q->D2BC">S/
MBY[[[JY2<X>RM6%XSS$T5C3X>C5BC7.Z2[W<&;5"1,NTZU1+%-GO\P@KDRK-
M!8C1+4^LGY[ CQV6XJP60VDH(JY<7&79TMR/';B,*D.EJ,U)<F-,HUR VW*>
M6XY(0/I7EK47!A6L<UZ2TO\ ,!1OVH5K^!H7#GZ,[^WN^E5> ]-/U6:3_P#$
M5Y_^8R:SO(KEZ<4IQ2G%*RH0(4L12&&#0WIQ&<[AJ/'93E2E9S]4M>?8VTVG
MM6ZZO.$-HQE2LXQCFONET@V:#(N5RD(C1(R"MQQ>TD[DMMI'?..N*PAMM *U
MJ(2D$UM[#8;KI+=8=DLD-V=<9SH:88:'E6ZZLX0RPR@*<??<4EMIM*EK4$@F
MO<_I T<:T\.!**3)*G;#+($9D9QQ[$9,O 1UO"XD1Q7BHZ$M82RIW#2),K"$
M+D*RE##+'D/3+2M_2Z[F>J.B-$CMF- 8U4<^(X65Z\EY(UG''%$KU-<M,!10
MT,EQQS](^3#D\C<G&C@M29CLZXS'4S;M)YUWH:IG-ALM08RE!###* &P\6TR
M)>J'9!2 RQ']!.<G7T:G%*<4IQ2G%*<4J-UWZNP_MDG_ +WA<4J2<4IQ2G%*
M<4IGU8SG['%*I+IQ+[5V[MC9%_DT*3KG2%3A+H]11; !D)M/95J%7(?&*7DD
M/FOP%U/7(S,4H'J@(Z(D'[+(E/6E_ 2&T/BR:;J8C+#,=#H?EK4EYY32TKCL
M(4@E+*5)"@X^H$+<6A00V &@5$JQB6AZX2Y<F2N,8EL;2J-'3(:6W.F/MNX7
M*4A128\1&%ML-N(+KY47SS: A*OH-Q[,=OV.<S75TXI3BE.*4XI6AN\]M=0U
M=V980&L@MEF5 /5/+"I9.B+S9X\ Q+@CIM7:HI(2B3!V3-?-M2P6QF&I@M%?
M#7"L2J^-?D4;9U@&JD 8SGR9[?ZCX,;\5AZUNGJ++[$ A9@*W"Q)7:<P%(CF
M.G78\ *.KP0N(9MDDO>F(TL1 J;HF5-"ZH-,KFR+O:<-[#L5@K- @DJ6RILQ
MZR/,/)Y]VXUZ%<5%.*5^'&T.H6TZA#C3B%-N-N)PM#B%XRE:%H5C*5(4G.4J
M2K&<*QG.,XSC/%*Z0D0* "AH($,'A0@:!$%!PXF%&&BA0L?';B0!HT?#:9B0
M8$**TU&B0XK+4>-':;99;0VA*<*5QFFS+@J>BNR1<,XN.K R4:@RB0IF5C/:
MVJ?!@D!4R3'^JPIN.1BN8RKO)<]64JD8R-8$CK (!QX"00.PU!S@XQGJSN\N
M,>FM"+'UGWK16SZQJGJDT]&I[&SW# ?2F[]:V65<M0;!O P.2-PM:V=@P$KU
MLU3L2Q01SJJR#*1+37K"^W*A!KG.FQ'H^,Q,1#S:G([NMS>"ZRXD(=0@D)YQ
M.%*2ZVDGOB"E2=F4 '-8JI*FG$-OMZO.$I:=0K6;4L G45D)+:U $I!UDG<%
ME6 8GX/#P@],ZQ="Z7) 6+5>]K+U]3T[U56JY)]%==WCR) ^PIL]T,*"T]DA
M.(Q)-@B4X(9,W9NOD(!#-9Q$?:=57/@KB/O)5JH;YQ?,ZRAK.(SE.J@97@ A
M)64A&L" JJ8<M$EEM2<J7J)YW5!*4+U1K)*SA.<[0D$JP02D YJSD>$!TPOK
MM7T ^;K6C:2:$[<&[8N*,30I!R."B7&3KJ//R3\[.W2-0YT6ZOQ4B<PF@CF%
MKF)?REI5'07NA=.RCFN<U-7)UP"2D.8QJZFN"CX6=;JQ5?2VNE=$PKG-37UL
M#4S@*U <YU]0Z^,8U>OJK##O"1]/;G4)U>=.E@=/5"T]&VMX&V=A'#S8E("P
MT3-4%VRR&:CF&4DE)2:=%.@H1M@B.'NJFF(*8&);;F5IDV]_F(LA(2M,MPM-
MI23K)7K%*0O( &N02G!.P'.#4":QSTAA1*%1D!Q95@)*"D+4I.TDA 4 K(&T
MC&1MJ%4+PI.G;UI#I!ZB$:_V8 U3U?;<(:3"6,RQ5O%ZON_I3:*55VMF-PK'
M+\@%7*RU,B,%%@RB\."Z_!\]N#LRFTYK<MKJ'I<?G&U.Q&@\I(*OGB E*UEL
ME.TH2L$A6J2,XSBJ43FEM1G@AP-R7.:22$]XO64A/.84<!2DE((UMI .,UD9
M/A-M3MZ]+[7B:\V60UTQUB!.C.JVF,Q6$P=@W G<&*).V!4?'6)M<S6HBT*F
MBW3#_D\^>^*()'#'U1W$ICN<[KALK;#G1%3%I)5E"$HYP-K[W8X4X(3M R,D
M U/3&]4K"'"CI*8R583A:RL-E:>^VMI7E)5L)U58!P,[#[WZIZ?T\;'Z<:-?
M*W:,!.I+8\S48'9$! A5,INQ'P[A2EURZ.2R<4M%>V&_&G!JM(%CB;"BL-UD
MFJ RMI]>.S&6^W(6A2<QVPZILYUUHU@E91L(/-@A2@2#C=D[*NNOI96RA85A
M]SFDKV:B5E)*$JR005D%*< Y5L.-]:[(\)QJ=6DH?4BK76STZ+(]4[/3..V-
MF-5_,\L7(NJ]<,;^;1FQXD8TL]>$* M$\HS9EN8Q(Q6_$*2K.1W.=YXQ^<;Y
MX1ND%OO]8'4YSF/@XYX(VZN[JSG95H36RT'M1P-%_F O"-4Y<YH.[%D\UK[,
M_"Z]6MD^G;J>J'4N0WHBBUZTP@&C=V6S0\VVG&!C .[W"AMPV[A-I2H1*;,F
MU\*5F>95$Y\8>F9/C2L0VWF65.<QWXZHX9UU(*GF4O!*22I"%YU O( "B!K8
M&< C)J\R^E\NZ@4 TZIDJ4,!2T8UBC:<I!.KG9D@[-F:V5YCU>KYJ_"T_P!M
M&+_O3U/^'+;SV#R$_J*?_P!^SOXK K\X/FK_ .Z=%_X4M7\>N]>8?/L]>9J<
M4IQ2G%*<4IQ2G%*<4IQ2G%*SM7_--7?V=$?PA'YBSOTE,^Q9'\"NLZU_1*W?
M9T3^,-U]+.POS16']FB?[^D<\>VO]*0_L6/_  *:_2J_?1*X_9TS^&<K7@_[
M7/NJ_!SJXV]'C'H%<9*WJ\9]*:I8Y_OOZWG01MZ/&/0*Y2X?!/E])JD+#_OG
MW%?N,<Z6'])Y/EK@[AO5Y/PA5+6#\_\ KL_Q<Z*)U_[*OEKC+CN/B^2JLF>U
M7W5?@YNJYH[S^X_"-1*7[?\ #^ZXJ1N\JO2:BLW_ .K^/BJ'.KR_)7GYU%=,
M5LVWL#%M"V"NC8200X5F,4R2Q*\=">G.K<QY)!D->*6F2G"/ZYA7:E7:G&.S
M.=M"N#49DMK0XI6NI0*0G&" !O4#G9PKZUH1RB6S1>RFV2X,^0Z9K\GG(W1^
M;U'4,I"?GKS:M8%LY[W&",'?BC1O1YM:M2G9X6_UP7,<@DACDD?)/1GW!QB!
M)%%8*W&QJ5*BD1LN5 FL9SEN3$D/1W4J:<6G-J\,6#2"(W OEHC7:$U/M=T;
MBW"+'EL-W*RW&+=[1/;;>UDIEVRZPH=Q@2$@.Q9L5B2RI#K2%#MXW+G:X+I>
MB0;Y&=6S(CJ<87%;6IB4RN-)94I,H$M2([SC#R#E+C3BVU@I40>8ATU;>>B/
MC_3>G0(,L &K!.(#@R 48R(K[[,L6T<9$ X+9J4S+C193I$FF40F2HL:1,DO
MO,-+3IXFC>B<.8S<%6V5<9\+2&]Z46N;?)\Z_P JR7G2&/(AW9VP/WJ;.=L4
M1^'+EPV;;:50[=#ARY42%$CQY#K:[SOS05O6TXP+?=F&78,2!(:B,6R&W+C0
MG$.1DS4Q7F4S'4.MMNJ?DAU]UUMMQUQ:T)4($[TCW1GMRJRU?.,?8R6_C'XY
MU@NC)('-N[? C^76K/+=80,]R+OL&3^DOQFMIPPIX%6J\$D.-/2 P02*?>9[
MWB77AT%B(ZXUWTH7XI:V5*;[Z4J[N<=Y.,]N,8*E!:UK&0%NK4 =X"LD9\.V
MO-6D,YNZ7J[W-I"VVKC=9TYIMS5YQ#<N2](0AS5*DZZ4N!*M513K X)&#79Y
M-:6G%*<4KMP(3Y*=$'Q?%>4S7T1V/'OM1FO&+S[7'WUMLM-I3A2W''%I0A"5
M*5G&,9Y@7.YPK/!D7&X/ICQ8R"MQQ6TD[DMMH'?..N*PAMM *UK(2D$FMM8K
M%=-)+K$LMFB.3;A-<#;++>  -ZW7G%$(9CLH!<??=4EIIM*EK4$@FO;#I7Z:
MJ=K"MP=@7@H"3(*-QG6S!"?"CCG<2$8=C,0Y<EUMC$179E;"4N>,F*1Y0O'8
MEMMCR5IEI?<=,I^LI#D>UQ5JZ!;MY3O'290&0N4M.03\!E!YIH[5N._HQR8<
MF=FY,[1L<8F7^>TWW7O2@E*%9PL08"G,*:M[*@"!WKDQQ(D2 -5EB/O9Z15H
MJ1KDP(="$QT&091*EC"<&;#B>*"NNK3(D17G&6,MLY2ZO#BTY2UG"\XPCLSS
MCE-N)("D*23N!!![#7TY+K2P5(<;6E/PE)6E03@9.2"0-FW;U;:D RVU4U)\
MC#V4 6EX;4]F*-,#YTC#2,IPMW+,60ZYAM&5)PI>4]U.5)QG.,YQVRIIQ(RI
M"DC=D@C:=PJ$/,N'5;>:6K&=5#B%' WG"23CPU^)%QJ,2<H7*M-=C$T/(CJ'
M/FAK,Y+[G=PVRJ(Y)3(PZYE:.XWEOOK[R>[C/>QV@TZ1K!"B,9S@XQXZ%]E*
MM0O-!>0-0N("LG<-4G.3D8&,G-=DK9:Z"4R@V>#!UR$K7'05)PAZGT-Y3A:F
M4RWV<N)1E:<+RC"L)RI.%=F58[82VXO)2A2@-A(&?14K=:;QSCC;>=HUUI3D
M#>1K$9QD=M<CE@!,BTFW30IH*M+:D%W"$1 Q:7G,--*3/4]B*I+KN<-MJP[G
M"W,X0G.59QCCFUE6J$G6V][C;LW[.(WD;\;:DN-A <+B V<865I"#DX&%9P<
MG8-NTT%6 "<0\Z$-"3#4924R'!9&)/;CJ4G*DI>7%>=2TI24J4E*\IRI*59Q
MC.,9S@IM:,:R2DG<",$]6[?OV>.B'&W 2VXAP#82A:5 '@=4G'EKIC[C4BTI
M$$5:*Z3FN)6IN&/-#9DI:6TY6XI$>/)<=4E",96M6$9PE.,J5G&,9SR2TZD9
M4A0'$@@52A]EPZJ'FEJVG50XA1P-YP"3LZZC8NX5(7/L@\G:*\.GHLDOOPIQ
MH=$EH\;%@+:[T9^2V\GQB%H6WVHQWTJ2I/;C.,Y!IU0REM9'$).**?80HH6\
MTA0QE*G$)4,C(R"H':"#4O*V( "2PHV<$!TRLN8C**DH8_$C+7<R[AG,MYG#
MN6L.M^,PCO91XQ'>[.\GMA+:UYU4*5C?@9QOX>(]E5+=;;QSCB&\YQKK2G.,
M9QK$9QD9QNR.-?W%@ J%>?4FA.0F,95DQ@C$R+[N'LQLJ\X8>\D[N)&,L95X
MWLP]C+7;XS'=XYM>MJ:IUOJ<;>.[Q$'' YISC>ISG.(YO?SFNG4QG&=;.KOV
M;]^S?7Y$V.OGO'^8SH<SY+XKRKS42AD/)O'>,\3X_P D>>\3XWQ+OBO&=WQG
MBG.YV]Q784VM&-9"DYW9&,^+M':.-0AUIS/-N-N:N-;46E>,YQG5)QG!QG?@
M\*ZD2XU&?-0-@VFNS2+BW&VQ\0T-DS5N-)6MU"(K,E;ZEM(;<6XE+>5(2A:E
M8QA.<XDLN@9*% <2,#MW5"7V%*U$O-*620$I<05$C.1J@YR,'.S9@UC=#5;J
M0V1U6N$K!7I>L] :L>)!Q%5(P@12R;SL$\<VUZ=')784Q4=>5K,M#],$#Y,*
MU'SC#A.R*'#HJ +EB=)A,P@RRKI$R0 IQY)6EN(@$_.4?!YQYS'SU1!;0@ZJ
M-91*A:A-761=5O/)Z%;(96TTPI+3C]S=4D R7#\\YB*SG,=""A]UT%;NHA(:
M5ZY7BK!:]0K(L9!9CO25#%R'DH3AQU>3([O94K&.W/;GZW;V?J<YU))4,G._
MT5TZ@ DX'MG^NKDY15=.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7GOX2HQI^!T]
MQF-J[IUSI:9!V'0+[KLKL<Y5P0X]?=6V2#?P(*%-L;D=^),DR06%MS@DT=/8
M6VAF;*D 9)@23SK>'2^>:9<>RVM#@;2I12AU);4HA.<@!6X@@[<#(!&+,+0:
M^>.-M=^A2"XI*05MJ"T@%1&W*<]Z<X'6,@P/P2)O0D+I,JVIM'V?35@^"K.!
MMTSJ"]A[VS/M9EM)2P6^S2PL5F$,+7&Q.&C X*S..8#U9RNCW2V'V5CA]=T2
M_P!)4Z\EX<Z,HYY"D$(&Q*$A1R0A.$DD)RK6(3C::(!8$=+;"FE!O8KFEA8*
MCM4I6-RE')QMP,;<8 \VF_![^$.9V4"ZV,$:B[M1/A "W4M.Z8?-5&1=!FM+
M 5;T^1K^.HC&S<5DB.;Z=AHO**:F U%0K+K34Y1Y+L.1L#.@:BH>%<UT$1Q)
MRO5+@'/:W,<UK F05=_DG;M&-HPNAS.<$G61K],+Y9PG6#9^<E//:^" P =7
M&,[-IJ^++X)4QU%]3'4!N/<)@IK 48ZN8%O$(!/A#Z=_=+[NH=.5RWZIM2!5
MA9F5P!;K9K04U(2;9>GPX88CA%=<:-QB+%E-T#$>.RTD.%,4I)5K)YB3SKRD
M.I!3A2D(<."#@E6TY35Y4 O/.N.*+8,G7 3A7/,%IE*VU;=B5K;&002-78-H
M(EM0Z%-MK\#YN[HYN>NH2]MRE]3I?553;M-7PVJSE-TWW:^B#,"SP#?F$'*P
M7F50Q&=F&!^1#F/)C/D.&Y;**%S6^ZK,M#A#8$9+JBE1[U++;3X*2DE0P%)V
M).=XZC4IBN=SGHRD#G#TDMIUAC74ZXXPK6!P,**%9R,>2N[U ]&6YAG@U^C3
M0V@]/C+#L[I\OG27LBR:N;N]1J<><9U=.AV_:#.;H=)8KJR1BW*+OS##4LEY
MP(DY)2.V12M7C(9EM&?,>?=(;D-RVDNZBE$!T%#9U  <!.,# P !LJ78[B8<
M9IEL*6PN,LMZR4YYI25+&L3JY)!R=N22=M7'U>:MW]UQ^#@W;0;KTU,:KZAS
MPYZ?K74[FX*1=90F[TZQ##5"M S:09VNU@40D2(.9+:ES(&83"I Z?)6Q+>;
M<M1'68<]AQ$@N,)4.<<YI:,H4DI<26SK*(P<;CG81NJY(;=E0G4*9YMY224(
MYQ*BE:%!3:@XG !R <[,;CUU@^I3I!V3<>@_IMZ$=1:^&AJ+8"73YK3J#GL'
M*S#;U?I*D.!+-LTJ)\O*MRK-;"Y>MQP\)ZOH+D9<\P0.NR6W,8(9JCRFT39$
MUU94M(?<8!"CSCR]9+85@=ZD!1)UL; !X*I>CK5$9B-I"4*YEMXY'>,IP7-7
M)[Y1U=48R=I/AJV_!ZZ%VKTMPNI#0UJK+473 +J%N^P.F:ZH.!"<FRZQV[-D
M7DA6C,2,6G6AD]KVVSC(><7ML*!(/QIT"2.=G1HSKC-F<\U)+#R59=4PVB0G
M5("76@&PI.P)U5H"2 G8D@C V5=B-.,!YI0^=AY:V%9!);=/.%)VE64+4H95
M@D8WUZ*\P:RZ\YNJJN:4+;-C2M@ZWC6PZFK"F4%'HE??6D>B:55'B=\H(G2>
MQIU<A>$X>PUC+N<I0E6595];T(8TK<LRU632F39H?3GPJ(TV5)+_ #;&N]D+
M3M6DMI(Q](*\[\J<SD^CZ2M(THT#AZ2W(VJ*I%P?<;2M,4ORPU&PIM1U6UAU
M8.<9=-:U>A'2Y[D8/Q=3OYN<[#HO*'\?YOVE7\Y7S?NER-_Y([;]N9_F:>A'
M2Y[D8/Q=3OYN<=%Y0_C_ #?M*OYRG=+D;_R1VW[<S_,T]".ESW(P?BZG?S<X
MZ+RA_'^;]I5_.4[I<C?^2.V_;F?YFGH1TN>Y&#\74[^;G'1>4/X_S?M*OYRG
M=+D;_P D=M^W,_S-/0CI<]R,'XNIW\W..B\H?Q_F_:5?SE.Z7(W_ )([;]N9
M_F:>A'2Y[D8/Q=3OYN<=%Y0_C_-^TJ_G*=TN1O\ R1VW[<S_ #-/0CI<]R,'
MXNIW\W..B\H?Q_F_:5?SE.Z7(W_DCMOVYG^9IZ$=+GN1@_%U._FYQT7E#^/\
MW[2K^<IW2Y&_\D=M^W,_S-/0CI<]R,'XNIW\W..B\H?Q_F_:5?SE.Z7(W_DC
MMOVYG^9IZ$=+GN1@_%U._FYQT7E#^/\ -^TJ_G*=TN1O_)';?MS/\S7<'T?I
MC5/@IBZ8AQ92ID;$:4D=3<JC/Y>1AE].,USLRIESNN8Q]?*<<M/1>4$,O%>G
MDQ:.:<UD%E6%IU#K)/?G8H9!\=7XMPY'ERHR6N2:W-.*?92VX'F<MK4XD(6,
M,@Y0HA0P0=E>A5FZ;!UP(K+6&YE",]S&,+D/5>BJ7G&,=GUZYSSX%J2,#Y?7
M7L8H23DC._Q;?/YZCGT(%0^V.;\E:)_-OD\ZOCYSZZ<VCZD4^@_J'VQS?DK1
M/YM\<ZOCYSZZ<VCZD5_/H/J=]L,SY*4/^;?)YYSZH]JO73FT?4BGT'U.^V&9
M\E*'_-OCGG/JCVJ]=1S37U">RH0'Z1:>Y>KM'R?E83'&4]25>BU&SE67FSRE
M=J55W+:>[W,8QE"$J5VY[^5=B>ZYU>,ZQR2<[5=6,=?AJ.:;R1J)QL(&!LSG
M/HJ;?0>TW[8)?R3H7\V^.><^J/:KUU/--?4)[*?0>TW[8)?R3H7\V^.><^J/
M:KUTYIKZA/93Z#VF_;!+^2="_FWQSJ\YR<\<G/IIS37U">RGT'M-^V"7\DZ%
M_-OCGG/JCVJ]=.::^H3V5_/H/*9^C\KY)T+^;7'/.?5'M5ZZ<TU]0GLK&&NC
MZF-ABSF#TK.4#)Z\8]$Z'CMRF*ZKL[4UO"L=O9V=N,XSCVXSC/'.K. 5'!.#
MM5ZZ@M-@$A"<@9&P;Q72J72!37ZK67LGI2<O5\,[E.*I1%8QEP=&7G'>77%+
M5V9SV=Y:E*S[59SGMSP75@G!W'B>KRT#39 .HG:!U"I!]!W3/T?E?)*A?S:X
MYYSZH]JO74\TU]0GLI]!W3/T?E?)*A?S:XYYSZH]JO73FFOJ$]E/H.Z9^C\K
MY)4+^;7'/.?5'M5ZZ<TU]0GLJBMF^"NZ<MN&X5AO8D-9"H^)B!&E&]=ZV)K1
M"2ZX^F+CRJKKQEA+SSKF&\XRGO.+SV>O/;=;FRF1AI]UL9UL(6M/?<=AW^'?
MC9FK+L**\<NQV7-FKW[:%;,Y(RH'8>'';5@V+P?NH+=J<-I&TL +#K&NH%-@
MJ8:U?JPE6Q"0<=<4-@>&EU%Z#%\UQG'(\#Q+*/)65J0SW$JRG-3=PFM/*D-2
M7VWU:VLZAYQ#BM<Y5E25 G6.T\:LOVJWR8J(<B'%?BHU"B.\PTXR@H&JC5;6
MDI3J D)QC5!(%0:D] &G])K$T/7$8!4ZG>)EL59*_7]9:P$!R[DJHO#9CI,;
M!J;,,@N8,;0.D*ELN]^&A+&>U"<)Q4]<)LE8>?DOO.MA(;<<><6M "M8!*BK
M( 5E6 1MV[<U3&M5N@MKCQ(,2,P^5EYEB.TTTX5(""5H0D)42@!)*@<I !V;
M*[&J/!A=/&D+AF]ZKKU.H=HS"E#,F:IJ+4@$CD9-<8=E#_*QU.8>\CD.1HSC
MT?O^*<6PRI2<Y;1E-4BZW&4V&I$V4^V%!>H[(=6G6&Y0"EXR,G!VXR<==6XE
MBL\![GX5L@17M4HYR/$89<*%$%2"MM"5%)*02G."0"1LKJ6WP6735=MC2-L6
M*I44GL"69A6&5;)NG-0R3\@X/7'7"+/%GJ:J:Z0BJB15,2UO9>:RPUE"\>+1
MG%2+O<VV>CHG2TLA!0&DR'0V$'.LG4U\:IR<CKR<YR:I=L%E>DF8[:[>Y*+B
M7525PV%/EQ&KJKYPMZVNG5&JK.1@8W"I=NGP=>D^H-ROR-OCJQL"75XLJ&#F
M6[56J;!*&1IRV')K$%\G4)#D5J6[%C.2&V5)0\MAI2TYRA.<6XURG1-819<B
M.%D%89><;"BD$)*@E6#@$@9&P'95V99[7<"VJ? AS%-!0;5*C,OE 405A!<0
MHI"BD$@$9('"LC-Z =1E-.1]"%&0!'4L5B%&BT&;J_5DFI1F!D]!4:TP >J*
MQK2(!)IJ=$2B/C$>6VA]KNN)PKE(N$Q,@RTR7TR25$OAYP/$J!2HEP*"B2DE
M).=HV;JK5:K<N&+>N%%7!2$)3$5':,9(;4%H 9*2C"5C62,;#M&W;7%ICP?F
MH^G^!81>I$ Z$/M#C#QV'5-8ZM!1RC\9EZ/'>GM#JDPB4ZPQ(>99<>PM3;;B
MT)[$JSC,R;A-EJ2J3)??4@$(+SKCA0"02$E2N]R0"<8SC;2':K;;TN(@P8L-
M+I!=$:.TP'" 0DK#:4A6$DCO@3@GJJ"ZS\%GTV:>N\+8>M*M2*1;1R)C, Y5
M]/:B"$X;!".Y$FL1IH^FL/L-2HCKL:0VVM*'F'%M+PI"E8S=?N]RDM%F1.E/
M-D@J0[(=6@D'()2I1R0=HSG!VBL>+8+-">3(B6NWQGT!02]'AL,NI"AJJ 6A
M 4 I)*3@C(.W940->"_Z;=R7^\[)V#4:-:+K(NSS4ZRG=0:E+FB&0PP+#'.2
MR,^GOR7<PX<:+$BHRYW(\>,RTTE*48QR6KO<H[266)TMID).JTB0ZE"=92BK
M"0K "E$DXQDDD[342+!99<A<J5:[?(DK4DK?>AL.O+U$(0@J<6V5$I0E*4DD
MX2E(&P"KGW/X/G3W4%!K<#<$<!L-NI9GJKZKAJ[5=A6(451"046.43J,E4-1
M' V!B:IC*,R<0XV'N_XEONV8UQFQ"LQ93\<N8YSF77&RO5UM76U5=]JZRL9S
MC)QC-9$VTVVXAL3X,28&=<M"5':?YHN:NOJ<XE6KKZB=;5QK:J<DZHQS0^@#
M44/3+W3^VR SJ!YEV.K7BM7:LS3L,/&E6-QK%>S4?-F$+/J6:6GR?LR44J=V
M>49RYR#<)ID],Z2_TK.1(YYSGLZNIGG H*SJ=YO^#LW;*D6JW"$;<(,7H!&#
M#Z.UT;!<+I',ZG-X+I+F-7X>59)KHZ3\'CIOIX<L3FG8U?UZJV('-V+T1U=J
MRO\ GC ?SAYI\Y>;*C'\L\VY*DO(?']_R7R^7XGN^/<[U4FXS9FITJ5(D<WK
M:G//..:FMC6U<JV:VJG.-^J,[ABF%:+9;N<Z!!B0^>U.=Z+':8YWF];4#G-H
M3KZFNO5SG&NK&,G,-IG@L>FO7NQ(.U:55:/5[X,(SR@^T =/:B%'(4XFQ+BD
M9,4G#IK4N._.BSYL:4ZTZE;[$J0VYE2'G,*N.W>Y/,F.].ENLJ 2II<AU3:D
MI(*04E1! (! .P$ ]0JRQ8++&D)EQ[7;V)*%*6E]F&PV\E2PI*U)=0@*!4%*
M"B",A1!V$UNM!UQ8ARUNP]EFF'7,8PXZBKT3#B\8]G>5Z.=N<^K'KSG.?U>:
MVMN!C=[;O545V=4KGBC',KVD?>0G Y2FU5VD(2K&"T#/K4W74KQV=G>QV9QV
MYQC&?5G/*D?"'E]!J%_!/D](JR&*O;&T92]LL](5E6<X6H#3&\X3V8QA/=:K
MZ4YQC.,Y[<X[?7V>S&.4U./"1V?*#7-Z-V?WAG/B2H?,/%,'B?-ZJ>C=G]X9
MSXDJ'S#Q3!XGS>JGHW9_>&<^)*A\P\4P>)\WJIZ-V?WAG/B2H?,/%,'B?-ZJ
M>C=G]X9SXDJ'S#Q3!XGS>JGHW9_>&<^)*A\P\4P>)\WJIZ-V?WAG/B2H?,/%
M,'B?-ZJ>C=G]X9SXDJ'S#Q3!XGS>JGHW9_>&<^)*A\P\4P>)\WJIZ-V?WAG/
MB2H?,/%,'B?-ZJ>C=G]X9SXDJ'S#Q3!XGS>JL82H,XREI)BVR2J8ZE*822JM
M&G)94O"<+4UB57'<-J7A*<*RC"<JPE.,]O9CD@D;B1XB1Z*@I!WG.-V0DX\U
M?T=0IX=+J1%NE"TOY1EY(ZK4:"E[+>%81EW$:N-8<RC"E81E?;W<*5C'9VYX
M))WDGQDGTT"<;CCQ!(^2LEZ-V?WAG/B2H?,/(J<'B?-ZJ>C=G]X9SXDJ'S#Q
M3!XGS>JGHW9_>&<^)*A\P\4P>)\WJIZ-V?WAG/B2H?,/%,'B?-ZJ>C=G]X9S
MXDJ'S#Q3!XGS>JGHW9_>&<^)*A\P\4P>)\WJIZ-V?WAG/B2H?,/%,'B?-ZJ>
MC=G]X9SXDJ'S#Q3!XGS>JM"NK3_=2C_M4$?OTMS[QR;?J><_WE)_@8M>2N7#
M]63'^XX7\:GUK%SZ!7QVG%*<4IQ2G%*<4IQ2G%*<4IQ2N^+SG!,=G'JSB?#S
MC/ZN)#><<M/_ * ]^U.?@*K*@[)L/[*C_P ,BO0.R[ZMP<P9@11M<<8'DY\-
MA3\0DIU;4:6ZPVIU399M"G,H;QE>4(0G*LYRE*<=B<?!8>C,"1'CO./2PIUE
MEQ00MD)"G&TJ5JA4<D#*M@)) WDFO6]QT[NT2=+BMQK<I$>2^RA3C4DK*6G5
MH25:LM(*BE(UB D9R0 -E0:5U07YCM[@BHY[,?GH)C/UL9^L=3]GFS;T,M:Q
MDR)_D=C^'C%/"M0]RE7QO.(EI.,[V)GAX3APJ,S.KK8\?M[@2E9[/^./.9_!
M84\S4:!VA6^3<NH['HO6K5_8?EK7N\JND#8R(5F/CCS>O_S"HU*ZTMHL=O=
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M=G]SGEY&X^/Y!6KE?3>7_FJ!$O:O[O\ %CF6CZ7]S\E:*5N5XCZ$U!"WL_\
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MM$J7)@M.0X3345MMI$E,52&FDMN1H[3:D$:V>83T=A( B.)E7*0\B%6M2U2
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MLLK8)<4VL*"M=Q:UD*WC76HJ\6W9U5+=B=*^HMIAM"URYCS9*N].-[HNR==
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M?XDM>>O_ %:I4KI-U8OZO25Y5^N):X5^'8^>/=)I!]?;M]TI_P#/5'N*T/\
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M\#YO73TM/^["\_&&M/RA\8'$>?U4R>!\WKIZ6G_=A>?C#6GY0^,#B//ZJ9/
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M!!((((."#L((W@CJ(IOW5W.12G%*<4IQ2G%*<4IQ2G%*\P/".TBX7C7YA&N
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MLZT22Y"1JM@7YV;!YG1UO^;<SVER4U=!:[FES55TP-IF$ZRL&,IU36KJ_!&
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M/=?K=,_>[G\FGH3;_M:-?%\G\7QW2M_[,C?;D?RJ=Q[K];IG[W<_DT]";?\
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M-E"R)K)XGM--4<!V#V]L;ZN)NJZ6<*O@_1'7;1=B<D;YODU8#$E2)N1#)[+
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M6P =V:9;D06F3Q/:::HX#L'MY/+NK.@QW3!9HEHGUVIZF.Q*5=YFMK4\)HP
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MS:D!*898RPCR@0>FL8F#LN8(1;=7*\_F>G+HTWR;9LE4W<6F/6T\JW2_1>R
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M>IA)X,(+T:B6>V5_7X6]PM9E"%ALYC6>TKV4E:H&7<G9C@.\3#@8!&+PQ)6
MJ!G<.OV^3:?!OWU4[G2%TGS54ZH2]R]1XTO-'4(3 8+4VP56P1ES ,O18FP;
M/1.T\&S6">W"@^<T'/;'B5Z'LFZ!A<.%Z85ZCU.K5Q4Y.<X&\GKV]?F\&ZK8
M@4;I'IX3<B1^X+"1:V!?'*39)(FJ0[7+JI31VV[YOHW7CD2MZXGRS5'JEDVP
M<9V+8=EMG:W(I)B$*LMF;C%ES2"HX;.K=XQC..)V>:LO6];=*^D)A2RAMIW%
M%RV(-WW3(YH+7TV&\G+ 2LFDM/[)FU6OTO7D@A,.5#86LZWD  KP!ROBB-BM
MTL)77*@RTT"5))WD#J]!P..T>78-M=LQTU=%4\9KL36;* U<]&U6$LU FU>9
M5 EL]"H%UTS; -^8G6D&3+KDQB^LM<A0\THVMJ*.\XA($!'E4UME49()SQ.?
M'M'5XSNJNX_0OTRDH]< L[TV*]*(/V 9'@,&Z^P<R:(54U9'Q=E3Z+XLXD>$
MU\N,(16[E+8=#5($%K\:4+?M%X;V J<G:?!\H.>WT\*V*.ZXT_KT)T^!S>\3
M0FD:NN@^-& &"%5, -I;-L=CA$*F;V>^Y7I*G;&S=V)\NG.M20 1G8=FAD(4
M%V]#]>2P2HV[?;9UX^7'5X,U7Y3IIZ>MN!E[=B;T*9J=GO8O9]4N F;JX;YC
MNQ6ZYN0*<U<IM*3:"1-B=87Z<  70T4;K]3G#:B)##ID7,J4IDCLQXQO]B/'
MOVUTVNC[I>JES?L@+8RZHD=YF#D0[;>L"NOJ] UK%A45%7?AV:DG*K4C[=:N
MM3H.792H-T77_%LA'F2$\Z4=4R=F_9DCCMVY\V<UCZ]TQ],FDZEN36I'?%C*
M$M]U,GJ$FFPV6K6:WAW&=3R1-D@4X#$ 2IB#1.@T.$3*AY@LJVN/2!OD,",B
M-EIY3.[  QMV9\^WVS6(K_2STK;TS4[;KW<5S;B%I\,^TR"=#5-C:[H*ZSMN
MF+8H44I@F7<1]G+[+L3QVTAH\VNF*KL8O!'R&_&U\B$4R1L^7R8W[-P\.S!V
M;*D^U>FGIE+@*&S8MXRZ]7*33ZCTV F8QO791Q\U5P%[U=6(+4TA62YL==8D
MO;[TVQQ*Y+$+EF0=*E'(T477Y#$Q3).?&3[>+'IK!-=!W3Z-L(:N2]W[)R2'
M7 )9'A1:R5=B1;"!C8=MVI'J4PTNLQ9=B:+$G=@,RJPR2G%8=3N-O?<8B/GP
M!T:ID[3@;1CQ 8'JV\?+6VFQQ&E-L4>K5G9&R*Q9:8B="*%6IEHJ,41LK ]H
ME3TQK!B)Y/!D#E6\C$GK8K^!:&;D($P8ZV6VG1;ZFT'.ZJ?UYTMZ=T,=FSOA
MKLJ[0-I%@/$R]XL6NV[<U/L==K5,M^Y3Q=%:$EGG"DVLKL,I$Y;>O8]]M-Q/
M+ KG$A30%3?U>+9YO#O\>[;7]G]$G3#!$:_'5]437RJ!5:V*K1ZO2JDS8G(M
M;M.L]BUVQR#AX.8DS"0YG0[,05.SG,&'5YM]:AQ6V9DA^$IK'Q[]A\.<^D[J
MIU?@]NG3%2>E3-[7E=5%9MP,L=7<Z*R/CE;!6V-63Q1&QX!8D(BBQ\.OUR/6
M2Q:6@>]5P(J+Y$N?<V+@H3X /;(V;O\ J>-;$O:1U)BCZUU6K<4S%;UGL@+/
M)C9IW7I$I=-G#=E5C:@]NT$2H*66'W21>&(SCC-<D@BTL9<C8]<=R:6"$Q*F
MWAOX;-FW./!Q\7CJIML:(Z;BQ2T;2N6\R0<7$N,[;ZS0[.N'8%>/UEM(2RPE
M7=%&)6$ZF8*$S*B_0#MG,*R %J" :^UFNI<AJ9)V<=GCX>#8?%X<Y-=@/T0]
M-<"QB9%5OJH;HP\&K@JHM/:KL("-(H>J96I[)2XE3/U$R.P3+:U\S#[HA<%Z
MQ1T5P810\.4^7424SU^OQ]1V;>&*ZE'Z3>G76M'VT-=Z@#YV+M^B;-UY/N%L
MOE#FSJ\.+:VI=4V3*JLI(F.-9)0J_JVLV@]$EQB D,1$S2&1 X.ZX/95.3U#
MK!V#P[/3L_Z5BB_1YTMW=IBUP-T$! (J2"D; U6K50 (2SD[E<MA[8@X-MQ@
M49YB?=(6Y;#6XXY;S")VM2L8,/&HDMC#4%49(ZMO$YR/%XL>3;78L.@^E[9=
M4I<9&^2**OKW6*M1BB\8CK^4@LO5E;OXMZT +&>IQ#.;E5R!<C>;G)H$J-&+
M6"E4F5:X,@ "P***9/#P]N/-U#P$\:P3?05T[18 M@AOC8+,*8/D7^5$.VVH
MBBANH*O6Q=EDY!AXA7X5D<J,=6VK?5Y62[[S(NF'RXJ:^DO(BF1BIR>H>#S
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MVYZCY.K%5Z[TQ]+>Y059!B]G^?P%;T\&TA6X, O29Z_1[6X/>73_ !K(-<(
M),J9.8-;?/1<F!^%UV7?:91Y(YC+XAV,14R?.3VX\Q]%0HST7],4-]<,COZ[
MQEE=H>E+V&[M4992$2<C7?;P\)D]Z/3#=<&, G]G67,F62B02  Y:SQ#$DW'
MKUCKZF3Y@/"1P]&[AXZL#/2OT^PM%#M+?#80BUD&=@;6,6F1:]?/GYPF35\4
MP2].)$@\J(*J":I."!!,J"Q#ADP\$97#LFR4TU9*S9%!D'P[O/G=X^JHY'Z+
M=%S#5:-KZA[26/ XI&,")K-:<?+(&:_M>LKIGR&>S2,3FY=&V3J\?<K$8B/)
MFN6&X[#:LKV8ECA0@BF3P\W'/9D<,;AC=6.B=%_1Z407ATW9$$6W0ZL\2.XK
M1/64@0!I&P-=6O5$=%FRY698WT9,:Q!1:HP[.?9E)!ZX"SX)* 19F%YJF3GP
M^+PY]/JJ(/=*G2?!:V,:([^O!.+HH-1+#L,W)34288#YNTV0##Y5IEP]>+!7
M8M<=?3Q1J]@\9+G[T$31H5ZCF@TRI17U,^ #/CV^':3NZB*X373[T8^0W&'\
M/5BAV Y;J2FQ'!3=8D6F1>.ILSINP:S:!-B:!F8.(V*RZY@7+7D&CLC<429<
MK>;!HKHEN#D*J<D[",X'8!GAC=GQUNK2.H;IY"!*G5 ^W0U@@YB 85?*1H"<
MB8X8]'K$RHPYI2L5^!40<*"&ONMA#;L[S4B%Z::[BFE,%[S7$FE0<^W]?7G/
MGX5GT=4^A5QXTM6P&(\63"-D%2)H"UCV!\0!52]ZEN''9P*.BO*G4@ 9N-;9
M.J'/W"K#95@J;9H2WF7Q0@C?Z1['R;JD<S?&J142AS#MI56$;*4>S3XMN V:
MHE9T:KBYINPDR(6S!A1>M PPJ Y-('[/!#A8[,L1WY^%G0B2"HQGV\GRU94$
MX%)RI<(:8%D)D!@?)G1()")+E0HQ9ER0*D2X\=YQV,P2CM.OCW7D(;F,MN.Q
ME.(0I6%*RG%*<4IQ2G%*<4IQ2G%*Z[\2))[N9,:/(RG&<)R^RV[W<*RG*L)\
M8E79A64ISG&.S&<I3G/KQCL4JC^IBI:SO&EK77=PW"?0M=OSZ43.VH6>C5@B
M-?KM\K%C LPSLF+,R/D%+&)$"&W(+*##BI_DX*5!-.P)L=4C.=GKWUJ/0.EO
MH]-%]9[ UQMPLMN1N'9^T*X+!WZL#@UZLEZONO-T2Z1)JK02%B37-?/:WU\F
MGU,5 &D -2%QR!AXH;)/VA]3)VCB![#QYV\<GC77LW39TA7^Z;9MUPZAC1TE
M8"^QZ\9&'-IT5@;KLT7&;%U3<8=.9F@F9E>) 7]NYK;;_EDM0BQU37D%]2S(
M2<@PIMX>$>ORXV]56 ]J[IKJ8;6.L"6_<H)TC9&P)V/26X:SLM@MEF.@;/9M
MAUN]0K16C8QCLH\\W"FSF1-?M(:HO.Q(]CB/FYDHJID[_7Y/(#N\51K7?2OT
MHBDU-6=S9VHN%,HXRJ/VFYZD+Y=5JJKZ8)#Z^%]&:H$2M*A&E-,7.RQ1W80E
MJK <^\_'AD9BIZI).WRD^<=?5DGRFH-3NB[H]=JUGU8%WW;;D]"UV,ESSDG9
M-!LEHIU%#NPZ?"/Q;$BJO,!H+)S2U-:ERI650<G-'5V(N.Q! &!<Q4$GACCC
M9U=8_J&^IKK?6_3K5]H;LL\7;L(T)J&CD$YF!!)+8;7%&VO<-U[:LNSR5NK8
ML92AEFL+UMM0RGMB%H+TW5=4@2X3GF^XD7I:FW=C>>&_&SS>D[:J,5H7H< T
M4=(7U)WF% >TU$NC!VP70,%LMCI)JEM.4RY^0SZ2+*E35(TY!L-*KM?%CDR*
MUKV]&(IRK^>"5/+BE3D[\#?Y ?0.K;\E32-T9],:03@X5U&[.(,V<40M$EX3
M>-<6:W6E!<]K1ARYPGXFOBME??5M36=0MKY&N-QXT_933S11$N$[FOI5&T=6
M.K./8;1X/#OVUSUCI*Z0(.89-_J#GWF'7+91+E/59]GZK/1)5@KFX=JVVKYL
MLU%<;E3H) SLR[ZH:&D9RF9U1816(_;8H<HPZJ<D=6#C&XC8!YL;#_57\UMT
MV:GI&Q=F5E[?,%P:5UN6T!5(,.;48UXKY;:54UK3[4[+NKE<9:E;;,0]"4R=
M%J4J78'69HJ2>AU4!7IPNM051G@.O)'5L\' 9QPQ6#N?33T=3+83UX3V/MRN
M62OV.?@ZS71,\($-&R-<W1M [KE%@&:N33K*>-ZLZDK"E[7H(I/N3NKP-4AC
MQB1P&PNE53DC&P>#S#/_ /;[9%7AL30'3/MZ^0]DE-O.L'BU@,61_-:V+3(T
M&U5RGUJGU:WT2:CR"6^6U\&A4J0]98&)3DRORKCL3."PAFS/LQ51U;ANQN\H
M.>/I%5*OHZZ6'JZ<'%.IBS$JC8JFJP66'+V#I-D*1IA5E-=#V%M<2AQ6:[4X
MQ]BNE SU7<!57TLJ-,A1(Z0E?'UI*IR=F$@$'J!SXCMZ_#X:N@+TGZ;HY:X$
MI^U[DY(O.JKGK4DR6LU#!*0"V!DC9SEMB/@*I7ISUQRBO6XZ/MY"1/F,,NW2
M4M<D;$:9"*C)[#G/BJLZM5.D&3'WK2Q.^9IFU;BUPNI[(RA=,A6.+7J96R=C
M(1*_3Q&O10 *3CZYV")@%:F.JBU3:I7A$I^O/'!EI-3E3M/5U^'>3CKSUCKZ
M\UE$]('2Z[/#[-9VY88T?4Y-E%P+1=@TL6 GNM&:A?#@7:^(0*$/2]8KF.=O
MMF;(^:BRCFP[?*BO#(YL2R(5&3C''QYX;/1XME3?9?2]TO7F'>)-H.UL=;]L
M;(JUW)[+E_!,6NLDI6CFM"8>GBI-YJ-EK\RIRPM*HE%)5F?7ROGNDR&!,]V5
M*)1R.5 3D> 'Y<^'K)J"6[0_3T",B0#'4';J 8AE:,'>!:T:T^(FC+[4\$R%
M/M4\75=126]=3(S=GB2B\>+"J>NC$%@8BR@I(L[:F;6H#X <9X[N&_JSGCUY
MKBA=+72M'@@:G2MS6BNU5R]UZTUD7&V%6[B/>MS=;INHJN/H>P]C@[K:1-P%
M#M 3@ !ZB7F#L.MY(;"A#)XV(5@L"E3E1V_)Y>&[;MXYVUVT].G3Y:A)2MQM
M_P!@LXI=<FEXS[SVE+K5JUK:JVRVSC8>6\6U<<I4X8U>;8HX5-WA)F[RK50:
MF?=L#Q*C$)BU1G'5CVW\?#P[3G,D])],F_FQN$[G+6Q,;6L?5HU'IK5#)N6.
MH\??/3^J\HG64"4LI>PR++MZW1E7/,J4%L5[K%',04SG(*\&U,D;.&WT'Y!7
M6H&E.F'3>T#VS)&\C%ML-S&6JA38=VOM3/5D&-NT2Q[U>AJ:$ H":G&:K8&_
MV<(0+DX0YP&:M:T.2_.\)+:F2?-YMGR[S59UOHBZ0M=#G7!W4%9X4T(UKZ]$
M[4;V?JN85BH#2M5GZS=23Y"I>:X*;%;Z,5O[9[$")$FVG=.TY(9R,&.54-5%
M,G=@=FWK&..XX\@JVYG3ITQ%-81=2US:[-8JV;&Y?V%U&X:U:)K&ZVU]#TG.
M&#Y4@"0:&U2GTX",JAY\+&@SF6A#H*UEYH8K:0AQ3)!SU^'P[<]7D_Z554_I
M)Z3;^$>83U'6F7&T\.%RGK76[[JH*JDU6[4F: 1%L5IKU('PS,.]59;)<L8O
M$VP&K#-A"C\XF^R]AN:J<G)V;]A&W?XCUYW5WW.G?HSD'9M@&]0**_/I9%D4
M==A7[5,&+%M(?<J-Z/ER2BU5?8S8\; OQ"&4(LKPRL=>BM3?;0N:TS%4R=V,
M^3;NQZ,=@-6)I33W2WJRW/6C7FXH,ERH"C];+@C%DUE.B0$Z@,[,KLZ?)G2*
MQ&M0=6IX.P[)K6=,#GA@L<"$"0]F3-GP2<LDJ,DY\?I]>/-LJ'4'H$Z=L>39
MB;CV%M: 0,"S1B':+AK:\LVM5.&:@;$CW2":.X8$"@\G6>N['/CTLI6W2!)8
M_!N3,!) AX"F?)PQLQM)^7'BJ1D?!OZ>*#!(Z9L'<KDB&"R!-V#!^FM6FX-.
MN-E)LVPGV*$U.Q()6]X]>Y@\,H16L6VSS2$,!$9KNO(M*4SMS@>WMUYSUYK/
MF.@'5)R+9\S;AL)L_=)M9D66VCFM:BCDF'56K_&%A1"1NN(HFIA_(M@S8$N+
M4Q@5PG !A(!AXE E6Z+:E <>WMU[?'MK.[/Z)Z1M78UKV6;V5N 86LX6*'BA
M@Y^LXK51=B3M73V#U.&E:>4D ;/'>U6/4-LL:=Y]!2;/;"P$@+.+K)2L*9\7
M9MZ^W?NK^W3H9T[?KCJRZ6$K?G)NI*K1J?7Q<(Z)'@R8F@L7"(+4?@Q:\AV3
M+(PKP='&G1LH4U)$R9 :*Q"$%#T$LID[3Q_Z]?IWUP53H<UQ3=3U[4HB[[,D
M#JW<6;G&LE@FTJTV*?*C:I>TG$%&(]DHQ6J$P@_7"XP<7 E5A>!DD6'GPELK
M&1FDJ9\ \6W'I]O'71'= ^HH)L787['?R18")#5T!)F.T9&!5<K^SJCM<6,2
MW"HD1)&9FQUDG$,VHSYRN=G#WZ]Q+-8BSQ$1*!J9]O)C?O\ )G%1(;X-K3P_
MQ.%WW:Y%"@@JK%HQ1[6<X<8J(R>=D9K613^LE#0,"4&//TEF34XH G6*!'CT
MVASJD#\;%<4UC[;^WQ[>&=M3W5/152M%QYY;7=MNAN^P:1;JA0[1M$B-MZZ>
MW91%)&LXCKBA0Y)^%&7KFI.2&7)ZWGVV";3;K34]+3"A)._CGT[NT_+5;L^#
M2T^FCF*(_L#:KHVRTZMTRR26%ZTA2R,.D52KU*C31WDVMDLU696(='I,]::F
MV%BW$C4*_P#"+'N(^(Z/DJ9Z\#SGTGKZZE4+P>VFF2%UG$K/LVQM7<I=R<H9
M83E<)#0:K^2V+-.1:RR[4\/!8S4+<.VZ\,3'?RY#!;&L[?C'2DEDLPIK'9X/
MZM_'<*BI/P9^GS(MD&2V;O-X+D+!#DQ+-FIL(<<6-US5=;12Y>#"H#$.48S!
MI%1L\J9EA.9=UK@HZ\C+;<J#+5.L?;QYZ_&1X0=N:M[<G1CK+=I@O8K-8;^'
ML!*Q4JSPC=4,!PI6OD==)#9I+ ,FFO/DXPP!)B6N9$@/S9",R-H;&4M:D%A*
M0:H!(\^SJV\>/_3A6-UST/:MUC>:]L$!9K],.5TA09S233]*E1I^-<:?V)I*
MOQ9ZX=('D/$NU'8TR46>B3XDV><KU9F9E,Q8A""34)SU#S\<]9XY[34.L'@\
M=:6(J;.R=I;L@&3-BLMH03"'J4%EABUEV9JW;CS@)8V@QL#&(5YU7#/QXS"<
M,2CEOO5J+((W$ZBQ0E,\<'&-_@]O+@5@ G@WM>1ZSZ/&=B[!5Y$?L3E?DU]F
M@") *F$29N*,JK)-RA2SLYQ5)73*N?,E"DXC+A4F#7A#P;7YFTTNP*$YVX'A
M\.[>-W5PJ\-@=(M#V'?INQI]KO@>PDBC,Z<H,_3U,N08B]+31X&,X;IIF>/%
M#CNBZQ882H,Y@DR2/WA.".85@9B#5,G&/;K^0X\6.%?BP='6K3D33HEB?9Z_
M7='49RB4>M O11L.W#9FT<R",SV2=4)ONG:O9];TJW WXLB' 19JZ-(D!T]+
M*H[BF3M\._V[1Y=E1:C=!^I==U#:]'K5EV2D#M00H J*5/!S35'!*L5CM2PE
M,A$ZY(&M@WB]GFHF +'!L0(@(BP@LX;(@+*ME%"<^08J)#_!QZB&S[64C;%W
M8T1MQ55KE3(MHJPW(C8C]RJ=\G;)K4 32( 6NVV=9*A&G.*$BHH-E9JQ*C!6
M7)L)8Q36W;!LZ\;=V-M<D;P<6DATM^2'M.T!46-L$7LBH@VC57G5R@F EDN5
MI$B*J%+T\C$9J$.??+# Q526"(=\"[%%/QW,,NR)"F3U[=F/'X_;J%8L!X.3
M746<:(6+8%^+N3#9LF)C16:#!C#W"%<UH!@F9B_0-R02LL$OIW7.RHBW'6JT
M#V+7V9E9K@BMJ775J9\GBSZ_"1XC63?\&YH)RROG6"VQH(J< ;JQ2B0C@!JA
M%*['C;# 00TRMKJSD?,&!KS9]GU5&PRMJ0F@YA0,R<E<$3))3.S! /7GKX>W
M$[ZM43TB40#5-DU41:KO%;V9MRM[L(EUYI<LH&N]:M]8OT? 9N53'1"Z_/N%
M70<( #0HO"Q).6) S UHBTB(IGR[,;>&ZN(3T:ZJ%4 9K+SOL*34HM\I6PS,
M=JUYKY*VFM<4NLTZBQCQRG#ZV8CC:P]1J+;QS-9FUV5FVTX))DS) ;SD#(J9
M\79\FZJL%>#BU #)"S8K8.Y8IH,+UA$&DG3=%(JC'=,4:#0-7WGS>6UY/#/W
M6G!AL.0++2AC\=4W$Y$L?)%F38PDIGQ=GM[8X"LP_P"#UTBJI2]=1#FR8&MB
M$2P09](18A)*++B6"S(V$ZAZSGJX7OSDB-M=4_:ZB;MM<,&KB1<C6@@>I\ -
M51JF3M\/MZ-G#!-20YT6TRS/LR[%L/81V6B3=3$ATL+U$100M5^JEHH-BL!"
M+,U8_%F1)E!LL>D/T>2R[K>?7*A2HQ6GD)061,(J9]6.K'I\]9.=T<:[DU_7
M(2%9;H%D:N]))57+C&J'WT&K7MNA;K+G)->G4:;2DO)N^O13@<,-K ZJUT7-
MG0:^ &JAUV0"4SY>KS8]%6GH[1E&Z?:2Q1:(V0=@(>8=E%SCL&782V!PL=70
M39@E!'C$D$URIA*_40KCT;,EBO !,20_*?8=E/J$Y]C\N:N/BHIQ2G%*<4IQ
M2G%*<4IQ2H)L>@C]EUA%7)%C8-AFTT&W1R=>6*04CE==7RM;#"(1Y[$G!CD*
M49J\"&68D#'E21+\Z/&=ARG6)L=2M8ZOT%Z6I]SI5S!E=@Q\TA%0;B5A9T.Y
M42[5 JFN*I2FS0KT;2_GT>3JBCV!AT/.#R"%E"0R)MXHS"&PX*ISLQY^OQGC
MY?)7!<N@?4%Y:+>>;/LUF>8NIVY2#(LU5QY1MFQ'NH<^1IS;K--S&?IJGNI_
M:D%,&?%FE5P)8?$DU(FC5392F3G/#'FQZA_TKJA_!_ZE%W.1=YEVVY9B4L@-
MF2(%KL-5-B780?:X+<8T$N._24RLAHML#SHWB\3<3GP%MMXF5/?282]%4R?;
MQ8]']58&7X-G1,I"&46?;,&&JI#:?.'P++7&().$$UY1]?@B<MC-.<PR=$/:
M\K-^9(C50,SMAPVSAEDG AB@XY3/KX>C'GW=6*N&)TCZU'Q=J0QI:VCH^V8=
M;A&&8CM43&!M5#85^V-6VZ_ <J3@YR ,FW^164@+-$LM9ETBN5NL$ LN&@ZL
M\IGY?/[>.OP.Z0M:0:-==>R3FP28'96SHVV=B/.V6.',W"S)R!G%8<PQ4Q-=
MFA:Y8[. :MYL'4G*[%67)FQ8[(VFE'ZMQ3)V>#=5;8\'OJ;R9D(Y?-OS*0U$
M.CUZ],&:/8:M('G]>5S4S\:0]8=?%;0X\/UM7,TP.7Q94GQH.RW>*P6[;I8W
M""F?%X/!O.S'A/BK^%O!Y::+';)85W#;D*;9K'B\/MPK-74Q1>P,7AF^^G8%
MJ33I2Q-@P620B-LL.Y 1QAZPHC!&9YB806IGP#9L]/KSX]V*_%H\'-T_V>.,
MB>5WVO11!&9+@1JP8KPJ,T.)UVXT@I651U562PY7B.N[4.UQ(BN-JFHI="H8
MR+/C2!92::4R?![8/I&?&3QJWB'2O0)L?4L1@W<1+&HKJ3V' \T2:S$DV^V'
M;C#OEC)W6>JK/$9>+/9F)\^S1*_+K<0_Y],-E&9*%P/(%,[]@VC'7L'@V^+L
MJ/6+HZI%MLQ*Q66_[2+LR=L#]W"*\Z0HT0)5]D#%UV'$.B'AM!A6$CAJHUU.
MO&H=O/6>)%HY@T,A-19TB(4A*9]&#54Q?!KZ;A.LR8^QMY,2V:FBGID1+74!
MR$CXC>QH(1^) &4&$*$N5BO[2M5/K(X) &5T-3<BZS%!X%#(\?BF>O9OS[=?
MR]ISR+\&]J164/,[0WQ#(,K7,CE8%JI<$@@_)/1[.0MDQ<;7C<<[9YYU,\BH
MK9(YE8Z08G+!MBE1PV12IUCX/88ZL8V<,=E63?NB#2VP;?K:XD'+<&EZGK50
MJ=-#U\N.BUR('H[5KB 6I@>>$),SE-B;K8P$M+Z\L3:X5)5^0PH28-Q":HS[
M>W#&:BPOP>VC101->9*[!?%MC\ T-RRM9<?36/-.[@*JNJ8BH-2W@R@F^;0+
MQF0\Z3;AUZB(9)-JK25RU,GRYSGKZO5Z:L0-TDZ^K5$;HM:L=W!)BV#6-G'6
M:,]3I]A'F-45JJ5RMR4QSE,+5,EB2_5LVPLV>JY=+UYL-@M<#S:4=%.B5,^
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:I3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g155225g13a00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g155225g13a00.jpg
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M 0$! 0$! 0$!_\  $0@!:0)> P$1  (1 0,1 ?_$ !X  0 " @,! 0$
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M9%%").UW0\,GE2[+:8GM0H,<CQ(S2&2-"K<R1-"A9-8D(*.0$4DL*KDO8D:
M+F19B2'19& 30[!AH1@QU)I* ZE!+$ "MH=&\S_'GE=BM-8MEIM3Y"@L0I71
MIM-Y)U_I%:YE'(CF3$1WIEOYY1+15.>^X'DQC+C5O,AWXP:3',2FF1;J)FZH
MK&YF5'1$Q+GE"2:")Y<'2>4DLB/+U J-"ME@5&6!%6274$;,K,V4 ,A6.1UC
M!&1S'1&5-M^HC P3@$&N??=2TOROY]Q,*BLE.=W;QCO_ ')JRQ=2Y9B45K?1
MN4U0"D44CE-A7JR2!WTC/>U\7)ERI+0R1$*,1$/QY?/+J+*2X;6)8[N*WT'
M 5XIG;4"-0<-&!W  R""<$.<?-)"-)1[=YM0R22LD:  @XTD.3G![#!J<]:\
M@.6\3>K(^^&#F[!=7"K=/IE*HU[Z??K1H$S&D')(*A<TK5MN!$<$:FP5F2S
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MEXY8IE63!/+<Q.X1\ ]+Z6.#@'!J4=Q%*VE&8-IU!722-BN<:U$BJ67<=2Y
MR,D9%8"H>9GCE>KB&I-9O<^9-LYHM6Z99)="Z,'YE?[&"1.=+5_G?7C52'\L
MZ :AM#"#GQM.N!J5);@3EPFI.H4O;$GL;J-&D>, (H:1!)$TL:MC#2P*YFB4
MY&\B*!D9QD9BMU [!5<G42JL4<1NPSE4E*B-V&#LK$G!QG!Q$^:>5XR57>_V
MSLD^NU %RKRGNOC]5W@HVP3"%A8&3*J+IL!H)%>L1RS7JQ%;%]@R,JXW;I-_
M;#8T$UM#VU62V3!K9( SM-9QW+ZBH"9UER6.E4C54R6<[;Y;M48[D$3M*541
MW+0+@,2VR:1@:BSL6QA1OZ"K(=0MQNB\VO%UK-*.='L59JALY7Z!7?0V=N1F
M /?DBZT.6^E2(THQ-0Q!U(=:=^T2\I]3#VVO97DA19)8XWD6)'=5:1MU120&
M<X[A1DX]?B.]7R,RQNRH795)5!L68#(7?MD[?+X>E4<,=B\P>"V#@!OR"(\
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M1NDK"TO2NI8W8M"J2&-P%#$KI=5R-@P(VQ5\NF>2 /K7.B"&/$;M/8>20K*
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MX:CPSY>RQ)HWHW0PA^*4.2C,N>B/:0MI'V5D1K9XC$'UULLFO!A6AX4.+@"
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MRMG2P.D@'!S@E0P_.K*1\B*DF1J582S60#3:W8+?:2D0'6*H$*V2QFR#GLP
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MJZ7B_538_GFG[>$,PVH/1.J3^10KZB7-OE0Y,;MY=5)$D)1YV;8@[CE;<8U
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MZ*0*PZ4A'Y([:96HOXO-V-U&-C_EI(XYZO"U5C.'1L:$]NMS%:& ZC@B>4$
MO[H09UC5E3I!7!?$@189<Y?,30O<<T:1GV2')";,6QTD@9&K!M!XDWB7T3@M
M+LTVP<\L4A:CH=;O,.=6_DE7"[KA\E7UU-7-+Z8.6ZE':BX-<KMC &Y;4F":
M'36TP(#'M16\E[&(KB1 LJCI;VTL<[MJ4-KYL2K'(K@ZE91@J1N3O6BV<O"C
M$H>X]FC1J-)*Z>6Y+(RXTLI.0P(P.U61S+5],4IBE,4JNW>O^8O&K^\2'_RM
MZSFJV]V[_P!*W[6&J)O>M_\ /7]G)5B<RU?3%*8I3%*8I3%*8I56;SXL5@@?
ME=!Y'8"W">IO_5Q^TT1IA *Q.I4IQ+-YHKWHKEIB+>6M]_;K$.>_(4E]^>\I
MM*,]6WXK*L8M[R-+^T&PBGSS(Q\8)QF2)@-ANRA=@HSFO/FX?&SF:V=K2X/>
M2$#0_P I8CT2#.YV#$]V-5#\J/('JO-N+7GE7D5R(,=E=$J=KI%4ZA12<211
M3!,I7B$8<6G5TXTLS7C@>4[$*NPE;6AU^.]*#/,HBM;WZ_"[&&>\BO.$<0FM
MGMW25HI-<=U"-0R$FA90Z,,IJ!R 0'R6->/Q=HYK"?AW'.%VG$;6[1HF26*&
MZLK@8R!-;7*.I*L%?2Z$:AE/=!K>O#W.#>:W!(FK1Q6O/56K$GJ%#!V(8)DO
MCGA 0'+?GUV>+9BRZ\F0DLE#3@B3!F-[;=W[NM.?3(2W_'?#'%#/8\9O(KN=
M1<R3PSRCG:GD4"Y21G2XW0DK.LBG(R#7F<0\'>"/&W!(^%<<\*<&O^%VH-K:
MV=S86X%BBHO_ /S98$BFX<0K:5>QDMY%&0& -0M?A5U;BJU$/#CR(LU$&,J4
MZWQGK:Y'1.3/ZVK:OL!C\M$D]4HSG]'3TR$P7+O;U_\ J#:?3Z?I!XYX1QSV
M?C7PW:\0E8!3QO@X7AG&%[#F2JA6VO'&Y5)##""?N9&<_DK?0EXM\$%KCZ&/
MI&XGP&V0ET\%>+VD\1^$7&<BWM9)EEXAP>([:YX$O+Q\ &X4 8^F_-CI_%W$
M#O,CQYM//![2T,K['RMN1T;DDC6]Z3]^13 5*.U2.[_2VQ F.F3#GT^JH36O
M5I/#X%X5QP&7P5XDM.)2$%AP3BQ7AG&4_P#IQ\S1;WC#LTD8AA&=G-=7Z</%
M/@IUM?IG^CKBOARW4A&\:>$UE\2>#Y-\>8N1;F:_X1&^_+MIWO;UL9,"@$BZ
M_-.P\M[&&U8.77VL7D7I+>WW0!6-,DP%.Z^J&2P[U()!Y6]?M^T*1(<I.OIM
M3.M;UGPW%."\6X+.;;BW#[NPFR=*W,+(L@'=H9,&*9-_?B=T_O5^W^&/&7A7
MQI9#B/A7C_"^.VF%,C\/NXYI;<L,K'=VV1=64I&_)NX890,$H 16O;E8.E1?
M(_D=.!VX,-Y]:.>]+M-DK\FH()&)I'GA_G0]M$&RJ-Q-C8QB+T9*7T;$RU1'
M 33C*W/D'T,946(VTSLC&1)(D1@^% E64[II.2IBVZAG5OVW]YV<7$2!@$>.
M5V!7)S&T8V;(QGF? XT_/:Q69JOIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE
M,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE
M,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4KSG\Y9E(1T/Q<$V'I-
M@X#8C=@Z?& ^1 7I]4Y>W00<6JBIEKJ2Y%\IUXI5T*=#=9KNA5%/"A^IK56)
MV2 ?@3*LW$)>GP\2<J[9(EN4582ULT+S<QB[!'Q&\<D8B&O5(K'&L(5(?(PW
M;('MPTAA9FDQ.)%CT*%!9<NK(QDPN$8#.DL""F\__1\%:H:\: Q"IM$WT*Z#
MV&+9K02OK?5-=%O8[J=L'W?I@KIL<%5X=[ 7NR12%A!'Q]8K@Y0R9&'P 0N+
M :ALU\3#K=L'P/9P%$$1AY41A0QQ-$68QM&A"LI=CD$EB235ED5, *@^_*&8
MOS-;B1@\@DP-8=@64A5&"    *NSF"M5,4IBE,4JNW>O^8O&K^\2'_RMZSFJ
MV]V[_P!*W[6&J)O>M_\ /7]G)5B<RU?3%*8I3%*8I3%*8I3%*J'YN<DI_3N
M= *VID@[+YA2.@="JNX4Y<-MJQ@Z4:DP')R$(5J9$2ZTC;L5>T)<3]=;5KZY
MZ?"KZ>RNEY!0<]HX9-2ZN@R+G&XP?G6'B%I#=0,)0QY2O(FEM.&"'&?B/E4
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MI"P\E+N.+4[(0#<4ZZ?H,V2XI;BGPTE^$Z[IAA<6+";4C/7'$H+P"/BL'-;
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M&UM:G-MQ(3#<:.WMQ>]K7M#+2$[6O>U*WKU*WO>][S$26))[DDG[2<FM(&
M.P 'YJI1TKDJ:AT'QL/ZZ5UNS[5Y!0F/AKA=7#@!/W7+NK*]Y(U4".G3\?T_
M2*Y[O^Y2I6M:5]<]"&;7'=+RH$_FK'4D>EMI8?7)V/K622+2\#<R5O;C9G++
MO')Z'X>E7DSSJV4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4
MQ2F*4Q2JJ^8UMK52Y*"E64U "QY/<?&Y<=V>_IE+R 7?^:VHTXCZZWM38JM
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MAN-R%OJZ^R@\M)F0$KL,8 SU'.$./1RI)V SM3SEMACSDPAPW?.YQL,9;?\
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MG:HM=P:05FCU/D)JU8SG'6 -2C/JP&V_:M>^/-]J_+.55[BMSN@@O:^!<T#
M+"4K%0Z!&KQ !1  T1%(AIA4(Y%L)B6.C1I$@+5B)R:[-<?C#8TCV5)39<V=
MU-.\Z6LZI<S,ZJX76K2,6(8 Y10Q(U.% &-1&:A!/#'$L3S1%H8U5BI(4A%
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M*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2J21/'GC1CR
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MQ2JL=[YU0K5TKQG(66G5L[-G==+U^=**AX,YZ<"A\)[C;(@>:N0RO<P9&LH
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MV.WV_#\M<R/B-^V_>OKY09ZY3?R,#W(*%.36_NX_KAMH_P"VY*1[GJCH1_\
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ML@:3D]A@Y/V?&F1\1^>OOY09ZXK?R,'W)R$N0F_NX_KF-K_["XJ?<]4A"_\
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M&J32A(TY/5)@;CN=\GN<5A.E^2?B%S2=4816JHMC% J /IP\MSKBY+H0+B5
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MIYH+ J%A"CXD%->/G@,"?4 #. *DL9&@@$,7ER<;@,'TY^6=) ^/:H,'\?\
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M;^,5N6J+,D*!&HB>B[N;Y5MZ,Q!6]7:B>";E$8:VS*X2"$R#5]:6&DGS&X.
MO*GU'<;@\O3CUW8'8[9P#9Y*YR!RMB.^N/ ^1Z\Y^P$;]^^)3P)/8MW:^.W7
MFYWG%#37JK%K<:TD^:DS)JTQR]M582<5SGEYO.V0>PSU9;B-&Y(N7]U]XIL<
MG_>N;\GB]S:W*V_(EYKH9=9"2*%5A'I'M$3+95LZ01C&];;&*>(RB5-"D)IR
MR,207U>XS8 !7&<=S5K<\6O1IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4I
MBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4JNW>O\ F+QJ
M_O$A_P#*WK.:K;W;O_2M^UAJB;WK?_/7]G)5B<RU?3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*I)Y'\4Y1;>N^-!>RT*NFB=W[86JMMFSX6GGS]=%>,GD+8QP<BO:
M]>]"AG:O7BC#7T3Z)8B$Y]=^U]-^M97]Y!;W4<-Q)&D4 DC53@([7=LK,-NY
M5W!^3&O/NK2VEFMWE@C=GE*.S+DLJV\[!3\@54C[!6\>NS8M)Y^+:@=#A\=
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MK;>6B5&VE&_N&?7:()F,86*0F8$Q (Q,@!()08RR@JP)&1E6WV.*S+& Y,B
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MA$3OCU=+7>.DV-P^+K<,S8I<D,XVQ.G$+,!?K_+6OQ>SN1B\=&J)*)U$_&(
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M%E9<B;2I\V 3VS!L$'=FGK'6 4M15![HXK&4*-#(RF!X1'S2J &6Y==+)I=
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MU>X3'S;+4L6/&AQ%D;7/F05$Q,F:VU-F06TLC96R33CR)D5EW<5>M>AP^>&
MW?.+A9K*6!0A*NS/)$=(8*X7*JV[+H.-+=ZR7<4DH@Y04LES'(2P!5557RQ7
M4I8 D;*=6^1VK1\?Q ,1!$@''O@;[.WUZ  Z$Z]4Y2Y49N'U>W=:<>YJM-A0
MW5DK)W4H'B1Y[9=J P/ ET:?GCG&)6X\90N)#;R9AE:6W F !+6D-H/,CEGF
MG3 LC%=!8O(F0K C*.&L%*"9<2(J3'EG( N)+@\GKQ&-4K* 0P4*C;E<'*D_
M$MXD"N@EVV#5/VBA=XIL.8]7EN[$R.R]6)=(CDT)41]:] &IS0M]EIQAP@]'
MU,;?B)VEA,$XN$>%A"V(KBPG($F-8LK06Q7W=N81K!WT@Z<-WKIX<2DJ&1<R
M17<8;1G2;F<SAAO]YG3@$:B <CL,A;_&RT'Y%P4-MP& @UT6?T.ME&XEY"6R
ML3C]-BU,[&8L-/OM>^X85J!&?1$E090TK >F"RL':E1YS$8>)Q1B -#(W+ME
MMI4U0/%*L<YFC)CFMY<'+$$JRLC!61NZF4MC(_,TR(-4QF1\2K+&7B$;X>.9
M,Y(!P5*L"593LU6FK J:#K=>"$2SQ\@'!B14\[)CLPY!J:/@1XDHL_$C?6/%
M>)/LN3'8[&_986\IIK^@E.>5*ZR2R2*@C5Y'=8P2PC5F)" G<A00H)W(&3O6
M^-2B(K,79452Y !<J "Q V!8C) V&:SF5U.F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2JT^21\( &5=X]TB
M[U5F9,+P@?/^82X0SHO6K>]!:_'PE?*.NMSHT,%I) R82A\57([.HYV^V$32
M 1Q$W7:JS%],4;X"EI906BA3/4S*!@EME7NYW6-6D9<43L%"Y=USD*D9 DE;
M'2JDD$8W)[ #J=@JFJKMVWN5**5FW=4O8:ZM4N-XQU+H86A=L8!DG+W=V:L$
ML$ACEX;G;XNSN6"V6'1>) G6&GZMX#Z1ZP*@?2/">U\NWD#I#&T?,-V\320%
MARXR[*#*TH*!4722$D,;;N3WK,&F0JTCJ^@6ZR!)L'6^E6]F(\$LQU %EU@X
M4#&*FOD'TTZ\>[E,KG6)U-%\<\7HG7^62:P5%K#6[IK-I[(&MB+!&]F8B]C*
M60Y[SZKDZ6A[<2/)Z!,B$HFK 4J\P7"VB4+;AX0YGO#!,'!U)$4@9-!R.6T@
MEE<2=R(P0=*N#.:1M4VF0J(K?FQE3D-(&E#:AN'"%$4I_?(/45Q?D1)F310R
M80A;&D)8^%)G#E+TZJ!,?C-.R82G-:UIS<5Y:V-KUK6E[;]6M?3>>:P ) .0
M"0#\1G8_EK8,D D8) R/@?A5#>YV;R7<L?CYI_C?&8^VN_C%AU?[0UP=;GS4
M\WZBAF.2VCQO]P5&<A*E2%RXS1EQJ2RQ$U"<:DN38OI6Z6FFYQ/.?YLVK^:Q
M[#FQ9(_G74<X&#IR-\C&#CF:?5#F*(>V&/;MN=$FQ]AL,9.0#OMC?(WS^3^6
M7[DO'K^)_H_\HV9M%E_:+K]3B_CJNU7/XF#]8D_A:?D_EE^Y+QZ_B?Z/_*-C
M19?VBZ_4XOXZFJY_$P?K$G\+3\G\LOW)>/7\3_1_Y1L:++^T77ZG%_'4U7/X
MF#]8D_A:?D_EE^Y+QZ_B?Z/_ "C8T67]HNOU.+^.IJN?Q,'ZQ)_"U"@_8?)P
MW=[K0XO">%-EZ*/J1$M)D>3=^2.DLW)DT^,0.=;\4'9+KL=(.7J=J3$BH;4Y
M'U'7)TIS;5C06BQQRFXN=,ID"@6D61R](;(\[@ ZAC!/8YQMF(EN"S((8<H%
M)_G#XZLXQ_-OD<["IK^3^67[DO'K^)_H_P#*-E>BR_M%U^IQ?QU2U7/XF#]8
MD_A:?D_EE^Y+QZ_B?Z/_ "C8T67]HNOU.+^.IJN?Q,'ZQ)_"T_)_++]R7CU_
M$_T?^4;&BR_M%U^IQ?QU-5S^)@_6)/X6L2?Z!Y45T$:L$WAW 788(22,RVHO
MD[T-<ER,,AO37VXZ'?$IEI;ZVF%I92X\TVIS:=+<;3O:M26.S9E47%UEF"C-
MG%C).!G^?':N,]RJEC#!A02<7$F< 9_LM=>K=(\I;=6*Y:QW#>!L#[.!$6&
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MR?RR_<EX]?Q/]'_E&QHLO[1=?J<7\=35<_B8/UB3^%I^3^67[DO'K^)_H_\
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M]X<:Q",8S+ECS C!<1DQ0+.2Q)#!61U53@X;63LN_5NM2APG2-!89RW7*8@
M ,$AE8GXC2!N<C+3?)ZZ"ZH4L<ZF5%Y==&U:W'& ]BLAJ*JGVRN [*R['G0:
MBN.+:K<6>73<+C8%CZP!&P*S89;;<2\)AUK@M$9U42.-9=%U*H.M'9#D%QDN
M0-$:Y=B64$F/+C<.%+:$. K'#,1AE#=PI  R=3DA0-).SG3N3DG4[#>S-N!V
MRKHJ!,,T/-@QWO+ENE:89-6H,$L>YC;CL139%^JSD)B;^TGL*95)=@Z%S@Q
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MI-JM5,6)JK@8D0+RK.0H/H.]J4EP(QT'950L9#!$J!6$:X"3!W9HM"2 OJ
M19,B+/J3)<[YR2P4*)7)RI=LEHRJ@2:F3"X).HIZ*9YE;:KMT_\ \=O&/_\
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M;NXR'6T176DZ]QU-L:HVG47+%]/+1<L01L5)."2V%T]]\BH,S#. H 75J8X
M(.X( SC3DY_Z5I&'UOL\D%P<D]4^?1"_8#$&+*K,HI:6"@P+*^7M<HLGUB?3
M DA>6"EERPXHG3;-X<CTMD@]]_ */WF& -<#7(5@!.L!""1I0#WMPTQTJ5_J
M_:$;$"D2RE83H0-*<:26R <MGW=B(QD@[:^C.X8R'F_=IEON\NA6.O,U0X,B
M1]D(\QZ>U(V=+@1EG&U>%&D0D>X2$C&[@DN]-?@:,#Z\,M]5B$J]8)&P$9;<
M)&)%;6I)QC'NJS(6)![$Z-.,@%BCD.HU2CF+L49=+ #.3]\5#!0".X&K.<9
M#KE6VA]V\KH\#3(BC4*T'+$9O$:FU.66_&(%;L489V4#Q3H=I&*7<(I5T90K
M6?'0GX!>-7"%BE%@<D%J36Y9"R"II9YZI)$55CYCA=3.I:!IXD/05S(BD@J7
M5-+!L. I@]R!@(C,S.%7.D!@)5BD89;.$9@,,%U$C'22PGUW\CJ;S^UDZP?"
M6U,4(U ^:M[$>NMU(5.,5JR6D&+F3"%E@%4RB\&JE(K$MH.Z&@D%CV#146T0
MC/KKCM7E0.K)EB=*$OK8*Z(Q "%>DNIQJU$9T@D$58\ZHQ5E; QE@%T@E68
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M,#X%1M763EED'LVE+D2*JHH8L65D$H(TGI,>H[%00P)M$ZE-8#>\$"]))9B
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M821Q%<<LLQURH R*T9R2KD*Q$!=QL 45WU8P%"Y*E'<-NP !6-CI8AQL"H+
M'O?[75?8W9G)?-NCOQ A>[-BY )FJ&5GZG0J74[R;NC43=G@RAT%0:VP'( 6
M6WNQ3EJCPHXUPS*T(9YY)CHQ+$"PCR&UKI>21XUCSH.3J0Y8=(P23I&H]\RO
M5F-\*7QC2<JB*[-[PP,-L.Y^&3@60J%P"WD0\>KSKDH0@U8 <:?O37VY%^LF
MY]=)RQZVGGO?';+#)S$.6KV]36F-2XZ%PWXS[V5T:-M+;-I5B-\C6H8 Y P<
M$9'IV[@U>CAQJ7<990?0Z6*DCY9! /KW&V#4HR%2IBE,4IBE,4IBE,4IBE,4
MIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4
MIBE,4IBE,4IBE,4IBE8.QA0-J"F:=8XL4F&M0,P%,!9+JD)*@2438LU%6AIQ
MJ1N*]%(ZB276%H4UJ6WK3C;CC>]R5F1E=20R,K*P]&!RI^&01D9^%18*P*,
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M.)8UY.0@U :0P)"J2^IY';F$@EU)E?,9S&<YT9))@+:(%CISJ((!)PN%1!H
M("D"-<,.L8P&QM4\"\4Y=7HRX@JHPV6W9PDI(<D3"I"9,* ^A%NL#2<\@1GR
MYY DUT@Z9N3\^;)?ESCA*9+GO2=O*3NMIY6.6<G8@8   :)82    O*58P
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M'SYI<2HTK@JSS*5=G57SF5)B=+ J27C'O*1N< '!$6A1Q&IR%B.5"L5QA&C
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g155225g22b30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g155225g22b30.jpg
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MX5C.<?#G"L9SC./Y\9SC/Q\?_/U<L,>B%_XR)_\ 98__ %1RN;\%+_\ ;?\
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M@RJK2%8I72)6L*TTB(R1*U&C(RBMS2[XMCRTTJAT4$$E5!=%9V4 E8T9@\A
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MK/Q'0W_H\S_[['/]G.C_ '\S_6)_"P_,U])7OC<GUQKO\%<?[X_NL_$=#?\
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M7X5QUJ3W4_4W[V'T?!XR>8?NXT-W)^2+Z6-J[)LM^LQ;;C1P^H4N<V*MH&+
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M[Y=HM0J;\@A%8L]TGTRM'H-/!/O""^6"-CD#6'XP8W.9RN $+RH54>7EE 9
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M"D!FJS#=<-U-JO[1;RVD%&K\E>28U,]O$K698^(_!S"1D2PEI"2HD@2&-:%
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M*O$8W)A( #8SC<#,N18E1ZH7#F)"%'F)$>?!8[E=",DFN"PXUK,K6BJ00\9
M.H\]E[8(]D@@XOS(9U:/3-10A6B*TQ8$%&!]D<K+4I!/:O;%+[<TAU0G8U9M
M*(&HK ;@6+H_@!ZV-;LL%C7(F@;CTW?=F-@HS?:.]0SK?6)UBM!",ZT1F:_J
M-3$1(+I*M1%3[H9LJ"RDRJ"N<)8E3Q#)#/'%J)W+!'"H#L)'<DTYJMXLP=+?
M>RP;*THU!8Q'+%))0Y474LQ%$QHJ@6HO;#<B)T>V],)PCAO <)N_*+.^SYS
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MVVU,Y0EFB..]58T*U;@NJ*LAOOMPQOON\,O?!2^\LR_)&=F0=U4A7;NY8O\
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M RGS@0.FUR[!?C:YK)IY<Z P"E5@=E&6)O%"IETQNVB<0!=9)))DMR0!VB5
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MJJR:%D[FAX8B<M U:DA.D:5N-#I4<@+Y#Y#;$DK^H-;U>PN6$&6AC7&J=7*
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MD;[$UN-SL=MSXX@N.G31,.JHH];S5:/3UV8':R-;HE&AU,,:) # T[&:+P!
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MCX4UAYN3%8=;X<UFV;4T$K,05+&=2Q4@J19WH@D$71!(Y''1! !0G0"P:$;
M6#8-#O! (/B,2"5KK6$XF,-3;A7YAD*R1CARTJES9!,3',(CMEF!D]YM<J R
M4;AQ&R+45UI$U$6.B2EU+#6$QX^9 (&6< T2.*E$BZ)'(U9J^5FN>'!AL'K"
M6+H\-K%\Z/SH7]6()"Z<>G\"+MHZDE:;K>1=ALX<>.:[UO%J1^3Z<Q(9S.R1
M&"V\O$HJI3TF%*FM2\QY:O2,(4OM[9G.9LE2^7DD"$%5DG#+MW43R\0*VVQP
M9>  Z9T75S*QE2>>]CF1>Q-UB?B:#KD$*&! ]\&#A 8?#%"Q\6L%VXL <.C-
MQ(,.,WA78VQ%C,M,,HQ\"&T)3CXN0,^88ECE6)))),J6239)V[SB0AA H9A0
M!L (VH#PQD.ZU*^<B']6S'VN<XT_PK?UJ>F'"A^(7R-C2#J6V?LO7F-* M5(
MHR+/MS<X_62B&P1)\V!$CY5"O]O>GI'URPUD@],Q(I\6*UG)'+"694C*V%K\
MVMOT8(XWXIDUZ8HC)2%0Q/$C0"V5A7;)Y=V,<C,N@)IMW"VP) &EF.P(-]G;
M?U%2,=9DS7$RT4+?%*G3]K5C9M+UH.'Z-#DK2-V#(V91K+?=?EJX'-S8I<+D
MM#I]F DQI4A.8"G!:'Y!M826X2@V]5$FEX7 C:-Y"9B%*<-U1PQ4$&BZL" +
M4\K%& F*ZED7M*ZIV 2&UJS*0#N+TLI!NB.=;B[XG4UKN3#@2WHMG'>G[O>Z
M?E1B N&U)@[!BCIA*4B?AHH^RR&C,P9+;Q%IYY6'T>2F,I&?.<JZO)O6DU")
M]CSC) %;<]P:\/GMB8E4^/M\/<?TJO\ 5\\0_5'5S7-T;& 4JET"]PP-BU\8
MV@&O=QC#:T)LU)@FA]?&V&F"?3R)LV,*DR,9+BBD2N3QL26,G/CG(Y2,KDY<
MJT49=W0LKK&44EBK%2Q5C04$ =Q8$V+L''$E#L%"L 5+AF  9; !4631OO"[
M4>_'C_ES:#1$6_**'H4UK56Q-N/ Y8AE!QD%K&Y3:!902X+9!S"K@JV#"HD4
M":><R1?%SLMRDI9[5.J370"FY$B!#;%I$#J;KV=)!)[K%C'./'7,WH9ZK<!6
MTD>&K58 O<@URQ"&NL>P1]NU;6:M;&K7&M>^-EZI68K(A ]57@4FCP[0PP0:
M*VB2@W8(#LE4^T3H2AHEFL,RY@J'*)0T0)LCE5X32<0+IACDIC>HNY7;2MA2
M!V;LZB 3OMSC$.$TEM4C):T-.E0V]G<[[U0K<<J/.E.NJK6^JBR&U@)_7TZ4
M!V_9>^#U8G0-8'!FFC)1%S;JQ.06+FY<NN5V+'(E538$>#.DQRS8*9/5#<BL
MILHR,1&P<7$NG4.(IE4%-6P4!F) HV!18"\<CG# %P5L.=5=DA++5N2=*[G:
MC1KE6,/)Z_0H:XV)ZV:XV14=:A=4ZSNT-HY19"=DFRFT-I*U[7)88*-L1.*2
MK4]N8)>:@LQV[3%G8)1)L!$]EL3R0R19%T21M(9)$-/][ CCXA!8J*;8BR=!
M%$&M\./VCJ1U4(C;KVCK?0" ";'+:M5V*O;%L3^L>C!#]= V;7FY*G@Z9H]8
MEF;+3Q@H-6K9L+U.W6ZT:=>LN9\R7F98 HPL5JH^RU@$4GH@%ST-^/,3&KZJ
MY5F62%](=M*N266.]3#LT!2D@,58@6%HBYF4 J"KBRHLK0#-5*=]]R 2H90=
MBP.V/%'ZZ="2H.)+1&Q>L%:;7NU-=4'938%5UN\+ULJOX@Y(>:[[=^6\UO #
M,G"?3U)[9N&<^>P.4F!KLUQ>#JOLZM.L-=7H*=K57+F,<X\?B;T<2JHUJTUX
M:M79J^>,Y1>K[6]_OHVA#:YLH4LY<=BZ\KUNL%20.I%AO6K5GUVZKAS;126]
M)G1AM8-&(DM8]D/-B09,-HG@[$FB(W'RLD:%RT9TK&[*K6ZI+6EB"!M;!2 2
M02#6D@GHE4L%IA;.H)% LEZ@#?.@2-J(![P0(=O+K#B:_)%*M0:?9;8<K>T]
M,:TMUN=K;\O5U5,;+N='AD*X8/1C8P@BT,4>V)+P5PH,X(.,S@ XW,3.G-!Y
M4H<J7"L[JJM'+(JZJD81HY#!=)&DNM&R"0&*BA8XTH!TJ"2'C1C794NRV";!
MO2U[ @$J";-8M*)U0:MDQ*=/=D&1X^Z["VWK8=/(P(\6) -Z4C;!F7B<9>S/
M6F"#9C:SLKP^>GS[DE&("GHL7$AWT>LY>0%AL2B1.0"22)= 0#;=OOBV.7.B
M=KGQ%H$F@6=;/<4UEK^78:C]5UW>'3?57K7=UA16JT/N0(B2I^-AU+-P!1PS
M-ZH.2$,8JVUGT<F1D)@-2B8C+XZPQP%B8C&14UX(B),;>YV7+20KJ8HP#:&T
M-91Z)TML/ [KJ6P1=C'$E5S0#"UU+J%:EV[0[ZW&S -N-L;<U3]>P_[LG]U>
MYBF]@_6,:\M^%'U-_=BWN9,>CAQAAQAAQAAQAAQAAQACA7Q9_LS_ (<88B'/
M/QGPXPPXPPXPPXPPXPPXPPXPQ S7ZSD_]']W:Y[&5_X>/_K_ ,;8Q2>VWUXQ
M?-&(8<88<88<88<88<88<88<88U[Z@M+V3<,?5TJG[ A:XM&J=H0MG S9*F8
MO8^5,B5"XU!0R8#S9:IVLNQK@_+Q)P3SEMR&VWZ.O#V7&KH95B,@=#(LD9C(
M#Z"+='L'2VX*#:N_%<B%PNEM+*X8$KJ'LLI!%CGJYWZBL@/2&_&LE9V#;=I$
M+GL^+O,)NN[VZ35!P>):,5?5EVU35Z*"KHXGB+3JU7Q%Q<GP7%2[$0=GM$G9
M[\Q\PJ3!M;,@JR+&$CX)A1=1)75(DK.S$=IF9*.RBB .6\1%5$L6?B"1FJ@=
M*,@4*#2@!K[S=DV3M'K)TAW5RZR[/6]OM-TZ#O.?U*@]8S*1$1+E[.F5R6(E
M"R>Q4GER&ZK*F2I,T>RQ4_2Q#\YU<MXZS$AQVNKFD"!6B[9A&7:0/MP]0-B,
MKNP  W>C6P&.<(AK#]GB<4+IWU51[=W1NP-.QW[6U:[=!^BMZZ1NU5A&]:$1
M -S7TFO;4M-]!4",4&E!S3! 0'UE::ENW890Z"(VMTE/)0WJ73P$B(M!N0W&
M/99@8OSDT,R,5D!;B:HU1G((-@F16AC"L%H ZW8;J.SOBO+I)&0&2NQ3,P6Q
M7)4*R/8NR0545N>UMBZ3?Y.G79K8A_83EM*QY9[J(J>\71[8S&6&Z^"27*V#
M4RW?6R</5:YWFR6:YEWT,1VTS"N(V14EUAXA,J7/2*BII!"P-"#?])J59.7M
M+&JH/$#<[[3.74L6O<RK)R[A9*<_99B6;QNJ[\6/)Z42T*UP;Y4=F1 ]N%=0
MVP-YC7S5&58 B(&RZ&G7MEIDP3&MX&7*>;$>7+$V5DO#]$(>;5( S(Z%L.U]
M8!4HT9*F!(2 ]&XWUJX.DT+V*T;'](8EPNT&#41(SBUL4RZ2M:EO;<&Q1[CR
M.$?Z(*\4U_K76]AN\XD HM8ZA*F47$!-#9MC';_@FQY!V,\HO.0"EUMDTXY#
M=RT71/?CMN.-1$J4C$NN,'D=4 +F BVO28--=PO5IWY5>V.< :44L2%$@Y42
M)+'B:(!^=G?;$>7T4WJQ&F[#LC?[-O+0@VBZR*<':JBUB-% Z,W$$VV/Q*8;
MO!54XU:9 J2-.%//1XT>21R1'BV8<-@(KO6T5=,<.D$S,;D+$M-$T1JT%!00
M0-R:W)))PX3$VTED","DT[1N']XV2003\[   7'5LCH/Q?\ :UDV,G8E<ALV
M7:6L=JO.&M1"+5L<7-UK*J#T>D@MHS;1#(A-<$$53SR*Z*!Q)D F3ER,F9PU
MX@&)(\X4C5-#'3')%0E*QD2:^TT84@N"_M$D$#D#1!H=3E]0W='W0,PT:1I#
MV"%.GV0+!).H@D'I1^3IUVB_IOR;:5Q*1U+N;\2,P,[(6*VY(1:5:>PGUOYO
MNK[4FT;%](]']$]-3ZOR \YG)3G>O2:-&D?\/P;LWJ]GB\O:X?WOQK^E79PZ
MNNK59OC<7Y5>K15U7$[=U\JO?%PU7I;8K#^H7DW9V;[*=Z;RW6A.:\B/Z]<W
M2G;:5UM><&GO5J*Y[4U906QB<HMZC3VC1WK+/H%3YDOQ>Q7%BAB]KEP3&=7+
M?5P^6U7S-;S$?L;^Q)))RYZQ**Y]W$Y]]<A>T-OO1_8[1:;D]6MR=TM;;%W#
MK/>MSH+^OHEA(3;[KHA0I3F!-P<M MX37[.SKNNNDAJPA";$,Q4SX)9 MR8!
MF33-*JIJBU21Q20H^LJ D@?FFDVR\1@#J TFB+[6(F(EB0]*TB2,I6^TFGDU
M[!M"V*V(L&B1C#)Z()\FWB<F]ONE-/5_8&^;X(U:W0X<$GESJ'KNQ@UT%E+\
MW9'9,]H7,V29EU>4S7H*X4!<@839+R'H948.;&DU%4I2%#)K)'W@H5(330)$
M8U=H[[BMP><$V+<E TC:-(!^^!PP+79K6=)H$"P;--B6=-G2%%Z?CS1ERQ48
M]@-24:_K>:KHZB:S.2 R9@Z2LU?[6&64/W:X/LB!\.42BRZP!EX3+GS*Q(*2
MFYL7D^:,RZ=+K;ZVU3/(+HBD4TJ(+-"F(V 8#8]CA$9NU/9T@B-4-79+$$EF
MV L:17-;).-\JI^O8?\ =D_NKW//F]@_6,;<M^%'U-_=BWN9,>CAQAAQAAQA
MAQAAQAAQACA7Q9_LS_AQAB(<\_&?#C##C##C##C##C##C##C#$#-?K.3_P!'
M]W:Y[&5_X>/_ *_\;8Q2>VWUXQ?-&(8<88<88<88<88<88<88<88U-ZG-H[B
MUO8.G,=JL!3S479&ZF*):L6FS3*^M^*_2+C8806)F-2K9F+&GXK\XE,L32D3
MADD&-#1Q)&-9IQ2OZ<O'%(LYD9E,<6M=*ZM]:*2>VMUJ "\CJ+$C2 U4C.IB
MTA2'DTM9(/L,P I2!>DDG<C2!1U6(M5.KLM8K=27Y6L8XS2NT-O7G1VN]DMW
M7$ZS$KS1G+I%<FGM?8K$5L'5;*2U[;1M?(Q[:7*-NP(4@T%%QRK:HTFRP57J
M2Y8XDFDCT$*$?01I>S;*)%+ JHW-$UOQ92Q'8I&=T5]6Y*:@25K924:B&)V%
M@7M46^NKHGKOK*U1KN!L6H!]>@25!J.UZ&1(UR/9[6:WSBV#*N8$QIZE6#(_
M5\H-2C9Y\.EJ&@;?4N%'%,,8RS;#E@^5DD*,7(D>-P&*J(0I*DCL@R6X%[DH
M O,XA),5F1 RA;564UJ)DL B]Z0A2U4 'LG'XT'=]K;-WAL9BP;.ZEVQ%3ZC
M]TU86,#Z^U4G0?='7]O,1PM7+W*1K^3;T.O#8+8B6IFQLDWICD9IJ>S(>R_Q
M,D<<*$1Y<EH(F),DG&U.HM@FL+L38[)%<Q6V$;,SL"TFTC@ *G#TJQ !;1?(
M5[5_WXV8ZS+1L.H]/=H*:IM2:1L";;-05:N6I8T>8:"OWC<=!IDR4\-*0Y\*
M6QD:?F,OM.Q7%^9=6J.IJ2EEYO/E%1YU$BZT"RLRV1>B)W&X((W4?_[MMBV4
ML(VT'2]H%-71:1%W!V(HF\:ICNN6R1#Y,G8 LI\Y5-1UJI7#2,%\:/<A=3A/
M><74BPV+!*B294 *4(%@TX:7?=F0,T8D/LC(Z9(>0R_J.34J I 5I699B";R
MXAXMZ1S( (*C?6"I(Q4LS6;&ZHH:,;5*9.&0&(V!)!!-C20W?C=+2VXC^PC>
MSJ'?*8.HNRM1FJ^-M(@!:7;K5YPZW5V-9:P>KUDE5VI3Y46?"=E1I<,C7!DP
M>0'R65)D,+CR7<DT(C6-T8O'*&*,RZ&M&*LK*&86#1L,001RW&+D?464C2R$
M @'4"&4$$-2G?<$%001WBB:4VM>]U6B[[RK.IB1R'#U$&T6$F"*I!J\JVEWM
MA7(?:]L6"MKM41\<NT5G3$)$*@0):_5T@^;,NS(D^:@,B+9&D2I$T@6Y#,P+
M%M(X:%8U8(;TO+>LC>E%4+N#,Y+A+[(C!H*3VG!<KJ!&H1^S>Q)-]U5+TI=3
M5GV];GZ1L;8Y4 ;'U8EK&M"6JS S-N]_@N6$Q9-@%;@)K4[7<2X! %:?$@J8
M).(BE9M6V;;XM=*U/U!,C6YG+K$@=(P06$C'4:1#2J@0MQ"C,UEBMC5&A8-8
M,(92Y*LP! T 4+9MR6U %0P K2#N5D8*5Y;G=->P3FS-,U2RVIQA^VPI5LI-
MPEQ6$18I&W:TN5@US9B\6(UVM0XIDW5IQ:-#:RIN)'FMQVU*0WA6<LZ".5E4
M$*0KJ#N0LBJZ@GO*A@">\B\71L60%O:%JWS9&*L1\B5)'RQ>G*<3PXPPXPPX
MPQ(JI^O8?]V3^ZO<JF]@_6,7Y;\*/J;^[&N76%U"V&@B#=3U9;@E7NM4KX?8
M=WL!! $@[7ZM*/MBJ]6AXL^U+@RK)L,A')MM^='S,"*=7[224H88FU&9(GE,
MNKD/*A9&9HT4:@&<+;,2M$+&".\6[*-P'&+LS,4#+&P5E42.QHZ5+4JB]M3D
M'N-(K'8E"=B=QWB?6Z2(D52>PT9O5SUW0JX:91$(,CO:#; P&59X;<AN4-GO
M *_/*605'F,R1I*:.APY33T24XE6>% SD.#2)([+N">&C,%/(C4P"M6X!)&X
MQ?*Q5!IYNT: [;!V5=0O8Z5)87L2 -[QH[=NI#9@3<UQ'=YMAPP +?\ K?7H
M(P&HU')]*T&E%W*?'MT':>T)-7FW6O["A29-N"$6(MN#PPUUF4$0W#]#FE$R
M=J9>)H4.F,LV7ED8%Y!FBZZ]!BB#"-HS2,+0ED$ANP",CSR"5QJ<*)HT4A$.
M7"-HU"20J75P2X(UK3E!6YQO/J^X%CIO<%2.R<3R.L]GR*Y')XCQXJB("RTZ
MH;-KGEQXC3+"%@A=[:IRW?(P^076%%9652)ZW%XI451"ZBA+$&(W-,KO$VYW
M[31E_EJKNQKC8DRJVY20J#RM659%\H?3XG39YXMWE.+,.,,.,,<*^+/]F?\
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ML]KC7.?2-CV/><FT%J?WPK8C< SI\C0IU>$%!XFP%J[)T56Q+D<@*)'Z_#L
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MM]+$$T7P;/NX2])E"Q4D^9E APN1.<<Y8W2R,F@[6JHSB$B1T2M*,W>!I7D
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MVFD<G;OD=R/!2!W8FD1762Z$O(7-&NY44?H1%!\6L@"ZQ8_=0O\ T8?B$/\
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M:-)L\33NO8B9YG8-CU1:=)VT[.Q#=DV"\1-<VBM2KN60*AYDR"%C(@(9ZP#
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MG/+<]_<-SAUN?WQY5[^7=B2U_95RFEHT:249<9<2_P"6G H.WG/D,.+3^DW
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MAAQAC67J9HQG9FH]PZ_KKD9L];Z#80(9,YW+ ^22( G&84 D]A*\LC",C+<
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g155225g22z92.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g155225g22z92.jpg
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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MP#W5LA\2VHCOY@OS9_E)?4V0X#(:"T2Z)R'<5FML!@<0^T .O:9$ $?L$4S
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M_'>0QB"*8E.)3& !X$0&G==G=VO(]1^W12"1HO)UXD7Y-U#/I9;J<\-BP/-
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M]QL; V*FCG/KKDPB81,(F$3")A%]%$DEB@15--4@*)*@50A3E!5!4BR*@%,
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MQ[?_ !99V4N*?4*U0*M7Z3389C7JK5HEE"0$)&H@@RC8R/1*@V;(D#DQNTA
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M5FKES@8FU5"?A;36)YDC)0=BKLHRFH.8CW!>Y!]%RL:NY8OVBQ?5)PU752.
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MZO'-F3ITX0*!%&Z1$DDQ%D!_+,43<\!V\"//QQ7ODSW7N!!O>Y]F8&8N=25
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MUW#*6>I%*!5P(B8 $G(G[R&+Z@/(\_'.;>P,>0+$7(:>E\A?T9'2W>JB;Z7
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MIUO745&"A'*-'Y%9-PB0R8D62; (^2N"?F <P<&*8>WXCQEJG86'> R+2.
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M/EIEY\K<=58%"5V8KM)F&%+90C=[%ME0II$S LT<-3H"1JY<F3$4O:UQ,)E
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M.*0QQ;V;6GC8[N7*UP>-^29<=;Z'A;/SZ]UE<R@M"L6PMFT_ P3$" 1DW@&
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M6>NH=!6MUJ,;,(@L;+A4RP35*8@X1%U&''\S9E["LG<O&PY)!N_FJ]%/3H,
MCXUXB"JYY^WGWB_I3='+3W\;>A%NF;1KB,+$N:"S<M 7=*J*.9:Q.)%TV?1#
M6ONX9_,+3!Y>1K#B!8L816IOWSFLFB&+*-&)]B9MD$ESS_?S[^NJ%H.H]_9T
MT6;L]6:^CU&BS*JQC=1C+.9UH=,JP"A+O*@G0G3\G*P_QZU.23KYQ'DOL! *
M!04Y4R$L/?NMZEAI^FS1JCI-V?7<.8Z46,0DW%Q*_1R;0VOUM5**IQ02'T82
M37ULN:D.9HK0)ES6DVL4X?JM630B$W//VZWUUUS[TW1RZ>BWJR7)=].^EW[V
M3?/J%%O5)<EJ3>MG;J6<18$O4-(0%W!C"K2!XB*_/*+E'R5K&+8LQL3A8LC,
M"\D4&[M)<^^OGU]B6'+PX>;3T+[2'3UIN5;-VDE1V+U%#Z1(L+B0FU%Y9K,H
MQ*,W&61T,G[5:H2>) PQI^"LJTK#3BT8S<2S%XX1(J"Y]_HY=+:<$W1RZ^_F
MSY\5D5;K>ME7PR%8CX95]4;->TC.8\YU#0UIN<I]/W](P@H8A'\O+/O;I9(0
M,";E8Q"E1$IDRC?CT]67H2P]?[5U#S1&HY&1LLH^H\6[<VYA8XZ>2<*R"L<X
M;W%%-"WJ,H<ST8B&?VU)),+1*PK&/D["8H*2[QXIR<5SETT2PSZZK;>0I5=+
M;_"US/\ T=-9_P!I>VYU3OP(B_M5/_=%.N";_P!:$W]@J?\ YAJE8MG*KO4P
MB81,(F$3")A$PB@KUN_\;]$__KT:?_L9M+-W@OR,9_U)5_IZ5:3&?\)@W^N:
M7]%4*=6:1;M,(F$3"+2EEW9#UZY$J)(=])BG:]=4J2E6SANFTC[)L<)9U'QI
MDU %59>)A8]A-S!>4O+8V2 ]E]J4<N@9OI]_?N*B^?O[Z9^;FM9O-V1-"M<U
MK#7^M32,P&W[17G*#FUQU;B7EAG=<5_J'M%D-)2I'PHDD%-AK("S\L#&E2.A
M;D09"@0LZZG0<NX#B.BB]L@.-LSS%^JQ8O6I%ODGJ\11VI4X*EO[A9"VG9=(
MJ(MQA]A;3UK,1==>/G+F%M(-Y[45C<,III,-(21B'\!))O46TEWH3N\STR!/
M 'IP/H*@NRT](ZC+GIZE)&A;3B+\^=1[2.E(AT6G4#84>TF$0;/G=/V-'2"T
M&_=-.1-&R+:8@;-!2L.L=5RP<1"3E4_D2C,,@BWG(\RJO?S ^=;/R%*81,(L
M#VG_ .##8_\ Z!V_^STCE^E_QFG_ *>'](U6*K_%JC^@F_1N6D>AG^\VZ8/Z
MC=;?V7CLS,:_ROB7]=J?TKEAX+_DC#?ZE3?HFJ56:Q;-5U>$K_@YNE/^KY[_
M &NLF=5MO^%>-?UIOZ"%<'\&/X!;-?U%_P#Q50K!D)-BY?OXQ!<%'T61F=^A
MY:I1;DD"*J-!%0Q"I*><1%4P D<XD[>% ((E >57>+1+/0&A'LI:&+>%"5.F
ME8XR;J"][N4Q5ZJ;9$._3LA(77[NSNZEK^1M-?L,H1PYK$#7Y%Q$6"0!%8K.
M9=>U3<^XUL?3GYSKHHL-._+OU[OV]5DRFB-8JPB$#]#S22+6Q-[>VEVMYOC.
MX-K2WK*--&PM[ZTLR-W0F'E62-!RT@E82.9J/=R2,NH^^E9,7:Y^CZ?6EAZ;
M^*ZM;IQTL86QW%1448,(M.-+"K6BX*591%M4W5'3DI"IGL!JS)V%.HNW$$-K
MDHEW9C,12*:7,HW;J)+GG[WOKWYI8#AIW\K:<3;Q6-4S5G3A>H2<6K+1&^1L
MJSD8NR2TO<+I<I*59;/UE25'3.9G[3/RDW)(SNK7E'%@1Z_7"/@7$<$7[ 91
M4!$D=+=!P)Y=;H #UOU/$#GTLLKUWJ_3T%+2LW2&KE_8(>T6!&=G96WW*X3P
M6M_7*=7)XDU,VZ>FI.1?C6JE3(L?;W3H&C&)8ILQ0Y6%02=/?B?I*6&O[>A]
M2W;D*57+U3_W]7A>?U@=5O\ LNW#.KP;\&]LOZM@G]\P+@MI/PT^#G^N[3_\
MN52KPWU^4&5#1F[MN:7=],%DL;G5&Q[GKMQ8&^TXN-0FEJ?8'\"I*HQZE'>*
M,4GYV(N2-#NW)VY5 2,NJ)1.;J<-^"^HQ+#J'$&XQ#$VMI*>J$3J-[C&)XFR
MAA<*AH<6[V[O "]KV%[+A,:^'*EP?&,4PEVSE1.[#,0K*!T[<2CC;,:2HD@,
MHC-&\L#S'O!A<XMO;>-KG4W_ .)@I'^:-:OO@B/W?9F_<CJ?RY!^8R?65K/_
M .(2C_DO4_.L7U%5B>'1XLUPZ0=PV6.NJ<O8NF/:5YF;'9Z25P,E*ZXD+'++
MNU+C2._RB'=-2+D+9(),K9G9VK?SDB-9A%HYSL=J]B8,=H(7TYCBQBBIHXH:
M@C<95LB8&BGJ;7.ZX@]E(=YT+C8[T9<U>=[!?";5;+8K41U@EJ-G<2K)9ZFC
M#NTEH))Y2XU='>P+FAP%1"-UE2UMP&RACE[CZ%?:;M&FUO86O;)%6^E6^*:S
M=;LD(Z([C96,=D[DET%2\&(<A@.@Y;+D2=,G22[-X@@Z061)\Z5--44=1-2U
M4+X*B![HYH9!NO8]NH(X@Y%K@2US2'-):03]BT5;28E24]=0U$551U439J>H
MA<'1RQN&3FG4$&[7-< YC@YCVM<T@?SW/#^OL_*>+3XF6_(8@O)I7;6\#,U3
M$!8J3"[[VL[]-J & P>S)M(%H@DD'( BV2(4.T@<9^#QB2J-Q?=83YR/?NY+
M9OL(F ZV&7A<^S+GRNO1/(=2-C*S%21@ZQ)O2)D^NXBFWEAYP&44[A,ER94A
M_3[?Y1O7C.O:T?(&]<6)L<LAURXBV0\Y5C>-P<LKV%O?+/+E;1:*N'5M<(QD
MK[%&U6,$1 "FCX)LLOWCSP7M!+ZH>@#W?$! /7D>,V-/1.DM>Y-[9YG,\"1Q
M!ZZ*";WRU.=O3QYY^]E'>&W';[OLALC;9]U+%DDS)MFKLXE:-S@4%$B(-! $
MDQ+V#V]I>X/40].<R*RA[&F:_=M>1K3IQ:XW.6FAXVXIU\. ]"E14IZ0K<FK
M+PKQW'2!BI+NG#910H+J("8@"<O<)?Y(E#T* < .:L1@W#AZL\S?A?CK;4E!
MX^!]8X]WN-QJ=03><:@RV+4X&Y,"  E-(()MWQ3)J$,55!V0"&%<IB\E#GUY
MY[N X''FC9%9S'.9=P'DG(W%\Q?NRMHIWN8!OQ]MN7GY%9% =0VI(251:L65
M_J9W?<X,FRDO:XU8_P!0O:8BYSD((_5[>.WM*40   1'(^(25#26EG.Y;GSX
M9^.>8Z6,^1U'F^FZV/.]0E D&[ [AY<';I %C,%A=(HG1-V#W* JD83%X3 _
MQ 0'D.1Y],Q8\+D;-9Y:6@$\3IR'#.W<;7!U5.5SK;W/(\,N_6V=HL3VH=<]
M6%O?KQ+RQ5JT5R-\ZES;^4-(-7<D0BBK@)!F)O5-8Q>TJA0^J?M]!#TS8EYI
MHQ8 @. D#;"P.5P.G6V5^0O(L20+C+*_J\U_"RW/HV><[/T1MC6=F.4]HU@\
MD(UP5P(&=-7S9J58IB!SRDC]18B!/B4HF^T1RQ(XQS1R@V$@+7V.1%C8V[R!
MGR!-Q=5-%VD'A>POIZO3U&E[QUZ8Z*UVILQ.-L")E8N%9_2SYL4PE1,+0QB)
MIK>O @L F,8IAX,)?7X>BH> PNOQME<YD@>]]>JH:W>-N\^_OHNUWIU1V&&N
MBE'U:=G"Q;-Z>$:P</&I)R4@Z35\DA6[A%,YQ5,)1^WU#N$1YXRY2TCV2/ED
M&\!$\C+CD1PS-^ISX9I<C(>(TSXWU[OVJ55<U/9+7J5^TZD7S29BK7%&44I[
MIDDK*-FYD/,025>F3*H500^L<H'Y[@*(CR 9A459(VL>(BWM 2 7$@#RC<ZZ
M#2_/,9*0>#ODG,V'+EPU](SXJNKI@9P];IB4#$)*(Q:%PL2<<U=" KH()22K
M<I%#!Z&$$444R<<_5( #Z\\[3%'F5S2X@EUCW'=M<7Z\21[(MR^C//(VO>_3
MQXJS>$0Y8HB?L GED$.WD>/3TXY$> _3^CTY]<TXB(^GOSOP][<!I'H7'L$I
M)Q230T=&?2J;E^V9J>2?M.V36,85'9C!R/8D!>#%^WO ?@&4N9N"_'(9BUAF
M?#WU2_ Z:^/=^WS:KLDGS%P55%JLF=9LZ4(L5,1'L$2@(E-SSSVCR'(#Z#S^
MG*472I]JBZP*<F#S!'^?N ?00_1Q_P#OE%_*(SX&W#3S^92>'=])7,4[2)F$
MBQ^0Y^H//':(#R(!_-\/_P!^,J(OQS]%Q[#ZN\&%6IXL<,E;O#MZJX=P7S0;
M4!E9"%, #VJTRWUJWHJ!Z#P*:L&53D...WXAZYA5K;TTF>=@2#F;M<,[@\+=
M;9\RKD8(>WOUSXCPX*?7Y-S;UK9X/G3 @Z5%=U4)3==054,/)@18;NV#)1J0
M^H\ VB)>/:IA]B2). SG4E%I'6Z'S@$^E7HX5M,(F$3"*NKQ4O[S>Q?UQ]+G
M^TSJ7.JV+_R_!_4<9_N>N7!_"3^"D_\ K;9S_F'#%8KG*KO%%WJ;K$C:W.@(
M]IKV-V?'M]W.I"PU.>4,A6G,.WT5N],KFPN%(F;C$F;>87B/H\DW'GB7MB4A
M(U9=HX>MG24@VOPRX>'4*EPO;*^>G/7]]NBT)&=(EN91)Y&PQ-#O%E8HZ69!
M$RTF\<L)JDTQ55W=-5%GY6"<NT*LJL$,2/3>QWL%X-3:VA=&+-D)ACIWAU&9
M/7, 7X"^O=?)1NGIH.ZP)-N)MIWV6/3'2!LEVT=JQ\518EQ+PI6AF43*QIE:
MW4H_J/?;:;:5CY"Q:^GHU]3WM!E@J1&KZO.Z:BYAB5EW5E:0X0*C.\.9X_\
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MHBV#T0=.:E1V??I:Q7.]RK>Y3=$1DR/Z+JUZNT%-2OU3@% 7EG15"*W.8:.
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M&_A?E8^FUNI4>_K]^>G"RQF1;/GQ3(Q\<O(N"EY(5JBHX%50/@0Q42"< 'U
M1+R8/3U]>,O#$>O/+.^FNH%QX<="%'G]&?7W\R[:G]..\MG/4O8:*O%LG!P(
MF]?IN6+%JF42]SE51Z!%1 HF#DA2B4P"/'PS$JL8$,8.\ =X--C<YWY'+3PY
M64V(_;[^_%3CU]6:WT65>:FK+*-+SL^?3!C"0%9 5P(Y==J2#$@AR("JX\LJ
MX@(B*/F<?$,U\DSZX7:XM:#O.<?X5M  +Y:FYT(T"K&Z!?4GT7OKF->.E\^%
MUBF[WDWTN]#UM0GWCA]M/<$C,V"30;$.X62D;M(@]<M4P*'>4L7'KIM3"//
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M8@(622F'-!DE)*G2X+V2-6CVT_$HM))--\BD]3?-DVKFK?)-BPMN-^UP00"
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M+4QH5KMK1>A[;2-Q6"7.RKK2+E]@VL7R@6"$DEX=6=MK0S,[N2L(,9) J2B
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M/@(_H'D,ALL<+B6@$YBS1[C+DBUJ/2S .W!W+^>?'564\TY42@0O=SSP!A*
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M[F^FRZ=/P@^OLY^TVG(I$O\ RBFT-6B0/]"-P54_U$'*SM7@?XVX]!35/TQ
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M3")A$PB81,(F$3")A$PB81,(F$6C^I/IXU;U8:,V7T\;G@26+6^TZR[K=@9
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M\;R"*R;Q&1;+)%4;K-G#<YT#-UD5"*I*)G.FX3,55)0Q! 1]$I*YA#2T[S2
M018@@YAVEL[Y$$@BW"ZL=.^X/JS_ &:<E'16JO693I?6,H*H'*)2<"CY9^\0
M .! >0*(<CR(<AFV?4B6+<N- XWUY7.G#B/1FH\_H_;[5-O6GMDS!-'9'3@Z
M"R2;<S3_ !$#MP\L> XY 3\"(^OZ?7.1KP!(?&W'6QUMW&]N%N*E;L)5)%RB
MB5HHX;+E Q&[A,/K("H0Q#& 1 Q1^H8Q1[@'X_IRW3U;*0]J_P"2X;AUROIE
M>_#2_>"BX=>ILC!2J"AUG2ZS7O("X@/<H  <W')0X-_C?$H_'] 9F/KH967
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M<T'/0^^JKKZ;O#.O-DMCV1W\T6J-,K4NLR& 9/D59F[KLE  18OV2BJ<=5W
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M9(/S:FDCORD\Q:%? #&90  Y.)F2IA%PFF AYCABH[:E$0**_=Z9=AJ89_\
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M"D3<6!B(NXV0;^8F5RH\:M'[3O15DVATES2!>,J&XAA%6_#<:II*6ICMG(T
M%IONR!S;LEB=:S9HBYAL;DD.(S<:V,H,4I#C>R$C)X7[SI</8XGRA8O;3!_W
MR*9E[OHIK.SM#N_>X768IJ)K)IJI*$525(51)5,Q3IJ)G*!B*)G*(E.0Y1 Q
M3%$2F*(" B @.9.NB\K<US7.:YI:YI+7-<"'-<#8M<#8@@@@@BX.17WPH3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(O@Q2F*)3 !BF
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MME9H<6M%N)NT$BY)NO(ZBHGK)YJFIE,L]1*Z665^;GO>27$D#(7.30 &BP:
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M=0P;P9G;(&[G$@@D/&8LNC^$3&#6XR,/B=_T;"H^QW6FS352!KZAP XQCLX
M+>2Z)]LG$'0>W.H7J ?[$J%Q92"\=68V[1L?'U>)573%\S6?(LR&EDR-N^2(
M998A.!*B!.X3C]4!,'<TF%TAHY'6:26YNSN+CD79"_G(\_GV8X7U-N&AS'MN
M._)3!W!U .AJP24Y246RT07SVBZR;J52%^*8?Q#QJ5-))N3NXY4<.BI@(_RA
MX].?I*-@JWL#B;7%^-K$9 $9CD-,^5U'O[^A5,V;9VQMAJ.)JVOEGKURF9&)
MA&R9P:Q$>!N 1:H)@(D]. !0W)> ]#<AG=89AS8J21S0.)-KB^1N3F>70>"$
MZ< -;GS<LSEGTYE8G?M4SFQ*NV]NNI8ENYB%D5H8$4/.3E42#RJ*JO:[,0.
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M)!8^?M2QP)#V;KP;.7.[!T-928$^LQ&%U-7X]B>);15=*Z^]2OQ:I=/%3N!
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M;T@<=/9;GEYK*]V;K<1.P,"A0YIM'O*U,0TU9CNFZ3G\X8X"G,+5_)M_,=H
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M-F(4\D<U)7,8+ &>!TNZ&M$H:U@;KP>D+J]#T3\3?>($#T("FD>F]50"AZ%
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M$IE+$DSL:54=NF-@;:H41@GC+CVMC+RDE.-T7S3D0 '+<3MUD3<@(*(E$!Y
M,M438Y-H\'9, 8FU-,]X-\VLF=(;VSSW ++UG9@_%_@_VEG&3Y9*^*XUW7T-
M+ /,97GQ7ENU3I+8#6]M7+U"VNWJEBDBI3;ABXC&:,^D\!=2-3=+N#N'4P)?
MK@#8JA# / <Y[U//A(A-RT7:X ??!PR! &@R&M[Y<5Y-Q]GFS_=H-5[;]<(V
MH.G&KQ=L763M2M$9LWBRP\.2/18 D'FB/(F5[@ #B(B8!$1/QZCGB4()J&FP
MMVCNZUS]!]=DOKYSXYZ>H>94\7!VMKN4LKIVW.#V1"1BA  Y,14P&#SA-SV@
M(\^IA$ _2/QSM*6VX-;V',7/JL ,_42GOZ_?SJ$\ML2(@*1:8RSI)N)9\JBS
M9.WH"=HHR<";RUD!#N\PP^OU$Q$X#P!B^N=%AU-;.WRK'/4W-[:VTOPT.=AJ
MZ<^=O7Z^"C"C8EY%)^M7J%%2#5NHFDX64BO/(1)50$BBIW*#Y!3&-];S0* $
M QS\%*80VTMV W/ Y<=+\-=#<C3/@BV%;-8Z=)J&QBTIK-I(7*)*_M;MX@A"
M-2/&!1]K2C6JB1F0D0>CVQQT$A*F B<YP ><PZ:ND>\ @FU[7YG+E<W&M^FF
MJ>_G_8JF'+-*I3RT5*1[:9JDRLT]@)#O%BC!.D5P=?2\>#?VH>\BW'<D0OFF
M'U*GP(YU5,WM&B_&PT(M?+3*]SQS-^N:>_O[_0K(&?B&VK5H,8!U6&5K>-8A
MA'QTP,VYC3NR]I0*I(,%T&[%<P%X*/MD<0P\#ZB(^NHJ=GXX2'6MGD ;'/,?
MPSGR S]27 OTX\K\=.GAKEJH@;%D[EU.[%=I2C^.JB2J9/I5K&-P]B516!3V
M=)FN0ID4?( QNT3G* "N80^W-E16IF@"X\FQTTTYDVRS&?#BHU/0:]^1!.?J
M'>OSL%4B>G:7CZ;$6"RW>329(S2[=:88"Q9N%FG8Z1%R<2<*)M1[@2 3&,(=
MH%,;TRV([@^(T&AL>8N.-[\<NDGIZ^'ISYCP6;VV^;,N5%I7YRKOT*7&+JB"
MZ96:03K9PZ%1$7QS,P,IR0>?3V80X]0#T# BL>&5B,SG;7C?U<!S*@G(G3(G
MW!/O;-:<N-QKA62[1VQ!%O&K)R+(C<#N03(T#^+(JW*4R!R./\8X<E+_ (PA
MFWBC86DWR&HMRSX<SK]*F.XIW6RSXVT!RX 7XZ^< K:/0_>U;KU.:LGF==FD
MQB)N5CSR35%!&!1:RL/(02BKI8#@JN[6:/CI]I .3ZX /&<!MW%'+@&*@"^[
M"V3I>*:.5IM?@6996%]=2.Q^#=Y;CE,Z]R7O9;+(/BD8?0X\!Z5[NNF9V9UI
MBI@<1$S52=:<B/(B5.P29TP_H(DJ0@!^@H9XEAY)I8K\-\> >ZWL3;Z,1[58
MD0+"04<EAS=14X<?%S7$]2M]9F+CDPB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%7)U6P[)_M^LMI1+SHV6K$
M,BN0?0%.R;FDA((^OP,")A_F,'/'/.83"&8UA[B; OB%^1+WM]!(/BO6=FOO
MWP>;1Q#6*6O>0-0QE'1S[Q%[V\E_@T\EF.N:7J^G,5G+*OP[1)61/+.SN4R'
M0(^<!PNY0*X*L9!P''_"FX"X'[ XSIL2^-.L(27-N,PYHRN#<WMD;Y\N%\UY
M,;D^OKEZ/>U@N3:=@*SEPBYM@K)-8&LLU$VK(3\(33MR @=9X4!#E)N !VE.
M!>[_ !0'[+=+2S:%I%S<G>;J;"U[]-0;WS3(#3NY<,OW9YJ*>QX*D;+"Y?3,
M[$UMX,6]<MU7KE%IW2)RF$A" KV]PF$  #%^H'(<CZ9TD),3(AV;G[SFL);G
MNMXO/=T!.>G!2!?4@=2;<[#CKQZ<BO/?L",V$\L;2/!D\L=<(Y=-G#1LR]J6
M;*('6(V]A*EW*'X%!05!*!BI!V"IV@<@F[:EJ*5H +[.L !9W$#D+$ZY=,LM
M('O?W"Z:.V-%:79N+%)NY-.89'4B&%8=.V""#EP[3,U.=W&+K$=M_94Q7<@H
MFDY*)ER@!A.00+G&CJ*RQIHP_2Y)8T6!%_E$'T!#[^%\AGR[O0HS;9ZG[5=9
M87CN+=V*/<04G%QL,D($AFRKAT51(YTVI_XT3)@(]P ;CU[A*(\#F#"Q!8N
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MWIGR/':SRR2;@<(V7W8V,8&M%$75K/Q+S8$LFU IS'4$BH)]I@ W)A]1*/\
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M=UU3)8DLE+?)HX+_ 'MI[=Y.7;W'E*4A2D(4"E* %*4H 4I2E#@"E .
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M<V$&.8_1 -?N5<;>+V![K<]^,LE)ZR!Q6P-%\'&.G?@K'8-4/\IT;I31-#N
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=9IR/C'AO+;OVBGG$;F;F\WL(J8Z:A2%!!!L5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g155225g23a23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g155225g23a23.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #! =8# 1$
M A$! Q$!_\0 'P !  $$ P$! 0            <$!08( @,) 0L*_\0 3A
M 00" @ !"04& P4$!@L !0,$!@<! @ (F D1$A,4%1886!=7UM?8&B%6E=35
M&2(C"C$T4;,D)2AT,C4V<W:U,S<X06)Q=X&(L;;_Q  < 0$  P$! 0$!
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MFS'.BF<.]=$<95WV0]9C5+&5-LXTQG/&UN>#Y?>X/'PY].>.<BQQR.>W/?\
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MH:U<$5C&SK00BQ07<IJNU2N[)[H-3;ZJ;OMFCK5KA7+=7&D!'()",0+)(4D
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M88Z^UCX;76U',):NH?O;ZPYVL"$ --&Q (CJZH(3[2]CP]=9?3A)ZM-Y!]V
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MC,E>T3R-6W;TR4D)Y7UDYC4B8AE@ED+*((T<+-)%'*3*K[]^P$11(MD^^-Z
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M4$DT4]?-HDGIIKKKCJ    [  #X\#YGG.<FR3Z\Y3\G&.,8XQE[ _P#&*_\
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MJ:LF =!LXV5W<-T1C6U4F2:"^ZRVZR.B&J:NRJNV^NV5-LY@_P F7Z>LQ9O
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M]9*XTWAND>9BD".55%D0DM0-T+.?F>LT[SZ_Q)E:-5BU<V]I)%C4%YI HMB
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M3ICMZM3?3TODJO#'G]#;.OG\WS_Y\WG\WG\WGSYO^>>? C0V >KW /N>HO\
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MZ@^F/@KO#]?_ ![!_M?^C_WQU!^J?[P_PX];Y0WZ@^F/@KO#]?\ Q[!_M?\
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M\)OWV/LO3?K3_P!^/]UCY .VGU7]=?!S9?ZV.*E_7C_";]]C[+TWZT_]^/\
M=8^0#MI]5_77P<V7^MCBI?UX_P )OWV/LO3?K3_WX_W6/D [:?5?UU\'-E_K
M8XJ7]>/\)OWV/LO3?K3_ -^/]UCY .VGU7]=?!S9?ZV.*E_7C_";]]C[+TWZ
MT_\ ?C_=8^0#MI]5_77P<V7^MCBI?UX_PF_?8^R]-^M/_?C_ '6/D [:?5?U
MU\'-E_K8XJ7]>/\ ";]]C[+TWZT_]^/]UCY .VGU7]=?!S9?ZV.*E_7C_";]
M]C[+TWZT_P#?C_=9;C'D[>UQH05#.>V77I-L6'/ACA1#IU9&JZ:#]LJU5W1V
M4[JJ)ZJZ)J[;)YW34TQOC&=M-M?/KF1U@00\?!!_FF^'_P#=C[+TWZT_]^/]
MSGE1^R\2SZ\8[X427ZF^>E]IZSTTWX,O\1D_9>D]=1^)'^XQ^R\2SZ\8[X42
M7ZF^/M/6>FF_!E_B,?9>D]=1^)'^XQ^R\2SZ\8[X427ZF^/M/6>FF_!E_B,?
M9>D]=1^)'^XQ^R\2SZ\8[X427ZF^/M/6>FF_!E_B,?9>D]=1^)'^XQ^R\2SZ
M\8[X427ZF^/M/6>FF_!E_B,?9>D]=1^)'^XQ^R\2SZ\8[X427ZF^/M/6>FF_
M!E_B,?9>D]=1^)'^XQ^R\2SZ\8[X427ZF^/M/6>FF_!E_B,?9>D]=1^)'^XQ
M^R\2SZ\8[X427ZF^/M/6>FF_!E_B,?9>D]=1^)'^XQ^R\2SZ\8[X427ZF^/M
M/6>FF_!E_B,?9>D]=1^)'^XQ^R\2SZ\8[X427ZF^/M/6>FF_!E_B,?9>D]=1
M^)'^XQ^R\2SZ\8[X427ZF^/M/6>FF_!E_B,?9>D]=1^)'^XRZZ?[,I8Z;3#!
M/RA+'1CJQ<#,,M.L)[5I@:Z?:$W0[#?7M#A'#%R233(.&F-/9UGR>CM1/9?7
M53$?:6JN]NENP;Z$EV!0-^T=P. ?@,G[-TW;?J:HBNK'V)LC^8[$\D=KYRXC
M/]FMM\([4?AO*/*"'RP3:-*O1G6^3L':L<V;IM-@"CEIVF26W";-4DFVPK;?
M+'+=)-'*'J]-=<0?$-2PIDTA%[J,$A&[ONYU'>_CWR1X=IP;#ZH&MMB9 =OZ
MO\SV^7;.QE_LV5QC-9%H-\I$X'Z2]OLSENK+KE*6FLH:;Y4VV:R+5#M.G@VW
MVV55VV0)X<I9RHIG.N<[[>>#XAJ#MN/1G;RMZ>0[3ZK]_P ?V5C[.T_/GU7F
M%-]\GF'H?N>1^W+7^S+V5GVCS^4+9Y]L$M@#O_PQ'_\ M0)G['[&%<?^*+_7
M$M?=P_V8:KZ3-#V%GZI'3V5#T+?:.JX\NDX)8?<2<,;MA_\ (X)LV>YLY'V;
MIOU]3VV_SL?N^G\QVX'';C+3^R\2SZ\8[X427ZF^3]IZSTTWX,O\1D?9>D]=
M1^)'^XQ^R\2SZ\8[X427ZF^/M/6>FF_!E_B,?9>D]=1^)'^XQ^R\2SZ\8[X4
M27ZF^/M/6>FF_!E_B,?9>D]=1^)'^XQ^R\2SZ\8[X427ZF^/M/6>FF_!E_B,
M?9>D]=1^)'^XQ^R\2SZ\8[X427ZF^/M/6>FF_!E_B,?9>D]=1^)'^XQ^R\2S
MZ\8[X427ZF^/M/6>FF_!E_B,?9>D]=1^)'^XQ^R\2SZ\8[X427ZF^/M/6>FF
M_!E_B,?9>D]=1^)'^XRL8_[,)+F2NRNO>Z.;YV3RGYL]4B>,8QG;3;S_ +NS
MG_X/-_\ OR#XEJR*/LWX4O\ $8^R])ZZC\2/]QG]<+K_ (EQ_P"_6_ZFW//3
MW%_W5_[#/1;N?VG_ +YT<MD8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC
M&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8
MXQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,9WNO^
M)<?^_6_ZFW*I[B_[J_\ 89+=S^T_]\Z.6R,<8QQC'&,<8QQC'&,<8QQC'&,<
M8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC
M'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<
M8QQC'&,T3[+7)8*5YLJ.@]F"J+ QVCYQV/MBWGT0&3DL.B,>E+"(!X_&@1S"
MX1#*[]P7-24J_&%ED!8EJR&MV[LA[3CKTL2>SB9XS,S21P1Q;B@+,A<EF4AN
MP 4 CD\G.342OUNDD@A58I)Y)2@<A58* H/EY))8D,:  HG-;9-VCOHA4-%2
MD'9+ U!WLKMV,7IV2ZS4N9NI8-M"'B3.MGF]7%!!%[$49@T4=N['50CLP9Q
M^,U""GB;4JU>)=*Z:'JS*8RKA(FAT^HE$6[>+D'5! 8J>$Y7<#9['.=M1,8H
M660%"TBS3P1-+6RNF>FP.P,"3(:8*P 4T<H']P]EY<$ZGRFO^X4#,@[\N-W2
MA(S7U+QYX"T1"Q:U9%K,<#IXUTE$?FCU*!"F4P@97&C*-GWAIJ.7V9-V6NTB
M+3HVI5](X:&+K 22L&.YHQLM"5*#>=KBRR@$\WD&34,-.R:I2)I.D3'$I7@2
M'?3C<&(4!D/ -T:K/7H(T(L PAB8*['BS,8P:%#FS)L-V,D6[5)%Z5V',_\
ML8_8BYT5>99-?^S-<K900_TD].>6Q!8D#:"20MD[03P+/)H<6>3GI@$  FR
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M!8#:$L<2UP-D@TU-!4(D#I]&HCI%B \\"AT=LB&FI [?2T"\<(.) U#L'I$
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M&;F0KJ1OX8_KF1DPCR)%-S,.>OMR371)(UATD,DD:?N2KF)GD]7#4<H>-:E
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M%W2-(Y%42*QXDC*<$6"&613\QO10?D2>X&6>-F,9 -I(&H@T059&^BNS#U8
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MBR;/([G.H*0  #P*[>F5/QE$/XJC?\\%_P!5R+'J/J,FCZ'Z''QE$/XJC?\
M/!?]5Q8]1]1BCZ'Z''QE$/XJC?\ /!?]5Q8]1]1BCZ'Z'((;P.J"4HM%2=)U
M/.XI-9@!L8*UE6(O(=PTEQ 8Y7A]DD-,(/&K=#5A!@I=H505]J=N)&88*H-T
M!S=1[N9R$BV2%&1&C;:Q7<N]I%-@CXN5(_U0>Y.8] ,TG4C5U9E=0R!J;8J-
MP01V0&^YW$?#*.05A7.K\25JJQXY23X?$CT!<:01K TQ+B)2(NG('";,&Y;Y
M%BI"&/9?&8R<;MU&[$B;.JEPY](CE!*5U- B2IAO60;W:PZBN2#;*RTK+8L
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M0(YC0@/(%8HI;W0S ;5+? $@GX94N@8(64.P)5"P#,!W(6[('Q(''QSJ:V#
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M=CFZRHM\OOOUSQ6NI00KTE]G&A9(E#2,[H$5)%7=,TT)DD=2SDNH- J*YXI
M# _4.\]8ZH-(2$50Q<LI.U!%*$12 H56('E/%[[)3N+-YY&99 ;,;OI(-MGK
MVA)&XV]Y>/FPF,'997[ME&J@H5D@T@5H@K7C!QRC(C! QZ! :9/.V.TM*P\-
M&14:6-S&Z21$*T.I*;M,AC9U24%Y]22986A=;50M@JH/35RYM.ZAU9)+;J0
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M]ZV[FV]JW&J]*NLG:EW7/KM%_6\Z=["[.[R;689Z,)ZR'W K&%7Z?9BO$O;
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MUU?2423=R(F9<#F; 4/&O%GS@N+;,\N';KV?1!IS/PLD2MYO*[,#M1=[/PC
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MY(E:8F6-5:%TBZ8EW(3*)PXDVADWK'T@!81G8 LV;12-*CD1@1N6$BL^\I3
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MR@%)VNZ&:@]EFKC1@53T40UOIY8EDEDG>7=)'J$\D:2$G40R1EV+2QT5+[J
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MI7DXALM(LKF85T8F)"M-=SDFI^)2F5$=CU9"["?V]!P)D7$C!>(EIU!HVVE
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M(L;RNTNG,9V(RK]VG4/48NX6MR!2;<JH)&"ZG<MJ(W9G5%$<H<;F5F\[;5V
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MDW%56-2+\J.S,6 55^+%5:\TZQ%5.W<X8C>XC0*FW<6<W7+*  "23V !(S:
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MV8@E4(!S,Z@[!(L9:/IF4L6"CIBR-I(HNR#?M)4 $!F%YE1WLA'1=L4S5(P
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M"3D@MV,</DXX=0*0XXLVU=[+I,Y1'C8Q??3"+QDX:[JH;Z1RM&0*#)O5F0V
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g155225g23s23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g155225g23s23.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M20I43<MF,MCD(3(NHS;:5#-K;JE'YA@/^N.%.HXKIRPX+=#M=*5<+$$"I+-
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M)-*UH0J/:$RFAO4OJ8T+6-+G%4"E4N54U;E5#=0$
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M/Z)A0MH;OZ5B+U7555SJO[UU5]:^,V0!
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MBI"R6*"ARHJYM:Z_/G]N=?WI>6& 4@
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M>,JL>P9M+=TU1[W ,/I-]H\958]@S:6[IJCWN 8?2;[1XRJQ[!FTMW35'O<
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MO6#Y+ULOIGDIX[P>P#QRT!^SYFWNY*'>0/"F2W%5MXKU@^2];+Z9Y*>.\'L
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M+ULOIGDIX[P>P#QRT!^SYFWNY*'>0/"F2W%5MXKU@^2];+Z9Y*>.\'L \<M
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MC3$1&HQ'QXL2,]&(JN1B.B.<Y&HYSE1J+<BN5;KU4]$5'"
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M0]&= EVJV##70H<-F&&U51MS;\^=5-ICL&/
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M*QZW)19J% EYRJ24S.34Q#=$EY&#,09.,V'&D7S,Q"BXGJJ-GB+P:?
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ME57.<Y55SE5555556]3]A)2
M                   !&/-GZ&>7'\,<]_RJ=8$MU4]:?>2< @ "M'$7Z>.U
MF_?)BC_1?#X$KJ-]7XJ67 0 !Q99RT1KKE]D3JJ6\;]5'64G-RS5SY,S^U7#
MK?Y5^WSNW&X9H0D8]X?^<02J:2=BK]FSIP1JJKZ7[YSV)L@KM,1+UB5"<AOO
MO_M0V/1C':[6I<AZFY)75U,FEB4EW6Z2!X/2&A)(6"L=4)+!H>;2T].PEFYJ
M#L(TPJQ7IG>MY%/BXF^RQ2WN,F?BQ;OZML*;PG/],V)CM'L\HO)M83JAQ<3?
M98I;W&3/Q8?U;84WA.?Z8QVCV>47DVL)U0XN)OLL4M[C)GXL/ZML*;PG/],8
M[1[/*+R;6$ZH<7$WV6*6]QDS\6']6V%-X3G^F,=H]GE%Y-K"=4.+B;[+%+>X
MR9^+#^K;"F\)S_3&.T>SRB\FUA.J'%Q-]EBEO<9,_%A_5MA3>$Y_IC':/9Y1
M>3:PG5#BXF^RQ2WN,F?BP_JVPIO"<_TQCM'L\HO)M83JAQ<3?98I;W&3/Q8?
MU;84WA.?Z8QVCV>47DVL)U1HR?DAB*K995AO$L<C)HM-4**)ZAN9-3XX35M#
M39+;9Q<OGRK@.:%B*"72[)FZO+A'_C:&E4&E-$TYS+%AW9&-)P(D9SUI\-'R
M<Y!16U"=B*Y\:7B0V,5'.5&M>YR-<]$Q,15<U45$4Q"VE*M?6I"D2\E+6^G8
MDI:RR55C0YBP=BY%D*4I-?D)^;FV1)=C'1HTI+P(DQ DXBK G(L-LO':^%$<
MU=Y\7$WV6*6]QDS\6.E_5MA3>$Y_IF7X[1[/*+R;6$ZH<7$WV6*6]QDS\6']
M6V%-X3G^F,=H]GE%Y-K"=4.+B;[+%+>XR9^+#^K;"F\)S_3&.T>SRB\FUA.J
M'%Q-]EBEO<9,_%A_5MA3>$Y_IC':/9Y1>3:PG5#BXF^RQ2WN,F?BP_JVPIO"
M<_TQCM'L\HO)M83JAQ<3?98I;W&3/Q8?U;84WA.?Z8QVCV>47DVL)U0XN)OL
ML4M[C)GXL/ZML*;PG/\ 3&.T>SRB\FUA.J'%Q-]EBEO<9,_%A_5MA3>$Y_IC
M':/9Y1>3:PG5#BXF^RQ2WN,F?BP_JVPIO"<_TQCM'L\HO)M83JAQ<3?98I;W
M&3/Q8?U;84WA.?Z8QVCV>47DVL)U0XN)OLL4M[C)GXL/ZML*;PG/],8[1[/*
M+R;6$ZH<7$WV6*6]QDS\6']6V%-X3G^F,=H]GE%Y-K"=4.+B;[+%+>XR9^+#
M^K;"F\)S_3&.T>SRB\FUA.J'%Q-]EBEO<9,_%A_5MA3>$Y_IC':/9Y1>3:PG
M5#BXF^RQ2WN,F?BP_JVPIO"<_P!,8[1[/*+R;6$ZH<7$WV6*6]QDS\6']6V%
M-X3G^F,=H]GE%Y-K"=46@;/?9Y1YE<:7'I(C$9E4%%$M;1TE\0=D_-:^JWY-
M2E%JW*6X>(.58IXI,H;BNJ'S9NV4TJH.6TRS;OZTWKU&N042B0*DKXL>7@Z3
M1KVMC2E0FWN68:Z'_1JU\3,W0W.<JW:N&Y<ZF@LM&6JMY.H<I2Z)6*JEKHLQ
M*34Q2;6V LK)2[*!,0*BU9Z#&D99<4PL]+2\&%#=$5%A.F'.9>UBEU4 [+[%
M3&J4D"88P3Y)L/-MEUHJF77%*+M<R33:7T8\@J'*$=5.WB)FJI/43--BN[;J
MU+W];=^WX+ENG73*Y*S]-D)ADU+MCI%AH]&J^8BQ&W/:K'7M<Y6K\URW7IF6
MY4SH?*ULLO\ E$MW9^<LS7X]"?2Y]\K$F&R5GZ;(3*NDYJ#.0,$U+PFQ8:)&
M@0U>C7(CV8F.O:Y4+#Q>S2@
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M3-0FYB<CI"8KG,AI&F8D2(D-JO>K68L+5<Y41%<M^1BLZ(
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MO%AN@-B22U)(CGLB,5S7LGKD1B7:K6HY777+AO/BONJK8+-,I5B*E-91^_\
M2I^!6IF0MG#R<NI\*3FY"9A0(\I-6&1[XDX]8B(L*8CN@L@K$5S$BX+N@<9H
M?&0
M      1CS9^AGEQ_#'/?\JG6!+=5/6GWDG (  K1Q%^GCM9OWR8H_P!%\/@2
MNHWU?BI9<!  '(KF4[I9)943R51W[EHG)=B27%;($6?M1X(B=KE2U)G^[LH4
M:N%MF5ME)M&GS%V^IF+QLA3_ '=VY5K\XUI5(LPE1G$;'J36I'>B-A6BDY:&
MB7YD9+O8KX+=9CE56ZBGI3DOIMG(N3RQ\29H^3B/,/H4BZ-&J?<^6NM)4(D1
M8?SG3E>DYZ'*U6.J_MSLNQL*,OSFHB$9^F\U^LG-CKBL;^Z@Z&C3.Z*MQHD.
MK,\[TV6\A9*OAAMO^8CIO-?K)S8ZXK&_NH&C3.Z*MQHD.K'>FRWD+)5\,-M_
MS$=-YK]9.;'7%8W]U T:9W15N-$AU8[TV6\A9*OAAMO^8CIO-?K)S8ZXK&_N
MH&C3.Z*MQHD.K'>FRWD+)5\,-M_S$=-YK]9.;'7%8W]U T:9W15N-$AU8[TV
M6\A9*OAAMO\ F(Z;S7ZR<V.N*QO[J!HTSNBK<:)#JQWILMY"R5?##;?\Q'3>
M:_63FQUQ6-_=0-&F=T5;C1(=6.]-EO(62KX8;;_F(Z;S7ZR<V.N*QO[J!HTS
MNBK<:)#JQWILMY"R5?##;?\ ,32\YS5D4QVXSE%NS!F4C&EB8(>:!Z^?VJT(
M/FT;0WA(C?;RZE64YMM\D;1CJJEJ!H@2>"A<NH#.,W[;B7RIM)3S1>YW)+1H
MT2*U\Q5;F2LW%2^TLK$^?"@/>S-!:UR?.1/GO583/VHK7,1R+B=L&T.DR-*C
MR-"R6:)-6HLM38V'N;K1R*Z3J5<DI*<OB5:9F8$9NEHT3%)RK(=3G&WRU,F)
M>>B0(S-T=-YK]9.;'7%8W]U!T]&F=T5;C1(=699WILMY"R5?##;?\Q'3>:_6
M3FQUQ6-_=0-&F=T5;C1(=6.]-EO(62KX8;;_ )B.F\U^LG-CKBL;^Z@:-,[H
MJW&B0ZL=Z;+>0LE7PPVW_,1TWFOUDYL=<5C?W4#1IG=%6XT2'5CO39;R%DJ^
M&&V_YB.F\U^LG-CKBL;^Z@:-,[HJW&B0ZL=Z;+>0LE7PPVW_ #$=-YK]9.;'
M7%8W]U T:9W15N-$AU8[TV6\A9*OAAMO^8CIO-?K)S8ZXK&_NH&C3.Z*MQHD
M.K'>FRWD+)5\,-M_S$=-YK]9.;'7%8W]U T:9W15N-$AU8[TV6\A9*OAAMO^
M8CIO-?K)S8ZXK&_NH&C3.Z*MQHD.K'>FRWD+)5\,-M_S$=-YK]9.;'7%8W]U
M T:9W15N-$AU8[TV6\A9*OAAMO\ F(Z;S7ZR<V.N*QO[J!HTSNBK<:)#JQWI
MLMY"R5?##;?\Q'3>:_63FQUQ6-_=0-&F=T5;C1(=6.]-EO(62KX8;;_F(Z;S
M7ZR<V.N*QO[J!HTSNBK<:)#JQWILMY"R5?##;?\ ,3ZB+IGA4.DTU-?N<2BH
MJ)HN13T\CM@L=#9T\=-WJ"Y4F3*EVC<OF31F_<MV2Y>Q;KO7KU=%NW157533
MK+8DVYR-;'J[G.5&M:VT\BKG.5;D1$2'>JJN9$3.JYD..-3[(2\*+,3%&R30
M($"&^-&C1NYDMK"A084)JOB18L1]2:R'#AL:Y[WO<C6-17.5$15)2,G&+: .
M)YM%ON9H;5AE-M=<Z"CN!Y&MH>P%<LTD-352A)6<QA**1H7-*=A!(7S"K>3R
MU^R8.VRE1:S=MW+M-=-QA4^LOBPV1(5HX4-\1C7Q5KD%R0V.<B.B*U("*Y&(
MJN5J*BK=<AKZK6_R-2-+J4[(5/N=ZK/2=/G)J2I</(E5Y:)4IN7EXD66D&3,
M2O/AR[YR,QDNV.]CV0G1$B.:YK51>ES'"#KV/,8DHVORQ+$T7":NKJNKYFAT
M:O!\F=%8Q3?T3C*UJ6*ZW$Y.X/$IQ?B=.3V=:J>%5X?",\D9-9&72 LS,S5S
MG.T:;B:+&7$M^%7W)>UNHU+LR'P?;FUK;:U^+766<LY99(LM+2_>FRM/2F4E
MBRS%9H[)1'Q$;'CWXH[\7SW(BW(;X'<,/
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M1H,1N'YS(D-[F/3QM<J$VQ=35(
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M-5;Z8YVT](B?6\,/X<,7IIQGEQH"[CB_#56^F.=M/2(GUO##^'#%Z:<9Y<:
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MV:F)>F9-X]C(T*620G8*QHD_%B/2:AI%BPF:31$57/;&ONA%VPRP^40
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M>-$<Z)%C18CG1(D2(YSWO<YSG*Y54^X2<(
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MGI2GQY68LK+0X<25?)S$VCX4:,Y=%5'.8F%EU^(S(^.@
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M?"UFCS<>+,QL#;\+-$C/>_"V]<+<5R7K<B7GL"HZP
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MN)(I5FTN68D&0@SZTV'#DW3$& UK'N@M5KE2_$Y<Y)0=\P4
M
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MZ*AQQIG4#O-0OH]8'X/,IOYP.G4F>M#)SKZ\/>X@:/%W14..-,Z@=YJ%]'K
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M3L9T_-I'EV(NB,AX688J([$NH34%V-6
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M<^(]SG*JJJGLBLZH
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M4K#2-GJ_*3L6Z/,2S$A87RZPX>EWPXS$57-BN2]2]H9@?(8
M
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MBRCHK*M/L<Z+(4]T>;APXCX2,=((K'T_'N'R*+<[SG%<'C.2[)S'4QQ?#X7
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M1#V16=4
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M62&Q[T=. 78U.
M                                 4'[2:?W4V\AV$O15F-ABRF5&D03
MHU)0@#)F=X0;<<SU*=+BA,V8Q^=J6['87=+#>]Z+70JN5&?I1 /D68IWVBG/
MLGJTGY6642^;]?K]:Q4B9E147/=<J(MZ:N?6N7_QJ%D6SHK>E>!>'E4C.(H[
MGY\G*)*7<YR#U;LCD5U?MLQ)H4E,D_6BM.-KO H;,TUW2[A;R\L(ZI9JH-)Z
MB:*W+=VH0Z[$Z[4O6[U7YB9P$   !&/-GZ&>7'\,<]_RJ=8$MU4]:?>2< @
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MN342];[D\R:B'Z 0
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M,2*BENHNIJ@
M                                #GSVQJ8R7G/&-#'/WX0CM_%H@GQ_
M(4WY,9;Y(8J1<1:+;<$3$G;%C24,?) C\VZY"=QM6;SD4ZUQ2OV&JTFA<5Z4
MA>TN:%"K]?KV'(S,BKG5+T141&N6_.J9G(N9+OWZY;!@L\T.1<,L6GZVFHY6
M*WWC \8.1&:#P=KC?SD;Z<KM)+.E4U3?;O,G'2]:K-J]3R9VN$Q6L.0G4765
M#2V9.W+5 H7,J^M=9/'K)F3]V8E8!    1CS9^AGEQ_#'/?\JG6!+=5/6GWD
MG (  K1Q%^GCM9OWR8H_T7P^!*ZC?5^*EEP$  <>N::\XB^5\_6"SJ?10O:D
MQQT62R?M><>(9)6*-#7[-LK%3D(W%YA6:=/FH;2M74=3M/[N]KK4-859\3OE
M.W/C(FF'HB)::0E42Y;LTM$31(*:T-V=NH>FN2R4D7Y.K&OB4ZCQ'NH,BKHD
M?N:K;VHC/58>=T2T,A&;)5AR^.?ED2%'_::A&'I(Z?3*1NO&Q=[.%OQQ-LC\
M;:;S&?:2IWDNA?"9E#Z\=)'3Z92-UXV+O9P8XFV1^-M-YAI*G>2Z%\)F4/KQ
MTD=/IE(W7C8N]G!CB;9'XVTWF&DJ=Y+H7PF90^O'21T^F4C=>-B[V<&.)MD?
MC;3>8:2IWDNA?"9E#Z\=)'3Z92-UXV+O9P8XFV1^-M-YAI*G>2Z%\)F4/KQT
MD=/IE(W7C8N]G!CB;9'XVTWF&DJ=Y+H7PF90^O)+XGQ++.04QM%M(!O(58:Z
M8XVV>D=Q,#:[01+IIAL^^LEBYUT*;,9Z"=5U8B5TX7_#K%-NZI54ZD[%?&W-
M!WZ;*S,[-0H;-.NAMB0UCQ(-I9*96#"5Z(L1T*$U7N1-BF=VHF<P/*-:6S=B
M[,5*?G(5B9:H3$C/0:'(UCN:[96;AUBILE8CX5/@52ISD*5EHT3-_3O5S("+
MHKTPM4[$1M \R#4,T0>PYZ0&FVI!+J9E+9<KQ/,Z'0E*5Q,O6WO"[^0I)8]\
MS>M45ZF$ZPYVZFW5)/JTTMJ!.F\4N5T47=:M!*+=[%3VHJ+]2FW@(
M
M               YR=J0Q9\3)X:M<A9#9(*.)[[0'V[&TB,#9T8YYMH$436V
MS#&3(]81-#/8^2&^T3I$EJ3S<)%W.\T:U5U I4W4]Q(%!:_>U'(U4NU&WZEZ
MN5N;/G_:1-;,FLN;4NNBPV49=5L3<<%2?2"XES8H0M')N5"#F2VZA.$L^K[7
M3;CCH6T!I):(VV\IZJ55^LXWD=(3B:#?JK2*"MJHG52!0ZZ];M2];O5?F)*
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M##47&H<5$MUIYJJI*4$ R?**UJZ0O7[=0J;=?GV+O;A6[Z]3SD^@*0
M
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MAMVU0G%#EVV:<3J6DM'*W[]NT1+WS=%T\:*E:+M^@/U[-4V"
M
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M6EI:M>N+ZHA-@\1;]@S8+)QA7OE+2BIIA.N\=LB46Y;_ #*GM14_$ER!
M
M                  %&\T[..&''D([)<)[22<8$=!B>U;(XE'32?&-!-"C^
M:%^(2\(K+K1DQ_18Y'$645",M*T*NPMJ2A9L6CE9TG8+G*2QJR.1'+==@1<R
M)?<Z]41;]5%3QEQ,4H];>C1B(5V15N7;B0U$1.KE%R&F^=7Y J*$+-FIW+)Q
MJ)J,V3*DNZT<X'+Z"DIR5<OWZZB),O8UHMTCC757-=YM;S9\_M,_    !&/-
MGZ&>7'\,<]_RJ=8$MU4]:?>2< @ "M'$7Z>.UF_?)BC_ $7P^!*ZC?5^*EEP
M$  <4VT!-P/1F=D30Y#^!UI=ID0_HIVY(;NT0-/JDUR,CPM'.8BU*O1]=4^#
MP>,K:=VM)UHXO2U5QFEP:IK3I-*K/(]:/CT=V+1X596-?<E^B+ :L%7:^AKA
MUCU4R,LM@N2VQ*R,#*\Z4[R0=+NH<WD2925AZ+&N609:"8;6FR]]^%*DU)F^
M_$EV$AYRW&OSELU_RMM3NQA;,<CKT+_HU_HFS<%NMSY<]_=SSVH<MQK\Y;-?
M\K;4[L8,<CKT+_HU_HC!;K<^7/?W<\]J,E9A?&1=>#40S9G9RG"JRY4)*,DT
MQM[4(NI&RZBJ%2EXLGWU!*L$+!Z_;O56BEX]>LD[1BNW69NV[--=>G)"T@^+
M"8JT-4?$8U4;"KR.5'.1%1%5MR*M]R*N9%U<QT*I&M])TRHS<.%ENA1)60G)
MB'%F)SN?GP(;X$O$BLB1F09A\9\)CFHZ(V$UT5S$<D-KG*B+VZ8[XK0%B>VU
MUH8^QZ6CMN.5<T<BVFEEYU+])Y;T(%4O0]48=BZO'+-6A$D5+\26,62W@M:5
M\3QM5==6V)*G2=.AOA24!($.(_1'M1\1^)^%&WWQ'O5,R(ER*B9M2\\H;;Y0
M[8Y1I^4J=M*T^MSTA*:0E([Y*G22P931HDQH20Z;)R<)Z:-%B/QQ&/B?.PX\
M*-1)!CNF%@    $5<NLA%G&YCQ@[$1O)CE,/W)S&&!C915-&BEE/2)[F]EQ2
MKKY:LIIK7=44!/=)A632UWP%C)PK9L&M=+%=>H$HEZ_N<OL15_ E4!
M
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ME]*5*"]1%5)'2%^^6N"454U-94_<J7+]2FT (
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M[+M77PK=^^^Z[SD^@*0
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MYL*PL>PE0EJA6EEYE92?I\R]T::AI39:ESLG'5K6M9/QD:KL2X;@!DQ\S@
M       &L)7F2.X216TX9+7;C?2'=),:Q&WS5M)6%C4\_P"77HCQ\P$2JPB$
M%$P5H6W8OI296J&[5A)2Z3.IY7/$4^Q?-6A*(JZFLJ_N1+U^I#9X$
M
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MJ!*+<O[G)[45/Q)5@0
M                                       !S73W!C?:>0>;M>36R7DC
M:)NC)%^6%['F<6>QHDDI#38NOQ0R6<UX66'M(#R07-B]_9V\$5QWKSD;R?9L
M&[2U4]R9LVIV"]%Q^D.1%S-PNPW7WIG3/KYDSWIZUNS77%VF%4<2E#^(>,\5
M3<O]*)=CN#HS9TC+FJE<6M3CN;[32TU:HU7+VM5]>U)FR]PCJO7ZM3"WJ6U5
M;^NMXW6!0Y45RJF9+UN]7B).@0   $8\V?H9Y<?PQSW_ "J=8$MU4]:?>2<
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M<Y?8BK^!+D"
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M*OR#?S#E:'YS8?6:ZAC9_A</_P 1H<YM%7Y!OYARM#\YL/K-=0QL_P +A_\
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M'[QE'IO7-"7"U$+=>MVI?F)% 0   $8\V?H9Y<?PQSW_ "J=8$MU4]:?>2<
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MA-OAPFX8;'3,W%C1G,AM^:QJO5K&YFHB9C*1R%N
M                YMMJ=#S!)9N10[T(LO%Y8E>"Y,OJ3BDK:>2Q@K"1!ML9
MRPZCF6\SK;'3'(M'GNKW32&KJS7;!AJ-)2()1QV.-#=3F+EUIO"MJYE3Q)<O
M[#7+X]>[4SYU7-XM4N]Q":+?8.+>/[+:K=9;2;K8B5D(R.VHZD-3EMBHQ(DA
M$[5HBU)16BI)7D)$M>#7D+R5"A8^XK6NBH;LV[YFNG04KJKX\_J^HD8!
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M:=FV2LK)MC:2D9:G2UTM)09>6AZ'*2DO"70H+,:L6(_%$<]SMM#LF-@
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M#15O555=ICL&/
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M/<]60F7K@AM5V%C;UPM1$O6Z\^X2<0
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M-]7XJ67 0 !6_*Q4W7(KNKH(*5VBI7NZTW+6/#1=-NK3B[7ST.$[<I-JU/\
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MCVUF9M$QS(53F83%AUZ=NFZS"5K$T*IS*)&G8>"8B(CHBH2#'=,+
M
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MJW*LJ*B^".=+O_A*E>/_ "%N8R4^:P
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MAVOKU<9/0(,&.QLE'DJBC9=&),1(,VV+<Y[(LM#PHEZJEEXOYH8
M
M         *R,_P"9$N!GK!4@.UVQT;9)AN3*S#D+OS(8] EUZ.1W78Q3$&0T
M>S83%5+?_P#9X2K7&I?35NS8T:ZG+""Y6X:I=EE%L&!*)??^[/=?=_Y_"[45
M23F&9\VJXNPNK&Y 3)0T5F?:54][(KL<+_1U-"4E \>;I)*D1W$DYUR0G-Y
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M:B(GJ2[[C#8D6)%=CBQ'Q7W(F*(]SW7)J)B<JK<GB2\^@24
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MJJ(P2BDDII0V69:,IG#BBE->S>H1$X\;,FB9&S?OW:ZPO77\_P"_7-C@
M               JEE+$?+,_,C\>T4/'&TNT'%EC'66*#:D-OR48>9!R,G'F
M-H%--=1/-M3+)=:0I$&*<,T'2=NV?H3EJZF7*JK.EVBL57I=GOU+O%KWWZOU
M?668LC1[:--"TDBMJW'SH1HZ35LBVKV6G4I<.OC-4*TO7;ZQ01XOB^!2H7KA
MCA\/A5<'@@4FC,V?H9Y<?PQSW_*IU@2W53UI]Y)P"  *T<1?IX[6;]\F*/\
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MZ&>7'\,<]_RJ=8$MU4]:?>2< @ "M'$7Z>.UF_?)BC_1?#X$KJ-]7XJ67 0
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M*J>(^X"
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MPYZ4<V9EM.R3YB2B18*H]L*8>J(O[*]"XK+2
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M"O)SOT5K3D*"%3,NKF5$O\2WHJ_AFU;TSYM1;'@(
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M]2VFM)5^N<S4
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MAGEQ_#'/?\JG6!+=5/6GWDG (  K1Q%^GCM9OWR8H_T7P^!*ZC?5^*EEP$
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MV4PK<O*:I<+TD4LH;/7[!>X):MRY]9R>UJHGUJ3< @
M
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M)#@0
M                                  1ZRY0%MUXHY.M=LI*@ON1R8]32
M@-]"2"EX^JK2VL1NY4Y*24PB6HN&#J@HGS)<F2*6+==XR9O6K-JBJNNFG42F
M94]:&?1U*S0E,JIFFG0\+&B/?+%E(H](VDB,E4K?-6[MVS;U1I*:;25[FO L
MW.-ULDKE)>K32V8UM7*Z*:A!L< 5HXB_3QVLW[Y,4?Z+X? E=1OJ_%2RX"
M( OLL^5N3'>FM>F3E6[8/WS&B<UL@FLC6[!2WR:W7>LM2M$.J2*4HNWK5NJR
M:KKUM7+M&E5SPWJ--:T5+DOP_O:JK[;SC6]56Z_574>GW>(_9JQK*BROIZ:X
MK,^-1&-5&-#K@N3JBJ]"=3;*W[UFK5.*MNP8,\H,V[)332W=HUMZW]+U7AHM
MU4ZRJIXL*^;"J?B$1;\^)//B1?P)"MV#]&\N)JW_ &J2\L\VF:3/-:X\-#R0
M=X--5/$'R?(+7*+&O"\-5OC*?#KI3KX?F%*NO\34]29RK#Z3O:;S%)4
M   &C)^@!H9%MEE-5Z*CD22#$FJ%)U2;[8-)A0X9=<$R6W)3:::HUJJ2LV;K
M>4E]L$"3A+%K!12-)%XW8355*.UV3]@2BW>Q4]J*B_>;S @
M
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MM%_NNK>^Y"'=H!<W9?94?*>VB_W75O?<A#NT N;LOLJ/E/;1?[KJWON0AW:
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MG6KIE1?#SCQ%EE766]$3:4#RX<4S*()NS7Y_'=^[]_KU,Z:NH6? 0
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M2@:!5ON\R7)YDO5?O53>($
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MNKRBG(Z??,4&U,\00K%]:.E"5F^8*I-FZHW[=LG;KO: >Z
M
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MSS<I4:^8.1DA0Z[YMUV=MZW:]Z^+Q9KOO+!@*0
M
M
-              /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g155225g24x25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g155225g24x25.jpg
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MDJ&QTM?P&B0F-D)S=WB#LK;!X3=6<IBSM+7")2<U0T9'=826V/'_Q  < 0$
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MCC&.,8XQCC&.,8XQCC&.,9CK=>KWI7UOM(#I#8'47I6E;BM$\(+KVK[1LFI
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M ,UM1VOI]*5741:B(N"5#(ED T2*D/CD3?U]#I5_M3=4?\7U _TK\R?B2?\
M=.B_G9?^3FO^B'L_SF_D+_7RUZAZ;CI?!B9<*9JCJ=6\_:+P81F/0:&M&(MA
MNM@/P4J4O:C></(A$XZ)*,)RAN0EUM#CJ$I=6_$LYY&JT7E^FR]1P?\ P?,9
M)[?T"FCWP- _,7HP# _IGB"#].7F/].#TPE9\(6/T_U32YY*7&@08K6O=?\
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MLQ)4*H LDDB@ .22>!US'?\ JO\ I(_;@]/G\=^G/M?G?_0A\+/_ "O\(O\
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MM)4XA*D8SGG,U_97:G93QIVGV;K^S7F4O$FOT>HT;RHI 9HUU$<9=5) +*"
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M5_=O^#_^3];_ "A_RL\=^AOM#RC_ ):_UL?UG;TB7]IFH_QQ:_\ M'C^[?\
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M9?P'?KMU_P#Z>U?^\>R<\Y\*/U/B_C<?]%/GDAY^J\\%CC&9U>C-_5W=-?\
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M4D^VOS 9C9@:I%3]Z7-^W<S?56;'O10?JW=:?_H6Q?\ L&?YI=H_X*_[Y/\
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M_P#JZ;W_ /[2<^6[NRO\3VA_I.F_Z3.]MUO^-TO\Q+_U&:V.L?KY](%T@[+
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M5H=T4=)#H^ XYTZ:C6XY"BK6M5,$94I:V&U*4K/J_ORI6<YSG\.<\CXWJ?\
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MI$0-4[ ;+XB6A;^MJN3S: =?KDBVR2<P9D@R)JL,30&6W)C9.\4-'9#,5]%
M6=56T^5==C,^P &BUFD<2B.E <-M8AJ!47RQI68^E\FIW!5+$U=7OIV\'KEJ
MP)L.Z?!Z V?A3K,,EA6I\ 6_1I+K\VJ6"1&+S)LP:^:JWL^P31\J2IX3F?D?
M*\,F(_S'/&L<S11[CM(0[J)[P !U!  (5[4$"FK<.",M$[-&'?:+!8$ @;.J
MM1)()6F(OBZ/(RP-MV^B6NG"K6&7I&Z#]>W43:OA)L2,FVB]?V06.*?!@_5
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MQ&@6B:_92)2G<2,+SQ1,H3NMTKJ7(*J2&<1;S0MFNP+\$:SP 9/V/M>YTG9
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M0EB$9C D#B2-7W4RJ+=E(Y](J"MV54D?L1D)(7$A*%3&Y7;88FE5@>.+(8<
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M9UO)ZVOAQ%8#EKWKZQ7*HRA<8M(!U4\3JA)49DU&*RXIB<(#3A3D0R4A)BV
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A-62;/   ]@   Z   4!F0*% "@ #H![_ *SR3XGDY__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g155225g31v63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g155225g31v63.jpg
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M\H+:.8[_  <T7+.O.K% OS!<X[K<8J_/EJJ-&\>,I F.+/J19+,*KP0#)%]
M[IA#VR^V&0E9AN)=K)MG11D_=,VBR'&+6M%K&0Q-/#8;9MC/PPRYC9]P=-Z,
M0LTPZ.1^)X=I@$ACFAS@>5UA62^)$BNDF%\6)(1(OXXP9$?9C2V0TX8B"&YL
MN#^&&6F&XAKGM>YK2.J>ZH=>)"RL%F;K86LRLV9C;)FFB9:1C\.I^&TWU93D
M4JP--%(E*M--U/G<AB:@(F_QMODBZ=9SG/,H=KVE"=+.AS3PZ5@.E8'X(3J2
M[S^*7>',<(T$FE(<81&-U- 6,6P;(C-FVQ9*&6SLRR=F0(D9FE-PQ1LU#+(C
M3+S%*Z4: 841U^DXU*QI7J'UBEM<PFN756QYS 83L1(0=J')G13@5F2)+^/G
M3&4 #+&1.M)6D\7WDN[@TZ3E.%\JG/&6V==L9,MFU8,U'F1-Q1,Q]%LPZ(V&
M\/YHCFVNA1&.A@P2T"$ P&#2D/16$3D]8DQ)RTFZ1@NE)4O?*MAOBPS#YX'G
M7-CPHC(SA,!Q,<F(X1ZUBZ>M<,VZ5]6K#6C2TKIJ,/,1&-B(:%;#US4='XB(
M!9-P$BY87'"HD=(X\*63U48!I&U*CFNV=_D6VN%5<;V!;MK2PBB#/16\]%?'
MB%P9%=ST04B16/BL>Z%$>#1SX18YUU3<%)GDU84X8!F+-@.Z/!ART)K#%@LZ
M/"-84"(R#$ALC089O;"C-B,::T;>5^"/57JE+;5Q9#NM824LR.D(\5=;LR+U
M)!J8CC9-K%RYV%#2Z,8>%PS5%% *4.1]R09HMT-&CC35!'&AMKVO!E.BB:CL
ME8K8C&AS6DED4UBLAQWL,5K'DDQ&0X@:XDZ0-2H^PK!F)_ICI*6?.P'P7NT7
MO#6Q(+0V!$BRK(@@.B0V@"$^+!<]H T30"DWR!I7UAQ@L"D>(M+HB1<H"#0Y
M^N.*A'3Q-\T4;C'Z>RJK79UJ1PRRFS5S\M\ZRWUU3^4VTQGH0W3,M%9$A<]!
MC,!>QS0YD1K2TU>VX$-T=*KA=HUOI5;2*V4G($2%&YB8EWN$.(QY9$AN<'MH
MQXJ6Z0>&T:;]*@I6BR$SAD4L.+'81.  R41*2CUA9T 8;:.QQ)BMX,[(KH[_
M /&VBFB:R"Z>VCAJY21<ME4G"*2NF,"/&EHT./ B.A1H3@^'$8:.:X;0? @U
M!!((()"RF9:!.0(LK-0F1Y>,PLBPHC0YCVG8X' @$$4+2 X$$ J"(QTSZQ1"
M'SJ!AJAC^T7LQD/&SID;>GY2\D8X/X=@K!X;E!<P=39@E? Y MFA)NB#>:Z/
M1.C-WIHMKL(MMVK&C2\P^<B"+*.<^7=#;#@MA.?_ )N;#@L9#TH@NB$M)B#\
M+]($A:N!R<L27EYJ5A6?"YB=:QDTV*^-'=&9"_\ 2:Z+'B1(H;"/XH0:\"$X
M!T,-< 5V0_3WK2#K.44^PJ..;5[-7Z1:6!B2YDT]/EFV4-F)4E)3)1_*5R8O
M9JWV#D,FL/ ^R.FPM9IG'AY'VU:D2:A3KIR*)F TL@O8&0VPV.KIL;"8QL(,
M?I$/;S>B\&CP58?)VQ84E'LYEGP>AS3@^8A/,2*Z,]M-%\2-$>^.Y[-$<V_G
M=*'3\!:M_J*D*JHB/O8O4\.81 03*KG"VJ#DF4)&3#E-)%4F;.G7Q0Z9?901
M1;Z.2A)VJDW23;H[:(Z:Z8Z\Y/SEH1&Q9R.Z,]C!#94-8R&P$D,APX;60X;:
MDFC&M!))-Z[=GV9(65!= D)9DO#?$=%B4<^(^)$=0&)%BQ71(L1Y  TGO<0
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ME9J?TW^*81>XTTQK&6S:;)B8FA-.,>:T#,.?#A1&Q3#IS9?"B0W0JPZ#FB&
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M1K0ZC6M=T;#EP(-JPXS9:-*CD=%AQYJ1E8LE!EXL&L00[2;%@0FS%JL/XF3
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MU&SX:"7$DT %3J6$&9Y0R\&%+P>3DBR# ALA0F?^('.T(<-H8QH+K+<XAK0
M"XDT%Y*S7G0[H?=)J[]5NW]#<X^B6'ZYFOA!_D%R]/Y2_EZ1^/\ ]2GG0[H?
M=)J[]5NW]#<=$L/US-?"#_()T_E+^7I'X_\ U*UF8G^U5@1DQ#)ETSJ8_%Y
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M<1E-0@&FU8SAD8"F8@?<8V<O [,B(,,'"3!P'D[!TQU75(+OO]-ZHJS^"<K
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MFPEV:$MGZC=8BST65.[@,DI[>)S6?\V\*^Q-?\\I^]XJ=W 9)0;^)S77T@4
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MB2][#M>PHA.'EQ1&/5G<5>=5;_)-0USLRL[C-*U[>"\V[2QMK2BPVW-(#?\
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M&X?[_P"*#$>.25=V?,$\I91ZNCOXW#_?_%!B/')*N[/F">4LH]71W\;A_O\
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M&X?[_P"*#$>.25=V?,$\I91ZNCOXW#_?_%!B/')*N[/F">4LH]71W\;A_O\
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MK#Z[ #!+AZB]7C0-PVE<T-2$MAB#%"1+H.-'-U2A\W(&N!8\+(2MU]3[+O\
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ML'Q 6E:T\4(L&)51^B+>/6.DLRY:M22HHFDP<+I)HO%!S_1ONILS<83(N[K
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M8P838PBH(W*MUCQU:J[U,7:ZQ6,KZ.7[8%:'7+P$^J&>[[245H3%D&,5:-R
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MG")PB<(G"*DO=JSZ?I^.U=/+)JXI;LS"V$MM1L8;B9 _!#;*(Q*1 =Y9+2[
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MNFR,D61-II-&^V=V\OT;/:W71UE"&^VVZ)_73!9+;;.VCO7.<YXNQ/ 9I5V
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M1FHL2A/$#WG4H"[%=^JVH)&V'B31:P=J9IV\K*EL3C NPW<U>F:98=>C3L.
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M1"2$0Z,1E&0Y*9ZP5JI[OCU[:#!6L>E!8[*)/!K%G,?CWFXM[*@H359<[%+
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M"=7ZC;[5LMDW,'AD'ALMCJ3.9.+,EU;0NN&C0EJV820A9IL8P&%]":39]G
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M$<$:NFCM<? Z^KB$UC'W+]5@NZ9Y=RHK%9+.VB>B_P \'QZ6 0IENR."B3-
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M[@,D3R#9>D,X]LS_ .]XJ=W 9(GD&R](9Q[9G_WO%3NX#)$\@V7I#./;,_\
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M?T%,GZFA<@J"'V]()I<XJ,:6G('E!SVFFI2[8A-B4GU=$)-05M W=8,@4A9
MX(Q-10LE)"R('XJ"ZKJ&_4-7L(P(OQ5M_A.(9,NQ0R!=3H#$)/,7DF V;<DI
MS$Y#$XX]BJL!BZT2I&0.R$P/QT8D[C_8"P();T70T>K/'Q6D'>$F#QFS(Z:E
MBTTOVZN.OP%/?K5 F-ST!>';)A<W9B6]"*J\MNAO1$C*8=W<@\'DAY&5B[E[
MQ#+O@-0%IQ:U?L8L=@LL9$HG-7J(B=--2FD2<OV&C=BW;F"RH[1_"''\3O\
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MP7WR@E_H Y]I 7^[B@Q'CDE7=GS!/*"7^@#GVD!?[N*#$>.25=V?,$\H)?Z
M.?:0%_NXH,1XY)5W9\P3R@E_H Y]I 7^[B@Q'CDE7=GS!/*"7^@#GVD!?[N*
M#$>.25=V?,$\H)?Z .?:0%_NXH,1XY)5W9\P3R@E_H Y]I 7^[B@Q'CDE7=G
MS!/*"7^@#GVD!?[N*#$>.25=V?,$\H)?Z .?:0%_NXH,1XY)5W9\P3R@E_H
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MX-1X]S&39P(U7>Y<*,1YPTV9[()E7^JY/W4#1#I.TA/064='VECR.2Z2.A[
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=MN_F3,O?7'5UG^@R?=H'R)UM:OK.T.^S/U%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g155225g36n42.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g155225g36n42.jpg
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M(S)A%W$8)$*!D3,E4J&QP? F5)/2)S0U8G+1*$-C_\0 '@$   <! 0$!
M          $" P0&!P4("0K_Q !D$0 ! P($! 0#!00' P4)"!,! @,1!"$
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MVZ3?;?H$Z@")M;T O>=S[$W$]L;4.I*O<!!Y5P%$) 2> /L)Y('!(X20/!'
M\#T4J*@28DBT^VX/?\;D6P"00KS=]H]=IGTZ;B1OB@7\0Z_D#3IP^%)6E[-;
M.DQ%:$*5[BF<OR2HI7BWY[@LU+5\.X*3V)[B>.%>KKP6VHOYA4%*5I9*@D+2
M%)\XY<D&08U2+7-[QBO<1.!+%&A*U)2J H))23<=001OWO D1@$YE9NTZ,2Q
M.*4?0UM9!AJJ6VB2SVQFF_J5$)25+ !Y21X6">//!O="VE0<6I+?F.W);@7(
M@ I_TVZ@#/\ ,%*U)0%NC1*@4O.220)DSL.@[CK;$&R5/T@BF-(2A4<J4E*
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MOY;>G2 (Z8$ S=WH0.>Z)GL=6Q]A?<",:S.0AI#J6W)*FG"LHX[4.(2E2E*
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M+#>A)DRX$O'Y=+C[D&/:*2?7G'WAGPSQGP1FG%G!=&/ZQ5[%/QAEH%0ZE%0
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M'GT,%._I_*?XXRY\@?D@G_L"/_[C_P"/QZ&!-X])_'")R3PXEKN[5GG@#GR
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MCDD?'((](+BNB5@]/)O_ .L=O3YX')3T4GIU5U[>7YC"=S.^HDN(6G']>(*
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M>T-F?D8"R4DJ !IC^.>0E/X[N/'H%(L0%@=/)UWWU"?3VP7)$CSH_P"TKO\
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MD<618Q!)@K><E3F(:$-.-NH6E92RH=@]SL0>X]QX'GD@\@<-!H)2M)F' D+
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M'WG82V8G2]J3R%@&TH?#2[B"4 %,3-D*2=7YU;7LU;<>!6[?P+#-S1HC*?\
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MR18<?J26_M"&%)!%Y2I:-2C  DZ4G8!-X422$Q6'S1YBT]4((TK!4V+";@$
MWL)!Z$*F=QA(_>JM\P<M8,*\A19LF6I4AB'[OO,OPJZ.PB4TP'V7V6W8TCAB
M0"CE25=R.Y2A*#%4RRE*&@%A8,*,)4D =22 20J]C\L+<J6JS,:ET_9-K! 4
M3(38[WB+@7Z]\'O4TFPKI>2JJ538C4B)COU8K6H;L#]09_6DR&8XD.>VW["%
M,AQN.XXTRXXJ-_3]@(%2XL73*_9X?TMO)%4%H*B=-V($@;[]!:")W,)P5=.
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MTER45)6$K)]M"CVA25CN(*U<]W']OGSS\-$Q(]@1VF1(Z1MZ=X).'T?=!B
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M[8P+Q>0VEJE<2L$JS:M;/_6134Y(C>;FY$"P%Q@A7T^#12&LRCQFL@C5L2?
MR>@>C-B+E6!745=9FV(S4OJ1'D,VM*IQ^(F4XW$;O85/+E.!B&H#T#XG\&4_
M'7!F9Y.XH,9BVINJR&M,E.79LP%.MU*X(("FT.,Z@#!7>)QE?"^>.9#GM-4
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M8,&9(CTC\9YK^P529"K]6J;%<>0U:S97;7RRB.Y.;BLQFW&BPE00IJ LNO\
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M2;*9([RJWNK4H<LLCNY#ZENV-_>S+&WGO+6],FO.N%9D-LM,-J2TVAM)LK3
M*B0=2E&Y4KJ5+)49,JDV8<J'JA86^ZMU5@"HR$@$0E"=D(&P0@)2!  @1@],
MR9S"5AR/V14M$ML)X[E *)Y^U':4J!!Y("@3Q\#TD0(&_783VV[B#,>LWW+\
M-NAC?:XCV(OUZ84.0)#S=?-*_=C.=RF6!)#*HSJU$*6XD'N=!1]GM=H23Y'S
MZ0OIOL>@M!^8^5XB^'$ @'^9M._8F8DQ[0;XFKK:)K$-45M'U]6A,A+:F_;1
M) ! Y*N04GX'/Y[O''GTT5@&.MOYGKVPZ!:>WN#](V_#;Y-T<V ,R;+AB(_;
MR8S:FPZTI#+#/*EN)!0?:;64I#B^!VI5SYX/!*6""!-^\8,)O ,2>L[F/0X=
M&(,IIOVV6H\AMU1*V$->ZVR_WE/N>\2KO0MM16H)20DGQP/3*E:1/0F)'?;\
M_P",^KR4%)[V@@="8_(VZ7]<.:BY'>3!=C_\NT$.?6QWBXRZON!4E3:N5)"3
MR@ <'D'D >0TLA1F]OQO;T/2.QF^%G?_ $OUFVV^QN-L*?JDJ?DHC(^>.&W1
MY0$\*3V)\_9W*')'[^?GT24$DD$7O'7TO?\ 1[1AU"P+ =+[?@29%]K]L;&I
MD>:3"]U+,L<%XJ2H*<4KP #QP!W$#DJ! /CYX]'H*;F\$6'Y18>T^@G;#@(,
M@23(CIT&X%K6(^4[8;9S+<-+AF!7>EA*BU_<EX+4I'=[8\%(4D\J \>>?W]*
MY@D2#]=K?('ZG\+)4D$&X]-_T2)N).^YN17W<VB->[R:I6,]K9LIG'X\A58Y
M6RIM>1&G&.F= =>9!#L*48T92P$MRXSC"7($J*M;RG>%G7#F3<1KH#FE$A]5
M#5!]ITJ/,0$P>6$B4*2HC40HB\7OB\\!^*''7A=4YG5\$9VO)GL[I&:+-5):
M2ZE^FIEO.4R4I7Y0XARH>5KB4A8"=R,06'IC'L7EF7K^VR#4EA&,=")^$6TG
M'?>6TREJ(JRJZ]]%)=1&&F4,QT9%5VS;;:@A+8^/3&>>'_!7$O*3G'#&6N*I
ME\ZFKJ53M+F:'DP$K;J6M"6!I2 H:']43;;%-I.(<]RQXO4>;5145NK<0^VA
M]I];KBG%EUM>I-RL@0" )ON"/\MP#);=%I$RVOTEM=#GU$6UEYKJZNJ\MM(\
MIE;3T>5F^LK7 )R&I$=:F7R:>6ZZA7W*4>5*H3G@)E[=4U7\.<7\2Y54,5K5
M?1TE<JBS>DH:JF7S6'6'WF*>L*VW$MJ YJ+)A1$JU61CQ(KPPY1UU"P\T\E;
M:A1K50H*'$*2XDTZ26%AQ)4VK4I/E42)( (69Q_!<3AHK873KC-3&B/NI$?'
M.HS;D6,MZ5)=E/NIC9#B>3NH#\J2\\M)L7U=[JRMY7')KW$G@+QCQ?GF89_G
M?%'"&=Y_FBJ=S,\TS/*<RHZFK-*R*:F3HIG?@VTLL:6PTR5;:A !&)^3^)V2
M9#EU/E-'EN8Y914X=6W1TKU(^U3NNKUN)86\\TXIMU2E.++@!YD  B^$;EUA
M9;2IW2=S7MEU3:W,<ZBKF9/;X*ON1'R+5<J IW@<I2Z\TVOMX^U)(]5ZH_HN
M\1@:A4\"53J4J5H0K,F%):0D**H**B1.H R0;C2("C._Y;,L0-1:X@2VA2B\
MXEBF>2RRVRXZ[4.*:J" VTEL!:00L<Q) P-L8W!T\YK:"FQ[.=^ZUNE"U=CH
MSK :';&.V":>P>K)+D6RU;84]Y6P7)+9<8DV^-_6.P2)Z8"XY3ZQ@^%^<UN;
M5^491DRZRKH"L51X=<9=DH,*THK%T[B@8L DJVV-L>@>(,GXDX2X1X9XVXF%
M+E60<6MT"LDJLQJ$T[M:O,V$55"R6I<"'7F%:U$JT-" \I!4 "%D*+[%,0N]
M@N/8SM?6N-0I,V_RS5%G_-*\=1%85+=CY;C,N-59;B4QN.@N2U7M)%IJXD(G
M74?[BBKTW!.95?$66\-4']BS?,<SH<L11YZEW)W:=W,*QJB;74&O;:"&FW'@
MIU3:EZ4I5 .F#7U\2Y:U1U-<\ZDL4K+CSJZ5;=<WH:;4N.;2*=:U*2G0D%0)
M60.LXQQ.@P3;.*5>5U5<L1+>-]4PS-B--3&V_<6VI#[:%O,J5WMK"'H\B3$D
M-E$B+(D1G67G>3Q1E&;<&\29KPSG#=,O,\@S1RAS!5+4"IITN4R@5MTU0WY'
MVZME8U%,%H%3;H;?!0)F4YC39UEF5YS0+6RFO:-71+6F'6FFW2RM2D:B@*64
MD!*C)201 @B)_P##)BS5I/M*3&A&M;%?_,RI)D*BC@CE3,9;ZHL8.E"')'TC
M494IUE+LE3SP2XF76^(/%6;<.\/<+YGG#[^2<..U+N29>&613Y IYYU8_9Z0
M$FM*FW-"UUJT$2I+?D@DJ;(\LR[-LTSG+:!N@S/-&TM5=:TZZXY5H"M3@>9<
M'*:YA)4KDZID3@\:XTE68DXN>ME,FU?2$NRU,H2EID#[(\5 ^UEA/]QX45+6
M.5]Q"3ZIM77+<!!4!IF=+:6DD W*6D%24 Q.A,I!L# G'4AMN VE+:/W$ GR
MIF G?8?Q)M-O>H38E)JS )5M8Q;2<T'HU>B-41X\B6Y*GJ+4<J$F5#BLL^X
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M/^FX;FN-HCUCN,PGDQV?:K[.<)=-,6M+IFQ<HQ2QBH:+DHKN"7>16A&E*V%
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M?1QU(6N82HJ<3.?B+A **HJ%I5WHFH33TH^'IUMJ?22H:R2VE6X! DJ"3 )
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M1R;R!.KZJ<$0Z%3$J?*R%SEHBV2VRPI-LA*6V6$L%302D-..*0E(1VJ5P<^
M7\.TGE(0P[5!.NVH.)I7 ?*DDJ 4$JD[BUL1ZD/RWS%I!TF!Y@0+65<"1Z3O
M?']04\)!)/ 'XX\#_;@<^?\ O_CUXCQ6"2DVZR;G:+VO;J<>^A@BN -IZB^Q
MV_AUP@?6I8^T *3W $?/!!!\D*X_?X/GT2I M^K'^,?J^%A(!)O?>_K/Z]SA
M$M2NT(5Y(//)()_( 41X*ODG@ <$>.>?39D@)W(D^L;";_H1&#PF=/"5<*[5
M=JNT? *B"!SXYXYXY\^!Z!O.JQ MM?\ C^-NW<8IIE@='4%8ESDJ&M:G[E!
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MWF03RUMI=4-2"HZ1JDI6TH  I*@0)2% @A201CJ.U@JZ%8<'VZ00T5"%K*9
M"P1O8 0 (CWQ <RR(3]>813K?C4D"[9^KO;-+16[$CU\<.S'>"IIR7.E.@>V
M@.LMH0I+7<TI\N-2J>F":BK<6"I30<)$QY 2H*!@E-NI"H,DB!I*:E:E4##0
M0A!$$K2#JD"^HS$ G:!;Y89Y,NLPNDD?I$"QLHBVVE+<R-57-='#Z_;,"351
MX\>E??=BGV8O$V/(6I#1DMN.^^'VTJJG %.K;6E)+323I;7$#S:DDK,& 0I
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MCP%<J!//!)\<D\:5P/']M[_9=O\ B-^NTB\XS?CVRLNBP)=)Z" $>G<][?7
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M2B@9$FH?"6RHM3]P*69"8,NHJ&::G6[4OL4]( "^\]!2A&H04&8"]8%Y%C
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M&I63P:=[N2J)B&89=B-5-0HD>Z]68M>4U;,4M!!6J1$62%!*CQX]>E,P\/\
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M24P4WB)(PG,*45=-J("N6M:UI($**TE)U"!(4"4D=C:<#.)I6WQG,=CXG89
MB_QK$H\K^5+&196-[+V)K;-S$R;#\GFKDN+;GR8=)8/49O6'4K,Z%91(+;+#
M*DCZ&_T?ZG/,[H<RXDSK/35#,WU9=5T3[BG$IS.F445*M))*7%5 6H$0"2%
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MVY9LOH/:IYEM*6'&W@I;L=QE+KRFULM.AQ@^ZA9*U"802F!)3IF^Q@F0(@S
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M)6D932J6]\5F*&P.:ZEDM,0&T.<TD!*5 $BZYORE996/&F.9N"G)33)(0JH
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ME:D:DB$R<<^]1T>::IV#L;3.R)D:;+PW)'*FBEI;#;UUCJT&;C^1L+;;0RY
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M&\8O=JSIWZ<]IZ+Z;G)MAD.+Y9E.R>K]>QMC8V(%J[6XQIK06#;Q:JX]'/\
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MU#E/3 F-1WUKBU@]+@S_ .I5I$N B1'5',U,+F3 D3G$(6\;K3UCV<9/1U:
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MK!,ZD)2"G0+JU?XB1TG?$UPU]A^*N!.6ELH^WM7XY'@<CR.#P?GCGGG\?+]
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MATPXIC*C/G1HPD.+,B7(<:0M^2^""7I+ZP7'WCV\J=>6MQ7/E1)\U)_.''0
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M3EAIV@*!A"*D,,KIV4Z6334P4VRVXWJTZ4:](4G2L:B0HE1.%+I:94<M*DA
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M5-4+;RT-TZ(2 XTTI:E $J+325$'0K"FF*=;:@A4/*; : .E,H"B" ;J&B9
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M@$&Z9VJ?N3%<YRF2Q<_Q$>JV)A;+#27ZCIFU((&;9G AH_\ 1JF<%Q*>WK3
MHO:6Q&EWUUD<V$L+1/J&%I"303I6HN(*PM9E3JW%O/*-CYU.J<23,BR8
M@PZX U_TA]:U"VEC02.L6!"0 1  ,=KQA/I+JAZ7-.9OCS>NNC&ILL/C3HK%
MML+;-ZWL?;IBI6$JR"JIYE8<!HK.&D_5-1<9JZ94A#9CHELR%!Q<:I-34MZ&
M'2PM()0460H@&RI"B00"?*4D&+P+H-: L-ML(;U6"H)6FTRE2I -CL.QC&SJ
M>J=U9SU"4N-;,ZCKJQTSMM^NRK6.P[&TO/\ 3V%K7)9J2PMS%Z5]BO;7B*)"
M:VXKUM-EE+$2SGRH<"P1(;BTM8'&=9 2XVYRUH=D.G2"2L722F0!]TR8O@%2
MG5MH<6HA2KF9(L02-[]+Q:]ABNEUI;+= [FDXC>1JUO+M>Y#4W]5(7 B6V,Y
M%&A3(]UC]]%@SXRH=[CURTW'D.PIT5276C*J;..U(8EQ6GQ4\U*M!T$^4J2(
M6">Q,QN#Y@;D>V&2>4Z2 E90KRE4JV,C_"" >X@]HP<>J/7N*94O7_4IB.-P
M,;I=T?78[LC%ZM@1ZK&-UX^E3U\(<5"41X=;F-;VY+ BMM->\TF;:R ERV4P
MS!IEN!QQAYUQ6E4-$D:EIB9<)$$DD@D)%@+7.$O*D:RE$J\Q\IB=NBK>LGH(
MBV)ON3*]@S=#=*&Z*/,\IH-F:XS#-=$NY)5W4Z/.LH-57P,RQ=^8E3RXUBJ'
M1F%7SUV,>8BY>"GK5$Q1Y#C(2:BN;4 4+$&R93*T_=(2(@1?U  WPMP<MIMU
M*B5$F0HVD>@Z">OH8POR/9%ED&)X[UMX74UV+=0.B<ZQJ@Z@:ZDC_IE-L"HR
MEQR)C>?28,8J9:1EKC=CB>5H6"_,4Y-F.O\ N4T"7,:Y04M[+7VP]3O,J<80
ML:E\]OSH4"F!J:("D^6Q%Y3(PM"S"50 3(,BQ]Q-R)W@'W,XZC4^18XF5 RZ
MH2)F&LP\7SRM@/LM.M3M(;CH _=X],8)+2XT2OF91#@U!3])$53X\E84J"E(
MU%BE7XC>$^=Y4ZM;F;\/L5!RUY<?%-U=.VR[2EI:DF5U"0MEXA(UM,H"-"DJ
M49.1UW[#S^AJ6W%M-U+H:K7$J@\IPCE)03$ K4N=0-C%B)P ]95KF#9WL+3T
M]:Y'\B9=>8U#7(<6Y)>IHLI3V.2Y"U'O<?FX_*JICSQY2ZZ^M:.Y)!]>$<_1
MK=IZY*%(14-AQ:$ )4VLR%I-E1#@(((D7F,>L\L<YK(+B4%*-"=!NA2>H6)!
M.H2%04S-B(C$]Q&NKM=;7:QV8I-1KS=;,77N6KA-QV44EU.L/JM=9U$3V)BL
MW&%YX_ L8L^1_3KX-I>3/O>2 N;D7$.8LUC69(KG'<YRRH;S"BK*C2[5%=%2
MNLN4I?TI>4Q64<T[S"%H"PAH-EH A43-,FH'J!RG13I11J9?IW$-)0W%)4U
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M,!IJSDRV(UNZT4N6#;+;DFIB!EAQ#5E/>,+KU^;U--3H<;U5M6Z0AM2DRTT
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M<L=ELJ)&:*E,P2U/AIDOOK+;#:2][B4)4Z'%>TLA':.2EZBJ:JG5R$)*N8@
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MZRO0=CI"TS&VH2;XA9@$<RG"KJ+U)8D:C#@((!()C<6,&9V&&B\EN?\ %]M
ME1$A\:X?LVR2.+%W4^"JE!9Y)*@/;*R>>5%1/GX\&<4M(9YR$;#-,Q9U'JAJ
MH> 3T$)D$CH3>)C'L'A\E>7LE9*BZVW)5NM1;1,']XGTO[&9+VZ,;;O,(F*X
M6ETQ%D/-*+3[2DH)2MIY'"V5H/"T.H4%-*2'$DE(]9_E[HIZVDJ-DM5##RP)
M\R&G$NN(/?6E*DD&R@8(DW[RV];+[0VY#Y*1UT,K5UW,IL+$D[Q;$ZH+G]7W
MI@65R'4(_P!6\7U1FENS'"66V<CW!K^?J>X<9:20EH0LIKWK=9;2"B9]0^M/
M?WJ/L+(*FKS?^CEX@Y*R^[KX=S!ZJ0M"BK135#[6:)0V0##:$.K@), $W&//
MV;-MT7B9P]7K;@9G0DN+*1]H]1IY*'E']Y8:2AL*F0 $S(C'('ITJ=AZ&RMW
M*]=V**_+,2EVV(9)536_K<?RF#6RG:C(<4RRI6I+5M1V$F$]'E1W0EUAU+4Z
M$]%L(\>4C ,PS1M50E2G-"%*IGZ13)(73.*IF5A;"DG4VK65*2I,7OYAC<5M
M,5E(65(0HOI.L$A15^Z9!F1:(WWOOB\<R/F,C-M6]1.@<KNL<U[*R-=-D6'V
M5BS8C0>?Q:%PRM=3JQQ#'Z[AV7,NNJQ2Y6@2[:%9IQVPDPZ^36Q5;EP1G6;>
M*U?2>'W%^9MOY4]0MI2Y4J"WLPHJ&C+='5Y:XH*Y?$-,\AE%0^DE]:"\2-)G
M' SE?ASP7X:\25".'*A/B/39DS59+GU-J115N7/U"?BJ"O0G2%MTK96TV/N:
MD);86FK;?4N89/$AX%,K]KX)!55:RR^\%)FF(LJ6\UI[:DI(L)>--*))3@&5
ML."\US/#:(D6-(_EQQNJ6Y04WK$./.#,UX7XCK\ES9'_ #UEY;J&WVD@?M#*
M2Z$T&9MG[I::5HIWD#S&J(?*923AWA/B&ASO+::LI7/L7VP6UF2XY4I,O4SH
M420U3)!+0,)UI3H),0EV8[)B43.U,0DV$3*,%2,THI])'$RVCV=&C]085#AE
M(3-6Z&?9>@.A3%C$=DUTQEV',D(]5GA*C77<09?D*:RDI4YYFE'EA7F5>W24
M2:FOK*2D#[[SZ'%-H99"D*>84%4R#J2 5)QW,VJ!2T5;7.MO.BCHWZI33%$U
M4NO*9 4A*2X);(DP4@E6]PD8DE-GS=]7Z]ZGL)IW:^IM,J@6&4Z^9*6TX-N&
MGL&,ARS""AY23&Q;9D5$K*,(LWP$FMO),.0:TJIJE7MOA&O.9Y%QSX!\39Q1
M5^9Y52YA0Y#FU#4)JJ*JR^@=<>IF&*Q"4?M!>55'*+JECXE^E)84@\HD>:\[
MH#EV;\/>(M!15E+25*HS.BK&DMNI^*<6ERJ4T@P Y 6'"/,(42 JU>4ZU1IK
MJ!R%F+81;#3VTS)V3I:U3'[6;+&,EG+LI%:AQ<1IV-889.G/XO=54V5+LXSD
M:JGRH]2FSBQI?E[C$\.-\)<+4C&39SDGB-DU=FF6\>5E>^M[**ZMI@Y3T])1
M,%2D,%;"15!U*&D./005J@XW3AVHS2IS#,:E_,<OJ^'ZZDI'>&Z&F:2C,:1P
MH0Y5O5U2$#GTSB2I5.VI:RD%*1&DC%KLAUIC^7T*D_3QGO<94!PA"O/ XX[@
M!\_X\<GUD;3[S#B76RHJ0L.?>(.I)/F@'[PZ3>1([8N"0"H%6XNF>B@/*8]/
MR^6(-K;*;"#;8UH/)[Z/79_4LS_^&3,;F4&?K&HI;DV6A\LL'CRO%<@Y8:P&
MRGJ6G&;]^-2QE2F)-5CMKZ,\'.,>(^&W\TXIR_+<VS+@O*12/^(;.743592T
M&6O"J;ILR?2X=3%2RZ'ULK825K;14K4DI0I:<J\0^'\IS%EBF>J6*7.JGXUS
M(DJTI<J*E"6"^REPB$MNE5,'DDI"CHVT 8E.QL3A; Q=.35<*75R#+$'(ZU;
M0%QA>:53[\&4T]#=21%FP9K<VOEL2DAETF=636W8C\AEWZ$9/74N=Y92*9J&
MJNFJ*-FKI:D*2I#C;Z0XDA9.DJ3J"'-*H2L:1YK8\PH5F?"><(S*BIW:6OHG
M0,UHGE'2I]LPZ($!3*E"69D%!E),@CDEE5'::"RZ7<1:^6SKZYM*W^;:*H#B
M7\.O%..-4N58HA1<6Q#D$.KQUSE49]M$[6]RDO-4+;4):'LKK/O+" H**1,*
M*53!]3$>NK'JOAWB"@XPR5NNIU$U)2@5#($<M]21S6TI.R4N$IO 3 ,C%V:2
M1A>\Z6!69=78]DEW @L6U5/>B1IU9E%.^@?19%3.24N]K<A(6S*82I3\&6),
M)TD *<M5!F#K;8?IG%M(<A*TH5M/=(W!O!B 1/;$Q5.CF!#R$JT @!P!4>DP
M4@R3UF/G-<^K.BQS76B,KM\8QV#46S"(%-$55QD0$06K2?$JW9/MQ4MME49F
M2IR.5H6A+S;?>E2$E"K;PX\_69M2L//K6TM860M6H*2D@[J[S<;7 OB+F*$,
M4ZG6T!,>4Z$C][J0!>(($R).US-6M*:=UQ#TS$V!EMYV)M(J9<:!&DQS+L[!
MUL16&F$R4/+6_+DM-0:FO@(CO)CH83*$F:^^6[!F&;Y@K,UTU+3A4.%.I:#"
M$I.F!LE*$H )*Y !!F/O<ZBIV44RZAQPA3B2K3J@ WD &8C;2#/>2<;\/Z<<
MXW(N@QW4,2TRFY^L>QVAP[$)+)R&\M[.Y3;Y)D$9;ZV:AZIK+$B$[+N6Z^K1
MCN,IOI-M7U[AD):JLYI<K4Z]FBFZ=M&FH<??E*&0D (38%6M7[C: IPNK*$H
M6L@%C2E%(*M3@"-12)5!N;* DDG8"!)@1?!VV_H/76+:W.J<"I+;JVZCJ*RQ
MF+G_ % 8HWD#.BNGNNQVYKKV7AF-W6._44NP,F=KHDJMS3.;N9+PVDC29-%A
ML*=<RIL]CFY5FU>Y5(S*J?;R#)%A[]GY._R1FV<N/H6VFMJ6G?M**F23KIJ=
ME(J7E>>H4ELI;7%0':U]LJ7RT[,A1 =</0R;I$D0D22=SL,5JV)J"INL3JDY
M]29)C*J>/3XK7;33BUL,.F2%5\:?75MA9+9C5\Y4F$[$M8#T>>AX0GDSHSS+
M+CQ<[='F!IG2Y1O,5.LK>=HEO-J?"M90MTLA7-3I6%-J44>58*29! Z3J*9P
M"E><',192A!4LI,:IO)3$!0,@BVQ&!-E?1=M_15/4;<R%#3>/3,F5B]*)S5K
M46DB3(H&L@BV[=?>5,V-(Q^?#F*C09[$GVE3?J$!E3+ZI"GJ//LOS6K?RQAI
M27RRJHJ%T;S?*5]L65)<TK4KFI(.I!"=,J4;JC$-+"Z>HU,K#P;1K;45!S0"
M0E4KDD*!3 3*8$S)49,V8X?U/:XQ:HP.379U:8WO2DP;=,>CH*=4TY)58Y2Y
MK&Q&]L;)$1QZEJJ*BRO,E.U[LF)6NQK:4]88ZIVOC2(K%/49!F3KE:%TK=1E
M#E7E?F?0R0MU=(JI93K6$.*==IZ4:R"H*; ;5YE!2G'TZ]2G)6-34E1D%11K
M0(*A<I2+V.D0=Y"=QIW:%SCM+-R7"+:FQ?*:.PC:NG5]<NQQ[*),YQ%@MN@O
MF4OL75W;S(\)V6W#+LIV'&CPZZ,(R$!$E689<U\0EI:.?2K2:M"WVU+82E7^
MU:G6RA%_,M,"%2HDD8)MM"P\F6_(RM:DE0F0I(N"3! -R;VN(&$^IL0R*FEU
M^(6FMLF@9[8I=R.CQ^SPRU1E>45%DB;(J+#'Z9]B/=65.Q%_47C-A19,>5*3
M(<<="*]A:9&8UE$IU^K5F+!IEJ05OHJF_AZ=:0E*D..I);;="BE*FW%!25&-
MR07LN=ID!2E\H!L.)(40)E14-R)WE70*!F"#A9@6JLNV1.SMAC"[Y^DP]FV8
MO94G&+SFA<J9:WIS<YZ(RVY3*H8DN&JU;G>W^G1I=2)@C+7'=45;745(<L=^
M*84\^R AQ3[?-?:>6OE(02H%Q+Q2KEQJ#D'1.D@*I&6JMRH*'&V=2QRQK2BZ
MDD0D2+J(, ;W@7Q"K;51QNE>R^LQ2_M,1KK,P7L_J<>R6;KZJMDK"A%DY%&9
MG5AN%+6A0KW9#DT.*(Y9'8ZE]NN:=<%&*M#*UHYBJ,/(#ZFQ)*PP5:U)D25!
M.GO,'#3K=%3KTA25+!L%&229VTZA<3$QU(N1@D9-K'=\O5669U+UYES&#8K<
M851Y/=V6/OXK7/W&7V.2P<=+E48_O6"G+/#+JHO+1GZ2'1O,Q8U]Q:2ZUB3$
M:S#(FZ]EE&8,OUCK-14,,MNH>4XFF%.5I4I!(2=-4RXVVJ5.IU+0%(:6I(%2
MIS11TRDI#RH*08$1O:Q,D6B\DBTXW8U>(Z>[:KR['<JKX66O5%O"MZ[)*&@R
M6GRBDN*>359'69-C.30+*FLZ&]C6DJ Y3W\.; -?[C3L5;3K2'6:P',FGFJI
MA3](\ZVZV$..L+8=:4E;;C#S"VWF'65H2L.M.)4E5@H$&'ZFAHVTH&HI=0V
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M\BP<-8XS+<<DK<CN./)4\^EI3B5#N93QW*ZM+I#(BP#AM]ZX;;!5[:IL/D3
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M2E/ /DI)\\ $^#>N"S>M$;%L]HF0??86.T3BA<;#R4)F)+N\6^[?W'2_; 9
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M@0[%EAK),F;IJB+"9^$=6A06Z@DTM13ZM;J@I;P;AP-E*4,I!;NVVF!.Z@
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M+U=/N*7"L2-A;-/$AD^TMT*!![$]H25<=W@%?)'@ND#@=H]8]QM2TK.>O+I
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MF6&XZ935<6VX\=E^6\&0[ZVO+^+:"J:Y5<PYJ=1R.<E20 A2='F2$$G2"5;
M$B>N*2_EU2VLNTZDJ2 %I1%BO>=15!$P=4@Q:^&?4.X=H9?E2=)[E2QB\ZCA
M6-I&L'PW&1"9J6'%3)$D"191YUE CAV3C\D3VZJODQG;64W+?J:^O4==EU)3
MTK>;Y>"\*E?+"$CS!6JR3!( <@<S2F5 %/EU*);;<J7U_"UD-I$K*Q:Z8$$3
M.RC?5%I)V&!G9VM#3[-!K),R/C\,*HZM[]/C6$J16N-+5B%@\R[8LFN5%J1-
MIVWK%#\E$&)42WZYU]\=_40A]S+2X84\M,/('E*%J4%+),&4@@*B!*E+@@)Q
MSEI^&JEAJ5-D0E6XZB4SZ>O;J<#72V.9CF&7[.I\1L4Q)D&[L9RY<R7%B,,1
M)3N0PW)$AU^@=YD.M!3$5*##5]0X)(AM!@O,O5M73TPRQVJ:+K1I>20DS"DO
M.'5:ZA*;B8($&TR3#;Y+[<CSD$$]"H*FTS86/8"1U.'V/>WF4W;>+9)=.NV-
M7'LV*:H8EST5!%9,<@I9:77W"6P[*+,IQ3S4J4LL-(3 A!/OI]/*32TM.VZQ
M3ZD/J_M#\@+0VJ94923Y1$"VQ)P\IQYUU;3BR0A "  0E*@!<C_,3>/4U:E8
MQ&'DS]%<M250)=?-RU^+>%I^3$F0!$I?Y?L"EB.)?Z',K<BDURW(Z/>8L&IC
MT=$YI2D<K,/B/APZT F74LI6F1(*5.!:95(UH*"H$F"FTC>10%H5)2_YD);*
M@.LA2 )]0"H="9],#?;_ $V.9E.L\DU]#B1TR9*Y$FF;?CLLIF+25EZN=>!B
MMRUD]LZ,X6H#KH4E#Z7FEK5+R[-FZ9L4M8HE*AJ"].H@[:Q8P+3$$D$$@2"'
MJO+C4J+E&H)1,%(^\%STD 'RD6(B 1T$"7#]5Y?4W<"/FL%V"W >'T%+(3"C
MFPE1S]6')28S[S0JD?3HER7T/S'YJ8[<9"6X_>'IS]?2N-%JE=\[M^=%U$&
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MI81*Y7=-LS4E<RW:7)CRGK%$:,DNL?2M34M/).;I<?;:%14H6P-5FF8*;D$
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M+*!Q'<8YBI+C@00 6TJ(22/400#U @F!!&(SGF&TZ\;72.,P*77S$27-RV/
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M+/$*1-9#BQ[2AR.>]'*BA0^P@'@<I (5P1QX_!Y] P9]B1-^DF#/M^,6V3
MCI.X'4; V]QL;P8O?G;UCZ.V1L;/*G,M<:Y<S+(8^OOY<H[*T=U!D.N4WL?*
M7KZ'6;+Q392J3.,/H(\X5=JWL70>5KS][V9<.=CDMW'L5,O@9A3//.I<89+B
MPWH25_#J:UA9<"7FWM+C:0=*@]2N!T@:2@Z$3WLHK&&&E,OOAI)>YBDI^)0_
MH+0054[K&MEU2DE2/AZUOD D*2M/,<TI,7Z3IUEN2N?S/2.*O8)3]2>\]KSK
M*R8U[:XSE%7L' 68^%VJ,>18R[B984.0JDPGHV1X]#DU-JAFXJA(C(9M&DHH
MB:A(73-EH5E2\5$-*0M+K1"%<N2HE"R0>8@$*&H2!JP^YF*12D,U;@?70TE.
M$I+R7&RR\>:G60E"4K;A0*%G4CRK(/E(2PWHOW!$J+RARO"L]R+((^K][8CE
MN3HS[ISU[CFYYVQ)".YNGR+#=;WVWLJE9A,[LO==WX:>MQ?(8<6/:JS"%*GK
M<BMT#P2M#C;JE!BI;<5S*-ENI+Q_=4VRJH65GSDU6D(6!JY@)Q/5FE,I2'&W
MFD(-12.--EFM>73)8!^^ARH13MAH#E?V34IQ"B4<H@1))/3-M69AJJZ[TWD;
MS%1N>7G&*-4M+T=UFUW6;34$+"I^0;+T^]-M.DG/(ME+CR,<?DXWD& YC#H&
MHEY!8CVR[!AU/PKW+A3"X34J<0$IH0^ 6 VI3S))H7 22B4*;<TPI(U2"E-=
M3AT%-4B33):7J5F2J>4U)=#;%3"<P9*00L!:'FRLE"CI"3B]^/:CV)9=+.N<
M-NKAS3VR,5P?!D0[S6KLUS'L-SK#F:MVKA)I7+-Z/DN"1YU>U59%AUG93:F^
MH53ZIN>$N0K5CHAEPTC32EAAY*&A+).E"VDB$Z22%HGRK;)*%)E.H65CGJJ&
M4USSR$&HIUN.RE\)UN-.%04=02-#I!*D.!(4E>E12;I)(T#O$9+:7NLMAU]?
MKK?N*142<NP0V#C]5;UBGT18>P-8VDIMES,M8Y \ 8=LPP+/'9C_ /+6:0:/
M)HDB I+=1S"IIT<NI0"5MR84+)#C2CIYC*MPJ I/W7 E8( >IN6 \PHNTCBH
M;>@!23!):>3?EO(&Z3Y5C[1LK;OBTM22K^DR.UJ0\79(#K?'O*)[NYTCC@#^
MT^/''''I2IDR!T];VC;H/?YVG#(23<3!).T3TZWGU$3VP^F5)B-NQFFVFV4/
M!QEXA+J4E:>#RL'P>$%2B/'))'!^$DP#T $^V_3TCIAX"!<#M[["_6_MZ$=Z
MZ[7T' W1DF.9/AEP[K7?.,M*8PC<%/!:D3H,$.*ER\:S*J#\2/G^L+-]L*R/
M!;V4B*[R;7'YV,Y9$J<DK8M2RE;?Q );=;$(> \PD@E"D$RMLD^9LVZI*5!*
MA*IGUH/*4@/,*4%.L*5Y9$?:()@MO)'W7$WCRJ"T%2<5G_B-=54_3FN5LXQ9
M,#969"=JW5CM4RJ,S4LP8"*_:&SH,%R38R8K49N1(QG&2N7*>BVLVWB3W)#@
MC2!F/&N9.K<_8C3NE+(169DE/W*@ :F*(J'E4'QK6HA12@H"5J2HC$E84%*6
MR-3BAI0# TM_O$DD &8N1W@&T<UD[D>_AZX+7:1PW$,,RK=&?4]7EW4G<9[$
MD74.J-_'>E8]I]R$Q*BJDOTM)829N8F?+D)3DE_9K4B:P[7IC9=54R:W0XMV
MI*&R2T$.:4MA)A-.E&M)":<?8I, ++>I)*2E18=?+:33- E252N$$C4KS$3L
M8).PNJ9Z@0['M:=/O4(IJUU%&8Z<-U3OO1K;)+E^UTGGD]P!:X6%97,0];X1
M<R7/>^EIKD2:A]TMPZF'70&I-BU%6M=,@K@O,*,*7NM %B= )62D;P/,=KWP
M6AM2>RX]0 KU.PO8G8STWPFQ.1FVK-@(KIL:ZUMM;!+)#KL*8CZ:RK9:4\MR
M&TI6J+:TEG%<"D.L.RJ>]IY1<CNRH4Q#CKVEIYDA4.(<;(3$'3,0"1=*A<0K
M2HR?*=L- %!E0B+#OZ'VC\"(Q8G.G+"GF5?5WI-]_ [J!<1Z[>>+XS[:$X1E
MM\R_6,['Q^*XEUES"<\3+F0+R-(96PU8SWD.MN2I5VJKBT[SK)^$>^Y"A3K)
MDH0;%-I*23!]3/0X<YKB96S_ 'FQ\P3Y3O\ >(O[0")$]!,;AM.7T4W<^LJY
MG'-@8JAC+-HX!C+99J[VMB269:]QZK@=RU0K"IGI9L<LQ9@%"7PJ>TDV!8D9
M:R2NE6BG=476'"2=4A)!45;FW4C\Y$@M*(6M4#S6D; F+]@#-[&)%S:#HV!.
MI[:?B_4%CK4089N=H4NP8,-)5!QS;M="0JU[FD*X9K\QK$(OZQ;G:\\4RYDL
MHD63;:'*):VG7:-X!80DJ2I1 TR+$$[P%6B;2+1@+22M"P+),]+"!?N3OL#/
MIB19KB]ANH5618C/9B=0V*TS5>N#,DMQH6^,/IVB(7TTI\MQQLREACV7T2%L
M)R"$@N)4VP((J@W_ &53@4D\A9*M21J.LF+I2-0\NH:B!TF2<+,."$W5,]@?
MU-MKD]A(*QRDO=T9%%QFII943*ZURS=MHV12[&GHL&-<AN%DN59<S*48&-QZ
M*/';B7UW*K?UE#+,6B:3,FOU]5(Z*" @*D%+D%,7%B/O1)2;=>^\X)MI2W E
M7E1?43^Z+23Z1V]MX&(?E><7F[Y-;T<=)+]U;ZN9N+2TS_/77?T27N3)2U"3
MD^6W4@O?0XAJ6FB5<-F.S(D!D4-=!=M9UA(<5(MG$TK2JE+S@"7&8M&]IF1V
M[ GTDS,I;:78:I[I1]TF4B\%2CJ[FUN@ B=[W=//3_28C4)J-63G(M;(B.U>
M8]0$2*J!DN:!8]FPQ/0XFQR[AFNEE+\.UV(ZA.3YF&EFH5%K3$13:'PQP:O-
M"*W,M35 %:D4BH_M0'[A1,H3/F)6!)%Y, 1UU"&DENFO-M9"DE4F8$B4ICO!
M,R2) %X,5PC%,5HD4..5/Z3"KV)4EM$.(Z6SP>^3,GR2I]Z=*E/%3\FPD.R)
M4V4MZ3)>=?><6K9&6J>A;:IZ5D-4[01H:2!YBD@:  ;F"2D09,) )@8@.,NN
MH?" V%N-D%QQ.OE!!"RI"1)*E:='E!5<]#CF+D^,4_2?D>2;KE6438VWMIWV
M:L]/.&SH+T>##@WER9V8[#V>RB2)&48]B-JY$I\;KYCK</(+^MCN+BQ&8D6:
MSX^\4\\J.'^+\]R_*.(ZM\YC SI5*7FVZ"FJ&05Y45*2E+]44A*Z9QHK31N+
M?4Z6U2%>S*3C=KC[PMX%X./!>1Y*SP\I+C^=+I6EU^95#*CRJM"D(4ZS2R=-
M8PL(74)2B$*L0P:ITQD.;Y!8["V-;6669IDLXV5]DEZZ95C82U_< I:DI:C1
M6$E+,2!#;CP84=*(T.,RTVE"?-^9YVM<4[*E-LID%:I4M0!A)<))*G"(YB_,
M%KUK*CJDS6:=MLD!(0G:! 23L2@#[K9(E"2!H04I(!!!OM38G1XI"0IQMIH-
M(\DI0GX ))X/QP.?SX_8<@4]ZK<6H)TNJ"G0A0;!)$QJ,Q9 $E:S" D*).)
MN7$H"7%I23H!$J6!Y-.Q*@N"F),Q$]8*_FN=Y#ETRIQ7&:FNU?2T)L<LW9E6
M1P\:P3$++ZJ8VJKM9\II3;S[49B$^FOKE3KV<BS0] J7F($IQS2<CX"R+-.
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M_O(FL/H#8)I;;"4(5H<BH221K.A)3=Q.DA"B@D64%I)$:3> XA;A44A2?(H
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MP=MC&T&=SM/;J8><7@7N@]J3\/K+']37B$F#EVM+QUU;D3,M:9 A3]*B7)0
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MFWR>3#Q'%.H+-L.A0VK#9VQ(57!@3L19O(C$)ZUIH-DF2+>RL%M0BE"F>R+
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ME)[>2L)X6KM^>3QVD<_/;QYXY\\^D82?^&)GK]#_  ^EIPW/\HX42$DG[?*
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M.7_P=;<IO_V9_7:V$,O1^LVEH+.!XV0I'<2(,;A3@42$N)6WRE*AV([T>V
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M<6X4@Z=1!CY;W[D#H.L8WP/887(@.NLR0IMP=_L.)B<]I(0R2.5+Y' *1SR
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MT_*9PX! &_SM^OY8=6%,,(+;3H;!=4TIKN4L@<I*NXCY2KSV'D\>0."1Z1$
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MG2G4+D#!;*G+++-I:TQ.3)2E(X?JZ?&,2RQ#;JDCN#5C<.)"NQ)[4E0'>;\
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M#CE):,A^NLVTJ27ZZ5-AJ(;DGN[&7/<IS2MOG-/RV\W$ZD+!0HQ>"D$KF"!
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MXF4. CMA\<_X[?!__J/[<\>?^WKRN=)?0%;J60(M?03UV$@;WZ8UX6*518+
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M&6:M-@AMER=*?BT-)+JDI$0#(A:@;D"3>(N3PE4#*''"LN!*TD!&LA 6HB(
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ML_QZX/\ UZ_KY8:+6,F2&SWN#M0XD^VDK[D**%E*OQVK4TA)'W=PY26UIYX
ML;_,&1^5]C@B8_1CKO /XVZ],)BL1$(:*RXM:UE)>>\DJ/=Y4L<A/D]@"2$I
M[4#X'HY]8@$6$1'0FQOO?:??"8)C<$[0F+"1'3?>]IQK[$-EI(;20KNX4A(]
ML^24*')/'</N '/'R3Z(P$*L)(WZV'MTF)D3@)-X_,F;#M>XZ[ ]-L(Y202I
M2RKL2>>T#D<\@@CQR2."..?R?3">P OW]+_P_G-H7AM4][S;CC3/O*;/VH/>
ME1':H]J">T$?VK"#P"K@+XX\&9!W@VWZQ:\7Z3Z7@[$F/SZ[D>UQA.]'=>4E
M2RA+31(6A06.]*D)*NXI[%H2AU((;0K@M@ J(401UM$Z3(%Q,1UL=_X7.Y?E
M_#]>F-J%AP.*:(/V]J%CM]M:T@(Y(3W%0'';SW)("0E0'!]&#>W7OO(,]P(!
MGYSO@]M_I]9GL?EA,ETJ^X(4"@#OX4A"$%)^\_<. %GM X4KGN')'(Y(F]S>
M(C;8&_3K<3>]AM@X^7KO[7'SV&__ *JULK<0%>VGM]L]X)4%A03SP 4\?*P/
MNXY\DD!/@"!UZWM-K[;V-Y[VD0;IQK;:!27E(X=*"UVI*P#PX5)X*D([5<H2
M2MM(!'(*U#LX%A "9G8GKM[1OOM.P['^'7N/X[?/&M4EY'LAQH(4\7.$..#A
M(004DK4D!)62  ?' /(!''H*.DQ!!*D@)BYU$ $"QD3( N#;K8:2LZ08-S(,
M?=\QO?>(]=L<V=M7CNU>JW$<7J%>]C^FZV;F^3R1Q]/&O+J&JGQBN+A2 ITT
MZ;:Y>8)#D8V4,K+:GDH&KY32'*\F:2?*Y5N%2DQI<42F94DPHV)$P9[DXHF;
MU1JJ^$SH82=4 E"3<:C^Z"=I,&^\B\;RJ8]D%_=*CNF,XV%)"E%"0ZV2.4I4
MKP5% [1SP4GS^W%KI4%MEL&3J!5<[6@[CJ ;'\-\4RH4.<X9F50"(-I)$;@@
M;V'8WG#'3^S%B26)#92V[_13[A^I4R".U*U/CPK@@\#@D?\ 3R3ZD0KY6B^\
MD;@WN.A-C8'#!(GH2#>QZ [QV[BWI PA>BSO=B5ZXS2X5<Z);<M+J$J6V5%P
M(6%D%7=\!/((YX( 'H2#!F)Z09-I/SB+C?UL )(D['\B9WFP$@]3O:+S@AN1
M*=,Q':U(*UK:0M"774K[R4LEH?:EM2%?:KGPD#@@'CT9[#>UC/<]3%YVN"8!
M&#M%QTW@; ;V)M%K;3N,*(_U;5BVDLLLK!0I(*7&R2/DE)'8LGDDD$\GD\?G
MT4B\S%C?I$>][WV.T F^!!*=S?\ &9]B!M':8(@86.O?0OEU*U**GR5)<(6Q
M[BB>Y(X"5(^>>/NX)_SR08B#(L!>)/N9@^TSN>V"$DB--IV]8.UCZ6]CUPO=
ML$-H49*6RV_VH0DHX2T5?<5)[1R0/_=_/GU& DP!&]]MCTZ>I]=H@0^!-@-Y
MF;1<]AWWM](Q@(*([8F%Q*V>4+]\<)+22\$K2D$ I0!V@D@E1('D'P)DP=HB
M#(!-IN9._P ]O7 $G8&#:(,$GK-[SUWL/6%C-HD+E&.'4J94AMU8;*W?;2H#
MEKM^6^/GM'QSXX\^D*";;;7-HZP-A%K';>\7PZE)A/29C^72_3U.'"1+D!]H
ML)0X%D(0'.&4(!)4Z7NX=SCG/ED#@)YX)\ ^F#$F_?UZ]C'I$$QO[&G<>X_,
M8>8TIPJ@<A+S#ZEL.-NAM+C;J4EP)7]P!23P$GGC@!/CGT%@1((CM'S-HDVC
MOO:-L/$?A]?T>O?#XIU/LH0I*$]DA!2U[06E"4]Q'N*2>>// )''C@$'CTV2
M1VZW[0)[&+7Z]HZX<0-[]@>QD^_R'OA1'=#;2W?>2AQ^1WI9:04IX60.Y(^.
M4^.5'CXX'[>FE;F;R8V[]+[=K^V%GY2.\QOO.VWTGI>5KZ$RF' [)/O-@)*'
M.]8*A_;\$%*0DJX)XXY\?GTF^\D$=;B.L@"-NA_,C#Z;@3?T(D=K>G<&W2 "
M)$682G*^-$L%-N*7C4RKNE10%J6ZJBMX5VEI"#Y'U*8!841Y"'#RH<\B#G5&
MFNX>SNB"4E=9EU0T@:05*<LM,)B5*!2"FQ,B>F&N8I+[9U*\JQ'F(@29[ "_
M2!,7Z8X?8?65VMNN?>_3_ERTQL(WI)V%KMV9W)5&$3<B(^8X+8L @(*G,E>I
M:>._P!&5,=4M:&V7W1Y:=E_+J>H!47:)XJ6 27'7:)0:=2J/,I:]22XE4J44
M@J!*1'2)E2C,A02"0;$B_M$_(&>HP,=$1\NUIF5O0OV=GB.Q=>7UG2R+&KD*
MAS8-A6RUQ)8;)"F)U7-=CA_Z.:Q*K;*(J.^ZPZ@L*$A914)2ZI*5I4E+H"H(
M;+H2M2>NA22HA>Q!!!$ZL,*D$Q( B-Q^5M_7?%E=E&M9J_\ B(PIRGU]LS#,
MCH#M&HQMQBHI<O1>SS7TNTL,J77%L5^1-6I<B9K1,-R(\[ZN386++R'G7\CB
M:%%]=(I"GT(1S#J3S4!)O,04@"\S L??#JB().X%SO-MS)WL29)GK$$F/X;"
MR6OS]W<E-D+/\S7ES(S-VP8KHU9!5?3W'9$DBG@!IANOFMOR85I&0\7;*+-G
M"3*6]-=>]./(;4TIM00 !#6H) 0Y/E*2;)4 2 H$$"0")Q')DR.X(/\ G^$[
MGW.)YFYQ&-96VRL%R#%<<@RV7[G8&G\COZVBR'%K91]VRL,$1:J@0\TQ6U?#
MDB# I'G;J%+D?I<&J?#@JZ%%(:E(#;P#VDPE:/M923;6H R>P5T CI@! ,.=
M4BZ)%^MAU@;>QVM+YD%2SG.OI]UC-3 Q_:.J<9;R%QF@CKAUNT]<T*(\?(Y-
MI6AQY(V/0!UJREVD?N<RH2%H>:E2)+#>.AU:FJQ)=D,/:2 @$<L)2$DK2("9
M(*K@2"5&9C#R5(?"4!"6R/W@ B9L-4 'KT%]Y)V:-1.T6YAD&F;FW735>]<*
M=HJ^YCQ!8&FS;''1E6'W3L-3T=,N/!5"NF1&$EAV7(GQHJ7FDO+=;;J@JDY-
M2D*4&5>8)!42W/W%1?09G2?+>0+3@4H*U%LZB+ZC)@1/2=HZP /J"\NX[ G;
M&J-68I*%MK_ICP^;B:+2<6:R)=9:T'<FVWG=@@S"Q%%C=/+AL):F/2(2V#30
MGY'>PM75;>"FT)4DI4[I6)LHI/[HGS:22"1)$@0+"-R\/N':1ZE&;Y@KDL@\
MFG6MA3@<<6H!,2E4B"IR1]TIW!(GKYI464:IN+VQ7$_5<C?;L)3L"([&@1HS
M##<.DHX##H+T:JI*AIB%$CK[ E?U4LLLKE+:3K7"-,AAI)@#F)U&P%]($*]3
M;>\>DX9\0J%G)A\"T\FI=;A;CP:"'5!XEQ(6=(6O2@@#5($Z;8-5[11+2M5$
MLX<.R@6+3D*Q@S&&9M=/B2D%#\>7$D(<8E1WD$H=9?0XTZE12M*DE0-W !!&
MD01$1:#8@P-C>>XL;1.2+_O"4C3]TH*1 !L09 L01,P#O<6Q2S+M?9OTVY3?
M;AT-CDW+==91;3<@WKTZ8^PAV6]83WER+S;FA:\J9CQ,_>*W;'.]9LKC4VUU
M_475&FKV:Y+=SA@I<9476@5(4K4\RD&9W+C(.R^JT"$N7(ARZI"%I?2EI\A+
M@2$M5"@;!,!+3Y,RWT0YNU]TRW!;M#K[/,2S[%\8V+JO*X&18GDE:[94=G2/
M%42QCN/JC/1Y,:2VU(A38,UJ1 MJFP8CV=18PYM79PXEC#DQ$+*6:EH:D-OM
M.086A+B3I,C4A8()!2++$I5<W%HZDNLJ6R0IN^EQ )2DS!N!(4D@ @W!)U3!
M&-.283 NYIEJK:>?8!7>XI4)CO"GT@K<:!0.%-_<OM3RI3A[E'P/4H.A0'-3
MS%)LE2T\PH L$I)G3IB0  .T3B$[2(=*26T6&F-(  !/3:\G:!?UQ!,FZ>=9
MYO'ITYQKFFR9RDD./UGZY$:?D1Y3H2A:HB@M+C4.4RVRW/@*484]MEA,V/(0
MRVE+.84=#F;3*:^CHZY+2@MMNLIV:I+*@9"FT/I6&U#_ !)"5 ]^E@X:XBXH
MX.76N<)Y]F^0+S%LLYA^QLUK<H^,:5NU5? /T_Q*" /(]J2=XN,%&HJ8]&XV
MB&VW&0T64MQ^4A##$<A*T-H1V,L>SRE#2$I2E"0$@< !,AP(4E.K2H-I"6P8
M(0G8)0#9 BT)@8Y"!YQN/,XL$S.ITE3BNIEQ0!61=1N9C$]E_P#.A2&D/+?^
MC#B%%:5>Z@<)[GG1R%?)*$^%< ^3\AD0)TP-@=(BV\&.F_I<VL<.N0J.ORF-
M^D[08._60<!K(,?A.('O-A2EEUQ7NMJ5[2^"A#JDE!"TA9(25$\G[N./4IET
M(TJ5&MIQ2VEF"II2@$E;:B90I0 "BF#  )C$%ZGYA /W4R0E6P-O,!8!1$"8
MDP!TP.,RU/B&:8K<8AD^/0I-5?T\RGMF652FWIU?:17(KX3)94F1'6ZVZ7&W
MXZV7H[H0MEQMQ#:TIJF::N9=9J6T/-/I<0XE825'F!25$:IA<*)"C!3.J9Q(
MHJJKRS-,NS;+'"S7Y4ZW44SRP0EJI0H*#J3N 5 <S207$RE4@P8SH#I:P/1U
M'.8PE5C-F6=FQ.M+/(IK-A;RU1&W&(41?TU?6PFHU<R_*$9IF"VI2I+[LAQ]
M]Q;BN'D7#62<+4ZZ7)*?X5IR"X:A2:BI7I,S\22I>XN2L2GR[&#>?$KQ)XV\
M7L\I.(^.<PI<QK:"A:RZB334Q89I>64A2Z9DH 8#B005-)3J2=))!C%F50;N
M25."WM(B8#@>0A;[C/ML'N(,?VEE"FN6SRVI(\)23P.!Z[.MI!5"6RIWR*("
M22)GS$22!O>T_0T!5.ZHZUJ<5 !5K*E2 ;#S$DA)$I3\Q'6M6Z[5<7+*?.;*
MJ9GT<>HLL6S^&_$#W\\ZZO(XA9ACLV*VD*G)DU(5:5L=U0;>OZNI2ZH1B\A=
M*\2>"6.,^"LSRQK0WG-*A>9Y'6%*0]3U](D.!A%0!S6*.J:2M%8E"DMNPT'=
M9T =7AWB-[(\\I*IWF_!K4W2+;!6$E3R@D+* 8(28.HV2),XH+@-I<:TW;LO
MI^LH\^77X'9A..Y:Y(5*A9!C%K&@7.)3%R5MI:>FV&,7%7(?=CO2 [8Q[="V
MXK;,9V;X)XEX0I:7A+(N+T9[DCU9Q)F#^65/">7<U&<Y"[0JJ.=6UR'7/@6*
M1Y5*%);ID-/);J&4DK67$I]+97G3M5FM=E*<MS6FI*2@IJBGS9UNBJ*6M4M#
M1467W9@.:E>1+A?1YM: H **6R\3&00)"%-^XEYE?=]H/(6DA04D\\\I)!Y/
M(!\_GG.6W%-K2I*U)*4J)TJ*83'F)*8@!,S:()Z XM9(A5QL9*=B"(4"9@I(
MD$&T2#8D8I1C'^N>A+3($:FRF''QO)I"'\CP'+Z.MS+7N02&O:#,BRQ:]:?A
M)F(;9CM&?5NU=BY'CQ(S\MZ-'::]7/*\[<IG:?,&"XQ74E*IBBS-NMJJ)^G9
M!4YR:9]@A"T!16XVP\KE-N%:VP%..$\ZLRNBS!DMU-.VXT&B=+C*5LE!%BX"
MG1H$$I-A<QOB?0]T]966SIU17C6&HZ9Z&8JLGTOJ[#\'R:T:E-1T/Q&[U3N0
M7E?'X=L4.JA?I#J%MQG(,ET.K6WHW$G%F39AP9PW6,<>\:<1\3U;U6QF_#V<
M/ 9/2Y:F$M5*:U"F#6E<*T,//Y@V0"/AV0"E=&R;('Z;/ZW_ )BRRER1JF0Y
M19K2-TK;ZZA?F<:2VTHNK0D@'5I"9B%*$P5]+Z(:Q51ER _*G2GW9LZ=,?>G
M6$^;+=4_*FV$^6IR7-FRGE+>DRI3KTB0\ZMQYU;BE*5C&89BAQ(;:DMH"6VD
M@!(;;;0&F0&T)0EL-MA* A"&TMI2$I0A"0D7]DJ:0D(4I(*03IE 45 22D1]
MZ"2".IF\XL=LA^TQW7N02J6O;L;F+33WZFK>D-Q&["QCQ5NPH;LIY2&8J'WT
MH;6^\MMIE"U+<6A"2L1,E9RVNSC+J;.,T=RG*5UM,C,\T8HWLRJ,NHENI;J:
MMJC8<0_4+9;5J"&R5'_"K;$6O>JV:&NJ*!MM^MIJ1Y^EIG$I4BK>:05HI@"(
M"GHT@]"09Q M2U-UD%!J6'=P&Z_(L6T+G>P+VMCN%V/]=N+:%I(QXH<:D2D!
M*\:P&&XMA,J2(Z))97*>4E#Z_?7@QDF3Y)Q7XC_U;S%S.<ERMGA[AW(J]5.]
M1N9C3R]7/OZW'E\L!]3)4D!GEK82XI 5I"?._B+7U>8Y3PXUG%$BGS&K?KLS
MJ,N9=2I#3K#:&\L6BN2I20RI3E9SF>9 6E#9E0Q6>@MK[:-AF&D=MZ[V#01<
M%SC+,OU!LW!\579.:XBV$QF-84MC7VMI!:SW#]@1XU=ELV!B]@Q<N9/(ESJN
M#[; =J*9XA^'G$?%?'/$^;Y;PHIH_'MJ?07S2MU@I  U6TE<K0W55#Y*WBXR
MXMP..N%1*RJ=B']2.!_#?P^SC*O$'+<\S7.<N0G/<E6:UK,<KK%*5\915:*:
M5-TK#LML*<TH=:2A8&D@D[ZWU?;45]%L<4G9KG&:,-/Q*+.,RUW-UC@>LC*8
M<ANYA_+^0W$[*<PR>LB./NXU$9BU])%M U)L9R%-L26.?PSX)<0UU:E%7EJ\
MCHH K<SKG]=0*)T_VNBRZGH-915<E3C5/5.Z9=T.N+W5BD9UXAY>BC4W1O)K
M5JUAE.64ZT,,*((;34+S!+2RTVK2'%L25("E(FV+-JHJ.AH:# L>?1)HZ"OC
M5GU+Y4[*FKC,>T_-E2 E >ER'6B](D+_ *LEY:WW2XXXI9]D97E=/0Y:SE='
M3J^$8H*6@RVG:'(0RW1)0D*4A.E+0*4B;)U?CC!,T=>S!^K?JBLKK'5.*TE2
MM3J_+K<(WD)3J4J\ 22(&*@[CE:EK6,<UGNN:N#BL[(+;(=6YA"JIEMD>E,J
M84Q+NLCC,PVGC/U/92G8#F>XS8/PX+<V1"M*UYFU%?-I<!\8.&JKAYS,N*^"
M\V>R3,>+:1>1<5<*9?6.98KB2A=2A-6^S44RV$_$M!1<>2J7*]*N4K63?8?"
MB@SSCA]W)5<,GB-CABG;S%.8$I?%"4$IIFEA>L\RH6 *8)A0<9TH!^[B1XOF
M&4:RO(.%;"^A+LVO:M<7R:IE_J>)YSCCY;$/),3NFTI8M*B6AUE12H,6->J0
MS'MH4&4XAI7A;-\A>IT//I6':>G4BG4\XV62A2$)0A+Z'$I+#I2$GE.:57!
MA48W*DS$582A8 6X!NH$R9(A4DJ@3"A( L(B,6C@3X-[$0I*TN=Z>X%/:?!Y
M[2".1\?CD<CCCU4%)Y<G2(W@@08W!  D6Z#MUQ.U*:<!2Y!D $*A4CL9!D&]
MMC.*V[=TQ!NW5WM6S^F9-$7$E5]_6*^ANX<FLD)G5DJ+;10W.CR*V:!,KGFG
MT.0I:$R8Y0\GN-AHL_S%EANG34U+]('WG_V<_5.G+W*BH&BH=J*1:S3N\U/F
M>*VU*=4AO63H20A;-.MY3[K25O/LLTCKP;2IU=,QJ^'8=<C6JGIP5<EI2BVS
MJ.A*9.'+7F?/[$MQ63H\%C>ZVG(V=8#(7#IJ/J#@U\?[<\P=Q]<.FJ=L1(+/
MN95C"W(#&2LPW[FD2AR+)3Z]1^#'C(.$6:7A[/:JJS'@WG$T&9,!Y.8<-5+R
MI<:=:)#]1EB72--*D*8T"0@FXQ3Q"\-U9BJHS;*6VQ7!)YJ A(_:*0/+3K7I
M^S?"1#52HRVF6P4I)2'RRPBKMJZSN\$F/V=:T9%?D.,V+3E7DF,3V5.M3:ZX
MIK!$>2TY&67&)D=^,W(:<2XU);0HJ2OWIE6=L9K24U4Q44M?2U1/PV84A;73
M5>ZARW&I;YR40'F0>8PXE;;B4K;4D>9:_)JFG>UJYM-64R5K^%"7&7VT()!*
M6B$N%*(TFH (> YP60L*-#-M=.=1EM0@0:A,J#$;4TU5Q7X<2^QAP+4ZE>(6
M4Y345RK$A*WW\+MWT4RB/?H9F/3XL/N3F>3(?*WV-16V"2 %05 24K@&;&2#
M!B)D$8U7@'Q7KLMY>5<1MOYG0DM!NL8+@>:;>.EI;Z3#CC*B E&N4.$>7588
MJ%LN\H=>ZEJ,AR'.TYEE-3*L6V<A=J)L6=,PQV (M)C%XB]CIGV.1QK0,RX\
MYX2+*KB-FI%](3*>F7=,K*^H8:4RW4U 4TNZ&GW R" H1I0H(!'L"1.^^/67
M"N6MYK6T=>*+7ECS14KX^FEH%:04@A]!;YA$E ("B I0'WB)QT5]8N=+QJNQ
M+?[$+*-893<PJ/'GKJ0M_*:2'9V*:N Z\X^GBV@,/28+2Y3CZ+1)2_+49Z"V
MXW.RC-GW0CFE3=4G3RWA,D#9+JA,JGO*HB-[-<5<'IHF5YG0/!# <<4[3*7H
M*%!9TAAJ1]D$D :4A)5TW)LYUDZ+I\5UKGMG05\NPB&K9O(<QV3*DI3!ARF)
MZ_:#CB@X6H;+R@E7NNG@@$GGG3^&<V>?S&@#SH:4AX(6$Z6P2H%)UZ=/E),$
M$Z8.*&5"II%$)UDBR"G4H "#Y;Q<=!UN+B.1N(9I!QJ;B-Y-A(=JZ*8AY#;2
MXS+#MA&H\4ID_4*>=9C";6S<8>>CLREMHDQK-+T5Q;_>@Z&YEI4BLIRXEMUQ
MT):4M105(APD)GS*0L."Z9^Z)$@1PDJ2C2YI2H-*U?="@-Q)L0/PW,'O,[_-
M-79CNY[*'77L)QUQ +-PY <1&5,E8[9QYTZ0]#+C4-M^P5 9>4Y)CDGW)RG0
M5K=,5=!FC.2+H5I-25/-D :G5A#3B7 $B]AI(3:+0!<8>6XE=2VI*DAL@ZDI
M("9WD@>7;K!/XC$#H[_:%/!R7 ,?IGLWHJ],QV!D>-J%A"15AQIURQ;EQE+:
M2Q,E0X4F4J4J*A+\%49I\1'5E<NH&6O/-5SSZZ&H>+9+3C2BL%" URS8%,PN
M$&Z@J2%2))16I3H05%!4;)E2 (!)!$I F(WL,6AZ:]O8-B^)3:UF,Y>6ZWHD
MN^>BQXR8L26M,F/%@1I,QR.B>U#AQ6HWUD$.P)#C+CL5]UM85ZJO%.7UE8^P
M\DE+&JH33A84@\L%E7]V1+<Z@K20#"@8B)8J%M)2T VT3I)4K2F3,1)BY'K/
MTQ_06E=J7//CN4L >3R1R>/ /R >!^3SQZ\@N_N?]7%83NKW/Z_/#6&F!WN(
M0E+KI)*DA(4OL)2.XC^XI3VC[B5 <#P!P(:_O'Y?D,&0#O\ F?\ 3#7((90M
MQP]J4H4HGYX2D'\>.> /CGS^_I), GM? 3M[$@^_7\<1EVS8:#98;6Z9#CQ5
MX+82M* X2HE*P.[N2"H]K:20%J;*N?316E=A,[B1$_7??I/I@X[=Y/KOOZ]>
M]L-O?9NB0'6D!A0):4X .TDH*>$,I[U%*2KM!=45D*2KM4D!8(DP)%A:?YD1
M>!!O$&.F"-YM.UNGZ[^VW=J=9L)(9+BA#D)=2DJ;!0I+:2E9!!;[CW#N"5.-
MM+'82D\$A32D*)) @=+S\]C(B >G?MAQ*TI %[=NW?V]=O7#D1[9*E+6KE*/
M':"!VG^[N'@?_#D<#_/H*6D@CK$"WIU,7/\ GAJ+S W-Q\][7Z?.;[#"1UU+
MJRWRHI \\)X*3X\\G@$'GX!)_/' ],_K_7MA6-*5(22E/QQSX'VCR1QR/ 4/
MR#YXX_;T9G<_3MZ &_\ #M; QI4>]2@HC@GE*? 5VI[0>[A2N4DGQR$D\'P1
MP2-HC?O[?7T_EW&-#A]DM-MMJ[77"DJ1V\-D(<=[E$J[CWJ1V@ $J6OD<@*'
MHP/J3 MM_/>]C ^6#WG?]=\:776"TZMUU':RHN+(4.Y/:GRDA!"@M02.!X//
M['T=]S.YGJ.F]XC<&X_"Q?C.,(\UB;'4]$_JMD+ 2ON2%+2D'M*E>0%<I'<G
MN2/)'/!'H$7&YWD'>VX'?T@X&,TNR ./IPD@I 4%\MJ2> /O4E*@$CR>&E$D
M#CD<D S-[W[VD[1.X'6>\>N#Z?Y#\3UZX%>]=EUVI-6Y9FMD>]%136<T,MJ!
M?E-Q6^X18X21WO3);L6L:0E8<#TQI;8"@E0[W#67',\S:#H!;IEE503!"0E"
MBDB?O>?3L8GL!;GYG5"BHW7B84$C1%R2I246 ,[*/RG% -3X_;X/J^5EN3J4
MO8NX;&1EV8S^\!YB;<J#R*UE2P#]'41!#J8)*4<5T*, E/PG4%?VRI"1=JF0
M$MR")4DZ2(,F(2?3M<6SRJ>4TPLFSU484/\ AF=Q8&8F_P!3;#+*@LKE_P!-
MA^0XXEQY]3BUK 6GE(((XY"E?(_M'G\^NNVH!*0HQ'E!WD"+3/6"/RM;'!4D
MJB.P3!MYO-(_'?8F1ZX6,AYV$W]!&0%C[G0OM0VMQI)4I !\A9 /:D<*)\ $
MGTY-MX,6$QT/2/I>]I,[I*#)F-YGK:-CL?41:XB-FY$YV7''*%/+=8<<::<<
M0RZMYA]3;B&0LH4L-^$G@'SR#Z F]A]9$7(MVF(M83>(P6Q'Y1<R!]3$S!B8
MM)@L]?*-;-B(DNMOQK1:VTI<D(3-8EA7 ;7V!0*!_P!)4!R.?/(]*[VO%]KG
MOM[P8OU$1@C>\FQW$F! F3(^<$^DX?9MN2_[K;4=#$9U$=3SI470L@>XI*4@
MAQ \\*''D'P/13$#J1Z@6-A_ 'KUF1(@$3??TB\ GK[](](G"&SF?T$I[.YQ
MQQ(#\;D-*6I"EH]TK)[5J//<0 !_N"/0(L>\=S:PF/2-Y,3:\W4+'O)@#8F2
M=]NLP!<SW&/8:IDHK2^@MLI#:DIDJ:Y+HX2KVNQ1!3QP4\\$_D#GCTS8;#OM
M\IL/EB187CH3:VT6,3Z3[=K8E4IN(JCF !\NNLAI"G$*0UW(=0L$* [0D$'D
M\@'P"?SZ;%R-IF3M$?B9]]B1$8#2D@WL3$6L)^?;\]I&%+:UK>KDH4TVEJ&2
ME+120])4 %I>Y'EOM)*>.2%<']N6E)N8W%KCM?ZFPOM><+D$2+C8>US/OTZ;
M1!O'MCPAT/O<ELO-^XVH)Y=Y0.\HX'V<<$)'(X\<^F^I[CK?>8FWO]?H3!N+
M=1?Y]?UVP^(C1WE,/LLLM(]M1986XH.K<YX2ZH<\)'9X*O[CYX_P2C $GM:1
MTZVWM '^+T$8=)B_UQ**YLK>:!!4.Q;3K;9_J.$#N!2H\$I/(2#W<GCSSZ1>
MWIW_ %O8W@6,^A6W^]8F;V^A'0R8N._MC<78B)<=!"UPO=2N1VI2ZZW[2N4(
M2GD*"5%9[R?R@)X/'IM29,[S'4':=_QGIAR=[&)N;#YWBW<F_:>FNPD2G)DY
MRN;D*2ILN]O" X6B2D<H'(3X()!XX_)](Z=>O?UZ]/0_3IA\$V[;R9])DV%I
M/?:XG$/O8,^4R\]+]T&<&H(= #;CB@0ML_<@K7P.T*7R H<^5 ^93#J$%(6
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M&YP\IB(5 2MV3]4'?J7$R6UMN)#"P4M)(1SVI;[R0#YX!21R>?394E!3,B3
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M''?%?AQ6UU?P5FU1D5;F;#5/6K0AE^F=98=%0V'F7!J4XEP0RL3HUK)C5!O
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MTD[&TVV[^F&TWGU)L?7<;@[3N(M/2,,B%-(00E@)/<72VA)4HD<@+')4I;G
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M4KAU04"H-<A!^/)]$E6H>O<&8O86@G?J?K,$B2;; ;2.L>HL-]@.NUR$SIK
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MZS[A9G@Y=/0L92PUDU#'";]/2TK%*0<UY;BP5\KF.J<80IEU;K:2I"4K7IG
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M2$AUO]Y10HA0@VB;IV!%K$)4+@8L_-8<;DI03(() U)(!A29V4-@L0;D3!(
MYK;G9.GZH8B]75NY=+MR2Z-69U*FJ3CZDMK09^MLSB%>3:UM66.UN([1O2*J
M*CW$L4[#\EV6+;PYQ97\/UC>8Y775F15RGO/F.6*6EY988J*FH<S.F2>75M/
M(;;;54/#7JD*<)QQ,RR'+\\:735;:*KX@*:0E[SNH4$E:G4K)U )21Y9B1WP
M]XL,(W5%GV/3YD<_+;>K;<E9'H[-1$J]S8VQ&4/K)6/.LF/2;7QU@][S%EBJ
MQ:!A4.&F'>73SR$^[>&O&S,>'D<.Y7XPY*KA-_B')J/.,BXC:4JHRK.*&I90
MXFJ>IJ=(50./:M2FEA#FO4K2)@>5\_\ #%NK%?F7!F8?M9JCK#0U65.F$TU5
MI2I2!4E2G-))U#=()*01 F(7>$469HER(O=77R&)-).D&&TBR0AE3S$W'\CI
M;2._#N:]EWWHT_'LB@O-Q5_4%MB'.0V^CT.XBASBC15-5%%5,.V8K<O=#U.\
MK< E-D& =[V'J,4#A[B7B#@_,%(RU=6SH4>?E^8(-.PZD3J0EA0T";D%(FP/
MKBF68:0R37%K*RO K,ZZMGVUMSY45#\K5V4QVTAOZ/(:^S79NXNP^D+2BORM
M%YB\94AN%1Y;C:$<HKK^4OTBPZV2XV2$A*)M8J!.F?+8B+=-QMZ:X4\5.'>)
MVFZ.L0,LS0C2JGJ'"EAQ0A&MITD'5*Q#8@$21,8(VO.K+(,*EM81LVN1K^T;
M^G=1 OU29>NK=#BBAJ72W[IFS</;FN!XQ%2I-YACR@B-5WR6FU*"FLP2DZ:A
M.E8L"("B-I)$3!!L;WOTQ=ZG+E).MI3:@4A25-.%Q,&8)Z Q?N9&^.@FO<KU
ME=-V4ZWL9.,VKZ:]V77V;P#*O<$LMOUDQI:Z^RKU\+]J972),9?' =*@?4BI
MK5:&E(*5()<"2?O>71(5ZWWZXY-:M;89;68*0LFW513/?L+&(,_+]2LL)4I2
M5H"AW$@GXY"B0.""#P0#QS^W_?#' ($CV]OIMB@ B2!'<QW,[^ML(%D ^W\\
MK(YY_!((\?M]W \\?;_XBJ^\?E^0P)V]3'X$_P ,-\DN))^Q(;X(40?*B/C@
M_;X'Y^>1X^#Z3@'I;KUOZV_SC\ICTYIEP=SK:5I!)4I94$I\$CNX^4\*(X /
MG\CD<I5M\_T!V]?2?; ,=8Z?0G\C].^$RNY;?>KM*T@DAL$A7 \!/=V$?X"N
M//\ CTT=['OVZV/I\Q; (D6]?G8C#7[0D.%PE0 ;;0M/S]Z2M14" "E0#Q0L
M\D$A/:$=O;Z.X!@VF/E>/0S!G_,X2HF+=Q](GUMT/0P<>/MA"4J3W$H2H  \
MJ(X^ I1)2"?!//C\JX'I)-C:PGH.U^D$[;X)-S,;$]!%P?3T F?SPSR/K%J0
MMH ]J4<\GM0 KVU*!^X%:>.0.Y"2DM\\I[@/3-IZ]AL;29F 9]NHZ[2Y[_K]
M?H'"GE*TJ7S]J>///*5\#@K!2KGCYY/SX//CT#/8P8MT-K;1,Q@81M\MJ5[C
MB%=W:H*[B/N*4I4E(5SPDE(6 5D@N%*1PDD@@]OYWVMZ&18#V$B1^OU^KX^?
M:;?0XRL$H>2$J/':?!/!'[D$ CGD> ""/!(6'K/S$#V]?PZ1.!C5%@HBM^TT
MKNY<#BE.! (5PEL*'8$)2$I  \<^!RKT<S<R(ZS/L/3;>][G QBAAYMQ\>ZI
M84M);0Z@=I)"R!X[>4<I'<4][G//R.U( DQ%C<#?MTL2-^]K[8.W6=_P_GC*
M)%]E2WWF6D2?<<*E,J</<A2BM!4%^%.*3PIQ*1V=Y6L<=Q] [>@B+=;]B(N)
M.]QUB27Z_7U^>')3(D *[1W<I';X!*"D%:0KCE(/<"2/D C_ *N08E),7,$6
MGU$&.X_/ P%=Y:]ILNQ:5:2(D15YC,"SE0G5L)YL:1UM*\AQ6>V"$R:F_KT/
M,!A]7TT6T8KK131,=25]O(,T=RJO8("E,/.)8<;E7+ATA(7I$)E),@D$BXL9
MF#F-&BLI7ONEQM!4DF%*)(TPFQ)L18=+XYEZ[4^[ R'&;&4_(3K_ "N^QU+S
MJUK=?KH$APT[DA14"M[],>AEU2D_<H<@)' ]:]*6W"VWJ"6X$JD:]0UE:2?O
M#SZ H2"4D3T&75*.65)@%29"C^]()-^H,1-]C;$K=AL%EV4W;*"R@*+( (4\
MGRWV]P"^"GE7 [AP../D^I.J8M/R)/8]_6\GJ#B"#$ @6Z0;#K(]09GW'7#6
MPY80FQ*=<<<9EI0X\0.U#2VRI7A93QW*2H<\\$\>.3Y]*24ZNT$]+$Q[&_RD
M>HG!+"2# N+;"]QU]-]P2)[DXUU"^^*\\_(=3!$A<IMKCE0"/[G#P.Y24J/
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MM1&&(<:/"JHL!1+94%*@I3!!,:@!_AMJGL0=4Q%HDZBHU:>6W" 8!2/+(WN
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MK^T"%(5I6I*M!"3H,00#!./W?/I"O<Y_!61Y(\@D_CY^/@^LI7<7Z"WRQ60
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M .%))3V]H!)!(X\^I+0*GJ>( %0S<Q A8WG>>OKTVPT3"%6,:%6N38?R,G^
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M"LNJ5LB[C*X:+:X^NL\[EK0G@^YS1]I\CYXY/GXY](5X;<6F(H&?_3J/T_\
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MD#@<<GXY!)DCZ=>G;Y&VYZ6!P1,R9MTG:.LC?H8ZGI:<8L%V5-^C=E)+2/\
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MA]![3[K2E#L4V6W6EO-+0M70:>+2RAPD:5:=0V)!(GI(.X]+]SBN55.A0U,
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M&]'+2[3:*AQ@O--A+C:G6W2G XD]&^:0 Y>V6R=/UVJSAF)YS"W;*O\ +/\
M3BUJ\XR?+\+QBNK8\?"']B/Y#997KW/Z=5$Y@#,ZO.%9):V;<*AKE6JYZ>*J
M1PAEN@S1S,?BZFC7E"6:7X]IRCIZ6KJ''%*K$T(8;IJZB=#PK2ESXNG;;UO.
M!O$8Y,^G[1531HI"RT^FN4X[\,M+[K[+24@,&I+BGJ:H1RS3A2>0ZM82VDKQ
M(:SH&W/,EIJ;3(-68MDEILS,M/X3C%_F;QM]E; PS%\&S)ZHP5VDIKJFGP,@
MQW8^'SL7RBUMJ;%+0W5?&<O(DFRJFI\=SC7*4I+K;&95%.WE])FE94,T@Y67
MT5745E(ERL#SK+J'&7Z"J144[;3M2WREJY*DMNE#B,@K5'0MRE:=55/43#3C
M_GJ:EEJG?*&"A"VU)<:JF5-.J6AE6M(+@*VPO9@O1Q)LM>[ R_-LUQ6KR:JT
M#3[JQ#659D:T9XU6Y=G.O<?P?(LNKI>-2J,XMDF/Y@[>,55+DRLRBPK#&;RS
MK*VEGH7,*MXK2W745+1TE2[3N9V[E%5F#E/-$7*6CKGJQBE<34)>%33OTH9+
MCU.*52T5#+;CCJ/(&<F*J:H>??:0ZB@;K6:5#D5&EZHIFF''DJ:+?*=;>+@0
MAWG!*FG%)0A4GW,>BK(\%&0XM<YGJR9FF,;EH=3Y9DU?M2'%UWKV[>H=KV>3
M8KF3MYA]6'<AI3K27/DV=#DL^''92SCU=39+D=]$8J12<6L5A8J&J3,D4E1E
M+V9TM.YEJE5]<R'LM;IZFD#-6Y##W[00A+;].VLJE]QZG8947#?R1VGYK2WZ
M13S-:W1O.IJP*:G<**M3K3Q<81+C9IB5+0ZI( #:$.N. (2W/2%)PC7.U<XR
MK)Z[(X53HS$-S:DR7 I5NSC&60[OJ-Q#15RW<UF;X=C690T5KEAE240)M)C<
MQ5C!J;6/(L**2V+!;/%":RNRVDIJ=RG6[G%5E69T]:EHU-,MG(JK.&BTY1U=
M12*+@13$K0]4(Y:W6U);>2>63F3EBGJGW74NI10,UM&[3E8:>"\R9H%ZTOLM
M/C05/#2I#2M24+!4V1J["?P6&H[_ $Z[*:29#<[_ %KLN'&&RL&,O!<'"FU*
M/*4A2DK!X'< KGDC@>LF\7CHS[+U1J!R=M,2/_#JP]9N1(%L67A(D4%0!(/Q
MA((W_N69'SM';UZ=M&V4/16X<I*$,)9Y2ZA:0N.\/[. KN(4HD>.!P?CSX]9
M&0F9@#M)@2-OKUMTVQ= \XH""4D6W&]O:/7YSAG_ $Y5='6#82)4F8ZR%J<;
M2YW,)<!3%0I"2MU;A 2.1PD\\_ ]&%)%M ]?->Y[1:;6Z2!ML-2R8U&9M/?8
M;^\B)WGN0[,5\>4%K9[H[S(<]TNE:Y'"^"IA?M$! 020A0Y(X//!])F3V M%
MB(O! W(,Q:)! &V$S:29W'U$2)N1'2UXPW.R%5DP0_+S<AA)A2GW7%I5*(!^
MF6RMLE/'<"E7>HD'R1Z._4["\1ZWO_E<=L')%O0CT-X.\]C'KTN1@7[SVY@N
M@]4Y'MC8[DJ#CV,0H;DIFMB,3;6?964^/7U=55QO<81,L;"9*;C1T/28\5D.
M+E3I42%&DR6>GD^45F>YBQE= E)J:DK""XHH:;0VDK<==6-12VVA)4HA"E*L
ME"5J4$JBUM8Q0TSE54:@VV!.D$K420D)2) *RL@0K2D7*E 2K'*T?QM]%,Q5
MPX^I-KJ0M?<77D88E:0">.Q",D4$\@^05J //D_/K21X.YUUS3*[B#_TLWBY
MDT\^G2P'RK7]<J*_]EJC[\KM!_VDW@=8'R!#BU_'"T*PTVEO4FX$N)!2XH?R
M4 I"AVD!7\QE0Y'/GQZ/_D>SJ2?VKE=^G]KM_P#J/U^9CC.A"@KX2JGW9^OW
M_P!>G7YW^.%H-3:DM:AV^EPI2$.J.%E32ASRKD9&"Y^X2KCX^1Z/_D?SK_XT
MRO\ ^M__ '#"_P"NM#!_LE5?_P"9$;'_ 'A[1_.!C*-_'(T7'*O_ -DFVW0M
ME+;BG$X67%J3R.[D9']H4"0I()'^_/A"O!S.E&?VKE8^57\_]AUD_7YX']=*
M#_P2K_\ U7R_VH-OH;6D3C2Y_&^T"XMY2M/[>*763'*.[#!_1\<)Y_F(GE*>
M4@^3P>>?P%#P>SH #]J97_\ 6_\ ]W_76;8,\:T'2CJAW_N>X(MS/2_X 2<(
M8W\;/0D=7:-3[B6RA7]!"G<.)9;\?TTDY&21\@'D$ D^>>/1'P=SLB/VKE<_
M_I8'2\<@WW^IMA*N-*%0TBDJQ,3_ ')VC;[3K%[] -AA2Y_&XZ?WF5,+U%M[
M_P!=+C+C@PQXQ@5#N4AO^9F?<4D?<E!<;"R DK0/N#1\&\]TJTYIE)5!B36
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M&VY'2GW6XREI3*QC#7PEQ_VVY-NRN2M,3'5I;B%$G58@$$D;;GN+6BV]NCR
MFA0@KA=2X1RT"_+*ITJ5,RH2(D#8:A/W8MCN LP$V'5%U;W]UD;^52_J*VL<
M=]G-=T70*E5N&:\K5.M/U.#Q%%+5SD<?Z:LKJA;T>CG/3WK*\H7%*  4=C)
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MPX*''I55&;:D9'CUD+&N@!*;"U=R.(D*$1]"J=!?I24N!6I30)4A9,"$@V0
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MJ/D+:_O+"X5N2! (WQ2F-DZ-0[ >U9F,&^A:DSA?\QP<_B0I$FOU!L-M4J'
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MZ#'(?1<FPOJW-.HK(FT/Y1M>X=<QQZ6A1-/@\%YV+BE1""P2PPQ4]DIQL?\
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M*F4*<42S\,5JD%*G33$TQ>(+OPY+&OE$HP!75J:<4B:I]-.-F0ZL( Y@=T@
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M*5(6D%*TD"0H*A*A-XBY@SBI:OX>O1<05N].^#)#B5%MUI-OVE?=Y/8W:A
M(/V]B0D$  #@>K+_ %ZXM_\ CVM BWF:FXMNU'SG<>^.-^P<G)GX!D#L2L;]
M0-4>H-YB-MMR/X=O1*B.I:]!X.M90%$%-T5)4#Y2D"SX(/P//XY\?'H_Z\\6
MC_\ CU<;]2U&VQ/*C?Y](P/V!D__ ( U<[RY;<1(7 O[[Q!(&*7]<6J^B'HO
MT)9;E>Z-HFV;9^V@8QB>"X6)K<VTR6VC3Y-<BVDNVK\ZNI6FJZ0]:S:BGR"Q
MB1T%YJFDM(>=8C57B#Q;2M<S]M5[AU:0E):NH@D RT83:Y *HN ;D2:3A?)Z
MM\,_"T[0A2UK670 E) @#F;DFP)3/4@Q) VCTH]).(R=,83BO3%KF\V?NC-8
M-?!II<B^37X]@&.IA7^W\]LG(UHI]-3AN*$UM6M80U8[ RC \<D.M(OO=0M?
M'O%R2VA.>UJEN+  EN @07%F&IA*2(V\ZD))OAMGAK)W ZM5$T&FDJ)(*Y*S
M(:1]^"5*@G>$)60)3&+#1_X>?1B^PD-]/F!+4@+0M]:+I ]P#E'N#]5' 4./
MN2./)^2!Z</'G%8WSVMWZ%J+FW^S'\OE@AP]DP$?L]@F;G4[ C?=S;\YWD1A
M%,_A_=%,=5?(1T[X>M)0MN;%:%PX"^>&TAMTVH205 *2?)2%<GX((5QUQ:!(
MSVMOZM'M:>7'>_IA0X?R4 DY>R1;JX+'K]^?D1Z@Q@7ZBZ3>B#<&%L9?4=-N
M%8W9Q<JV)A]SC=FY/LY=%D^K-AY1K;**N6H3DQ9B&<AQ&R+#BHX9E0W&'O:+
M;J>8O]?>+W6B4Y[7))+B%#6V""A2FU0I+0((*2000;2+G'69X8R%+S85EM,L
M>11*N84E*TI6DE)601"AN"#<&TXLA>8=54==#A4=8Q54U9&;KZBLKHC<&O@Q
M(C*8T>'"@LMML1HL9IMMEAAAM##32$(0V$ #UGU:I]];SK[BWGG%K<===6I;
MCCCA4I:W%K)4I:U*)4M1)49)))QM7#M6S3I98;0EI#24(:;:0E#;:4)2E"$(
M20E"4@:4I2D  0! & -F,*KR?'G<.S6'*GT2+&MNH;D.QL*2WIKVFEB947E)
M<5;T2?66=9*'U$*=%?0XVH%*BXVMQI</*\ZS;AW,/VGE+S+#X:12+8J&&JRE
M?I:LKI\T+S#Z5-++E+H :<0IM:I2NP!Q=LXX1R;CS*'<HSJG<?8<<R^IHZAF
MH=RVJR^LR^J57T];3OY;\/4JJFJAQ;*%..E:F5JUJ()3B,XUC6O,)D-,:\UW
M1U-]+A2HMEF[D1FTS[(8\^<JVGIR#.[%,K*+D3;1;D]Z-/M'8@D%OV(\=IIA
MIOGY]Q9GF?+2,VS.H<8IRXNEH %T>7T;;%.REI67951J30,MM,L5"26V"LMU
M+FG4O3BP\%>&7!7 H4[E67,,UP8S!!J*A2ZS-JP9I5IKGT5V9U"'ZY]U->/B
M="GT-.K0PE]2&6E%-(_XBN7;(D*H<8QY42B1JZLPO/\ %%US:HFS+O8&>7UW
MC$2PPNYKZF7E?Z92LUZ*^\K,3L:9YY-@[.L)5FW6L0H>[^!M%DK.4A^L2A^I
MX@5F[.8BI+;F69?EV7M,/LU=12NU"6!\0MZE>I:C,:92$2R$(2IQXM^4_P"D
MUG'$-;Q;5Y>W4&FRCAS*^&*K+GJ)I(S;-<VSBKJZ1L9>_EW,S%IW+::@>RJI
MI<OK<N74!]Q]58)<2.>^.8+7VE_JV'88E-QC(,IP6KMY]]>W&-JKKF-&R[-;
M/*,W3+R*"Q^E0;3&VK'!*7!H$U4"\RFCI'G4V"[5<QK>J[,_A6>(WW7&,^52
MYG6T2<HI:*L>50-M4&4(ILL0Q1IY+]3\?44>:U5>L.BC8JJUBF20TL-^3J7)
MC5U/#67TC59P=S\AR^M5FSC5!_SZEUC.FJU\5N9LN,9?2NY2C,*7*Z!ZEI_V
MLMNC75H?71NJ>[PXE)PRHQ;&[7'K',)43/:JOV+D%[L::Q?; GN7M7'N%LY'
M;5T.(W,151G3'@08,-$*,P@K@MK,M9<\&\?YGF.8\3UF2U;66%.4U#N3T=%D
MOQ-)E[-30/FE+U*]6U%85)JEM%*G'"TI3:M2RW>/K%X'<-91PYX<47%- O-!
M4<09?3\156:YXY19AFWP^8T::U--4'+\OID."D0X%)Y"G4E:"4<S4-7-C9VT
MMP[ZS6-_IQK/,,YP3,9N=,Z88F4SNN'X\'&VL<D2,XPJU@YUA2LNRNC81<+M
MZ/-WK^MAPW4S8-?#^I=BI]*Y7P;P?P9P^Z]F-?D>69QDU!2_ULJ:ABESP(<S
M2HS"I9RS,:2IRW,*2ARI1JVV/VEE**2H?7S*<U#A6VI7ACB3Q&XV\1.,>11T
M^>UF29K7UM3P)34M579!\1D]#1Y4Y79S0/T69Y7F%7G!4TW6UE'F[C]&^VND
MJVZ2G#;[ N#09%(>UM7:=ZAZFMR3+V\?L\;SV%/,&995DJTAV](\&+F,E[V+
M]O&+0ULS(*B0X[-4_,D,V,Z/8.2)?@;C7Q%RS@WQ+SG._#-_]G9&UG%+7T:*
M)=32454U1NT%6AFC90&F49<[FE,]5-4KZ7F4LA%.\P$%.GWEPEX<YEQAX291
MDGB<A-7G55E;S-5452VJG,FU.IS&FIZQ\TJF0BJ3EU8*558A?[0<>+E0NK=6
MV=3MA^B]78=G5=L;#LBV"[]' G2W<2R/(1D%-.S>UII.-SL^?>E,(DL7DW&Y
M/Z3,9A"-"D?2097LMNL."0QQW_2;SKC+@[-N&,QRGA]+F<4]/1O9I241H:ZG
MRFAKJ>OI\GIE4SH8:I#5,JJ02TI;2UK1*PL%-3X?_H[9!P5Q-0\0Y;F>=AJ@
M>JJX955Y@K,Z&KSFNI'*-[.JHUS2ZIRK33/.,% >2AQ*6B-*04X97<I:UMDE
MY79>Q:2M,YY91)^5)JFR[=8'E$)I,6FVMAZ?:>)NZ-A"(=_6M,NIR?%PNIEP
M;=N''J++ ^&>*<PRO/6,^R^J2QF.6U*ZND0LA%(^RX2U545<0/M:-]E2WT(+
M:TTSR@&D^75BP9_PK1U-$Y1N(;+)96VTI2B5M$H(2J2"2I-BE14#*1)Q9%:7
MK-ES!\NFQ)]HQ!J+S&\KH)A:@9)C\S_G<0V#A]I#DN2&(MB829]=+AS5RZBZ
MKY4%$UR75IG.?0G@[BC)/$?A9W,'VFG4U#1RWBC(JM"$O4KC:/.R64*<+2:A
MM0=IGTJ^Z4D:5 @>0.(:.OX6SA:$EUKDJYM!4K!',0BY:U1)#@\L#IO@=Y]@
MF0Y==/9EC,=N/U P&%S,IQ^(Q&@0NH;'ZN,V%9?BL6.EF#&VS0UK+2,JQEAN
M.G*XC0M:AMMU$>#Z\9>+'A=5\#5JW'U.U?#=94$9'GKS>EI@U9"J;(*KE)46
MUL@*31OK26W/MB^XSI3KVC@KC9&<4J!4+#-8VVE573$)!;;!(2ZV-1*T#S<Q
M*1KNDH0H$A+IK+:U7E4)#;CI;EH[F)462%-2(TEAQ4>3&D,.I0\Q)8?0XR^P
MZA#S#R'&7FT.(4E/GZOH:BCJ'*>H;4W4-W6S(*T'2"$%8):4I0(*2VXM"@00
ML@SC4=:7D(<:)6EQ"%H*8*E(6)2O2?NI6#("PE8_>2DC$OS/":K)ZY]IUII]
MMUOM\!*BGD>/W/SSQP4GG^[CCGTFBK':<I(<+(4-2SY5*;B)!0"1S#LE)(25
M>75AG0E]*D\Q)*@4K;25)=0#]Y1"D@0D$DD*-A:;#%1=1KS7%,WV9I:VK6'<
M/?JKS9.G'$R&GWH6<8C2N9-DE1&:5*=>@UN=8W$R>#<L.1HT.%8PX5G61Y5E
M:V-@OTSD'$W"N3Y-PEG^79CFE5Q14/ACCW+7J9E.5#+EN\EA_*E)>*W':?4T
M70ZTQJYB_/"0#3GGN*OVQGBVS3Y?EJ&FOV%44KBQ4IJ*9.O54_9@(#VE?W"Y
M!"4WF08KW2-7ED5O,L"N9^+6F1P67GWJE33T&[;D(2IMNWH;%B9C]PVZT4(4
MJTK)+R65>TRZT"0-VXE\/&Q4N.Y4TI5,4IJ"I%F@:E"'80H&;))UPGRGO:=%
MX/\ &#(>+*:CR_CK+W'G$T[*1G--5KHLP2I)<0%K<96C5I4U.@D@BTP<0*-T
M0;7O9"K*_B:PE5#D4,HIXTTZ\7,4H2O^==47,OKX4A)>C*2S5X]!@.(C+9<B
M-F0U(AT4\(9J5E#*5+2# "5*$?XKK0@65((O'?KC5J?CKA;)\GS:ERKB=6;Y
MI4O,)RY6:4+"DT=$E"$K:+RWZQ!<!U0L4GF@*6HJ))CM]_#9O9[;"L9Q*L^M
M,E)FNO['P^VKFX?MNJ<$6/'Q"GLG)A<#:&4K6EI(]Q3O>$H2J(OA.J3J!)0]
M,H0XW4RISHD%+"D^90 )*M/68&$<->+%+39O2-\4L\.NY&JF=:KPPF:EUPRE
MM3:>0RD2F"M:5(T&=(@ $'YUT6VV$-&3;5.XL%7&:[U75-B]'DD,O-H!<>83
M@&R/U[Z="PLM+34N/I8'>4!04A+2>&,W"B32\[2F2A(79(_>.M#:0$@Q8S>8
MWQ5\_P#$++,U0I+G#.4ALOOLH<H:E3H?IRHEA1\B5\T-@J4"D)2 J%'J/,;3
MU08M+;J=/]45/>JE>(VN\_R.1C-Y<-J)'TKF([WIZ^!):<1]I9C7JP\"L-K5
MRGT\,NJF4I^)H*RF3!TN!G4TM(MJ"DJ5M\CVZX\X<7JR5:J@4C8IG#J*Z92E
M:V5*,A"TKN@QY@+^4])$K;#9QUQD5?(ZONAJG6\N2T/YHP.+E.HH]L^5=RGV
MZ;&,@K=:9D7C_5EOP[(B;\+^H0X4E:6G_NTE9! ^YRT.+3'="2IX2;@*0#>1
M*2"<3>*F5'[%#J9)"A))W/0I%B8&XV!F,2K:V*T_5ELN7N/0&T\;R2_1CM)5
M5/3YG ;UUEN$T]!51:UFCUY!ME1<6L*13D9$MN-'ET[#<EY2(K]@E,7V$L.5
M5.R!6G[;62ZX@$MAHS!-@1%I2$6-A(&.>]]JK6''4+F0AT!"3VTZ21 $@"P@
M6%HQ#<5USU1[<R"BQ3/L4V9.H]40V*JLA; @/89K76%15L>VJPM;"Q@U&-0S
M$@LNR'+:P5:91<,(DNPG+>;++<CH)A38=2M 23H;451S%6(;0%#45%,J2F!.
MDQ>Q-+-0XH!12$IC4I1*0$@Q D=)-A<F  28P];3Z@,<_39W3WT[7:+YFXC?
MIVZMSU32ZYK*H;#B7'=<:V<>")-9@(?2A-K>*4W,RR1V/.$1408=*E2B@"4K
MF)(@:Q!,!P3Y0=PDD]R=L./.MH2&F(0) =6LA*E$;E$2=,&0"038GH GSVWK
M+W#\3Z6^G.GR"_@Y)<T<G-KM5'+H\AW'FE8DJQ['*;'YH;G4FNL+6M^;'_5E
M0VGI"9=U9+:A&UF+;4DE)<*2DS+.O?:"5&\0=41-NMY)$)< IZ9+BDIN%D :
MU&Y-B; E24WL))W)P195-0.[JZ;-#4MO M\3Z68B;#8^407BO&W\OA9"O=&\
MYL:<OVT+I*%NG=HJZP>2V'IBT0%I3)[XR4*"VU/.AO45(T(:(\ZBOR'R]0-1
M,SL#.PAY"4OU:&P4EBG(4"I10"$^94*O<DJ [V!WL2M5[0V_47NJ<-Q'"*^P
MO-KR+O:O&1+FUTMBLV7G.6YY>35S4H^BH8&!T%HS-R"PLX]BEQ:A"$2O<2W)
ME:]6<7#@+*^%LKJ\K%?0#+'JNHKWG%,4S*_[P-(>3YEN'44H9*4I42"2",:A
MP9X99/QIP;Q=QAF'&K.1UF45C=+DV0H9;55OA1"00F)A1_>U& 03$X:]J=:N
M6Y'L&5@O3=#I;U54Y)CW^_LPQ>'ETN^M8A:;?DZNQ_(XT[&<7Q.+)>D0*O)'
M:ZUNK]<>:XY[-<*Z7-PWCKB3B'/>$4\=UG$U+E>05N=+R7+.#<MKU9;Q =+0
M?-=F+C3*W4L'F!"J=#D! 0LO%;JVFNOPKP[E-!FZ,CKLCJ7:]O+1F#^<U:)R
M]94M:$!I86M*E+"/*E2$DG4F D:E27"=O]<B46'ZGOJ_F@B&8Z)&$:M6B..)
M(<2PC^1$)90H!OEM"4I'8D@#D^L@R3.F%FI*W\R<4I%.O6C-*PMJ\U2V="''
M5: %-*D)@*/F-S O-;E+ ;I]+=$D%3]DT3+406['2!K-YE5Q,6VQ^PAP\GR
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MBL5RV@0F7+0TP79+2U%QIMX.J9!2I+C#A:;<:44J!!5X5P0%.@DB(,D7OL2
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MHL@D'E9+V09#</.D$E3[KI/W%7J*SL^D3'/=O8W,*-K"Y4K>(,^F.BMX@TX
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MJ))5J;U%2VVUI\H4AHD)!Y8"9L5:2I74'76T0V\A5T5"$C2OS*1!)24+(E*
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M5ZLP_7OU.0V689'>#(5Y9;73BZI5'-:?I@VPHA:-9;<;2$-A(+K[K)0!YE$
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MI2HEAQ2!R2)V)H''/$*<Y=124*$MLMJ>4ZZ1*'>9RN7R5J$*".4K64F25@J
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M@^2.X=PX/*1]I!Y'')!Y/';PHC<'VP>Y!W[?C_#KL>D=65@V"W7A+2AMM*?
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MY!$"3VM,F!$CN+1 %ND7FQT.H+3JB$%Q"D=B!_:AM9\J<[./ \ ? \D>?!]
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MN@H)"@M!+8GK!$$81,Z?I$/I=;@1P0L*!#:. ?P1PG]OC_?CP/'J/\:Z"84
M@WT!2B$DCS: 94E!-TM24MR0G<X-(2@O$I:!=?>?)0VAL_:F0E6G[_+@!"B
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MG>,1[ .CBOI9LVSMY<N]LK&4'WK*V D6"VDI"&TR)C@5(F2.T)^IF/N*=E.
MON)#JW5+M/'7B2KB\\/<C(<BX=:R'):/)C2</TB*&DS!=(A85F=4RA(!JW2H
MB0HI;0"A)*3..3D/#YR+]I@9E65W[1S)[,=56H.*I4.2$4;*I4>0U/EF"HD$
M@6Q<;$M04U"$%N&RCL'(6M"1VC\\<>?'^./'S\<^LS?KWW%**EE6J\;:1_A
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MWVZX*PDE*>NQ5]09$'>>]KVQ@KIGWRA"@?XBW5<A">00=;=!_:>%!(_MZ->
M%*/@JX!Y\\'Y&I)_<3TZJVCIYAMVZ_+ D&V@&#$&>G8S!]I[XT)Z7-[H4E\_
MQ$NJM+J!VMAO6W0>E/!24I'8.C4)[@G[22/@#[@$CT0Y=B&T@SN5+-^NZC-N
M_4V!P-8TSI2)]5?S]#TZF ;8^<Z9=]N.MI1_$5ZK"XKN 6YK/H06A)0#RD=O
M1LCM5SP>>\\ $ $D$*U"/N"-[:QTO/F/2PB 9OU@2"/N"]]U"Y$;SM B1O.!
MI3]%74M7=3NO]V67\1[J/RK6^(88G'LDT]D&':#AU>Q9OZY/LTL7S>#ZHPC#
M(=,S%?1%5;)P2RV:4RIC%#L+%8S,=#A%:"VMLMC2L#5YE"8@CK(@WL1A1(T%
M(0D$];VM'K/6T1Z=FSJHQ6?KS853L^CCN*;KI,[)UQ8S7F=CEDJ,ULFD;XX]
MR3$EF!G4=+JE+D_5642"T?9>#>D\,UB<PRM5 HE3^7Z5.$V'PYLRB1'W?+N"
MHZ!),WI^>TJ:>I;K2D:5C4[=7F4J 21(%[;1O&Q&(AD\"'.ELVU<ZS)I+ZO8
MGQI+:N$H]X)44(4.4% "B4 *\ #M">?5FIEA(#2C+C=G%6DF(N!87[ "?:U-
MK62V[SD^5E9.A$3 V-S>UK$WCIB"6JVH[4EEIV3$*WF%.RT@.ND-I ##+?<A
M:D/!(2I22.WDDD'SZG(&HGVL"3WZQ-^AN3M;<8Y[D )])@'Y[@[7W@DP.F&%
M+S#\U;,Y$MF8MQMME];O+C!+:2AKV%GA:%\I7P!R4D>>23Z<B-@(C5'J>LG\
M-NI,6PD>AB+=+W$B.DGZ6C?#S)$OV4-RW&Y*H+X:#@:+*Y"5H/:KL405I;!"
M5>/@ ? !(,0!MUVD"W?:T[["(D6P0(F1[1N=^EQOV-YN)OC1])&9FN(DR8B1
M(2D!3B5!H(("BVRI'A#G/ Y) '"C^>"-@+?E C<STZP9ON3@&\WL(![]0-AU
MFX.QFV'<P.WAIMYOZ7S[;:'B5.)]L*[N0.% $^!]PX^!SX]"8W!$;D"T ["0
M !U]@!).!8@P;DR)M'K:\B-^G8)OAL4A:51T*8[0W&<=D)4I2@ZELJ(/]/D@
ME(XXX!^.1SZ &T;&($[7F;VZ=I] 9.#D'Y$7B=P;"+[^M^]XQK3&@IB+>;94
M5.**DJ?]Q)90"H]H]M7*.T^ 7.02?( X! 'X6OUM&XVWBU["9M!7!@WD@B#.
MQVN)CKV[1?"^,KZE,:0\4]L=+;J@.2?N)0&B5 <\]BT\CG@@_MZ;4E('ED&R
M8!,Q?:9^1_$7PI%E^D':)F!($;$>PGKW#P$J4PXMQ[VDJ<+K#*5J2A#C9Y 6
M/)YY(X!'!\<>.>&K3;:3-CUF=O0"(,Q-CMARQ.]B=@/J1VN!$28^F-?O.3?:
M4AU:IC;G<6^WM(2?M4WQR.4D>1S\_CGD<F!!(BU_IWF!$7W,P3Z2J-,SMZ"_
MO,;W.YM])<G&1([6$+7%"R4ONDEKN6%$A(3R>4I3P//GGY !Y+*TI&J!T/Z]
M_EAS\;=?U],.+?/MH)_NBH+:>PG^HE/ 2>4_W%7]QY\ \CTS<$2/43M>_<#^
M&%HW^7;;];?3"II+A<2ITJ*W.U190L E*0>$]OR5$D>.?W!/'HE3()O,]+B_
MX7$VDS$7PYTGT]OSVQ6_;6N\MQS,VNHO2->U<9[$J86/[7U8J;#J8V\,#JU/
MN5T)B;.6S6U&VL*$F=(UKD]BXQ7V#$J?@6538=!<0+[$X3S:VW/B:< N0$O,
M["H;3, *,!+K<GE+,)()0LA!"D=*D=;6S\)5$I:*E+8? *C3.JW\H&HL.0D.
MH$E,!QLE:2E<ZT/U%:>ZA8.63-6Y=^K2-=WL?%,^H+:GN,>RG"LM>JX=HYC&
M3X_>PH%E77%<92ZJT94PMJ'>UMU2./?J--8QXQLU+%2EPLK!*%:%I*5)6VK2
M%!"T* (()(5V4%)F4D8*HI*BD4WSD:0ZDN-+"DK;<2%%.M"TDA256*>Z"E4
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MX'J1.UK$B(F(L9/M$_HXC$CH)$CJ8B+2>AM/IU.XQ+&)*WV6^QI?M]B%.*4
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M25)45)21Y2 L";%20H3.WD*;"8!BT X6I"DA"E PN5(@@@I"E))3!L0M*A!
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MIWV""?C:6J2_2O &Y9"1K;TA.E2'"529!B<7QI]FH*PA6LMP%&((D]K$&QW
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MQO!^EVOU?L6J<K\_OZF/F-Q2=0-<G<-IBVSX-13Y)$8<N*F9;Y79HK5H53/
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MZ5KR-;1)DN= N;'+\:U%FMO:5,N?!K)RJ>RO;^?-I4RZ^%+CU;\-E^.R\TI
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M8W@ F(O Z>N,FFYE?</M/^VPRF$VH-I4MXDND<A !X<65E14.SP>"/[E>@;
M$F;]@/PM'S]>UC.\DR!>+"9]/7?8G:8Z:Y./P((#5/5UK";"9*>G>W%9CO.3
MI;BI$V8/;;0/K);KKC\EQ9]U]Y16XI2RI2B$#ZS(N+FY,6$W)GY&UCNH@F21
M:Y!M)  @=+]H D1:)#0QG4.6T..XIVO9AQ EN03(?3,2"I:D^X>0G[O[@./!
M /@#T"8G<VOO-K#\9O$F;3!P_81(!N(F_3>YF(BQZ"3!(PZMQ([T)+$AOO"&
MU+#C)2A32DJ*B V#RL\@$@CD<^.#Y("@JW8"QB-^U_E?"H,=)FQ^0WM-]R3'
MJ",,+S?Z@9+4.0D. ]B/?<+824I[4)<*^WM!^[@)*P>U7/G@>C(!(WZ&#MU!
M]01UCK$C#"P28ZP-ON^]MB+7'?MA/029+3;\268QCA[CZEAKVB'._M6VM)':
M5 @<.(2 OD$\_(!-E#8 $?.+==C/I^.'18 S<";;G>9V$B3>]AM$@R8SV5,R
MHG"WNQ]+!<0>$\D)4%I/">\MJ" I*O'W$CG@ ,H,$3T[?E<[=O2T#!DWU#V]
MI!(Z0>_4=B9$9%IB/W3YKZGWGF6DM%] 0 @$%21RI2NXGA/@$>>>1XX-9!VD
M>\C;N1M;N?E; !O)GJ.AB0+ 1N#O ]\-,RI;1(,I3(;4_);>9>2I)2R7. M*
MTK2$!78D)2GXX)(/)]+2/*)M,[3W.Y]]CUVBYEM2"3JG^!M(OW(]#L+@;XV5
MS,FM0)#:#*9]]Y<5AAP-]SBP.$O*'  ^5=HX^#Y'HR" >MKD^UR(_&3>(O@@
MA0(-C/7VG: ;[F>N%OU\PA3]K#C]JP%-!I)/TJPO@I(\APD\%1^"21P?34$F
M$D B]YN!V@7WZ?GA1&H00"DF2)&^W4[]1>]X/:-V]+6RHS[JJNO;4\TM*7 P
MS[CCKYY!4.05E?*@!QSR1R.?B2EYU!3"A('K<_2(,Q?K:YG##K#*DPI(U$&#
M:WH28@@W-K](G'*_>G3!OG_B1QK;&HLZCXM5T:<;^@MF;2PAY#@S$-Q:<LIX
M%":Z;07-/ET=:7YK<M2V+B6EJKOVFJVIKG7<QXW\.LQX]SW*WZS,Z8\/TS);
MJ:%WFIJ&9)!-&VVRME50M0*TUKK[3K,I0EI0;"CZ$\/O%3PTX)\(^-.%,RX!
M?S#Q"S>H+F1\3L)I5TJFRNE<I1FU4[5LUM,SE:FJCDT5%1U;-=\4XJH=9(&E
M/FF(7%=87VP,%HV:3,*)B1D&X]34<1^-565.R_Q/W!J2MY<=70O+?;D9_@[2
MI-CC-E)-A#5.A3(=CD?D[Q0\-\TX.S=S+ZY:ZMNO<0]D?$"M*37TH!U976+(
M2PQ4?NA25K;6E(6MU"B0'N$N-*;.Z()U:'$&7F7 D.M&TRVE3GV943RU:B0(
M!@&Q*UKLVES"O0N#80YBD(9^J0Q(9><CJ?90^TEU#:U*0765I=:[TI#C2PM)
M*#W>L0K*!YDI6IIP(<*@T^6G&V']!TK##CB$"H"%66XQS&@8!7*DS>90M2T)
M<:+C93J0A]EQ2=0)3J2TXLHD QK"5=(FV"#=4<.XAK0IMI25MK"@4]W=R#P#
MR#Y\G]N!^1P.(#3JD*Z@ Q?H;7 G\\ *CRKO/X3 ,[ BW?<>IFD%UBFP-([0
ME[6U_-AV.-VF.C&\\U-;Q%N8IL+'%O6*K&JON'5QT*DQK$_IEE^FR+&AL(Z)
M$9^55R[:CL=;R7CC)Z/@E[AU?"E&.*$<1)SG*/$!BI6WGN24WP/PQI:5@-(2
M\ \%J#:ZMIE2'G%+AQ+8Q6LSX?JLPSM.9N9J\[E:<F5ECG#+K21EM4\I;ZC5
M.NA:RAP<U(#B:=;GV24@A!(-M86_=?X5JIG/46MK+U+8V;-3CEQ8QIUIFV!9
M@MV,S(U'F\*N196L[)HKTQ QB;&9L%9C1+B6#4BP6%6]QZ]\,?%RASW*30\6
MUS.7Y_EM/^T%5#B@*3-LL$-_'9>X#SW6=:D!2*JFI'I5(9(DXR&N\,<]K,_H
M<FX5RM_-:C-WQ2T%#3@<]M]2%+"GN:I##+6E"M3O.4AL2X\I#:5N)LIJ'9.+
M;3Q"DS' \D9R.EG*D=CLN)*B%J3!EKKYT*9!G1H-I66$":P_'=AS(C,AEQLE
M390I*UZ[2YA29O1LYEESJ:JA?)#52V905)-T$2%!1 )N-, R1L:IG?#V=<*9
MM6\/<19?493GF6.AC,,LJT<JII'BD+2E=RAT*;6AQ#].M^F<;6VM+I2X@K+L
MO(I#*FHT>)!?F=TE;XG<A 6M:$)2E0(+_*$J*4@I"$I[E<$@!X-!=RI0 L(^
MN\WWB^P'SQRB8/0VD3%IO>#?KN;S]5&,3$.R+=YVFA2"M<1!:?=5V1G&TR/=
M1'#;:P&EJ7W_ '+4HGY/CU#K4I26DW("" 3).]YC$VB! =(( *QN?3U'3'5S
MU3,7''WH8'S^5OY3^./O0P1V,]L-S[B0L(5R%N?:!X \^ 022?CCD\?:2/GD
M#T2C ZWM;U_7K[82F ;$FQWVW&WS[82EM7*DD$)2 HJ*4J[B 3PC@E1X^/(0
M>>?GTWI,&;#>8[#\#VVM,]L+PE>=#0[^ &^.2M9"..>. 4GSR>3YYX\>!Z 5
M B)CK^IZ^N!A XR70LCPG@>VX"%<I)!)XXXX)!3YY!'X^?2%#RJ,6 _1^H^6
M!AN6V$IX0$E0*@4-\^3R6P5I)Y!;!//;V#R"D>H^"/X[[QM_#H??&<A24H4I
M:@A"0KO*@0$H3R25$^$I*>>3P>/@@<CT,$1,$S(F(OZ#T[$=OD<-"E^^V%-^
MV62I25$=JC\E*FR4J"DD_;SWCX">!\>A@^I-_K8[7CIC2XVI*TMCGM)4H<DJ
M[B  !X''G@^2KC[>WCD@A&@=S]?\L'C2XP4J4XX K[4=G*!]I[E$\$\DD=J"
M"#X5Y'X]$I( L3V]]S^8&"$$FX.W\_K/Y#J,9<H5RGP>#PH?L1Y\_P#C_P"'
MINX]/Y8/#:M+[<DK6XRF.M26VV^U(<+BN>Q*3V]Q5R5J #G)[E<HX'(5(@ 6
M_*;;^\=9 ,7%\%?]?Z?A[7WG>XE:A]H"N>>?(!':%<<!0())/!X4#Q\?!!(?
MK>?;_41<S@7]/6YV^F_ZG".1$9>2@/MA1:=0\T"K[PXVKE*T=G!Y!Y_)23P>
M"0#Z CW@@GK8;_7UVZG FU[>F^WX1Z[>HPH6@]G:1R$J*T^1RD<D<D ?D?)Y
M _'XX] =QN(]IWZD1VV(MZX!CK'0[_3\<-DM2DDE1(:0D=W:%>XM24NKX"PG
MA ''!5SP!]H^0/0(%]]NIZ$7[?YR/FDW,29$ &^YV@"!/3:_L#/-#^(CL1N-
MB&,ZAJW0J]VGDL#%$$(451:17TEOELMQ/'<A**&&B,TZ"$E^\8840$\F_P#!
M-(1\76J0$D,AE$;$62"9DF1OT&_;%9XHJTM-,L>76O2%R;I 4)T[$3M/SVP.
M;]:V8E)![DNFNKXL=*^ KRAI )6H#R>X$!0XY^2/5ZI!Y%J_Q*(.T 7,R(GM
MO/7% JUA2D)!L#J'^*]@(^O2+1:9Q&7VH\I*4/$QU]O#C@2?</*P1V@$<)'
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MYY4H<\D?]((_!]8)_2&G^JV32(_Y^1[?_!]:3;I<W^6/I]_W*C_\O'&W3_\
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M'"?0G>]AZ#>T;^N\D1(V-\&.IM%A8"]][_CMTVZ2&,AE,=A:FDK=7[;G+:5
MJ"4^4J]S[@0?)[@"/((^/2H$1M:/X ?CB0)B1:!<3O:>A-R-]H(L=P,/U5;R
MW64+67'&RT@K4A*4]W/"P5#LY2  "?@D>1\^FPF"#>?I>TC:1;I%]YOAH*YD
M)-I@2!%Q!%NXF/:^(U)C,PY+J7'#*E2FF"%J;4IYEYHD_P#KQ_"04D!12 "
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MZ_AL8Z;@D8!$G?;<?KOZS(MU,[5(*N?L)!(_N2%<I X(X)'()\CX\?;Y'GT
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M+_T=/&@=_#SB3_[ <Q^VYA302P&G%.--NEIP(+BP(W?_ $D(6O[R0"H<GCD
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MU_G<WN<+*R,RS"GE+R279*Y 9Y4D-)/(2&N04JXX^!\<'CP?*A?L;F/3>/\
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M9,F<&>\383Y?6?2T6GK'2V%T^ X&ES @_6+J6XRD,R%&&%>^DI<9:/R[[:7
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MTW"78)J@'V&7(]A)KVGI<.-+0PN<TV5PP^ 06EJ2K3!ZQ,]>W<R ?0C @P;
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MH2X5*^_CVVVP4@$-H2'"">5<J'CGD^NMS4MPHDF\0$=3[NGJ3/\ EBN*IG2
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M*0$D)*B2=4@*2(@)3_BW,^QG$NDF7+$5YEY*DI8)<:D!26U%WE"2A+15V%'
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M$)D(5N)F.O6T7PRW3KUQJ3,&\'K&_>W6+X)/TS,B6/;2&YJD(0)':"VE+?W
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G-;4 J;,*,I)DD3OZ=ML/T31(<(#:05)L J!"8,22;[F^Y/2 /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g155225g80r72.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g155225g80r72.jpg
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M 0$! 0$! ?_  !$( 1H"70,!$0 "$0$#$0'_Q  >   ! P4! 0
M    ! <( 0,%!@D""O_$ %,0  $$ @(! P," P0$"@<!$0(! P0%!@<($1(
M$R$)%"(5(Q8Q,A<8)$$S-%%X&24F-S@Y0D.VMS4V4F%WN+D**$1Q=2=%2&*!
MD4=46&.7UO#_Q  = 0$  04! 0$              0(#! 4&!P@)_\0 2A$
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M8;]E5C7X7:"^]&>L7FGWX+;;4A''SCJF!G)P)V_W\Z<_^VGG-&_U_@W@TOI
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M#C;@$H&!BHF*J)(J*J>E*UZ[PS#\FQ:9@^28IC60858UPT]AA]W15=KBTZI
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M:S_Z,^H3SAK/R\D3W^(UYTBCXF/_ "MXD9$JB:]'\JI-DG[)- 1B2DCH/O\
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M0+'_  S\S4.GH<ZLU#Q'U<\:K5S-KYE:XB=M$!NLS_<^<7(,?<J9(Q 3.?\
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M)<XQPO\ DJTK.Z4MJXBH*!4X2@A*=-<=CN#OZN[8?MR9(4TZ00.B6E)6DD1
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M"DJ2<A25))!!&002#6B(()!!!&""((/0@[5>147Y1>T_VIZJJ*/2E'I2H/\
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M6UHEI"<]Z]87R(0$@%9+=PN"0-;BH2)F(2D)J>X:2-14I1(R$*3O@@0I($=
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MMJXKWMY;)?R^]PRGAUUG/S[75$=B *GII$ C))\R,G'3H)Z;5.+^S7E3RO\
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M$PG5C)7]J!@JLUE?A<2-XA14?(C&_P"R"1)H$E%4ITGR'R$O:;<;O)PQH_\
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MTI4(.*?_ #^_4R_WT]>?_3GX$>E5*V1_A/\ YJJ;_I5-'I2CTI1Z4J$&!?\
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MB6'1Y'[]9K;7--AFM:-S\Z7$*]PW#<5!)/IT&W[\ZDUZ5%0AW?\ ]-C@M_\
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M&]:P!/BRF!DDS;]G0G$$ 3A, #)F)F)Z',S !S55=D2Y"HX<T(L8OS5Z76,
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MA1TIA>0N$I]HTVVB^X:JJ(K0.J-]JPU-ZR'E-(,J#;K=ZVHJ)(D"'0G8'6)
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M$!!!3$UJ7+]%XO!#8&$HZ]%(DR#$P,[Q$8JQ*?%CS_%77W/P5LFQ^X04'_\
M.4;^ER."_P YC:"2#TC7?R;F2W9&[5$!*L_6I/N@$24*@I"H! 2H*41,=19<
MO$V2=2EG4G&B05**A 4I.^9)U1I!)G:L7KFPS35UF=]C>?Y>=VEQ8W<>?+L8
M[KT>/92DEG3QCA0H8VN.14ZCQJZQ&;):AH$62L^(+$<?4>!]J^)=EN*VO&NS
M)1V>OF+.VM7T</#[=GQ 6R2GO.(6;KSK=P+J2NZ;4DI6Z>^8;:?TK'!\6MF.
M-V[EGQ)M5[;K>6XVNY"57%J',PP\A""@-22V"%$#!*AOUAUG]0368XO-F;UM
M:_7$VCB!(L<H>;EN8G91@5&BG$[$9F.T[R(HJ^$D/T]27]N6RZ7V#'W3]%_T
MX\$[<AKA7%0SP7M*$@"W4[%AQ,@97PYU[0XEWFJR?2EX3]0NX2E2D^$]I>Q=
MYP0JN;51ON&ZH[Y ^LMR282^@9T@%(#P 05'2=)&=P3ZF/T]1\5F\TN-5,A(
M)(N2;>PS&!03$E C+(K:L1L342;$C44)Y%815>_;]>[5Q,'H?D:BQQ5YV<(F
M]X?4,LW>8W%=JNS3EW@618=.>Y!ZE:B9701^ W";%)%WCDAS+A:NZF/E.*Y/
MC+]C6E)B,Y#C=_2NO!94]C&C*J(,(P?=/(_U*KH'6<NN*%WX?HW)WCS;^Y[7
MA^F;IUO/\_?[]CP^TR5WR][Q+VNN_<\5\.^E]*I((W!'K3@5FX=1W7A^C;2U
MS;>YX>'Z9F^,S_/W#\ \/M;-WR\S_ .N_(_Q3M?CTJ*WJ'8U]@V+L"=#G-$A
M$+D.4Q);(0-6R439,Q5!<10)4540T45Z)%3TI2STI4(,"_ZR/E9_N0?3]_\
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MIQYLZB9 U%^4F8$-M-Z$H)\.25ZB?LU6EQ"_<< @"8\.).,S)/D-\\S%\7P
MPBPW8C*(**X3$NM:=:;Z3\ *)7//_</>)=$+IF ^;Q?G[:.8Z[%H)#RDN%U4
M=WWP>)]2AY]I.F( ($F/%@S6253&B#C,>+;F=,_(D20,<J5?<(Y_@XRR8W@
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M6O>+W7U1]P7._-\4#VW_ (\1)E!5J&^J>(H^T",RQ\0?0T< BZ-AI-J EM*
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M;P08JXR^R:E*?C0Q[%49$J>?(]N/WY*XJJV"HZ_TAN=J*@ M@J"0F1X[E@"
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MIS\7"PW7=Y&N\.XW4]@RJE$R+9\'-ML_;N.,O:IUC=LQ+EM4X$<S]P\O/SV
MZFI/:.XYZ>XZ4=I3:IQ%JGEY+/"ZSC,;>RM<LV1LG(Q:]D\HV9LC*9MOF^P,
MD<;[:2XRN]M)<>-X081Q:]F/%:5!).YVV\O0<J9#B+_SL?43_P!]Z'_\E?#7
MTH=D^GYFIJ39L*LA2[&QEQ:^O@1GYL^?-D-1(4*'%:-^5+ERGS;8C1HS#9O/
MOO. TRT!N.&("JHJ*@)+Y<Y]R!E2<8X&852['J!D/0+;EILL+>MXKXRXRX3,
MIS7YU;T#+>4%W$,'!9@ZJE5.KW)3;]?=[QQNTC.5KBJHCWL'IS^/3XY\J8;5
M7&6LPCZE5%E^V<YR?DCN4.'E_DC6T=IP:-W^#KF7N.DII,73&#U,"-B.E,9"
ML?EUK<##835_:P)#BYMEF9W#TFXE*B3$8 \N?KF3'+I/G73C,-P:JU\IAF^Q
M<+Q=\!(EAW61U4*>J"B$7A7NR4G.JB$*]-QS5?(41.R%%U][Q;A?#4ZN(<1L
M;%/6[NF+>?3O5IGX5<;8>=_LVG%_X4*5^ J/=IS^XI5J.HWLMZW-KR[&DP[-
M[)HB T A&:UCHUR*BKY(KDP ($(A)>E]<G=?2=V"LU*2]VFX>I21)]G+UTGS
M'>6S3K4CF"L$<XQ64CAE^N--LY!YF !ZR<?&N7'+[FSE&>;NXZ9GQ<J%I_[+
MZ_<$#*=F[.Q<+>JHX6S:3'*.//P[7=?F>.6.;Y#6LTDF6U7Y'DV"X^R<F$]+
ML;-&9=.YS-W].OT>VH.B_O[U0) 39\-N7-4<TE8;20< $'<CSC8-=F^*K@]P
M E6)*QU!S )'+,'&U)]5\B]=:IRN5M5G4.:[YY 6M<_77?)#D-LBEG;#2OE(
M+DR@PJKH\.+#]/X$^_Y$>O\ 4-/AN)2E;8G6L2XN%DVK_*7O\1_9]@*-IP'B
MEUF$][<V-N3C!* Z\M()W"DA6/=R*S6^R=\M4..M-HB5:?$ F2)RI.J(YF3'
M3(=6\^I/O^>)I0X+K7'&%(U27/C9'?.M-IV@^*)=5+3A#\DKIQ :-/%1%![[
MY2Z_B6OE^&S[-V=N2<+NKYZZC) EMAE@ C$@N<B08.,UOL@@B57:UC$Z&TC&
M)W48,3&\=#4<=E<E=\;9O=9Y+DN9QJFQU!F]ELC7\G'<8K*=JBRZTUKL/4<V
MU!N7&M)D\"P':F<4S3%E.?BLN6K5LPRMI75LV-QW$OXA>WEPHMV@X;9X(FTX
M>%JR=]=XY=I24B(&D2),S%;:V[)<*!2'7'3J ,+<TDC!Y>$@F">D1F:;6KRO
M8\:?FEM"VGL"MF;"RK^.<UFQ,VR"F#(\K7'<?Q1;Z975TZN@G,7&<5QVF]W[
M=IO["G@M"VZC7DO&WOTO_2%>D%WM)Q)*<C38*:LMLY+#*3F8!,F !L$D= SV
M6X(V"$V:5GF5_6[#,:ITB<XQ.8ZZZ]3C92RGS7_U22Z1&];6L])LYXB+LS9>
MFF\2$I(BH_T($J"HHZ*]^N*O^T/'N)*5[?Q/BETHR5(?O[E],*C,+= SSZX)
MDB:V;-IP]@)[FW8:4#[R$MH)B")E*YB#M$>8-*&:J$)(L0 8)%5')GWL!UQS
MY[46U<D@JBJ?R+KV 5?$&SZ5!TY=>CWUJ&^-*B-AS5,''E(GK6:$ ;"/,)$G
M?TYR1T(Z5D&6F!0FHS\5I/@'I!I5NF1#\="93_)QP>U0C55!I?P%%42 ;*TK
M5)5*I/NE:0D R?=DC5U5).2*R$NN(") \)F0 F=\&)C?[NM7@:C=DTRY%3Y3
MW9/N 1^7RO0G^L*CCR_*>2]HUVBKVJ>WZQ5MJS"4Y5@:@8D\CJR8@=.9$P*R
M!>%6740G>4)E4^9TC!DY\AB:6-.BWW'B.)\=$\[]Z*H"DJ=D7N2)/N2#1$_K
M\O!/$W/Q\!<@MNZ2"HA,C&K$R?,^N1TG$&KOMS8  0\0.13C'/>=B/G/2KW[
M9$C+?VZ.*GD;[LB(^0>7PKKI'7NFXZ2)T*$I*?79="*IZLJ:*1[LXY!)P<#<
M;X)Z_*JVKMMPJ!\$'[<@3YQL>@ 'WU>5MEE!886(X\:*1$:Q"44)50GWE;IT
M(E[']L5^3(?$5$!,FZ @CQ=VN)_I&<@9\.^WY1O63[0V-W6X\U*_$S%7?<2(
M LQG&T=<4B14>5LB+I/-]TH]4V2"':=]>**O@TV@]@B4JM@N7"VL@QS<!Q S
MI4D1@'83UR*J3> 8#K82-AJ)&=XD=>O.!XJ])(6**"KSK\AXE7R6=;J;KJHB
M$X:M101 $112_P @!!;;%?P#T%L-!/<RGF$H,0.H*E$G$DD\H@9%2;V?=?0
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M(R>FPU7[6T86+]N<CZDX)QVTXU;I6T>ZN4)2;BU41K;40)*9RMK5(2L 3$$
MXKL. =I^%]HF5.62M#[1A^S?\%RT 8"R@*\3:OLN)P>>DXJ5']UCD1'[6O\
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ME+0V"S*<9S &)QF=A\:B^*>W&@*RVK:)[CD=*T59:_F@@$.'9&3S@]^*(2$
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MV52'7N@B==&\BHHI^+1*?;C4%"R !!<,P(!)$;^(&2#N#\1F*O)4$G,Q,G)
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MV@9P:UJ[]U;JBY"D3(1L$0G[&\$Q)]3M-)GI?W:(H=K$ E%7U<*4A]HO:,3
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MNOCD/77[3-@0E^2$ZX"JB7)4TI24M0K(*E!2E#)$IR #G<CY'>REU*R84@$
M[D#<8B1'+IC!JA!\*$5MH&E04^Y2.PC(('XDC+Z,VK9&'2IYN2@9:/X53('!
M&MEM.K6\M,<D9*E9$ZTE((2<[&"<15IVY0 4M*"B9!6G.GH4G )!!GX=<^%5
M([?D(N2E=)5$E7[SWC .E(WD<MF6@;14[<6'&;:'Q%$$? /65[.E]7@08D%2
M\H;",X2""%*$@B!.D'.#6&J[6R"HNJ.(2E49)RD @""1)Z&"<YBJ"3P^<AQ'
MQ140&0)7(+2@O:KXLI-B$8I_WTFLBKY)VV$?R,?5Q5F6P.[2%G5IU$@0F"/
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M >GF"[3_  DEI$3M![57GO$5: _P5ESRE-Y-IP9QU N7V=2$+A"2""H &#(
M&#!YXG?%8'%.TK5HI5G;7"D7#K7UBT^)M+:\! 7D:]]2001OM5&U1H?:1ML&
MR3R".)(+#J(**CU>ZBI[+@ /G[:*"(OD2* JLDM@ZTAPIT)"%)TI2D;#9('Q
MS\>4UHK>^6A02XHK02-141(D;SSSF,[1,9K 3[99)$++BK$1?:>E$"H3_72K
M'G,H@JD;Q7I) H/O"J]*$9?.9O>%\#4)>O M!$*;;, $QX2=L$:5^4QSKG^/
M=J ASV/ARDN:3J>>,Z8 "5);5M()(5F-YWJC;@>/D';*LBI>"*BO16_A3*.7
MP,F#T@JK1"I!^(H@$C;3>S=:4TO24%0) !2("U$9@"",\\]36D;N4/@E*@I0
M$J$X2/[RLB!N5;;SSK5Y=\*F+$%>@530);0"0$GRAE5 :*)-(G:O1GQ,>@58
MS9H+;I]%8]G;EUCVBY!2F$E-KJ$K!W).P&<B)CSR.9XGVLM[1X6EHI#SDK2M
M_P!]EE8$:D$8<CDH'3(\LH!$53W Z,G15%<3R?5UL?)%04<53D,!T:.P'"]^
M.GF,8N@#O:(9#">[#268Q"0-MY)).K'7D#'GS3UR[=N!UQ\O%S(42( )F!.R
M0>1VG<<\=/N8E<B(;I.21!599CJK\GP[4O)"5>WH*])[@.H+S!(J-H;GM(.T
ML.&77$'DML-K#8C6\M)#;8$?:^VDB-B#TV$:WB'$K3A*%.W5PE#B("66UZGG
M%0%)2D((4$D?:V$@B"*Z1</_ *EV2:S=KL W@<K*=>$3$6IR2,9SLAPZ)T+#
M+;9N$3^24$1L!5R&ZJ7$!OW"KRDQVXM4?HC5@JTMVF@\Y<+0DZUN@:CS@0,)
M2,)"I.F)5(@^I_1I_$B]:7+?!NW""OA*E)9LN-MZG;FP2)2AOB*1*[Q@  >T
MMH%PV 2I+X(TSRXO[UU/O_G_ ,O,MT_F</.,>I^(' O$[2RA0K: D+(ZS=?U
M'K&?4RHUQ75LMJ7&A7%;(<18R-^,L!$R,7!"@@C!$'H:^TK2[M;^T8O;*X8N
M[2Y0';>YMG4/,/-J2DI6VZV5(6D@B"DD?&NG7I5^CTI7(OZ[7_59\DO_ ,?<
M;O\ YJM(>H5L?0_A52/>'Q_ UUT]35-1UY:CL]>..V3TU.R"OV0QC22\==Q2
M$_.R:4$*SKY=W4T(PX%M9PK:\QYFUI8-S1TM]D=!(GA>8WCU_>UU=33E2(D3
MM.:Y?\,IWU)WN06F Y%,;5CX8[K.:YE4:Z:JI.NV]=KCN8'BCN4VS=-42GN1
MHYY_ <;(FYT2HRQ[&?U.3844*(5H#*I.F#$<HWGSWY;_ +BNRFQ,MM\&Q&SR
M:CUUF^UK.O. $?!==NX0SEUPDRPBPGG*QS8N::^Q$0K6)#EI/_4\LK36OARD
M@!.L%BP)*J:B](Y;;1C**.?3YYKDIHJI]NYP]E(G72+Y+%Y>/("_/PAJ*K\J
MB*B+Z5,#J/O_ $J!W +8?+/=?"/BEKO06!GQUP6@T-K/'<KY-;UQ^+:Y#/F5
MV+UT2VC\>=$MS_++?;=!UBOVQM:UQS782 8NL4PO<^-O(9JJ( )G.3@'SYG]
M)^'/IGHOBCJ?0UC<YA4,Y!GVXLNB,P\_W]M>Y+.=TYTPPZLAJOMLPFQXX4>*
MQ))$_4:[P:MQ/6N-F9#C6'4[9$"JI)GTY#D/3]R><U)7TJ*YO:6VUK+262?4
MGV)MW.\7USA%-S=KTL,ERVWB4U8V_(X6\-6H=>P[*< IUM92%"'44T )-K<3
MW6*^KARYK[,=Q54$Z8Z?F:A9R>YJN<AF!Q#$L1V=KW7U%<%(,]BXE.PS*L_>
M2,P_57KF"6D?^*<4QQAF2;M14YS78_EDN2X4^[Q.E*%5.2? /I@[1N/J1V5L
M7%:$H1<\7*"!J*R%6MH28G2![0XD3E3),%-:;B'$D6SGLZ7$!P!*G,S .0G&
M)P"3/2.=0L^Z<DR5Z>LB:C*B>/VS#(G(4$5>_=C-*J,@2=*2D/O'VGBZSV/A
M'L2B!+ $1_U",YSF<CGL><9QIE\:&4]^ 0>22K8F0!!P9_$[37H'O>DJAI9$
MW'42/J0V J_TAM@HMR&T_:!1=5.OZC9-/D?BAZP<6D(%NF% $0X9D&8)G,1/
MQ&9%7+?C;"%ZGKE0TCPE+8 3(SJ$ \R($P8ZU><D \\+'LV7M@@O/]RO@OE4
M9:7_ !R?!&*NFG\_%H15%!U?6'_)51_]LV-R0'#.\\CN3GT]:S_^([3;VU4;
MY02(R,=/R^5>)4H#\8R#9C[J*;OC(<-08%4\DZ&2Y^3I+[2=_P P5TD52;Z]
M$\)*5D+MTE)W <),1OOB3\AMRJVYVB8+:@U= F(22@@S.<0 ?7;>:\/V! (M
MLRK-IQ]4;'N(\ZK8(BJ\XBK$>\?!M%0.E0/<)M.T1?5X\):)U>SI ']XDP!F
M!&8F:LM\>>($70(DYTB9]".L8\L5>*P2*P*#8."70LL ^U&93W%7Q;'\XC:>
M(I^1JG9(V!+_ -GU:'"K=,E3,B<!*B!$;9 )VF-MCOMDHX_< 0'FE&9E28,X
M(&!C/PW)\_"34BLJ2VD0P 2)?<1E7''"[5>U!YGR=><5/A![(RZ3OU>%J$B$
M(4$)!  SC)S)F?3&WG5 XFXLJ4L,+4I4^)<',"!\A!,Y)G:E##DAMI3*1",B
M4GI!HR9#Y$**2(XDM?P; 4;!5'X; >T[[]4]PGJK.8TJ(QTF<#-3_,"=VFNH
MTN=-_/<3S^ZK3(2'$*0]'AN&_P!%^:$T8-)W[+2B3;JIT*J1BJKTZ;G2_P"7
MJA3'B(+CN#OH,$';('D9S]T54WQ$"06DJ\PI6,F#]D<L3TF*\LA[I%)*O@$)
M]@PBN)TC(DJ^:#]D0_OG^YY=_DTC/:=CVMLVN@2%G/5*8Q_\?7Y>M5^WHC(<
MG(B1CU\6.?*K;8JZ^;GZ7"%IE3:9\'O'MSOIYWXACWTJ(R*IXJ*@_P!*HN>H
M-H4YU)C;"$<\D^[O@QOO\:G^8B()>.W/YP-?RW^%7$(GWD3[$!;C*BEXROQ.
M0J=]+^ ]HR!(J=]I[CG\T)I.AM #)"")Q @R>>$@>FXS5W^:!( 3WID;DXZ3
ME0SC?:KGC[[WMK&?]IGP<=09[OB;BKY,M=HZB%X*GO.HO2I^Q\*!]>L9^U2G
MW2UJ5D^%?/(!.GD3G?Y5G6G$"L*4M3BFQ@(,05 C*3JY92=CF0#%77@5]Q(X
MQY*#XHX_U:R@_:550&R07.E]\A,2_FBM@ZGQVB^L86BPD#6A<C*=*^<\RGD1
MSF0#BLT7S,B4J2)F21N!ZXGYXWVHDK()4C@R^/FB&X:W4_\ ;91>B[\>_$GE
M[!M>T7KW#'_1JB4"Q5I$D!1&?[7;H/#\,CEL8JH\3/V7EY^S"=N8!41.T"3Y
M9B*\/R0;1J.ALM&XA"BE=2D%EH$1#,45M$1411;:_G^9#V)"AIZK%B1!*M*?
M+D#B1K3M)G)F8C!J/YHK^^>>J1.=I ,<\Q$D":#E,-BVQ'* !$*@V1VCKHLB
M IVZJ*TJD+:*B(A=>;A "D/GY)0Y9A,K22HI]WPH/( G.,3Y[>M5M\06X2)*
M -U%2HS,$[XQMUYU[]UEH :92(Z9JHM^*29B*J?)O.*(HI(/:FX2KVX1(*JA
M.)ZM=PHD*"#'_P#J0=MR2<'K$@35X79Q+R"-E +6)'.=ONSTJBFRR(LMQX[K
MQ(O2'23C)UQ5\C=<=,A%1154G"3I$_I!%50!;1M%:E*4-( )!*&TID &-4F.
M9D#'KBLM/$$>ZVE)A.^I4$CX'.!G&(SF3[4AB-=!&85UTB5%<KFF%==5/(C+
MWI@>(#\*JH"BVV@@ _ "MLVR%B0L*C!@A0)Z2%8ZXVGS%7D\0=! 4@)3()TE
M0(!,&! Y9VR9KRV^PS^)$V\^Z2KVV%.U[CG2(JJA2'R;:!$0>_%4!M$3LCZ\
MJ.Y($*#.)T9.K&3.#TY3 \ZR!=MK.D*6HGJ%1\2=OUKT<@(39.HX1..?D9I]
MH(_ATGP3-9)!MAI%%$(E\10D(U)TU4[8@ D*"4G)(U03RW1)B/A60E*EJTH"
ME*/V4@DG/0#J/COF,+(GWST=J2IGXS%06WW#<:)]>^A"-%6KC2W66OZ^Q!IC
MVE<D*\*D2EHK_BEJTI33:%W+Z DJ2%?52J?"5B,IC[,XS/7KN&=F^(O);=NG
M1PVU.%NJ 4\ILP"I#0"ES@:2I(W,16TQZML76FT)\SDN@#TB4Z3SZLL@3[HL
M@I$Q $P;=:$HXNR4]]%28A*J>N-XA<W=RRXN\6A#0!0BVMD$->+">\3.I]1B
M(E&E4D+Y5Z3P6TL;*Y;MN',*>7I+CU_=K"WU0,Z%$:+=*9D* 453!2(%9&V?
MHW6%J93<>=&G$4>Q@_;I8!(B T:O,3V5;?!YI[P",^U+0D=;=-MQ"$B%=7PZ
MPXDD"[L&GK==NM#C3K([A2'4J&E2"2E2%(5!"@0I)B#)K<\0XUPME7=7EZR7
M5)*5-+6'GBV1$K0/$6U D24A!) @3 L-2:JLKJRCIJ=(%9&"%70*ZNAP*^!!
MK(+7808D%MV,S%B-1(WVS,9AIIIEKQ  $!\?6Q=X3Q9ZX=O[YU-Q</*6]</.
MW(>N77'% K4ZI2E.*6I:M2RLG,R9(K6H[3\#"4V[!=*6O A#5FXEM*1X)1"0
M@(]V-."".59"7;M_;$"1Y0&\K<?Y!I4'WR%I210?-54!-7$1$7^GI>OGK%;X
M->I7JTMPF2=3B$ C8Y40)DS$Y$FLK_B+AFE*2XZ@ ##C#B$B ?#D0#(B!^&:
MNO7<!E@R1)(^ =-ME!F+Y&G0@UVVP8)YET"+Y>/S_/U8'"^(%Q([H1)TJ2XE
M28WP4S@F!(QFKJ>-\*6E(3=)"B),H4( R221T_2K;<BEC,-^Z[% F6D\GWFQ
M8=)03IQU3,&R0C+R,OE.U555%^/5EVPN7'#JLW2G4!*FI2(,$A4%,2#$9G$
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M)VJREYKNB\IU#;:1J6I:@GN]61JR-SB0<D9.]!&[(\'7D$&C5";;)%"(ZI_
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MS>I!*8<;;$0KQ9#@.X.01N#)B,G07O:5Q@KM>'N!6%!U\C^R/]34D@DQ"B1
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M2V$I*UZ4I(*1))(0 ) V@ P  >< :^UXHL:ENK)205+<$!?]6I>08WD DR1
M.81M/K+0I JLIA?VVXK_ &DF,TG1#TKBH7O.KXOD$GQ=\2;[>1&10LU'#?96
ME)+92XHI4X%@  \])$XV(! V/2M7=\<]K>"FUA;#80EI:% J)V4I?BF/,F8'
M*O$R6B(#+1K(4E4C$E\)L%M$3R-LR47$>7\!9!X@<-2)[WG&VU;*JUX0NZ6L
MMH 2UXBF?"M0DI QB#$IQ(G)V--[VB38VZ0XL+6^=#:D$:VP(!4J")!!@*.H
M](%6@0/!7&B4VT3P]\0_>#Y12;FQUZ5].R52)11X4-541)2>7.6GNSW2TP4X
M#>GF1J(T#!!F1$'.P)FM(AU+X[Y"DN!9*BXE0.QP5DY\,"9&(Q'/&NRW7T!I
MDO\ #E\M.-.=+(3I5[JY**A,(H=]MD:(X"*C"BSY2'-C;<,0H)?>3I($I:(\
M.-]22(&,QD;$<B=3><>>;[RWMU#(*"Z0%Z<9*)*@8!( ,1R Q7EM5;%11&U;
M7H34P\67%3KIN4TJ=Q9/?BGO"" 1()$*HH,IM"RA:!I "AX=H3').),>@SG&
M]:!FY<0J%*6XD#Q**I4H\R9,&?-1]:0O3$D%[0$ZC#2*CCO\Y8(OPC8DB%]W
M +Y4S)#]U15$]T44DS[7A;@!>='B'N-J/ATD#ZPP"5?W01ND9DUJN)<?92I5
MM;*U!0TO/HR4@R.[!D:1S64Y@['$>_)$'R_:3W?R5"5$@S1\/-2 E\O9=4$\
ME_FBIY=B\@HZ&80N2(DZ@- SJ5$ @'!Q WDD;8,:,.HC4DQ$E*H!@[ZA) )G
M.2)(.=S6%<EE-5#%3*)'/]IOI?OHSJ)\2"5/(W6NNT:#]Q2;4G%5\'$!C=6?
M#A;+6XZC0X\T "L"$(,& HY2J<"!$;J.(Y7BG:)V[2&+9]*K="R'%I)4FX6@
MZ2AP$Y2G^D@I)&H TJ_4 C-$[),/:41\713RCRQ+H1#Q[7I\B7Q;!%)75)/:
M5SLFAK<L%/K"&T%:G%A @$Z9G*H$A(ZB2# B*HM>,HMT*6XL(0V@O.H5X&PV
MD05I@R$IP%!("E2" 0,:^Y+.4ZCZ^ZB,+VW%3\I-<!(B(3*HI(^!H/9](:*B
M*T'N,@C =+:<&9L&2TXD./*@K=*01JS*4Z@"$C,1$DD1B*X_B?:-WBSZ7F%:
M;1HGV=H&$J$#Q.)!.H]"H&),$S K(LF(K/NO*VCC_0M-ITL6R<)%\ $24D:D
M*B%Y&B+^V*FJOM@K39OA+S]RAEEM;C:R9=$D( RI2A$%(YR8CE5E?%[>UMW+
MB[<[GNB% @A+[IP4!N5 J$X@J'H08&$&2;YK),W7"%1\Q[7[N!_/Q%C^LG(@
M_EXCVXKGYJJR4,P'HVN&,632F$MY6=17[VM4;F=XW3@Z>6)%<G=<9>XH^F\6
MZ5I0"AIL'2$"9 4DG"H!UQ(F22>=JPNAB-"K9,K.E(B,FGY090+^'NR0%?VC
MZ7Q;Z52</Q;;,P5UIN_9<'=NW='A[@RIQQ6HKPH2E"M)E1))@E((!)VJW>]H
M&;"U4\[#C\)[ID&%%:MAK!"D)1.J0<Z0F()C",N>2$0(X:B2./,F2_<LFO:H
M_'<3Q]P%7OQ$5\?'MMGP0%C+TAM$6[:;?N@EL"$>!,$#&L0" HX5DA6<<A7&
MF_<NW5WBKA2W7%2I4J2I1R=*DCU@)\21$ 0:06U\;:)&8<1'R\0>L6T\15OO
MXB2FP\4"0XB^)D*MJRAK[:QG76T3,X5V?1<O%U\N"V:T*:&@!3A!DSN%M@B,
MDSD!(C-CBW:(VEL&$)0;Q0&HE146FB!I6DSX%';PY$R2.6.CNBX"MM-^!(B$
MY \T'Q\%3MZO=10\$!414%%;0?Q7J.:JI] ^RI![I: 4'#8(E! !  &1,>%.
MV0 -A7,,W(>)=2YI6!J<\1"TG=4F=1"E$DD$R#*LR*P-ED!S%$([W^$:)066
M/PL@VU[5B<TGC_AFE^/-$#R-2<46!$'']GPKLZVA:[JX0L+4E)90M,=W($D?
MWIF!MD0>5:;C/:9TA-G:+2H#%PX(4ETC(;1G8" X?#*P1!]XV DM@).=I'1D
M5D.QU<0! &_ZI$!Y5%!Z1>R1?!![3OV5)?//>M' H-%LNAQ00B)(451 F)!Z
MX&01*@:P+>]:+8=0Z&E)25.!6"V$D@DC T9D"<BM6M;Y^U3Q%Q AHJ@A>)-C
M+(/Q']481$5MP?A&NQ% +Q5P1-083J.$]GFK%7M#Z4N/S*$.(2I" 8(*0I)A
M23)2H"9S,BN=XOVD?ODBVMEA%L)UNMK6E;BP3.4D0@P I)(SJD9@J:%BVN[.
MMHZV#/L[>QE1J^M@P8[LZTD2Y;@QXL-B.P+C]BU(?(&VFV@=>4U007W$[8R;
MZS2VA=RVK" %+0%!,"3*D@G2=CC"IP,UC\':ON+W]CPFSLKF\O[Q]+%I;6K:
MWGGG5*2$H2$)60KQ"5J3H0#J) "H[^<0/I?T^.L5&PN1\&-<Y (C+JM6BXW*
MH:3R$5!<HD,D07,E>A<6@8<.EBJ -RW+/LH['.NW*G,)E*2,G91Q&3.!$8WF
M<U]^?19_#QPO@+=IQOMJRQQ;CFE+J.$JTO<*X>M201[0A6MOB%VV<:U3:MJ
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M]L>WG$]M%$OMR_S^,6ZM>Z"4%3:5*@^ :I!Y&$CF<[Y$5E6?$M9+BE..$3I
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M(U0/+7/LJ(UJ6=""G2@I)4HGER5&V95@=*Z"RNVI0VVDJ=*07G"1I0F-S_5
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MWMY>>25N)U1K+BX!!R))3@;8Q'*K\68^Y[SS<< 1YXT I#O9HVS^R'3;(D!
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M;5'6R_%B8R/0]H/2B*HBBG\E)@E05563%5VMW9*ME)!.IEU1+:],)21(*3.
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M I%)%=!")(]FXWV)&/P2*D9%\0[\U![LR1YD6C7/X%V>]D4GB=RWK<>0H6I
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MO,M$BOQFV]B9&V+2BJ)(%!;OO$14G&W43Y4C==[1!%%7E4WO:D0!QN\]/:7
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MRK0P&1]\VX_92R,O%XQ%U5 8S:+X-*X?XN=_BO\ EVOK,:[*$A17>\Q[C6J
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MAB!)SX1B< #%>;V\6R?C5KAB$F"RDIU0Z%3<>/Q8D@/7X$R#:^8*G0F^BH*
M0HM/9KLZFU5?W+B0JW? MK91)*0A*@M82L&=044RJ0HIA.HI)!N]J.T"KECA
MUNT2AU!7=O:3$E*2A!4B2"E2=1"3X0H Z02(O0;!4;62J@#\0262*JH@;7CY
M'\JA*++P@I"2>7M&'2^:MFA4\2X<M)+."X5'N%Y3WN90@%/.<0/%.><F.&<1
M;<;[\R&\)>3(^J)'B40HQ[IF<B!SC&I.V_ZI*.::D$6:XB,"J].0" ^F6_\
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M7MK)I##QL+9ND"HLAE A,NCXJO3K:*W!)54'%0T\21$!T0'I ^)'9=L^Y;W
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M"XDJ #>H?&,C,3\_*M:[VE4VXM";0*2T$A2@LD QD3,=>D3ML:&LBF'(??\
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MST.,VH& "5*QH7&% DXC>9 (&"#*2)B$3KSLUYM2<5%;%1@/=_B;2$OF3O\
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M2.]%V2HMUOLY?P2Z$,HC4(*'5QN92C4 !F<S D@5?%U;DEN5+4HRDIU*2%
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M^/2LVJ^E*A%QM_Z47U$O_C?I#_Y1-$>E2=D^GYFIN^E11Z4H]*4>E*A#J_\
MZP;F+_NU\&__ !IS5]*GD/4_@FIO>E11Z4H]*4>E*A!$_P"LCR#_ '(,/_\
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M2DG?DP2]?"HJ=(9*OHURP4+6VXCQ(GPG$P.>-C$XCK,5R39TD!2BMMP ZC
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M#-+_ "BXW#DU)CEYG>1YY:9#*SG)K:?25Y,Y!D=E6L,K%@L.&JA1DG,[08C
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MJ+T*$O2+\=(@JORO2)X%VOP/R&U4E(2< I4!*09T&)^ !D"9,;SO5]YEXJ6
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M"(+GEWYBGB7:?'I45H<[@[PML7@?F\0^,$J0#@/-RWM"ZL*;'D-!X,28TO\
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M2*H/ *HO^:>"$'=Y.E8B,IWCD1N1SQC)'SBMSQ?A8!4'<L/"6"5"02H $B0
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MN:[+O<MRNY>%)-YE>3V5OD=W+4I=M:3))$ZJJ:=3TI1Z4I!:6E91UMA=75C
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MW2$)0V/Z0CW,<PF3CG."*K-E*X[']M$]R.A.N@JITA&J@C2_S^"%'2$D3X[
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M6ZZM%.&BGD(@G<[QMGH/@/C4^VN=^N*]EN/,T#S>I&(S2,M,,<&N3ETRPTP
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MB7)19#T2:F@N-6=9/CUT\ON-.LP]E;Z:Q7'*^8#$^HU5M6CD"X2JM!&2E1Z
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M?!'QP6^41Q"U4\R^R6G>\MRPZI##7?+/=71=0%K2XSJ;[O3*U$U@7)A3'W9
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M#>.P LGL3UW2?K%G#I@KCM[)Z1-B55545BW%C3TS4^XN+"OJXDFZN*BFBOS
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M5'Q]4G8).-B))RD3 .(.HYB#[NXWKHNS]@5"YOR#*3[,VDI^V=*GB#!)TIA
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M62$2HXB."3JN&':LB21B5A51(Z#[_P!:%XE[R855K?J4\UHJ*O:,S</X!W3
MHH>)=%9<'79RJIH+B><X@#\Q; !)$%4R/Z4_-7^JJIQLY41NOLOJ*[JE]%W_
M ,H]%\1I_:*'B0+_  ]H[$OA"1'&E11(34T<)YM1 %1(_I'_ '?ZJ@QEVW.:
MV0Y5<:HX8\LJSE9M+'[%RCS');3CAKRFXW:AMV51B;&VYO;&[^OJW;^L4D.;
MJ_4U/L?:T*: #D&*XY32TM(JI@0)!'QR1Y"/O,3F)Y;=9?3PYE9_G])MG>_,
M_06^,GHF*67B>NMM<*\NRS0.J\EB14&QN]?ZIQOF!KG'K*]>F&\] V#L2!EV
MQZ5/%O&LEQJL=?IUD$I(4DE*DD%*@2""#(((R"#D$9!H2D@C3@@@Y!D'D93L
M>8P#TKYJ/J-_3PWOPOS)[-LO8U]D6M<WR:Z>PG--1X[EN*836/RR2>[A-MAV
M6Y)GMO@<EQH9,F@HY&PL\BOUL#R@9+(=@2ZZ%]O_ $1?2*UVNX4C@_$WS_Q%
MPUA*;DN% 5Q*V0HH:OF(,K>;26V[T%()=4'<AXZ/GCMQV0/ KU7%^'- <*NG
M(<;0"H6:U$+4TH0 FV6L*+>2$(*V_"D)%<CTL7CF2)$OS WGR^[97LCCN(O2
M$V"(I*T*)X=B/1-B)BJIXJ?KZT$*TB,04G&E0@1*B2)(R!,"2.9C<6+=M_+[
M4VQ)2EG./$I9<5WDI!)"DN!2%]5I)$C)OS(]Q;M,XY0U=I<V5PX+$.#45\NP
MFNM(HFX(Q8C3L@A<+P;;7V_DS]M/+\43'>O;*R^LO;JVM4>+Q7+S3*%$"("G
M%A,@&2">70F<JPX<JYN0I*"IMOQ+2E*O$)!2DITB05 $X$1Y13IQN+_)EB_P
MC"K/0^UX6:[%?-G7.(S<(OXN:YNS'1"FV>/8H_#;R2UI:<2$[O)XE:YCU&P0
M2+FV@MJKB\=Q/Z3.P7"@HW':;ASBDSJ9LG%<0=200-(18IN")_I)$;P!72+X
M+?NG4BU7"B=164(2-0DSK4)Z;2<X.:^F_AUP@^IWIS3D+3&7:NQO'-&W%S89
MAGF$:FY/PM.;WVID5PS'KY-3L_;5#@^:2\3P*OIJFJK(F-Z2RW$<ML269-N-
MB.5UE+Q)CXX^DOM4SVN[5WG$[1Q;G#FFF++AQ6EU!-JPDDK+3H2MLNON/.:"
ME) 4 H3-=;P?AZ.&V+=N  X5+==@ I[QQ6V-]* A ,$0D>H[L\4F;K!,5EZQ
MF\4<+XDX'@]7"E8M08=L? ,LQZ>,QV6Y>/'!Q.MI95;-CNMLV%O=W<-QV]DV
M93I-A)GK--. K9F-YF=\14OT5%3M%[1?E%3^2I_M]*BCTI1Z4H]*5C[.VJJ6
M.U+N+.OJ8K\^LJF)-G-C0([UG=6$:HIJUIZ4ZTVY/MK6;#K*R&!+(GV$N-"B
MMNR7VFC4KGMOOZB.HM(;\P;6CFQM/9%CM9;/8MR9HZ[-(#VW./K^8%B4?5>T
M<CQAFR(6]21;Z]KL6VY,E0 L< ;V5K7/+636X:U>2'E5!)(F#Y8P=Y$]<&/0
MBN4G,'1W(C$8]WQUQPLJLDFS+W!M,H_&S#*</V/QTR?8LG;&L\WU+7T5Y4,X
MQSH^FGG,Z3E>%X[7SZ+)]NZ'PM^ZIW,PG07J_ E5 IW(&()  W (@[RE?,C8
MGY]WN//%/4O'.M<D8GC=))S^YC3SS/8ZT<&!?9!9Y'<.9?FH5++/OLX-A>4[
M&L,AV.6L,1=K<!I,NRC(+6FHXLNSF/OJH)G]_#\ *DH#8- #;0 VVV(@VV H
M   H@B  *((B(HB"(HB(B(B(B)Z5%>O2E'I2CTI1Z4H]*4>E*/2E<H-^?5"_
ML*/>3%CQVRF5-TGM7,<+?A7F?8S1/9;@.M.)F8\PLYV?4.TL#,XL$9VN,#O(
M.L\-M)#%QEMS88P.72]:19]Z[C"J@F2!(R/E)C\=_COS:_/OK(U.&2=DQ8G'
MVSNW<1O-JR,2\]E1:D<QUQHISGHWM7*;4G\'DIAN6Q2^GAN?^",#=_78F5IE
M6L%N,SPW]2SC^ %2$3!F ?(G^G[O&/O'2>KDW56ILXSC!=VW6 XSD&PL/Q^;
M"U[FE]2QY^08;4Y.D:7:)C+M@V\6.3K5MMABRGUC<2TD1!6ND2BAJ<<E42=I
MP=QUC:G3]*4>E*YB\S_J64'"K9"XKG.G\HR#"V-1Y)LQ[.*NV>AR[:RH=8\C
M=I.XOA]"]C,FFR%JFJ>.<VKSZXEYK13,*M=J:B-,=OJG)+.SH55!,[=1RZD#
M\3CK!S.*U[5GU.TS_>N#Z&NM'NXQ?S<YGZHVC<0-CADM7@VRGLMYEXCBD/$1
M<P7'Y&R,+O97"+9LJSRR0.#6F.1\GP,7,0LG964CBBA3B9^[?W?7/B'Z[5T6
MVO@5AL[ [O!ZW8V?ZI>O2KF9&;:OG455G,"LCVD.9;UU'<9!C^2QJ1S(:N/+
MQ^3>5U>QDE-#LY%EBUQ0Y%%K+F"J 8.P/D=OW^S6$TMH+4''C%G\0T_@]7A]
M986#UUD$YMV=;Y5F>12O]>RO/\VOI=IF&?Y?8KTMEE>9WEYD,_H4E63H@ BJ
M"9IX/2E1MY,<K-2<2\:Q#+-O2L@BU&;YJQ@E(6/4,B]D%<N8]D&5/D^RRXRJ
MA'H<7N9;,"(4N_O)4=FEQ>EO;Z;"JY"I )VJ.-_]5?B+C7\6_J=WG@_P9E%O
M2VOL:_O'_>Q7'/[9DRC;U;X#_C-18VO'C=:6>7)[;CO]G]A^EU=C^KXO^NJG
M2>F_F/+'KD8WS70'*PRAS&,C#!Y%!$S0Z*V'$I.5P[&PQB/DQ0)"43V1P:B=
M66LRB;LUBG;1JRQ@V#\!)#<.7'D$VZ*J:B7K7AG10\TI=U<C<WMN4?("C?*?
MC>9YW5PZG7.I9SH$TX/'W2<.1/PW5"@P9PDS W,JW#:UZK"RG:>11_%L%3/3
M ^\[;GGMMMT&]33]*BM(S1K7%/07>4[$;PBJQ:@K;"XR/(\T"A@T%+3Q62E6
MMI=V]XC5=6UL:.T<FPG3I#,5EELGI+H@"DBE1RB7/T_]@)5.0;7AWFPY)CV3
MY?2'$G:5R1+_ !3#GY5?F>451,NS4M<>Q:3 G0<GNXBOUM&_#E1K63%<CO "
MIR,9'(C/RI71\7N!VUL<J,SQKCMQ&V3B.116K*ARNCU)IO,<<O82*XRS/J+V
M!C]C66<5%!UIJ5#E/M(HN-@YV)(BDJZGYFN=^3?2BU/RDR"UB;+X;<0N).A8
M-K,KH>*:FT;H>TY2[6IZ^>^$>=E.[Z+"WZ;0.,7:-I+;QK3,K(=G.UTMF5_;
M-@EFY8XXR@=-MJJ"B-BHG?)P#Z29]3'IBIF8_P#2O^G3BE7%J,9X<Z+H(T5B
M*PDBIPV+ N)90VFF8\VUR".;=[=6P@R!.75O93K>0]YR)$YU]UUPU4E2CN2?
MB:S?_!N\+FT486F$I1Z<%$QS86U<90!=+R,6TQ[.:Q&A\_W0%OP1MW]UM!<_
M+TI)_8!_?ETY4?\ !U\76U[A0]]4_1>2?P]S)YCXVB$H>!(@T&^ZU!1P53W0
M1$%XD$W1,Q$D4U'R_P H_2J)]/K2;'7Z9LSFW5*/@@HQ]1?GM8-BHHH_ZO?<
MCKB,J$VJ H&R0"B";8 ZB.>E3J.\)_RI_"(J#F:Z2V?L/+\EU/PWSGG/1RL4
MNI^*9MR8Y!<FN1</1^#75/+=A6,37V%9ED);"Y+9+4267XYMXQ(Q+4,QYMQF
MUW8]:0W:5Q^_W^_2D\S'H /RB/W@BGAQ/Z3>-T^88OM_+.9'-+8?(/',1_A)
MK=>5; UQ>7]=$DIYVX8'195JG*<>U? MWU[L(.$PZQ^XC-1F<HL<CD-.S'U-
M6"(3$SM^?E..G**D)_=#VVRJ+6_48YPUB(7DB?8<([Q$1043!5RSA=D)$)ET
MYV:D;9ITP;3:D"JB1T'W_K5$XP<EHO7V?U(^3,M4\5ZR+4'!R>)*B*)H?Z!Q
M3Q0E!4Z($$P<!U%(G7&E]A(CS/IC])^^DCH/O_6A./\ S%BI_@N?]_,5$;\?
MXEXTZ,L$)6R5?W4QVOQ#R1X%\9*-*QV2(<98B=@4TD9Q]^PG]B?NZQ,W/N#E
MIJC+2U!KSE[AG(GD9)KVYU9H' >%5;E>95D&Q\EILDVI>U_)S7V$:6PB0XBC
M_&6T<AQ&LN([;\;$X^07P,UDE4XQ(@=9B?N/W#X5KV2<*/J9<EJC"[+E?RTX
MH%3,5CI9CQ(Q7C%N>ZXZ7MJ[**1#>V#DE%R[U+GFY8\*.+$:=A.9#_9#8/>X
M<[ ;EZ-%M7E3*1,)/J2)'IX<?ORB85+A'U#L2J*N@Q[/N!84-)"B5E11TO'/
M>&!U%760XXQHE95U\'D?E$.MA06VVPB1XL88X1Q&*U'CB NJJG'GZR#^0GYU
MDO<^I/%1.X?!V\44;[3]3WUBJ.$)=.HB_I.9*RCH_FVO4A8Y)[9))1?=13'4
M_('\Q\_N%"Y-]2>*B]:2X.WJHCG2KRCWUBB.*)=M*J?W/\R5E'1_!Q.WUCE^
MX*R47VD4\/4_('/^85B,@W3SWPFDM\FS7B_PQIL:Q^!+M;S(R^H+L6NI*>KA
M,+)E6=K99=P)Q6OK*V(P#AS9TV:RS&0%</\ 8\G@4A/(G_*-_P#-41*SG3]1
M3DSA&2O\1>$NOZJ -G65E!R/SW>+]WJ+(:F6JI>9+IS&,CUUIS)=Q)4M=_H>
M1@]C^I;Z03,ZESG+(4>36OJF -S'01GX[Q]];/I7"MY:=RA[:^8\#=S;\Y#6
M=<5=?\A-@<E>,.:;$^PF%Y6>.8#%M,GUWAVHL&>>Z=;P#5&-8+B<T6VIMW!G
MWB/V$E0F>8 Z"8_.3UF>63RE67*?D3%[^^^FKRVDH*&IN8]L_@-9MI[:IV0!
M<<S<:E.@X"J3*-Q5D&0JV4=LE!34@?U)'KJ_))H7F%LQCM+/Z>W.*L45)"1(
MW$B]Z)!\Q1"Q+EKD0FAAVHFV1MB2>RZ;;ZHTJH@=1]_Z55.;4AE>K+AWSAK$
M\O%571]7>(B*'D!_\D\[R%5$R[:Z%"-LT[>!II1<)2/,;QN/W%-CG/U5N/&L
M[O$,3V!K3EWBF<[%E2Z[6^ SN)6[YF:;#MX,-Z;,J,+HJ;%+.1>S(C3/^,<C
M%]A %QJ3.FQH)_=(H$D]/61CUS_O42)O,G..3TN6UNZFYQ<)-"K(EL?V0Z\X
M-\\'N1^Q*IAXV75VAR(Q#CG98=INDE-B#LG&>.N19#E80WFIK?(>K!V;0-JJ
M"8V*2>I4F/D3)^('H:EYJGEQP!T-A4#7FK:7.-0X75N2I+./L\0N4V$QW+&4
M0O6=O:E=Z2KIMOD=P]W87-[=/S;^_DF]:V<Z=(=>E$JD@^OQ!/XS3D_\)'PC
M;7QF[\H*=?+Q7^(L=SG&T15#S'M;_%JU$%P>_:-50720@:(S$A132>A^543Z
MF7T\P1%F\UN,E,*H!*61[DP?&! 7%\1)TLAN:Q&A0_VS)U0%MW]IQ1<_'TII
M5T/R-9VM^HC]/^X5$J><W#RS(O#H8')G2TLU5TE!M/!C-7"[<)%$$Z[(D411
M5^/2I*5#=*AZ@U%/(/JDZYW-D]YK#A5LCCYD,JDFR:C+>2^Z-F8]CG'["9<9
MSV9:8/CC.24VP>2M["<5 ;BZ]<QK51R%6':[PI[-DJEY3208((,3$9_V^/R-
M/3I#4'&G'<TB;FSW?V-<I.2#<>9%9W9LG.,%MYN'QYK2+:4&E,"HI;&!Z/Q5
MQLB8D5VOZ2!D-Y 1A<^RO-;-LK9Y43RV'0?GS/Q)CE4^85K5V8>Y764"P;_'
M]R%,CRP_,?,/R8<<'\A_(?G\A_).T^?2HI?Z4H]*5&'>/+75FD;RKU\3>2[3
MWGD\ ['"^/.GZIK,]P9/"%Q&/UEZC2;7T^"X8T^OLSMD[.OL)UQ6.HK-AE<>
M234=U4@$^G4[?ORIC_[OW(+E+_QCS#RX-8ZEE_N1N'^A,OMX\&Y@DJ&U%Y$[
M^K&L>R_9)O-$K5QK;6;.OM5F)RZ#*)>XJ4@GO*2!L,]3^FWX_"ITX=AF(:[Q
M>CPC ,5QW",,QBO8J<;Q+$J6MQW&J"KC(J1ZZFHZB-#K*R$RBK[<6'&99!5)
M1!%55545LOI2FRW%J#7N^-;99J;:>/1LIP?-:UVJN:N2/1@+O2QI]=*!/?KK
M6LE"U/J[2,02JZ<PS*8= FD5-APKBE_P3B-IQ7AEPNUOK)Y+UN\@Y2I)RE23
MX5MN)E#K:@4.-J4A8*5$58N;9B\8>M;EI#S#[:FW6EB4K0H001^!&08(((!K
MY1,(^G%K+Z>G+29=<W]78MN?AEEJR,?U_O\ O3L7Z'7M\_*69AT79N(UUBQ%
M9L+$!>Q22U94M]6VME(JYE#)0DEUP_1G:+Z5GNUO8T/<%XX]V:[2\-^OXGPI
M#J+<<3MBG3<JX;>+!=6IDI3=(8;>:N.[+S9:>A"QQ?">S0X)Q)Q/<B]X==I
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M^O[]/NJL"-]S@1!CSQ((Y$3$'.XB77&GZ;N?YE)PW8O*783F3XT&Q]F[=O\
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MX6Y"JB?2%T2DK9IVPK2*2+'Q/W?I21T'W_K6=USPMP'&L]KMP;9S?9'*?=5
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MM+,6J8>\^WKMO66<+C&#1 ]N9KU^AAWV/OC<7N:R,I55J(CE &!.X,SZSO\
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M4>E*A#Q3Y?67)?8&^<#=U]2X<[QSRA[6V<V4/8];F 7FQ8F4YE42W<)A5]-
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*'I2CTI1Z4K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g155225g92x08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g155225g92x08.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[14.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %/*^4V(X0DE-! 0      #\< 5H  QLE1QP"   "V  < E  #T1I<&%N
M=VET82!':&]S91P"!0 74&]W97)0;VEN="!0<F5S96YT871I;VX .$))300E
M       0LT,+V'L^98WVR ]+Z_Y]=SA"24T$.@      Y0   !     !
M   +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0
M  !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I
M;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    ,
M %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !
M $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7
M $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B
M;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M  !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M          !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
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M8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M    "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#
MO_XU  (  3A"24T$)@      #@             _@   .$))30/R       *
M  #_______\  #A"24T$#0      !    '@X0DE-!!D       0    >.$))
M30/S       )           ! #A"24TG$       "@ !          (X0DE-
M _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $
M,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M '   /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z   .$))300(       0     0   D
M  )      #A"24T$'@      !      X0DE-!!H      T$    &
M      $)   $\@    8 9P Y #( >  P #@    !
M      $             !/(   $)                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     "F<    !    G@
M "$   '<   ]7   "DL &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( "$ G@,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M       #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*
M"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R05
M4L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C
M\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 "
M @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%,@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^$_)&AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M)18R.]P^S6^N/ :;P249E.C67*X)0#4N#IRW,[*=JU+VY:TA\98C* RJPU:
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M\@  ]@ /P /D&NA<_6J5R]*Y_P!JN<Y/;/N2P?GV)!4Z^*,EU6X/6B B"DI
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MX2U>B(<4PF8ANN+6S5Q90#$,1K9ZRZEZZ],4Y# TE%^TY1X,'U<0K<02P/\
M1E1DS]DD>5OW&"L/4"OF"5H)HYEYQN&QW')E_>4E?<:M7J/=*WD>EU'(5-DT
M)NHWJLP5PJ\PU,!F\K7K)%M9B&D$# (@*3R/>-W!/?D 4 !]P'7-W1HW>-QI
M=&9&!Z,I((^!%7E65U5U.5=0RD<BK#(/Q!S7MIN:BJY#2]AG7[6*@X&,?S,S
M*/52H,XV*BVJKZ0?NUCB!$6S-H@LX75,(%323.<P\ .O "Q"J"2Q  ',DG
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MV6K$["V: ?+1D[79>-GH22;F[7$?+P[U"1C'R!_[*S1ZV0<)&_LJ)E'Z:O9
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M:>$IQ)<DQ^HC&#(1[P53W.<'(J.X1;^-<^(PREN _H9#D1CX$%]CD%5SL=[
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M+R*\,3)&Z,@8$L5P5."!L3R(/XFL+^GCN'#:KO7VXYS=.SLX&H9)B6=S6(8
M E MZ;BF7Q0Q#&*FJ9M4;!,.T$U1 GJV[=3N(8A5";=[![5:3P  L\9T _[1
M?/'N>67516K:3>SW,,I.%5QJ/[#91R?<K$]MLU:8E,4Q0,40,4P 8IBB E,4
M0Y 0$/80$/<!#V$/<-<YJ\5X4HZ38QDB^6'A)FQ=NE1#Y@FW;J+''W]O8I!'
M7H&2 .9('XTY54(K+BZ65<F'DSA0ZXC^(K&%01_Q$W.NGXQMVV_"N?\ .K(/
M;;MTKNZ#HHX+VZV,4V\=E?95CN%:OU2 K\$LCZE1,Y5;(F0Q#@=>MVQ&(L#<
MIB'*9>.3 Q3%$0&AW%PUMQB>X7<Q7DC$?:42$.G[R94^\U<881/PV&%MO$M(
MQGGAC&I5O4JV&]XWJN<LM=LV/;A/U*QLGE=N5&LLK7)Z.5$[>0@K/6)5Q&2C
M)0Q>Q1%Y%RK%= QBB4Z:Z B40$ '5[5E=593E74,IZ,KJ"#UV*D? U3V!1BI
M&&1B".H93@CT((^!%9,[(=M=AWK[O,/8&3<2*X9)NY'=\GP,LY?1M)BP<6;(
MEB7=G[^)!.N,)8[%=VJ4KR=<1[0ZHKO$P-KW=P+.UEGP/FD\B\@7/EC7';41
MD#DH)Y"L]M";FXCBW/B-ESN3H'FD)_=!W/UB!S-3F^N]48J)Z1V>*]78QK%0
M5,# C6$BF"0(,8F&A<U8RAX]@T1(':BT8L#I-&Z1?NII$(0.  -4_@SD\4A9
MB2S^/DG<LS0RDDGN3N:LW%%'Z/F"C 7P< <@%FCVQV JNZA'QXR9B)),W8>/
MDV#XA^>.T[1TDN4W/T[13 >?U:O!&01W!'XU4@<$'L0?P.:MZ$5DW"*3A(W>
MDNDFLD8/D9-4@'(;_$I@'_'7,.57^N[I2FE*K@>N=M>KFUSJ$Y'C*81JSI^9
M86*S[!PK1$J"-<<7Z6L+*TPR:1 *BFU"ZURR2D8W;IIMV,/*QT>D0 9B(WW@
M]RUS8QER2\1,#$_6$870V>IT,H).Y8$GG5/XG (+QPN LH$P &,%V8,/\2L1
MC;! Z5P3TJ=M5:W:;]]OF&;N4BU&?V23N%T8'[A+-UO'5=E[T^K2@$X,#:TJ
M0"%<?*$4150CY1VX05*NDD Y>)7#6ME/,GTPH5#V:1E0-^[J+#F"0 =C6*Q@
M%Q=11M]#46?U5 6*^YL!3RP"2-Q5GD0A$R$33(5--,I2$(0H%(0A0 I2$*4
M*4I2@ %*         :Y[5UK]:4II2JC+(_\ 2'?/VSM'^>/M=.3Z"_=7\A5
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M/#C[ZWSN/55#./NU6J1<7(34E'0L.R<2,K+/F<7%1K-,RSM_(OW";1BQ:HD
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M<0U21CNZ#\6 K9<X1CV5C^ )JH[1+V(I$_U$R%_]I0#_ .M=./,^\_G5  P
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M*959=4Y2D223*9110Q2$*8P@ UZV&;FW&PS/$,GD/G%Y^E34_P#0S=?FI/\
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MN?PJV"VJRJD[M>VW3BJ2B"LS@3#TJHBJ4Q%45)''E=>'25(< .51,RPD.4X
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M5BV2[U5&EV15[8*-.27ITC^DBX"V$G(([M4W:>1OL2U]A,35E^3UUI>:U9@
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MX^7FY%J:(#[?42PBW'O[?7V]_G]W7S_V<E_WJ/\ ]-O_ -J?IR+I!)_C4?\
M(U(LVLYFM>X; ^/<U6[%$MA5YDB&2M$3CZPSB4[8HRLR0BM77\\LA$PZ,>_G
M8L6\T2(!!9Q','S))^JE)"\8,X*YA2">2%)1,(SI:15TJ6'T@OF;(4[:MLD'
M&1@F8@D::))6C,9<:@A.2%.ZD[#!(P<<QG!WR*R#U@K+32E=L443"(F23,(_
M,1(41'Z>XB'(^WM[Z4KJFFFD7L23(F3D1[4R%(7D?F/:4 #D?J/'OI2OWI2F
ME*]>^B8J3[0DHR/D *'!?7,FSOM#GG@OGI*<!S[\!P'/O\]>@D<B1[B1^5,
M\QFN\T8LF"8HL6;5DD(\BDT;HMDQ$ X 1(B0A>0#VYX^6A)/,D^_>E>5KRE>
M.9HU/QWMFY^/8.Y%,W #\P#DH\<Z4KR-*4TI32E! ! 0$.0'V$!^0A^ Z4KT
MQ*[7TW'JR04,1USW>I)&,BN.[GGGS@0!3GD 'GNYY#G7NIL8U'';)Q^%>8'8
M?A7N=>5[32E-*5V%FK5P)3.&S=<Q X(99%-42@(\B!1.4PE 1]_;CWTI71)F
MT0.*B#5NBH8HE,HD@DF<Q1$#"43D*!A*)BE$0$>!$H"/N :9/+.W:E>1I2FE
M*:4II2FE*:4II2FE*:4KMJHHKE JR2:Q2F Y2JIE4*!P 0 P <! # !A #![
M@ B'/ CI2NT5DS*<JA6C8JA!Y(<J"0'(/XE,! ,4?U@(#I2O)TI32E=! # )
M3  E$! 0$ $! 0X$! ?80$/80'V$-*5Z@E=KZ;@'2<'#IN@'D')(QD5P \\\
M@L5 %.>??GNYY]_GKW4V,9..V3BO,#L/P%>XUY7M-*5T$ $! 0 0$.! 0Y 0
M_ 0'V$-*5Z\8>(,J5<T7'&6(8#D6%BV%4IP^1BJ"EWE,'T, @(?CKW)[G\:5
M['7E*:4II2FE*:4KT]@BUYR#EX=K-R]:=2<>[8M[# &CBSD(NY1.DE*Q(S$=
M,1/Q!BH8KEJ63B9./,LF0KQ@[;BH@IZI"L"5# $$JV=+#L=)5L'D<,#V(.]>
M$9! )!((R,9'J,@C(YC(([@BH$/5FW1;]<698S;LAR1O#F<[X=D$8]O)-;1A
M?"M;=2L(\/'66&:2"E>J(.4IB#<$CE26"$>PBRDI'IRT>SAS&2:M[MPRULI(
MH+R.T6"7<@K-.VEAE21JD((89\K!A@X)/,U:]ENTDEM7NFECZZHH5R/*P!TH
M-QD>92NXR O(:(V]5]0*8>O[.\@&_FO=QR7NX_G!>?PY]O\ =J6+X)&.1QS_
M .E1OA^O\/\ K7T3+&WK$15^->7PH8G;\.[_ )%*///KR_/NXXX^GS]]>>)Z
M?Q_Z5]+%JSYL8]/^M?4IX1\Q--3[3\>8FFIQ\%YX[R ;CGXL'/'/'/ <_/@/
MEKX,V"1IY?M?]*^3'CKT!Y=QGO7U$7@)PS<1TJTN*2;IHNTD&WGU9L]0(X;J
M)N4?.:O99=F\2*H0OF-G;=9JX(!DG""B)SIF\,_,:.X^D1Z<P,CW@@CF#FL@
M@P00^X.1Y<\O0G!^-3DNDEC3=#DG'M8W-;AM]6;LS,I5>10K^'QB:S3*-'*,
M%/2&<VEW&DDIVWF*;A=BT;/*O%H#RG)1\R0"=E0XI);1R-;P64,)&"TNIW<Y
M&?*"0$YX).LG&Q7>K-8).Z+--=22 YTQZ45!@D>8@$MRR,%0.H/.MYNH:I*F
ME*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4
EII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g155225g96o04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g155225g96o04.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[27,4&AO=&]S:&]P(#,N,  X0DE-! 0
M    );"^ED@X0DE-! 0      # < 5H  QLE1QP"   "   < E  !$Y3,C <
M @4 $T-E;G1A=7(@1W)A<&AI8RYP;F<X0DE-!"4      ! 8]E!^\8GB1PRJ
M_4/P1XYM.$))300Z      #W    $     $       MP<FEN=$]U='!U=
M  4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0
M  ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    *
M $$ 9 !O &( 90 @ %  1 !&       /<')I;G10<F]O9E-E='5P3V)J8P
M  P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M    0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-
M!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M    0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N
M0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M     $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M    4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!O
MX            $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M            0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL
M0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G
M4',     4&=00P    !,969T56YT1B-2;'0               !4;W @56YT
M1B-2;'0               !38VP@56YT1B-0<F- 60           !!C<F]P
M5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M  QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M       +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU  (
M 0.__C4  @ !.$))300F       .             #^    X0DE-! T
M  0   !X.$))3009       $    'CA"24T#\P      "0           0 X
M0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      ,U    !@             #6@  !V0          0
M                       !              =D   #6@
M       !                         !     !        ;G5L;     (
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M        3&5F=&QO;F<          $)T;VUL;VYG   #6@    !29VAT;&]N
M9P  !V0    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M$@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R
M:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,
M   !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M          !"=&]M;&]N9P   UH     4F=H=&QO;F<   =D     W5R;%1%
M6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M   &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M"&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC
M94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L
M:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M$453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M       *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M        "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M        .$))3001       ! 0 X0DE-!!0       0    +.$))300,
M !M3     0   *    !)   !X   B.   !LW !@  ?_8_^(,6$E#0U]04D]&
M24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S
M<$U31E0     245#('-21T(               $  /;6  $     TRU(4" @
M
M   18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=
M @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     49&UN
M9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D
M;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P
M  @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@
M*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M$G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR
M+C$
M         %A96B        #S40 !     1;,6%E:(
M  !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:
M(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI
M96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                                    9&5S8P
M       N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C
M;VQO=7(@<W!A8V4@+2!S4D="                             &1E<V,
M        +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV
M-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@
M:6X@245#-C$Y-C8M,BXQ                                  !V:65W
M       3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58
M4    %<?YVUE87,          0                        */     G-I
M9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M #(
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M(@LY"U$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-)@U
M#5H-= V.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/
MLP_/#^P0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%
M$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5
M-!56%7@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA
M&&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;
MLAO:' (<*AQ2''L<HQS,'/4='AU''7 =F1W#'>P>%AY 'FH>E!Z^'ND?$Q\^
M'VD?E!^_'^H@%2!!(&P@F"#$(/ A'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC
M."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G&"=)
M)WHGJR?<* TH/RAQ**(HU"D&*3@I:RF=*= J BHU*F@JFRK/*P(K-BMI*YTK
MT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP-3!L
M,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43-4TU
MAS7"-?TV-S9R-JXVZ3<D-V WG#?7.!0X4#B,.,@Y!3E".7\YO#GY.C8Z=#JR
M.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/> ^(#Y@/J ^X#\A/V$_HC_B0"-
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M$7AN>,QY*GF)>>=Z1GH
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M9G)SLK/#V&=XI*6UN,7_Q  : 0$! 0$! 0$              0(#! 4&_\0
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M@?G2:?/T,''H'TI]8QVUVC58#96W=97VM;3TU;K1!O 2SZ;(#Q&S*AU!5W5
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M=4R&S:@P9OV+ABI828C/C"TBA3ZP+M@[!Z.IT%#+BB5RK<#(>>1BE)DPFB-
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M%$ AH5-2T_")B2L1Z 1'RV%]J'HLR'(>C2&EXREQIQ:%8SC.<<(OY]9/@_\
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MC^#X_$\T'^K\-]3PDG,I]K'\'Q^)[H3]7X;ZGD@9!).9U*?:Q_!\?B>Z$_D
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M1>!:0[&I  ,@K9+I+ZG-A=0)O8\"Z:O9H$*IM!I0IQ-E!E"T>03-VX1,J-N
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M-"R#0T=)PK-*T7=K&]K^U:Z6Q4/I45&9H0 =Q.,0I+_=\Z@_Q(MQ_K6Z9O\
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M[N0[H>@L[-J53L0@_?!#,%;,E;CYFD#[ )9>BLKGQ7IB)0_Q9K,=2<OAK2X
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MUVI6>R6Z3=!,(Z2KI2G#ZZ[ +\[-\O>'!H !@%H%V#$G>"9O02Z=Q %>MI9
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M\208'--9AI><EP&GE2&D1U$!Z)2E-X\E7/@HD=TJ9&P[&77ASF .:QUUQ $
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M,85PK-/FKGV8]'HQV8^#_+C/O>_C/Y./QI]-WDIZS\\_/Q5JC@0L4R2L487
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M4]JIO4Q'K8*SDQF8T<W? A4_T\#)UO?DERT>762$T=9)\95@+'B+8?I+T7U
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MJ:.@6 94?)TV#)T:WMS+$'AC3"X\BOF$-Y0R3W[E9#NOIWM.U3])VP)ZF -
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MYJ^U&PTYX*0+U@@5*.T"G5XG0Q(J+C7^%C[#+<CGAPY18.;O5.($/B#) <:
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M8YI<3</9+&D2(:8Q; !)-36=P(Q72TM6. CK!#KYF"2Z#$.+C ;@*>)$E:T
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MNZU*)09M+I8XYK9C5%E)CKEN%HGFA#B.P$OTV95 1NN4N\UBYU^Y(&E&C$8
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M5Z/\G"0<C3&B>GXE>JKV<)!R.B>GXE>JKY\?%\V>$@Y'1/S9S\'H3G/\V.$
M)P!3M^97JJ]G"0<CGJGI^)7JJ^;YOG_F^/A(.1T]YC5/3\2O55\WS?V[<<)!
MR.GO,)V_,KU5>SA(-3&&*?F5ZJOA][X.$@Y'^N"?F5Z/_15[.$@Y&B?F5ZJO
M9PD'(Z)Z<_ KX_\ !5[.$@Y'1/S*^/\ P5>]\?O<)!R.\Z*GO_[%6?3\"<Y_
M/GT?!^?E^<4]BG[)!. GW/L)V]OP9S_[N?9R*0??C[UHJ^GXE>JKV<*P<(,X
MJG;[WHSZ?FSV?Y<?V[/3Q[]^]Z0?ZT_%.WYL^JKX?S?#_EX2#E[(G\$^;LSV
M_!VIS^3XL<8>6_=1((,16GXP/JN$?0MH;;]1+:]VV_J"R2I ]VPF9-M>L0JN
MFUU!K6EQJI_0TFGVLX#,1#AW?4E&U72!(3'IY)U]L]/M312/&8=\E@UPNN+3
M@9=(!B"TM()!^(%V !DE>ZW<TM<V]EV8) <(-Z0T[NR:SNC>I!ZH>CGJ!OA;
M;KM+Q<;'4;EO*M[(:K;E_K,DF=8A=/ANJB41\;!).@ 53IFXGZV2DUZ.@81A
M Q;]@HB6[<."SEZM+.T)=!):7AP!(,]D@4-  \M\0!(J I96C&M:#V7!I;,'
M<\7L*F6EU:@DP8W[)=3>O=O=0/3*&HD6C&UFQ^Q*S V;7(DZN#RMNKM$G38Y
MLK06]BF7*580=DL(\27"PMHSDQ"E.>DS9T9-E:&(QNT:7V<"I!%X"?X<8D@&
M=P)J,:KE9EMG;%VZ'%I@P"< Z!2!(,8'"BB&QZ!W_8M?=%P$AJ\O)VUH/]QV
M.9V<G; B8!$2ZD_JV;?Y,V&4M"[*7$6T6.LE?FVL2S/V#,FA"0%\:JD7*:1*
M0V;HL1!);=O.O81=+I$@UPD;P0!!!6PYH?;$.: \.AMTS': @@4@P;IEL$34
M0HFZ3>FS9FB]T:53?JC81YXM>[H<FD24FO624WA?3\7!;,+MFZ(^4#P*/;+W
M#I,T5+ND^-L:WGTI)W1F46BP'F\,86/;-)<ZN30TWLP&EP;D21)@K=HYK[-]
MTX, RDW^R*B20+TP8%,5W!^?L5V?'XJO9SU+PP<CHGI^)7JJ]G"0<CHHH@Z4
MUZ,MYF\P!)"-8SBI^9<A)VP+AQL&R(,M8VQ0A9)8D*U:B-;"2K4T*A0T6-V
MUDQB9XSO><VV-FRSM+$";*U<XVEF8<Q[76G2[5S"' S9FUZ;TJUN?#UELYQ!
M(;=ZFUM2YCX <R(<UI82\6=E8,M'P0'VS;&QLK%EJZ7LLVW&.:TD&.WNCCIN
MGB(H0YJP):(HTC4R0>3;LD+47 8HQ(,4J0JO&[!*(%P5>"2P Q,:N"9L0*N*
MT]#D07HLN8T_IC QUD\2ZULK?[RVV?#[5UO%D#;6MHX%]K:%MA8M+[1SG.;9
M,#B85=:VCNN!'9M^COZ-:L AAL+7[Q>8&#LMD]*Z06E@:YCK1Q:06B-F_3\2
MO55[.:7&#D="LTJ'_G'W_P#<F/3CL]/]\_-CT^GT_%\W/G?:!;_93'_,BD]S
MS7TN@!T6L3BV:QWE(64ISZ<I3G/QYQCV<^3)S.J^I R&@3Q$?<I]7'LXDYG4
MI R&@3Q$?<I]7'LXDYG4I R&@3Q$?<I]7'LXDYG4I R&@3Q$?<I]7'LXDYG4
MI R&@3Q$?<I]7'LXDYG4I R&@3Q$?<I]7'LXDYG4I R&@3Q$?<I]7'LXDYG4
MI R&@3Q$?<I]7'LXDYG4I R&@3Q$?<I]7'LXDYG4I R&@3Q$?<I]7'LXDYG4
MI R&@3Q$?<I]7'LXDYG4I R&@3Q$?<I]7'LXDYG4I R&@3Q$?<I]7'LXDYG4
MI R&@3Q$?<I]7'LXDYG4I R&@3Q$?<I]7'LXDYG4I R&@4*;@BSGS.C%0(MA
M?;C[K%2"2J_2P5MCQQR:%L)IR19IAE"GJ37,2G8C3]R!>*<BE'1(-E6(!\AC
M*3F=3\T@9#137XB/N4^KCV<2<SJ4@9#0)XB/N4^KCV<2<SJ4@9#0)XB/N4^K
MCV<2<SJ4@9#0)XB/N4^KCV<2<SJ4@9#0)XB/N4^KCV<2<SJ4@9#0)XB/N4^K
MCV<2<SJ4@9#0)XB/N4^KCV<2<SJ4@9#0)XB/N4^KCV<2<SJ4@9#0)XB/N4^K
MCV<2<SJ4@9#0)XB/N4^KCV<2<SJ4@9#0)XB/N4^KCV<2<SJ4@9#0)XB/N4^K
MCV<2<SJ4@9#0)XB/N4^KCV<2<SJ4@9#0*#>I/9AC3>D[SL>O00\DO7HP=$61
M8$2%5L&@U8@]?EVVT)B28,E=6I<,K(MMF0R0'+6""D$X)#NW,UA)S.I2!D-
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MH:LA -S">JYQ1 @&':U8AG=%[BINM:<'#SBEMFQY\NP#"IDN0A+PY+?EI;1
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MIQ2O%:">=_E"5PXZ93<B8G"-&UAA>6T#@V)S($N('9%:X_FL"P!>&!_\!>3
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M.R9NF!)$S()((@&6E0=-\)JF(*@DD4?7;JGY@"IOP)^V3E:,YNM@L!"O/E(
M.QZK'%96IZ7)&$<WZ_O1HK@3(*T+'!#<,&B:2QUX@&Z*Q0N(),@8$3=WET#
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M@$L79:]9*O U3172<F[F2A.P;8JY^4:4#/5&F&Q!H02"CHI9,&>N'R;;.+W
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MUO,COG,5AA^+<*M(9>LJLQ,)KS3K)I:'#><SX.,"D*S.SF9$QACMD,^.VF>
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M6B/Q6IXR%T;;5V ;E33[%NVCTGU<B/-7>RTRX5HL$K0$[*A6LD!LK@.KUJ\
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M#K6T!B:-G$2),0)& F2: 2LCIENYMX6;8F/B D[X!J8WQA()HK?:NM73=,@
MR)RX"^ZM%9K]NJ\80(LUC*6@/;52,51-9#UX>4*V M96X1.2" "(4PZ5A"#4
M^&.=A!2C\3)Z#8")MGU$CL@D@X0 )GPQ5'2^DDF+-M"09($1$R20*9^(^<JT
MK=(78M7$72E3Q-@K)V.Y(&%(F)B$.]Q(>ARH[[$C+,N%/'SH\D>4'38\8@,(
MQ90^?&C3(S[#>Q]GV1 (M7P8(HW ^<5\#\X6#T^V:XM<Q@(W?A42"(WBAQ"R
MGSTG_>D/Y_\ '>]])_V\NS;/B6GA1OO\5-HVO<;K^R>><_[UA_Q/?G_VW_)_
MEY-G6?$?HU-HVO<;K^R>>D_[TA_Y[XL_!WGQ]GPYY=FV7%?/DU-HVO=;]57S
MSG_>L3_/?6\FSK/B/T;Z)M&U[C=?V3SSG_>L3_/>]]+_ &]_YN-G6?$?HU-H
MVO<;K^R>><_[UB?Q/?6\;.L^(_1OHFT;7N-]_)4Q<Y_PQ(?O?!WWO_2^]QLZ
MSXC]&X>]WU3:-KW&^_DGGG/]/]Z0_F_QW^7^Z?\ 9\_;Z+LZRXEIHWY^]_@F
MT;7N-U_9//,A]Z0_\_Z?\YZ/\O&S;+BVG*WU3:-KW&Z_LJ^><_[UB?Y[ZW^W
MY_1-G6?$?HU-HVO<;K^R>><_[UA_E['OYN]_Y_XN-G6?$?HU-HVO=;]4\\Y_
MWI#_ ,]C_P#5SQLZSXC]&FGT]Y)M&U[C=?V4%[EM+TPUHI;HUN2L;NX3/:5&
MUZB^)AO)H6PXV)4N>^[XVMXJ6Y2V5[#C?WQ"=>:K6.QJT.\A^SF"[#[0WG11
MH,#,Q@)I)&)%*TTWI]H0_LLEK2X22,",,S!PQ.(WA3AF\R_@8@]OSY>^MYK9
MMGOM7?[#^:SM&U[C=?V5//F7\A!^'X7O>^#_ &W'9\_O\;,L^*[_ &>J;1M>
MXW7]D\^97PL0?6>^L].?S>WEV99[K1YY/K6@\9]$VC:]QNO[*OGS*^0@_P ;
MO;_^;Z/A_+\'Q<FS;/B/_P!GOSRWIM&U[C=?V3SYE_(0?XWOK/1_EXV;9\5_
MC\'TK5-HVO<;[^2U^V)UR]/&H]H4/2NSMS:KHNVMHJ%)UWKRRV:*+M=SR;,O
M5T0FOB)$I,HCDB=COB8G<(5WTYI;"<97C..8=T&P:X-=;D.=@#=K6*9UCYK;
M>F=(>USVV0<ULWB,! D[MPKY+8'SYE?(0OA^%[\W^V?Q\WLRSXKO]GJL;1M>
MXW7]D\^)7R$'^-[ZW^WY\9XV;9\1W^SW[\$VC:]QOOY)Y\R_D(/\;WS?^M_+
M_D]_C9EGQ7?[/5-HVO<;K^RIY\R_O>#^3M>^?X>\_)\'Q\NS+/BOC_1^$_FF
MT;7NM^JKY\R_D(/\;WUOQ]GH^+M_--FV?%=_L]<M^=$VC:]QOOY*GGS+[/2Q
M!]_T^E[WOI?^KW_?[.-F6?$?N[GK[I2J;1M>XW7]E]//2?GWHL/X/3V/_%\7
M>_\ /_-Z9LVSXC]&_BFT;7N-]_)8O<=SB:"$Q8K9(@" V3-; 9G.L3WVD%+=
M8Q=3K[#N(B7W&6YQXT,@JE.(3$AXD^4S7X\1IZ0V/V?9-$NM7@4$W0:D@ 0!
MF?S5'3[9Q@,:34X[@"3EN$_11V&ZPM.GFY3P_85(S%A%;V#G3I9)0T</+:UM
M8ND7."1($7(D."^*M)L0(;1*?:]TGB$5T7F;'=2]S/W&PXSHD@DAH%" :X3)
M%*8TD56STSI QLA@#&)J"1 $F(!,X""#59)8NI37]4GQA)RVU&*6E6&JU9(E
MLEB85CG+O-0.J<.<-@O29HY!R8M+,&9/8C0G,X4O,A+:%J33T"P%#;N!D".R
M34Q4"H4'3;=PD68(B9FD>9_#%6FZ]5FM]>FZ17[98AP\AL-Z,U5W(XRP%ACS
M4Z>.$CIY8V'A$ U:$E#!<4&%&+)/$BRA<C"&0)DB:^AC@] L6P#:V@)P[((G
MQ.X5%3FC>FV[@XMLVD-QKACN-2:8"2KN#ZDJ!8QMW-B+=3Y(36]J+4B\FUE$
M10U9M0%@=(-!BA:6^P/8DBDE8+,_/E"FHLMY4-YU$MA]ENG[/L:Q;/(:2"8:
M "/%0].MP0.K$N < *D@X& "=WFO?(Z@J)%:<>E7?7L9EJNL6]UU^U"&FFZG
M*>1'C6A;BR:4HKLB0XB.P:5G UY]6&6Y*G,X3R;/L>,<)Q;AG^?E57[[TCA9
MC XC=ACX8K]2]_T<>YW,ZZZ_A/=X(9PU+M(F,YWUA1WE?:[MXFA?>G&\X<$-
M]GCDF\^/"P^GT\;/LICK7;N[-<*>.[-3[];\+/<=U#NW$$'+>LW\])V?]RQ/
M\]]9R[.L^(_1OHL[1M>XW7]D\\Y_WK#_ (GOK>-G6?$?HWT3:-KW6_54\]"'
MWI#^#Y;\_P#MF.WYOX^79MEQ+3E;\O>[Q3:-KW&^_DOF]>9,=EV0^S 988;6
M\\\ZMQMIIIM.5N..+4[A*$-H3E2E*SA*4XSG.<8QV\FSK/B/T:FT+7N-]_):
MQA/" =/EBB5:>)OPU^%<K5YG );U<NL&-(,.LU60/?FO3@D= >OG6+Y1'*U:
MRZH-8LV+O4< 2Y#-C$XE\QT/HYC^V?4Q\.F(%"<"8!W$RNIZ5TH3-DT0+Q[3
M12ISQ@&1C0T5^NG6UI?7EK.TJX7$:(L=<$++E(:@=KEQT*2.8,I 0R< 7+%%
M+J^$DQC<2ABYLRYS TJ,5C 78+[4A6CT&P:8=;/%)^$1@3$Q$T-)G?@HWI?2
M7-O"R:03 @B<8F)F)H70&@XD0LMK75#K^X4JJ[!KE@%$JK=#N:Q79V(9F-+F
MV1DR1KY&ONAID:,:'&@9D,;@V,82'Q)E;<!FU'&8#8@BN,'0+ @.%L\AQ@=D
M5,F1&,B*C=!F(4/3>D!Q8;-H<VI$C"E9P(((@@D5FH5AD]8VIVM5O[I@V@;9
M-;MV2;48U@I@FQWA1BR#[O)US*$UT148)DU9)6+E#E!F, 1Y%,I;#DN*IZ"G
MRK-/0+$-O=;:%M1(:#68@  DP<1$^2#IEN7]7U;0X[B12DR<!A6I'U7V(=7^
MJ [L&*=MP2N$)NO(>UW!-CB&@)L-KN<;!UQFUV@(7BPBM3&MF["-'2U6:()>
M@OI)9FM,-A3"X(] L!$VSY+;T71($@5I3'?7>1$Q?OG2#A9M/:NS(@G&!G3>
M*?@IL3=9ZDX5B+"SA6,9QG'?9QE.?3VXSWOPXSVX_P"OT:V=9<2TT:N>T+44
MN-D8_G[_ !5?/,A]ZP_?_P#78]'TN?3_ &_+-G6?$?HW'WO^B;1M>ZWZJ,MJ
M=2U(TJ"AV+9)D> 'DR: PEEH><-F31146407!"5X!%*'3,F*,@D"\]L8.E9'
M!AI$Q.\G&P)DEB.Z!8M$NM7@8?""2:T  DY^4Y5TSIMO:$AEFTD"36('B3 ]
M3@O8#ZBZ-9B]M!5^UU(N4H0T&7ND4>23)\V!]DA3B01XV\W(RP.7/&CI9%N/
M)<1);@)9FO--QI,9UX/L^R,Q:OH 30343EEKYT0]-MQ=FS:+Q+1)Q(@$#R)%
M<%$ +K_Z?[*NN,A+U"G2;19,U0=!35KTT1AE5( N17+&.?!-3:D%*-6NJOA;
M+:6 ]>.1K179(@G-8,CW)&1T+HYB+9Y),0&@Y5-* @B"8!S@@KH>D])!=-DV
M&B9D017 X;CA."R;9G6?J#4$Z:,O]K@"20W I1*!!!VNR3!S)B":+QI,^-61
M9=Z)$C ZX<L)>7(0U&!5T:^>,O01.6I:Z[H-@TD&VM*9,G<3N!_I)PQPWIG2
M7B6V;2, 20,(G$BE0/.DDT5XL75EK&J7VJ:S/6D/#N5U'PRH <F$;E0UCRCA
M)D)))G8462  HL<@,8BUG!TF-79)@DG$!IGR(,EMJ_<+ $--L^2)%!%<))@
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M:F0U6VB-, C@,!:7IT@-=JQ:X&P:J5!O2VA(( 2(DR<W;K.\X.O78 !(:"Z
M28#C4 G$5%! G'++:XPMNS\4$DQ415N!@X1!J9G!1;4^@V?K\(VJF[M--WBF
M[59O.EK):JB/LP/75#"5G8-+IFEB5707#R;72:Q5]IWN&S,C62L'WIQ:)/CD
M1Z1R(C\%D6CLO-X&6.+0;H (:T@GM!H)K0[L%H](#CVK,%I;#P"07.)!<\$"
MA) H;V'C3=[7U>L55J(D);;I/V%98WET@S;R(H2#<+3B1&83>3$"A6&8 H0.
MS,P+!CO'G3(8:% 8)ES1)$LO-Z-!  +KQWF(WG=N\,:165Q>X.=(:&B  !N
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M]4^P7Z,/Q4NGG]3]"_J'CJK'@V7(%>NMN*^O^(^M/DGV#'1A^*ET\_J?H/\
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MA=_8Y.LL^(SF;ZIU5KW':)W#_P @_P#0N_L<O6,[[.8>J=5:]QVB=P_\@_\
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MW]CB^SOMYAZIU5KW':)Y._\ >[_T+O[/'6,-;[,OB;ICI],$ZJT[CM"G</\
MR#_T+O['%]G?;S#U\1JG56G<=H4[A_Y!_P"A=_8XOL[[>8>J=5:]QVB=P_\
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M[!3QJPY.PHL%F%'-O;:W$BZ7QEZF1H;EL'SKX-K;(>-/*15HF6ZPXLC:YD8
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M.$XQC&C:,))-HTN)+B2\$DN,DDDDDDFLUDK'4V@  LR    &P  (  $   0
M%G%2:=1[H>.VXCM\D[/';6CM[/*>WL\9..WL[<=O9V]G;CWNWT_.Z>YAZJK3
M'6808^#*87OZ$U[!:7@YLEN-)B\I!Y\I?53A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$4$;KBC9)S0"B#%;><B;V$2ABK#6K18I$<DG7NR6FWZQ(K;[$:KV
M1,5Z8VQ9;7B15XXMTN*D1U%RX9QHBG?A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M%"?45M(EI?35TV.'%CRQ<$R&B"XQJ4_" 1R-CL0BKPB]EFQD+DPZN!DFFC=F
ME1DYD1P(\@ZSE+B$JP1:7G^MV_Z9LDVO[7@:EVJ*J;WDVP+?H<\^+75O=J^Z
M-I-74>J-S.D\@CC3FYHQ0[54VPRI%9A0K+'/-/$F:WPH=W[Y9[OF#JK6-\*-
M52(ZP3L:4OS:JE2R.T+,RHF*C)':U%!ZH;FFX<@LR);L!9$2U--1!]=P4KI:
M3"=6(N,X>\T0P55N/^%=H]=F!ATO2&TII"U:X&[HJ44!D;:'2VIB,?84SW=(
MLUG!B56;''C:\G8>K1^/"B,R"D#$NQ1(48S/&$4W;NZ]*AHZ]VZJF]=W$T#H
M6N*%L6UVD/- 9?CQMF0MQR:@($5)Z<FR&I[K^EST0RMB(RR)R7#RDYFQ&C;H
M<B_?3YUQP^H+:-IU0-TY?J>:U^-=)WLG;5Q@XX8PZQ#?#^XPTM'%6TQ[K9(Q
M&>V?60'D;B)KBL/Q&8DF>11 )\*$ F#XY<KHF^@QAA>N8-:>?M-'ER"IK;^N
MQNS-=#9;,8IW 9F< G.M60E*F.0ZW.CH0A9>,^Y*BE/W]^_I$+\%_";1O<B_
MKK^CK0\:H1'8]%)J*6RH^X;>UJ #Z@RCM=8E#"$R42KDJ3TXW*.NS-,PW&FB
M]77[E]_+-1P!539TS]7Q?=.R+KJFXZWE4RQ )FYBE=-PBPPI7K'4-6;]M&DW
M%J:9GR"8XVU)$C'9:9+.(9%U^=*A8B1FV(RB+>;A$X1.$3A$X1.$3A$X1.$4
M;[,VQ2M1"(AR\2CD0=.E/0HSH2GV^WN>4,0I$]SRIBH@SCPV,F-%>5D@31#'
M)6E+2Y:77&T*(N?5 Z_;-MKI]N.T*@%H@*U_935/IXJD0U)+&@-1&W^V:W"5
M^Q[&9A30L@@;""-@,2[&" %QXQVQ-LUT=8O)7$G7BGGX09QI6!NP5PT;UI[4
MV)N[3=(M ?4N:)MFCVE.25*(G2!JO[/I%4 6B<&(R9!&4Q$5;QDNP6NKU6<"
MC^3ZWAUVV.WLJ3L2:O#*^]WOWY*WUCKGV9;MU"ZI#K.O0VOXTK4LTHP5</.W
MFVUG?^XML:JH4RGO)(01@Z=286MH5NV"U/%&VI2#LT)"R%<!8)DR+R6SPA!
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g73339dsp031.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73339dsp031.jpg
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M P,# P,# P,# P/_P  1" '^ T@# 1$  A$! Q$!_\0 ]0   0,% 0$!
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M2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI48J1Z0YF9RHUV<,N3&,E'A;0=?\
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M?(F'BJ_!4*H15F=O7E9D\6-[XY*N:0/Y'Z;$(INBD;N7%4#)AD8W;N+ERR+
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M^D9.'H3EBJS:Q:"LL[>>L^7'4*J0[CRJG.0.\Y@$=5Q\IEK.L\C;P,@3E;
MR W)T M?II8>P5F8?U)[HAYF'ELV89*)SR<N\)5(XY<U7#M(1$J;/4 *D1[5
M )VJ#:JD,#XH+7H:LO:9$2L=#3TY:TBR"2KD[RSVIC8XVUS$D=18YY$]D86^
M4;O$%Q5;*M7JB I^'M( \MR'K-.LK*[(J:>"J5*@>S:44@BQ!4&]]:ID^IO?
M!Y7(YC'Y">#+R,6'&.PA0N/C/!)C11@ ",8[XN.\3H%D62%9 _J78MYKQ=P<
MSBWD4C3GA_6.ZR]+,NKG>WUOC5J61\E425^\O;,XN59:5E&5>)L4(Y^U0;)O
M7)4R%*Y7!2ZW.<HSAS(- PVA$"'?;?N0+L8M8;BRDG:O\HMM9OK/]2,C-CS9
M,^,>FF0GI+B8:8L@RRARC/AICKB9#9!CB:9YX9'D:&%F8F*,J]*_AW&E61IJ
M$#4V+ M 6LKJJ* XD'+J.?7,'7YMDW#UX\</)B6LJKU95\[>G<N73A8ZRAS*
MG,<<:;DLV<R&60GU@H?06(2VP6 L M@%"V    MI7/<IW_WAS4G(2<GG22GE
M%QUR1MC573$V_*QJBHJQ18X1%ABA$<<:(J*H10HP$3@+'57DJ.^I4*UJ"%*L
MQK.5A$(@9*9<DQ;)8D8MI%=V==T"$?67B/9V' 3*-2F-N8ZAC7I.6S)TE7)8
MR&5-MSX#U1*2+::L#^OW"MIG?5#NSF</DL;N'(?/DY'#^7WRG6)3R,?)NT:J
M%7<^0CWN+!9"!8*@5QQ6(<:PB<*A&T^*1;UZ!N57B&RH.'C5M7LA2T9.72(.
MU>KN&[QE8I6&;*N"+E4W%("E[2B8HV9.1S92Q>1BSNC$Z EHP50W%K%02!:W
M6M3G=^=X<B^1)EY\[2Y>5B9,K#:C-/@Q20XDH9%5E>".614*%?BN;L 0VX[C
MGA6)IX4)C0HY.K!.P=E*P5?3+MR2<K36$CX"03F7<DO-IJ1$77&+- I7($39
M-B-@+X-TQO/S/)R9/S;RGYC8RWLH&UBQ86 VZEF)T^(ENNM;?+^K/U$SN?\
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M%C2N@\A>.^WSR;\K'X:IK=Y/NI%F282ELHPV6HMDX3*U:UJSU^IU6IPYXHC
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M]-^\>3@Q,G%QE,&=$\D!,B#>L9"N=6%K$@:VKC,[Z@=K<=/E8V5D$384B),
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MC\YU_P#O9_\ #K?T-/E)_P"6F]:/SG7_ .]G_P .M_0T^4G_ ):;UH_.=?\
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M-ZT?G.O_ -[/_AUOZ&GRD_\ +3>M'YSK_P#>S_X=;^AI\I/_ "TWK1^<Z_\
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M;^AI\I/_ "TWK1^<Z_\ WL_^'6_H:?*3_P M-ZT?G.O_ -[/_AUOZ&GRD_\
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MHL"=%Z:C]8K#O/J\\&&2#M=7(]G.#(XD632QG?5%.X-P "C\A!+90P=I!$P
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M+Y"YTK(4_8G#&],)6P7Y_(-I..]$J^5BVQUX_P"^V#&EY2"_S,>##-A'1\C
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MF*)%02$ ]H&,&VH*VZ[A^BHU]M?1.JF!A7:O4 *F54QS(&43*100!,XJ(>4
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MA6)R) K!O(0NU2BNQ#,0K,%.EP-37CKAF&*1&8R_*LH]%+@Z.+EF#%5\JC<
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MUB+@V8 V(((]H-Q5EK,P[URJS92L:[=H@<5FK5\U<.4@3,!%!5025.JF!#B
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M'H&GF;[A^H5&@^^OHE<*%,HY6*T2*43F*B8@BF0@"83K.UB]A.PI1$W: %
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MY5NI[/;L582B8?\ )J;#W?JIX_VU;]8L;<&OS%P(")3&\#1RV(([_P!:X0W
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M*!KGX3L078MKKA>(*/DD*_(P+9$U$D:HE UE)P*<2]9I49F:N6&"DH=5E6V
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MLIF4KA;8Z+) ZK.5D@@YMOD ]R@[31V2H#*9;@(^MY+EJ4>JS59"MC)Q,#&
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MTAZ>=8 VW#?H4NX"<WZ $0D=+GI4'V>-4]J3,@J?&JLJ($$P@47#I4?83W%
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M4;\:>)93S:*\H"C\JF,Z.<&OHW#A2)10;CN</1IID(902;; &O@/U,$A^E7
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M7&>68>FR9)&#X_\ 'RJY6E<0-^P2JC&A98JC-8Y*-6[2HO5&S5>4D$ $AI(
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MSV!E&\MA[BG4'^:IZ 4;J^G%[<K7#K,<64-FT<!X'3B9L#%) =@4$IB[#?\
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M+NED_E@(KQQFVZ93+@8,22=XY IMZ=9$<*O'<7WUTO\ JT?4";_3KX8V+/\
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MA(&K_%X"HL>@Z5;3*0YU$(H2I()!_;I8P 41Z <K=L8.PJ@ 0>XYB=J1 $
M=Q':JYM>3KX"EC_#^DTF439+)+@4$THTGD2>/W"0K.GZA0W.W:)G3,(H$ .I
MP+\1O8 [&$0+ ZZR> \!]]01^JF>]@X])8J$81>.7>E*"$.U RA5AV$X*S0"
MH'XQPZE:D-XTR@)C[ !A"\'8ZM8@>/\ 5_75LI<Z?;[ZK;1)(EXW"9$Q'ICA
MZ=P5JBM"G H (IGBP[6QPZ[ */8=,=A!,OWC1O,@\FH\? _K_KH$*G44[T5
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MOQN\=]A( CT.'32U[,AUM2QZ&OH)J(.R&:* LDNT,/@65$X"5LLGV>!T'><
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M'!$V,RX=NTTFBKPHM?5W,)RDL&7S$$0.5ZHC6,;P\>,#LF"$$LK2,^XI8ED
M!+!;'RYQ+<8DN+QDTK"!HM[-IM?((W1,U]-L:KMOT#DZ"^BO']I<<<K'.4/+
MZ\W.T')S!]<V$W 1<<]DF\[.RSVTQN3J&="1E&II!9P1W$6AD15@]7?)'.=$
M%11+IDXR=UX,?)\"B)R6(1$Z.Y&Y4 0PR#:#8^5X6((4"U[7-1B94W;6;)@\
MR['CLF[HZ@&Q<EA,FI%^J2BX))O:]A6[-)Y*UG 8O7%"M]4Y"7>Z0+F(QMC"
ME2\U\[DHRU+Q\.O>+)&U]L-EK-1IDFJBF]8R35L_?.E54$>PK915/Y]R/;67
MSS)%E8[\7AQR;LB>4+9=H)$:;C9W-B4*&P%B=6%^YPNX<7A$D;&G7DLV2/;#
M#&6N=UAO;:/*HO9PVM[VT!M K?(&<XZ81O[?CCQA4>-IE]?$;FTQ7@A!U-'?
M-6Y$:.2?B$DI$L0JV7.BR<M'1'(SJ;A)NY6<M4DR[QL+MZ7'/%R<ORA0J(]A
MGRR !<^H(SY?82K @+8E0&O6H^:YQ)%SX.,XT2!B^[T<?7_<W !K]0"+$M<!
MB14Z9%Y+4;.D@I;[7?JYAR;KK-JVR#B.V.Y9]DBH.8=1>LL%HR&D&:5QM2.0
M!;EDX=1HT,5!=^HQ=G24;'.;4<5VOR7 @X&/C/R$3R$P3I80R*;,=SJ2J>G>
MTFXWTNNAK:<CW+@<R#G2SK@LJCUH6OZJL#M\BD78.1=-OMLUB*TRM-QF>0=_
MC5L3R,Q5<:X.;U^VQ4G.1,,5U&S4&@,I^>;2@O*1,7*9:N\O.Q2$,Q2/(*-E
M#1K7^J,\7-W<.-B]K<9))S2I-RN>IC*1L=48V])+*2L,*JQ=K*&\[?RWXR?*
MRNXN20<7OBXW"(<,ZBP8"_J,"0IEE+*%4%B/*/YJ;&6AH\RYS+C6IS4NZK-)
M*M-8QLZZS9A7AL4,]CJ9DBM55DPC'D#!8[R*$:NYCQ)Z@3+"WE"-%G:BX:R>
M#')P#!Y3,C0Y61=<A-I+^FX:2*1R2&DEC!VWL+"\98 "K?,R\=/+F<7BM(N+
M P:!R0%,B;4DC4 %4CD(W6N;FS@7O78_Z:7S8/J.<PTY&;;.D$>-/%%)G!M)
MQP]1C'!,94$LJZ"">K'>0#=X[  ;E.1,RR9!$Y0.!@U\A^IAA;Z6\&8HRKGD
M\\[RMMP]:3;YOXC;K[*^I?3\,OU$YA792?R_#NH-['TDOIX"_2O07KSU7W.C
M2E&E*9>1W'I,>7QV+@6@-:9:''J@F)VO"V\,(^4]0$_5V,G9H,4>WN]9'-G#
MYMMY$$E%2D*.3A+NS(EM>\JZ65K^8?PL0K?<Q"GH2!70]I1>OW7QD&W?OY#'
M7;Z4,^Z\R#;Z&0\>/-?IZ4\B0R?!*ZH68:F<;+-GF8JE-7@(?$=DQ2XF'B;Z
MWS/('D#?LAF8%FG*<VJU4RI@V$F9AXP6!5-H@]>-4.PA"%4(F &UO^:@XJ.>
M02MD)GA19!CP1QWVC;_=3L #I<@$]3:]?<?J[P_TSP.;Y"/E)^=Q.]DQT*8L
M7"<)A8._TE,(8<;S$T42N-K2O%%(]RS,C/<5O/KEZ\VT:4HTI1I2C2E<XN+L
MA)26><G+3+F1</F<A<HI-.I2>09?$39$LK$/Q.WE5+A9J?+W%ZBY1]8O)@A(
M@NBNDS;MD45T]=ESB(G$P"(*%(0^<1B4Z$=-BN$&M@MUL06+$@UZU^L^+AXG
MTRX:/CTB7&DBQ)"<J/!BY1CZ<J6:,8N/E18J%6]),??!L>)\B6:22-ZQ?%MS
M$?QTM-<08QJC2O+W1S4S3C/(!\@PL,U+7*TPCWZ[%-_B"-AXIBW68QK0'*#]
MK'B!4$0\[X37.=$GY4DQ+;GV!]IC],GS,2+VF))(9C8J6ZG1*S?K1%G_ /37
M"Y:6283Y2XBY(A?!&#-*WKY#NBN4Y2261V2;(E]-X))[F60^GC6Z8ZXFO'M<
MULA,\#%Y6,YF>Y)Y"K%_=Y4QI"-<-P:<^ABF:MD+!TM:*C+Y7V4.[A[#9)AO
M<H@S:<>.VR;1=Q&MTQ%5KXS]IB-ROY"8XL*)\08\I,QV^J$9GN48D%578]T
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M2<@XPR5 5V(9),Z9A)TQF9=^W3@GUXE$HB;?/:K5*Q2JZ#Y[ N#(,8)=:2]
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M82%K</6ZK6HMI!5JO,8J K\''IE080U>K<:DRA8ABB0"D2:1C%B@BD !T(0
MULET!MX#3]U8)_IKP_<HI5YPQ_\ 4VP5UXL0RV3+?D]U7;1?L/U82-WB]JS;
MBR::Y*HZJJADF";B6;M6UM-W& B"CPIC[&+K"^'*%M;GI66/-CF]2-_Z6"NU
MW*_(_GARCR'/(2G(?T,''A!OB*!-1T7F>Z62XY-N9!7*"A2R-HKC.), ?B(
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MT<"?<0 1V^PPZ&]@4]G3Q_MIIT-5I"NW=.S?BND (U3$P!W.D^PJR@#L&P.
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M35XS7@O^TXV5@I$L["V^':S))!"+DFDLQ*58RR9/F3!=9D=4$US"7U)S_>G
M^I%-QV?BIF1.6'XA4,I&UHW9;,04)Z'1[/U%>9^'[,Y]XY%Y#!R3C.@'P7*L
M"&#J&N-& ^];KXTZF^%[Y6J;8,*7/#F8<M4>4AK9*X_MU:CYAJK2G"K&FNHM
M.2IMFCW8PC^5<XV:)N63&QB51S(J*&:KG!(Q-6W=/$Y^:G<7%\G@87(AXQ*D
MA!$EBX(]2/5@/4)4O%>R@;AK6:O;/,8>(W \CQF;EX6QVBD06="=EB5>PN=@
MW!9 !>]C68K?&'/;*N/4T++<\/U*=9OI<N/<)U&1C+TH6;1!1] Y)M)I%-I+
MV)E8(&*D04/)3#-8AUVXHE<&655C.[X[3?+ =8<S/B;;ZV5(&B&TW5X4 T7:
M64C:A^$_"+!A]E]TKCNR&7%Q) 3Z4"[9;$:I*Q-B20K [F'Q"P/7'AQ/RJ@W
M"53G>0R]9*5N>-IJ<S+)Y28SYGJC%8LS<E&B4+)T"-AX]N_09)- 74>'[>U%
MRK(.#UKW]VX9RKCCFR?A,K*OI%+!KK&+$2$W0MN\H'5@%40>Q^XQ"&7YX8W4
M)N_%#7(&Y[D&,"S!;:G^4EF*B[<:<^.X+S2\M<<[T^O,B*LZ1DJDR[[-#!N5
MC!5:(B*%<C2I").8:)1=/7W9+-4'IWBR39DF9/N/1QG>G; RFCQTAXWD)!M,
MT,NW%8DL[/*EM06VJ (]VT>9O97G]G=RF!)YVES\) ?PI([Y"BP55C8&UP+L
M26 W=!XE/8\*7^^PL5BFJ8MRYAC%U%:5V0EI>>BI&:>76PEHE@8_.8:DP,=
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MJ*-*4:4J-E&:@Y?:2'R.!%(N-I!F-E-(@%G34/9XQ8(-.(]6!CP*Q2"X.Y\
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M]Y@\Q=DR[EW']H=+V6R?$#U_J_KIXZ]*I ?(X?*..YLS\;,X(CWE67 Q542
MMVAWD(<4MB(D#N-OL;]W4]  -6U_1]O;4=3<]*1K%.HS,0Z6PO'BR+./'8A
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M&TWG*>2,4/LE7V$BK!.IE@ZE$I,ZF5[/SKDPLXB&:OEE>X2&2-8C.U]Q!+;
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MYIR]0-Z==586E-KDVUJ]!P'T;)FKX^B(2M<%5:M?<BVR$Q_!MZ[CA)I,Y.D
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M8R41:['F9?!ECCK5*LI+R05KQS+(YTK5@;0DG&N5$WD?,0[)RU<MRF(*A53
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M'G;=X]3[Z=*J6 T2@0C<.YL':V13^(3LU#%["*$#8QCM$P 3G+_LP*(A\/0
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M<-4E6SCN =NYKZ\.X?W0..LAK$V\+D_U_NJD5F_ 0CI*),4HL4T_.D4VXEV
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M]3D6=R'%]Q]L<?VQQN2D61E97&QRSAY$WA(,: 1+)M3S$R2PC6P=N@T[P_\
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MOIM;98GS>-O9X?MJKQJIBNX6542!LB1NF@I\N1*S3$0CUQ$JJB@F(<P&#[@
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M[>/NJ=3J*4'<R*Y$TF[8%A<)>0[@6"1C-VPB8AE3'32[BKF.42$*([]X#O\
M='5.V,$EC:WOH:N%.U2*1)2,33*F4$RE147;B!"@   %.90N^WO[>HZ$D]&U
MJ?<*^C\L4  W>-Q^T2HN2@/ZP% ^W\@CJ/Q/"QJI;WJX1L(;&:R#<1]P&44:
MJ .__P *4";[_P"GJ-POJIH_76KRAY5,@"ND+A$ #M.L@1RGV^[M7[3" =/<
M8-19#T-C5-)_,Q4_K&9TC>P3M5# 4!^WQ+^4O\@&#4^<:@@BJMI]HKYZ9 ^X
MH/DBC[ (Y*9L;]  ?\5$3#^DP:;R>H--MZ7)H3)$Q\A!%J %$3NQ2.R HCT[
M55>]';_5'?;5):,]/B]U-I\*^&&('^O QE>X.\8T3$1'][8'@"'ZNT #_EU3
M9[Z?#[ZJ%P*J[.\0"*](8W[)3$'UN^WN%WW)&,'_ ,&/M]@:D,!\=_M]U1;2
MDR[.04$#R"HMP'<2B^5,!AV'80(D/>J.P_NEVU6'0?"+_=4;:MB2.2V[CN79
MO>")"MTMP]P** HH(=?W '0-(WL%-I]M?2NNH$9L4 -[A%,[I?[=Q!8QRAN/
MV%#0C^8F]-IJ\=*34+LY<>G3']A=R1L0 ]^R &*(?R$T!6^@U^ZH'6D@HLT]
M_(\\@^\K9 R@^X/OK"B7^74@L3H #5P@GI57DC4P^%JY6']YPX!,!^WX$2;A
M_P"]I^(3X?HJV015"HN%NQ1A&MBK(&$[<WIUG!3@8 *H@L94ZP DN ;".WPB
M &#V: +T=C5)_;5M5U(ND?3I)E2.]!5 R9DVS;TY2?"Z.N402$HM1'8 $?B4
M$NP[=0G:JG<U]/L/UU/6K)#O8],&BTAW+D#^S">2 RLCY5/O&.0Y@4=]Y_Q_
MLW[_ &#L$G:^H&GW=/[/947'2K'IABP6>.91J=%<PK2*I55SE06$!W62*5$Q
MO2_LB7KL(]_43''4EE?RJITZ?;VU&@JH(Y4P_,1?LBO03V3145<E(5F.QA8G
M-Z<2E%7H<Q^H IM^R7;3>GPV.W^GVTL.OC5#9L$LGZL'R"91-VL2BN=%=HH0
M1 70@=,/$[$_W0'_ &>WN..A8)9;'W_U?=2P.OZJK;$?R"BA55TE?2]Z0(IO
M4Q2="H!DE'R9#K *B!P[DR;;]H]WZ!T)0= 1?[6H-=*K;JS/J01<^K<(-#*)
M,%%TP=$=J)%,1P)SG*H!UF:8BD'[X=QPWZ[&$6VXL">OA]K]:>-)6KT"N3)N
MFK-=F0J[:.$Z7C 4^H/4SF0,B.Y0 2)B(=4"#^G>3&"MU)W>/]'V]M!UUZ4B
M 6BK)RW%-RT>O!2/%K IYRE0,J5)AN"H%4 S$-C*;&$=C;COW#JKS@WT*CJ/
MW_KIX4F\"9IF-.U,W.11=!@*2@F05;.D(Q\FNCVJ;)";^U)%#8P@8I=_LTW7
M0[K^W]H_MJ+B].[ROF)A3-YDP'VIJ /C,'V"FH IG ?T (:L[4<7!JK[JJ]0
MS5_WAMXS#M^*S[2>[WMS[I&_YHDU!5P?*=/?58:PM7P6!S%%1HH5T4OQ"5,#
M N0OVJ-S;GZ![1*)P_3J0XO8Z4VU;2>+HE%,3 HD.^[=8OD2^P1 AOZL?TE$
MIM254]/UTM;[JK5!JNDHHD<K11-)0YDG"F[<>P@F[DW ]4PZ>Q3</]+4"ZFQ
MU%02*842B5%-H5R0Q42QSE1TF8-N]SY#I-TNT!,!CECUC 78>H&)K)=MU[=;
M_;]M6PP'6LB0BYF7I>[MEE'!]E>@^G5; 3Q.3;% 110:B0O_ ,()NW]H=0;;
MK_P6^W[:J\/?5Y1,'35NT9[('3*543B/<+(Q!.0Z1C!L(K.5.],WO$HF-]FH
M!*DL>G[Z==!5Q4"2#8K)'=N0"%!<Z8]BD>*0@4J"0AMV.2G3$"C^R0.[WAO
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M"("'WA,V R1@[O<'<?;[-20_4FX_;47I0HPEQ#8JA2MNSO[FYB-4@)T 3'3
MJ*Q>H_M%']>H#Q^RYJ:Q'IFA#=R[LRG4>X&R0J;[>W95<4B#U_7JX68CRC6H
MVU]%1H0=F[,ZIA#H+E4QA$/TIH B7_*.I4,='-&-A>E1?F1@ R;5%H3?<!\"
M"&WOW!5P'DVV^TVH_#&ER:H)O5E4'(%,HZE42D*!C*"+M1<$TR@(F$2H$.&P
M%#V:D%/!=?NJ+UA$F:!3GD?4JG<N>WSM$6WWVI>B"29EE$0!VB3XM^@',82B
M/0HA<+/;;8;10=:J(C%20^I!60,BB<Y6*B8()'27((D7<E _=LH!MT@*8/N@
M8!#8PZC=(GELOO\ ZJJ*CK5!%&+IR+)RFZ[V9 56 JR)4GBH@4Z1D0% WP(D
M$%%$Q$1(82;[AL(KN%W"UC^RIVCWU0X!@W.FS$KX(]4OD7-YT3'8-BFV%(X^
M'<S1RJ($ ?:D3NW^$ [9#2'S +?]Y_KJ-HZ:VJ_((,MRBP5>)N70E143$C<4
MU&Q2[J+D.!TBD=((=$C[;&,8I3=-A"%:7^(+8:U0?=>K;ENP6:(_+G_@<D.#
M5F*[19,[-4Q>TY5R$%8/&DB414(/W@*&P[[#JI6<,=X\O4^^GAIUJKTRPM/0
MM5 3=E%%!N1H[#S$5-L5-ZU/^&X,"("*G=V[AVB4P;[@,%ANW,+CW_N-#[*H
M=JNRMB04@03'6\;5 ZZ)-UD$P[SN6QU4Q51<HHIB)@ VY3_$&Y1WT"I?U%-A
M47TL:^*J(/'+-FY0!H\; X>-W301%)84DP035].L)B@/]I$JR13ATW$/AVV!
M2H+ W7V?;]E#6%?L5UT%7;19,5PFD_(U,;L6;OD&X)L3BF;8RK9X<"I"8G=\
M!BF'V&VN!U&C#3;U]WC^JJ>OZZ=C:04\"2B)P4:+IE4(BL +)=I@W[135*8$
MS ([#MVB @/OU8V@GWBK@'ZJ4;,7( /^XJC[MQ4:B(?I$#+H;_\ /#]6HNZZ
M=:J I.LW<,U"BIWE$?C15(?<AP]QTE2")3!^D!_FU4"CC2IW>X4H!V@Y^&03
M$3C['J( #D!]P*E$2IN"_;OL?_2U3M9=4_5X4ZZ>%8:QH^BC3B @Y)(*(QZ!
MD1$2K&>J%0.GTV.FJ")S#VFV$/\ +JY$VY_81K^JJ'.WI6+9N$T6[(':156+
M*6<&.1( %521<KNFO8R. ;@1L)RE H[D,< Z!V;A6PW$E39B/V#VU3;2LBLU
M49NQ52$'2\J@50@@'P-A9G ADG  (&2(V3<D[S?[4WW=]P +:ON&U]+']]7"
MMM:2)D](X69('%1P[*5\=8X ()G. (N'"Y Z!OV%%-,/:([!L4!'5P^8;CT&
ME4>Z@H>C=BR;?&H]*=R)E#=X)."[ Z<N1Z"87!.T2E#83&*.P &^T_$-Q\/L
M!4^X5A;45-C SGB RJKV F4EP$P =4_R]P*3UP< $"%*?=/?MW'N*4H=  )4
MDV/@#]A5+:5*L33*C*1E?F9*#9O)56%QVNH^5,N58ZU(44GJHH($6*0#0DO)
MKKI=.IU![NX-@# &5D1@QHQ$?GT'^^ K_P#:  /W5T>'W)SN#@KQ^'DNF$JY
M(""U@,R)(<D:@G\:*-$;7HHVV.M-JV82ILY6W<#7VS2IK.T8ID>009J2A#1<
M7992U$CU6+B0;E5(69G7KI _D*9!XJ17X@3*GK+Q^5R(IQ+,6D )-KVU*A;W
M /@J@^T"WC>NKX3ZE]P<=RZ<GRCOG1HTKA&<1GU),>/&+AU1B#Z4,4;C:0\2
MLGE+EJCQ_P 96[TSP_YV. NI"ZR'8YK:+M,YK8BT1*W?$&:2]<W<@U_[< 1)
M\\W !]-V]<M.=* #TNBH-&M\%^GETM?R?R?[U=5B_6>7'$:_EJV2+$3RY!4C
MY8L=R'TCL9=W^#.OR=M/6OIE&/'5FSF(^35N+Q\BRL=>FU6SJ(3,N^1@H<(P
MZ3E\$IW#+O@ 6WKP)W)0QA8 D8!\^J&YIFC*".Q*,MP>FXWT%N@Z[?%_/?PK
M"R?J[D3X$N&G'QQ228D\(9939#-+Z@*IZ?\ =)_>>C>S98&3O']W4N,<:X\C
M5HQPQJT<W6A_R]\L.0[H1:?E2OR=5KOC[G)@'Y57IETU3[M]TUA[NXVPAKGS
M\QPP:1B&W7Z:[V#M^M@#^BN%R>]>Z\N.:+)S97CR/7]0';YOF9X\F>]E_P"\
MGBCD:UO,HM87!^,L9X[CCQ"C&JQS8\$E5$8@R9W6[%*C,Y:/J9$NYR8!"$93
MKM-+NWW!<W=W#L(&S\QPP>1B'+WZ:[R"_P#VBHO]U,CO7NO+6=,G-E=<ELDR
MWV^<YCQ/DD^7_OGAB9K6U0;;:W^,\98Z8%BBLZI'-PA$:FWBNP[K^Q(T9W+/
MJFFD)G)A$(1W..SI=V^XKF[NX-@ V?F/NW2,=Q>_37> '_[047^ZIR.]N[,H
MSG(S96.2V2TM]OG.8L29)/E_[Y88@UK:(-MM;_&F,,<L2QY6E4CD"Q2=<1C@
M(=U_9$ZC8'UJK9$^YR/2)L,DNZ3WWW44$#=Q=@ V?F-?=(QW;K]-=ZA6_6H
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MO.82]-ORT>#]1H-W!<K)%*%UQG.U=/YD 5]-;O\ B*/X1K7UKZG\7V7_ /:
M\#N^B?U1SN.Y),<&3M[*/HXS%0;G(PXQ#E$]=^1NY''4_P!TH!U];>$LP4_/
M^)J!F>@&DC4[(]<8V> "99ECY9%D] P"VDV2:[I)L_:+IG25*155,#D'M.<N
MQA^ \EQ^1Q6=+Q^5;YB)MIL;C[P=-"-1< ^T"OPQ^HO87/?2_OCE/I]W0(1S
M_$Y;X\WI.7B+I;S1N54LC AE)56L1N53<"4M85<71I2C2E1DH\3#,C./^<V<
M%C8RD7@5\J _DU1,EIBT!F5G/G[0LZ)C@@F3Q[BU.<>[IL/3+"W^37R/1Q=G
MYFB^K?\ Q /H.?3 M_<GXB;_ !A1;QKAGR4_ZEQX?S.=ZAX*1_E]O^"(&5$O
MK%MW_F@3L5=O]TS'=X5)NN9KN:\7/.!.N,^8/U%I1ZZ^>MAS1Q:"=K#=E+Q;
ML$T,=6DHQXVPS!TS,F^()7 $;]PM-N\2CU$/;'8CY4O9_;,$/X3#"Y#;(=K
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MLH N:8"[AW-.$4V'<C&&'N;* 4AUY4P#L9V1(3;$B6 & W>< *JKV!UZ%UE
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MM$I'D>J7!=FP2(BE*E</7T753-A<QI# Y>.557"!B-TA3UGXN-Q4ZAGD9/Q
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M.&2"&-L3@63<BZ0"(=FEECF  :*G],5$$C=0Z>=?J+)*WTJX:-E.P<QR-FW
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M7)\5W-VQB\E X>.6+)Y*.6-QT9)$P%9&'@RD$>!KM+Q:M>,[UQUPW<\-T_\
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MSD?5.Y!R9042-F+9 JBSMPHJ':4B93&,;H&^JG[?YY$:4X65Z2"Y(B<@#VW
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M&FY3=3#NE4ZA59VRR':\GE.X4I]!LU->.8VXQ4L_G(:!<N)Q-PVAQ(+-,I%
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MW#IOH?Y4Z^WW_;]-4#4ZU2HD=PL9Z\'T\:"7:P2$PD,[;KBF?U+A0H 8/.!
M*1%,1W !W$W=MJ0;#:/B\:J9+:GI2ADHI*JE8D[V46BKW(*@4J:BL@4AT"%0
M)VAZ1JB0PD.8/B$Q@V HDWU2X">8ZM_154=86U-1/7[##-4#;FA94%T42F,<
M.YDX\;8.W=0SMZL !MU.)>X1]H;U1$&SGV_;]542?$?93>A\C5QK$0S-<\VF
MY;Q$<BJC^5+5N15NT;I+D#MAQ[O$IT$0Z;ZU[12%B0NES5WU$\;WK(FR;5B[
M;JS@;B!0_P"Z5MZF$=@*'_8O4QA]@>_5(BE/\/V_73>GOH')M7 !,*LX   B
M(C4[:  !0$1$1^2[   '73TI?Y?M^NF]/?29WEFF,&BT@_?R;%@W04<N7SRM
M6=JT;-TD3N%5W#EQ$)HHHI()F.8YC 4I"B81  $=5IC9,L@BBC+2D@ "UR2;
M #7K>J'G@B3U9&VQ"]R>@L+DG]%1ZARUXY.BF.TS)17:968R J-IQNN3Y>7P
M=TAW)&,7T(>I)^-_5_&7K\0:VI[;[@4A7P<H$Z?W3];$V.G6P)MUK 3F^%D4
MNF7C%0+_ -ZFHTU&O37KTJU'<O.-<PX?M(C->/Y9U%,7LI*MHV?;/G$7%QK@
MC20DY%!J955E'L7:A4EEU *DDJ8"',!A -52]K=RX\:RY/'Y<<4CA5+1,-SF
MY"BXZV!-6XNXNWIY'B@S<5Y44LP65"0HM<FQZ"XK+1W)W!4PL+>'R;6Y=<L<
M_ES(12[B27"*BRG/)R8HLT%E0CXXI!%=;;QH@&YQ -8\_!\QBFV5C31>8+=D
M(&X]%U\3X5DP<KQ>4+XV1%)Y2?*X)L.IL-;"L:7EOQP.8I"YFHAE%'0LDTBS
MB!E5'H'%+T94RB)Q>"J';XMO)W=-MP$-7V[9[A1=S8.4$V[KF)P-OMN1:WOJ
MPG/<(YLN5 3NVZ.I.[V6OUK(RO)_ \"Z<L)W)]9@W[--DJ[8S3I:)>M4I)JF
M^CU7+5^B@N@1\R6(LB)R@"J1RG+N4P"-G%X'FLU!+AXD\L37L4C9NFA&@]NG
MWU=R.7XK$=H\O(ABD6UPSJ#KTTO4?9,Y7<<PK-IJSG,E!:V.4JJYHV#D)YBR
MD7:<U&'<P[I-C(K-#*M)-J8%4#F[4ETOB*?M^+6=QW;/=$TL>1B<?EO$)1<^
MB^T%6&Y6-M+?Q>RL/,[B[=QU>')S,=)3&; R*#9@0K+<@&_5?;7D?S@UL;.T
M3E!N;V263H%8L/Y=R&Q(H*>4:J:8/^6'ATXA*0;O9!["SZ/@60DG;P?4-67C
M<*-P,7W#VL^)+QD6;Q]B,ID#PW_N)%0^H &((4,IN+ ?$V@.OCKGTRUY&3#S
MK#Y=6VRC_OD9KQD[0;L5.AN3T74BN\GTXY"(>_5 Y8!'LTCN_P#@]XENGTX6
M5=NCOTGN,<5+1[=2+68,FL6HDCWJF\/10%B]P 8NP? /J,LZ_2KA#(Y]+\VY
M&RV&A$\M]023^GIX5]Q[&>-OJ1RJH/,.*P===?PHO ]/#[Z]"^O/=?<*-*4:
M4IEY(;@\QY?6@MA>@ZIEH;BS"%FK(+L%H-\GZ8*]6Y")L4\*_=V^B8.FSUUO
MXD%4U3%.&3A-MS(FO:TJF^Y5MYAKN8%5_P")@5'4@C2NA[2E,'=?&3A_3*<A
MCMO]6&#;:9#N]?(26"';U]6:.2*.V^1'0%3J9QLJ^=XBITU*OS.):KBEM,/5
M'U)E^.>=\>9 !@,TZ4G$VR>2\^6"5A'DBN*JC1P\9NT.PY%"I'3$"ZZ#FI^*
MDGD,RY$F>5%G&1!)'?:-O]W H(&EP"#U%[U]R^KO,_33/YSD'Y3'YW-[V?'0
M)EQ<[PV=@[_240ECQ_"P1S)&-JR)%+$]PREU:YK>?7+5YLHTI1I2C2E&E*-*
M4:4HTI7'[)3&J%YD2LG+2&!E9!?D7@9E&1,K<,H0MW0DH^J8H4!_+T5DY7J^
M0;.JK--21#UDDU;P:Q(L9(7*"RXM?HF$V1_EQ4C7+V##G)(2(I8M-H'(W1KH
M=ZL27'J;-I W>]>T,GG&^@$&'@Q=S#%7M/FGDECQ>.FPVC?)Y(;(LQU&1@XX
M$,ARH9FD?,0YGR@ADCC];L#KYW7@JC2E8V915<P\JW0(*BR\:^113 0 5%56
MJI$R )A H"8Y@#J(!JN,@2*3T##]]9G'2)%R$$LAM&LR$GV ,"3^@5PV^BQP
MYLV)>..2Z_R>X^QE>NC[-\S,0;7(]0K$M,KUA>D45F@X9NG"4HJ6+&49.BD(
M"@$!4J@@7XA$?J'U)[DAY'F(9N$RV;&&,%;TW8#=ZDAU (UL1[[6K](?_M#/
MK]P_?/U9X?E/HUW3-E=O1=N113-@961%$,@9F8Y5U4QCU/3>,D[;E2H)T '8
M?^!>$O\ ^CN*_P#_ ![4O_X1KYW^:\I_ZSD?_K'_ *Z\#_\ 4KZC?_W_ )O_
M /SLK_\ JU(T;&1L,P9Q4/'L8F+CT$VK"-C6B#%@Q:I%[4FS-FU32;MD$BAL
M4A"E*4/8&L)W>1S)(2SDW))N3]Y-<GF9F7R&5)G9\LD^;*Q9Y)&9W=CU9G8E
MF8^)))-+M4UC4:4HTI4;J2@AEYI"_FPY0/C>0E/R-\J.)%Q3L\8T_-GSSL\9
M#M?+Z/TG=N8%O)ML7?72+B__ $@^;\H#;DD3YG?J+PNWH>E>YW6]3?;3;MOK
M7$OG$?4:/C/S @'A))?D?2-FME1)\WZ]K K?T?2O<[]]M*DC7-UVU>+KG]/W
M27S-]16)M;YZ\IT)R5XW_D1H96 =HP2IJC=@?2#<S5=&=CG OVZ1TU''89LH
MDD=NH42 .O:GT[Q./BX?MF:!2F9+QN?ZK>;S*)8[#73X;@[>H.M>1N_,C+R.
M4[BAF(;&CS</TQY=&*2"_M&MCJ>O2M/8ERTR/.8]B[)%1+*+S58YG&.07T>Q
MC5A99?DC5B I>03O+6[8TF**_ATH$[MBB1RH_5:OW[A !!3S]CD1#ADRY\9F
M.3@Q)/%?==L9BS20@H#(UCOLQ("@QH#TMR4+CDFQ(IPBP9DC0R'33( 54ELU
MD4L-EQ;S6=B+]9I@(5_:,3TFL5UA#IN\>NFM,R[B$B3YO>JQFBRS3YA-*E5*
MW30OK"]2T&#AE*,/4ECV3;TCE-D<J(.-!+R"X/*965EB11DAIL;(#!HI,= -
MJB^XHT:L0R';N-BM[FV\AQI,O QX,:Q6 B')@(VR1SL3N.@ 9'8 AANL+@D6
M%]A'N?\ -Y*K=>-/&"(QY7R/3)U6Z9%RA55KE4,MW&$([86*LXMI"<5)UD*_
MC6OD.C(65W&3"+Q^V*DT*10A%1YF/M[@GGQNZ^\I,F11>2*+'?TI((SJCSO<
M/>5K,B!EVJPW>P= >=YB-)NV>U4@C<V25YU]19G&C) I!0!!HSD-<KI[:<QK
M)]1[BE=H'(%HRAQXRA%O<65J#]$ZPXSQY+NQ7C)-2$Q97;O3Z90)&IQCV;9F
M9QDNI)^G,)FSAU' 0@)DL10_2SO;'DX_!P^1PLE<IB&&095 N+SR1R/('MU=
M M^JJ^MSESY7U![1G7D<O(P<J$P*MCCA"UQI"KHB%3?17W6Z$KX"&9A!;+%@
MIU_Q5 FQNTL!K"Q4B<D+A7Y/$TY2Q;3=JH]^E#M(]!O,4AB?YFU>G3*>1C/&
MLV3/YDTE-W%.O"0Y'&\W(<MH%0V@.Y<A9!:*2+0C:Y\A0?"UP3H36DFACY?(
MAY+B4&,LI8'UM# R&\B/J-5%G#="I%AT%:[9.18/Y>VY<Q;'M9Q_EC)D!B7%
M%C2JT0G!VNXC$)6G-63(G'$J2(OS&OO[E.'B6,8D@)GJ$N^,JQ1.D9H;IN+:
M2+'CX/F-T*8F&^5DQ"1B\2%MN- SK="^P;V8G1E502#>N9Y-(6DDYCBPLDF1
ME)CP/L 21K7GG5#Y@NX[0+:AF)%Q:I#XHS41(\\>,43$QC<*O3\P.(2C"Q44
MD3>A5DK1(SUE<S4I_P!J.YBU3DT_>.Y!8@/73=PDW7$J2""*6+W=@OC?3ODY
MIW8YL^('EOH/^["(%'E41J%4*N@()&I).=VMEQR]^<?# BKBP912.US<><LQ
M/4ER6))U(('0 #V<J+).A]+Y50\;9HH7N$R3A+^SIF172W#?;V"4Y0$/=UZA
MKP_:UVM_$?WU[+0[D!_W1^ZK/JCI?@/@#8WX9' F,#9P [@)%-S"5!4WL$IO
M@-O\(C[ !2=5-3?P(JL@NT#II)IK/$##VIIIB91XAO["$( ]SI$-]@V_%* >
MPWN6OK>Q_944*-G).Y9 ITRG$#*MER*IHG4-O\8%,GY6KD_:(?=V.(=2[]=5
M>YOU_;K4?=5]ZB8HMVP(NV+[QE56.9 3>4QN@)'$H&;.46Y3=@?$!B&$VPE$
M1U;CNVO45?8V6DB;9=^HFV4:&7'N$2N8XWD,D7;M.H"1A*LGL7V@ J 8.@[Z
MK)"@D&WWU;CZTF<H/NTYFY%%8Y$!3!I(Q[]!)!)$XCL1TFV,DV6)]X0 @$*8
M1Z![0( +_P Q]XJ9/"D[1N\354.DW?,E@[A)'NT%I!J_<"4PE)V"Q [HA ^,
MYDSB8"A\6JVOT.H]O0BBH#K>L2NRF0<'[ROX=TL)BF43:K"S<B/8H;N3D2)-
M#AN8 #R%*8 '8-M]5@J5T\P^WLJW8EK'36K UM04#I/?FJKAT83G4CUI!VT%
MLF;L,5]&1J:;<J*IC@42J'\8!^U[!U D);0#]/7]%_\ ;5;H%6XO24*FU8MU
M -&"P;F4*51?R+!%F,0?&GZB-:*>9(ZGD !_&WW$-S^S4F1NH))'VZU2B ]:
MJ?TY(S=(&*,R":9O*,HR,=I&'5'X %"4,U4D 1:%^ I5P7)N(@!MO93',6U.
MV_L\?U?U49;&VMJ^-#3K 4F0*H.RG4$IRQ[04Y90@#T SA-99O(+)D-M^&*(
MF$0^$N^VJSM;4C]?2J=>E.!!RH8JJ[**<LTRE,4[N7["K$2(([BLJD/@2V.4
M1/N<?B#J!A#5)0V\QO\ =4W]E76IXTZHO'[DLLHV$?"W14*JV37,7V)F$$T#
M*].JA2]Y"[]H )M6VW6VJ+56B@ZFKSM5Y)B*L@N6/8"!>](IO JN0G]6W*HJ
M4IV[0NP;@!4SG#X=MA$1* OPZM]OUU#"S6\*^.WCE@P>'@H]DZF3,W"T:28<
M+1T,5QXE#-GDX]!L\?%8BJ!>H(*&,&Y@ P>V!9W"N3Z=Q>PN;>-AH+^ZXK+Q
M(L9\F-<HR+BF10YC4/(%)&XHA9 [@7VJ74$V!8=:B)M=K\E<VM>L>-A?U4D0
M5Y)7^!MC*3@&\L:(:ORQ3&%<LH^7E7*\P+EL0RR:6X%36^$HJ GLCB8@Q#-%
M/;(W6",A#$7(N6!(&ECI?Q'LOWT_:G:4O;+\OA<X1S?S&R/ GQ7BE:/UFC]5
MY%>2) (S'*0&D-V:, D(6Q3',&68M-8LQQ?OJDZ<$E3MHJS4V29H'!,R8-&I
MC/R&>J-? !14 OC#R 80 O>8MYN-X^0WCSH?3]I5P?O.FEZWDGT[["+;L'O;
MB?E2QUFQLN-@!:Q8!"%)!^$FX*L!=BH*V-R;EN=M:L>MQVN[!D5H[(WL<A9J
MX>+*_11=N%TW)TC'7.FX,V;MT/"4X^58Q3]G:;MHDP..BQQ(,R)GN/*%:]KC
M]&ER3?P'OK!G[*[&AXL<A#WAQL^5Z@!QX\;(]0JS(NY=WE&P%V?>0 J77=<7
ML!EO)J:!&CKCC<7,\DY47,U3L5?192$:R2262EV;!TJ%B;1KJ27;H[+M#*D
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M26DM,1[;CG>Y!LW4D#1TJRL]/<M)!@1R\"+4]'Z\IR.W\8#155$Y3F;K.O$
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M4?SBP.C5WDK)1"&8(E&#<2GE5;>F]!)JJ1_J73&/5?E9BW<)HJ'0 [A%NHY
MI!!/P;/O>?*E^G_(?-[1,<)BR@ &^Y?-U8"]P2!H+V^^QVACX\?>V <>Y3YL
M68G0BS&W07MJ!>][$_=[)G9TC*I>L1%MVMVYD'*9]D""9ND "V=IC^"00Z;'
M[0$OMW#7AT V-M?.?OZ^(KV6MO36_P#*/W5] KHI/NE?(&+]X!(FJ<H[_>#_
M '1QT'KL)-_L'WM/N/V_3345@YFN5JUQ+^I65LDYK=@;*14] RWG38/XIV8I
M7C14I5F[A-%5/??TZQ-O=J6!(U%]/#[?OH-#I7*;!7&+/E"+QT)CF.6P_)IX
MKY>FS3-VZN6'*+)Y8Y?*F-BXICIZ&6RO25TK,]I$*L:&=B_= W8(+) F7R"(
M8Y+(+J;'7K^BLGRMUUZ5"@X7ST;$-+C<M4W/4HO%DPXY=Q4AC^SYXJCVQ1/!
M_"5%GFN2<6U')%'R7)-D\HQTZ@RG828*I7+,V4=.BJ Z!T2=AVBP]E1O&[K[
M?=XFMSLA5>U2M X>2F8<2W2U8TA*;(LN0^%J5)6C*5IC<B/L:5EO07]T;Q$J
M6VYEKM)GF4RR>J=\@J,M(LY-R146YG:$L&+!3NM;IUJ@$"^TC=^JM;\>8PN+
M/DTPN-OQ#E:O5-&$XX$QM'Y"HV4^0-AJ#" J<@RD8F1S_7,SM:C0INORBC89
M=23BI\S=P45%5G)2".I 8-T.W[OM^NC-=>HO]]-;"O$3+L!0TZSFFE)S"-PX
M*/P:,Z6G?(LRO(5FE 3HQ/(KYSEJY*R><:],-VIZA8(LD4R=>JGDETTSE:D-
M0JL200>GA8569 #Y2.O[/=3GGN)65G\;A7&U%ILC#U)YC_@V6_MK/$VZX4IC
M<8:TYQG\]+W6(0R)5YB><M%)6+5FR$E4/4&7:]RAR)=FJFW!-=.GC[SX?JJE
M6&Z_O/\ 12#/& ,M1=VK$!&4:W2N)Z[?,*^>/K.+;_D'&*T9"<9N0$'87L/A
M.K9EB+4-=0RG88<IT?S$X] _<-UUA= D!@D+IX$7ZC7P-5EM/?\ ;QIQ0V-;
MS <B\1WJMXKR4U,R?X C&@R>,+Y2ZC4J'&5I""OUBHMYCLLKFPG"1(+R#FP8
MQO,38'%AD$P,W=J^N;N&T-N8@"[)[]/U?U5"$;3TO4V9XXVEM.>;=E.NXTLD
M](/N'N?"1]OKTO-QK=YR#5>TJ)Q@LE%$G&,:6[EJZ;]&/5*V4$B7D'N W4:F
M07\MAI]OMI5&ZQ(]XJ ;3A_FV[:Q6-I!^A<F69.+O'+#UHL-=96; ]>QM$QU
MRMUHSPQN4^TNF5)MKD67H48,$E/QT>$@5],LQ32'M%1.D!V/\1/OZ>_76KIV
M $VI_P#'OC_<Y/-^'<@9MQ&^'(]'P9D2BY O!YF=-5[?F?&^5\;T[&&48<LV
M_C8V86O>)H1S*Q[OY:U5%NZ=$6125*9/5RS [F\/MX?TU:!4W4=*ZI+#)$%-
M 7)V3=L'C(0@NR"H.X"HIZAVG(,Q\A@VW* ;  ;"&JEVG4BY^WW52WE(VZ"K
M[%FW4.*ZI7#PC=,55%#S*"AU.H FF4Y!1.3R*"!=RE*&V^X:AF(T&GZ*J505
MN=36-MRSS\L651*NQ,UM!RRI:](.$OETR<K!80B'B9&[A 6;\ !(_>!]R&'<
M!]]W&51.@WLGF'F'5=>H]XZ^%;/@/Q.=PD?)DPU.7$/7COOA&]?Q4L5.^/XE
MLP-P-1UK3>?8-+'4_EL[Q"M4>W=RD6LV)49RL57YG+(0KR);/D$:L8)!6 28
M6!XR!=V<2IH*G!3M2,)PZ2!V@R-\?)1LP4_&K-8;@2/-INNH-AXC36O1W$9;
M=O\ .?F>#]1,#(SD@E7_ !4.3E>C$9DE=2,BZ#(+P0R[8UW%T4I=U"E[O</S
M>8H>J3!,:/*RX@H7\K>ALV9+-7+)!,XF8D?^R3J4>'L44X0>>)JY%5<YGRH&
M*14OP;J8@Y*/C99(Q.'5WW76%65BP&OG92+:BPT]G73G\#OO&[)Y#/XX<S'E
MXF3E#),N/Q&-/!.TT4?X@&;-CRHR[I(MJKZ:D%H]7\C4/AN#8R^0ZC)8GRHE
M",T'YX*VAF^7>EN#FOK'-!PL0BY>IJUY*4(U:J"X<J$.D]3.83BHDDH;)_,Y
M6CAG3(Q_6)&Y/0 V;OB8Z>:USH.J^&I Z5OJ3GP\?Q/)\3SO!/R[N@GQ1PT*
M'$2<#UI92J%9A$7E&Q%(>)@ NUW01U</D]*H;V^9(X]9NBZWBBL?.K)8Z_D^
M-DS,J[5I*3M$P[^9L9,]FLJ3$TH_,H4#G%^0H *8&%L(9F+ZF5E#%P<S%:?(
M?:JM$1=G 518C:M[+_P^WXJZCM;%Y?N?NI>V^TN[NVLGE^>SO2BAGXV2(-/D
MQQXL*".2,8^.6$< 6X!A8D[R/6IB'S!AMM1\=/EL19<A*!R#NM,=86N#W(#R
M>E[_ )2M57FSX_8-#-R/[A IRSN061,X,4B;/U8'740$HMBY0X[DGS)D&3CM
MEX43^L@C"B.-'7U">B-M ! ZFV@/6NN?L/ZBY'<_+XF!SW S]Q=H<=F+R^*N
M D,>'Q^+DPC.E<-Z>)-Z*1JZH"SS&,B))05F9B$R=AQRSBWC_!G*J*J;6^%Q
MJ.3I">R&PQ6I<HN]_P .UIN0O1VBTHS(G>F!X@57H)-5%1 K@P; HGF/@\DK
M%$R\ Y#0^IZ86,R["GJ;0E['\,[[+<CP]AZ0]C?46/(G@A[H[%FYZ7BOS$<<
MD&!)R8PY<+Y_TDP@PC<G"<906'=(!K$"-R-OQ-V5ZTG[DB7B,H[68K6<K^ZP
MIZ8S>OH/^VQB,CZYXW+8PG9V&.HH7<H&5[S@58P=IC\G% AAB)Y&P(6R-O(#
M:&U@=NU6T]WL]GEG#P,4\/QQ@[^7'PW3&$>',,MTCE\DAC"(QQQ##,%4V)(L
MI9 ;JNL6!L@X@R=5XK%T#B7)U!89<L9K7C,^6YG(M5JF:(RKQ2]B^?8UR&RK
M\E(2LO 1D4WE&T:Z!B5^BDH^1!5),^^ZY;#Y' G;D)\B"5\=-LGHK&[0EF"[
M9(RP #$E"PW;20IL2*^W?4CLOZ@=C\Q/WYS_ #W"\IG<'A_+\BO%PX&3D\.^
M3*N.,?D<%IXTCBF>5\63(B,WHR,N-(4=ULOBI'&#S(MRHU?J&0YP,#=B^;IB
MLYMOB]?H"[A"WR#U6/),,(>3NZ$&SAT_CC43$3E$G30P@[9)]]#KGKAQY4LD
M*?-Z0JT$8:2VP"^TD)N+?Q'X2K?"QM3GXO?4?:''=R9F?Q.%_FBXX>+(X?!7
M(SE4XJ()&A>6/",[S-Y<A@6QF@G ,&2^UCDSIQUJ6$4LO!0,L3N",FVNMMZ;
M>&V1?FZT^XD[5(UNM-&]9DW"L_5)"8DGSLSU@DS079 W.8_8*"(DRORSELGD
MOD/6@3E(8R70QE=HVAF)(%F  6S$D&_O-=./IE]6^:^I#=@S\SPL'U2X; R&
MRL$X/HK L>-'D9#ODQJ(<F.*-(A#.TK)-ZBA=PED#7X'D9BNLV6/64XZ<DV4
M%6KI8<+SN0KK/W*4QA5[O89<N,)B'L%RD6TM4FZ+*S3;J.6>%6*DU=J_")@5
M/VS+PW(30L/G,(R/&LRQHJ"5D4>J&5!9S=5# 6N0->@JK/\ I3]0.9X:5%[L
M[,DS\WCH.7@P<2#%CY')PX(OS&*:'$C:/*8OC0Q3K$4+21+J 46\DL8_'KR(
MN<U6\-9LL-3IU@R# K7.O9.DV\3'EPK;WU.L\2UC[0ZBG+%!0U1=)*E8M#MU
M2$ &PB($,G@N^8LD44^3BID2)&P1H@2?60.INH-_C!&YKC^+W\CE\CW##R7&
M\7R_<';F+W%R&)@3KB3<<CR.>7Q4R\:4R8ZR!R!E1LIFE#H6O,+;E:]BO,%0
MMT)C.O5+B!FN\4R8K;*P46V9*IMA*TBU+6*UA710R3EB#91KN!=MCLCQRB*A
MUGH'^!/O(4IXS^-R<>6:;)Y+&BR5<JZ1NMSL\O\ =Q$D,#NW @!?$ZU;[[^F
MW<'"\GS'+<_]0.W>-Y^#+>#,QN/RX!(XQK0*3@<7,SK,K>LLZR*%BMYG 8LJ
MJP9HQOBG.GKK7A2_8SNLM42ND;<^L#U>F59B:8KV'8J1M[&OL9-"GTB5F2Q$
M6E,(QZR $ BI=TDE5$:8>,S<_BMF/DQ3XRR6VA0'8V:8A"Q&]P-[%"P-[CJ0
M#C<=]->]N]_II\GP/<7%\UVU!G;&QTA1<[(?TI^5E3%DR'C.7F11'*R'Q'G5
MR=T9.^1%D1\B*?2^,&%K/F&\4.S2=*KJ\4VFB8[SOD=VE"PDR1U&)RQD',*R
M?&,XM4JR9@5NFY$4G@N?A,W(4*N'R,GG.33CL:9%R7!(]2"/5EUMHQ_@#'4C
M4;?XC5SZ3<WW+]9OJ'A?3WMKE,'_ ##E+(T39_"\>OJ30E9#%=)G46QHII;R
M-&-\(ALPE8U7<;%BC".5\!-&V/,FVJP9H8)2.,8QEE=R_;3,S!UYU9['%O8U
MV_!D^K]2@%$'B;UYV-5W#DQ$ [P* QCPY_)X&6S30I%C-:4F( JK-M4W N&=
M@18:@ 7ZU';W"]_?4?LGNG)?E^&Q.+[=D,?(LW&)&T$4TZX^.ZRHFY)LF</$
MT,(]1$C#2^4DB$8++N%K?#4]:.XX\KHN S&:H5_&TC.S=HI>/KZM+-BS, A#
MRP(-Z<TF)B.!0S%-T#=.5.0R93&,L3S[67CN3QY9 ^9Q[38V]I H5Y([&S;A
M\9 -MQ%]G7P-OI?)?3OZC<)G9\6=W=V-+RW;WS4_(18\.-EYF$(V]*9IH[ME
MO%%(0)FB,C8RLKD*(V])_DRYARW7:J/F>$<^S,9E67_*M>D(Y_<:QCRS7B$8
M.R34!"6ERA!T.V.HN'HBYFS@7_;)+1ZWHU7*9$SAB?EW)8^+(CY6(KXZ[F!"
M-(J$C:Q3S2*"T@N-OE##<%-ZYH_3_O\ [:[7SL?/[E[6AR.#@^9GB>/%R,W&
MPY9%,,TN,K39V,LDN:@D0PWQTGC^8CA=G4S.W-'82I5GR%*8 O3RO0U?DT<B
ML\CY!);3(4N@P#.VM[HK#R(*4U$Y)%!4AG*105$D?W% ZIA(76'U.3R8\.++
MB$S,#&8X]GGD8ILN//TMH=/-[-:^=O//]3.X</M/B.Z>*CY?(RHS@-@X)Q2<
MO-F?%;$66.V408RI$;':#/M.V,!BP(G+6.,_6>HXU/Q"RW1GC%1"[0\=XE,/
M.WE)EY2"K\GDAC'G;UUK98>"D&D.F_; H=ZP6%KY4D_P3&RY,#-XF"3,_,<>
M4-Y"?[[S@,PC)NQ5F!<J;68;K$ZUT?(]E=X_2OAL[O&?OW@>2Q9%;#FE5OS0
M)F11S3QX#ONR#!+-&V6T$A589U$VR1_Q%"2XY)P]=:!F/E8B[-9:G@=2S5VT
MR=-RCE*%GW#N@($BX&/+6"U"%9/8>483(NV;UN!D'!) SIL9R4Y3EG&P^1Q,
MK'X)@4GR@K*'BC86?5CNWL;@K8J=?+M('2JN![)^I';G=';_ -$HB<7F^Z!C
MSXT>9QW&RPJF<?5GD.2<N9TFB>(130R6D0P""58BI4MJSSN%("H<>)>RXYRT
MXLO(S(Q8C&D*QS1.O'TM\QK"]IK5A2FRNDF3:/D68M@3[O$BW(_6!=0/*=-6
M_#%R<F3EQ0S8XAPX;R,8% %FVLI6U[C7[RHL.A&VX/ ^H?-]P=W<;QW*\ G%
M=H<.9>1G;B(42+T\E<;(@,.TNTD;^H3;>TA@C]./R*Z,5AR$Q#?I2B6.+P!R
M=@HJ^-HZ&QY;)*3LF/J9;)V%K"R$/!1]U1:)-9N0E82O*+IE5=G.\-'*J-BG
M<'\3C+?A^1Q$EA?+P6DB),B@+(Z*6%V*7NH!:V@L-P!(477>Y?T@^I'9F/RG
M'97=G9>3)QK22Y^-'%CYV7BQ39(:6>3#9RT,<<LZQL4C"Q>O&LS+"N^&0;):
M<6.>+T#G]QB#+41C)JTE,B,GJ%]E O#FE6V J21IR-<197,ZBTG6231NV0=K
M%4*9L)3;',EWX4$.>.=?B%R<=LZXC(],;-Z,_E-_+<&Y) /73QKF^.X/O4_6
MG)^E<//\#-WVTD6 RM@QG"&9BSY1,$BRE82T3&5Y'C4K^(&4[5D 6X[,E;)B
M4EJUQ@Y54]]364#985AE5]?*5#R$HRL%=06AHT[MJ1M.N%SNW;IR@JX.0Y&)
M3 FD"JRA8S!Z$8BGSL"1)"RL8@CD JVIL?+:P (&F[J; '6]X)-V_P ;#QO,
M][]B\CA<E+/C3OQD>#F2I$\&01+*%8M J[(HHW6,,K3$%W,<:G*6WD)C ;G+
MX.D^*=@B<A63:C+_ "IO5X-25D+?"627JM<DK9$-$V]<LU^K%7>N6!%7:?<F
MD(*'(=1 BMO'X?/&,O)IGHV*GXGF+M8(5#,$8W98V=0U@=>EP"1C]O?27O2?
MMS%^H^+WUB3]OX5\Q/5;)F418DV/%DY*8LSELB'!R,F&/(*Q,-[71759&CG9
M+#:A:O5JPC14X*BIR41;#0=ARW:XVZURR3C8[:P'64B(5ZVD95BC(N6R2(R"
MB3H3F H)'-K5_F0,\F092^5M9-RPH495-UZD$ V!)V@CWU\BE^HV1A=Q\ASW
MYG)D]S-#+BF3'XK%DP\B"!@T!19ID9(I#'')(1 KQA5-W -V!'X+3L$1<Y%3
M"^78F8KD>>,IL6\SM*O6EQ>N'2+#9NN]<D;0B+@&B2BIGPB4&RAR^(RBBI39
M3\J8I(D&5C-&[7<B  H+7\!=NIM;Q'6P%=MF_49(<KCDP.Y.WI</*F$F7(G"
M1(^& AD-U5=TQ!9E"16)E53ZBA(V7"MZ\2/ADZF^XQYL!NXL9G*BCG*<0Z53
M4=QIXU-4LD^E7\U!1C-NN51-%$$S('$1(8QQ4(>Z9]\OKKG8VX);2)AT-^@
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MVP]+EDXEK;L3WBR6J1?T).XXTR#+N5O 2-5<J1*LDY51:*-BM@[SBLJ//_\
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ML8FY$%6Q_D>@V#*\]/1#2F5TDC EAKQ$1LP29C2KKMV4BX: F^1(=Z8&=?\
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M_P ['PG<',<MQ_;W-8'=&5R$PRA/R<D\',&?(S?0E&*TF.V-GQ0RI!:Y2:0
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M\F1CAFC@"_">*'^.RC&&,V.?2.U]NZSCZ_V"6RK*562LP2$# +V[Y,_3:Q+
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M8^1E>3(5%AD4D%E=;% P4 (6BVM;V#4DWKN1],U9#_Z)+S.:%B&S15KQJXF
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M(AN^08S@/9669(Q:$( -Q1<I)%<HB G\*S@X7AEVR!+)G8FYAK:([1:Y%UL
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MZ[._34!VW^H]S*8'GBOF#3C=Q.39P;F<D9.2@U$\949%P=RS?E,>.5D/$47
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MBKI]KAZ\;4:4HTI1I2C2E&E*-*4:4HTI1I2C2E)'[L&#%Z^,05"LVCEV9,#
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M&E*-*4:4KX( (" @ @(;" ]0$!]H"'O =* D&XZT             &P  >P
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MB[]X]3>9'8$1%@MQYB"XO:MIDG%XW%;-YZ&*3G9X7$<+':8D;;M/I[=H!_$
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M#SKJ AI$C<@JJHF51.H9NH8BC8P&Z'@XSB*5R]SQEE"3"VV=&6\;@:KZA7V
M!K;A>]ZTO-2MDC_#A4E527B-P8G5K.NOF]-3[2;7MI:N['TY4I0?J3\T'/RD
M(^KK\>>+IZZX4CX<KA]Y<<451X5:99IDEI,6)?$F/K#*B!MQ3/VCKX)]1'B_
MZ6\"BECE#D,[>"6T_&DMH3M!/CM ]]?;NQ0X^HG,-<&$X&&18#_PTZ'J1]Y-
M=^=? :^V4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4
M:4HTI1I2C2E1PI&F'+K27_*S0Q"8XD(W\ZC+B#]$REFC'058L#ZGM.T<@EZL
M7?A$2G2!/O#N[1Z-<D?Y1?$^:<,>21_EO3\IM"Z^OZMM&6_I^GNU#%K:7KBG
MPF/U%CY'Y",J.%DC^=];\0$Y4;?*^ANU1K>J9MFC($W:V,CZYRNUKQD\H'*\
M!RU^I)8:3+O0L[+DWQBD';56%!O%,G,=3;TMV/G*L@ 6M@NB!5Q9KII,2N")
M'5(Z2341/[.[:BCRNS>U\?.4##_+.0\P:[:R1WL+>1ATW"YL3:Q(KR;W+-)B
M=T]PY.%8Y*YV";$$#1).NOF^[0=+W J.E91_'0]HHV)6$+"6W.,<YS9CQA&1
M8Y#R 96I1CDU@Q.TE[<Y- UIS5KRI/N:XGV-QFFQ4UNU ZBQ39*8\,N7%G<[
MOEQN/_PTVYO3B =@(\@! 6=601[VMY6T%[7&#\S*F/+A<1LBRN0_Q$0 ]27R
MJ2\-S95=7+[%O9A[+U-N"8*#Q=C* N=?6ITED"XQ"5U99"8>&:B\>8\?,5(V
MG1./[.Z7=QXJ]RCE27DVY4>Q=4[9NH8R9S&T_/Y$G+<G-C2>J..Q7],P%B&E
ME%F=Y$N"%M8(IN"OF-KBMUPF/%Q?'Q20&)LV5/4$P%PD9NJJC&^O4L18AM!T
M-3%R,9<9JY@VHW?E7FM3&F48H%1PI9H-U*S]U=4)1!1Z+5*@UTLU(S=:"Z"4
MS>464CQCU4@11>=B1FJNB[:?NG+YR;![+PQD\/,/\3$P1(ED^'29K!)-G55!
M)N;KKNK>=P1=LXW"0YO=62T',(?\.ZEFF*?%K&OQ)NZ$D6T\VEJU)P!/?3)O
MF4:S4+WR"R$6M2#6"G%J3DNF73#L!9Y^=B#LI5R>]/)BULH*FJ0ZB98AP9:(
M.LW5**C],J'F7Z_N3"^K.!QLN?A<?CB:-RAD@FBGD10=/(%1GDN?-8-:VBF]
MAR/!2_3;-Y%,7+Y#(,)(;;-%)"C,1J"]V 33RL; WU;2YWKR4]GHF\V&K91"
MOY%J[]1G8;)1IZ.8KQH0K83H(34,5FY,:M#&P/C/$NF!FY61.P"B"8 77!</
M!A38J9'%F3'SX_*)U8J=^A;>#:]VN&#D@F]_979\F^5'DMBYXCFP)?.T;#==
M=0NPCI8$%2@'A7/E(9#C3DC)\ZZFJ_8\-49I%*SOSBF1=T2G_P"*+2>84:C7
M* (^6ME1NLAB3(#Y9\@T4*U"&^<KI*F2<)@G]%V8G=G&8F/%$R]P2NP4K(4"
M+ 5:66-[;&C$R* 3KZAC4C0FN##Y7;')94S2+^2Q*-P*AM[3!A'$RWWK(8G)
M( ML#D'45)?'1O*53E;Q4QHBDU9F@<PL;)D)_"6%_8F,QD&Q-T'CN"CYZ4<N
MW#VC5!H 1H)K@JB_=O7#Q$C)1%$YM=W"L>9VERW+3;V:3"*0JX"LD2,%]5E7
M02.?.-IT4 &]S6P[?#8W<W&<;'M!3++R%6+ R,-WIJS:E%'E-QUN1:PKUP*;
MBFV,)2$W:M?A(("F4?3I[E3$!V$A?8&W00UY"']XVM]3^^O5:@[!IX#]U6=5
M4HTI64$.^,1V#<R:ZY/U H0AP#V^\2CJR3:2YZ5='05CB=#E$>FP[C_)[=76
MU4_=5M?B%9*4_KU!Z?B&*H&WO!0@'W_^2U:CZU6W2J8T?B6('M4;KEV_4GWA
M_E+J9*)T-(%1 3F$/T?\@:K3X:I;K2]4!-'(=!W376*._P"Z8B1R_P"4HZMK
M\=7#\/Z*0H[^0HA[2B!M_P!0A_[=7'^&K:=:4R0"#U<1#H<_D ?<(*@"F_\
M,;41VVU+^%7V.QDUT]^IFROZ]R'*K_R)ZMR#6_A52U\32(4OF7W*B B!2@(
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M311 Q6_>4 +T$ZH]P!WJF#[QQ]P!T+OL'VC'3KUJ;^RK[DY6Z[@X=IUS*JB
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M6*2[1<K)\@I^0[(5-2/?F36]&_*<P>)8"&%(P]P .VMQV[_^4.#_ .]P^_\
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M%)=90;$-HP/L(.M_=:DRKYE'"=([MJF\( ^85'*!!:AMN8@%.H404V$!$P]
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M!Z+F.8%)!U#>4C[P;$5:46;(J>)9PW15#;=)5=))0.X ,7=,YRG#N*8!#IU
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M ,B6J8AK>AL129JEY%4P /:H0FW7]HP .JI2!I11II7UZ8%':YP]AE#=O^J
M[%V_1VAJJ.Q05! O2EN7Q-GAQV_W?QEV^U90A1]O^COJU?<X^^JB-*QH  C_
M "ZOFP%4 5DG0@FW9I[!U(HL.W7[Y^PO_P BGJRB[B2*GI2=N3S*D3 -Q.8I
M0W_TC%#[?TZ-Y:FAZH55PJ8 _P!H?8?M*!A /9[>FKB+8:U3UI)L&J["EA1L
M&EA2PJ#N3QB$XZ9L$2$.8<4Y)\7D$_85?\AV84CF[$'1A*40Z[)J#L/0IAV
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M6LBW0.B0#=Z:CE4J)3LU";+C,7DLA((\'),OK,XCO$&9FC =Q<M<E5*DW]H
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M)>JE4K38FBCT"1[]BW3<*D\)DFBIT+Z29F+\CQ8R8%Y809!>&2.WJ+(PVPL
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M[\>Z_EW'ETP).XEK&8^%M_A\=%1SE/VB&/EC 6#K&C87D\NSKE=1^:7G%K!
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M+B+&+MTFV<,%53 D59NJ4P!K%BS,[,FD9(8C'M6#:)(@0QD5EL9 Q>Y6PN&
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M/2Q:>.W#F3^:.>*68HV3=O M3].I958P->6,WDP,T@B,6[^)[&IC.E5ACSD
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MLUJ+FYN;L8VBZXBC8"IL&[2/,Y!5*07%RF':0AU121'#RN)YO'D$V5.T<<9
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MIJGPD''66&M5CH!;#;,@VR&O3&J6 E9LS9G7*MC2U'.@E93D;*)/FS5'S;%
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M.C'0,5$J.RMB'$ZB,:=!(BIG $6VTO#<WAH/6R$VEE0:1.S,WE TD)NQ:U_
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M;<NGQ:$5'3[P( Y9S^/,O8F]4U=/73&:J3G(-82@GK23D%&$1=:]%1AIH[J
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M78C?*Y=K,[RMJQ)\TDDDA]KNS'5B:S.K5:ZC2E:^\KFOK.->=&_B(OWXBR<
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M8RA%/.]:J&$#**I-LMYX@'5['/V!GB+Q#9$?*&+;_#Q%CT:W2YQ?3E#+HQP
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M<I6H")#")U0_"'V&(W, _&(^WR* .P#[MAU32K;<!4[F_N5_J_L*L4!$FWV
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MVM0,:OEI&<P;(S:XS%>K^1$\&7ENJ8DLUDL59CDG4VE"GA'<_%UOQKMEYU0
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M.2W =SMBR8LLKM^/ J!E4@F#<;[5MI<#>G\Q(KH>X_ICQ_;V..6[?$ZY$42
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MN.K47.<C$BQ[E=5-_.H>_LONO>W@*UW&?63O[B\*#C_F(,O&@E]0?-PIELS
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M%?EN0>83"1E.ALOE73IY!9?OTUN;]:YK+^J'?65R@Y5>0FQY%:,B+')@QKQ
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MMLM<A!87-S>PL^TD_$)UE0#\$VQ2#N'<L._:78=MP)]X?T!K$KE:%-ER"N
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M6.0;[9\@MU'E+Q8O8H$K.5IN.*I'OD%IYPB[1>/WZAFQOP"B<+6!C\?-Q_\
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MY]7[(LNY=)Q$<\,\W!)),O6YT7'<5 .Z^,B3Y59!#DF,#TI)I%O#D0H#92Y
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M(<GX,?)U]A7EZ3>[;<$F#Z(QQDW)F.9&C5R(I[QO)2#1')JUF?.A^9^J:MY
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MZF VXK;#_P!![0'V[Z@ZU-(UTS$.)3;F,41W$/V@'8P&*._4# .^JA:I%+0
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MW%,@=O9T#RG-_LO>&VW4=2=:DFJ71!\NX#WE4W4(?IN8IS#U'W=P#T$/<(:
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MV.TEXN"74<JIF22/ON0RH\GN'A>7PY7;CIH@(IU;<[L6+->]QZJZ1DZW224
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M*M-OQ!% WW%>F_3\,Q0W!3<1^$"_M?:&^IJ*I=&V4%/80(E^&F4?W?;W;_\
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M;47&Z^G2H@A*5GZ;OEJL?-/"63LDXM8Y+R? S50Q6C.6ZO7*^QN'>*]-QAR
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M\1L!:X)-_;I;I6+BR5>2GIZ:BXJ5!PSN"T;:+?8F$[E'%#NXJ/[ ]Q^K%QM
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M_< B7;H(=-144D:"!#F7-OL@7O /9NJ(@"11'W?&._Z0#4U-7%2E6*9P4 W
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M]VGNJ:J,!W":1PW,H4W@/MU$=_C2.8?=\.X"(_9I[J4%6(@)4TA**13#YS
M""VX;'#<?V"E'I^GKIUJ*^> I%%0.;9%+;<_3<Q#;"D!-]MS*E]GZ.NE*J%3
MU!%$Q  %/\5$@!T*0-@.F4?T!L;_ )H_;J*50G^"4%C;"<P?@D'8=@Z@*X@.
M^X!^R ^T>NII0M^)XEB["*WPG .@^H+T.&P@'WP #!]N^G[J5<*=-N;P&$.Y
M3\-T.^_:0_PBD78?:G[3"'M$-O8&HZTI/X1.MX>G<43;F,/:4I0ZB<WV% OQ
M?JU-*4B8BB1T$_NH!YDAWZG  [5C"'7<3 /< >X U%*Q@?>V]V^W\@]-32E;
MK=0B2_3X]R*;?]*F !_\D00'].^E*MME 2.4XAN &V,'VD$-C!^H2CI2J'"?
MB6.3K\(]!'WE$ ,0?Y2B Z4JSI2C2E&E*@/E*JDGQUS0*I%C;XRR*4OIW;2/
M<@;\AV4P>E?/V[QDT=&*42IJ*I*ID.8!,0P!VCN^W;_GF(5T(R(OU^HM:?GP
M#PN4&Z>A*/T;#7CRI+)_,*LB8V8VMBV=)MF<5%2]H@)*8<V0BY%) WGCZ)%
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MYEA9.IS$S*HO7CZZ-FU%5N#P\!%Q4BJ1M;9&A89(X":C$&TS()5]NF#M51%
MFA %2-YT!Z4[:WQ7^GI)XO\ G$/C/"YL?69A9X$LX[L#@B#D^8;?2,E7%DYL
M$G9!E(R[6W(%,@9EPH=TC-!-LD7'>1SW'&-*B[7M3EQ[AKB[QLR/$2F.&,5C
MZ::T2P8V- Q$VNYK\+$S%NLF;;7:\C+/7;]^TLENM3-ZY<V&QO16?NP,B54R
M[@_D:7JHW(UJK_A9X,.&#QE%XTPF[C,EKA7G35I+LUD[D^C<Q3/)0\(S%O/B
M,R\9YLLCVUBBV$RY)%R=0P=@@72PJ S>/V\*;%3XX\ D,U94@:OB?&!<SVU&
M#RODS\N(RJK]):(S SNS-\JZCY,\/4':N9XE*=DH=B+ 9"63!X];+'-Y!:?I
MH2W7PK[G_%W%"\95B,DYHN-%?$DX!MQ,N-%F9B'D:UD.0MF1ZMEC%M2MB#-X
M$G!6RFY!HZ\C#]QF_P"&^>E6#L$#$&U%)M8??5:7'?Z>V>VM,R/&43#-Y'(%
MAM7(*I3S2678O[_+73\KOL@71%LTF8J3L]?L+RDQ"LW'/$5XA9>);'<MO(@4
M2R+5%W&GZ*<<]Q?X-Y0K,1C6QX]Q!:((<AY+R/6ZW%61%.34R!D.5L4QFB9A
MW%>L3>PN37-_89(;,P17%F_2<K(O$#([IA&E 6&M.%KQIXCV6R3,ZWQMB6<F
MYF?R2G/2<6[:NUG,[>,:U;#>6&SE)A+&10D)?%53B(*4; F0R$<S0*)$AV,*
MI)-J8Z_T_."2CAU;$>.^+2A+UAQ3W;L%Y4D.XKEGQ.WP'(M&S-.?3KX%N.'B
M-JT[=H(E=2D<BV1655,BW,1:@9NA-9"\\.>#ERG;"C;,5XR<6S)#O'*<LF-F
MD82R62=PS4']*H3N -$6B+FX^W4ND>KA@=Q8H2*T051DX45;D%(*@!^@U 9J
MENA4GCKAW\]/\:L,98[5<+4UID=S!2\-%-6KW'5#AZ'2XBSE-(^G@GE5QS66
M3%FBJ"!DV+,NX#VB;4:"]-3UJ#)7@/\ 3VC6UHNLE@;#< UN-AK62+%<_7K5
MMHA-L[)(VJ%L%5M32?C4:(DM:[2^D?'!N(YF_=R;A51-4[E03Q86)\*;FZ7-
M2!7^%O"RJ1\*S@<*8FA(RGJ8V85AJ4B9F$";#;>_S>,(U!NZD%6I4*,TRA8'
M4>V,442,I=<1(*)@[8TIN-1"EPY^G:PQP[Q\CC#!2>-F-DKV5E6(W03-*],5
MIBK2JK8V%C6N1IBJ0$'".U8!@W:O6L0A&N58Q-$&ZQVYZ@MZG>U_&]2T_P"/
M/%68QOC;C*ZQ_C8^.L9.J5:L38A8RI8\:8YQ<_:3M'GZ5&Q4VTLL<6HNG"*S
M==LIV)HK@4PBBKVFG;]U1N\=:AEG@WZ=%Q;6O'S3'N%'47C>O5?#DN4K]2,A
MZ]#7.]?QVJ50K%N"=:-B2I\G,PL#)6)>_,X^<2*9)5%8A2!&VIW-UUK;K&M6
MQIC:M1F)<61]=KU>H#)*.9TFOR*3UQ6V[]X^=%^9ME7[^:3>2\D+I91P^,9P
M\="LH<ZBGD-J=IZ5&Z^IK4OD%C/Z?^6<KX#LV<\:8OS'EBX6Y7&V'9-O$JWE
M],R./E7607L19R59ZM"35.QG(,3RBQ+$1W&0KXY3E(FX6 #05J0QL;7M34L&
M(?IA2N9,K1ECQ_@MWEO,3S(&,LQ!().D$9.8?5S'-\R97+ JL_;5:HV&ZP5E
MK3V67:@Q>V)0R)%U7*R"A$VVI#-:XO:L_G?AUQ"Y*4++V+YB!A,>6S,DYGFO
MN[HS:-(;(ZF0<DTV QWFJY4>+N*AVEHE+'2:Y'L73E%FZ8KLFJ8E "[F,VU
M<@W'A44Y9X[_ $KL4L&F)LD<<XF890D)=\JVZ*IF-<OY*D*M1,CQK:DWZ^YC
MFJ&G/2L=CFXP]$1CU&\\X68.65<(5NU,WB=VT$6H"YU!K<1]Q]XS'6EY'&2&
M-:)E2(=6W,=1R)%!7;/8<=7_ "WBI+$#W-1J]8Y!W&R#JPX^3;QW=))&8/V3
M<$S;@8PC%O&FX^/2H,X\6KA5P+XFQ&&L=9/0L&*.-!+! W.X14<-D</+VN]K
M%PMGSL]%ADH,]YO=ES$P7CXR/2*5TI(^G9$$C90B,@VJ"&8W/4U*W'3$F(J,
MTJT_7[79GM[N=SY,WU;\\+FHUGOEKS/DIC;<I3,KC-T6,7>&JKZLLXR+$&ZA
M8N%9I]AC%6%4\C2H-_W51*XTX-R,P]JJ\3B>:G^2LKDN(/'M+&K,&R-,HO(W
M)^66D,:-FG3>%DV5@@6<^\!B=BNWEDRO"=CQ03FC2I\WZJ>%2XX\4D:O9EJQ
M0Z!,5V\0.1X>VSR%@?6=E9HN^N*XKDU.?MK^PRKF:=VI_08T\PZ6>'757CRF
M44\@',,VOTIN;QO2&L8'XDQ4RWO4+5L:'D;'<&DQ 2J=L/+MW5RKENE;@BQH
M2;RROXB#^77R2>2;F*A$F[,TJJHLLV,OU!87M0DG2J*AA?B/07%<MU%@L8Q3
M<+"S>46PA<B2D7'RS*+ME&C("@NYFSR$5#PD+'Y%FXME Q/ABF7SAPF@T346
MT \MZ;FZ&FV?AMP@8HR==1QQ0F<A3F])5>)I7ZS,+!CZ)K VP^.D(B03NR%E
MQM7*H%RER0*#-:/8L49%P1DFFFH)1BPIN8FD%5PIP<R]6Y<M9I&/WE7H5@_(
M,@YK3V;IWRUY1*V7%!:_'S$),P3M>HJU% (10J*YX:;8D\:P.P#30U)+5,&7
ML+<?\J+4ZCY4J-*FQAF4XQQ_5G<JK7)$:RM%LXRTUR$C(*7@Y29H\E!-6Z$S
M#]KB(>-44BO&ZA$R=KW4%QJ*50U2XZ5E12\0;?%T3(4BV6V74L;"=AF[6HV_
M*J,6SN!W#PLK\OB)RY(E9$.W/XQ.0R0)$#N* STJ-3I494_''#[)T9)WBNUC
M'\LVY+8]LUXF2R;Y]'2=[QMEU&I25VG'=1FI5K(0]?N9ZG$N)8Z+-HF=XU!1
M;9P94QVE#N'Z*D*FX]XXUG)$Y?,:-:&A?K7'V"POGD#<2RBIHZRV%*0O$_!5
MC\P/H6L1]KN,.1Q./(MDT)*2C4%'JBJY!$ M4>8BU0O8L*<":!CW(V5K15,:
M1N/+$PLUPL5P86B8DDG+J)M$GFRQR.,WD59G;N&M+B]0CBQK%J(M)%U-LR.M
MCND4S$@VJ?->WC6<M> N*=#@:KD); RDJSQ>T@"UF.Q]3;[>[ LW;VQS<J^^
ME*)459.1R:]@;S/N[$F[F&4JXC99VZE .FX467&HC;0%CXU"=&:?3AS[%8_8
MQ..DX%O?L<PB^.&MUIV5,$&R#BRE5NIXQK@PKBQFI;BXU%_2<E1=>(T,=P6P
MQ9TV:R;M!D!$*=*GSBMG+IC?C5G@:C#Y$J%6GW$ K=JQ3ZQ/J/Z=-NH*$DTJ
MQ?*PPK3:1K\I:L92:U8;D?1BJ#RO2C5JV55052*B8)TZ5%F%,/,F2.(&+&&5
M<#WVNO'U;NK"5N/(*%JF,LB7>FU.O9A=R#%];LU3U,AY2.QRQNQXQTJ+ETY:
M*)-V:KLA46R!W!&EZ@!CYA3Z>8-XJ/H.8IDQ4<:+Q=.A;BUE8V2L*2[RJ,<M
M6Z$R7;WLO(.9\\W O[K=:RPG@DW"Z3PTDR1>-UR*D*H BEVZU#LYE+@Y3<'W
MRBN5*[:\'-9N<HMZ@(^)LF48NTWVU9)B*5-TZ2DG0SLM=\G6C)5O:[@J[=2;
ME=;UI5O$B+A-86JOS7]].*%XT<++-1H6!:8X@$FUL*MEST%HL-UALOR .:X:
MEO++9)RP6EOF11C^3%A@GR$@^,S)&;L%D_3AXM+#I47:].)M5^'!Y^HT]G&8
M<5E+_'Y/N=+AH-]&JL+!#PF/:KAC*\Q #"OS09(Z+QBO%5]\1(R:2,>4J:9"
M^)0Q%A^NEV/MIDT[A+Q$B8W)5C"LUC(M?RM*7FR/[%,38R%9BJM;7,"Z?150
M=1LRG7:W&PK>F1B)9EAZ:6\42V\SPQFQ!*"WUJ-Y\:?5=P+PX80\DUC*CBQ>
M,RZRE8AX^<V\9Y7*(VR;A9B;0&P2MHE)&Y2-IG:JT7=+D<.73MXS QSF4 ^\
MD "H):])\)0F),59-S%C^'O#"XYQS!;[7R0RNY:P\)%/5A0&D8R8MY-G5T A
MX0U0KK2!BTFKI49-X(*OU@.HX7.$6UMXU5NT]U;3>0OV#_D_SZJVFHW"CR%^
MP?\ )_GTVFFX5 /*@Q3<<LU !A(/\+LCB7<J(@80H%I$"CYC F4 'XMQWV[?
MLWUONUQ_]0X(/_KD/_,6M%W-KP.7;_U67_T&KR$0%N=5K$,A(M7#^SR6)P8L
MB0KZ?E6S"PXDR)/P[2\5E]\A;/[/8OEUI1;/XDP%,<KV<D5797+599/7LK,X
MU.0YU8'(A@S222$4E,B$$Q/YBJKO7RN.FU%"V8 UY(Q>1.'PK2Q[I)L,!0"Y
M :"6WJ*=H+-L;5#UW,Q-Q>MF./E7KM!D,FU2I&DBW*U56&M]5F+"HPK-PN'&
MV]5YQF<7V+JT2:<34G,1 H.&US*8CF77%D9QZ-)HH<A.6[BY6?E%Q<[/5?RZ
M*9XG";FCCS87]$>N=HT;0P:[ &L3NM?IN!P8N-ER,7"TSS"DB;K;Y,25?5/I
M"YU743=6)%P-MZG&H\AJ'QJJS295J3[(N4<O53(#&AXW;R$$VC;!CIVU\-GR
M)>;!(L+% 4C$Y/1^G47=1ZJKQXKZ9N@82KG)SV9VUR/>&2^-ZJXW%8,J&7(V
MDLDI/EBB52K23V-P P55NS$:7W>+SO'=L0KD!&R.0SHG$<!-A)';S2.S JD-
MQ:Y&XFP ZVU0-DCD?"QT;E"3^G1Q&)16=_G[22II9%E"V)DFE!!*F=/)1?(\
MM$OJND5)5=I''CG7BDF2ACL.PXIK]D>([3R'?A8NZ.9^?^550QA7TVNQ\H41
MA@]SYCO!V-\?LYE.1[B1%YANWN*^2^99MN]MX(47))E*[0!IY;;A\/MVRR%G
MO'_(AG.9/CX25I%ZQU,U6JYIH,\XBQDL;BUA6T'4;/'RT:C&QUSQM;H.,*I
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MJM%M!MU>>FK-:FIFJQMLOM3.^2<A7OFTFZD*\DP?H*M6R3QL96.:WQ8)@R#
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M^RQ'Z[WK6_Z@>2Q>6^L>3R.#B8L!D7#+QPRYF7"\GHQ;B&S(8,EU8V4HT8)
M^)BQ8Z4_3=D733(-NCJ^@O9(5[4JI'3<XTNM-2:A$0PVUU6<K6N!9S4K*97O
MF3GZRK-[=8X$HZ3!H02$ $C:Z7O-%;$C>6R2"5R%*/?<=@:)6( B2(6*PM=E
MOJ=:]#_ZN,2"?M; R^49<3D(\[)DAA;$RRWJR_++D<;C3/#''QN%QZ!98>)G
M+3X_JL&8EQ47<F;'CZL<A<RVBQS-2R V0R+',' Y/Q7F"XR6.PJ.&:=<<AU^
MB.Z3FBKPX8VQG3P9V&8>?)&HHR-F*V3-)NU03+G\+!F3\/C00I)$QAN/2EA0
M2;YG2-I \+'U)'O&@WGRQ%CL45VGT>XCNGF?I7V_PW$X^=Q<S<3(Z_EW)<7B
MQYWS7+96+@SYBY?$Y$OS_(97JX.+%\W(&@X\S,,.!-Q[T%,4Y2G*.Y3% Q1^
MTI@W ?Y0'7RCII7YDD%25/4&JM*BC2E1LI& .7VDS^5'9A)C:0C/SP$H<&*(
M*6>,=?E0T+MV'=N12]8#K?<I$13_ &M=(N5_](/A_-H >21_EMGF-H'7U_4Z
M[5OZ>SQ+;O"N)?!!^H\?)_E\A(X22+Y[U3L6^5$_RGH="[6]82]0$*>-23KF
MZ[:O%MS(< ?DI]39)6'BH91/D-QI*>PE:S1UYUNK2LA%:IOUUW3F+>%:F_ *
MBS:HK <2E%4YS%*/M?LA3_EKM8I([$\?G^72R_BQ?#I<$];DGW6KR)WAKSO<
MMU4;<_"L==?PY>NMB/N /A6J=4GSQ9,4-B@E8ZU+YAI\W+61>-)*/(#(L2M9
M&+*DQT1NJ>'<W>$<M54Y=ZU43%%(3E%)DV54#K^0@6?YV4ADRTP9$6,$ 20L
M$W2,U@"$8$;!XD:%F%<GC3&)<1+JT#Y<9:2Q/IR@M9 +W!=;'<?V*#6Y&%;*
M>A\[+0$?9VL'W8VG9Q*"DXR=MS?+5NK&+'=PJSV/9LEC+PUF;6BO Z<61!4(
M=5=N=1LH=J[,@O\ .N7QOS#Z:8TN1%O(RXXPZLJG'B:<1NA)'F78Q7TCYQ<;
MO,MQWW$S'!^H$\<+%5;'9BK*6$TJP&1'M?ROO&[?\/6VC6*_Z7]+B,A5;'&7
M;-=F%YL]<QYD[)$J[M=1R#88"&N4==IF53;R["&;NY6QR<(H*WS)!DS(2615
MZ+.1[0"GZMYD_$Y^7PN+ ^/Q\DV-"HCDC5VAV6.PD6C5@%MN.A.H%5_37"BY
M)(.5R9EFRXX\F9O45RJRAKC>!JY4ECY1J!I?2MGE,KY(YQ\>LP.L\X8K^"['
MB6KXJGZ/&,\:Y#86RRQD]7UC+YB@I%>MPU?6JV1#.5U8&"653D(P$3"LH3M,
M#CC9.-PNPNX\-.V\]^1@RFD62TL;1J=P_ <*S-OB-M[_  L;6'LZG\RR^\^"
MRFYW$3 GQ5B:/\.178%;^LA8*NR378A\RB]S[>?L%>GT/A[ZCM#;9G:MZW6>
M0N)$*',R%=MZCA=WD*#L%6O6-8:7DEO34>?7J6/V;-S-/U%$')V)R$>"#TZJ
MOU7)XR'([B[8S)<)_F<CCLDS+ZB-?TG#1S. /Q5#R$A% MN!VC;8?.,;,EQ^
MWN>QH\E/0CSH!$P1P;R*R21QDG\,E$ +,2#8ZG=<MVRS+FG8OXER=3JS23MG
MJ3SM5H3]O(/DW4V>H2TJJ*<RY!G-5FSQ[IPSM#F24.W92"=E C(BH,G!$J,"
M,YG/\[#FSLF*H"/,+'RB1;+;HRFQA":E2EGL64FUGLV%P_"_*0[LAF+I"UQY
MBI!:XU5A<2EC:X;R_"163X<MXAAS<P+&1UG2G8J/S!&H Y!LGW/5$VK\[Y)-
MY'G")?HIOW CYV@BW<BFFJ79,5 <['O1\F3L+/EEB].9L(W%^FJ[;@Z@V T/
M2Y!Z"V+VE'!%WM@Q12^K",L:GQ-C>QZ$7)U'6P/MO[1#"4$&8I[^/T;02 8.
MT>STR?9N4  "CV[=-NFO#)UE:_\ ,?WU[0C $:@=-H_<*M]_Z/\ +_\ &U7L
M%3>HESYCI]F/!F9<1QDFRA)'*&+KWCYA,R2#AU'Q+RWUJ2@6TD^:M-G3AHR6
M? HH1,>\Q"B!>NH,>E2#8WJ#>/W#IOAC+5?RNV>4=.3;CS)<W9_ UDT58+L?
MDOR"J.8*6::F2HINI@,>0]?4CU0>'6 %U@,T[$N\!QV%FL:KW7%ONK1*+^G7
MEG)-)GDY\V-,)2K6^9UE(-A6HZ686K,#"U\Z(SD;#)\AYR-:OFJL"_K6/6K6
M/%H6953)85G:B"8)GC5J_3(!-3O%_;_LJ4H7Z9*D10,DLY@^*K%;[U1J-7ZN
MYEC7Y<*'(UODGF#D#9HFM9)0%G=Z[#S*F1V#=!U&,FK(LG&^I6@U8_MB1I1=
MQ]]J%M?NK&4GZ<V4X1S!I3=[PO,K+6?$]Q?Y ;T=Q%Y0QF&(;+9YN+QEB)W7
M:Y5JR>G72/F4F,[)"T@%7:K^=>*1BZDMXF\M&1:@<6K8[!_"A#!U*R#CV$GZ
M[4V-ZXFX%XZO)+&-?&L2$9>,4T')U(L^6D")"U1>34V:]M'#)=4XOP^6$*NL
M(%2$LI%N6YJ"^OZ:BO$7T]9"#R%BS(&0V7'PD/BR6QZ_-B['%%DPQ[,NL4X'
MS%B.MY-/&V9DW;H95GI[*K5\NJ9LJ$;'0+)LF\>+HD<EHVFX4]+U);J!>GKE
M3AQ/9%Y-3>9'88?<TNR3O&FR3,C)U>;DLXP[+CDO;)*4HM1DBHC!+UO+Y;":
M*D"J.FHH13N12.B\%X4J%QHR#ITJ WEMXUC.-G%.XMN'>:<=W><M-,O'(6MW
MO&M=GK!%MVN0\:X&KE5DL+\9J[9XR/G'J 6:I8L9M)27;)/@.>:E)#=5-50P
MEMA=U&;S7'2HCE/IXYS<&RQ9Z9(<4\<6#+]8R_C>0I5,JU]C<9TNL9?X[86P
MB[L\*BQCHV1FK1%3&&49 &:C1@S=LY#TQW)%FH.G,:_IJK</?:G(/#&XP_(G
M%L>19>3Q_+9#R7E#D%8&$"5O3+1CJO7RL98P#BQ_)2,B5XYOM<SI7D'_ (46
M:S92O/)8JBB95B$.VGPJ-P(J1>2O"/).<^0U>RU'7O'\11X27X^S3074$NVO
M<>&)+S.V.V0ZC^,KYW]I-;X^?52CU'<ZT8PQC+D&-<@Z.Y).I-O&H#!5M4''
M^G5F^>J$#%VRZ\?WDW2J)@7$M/5;5Z\NXM&J8:P)R>P(\MKU[*,C/XVYSK;D
M*A/-6C1$6K%S#@S,Z5 Y7H4D$:54''44ZY?Z;DS59=G)4%#CO*P,?$5B/:X8
MR%1Y9'#KQ^3CFQP/9+W)0U=CGR1KFU5AT'<<L#(YW,6N\8K+-E%TW20*3TJ-
M]^OVUJBN?3CO5"I3,F-KOB"?S-#W:ZVU'(F6,>/9Y"]H2O$];C?44,H-$3/)
M&S&K4BJ:9,R77<LCD,*!1,<ZAS2R;?NJ=^MCTJ/5_I>6Y9[BU5&5Q=48^JP#
M&JV>&K%ER*5,TLVS4WS78\Y1<LQJ-7DYK,62I]PX&;23-7&R3QG&*MWGI6OH
M E8R=:;ZVNXE<.;=QXR9(7J<>8E>0[/"T1A5A+T.NS41D'(QH3*5ER$3)V8)
M!^1)BZN,LA8Q3>$0,\ 9-1VZ!V<CHJ#:FVM03?2M8:%]-+*T-D")O-HN&"+,
M_B;3AB:6B$Z@_CZ]8W&,\Y6[(\[.E@8JH0<+2G-@J=\?-V3%%O+K,I)/=S*/
MDW2JJ4[3:YJ2XZ:U]@?ID9)K]:KM-4M&"6Z+"#PDQ_B)%U:SHY%HJ?']C/0\
M+#XG6*S0:1%6S''N$7-F2,Y;^@=S-@3(24*^243=2!3<";U)-=^F+#5QK75Z
MT\QE4)NOMN(#2'LE/HQ86RUYEQUKEI@LB.JA(-VR3F)?Y"<VQV[;BF8@&.LJ
M+T5?(?4%;'W4WWZ^^M=&?TWLJXIQM7JC5+"+[*\U9L&8K@,CX^">FHZIXPKU
M*R'BC/63\@C9UZDPJ+JXX/R;/&9(,&LH^;65G#IJ2$H*;86JVE_?4EA^BNFF
M2,/WC(G':9Q+%1=!QO-P%OJ2V)XP5I67HI*9@G-%6NF'65@-&E^:1S>UU''D
M<VE"M"K*1AW:@I$5%$$C+5%Q>]:!?\ V>)?.=S?VUMA8(^[MH"]V#-+"%L*M
M@QM8)'FGE?D8^JV!7CTJDJG;8*!>QC)Q(R 1;95RX;2!!.""D::0"?T4##[?
M=3WJ?TSII.U8ED;N_P '255P_+T0K^+A*5+K2/(*%IURN%S)D3.#>70-%R&5
M_F$T@9'<9-NF^=R[P7>SU-NA%O"A;J*FFV\)K%*\-<.\<X^8I,O8<16"$L$8
M_>N+748!-O 25R+%)U:0AXZQFK[V#B;*5!LE(P5AACMD%&JT:=-5-5NMI:H!
M\UZ@>T?3ASW:Z'+8F>Y8PJZI]B:GL\]9FU%L%:G'.0G?T_)/A,I%1E(KA6M)
MKM!1=G;SZ1FIR* V.I')M40336,\+5.\7]_]MZ?F8_IL1LT%NGL;(8NI,G,<
MD<:9C@H"&KB5$A).BX^XXUS![;$-CGJY5K$ZBX-C96;VTQ16\4_CF\D"!S,A
M6.HX)4@))4=:C?IK[/Z:CF"^EP:)IA:^E>:M"W TO3@1RA 0%@<7VNTR"X96
M3C!*5FM6:P2;^T@U;V"R*2T:@O(^G".2*@IV*B'9=](U'J?;]-1S;/I;9*M[
MB4GE)CCO3UY(X1BF*\;1]YIF)7,>O@.NX07N$FLA6GLHXNC+\N>J;H(QR #$
MR#B-"016*$DK3Z36]]_MXU/J#WUO-B[ATPQSA#D7BMM8V4=:N0+O*Z$EF"L1
M+IO>$(Z\5(U0J3^<FI-\XL5BL5&9*"LB=S(K"!Q'L7[CG5&OT=.M4%[D'V5%
M6%^#$_2<TX_S7:$<#5U>D/DQ3QWARFRT?3&",5@J4P\RM5;6FX^/<QETM#Z2
M2=RIP;I$1C8N.9%6>*-O4G@1'QTUJ2^EA>DF3?I^#D_+&7KG/AAV0J60)7-=
MJK[":I;B5GFEMS!Q?Q=Q^3D+$BYCSPSE6G2V.EY-L\144=*MIA9,"I*E,988
MKDZT#V  ^VM,6$^G3DR!OF+[LSR+C1U,5+(C.VV"V2,1892:5A&N3(#(3^$3
MJEFC+/3[2[F$HYTBTD _+DW 2C@)!"4=$*#$M+)M(J=X(Z5NK?L*<A(?*V0<
MN\<K?BB!DLXXSH6/+L&68:TRRM#D\7/+V:E9)H[>NK TMJB,3D-V1]7)/T#5
MVLQ;*DD$"J.DU;3'72BD%=;UI!;?I:WBU6[/$K,91KMB:Y<#,"Z%ELXV56QR
MPYN&FC,5*YTN%:QU4"K0;*M*H(!ZN304;(QR;=A'&:"L>+55O&E/&]?36>6"
MW9+/776%JYCNW7VUVJK5>/HBB/I&]J7X=O7,--0C&/2KW97G'&9^DT5;=Y5D
MYI(3$2%);R5 "^M _P!]_P#;5UO]/_)%=E[J]K]@X[3JE\6LZS.X9-QC+WFQ
M84?_ ,4<_9'KR&)H$Z[2)<,9)+-+9&3*N^CTV[MH]6!*02>$;H05(.M-P]]0
M[&_2ERA\EM[5]DC%T#*W..M]?4>5Z(EW\GCV+OG%!QQSE;'2I-A5J$P1L:$Z
MQCI!)FSBH-H,2=1EWD5;HNEEJG?KTJ>X_AS?\;\)>:^,6+6 L60,\T+*AJ[2
M:E+ST[75K#+X)C\80%>8NK6UI;11>QN8-([H&T;"-"IK)IJF7635?KU7T(M5
M-Q<4Q7_TT)>^R>2+%;WN&*/*7_&>;:36:GC"CR;RCX7MN2Z#QTQ[ W/':$RW
MA'+65<1F#WJM@5;IQCU=&:!FW6'Q+.UVWRW\*D/;VTR\B\ \R3.0(YVUQ]Q<
M+'Y3KG)EM:(5M5IUS@C JEUQ-QQPS R>/XSY;&34AD2PHT"0F5%4HR-;N@14
M8'7:F L@O2 33<+>-*F7TGK.L\R6RFLH05TKUL3O236TWEY;9FWW>.R#E7%F
M19VNY(K*31G6GS.*A<?*Q@+*O9LKT/1'2;Q@(+$7$:TWZ7I[J<+[!%<C\9L(
M!@FUQ5+Y1RWE?,ZM?J[6)QX_Q/%9*KV8N.F%%%%'K?\ [YU#-D$V=%:M&"K(
MU><RI3&2*LF0]9C(_54>II[ZE7.?!^T9)Y7P/(5&\Q_R0XX >.XJ8F+4PGJ*
M]P%;[1:B%I#:OM"MI9*]JV J;I-Q*1*+)4%SN4I9!P+,D(NYK>%0'LMJA^L_
M30EZ43"SFD$P#,K8IQ)@BCV'&]MHTBQQ3ENXXTH7(6A6O(%W9Q48]7>RCA+-
M[>2AWCIH]>@XBE$'!B NBY;RZ;;?=4^I<:TPU/I=7]+&K'$Z=ZPUXTJ/263G
M+7Y1M+;*D/.TWB"7BZ?%U5,4[E-C@&<?H?.3(*2(.VS&1DF(LW"SDKXDK$2+
MT]2S4[\G?3 G;=.W@N-+7B[!U NF)I/'+Y:FUE^>7]0\P>SQ2W9,JDZC%&%+
M,I+L$G3^9JTU!#*0/DC'D4NX44DS4%3NM4^I8>TTU9[Z8^09:B7>&:RF!'\Q
MDJI\@J3)U;(B%]R%CW&P9NKN(X%KD[';E>$@UE<DUPV)2'6*VAJVT=DDMRJI
M+MUW$B*V%Z@/KK>U=DH=A/1\8^:V880SDKN5907R4\D=%S7$Q,UKSN7^8D25
M+,F8 4SXJ("V%<1!$1)UU4/,-:IO:N:ME^G6\NF%\6XXG;'CJ7LN)>!=OXJ5
MVS3E1>2B</D:P/,/N(W*U6([36?03:)'&AC$%$4Y-,RR(I*%$AM4$:VJK=K?
MPO5$7P%R#7.05#R_&W/&I!A<KV[(%FD5X>;E+&[K-@Y!YUS*A2DZS9(RR5)Q
M,FALQFCFEBC'%7F8%V+Q8595!9%JBM4[KBU3[><*<AJUE/+E]X_WK%-99<AH
M['Y;N^R=7;/.V?&%QQ]7OR$2]8_BHG:OWL)*C),RIP<VK',V\HR!P=PX0<K-
M2U(I)TJDD6L?"M-V'TNIE_D&SR]LO%0NE6F,L/;TX/:_S//RV0*U:N7&+^2]
MCIV1J@:-CZ<=",AZ I M166GD':AFRR:<4@5PU7EU*FU5![C2GT/TZ91OD:[
M32SS#K2C2.8([(%6K[*D.RK##(<NL-\G'L=/QRL>2!3EF<5CN2K3-1J*R)D'
M#90_C3\R):TCNMS5)?P\;?T4S('Z<>5ZSC:RX_@[+QHG9*9Q_!1[?+61<52M
MVO\ 3YN!X^-<"+4>H,)9%>&;8MF@:GDQ6='=&9IRTHV/$/1= N6V5\UA56\>
M^FD]^EYDB6JES@ELC8SAI"]N^1X+R3)C9923IT-G*H\:F[.*@[ G7ZP>3_[U
M<>W#2P C'P;60@;0\%N@BL06ZU9C-M:@.+_HK:.#X<7NM<1\PX.BK#0(R[9C
MO$S>?[>G+9"QY"?,YFD&D:V?\Y5DS=V:<@Z@H"CY&KMV+.4D1?%B'"J2OJX1
M+J?;4%AN!\*@&N?2\GD(2XM;9:,6RM@E8/-#2BO'->F9TV-IW+&>Z+FMG)Q$
MM*1D8[1?5XU3.V5?,&D:LX>F3=(H-2B**<%3:WLJ?4K87C3PXM>!,TR=]FI#
M$KZ(CL5WG%,=.U*OSC#*F2C6K-P9=0O>9)=^BE&O;,U0,HT<$04?>=^LY>E7
M(1T#5N13<7JEF!72M_N_]'^7_P"-K(V"J+T=_P"C_+_\;38*7J!.4ZA2<<,W
M&%(%3FQ1DLB/3N.DL;']J BR)?&J)E2  [ !1WW'H(=!W/;2_P#U%@@?^N0_
M\Q:TO<9_^ YG_NLO_H-7BHK4P\BJY>9.$%A<I1"E2L3(5E8O9$#0['6)EM9[
M.J@J[C59]*J+F:2*S5 X('*'J5]VY4PU[OSX/4GQ8I=T4/S*N)!\1F1U9(Q8
M':9-5#'I\(U->*<&5H8<B:';)D>@R^F?A]-E(>3J-PCT:PZ_$=*GW(L^C7X'
MB?<H2U!4%V:,>#/);J.D/15^-C(BL)$0D::W9D0DH"=9-5Y%"M&;_.P5<+$=
M-U$7B93\;PN/\QE=P8&7$)H2Q8P;EW%R7.X/_"ZG:/5OL.T$&ZDUU'*R_*XO
M"YN/*T4Q4 36-E4!!MV]60C<?3MN\Q!%B!4[NXEKG/GIRMI]CN15(FL96X\X
M[I=!;UBY-HM+'$)4TF;*6%@NX4^452:CU%2^A5/(O&+I?R^$HB"PZ%9INWOI
MIQ'(\; 3/)#E2RS&1#^*TEB/:\BGX6%ETZVTKH&A@YSO[D<+.FVQI+CQ11B-
MP#&L=P1?X$(O==2;]+ZUT@8YMR%;N04KP;FL)49IQS;3=PH$=G8F*LLM(BT.
MH+$E;D$<-QKA2GC*1F1Z^Y>N922LSI52)?L@[4P4 125^6R\)@8?;"=\X_(S
MGN9E63Y7UX3(EYG7YAK-K$U@JQ*/4#:G34?1(>7S<KN)NS9\''' ;VC^8]&4
M(UH4;T5N-)1<LTA.PKH/?S-Q>LAB#G#B^DL<F TK-LP'RNBLBPTE1[G,Q=5A
MX=&X7.+N;ZK-W"YK96&TUCR*,UC&YTU% C#F5:%!T<5_K/++^<]A9G)38C+E
M8_*89QY!*B[RQ2-HT8_W9=';<6N+M>^@M\WXY5XGO.#!CEOAR\?DB9"CL$VJ
M[AW ^,*Z+M ULMK:F^OE-D$WG'+DY<IV:1EI&8D'XS=^6;O+$C<UUXAC(I3C
MB&724;O:M&3TNE%EBVJ9I-BK;@=.@0;M%_3]%R$13NKAL""$"%8KI"I"&(W8
M;;Z>=E!D]1CM(A*K=F%^;PI;=N<KG33;IV>S3,"1)T.ZQOY5+>GL W R@FP4
MVBG),@\EEVLQ,*MZA9I:N(H/J2U(1XWJL#"-BUNDD;+H+R)HY=W",T':;%X8
MZK,QTQ+WMCE25Z+B%*1&"#\7'CE)$QT,K,"TEQ;4*]U+#X@"?BU&AY5MZB6?
M\+)>, Q==B@A4\=-RV8*>AZ"QL?07],Y=F;ZD7-%NTB6;8R/'#B6+F;2/.@[
MF#FQ?1_ @X1DGSN. L6W[2 +8J9RBH)5>\P ;7G/ZE!O^F'!,TC$GDL_R';9
M?QI.EA?7WD^ZOO\ V 5_ZA<LJJ!;CL+S:W/X2>TVT]P^^O0?KSW7W&C2E&E*
MU&YD8VPWD['M=ALV9-IV+*VQN*$E&S=V1Q8XBW\T,!/1P1*"66XJ7KQGCB+?
MN3_@I [%),X ;QBH ]#VYF\E@YCR<9!)/,8[%4]6X7<IO^$0UK@=3:]O&U?=
MOH!W=]0.S>ZLOD/IUP_(<UR\F 8Y(<0\DLB1>M"_JD\9)%/M61(QYV]/<RDC
M>$(:N)[)5V7&C*L+A/)Z&?&6)262DPLG!&H>.H*+>0]$KDXRI]6L.+(.FU%&
M(@8J;;*ED&0BHFNLJD9R55$02OY\,[\W!+R<!Q&R"KL&]21B#(REV65G>[%2
M-I\ #ML==UWQQ',Y'U@X3D?J)PS=L9'.G'RYHYOG<^:1)<R>%\K)@Y*;+RC+
M-)#(I@ELK(J.(2DEWBS@V2FMKE9&^+07F<>I5ES -[*OEJS34PNM3BT)DQ?7
M7$LK,OHVMS%DE9:<;L)+T[>049P"A5N])= =9_=!R6QD;/LN67#;?251Y_4)
M"2@ L% 0LMRMY!;4&NU_U(MS\W;^'+WIMQ^ZFS%G;''&8\40&4<UW3$Y.*))
M,B+'CBPWGQ][P++FJ4VO'(*CR >0SCE6LZ81SQUE9/*KN5OL"^SS:824@X]6
MYU3'=:95*/:V$(_(\*?&#-W8Y>&4;K1C9&+%H9-!<$2%S)5E' A68#C_ )<!
M&$"L&.QI&+DK>,^J1&CW#$MNN1<UU7*0<A%]$E@RI8T[(/"+'A3)PN--',XQ
M,G.R'R7:#U,"8<B\6!BY:NN1(^0)PTD?J,7KS+/5'V8JK%750(R1<5ZNP.,S
MS.7+'C^H2(6JX)*Y,L$M)U^?AU:.]HL!66SMD[1%-_(N !-N=4Z14R8W;?S"
M<;(^+YEWLTEH5D<;$_#4!E.\.S$$&ZJ-2 #<\]_I^'-XW8.;F]NCUL5<J>;D
M!%Q<&=E1_+8I''P11SP2C,3,GR)(I8FW001W>545RS23R.E8X_''#[G*L?9:
MG37JV/Y;)JC;($N^G:FO#5O\U1T-(RC-^VDLB*N;G$M&#IPJ98IP$[Y4GP>1
M/"X:-QS.2, I)D@2"+\,!7W-L+ $$1V0E@!;^4>P\A])<++7ZM<_#V3+AYW<
M$:YL7'AL&)(<D2Y'RTDL<;HT> %Q)9)HT4(19<9&\VQKV#'UBB.)U^=0E;0]
M=&1DY)5EA!9UG+M"/U9&AUZQ2#>M9$EIUZ[J,?6++*/XDS1J^(U9.XM8[4Z:
M:I!+'*)#)S\*RN=K,H8M J,+2,HW1A0'+*%>Y6Y# -<@U1]2<;B<_P"N'%P\
MCF-\M--#'D/-PT.),@CS9X$;(P8X47*?(QXX<D2R0F2:+(C6=7=&!C[@V2FM
MKE9&^+07F<>I5ES -[*OEJS34PNM3BT)DQ?77$LK,OHVMS%DE9:<;L)+T[>0
M49P"A5N])= =9?=!R6QD;/LN67#;?251Y_4)"2@ L% 0LMRMY!;4&NI_U(MS
M\W;^'+WIMQ^ZFS%G;''&8\40&4<UW3$Y.*)),B+'CBPWGQ][P++FJ4VO'(*C
MR >0SCE6LZ81SQUE9/*KN5OL"^SS:824@X]6YU3'=:95*/:V$(_(\*?&#-W8
MY>&4;K1C9&+%H9-!<$2%S)5E' A68#C_ )<!&$"L&.QI&+DK>,^J1&CW#$MN
MN1<UU7*0<A%]$E@RI8T[(/"+'A3)PN--',XQ,G.R'R7:#U,"8<B\6!BY:NN1
M(^0)PTD?J,6;]0>H,)//M9688SK61K19:YC"/0KEEKS*0:6A"OY#EWI8X9>4
MX8YQ)&LXE!\NY<^FM\6()_$JT .PSG)[1R&3B) \[PP(\IW*Q&TM&!>PS(+D
MV %X6]S?R]#_ *6.>R</Z7YD>3S&7Q/#8>7R+F?'G=&QVGP8DW^E'W7PYD:4
MHD<?J<7D7;1)R=PBZSXA?O93$^,9*1BY6$D)#'U->O8><)'I344[<UV.6<1\
MNE$PU=BTI)FJ<4URMH]@@54I@(V0+LD7Y_R*+'R$Z(RL@F< K?:0&.HN6-CX
M79C;JQZUX:[\QL?"[XYG$Q)H<G%BY7+1)82YBD59Y KQ&66>0QL &0R3S.5(
M+2R&[LY755J[YR_>/JW /'<H,(,FZ=0\<X<R(UEZ>2K@OUUFYU78U^14,NQ\
M@F](L83I=IA$=65R)T4*CN%7=8 D ;A9K:Z;AHWM&AK40<WS6-#%CXV7E1P0
M^MZ:K+(JQ_,((Y]@# +Z\8"3;0/50!7W#2N3GU4[@XK1L61KF3BFD)9JQE&'
M0BW\O*"TLEN=C3FU<@KG7F6?,&L6^+'Z"[M.<G'GSEM&E.DD=!,KD15[[L/'
M6;UW"L94DB-P!=4&\LR,8)SZHTV(-A;4W-M/</\ HHX&+EUYK+AAG?D</-XZ
M4R)%'NQ\5?FFGFQ)WX7F';D4*Q-AX<7RDDY#NLCF$!-DN2"-BKG"Y=C=H@^7
MYTJ5"8RK+&$6I3F;Y-_<X0C-:%BHFIYN<M(.N,5T04])%2IUV[8RA2HE.)T=
M-PIAF[E#8S?+Q?B$&4[R+(U]Q+P@LQO:[K8FUS;7Y'])'XKEO]0JY/;LXX'C
M2<UXWY&093(4Q)BPEDER>(5IIW5MOJ9.,$>0(6D*A9,QPC;.D>,::'R.XPT>
M:RY44K$5E*N-:A8ORN[M\\YKI)R,B*[6%BH?+ER)BX-%-'*Q"B<2*B(+*V^Y
MV4\Y??&S[(MQB8NNX(N[:2S>.MMQ Z7'0:__ %%S0R?6,R_,X&1E##XT9$G'
M3ME0?,KBPK.89)9\@%O4!8(,F6-"0H9 #&FC_P!,>J1S[*.0Y.7E:[)SV.*9
M0HNM-ZWDC,2R]<@9MI9&YJFE2[/DJSPLGBR!=F>MH):39HNB.T%U44_8H3I^
M]YW3!A2-7$4TLA;='#YF!4[MZQJPE8;2X4D6(!/@?1W^L;F\O&[+XK#P(,N'
MC.6Y#-DR&R,#B@)YH6QV&2<O'X_'ECY*9?1DS%QY6C,3QI(_5&P/.:H95QWG
MR9RM"56&L<)D^/)%1+FMUVDV6RS4GCY#'<G 8DGBJ\,,IR[6R7>PH>K@$Y&P
M+,SGAA.HY:@BW22N]KY.!E\2N!)(R30-<[F=5 D,@:5?\9$"J+I)MC!\^@:Y
M)V?^FWGNR>Z_IAC]D\CFY&)R/#2^I*N1/EX^/%'G'.CGY.&W=G'1-CX<#>EF
MM!@I*!E[5AG,DKOW6U\LK\U:-*4:4J,E&"8YD9RGY>G#*EQE(L M@/#!6DDU
M+5%N!KRD?X>TTXN9,')%O)N#=,Q>WKN'3+.W^37Q?F(-IY-&]#;^,2(''K![
M_P!T+["MOC(-_"N&?$0_4N//^3RC(."DC^;W_P"& .5$WRYCVV]=K>J'W:1J
MR[=;U)NN9KN:\5'.D\FAR)^IHQ>V%,R1\[\;9=E"NYJ5=KP422EWD55E8\#!
M'P4?,+N"*H*(!YE"'4[S!MKV[]/7@3@.U9%CL1@9ZEK"SL9(R #XD6M8^->0
M.^5F;F.Y8R^GSV$P%]0 C]1T -^HUM6J5):O*O+X9C[DV&$JC"W&S_D\K])P
MRB655QTY15KU><F8/U'C.<>PR#YTQ82$&Y45)/HR+79,JBA>KY3(3D(<Y^.;
MU,OTQA06 )+S?WCFX%U5K LKV!B*G72N5P<>3#FPH\X;,4R'*F-R $C^!="?
M,=; H39PP]M;"4>WR..D87,9&$Q)YKS:RJ]WDIHSB*5QQC2H%?JNX[#E0381
M31K/1WR]DQ9S#UOZ0&J[,&#<YVGK$E>3RL#\S+\%>*/MSC3)"$))FGE"@')D
MUNK7+,@UN#N-FVD=/C9QP!'RH]5^<SBLQ<6$44>I&.G\PL KG2Q\HNMZ<437
MLH\4Y-OG7$V*+SD#$%;=2-EQ>CA>$)8;9C8;%,/W=AQ[F6I(+JE1C(*3\SZ!
MLRL:[;R;5#PNP%0H GB-E\-WC#_EWFLN#&YB0*D[91"I,(P/2EQI.NYP )(P
MP(8DJ;=<I,3E>UY%YOA\66?C(RSQ""[/$9"3)'.FOE4DE'*D$  Z]);S%STR
M=SK3AL1XRP'R<ND<A5H&<DBNJ(UJT&UN\3%2CLU>M]M:(5M&K59)XY2:2DTJ
M\!B#<KI=HW*!RZT_"_3_ (?L%WYGE^4XI)!.Z#9+ZC^BU@62.[!I"-53;NOM
M!-;7F.].6[SA7B>.X_DFB:)"28]JB4:V=[+MC!T9]UK7(%1$=@EA!H]Q7>(6
M'R!(7^5M4[R0''SHD%!VJT3\-$UPC2E2IT'1BU_&\3%(*1<H3=X_E4#.P72]
M6L0=ZLTG<K?F?&2-AQXJ1)A>L-SQQJ2^YP"//*U]R?"(R%L=HMIVBB[?B''<
MBJY4DSR-EB(V5V("@(UCY8A:S]2P+7&ZH*R&YF,<PD71:_(N+G.<<,A5._U=
MP^:)#DZS87R;4XPLC3YNI0)*R92;I5J=E@G<6:5,D\8RI?"FJQ0-V;_BXUY'
M(EY;.5<:/E,22&0J088\N"2XD1CN\DR@RAMMU9#>S&M'R4GR.,.,PV?(GX[)
M26,M?U7QY4U1E%M8V/IVW6*G2ZBGOQ!K4E4^?6 H4R)"Q;?+[!W7W"CIJZ+8
MJPZ"9^1RJ,G&KJPTJ445C(F>-W#AN*Q%DDQ. "74]X\CCYWTWY&9#?(.$=X%
M_(UU#"S ,.FZQ T(-JK[4P)</O\ P$8$P^O= 2-002-02#:^VX)Z$7KVG',/
MC;@( 7^S-MBD,4Y"!Z=/X"G+\)RE]@"'00ZAKPH+;V]MS^^O9Z&T8^X?NJSN
M&KEZFXJ".4KZ[1O&/D9)XTEIB!R)%X*RS*46:KT<:7L$9;(RB3K^"=P480#*
MO9I.1;I^D(0#*>H$@D*8X  TL?*;=:J4C<+]+URRA>3',7%5"R3?Z<_/R'K]
MSL?*E_CZ$FL96D'<03'S*@6&H7YK/-II9X_ITBRE)=\E )-6[59B@FW8G*JD
MH=?%8^8VJ\ IMX5M!3^2.?)GA?F?,2[W'2V0J3;[!!8ZO9H:<D*3::C'RU-:
MDN<XSJ%?DXM5=@2:E6BDG#H/JPFK'IO7)R-4Y!-"]N)CJBR[P!>H*HO(SE+:
M;2TS&RFIQ6JL:IP]IUMQ_/8@4/$Y'/=>:.?\)7BVT9]6;U8:M @SQTLQFPL%
M>,^:3R+2/?G2;1ITFA*([@W%5,% L?MI6.PYS-Y;YFR77L?UR0@X6(O5PQ$J
MC?)O!!SOL=05F9\E)*_5&2JL5='\/"6*%1Q-76YFDY,.YNON98WS,GD<MFI(
M=F.GA0*H%Z9D?SVYI359O4W-Q6,: ]CY6KGL3&:KCY&6PM*R=\NL!)8MD)-_
M%NJ!%S[F!@VIVKR\OHQ-1TDJ<54FTI&*(U*S!+>%"%O:N@=NS+GV<Q5P\G\5
MQQX.RYT*$WDAI:\2ODYU"+@>/-VS"K4TZ:\MSIKC*P7BY5=G"$4D)*43C"R
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M8E)$Z@DGK0JM8#%_*7D]8<OQLK/7"':V;(D+Q6K->Q$WQE>)^L9;@I[/F?\
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ME8<S8(3\58Y BMC/ZY2$)9C":<0,:39<!Y_9#6J/5<>O9J7AVY7N46]KJ;J
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MM%+19O6.BH@FX<12*#TQE-?+%V1ZC02<*3)Z2QLH1 #%>Y4,%#!@H#;[ $W
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MZ]AR4[D$LV-Z?>760J9"949I0K9@O U"TOG Q\=!)0+4C)PLQ435:*J(FK9
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MZY4-M>&.#>>T-0@2U6I5>KD+$$)6Z["0)"P$(A68$I8>-;1Y2PE;:N';6OQ
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MTN:?224[#KP3G#&1J=(/5&IED4W#:P-I%D5V\BDVI(-SK4AA;7K_ &TY^5F
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M.Y&EH"+D,]5TTMA][79&&31<M4L=2N$\B2,\LD "W4ME;C%#)"NH"Q(/NZ5
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M920>U)>3D(E[8D&SPP+*H1@I(]FJFC.!F_D_=.9)-Q,MVQLEU$164>;89PR
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M]VRURUQOD>WRSX&L9,VG'*[SCL*44U#T;L7;N.:=R2[EP;5 :W32IV#J.O\
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M6VBJI-KM,&WQ;Q0R@PQ--QEFGI6'B8*NY"O<X]%ZDKYEX6OQZ>[M1P(B<M-
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M%\'+UW'MGNT1^12).Z&4(B,EI./V  (Z7_%[U!DMY=* >:QZ6_HJ$F?/W/\
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M%VW'IL)EA_FU84 R6/2U5N/96**]1 W:=TW-_HE43,/MZAL3<PZK= !<"H0
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M"/7C&\(J>=-^T41 H?VM,P"X"OYF/E.=^:F411SY&XJJ[PH9N@4AMWW;3?\
ME/2LH]P87U%^M [EY2"/CL'E^=$TD,$'S:0K-.&,<<$D<PGM?;L:&4,2?P''
MX1U2X.&I!;Q9BXL;,7E%2JSBMI3+G*EQF+T4E)+0(^)7OF-)S)%QAXYU/RTM
M/(L)!-HV>H,H0J:I_&[2*.^[H^:.*ASR1E&0-M$2!//ZA.R18T)V@1EEN5)>
MX%U-?;O]2 [C/;>&>]7EC[D;-7(,2\;BQ8=\OYUY5PN0AP,6618(HL)YX6ED
MB>7++(N^!R(Y@I&O/>5)E&<9%.,K-,M/IFZ1DSG>\,7K%%Q=JKCFO-L<)MLN
M+1%Q0;XK9/9J;AW$49@4\8$:+1!7QMT\V5)EX&S,PX\XX"$0(0?(TC&3\*Z?
MBE41PV[S;]Q%R>LY+$Y7'^BFS(FG3LA^#2+$DBX;#='*XF3GSMGEN,$N*6Y)
MX<3$RH\D3$9!R_7E3?*[WYFN*:\S#6H.^!$LWDA6ZU7L>N+)E>XU&EJM+5<B
M+Y.FK<A5\HTE6JK5F!J[9Q$N$6OJY-ZGV).%C( DVQ>VQDKQSRXFXJ'9I-L2
M.]T3\)4W1/NW,Y# FRC4J+W;G?\ 3[%W!C]@Y?(]L^O)!%EY$^<N/QN+E98;
M&Q2O'0XIR..RQDC(FR)$R4>3TL>)MSQ1B4O+)7(R;C$>..&7V5(R3K].=+8_
ME\CHPN3I]S-UUU"58UJBXEA-L+U6Y/)7_?*(:-G#I=^^[VQ5)!1,XD%TAA<-
M$YYG)7 97R0)!'>)0K!GV$E2C"/R$D *NMD!%]IX_P"DW'9C_5KN''[*FARN
M?1<Z+ ,O'PK#.LV3\M)*\+X>1'Q_^$EDD2-(8;2%<564-Z,E6"WTS#<2LANZ
M_!U)-Q'1D]*UU"JYNM%@J+UU)T*NV29)&WN<R%+R]&;5VU2DA&*-F\VQ;(+1
MIW+=1JFX*J#E$BE[@A69Y"&90Q:%5< 2,HO&L8#[E"L"48D,%(8K:GU*QN/Y
M#ZY\5!RN3G&*6:&.<Y/$8T&4BQYL\$1DPX<&*+,:?&C@R%DDQ)I'2=894F:(
MH6%P<-2"WBS%Q8V8O**E5G%;2F7.5+C,7HI*26@1\2O?,:3F2+C#QSJ?EI:>
M182";1L]090A4U3^-VD4<KNCYHXJ'/)&49 VT1($\_J$[)%C0G:!&66Y4E[@
M74UTW^I =QGMO#/>KRQ]R-FKD&)>-Q8L.^7\Z\JX7(0X&++(L$46$\\+2R1/
M+EED7? Y$<P4C7GO*DRC.,BG&5FF6GTS=(R9SO>&+UBBXNU5QS7FV.$VV7%H
MBXH-\5LGLU-P[B*,P*>,"-%H@KXVZ>;*DR\#9F8<><<!"($(/D:1C)^%=/Q2
MJ(X;=YM^XBY/6<EB<KC_ $4V9$TZ=D/P:18DD7#8;HY7$R<^=L\MQ@EQ2W)/
M#B8F5'DB8C(.7Z\J;Y7;W--\Z9\SL1Q*+F@-HJW+8'C;149O,BM/<94;Q>2;
M7*UP;57C97J -6./)YN5Q#>"!FE9F2?^F,1RF0S9.]VTBOVWD2'UC)'ZY5UA
MWB*\:!MK>D]S(NCW= BKN\I.X[;_ $\XT,_^GSG<Z1.4?-P%YF3'RH>*&4O&
MM)@8T4_RT_Y;E;GSH6*9>_,Q%Q((?6#1,PE;L^         ;  =   ]@ 'N
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MBHE)L*E82<IP,M;JA 3[^$(_222=(PAY9BNO!-G22! 5!,Z7>1,H&(.P!J6
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M5"7)X[9WQKSR@8X !<.91!RFKY$5TDCT"S)B<I0+YP'N.&QDRG$>O;OK;=N
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MRX\P!C?KHX%K:=+6^[[Z]@AU5ESID0*9LB5FU RZQ0,J;^RHB)6Z8[%/L(@
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M,.Y=Q#<AONC[AA;$6:JG-S<5D6#YK(M0:RR1C(B4R(&,("JS4*82J('$W0Z
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M/'%VR!BFW1"KI>9S1CJDGKS*Q16\&UM$FUN5!AE$57K5TQ9SK-@O*>8C9%1
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M"X'.ZC%GPHL10133!QERY9X7-QDYZ-H^)S&^:R&4AHS.NUD1T?\ AAC= %L
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M5C8,\TGJ)\NJ @[G4!D8FX1 ;L ? 7KO,+DL7@,&<\VD65Q\@*QPJ4<3EC<
M(QLRC0L]K D>)M6A80^"6%H&Q&^F'C-11I8I>U2,:$/EI2&=5EO%LY$E/80D
MM9GU5:3L/&R2,P*ZD4NF!%4TG#0J*:Y3_1FR^YI</Y+_ #9E;_3$?Q0DB3<0
M79E02%"1LMN!O<ACI7"/%P:Y R&[:@,?J%_^] *6!V*I<IN%]VH(M8%1K6_%
MXR!6\\0$#=\52]2I^%:['HQ[EG/R%8J:&'S4UF>$FH*>AH(S2!JR!YAD=_"H
M(H&)*PSEHHT1,H<R9/FW'<5/V_D2X7,K//W 7+(R!W.2)""K(Y%Y!;22Y\C
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MJ8VQ 3MRDH?PSIX^\U7& VK"K,E7GC)RJ]B#&2=$ 2.8Q<_:@Y(&XBBD<Y5
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M*(@ [";8.GLU<M(1J=*BQI+(N&ZPMEEA>+BF];&W4.@3M*<3H#ML0X%[?/T
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MDCN\>,-LD:FQ/F)8RL1YI"S!B1<'I?'Y+MKCLV5<9,C(/*K)9)9SO20K?0J
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M&[OO"/01U2) _P 6C52+6TZ4K;.@23%NY2%=OW;BD.Y3HF'IW(J;"9$XCU$
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MQ#8?5NVY/BV]@E%L8"F*/VG.H.H$=_XJC<*QYW+1\?N7.\1-M\.QB.42!OU
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MZUA0R-1G3J)7_.M$>J.55&<;&DO,)($5'O!,18(I3(_,WS1UL4XI%-X@,8
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M%ULHQW4.W$X]Y42% R3=HN'[PJK;IJB/<<Q?B'OV,,QIM4N/C^WV-5,P-6'
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M6Z]R%85;*./G-1B8V,I]1S5+XY:25\Q9>EE+K,3T]&6C($LV6AI!=-/Y2G-
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M8D V*$/%F<N2)>%HU,NG\]SU]/Z:8BRR.CR92R&(!6.3$DRRLQN?(@C4G?\
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M<=0!2;+*@@BJH7NW*H@[W4/]A-_LU-M?3/AK^FE_&K$9NUFU$DECI^E9.X]
MA#F(8S9LI'N4A$P;";QA("7[1V'^2&"^GH.IO^N_]5!UI[IOG*Y2 Y(J[(@
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MO0R1CL4FZFI$+#4'7_;5)D!\-#_96#1^EIRFAJU3J]4.0=5+%<?Z\XQ?C1V
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M%N;?4;@=&4VJ-:H:#.&3,Z43<.!=""FYB)NR@@4.UJ3N,1;H"/Q>W[QQT81
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M@#$(1YM][Q( .RH!M\8=VW01FUUN/B/A]WL_32]CK0<!1>)@B05&;=(7)VQ
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MKC6NOW_T&J%Z'[OZ:S./,N8^R1B^YU?&->N\1"UC'$^V8N6LOC^FINA-#R+
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MS"LF!1$=N]01W'[ A@2;+TZ_;[:4O;4U]9%.L39YT!F<4DVI]A'\, .@X=B
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ME[T5K_,80QD595EO%L:[6VAPOF=KA"NP )M(<FXK+./VL4 ./EG(:Z-'YRX
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MSI6-\K5RD8>IPPN)>"&$(;"=&K-4DT(B+J^<>6TO1Z+0*HRLME;6-A )8JQ
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MP+?W!^(F_P#>!1;QKAGR4_ZEQX?S.?ZAX*1_E]O^"(&5$OK%MW_F@3L5=O\
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MQ:EZ;"\2$=_]!-90O\QR!HNE_NJLTG?M]V[M5!46ZID5>\0*!DEO@$/[0GN
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M%"()G4-OV)%W[0^\.W0A"A[1.8VQ0#[1U2!N-A2]A5+=,R:*9#[ IVB=7KL
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MKQ%)<YBB [*$Z#L7?<8/P@C5/'W'^B@__.KX0W:]40<;LG:P^9FNF/<@Z[@
M'"("80*J)3AWBD?8X IN7J'=J3\%QJHZ^[V?[:6]NAJD@BW?*)*B1BY7,*[9
M;<#,WQMMUVI@'M$QR&+W@4VRA0./:(@ Z=4N-5'7VCWTZ'V&D?IA$IXP" V<
MI*>K9-3J"1-84S>5)U&.2B42+-E#]BH  =Q1^("B83:KW:[SJO0G^@CW^%1[
MJQ[1PZBESN$D5E8YRJ(R+$Q2E<QCTPB*B@HAL5L+@0[@ZE;K .Y1*(E 98+(
MMC\8Z'VC^S]8]] 2-?"LN]G@_";Q"(R3MSN")RD4%LD(  G,H %!54R8?>*
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MY"EN:U:)>W6S%4HU&1ATVLI6(IHFO4G%.L+^YB1.55=+I1KE.3:LD%ED6CP
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MS7YDJ\R$['K Y0A+S4Y+R!-( =,&B:"RAU0;D%4-W%-+@X.7QG=S)"\16*<
ME@59+(4MU1Q8H?$D:;M*U$N-#DY>-F]LAI1+NDBW64A@WGW^QD-[CPMUMK6N
MN16<#2;AD3-..(J#E"*WROX^QNZK<A-FQ\YRW:(?\^Y01IN1JJY78_P^I03B
MD4F_4-_O3YD=B\%%J1R3I.,,_,8&)P7*>HB#'DR)@UA*,:,^E!ZL3 'UI0-^
MW3RJVY;FU<[R$46!G9/,\;L<G(CAB9;F,SN/4E,<@-MB?"3[2NUK"]2[Q<F(
M%SSVXXP<<V>OF-)S(M7B2<J]3?RMQL;V0G9.R6J=DHGQQ$JZ?/%"-&Y2D"/8
ML8N/(T2(= %E,#NG$S!].>3RI]@DFPPPVKM$<0VJB*K>92 -[>+.SW-C:L_M
M?+Q7[ZXZ"(,4BRF!).[U'(D+DL/*;L;#P"A;:ZU[#G9@"10-V%2*M&I)E3 >
MXI#$1:JE2 W[0$(8P /O -]>*T!V,+WLY_>17L5OA0] 0/W=*;%UM$!1:E8[
MW:Y$D15:+"2URM,NHBY<)15:K<8\E9^45;LT7#Q=*-B&ZRYB(IJ*F*F(%*8V
MP#6"!>_2U3U.G6M&5OJI\!@PE,\A)'/*E?PE'2=&KXY'MF*,U5"ORTEE!"75
MHP5,UGQW$N[LRF6L([<&=0Z3YJT;("JX423$IAMB:,#??RZ>VKGI/?;;S4_,
MH_4.X887R=6,+93SM6:WDBV1U(DDX,L+;K%%0$?DJ02B,>R%]ME<KLS3\>1]
M[EEB(1"TZ^8)OC'*9,1(8IA-(B-M)U^UJ@1NRWMI3>;_ %&>%K2W99H+?.T?
M\YPC&Y>FKZ)Z9DA>GQ[# [89',[&OWI*H'J=JG<6-SF"9C89](/&HD, (&,
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MLI*0=.L:SR<A1=!)0LM7[/59= &)V)'QR1ELAH1\Z29#*M!6.DF<J17C<QA
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MY'*7.Y"?-5=BS3.X7KM#L6MT'2]N@^ZO*_?G<D/>7?/,]WX^.,3'Y7ELO,6
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M);&=GP]R#N 7-Q7J)C&M76MO:?*8Q?E\4+(R4S,NGZ/23,OMMJV\+/8E[O\
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MZ?\ TNX;:A#_ )MR-VL!<>O-87ZFW]->ANQ"Q^HO)DMY?RK!TOT/I1^'A?\
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M:E!"$3(":9"D(7?8I"E*4-_L*4 #5.O4T_=56E*-*4:4HTI1I2C2E?0$0$!
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M+?KJX3*QNN^*^1"(;[ )L=)JAU]@AW3*OL_1UTW#V _H-+>_]M70RFJ8 /\
MPPY#]@")>N,4Q WL'J(2.^Y=_P#+JG</9^^I_3^VJ#937W[?X4\BE@ZAVEQN
MFGUW$-O_ ++HGV$2C_-J0PZV _0:BQ]NM4CDY<=M\.\@3#N;8'%#> 'PB8!
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M-A]OM[:=.M0SR)W6X]YW%T@F+=;#^3$"-UNT/&"M!LI3.G1A36)T((AXQ*)
M*(]VX]-;3@A;GL#;\7SD/_,73[JTG</FX7,5M%^4F_\ 0:O(A7(20A\<7>[5
MMN^D+*NQAL54Y6"2%_)FF\DKJ1TFLBBSE(&P( E4BO&ZKML=P2.^8IJNTSMC
MG,;VAF9B3<OB\?FE5Q@S9+WL (X=5%R"IW. 0--P!"&XKQ_A021<7DYN(I>8
MA<=0+G<TO4Z&]@O4ZV)N1:MM:+2*U:9^!M4F1M8:EQWCJKCBH152F82=I%_S
MW$XZ8LK_ 'VUD:5&"=0%5I5[B&31FR>H.SS"<.*)T%H_=0_!9N3G8^-+A8:^
MAE\H[SR2.K(\6(TI,$,?G\[2Q$LY4@*'\'KN,3&PLF9,F<^IC\:B0QHC*R2Y
M(C FED&WR*C@! 1YMO3;3RRCAO+F8GW_ !"XYAB7C);J&CH?.],K+J+A,HY"
M+CN$7AJ/FS&;PTB",[8(IBJW:R]<<G4^8)'3>,R%<D, 8/#\_P -PT+=N<JW
MI<0DK-B2N"\$;3,#+CRJ/,L9(9EE6Q7X&-C63RW"\QRSCGN-0S<HT:KD1C:L
ML@C'X<T3'R[P+ H20WQ $BJY?ZE?):Q8=)Q^:<9.7PW%Z5]0%:V&'D2R#"!9
MU@L5%N5Y(*44JI@?*>)9$$T%TV[,3'5\:H %^'Z4]J8_,'N&7EN$/$!5D5O7
MNID+W92N^^T:D>\V\*IF^H?=,G$?E"X'*MR)W1D"*Q"[?*=WI_$- V@T%^AI
M5CS#V4<!+S68;I'Q=,S+:8R6Q]BF ?/(NW7+"^+[7*Q\O9+'D>5*Y>,9;(N0
M7<045(=$5HVOLE'30Z;A5XZ*&)R?/<7W+Z?"X>Y^"CD]:>2Y6/)R8U*QH@T(
MC2]PYLTA"FX"K5_C.%Y3M\2\MF%4YN9?3ACL&?'@<@R,_@7?H4%P@) N2:BO
M(>.*]4E[]#TIN>&I?)F(O$+28*U6*'91^.>0\.>NNJU6J2W>5B;F[14\E(R!
MXYDL59JHT>I,BO?2(M6YC[?C>3R\WY;)Y(&3-XB2)I941BTV$Y8,TA#@))#U
M(-[J6V@EC6KS^.Q,7YB/#8)B<G'(J1LX"Q9:6(5 5):.3H+6LP&X@ 5J]=X]
M&PTVBY*E47C29O5.4:69>P-DV$B[M='*K3IL96*?RUEF6JT]#),I 4Y-<':[
M60\QDRH+ 0W<\9,^-F9/#XY1X,:<&,#S#TI3O6S!5!V,60E;BZVN6!(X_DX5
M?%@Y*7<LT\)#EAM_$C\C74DD;ELPW6-B3:QKNE].M9@;ZHW+%%-O+_-4>('%
M,'SAW(,WD:FR#'&+/EK1DV1:I.8MP)A7453454!7<IP!/?8?@?U&]1?I1PSM
ML]'\WY&UE.Z_KS7N2;$>RPK[AV(%_P"H_)VW;_RG!O<@C^ZB\.HKT):\] W%
MZ^XT:FE&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E
M*-*4:4J-U'*G\7VC/YO6P2'&\@Y&!,Q*-O44+9XQ()=*2]*)RUM(IO"HAYP
MSHY#]@[=P=(L:_Y0>;T<G?\ F2#U=W^' ]%SZ93=_?'X@VW1 1NUM7$O._\
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M(?9KR1&BE!8Z[CU\:]67NHN/"L2FH01V9O!0/N.Z)=A3W$0$>YDL4.P=_;V
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MGW5HX!^WO:B/\X[CJ+,?;3](I0#Y, V!^U /L!P@ ?S=VHV>XU-S[11ZY/\
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M^747Z7%9?;G;'<L/=>'R63@Y(QQ,S.[+8 M>Y-S<=;#3V&O2R]8OC+'$K)Z
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M\B@ZV_#]W]J<6A23EL,^8W8R!G=S\3N0/XC\/@  / 5KN4[5[KY$LT7'9(!
MLHCVJJ!M$0$_PCK[3KXFNN'!>@6BO?5'Y>6BR5BR0BTOQBXW0ZZ[ZAV"O5X9
M*%H>,FTHUCK4Y:EKUFDTY5)RBY2;K'59&:BF/<4/A^/=\\GBY7TKX3%AEB=D
MY/.:P=68*\TI4L@.Y018@D#=>]?6>T./RL?ZD<ME312)&W'8B7*,%++''N 8
M^5B"-0";6KNWKX77V.C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*
M4:4HTI1I2C2E&E*-*4:4J.%$U/XN-%?1U 40QQ()B_.N3\_%4&S1A@9H-O/Y
M!J!R@)U5/&)0>@F'< CL/1JR_P"473?F;_S)#ML?E;>B_F+6M\QX*+W]/<;>
M-<4Z/_U%CD]/C?3_ "60>H6'S]_FHSL5=U_DR/,[;;>L$&[PJ1]<Y7:U3M]N
MP^T/Y!_1J@H#;0?;V5-S7W;55K=-*BC;WZ@ WI1M^D>OZ?\ XMM1M/M-3>C;
M_P"+?4VOU O44;>[<1_7_P#$ ZFU*-O_ (MQ#4!3[?OI1M_\6XC_ ,NA4$WM
M2ONIM2OFVJ=H]E*-M-H]E*-M-H]E*-M-H]E*-M-H]E*-M-H]E*-M-H]E*-M-
MH]E*-M-H]E*-M-H]E*-M-H]E*^ZG:*4:D@^%*^==4^?W4HZZ>?W4HZZ>?W4H
MZZ>?W4HZZ>?W4HZZ>?W4HZZ>?W4HZZ>?W4HZZ>?W4HZZ>?W4HZZ>?W4HZZ>?
MW4HZZ>?W4HZZ>?W4HZZ>?W4HZZ>?W4HZZ>?W4HZZ>?W4HZZ>?W4HZZ>?W4HZ
MZ>?W4HZZ>?W4HZZ>?W4HZZ>?W4HZZ>?W4HZZ>?W4HZZ>?W4HZZ>?W4HZZ>?W
M4HZZ>?W4HZZ>?W4HZZ>?W4HZZ>?W4HZZ>?W4HZZ>?W4HZZ>?W4K[J0#XTHT*
M@TKYMJ-H]E*-M-H]E*-M-H]E*-M-H]E*-M-H]E*-M-H]E*-M-H]E*-M-H]E*
M-M-H]E*-M-H]E*-M-H]E*I4.1(AU#F A$RF.<QA[2E*0HF,81'H   ;C^C4V
MM2M2.-_-C O+&^Y\I&";,2]L^/4S1ZW;[O#J-G5*EI^[0#^PDC*K+(N#GF!@
M&K,$WJY4RM@<*>-)102*=D6%O):]5,I%B?&HJHWU&\:7K*]%I"&+LPPN,\N9
M3R3@_"_)"9C*:7#V4\M8G+<1ME2@BQ]T?Y B$':F/)Y.&DI6#8QTTI$. ;*F
M 4#+1:_M^_2IVD4ID_J'X\C<SK8X_A7F-YC=AGR#XJ3/)%I%U$V(8;D78D(X
M8S';MFK<$LEJL?G$RSA5Y]& 4@V\\Z(S.Y 2J*$;1[3^R@4D7TO:]3%R4Y9X
MUXP/L'PUV:V.:L.?\T4C"M&@:HR:OY!*2N,[&0#FXSQ7;QDE&46I.IIF$D^,
M8PIK/6K=,BB[I%,\G3KK15+7MX"F_FGE\AB?+L=@^K8 SWGW(#K&I<L2D?AJ
M.QBLSK%/<V=[48MS//\ )&4,<HINYF;C'1&R+;U)C$;*&-V@73;8]30+<;K@
M"]*,]\M&F%9C&-$@,,Y;S;F;+,!;KA7,-8P2HR=MCZ7CUI N;Y:K-+7>[5*E
M0D;7GEIC(TA329UI"6D$&S0BPF.=-8GJ=?<-:!2==+"J+!RW%+$V'LPXTXX<
ME<X0.8H-K864!CRG4Z'NM&8/8EG*()Y(K.5K_C9W6Y$%'9FBC4AG*R+M!4AR
ME*4IC1M%O;3;J02!:GYQCY#0O*+$[++E>HF1,=Q+^QW"LH0.38VOQUA4<TFR
M2-4E9)J-5LMNK\E NI>)7!F\:/UT'21/(0PD$HC(!VZ:&W[:AEVFQUK8/50O
M;7K5-&II1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1
MI2C2E&E*C91HH.7VC_Y)7Q1+C:0:#8S2!0M*:AK/&+!")17JP,:OK%(*YW'@
M$"N4R$\@;]H](LR_Y0>#U\C?^9(WH[/P"/0<>H9-O]Z/A";M4).W2]<2^.__
M %'CR_E<,QCA)$^9]3_% G*B/H"+?<XY ]1I/3TD55WB]C).N;KMJ-*4:4HT
MI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E
M*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI
M1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*
M-*4:4HTI1I2C2E&E*YQ<:"$3^H-]3 B9"ID!#A?L4A (7KAJT"(@   ==4CJ
M:J/PC]-:>X$Y#\7^8?*BB3+[/7':@8_X\YFRM!</>']6O5$C,F9!S#$C>L;6
M_D'DNDMWK67C73A!]9!IU8:,B*$8OU)V056=.F[=BL.M5L"HMK<]36#Y@\@\
M<Y1RMA?\B9 G(S//'[ZB.+<1.N!=M>4OT.:7H93A&DCGUYCF&2-D9RUJ^++&
MMD*JVDT@6#9IQ22[UF==(P)1?]]2N@-^A'6FW]06&YA5[,JV59'!&,[Q3I[E
MSP,QO@FV'Y EKLC 8WK6?\96\M2<TEWB:2-!SF5,RBHM/2R<JN5*-918"@L6
M/ J@W&IHC"VT>PT_OJ0R'$V%R=R)N61<^9TX\\JZ;PF@YK"3^O9EL&(ZM;W4
M!8\OS..E,/055FX=;.V3*_E%Z+*6KL@A,-SI2L<@6/,#XQCR2+Z]:1DZ* "M
MZ96>XR.EN3G!S(_.K,=LXS5+('TYL@U.^V:M9>G^.D6')9G8,&9)LU&DLGUB
M:JTC77:#1*4E(^)+(-22JD&<#IN2-!1$??TJ0;(P77S5)J'(+/?_ -!SPG.V
MRTV<G(WDHUQ7QNH]^G6!XF\R#OD+EYIAZ@Y8D6I$&*K2X_PCGD;8JIXDS"]2
M%02%$>W47\MZIT,G30:UV<H-&JV,:/3\<4B);P--H=9@Z?585H7M;Q=?KD:V
MB8ABE[S%;,6A"]P[F,(;B(B(CJNK9-S<]:=9SE3(=0Y@*0A3'.8>@%*4!,8P
M_H  TJ*JTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HT
MI1I2C2E&E*A]5]%AGUC&#!LAFC8?EGQ+*,@Y"13BR72&;JP98KR>C,R6=J$<
M&<"7RE43 @#VB(:Z]8,K_(+Y(G?Y(<PB^CL787.-(1+OMNW!04V7VD$FUQ7S
MB3+P!]78L$XL1Y0]MRR#)]1O4$0S85,'I7V%&<B0R6W!E"@V)%3!KD*^CT:4
MHTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E
M&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4H
MTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&
ME*-*4:4HTI1I2C2E&E*-*4@0^6>M?^E]#\Q_LOS3T_@];_5&]#Z_Q?VC^HW\
M7D_8W[>FHT_34ZTPH[^#GSM'Y3_#/\R>L4]/\N_*WSSYA^)YO#Z;^W^L^_W=
MOQ^W?WZ:5/F]]JR!OX8_Q#0[_P B?Q7_ "\?TWD_+_\ $3\J>H-Y/#W?]Y?R
M]ZK??M_LWDW]^FE1K^BG<_\ EOB1^:>A\/K&GI_7^G\?S#SD]!X?4?#ZSU/;
MX>WX_)MV]=M344UK9_#?YI3_ ,]?DCYU\\#\@?FSY#\T_,OBZ?D_YQ_:_GG@
M_N7]H[/T::>-3KX5]OO\.?D/_P!U#\E?ECYE&_\ V^_(OD/SCU)?E'_VP_\
M9_S+UFWIO]KY-NSXM1IXT%_"G*_^4=C+YG\N\?KV?RWU_INSYGW_ /9_HO4?
M#Z_R?U/C_$W^[UTTJ-?"LCJ:4UI67?D:229:O/*D(V>$!=)>L^-4I4E !5,J
3UC16[#@&X 8I#;#U !Z:5(K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g73339g0101013030822.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73339g0101013030822.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  L ,@# 2(  A$! Q$!_\0
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M/A!)\VTGDM@]Z]C90ZE6 ((P0>]>-7.C^)?AOXBNM2T.S?4-'N3EX5!)4>A
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M."/0UZ[\.+>>'X7R1302QRYG^1T*M^1JC\&+*6+PQJ4-Y:R1B2YP4FC(W#8
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B% !1110 4444 %%%% !1110 F*6BB@ Q1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g73339g0103014621857.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73339g0103014621857.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  S +(# 2(  A$! Q$!_\0
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MEJ)8HFV,Q<+\V,X%8KH\$C1L-KHQ5@>Q!P:+(5S=D\9^)@I*Z]?_ /?XT?\
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M^"A_Q9SQ$%'>;&!_L"O(6C<;B4<<]2#30,]#^$FO1V6OS:/<M_HFI)LPW3S
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MKXY_X1_2-0TJZL?M=G>#E"V-N1@_GQ^5<L&!;H=HZ9J$, 2>U2*1ZT!<]XT
M'_A'-+_Z](O_ $ 44>'\?\(WI?S#_CTB[_[ HI =G+X?T>[F:XN=+LY9G.6D
M>%2S?4XJ/_A%M S_ ,@6P_\  =?\***0Q3X6T GG1;#_ ,!U_P */^$6T#_H
M"V''_3NO^%%%*XP_X1?0?^@-8?\ @.O^%'_"+Z /^8-8?^ Z_P"%%%.X!_PB
M^@8Q_8UAC_KW7_"@>%] '_,&L/\ P'7_  HHI78 ?"^@G_F#6'_@.O\ A1_P
MB^@?] :P_P# =?\ "BB@!#X6\/D8.BV'_@.O^% \+Z!C_D#6'_@.O^%%%.[
M7_A&-!(S_8UA_P" Z_X4?\(QH.,?V-8?^ Z_X444KL!?^$9T+_H#V'_@.O\
MA1_PC&@_] :P_P# =?\ "BBG=@'_  C.A<?\2:PX_P"G=?\ "C_A&-!_Z UA
M_P" Z_X44478"?\ "-:&.FCV _[=U_PIP\.:)C']D6./^O=?\***5V*P?\(Y
MHG_0(L?_  '7_"C_ (1[1?\ H$V/_@.O^%%%.["R+*VEM&BQI;Q*BC"J$
)[4444KL+(__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g73339sp23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73339sp23.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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9;^>[AM;>.XNN99$C_>2UH44 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g73339sp32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73339sp32.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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M_P!DKX"?!;P?;^,_@IX-\/:1I_CC3X+V+5[.*22YO[*1!)%F2XS+Y9'/EY_
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!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
